PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Li, JSS; Cu, LW; Rock, DL; Li, JY				Li, JSS; Cu, LW; Rock, DL; Li, JY			Novel glycosidic linkage in aedes Aegypti chorion peroxidase N-mannosyl tryptophan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN C-MANNOSYLATION; FAST-ATOM-BOMBARDMENT; MASS-SPECTROMETRY; LINKED OLIGOSACCHARIDES; O-FUCOSYLATION; RNASE 2; GLYCOSYLATION; COMPLEMENT; FLAVONOIDS	Aedes aegypti chorion peroxidase (CPO) plays a crucial role in chorion hardening by catalyzing chorion protein cross-linking through dityrosine formation. The enzyme is extremely resistant to denaturing conditions, which seem intimately related to its posttranslational modifications, including disulfide bond formation and glycosylation. In this report, we have provided data that describe a new type of glycosylation in CPO, where a mannose is linked to the N-1 atom of the indole ring of Trp residue. Through liquid chromatography/electrospray ionization/tandem mass spectrometry and de novo sequencing of CPO tryptic peptides, we determined that three of the seven available Trp residues in mature CPO are partially ( 40 - 50%) or completely mannosylated. This conclusion is based on the following properties of the electrospray ionization/ tandem mass spectrometry spectra and the enzymatic reaction of these peptides: 1) the presence of a 162-Da substituent in each Trp residue; 2) the presence of abundant fragments of m/z 163 ([ Hex + H]) and [M + H - 162] (typical for N-glycosides); 3) the absence of a loss of 120 Da ( this loss is typical for aromatic C-glycosides); and 4) the cleavage of the glycosidic linkage by PNGase A or F ( typical for N-glycans). These results establish that a C - N bond is formed between the anomeric carbon of amannose residue and the N-1 atom of the indole ring of Trp. This is the first report that provides definitive evidence for N-mannosylation of Trp residues in a protein. In addition, our data demonstrate that PNGase can hydrolyze Trp N-linked mannose in peptides, which is unusual because no typical beta-amide bond is present in the Trp-mannosyl moiety. Results of this study should stimulate research toward a comprehensive understanding of physiology and biochemistry of Trp N-mannosylation in proteins and the overall biochemical mechanisms of PNGase-catalyzed reactions.	Univ Illinois, Dept Pathobiol, Urbana, IL 61802 USA; Penn State Univ, Dept Entomol, University Pk, PA 16802 USA	University of Illinois System; University of Illinois Urbana-Champaign; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Li, JY (corresponding author), Univ Illinois, Dept Pathobiol, 2001 S Lincoln Ave, Urbana, IL 61802 USA.	jli2@uiuc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037789, R29AI037789] Funding Source: NIH RePORTER; NIAID NIH HHS [AI37789] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECCHI M, 1989, BIOMED ENVIRON MASS, V18, P122, DOI 10.1002/bms.1200180207; de Beer T., 1995, BIOCHEMISTRY-US, V34; de Peredo AG, 2002, MOL CELL PROTEOMICS, V1, P11, DOI 10.1074/mcp.M100011-MCP200; Diem S, 2000, J AGR FOOD CHEM, V48, P4913, DOI 10.1021/jf0003146; Doucey MA, 1999, GLYCOBIOLOGY, V9, P435, DOI 10.1093/glycob/9.5.435; Doucey MA, 1998, MOL BIOL CELL, V9, P291, DOI 10.1091/mbc.9.2.291; Ervin LA, 2005, INVEST OPHTH VIS SCI, V46, P627, DOI 10.1167/iovs.04-0894; Fan JQ, 1997, J BIOL CHEM, V272, P27058, DOI 10.1074/jbc.272.43.27058; GADE G, 1992, BIOCHEM BIOPH RES CO, V189, P1303, DOI 10.1016/0006-291X(92)90215-7; Gutsche B, 1999, BIOCHEM J, V343, P11, DOI 10.1042/0264-6021:3430011; Han Q, 2000, ARCH BIOCHEM BIOPHYS, V378, P107, DOI 10.1006/abbi.2000.1821; Hartmann S, 2000, J BIOL CHEM, V275, P28569, DOI 10.1074/jbc.M001732200; Hilton DJ, 1996, J BIOL CHEM, V271, P4699; Hofsteenge J, 2001, J BIOL CHEM, V276, P6485, DOI 10.1074/jbc.M008073200; Hofsteenge J, 1999, J BIOL CHEM, V274, P32786, DOI 10.1074/jbc.274.46.32786; HOFSTEENGE J, 1994, BIOCHEMISTRY-US, V33, P13524, DOI 10.1021/bi00250a003; Ihara Y, 2005, GLYCOBIOLOGY, V15, P383, DOI 10.1093/glycob/cwi012; Krieg J, 1998, MOL BIOL CELL, V9, P301, DOI 10.1091/mbc.9.2.301; Krieg J, 1997, J BIOL CHEM, V272, P26687, DOI 10.1074/jbc.272.42.26687; Kuster B, 1997, ANAL BIOCHEM, V250, P82, DOI 10.1006/abio.1997.2199; Li JS, 2004, INSECT BIOCHEM MOLEC, V34, P1195, DOI 10.1016/j.ibmb.2004.08.001; Li JSS, 2005, PROTEIN SCI, V14, P2370, DOI 10.1110/ps.051419105; Li JY, 1996, INSECT BIOCHEM MOLEC, V26, P309, DOI 10.1016/0965-1748(95)00099-2; LI QM, 1992, BIOL MASS SPECTROM, V21, P213, DOI 10.1002/bms.1200210406; Loffler A, 1996, BIOCHEMISTRY-US, V35, P12005, DOI 10.1021/bi9610515; Perez-Vilar J, 2004, GLYCOBIOLOGY, V14, P325, DOI 10.1093/glycob/cwh041; PROX A, 1968, TETRAHEDRON, V24, P3697, DOI 10.1016/S0040-4020(01)92002-2; VARKI A, 1999, ESSENTIALS GLYCOBIOL, P85	28	14	16	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38513	38521		10.1074/jbc.M508449200	http://dx.doi.org/10.1074/jbc.M508449200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16150691	hybrid			2022-12-27	WOS:000233239800049
J	Hemming, ML; Selkoe, DJ				Hemming, ML; Selkoe, DJ			Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSERTION-DELETION POLYMORPHISM; 2 HOMOLOGOUS DOMAINS; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; A-BETA; ENDOTHELIAL-CELLS; MICE; INSULIN; DEMENTIA; CLEAVAGE	Human genetic data have associated angiotensin-converting enzyme ( ACE) with Alzheimer disease ( AD), and purified ACE has been reported to cleave synthetic amyloid beta-protein (A beta) in vitro. Whether deficiency in ACE activity, arising from genetic alteration or pharmacological inhibition, can decrease A beta degradation and allow A beta accumulation in intact cells is unknown. We cloned ACE from human neuroblastoma cells and showed that it had posttranslational processing and enzymatic activity typical of the endogenous protease. Cellular expression of ACE promoted degradation of naturally secreted A beta 40 and A beta 42, leading to significant clearance of both species. Using site-directed mutagenesis, we determined that both active sites within ACE contribute to A beta clearance, and an ACE construct bearing mutations in each catalytic domain had no effect on A beta levels. Pharmacological inhibition of ACE with a widely prescribed drug, captopril, promoted the accumulation of cell-derived A beta in the media of beta-amyloid precursor-protein expressing cells. Together, these results show that ACE can lower the levels of secreted A beta in living cells and that this effect is blocked by inhibiting the protease's activity with an ACE inhibitor. This work, combined with the genetic studies, supports the hypothesis that ACE may modulate the susceptibility to and progression of AD via degradation of A beta. Our data encourage further analyses of the ACE gene for disease association and raise the question of whether currently prescribed ACE inhibitors could elevate cerebral A beta levels in humans.	Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Selkoe, DJ (corresponding author), Harvard Inst Med 730, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	dselkoe@rics.bwh.harvard.edu		Hemming, Mathew/0000-0003-4674-7778	NIA NIH HHS [AG12749, R01 AG012749-10, R01 AG012749] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG012749] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARREGUI A, 1982, J NEUROCHEM, V38, P1490, DOI 10.1111/j.1471-4159.1982.tb07930.x; Balyasnikova IV, 2002, BIOCHEM J, V362, P585, DOI 10.1042/0264-6021:3620585; BARNES NM, 1991, EUR J PHARMACOL, V200, P289, DOI 10.1016/0014-2999(91)90584-D; BELDENT V, 1993, J BIOL CHEM, V268, P26428; Binevski PV, 2003, FEBS LETT, V550, P84, DOI 10.1016/S0014-5793(03)00825-1; Birkenhager WH, 2004, CURR OPIN NEPHROL HY, V13, P225, DOI 10.1097/01.mnh.0000119534.79618.7d; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Coates D, 2003, INT J BIOCHEM CELL B, V35, P769, DOI 10.1016/S1357-2725(02)00309-6; Cole J, 2002, CIRC RES, V90, P87, DOI 10.1161/hh0102.102360; Eckman EA, 2003, J BIOL CHEM, V278, P2081, DOI 10.1074/jbc.C200642200; Elkins JS, 2004, NEUROLOGY, V62, P363, DOI 10.1212/01.WNL.0000106823.72493.FF; Farris W, 2005, BIOCHEMISTRY-US, V44, P6513, DOI 10.1021/bi0476578; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; Fuchs S, 2004, J BIOL CHEM, V279, P15946, DOI 10.1074/jbc.M400149200; Gilman S, 2005, NEUROLOGY, V64, P1553, DOI 10.1212/01.WNL.0000159740.16984.3C; Herrmann N, 2004, NEUROLOGY, V63, P200, DOI 10.1212/01.WNL.0000134774.19232.09; Hock C, 2003, NEURON, V38, P547, DOI 10.1016/S0896-6273(03)00294-0; HOOPER NM, 1987, BIOCHEM J, V241, P625, DOI 10.1042/bj2410625; Hu JG, 2001, J BIOL CHEM, V276, P47863, DOI 10.1074/jbc.M104068200; Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Katzov H, 2004, HUM MOL GENET, V13, P2647, DOI 10.1093/hmg/ddh286; Kehoe PG, 1999, NAT GENET, V21, P71, DOI 10.1038/5009; Kohlstedt K, 2005, HYPERTENSION, V45, P126, DOI 10.1161/01.HYP.0000150159.48992.11; Kohlstedt K, 2004, CIRC RES, V94, P60, DOI 10.1161/01.RES.0000107195.13573.E4; Kolsch H, 2005, NEUROSCI LETT, V377, P37, DOI 10.1016/j.neulet.2004.11.062; Lehmann DJ, 2005, AM J EPIDEMIOL, V162, P305, DOI 10.1093/aje/kwi202; Leissring MA, 2003, NEURON, V40, P1087, DOI 10.1016/S0896-6273(03)00787-6; Leissring MA, 2004, BIOCHEM J, V383, P439, DOI 10.1042/BJ20041081; Lendon CL, 2002, NEUROSCI LETT, V328, P314, DOI 10.1016/S0304-3940(02)00553-0; Michaud A, 1997, MOL PHARMACOL, V51, P1070, DOI 10.1124/mol.51.6.1070; Oba R, 2005, EUR J NEUROSCI, V21, P733, DOI 10.1111/j.1460-9568.2005.03912.x; Ohrui T, 2004, NEUROLOGY, V63, P1324, DOI 10.1212/01.WNL.0000140705.23869.E9; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; SANTOS RAS, 1985, HYPERTENSION, V7, P244, DOI 10.1161/01.HYP.7.2.244; Savaskan E, 2001, NEUROBIOL AGING, V22, P541, DOI 10.1016/S0197-4580(00)00259-1; Selkoe DJ, 2004, ANN INTERN MED, V140, P627, DOI 10.7326/0003-4819-140-8-200404200-00047; SKIDGEL RA, 1987, CLIN EXP HYPERTENS A, V9, P243, DOI 10.3109/10641968709164184; Sleegers K, 2005, NEUROBIOL AGING, V26, P1153, DOI 10.1016/j.neurobiolaging.2004.09.011; Tucker HM, 2004, NEUROSCI LETT, V368, P285, DOI 10.1016/j.neulet.2004.07.011; Tucker HM, 2000, J NEUROSCI, V20, P3937; Vekrellis K, 2000, J NEUROSCI, V20, P1657; Walsh DM, 2004, NEURON, V44, P181, DOI 10.1016/j.neuron.2004.09.010; WEI L, 1992, J BIOL CHEM, V267, P13398; WEI L, 1991, J BIOL CHEM, V266, P9002; Woodman ZL, 2000, BIOCHEM J, V347, P711, DOI 10.1042/0264-6021:3470711	46	244	260	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37644	37650		10.1074/jbc.M508460200	http://dx.doi.org/10.1074/jbc.M508460200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16154999	hybrid, Green Accepted			2022-12-27	WOS:000233044500041
J	Sneck, M; Kovanen, PT; Oorni, K				Sneck, M; Kovanen, PT; Oorni, K			Decrease in pH strongly enhances binding of native, proteolyzed, lipolyzed, and oxidized low density lipoprotein particles to human aortic proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMERICAN-HEART-ASSOCIATION; HUMAN ATHEROSCLEROTIC LESIONS; TO-RETENTION HYPOTHESIS; CHOLESTEROL-FED RABBITS; APO-B LIPOPROTEINS; VASCULAR-LESIONS; ATHEROGENIC LIPOPROTEINS; EXTRACELLULAR-MATRIX; PLASMA-LIPOPROTEINS; HUMAN MACROPHAGES	Binding of low density lipoprotein (LDL) to proteoglycans and modification of LDL are key processes in atherogenesis. Recently, it has been demonstrated that during atherogenesis the extracellular pH of atherosclerotic lesions decreases. We have examined the effect of the decreased pH on the binding of LDL to human aortic proteoglycans. The binding of native, oxidized, proteolyzed (alpha-chymotrypsintreated), or lipolyzed (sphingomyelinase- or phospholipase A(2)-treated) LDL particles to proteoglycans were measured in microtiter well assays at pH 5.5 - 7.5. We found that the lower the pH, the higher the amount of binding of LDL to proteoglycans. At the lowest pH tested ( pH 5.5), the amounts of proteoglycan-bound native, proteolyzed, sphingomyelinase-, and phospholipase A(2)-treated LDL were 20-, 23-, 30-, and 37-fold higher, respectively, than at pH 7.5. Interestingly, although oxidized LDL failed to bind to proteoglycans at neutral pH, there was significant binding at acidic pH. Binding of native and modified LDL to proteoglycans at pH 5.5 was blocked by 1 M NaCl, indicating that at neutral pH LDL binds to proteoglycans via ionic interactions. Inhibition of this binding by acetylation and cyclohexanedione treatment of LDL showed that the positively charged amino acids of apolipoprotein B-100, lysine, and arginine, respectively, mediated the ionic interaction. Taken together, our results suggest that in areas of atherosclerotic arterial intima where the extracellular pH decreases, retention of LDL by proteoglycans is enhanced, leading to extracellular accumulation of LDL and progression of the disease.	Wihuri Res Inst, FIN-00140 Helsinki, Finland	Wihuri Research Institute	Oorni, K (corresponding author), Wihuri Res Inst, Kalliolinnantie 4, FIN-00140 Helsinki, Finland.	kati.oorni@wri.fi	Oorni, Katariina/G-2484-2011	Oorni, Katariina/0000-0002-9525-0250				Asatryan L, 2005, J LIPID RES, V46, P115, DOI 10.1194/jlr.M400306-JLR200; BARTOLD PM, 1985, ANAL BIOCHEM, V150, P320, DOI 10.1016/0003-2697(85)90517-2; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; Bjornheden T, 1999, ARTERIOSCL THROM VAS, V19, P870, DOI 10.1161/01.ATV.19.4.870; Boren J, 2000, CURR OPIN LIPIDOL, V11, P451, DOI 10.1097/00041433-200010000-00002; Camejo G, 1998, ATHEROSCLEROSIS, V139, P205, DOI 10.1016/S0021-9150(98)00107-5; Casscells W, 1996, LANCET, V347, P1447, DOI 10.1016/S0140-6736(96)91684-0; De Vries HE, 1998, FASEB J, V12, P111, DOI 10.1096/fasebj.12.1.111; Flood C, 2004, ARTERIOSCL THROM VAS, V24, P564, DOI 10.1161/01.ATV.0000117174.19078.85; GUYTON JR, 1990, EUR HEART J, V11, P20, DOI 10.1093/eurheartj/11.suppl_E.20; HABEEB AFS, 1966, ANAL BIOCHEM, V14, P328, DOI 10.1016/0003-2697(66)90275-2; Hakala JK, 2003, ARTERIOSCL THROM VAS, V23, P1430, DOI 10.1161/01.ATV.0000077207.49221.06; Hakala JK, 2001, ARTERIOSCL THROM VAS, V21, P1053, DOI 10.1161/01.ATV.21.6.1053; HESSLER JR, 1983, ARTERIOSCLEROSIS, V3, P215, DOI 10.1161/01.ATV.3.3.215; HurtCamejo E, 1997, ARTERIOSCL THROM VAS, V17, P1011, DOI 10.1161/01.ATV.17.6.1011; HURTCAMEJO E, 1990, J LIPID RES, V31, P1387; IVERIUS PH, 1972, J BIOL CHEM, V247, P2607; KAMAT BR, 1987, HUM PATHOL, V18, P1036, DOI 10.1016/S0046-8177(87)80220-4; KLEINMAN Y, 1988, J LIPID RES, V29, P729; Leake DS, 1997, ATHEROSCLEROSIS, V129, P149, DOI 10.1016/S0021-9150(96)06035-2; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1979, BIOCHIM BIOPHYS ACTA, V575, P81, DOI 10.1016/0005-2760(79)90133-4; Naghavi M, 2002, ATHEROSCLEROSIS, V164, P27, DOI 10.1016/S0021-9150(02)00018-7; NEWSHOLME P, 1987, BIOCHEM J, V242, P631, DOI 10.1042/bj2420631; Oorni K, 2000, J LIPID RES, V41, P1703; Oorni K, 2004, J BIOL CHEM, V279, P34776, DOI 10.1074/jbc.M310814200; Oorni K, 1997, J BIOL CHEM, V272, P21303, DOI 10.1074/jbc.272.34.21303; PAANANEN K, 1994, J BIOL CHEM, V269, P2023; Pentikainen MO, 2001, ARTERIOSCL THROM VAS, V21, P1902, DOI 10.1161/hq1201.099423; RADDING CM, 1960, J CLIN INVEST, V39, P1560, DOI 10.1172/JCI104177; Sartipy P, 1999, J BIOL CHEM, V274, P25913, DOI 10.1074/jbc.274.36.25913; Schissel SL, 1998, J BIOL CHEM, V273, P2738, DOI 10.1074/jbc.273.5.2738; SCHWENKE DC, 1989, ARTERIOSCLEROSIS, V9, P895, DOI 10.1161/01.ATV.9.6.895; SCHWENKE DC, 1989, ARTERIOSCLEROSIS, V9, P908, DOI 10.1161/01.ATV.9.6.908; Skalen K, 2002, NATURE, V417, P750, DOI 10.1038/nature00804; SRINIVASAN SR, 1986, ATHEROSCLEROSIS, V62, P201, DOI 10.1016/0021-9150(86)90094-8; STARY HC, 1994, CIRCULATION, V89, P2462, DOI 10.1161/01.CIR.89.5.2462; STARY HC, 1995, CIRCULATION, V92, P1355, DOI 10.1161/01.CIR.92.5.1355; STARY HC, 1992, ARTERIOSCLER THROMB, V12, P120, DOI 10.1161/01.ATV.12.1.120; Stefanadis C, 1999, CIRCULATION, V99, P1965, DOI 10.1161/01.CIR.99.15.1965; Tozer EC, 1997, CIRC RES, V80, P208, DOI 10.1161/01.RES.80.2.208; WIGHT TN, 1995, CURR OPIN LIPIDOL, V6, P326, DOI 10.1097/00041433-199510000-00013; WIGHT TN, 1996, ATHEROSCLEROSIS CORO, P421; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; Williams KJ, 1998, CURR OPIN LIPIDOL, V9, P471, DOI 10.1097/00041433-199810000-00012; Wooton-Kee CR, 2004, ARTERIOSCL THROM VAS, V24, P762, DOI 10.1161/01.ATV.0000122363.02961.c1	47	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37449	37454		10.1074/jbc.M508565200	http://dx.doi.org/10.1074/jbc.M508565200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16147996	hybrid			2022-12-27	WOS:000233044500020
J	Tarrega, C; Rios, P; Cejudo-Marin, R; Blanco-Aparicio, C; van den Berk, L; Schepens, J; Hendriks, W; Tabernero, L; Pulido, R				Tarrega, C; Rios, P; Cejudo-Marin, R; Blanco-Aparicio, C; van den Berk, L; Schepens, J; Hendriks, W; Tabernero, L; Pulido, R			ERK2 shows a restrictive and locally selective mechanism of recognition by its tyrosine phosphatase inactivators not shared by its activator MEK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE KINASE; SIGNAL-REGULATED KINASES; OF-FUNCTION MUTATION; PROTEIN-KINASE; PTP-SL; FEEDBACK PHOSPHORYLATION; SUBSTRATE RECOGNITION; CATALYTIC ACTIVATION; BIOLOGICAL FUNCTIONS; MASS-SPECTROMETRY	The two regulatory residues that control the enzymatic activity of the mitogen-activated protein (MAP) kinase ERK2 are phosphorylated by the unique MAP kinase kinases MEK1/2 and dephosphorylated by several tyrosine-specific and dual specificity protein phosphatases. Selective docking interactions facilitate these phosphorylation and dephosphorylation events, controlling the specificity and duration of the MAP kinase activation-inactivation cycles. We have analyzed the contribution of specific residues of ERK2 in the physical and functional interaction with the ERK2 phosphatase inactivators PTP-SL and MKP-3 and with its activator MEK1. Single mutations in ERK2 that abrogated the dephosphorylation by endogenous tyrosine phosphatases from HEK293 cells still allowed efficient phosphorylation by endogenous MEK1/2. Discrete ERK2 mutations at the ERK2 docking groove differentially affected binding and inactivation by PTP-SL and MKP-3. Remarkably, the cytosolic retention of ERK2 by its activator MEK1 was not affected by any of the analyzed ERK2 single amino acid substitutions. A chimeric MEK1 protein, containing the kinase interaction motif of PTP-SL, bound tightly to ERK2 through its docking groove and behaved as a gain-of-function MAP kinase kinase that hyperactivated ERK2. Our results provide evidence that the ERK2 docking groove is more restrictive and selective for its tyrosine phosphatase inactivators than for MEK1/2 and indicate that distinct ERK2 residues modulate the docking interactions with activating and inactivating effectors.	Ctr Invest Principe Felipe, Valencia 46013, Spain; Radboud Univ Nijmegen Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Cell Biol, NL-6525 GA Nijmegen, Netherlands; Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England	Prince Felipe Research Center; Radboud University Nijmegen; University of Manchester	Pulido, R (corresponding author), Ctr Invest Principe Felipe, Avda Autopista Saler 16-3, Valencia 46013, Spain.	rpulido@cipf.es	Blanco-Aparicio, Carmen/I-3162-2015; Tabernero, Lydia/F-3795-2018; Cejudo, Rocio/I-2794-2015; Hendriks, Wiljan J.A.J./A-5214-2013; Hendriks, Wiljan/Q-4325-2019	Blanco-Aparicio, Carmen/0000-0002-3249-6595; Tabernero, Lydia/0000-0001-8867-455X; Hendriks, Wiljan J.A.J./0000-0001-9481-8281; Hendriks, Wiljan/0000-0001-9481-8281; Pulido, Rafael/0000-0001-9100-248X; Cejudo Marin, Rocio/0000-0001-5389-7200				Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Bardwell AJ, 2003, BIOCHEM J, V370, P1077, DOI 10.1042/BJ20021806; Bardwell AJ, 2001, J BIOL CHEM, V276, P10374, DOI 10.1074/jbc.M010271200; Bardwell L, 1996, TRENDS BIOCHEM SCI, V21, P373, DOI 10.1016/S0968-0004(96)30032-7; Bellon S, 1999, STRUCTURE, V7, P1057, DOI 10.1016/S0969-2126(99)80173-7; Biondi RM, 2003, BIOCHEM J, V372, P1, DOI 10.1042/BJ20021641; Blanco-Aparicio C, 1999, J CELL BIOL, V147, P1129, DOI 10.1083/jcb.147.6.1129; BOTT CM, 1994, FEBS LETT, V352, P201, DOI 10.1016/0014-5793(94)00958-9; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Buschbeck M, 2002, J BIOL CHEM, V277, P29503, DOI 10.1074/jbc.M202149200; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Cha H, 2001, J BIOL CHEM, V276, P48494, DOI 10.1074/jbc.M107601200; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Dang A, 1998, J BIOL CHEM, V273, P19909, DOI 10.1074/jbc.273.31.19909; Dilaver G, 2003, HISTOCHEM CELL BIOL, V119, P1, DOI 10.1007/s00418-002-0489-9; Eblen ST, 2001, MOL CELL BIOL, V21, P249, DOI 10.1128/MCB.21.1.249-259.2001; Eblen ST, 2004, MOL CELL BIOL, V24, P2308, DOI 10.1128/MCB.24.6.2308-2317.2004; Eblen ST, 2002, MOL CELL BIOL, V22, P6023, DOI 10.1128/MCB.22.17.6023-6033.2002; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; Farooq A, 2001, MOL CELL, V7, P387, DOI 10.1016/S1097-2765(01)00186-1; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Hall JP, 1996, MOL CELL BIOL, V16, P6715; HENDRIKS W, 1995, BIOCHEM J, V305, P499, DOI 10.1042/bj3050499; Heo JS, 2004, EMBO J, V23, P2185, DOI 10.1038/sj.emboj.7600212; Huang ZH, 2004, J BIOL CHEM, V279, P52150, DOI 10.1074/jbc.M407820200; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kusari AB, 2004, J CELL BIOL, V164, P267, DOI 10.1083/jcb.200310021; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lee T, 2004, MOL CELL, V14, P43, DOI 10.1016/S1097-2765(04)00161-3; Lim YM, 1999, GENETICS, V153, P763; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Marchetti S, 2005, MOL CELL BIOL, V25, P854, DOI 10.1128/MCB.25.2.854-864.2005; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; Munoz JJ, 2003, BIOCHEM J, V372, P193, DOI 10.1042/BJ20021941; Nichols A, 2000, J BIOL CHEM, V275, P24613, DOI 10.1074/jbc.M001515200; Pouyssegur J, 2003, EUR J BIOCHEM, V270, P3291, DOI 10.1046/j.1432-1033.2003.03707.x; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Robinson FL, 2002, J BIOL CHEM, V277, P14844, DOI 10.1074/jbc.M107776200; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349; Saxena M, 1999, J BIOL CHEM, V274, P11693, DOI 10.1074/jbc.274.17.11693; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; Saxena M, 2000, SEMIN IMMUNOL, V12, P387, DOI 10.1006/smim.2000.0219; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SEGER R, 1992, J BIOL CHEM, V267, P25628; Sharma P, 2002, J BIOL CHEM, V277, P528, DOI 10.1074/jbc.M109324200; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Tanoue T, 2002, J BIOL CHEM, V277, P22942, DOI 10.1074/jbc.M202096200; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Tanoue TJ, 2003, CELL SIGNAL, V15, P455, DOI 10.1016/S0898-6568(02)00112-2; Tarrega C, 2002, J BIOL CHEM, V277, P2629, DOI 10.1074/jbc.M108874200; Wang PY, 2003, EMBO J, V22, P2658, DOI 10.1093/emboj/cdg255; Wang ZL, 1997, P NATL ACAD SCI USA, V94, P2327, DOI 10.1073/pnas.94.6.2327; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wilsbacher JL, 1999, J BIOL CHEM, V274, P16988, DOI 10.1074/jbc.274.24.16988; Wolf I, 2001, J BIOL CHEM, V276, P24490, DOI 10.1074/jbc.M103352200; Xie XL, 1998, STRUCTURE, V6, P983, DOI 10.1016/S0969-2126(98)00100-2; Xu BE, 2001, J BIOL CHEM, V276, P26509, DOI 10.1074/jbc.M102769200; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029; Yung Y, 2001, J BIOL CHEM, V276, P35280, DOI 10.1074/jbc.M105995200; Zhan XL, 2001, CHEM REV, V101, P2477, DOI 10.1021/cr000245u; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; Zhang JL, 2003, J BIOL CHEM, V278, P29901, DOI 10.1074/jbc.M303909200; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; Zhou B, 2001, J BIOL CHEM, V276, P6506, DOI 10.1074/jbc.M009753200; Zhou B, 2002, J BIOL CHEM, V277, P31818, DOI 10.1074/jbc.M203969200; Zuniga A, 1999, J BIOL CHEM, V274, P21900, DOI 10.1074/jbc.274.31.21900	77	21	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37885	37894		10.1074/jbc.M504366200	http://dx.doi.org/10.1074/jbc.M504366200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16148006	Green Published, hybrid			2022-12-27	WOS:000233044500069
J	Blachon, S; Bellanger, S; Demeret, C; Thierry, G				Blachon, S; Bellanger, S; Demeret, C; Thierry, G			Nucleo-cytoplasmic shuttling of high risk human Papillomavirus E2 proteins induces apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E6 PROMOTER; TRANSACTIVATION DOMAIN; NUCLEAR-LOCALIZATION; CRYSTAL-STRUCTURE; VIRAL-DNA; TYPE-16; REPRESSOR; COMPLEX; PATHWAY; BINDING	Human Papillomavirus (HPV) E2 proteins are the major viral regulators of transcription and replication during the viral life cycle. In addition to these conserved functions, we show that E2 proteins from high risk HPV types 16 and 18, which are associated with cervical cancer, can induce apoptosis. In contrast, E2 proteins from low risk HPV types 6 and 11, which are associated with benign lesions, do not cause cell death. We show that the ability to induce apoptosis is linked to the intracellular localization of the respective E2 proteins rather than to inherent properties of the proteins. Although low risk HPV E2 proteins remain strictly nuclear, high risk HPV E2 proteins are present in both the nucleus and the cytoplasm of expressing cells due to exportin-1 receptor (CRM1)-dependent nucleo-cytoplasmic shuttling. Induction of apoptosis is caused by accumulation of E2 in the cytoplasm and involves caspase 8 activation. We speculate that disruption of the E2 gene during viral genome integration in cervical carcinoma provides a means to avoid E2-induced apoptosis and allow initiation of carcinogenesis.	Inst Pasteur, Unite Express Genet & Malad, CNRS, FRE 2850, F-75724 Paris, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Thierry, G (corresponding author), Inst Pasteur, Unite Express Genet & Malad, CNRS, FRE 2850, 25 Rue Dr Roux, F-75724 Paris, France.	fthierry@pasteur.fr		Demeret, caroline/0000-0002-1103-6805				Abbate EA, 2004, GENE DEV, V18, P1981, DOI 10.1101/gad.1220104; Ameisen JC, 2003, CELL DEATH DIFFER, V10, pS3, DOI 10.1038/sj.cdd.4401117; Antson AA, 2000, NATURE, V403, P805, DOI 10.1038/35001638; Bellanger S, 2001, J VIROL, V75, P7244, DOI 10.1128/JVI.75.16.7244-7251.2001; BELLANGER S, 2005, IN PRESS CELL CYCLE, V4; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Boya P, 2004, BBA-BIOENERGETICS, V1659, P178, DOI 10.1016/j.bbabio.2004.08.007; CHIN MT, 1988, J VIROL, V62, P2994, DOI 10.1128/JVI.62.8.2994-3002.1988; Crouzet J, 1997, P NATL ACAD SCI USA, V94, P1414, DOI 10.1073/pnas.94.4.1414; DEMERET C, 1994, J VIROL, V68, P7075, DOI 10.1128/JVI.68.11.7075-7082.1994; Demeret C, 2003, ONCOGENE, V22, P168, DOI 10.1038/sj.onc.1206108; Desaintes C, 1999, ONCOGENE, V18, P4538, DOI 10.1038/sj.onc.1202818; Desaintes C, 1996, SEMIN CANCER BIOL, V7, P339, DOI 10.1006/scbi.1996.0043; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; DONG G, 1994, J VIROL, V68, P1115, DOI 10.1128/JVI.68.2.1115-1127.1994; DOSTATNI N, 1991, GENE DEV, V5, P1657, DOI 10.1101/gad.5.9.1657; DOWHANICK JJ, 1995, J VIROL, V69, P7791, DOI 10.1128/JVI.69.12.7791-7799.1995; Finzer P, 2002, CANCER LETT, V188, P15, DOI 10.1016/S0304-3835(02)00431-7; Hegde RS, 1998, J MOL BIOL, V284, P1479, DOI 10.1006/jmbi.1998.2260; Hegde RS, 2002, ANNU REV BIOPH BIOM, V31, P343, DOI 10.1146/annurev.biophys.31.100901.142129; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; HWANG ES, 1993, J VIROL, V67, P3720, DOI 10.1128/JVI.67.7.3720-3729.1993; Hwang ES, 1996, ONCOGENE, V12, P795; Irusta PM, 2003, CURR OPIN CELL BIOL, V15, P700, DOI 10.1016/j.ceb.2003.10.007; Kassis R, 2004, J VIROL, V78, P6543, DOI 10.1128/JVI.78.12.6543-6555.2004; Kim KH, 2003, EMBO J, V22, P2104, DOI 10.1093/emboj/cdg210; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Otero GC, 1998, J VIROL, V72, P7593, DOI 10.1128/JVI.72.9.7593-7597.1998; Prikhod'ko EA, 2004, VIROLOGY, V329, P53, DOI 10.1016/j.virol.2004.08.012; Raj K, 2004, J VIROL, V78, P7199, DOI 10.1128/JVI.78.13.7199-7207.2004; Robert A, 2002, J CELL BIOL, V158, P519, DOI 10.1083/jcb.200201106; ROMANCZUK H, 1990, J VIROL, V64, P2849, DOI 10.1128/JVI.64.6.2849-2859.1990; Roulston A, 1999, ANNU REV MICROBIOL, V53, P577, DOI 10.1146/annurev.micro.53.1.577; Rowland RRR, 2003, VIRUS RES, V95, P23, DOI 10.1016/S0168-1702(03)00161-8; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Skiadopoulos MH, 1996, J VIROL, V70, P1117, DOI 10.1128/JVI.70.2.1117-1124.1996; TAN SH, 1994, J VIROL, V68, P6411, DOI 10.1128/JVI.68.10.6411-6420.1994; TAN SH, 1992, NUCLEIC ACIDS RES, V20, P251, DOI 10.1093/nar/20.2.251; Teodoro JG, 2004, GENE DEV, V18, P1952, DOI 10.1101/gad.1198404; THIERRY F, 1991, NEW BIOL, V3, P90; THIERRY F, 1987, EMBO J, V6, P3391, DOI 10.1002/j.1460-2075.1987.tb02662.x; Van Tine BA, 2004, P NATL ACAD SCI USA, V101, P4030, DOI 10.1073/pnas.0306848101; Wang Y, 2004, J BIOL CHEM, V279, P6976, DOI 10.1074/jbc.M311376200; Webster K, 2000, J BIOL CHEM, V275, P87, DOI 10.1074/jbc.275.1.87; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Yasugi T, 1997, J VIROL, V71, P891, DOI 10.1128/JVI.71.2.891-899.1997; You J, 2004, CELL, V117, P349, DOI 10.1016/S0092-8674(04)00402-7; Zou NX, 2000, J VIROL, V74, P3761, DOI 10.1128/JVI.74.8.3761-3770.2000	49	63	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36088	36098		10.1074/jbc.M505138200	http://dx.doi.org/10.1074/jbc.M505138200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16135518	hybrid			2022-12-27	WOS:000232726900039
J	Khan, AN; Lewis, PN				Khan, AN; Lewis, PN			Unstructured conformations are a substrate requirement for the Sir2 family of NAD-dependent protein deacetylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST; DISORDER; PEPTIDE; ACETYLATION; PREDICTION; RESOLUTION; COMPLEX	The regulation of protein function is often achieved through post-translational modifications including phosphorylation, methylation, ubiquitination, and acetylation. The role of acetylation has been most extensively studied in the context of histones, but it is becoming increasingly evident that this modification now includes other proteins. The Sir2 family of NAD-dependent deacetylases was initially recognized as mediating gene silencing through histone deacetylation, but several family members display non-nuclear subcellular localization and deacetylate non-histone protein substrates. Although many structural and enzymatic studies of Sir2 proteins have been reported, how substrate recognition is achieved by this family of enzymes is unknown. Here we use in vitro deacetylase assays and a variety of potential substrates to examine the substrate specificity of yeast homologue Hst2. We show that Hst2 is specific for acetyl-lysine within proteins; it does not deacetylate small polycations such as acetyl-spermine or acetylated amino termini of proteins. Furthermore we have found that Hst2 displays conformational rather than sequence specificity, preferentially deacetylating acetyl-lysine within unstructured regions of proteins. Our results suggest that this conformational requirement may be a general feature for substrate recognition in the Sir2 family.	Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto	Lewis, PN (corresponding author), Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada.	peter.lewis@utoronto.ca						Avalos JL, 2002, MOL CELL, V10, P523, DOI 10.1016/S1097-2765(02)00628-7; Banci L, 1997, BIOCHEMISTRY-US, V36, P9867, DOI 10.1021/bi970724w; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Blander G, 2005, J BIOL CHEM, V280, P9780, DOI 10.1074/jbc.M414080200; Cuperus G, 2000, EMBO J, V19, P2641, DOI 10.1093/emboj/19.11.2641; Dathe M, 1999, BBA-BIOMEMBRANES, V1462, P71, DOI 10.1016/S0005-2736(99)00201-1; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; GU W, 2004, NOVART FDN SYMP, V259, P223; Gu Wei, 2004, Novartis Found Symp, V259, P197; Iakoucheva LM, 2004, NUCLEIC ACIDS RES, V32, P1037, DOI 10.1093/nar/gkh253; ITZHAKI RF, 1964, ANAL BIOCHEM, V9, P401, DOI 10.1016/0003-2697(64)90200-3; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; LEONIDAS DD, 1997, BIOCHEMISTRY-US, V36, P5578; LEWIS PN, 1988, EUR J BIOCHEM, V172, P135, DOI 10.1111/j.1432-1033.1988.tb13865.x; Linding R, 2003, NUCLEIC ACIDS RES, V31, P3701, DOI 10.1093/nar/gkg519; Linding R, 2003, STRUCTURE, V11, P1453, DOI 10.1016/j.str.2003.10.002; Liu BS, 2005, J BIOL CHEM, V280, P16659, DOI 10.1074/jbc.M414008200; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mujtaba S, 2004, MOL CELL, V13, P251, DOI 10.1016/S1097-2765(03)00528-8; Perrod S, 2001, EMBO J, V20, P197, DOI 10.1093/emboj/20.1.197; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rustandi RR, 2000, NAT STRUCT BIOL, V7, P570; Thomson R, 2004, LECT NOTES COMPUT SC, V3177, P108; Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Yang XJ, 2005, ONCOGENE, V24, P1653, DOI 10.1038/sj.onc.1208173; Ying WH, 2005, J NEUROSCI RES, V79, P216, DOI 10.1002/jnr.20289; Zhao KH, 2003, STRUCTURE, V11, P1403, DOI 10.1016/j.str.2003.09.016	29	37	40	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36073	36078		10.1074/jbc.M508247200	http://dx.doi.org/10.1074/jbc.M508247200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16131486	hybrid			2022-12-27	WOS:000232726900037
J	Reppel, M; Sasse, P; Piekorz, R; Tang, M; Roell, W; Duan, YQ; Kletke, A; Hescheler, J; Nurnberg, B; Fleischmann, BK				Reppel, M; Sasse, P; Piekorz, R; Tang, M; Roell, W; Duan, YQ; Kletke, A; Hescheler, J; Nurnberg, B; Fleischmann, BK			S100A1 enhances the L-type Ca2+ current in embryonic mouse and neonatal rat ventricular cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-BINDING PROTEIN S100A1; CALCIUM-BINDING PROTEINS; MYOCARDIAL-INFARCTION; CARDIAC CONTRACTILITY; GUINEA-PIG; CYCLIC-AMP; TROPONIN-T; KINASE-A; HEART; EXPRESSION	S100A1 is an EF-hand type Ca2+-binding protein with a muscle-specific expression pattern. The highest S100A1 protein levels are found in cardiomyocytes, and it is expressed already at day 8 in the heart during embryonic development. Since S100A1 is known to be involved in the regulation of Ca2+ homeostasis, we tested whether extracellular S100A1 plays a role in regulating the L-type Ca2+ current (I-Ca) in ventricular cardiomyocytes. Murine embryonic ( day 16.5 postcoitum) ventricular cardiomyocytes were incubated with S100A1 (0.001 - 10 mu M) for different time periods ( 20 min to 48 h). ICa density was found to be significantly increased as early as 20 min ( from - 10.8 +/- 1 pA/pF, n = 18, to - 22.9 +/- 1.4 pA/pF; + 112.5 +/- 13%, n = 9, p< 0.001) after the addition of S100A1 ( 1 mu M). S100A1 also enhanced I-Ca current density in neonatal rat cardiomyocytes. Fluorescence and capacitance measurements evidenced a fast translocation of rhodamine-coupled S100A1 from the extracellular space into cardiomyocytes. S100A1 treatment did not affect cAMP levels. However, protein kinase inhibitor, a blocker of cAMP-dependent protein kinase A (PKA), abolished the S100A1-induced enhancement of I-Ca. Accordingly, measurements of PKA activity yielded a significant increase in S100A1-treated cardiomyocytes. In vitro reconstitution assays further demonstrated that S100A1 enhanced PKA activity. We conclude that the Ca2+-binding protein S100A1 augments transsarcolemmal Ca2+ influx via an increase of PKA activity in ventricular cardiomyocytes and hence represents an important regulator of cardiac function.	Univ Cologne, Inst Neurophysiol, D-50931 Cologne, Germany; Univ Bonn, Inst Physiol 1, D-53105 Bonn, Germany; Univ Bonn, Dept Cardiothorac Surg, D-53105 Bonn, Germany; Univ Dusseldorf, Dept Biochem & Mol Biol 2, D-40225 Dusseldorf, Germany; Tongji Med Coll, Dept Physiol, Wuhan 430030, Peoples R China	University of Cologne; University of Bonn; University of Bonn; Heinrich Heine University Dusseldorf; Huazhong University of Science & Technology	Reppel, M (corresponding author), Univ Cologne, Inst Neurophysiol, Robert Koch Str 39, D-50931 Cologne, Germany.	michael.reppel@uni-koeln.de; bernd.fleischmann@uni-bonn.de	Sasse, Philipp/G-9866-2013	Sasse, Philipp/0000-0002-8502-9472; Nurnberg, Bernd/0000-0002-5995-6555; Roell, Wilhelm/0000-0002-2213-5024				ARGEL MI, 1980, J MOL CELL CARDIOL, V12, P939, DOI 10.1016/0022-2828(80)90023-1; BLONDEL B, 1971, EXPERIENTIA, V27, P356, DOI 10.1007/BF02138197; Brett W, 2001, BIOCHEM BIOPH RES CO, V284, P698, DOI 10.1006/bbrc.2001.4996; DANIELS CK, 1994, J PHARMACOL TOXICOL, V31, P41, DOI 10.1016/1056-8719(94)90027-2; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Du XJ, 2002, MOL CELL BIOL, V22, P2821, DOI 10.1128/MCB.22.8.2821-2829.2002; Ehlermann P, 2000, J CHROMATOGR B, V737, P39, DOI 10.1016/S0378-4347(99)00366-7; Ehlermann P, 2000, BBA-MOL BASIS DIS, V1500, P249, DOI 10.1016/S0925-4439(99)00106-4; Findlay I, 2002, J PHYSIOL-LONDON, V545, P375, DOI 10.1113/jphysiol.2002.028605; Fleischmann M, 1998, FEBS LETT, V440, P370, DOI 10.1016/S0014-5793(98)01476-8; Gupta IR, 1999, J BIOL CHEM, V274, P26305, DOI 10.1074/jbc.274.37.26305; Herr C, 2001, MOL CELL BIOL, V21, P4119, DOI 10.1128/MCB.21.13.4119-4128.2001; HESCHELER J, 1991, CIRC RES, V69, P1476, DOI 10.1161/01.RES.69.6.1476; Horackova M, 1997, EXP CELL RES, V237, P158, DOI 10.1006/excr.1997.3775; Ji GJ, 1999, FASEB J, V13, P313, DOI 10.1096/fasebj.13.2.313; KATO K, 1985, BIOCHIM BIOPHYS ACTA, V842, P146, DOI 10.1016/0304-4165(85)90196-5; KATUS HA, 1991, CIRCULATION, V83, P902, DOI 10.1161/01.CIR.83.3.902; Kennergren C, 1999, CARDIOLOGY, V92, P162, DOI 10.1159/000006966; Kiewitz R, 2000, BIOCHEM BIOPH RES CO, V274, P865, DOI 10.1006/bbrc.2000.3229; Kiewitz R, 2003, BIOCHEM BIOPH RES CO, V306, P550, DOI 10.1016/S0006-291X(03)00987-2; Kiewitz R, 2000, BBA-MOL CELL RES, V1498, P207, DOI 10.1016/S0167-4889(00)00097-5; Kosuge S, 2001, J BIOCHEM, V129, P403, DOI 10.1093/oxfordjournals.jbchem.a002871; KUO WN, 1986, CYTOBIOS, V46, P139; Maltsev VA, 1999, CIRC RES, V84, P136, DOI 10.1161/01.RES.84.2.136; Mason HS, 2002, MOL PHARMACOL, V61, P285, DOI 10.1124/mol.61.2.285; Matsushita T, 1999, CIRCULATION, V100, P262; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; Most P, 2005, J CELL SCI, V118, P421, DOI 10.1242/jcs.01614; Most P, 2003, J BIOL CHEM, V278, P33809, DOI 10.1074/jbc.M301788200; Most P, 2001, P NATL ACAD SCI USA, V98, P13889, DOI 10.1073/pnas.241393598; Podlowski S, 1998, CIRCULATION, V98, P2470, DOI 10.1161/01.CIR.98.22.2470; Remppis A, 1996, BBA-MOL CELL RES, V1313, P253, DOI 10.1016/0167-4889(96)00097-3; Remppis A, 2002, BASIC RES CARDIOL S1, V97, P56; Sako H, 1998, PFLUG ARCH EUR J PHY, V435, P749, DOI 10.1007/s004240050579; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Smith C, 1997, J CELL BIOL, V139, P885, DOI 10.1083/jcb.139.4.885; Wang W, 2004, CIRC RES, V95, P798, DOI 10.1161/01.RES.0000145361.50017.aa; Zou YZ, 2001, CIRCULATION, V104, P102, DOI 10.1161/hc2601.090987	38	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36019	36028		10.1074/jbc.M504750200	http://dx.doi.org/10.1074/jbc.M504750200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16129693	hybrid			2022-12-27	WOS:000232726900031
J	Zschocke, J; Bayatti, N; Clement, AM; Witan, H; Figiel, M; Engele, J; Behl, C				Zschocke, J; Bayatti, N; Clement, AM; Witan, H; Figiel, M; Engele, J; Behl, C			Differential promotion of glutamate transporter expression and function by glucocorticoids in astrocytes from various brain regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRILLARY ACIDIC PROTEIN; GENE-EXPRESSION; DNA METHYLATION; NERVOUS-SYSTEM; RAT-BRAIN; MINERALOCORTICOID RECEPTOR; RESPONSE ELEMENT; NEURAL RETINA; GROWTH-FACTOR; SPINAL-CORD	Steroids that activate glucocorticoid receptors (GRs) and mineralocorticoid receptors have important regulatory effects on neural development, plasticity, and the body's stress response. Here, we investigated the role of corticosteroids in regulating the expression of the glial glutamate transporters glial glutamate transporter-1 (GLT-1) and glutamate-aspartate transporter (GLAST) in rat primary astrocytes. The synthetic glucocorticoid dexamethasone provoked a marked increase of GLT-1 transcription and protein levels in cortical astrocytes, whereas GLAST expression remained unaffected. Up-regulation of GLT-1 expression was accompanied by an enhanced glutamate uptake, which could be blocked by the specific GLT-1 inhibitor dihydrokainate. The promoting effect of dexamethasone on GLT-1 gene expression and function was abolished by the GR antagonist mifepristone. A predominant role of the GR was further supported by the observation that corticosterone could elevate GLT-1 expression in a dose-dependent manner, whereas aldosterone, the physiological ligand of the mineralocorticoid receptor, exerted only weak effects even when applied at high concentrations. Moreover, we monitored brain region-specific differences, since all corticosteroids used in this study failed to alter the expression of GLT-1 in midbrain and cerebellar glia, although expression levels of both corticosteroid receptor subtypes were similar in all brain regions analyzed. Dexamethasone, however, modestly enhanced GLT-1 expression in cerebellar glia in combination with the DNA methyltransferase inhibitor 5-aza-2-deoxycytidine, suggesting that suppression of GLT-1 expression in cerebellar cultures may at least in part be epigenetically mediated by a DNA methylation-dependent process. Taken together, our data highlight a potential role for glucocorticoids in regulating GLT-1 gene expression during central nervous system development or pathophysiogical processes including stress.	Johannes Gutenberg Univ Mainz, Sch Med, Inst Physiol Chem & Pathobiochem, Dept Pathobiochem, D-55099 Mainz, Germany; Univ Leipzig, Inst Anat, D-04103 Leipzig, Germany	Johannes Gutenberg University of Mainz; Leipzig University	Behl, C (corresponding author), Johannes Gutenberg Univ Mainz, Sch Med, Inst Physiol Chem & Pathobiochem, Dept Pathobiochem, D-55099 Mainz, Germany.	cbehl@uni-mainz.de	Zschocke, Johannes/C-5885-2013; Figiel, Maciej/W-6152-2018	Zschocke, Johannes/0000-0002-0046-8274; Behl, Christian/0000-0001-8453-2378; Figiel, Maciej/0000-0003-3961-4635				AHIMA R, 1991, J COMP NEUROL, V313, P522, DOI 10.1002/cne.903130312; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; Butchbach MER, 2004, J BIOL CHEM, V279, P34388, DOI 10.1074/jbc.M403938200; CAMPEN TJ, 1982, CLIN EXP HYPERTENS A, V4, P1627, DOI 10.3109/10641968209061629; CHOU YC, 1991, DEV BRAIN RES, V61, P55, DOI 10.1016/0165-3806(91)90113-W; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; COUETTE B, 1992, ENDOCRINOLOGY, V130, P430, DOI 10.1210/en.130.1.430; Crossin KL, 1997, P NATL ACAD SCI USA, V94, P2687, DOI 10.1073/pnas.94.6.2687; De Kloet ER, 1998, ENDOCR REV, V19, P269, DOI 10.1210/er.19.3.269; De Nicola AF, 1998, J STEROID BIOCHEM, V65, P253, DOI 10.1016/S0960-0760(97)00190-8; Dinkel K, 2002, J NEUROVIROL, V8, P513, DOI 10.1080/13550280290100914; EVANS RM, 1989, NEURON, V2, P1105, DOI 10.1016/0896-6273(89)90177-3; Figiel M, 2000, J NEUROSCI, V20, P3596, DOI 10.1523/JNEUROSCI.20-10-03596.2000; Figiel M, 2003, EXP NEUROL, V183, P124, DOI 10.1016/S0014-4886(03)00134-1; Franke B, 1998, HISTOCHEM CELL BIOL, V110, P595, DOI 10.1007/s004180050322; Furuta A, 1997, J NEUROSCI, V17, P8363; Galbiati F, 2000, J BIOL CHEM, V275, P23368, DOI 10.1074/jbc.M002020200; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gegelashvili G, 1997, MOL PHARMACOL, V52, P6, DOI 10.1124/mol.52.1.6; Gegelashvili G, 2001, Prog Brain Res, V132, P267; GOTTSCHALL PE, 1991, AM J PHYSIOL, V261, pE362, DOI 10.1152/ajpendo.1991.261.3.E362; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; Holsboer F, 1996, ENDOCR REV, V17, P187, DOI 10.1210/er.17.2.187; JUNGTESTAS I, 1984, J STEROID BIOCHEM, V20, P301, DOI 10.1016/0022-4731(84)90221-8; Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092-8674(00)81177-0; Kim DH, 2003, J BIOCHEM MOL BIOL, V36, P110; KNISS DA, 1985, EXP CELL RES, V161, P29, DOI 10.1016/0014-4827(85)90487-2; KUMAR S, 1989, P NATL ACAD SCI USA, V86, P6807, DOI 10.1073/pnas.86.17.6807; LAPING NJ, 1994, ENDOCRINOLOGY, V135, P1928, DOI 10.1210/en.135.5.1928; Levy LM, 1998, J NEUROSCI, V18, P9620, DOI 10.1523/jneurosci.18-23-09620.1998; Liang Z, 2002, J NEUROCHEM, V80, P807, DOI 10.1046/j.0022-3042.2002.00779.x; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mograbi B, 2003, CARCINOGENESIS, V24, P1415, DOI 10.1093/carcin/bgg093; MOSCONA AA, 1975, J STEROID BIOCHEM, V6, P633, DOI 10.1016/0022-4731(75)90044-8; Niu HR, 1997, MOL BRAIN RES, V51, P97, DOI 10.1016/S0169-328X(97)00221-0; OCALLAGHAN JP, 1991, J NEUROCHEM, V57, P860, DOI 10.1111/j.1471-4159.1991.tb08230.x; PAYVAR F, 1982, J CELL BIOCHEM, V19, P241, DOI 10.1002/jcb.240190305; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; PU HF, 1990, GENE, V89, P259, DOI 10.1016/0378-1119(90)90014-I; Reagan LP, 2004, P NATL ACAD SCI USA, V101, P2179, DOI 10.1073/pnas.0307294101; Reul JMHM, 2000, EUR J PHARMACOL, V405, P235, DOI 10.1016/S0014-2999(00)00677-4; REUL JMHM, 1985, ENDOCRINOLOGY, V117, P2505, DOI 10.1210/endo-117-6-2505; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Rozyczka J, 2005, MOL BRAIN RES, V133, P157, DOI 10.1016/j.molbrainres.2004.09.021; Sasaki S, 2000, ACTA NEUROPATHOL, V100, P138, DOI 10.1007/s004019900159; Schlag BD, 1998, MOL PHARMACOL, V53, P355, DOI 10.1124/mol.53.3.355; Schluter K, 2002, EUR J NEUROSCI, V16, P836, DOI 10.1046/j.1460-9568.2002.02130.x; Simard M, 1999, GLIA, V28, P1, DOI 10.1002/(SICI)1098-1136(199910)28:1<1::AID-GLIA1>3.0.CO;2-4; Sims KD, 1999, CRIT REV NEUROBIOL, V13, P169, DOI 10.1615/CritRevNeurobiol.v13.i2.30; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; Takizawa T, 2001, DEV CELL, V1, P749, DOI 10.1016/S1534-5807(01)00101-0; TRAPP T, 1994, NEURON, V13, P1457, DOI 10.1016/0896-6273(94)90431-6; Vardimon L, 1999, J NEUROBIOL, V40, P513, DOI 10.1002/(SICI)1097-4695(19990915)40:4<513::AID-NEU8>3.0.CO;2-D; VARDIMON L, 1986, P NATL ACAD SCI USA, V83, P9060, DOI 10.1073/pnas.83.23.9060; VIELKIND U, 1990, J NEUROSCI RES, V27, P360, DOI 10.1002/jnr.490270315; Zelenaia O, 2000, MOL PHARMACOL, V57, P667, DOI 10.1124/mol.57.4.667; ZHANG HY, 1991, J BIOL CHEM, V266, P24332; Zhu BG, 1998, BIOCHEM BIOPH RES CO, V247, P261, DOI 10.1006/bbrc.1998.8772; Zschocke J, 2005, GLIA, V49, P275, DOI 10.1002/glia.20116	62	103	106	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34924	34932		10.1074/jbc.M502581200	http://dx.doi.org/10.1074/jbc.M502581200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16079146	hybrid			2022-12-27	WOS:000232403900065
J	Bandhuvula, P; Tam, YY; Oskouian, B; Saba, JD				Bandhuvula, P; Tam, YY; Oskouian, B; Saba, JD			The immune modulator FTY720 inhibits sphingosine-1-phosphate lyase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOSINE 1-PHOSPHATE RECEPTOR; LYMPH-NODES; T-CELLS; EXPRESSION; PHOSPHORYLATION; IMMUNOMODULATOR; TRANSPLANTATION; TRAFFICKING; IMPAIRS; S1P(1)	FTY720 is a novel immunomodulatory agent that inhibits lymphocyte trafficking and prevents allograft rejection. FTY720 is phosphorylated in vivo, and the phosphorylated drug acts as agonist for a family of G protein- coupled receptors that recognize sphingosine 1- phosphate. Evidence suggests that FTY720- phosphate- induced activation of S1P(1) is responsible for its mechanism of action. FTY720 was rationally designed by modification of myriocin, a naturally occurring sphingoid base analog that causes immunosuppression by interrupting sphingolipid metabolism. In this study, we examined interactions between FTY720, FTY720- phosphate, and sphingosine- 1- phosphate lyase, the enzyme responsible for irreversible sphingosine 1- phosphate degradation. FTY720- phosphate was stable in the presence of active sphingosine1- phosphate lyase, demonstrating that the lyase does not contribute to FTY720 catabolism. Conversely, FTY720 inhibited sphingosine- 1- phosphate lyase activity in vitro. Treatment of mice with FTY720 inhibited tissue sphingosine1- phosphate lyase activity within 12 h, whereas lyase gene and protein expression were not significantly affected. Tissue sphingosine 1- phosphate levels remained stable or increased throughout treatment. These studies raise the possibility that disruption of sphingosine 1- phosphate metabolism may account for some effects of FTY720 on immune function and that sphingosine1- phosphate lyase may be a potential target for immunomodulatory therapy.	Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Saba, JD (corresponding author), Childrens Hosp Oakland, Res Inst, 5700 Martin Luther Jr Way, Oakland, CA 94609 USA.	jsaba@chori.org			NATIONAL CANCER INSTITUTE [R01CA077528] Funding Source: NIH RePORTER; NCI NIH HHS [CA77528] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allende ML, 2004, J BIOL CHEM, V279, P15396, DOI 10.1074/jbc.M314291200; Billich A, 2003, J BIOL CHEM, V278, P47408, DOI 10.1074/jbc.M307687200; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Brinkmann V, 2004, YONSEI MED J, V45, P991, DOI 10.3349/ymj.2004.45.6.991; Brinkmann V, 2002, CURR OPIN IMMUNOL, V14, P569, DOI 10.1016/S0952-7915(02)00374-6; Budde K, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341073; Caligan TB, 2000, ANAL BIOCHEM, V281, P36, DOI 10.1006/abio.2000.4555; CAMPBELL RA, 1991, LIFE SCI, V48, P225, DOI 10.1016/0024-3205(91)90349-G; Chiba K, 1998, J IMMUNOL, V160, P5037; FUJITA T, 1994, J ANTIBIOT, V47, P208, DOI 10.7164/antibiotics.47.208; Fyrst H, 2004, J LIPID RES, V45, P54, DOI 10.1194/jlr.M300005-JLR200; Graler MH, 2004, FASEB J, V18, P551, DOI 10.1096/fj.03-0910fje; Halin C, 2005, BLOOD, V106, P1314, DOI 10.1182/blood-2004-09-3687; Herr DR, 2003, DEVELOPMENT, V130, P2443, DOI 10.1242/dev.00456; Honig SM, 2003, J CLIN INVEST, V111, P627, DOI 10.1172/JCI200316200; Jiang Q, 2004, P NATL ACAD SCI USA, V101, P17825, DOI 10.1073/pnas.0408340102; Kimura T, 2004, BLOOD, V103, P4478, DOI 10.1182/blood-2003-03-0875; Li GC, 2001, DEVELOPMENT, V128, P3473; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; Mendel J, 2003, J BIOL CHEM, V278, P22341, DOI 10.1074/jbc.M302857200; Oskouian B, 2005, J BIOL CHEM, V280, P18403, DOI 10.1074/jbc.M410928200; Pinschewer DD, 2000, J IMMUNOL, V164, P5761, DOI 10.4049/jimmunol.164.11.5761; Reiss U, 2004, J BIOL CHEM, V279, P1281, DOI 10.1074/jbc.M309646200; Sanchez T, 2003, J BIOL CHEM, V278, P47281, DOI 10.1074/jbc.M306896200; SCOUNTZOU J, 1989, IMMUNOPHARM IMMUNOT, V11, P657, DOI 10.3109/08923978909005393; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; VANVELDHOVEN PP, 1991, J BIOL CHEM, V266, P12502; VORA K, 2005, J LEUKOCYTE BIOL, V78, P1; Xie JH, 2003, J IMMUNOL, V170, P3662, DOI 10.4049/jimmunol.170.7.3662	30	120	125	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33697	33700		10.1074/jbc.C500294200	http://dx.doi.org/10.1074/jbc.C500294200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16118221	hybrid			2022-12-27	WOS:000232229700003
J	Huang, YX; Smith, CA; Song, HB; Morgan, BP; Abagyan, R; Tomlinson, S				Huang, YX; Smith, CA; Song, HB; Morgan, BP; Abagyan, R; Tomlinson, S			Insights into the human CD59 complement binding interface toward engineering new therapeutics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY PROTEIN CD59; SPECIES SELECTIVE ACTIVITY; CELL-SURFACE; VASCULAR COMPLICATIONS; CANCER-IMMUNOTHERAPY; ACTIVE-SITE; 2ND LIGAND; EXPRESSION; INHIBITORS; IDENTIFICATION	CD59 is a 77-amino acid membrane glycoprotein that plays an important role in regulating the terminal pathway of complement by inhibiting formation of the cytolytic membrane attack complex ( MAC or C5b-9). The MAC is formed by the self assembly of C5b, C6, C7, C8, and multiple C9 molecules, with CD59 functioning by binding C5b-8 and C5b-9 in the assembling complex. We performed a scanning alanine mutagenesis screen of residues 16 - 57, a region previously identified to contain the C8/C9 binding interface. We have also created an improved NMR model from previously published data for structural understanding of CD59. Based on the scanning mutagenesis data, refined models, and additional site-specific mutations, we identified a binding interface that is much broader than previously thought. In addition to identifying substitutions that decreased CD59 activity, a surprising number of substitutions significantly enhanced CD59 activity. Because CD59 has significant therapeutic potential for the treatment of various inflammatory conditions, we investigated further the ability to enhance CD59 activity by additional mutagenesis studies. Based on the enhanced activity of membrane-bound mutant CD59 molecules, clinically relevant soluble mutant CD59-based proteins were prepared and shown to have up to a 3-fold increase in complement inhibitory activity.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29403 USA; Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Cardiff CF14 4XN, S Glam, Wales	Scripps Research Institute; Medical University of South Carolina; Cardiff University	Tomlinson, S (corresponding author), Scripps Res Inst, Dept Mol Biol, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.	tomlinss@musc.edu	Song, Hongbin/C-1963-2013; Smith, Colin A/E-5713-2012	Smith, Colin A/0000-0002-4651-167X; Morgan, Paul/0000-0003-4075-7676	NIAID NIH HHS [AI 47386, AI 34451] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047386, R01AI034451, R29AI034451] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABAGYAN R, 1994, J MOL BIOL, V235, P983, DOI 10.1006/jmbi.1994.1052; Acosta J, 2000, P NATL ACAD SCI USA, V97, P5450, DOI 10.1073/pnas.97.10.5450; AKAMI T, 1994, TRANSPL P, V26, P1256; AN J, 2005, IN PRESS MOL CELL PR; Arumugam TV, 2004, SHOCK, V21, P401, DOI 10.1097/00024382-200405000-00002; Bodian DL, 1997, J EXP MED, V185, P507, DOI 10.1084/jem.185.3.507; Chen SH, 2000, CANCER RES, V60, P3013; Davies CS, 2005, IMMUNOLOGY, V114, P280, DOI 10.1111/j.1365-2567.2004.02086.x; DECKERT M, 1992, EUR J IMMUNOL, V22, P2943, DOI 10.1002/eji.1830221128; Fernandez-Recio J, 2005, PROTEINS, V58, P134, DOI 10.1002/prot.20285; Fishelson Z, 2003, MOL IMMUNOL, V40, P109, DOI 10.1016/S0161-5890(03)00112-3; FLETCHER CM, 1994, STRUCTURE, V2, P185, DOI 10.1016/S0969-2126(00)00020-4; FLETCHER CM, 1993, PROTEIN SCI, V2, P2015, DOI 10.1002/pro.5560021203; Gelderman KA, 2004, TRENDS IMMUNOL, V25, P158, DOI 10.1016/j.it.2004.01.008; Ghiran I, 2003, J BIOL CHEM, V278, P21024, DOI 10.1074/jbc.M302306200; Giddings KS, 2004, NAT STRUCT MOL BIOL, V11, P1173, DOI 10.1038/nsmb862; HAHN WC, 1992, SCIENCE, V256, P1805, DOI 10.1126/science.1377404; HARLOW E, 1988, ANTIBODIES LAB MANUA, P92; Hinchliffe SJ, 2000, BIOCHEMISTRY-US, V39, P5831, DOI 10.1021/bi9929608; HUESLER T, 1995, J BIOL CHEM, V270, P3483, DOI 10.1074/JBC.270.8.3483; KIEFFER B, 1994, BIOCHEMISTRY-US, V33, P4471, DOI 10.1021/bi00181a006; LAMBRIS JD, 2000, THERAPEUTIC INTERVEN; LOCKERT DH, 1995, J BIOL CHEM, V270, P19723, DOI 10.1074/jbc.270.34.19723; Marcenaro E, 2003, EUR J IMMUNOL, V33, P3367, DOI 10.1002/eji.200324425; Morgan BP, 2003, MOL IMMUNOL, V40, P159, DOI 10.1016/S0161-5890(03)00111-1; Murray KP, 2000, GYNECOL ONCOL, V76, P176, DOI 10.1006/gyno.1999.5614; NEMETHY G, 1992, J PHYS CHEM-US, V96, P6472, DOI 10.1021/j100194a068; Petranka J, 1996, BLOOD CELL MOL DIS, V22, P281, DOI 10.1006/bcmd.1996.0111; Qin XB, 2004, DIABETES, V53, P2653, DOI 10.2337/diabetes.53.10.2653; Quigg RJ, 2002, TRENDS MOL MED, V8, P430, DOI 10.1016/S1471-4914(02)02386-9; Sahu A, 2000, IMMUNOPHARMACOLOGY, V49, P133, DOI 10.1016/S0162-3109(00)80299-4; SHAPIRO A, 1984, CANCER RES, V44, P3051; Song HB, 2003, J CLIN INVEST, V111, P1875, DOI 10.1172/JCI200317348; Thorsteinsson L, 1998, APMIS, V106, P869, DOI 10.1111/j.1699-0463.1998.tb00233.x; Totrov M, 2004, J COMPUT CHEM, V25, P609, DOI 10.1002/jcc.10392; Xu CL, 2005, PROSTATE, V62, P224, DOI 10.1002/pros.20134; Yu JH, 1997, BIOCHEMISTRY-US, V36, P9423, DOI 10.1021/bi970832i; Yu JH, 1997, J EXP MED, V185, P745, DOI 10.1084/jem.185.4.745; Zhang HF, 1999, J BIOL CHEM, V274, P10969, DOI 10.1074/jbc.274.16.10969; Zhang HF, 1999, J CLIN INVEST, V103, P55, DOI 10.1172/JCI4607; Zhao XJ, 1998, J BIOL CHEM, V273, P10665, DOI 10.1074/jbc.273.17.10665	41	34	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34073	34079		10.1074/jbc.M504922200	http://dx.doi.org/10.1074/jbc.M504922200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16079145	hybrid			2022-12-27	WOS:000232229700047
J	Peng, DQ; Wu, ZP; Brubaker, G; Zheng, LM; Settle, M; Gross, E; Kinter, M; Hazen, SL; Smith, JD				Peng, DQ; Wu, ZP; Brubaker, G; Zheng, LM; Settle, M; Gross, E; Kinter, M; Hazen, SL; Smith, JD			Tyrosine modification is not required for myeloperoxidase-induced loss of apolipoprotein A-I functional activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; HUMAN NEUTROPHILS EMPLOY; CASSETTE TRANSPORTER 1; CHOLESTEROL EFFLUX; HYPOCHLOROUS ACID; CARDIOVASCULAR-DISEASE; LIPID-PEROXIDATION; LYSINE RESIDUES; TANGIER-DISEASE; AMINO-ACIDS	Apolipoprotein A-I ( apoAI), the major protein of high density lipoprotein, plays an important role in reverse cholesterol transport via its activity as an ABCA1-dependent acceptor of cellular cholesterol. We reported recently that myeloperoxidase (MPO) modification of apoAI inhibits its ABCA1-dependent cholesterol acceptor activity (Zheng, L., Nukuna, B., Brennan, M. L., Sun, M., Goormastic, M., Settle, M., Schmitt, D., Fu, X., Thomson, L., Fox, P. L., Ischiropoulos, H., Smith, J. D., Kinter, M., and Hazen, S. L. ( 2004) J. Clin. Invest. 114, 529 - 541). We also reported that MPO-mediated chlorination preferentially modifies two of the seven tyrosines in apoAI, and loss of parent peptides containing these residues dose-dependently correlates with loss in ABCA1-mediated cholesterol acceptor activity ( Zheng, L., Settle, M., Brubaker, G., Schmitt, D., Hazen, S. L., Smith, J. D., and Kinter, M. ( 2005) J. Biol. Chem. 280, 38 - 47). To determine whether oxidative modification of apoA-I tyrosine residues was responsible for the MPO-mediated inactivation of cholesterol acceptor activity, we made recombinant apoAI with site-specific substitutions of all seven tyrosine residues to phenylalanine. ApoAI and the tyrosine-free apoAI were equally susceptible to dose-dependent MPO-mediated loss of ABCA1-dependent cholesterol acceptor activity, as well as lipid binding activity. MPO modification altered the migration of apoAI on SDS gels and decreased its alpha-helix content. MPO-induced modification also targeted apoAI tryptophan and lysine residues. Specifically, we detected apoAI tryptophan oxidation to mono- and dihydroxytryptophan and apoAI lysine modification to chlorolysine and 2-aminoadipic acid. Thus, tyrosine modification of apoAI is not required for its MPO-mediated inhibition of cholesterol acceptor activity.	Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Ctr Cardiovasc Diagnost & Prevent, Cleveland, OH 44195 USA; Cleveland State Univ, Dept Chem, Cleveland, OH 44114 USA; Case Western Reserve Univ, Dept Mol Med, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University System of Ohio; Cleveland State University; Case Western Reserve University	Smith, JD (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, NC10,9500 Euclid Ave, Cleveland, OH 44195 USA.	smithj4@ccf.org	Hazen, Stanley L/ABD-5845-2021; Smith, Jonathan D./H-9723-2013	Kinter, Michael/0000-0001-7409-8918; Smith, Jonathan D./0000-0002-0415-386X	NCRR NIH HHS [RR15794, RR16794] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR016794, S10RR015794] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Agree AKB, 2002, BBA-PROTEIN STRUCT M, V1594, P286, DOI 10.1016/S0167-4838(01)00317-X; Anderson MM, 1999, J CLIN INVEST, V104, P103, DOI 10.1172/JCI3042; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Ansell BJ, 2003, CIRCULATION, V108, P2751, DOI 10.1161/01.CIR.0000103624.14436.4B; Bergt C, 1999, FEBS LETT, V452, P295, DOI 10.1016/S0014-5793(99)00677-8; Bergt C, 2004, P NATL ACAD SCI USA, V101, P13032, DOI 10.1073/pnas.0405292101; Bergt C, 2004, J BIOL CHEM, V279, P7856, DOI 10.1074/jbc.M309046200; Bergt C, 2001, EUR J BIOCHEM, V268, P3523, DOI 10.1046/j.1432-1327.2001.02253.x; Bergt C, 2000, BIOCHEM J, V346, P345, DOI 10.1042/0264-6021:3460345; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Brennan M, 2003, NEW ENGL J MED, V349, P1595, DOI 10.1056/NEJMoa035003; Brennan ML, 2002, J BIOL CHEM, V277, P17415, DOI 10.1074/jbc.M112400200; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brouillette CG, 2001, BBA-MOL CELL BIOL L, V1531, P4, DOI 10.1016/S1388-1981(01)00081-6; Carr AC, 2001, FREE RADICAL BIO MED, V30, P526, DOI 10.1016/S0891-5849(00)00495-0; Castellani LW, 1997, J CLIN INVEST, V100, P464, DOI 10.1172/JCI119554; Chen W, 2001, J BIOL CHEM, V276, P43564, DOI 10.1074/jbc.M107938200; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Chisolm GM, 2000, FREE RADICAL BIO MED, V28, P1815, DOI 10.1016/S0891-5849(00)00344-0; Cogny A, 1996, BIOCHEM J, V314, P285, DOI 10.1042/bj3140285; COGNY A, 1994, EUR J BIOCHEM, V222, P965, DOI 10.1111/j.1432-1033.1994.tb18947.x; DROZDZ R, 1988, BIOCHIM BIOPHYS ACTA, V957, P47, DOI 10.1016/0167-4838(88)90155-0; Ducret A, 1998, PROTEIN SCI, V7, P706, DOI 10.1002/pro.5560070320; Firuzi O, 2003, J PHARM PHARMACOL, V55, P1021, DOI 10.1211/0022357021314; Garner B, 1998, J BIOL CHEM, V273, P6088, DOI 10.1074/jbc.273.11.6088; Gaut JP, 2002, J CLIN INVEST, V109, P1311, DOI 10.1172/JCI200215021; GOODNO CC, 1981, ANAL BIOCHEM, V115, P203, DOI 10.1016/0003-2697(81)90547-9; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; Guidetti P, 2003, MOL BRAIN RES, V118, P132, DOI 10.1016/j.molbrainres.2003.08.004; Hawkins CL, 1998, BIOCHEM J, V332, P617, DOI 10.1042/bj3320617; Hawkins CL, 2003, AMINO ACIDS, V25, P259, DOI 10.1007/s00726-003-0016-x; Hazell LJ, 1999, BIOCHEM J, V339, P489, DOI 10.1042/0264-6021:3390489; HAZELL LJ, 1994, BIOCHEM J, V302, P297, DOI 10.1042/bj3020297; Hazen SL, 1999, CIRC RES, V85, P950; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; Jerlich A, 2000, EUR J BIOCHEM, V267, P4137, DOI 10.1046/j.1432-1327.2000.01449.x; Kojima K, 2001, BBA-MOL CELL BIOL L, V1532, P173, DOI 10.1016/S1388-1981(01)00124-X; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Marsche G, 2002, J BIOL CHEM, V277, P32172, DOI 10.1074/jbc.M200503200; McCall MR, 2001, ARTERIOSCL THROM VAS, V21, P1040, DOI 10.1161/01.ATV.21.6.1040; NAGANO Y, 1991, P NATL ACAD SCI USA, V88, P6457, DOI 10.1073/pnas.88.15.6457; Nightingale ZD, 2000, FREE RADICAL BIO MED, V29, P425, DOI 10.1016/S0891-5849(00)00262-8; Panzenbock U, 2000, J BIOL CHEM, V275, P19536, DOI 10.1074/jbc.M000458200; Panzenboeck U, 1997, J BIOL CHEM, V272, P29711, DOI 10.1074/jbc.272.47.29711; Pennathur S, 2004, J BIOL CHEM, V279, P42977, DOI 10.1074/jbc.M406762200; Peskin AV, 2001, FREE RADICAL BIO MED, V30, P572, DOI 10.1016/S0891-5849(00)00506-2; Requena JR, 2001, P NATL ACAD SCI USA, V98, P69, DOI 10.1073/pnas.011526698; Roberts LM, 1997, BIOCHEMISTRY-US, V36, P7615, DOI 10.1021/bi962952g; Rogers DP, 1998, BIOCHEMISTRY-US, V37, P945, DOI 10.1021/bi9713512; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Ryan RO, 2003, PROTEIN EXPRES PURIF, V27, P98, DOI 10.1016/S1046-5928(02)00568-5; Saito H, 2004, J BIOL CHEM, V279, P20974, DOI 10.1074/jbc.M402043200; Saito H, 2003, J BIOL CHEM, V278, P23227, DOI 10.1074/jbc.M303365200; SALMON S, 1992, BIOCHIM BIOPHYS ACTA, V1125, P230, DOI 10.1016/0005-2760(92)90050-6; Shao BH, 2005, J BIOL CHEM, V280, P5983, DOI 10.1074/jbc.M411484200; Shishehbor MH, 2003, JAMA-J AM MED ASSOC, V289, P1675, DOI 10.1001/jama.289.13.1675; Silva RAGD, 2005, BIOCHEMISTRY-US, V44, P8600, DOI 10.1021/bi050421z; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; Smith JD, 2004, J LIPID RES, V45, P635, DOI 10.1194/jlr.M300336-JLR200; Takahashi Y, 2000, BBA-GENE STRUCT EXPR, V1492, P385, DOI 10.1016/S0167-4781(00)00133-0; Van Lenten BJ, 2001, CIRCULATION, V103, P2283; VanLenten BJ, 1995, J CLIN INVEST, V96, P2758, DOI 10.1172/JCI118345; VISSERS MCM, 1991, ARCH BIOCHEM BIOPHYS, V285, P53, DOI 10.1016/0003-9861(91)90327-F; WINTERBOURN CC, 1985, BIOCHIM BIOPHYS ACTA, V840, P204, DOI 10.1016/0304-4165(85)90120-5; Yancey PG, 2003, ARTERIOSCL THROM VAS, V23, P712, DOI 10.1161/01.ATV.0000057572.97137.DD; Zhang RL, 2002, J BIOL CHEM, V277, P46116, DOI 10.1074/jbc.M209124200; Zhang YZ, 2003, CIRCULATION, V108, P661, DOI 10.1161/01.CIR.0000086981.09834.E0; Zhang ZL, 2001, JAMA-J AM MED ASSOC, V286, P2136, DOI 10.1001/jama.286.17.2136; Zheng L, 2005, J BIOL CHEM, V280, P38, DOI 10.1074/jbc.M407019200; Zheng LM, 2004, J CLIN INVEST, V114, P529, DOI 10.1172/JCI200421109; Zheng P, 2001, BBA-MOL CELL BIOL L, V1534, P121, DOI 10.1016/S1388-1981(01)00183-4	72	68	79	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33775	33784		10.1074/jbc.M504092200	http://dx.doi.org/10.1074/jbc.M504092200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16091367	hybrid			2022-12-27	WOS:000232229700013
J	Petrosky, KY; Ou, HD; Lohr, F; Dotsch, V; Lim, WA				Petrosky, KY; Ou, HD; Lohr, F; Dotsch, V; Lim, WA			A general model for preferential hetero-oligomerization of LIN-2/7 domains - Mechanism underlying directed assembly of supramolecular signaling complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL POLARITY COMPLEXES; L27 DOMAIN; DISCS-LARGE; DROSOPHILA STARDUST; EPITHELIAL-CELLS; PROTEIN COMPLEX; TIGHT JUNCTION; PDZ DOMAINS; T-CELLS; NMR	LIN-2/7 (L27) domains are protein interaction modules that preferentially hetero-oligomerize, a property critical for their function in directing specific assembly of supramolecular signaling complexes at synapses and other polarized cell-cell junctions. We have solved the solution structure of the heterodimer composed of the L27 domains from LIN-2 and LIN-7. Comparison of this structure with other L27 domain structures has allowed us to formulate a general model for why most L27 domains form an obligate heterodimer complex. L27 domains can be divided in two types ( A and B), with each heterodimer comprising an A/B pair. We have identified two keystone positions that play a central role in discrimination. The residues at these positions are energetically acceptable in the context of an A/B heterodimer, but would lead to packing defects or electrostatic repulsion in the context of A/A and B/B homodimers. As predicted by the model, mutations of keystone residues stabilize normally strongly disfavored homodimers. Thus, L27 domains are specifically optimized to avoid homodimeric interactions.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Biophys Grad Program, San Francisco, CA 94143 USA; Univ Frankfurt, Inst Biophys Chem, D-60439 Frankfurt, Germany	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Goethe University Frankfurt	Lim, WA (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, 600 16th St, San Francisco, CA 94143 USA.	wlim@itsa.ucsf.edu	Doetsch, Volker/D-5697-2011	Dotsch, Volker/0000-0001-5720-212X				Bachmann A, 2004, J CELL SCI, V117, P1899, DOI 10.1242/jcs.01029; Bachmann A, 2001, NATURE, V414, P638, DOI 10.1038/414638a; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DeLano W.L, PYMOL MOL GRAPHICS S; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Doerks T, 2000, TRENDS BIOCHEM SCI, V25, P317, DOI 10.1016/S0968-0004(00)01599-1; Feng W, 2005, P NATL ACAD SCI USA, V102, P6861, DOI 10.1073/pnas.0409346102; Feng W, 2004, NAT STRUCT MOL BIOL, V11, P475, DOI 10.1038/nsmb751; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Harris BZ, 2002, J BIOL CHEM, V277, P34902, DOI 10.1074/jbc.M205856200; Harris BZ, 2001, J CELL SCI, V114, P3219; Havranek JJ, 2003, NAT STRUCT BIOL, V10, P45, DOI 10.1038/nsb877; Hong Y, 2001, NATURE, V414, P634, DOI 10.1038/414634a; Jo K, 1999, J NEUROSCI, V19, P4189, DOI 10.1523/jneurosci.19-11-04189.1999; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Kamberov E, 2000, J BIOL CHEM, V275, P11425, DOI 10.1074/jbc.275.15.11425; Karnak D, 2002, J BIOL CHEM, V277, P46730, DOI 10.1074/jbc.M208781200; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kortemme T, 2004, NAT STRUCT MOL BIOL, V11, P371, DOI 10.1038/nsmb749; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lee S, 2002, MOL CELL BIOL, V22, P1778, DOI 10.1128/MCB.22.6.1778-1791.2002; Leonoudakis D, 2004, J BIOL CHEM, V279, P19051, DOI 10.1074/jbc.M400284200; Li YH, 2004, EMBO J, V23, P2723, DOI 10.1038/sj.emboj.7600294; Marfatia SM, 2000, J BIOL CHEM, V275, P13759, DOI 10.1074/jbc.275.18.13759; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Nakagawa T, 2004, NEURON, V44, P453, DOI 10.1016/j.neuron.2004.10.012; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; Park SH, 2003, SCIENCE, V299, P1061, DOI 10.1126/science.1076979; Ralston KJ, 2004, J BIOL CHEM, V279, P33816, DOI 10.1074/jbc.M401040200; Roh MH, 2002, J CELL BIOL, V157, P161, DOI 10.1083/jcb.200109010; Rongo C, 2001, CYTOKINE GROWTH F R, V12, P349, DOI 10.1016/S1359-6101(01)00011-9; Round JL, 2005, J EXP MED, V201, P419, DOI 10.1084/jem.20041428; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; Salzmann M, 1999, J AM CHEM SOC, V121, P844, DOI 10.1021/ja9834226; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Sheinerman FB, 2000, CURR OPIN STRUC BIOL, V10, P153, DOI 10.1016/S0959-440X(00)00065-8; Shin K, 2005, J CELL BIOL, V168, P705, DOI 10.1083/jcb.200408064; Straight SW, 2004, MOL BIOL CELL, V15, P1981, DOI 10.1091/mbc.E03-08-0620; Thomas U, 1997, NEURON, V19, P787, DOI 10.1016/S0896-6273(00)80961-7; Zarrinpar A, 2003, NATURE, V426, P676, DOI 10.1038/nature02178	46	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38528	38536		10.1074/jbc.M506536200	http://dx.doi.org/10.1074/jbc.M506536200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16147993	hybrid			2022-12-27	WOS:000233239800051
J	Post, DMB; Zhang, DS; Eastvold, JS; Teghanemt, A; Gibson, BW; Weiss, JP				Post, DMB; Zhang, DS; Eastvold, JS; Teghanemt, A; Gibson, BW; Weiss, JP			Biochemical and functional characterization of membrane blebs purified from Neisseria meningitidis serogroup B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPOLYSACCHARIDE-BINDING PROTEIN; GRAM-NEGATIVE BACTERIA; OUTER-MEMBRANE; ESCHERICHIA-COLI; CELL ACTIVATION; MENINGOCOCCAL ENDOTOXIN; SALMONELLA-TYPHIMURIUM; (LPS)-BINDING PROTEIN; COMPLEMENT ACTIVATION; MASS-SPECTROMETRY	Studies with purified aggregates of endotoxin have revealed the importance of lipopolysaccharide-binding protein (LBP)-dependent extraction and transfer of individual endotoxin molecules to CD14 in Toll-like receptor 4 (TLR4)-dependent cell activation. Endotoxin is normally embedded in the outer membrane of intact Gram-negative bacteria and shed membrane vesicles ("blebs"). However, the ability of LBP and CD14 to efficiently promote TLR4-dependent cell activation by membrane-associated endotoxin has not been studied extensively. In this study, we used an acetate auxotroph of Neisseria meningitidis serogroup B to facilitate metabolic labeling of bacterial endotoxin and compared interactions of purified endotoxin aggregates and of membrane-associated endotoxin with LBP, CD14, and endotoxin-responsive cells. The endotoxin, phospholipid, and protein composition of the recovered blebs indicate that the blebs derive from the bacterial outer membrane. Proteomic analysis revealed an unusual enrichment in highly cationic (pI > 9) proteins. Both purified endotoxin aggregates and blebs activate monocytes and endothelial cells in a LBP-, CD14-, and TLR4/MD-2-dependent fashion, but the blebs were 3 - 10-fold less potent when normalized for the amount of endotoxin added. Differences in potency correlated with differences in efficiency of LBP-dependent delivery to and extraction of endotoxin by CD14. Both membrane phospholipids and endotoxin are extracted by LBP/soluble CD14 (sCD14) treatment, but only endotoxin center dot sCD14 reacts with MD- 2 and activates cells. These findings indicate that the proinflammatory potency of endotoxin may be regulated not only by the intrinsic structural properties of endotoxin but also by its association with neighboring molecules in the outer membrane.	Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Internal Med, Inflammat Program, Iowa City, IA 52242 USA; Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Microbiol, Iowa City, IA 52242 USA; Vet Affairs Med Ctr, Iowa City, IA 52246 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Buck Inst Age Res, Novato, CA 94945 USA	University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of California System; University of California San Francisco; Buck Institute for Research on Aging	Weiss, JP (corresponding author), Univ Iowa, Inflammat Program, 2501 Crosspk Rd,D158 MTF, Coralville, IA 52241 USA.	jerrold-weiss@uiowa.edu		Weiss, Jerrold/0000-0003-1476-4485	NIAID NIH HHS [AI59372, AI18571] Funding Source: Medline; PHS HHS [P0144642] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018571, R01AI059372] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexander C, 2001, J ENDOTOXIN RES, V7, P167, DOI 10.1179/096805101101532675; Baik SC, 2004, J BACTERIOL, V186, P949, DOI 10.1128/JB.186.4.949-955.2004; Berg OG, 2001, CHEM REV, V101, P2613, DOI 10.1021/cr990139w; Beutler B, 2003, NAT REV IMMUNOL, V3, P169, DOI 10.1038/nri1004; Beutler B, 2004, MOL IMMUNOL, V40, P845, DOI 10.1016/j.molimm.2003.10.005; Beveridge TJ, 1999, J BACTERIOL, V181, P4725, DOI 10.1128/JB.181.16.4725-4733.1999; Bjerre A, 2002, J INFECT DIS, V185, P220, DOI 10.1086/338269; Bjerre A, 2000, J ENDOTOXIN RES, V6, P437, DOI 10.1179/096805100101532397; BOYUM A, 1968, SCAND J CLIN LAB S21, V97, P51; Brandtzaeg P, 2001, J ENDOTOXIN RES, V7, P401, DOI 10.1177/09680519010070060401; BRANDTZAEG P, 1992, J CLIN INVEST, V89, P816, DOI 10.1172/JCI115660; BRANDTZAEG P, 1989, J INFECT DIS, V159, P195, DOI 10.1093/infdis/159.2.195; de Cock H, 1999, J BIOL CHEM, V274, P5114, DOI 10.1074/jbc.274.8.5114; deCock H, 1996, EMBO J, V15, P5567, DOI 10.1002/j.1460-2075.1996.tb00941.x; Denning GM, 1998, INFECT IMMUN, V66, P5777, DOI 10.1128/IAI.66.12.5777-5784.1998; DEVOE IW, 1973, J EXP MED, V138, P1156, DOI 10.1084/jem.138.5.1156; GEGNER JA, 1995, J BIOL CHEM, V270, P5320, DOI 10.1074/jbc.270.10.5320; Giardina PC, 2001, J BIOL CHEM, V276, P5883, DOI 10.1074/jbc.M009273200; Gioannini TL, 2003, J ENDOTOXIN RES, V9, P401, DOI 10.1179/096805103225002773; Gioannini TL, 2002, J BIOL CHEM, V277, P47818, DOI 10.1074/jbc.M206404200; Gioannini TL, 2004, P NATL ACAD SCI USA, V101, P4186, DOI 10.1073/pnas.0306906101; Hirsch J, 2004, AM J PHYSIOL-LUNG C, V287, pL1, DOI 10.1152/ajplung.00301.2003; HOEKSTRA D, 1976, BIOCHIM BIOPHYS ACTA, V455, P889, DOI 10.1016/0005-2736(76)90058-4; HOLZENBURG A, 1989, BIOCHEMISTRY-US, V28, P4187, DOI 10.1021/bi00436a010; Iovine NM, 1997, P NATL ACAD SCI USA, V94, P10973, DOI 10.1073/pnas.94.20.10973; Juretic D, 2002, J CHEM INF COMP SCI, V42, P620, DOI 10.1021/ci010263s; Kadurugamuwa JL, 1997, J ANTIMICROB CHEMOTH, V40, P615, DOI 10.1093/jac/40.5.615; Kahler CM, 1998, CRIT REV MICROBIOL, V24, P281, DOI 10.1080/10408419891294216; Katz SS, 1996, INFECT IMMUN, V64, P3592, DOI 10.1128/IAI.64.9.3592-3600.1996; KNOX KW, 1966, J BACTERIOL, V92, P1206, DOI 10.1128/JB.92.4.1206-1217.1966; Koprivnjak T, 2002, J BIOL CHEM, V277, P47636, DOI 10.1074/jbc.M205104200; Kramer RA, 2002, EUR J BIOCHEM, V269, P1746, DOI 10.1046/j.1432-1327.2002.02820.x; Lamping N, 1998, J CLIN INVEST, V101, P2065, DOI 10.1172/JCI2338; Lamping N, 1996, J IMMUNOL, V157, P4648; Lorenzen DR, 2000, INFECT IMMUN, V68, P6215, DOI 10.1128/IAI.68.11.6215-6222.2000; Massari P, 2003, CELL MICROBIOL, V5, P99, DOI 10.1046/j.1462-5822.2003.00257.x; Massari P, 2002, J IMMUNOL, V168, P1533, DOI 10.4049/jimmunol.168.4.1533; MAYRAND D, 1989, CAN J MICROBIOL, V35, P607, DOI 10.1139/m89-097; Miller SI, 2003, CELL, V115, P2, DOI 10.1016/S0092-8674(03)00767-0; Mirlashari Mohammad Reza, 2003, Med Sci Monit, V9, pBR316; Miyake K, 2003, INT IMMUNOPHARMACOL, V3, P119, DOI 10.1016/S1567-5769(02)00258-8; Molloy MP, 2001, ELECTROPHORESIS, V22, P1686, DOI 10.1002/1522-2683(200105)22:9<1686::AID-ELPS1686>3.0.CO;2-L; Muller A, 2000, EMBO J, V19, P5332, DOI 10.1093/emboj/19.20.5332; MUNFORD RS, 1982, J CLIN INVEST, V70, P877, DOI 10.1172/JCI110684; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; NIKAIDO H, 1996, ESCHERICHIA COLI SAL, P29; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; PAUL S, 1992, J GEN MICROBIOL, V138, P755, DOI 10.1099/00221287-138-4-755; Rahman MM, 2000, MICROBIOL-UK, V146, P1901, DOI 10.1099/00221287-146-8-1901; RAHMAN MM, 1996, MICROBIOLOGY, P29; Schromm AB, 1996, FEBS LETT, V399, P267, DOI 10.1016/S0014-5793(96)01338-5; Schumann RR, 1997, J IMMUNOL, V159, P5599; Sprong T, 2004, INFECT IMMUN, V72, P3344, DOI 10.1128/IAI.72.6.3344-3349.2004; Thompson PA, 2003, J BIOL CHEM, V278, P28367, DOI 10.1074/jbc.M302921200; Ulevitch RJ, 1999, CURR OPIN IMMUNOL, V11, P19, DOI 10.1016/S0952-7915(99)80004-1; Vanlandschoot P, 2002, J GEN VIROL, V83, P2279, DOI 10.1099/0022-1317-83-9-2279; Vesy CJ, 2000, INFECT IMMUN, V68, P2410, DOI 10.1128/IAI.68.5.2410-2417.2000; Wai SN, 2003, CELL, V115, P25, DOI 10.1016/S0092-8674(03)00754-2; Weinrauch Y, 1999, INFECT IMMUN, V67, P3376, DOI 10.1128/IAI.67.7.3376-3382.1999; Weiss J, 2003, BIOCHEM SOC T, V31, P785, DOI 10.1042/BST0310785; Yu B, 1997, J CLIN INVEST, V99, P315, DOI 10.1172/JCI119160; Zweigner J, 2001, BLOOD, V98, P3800, DOI 10.1182/blood.V98.13.3800	62	98	104	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38383	38394		10.1074/jbc.M508063200	http://dx.doi.org/10.1074/jbc.M508063200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16103114	hybrid			2022-12-27	WOS:000233239800034
J	Yamada, RX; Matsuki, N; Ikegaya, Y				Yamada, RX; Matsuki, N; Ikegaya, Y			cAMP differentially regulates axonal and dendritic development of dentate granule cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; MOSSY FIBER DEVELOPMENT; LONG-TERM POTENTIATION; ADENYLYL-CYCLASE; SEMAPHORIN 3A; GROWTH CONES; GLUTAMATE RECEPTORS; ADULT HIPPOCAMPUS; PERFORANT PATH; IN-VITRO	Neurite polarity is a morphological characteristic of dentate gyrus granule cells, which extend axons to the hilar region and dendrites in the opposite direction, i.e. to the molecular layer. This remarkable polarity must require a differential system for axon and dendrite guidance. Here, we report that the axon and dendrites of a granule cell are differentially responsive to cAMP. In developing cultures of dispersed granule cells, dendritic growth cones were increased in number after pharmacological activation of cAMP signaling and decreased after blockade of cAMP signaling. Activation of cAMP signaling antagonized dendritic collapse induced by the potent repellents Sema3F and glutamate. In contrast to dendrites, axons were protected from Sema3F-induced collapse when cAMP signaling was inhibited. Axonal and dendritic growth cones both expressed type 1 adenylyl cyclase, but only axons showed a cAMP increase in response to Sema3F, and the elevated cAMP was sufficient to collapse axonal growth cones. Thus, the axons and dendrites of dentate granule cells differ in the regulation of cAMP levels as well as responsiveness to cAMP. cAMP may be crucial for shaping the information flow polarity in the dentate gyrus circuit.	Univ Tokyo, Grad Sch Pharmaceut Sci, Chem Pharmacol Lab, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Ikegaya, Y (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Chem Pharmacol Lab, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	ikegaya@mol.f.u-tokyo.ac.jp		Ikegaya, Yuji/0000-0003-2260-8191				ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Baba A, 2003, J NEUROSCI, V23, P7737; Baba A, 2002, J NEUROCYTOL, V31, P41, DOI 10.1023/A:1022519632041; Bagri A, 2003, CELL, V113, P285, DOI 10.1016/S0092-8674(03)00267-8; Barnes G, 2003, HIPPOCAMPUS, V13, P1, DOI 10.1002/hipo.10041; BEKENSTEIN JW, 1990, BRAIN RES, V514, P334, DOI 10.1016/0006-8993(90)91429-K; Butler CD, 2004, J NEUROSCI, V24, P462, DOI 10.1523/JNEUROSCI.3040-03.2004; Campbell DS, 2001, J NEUROSCI, V21, P8538, DOI 10.1523/JNEUROSCI.21-21-08538.2001; Chang S, 2001, NAT NEUROSCI, V4, P787, DOI 10.1038/90489; Chedotal A, 1998, DEVELOPMENT, V125, P4313; Chen H, 2000, NEURON, V25, P43, DOI 10.1016/S0896-6273(00)80870-3; Cheng HJ, 2001, NEURON, V32, P249, DOI 10.1016/S0896-6273(01)00478-0; CLAIBORNE BJ, 1990, J COMP NEUROL, V302, P206, DOI 10.1002/cne.903020203; CONNERKERR TA, 1993, J NEUROCHEM, V61, P627; CRAIG AM, 1994, ANNU REV NEUROSCI, V17, P267, DOI 10.1146/annurev.ne.17.030194.001411; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Defer N, 2000, AM J PHYSIOL-RENAL, V279, pF400, DOI 10.1152/ajprenal.2000.279.3.F400; Dent EW, 2001, J NEUROSCI, V21, P9757, DOI 10.1523/JNEUROSCI.21-24-09757.2001; DESMOND NL, 1982, J COMP NEUROL, V212, P131, DOI 10.1002/cne.902120204; Dontchev VD, 2002, J NEUROSCI, V22, P6659; Fabbri E, 1991, J Enzyme Inhib, V5, P87, DOI 10.3109/14756369109069062; FAN JH, 1993, J CELL BIOL, V121, P867, DOI 10.1083/jcb.121.4.867; Fischer M, 2000, NAT NEUROSCI, V3, P887, DOI 10.1038/78791; Fujioka T, 2004, J NEUROSCI, V24, P319, DOI 10.1523/JNEUROSCI.1065.03.2004; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; Grimpe B, 2002, J NEUROSCI, V22, P3144, DOI 10.1523/JNEUROSCI.22-08-03144.2002; Harris TE, 1997, BIOCHEM BIOPH RES CO, V232, P648, DOI 10.1006/bbrc.1997.6344; HEI YJ, 1991, MOL PHARMACOL, V39, P233; Hopker VH, 1999, NATURE, V401, P69, DOI 10.1038/43441; Huang YY, 2000, J NEUROSCI, V20, P6317, DOI 10.1523/JNEUROSCI.20-17-06317.2000; JONES RSG, 1994, HIPPOCAMPUS, V4, P335, DOI 10.1002/hipo.450040317; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; Kim JA, 2004, CEREB CORTEX, V14, P1358, DOI 10.1093/cercor/bhh096; Koyama R, 2004, CURR NEUROVASC RES, V1, P3, DOI 10.2174/1567202043480242; Koyama R, 2004, DEV BIOL, V267, P29, DOI 10.1016/j.ydbio.2003.11.008; Koyama R, 2002, J PHYSIOL-LONDON, V539, P157, DOI 10.1113/jphysiol.2001.013505; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Kullmann DM, 1998, TRENDS NEUROSCI, V21, P8, DOI 10.1016/S0166-2236(97)01150-8; Lamoureux P, 2002, J CELL BIOL, V159, P499, DOI 10.1083/jcb.200207174; LIPTON SA, 1989, TRENDS NEUROSCI, V12, P265, DOI 10.1016/0166-2236(89)90026-X; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; McKinney RA, 1999, NAT NEUROSCI, V2, P44, DOI 10.1038/4548; METZGER H, 1981, ARZNEIMITTEL-FORSCH, V31-2, P1248; Mizuhashi S, 2001, J NEUROSCI, V21, P6181, DOI 10.1523/JNEUROSCI.21-16-06181.2001; Mons N, 2003, NEUROBIOL LEARN MEM, V79, P226, DOI 10.1016/S1074-7427(03)00005-4; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Polleux F, 1998, SCIENCE, V282, P1904, DOI 10.1126/science.282.5395.1904; Polleux F, 2000, NATURE, V404, P567, DOI 10.1038/35007001; Sahay A, 2003, J NEUROSCI, V23, P6671; SANDLER R, 1991, J COMP NEUROL, V303, P177, DOI 10.1002/cne.903030202; Sasaki Y, 2002, NEURON, V35, P907, DOI 10.1016/S0896-6273(02)00857-7; Schaefer ML, 2000, J NEUROSCI, V20, P4809; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; Storm-Mathisen J, 1981, Adv Biochem Psychopharmacol, V27, P43; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Tashiro A, 2003, NEURON, V38, P773, DOI 10.1016/S0896-6273(03)00299-X; Terman JR, 2004, SCIENCE, V303, P1204, DOI 10.1126/science.1092121; TERRIAN DM, 1990, NEUROCHEM RES, V15, P1, DOI 10.1007/BF00969176; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Trousse F, 2001, DEVELOPMENT, V128, P3927; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Villacres EC, 1998, J NEUROSCI, V18, P3186; Wong WT, 2000, CURR OPIN NEUROBIOL, V10, P118, DOI 10.1016/S0959-4388(99)00059-8; Yamaguchi N, 2004, FEBS LETT, V566, P71, DOI 10.1016/j.febslet.2004.04.009; Zheng JQ, 1996, J NEUROSCI, V16, P1140	66	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					38020	38028		10.1074/jbc.M503800200	http://dx.doi.org/10.1074/jbc.M503800200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16155295	hybrid			2022-12-27	WOS:000233044500085
J	Orth, JHC; Lang, S; Taniguchi, M; Aktories, K				Orth, JHC; Lang, S; Taniguchi, M; Aktories, K			Pasteurella multocida toxin-induced activation of RhoA is mediated via two families of G alpha proteins, G alpha(q) and G alpha(12/13)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS FIBER FORMATION; HETEROTRIMERIC G-PROTEINS; SERUM RESPONSE FACTOR; C-TERMINAL FRAGMENT; TYROSINE PHOSPHORYLATION; P115 RHOGEF; RECEPTOR; INVOLVEMENT; CELLS; PATHWAYS	Pasteurella multocida toxin (PMT) is a potent mitogen, which is known to activate phospholipase C beta by stimulating the alpha-subunit of the heterotrimeric G protein G(q). PMT also activates RhoA and RhoA-dependent pathways. Using YM-254890, a specific inhibitor of G(q/11), we studied whether activation of RhoA involves G proteins other than G(q/11). YM-254890 inhibited PMT or muscarinic M3-receptor-mediated stimulation of phospholipase C beta at similar concentrations in HEK293m3 cells. In these cells, PMT-induced RhoA activation and enhancement of RhoA-dependent luciferase activity were partially inhibited by YM-254890. In G alpha(q/11)-deficient fibroblasts, PMT induced activation of RhoA, increase in RhoA-dependent luciferase activity, and increase in ERK phosphorylation. None of these effects were influenced by YM-254890. However, RhoA activation by PMT was inhibited by RGS2, RGS16, lscRGS, and dominant negative G(13)(GA), indicating involvement of G alpha(12/13) in the PMT effect on RhoA. In G alpha(12/13) gene-deficient cells, PMT-induced stimulation of RhoA, luciferase activity, and ERK phosphorylation were blocked by YM-254890, indicating the involvement of G(q). Infection with a virus harboring the gene of G alpha(13) reconstituted the increase in RhoA-dependent luciferase activity by PMT even in the presence of YM-254890. The data show that YM-254890 is able to block PMT activation of G alpha(q) and indicate that, in addition to G alpha(q), the G alpha(12/13) G proteins are targets of PMT.	Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, D-79104 Freiburg, Germany; Astellas Pharma Inc, Inst Drug Discovery Res, Tsakuba, Ibaraki 3088585, Japan	University of Freiburg; Astellas Pharmaceuticals	Aktories, K (corresponding author), Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, Albertstr 25, D-79104 Freiburg, Germany.	Klaus.Aktories@pharmakol.uni-freiburg.de	Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436				Booden MA, 2002, MOL CELL BIOL, V22, P4053, DOI 10.1128/MCB.22.12.4053-4061.2002; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Busch C, 2001, INFECT IMMUN, V69, P3628, DOI 10.1128/IAI.69.6.3628-3634.2001; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Chikumi H, 2002, J BIOL CHEM, V277, P27130, DOI 10.1074/jbc.M204715200; Dudet LI, 1996, J CELL PHYSIOL, V168, P173; Essler M, 1998, J IMMUNOL, V161, P5640; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Fukuhara S, 2001, ONCOGENE, V20, P1661, DOI 10.1038/sj.onc.1204182; Gohla A, 2000, CIRC RES, V87, P221, DOI 10.1161/01.RES.87.3.221; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Heximer SP, 1999, J BIOL CHEM, V274, P34253, DOI 10.1074/jbc.274.48.34253; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Ingi T, 1998, J NEUROSCI, V18, P7178; Johnson CM, 1997, J NEUROSCI, V17, P6189; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Lacerda HM, 1996, J BIOL CHEM, V271, P439, DOI 10.1074/jbc.271.1.439; Lax AJ, 2004, INT J MED MICROBIOL, V293, P505, DOI 10.1078/1438-4221-00287; LEE E, 1992, J BIOL CHEM, V267, P1212; Lutz S, 2005, J BIOL CHEM, V280, P11134, DOI 10.1074/jbc.M411322200; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Montaner S, 1999, J BIOL CHEM, V274, P8506, DOI 10.1074/jbc.274.13.8506; Nickel C, 2002, J CLIN INVEST, V109, P481, DOI 10.1172/JC1200212867; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; Orth JHC, 2004, J BIOL CHEM, V279, P34150, DOI 10.1074/jbc.M405353200; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Sabri A, 2002, CIRC RES, V90, P850, DOI 10.1161/01.RES.0000016165.23795.1F; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; SCHMIDT M, 1995, J BIOL CHEM, V270, P19949, DOI 10.1074/jbc.270.34.19949; Seo B, 2000, J BIOL CHEM, V275, P2239, DOI 10.1074/jbc.275.3.2239; Sleight S, 2002, BIOCHEM BIOPH RES CO, V295, P561, DOI 10.1016/S0006-291X(02)00701-5; STADDON JM, 1991, J BIOL CHEM, V266, P4840; Suzuki N, 2003, P NATL ACAD SCI USA, V100, P733, DOI 10.1073/pnas.0234057100; Takasaki J, 2004, J BIOL CHEM, V279, P47438, DOI 10.1074/jbc.M408846200; Vogt S, 2003, J BIOL CHEM, V278, P28743, DOI 10.1074/jbc.M304570200; Wieland T, 1999, N-S ARCH PHARMACOL, V360, P14, DOI 10.1007/s002109900031; Wilson BA, 2005, REV PHYSIOL BIOCH P, V152, P93, DOI 10.1007/s10254-004-0032-6; Wilson BA, 1997, J BIOL CHEM, V272, P1268, DOI 10.1074/jbc.272.20.12961; Zywietz A, 2001, J BIOL CHEM, V276, P3840, DOI 10.1074/jbc.M007819200	45	62	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36701	36707		10.1074/jbc.M507203200	http://dx.doi.org/10.1074/jbc.M507203200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16141214	hybrid			2022-12-27	WOS:000232901800022
J	Curran, NM; Griffin, BD; O'Toole, D; Brady, KJ; Fitzgerald, SN; Moynagh, PN				Curran, NM; Griffin, BD; O'Toole, D; Brady, KJ; Fitzgerald, SN; Moynagh, PN			The synthetic cannabinoid R(+) WIN 55,212-2 inhibits the interleukin-1 signaling pathway in human astrocytes in a cannabinoid receptor-independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CELL-ADHESION MOLECULE-1; CENTRAL-NERVOUS-SYSTEM; HUMAN GLIAL-CELLS; MULTIPLE-SCLEROSIS; TRANSCRIPTIONAL ACTIVATION; EXPRESSION; GENE; MODEL	R(+) WIN 55,212-2 is a synthetic cannabinoid that controls disease progression in models of multiple sclerosis. This is associated with its ability to reduce migration of leukocytes into the central nervous system. Because leukocyte migration is dependent on induction of adhesion molecules and chemokines by pro-inflammatory cytokines, we examined the effects of R(+) WIN 55,212-2 on their expression. Using 1321N1 astrocytoma and A-172 glioblastoma as cell models we show that R(+) WIN 55,212-2, but not its inactive chiral form S(-) WIN 55,212-2, strongly inhibits the interleukin-1 (IL-1) induction of the adhesion molecules intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) and the chemokine IL-8. This inhibition is not mediated via the CB1 or CB2 cannabinoid receptors, because their selective antagonists and pertussis toxin failed to affect the inhibitory effects of R(+) WIN 55,212-2. Furthermore reverse transcription-PCR analysis did not detect the expression of either receptor in 1321N1 cells. R(+) WIN 55,212-2 was shown to inhibit adhesion molecule and chemokine expression at the level of transcription, because it strongly inhibited the IL-1 induction of ICAM-1, VCAM-1, and IL-8 mRNAs and blocked the IL-1 activation of their promoters. The NF kappa B pathway was then assessed as a lead target for R(+) WIN 55,212-2. NF kappa B was measured by expression of a transfected NF kappa B-regulated reporter gene. Using this assay, R(+) WIN 55,212-2 strongly inhibited IL-1 activation of NF kappa B. Furthermore R(+) WIN 55,212-2 inhibited the ability of overexpressed Myd88, Tak-1, and IKK-2 to induce the reporter gene suggesting that R(+) WIN 55,212-2 acts at or downstream of IKK-2 in the IL-1 pathway. However R(+) WIN 55,212-2 failed to inhibit IL-1-induced degradation of I kappa B alpha, excluding IKK-2 as a direct target. In addition electrophoretic mobility shift and chromatin immunoprecipitation assays showed that R(+) WIN 55,212-2 does not regulate the IL-1-induced nuclear translocation of NF kappa B or the ability of the latter to bind to promoters regulating expression of ICAM-1 and IL-8. These data suggest that R(+) WIN 55,212-2 blocks IL-1 signaling by inhibiting the transactivation potential of NF kappa B.	Univ Coll Dublin, Conway Inst, UCD Sch Biomol & Biomed Sci, Dublin 4, Ireland	University College Dublin	Moynagh, PN (corresponding author), Univ Coll Dublin, Conway Inst, UCD Sch Biomol & Biomed Sci, Dublin 4, Ireland.	P.Moynagh@ucd.ie		O'Toole, Daniel/0000-0001-5422-8711; Moynagh, Paul/0000-0002-4139-3061				Arevalo-Martin A, 2003, J NEUROSCI, V23, P2511; Basu A, 2004, J NEUROSCI RES, V78, P151, DOI 10.1002/jnr.20266; Bourke E, 1999, J IMMUNOL, V163, P2113; Bourke E, 2000, J BIOL CHEM, V275, P39996, DOI 10.1074/jbc.M007693200; BROSNAN CF, 1995, NEUROLOGY, V45, P16; CANNELLA B, 1995, ANN NEUROL, V37, P424, DOI 10.1002/ana.410370404; Chakrabarti SK, 2002, J BIOL CHEM, V277, P13286, DOI 10.1074/jbc.M111857200; Consroe P, 1997, EUR NEUROL, V38, P44, DOI 10.1159/000112901; Croxford JL, 2003, J CLIN INVEST, V111, P1231, DOI 10.1172/JCI200317652; GALIEGUE S, 1995, EUR J BIOCHEM, V232, P54, DOI 10.1111/j.1432-1033.1995.tb20780.x; HAFLER DA, 1987, IMMUNOL REV, V100, P307, DOI 10.1111/j.1600-065X.1987.tb00537.x; HERY C, 1995, J NEUROIMMUNOL, V57, P101, DOI 10.1016/0165-5728(94)00168-N; Herzberg U, 1997, NEUROSCI LETT, V221, P157, DOI 10.1016/S0304-3940(96)13308-5; Hesselgesser J, 1999, J NEUROVIROL, V5, P13, DOI 10.3109/13550289909029741; KUNSCH C, 1994, J IMMUNOL, V153, P153; Kwon D, 2004, GLIA, V45, P287, DOI 10.1002/glia.10331; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Martino G, 2002, LANCET NEUROL, V1, P499, DOI 10.1016/S1474-4422(02)00223-5; MEINCK HM, 1989, J NEUROL, V236, P120, DOI 10.1007/BF00314410; Molina-Holgado F, 2003, J NEUROSCI, V23, P6470; MOORE PA, 1993, MOL CELL BIOL, V13, P1666, DOI 10.1128/MCB.13.3.1666; MOYNAGH PN, 1994, J IMMUNOL, V153, P2681; Ni X, 2004, MULT SCLER J, V10, P158, DOI 10.1191/1352458504ms1009oa; ROSENMAN SJ, 1995, J IMMUNOL, V154, P1888; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Sagan S, 1999, EUR J NEUROSCI, V11, P691, DOI 10.1046/j.1460-9568.1999.00480.x; Sancho R, 2003, MOL PHARMACOL, V63, P429, DOI 10.1124/mol.63.2.429; Schmitz ML, 2001, TRENDS BIOCHEM SCI, V26, P186, DOI 10.1016/S0968-0004(00)01753-9; SHRIKANT P, 1994, J NEUROIMMUNOL, V51, P209, DOI 10.1016/0165-5728(94)90083-3; SLIPETZ DM, 1995, MOL PHARMACOL, V48, P352; UNGERLEIDER J T, 1987, Advances in Alcohol and Substance Abuse, V7, P39; Walter L, 2003, GLIA, V44, P85, DOI 10.1002/glia.10270; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0	34	51	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35797	35806		10.1074/jbc.M507959200	http://dx.doi.org/10.1074/jbc.M507959200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16105834	Green Accepted, hybrid			2022-12-27	WOS:000232726900005
J	Lora, JM; Zhang, DM; Liao, SM; Burwell, T; King, AM; Barker, PA; Singh, L; Keaveney, M; Morgenstern, J; Gutierrez-Ramos, JC; Coyle, AJ; Fraser, CC				Lora, JM; Zhang, DM; Liao, SM; Burwell, T; King, AM; Barker, PA; Singh, L; Keaveney, M; Morgenstern, J; Gutierrez-Ramos, JC; Coyle, AJ; Fraser, CC			Tumor necrosis factor-alpha triggers mucus production in airway epithelium through an I kappa B kinase beta-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUC5AC MUCIN TRANSCRIPTION; GROWTH-FACTOR RECEPTOR; GENE-EXPRESSION; ACTIVATION; PATHWAY; INFLAMMATION; POLYMORPHISM; SYSTEM; CELLS; TNF	Excessive mucus production by airway epithelium is a major characteristic of a number of respiratory diseases, including asthma, chronic bronchitis, and cystic fibrosis. However, the signal transduction pathways leading to mucus production are poorly understood. Here we examined the potential role of I kappa B kinase beta (IKK beta) in mucus synthesis in vitro and in vivo. Tumor necrosis factor-alpha ( TNF-alpha) or transforming growth factor-alpha stimulation of human epithelial cells resulted in mucus secretion as measured by MUC5AC mRNA and protein. TNF-alpha stimulation induced IKK beta-dependent p65 nuclear translocation, mucus synthesis, and production of cytokines from epithelial cells. TNF-alpha, but not transforming growth factor-alpha, induced mucus production dependent on IKK beta-mediated NF-kappa B activation. In vivo, TNF-alpha induced NF-kappa B as determined by whole mouse body bioluminescence. This activation was localized to the epithelium as revealed by LacZ staining in NF-kappa B-LacZ transgenic mice. TNF-alpha-induced mucus production in vivo could also be inhibited by administration into the epithelium of an IKK beta dominant negative adenovirus. Taken together, our results demonstrated the important role of IKK beta in TNF-alpha-mediated mucus production in airway epithelium in vitro and in vivo.	Millennium Pharmaceut Inc, Cambridge, MA 02139 USA; McGill Univ, Montreal Neurol Inst, Ctr Neuronal Survival, Montreal, PQ H3A 2B4, Canada	Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; McGill University	Fraser, CC (corresponding author), Millennium Pharmaceut Inc, 35 Landsdowne St, Cambridge, MA 02139 USA.	chris.fraser@mpi.com						Adler KB, 2001, AM J RESP CELL MOL, V25, P397, DOI 10.1165/ajrcmb.25.4.f214; Alimam MZ, 2000, AM J RESP CELL MOL, V22, P253, DOI 10.1165/ajrcmb.22.3.3768; Basbaum C, 1999, AM J RESP CRIT CARE, V160, pS44, DOI 10.1164/ajrccm.160.supplement_1.12; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bhakar AL, 2002, J NEUROSCI, V22, P8466; Brouillard F, 2001, J BIOL CHEM, V276, P9486, DOI 10.1074/jbc.M006636200; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chen R, 2004, BIOCHEM BIOPH RES CO, V324, P1087, DOI 10.1016/j.bbrc.2004.09.157; Christman JW, 2000, CHEST, V117, P1482, DOI 10.1378/chest.117.5.1482; Chung KF, 2001, EUR RESPIR J, V18, p50S, DOI 10.1183/09031936.01.00229701; Churg A, 2002, AM J RESP CRIT CARE, V166, P849, DOI 10.1164/rccm.200202-097OC; DAIZONG L, 1998, J BIOL CHEM, V273, P6812; Das J, 2001, NAT IMMUNOL, V2, P45, DOI 10.1038/83158; Desmet C, 2004, J IMMUNOL, V173, P5766, DOI 10.4049/jimmunol.173.9.5766; Di Stefano A, 2002, EUR RESPIR J, V20, P556, DOI 10.1183/09031936.02.00272002; Donovan CE, 1999, J IMMUNOL, V163, P6827; Escande F, 2001, BIOCHEM J, V358, P763, DOI 10.1042/0264-6021:3580763; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hirota K, 2001, J BIOL CHEM, V276, P25953, DOI 10.1074/jbc.M011021200; Jackson AD, 2001, TRENDS PHARMACOL SCI, V22, P39, DOI 10.1016/S0165-6147(00)01600-X; Jono H, 2002, J BIOL CHEM, V277, P45547, DOI 10.1074/jbc.M206883200; Kaycan MKC, 2002, RESP RES, V3; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530, DOI 10.1164/ajrccm.153.2.8564092; Li JD, 1998, P NATL ACAD SCI USA, V95, P5718, DOI 10.1073/pnas.95.10.5718; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Nadel JA, 2001, RESP RES, V2, P85, DOI 10.1186/rr43; Perrais M, 2002, J BIOL CHEM, V277, P32258, DOI 10.1074/jbc.M204862200; Poynter ME, 2004, J IMMUNOL, V173, P7003, DOI 10.4049/jimmunol.173.11.7003; Poynter ME, 2002, AM J PATHOL, V160, P1325, DOI 10.1016/S0002-9440(10)62559-X; ROSE MC, 1997, AIRWAY MUCUS BASIC M, P41; Sakao S, 2001, AM J RESP CRIT CARE, V163, P420, DOI 10.1164/ajrccm.163.2.2006031; Shao MXG, 2005, P NATL ACAD SCI USA, V102, P767, DOI 10.1073/pnas.0408932102; Shao MXG, 2003, P NATL ACAD SCI USA, V100, P11618, DOI 10.1073/pnas.1534804100; Smirnova MG, 2000, CYTOKINE, V12, P1732, DOI 10.1006/cyto.2000.0763; Song KS, 2003, J BIOL CHEM, V278, P23243, DOI 10.1074/jbc.M300096200; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081; THORNTON DJ, 1997, AIRWAY MUCUS BASIC M, P19; Wang BN, 2002, J BIOL CHEM, V277, P949, DOI 10.1074/jbc.M107484200; Wu WD, 2002, AM J PHYSIOL-LUNG C, V282, pL1040, DOI 10.1152/ajplung.00390.2001	41	76	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36510	36517		10.1074/jbc.M507977200	http://dx.doi.org/10.1074/jbc.M507977200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16123045	hybrid			2022-12-27	WOS:000232726900085
J	Miranda, M; Wu, CC; Sorkina, T; Korstjens, DR; Sorkin, A				Miranda, M; Wu, CC; Sorkina, T; Korstjens, DR; Sorkin, A			Enhanced ubiquitylation and accelerated degradation of the dopamine transporter mediated by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENERGY-TRANSFER MICROSCOPY; LIVING CELLS; MEMBRANE-PROTEIN; PHORBOL ESTERS; NEUROTRANSMITTER TRANSPORTERS; REGULATED TRAFFICKING; STRIATAL SYNAPTOSOMES; SEROTONIN TRANSPORTER; PROTEOMIC ANALYSIS; EPITHELIAL-CELLS	Dopamine transporter (DAT) localization in dopaminergic neurons plays an important role in regulating dopamine signaling. However, the mechanisms of DAT trafficking that control DAT localization are still poorly understood. To gain insight into these mechanisms, human DAT was purified in large amounts using a two-step affinity chromatography procedure from untreated HeLa cells or cells treated with phorbol 12-myristate 13-acetate (PMA). Mass spectrometric analysis of purified DAT complexes revealed the presence of several proteins, among which ubiquitin was particularly abundant in the PMA-treated sample. Western blotting of highly purified DAT protein confirmed constitutive ubiquitylation of DAT and a dramatic increase in DAT ubiquitylation in cells treated with PMA. This increase was blocked by pretreatment with the protein kinase C (PKC) inhibitor bis-indolylmaleimide. DAT ubiquitylation by ectopically expressed ubiquitin was demonstrated in cells transiently transfected with yellow fluorescent protein-tagged ubiquitin. In addition, fluorescence resonance energy transfer was detected between cyan fluorescent protein-tagged DAT and yellow fluorescent protein-tagged ubiquitin, indicative of DAT-ubiquitin conjugation. Interestingly, the largest fluorescence resonance energy transfer signals were observed in endosomes. Ubiquitylated DAT was detected in the plasma membrane using cell surface biotinylation as well as in intracellular compartments, suggesting that ubiquitylation begins at the plasma membrane and is maintained in endosomes. In both porcine aortic endothelial and HeLa cells, where PKC-dependent DAT ubiquitylation was observed, PKC activation resulted in rapid degradation of DAT (t(1/2) = 1-2 h). Altogether, these data suggest that PKC-induced DAT ubiquitylation may target DAT to lysosomal degradation.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus	Sorkin, A (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Aurora, CO 80045 USA.	alexander.sorkin@uchsc.edu		Sorkin, Alexander/0000-0002-4446-1920	NIAID NIH HHS [K22AI059076] Funding Source: Medline; NIDA NIH HHS [DA014204] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K22AI059076] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA014204] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Carter S, 2004, J BIOL CHEM, V279, P52835, DOI 10.1074/jbc.M407769200; Chen NH, 2004, PFLUG ARCH EUR J PHY, V447, P519, DOI 10.1007/s00424-003-1064-5; Cooper HJ, 2004, ANAL CHEM, V76, P6982, DOI 10.1021/ac0401063; Copeland BJ, 1996, J PHARMACOL EXP THER, V277, P1527; d'Azzo A, 2005, TRAFFIC, V6, P429, DOI 10.1111/j.1600-0854.2005.00294.x; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Doss-Pepe EW, 2005, J BIOL CHEM, V280, P16619, DOI 10.1074/jbc.M413591200; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fornes A, 2004, J BIOL CHEM, V279, P22934, DOI 10.1074/jbc.M401337200; Foster JD, 2002, J BIOL CHEM, V277, P25178, DOI 10.1074/jbc.M200294200; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Galperin E, 2004, NAT METHODS, V1, P209, DOI 10.1038/NMETH720; GIROS B, 1993, TRENDS PHARMACOL SCI, V14, P43, DOI 10.1016/0165-6147(93)90029-J; Granas C, 2003, J BIOL CHEM, V278, P4990, DOI 10.1074/jbc.M205058200; Hammond DE, 2003, MOL BIOL CELL, V14, P1346, DOI 10.1091/mbc.E02-09-0578; Hastrup H, 2001, P NATL ACAD SCI USA, V98, P10055, DOI 10.1073/pnas.181344298; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Holton KL, 2005, NAT NEUROSCI, V8, P881, DOI 10.1038/nn1478; Huff RA, 1997, J NEUROCHEM, V68, P225; Jiang HB, 2004, J BIOL CHEM, V279, P54380, DOI 10.1074/jbc.M409282200; Khoshbouei H, 2004, PLOS BIOL, V2, P387, DOI 10.1371/journal.pbio.0020078; Kilic F, 2000, P NATL ACAD SCI USA, V97, P3106, DOI 10.1073/pnas.060408997; Kirkpatrick DS, 2005, METHODS, V35, P265, DOI 10.1016/j.ymeth.2004.08.018; KITAYAMA S, 1994, EUR J PHARM-MOLEC PH, V268, P115, DOI 10.1016/0922-4106(94)90180-5; Leontieva OV, 2004, J BIOL CHEM, V279, P5788, DOI 10.1074/jbc.M308375200; Lin ZC, 2003, J BIOL CHEM, V278, P20162, DOI 10.1074/jbc.M209584200; Loder MK, 2003, J BIOL CHEM, V278, P22168, DOI 10.1074/jbc.M301845200; MacCoss MJ, 2002, P NATL ACAD SCI USA, V99, P7900, DOI 10.1073/pnas.122231399; McCullough J, 2004, J CELL BIOL, V166, P487, DOI 10.1083/jcb.200401141; Melikian HE, 2004, PHARMACOL THERAPEUT, V104, P17, DOI 10.1016/j.pharmthera.2004.07.006; Melikian HE, 1999, J NEUROSCI, V19, P7699; Miranda M, 2004, J BIOL CHEM, V279, P30760, DOI 10.1074/jbc.M312774200; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Perroy J, 2004, NAT METHODS, V1, P203, DOI 10.1038/NMETH722; Raiborg C, 2003, CURR OPIN CELL BIOL, V15, P446, DOI 10.1016/S0955-0674(03)00080-2; Raiborg C, 2002, CELL STRUCT FUNCT, V27, P403, DOI 10.1247/csf.27.403; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Robinson MB, 2002, J NEUROCHEM, V80, P1, DOI 10.1046/j.0022-3042.2001.00698.x; Saunders C, 2000, P NATL ACAD SCI USA, V97, P6850, DOI 10.1073/pnas.110035297; Schmid JA, 2001, J BIOL CHEM, V276, P3805, DOI 10.1074/jbc.M007357200; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; Sorkina T, 2005, TRAFFIC, V6, P157, DOI 10.1111/j.1600-0854.2005.00259.x; Sorkina T, 2003, J BIOL CHEM, V278, P28274, DOI 10.1074/jbc.M210652200; Torres GE, 2003, NAT REV NEUROSCI, V4, P13, DOI 10.1038/nrn1008; Torres GE, 2003, J BIOL CHEM, V278, P2731, DOI 10.1074/jbc.M201926200; Vaughan RA, 1997, J BIOL CHEM, V272, P15541, DOI 10.1074/jbc.272.24.15541; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Wu CC, 2000, TRAFFIC, V1, P769, DOI 10.1034/j.1600-0854.2000.011004.x; Wu CC, 2003, NAT BIOTECHNOL, V21, P532, DOI 10.1038/nbt819; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; Zhang L, 1997, BIOCHEM PHARMACOL, V53, P677, DOI 10.1016/S0006-2952(96)00898-2; Zhu SJ, 1997, J PHARMACOL EXP THER, V282, P1358	54	96	97	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35617	35624		10.1074/jbc.M506618200	http://dx.doi.org/10.1074/jbc.M506618200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16109712	hybrid			2022-12-27	WOS:000232561200064
J	Wang, Y; Iordanov, H; Swietlicki, EA; Wang, LH; Fritsch, C; Coleman, T; Semenkovich, CF; Levin, MS; Rubin, DC				Wang, Y; Iordanov, H; Swietlicki, EA; Wang, LH; Fritsch, C; Coleman, T; Semenkovich, CF; Levin, MS; Rubin, DC			Targeted intestinal overexpression of the immediate early gene tis7 in transgenic mice increases triglyceride absorption and adiposity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; POSTNATAL-GROWTH; TRANSFER PROTEIN; PC12 CELLS; 3T3 CELLS; EXPRESSION; DIFFERENTIATION; DISRUPTION; RESECTION; LIVER	Following loss of functional small bowel surface area due to surgical resection, the remnant gut undergoes an adaptive response characterized by increased crypt cell proliferation and enhanced villus height and crypt depth, resulting in augmented intestinal nutrient absorptive capacity. Previous studies showed that expression of the immediate early gene tis7 is markedly up-regulated in intestinal enterocytes during the adaptive response. To study its role in the enterocyte, transgenic mice were generated that specifically overexpress TIS7 in the gut. Nucleotides - 596 to + 21 of the rat liver fatty acid-binding protein promoter were used to direct abundant overexpression of TIS7 into small intestinal upper crypt and villus enterocytes. TIS7 transgenic mice had increased total body adiposity and decreased lean muscle mass compared with normal littermates. Oxygen consumption levels, body weight, surface area, and small bowel weight were decreased. On a high fat diet, transgenic mice exhibited a more rapid and proportionately greater gain in body weight with persistently elevated total body adiposity and increased hepatic fat accumulation. Bolus fat feeding resulted in a greater increase in serum triglyceride levels and an accelerated appearance of enterocytic, lamina propria, and hepatic fat. Changes in fat homeostasis were linked to increased expression of genes involved in enterocytic triglyceride metabolism and changes in growth with decreased insulin-like growth factor-1 expression. Thus, TIS7 overexpression in the intestine altered growth, metabolic rate, adiposity, and intestinal triglyceride absorption. These results suggest that TIS7 is a unique mediator of nutrient absorptive and metabolic adaptation following gut resection.	Washington Univ, Sch Med, Div Gastroenterol, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; St Louis Vet Affairs Med Ctr, Specialty Care Serv Line, St Louis, MO 63106 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Rubin, DC (corresponding author), Washington Univ, Sch Med, Div Gastroenterol, Dept Med, 660 S Euclid Ave,Box 8124, St Louis, MO 63110 USA.	drubin@wustl.edu		Semenkovich, Clay/0000-0003-1163-1871; Rubin, Deborah/0000-0002-4192-909X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046122, P30DK056341, P30DK052574, R01DK061216] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020091] Funding Source: NIH RePORTER; NIA NIH HHS [AG20091] Funding Source: Medline; NIDDK NIH HHS [DK50466, DK52574, DK46122, DK61216, DK56341] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bernal-Mizrachi C, 2002, ARTERIOSCL THROM VAS, V22, P961, DOI 10.1161/01.ATV.0000019404.65403.71; Buhman KK, 2002, J BIOL CHEM, V277, P25474, DOI 10.1074/jbc.M202013200; CARR TP, 1993, CLIN BIOCHEM, V26, P39, DOI 10.1016/0009-9120(93)90015-X; Clark JM, 2003, JAMA-J AM MED ASSOC, V289, P3000, DOI 10.1001/jama.289.22.3000; Dodson BD, 1996, AM J PHYSIOL-GASTR L, V271, pG347, DOI 10.1152/ajpgi.1996.271.2.G347; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; GUARDAVACCARO D, 1995, CELL GROWTH DIFFER, V6, P159; GUARDAVACCARO D, 1994, J NEUROSCI RES, V37, P660, DOI 10.1002/jnr.490370514; Harrison Stephen A, 2002, Semin Gastrointest Dis, V13, P3; HERSCHMAN HR, 1994, PROG NUCLEIC ACID RE, V47, P113, DOI 10.1016/S0079-6603(08)60251-2; Inoue Y, 2004, J BIOL CHEM, V279, P44740, DOI 10.1074/jbc.M405177200; Li B, 2000, NAT MED, V6, P1115, DOI 10.1038/80450; Li YL, 2003, ENDOCRINOLOGY, V144, P3505, DOI 10.1210/en.2003-0236; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; Narisawa S, 2003, MOL CELL BIOL, V23, P7525, DOI 10.1128/MCB.23.21.7525-7530.2003; Ohneda K, 1997, GASTROENTEROLOGY, V112, P444, DOI 10.1053/gast.1997.v112.pm9024298; Peterson CA, 2000, JPEN-PARENTER ENTER, V24, P288, DOI 10.1177/0148607100024005288; Rubin DC, 1998, AM J PHYSIOL-GASTR L, V275, pG506, DOI 10.1152/ajpgi.1998.275.3.G506; Schwarz M, 1996, J BIOL CHEM, V271, P18024, DOI 10.1074/jbc.271.30.18017; SIMON TC, 1993, J BIOL CHEM, V268, P18345; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; Stappenbeck TS, 2000, DEVELOPMENT, V127, P2629; Stappenbeck TS, 2001, DEVELOPMENT, V128, P2603; Stone SJ, 2004, J BIOL CHEM, V279, P11767, DOI 10.1074/jbc.M311000200; Swietlicki E, 2003, JPEN-PARENTER ENTER, V27, P123, DOI 10.1177/0148607103027002123; Tang YZ, 2004, GASTROENTEROLOGY, V126, P220, DOI 10.1053/j.gastro.2003.10.077; TIRONE F, 1989, P NATL ACAD SCI USA, V86, P2088, DOI 10.1073/pnas.86.6.2088; Vadivelu SK, 2004, MOL CELL BIOL, V24, P3514, DOI 10.1128/MCB.24.8.3514-3525.2004; VARNUM BC, 1989, ONCOGENE, V4, P1263; Vietor I, 2002, EMBO J, V21, P4621, DOI 10.1093/emboj/cdf461; Wang LC, 2002, GASTROENTEROLOGY, V122, P469, DOI 10.1053/gast.2002.31102; WETTERAU JR, 1992, SCIENCE, V258, P999; Wick N, 2004, J MOL BIOL, V336, P589, DOI 10.1016/j.jmb.2003.11.060; Wong MH, 1998, J CELL BIOL, V141, P765, DOI 10.1083/jcb.141.3.765; Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324	37	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34764	34775		10.1074/jbc.M507058200	http://dx.doi.org/10.1074/jbc.M507058200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16085642	hybrid			2022-12-27	WOS:000232403900048
J	Watanabe, T; Blaisdel, JO; Wallace, SS; Bond, JP				Watanabe, T; Blaisdel, JO; Wallace, SS; Bond, JP			Engineering functional changes in Escherichia coli endonuclease III based on phylogenetic and structural analyses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE DNA-DAMAGE; SACCHAROMYCES-CEREVISIAE; EXCISION-REPAIR; HUMAN HOMOLOG; SUBSTRATE SPECIFICITIES; CATALYTIC MECHANISM; MUTY GENE; GLYCOSYLASE; ENZYME; CLONING	Escherichia coli endonuclease III (EcoNth) plays an important cellular role by removing premutagenic pyrimidine damages produced by reactive oxygen species. EcoNth is a bifunctional enzyme that has DNA glycosylase and apurinic/apyrimidinic lyase activities. Using a phylogeny of natural sequences, we selected to study EcoNth serine 39, aspartate 44, and arginine 184, which are presumed to be in the vicinity of the damaged base in the glycosylase-substrate complex. These three amino acids are highly conserved among Nth orthologs, although not among homologous glycosylases, such as MutY, that have different base specificities and no lyase activity. To examine the role of these amino acids in catalysis, we constructed three mutants of EcoNth, in which Ser(39) was replaced with leucine (S39L), Asp(44) was replaced with valine (D44V), and Arg(184) was replaced with alanine (R184A), which are the corresponding residues in EcoMutY. We showed that EcoNth S39L does not have significant glycosylase activity for oxidized pyrimidines, although it maintained AP lyase activity. In contrast, EcoNth D44V retained glycosylase activity against oxidized pyrimidines, but the apparent rate constant for the lyase activity of EcoNth D44V was significantly lower than that of EcoNth, indicating that Asp(44) in EcoNth is required for beta-elimination. Finally, EcoNth R184A maintained lyase activity but exhibited glycosylase specificity different from that of EcoNth. The functional consequences of each of these three substitutions can be rationalized in the context of high resolution protein structures. Thus phylogeny-based scanning mutagenesis has allowed us to identify novel roles for amino acids in the substrate binding pocket of EcoNth in base recognition and/or catalysis.	Univ Vermont, Dept Microbiol & Mol Genet, Markey Ctr Mol Genet, Burlington, VT 05405 USA	University of Vermont	Wallace, SS (corresponding author), Univ Vermont, Dept Microbiol & Mol Genet, Markey Ctr Mol Genet, 95 Carrigan Dr,Stafford Hall, Burlington, VT 05405 USA.	Susan.Wallace@uvm.edu; Jeffrey.Bond@uvm.edu		Wallace, Susan S./0000-0002-3906-0321	NATIONAL CANCER INSTITUTE [R37CA033657, R01CA033657] Funding Source: NIH RePORTER; NCI NIH HHS [CA 33657] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asagoshi K, 2000, BIOCHEMISTRY-US, V39, P11389, DOI 10.1021/bi000422l; Aspinwall R, 1997, P NATL ACAD SCI USA, V94, P109, DOI 10.1073/pnas.94.1.109; AU KG, 1988, P NATL ACAD SCI USA, V85, P9163, DOI 10.1073/pnas.85.23.9163; Augeri L, 1997, BIOCHEMISTRY-US, V36, P721, DOI 10.1021/bi9625511; Bajek M, 2002, DNA REPAIR, V1, P251, DOI 10.1016/S1568-7864(01)00016-7; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; CUNNINGHAM RP, 1997, CURR BIOL, V7, P576; David SS, 1998, CHEM REV, V98, P1221, DOI 10.1021/cr980321h; DODSON ML, 1994, J BIOL CHEM, V269, P32709; Eide L, 1996, P NATL ACAD SCI USA, V93, P10735, DOI 10.1073/pnas.93.20.10735; Eide L, 2001, BIOCHEMISTRY-US, V40, P6653, DOI 10.1021/bi0028901; Felsenstein J., 2004, PHYLIP VERSION 3 6; Fromme JC, 2004, NATURE, V427, P652, DOI 10.1038/nature02306; Fromme JC, 2003, EMBO J, V22, P3461, DOI 10.1093/emboj/cdg311; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; Hilbert TP, 1997, J BIOL CHEM, V272, P6733, DOI 10.1074/jbc.272.10.6733; Ikeda S, 1998, J BIOL CHEM, V273, P21585, DOI 10.1074/jbc.273.34.21585; Karahalil B, 1998, BIOCHEMISTRY-US, V37, P590, DOI 10.1021/bi971660s; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LU AL, 1995, J BIOL CHEM, V270, P23582, DOI 10.1074/jbc.270.40.23582; MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P1119, DOI 10.1021/bi00218a033; McCullough AK, 1999, ANNU REV BIOCHEM, V68, P255, DOI 10.1146/annurev.biochem.68.1.255; MICHAELS ML, 1990, NUCLEIC ACIDS RES, V18, P3841, DOI 10.1093/nar/18.13.3841; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; RoldanArjona T, 1996, NUCLEIC ACIDS RES, V24, P3307, DOI 10.1093/nar/24.17.3307; Sarker AH, 1998, J MOL BIOL, V282, P761, DOI 10.1006/jmbi.1998.2042; Shekhtman A, 1999, STRUCTURE, V7, P919, DOI 10.1016/S0969-2126(99)80119-1; Slupska MM, 1996, J BACTERIOL, V178, P3885, DOI 10.1128/jb.178.13.3885-3892.1996; Slupska MM, 1999, J BACTERIOL, V181, P6210, DOI 10.1128/JB.181.19.6210-6213.1999; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; Wallace SS, 2002, FREE RADICAL BIO MED, V33, P1, DOI 10.1016/S0891-5849(02)00827-4; Wheeler DL, 2005, NUCLEIC ACIDS RES, V33, pD39, DOI 10.1093/nar/gki062; Williams SD, 1998, NUCLEIC ACIDS RES, V26, P5123, DOI 10.1093/nar/26.22.5123; Williams SD, 2000, BIOCHEMISTRY-US, V39, P10098, DOI 10.1021/bi0004652; Yang HJ, 2001, NUCLEIC ACIDS RES, V29, P604, DOI 10.1093/nar/29.3.604; Yang HJ, 2001, NUCLEIC ACIDS RES, V29, P743, DOI 10.1093/nar/29.3.743; You HJ, 1999, BIOCHEMISTRY-US, V38, P11298, DOI 10.1021/bi991121i; You HJ, 1998, BIOCHEMISTRY-US, V37, P6033, DOI 10.1021/bi973042h	41	12	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34378	34384		10.1074/jbc.M504916200	http://dx.doi.org/10.1074/jbc.M504916200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16096281	hybrid			2022-12-27	WOS:000232229700081
J	Bosl, B; Grimminger, V; Walter, S				Bosl, B; Grimminger, V; Walter, S			Substrate binding to the molecular chaperone Hsp104 and its regulation by nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL DOMAIN; ATP-BINDING; PROTEIN DISAGGREGATION; ESCHERICHIA-COLI; ACID-RESIDUES; CLPB; MECHANISM; COMMUNICATION; RECOGNITION; HYDROLYSIS	The Hsp104 protein from Saccharomyces cerevisiae is a member of the Hsp100/Clp family of molecular chaperones. It mediates the solubilization of aggregated proteins in an ATP-dependent process assisted by the Hsp70/40 system. Although the principal function of Hsp104 is well established, the mechanistic details of this catalyzed disaggregation are poorly understood. In this work, we have investigated the interaction of Hsp104 with reduced, carboxymethylated alpha-lactalbumin (RCMLa), a permanently unfolded model substrate. Our results demonstrate that the affinity of Hsp104 toward polypeptides is regulated by nucleotides. In the presence of ATP or adenosine-5'-O-(3-thiotriphosphate), the chaperone formed complexes with RCMLa, whereas no binding was observed in the presence of ADP. In particular, the occupation of the N-terminally located nucleotide-binding domain with ATP seems to be crucial for substrate interaction. When ATP binding to this domain was impaired by mutation, Hsp104 lost its ability to interact with RCMLa. Our results also indicate that upon association with a polypeptide, a conformational change occurs within Hsp104 that strongly reduces the dynamics of nucleotide exchange and commits the bound polypeptide to ATP hydrolysis.	Tech Univ Munich, Dept Chem, D-85747 Garching, Germany	Technical University of Munich	Walter, S (corresponding author), Tech Univ Munich, Dept Chem, Lichtenbergstr 4, D-85747 Garching, Germany.	stefan.walter@ch.tum.de						Barnett ME, 2005, J BIOL CHEM, V280, P34940, DOI 10.1074/jbc.M505653200; Barnett ME, 2002, BIOCHEMISTRY-US, V41, P11277, DOI 10.1021/bi026161s; Beinker P, 2002, J BIOL CHEM, V277, P47160, DOI 10.1074/jbc.M207853200; Ben-Zvi AP, 2001, J STRUCT BIOL, V135, P84, DOI 10.1006/jsbi.2001.4352; Bolon DN, 2004, MOL CELL, V16, P343, DOI 10.1016/j.molcel.2004.10.001; Cashikar AG, 2002, MOL CELL, V9, P751, DOI 10.1016/S1097-2765(02)00499-9; Dougan DA, 2002, FEBS LETT, V529, P6, DOI 10.1016/S0014-5793(02)03179-4; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Grimminger V, 2004, J BIOL CHEM, V279, P7378, DOI 10.1074/jbc.M312403200; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hattendorf DA, 2002, EMBO J, V21, P12, DOI 10.1093/emboj/21.1.12; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; Hoskins JR, 1998, P NATL ACAD SCI USA, V95, P12135, DOI 10.1073/pnas.95.21.12135; Kenniston JA, 2003, CELL, V114, P511, DOI 10.1016/S0092-8674(03)00612-3; Lakowicz JR, 1999, PRINCIPLES FLUORESCE, P291, DOI 10.1007/978-1-4757-3061-6; Lee S, 2003, CELL, V115, P229, DOI 10.1016/S0092-8674(03)00807-9; Liu ZH, 2002, J MOL BIOL, V321, P111, DOI 10.1016/S0022-2836(02)00591-0; Lum R, 2004, J BIOL CHEM, V279, P29139, DOI 10.1074/jbc.M403777200; Maurizi MR, 2004, STRUCTURE, V12, P175, DOI 10.1016/j.str.2004.01.021; Mogk A, 2003, J BIOL CHEM, V278, P17615, DOI 10.1074/jbc.M209686200; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; Pak M, 1999, J BIOL CHEM, V274, P19316, DOI 10.1074/jbc.274.27.19316; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; Rohrwild M, 1996, P NATL ACAD SCI USA, V93, P5808, DOI 10.1073/pnas.93.12.5808; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schirmer EC, 2001, P NATL ACAD SCI USA, V98, P914, DOI 10.1073/pnas.031568098; Schirmer EC, 1998, J BIOL CHEM, V273, P15546, DOI 10.1074/jbc.273.25.15546; Schlee S, 2001, J MOL BIOL, V306, P889, DOI 10.1006/jmbi.2001.4455; Schlieker C, 2004, NAT STRUCT MOL BIOL, V11, P607, DOI 10.1038/nsmb787; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Scholz C, 1997, EMBO J, V16, P54, DOI 10.1093/emboj/16.1.54; STANIFORTH RA, 1994, BIOCHEM J, V300, P651, DOI 10.1042/bj3000651; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; Walter S, 2002, ANGEW CHEM INT EDIT, V41, P1098, DOI 10.1002/1521-3773(20020402)41:7<1098::AID-ANIE1098>3.0.CO;2-9; Watanabe Y, 2005, J BIOL CHEM, V280, P24562, DOI 10.1074/jbc.M414623200; Watanabe YH, 2002, J BIOL CHEM, V277, P5804, DOI 10.1074/jbc.M109349200; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Weibezahn J, 2004, CELL, V119, P653, DOI 10.1016/j.cell.2004.11.027; Weibezahn J, 2003, J BIOL CHEM, V278, P32608, DOI 10.1074/jbc.M303653200; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945	44	60	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38170	38176		10.1074/jbc.M506149200	http://dx.doi.org/10.1074/jbc.M506149200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16135516	hybrid			2022-12-27	WOS:000233239800009
J	Sirinian, MI; Belleudi, F; Campagna, F; Ceridono, M; Garofalo, T; Quagliarini, F; Verna, R; Calandra, S; Bertolini, S; Sorice, M; Torrisi, MR; Arca, M				Sirinian, MI; Belleudi, F; Campagna, F; Ceridono, M; Garofalo, T; Quagliarini, F; Verna, R; Calandra, S; Bertolini, S; Sorice, M; Torrisi, MR; Arca, M			Adaptor protein ARH is recruited to the plasma membrane by low density lipoprotein (LDL) binding and modulates endocytosis of the LDL/LDL receptor complex in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOSOMAL RECESSIVE HYPERCHOLESTEROLEMIA; MOLECULAR-MECHANISMS; CLATHRIN; INTERNALIZATION; MUTATIONS; DUPLEXES; RNAS; RAB4	ARH is a newly discovered adaptor protein required for the efficient activity of low density lipoprotein receptor ( LDLR) in selected tissues. Individuals lacking ARH have severe hypercholesterolemia due to an impaired hepatic clearance of LDL. It has been demonstrated that ARH is required for the efficient internalization of the LDL-LDLR complex and to stabilize the association of the receptor with LDL in Epstein-Barr virus-immortalized B lymphocytes. However, little information is available on the role of ARH in liver cells. Here we provide evidence that ARH is codistributed with LDLR on the basolateral area in confluent HepG2-polarized cells. This distribution is not modified by the overexpression of LDLR. Conversely, the activation of the LDLR-mediated endocytosis, but not the binding of LDL to LDLR, promotes a significant colocalization of ARH with LDL-LDLR complex that peaked at 2 min at 37 degrees C. To further assess the role of ARH in LDL-LDLR complex internalization, we depleted ARH protein using the RNA interference technique. Twenty-four hours after transfection with ARH-specific RNA interference, ARH protein was depleted in HepG2 cells by more than 70%. Quantitative immunofluorescence analysis revealed that the depletion of ARH caused about 80% reduction in LDL internalization. Moreover, our findings indicate that ARH is associated with other proteins of the endocytic machinery. We suggest that ARH is an endocytic sorting adaptor that actively participates in the internalization of the LDL-LDLR complex, possibly enhancing the efficiency of its packaging into the endocytic vesicles.	Univ Roma La Sapienza, Dept Clin & Appl Med Therapy, Policlin Umberto I, I-00161 Rome, Italy; Univ Roma La Sapienza, Dept Expt Med & Pathol, I-00161 Rome, Italy; Univ Roma La Sapienza, Azienda Osped SantAndrea, I-00161 Rome, Italy; Univ Modena & Reggio Emilia, Dept Biomed Sci, I-41100 Modena, Italy; Univ Genoa, Dept Internal Med, I-16132 Genoa, Italy	Sapienza University Rome; University Hospital Sapienza Rome; Sapienza University Rome; Sapienza University Rome; Universita di Modena e Reggio Emilia; University of Genoa	Arca, M (corresponding author), Univ Roma La Sapienza, Dept Clin & Appl Med Therapy, Policlin Umberto I, Viale Policlin 155, I-00161 Rome, Italy.	marcelloarca@libero.it	ARCA, Marcello/AAC-3883-2022; Sorice, Maurizio/Q-5079-2019; Sousa, Maria/HCI-9642-2022; /V-4899-2019	ARCA, Marcello/0000-0003-3786-0883; Garofalo, Tina/0000-0003-0645-2510; Quagliarini, Fabiana/0000-0002-1384-4857; VERNA, Roberto/0000-0002-1869-3912; Sorice, Maurizio/0000-0003-3534-1502	Telethon [GGP02149] Funding Source: Medline	Telethon(Fondazione Telethon)		ANDERSON RGW, 1977, CELL, V10, P351, DOI 10.1016/0092-8674(77)90022-8; Arca M, 2002, LANCET, V359, P841, DOI 10.1016/S0140-6736(02)07955-2; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1983, CELL, V32, P663, DOI 10.1016/0092-8674(83)90052-1; Carbone R, 1997, CANCER RES, V57, P5498; CARPENTIER JL, 1979, EXP CELL RES, V121, P135, DOI 10.1016/0014-4827(79)90453-1; Cohen JC, 2003, CURR OPIN LIPIDOL, V14, P121, DOI 10.1097/00041433-200304000-00002; Deneka M, 2003, EMBO J, V22, P2645, DOI 10.1093/emboj/cdg257; Eden ER, 2002, J CLIN INVEST, V110, P1695, DOI 10.1172/JCI200216445; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fouraux MA, 2004, MOL BIOL CELL, V15, P611, DOI 10.1091/mbc.E03-05-0343; Garcia CK, 2001, SCIENCE, V292, P1394, DOI 10.1126/science.1060458; GOLDSTEIN JL, 1979, NATURE, V279, P679, DOI 10.1038/279679a0; Goldstein JL, 2001, METABOLIC MOL BASES, V8th, P2863; Harada-Shiba M, 2004, CIRC RES, V95, P945, DOI 10.1161/01.RES.0000146946.78540.46; He GC, 2002, J BIOL CHEM, V277, P44044, DOI 10.1074/jbc.M208539200; Heinonen JE, 2002, FEBS LETT, V527, P274, DOI 10.1016/S0014-5793(02)03206-4; Hinrichsen L, 2003, J BIOL CHEM, V278, P45160, DOI 10.1074/jbc.M307290200; Jones C, 2003, J BIOL CHEM, V278, P29024, DOI 10.1074/jbc.M304855200; Lian WN, 1999, HEPATOLOGY, V30, P748, DOI 10.1002/hep.510300302; Michaely P, 2004, J BIOL CHEM, V279, P34023, DOI 10.1074/jbc.M405242200; Mishra SK, 2002, P NATL ACAD SCI USA, V99, P16099, DOI 10.1073/pnas.252630799; Norman D, 1999, J CLIN INVEST, V104, P619, DOI 10.1172/JCI6677; PATHAK RK, 1990, J CELL BIOL, V111, P347, DOI 10.1083/jcb.111.2.347; PEARSE BMF, 1976, P NATL ACAD SCI USA, V73, P1255, DOI 10.1073/pnas.73.4.1255; Rudenko G, 2002, SCIENCE, V298, P2353, DOI 10.1126/science.1078124; Stockinger W, 2002, EMBO J, V21, P4259, DOI 10.1093/emboj/cdf435; Van Dam AM, 2000, NEUROSCI LETT, V285, P169, DOI 10.1016/S0304-3940(00)01031-4; vanIjzendoorn SCD, 1997, J CELL BIOL, V137, P347, DOI 10.1083/jcb.137.2.347; Wilund KR, 2002, HUM MOL GENET, V11, P3019, DOI 10.1093/hmg/11.24.3019; Zuliani G, 1999, ARTERIOSCL THROM VAS, V19, P802, DOI 10.1161/01.ATV.19.3.802	32	28	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38416	38423		10.1074/jbc.M504343200	http://dx.doi.org/10.1074/jbc.M504343200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16129683	hybrid			2022-12-27	WOS:000233239800038
J	Okumura, K; Ohno, A; Nishida, M; Hayashi, K; Ikeda, K; Inoue, S				Okumura, K; Ohno, A; Nishida, M; Hayashi, K; Ikeda, K; Inoue, S			Mapping the region of the alpha-type phospholipase A(2) inhibitor responsible for its inhibitory activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACTANT PROTEIN-A; AGKISTRODON-BLOMHOFFII-SINITICUS; HELICAL COILED-COIL; MANNOSE-BINDING PROTEIN; AMINO-ACID-SEQUENCE; TRIMERESURUS-FLAVOVIRIDIS; BLOOD-PLASMA; CARBOHYDRATE-RECOGNITION; CRYSTAL-STRUCTURE; MOLECULAR-CLONING	alpha-Type phospholipase A(2) inhibitory protein (PLI alpha) from the serum of the venomous snake Gloydius brevicaudus, GbPLI alpha, is one of the protective endogenous proteins that neutralizes its own venom phospholipase A(2) (PLA(2)), and it is a homotrimer of subunits having a C-type lectin-like domain. The nonvenomous snake Elaphe quadrivirgata has a homologous serum protein, EqPLI alpha-LP, that does not show any inhibitory activity against various snake venom PLA(2)s (Okumura, K., Inoue, S., Ikeda, K., and Hayashi, K. ( 2003) IUBMB Life 55, 539 - 545). By constructing GbPLI alpha-EqPLI alpha-LP chimeric proteins, we have mapped the residues important in conferring GbPLI alpha inhibitory activity on region 13 - 36 in the primary structure of GbPLI alpha. Noninhibitory EqPLI alpha-LP showed comparable inhibitory activity only when this region was replaced with that of GbPLI alpha. Further, mutational analysis of the candidate residues revealed that the individual GbPLI alpha to EqPLI alpha-LP residue substitutions N26K, K28E, D29N, and Y144S each produced a mutant GbPLI alpha protein with reduced inhibitory activity, with the single N26K substitution having the most significant effect. Residues 13 - 36 were suspected to be located in the helical neck region of the GbPLI alpha trimer. Therefore, the region of GbPLI alpha responsible for PLA(2) inhibition was distinct from the carbohydrate-binding site of the homologous C-type lectin.	Osaka Univ Pharmaceut Sci, Dept Biochem, Osaka 5691094, Japan	Osaka University of Pharmaceutical Sciences	Inoue, S (corresponding author), Osaka Univ Pharmaceut Sci, Dept Biochem, 4-20-1 Nasahara, Osaka 5691094, Japan.	inoue@gly.oups.ac.jp	Inoue, Seiji/E-5128-2010	Inoue, Seiji/0000-0003-0760-1047				Arbibe L, 1998, J CLIN INVEST, V102, P1152, DOI 10.1172/JCI3236; Chabot S, 2003, J IMMUNOL, V171, P995, DOI 10.4049/jimmunol.171.2.995; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; Dunn RD, 2001, BBA-MOL CELL BIOL L, V1533, P29, DOI 10.1016/S1388-1981(01)00138-X; FISHER AB, 1994, BBA-LIPID LIPID MET, V1211, P256, DOI 10.1016/0005-2760(94)90148-1; Hakansson K, 1999, STRUCTURE, V7, P255, DOI 10.1016/S0969-2126(99)80036-7; Hakansson K, 2000, PROTEIN SCI, V9, P1607, DOI 10.1110/ps.9.9.1607; Head JF, 2003, J BIOL CHEM, V278, P43254, DOI 10.1074/jbc.M305628200; HEINRIKSON RL, 1977, J BIOL CHEM, V252, P4913; Higashino K, 2002, J BIOL CHEM, V277, P13583, DOI 10.1074/jbc.M108752200; HIGASHINO K, 1994, EUR J BIOCHEM, V225, P375, DOI 10.1111/j.1432-1033.1994.00375.x; Inoue S, 1997, BIOCHEM MOL BIOL INT, V41, P529; INOUE S, 1991, J BIOL CHEM, V266, P1001; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; Kini RM, 2003, TOXICON, V42, P827, DOI 10.1016/j.toxicon.2003.11.002; KOGAKI H, 1989, J BIOCHEM-TOKYO, V106, P966, DOI 10.1093/oxfordjournals.jbchem.a122983; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; Lizano S, 1997, BIOCHEM J, V326, P853, DOI 10.1042/bj3260853; Lizano S, 2000, BIOCHEM J, V346, P631, DOI 10.1042/0264-6021:3460631; Murakami M, 2002, J BIOCHEM, V131, P285, DOI 10.1093/oxfordjournals.jbchem.a003101; Nielsen BB, 1997, FEBS LETT, V412, P388, DOI 10.1016/S0014-5793(97)00664-9; Nobuhisa I, 1998, FEBS LETT, V429, P385, DOI 10.1016/S0014-5793(98)00602-4; OHKURA N, 1993, J BIOCHEM-TOKYO, V113, P413, DOI 10.1093/oxfordjournals.jbchem.a124060; Ohkura N, 1997, BIOCHEM J, V325, P527, DOI 10.1042/bj3250527; Okumura K, 2003, IUBMB LIFE, V55, P539, DOI 10.1080/15216540310001620995; Okumura K, 1999, BBA-MOL CELL BIOL L, V1441, P51, DOI 10.1016/S1388-1981(99)00141-9; RADVANYI F, 1989, ANAL BIOCHEM, V177, P103, DOI 10.1016/0003-2697(89)90022-5; SHERIFF S, 1994, NAT STRUCT BIOL, V1, P789, DOI 10.1038/nsb1194-789; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3	31	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37651	37659		10.1074/jbc.M507250200	http://dx.doi.org/10.1074/jbc.M507250200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16150695	hybrid			2022-12-27	WOS:000233044500042
J	Auerbach, SD; Johnson, KA				Auerbach, SD; Johnson, KA			Alternating site ATPase pathway of rat conventional kinesin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAND-OVER-HAND; T7 RNA-POLYMERASE; DIMERIC KINESIN; MOTOR DOMAIN; ACTOMYOSIN SUBFRAGMENT-1; KINETIC MECHANISM; ESCHERICHIA-COLI; CLONED GENES; HEAD DOMAINS; MICROTUBULE	The pathway of ATP hydrolysis by rat kinesin was established by pre-steady-state kinetic methods. A 406-residue long N-terminal fragment was shown by sedimentation equilibrium analysis to form a dimer with a K-d of 46 nM. The pathway of ATP hydrolysis follows the Gilbert-Johnson pathway determined previously for a similar-sized N-terminal fragment of Drosophila conventional kinesin. However, the rates of ADP release were at least 3-fold faster, and ATP hydrolysis was similar to 5-fold faster. Paralleling our previous mechanistic data, these results support an alternating site ATPase pathway, including a captive head state as an intermediate in the kinesin ATPase cycle. The kinetic data presented in this report once again point to the importance of the captive head state and argue against a pathway that short-circuits this key intermediate. In addition, several unique aspects of the rat kinesin kinetics reveal new aspects of the ATPase-coupling mechanism. These studies provide a baseline set of kinetic parameters against which future studies of rat kinesin mutants may be evaluated and directly correlated with the structure of the dimeric kinesin.	Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Johnson, KA (corresponding author), Univ Texas, MBB 3-122,2500 Speedway A4800, Austin, TX 78735 USA.	kajohnson@mail.utexas.edu			NIGMS NIH HHS [GM-26726-25] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026726] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asbury CL, 2003, SCIENCE, V302, P2130, DOI 10.1126/science.1092985; Auerbach SD, 2005, J BIOL CHEM, V280, P37061, DOI 10.1074/jbc.M502985200; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BORISY GG, 1974, FED PROC, V33, P167; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braman J, 1996, Methods Mol Biol, V57, P31; Brune M, 1998, BIOCHEMISTRY-US, V37, P10370, DOI 10.1021/bi9804277; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; Cheng JQ, 1998, BIOCHEMISTRY-US, V37, P5288, DOI 10.1021/bi972742j; CORREIA JJ, 1995, BIOCHEMISTRY-US, V34, P4898, DOI 10.1021/bi00014a047; Crevel IMTC, 1996, J MOL BIOL, V257, P66, DOI 10.1006/jmbi.1996.0147; Cross RA, 2000, PHILOS T ROY SOC B, V355, P459, DOI 10.1098/rstb.2000.0587; Endow SA, 1999, EUR J BIOCHEM, V262, P12, DOI 10.1046/j.1432-1327.1999.00339.x; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GILBERT SP, 1994, BIOCHEMISTRY-US, V33, P1951, DOI 10.1021/bi00173a044; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; Gilbert SP, 1998, BIOCHEMISTRY-US, V37, P792, DOI 10.1021/bi971117b; Gilbert SP, 2000, METHODS, V22, P337, DOI 10.1006/meth.2000.1086; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HACKNEY DD, 1994, J BIOL CHEM, V269, P16508; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Hunter AW, 2000, J CELL SCI, V113, P4379; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Kaseda K, 2003, NAT CELL BIOL, V5, P1079, DOI 10.1038/ncb1067; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13233, DOI 10.1021/bi00040a039; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; Ma YZ, 1997, J BIOL CHEM, V272, P717, DOI 10.1074/jbc.272.2.717; Mandelkow E, 1999, CURR OPIN CELL BIOL, V11, P34, DOI 10.1016/S0955-0674(99)80005-2; Miki H, 2001, P NATL ACAD SCI USA, V98, P7004, DOI 10.1073/pnas.111145398; Morfini G, 2001, DEV NEUROSCI-BASEL, V23, P364, DOI 10.1159/000048720; Moyer ML, 1996, BIOCHEMISTRY-US, V35, P6321, DOI 10.1021/bi960017n; Moyer ML, 1998, BIOCHEMISTRY-US, V37, P800, DOI 10.1021/bi9711184; Naber N, 2003, BIOPHYS J, V84, P3190, DOI 10.1016/S0006-3495(03)70043-5; OMOTO CK, 1986, BIOCHEMISTRY-US, V25, P419, DOI 10.1021/bi00350a022; Peterman EJG, 2004, ANNU REV PHYS CHEM, V55, P79, DOI 10.1146/annurev.physchem.55.091602.094340; Peterman EJG, 2001, BIOPHYS J, V81, P2851, DOI 10.1016/S0006-3495(01)75926-7; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Rosenfeld SS, 2003, J BIOL CHEM, V278, P18550, DOI 10.1074/jbc.M300849200; Sack S, 1997, BIOCHEMISTRY-US, V36, P16155, DOI 10.1021/bi9722498; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Schief WR, 2004, P NATL ACAD SCI USA, V101, P1183, DOI 10.1073/pnas.0304369101; Scholey JM, 2003, ANNU REV CELL DEV BI, V19, P423, DOI 10.1146/annurev.cellbio.19.111401.091318; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SLOBODA RD, 1976, BIOCHEMISTRY-US, V15, P4497, DOI 10.1021/bi00665a026; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; WOODWARD SKA, 1991, BIOCHEMISTRY-US, V30, P422, DOI 10.1021/bi00216a017; Xing J, 2000, J BIOL CHEM, V275, P35413, DOI 10.1074/jbc.M004232200; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; Yildiz A, 2004, SCIENCE, V303, P676, DOI 10.1126/science.1093753; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	59	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37048	37060		10.1074/jbc.M502984200	http://dx.doi.org/10.1074/jbc.M502984200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16118218	hybrid			2022-12-27	WOS:000232901800063
J	Feng, HY; Drone, J; Hoffmann, L; Tran, V; Tellier, C; Rabiller, C; Dion, M				Feng, HY; Drone, J; Hoffmann, L; Tran, V; Tellier, C; Rabiller, C; Dion, M			Converting a beta-glycosidase into a beta-transglycosidase by directed evolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGLYCOSYLATION ACTIVITY; OLIGOSACCHARIDE SYNTHESIS; THERMUS-THERMOPHILUS; ALPHA-GALACTOSIDASE; EPITHELIAL-CELLS; MUTANT; GLUCOSIDASE; BINDING; GLYCOSYNTHASES; MUTAGENESIS	Directed evolution was applied to the beta-glycosidase of Thermus thermophilus in order to increase its ability to synthesize oligosaccharide by transglycosylation. Wild-type enzyme was able to transfer the glycosyl residue with a yield of 50% by self-condensation and of about 8% by transglycosylation on disaccharides without nitrophenyl at their reducing end. By using a simple screening procedure, we could produce mutant enzymes possessing a high transferase activity. In one step of random mutagenesis and in vitro recombination, the hydrolysis of substrates and of transglycosylation products was considerably reduced. For certain mutants, synthesis by self-condensation of nitrophenyl glycosides became nearly quantitative, whereas synthesis by transglycosylation on maltose and on cellobiose could reach 60 and 75%, respectively. Because the most efficient mutations, F401S and N282T, were located just in front of the subsite (-1), molecular modeling techniques were used to explain their effects on the synthesis reaction; we can suggest that repositioning of the glycone in the (-1) subsite together with a better fit of the acceptor in the (-1) subsite might favor the attack of a glycosyl acceptor in the mutant at the expense of water. Thus these new transglycosidases constitute an interesting alternative for the synthesis of oligosaccharides by using stable and accessible donor substrates.	Univ Nantes, Fac Sci & Tech, CNRS, Biotechnol Biocatalyse Bioregulat UMR 6204, F-44322 Nantes, France; Hebei Univ Sci & Technol, Inst Biosci & Biotechnol, Shijiazhuang 050018, Peoples R China	Centre National de la Recherche Scientifique (CNRS); Nantes Universite; Hebei University of Science & Technology	Dion, M (corresponding author), Univ Nantes, Fac Sci & Tech, CNRS, Biotechnol Biocatalyse Bioregulat UMR 6204, 2 Rue Houssiniere,BP 92208, F-44322 Nantes, France.	michel.dion@univ-nantes.fr						Albenne C, 2004, J BIOL CHEM, V279, P726, DOI 10.1074/jbc.M309891200; Andre G, 1996, BIOPOLYMERS, V39, P737, DOI 10.1002/(SICI)1097-0282(199611)39:5<737::AID-BIP12>3.0.CO;2-2; Bak-Jensen KS, 2004, J BIOL CHEM, V279, P10093, DOI 10.1074/jbc.M312825200; BRASSART D, 1991, INFECT IMMUN, V59, P1605, DOI 10.1128/IAI.59.5.1605-1613.1991; Chiffoleau-Giraud V, 1999, EUR J ORG CHEM, V1999, P757; Daines AM, 2004, CURR OPIN CHEM BIOL, V8, P106, DOI 10.1016/j.cbpa.2004.02.003; Dinur U., 1991, REV COMPUT CHEM, V2, P99, DOI [DOI 10.1002/9780470125793.CH4, 10.1002/9780470125793.ch4]; Dion M, 2001, GLYCOCONJUGATE J, V18, P457, DOI 10.1023/A:1016034101436; Dion M, 2001, GLYCOCONJUGATE J, V18, P215, DOI 10.1023/A:1012448522187; Dion M, 1999, GLYCOCONJUGATE J, V16, P27, DOI 10.1023/A:1006997602727; Drone J, 2005, EUR J ORG CHEM, V2005, P1977, DOI 10.1002/ejoc.200500014; Farinas ET, 2001, CURR OPIN BIOTECH, V12, P545, DOI 10.1016/S0958-1669(01)00261-0; Fourage L, 2001, APPL MICROBIOL BIOT, V56, P406, DOI 10.1007/s002530100627; Fourage L, 2000, GLYCOCONJUGATE J, V17, P377, DOI 10.1023/A:1007104030314; Gao SY, 2003, INT J PHARM, V255, P57, DOI 10.1016/S0378-5173(03)00082-6; Gilewski T, 2001, P NATL ACAD SCI USA, V98, P3270, DOI 10.1073/pnas.051626298; Goyal K, 2002, ARCH BIOCHEM BIOPHYS, V407, P125, DOI 10.1016/S0003-9861(02)00470-8; Hansson T, 2001, BIOTECHNOL BIOENG, V73, P203, DOI 10.1002/bit.1052; Jorgensen F, 2001, APPL MICROBIOL BIOT, V57, P647, DOI 10.1007/s00253-001-0845-z; KEMPTON JB, 1992, BIOCHEMISTRY-US, V31, P9961, DOI 10.1021/bi00156a015; Kim YW, 2004, J BIOL CHEM, V279, P42787, DOI 10.1074/jbc.M406890200; KRIVAN HC, 1988, P NATL ACAD SCI USA, V85, P6157, DOI 10.1073/pnas.85.16.6157; Kudryashov V, 2001, P NATL ACAD SCI USA, V98, P3264, DOI 10.1073/pnas.051623598; Le Pendu J, 2004, ADV EXP MED BIOL, V554, P135; Leung DW, 1989, TECHNIQUE, V1, P11; Ly HD, 1999, ANNU REV BIOCHEM, V68, P487, DOI 10.1146/annurev.biochem.68.1.487; Mackenzie LF, 1998, J AM CHEM SOC, V120, P5583, DOI 10.1021/ja980833d; Malet C, 1998, FEBS LETT, V440, P208, DOI 10.1016/S0014-5793(98)01448-3; MATSUI I, 1991, BIOCHIM BIOPHYS ACTA, V1077, P416, DOI 10.1016/0167-4838(91)90560-M; Mayer C, 2000, FEBS LETT, V466, P40, DOI 10.1016/S0014-5793(99)01751-2; Paris G, 2005, J MOL BIOL, V345, P923, DOI 10.1016/j.jmb.2004.09.031; Perugino G, 2004, TRENDS BIOTECHNOL, V22, P31, DOI 10.1016/j.tibtech.2003.10.008; Perugino G, 2003, BIOCHEMISTRY-US, V42, P8484, DOI 10.1021/bi0345384; Prade H, 1997, CARBOHYD RES, V305, P371, DOI 10.1016/S0008-6215(97)10040-4; Rivera MH, 2003, PROTEIN ENG, V16, P505, DOI 10.1093/protein/gzg060; Ruiz-Palacios GM, 2003, J BIOL CHEM, V278, P14112, DOI 10.1074/jbc.M207744200; Sears P, 2001, SCIENCE, V291, P2344, DOI 10.1126/science.1058899; Simon PM, 1997, INFECT IMMUN, V65, P750, DOI 10.1128/IAI.65.2.750-757.1997; Varki A, 1997, J CLIN INVEST, V99, P158, DOI 10.1172/JCI119142	39	87	95	1	42	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37088	37097		10.1074/jbc.M502873200	http://dx.doi.org/10.1074/jbc.M502873200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16085651	hybrid, Green Published			2022-12-27	WOS:000232901800067
J	Hass, MR; Yankner, BA				Hass, MR; Yankner, BA			A gamma-secretase-independent mechanism of signal transduction by the amyloid precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL DOMAIN; ALZHEIMERS-DISEASE; CELL-SURFACE; PRESENILIN-1 MUTATIONS; INTRACELLULAR DOMAIN; ACETYLTRANSFERASE ACTIVITY; BETA-APP; A-BETA; TIP60; FE65	It has been proposed that gamma-secretase-mediated release of the amyloid precursor protein (APP) intracellular domain ( AICD) results in nuclear translocation and signaling through a complex with the adaptor protein Fe65 and the histone acetyltransferase Tip60. Here, we show that APP and Fe65 activate transcription through a Gal4-Tip60 reporter in presenilin-1/2-deficient cells lacking generation of AICD. APP and Fe65 also activated transcription in the presence of gamma-secretase inhibitors that prevent amyloid beta-peptide production in human embryonic kidney 293 and SH-SY5Y cells. In contrast to the transcriptionally active Notch intracellular domain, expression of AICD did not activate transcription. An alternative mechanism for APP signal transduction is suggested by the identification of essential cyclin-dependent kinase (CDK) phosphorylation sites in Tip60. Mutation of these Tip60 phosphorylation sites or treatment with the CDK inhibitor roscovitine blocked the ability of APP to signal through Tip60. Moreover, APP stabilized Tip60 through CDK-dependent phosphorylation. Subcellular fractionation and confocal immunofluorescence showed that APP recruited Tip60 to membrane compartments. Thus, APP may signal to the nucleus by a gamma-secretase-independent mechanism that involves membrane sequestration and phosphorylation of Tip60.	Harvard Univ, Childrens Hosp, Sch Med, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Div Neurosci, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Yankner, BA (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Dept Neurol, Enders 460,300 Longwood Ave, Boston, MA 02115 USA.	Bruce.Yankner@childrens.harvard.edu			NIA NIH HHS [AG0022, T32 AG000222, R01 AG017974, AG17974] Funding Source: Medline; NINDS NIH HHS [R01 NS030352, NS030352] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017974, T32AG000222] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ando K, 2001, J BIOL CHEM, V276, P40353, DOI 10.1074/jbc.M104059200; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; BREEN KC, 1991, J NEUROSCI RES, V28, P90, DOI 10.1002/jnr.490280109; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cao XW, 2004, J BIOL CHEM, V279, P24601, DOI 10.1074/jbc.M402248200; Chen FS, 2002, J BIOL CHEM, V277, P36521, DOI 10.1074/jbc.M205093200; CHEN M, 1991, NEUROSCI LETT, V125, P223, DOI 10.1016/0304-3940(91)90034-Q; Creaven M, 1999, BIOCHEMISTRY-US, V38, P8826, DOI 10.1021/bi9907274; DE SB, 1999, NATURE, V398, P518; Ebinu JO, 2002, NEURON, V34, P499, DOI 10.1016/S0896-6273(02)00704-3; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Gaughan L, 2001, J BIOL CHEM, V276, P46841, DOI 10.1074/jbc.M103710200; Geula C, 1998, NAT MED, V4, P827, DOI 10.1038/nm0798-827; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Iijima K, 2000, J NEUROCHEM, V75, P1085, DOI 10.1046/j.1471-4159.2000.0751085.x; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; JIN LW, 1994, J NEUROSCI, V14, P5461; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kim HS, 2003, FASEB J, V17, P1951, DOI 10.1096/fj.03-0106fje; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Kinoshita A, 2002, J NEUROCHEM, V82, P839, DOI 10.1046/j.1471-4159.2002.01016.x; Kinoshita A, 2002, J BIOL CHEM, V277, P28530, DOI 10.1074/jbc.M203372200; Koo EH, 2004, NAT MED, V10, pS26, DOI 10.1038/nm1065; la Cour T, 2003, NUCLEIC ACIDS RES, V31, P393, DOI 10.1093/nar/gkg101; LEBLANC AC, 1992, J NEUROSCI RES, V31, P635, DOI 10.1002/jnr.490310407; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Lemercier C, 2003, J BIOL CHEM, V278, P4713, DOI 10.1074/jbc.M211811200; Lichtenthaler SF, 2004, J CLIN INVEST, V113, P1384, DOI 10.1172/JCI200421746; McAllister D, 2002, GENE, V289, P169, DOI 10.1016/S0378-1119(02)00546-2; Moehlmann T, 2002, P NATL ACAD SCI USA, V99, P8025, DOI 10.1073/pnas.112686799; Pardossi-Piquard R, 2005, NEURON, V46, P541, DOI 10.1016/j.neuron.2005.04.008; Passer Brent, 2000, Journal of Alzheimer's Disease, V2, P289; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; QIU WQ, 1995, J NEUROSCI, V15, P2157, DOI 10.1523/JNEUROSCI.15-03-02157.1995; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; Saura CA, 2004, NEURON, V42, P23, DOI 10.1016/S0896-6273(04)00182-5; Schroeter EH, 2003, P NATL ACAD SCI USA, V100, P13075, DOI 10.1073/pnas.1735338100; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; von Rotz RC, 2004, J CELL SCI, V117, P4435, DOI 10.1242/jcs.01323; Wiley JC, 2005, J NEUROCHEM, V94, P1189, DOI 10.1111/j.1471-4159.2005.03266.x; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Zambrano N, 2004, J BIOL CHEM, V279, P16161, DOI 10.1074/jbc.M311027200; Zambrano N, 2002, J CELL SCI, V115, P1411; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	48	78	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36895	36904		10.1074/jbc.M502861200	http://dx.doi.org/10.1074/jbc.M502861200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16103124	Green Accepted, hybrid			2022-12-27	WOS:000232901800045
J	Quinaud, M; Chabert, J; Faudry, E; Neumann, E; Lemaire, D; Pastor, A; Elsen, S; Dessen, A; Attree, I				Quinaud, M; Chabert, J; Faudry, E; Neumann, E; Lemaire, D; Pastor, A; Elsen, S; Dessen, A; Attree, I			The PscE-PscF-PscG complex controls type III secretion needle biogenesis in Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECRETION; YERSINIA-ENTEROCOLITICA; STRUCTURAL-CHARACTERIZATION; SUPRAMOLECULAR STRUCTURE; BACTERIAL INJECTISOMES; SUBSTRATE-SPECIFICITY; TRANSLOCATION PORE; SHIGELLA-FLEXNERI; ESCHERICHIA-COLI; PLASMA-MEMBRANE	Type III secretion (T3S) systems play key roles in pathogenicity of many Gram-negative bacteria and are employed to inject toxins directly into the cytoplasm of target cells. They are composed of over 20 different proteins that associate into a basal structure that traverses both inner and outer bacterial membranes and a hollow, needle-like structure through which toxins travel. The PscF protein is the main component of the Pseudomonas aeruginosa T3S needle. Here we demonstrate that PscF, when purified on its own, is able to form needle-like fibers of 8 nm in width and > 1 mu m in length. In addition, we demonstrate for the first time that the T3S needle subunit requires two cytoplasmic partners, PscE and PscG, in P. aeruginosa, which trap PscF in a ternary, 1: 1: 1 complex, thus blocking it in a monomeric state. Knock-out mutants deficient in PscE and PscG are non-cytotoxic, lack PscF, and are unable to export PscF encoded extrachromosomally. Temperature-scanning circular dichroism measurements show that the PscE-PscF-PscG complex is thermally stable and displays a cooperative unfolding/refolding pattern. Thus, PscE and PscG prevent PscF from polymerizing prematurely in the P. aeruginosa cytoplasm and keep it in a secretion prone conformation, strategies which may be shared by other pathogens that employ the T3S system for infection.	Univ Grenoble 1, CEA Grenoble, Dept Reponse & Dynam Cellulaires, CNRS,UMR 5092, F-38054 Grenoble, France; UJF, CEA, Inst Biol Struct Jean Pierre Ebel, CNRS,UMR 5075, Grenoble, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA	Attree, I (corresponding author), Univ Grenoble 1, CEA Grenoble, Dept Reponse & Dynam Cellulaires, CNRS,UMR 5092, 17 Rue Martyrs, F-38054 Grenoble, France.	iattreedelic@cea.fr	Faudry, Eric/I-9154-2014	Faudry, Eric/0000-0001-9958-6029; Attree, Ina/0000-0002-2580-764X; Lemaire, David/0000-0001-6874-3685; Dessen, Andrea/0000-0001-6487-4020; Elsen, Sylvie/0000-0003-4611-4719				Agrain C, 2005, MOL MICROBIOL, V56, P54, DOI 10.1111/j.1365-2958.2005.04534.x; Auvray F, 2001, J MOL BIOL, V308, P221, DOI 10.1006/jmbi.2001.4597; Berthelot P, 2003, J INFECT DIS, V188, P512, DOI 10.1086/377000; Blocker A, 2003, P NATL ACAD SCI USA, V100, P3027, DOI 10.1073/pnas.0535335100; Blocker A, 2001, MOL MICROBIOL, V39, P652, DOI 10.1046/j.1365-2958.2001.02200.x; Cheng LW, 1999, J BIOL CHEM, V274, P22102, DOI 10.1074/jbc.274.31.22102; Choudhury D, 1999, SCIENCE, V285, P1061, DOI 10.1126/science.285.5430.1061; Cordes FS, 2003, J BIOL CHEM, V278, P17103, DOI 10.1074/jbc.M300091200; Cornelis GR, 2000, ANNU REV MICROBIOL, V54, P735, DOI 10.1146/annurev.micro.54.1.735; Dacheux D, 1999, INFECT IMMUN, V67, P6164, DOI 10.1128/IAI.67.11.6164-6167.1999; Dacheux D, 2002, INFECT IMMUN, V70, P3973, DOI 10.1128/IAI.70.7.3973-3977.2002; Dacheux D, 2001, MOL MICROBIOL, V40, P76, DOI 10.1046/j.1365-2958.2001.02368.x; Day JB, 2000, INFECT IMMUN, V68, P6466, DOI 10.1128/IAI.68.11.6466-6471.2000; FRITHZLINDSTEN E, 1995, MOL MICROBIOL, V16, P635, DOI 10.1111/j.1365-2958.1995.tb02426.x; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; Gauthier A, 2003, J BACTERIOL, V185, P6747, DOI 10.1128/JB.185.23.6747-6755.2003; Ghosh P, 2004, MICROBIOL MOL BIOL R, V68, P771, DOI 10.1128/MMBR.68.4.771-795.2004; Goure J, 2004, INFECT IMMUN, V72, P4741, DOI 10.1128/IAI.72.8.4741-4750.2004; Hakansson S, 1996, EMBO J, V15, P5812, DOI 10.1002/j.1460-2075.1996.tb00968.x; Hoiczyk E, 2001, P NATL ACAD SCI USA, V98, P4669, DOI 10.1073/pnas.071065798; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Ide T, 2001, CELL MICROBIOL, V3, P669, DOI 10.1046/j.1462-5822.2001.00146.x; Jin QL, 2001, SCIENCE, V294, P2556, DOI 10.1126/science.1066397; Jouihri N, 2003, MOL MICROBIOL, V49, P755, DOI 10.1046/j.1365-2958.2003.03590.x; Journet L, 2003, SCIENCE, V302, P1757, DOI 10.1126/science.1091422; Kimbrough TG, 2000, P NATL ACAD SCI USA, V97, P11008, DOI 10.1073/pnas.200209497; KONYECSNI WM, 1988, GENE, V74, P375, DOI 10.1016/0378-1119(88)90171-0; Kubori T, 1998, SCIENCE, V280, P602, DOI 10.1126/science.280.5363.602; Kubori T, 2000, P NATL ACAD SCI USA, V97, P10225, DOI 10.1073/pnas.170128997; Li CM, 2002, EMBO J, V21, P1909, DOI 10.1093/emboj/21.8.1909; Luo Y, 2001, NAT STRUCT BIOL, V8, P1031, DOI 10.1038/nsb717; Lyczak JB, 2000, MICROBES INFECT, V2, P1051, DOI 10.1016/S1286-4579(00)01259-4; Lyczak JB, 2002, CLIN MICROBIOL REV, V15, P194, DOI 10.1128/CMR.15.2.194-222.2002; Magdalena J, 2002, J BACTERIOL, V184, P3433, DOI 10.1128/JB.184.13.3433-3441.2002; Marlovits TC, 2004, SCIENCE, V306, P1040, DOI 10.1126/science.1102610; Mota LJ, 2005, SCIENCE, V307, P1278, DOI 10.1126/science.1107679; Muramoto K, 1998, J MOL BIOL, V277, P871, DOI 10.1006/jmbi.1998.1659; Neyt C, 1999, MOL MICROBIOL, V33, P971, DOI 10.1046/j.1365-2958.1999.01537.x; Pallen MJ, 2005, FEMS MICROBIOL REV, V29, P201, DOI 10.1016/j.femsre.2005.01.001; Parsot C, 2003, CURR OPIN MICROBIOL, V6, P7, DOI 10.1016/S1369-5274(02)00002-4; PASTOR A, 2005, IN PRESS FEMS MICROB; Rosqvist R, 1995, CONTRIB TO MICROBIOL, V13, P230; Roy-Burman A, 2001, J INFECT DIS, V183, P1767, DOI 10.1086/320737; Sawa T, 1998, INFECT IMMUN, V66, P3242, DOI 10.1128/IAI.66.7.3242-3249.1998; Schoehn G, 2003, EMBO J, V22, P4957, DOI 10.1093/emboj/cdg499; SCHWEIZER HP, 1992, MOL MICROBIOL, V6, P1195, DOI 10.1111/j.1365-2958.1992.tb01558.x; Sekiya K, 2001, P NATL ACAD SCI USA, V98, P11638, DOI 10.1073/pnas.191378598; Stebbins CE, 2001, NATURE, V414, P77, DOI 10.1038/35102073; Sukhan A, 2001, J BACTERIOL, V183, P1159, DOI 10.1128/JB.183.4.1159-1167.2001; Swietnicki W, 2005, PROTEIN EXPRES PURIF, V42, P166, DOI 10.1016/j.pep.2005.02.016; Tamano K, 2000, EMBO J, V19, P3876, DOI 10.1093/emboj/19.15.3876; Tardy F, 1999, EMBO J, V18, P6793, DOI 10.1093/emboj/18.23.6793; Thomas J, 2004, P NATL ACAD SCI USA, V101, P3945, DOI 10.1073/pnas.0307223101; Wattiau P, 1996, MOL MICROBIOL, V20, P255, DOI 10.1111/j.1365-2958.1996.tb02614.x; Yahr TL, 1997, J BACTERIOL, V179, P7165, DOI 10.1128/jb.179.22.7165-7168.1997; Yip CK, 2005, NATURE, V435, P702, DOI 10.1038/nature03554; Yip CK, 2005, NAT STRUCT MOL BIOL, V12, P75, DOI 10.1038/nsmb879; Zavialov AV, 2003, CELL, V113, P587, DOI 10.1016/S0092-8674(03)00351-9	59	63	70	2	11	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36293	36300		10.1074/jbc.M508089200	http://dx.doi.org/10.1074/jbc.M508089200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16115870	hybrid			2022-12-27	WOS:000232726900062
J	Shen, CL; Ye, Y; Robertson, SE; Lau, AW; Mak, DOD; Chou, MM				Shen, CL; Ye, Y; Robertson, SE; Lau, AW; Mak, DOD; Chou, MM			Calcium/calmodulin regulates ubiquitination of the ubiquitin-specific protease TRE17/USP6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ANEURYSMAL BONE-CYST; DEUBIQUITINATING ENZYMES; CALMODULIN; ACTIVATION; ONCOGENE; PROTEINS; PATHWAY; USP6; MONOUBIQUITINATION	The TRE17 (USP6/TRE-2) oncogene induces tumorigenesis in both humans and mice. However, little is known regarding its regulation or mechanism of transformation. TRE17 encodes a TBC (Tre-2/Bub2/Cdc16)/Rab GTPase-activating protein homology domain at its N terminus and a ubiquitin-specific protease at its C terminus. In the current study, we identified the ubiquitous calcium (Ca2+)-binding protein calmodulin (CaM) as a novel binding partner for TRE17. CaM bound directly to TRE17 in a Ca2+-dependent manner both in vitro and in vivo. The CaM-binding site was mapped to two hydrophobic motifs near the C terminus of the TBC domain. Point mutations within these motifs significantly reduced the interaction of TRE17 with CaM. We further found that TRE17 is monoubiquitinated and promotes its own deubiquitination in vivo. CaM binding-deficient mutants of TRE17 exhibited significantly reduced monoubiquitination, suggesting that binding of Ca2+/CaM to TRE17 promotes this modification. Consistent with this notion, treatment of cells with the CaM inhibitor W7 reduced levels of TRE17 monoubiquitination. Interestingly, the calcium ionophore A23187 induced accumulation of a polyubiquitinated TRE17 species. The effect of A23187 was attenuated in CaM binding-deficient mutants of TRE17. Taken together, these studies indicate a role for Ca2+/CaM in regulating ubiquitination through direct interaction with TRE17.	Univ Penn, Sch Med, Dept Cell & Dev Biol, BRBII, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Chou, MM (corresponding author), Univ Penn, Sch Med, Dept Cell & Dev Biol, BRBII, Rm 1011,421 Curie Blvd, Philadelphia, PA 19104 USA.	mmc@mail.med.upenn.edu			NATIONAL CANCER INSTITUTE [R01CA081415] Funding Source: NIH RePORTER; NCI NIH HHS [CA-81415] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; BLUMENTHAL DK, 1980, BIOCHEMISTRY-US, V19, P5608, DOI 10.1021/bi00565a023; Bootman MD, 2001, J CELL SCI, V114, P2213; Bootman MD, 2001, SEMIN CELL DEV BIOL, V12, P3, DOI 10.1006/scdb.2000.0211; Borodovsky A, 2001, EMBO J, V20, P5187, DOI 10.1093/emboj/20.18.5187; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; Ciechanover A, 2004, TRENDS CELL BIOL, V14, P103, DOI 10.1016/j.tcb.2004.01.004; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Cohen M, 2003, NAT CELL BIOL, V5, P661, DOI 10.1038/ncb1003; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; Henry KW, 2003, GENE DEV, V17, P2648, DOI 10.1101/gad.1144003; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Ingvarsdottir K, 2005, MOL CELL BIOL, V25, P1162, DOI 10.1128/MCB.25.3.1162-1172.2005; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li QW, 2004, BIOCHEM BIOPH RES CO, V317, P787, DOI 10.1016/j.bbrc.2004.03.119; Martinu L, 2004, MOL CELL BIOL, V24, P9752, DOI 10.1128/MCB.24.22.9752-9762.2004; Masuda-Robens JM, 2003, MOL CELL BIOL, V23, P2151, DOI 10.1128/MCB.23.6.2151-2161.2003; NAKAMURA T, 1992, ONCOGENE, V7, P733; Oliveira AM, 2005, ONCOGENE, V24, P3419, DOI 10.1038/sj.onc.1208506; Oliveira AM, 2004, CANCER RES, V64, P1920, DOI 10.1158/0008-5472.CAN-03-2827; Oliveira AM, 2004, AM J PATHOL, V165, P1773, DOI 10.1016/S0002-9440(10)63432-3; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Sigismund S, 2004, CURR TOP MICROBIOL, V286, P149; Soderling TR, 2001, CHEM REV, V101, P2341, DOI 10.1021/cr0002386; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Wing SS, 2003, INT J BIOCHEM CELL B, V35, P590, DOI 10.1016/S1357-2725(02)00392-8	34	39	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35967	35973		10.1074/jbc.M505220200	http://dx.doi.org/10.1074/jbc.M505220200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16127172	hybrid			2022-12-27	WOS:000232726900024
J	Clarke, CAL; Bennett, LN; Clarke, PR				Clarke, CAL; Bennett, LN; Clarke, PR			Cleavage of claspin by caspase-7 during apoptosis inhibits the Chk1 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; DNA-DAMAGE CHECKPOINT; EARLY EMBRYONIC LETHALITY; XENOPUS EGG EXTRACTS; CELL-FREE SYSTEM; POLY(ADP-RIBOSE) POLYMERASE; RADIOSENSITIZING AGENT; CATALYTIC SUBUNIT; TUMOR SUPPRESSION; ATR	Claspin is required for the phosphorylation and activation of the Chk1 protein kinase by ATR during DNA replication and in response to DNA damage. This checkpoint pathway plays a critical role in the resistance of cells to genotoxic stress. Here, we show that human Claspin is cleaved by caspase- 7 during the initiation of apoptosis. In cells, induction of DNA damage by etoposide at first produced rapid phosphorylation of Chk1 at a site targeted by ATR. Subsequently, etoposide caused activation of caspase- 7, cleavage of Claspin, and dephosphorylation of Chk1. In apoptotic cell extracts, Claspin was cleaved by caspase- 7 at a single aspartate residue into a large N- terminal fragment and a smaller C- terminal fragment that contain different functional domains. The large N- terminal fragment was heavily phosphorylated in a human cell- free system in response to double- stranded DNA oligonucleotides, and this fragment retained Chk1 binding activity. In contrast, the smaller C- terminal fragment did not bind Chk1, but did associate with DNA and inhibited the DNA- dependent phosphorylation of Chk1 associated with its activation. These results indicate that cleavage of Claspin by caspase- 7 inactivates the Chk1 signaling pathway. This mechanism may regulate the balance between cell cycle arrest and induction of apoptosis during the response to genotoxic stress.	Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland	University of Dundee	Clarke, PR (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Level 5, Dundee DD1 9SY, Scotland.	paul.clarke@cancer.org.uk	Clarke, Paul/B-1684-2009; Clarke, Paul R./AAA-6803-2020	Clarke, Paul/0000-0003-3525-2622; 				Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005; Brown EJ, 2000, GENE DEV, V14, P397; Busby EC, 2000, CANCER RES, V60, P2108; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Clarke CAL, 2005, BIOCHEM J, V388, P705, DOI 10.1042/BJ20041966; Cosulich SC, 1996, CURR BIOL, V6, P997, DOI 10.1016/S0960-9822(02)00644-9; Dart DA, 2004, J BIOL CHEM, V279, P16433, DOI 10.1074/jbc.M314212200; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Guo ZJ, 2000, MOL BIOL CELL, V11, P1535, DOI 10.1091/mbc.11.5.1535; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Han ZY, 1996, J BIOL CHEM, V271, P25035, DOI 10.1074/jbc.271.40.25035; Houde C, 2004, J NEUROSCI, V24, P9977, DOI 10.1523/JNEUROSCI.3356-04.2004; Hutchins JRA, 2000, FEBS LETT, V466, P91, DOI 10.1016/S0014-5793(99)01763-9; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jeong SY, 2003, J BIOL CHEM, V278, P46782, DOI 10.1074/jbc.M304551200; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Korfali N, 2004, J BIOL CHEM, V279, P1030, DOI 10.1074/jbc.M306277200; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Kumagai A, 2003, NAT CELL BIOL, V5, P161, DOI 10.1038/ncb921; Kumagai A, 2004, J BIOL CHEM, V279, P49599, DOI 10.1074/jbc.M408353200; Lam MH, 2004, CANCER CELL, V6, P45, DOI 10.1016/j.ccr.2004.06.015; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; LeRomancer M, 1996, J CELL SCI, V109, P3121; Lin SY, 2004, P NATL ACAD SCI USA, V101, P6484, DOI 10.1073/pnas.0401847101; Liu QH, 2000, GENE DEV, V14, P1448; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Norbury CJ, 2004, ONCOGENE, V23, P2797, DOI 10.1038/sj.onc.1207532; Russell P, 1998, TRENDS BIOCHEM SCI, V23, P399, DOI 10.1016/S0968-0004(98)01291-2; Sar F, 2004, J BIOL CHEM, V279, P39289, DOI 10.1074/jbc.M405793200; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Smith GCM, 1999, MOL CELL BIOL, V19, P6076; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Takai H, 2000, GENE DEV, V14, P1439; Tanaka K, 2001, NAT CELL BIOL, V3, P966, DOI 10.1038/ncb1101-966; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Yaoita Y, 2002, BIOCHEM BIOPH RES CO, V291, P79, DOI 10.1006/bbrc.2002.6408; Yoo HY, 2004, CELL, V117, P575, DOI 10.1016/S0092-8674(04)00417-9; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhao H, 2004, J BIOL CHEM, V279, P53023, DOI 10.1074/jbc.M410449200; Zheng TS, 2000, NAT MED, V6, P1241, DOI 10.1038/81343; Zheng TS, 1999, CELL DEATH DIFFER, V6, P1043, DOI 10.1038/sj.cdd.4400593; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	56	35	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35337	35345		10.1074/jbc.M506460200	http://dx.doi.org/10.1074/jbc.M506460200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16123041	hybrid			2022-12-27	WOS:000232561200032
J	Pereira, R; Cerione, RA				Pereira, R; Cerione, RA			A switch 3 point mutation in the alpha subunit of transducin yields a unique dominant-negative inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; HETEROTRIMERIC G-PROTEIN; CRYSTAL-STRUCTURE; CELLULAR-TRANSFORMATION; CGMP PHOSPHODIESTERASE; ONCOGENE PRODUCT; EFFECTOR-BINDING; HELICAL DOMAIN; RGS PROTEINS; ACTIVATION	The rhodopsin/ transducin- coupled vertebrate vision system has served as a paradigm for G protein- coupled signaling. We have taken advantage of this system to identify new types of constitutively active, transducin- alpha(alpha T) subunits. Here we have described a novel dominant- negative mutation, made in the background of a chimera consisting of alpha T and the alpha subunit of G(i1) ( designated alpha T*), which involves the substitution of a conserved arginine residue in the conformationally sensitive Switch 3 region. Changing Arg- 238 to either lysine or alanine had little or no effect on the ability of alpha T* to undergo rhodopsin- stimulated GDP- GTP exchange, whereas substituting glutamic acid for arginine at this position yielded an alpha T* subunit ( alpha T*( R238E)) that was incapable of undergoing rhodopsin-dependent nucleotide exchange and was unable to bind or stimulate the target/ effector enzyme ( cyclic GMP phosphodiesterase). Moreover, unlike the GDP- bound forms of alpha T*, alpha T*( R238A) and alpha T*( R238K), the alpha T*( R238E) mutant did not respond to aluminum fluoride ( AlF4-), as read out by changes in Trp- 207 fluorescence. However, surprisingly, we found that alpha T*( R238E) effectively blocked rhodopsin- catalyzed GDP- GTPexchange on alpha T*, as well as rhodopsin- stimulated phosphodiesterase activity. Analysis by high pressure liquid chromatography indicated that the alpha T*( R238E) mutant exists in a nucleotide- free state. Nucleotide- free forms of G alpha subunits were typically very sensitive to proteolytic degradation, but alpha T*( R238E) exhibited a resistance to trypsin- proteolysis similar to that observed with activated forms of alpha T*. Overall, these findings indicated that by mutating a single residue in Switch 3, it is possible to generate a unique type of dominant- negative G alpha subunit that can effectively block signaling by G protein- coupled receptors.	Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA; Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA	Cornell University; Cornell University	Cerione, RA (corresponding author), Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA.	rac1@cornell.edu			NEI NIH HHS [EY06429] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY006429] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Arshavsky VY, 2002, ANNU REV PHYSIOL, V64, P153, DOI 10.1146/annurev.physiol.64.082701.102229; Berlot CH, 2002, J BIOL CHEM, V277, P21080, DOI 10.1074/jbc.M201330200; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cherfils J, 2003, TRENDS BIOCHEM SCI, V28, P13, DOI 10.1016/S0968-0004(02)00006-3; Cleator JH, 1999, FEBS LETT, V443, P205, DOI 10.1016/S0014-5793(98)01704-9; Cleator JH, 2004, J BIOL CHEM, V279, P36601, DOI 10.1074/jbc.M406232200; Erickson JW, 2004, BIOCHEMISTRY-US, V43, P837, DOI 10.1021/bi036026v; ERICKSON JW, 1995, BIOCHEMISTRY-US, V34, P8693, DOI 10.1021/bi00027a019; Farfel Z, 1999, NEW ENGL J MED, V340, P1012, DOI 10.1056/NEJM199904013401306; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; FUNG BKK, 1983, J BIOL CHEM, V258, P503; HART MJ, 1994, J BIOL CHEM, V269, P62; Hoffman GR, 2002, FEBS LETT, V513, P85, DOI 10.1016/S0014-5793(01)03310-5; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Iiri T, 1998, NATURE, V394, P35, DOI 10.1038/27831; Iiri T, 1999, P NATL ACAD SCI USA, V96, P499, DOI 10.1073/pnas.96.2.499; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Li QB, 1997, J BIOL CHEM, V272, P21673, DOI 10.1074/jbc.272.35.21673; LIEBMAN PA, 1982, METHOD ENZYMOL, V81, P532; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; Liu W, 1998, J BIOL CHEM, V273, P34284, DOI 10.1074/jbc.273.51.34284; Liu W, 1998, P NATL ACAD SCI USA, V95, P12878, DOI 10.1073/pnas.95.22.12878; Majumdar S, 2004, J BIOL CHEM, V279, P40137, DOI 10.1074/jbc.M405420200; Min KC, 2000, PROTEIN EXPRES PURIF, V20, P514, DOI 10.1006/prep.2000.1326; Muradov KG, 2000, BIOCHEMISTRY-US, V39, P3937, DOI 10.1021/bi992156l; Natochin M, 2003, J NEUROCHEM, V87, P1262, DOI 10.1046/j.1471-4159.2003.02103.x; NEER EJ, 1994, METHOD ENZYMOL, V237, P226; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PHILLIPS WJ, 1989, J BIOL CHEM, V264, P16679; PREININGER AM, 2004, SCI STKE, pRE3; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STACEY DW, 1991, ONCOGENE, V6, P2297; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; Tu SS, 2002, BIOCHEMISTRY-US, V41, P12350, DOI 10.1021/bi026167h; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WITTINGHOFER A, 1994, CELL, V76, P201, DOI 10.1016/0092-8674(94)90327-1; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014	47	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35696	35703		10.1074/jbc.M504935200	http://dx.doi.org/10.1074/jbc.M504935200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16103122	hybrid			2022-12-27	WOS:000232561200072
J	Spath, B; Kirchner, S; Vogel, A; Schubert, S; Meinlschmidt, P; Aymanns, S; Nezzar, J; Marchfelder, A				Spath, B; Kirchner, S; Vogel, A; Schubert, S; Meinlschmidt, P; Aymanns, S; Nezzar, J; Marchfelder, A			Analysis of the functional modules of the tRNA 3 ' endonuclease (tRNase Z)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLO-BETA-LACTAMASE; BINUCLEAR ZINC PHOSPHODIESTERASE; CANCER SUSCEPTIBILITY GENE; RNASE-Z; SUBSTRATE RECOGNITION; END MATURATION; GLYOXALASE-II; IN-VIVO; BINDING; FAMILY	tRNA 3 ' processing is one of the essential steps during tRNA maturation. The tRNA 3 '- processing endonuclease tRNase Z was only recently isolated, and its functional domains have not been identified so far. We performed an extensive mutational study to identify amino acids and regions involved in dimerization, tRNA binding, and catalytic activity. 29 deletion and point variants of the tRNase Z enzyme were generated. According to the results obtained, variants can be sorted into five different classes. The first class still had wild type activity in all three respects. Members of the second and third class still formed dimers and bound tRNAs but had reduced catalytic activity ( class two) or no catalytic activity ( class three). The fourth class still formed dimers but did not bind the tRNA and did not process precursors. Since this class still formed dimers, it seems that the amino acids mutated in these variants are important for RNA binding. The fifth class did not have any activity anymore. Several conserved amino acids could be mutated without or with little loss of activity.	Univ Ulm, D-89069 Ulm, Germany; Max Planck Inst Kohlenforsch, D-45470 Mulheim, Germany	Ulm University; Max Planck Society	Marchfelder, A (corresponding author), Univ Ulm, Albert Einstein Allee 11, D-89069 Ulm, Germany.	anita.marchfelder@uni-ulm.de		Marchfelder, Anita/0000-0002-1382-1794				Aravind L, 1999, In Silico Biol, V1, P69; Callebaut I, 2002, NUCLEIC ACIDS RES, V30, P3592, DOI 10.1093/nar/gkf470; Chen Y, 2005, BMC MOL BIOL, V6, DOI 10.1186/1471-2199-6-12; Daiyasu H, 2001, FEBS LETT, V503, P1, DOI 10.1016/S0014-5793(01)02686-2; de la Sierra-Gallay IL, 2005, NATURE, V433, P657, DOI 10.1038/nature03284; Deutscher Murray P., 1995, P51; Dubrovsky EB, 2004, NUCLEIC ACIDS RES, V32, P255, DOI 10.1093/nar/gkh182; Francis SH, 2001, PROG NUCLEIC ACID RE, V65, P1; Frank DN, 1998, ANNU REV BIOCHEM, V67, P153, DOI 10.1146/annurev.biochem.67.1.153; Houry WA, 1999, NATURE, V402, P147, DOI 10.1038/45977; ISHII R, 2005, J BIOL CHEM; Kunzmann A, 1998, P NATL ACAD SCI USA, V95, P108, DOI 10.1073/pnas.95.1.108; Mayer M, 2000, BIOCHEMISTRY-US, V39, P2096, DOI 10.1021/bi992253e; Melino S, 1998, TRENDS BIOCHEM SCI, V23, P381, DOI 10.1016/S0968-0004(98)01264-X; Minagawa A, 2004, J BIOL CHEM, V279, P15688, DOI 10.1074/jbc.M313951200; Minvielle-Sebastia L, 1999, CURR OPIN CELL BIOL, V11, P352, DOI 10.1016/S0955-0674(99)80049-0; Morl M, 2001, EMBO REP, V2, P17, DOI 10.1093/embo-reports/kve006; Pannicke U, 2004, EMBO J, V23, P1987, DOI 10.1038/sj.emboj.7600206; Pellegrini O, 2003, EMBO J, V22, P4534, DOI 10.1093/emboj/cdg435; Perrotta AT, 1999, SCIENCE, V286, P123, DOI 10.1126/science.286.5437.123; Schierling K, 2002, J MOL BIOL, V316, P895, DOI 10.1006/jmbi.2001.5395; Schiffer S, 2002, EMBO J, V21, P2769, DOI 10.1093/emboj/21.11.2769; Schilling O, 2005, J BIOL CHEM, V280, P17857, DOI 10.1074/jbc.M500591200; Schilling O, 2005, BIOCHEM J, V385, P145, DOI 10.1042/BJ20040773; Takaku H, 2003, NUCLEIC ACIDS RES, V31, P2272, DOI 10.1093/nar/gkg337; Tavtigian SV, 2001, NAT GENET, V27, P172, DOI 10.1038/84808; Vogel A, 2004, BIOCHEMISTRY-US, V43, P10379, DOI 10.1021/bi049703+; Vogel A, 2002, J BIOL CHEM, V277, P29078, DOI 10.1074/jbc.M112047200; Wang ZG, 1999, CURR OPIN CHEM BIOL, V3, P614, DOI 10.1016/S1367-5931(99)00017-4; Wolter R, 1996, MOL GEN GENET, V250, P162, DOI 10.1007/s004380050063; Zareen N, 2005, J MOL BIOL, V350, P189, DOI 10.1016/j.jmb.2005.04.073	31	28	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35440	35447		10.1074/jbc.M506418200	http://dx.doi.org/10.1074/jbc.M506418200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16118225	hybrid			2022-12-27	WOS:000232561200044
J	Majovski, RC; Khaperskyy, DA; Ghazy, MA; Ponticelli, AS				Majovski, RC; Khaperskyy, DA; Ghazy, MA; Ponticelli, AS			A functional role for the switch 2 region of yeast RNA polymerase II in transcription start site utilization and abortive initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL REGION; STRUCTURAL BASIS; SACCHAROMYCES-CEREVISIAE; ELONGATION COMPLEX; TFIIB MUTATIONS; SELECTION; SUBUNIT; RPB9; RESOLUTION; MECHANISM	RNA polymerase II (RNAPII) is responsible for the synthesis of mRNA from eukaryotic protein-encoding genes. In this study, site-directed mutagenesis was employed to probe the function of residues within the Saccharomyces cerevisiae RNAPII active center in the mechanism of transcription start site utilization. We report here the identification of two mutations in the switch 2 region, rpb1-K332A and rpb1-R344A, which conferred conditional growth properties and downstream shifts in start site utilization. Analyses of double mutant strains demonstrated functional interactions between these switch 2 mutations and a mutation in the largest subunit of transcription factor IIF (TFIIF) that confers upstream shifts in start site usage. Importantly, biochemical analyses demonstrated that purified Rpb1-R344A mutant polymerase exhibited impaired ability to stabilize a short RNA-DNA hybrid in the active center, an increased frequency of abortive transcription in runoff assays, and both a downstream shift and increased abortive initiation in reconstituted transcription assays. These results provide evidence for a role of switch 2 during start site utilization and indicate that RNA-DNA hybrid stability at the 3'-end of the transcript is a determinant in this process. We discuss these results within the context of a proposed model regarding the concerted roles of RNAPII, TFIIB, and TFIIF during mRNA 5'-end formation in S. cerevisiae.	SUNY Buffalo, Dept Biochem, Sch Med & Biomed Sci, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Ponticelli, AS (corresponding author), SUNY Buffalo, Dept Biochem, Sch Med & Biomed Sci, Buffalo, NY 14214 USA.	asp@buffalo.edu	Ghazy, Mohamed/ABD-6832-2020	Khaperskyy, Denys/0000-0003-0583-7179	NIGMS NIH HHS [GM51124] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051124, R29GM051124] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bangur CS, 1997, MOL CELL BIOL, V17, P6784, DOI 10.1128/MCB.17.12.6784; BERROTERAN RW, 1994, MOL CELL BIOL, V14, P226, DOI 10.1128/MCB.14.1.226; Bushnell DA, 2004, SCIENCE, V303, P983, DOI 10.1126/science.1090838; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Faitar SL, 2001, MOL CELL BIOL, V21, P4427, DOI 10.1128/MCB.21.14.4427-4440.2001; Ghazy MA, 2004, MOL CELL BIOL, V24, P10975, DOI 10.1128/MCB.24.24.10975-10985.2004; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; GUARENTE L, 1987, ANNU REV GENET, V21, P425, DOI 10.1146/annurev.genet.21.1.425; Hahn S, 2004, NAT STRUCT MOL BIOL, V11, P394, DOI 10.1038/nsmb763; HULL MW, 1995, GENE DEV, V9, P481, DOI 10.1101/gad.9.4.481; Kettenberger H, 2004, MOL CELL, V16, P955, DOI 10.1016/j.molcel.2004.11.040; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Pardee TS, 1998, J BIOL CHEM, V273, P17859, DOI 10.1074/jbc.273.28.17859; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; PINTO I, 1994, J BIOL CHEM, V269, P30569; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; Sun ZW, 1996, NUCLEIC ACIDS RES, V24, P2560, DOI 10.1093/nar/24.13.2560; Westover KD, 2004, SCIENCE, V303, P1014, DOI 10.1126/science.1090839; Zhang DY, 2002, NUCLEIC ACIDS RES, V30, P3078, DOI 10.1093/nar/gkf422; Ziegler LM, 2003, J BIOL CHEM, V278, P48950, DOI 10.1074/jbc.M309656200	20	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34917	34923		10.1074/jbc.M502932200	http://dx.doi.org/10.1074/jbc.M502932200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16081422	hybrid			2022-12-27	WOS:000232403900064
J	Christensen, KE; Mirza, IA; Berghuis, AM; MacKenzie, RE				Christensen, KE; Mirza, IA; Berghuis, AM; MacKenzie, RE			Magnesium and phosphate ions enable NAD binding to methylenetetrahydrofolate dehydrogenase-methenyltetrahydrofolate cyclohydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCITES TUMOR-CELLS; CRYSTAL-STRUCTURE; FORMIMINOTRANSFERASE-CYCLODEAMINASE; COENZYME SPECIFICITY; ESCHERICHIA-COLI; COFACTOR-BINDING; DEHYDROGENASE/CYCLOHYDROLASE; PROTEINS; ENZYME; PURIFICATION	The mitochondrial NAD-dependent methylenetetrahydrofolate dehydrogenase-cyclohydrolase (NMDMC) is believed to have evolved from a trifunctional NADP-dependent methylenetetrahydrofolate dehydrogenase-cyclohydrolase-synthetase. It is unique in its absolute requirement for inorganic phosphate and magnesium ions to support dehydrogenase activity. To enable us to investigate the roles of these ions, a homology model of human NMDMC was constructed based on the structures of three homologous proteins. The model supports the hypothesis that the absolutely required Pi can bind in close proximity to the 2'-hydroxyl of NAD through interactions with Arg(166) and Arg(198). The characterization of mutants of Arg(166), Asp(190), and Arg(198) show that Arg(166) is primarily responsible for Pi binding, while Arg(198) plays a secondary role, assisting in binding and properly orienting the ion in the cofactor binding site. Asp(190) helps to properly position Arg(166). Mutants of Asp(133) suggest that the magnesium ion interacts with both P-i and the aspartate side chain and plays a role in positioning Pi and NAD. NMDMC uses P-i and magnesium to adapt an NADP binding site for NAD binding. This adaptation represents a novel variation of the classic Rossmann fold.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University	MacKenzie, RE (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Sci Bldg,3655Promenade Sir William O, Montreal, PQ H3G 1Y6, Canada.	robert.mackenzie@mcgill.ca	Berghuis, Albert M/A-6495-2008	Berghuis, Albert/0000-0002-2663-025X				Allaire M, 1998, STRUCTURE, V6, P173, DOI 10.1016/S0969-2126(98)00019-7; Bellamacina CR, 1996, FASEB J, V10, P1257, DOI 10.1096/fasebj.10.11.8836039; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carugo O, 1997, PROTEINS, V28, P10, DOI 10.1002/(SICI)1097-0134(199705)28:1<10::AID-PROT2>3.3.CO;2-R; CHAKRABARTI P, 1993, J MOL BIOL, V234, P463, DOI 10.1006/jmbi.1993.1599; Christensen KE, 2005, J BIOL CHEM, V280, P7597, DOI 10.1074/jbc.M409380200; COPLEY RR, 1994, J MOL BIOL, V242, P321; DeLano W.L, PYMOL MOL GRAPHICS S; Di Pietro E, 2002, MOL CELL BIOL, V22, P4158, DOI 10.1128/MCB.22.12.4158-4166.2002; DRURY EJ, 1975, ARCH BIOCHEM BIOPHYS, V169, P662, DOI 10.1016/0003-9861(75)90210-6; Dudev T, 2003, CHEM REV, V103, P773, DOI 10.1021/cr020467n; Elmore CL, 2002, J BIOL CHEM, V277, P48960, DOI 10.1074/jbc.M210173200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lovell SC, 2000, PROTEINS, V40, P389, DOI 10.1002/1097-0134(20000815)40:3<389::AID-PROT50>3.0.CO;2-2; LUECKE H, 1990, NATURE, V347, P402, DOI 10.1038/347402a0; MEJIA NR, 1986, J BIOL CHEM, V261, P9509; Monzingo AF, 2000, PROTEIN SCI, V9, P1374, DOI 10.1110/ps.9.7.1374; MURLEY LL, 1993, J BIOL CHEM, V268, P22820; PAI EF, 1988, BIOCHEMISTRY-US, V27, P4465, DOI 10.1021/bi00412a038; Patel H, 2003, J BIOL CHEM, V278, P19436, DOI 10.1074/jbc.M301718200; Patel H, 2002, ARCH BIOCHEM BIOPHYS, V403, P145, DOI 10.1016/S0003-9861(02)00203-5; Patel S, 2002, J MOL BIOL, V315, P677, DOI 10.1006/jmbi.2001.5271; Pawelek PD, 1996, BBA-PROTEIN STRUCT M, V1296, P47, DOI 10.1016/0167-4838(96)00052-0; Pawelek PD, 2000, BBA-PROTEIN STRUCT M, V1479, P59, DOI 10.1016/S0167-4838(00)00058-3; Pawelek PD, 1998, BIOCHEMISTRY-US, V37, P1109, DOI 10.1021/bi971906t; PELLETIER JN, 1995, BIOCHEMISTRY-US, V34, P12673, DOI 10.1021/bi00039a025; RIOSORLANDI EM, 1988, J BIOL CHEM, V263, P4662; Saadat D, 1999, STRUCT FOLD DES, V7, P309, DOI 10.1016/S0969-2126(99)80041-0; Schmidt A, 2000, BIOCHEMISTRY-US, V39, P6325, DOI 10.1021/bi992734y; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; Shen BW, 1999, PROTEIN SCI, V8, P1342, DOI 10.1110/ps.8.6.1342; Sundararajan S, 2002, J BIOL CHEM, V277, P18703, DOI 10.1074/jbc.M200127200; TAINER JA, 1991, CURR OPIN BIOTECH, V2, P582, DOI 10.1016/0958-1669(91)90084-I; Tejero J, 2003, J BIOL CHEM, V278, P49203, DOI 10.1074/jbc.M307934200; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; YANG XM, 1993, BIOCHEMISTRY-US, V32, P1118, DOI 10.1021/bi00092a022; ZHANG M, 1994, BIOCHEMISTRY-US, V33, P11097, DOI 10.1021/bi00203a006	40	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34316	34323		10.1074/jbc.M505210200	http://dx.doi.org/10.1074/jbc.M505210200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16100107	hybrid			2022-12-27	WOS:000232229700074
J	Ingham, RJ; Raaijmakers, J; Lim, CSH; Mbamalu, G; Gish, G; Chen, F; Matskova, L; Enrberg, I; Winberg, G; Pawson, T				Ingham, RJ; Raaijmakers, J; Lim, CSH; Mbamalu, G; Gish, G; Chen, F; Matskova, L; Enrberg, I; Winberg, G; Pawson, T			The Epstein-Barr virus protein, latent membrane protein 2A, co-opts tyrosine kinases used by the T cell receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED SIGNAL-TRANSDUCTION; ACTIVE EBV INFECTION; REGULATES REACTIVATION; UBIQUITIN LIGASES; ANTIGEN RECEPTOR; GENETIC-EVIDENCE; FAMILY KINASES; LMP2A; PHOSPHORYLATION; LYMPHOMA	Epstein-Barr virus (EBV) is the causative agent of infectious mononucleosis and is associated with several human malignancies. The EBV protein latent membrane protein 2A (LMP2A) promotes viral latency in memory B cells by interfering with B cell receptor signaling and provides a survival signal for mature B cells that have lost expression of surface immunoglobulin. The latter function has suggested that LMP2A may enhance the survival of EBV-positive tumors. EBV is associated with several T cell malignancies and, since LMP2A has been detected in several of these disorders, we examined the ability of LMP2A to transmit signals and interfere with T cell receptor signaling in T cells. We show that LMP2A is tyrosine-phosphorylated in Jurkat TAg T cells, which requires expression of the Src family tyrosine kinases, Lck and Fyn. Lck and Fyn are recruited to the tyrosine-phosphorylated Tyr(112) site in LMP2A, whereas phosphorylation of an ITAM motif in LMP2A creates a binding site for the ZAP-70/Syk tyrosine kinases. LMP2A also associates through its two PPPPY motifs with AIP4, a NEDD4 family E3 ubiquitin ligase; this interaction results in ubiquitylation of LMP2A and serves to regulate the stability of LMP2A and LMP2A-kinase complexes. Furthermore, stable expression of LMP2A in Jurkat T cells down-regulated T cell receptor levels and attenuated T cell receptor signaling. Thus, through recruiting tyrosine kinases involved in T cell receptor activation, LMP2A may provide a survival signal for EBV-positive T cell tumors, whereas LMP2A-associated NEDD4 E3 ligases probably titer the strength of this signal.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Karolinska Inst, Ctr Microbiol & Tumor Biol, SE-17177 Stockholm, Sweden; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Karolinska Institutet; University of Toronto	Pawson, T (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	pawson@mshri.on.ca	Pawson, Tony J/E-4578-2013; Winberg, Gosta/I-5686-2013; Matskova, Liudmila/J-3843-2017; Gish, Gerald D/C-7228-2017; Matskova, Liudmila/AAF-4201-2020	Matskova, Liudmila/0000-0002-3174-1560; Matskova, Liudmila/0000-0002-3174-1560; Winberg, Gosta/0000-0002-3371-4056				BURKHARDT AL, 1992, J VIROL, V66, P5161, DOI 10.1128/JVI.66.8.5161-5167.1992; Caldwell RG, 2000, J VIROL, V74, P1101, DOI 10.1128/JVI.74.3.1101-1113.2000; Caldwell RG, 1998, IMMUNITY, V9, P405, DOI 10.1016/S1074-7613(00)80623-8; Casola S, 2004, NAT IMMUNOL, V5, P317, DOI 10.1038/ni1036; Dawson CW, 2001, VIROLOGY, V289, P192, DOI 10.1006/viro.2001.1142; Dykstra ML, 2001, IMMUNITY, V14, P57, DOI 10.1016/S1074-7613(01)00089-9; Fruehling S, 1998, J VIROL, V72, P7796, DOI 10.1128/JVI.72.10.7796-7806.1998; Fruehling S, 1997, VIROLOGY, V235, P241, DOI 10.1006/viro.1997.8690; Fukuda M, 2005, J VIROL, V79, P8655, DOI 10.1128/JVI.79.13.8655-8660.2005; Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611; HAMILTONDUTOIT SJ, 1992, AM J PATHOL, V140, P1315; HENLE G, 1969, J NATL CANCER I, V43, P1147; Higuchi M, 2001, P NATL ACAD SCI USA, V98, P4675, DOI 10.1073/pnas.081075298; HUTCHCROFT JE, 1994, P NATL ACAD SCI USA, V91, P3260, DOI 10.1073/pnas.91.8.3260; Ikeda A, 2003, J VIROL, V77, P5529, DOI 10.1128/JVI.77.9.5529-5534.2003; Ikeda M, 2000, VIROLOGY, V268, P178, DOI 10.1006/viro.1999.0166; Ikeda M, 2002, VIROLOGY, V300, P153, DOI 10.1006/viro.2002.1562; Ikeda M, 2001, J VIROL, V75, P5711, DOI 10.1128/JVI.75.12.5711-5718.2001; Imai S, 1996, BLOOD, V87, P1446, DOI 10.1182/blood.V87.4.1446.bloodjournal8741446; Imashuku S, 2002, CRIT REV ONCOL HEMAT, V44, P259, DOI 10.1016/S1040-8428(02)00117-8; Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436; Kanegane H, 2002, CRIT REV ONCOL HEMAT, V44, P239, DOI 10.1016/S1040-8428(02)00115-4; Kawa K, 2002, CRIT REV ONCOL HEMAT, V44, P251, DOI 10.1016/S1040-8428(02)00116-6; Labrecque N, 2001, IMMUNITY, V15, P71, DOI 10.1016/S1074-7613(01)00170-4; Lay JD, 2003, J BIOMED SCI, V10, P146, DOI 10.1159/000068077; LONGNECKER R, 1991, J VIROL, V65, P3681, DOI 10.1128/JVI.65.7.3681-3692.1991; LONGNECKER R, 1990, J VIROL, V64, P2319, DOI 10.1128/JVI.64.5.2319-2326.1990; Lynch DT, 2002, J GEN VIROL, V83, P1025, DOI 10.1099/0022-1317-83-5-1025; Matskova L, 2001, J VIROL, V75, P10941, DOI 10.1128/JVI.75.22.10941-10949.2001; MILLER AD, 1991, J VIROL, V65, P2220, DOI 10.1128/JVI.65.5.2220-2224.1991; MILLER CL, 1994, INFECT AGENT DIS, V3, P128; MILLER CL, 1995, IMMUNITY, V2, P155, DOI 10.1016/S1074-7613(95)80040-9; MILLER CL, 1994, P NATL ACAD SCI USA, V91, P772, DOI 10.1073/pnas.91.2.772; MILLER CL, 1993, J VIROL, V67, P3087, DOI 10.1128/JVI.67.6.3087-3094.1993; PEH SC, 1995, INT J CANCER, V61, P327, DOI 10.1002/ijc.2910610309; RAAB M, 1995, P NATL ACAD SCI USA, V92, P8891, DOI 10.1073/pnas.92.19.8891; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Rickinson A, 2002, VIRUS RES, V82, P109; Seddon B, 2002, J IMMUNOL, V169, P2997, DOI 10.4049/jimmunol.169.6.2997; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Thorley-Lawson DA, 2001, NAT REV IMMUNOL, V1, P75, DOI 10.1038/35095584; vanGorp J, 1996, J CLIN PATHOL, V49, P72, DOI 10.1136/jcp.49.1.72; VANGORP J, 1995, HISTOPATHOLOGY, V27, P139; Wakiguchi H, 2002, CRIT REV ONCOL HEMAT, V44, P193, DOI 10.1016/S1040-8428(02)00111-7; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Winberg G, 2000, MOL CELL BIOL, V20, P8526, DOI 10.1128/MCB.20.22.8526-8535.2000	46	20	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34133	34142		10.1074/jbc.M507831200	http://dx.doi.org/10.1074/jbc.M507831200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16087662	hybrid			2022-12-27	WOS:000232229700054
J	Kwak, YT; Li, R; Becerra, CR; Tripathy, D; Frenkel, EP; Verma, UN				Kwak, YT; Li, R; Becerra, CR; Tripathy, D; Frenkel, EP; Verma, UN			I kappa B kinase alpha regulates subcellular distribution and turnover of cyclin D1 by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; DEPENDENT GENE-EXPRESSION; IKK-ALPHA; CELL-CYCLE; MICE LACKING; ACTIVATION; COMPLEX; BETA; PATHWAY; PROTEIN	I kappa B kinases (IKKs), IKK alpha and IKK beta, with a regulatory subunit IKK gamma/NEMO constitute a high molecular weight IKK complex that regulates NF-kappa B activity. Although IKK alpha and IKK beta share structural and biochemical similarities, IKK alpha has been shown to have distinct biological roles. Here we show that IKK alpha plays a critical role in regulating cyclin D1 during the cell cycle. Analysis of IKK alpha(-/-) mouse embryo fibroblast cells showed that cyclin D1 is overexpressed and localized in the nucleus compared with parental mouse embryo fibroblasts. IKK alpha associates with and phosphorylates cyclin D1. Analysis on cyclin D1 mutants demonstrated that IKK alpha phosphorylates cyclin D1 at Thr(286). Reconstitution of IKK alpha in knockout cells leads to nuclear export and increased degradation of cyclin D1. Further, RNAi-mediated knockdown of IKK alpha results in similar changes as observed in IKK alpha(-/-) cells. These results suggest a novel role of IKK alpha in regulating subcellular localization and proteolysis of cyclin D1 by phosphorylation of cyclin D1 at Thr286, the same residue earlier found to be a target for glycogen synthase kinase-3 beta-induced phosphorylation.	Univ Texas SW Med Ctr Dallas, Dept Med, Div Hematol Oncol, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas	Verma, UN (corresponding author), UT SW Med Ctr Dallas, Dept Med, Div Hematol Oncol, Dallas, TX 75390 USA.	udit.verma@utsouthwestern.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041860] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI041860] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albanese C, 2003, MOL BIOL CELL, V14, P585, DOI 10.1091/mbc.02-06-0101; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; Benzeno S, 2004, J BIOL CHEM, V279, P56061, DOI 10.1074/jbc.M411910200; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Doglioni C, 1998, J PATHOL, V185, P159, DOI 10.1002/(SICI)1096-9896(199806)185:2<159::AID-PATH73>3.0.CO;2-0; Gao CY, 1997, BIOESSAYS, V19, P307, DOI 10.1002/bies.950190408; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kwak YT, 2003, MOL CELL, V11, P1055, DOI 10.1016/S1097-2765(03)00101-1; Kwak YT, 2000, J BIOL CHEM, V275, P14752, DOI 10.1074/jbc.M001039200; Lamberti C, 2001, J BIOL CHEM, V276, P42276, DOI 10.1074/jbc.M104227200; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Lu FM, 2003, CANCER RES, V63, P7056; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pasparakis M, 2002, J EXP MED, V196, P743, DOI 10.1084/jem.20020907; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Ryves W Jonathan, 2003, Prog Cell Cycle Res, V5, P489; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sil AK, 2004, NATURE, V428, P660, DOI 10.1038/nature02421; Solomon DA, 2003, J BIOL CHEM, V278, P30339, DOI 10.1074/jbc.M303969200; Stacey DW, 2003, CURR OPIN CELL BIOL, V15, P158, DOI 10.1016/S0955-0674(03)00008-5; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Takada Y, 2004, J BIOL CHEM, V279, P39541, DOI 10.1074/jbc.M403449200; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Verma UN, 2004, J BIOL CHEM, V279, P3509, DOI 10.1074/jbc.M309300200; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yamamoto Y, 2001, J BIOL CHEM, V276, P36327, DOI 10.1074/jbc.M104090200; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zou YL, 2004, J BIOL CHEM, V279, P27790, DOI 10.1074/jbc.M403042200	55	54	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33945	33952		10.1074/jbc.M506206200	http://dx.doi.org/10.1074/jbc.M506206200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16103118	hybrid			2022-12-27	WOS:000232229700031
J	Anderson, RF; Hille, R; Shinde, SS; Cecchini, G				Anderson, RF; Hille, R; Shinde, SS; Cecchini, G			Electron transfer within complex II - Succinate : Ubiquinone oxidoreductase of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PULSE-RADIOLYSIS; BIOCHEMICAL SYSTEMS; FUMARATE REDUCTASE; DEHYDROGENASE; RADICALS; HEME	Electron transfer within Escherichia coli succinate: ubiquinone oxidoreductase has been examined by the pulse radiolysis technique using spectrophotometric detection. Electrons have been introduced into the protein by the bimolecular reaction with quantified concentrations of the low potential N-methylnicotinamide radical at a rate constant of 7 x 10(8) M-1 s(-1). Two redox-active centers in the protein are initially reduced, assigned as the high potential [3Fe-4S] center and the bound ubiquinone, followed by intramolecular equilibration with the b heme in both cases. Electron equilibration at 25 C from the ubisemiquinone proceeds with an observed rate constant of 7,200 s(-1) and from the more distant [3Fe-4S] reduced center at a rate constant of 1,200 s(-1). Temperature dependence studies have revealed that both reactions have large free energies of activation, with Delta G double dagger values of + 0.53 and + 0.58 eV, respectively. Cumulative spectral changes, as well as accompanying decreases in the rates of intramolecular electron transfer, observed upon adding electrons to progressively reduced protein, indicate that 4 electrons must be introduced into the protein before the heme center is fully reduced. Overall, evidence is presented that the heme, far from being a bystander in the efficient transfer of reducing equivalents from succinate to the ubiquinone via the flavin-Fe/S centers, plays a pivotal role in providing a lower energy pathway for the transfer of an electron from the high potential [3Fe4S] center to ubiquinone.	Univ Auckland, Dept Chem, Auckland 1, New Zealand; Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Vet Affairs Med Ctr, Div Mol Biol, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of Auckland; University System of Ohio; Ohio State University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Anderson, RF (corresponding author), Univ Auckland, Dept Chem, Private Bag 92019, Auckland 1, New Zealand.	r.anderson@auckland.ac.nz	Shinde, Sambhaji/H-6203-2013	Shinde, Sambhaji/0000-0002-3857-7847	NIGMS NIH HHS [GM61606, GM75036] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM075036, R01GM061606] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RF, 2000, J BIOL CHEM, V275, P30781, DOI 10.1074/jbc.M001256200; Anderson RF, 1997, J PHYS CHEM A, V101, P9704, DOI 10.1021/jp972311a; ANDERSON RF, 1984, J CHEM SOC FARAD T 1, V80, P2693, DOI 10.1039/f19848002693; Cecchini G, 2002, BBA-BIOENERGETICS, V1553, P140, DOI 10.1016/S0005-2728(01)00238-9; Ding H, 1995, BIOCHEMISTRY-US, V34, P15979, DOI 10.1021/bi00049a012; Hederstedt L, 2002, BBA-BIOENERGETICS, V1553, P74, DOI 10.1016/S0005-2728(01)00231-6; HILLE R, 1991, J BIOL CHEM, V266, P5608; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P3640, DOI 10.1073/pnas.71.9.3640; LAND EJ, 1968, BIOCHIM BIOPHYS ACTA, V162, P327, DOI 10.1016/0005-2728(68)90119-9; LAND EJ, 1971, BIOCHIM BIOPHYS ACTA, V226, P239, DOI 10.1016/0005-2728(71)90091-0; LAND EJ, 1970, J BIOL CHEM, V245, P1890; Maklashina E, 1999, ARCH BIOCHEM BIOPHYS, V369, P223, DOI 10.1006/abbi.1999.1359; Maklashina E, 2001, J BIOL CHEM, V276, P18968, DOI 10.1074/jbc.M011270200; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MARCUS RA, 1964, ANNU REV PHYS CHEM, V15, P155, DOI 10.1146/annurev.pc.15.100164.001103; Moser CC, 1997, J BIOL INORG CHEM, V2, P393, DOI 10.1007/s007750050149; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; MULAZZANI QG, 1986, J PHYS CHEM-US, V90, P5347, DOI 10.1021/j100412a090; Nakamura K, 1996, J BIOL CHEM, V271, P521, DOI 10.1074/jbc.271.1.521; Ohnishi T, 2000, STRUCTURE, V8, pR23, DOI 10.1016/S0969-2126(00)00098-8; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; SCHULER RH, 1980, J PHYS CHEM-US, V84, P2088, DOI 10.1021/j100453a020; Sun F, 2005, CELL, V121, P1043, DOI 10.1016/j.cell.2005.05.025; Winkler JR, 1997, J BIOL INORG CHEM, V2, P399, DOI 10.1007/s007750050150; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605; YU L, 1987, J BIOL CHEM, V262, P1137	26	21	21	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33331	33337		10.1074/jbc.M506002200	http://dx.doi.org/10.1074/jbc.M506002200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16085649	hybrid			2022-12-27	WOS:000232058100030
J	Geyer, H; Wuhrer, M; Resemann, A; Geyer, R				Geyer, H; Wuhrer, M; Resemann, A; Geyer, R			Identification and characterization of keyhole limpet hemocyanin N-glycans mediating cross-reactivity with Schistosoma mansoni	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; LINKED CARBOHYDRATE CHAINS; CELL LUNG-CANCER; MASS-SPECTROMETRY; LEWIS-X; STRUCTURAL-CHARACTERIZATION; FUCOSYLATED EPITOPES; ANIMAL GLYCOPROTEIN; HELIX-POMATIA; O-GLYCANS	Keyhole limpet hemocyanin (KLH) of the mollusc Megathura crenulata is known to serologically cross-react with Schistosoma mansoni glycoconjugates in a carbohydrate-dependent manner. To elucidate the structural basis for this cross-reactivity, KLH glycans were released from tryptic glycopeptides and fluorescently labeled. Cross-reacting glycans were identified using a polyclonal antiserum reacting with soluble S. mansoni egg antigens, isolated by a three-dimensional fractionation scheme and analyzed by different mass spectrometric techniques as well as linkage analysis and exoglycosidase treatment. The results revealed that cross-reacting species comprise similar to 4.5% of released glycans. They all represent novel types of N-glycans with a Fuc(alpha 1-3) GalNAc(beta 1-4)[Fuc(alpha 1-3)] GlcNAc motif, which is known to occur also in schistosomal glycoconjugates. The tetrasaccharide unit is attached to the 3-linked antenna of a trimannosyl core, which can be further decorated by galactosyl residues, a xylose residue in 2-position of the central mannose and/or a fucose at the innermost N-acetylglucosamine. This study provides for the first time detailed structural data on the KLH carbohydrate entities responsible for cross-reactivity with glycoconjugates from S. mansoni.	Univ Giessen, Fac Med, Inst Biochem, D-35392 Giessen, Germany; Leiden Univ, Med Ctr, Dept Parasitol, Ctr Infect Dis, NL-2300 RC Leiden, Netherlands; Bruker Daltonik GmbH, D-28359 Bremen, Germany	Justus Liebig University Giessen; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Bruker Corporation; Bruker Daltonik GmbH	Geyer, R (corresponding author), Univ Giessen, Fac Med, Inst Biochem, Friedrichstr 24, D-35392 Giessen, Germany.	Rudolf.Geyer@biochemie.med.uni-giessen.de	Wuhrer, Manfred/ABE-9168-2020	Wuhrer, Manfred/0000-0002-0814-4995				ALVESBRITO CF, 1992, T ROY SOC TROP MED H, V86, P53, DOI 10.1016/0035-9203(92)90439-J; ANUMULA KR, 1994, ANAL BIOCHEM, V220, P275, DOI 10.1006/abio.1994.1338; BICKLE QD, 1988, PARASITE IMMUNOL, V10, P151, DOI 10.1111/j.1365-3024.1988.tb00211.x; Chapman PB, 2000, CLIN CANCER RES, V6, P4658; Danishefsky SJ, 2000, ANGEW CHEM INT EDIT, V39, P836, DOI 10.1002/(SICI)1521-3773(20000303)39:5<836::AID-ANIE836>3.0.CO;2-I; de Vijver KKV, 2004, INT J PARASITOL, V34, P951, DOI 10.1016/j.ijpara.2004.04.009; DISSOUS C, 1986, NATURE, V323, P443, DOI 10.1038/323443a0; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; Fotisch K, 2001, GLYCOCONJUGATE J, V18, P373, DOI 10.1023/A:1014860030380; Friedl CH, 2003, BIOCHEM J, V369, P89, DOI 10.1042/BJ20021074; Geyer H, 1999, ANAL CHEM, V71, P476, DOI 10.1021/ac980712w; GEYER R, 1994, METHOD ENZYMOL, V230, P86; GEYER R, 1983, ANAL BIOCHEM, V133, P197, DOI 10.1016/0003-2697(83)90243-9; Gilewski T, 2000, CLIN CANCER RES, V6, P1693; Hamilton JV, 1999, PARASITOLOGY, V118, P83, DOI 10.1017/S0031182098003461; Harris JR, 1999, MICRON, V30, P597, DOI 10.1016/S0968-4328(99)00036-0; Harris JR, 2000, EUR UROL, V37, P24, DOI 10.1159/000052389; Harvey DJ, 1999, MASS SPECTROM REV, V18, P349, DOI 10.1002/(SICI)1098-2787(1999)18:6<349::AID-MAS1>3.3.CO;2-8; HASE S, 1994, METHOD ENZYMOL, V230, P225; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; Haslam SM, 2000, GLYCOBIOLOGY, V10, P223, DOI 10.1093/glycob/10.2.223; Huang HH, 2001, GLYCOBIOLOGY, V11, P395, DOI 10.1093/glycob/11.5.395; Ittiprasert W, 2000, PARASITOL INT, V49, P209, DOI 10.1016/S1383-5769(00)00046-5; Jansen WTM, 2001, INFECT IMMUN, V69, P787, DOI 10.1128/IAI.69.2.787-793.2001; Jurincic-Winkler CD, 2000, EUR UROL, V37, P45, DOI 10.1159/000052392; Kamerling Johannis P., 1992, V10, P1; Kantelhardt SR, 2002, BIOCHEM J, V366, P217, DOI 10.1042/BJ20011678; Khoo KH, 2001, GLYCOBIOLOGY, V11, P149, DOI 10.1093/glycob/11.2.149; Khoo KH, 1997, GLYCOBIOLOGY, V7, P663, DOI 10.1093/glycob/7.5.663; KHOO KH, 1995, J BIOL CHEM, V270, P17114, DOI 10.1074/jbc.270.29.17114; Krug LM, 2004, CLIN CANCER RES, V10, P6094, DOI 10.1158/1078-0432.CCR-04-0482; Krug LM, 2004, CLIN CANCER RES, V10, P916, DOI 10.1158/1078-0432.CCR-03-0101; KURAYA N, 1992, J BIOCHEM, V112, P122, DOI 10.1093/oxfordjournals.jbchem.a123850; Kurokawa T, 2002, EUR J BIOCHEM, V269, P5459, DOI 10.1046/j.1432-1033.2002.03244.x; Lamm DL, 2000, EUR UROL, V37, P41, DOI 10.1159/000052391; LAURIERE M, 1989, PLANT PHYSIOL, V90, P1182, DOI 10.1104/pp.90.3.1182; Lewandrowski U, 2005, ANAL CHEM, V77, P3274, DOI 10.1021/ac048399n; Lommerse JPM, 1997, EUR J BIOCHEM, V249, P195, DOI 10.1111/j.1432-1033.1997.00195.x; MANSOUR MM, 1989, AM J TROP MED HYG, V41, P338, DOI 10.4269/ajtmh.1989.41.338; Markl J, 2001, J CANCER RES CLIN, V127, pR3, DOI 10.1007/BF01470992; MARKL J, 1991, NATURWISSENSCHAFTEN, V78, P30, DOI 10.1007/BF01134040; May RJ, 2003, J IMMUNOL, V171, P4905, DOI 10.4049/jimmunol.171.9.4905; Mechref Y, 2003, ANAL CHEM, V75, P4895, DOI 10.1021/ac0341968; Ragupathi G, 2002, INT J CANCER, V99, P207, DOI 10.1002/ijc.10305; Robijn MLM, 2005, PARASITOLOGY, V130, P67, DOI 10.1017/S0031182004006390; Stoeva S, 1999, BBA-PROTEIN STRUCT M, V1435, P94, DOI 10.1016/S0167-4838(99)00198-3; Suckau D, 2003, ANAL BIOANAL CHEM, V376, P952, DOI 10.1007/s00216-003-2057-0; Taylor MG, 1998, VACCINE, V16, P1290, DOI 10.1016/S0264-410X(98)00055-3; Thors C, 1998, PARASITE IMMUNOL, V20, P489, DOI 10.1046/j.1365-3024.1998.00185.x; TRETTER V, 1991, EUR J BIOCHEM, V199, P647, DOI 10.1111/j.1432-1033.1991.tb16166.x; Ueda H, 1999, TRENDS GLYCOSCI GLYC, V11, P413, DOI 10.4052/tigg.11.413; vanHolde KE, 1995, ADV PROTEIN CHEM, V47, P1, DOI 10.1016/S0065-3233(08)60545-8; VANKUIK JA, 1985, J BIOL CHEM, V260, P3984; VANKUIK JA, 1987, EUR J BIOCHEM, V169, P399; Wang ZG, 2000, P NATL ACAD SCI USA, V97, P2719, DOI 10.1073/pnas.97.6.2719; WIRGUIN I, 1995, CANCER IMMUNOL IMMUN, V40, P307, DOI 10.1007/BF01519630; Wuhrer M, 2002, EUR J BIOCHEM, V269, P481, DOI 10.1046/j.0014-2956.2001.02673.x; Wuhrer M, 2004, BIOCHEM J, V378, P625, DOI 10.1042/BJ20031380; Wuhrer M, 1999, MOL BIOCHEM PARASIT, V103, P155, DOI 10.1016/S0166-6851(99)00123-1; Wuhrer M, 2000, MOL BIOCHEM PARASIT, V110, P237, DOI 10.1016/S0166-6851(00)00273-5; Wuhrer M, 2004, ANAL CHEM, V76, P833, DOI 10.1021/ac034936c; XUE CG, 1993, T ROY SOC TROP MED H, V87, P654, DOI 10.1016/0035-9203(93)90275-U	62	71	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40731	40748		10.1074/jbc.M505985200	http://dx.doi.org/10.1074/jbc.M505985200			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16135511	hybrid			2022-12-27	WOS:000233666600043
J	Campbell, GR; Watkins, JD; Esquieu, D; Pasquier, E; Loret, EP; Spector, SA				Campbell, GR; Watkins, JD; Esquieu, D; Pasquier, E; Loret, EP; Spector, SA			The C terminus of HIV-1 Tat modulates the extent of CD178-mediated apoptosis of T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 TRANSACTIVATION; 2ND CODING EXON; BLOOD-LYMPHOCYTES; IN-VITRO; PROTEIN; DEATH; AIDS; ACTIVATION; INFECTION; CD4(+)	HIV infection and the progression to AIDS are characterized by the depletion of CD4(+) T cells through apoptosis of the uninfected bystander cells and the direct killing of HIV-infected cells. This is mediated in part by the human immunodeficiency virus, type 1 Tat protein, which is secreted by virally infected cells and taken up by uninfected cells and CD178 gene expression, which is critically involved in T cell apoptosis. The differing ability of HIV strains to induce death of infected and uninfected cells may play a role in the clinical and biological differences displayed by HIV strains. We chemically synthesized the 86-residue truncated short variant of Tat and its full-length form. We show that the trans-activation ability of Tat at the long terminal repeat does not correlate with T cell apoptosis but that the ability of Tat to up-regulate CD178 mRNA expression and induce apoptosis in T cells is critically dependent on the C terminus of Tat. Moreover, the greater 86-residue Tat-induced apoptosis is via the extrinsic pathway of CD95-CD178.	Univ Calif San Diego, Dept Pediat, Div Infect Dis, La Jolla, CA 92093 USA; Univ Mediterranee, Fac Pharm, CNRS, Format Rech Evolut 2737, F-13385 Marseille, France; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr AIDS Res, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; University of California System; University of California San Diego; University of California System; University of California San Diego	Spector, SA (corresponding author), Univ Calif San Diego, Dept Pediat, Div Infect Dis, 9500 Gilman Dr, La Jolla, CA 92093 USA.	saspector@ucsd.edu	Campbell, Grant/C-9018-2011; Pasquier, Eddy/A-8112-2018	Campbell, Grant/0000-0003-3927-1994; Pasquier, Eddy/0000-0003-2824-5002	NIAID NIH HHS [AI-27563, AI-39004, AI-36214] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036214, U01AI027563, R01AI039004] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alimonti JB, 2003, J GEN VIROL, V84, P1649, DOI 10.1099/vir.0.19110-0; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; Aries SP, 1995, J MOL MED-JMM, V73, P591; ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; Badou A, 2000, J VIROL, V74, P10551, DOI 10.1128/JVI.74.22.10551-10562.2000; BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; Bartz SR, 1999, J VIROL, V73, P1956, DOI 10.1128/JVI.73.3.1956-1963.1999; Baumler CB, 1996, BLOOD, V88, P1741; Bres V, 2002, EMBO J, V21, P6811, DOI 10.1093/emboj/cdf669; Campbell GR, 2004, J BIOL CHEM, V279, P48197, DOI 10.1074/jbc.M406195200; Chang HC, 1997, AIDS, V11, P1421, DOI 10.1097/00002030-199712000-00006; Chen D, 2002, EMBO J, V21, P6801, DOI 10.1093/emboj/cdf683; CLAVEL F, 1994, J VIROL, V68, P1179, DOI 10.1128/JVI.68.2.1179-1185.1994; Conti L, 1998, J EXP MED, V187, P403, DOI 10.1084/jem.187.3.403; Contreras X, 2004, MICROBES INFECT, V6, P1182, DOI 10.1016/j.micinf.2004.06.008; de Mareuil J, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-5; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; Epie N, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-6; Estaquier J, 1996, BLOOD, V87, P4959, DOI 10.1182/blood.V87.12.4959.bloodjournal87124959; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; Gatignol A, 2000, Adv Pharmacol, V48, P209; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Gulow K, 2005, J IMMUNOL, V174, P5249, DOI 10.4049/jimmunol.174.9.5249; Huigen MCDG, 2004, EUR J CLIN INVEST, V34, P57, DOI 10.1111/j.1365-2362.2004.01282.x; JEANG KT, 1996, HUMAN RETROVIRUSES A; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kaleebu P, 2001, AIDS, V15, P293, DOI 10.1097/00002030-200102160-00001; Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; Li-Weber M, 2000, EUR J IMMUNOL, V30, P661, DOI 10.1002/1521-4141(200002)30:2<661::AID-IMMU661>3.3.CO;2-C; LORET EP, 1992, P NATL ACAD SCI USA, V89, P9734, DOI 10.1073/pnas.89.20.9734; McCloskey TW, 1997, J IMMUNOL, V158, P1014; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; Moretti S, 2000, CLIN EXP IMMUNOL, V122, P364, DOI 10.1046/j.1365-2249.2000.01375.x; NARDELLI B, 1995, P NATL ACAD SCI USA, V92, P7312, DOI 10.1073/pnas.92.16.7312; Neuveut C, 1996, J VIROL, V70, P5572, DOI 10.1128/JVI.70.8.5572-5581.1996; Noraz N, 1997, AIDS, V11, P1671, DOI 10.1097/00002030-199714000-00003; Opi S, 2002, J BIOL CHEM, V277, P35915, DOI 10.1074/jbc.M204393200; Opi S, 2004, VACCINE, V22, P3105, DOI 10.1016/j.vaccine.2004.01.057; Ott M, 1997, SCIENCE, V275, P1481, DOI 10.1126/science.275.5305.1481; Patki AH, 1996, CELL IMMUNOL, V169, P40, DOI 10.1006/cimm.1996.0088; Peloponese JM, 1999, J BIOL CHEM, V274, P11473, DOI 10.1074/jbc.274.17.11473; Rana TM, 1999, ARCH BIOCHEM BIOPHYS, V365, P175, DOI 10.1006/abbi.1999.1206; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; Senkaali D, 2004, AIDS RES HUM RETROV, V20, P932, DOI 10.1089/aid.2004.20.932; Silvestris F, 1996, AIDS, V10, P131, DOI 10.1097/00002030-199602000-00002; Smith SM, 2003, J BIOL CHEM, V278, P44816, DOI 10.1074/jbc.M307546200; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Vives E, 2003, J MOL RECOGNIT, V16, P265, DOI 10.1002/jmr.636; VIVES E, 1994, J VIROL, V68, P3343, DOI 10.1128/JVI.68.5.3343-3353.1994; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Wolf D, 2001, NAT MED, V7, P1217, DOI 10.1038/nm1101-1217; Xiao H, 1998, BIOCHEM BIOPH RES CO, V244, P384, DOI 10.1006/bbrc.1998.8274; Xiao H, 2000, P NATL ACAD SCI USA, V97, P11466, DOI 10.1073/pnas.97.21.11466	60	35	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38376	38382		10.1074/jbc.M506630200	http://dx.doi.org/10.1074/jbc.M506630200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16155003	hybrid			2022-12-27	WOS:000233239800033
J	Dantsker, D; Roche, C; Samuni, U; Blouin, G; Olson, JS; Friedman, JM				Dantsker, D; Roche, C; Samuni, U; Blouin, G; Olson, JS; Friedman, JM			The position 68(E11) side chain in myoglobin regulates ligand capture, bond formation with heme iron, and internal movement into the xenon cavities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM-WHALE MYOGLOBIN; NITRIC-OXIDE RECOMBINATION; SITE-DIRECTED MUTAGENESIS; STRUCTURAL DYNAMICS; CO BINDING; CONFORMATIONAL RELAXATION; CARBONMONOXY MYOGLOBIN; PROTEIN DYNAMICS; GEMINATE RECOMBINATION; MOLECULAR-DYNAMICS	After photodissociation, ligand rebinding to myoglobin exhibits complex kinetic patterns associated with multiple first-order geminate recombination processes occurring within the protein and a simpler bimolecular phase representing second-order ligand rebinding from the solvent. A smooth transition from cryogenic-like to solution phase properties can be obtained by using a combination of sol-gel encapsulation, addition of glycerol as a bathing medium, and temperature tuning (- 15 --> 65 degrees C). This approach was applied to a series of double mutants, myoglobin CO ( H64L/ V68X, where X = Ala, Val, Leu, Asn, and Phe), which were designed to examine the contributions of the position 68( E11) side chain to the appearance and disappearance of internal rebinding phases in the absence of steric and polar interactions with the distal histidine. Based on the effects of viscosity, temperature, and the stereochemistry of the E11 side chain, the three major phases, B --> A, C --> A, and D-->A, can be assigned, respectively, to ligand rebinding from the following: (i) the distal heme pocket, (ii) the xenon cavities prior to large amplitude side chain conformational relaxation, and (iii) the xenon cavities after significant conformational relaxation of the position 68( E11) side chain. The relative amplitudes of the B --> A and C-->A phases depend markedly on the size and shape of the E11 side chain, which regulates sterically both ligand return to the heme iron atom and ligand migration to the xenon cavities. The internal xenon cavities provide a transient docking site that allows side chain relaxations and the entry of water into the vacated distal pocket, which in turn slows ligand recombination markedly.	Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; Rice Univ, WM Keck Ctr Computat Biol, Houston, TX 77005 USA	Yeshiva University; Albert Einstein College of Medicine; Rice University; Rice University	Friedman, JM (corresponding author), Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA.	jfriedma@aecom.yu.edu		Olson, John/0000-0002-0760-5403	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008280, P01GM058890, R01GM035649] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47020] Funding Source: Medline; NIBIB NIH HHS [R01 EB00296] Funding Source: Medline; NIGMS NIH HHS [P01 GM58890, GM35649, T32 GM008280, GM08280] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGMON N, 1988, BIOCHEMISTRY-US, V27, P3507, DOI 10.1021/bi00409a057; Agmon N, 1996, CHEM PHYS, V212, P207, DOI 10.1016/S0301-0104(96)00179-6; AGMON N, 1983, J CHEM PHYS, V79, P2042, DOI 10.1063/1.445988; AGMON N, 1994, BIOPHYS J, V66, P1612, DOI 10.1016/S0006-3495(94)80953-1; ANSARI A, 1994, BIOCHEMISTRY-US, V33, P5128, DOI 10.1021/bi00183a017; ANSARI A, 1992, SCIENCE, V256, P1796, DOI 10.1126/science.1615323; Antonini E, 1971, HEMOGLOBINS MYOGLOBI; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; AUSTIN RH, 1973, SCIENCE, V181, P541, DOI 10.1126/science.181.4099.541; BALASUBRAMANIAN S, 1993, BIOCHEMISTRY-US, V32, P2202, DOI 10.1021/bi00060a011; BEECE D, 1980, BIOCHEMISTRY-US, V19, P5147, DOI 10.1021/bi00564a001; Bossa C, 2004, BIOPHYS J, V86, P3855, DOI 10.1529/biophysj.103.037432; Bourgeois D, 2003, P NATL ACAD SCI USA, V100, P8704, DOI 10.1073/pnas.1430900100; Brunori M, 1999, BIOPHYS J, V76, P1259, DOI 10.1016/S0006-3495(99)77289-9; Brunori M, 2000, P NATL ACAD SCI USA, V97, P2058, DOI 10.1073/pnas.040459697; CAMPBELL BF, 1987, SCIENCE, V238, P373, DOI 10.1126/science.3659921; Cao WX, 2001, BIOCHEMISTRY-US, V40, P5728, DOI 10.1021/bi010067e; Carlson ML, 1996, BIOCHEMISTRY-US, V35, P1125, DOI 10.1021/bi951767k; CARLSON ML, 1994, BIOCHEMISTRY-US, V33, P10597, DOI 10.1021/bi00201a005; CARVER TE, 1992, J BIOL CHEM, V267, P14443; CARVER TE, 1990, J BIOL CHEM, V265, P20007; CHU K, 1995, PHYS REV LETT, V74, P2607, DOI 10.1103/PhysRevLett.74.2607; Chu K, 2000, NATURE, V403, P921, DOI 10.1038/35002641; Dantsker D, 2005, BBA-PROTEINS PROTEOM, V1749, P234, DOI 10.1016/j.bbapap.2005.04.002; Dantsker D, 2002, J MOL BIOL, V315, P239, DOI 10.1006/jmbi.2001.5218; Doster W., 1993, PROTEIN SOLVENT INTE, P375; Draghi F, 2002, J BIOL CHEM, V277, P7509, DOI 10.1074/jbc.M109206200; EGEBERG KD, 1990, J BIOL CHEM, V265, P11788; FRAUENFELDER H, 1995, NAT STRUCT BIOL, V2, P821, DOI 10.1038/nsb1095-821; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; Frauenfelder H, 2001, P NATL ACAD SCI USA, V98, P2370, DOI 10.1073/pnas.041614298; GIBSON QH, 1992, J BIOL CHEM, V267, P22022; Hartmann H, 1996, P NATL ACAD SCI USA, V93, P7013, DOI 10.1073/pnas.93.14.7013; Huang J, 1997, BIOCHEMISTRY-US, V36, P14353, DOI 10.1021/bi9700274; IKEDASAITO M, 1993, J BIOL CHEM, V268, P6855; Ishikawa H, 2001, BIOPHYS J, V80, P1507, DOI 10.1016/S0006-3495(01)76123-1; Kholodenko Y, 1999, BIOCHEMISTRY-US, V38, P5918, DOI 10.1021/bi983022v; Kleinert T, 1998, BIOCHEMISTRY-US, V37, P717, DOI 10.1021/bi971508q; Kriegl JM, 2003, P NATL ACAD SCI USA, V100, P7069, DOI 10.1073/pnas.1231856100; Krzywda S, 1998, BIOCHEMISTRY-US, V37, P15896, DOI 10.1021/bi9812470; Lamb DC, 2004, BIOPHYS CHEM, V109, P41, DOI 10.1016/j.bpc.2003.10.002; Lamb DC, 2002, J BIOL CHEM, V277, P11636, DOI 10.1074/jbc.M109892200; LAMBRIGHT DG, 1993, BIOCHEMISTRY-US, V32, P10116, DOI 10.1021/bi00089a030; LAMBRIGHT DG, 1994, BIOCHEMISTRY-US, V33, P5518, DOI 10.1021/bi00184a021; Librizzi F, 2002, J CHEM PHYS, V116, P1193, DOI 10.1063/1.1426409; McNaughton L, 2003, J AM CHEM SOC, V125, P3813, DOI 10.1021/ja028064s; Nienhaus K, 2005, J AM CHEM SOC, V127, P40, DOI 10.1021/ja0466917; Nienhaus K, 2004, MICRON, V35, P67, DOI 10.1016/j.micron.2003.10.014; Nienhaus K, 2003, J BIOL CHEM, V278, P42532, DOI 10.1074/jbc.M306888200; Nienhaus K, 2003, BIOCHEMISTRY-US, V42, P9647, DOI 10.1021/bi034788k; Nienhaus K, 2003, BIOCHEMISTRY-US, V42, P9633, DOI 10.1021/bi034787s; Nutt DR, 2004, P NATL ACAD SCI USA, V101, P5998, DOI 10.1073/pnas.0306712101; Olson JS, 1997, J BIOL INORG CHEM, V2, P544, DOI 10.1007/s007750050169; Ostermann A, 2000, NATURE, V404, P205, DOI 10.1038/35004622; QUILLIN ML, 1995, J MOL BIOL, V245, P416, DOI 10.1006/jmbi.1994.0034; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; Radding W, 2004, BIOESSAYS, V26, P422, DOI 10.1002/bies.20010; Samuni U, 2003, J BIOL CHEM, V278, P27241, DOI 10.1074/jbc.M212634200; Samuni U, 2002, J BIOL CHEM, V277, P25783, DOI 10.1074/jbc.M200301200; Sastry GM, 1997, BIOCHEMISTRY-US, V36, P7097, DOI 10.1021/bi9626057; Schlichting I, 2000, CURR OPIN STRUC BIOL, V10, P744, DOI 10.1016/S0959-440X(00)00158-5; SCHOENBORN BP, 1965, NATURE, V207, P28, DOI 10.1038/207028a0; Schotte F, 2003, SCIENCE, V300, P1944, DOI 10.1126/science.1078797; Scott EE, 1997, BIOCHEMISTRY-US, V36, P11909, DOI 10.1021/bi970719s; Scott EE, 2001, J BIOL CHEM, V276, P5177, DOI 10.1074/jbc.M008282200; SCOTT TW, 1984, J AM CHEM SOC, V106, P5677, DOI 10.1021/ja00331a044; SIEMIARCZUK A, 1990, J PHYS CHEM-US, V94, P1661, DOI 10.1021/j100367a080; SIEMIARCZUK A, 1989, J PHYS CHEM-US, V93, P7609, DOI 10.1021/j100359a017; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; Srajer V, 2001, BIOCHEMISTRY-US, V40, P13802, DOI 10.1021/bi010715u; Sugimoto T, 1998, BIOPHYS J, V75, P2188, DOI 10.1016/S0006-3495(98)77662-3; Teeter MM, 2004, PROTEIN SCI, V13, P313, DOI 10.1110/ps.03334304; Tetreau C, 2004, BIOPHYS J, V86, P435, DOI 10.1016/S0006-3495(04)74120-X; TILTON RF, 1984, BIOCHEMISTRY-US, V23, P2849, DOI 10.1021/bi00308a002; Vojtechovsky J, 1999, BIOPHYS J, V77, P2153, DOI 10.1016/S0006-3495(99)77056-6; WALDA KN, 1994, BIOCHEMISTRY-US, V33, P2198, DOI 10.1021/bi00174a029	76	37	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38740	38755		10.1074/jbc.M506333200	http://dx.doi.org/10.1074/jbc.M506333200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16155005	hybrid			2022-12-27	WOS:000233239800076
J	Ximenes, VF; Silva, SO; Rodrigues, MR; Catalani, LH; Maghzal, GJ; Kettle, AJ; Campa, A				Ximenes, VF; Silva, SO; Rodrigues, MR; Catalani, LH; Maghzal, GJ; Kettle, AJ; Campa, A			Superoxide-dependent oxidation of melatonin by myeloperoxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; INDOLEAMINE 2,3-DIOXYGENASE; HORSERADISH-PEROXIDASE; HUMAN-NEUTROPHILS; COMPOUND-III; TRYPTOPHAN; ACID; HYDROXYLATION; MECHANISM; HYDROQUINONE	Myeloperoxidase uses hydrogen peroxide to oxidize numerous substrates to hypohalous acids or reactive free radicals. Here we show that neutrophils oxidize melatonin to N-1-acetyl-N-2-formyl-5-methoxykynuramine (AFMK) in a reaction that is catalyzed by myeloperoxidase. Production of AFMK was highly dependent on superoxide but not hydrogen peroxide. It did not require hypochlorous acid, singlet oxygen, or hydroxyl radical. Purified myeloperoxidase and a superoxide-generating system oxidized melatonin to AFMK and a dimer. The dimer would result from coupling of melatonin radicals. Oxidation of melatonin was partially inhibited by catalase or superoxide dismutase. Formation of AFMK was almost completely eliminated by superoxide dismutase but weakly inhibited by catalase. In contrast, production of melatonin dimer was enhanced by superoxide dismutase and blocked by catalase. We propose that myeloperoxidase uses superoxide to oxidize melatonin by two distinct pathways. One pathway involves the classical peroxidation mechanism in which hydrogen peroxide is used to oxidize melatonin to radicals. Superoxide adds to these radicals to form an unstable peroxide that decays to AFMK. In the other pathway, myeloperoxidase uses superoxide to insert dioxygen into melatonin to form AFMK. This novel activity expands the types of oxidative reactions myeloperoxidase can catalyze. It should be relevant to the way neutrophils use superoxide to kill bacteria and how they metabolize xenobiotics.	Christchurch Sch Med & Hlth Sci, Dept Pathol, Christchurch, New Zealand; Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Anal Clin & Toxicol, Sao Paulo, Brazil; Univ Sao Paulo, Inst Quim, Sao Paulo, Brazil	University of Otago; Universidade de Sao Paulo; Universidade de Sao Paulo	Kettle, AJ (corresponding author), Christchurch Sch Med & Hlth Sci, Dept Pathol, POB 4345, Christchurch, New Zealand.	tony.kettle@chmeds.ac.nz	Ximenes, Valdecir/A-5323-2008; maghzal, ghassan/A-9692-2015; Campa, Ana/D-4669-2012; Rodrigues, Maria Rita/ABE-1097-2020; Catalani, Luiz Henrique/E-2841-2010; Lautenschlager, Sueli OS/P-2164-2017; Kettle, Anthony J/A-8520-2008	Ximenes, Valdecir/0000-0003-2636-3080; Campa, Ana/0000-0002-6183-3378; Catalani, Luiz Henrique/0000-0003-3689-1792; Lautenschlager, Sueli OS/0000-0001-9303-0804; Kettle, Anthony J/0000-0002-8218-7766				Allegra M, 2001, BIOCHEM BIOPH RES CO, V282, P380, DOI 10.1006/bbrc.2001.4582; BEERS RF, 1952, J BIOL CHEM, V195, P133; Brzezinski Amnon, 1997, New England Journal of Medicine, V336, P186; Carrillo-Vico A, 2004, FASEB J, V18, P537, DOI 10.1096/fj.03-0694fje; Cuzzocrea S, 1999, FASEB J, V13, P1930, DOI 10.1096/fasebj.13.14.1930; d'Alessandro N, 2000, J CHEM SOC PERK T 2, P1862, DOI 10.1039/b003346o; DAVIS WB, 1989, BIOCHEM PHARMACOL, V38, P4013; de Almeida EA, 2003, J PINEAL RES, V35, P131; de Oliveira Silva Sueli, 2000, Biochemical and Biophysical Research Communications, V279, P657, DOI 10.1006/bbrc.2000.3993; Dunford HB, 1999, BIOCHEM CELL BIOL, V77, P449, DOI 10.1139/bcb-77-5-449; Fang XW, 1998, J CHEM SOC PERK T 2, P259, DOI 10.1039/a706979k; Ferry G, 2005, BIOCHEM J, V388, P205, DOI 10.1042/BJ20042075; Fridovich I, 1985, CRC HDB METHODS OXYG, P213; Gitto E, 2001, PEDIATR RES, V50, P756, DOI 10.1203/00006450-200112000-00021; Green PS, 2004, J NEUROCHEM, V90, P724, DOI 10.1111/j.1471-4159.2004.02527.x; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; Hampton MB, 1996, INFECT IMMUN, V64, P3512, DOI 10.1128/IAI.64.9.3512-3517.1996; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; HOOGLAND H, 1987, BIOCHIM BIOPHYS ACTA, V916, P76, DOI 10.1016/0167-4838(87)90212-3; KALYANARAMAN B, 1993, J AM CHEM SOC, V115, P4007, DOI 10.1021/ja00063a021; Kettle AJ, 1999, METHOD ENZYMOL, V300, P111; KETTLE AJ, 1991, BIOCHEM PHARMACOL, V41, P1485, DOI 10.1016/0006-2952(91)90565-M; KETTLE AJ, 1992, J BIOL CHEM, V267, P8319; KETTLE AJ, 1989, BIOCHEM J, V263, P823, DOI 10.1042/bj2630823; Kettle AJ, 2000, REDOX REP, V5, P179, DOI 10.1179/135100000101535726; KETTLE AJ, 1994, J BIOL CHEM, V269, P17146; KETTLE AJ, 1988, BIOCHEM J, V252, P529, DOI 10.1042/bj2520529; Kettle AJ, 2001, BIOCHEMISTRY-US, V40, P10204, DOI 10.1021/bi010940b; Kettle AJ, 1997, REDOX REP, V3, P3, DOI 10.1080/13510002.1997.11747085; KETTLE AJ, 1993, BIOCHEM PHARMACOL, V45, P2003, DOI 10.1016/0006-2952(93)90010-T; KETTLE AJ, 1988, BIOCHIM BIOPHYS ACTA, V956, P58, DOI 10.1016/0167-4838(88)90297-X; Klebanoff SJ, 1999, P ASSOC AM PHYSICIAN, V111, P383, DOI 10.1111/paa.1999.111.5.383; Klebanoff SJ, 2005, J LEUKOCYTE BIOL, V77, P598, DOI 10.1189/jlb.1204697; KLEBANOFF SJ, 1968, J BACTERIOL, V95, P2131, DOI 10.1128/JB.95.6.2131-2138.1968; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; MARQUEZ LA, 1990, J BIOL CHEM, V265, P5666; MARQUEZ LA, 1993, ARCH BIOCHEM BIOPHYS, V305, P414, DOI 10.1006/abbi.1993.1440; MARQUEZ LA, 1990, J BIOL CHEM, V265, P6074; Nagra RM, 1997, J NEUROIMMUNOL, V78, P97, DOI 10.1016/S0165-5728(97)00089-1; Newcomb M, 2003, ARCH BIOCHEM BIOPHYS, V409, P72, DOI 10.1016/S0003-9861(02)00445-9; ODAJIMA T, 1970, BIOCHIM BIOPHYS ACTA, V206, P71, DOI 10.1016/0005-2744(70)90083-5; Reiter RJ, 2002, J PHARM PHARMACOL, V54, P1299, DOI 10.1211/002235702760345374; Rodrigues MR, 2003, J PINEAL RES, V34, P69, DOI 10.1034/j.1600-079X.2003.02944.x; Rodrigues MR, 2002, BIOCHEM BIOPH RES CO, V292, P869, DOI 10.1006/bbrc.2002.6724; SAKIYAMA F, 1978, CHEM LETT, P893, DOI 10.1246/cl.1978.893; SANTUS R, 1995, FREE RADICAL BIO MED, V19, P837, DOI 10.1016/0891-5849(95)00055-3; Silva SO, 2004, J NEUROIMMUNOL, V156, P146, DOI 10.1016/j.jneuroim.2004.07.015; Silva SO, 2004, J PINEAL RES, V37, P171, DOI 10.1111/j.1600-079X.2004.00149.x; SUBRAHMANYAM VV, 1991, FREE RADICAL RES COM, V15, P285, DOI 10.3109/10715769109105224; Tafazoli S, 2005, DRUG DISCOV TODAY, V10, P617, DOI 10.1016/S1359-6446(05)03394-5; Tan DX, 2001, FASEB J, V15, P2294, DOI 10.1096/fj.01-0309fje; Tan DX, 1999, BBA-GEN SUBJECTS, V1472, P206, DOI 10.1016/S0304-4165(99)00125-7; Thomas SR, 1999, REDOX REP, V4, P199, DOI 10.1179/135100099101534927; UETRECHT JP, 1992, DRUG METAB REV, V24, P299, DOI 10.3109/03602539208996297; Winterbourn CC, 1997, ARCH BIOCHEM BIOPHYS, V338, P15, DOI 10.1006/abbi.1996.9773; WINTERBOURN CC, 1985, BIOCHEM J, V228, P583, DOI 10.1042/bj2280583; Ximenes VF, 2001, BIOCHEM BIOPH RES CO, V287, P130, DOI 10.1006/bbrc.2001.5557; Ximenes VF, 2001, ARCH BIOCHEM BIOPHYS, V387, P173, DOI 10.1006/abbi.2000.2228; YOKOTA K, 1965, BIOCHEM BIOPH RES CO, V18, P48, DOI 10.1016/0006-291X(65)90880-6	59	64	65	3	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38160	38169		10.1074/jbc.M506384200	http://dx.doi.org/10.1074/jbc.M506384200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16148002	hybrid			2022-12-27	WOS:000233239800008
J	Hausmann, S; Koiwa, H; Krishnamurthy, S; Hampsey, M; Shuman, S				Hausmann, S; Koiwa, H; Krishnamurthy, S; Hampsey, M; Shuman, S			Different strategies for carboxyl-terminal domain (CTD) recognition by serine 5-specific CTD phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; ACTIVE-SITE; POLYMERASE; SSU72; TRANSCRIPTION; YEAST; PHOSPHORYLATION; MECHANISM; PROTEIN; FCP1	The phosphorylated carboxyl-terminal domain (CTD) of RNA polymerase II, consisting of ((YSPTSPS7)-Y-1)(n) heptad repeats, encodes information about the state of the transcriptional apparatus that can be conveyed to factors that regulate mRNA synthesis and processing. Here we describe how the CTD code is read by two classes of protein phosphatases, plant CPLs and yeast Ssu72, that specifically dephosphorylate Ser(5) in vitro. The CPLs and Ssu72 recognize entirely different positional cues in the CTD primary structure. Whereas the CPLs rely on Tyr(1) and Pro(3) located on the upstream side of the Ser(5)- PO4 target site, Ssu72 recognizes Thr(4) and Pro(6) flanking the target Ser(5)- PO4 plus the downstream Tyr(1) residue of the adjacent heptad. We surmise that the reading of the CTD code does not obey uniform rules with respect to the location and phasing of specificity determinants. Thus, CTD code, like the CTD structure, is plastic.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Texas A&M Univ, Dept Hort Sci, College Stn, TX 77843 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Memorial Sloan Kettering Cancer Center; Texas A&M University System; Texas A&M University College Station; Rutgers State University New Brunswick; Rutgers State University Medical Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org	Koiwa, Hisashi/AAA-8182-2019; Koiwa, Hisashi/AAO-6512-2020	Koiwa, Hisashi/0000-0002-7421-340X	NIGMS NIH HHS [GM52470] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052470] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Buratowski S, 2003, NAT STRUCT BIOL, V10, P679, DOI 10.1038/nsb0903-679; Dichtl B, 2002, MOL CELL, V10, P1139, DOI 10.1016/S1097-2765(02)00707-4; Fabrega C, 2003, MOL CELL, V11, P1549, DOI 10.1016/S1097-2765(03)00187-4; Ganem C, 2003, EMBO J, V22, P1588, DOI 10.1093/emboj/cdg141; Hausmann S, 2004, BIOCHEMISTRY-US, V43, P7111, DOI 10.1021/bi0499617; Hausmann S, 2002, J BIOL CHEM, V277, P21213, DOI 10.1074/jbc.M202056200; Hausmann S, 2003, J BIOL CHEM, V278, P13627, DOI 10.1074/jbc.M213191200; Hausmann S, 2004, J BIOL CHEM, V279, P10892, DOI 10.1074/jbc.M312513200; He XY, 2003, GENE DEV, V17, P1030, DOI 10.1101/gad.1075203; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; Kamenski T, 2004, MOL CELL, V15, P399, DOI 10.1016/j.molcel.2004.06.035; Koiwa H, 2004, P NATL ACAD SCI USA, V101, P14539, DOI 10.1073/pnas.0403174101; Koiwa H, 2002, P NATL ACAD SCI USA, V99, P10893, DOI 10.1073/pnas.112276199; Krishnamurthy S, 2004, MOL CELL, V14, P387, DOI 10.1016/S1097-2765(04)00235-7; Lahiri SD, 2003, SCIENCE, V299, P2067, DOI 10.1126/science.1082710; Lin PS, 2002, J BIOL CHEM, V277, P45949, DOI 10.1074/jbc.M208588200; Meinhart A, 2003, J BIOL CHEM, V278, P15917, DOI 10.1074/jbc.M301643200; Meinhart A, 2004, NATURE, V430, P223, DOI 10.1038/nature02679; Nedea E, 2003, J BIOL CHEM, V278, P33000, DOI 10.1074/jbc.M304454200; Noble CG, 2005, NAT STRUCT MOL BIOL, V12, P144, DOI 10.1038/nsmb887; Pei Y, 2001, J BIOL CHEM, V276, P28075, DOI 10.1074/jbc.M102170200; Steinmetz EJ, 2003, MOL CELL BIOL, V23, P6339, DOI 10.1128/MCB.23.18.6339-6349.2003; Stiller JW, 2004, EUKARYOT CELL, V3, P735, DOI 10.1128/EC.3.3.735-740.2004; Sun ZW, 1996, MOL CELL BIOL, V16, P1557; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Yeo M, 2003, J BIOL CHEM, V278, P26078, DOI 10.1074/jbc.M301791200	26	39	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37681	37688		10.1074/jbc.M505292200	http://dx.doi.org/10.1074/jbc.M505292200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16148005	hybrid			2022-12-27	WOS:000233044500045
J	Li, J; Stern, DF				Li, J; Stern, DF			DNA damage regulates Chk2 association with chromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; CHECKPOINT KINASE ATR; DOUBLE-STRAND BREAKS; CELL-CYCLE; PHOSPHORYLATION EVENTS; PROTEIN-KINASE; REPLICATION; RECRUITMENT; ACTIVATION; SITES	DNA damage triggers cellular signaling pathways that control the cell cycle and DNA repair. Chk2 is a critical mediator of diverse responses to DNA damage. Chk2 transmits signals from upstream phosphatidylinositol 3'-kinase-like kinases to effector substrates including p53, Brca1, Cdc25A, and Cdc25C. Using chromatin fractionation as well as immunostaining combined with detergent pre-extraction, we have found that a small pool of Chk2 is associated with chromatin prior to DNA damage. Recovery of chromatin-bound Chk2 is reduced in an ATM-dependent manner by exposure to ionizing radiation. Camptothecin and adriamycin also reduce the amount of chromatin-associated Chk2. The Thr(68)-phosphorylated forms of Chk2 induced by DNA damage are found in soluble fractions, but not in the chromatin-enriched fraction. Functional serine/threonine glutamine cluster domain, forkhead-associated domain, and kinase activity are all required for efficient reduction of chromatin-bound Chk2 in response to DNA damage. Artificial induction of Chk2 oligomerization concomitant with exposure to low dose ionizing radiation reduces chromatin-bound Chk2. When Chk2 is incubated with chromatin-enriched fractions in vitro in the presence of ATP, hyperphosphorylated forms of Chk2 bind more weakly to chromatin than hypophosphorylated forms. Taken together, our data suggest that DNA damage induces activation of chromatin-bound Chk2 by a chromatin-derived signal, and that this results in dissociation of activated Chk2 from chromatin, facilitating further signal amplification and transmission to soluble substrates.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA	Yale University; Yale University	Stern, DF (corresponding author), 310 Cedar ST,BML342, New Haven, CT 06510 USA.	Df.stern@yale.edu			NATIONAL CANCER INSTITUTE [R01CA082257] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA82257] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Ahn JY, 2000, CANCER RES, V60, P5934; Andegeko Y, 2001, J BIOL CHEM, V276, P38224; AUSUBEL FM, 2003, CURRENT PROTOCOLS MO, V2; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Dart DA, 2004, J BIOL CHEM, V279, P16433, DOI 10.1074/jbc.M314212200; Duncker BP, 2002, P NATL ACAD SCI USA, V99, P16087, DOI 10.1073/pnas.252093999; Emili A, 2001, MOL CELL, V7, P13, DOI 10.1016/S1097-2765(01)00150-2; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Foray N, 2003, EMBO J, V22, P2860, DOI 10.1093/emboj/cdg274; Frei C, 2000, GENE DEV, V14, P81; Iwabuchi K, 2003, J BIOL CHEM, V278, P36487, DOI 10.1074/jbc.M304066200; Jiang KC, 2003, J BIOL CHEM, V278, P25207, DOI 10.1074/jbc.M300070200; Kappes F, 2001, J BIOL CHEM, V276, P26317, DOI 10.1074/jbc.M100162200; Katou Y, 2003, NATURE, V424, P1078, DOI 10.1038/nature01900; Kitagawa R, 2004, GENE DEV, V18, P1423, DOI 10.1101/gad.1200304; Kondo T, 2001, SCIENCE, V294, P867, DOI 10.1126/science.1063827; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Li J, 2005, J BIOL CHEM, V280, P12041, DOI 10.1074/jbc.M412445200; Lisby M, 2004, CELL, V118, P699, DOI 10.1016/j.cell.2004.08.015; Longhese MP, 2000, GENETICS, V155, P1577; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Melo JA, 2001, GENE DEV, V15, P2809; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Miao H, 2003, J BIOL CHEM, V278, P4295, DOI 10.1074/jbc.M204264200; Pandita TK, 2002, ONCOGENE, V21, P611, DOI 10.1038/sj.onc.1205060; Peng AM, 2003, J BIOL CHEM, V278, P8873, DOI 10.1074/jbc.C300001200; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Sarkaria JN, 1998, CANCER RES, V58, P4375; Shechter D, 2004, NAT CELL BIOL, V6, P648, DOI 10.1038/ncb1145; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Tsvetkov L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302; Zou L, 2003, P NATL ACAD SCI USA, V100, P13827, DOI 10.1073/pnas.2336100100; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	57	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37948	37956		10.1074/jbc.M509299200	http://dx.doi.org/10.1074/jbc.M509299200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16150728	hybrid			2022-12-27	WOS:000233044500077
J	Sarrazin, S; Bonnaffe, D; Lubineau, A; Lortat-Jacob, H				Sarrazin, S; Bonnaffe, D; Lubineau, A; Lortat-Jacob, H			Heparan sulfate mimicry - A synthetic glycoconjugate that recognizes the heparin binding domain of interferon-gamma inhibits the cytokine activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE; IFN-GAMMA; RECEPTOR; COMPLEX; DIVERSITY; SEQUENCE; PROTEOGLYCANS; PURIFICATION; ANTIBODIES	Cell-associated heparan sulfate (HS) is endowed with the remarkable ability to bind numerous proteins. As such, it represents a unique system that integrates signaling from circulating ligands with cellular receptors. This polysaccharide is extraordinary complex, and examples that define the structure-function relationship of HS are limited. In particular, it remains difficult to understand the structures by which HS interact with proteins. Among them, interferon-gamma(IFN gamma), a dimeric cytokine, binds to a complex oligosaccharide motif encompassing a N-acetylated glucosamine-rich domain and two highly sulfated sequences, each of which binds to one IFN gamma monomer. Based on this template, we have synthesized a set of glycoconjugate mimetics and evaluated their ability to interact with IFN gamma. One of these molecules, composed of two authentic N-sulfated octasaccharides linked to each other through a 50-angstrom-long spacer termed 2O(10), displays high affinity for the cytokine and inhibits IFN gamma-HS binding with an IC50 of 35 - 40 nM. Interestingly, this molecule also inhibits the binding of IFN gamma to its cellular receptor. Thus, in addition to its ability to delocalize the cytokine from cell surface-associated HS, this compound has direct anti-IFN gamma activity. Altogether, our results represent the first synthetic HS-like molecule that targets a cytokine, strongly validating the HS structural determinants for IFN gamma recognition, providing a new strategy to inhibit IFN gamma in a number of diseases in which the cytokine has been identified as a target, and reinforcing the view that it is possible to create "tailor-made" sequences based on the HS template to isolate therapeutic activities.	Univ Grenoble 1, Inst Biol Struct, Comm Energie Atom, CNRS,Unite Mixte Rech 5075, F-38027 Grenoble, France; Univ Paris 11, CNRS, Unite Mixte Rech 8614, Lab Chim Organ Multifonct, F-91405 Orsay, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Lortat-Jacob, H (corresponding author), Univ Grenoble 1, Inst Biol Struct, Comm Energie Atom, CNRS,Unite Mixte Rech 5075, 41 Ave Horowitz, F-38027 Grenoble, France.	Hugues.Lortat-Jacob@ibs.fr						BERG K, 1990, APMIS, V98, P156, DOI 10.1111/j.1699-0463.1990.tb01016.x; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Billiau A, 1996, ADV IMMUNOL, V62, P61, DOI 10.1016/S0065-2776(08)60428-9; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Bouma G, 2003, NAT REV IMMUNOL, V3, P521, DOI 10.1038/nri1132; Coombe DR, 2005, CELL MOL LIFE SCI, V62, P410, DOI 10.1007/s00018-004-4293-7; Dilhas A, 2004, TETRAHEDRON LETT, V45, P3643, DOI 10.1016/j.tetlet.2004.03.046; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Faham S, 1998, CURR OPIN STRUC BIOL, V8, P578, DOI 10.1016/S0959-440X(98)80147-4; Fernandez-Botran R, 2002, TRANSPLANTATION, V74, P623, DOI 10.1097/00007890-200209150-00007; Froyen G, 1997, BIOTHERAPY, V10, P49, DOI 10.1007/BF02678217; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; Gavard O, 2003, EUR J ORG CHEM, V2003, P3603, DOI 10.1002/ejoc.200300254; GIBSON UEM, 1989, J IMMUNOL METHODS, V125, P105, DOI 10.1016/0022-1759(89)90083-5; Haelewyn J, 1995, BIOCHEM MOL BIOL INT, V37, P1163; Hidalgo LG, 2002, CRIT REV IMMUNOL, V22, P317; Lever R, 2002, NAT REV DRUG DISCOV, V1, P140, DOI 10.1038/nrd724; Lim Wee-Chian, 2004, Rev Gastroenterol Disord, V4, P66; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; Lortat-Jacob H, 2002, P NATL ACAD SCI USA, V99, P1229, DOI 10.1073/pnas.032497699; LORTAT-JACOB H, 1991, J CLIN INVEST, V87, P878, DOI 10.1172/JCI115093; Lortat-Jacob H, 1996, J BIOL CHEM, V271, P16139, DOI 10.1074/jbc.271.27.16139; LORTAT-JACOB H, 1995, BIOCHEM J, V310, P497, DOI 10.1042/bj3100497; Lubineau A, 2004, CHEM-EUR J, V10, P4265, DOI 10.1002/chem.200306063; Lubineau A, 1997, TETRAHEDRON LETT, V38, P4087, DOI 10.1016/S0040-4039(97)00830-7; LUNDELL DJ, 1994, PHARMACOL THERAPEUT, V64, P1, DOI 10.1016/0163-7258(94)90031-0; Murphy KJ, 2004, J BIOL CHEM, V279, P27239, DOI 10.1074/jbc.M401774200; Nicoletti F, 1996, ENDOCRINOLOGY, V137, P5567, DOI 10.1210/en.137.12.5567; OLTVOORT JJ, 1981, SYNTHESIS-STUTTGART, P305; OZMEN L, 1995, EUR J IMMUNOL, V25, P6, DOI 10.1002/eji.1830250103; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; Petitou M, 2004, ANGEW CHEM INT EDIT, V43, P3118, DOI 10.1002/anie.200300640; Petitou M, 2003, BIOCHIMIE, V85, P83, DOI 10.1016/S0300-9084(03)00078-6; Raman R, 2005, CHEM BIOL, V12, P267, DOI 10.1016/j.chembiol.2004.11.020; Sadir R, 1998, J BIOL CHEM, V273, P10919, DOI 10.1074/jbc.273.18.10919; Sadir R, 2001, J BIOL CHEM, V276, P8288, DOI 10.1074/jbc.M008110200; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Skurkovich B, 2003, CURR OPIN MOL THER, V5, P52; TROST BM, 1981, TETRAHEDRON LETT, V22, P1287, DOI 10.1016/S0040-4039(01)90298-9; Tumova S, 2000, INT J BIOCHEM CELL B, V32, P269, DOI 10.1016/S1357-2725(99)00116-8; Vives RR, 2001, BIOCHEM J, V354, P141, DOI 10.1042/0264-6021:3540141; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; Yamada M, 2004, AM J PHYSIOL-LUNG C, V287, pL1042, DOI 10.1152/ajplung.00155.2004	46	44	45	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37558	37564		10.1074/jbc.M507729200	http://dx.doi.org/10.1074/jbc.M507729200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16155294	hybrid			2022-12-27	WOS:000233044500032
J	Takino, T; Nakada, M; Miyamori, H; Watanabe, Y; Sato, T; Gantulga, D; Yoshioka, K; Yamada, KM; Sato, H				Takino, T; Nakada, M; Miyamori, H; Watanabe, Y; Sato, T; Gantulga, D; Yoshioka, K; Yamada, KM; Sato, H			JSAP1/JIP3 cooperates with focal adhesion kinase to regulate c-Jun N-terminal kinase and cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; JNK SIGNALING PATHWAY; SCAFFOLD PROTEIN; TYROSINE PHOSPHORYLATION; MATRIX ADHESION; INVASION; FAK; SRC; MICROTUBULES; P130(CAS)	c-Jun N-terminal kinase (JNK)/stress-activated protein kinase-associated protein 1 (JSAP1) ( also termed JNK-interacting protein 3; JIP3) is a member of a family of scaffold factors for the mitogen-activated protein kinase ( MAPK) cascades, and it also forms a complex with focal adhesion kinase (FAK). Here we demonstrate that JSAP1 serves as a cooperative scaffold for activation of JNK and regulation of cell migration in response to fibronectin (FN) stimulation. JSAP1 mediated an association between FAK and JNK, which was induced by either co-expression of Src or attachment of cells to FN. Complex formation of FAK with JSAP1 and p130 Crk-associated substrate (p130(Cas)) resulted in augmentation of FAK activity and phosphorylation of both JSAP1 and p130(Cas), which required p130(Cas) hyperphosphorylation and was abolished by inhibition of Src. JNK activation by FN was enhanced by JSAP1, which was suppressed by disrupting the FAK/p130(Cas) pathway by expression of a dominant-negative form of p130(Cas) or by inhibiting Src. We also documented the co-localization of JSAP1 with JNK and phosphorylated FAK at the leading edge and stimulation of cell migration by JSAP1 expression, which depended on its JNK binding domain and was suppressed by inhibition of JNK. The level of JSAP1 mRNA correlated with advanced malignancy in brain tumors, unlike other JIPs. We propose that the JSAP1 center dot FAK complex functions cooperatively as a scaffold for the JNK signaling pathway and regulator of cell migration on FN, and we suggest that JSAP1 is also associated with malignancy in brain tumors.	Kanazawa Univ, Canc Res Inst, Dept Mol Oncol & Virol, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Canc Res Inst, Dept Cell Cycle Regulat, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Grad Sch Med Sci, Dept Neurosurg, Div Neurosci, Kanazawa, Ishikawa 9200934, Japan; NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA	Kanazawa University; Kanazawa University; Kanazawa University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Takino, T (corresponding author), Kanazawa Univ, Canc Res Inst, Dept Mol Oncol & Virol, Kanazawa, Ishikawa 9200934, Japan.	ttakino@kenroku.kanazawa-u.ac.jp	Pillay, Nischalan/F-9536-2012; Nakada, Mitsutoshi/B-2790-2012; TAKINO, Takahisa/D-8460-2015; SATO, Hiroshi/D-8454-2015	Nakada, Mitsutoshi/0000-0001-9419-6101; Yamada, Kenneth/0000-0003-1512-6805; Davaakhuu, Gantulga/0000-0003-3792-7101	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000524] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000524] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Chang LF, 2003, DEV CELL, V4, P521, DOI 10.1016/S1534-5807(03)00094-7; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Dunty JM, 2004, MOL CELL BIOL, V24, P5353, DOI 10.1128/MCB.24.12.5353-5368.2004; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Ha HY, 2005, DEV BIOL, V277, P184, DOI 10.1016/j.ydbio.2004.09.019; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; Im JY, 2003, J NEUROSCI RES, V74, P326, DOI 10.1002/jnr.10761; Ito M, 1999, MOL CELL BIOL, V19, P7539; Iwahara T, 2004, P NATL ACAD SCI USA, V101, P17693, DOI 10.1073/pnas.0408413102; Javelaud D, 2003, J BIOL CHEM, V278, P24624, DOI 10.1074/jbc.M301942200; Kelkar N, 2003, P NATL ACAD SCI USA, V100, P9843, DOI 10.1073/pnas.1733944100; Kleihues P, 1993, HISTOLOGICAL TYPING; Kuboki Y, 2000, J BIOL CHEM, V275, P39815, DOI 10.1074/jbc.C000403200; Larsen M, 2003, NAT REV MOL CELL BIO, V4, P700, DOI 10.1038/nrm1199; Li LM, 2002, MOL CELL BIOL, V22, P1203, DOI 10.1128/MCB.22.4.1203-1217.2002; Mariani L, 2001, CANCER RES, V61, P4190; Martin-Blanco E, 2000, P NATL ACAD SCI USA, V97, P7888, DOI 10.1073/pnas.97.14.7888; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; OWENS LV, 1995, CANCER RES, V55, P2752; Palazzo AF, 2004, SCIENCE, V303, P836, DOI 10.1126/science.1091325; Pratt SJ, 2005, J CELL BIOL, V168, P813, DOI 10.1083/jcb.200406083; Sato S, 2004, GENE, V329, P51, DOI 10.1016/j.gene.2003.12.034; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Takino T, 2003, J CELL SCI, V116, P3145, DOI 10.1242/jcs.00632; Takino T, 2003, CANCER RES, V63, P2335; Takino T, 2002, ONCOGENE, V21, P6488, DOI 10.1038/sj.onc.1205840; Tamura M, 1999, CANCER RES, V59, P442; Verhey KJ, 2001, TRENDS BIOCHEM SCI, V26, P545, DOI 10.1016/S0968-0004(01)01931-4; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Waterman-Storer CM, 1999, NAT CELL BIOL, V1, P45, DOI 10.1038/9018; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Westhoff MA, 2004, MOL CELL BIOL, V24, P8113, DOI 10.1128/MCB.24.18.8113-8133.2004; Whitmarsh AJ, 2001, GENE DEV, V15, P2421, DOI 10.1101/gad.922801; Wittmann T, 2001, J CELL SCI, V114, P3795; Xia Y, 2004, TRENDS CELL BIOL, V14, P94, DOI 10.1016/j.tcb.2003.12.005; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Yujiri T, 2003, J BIOL CHEM, V278, P3846, DOI 10.1074/jbc.M206087200	42	60	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37772	37781		10.1074/jbc.M505241200	http://dx.doi.org/10.1074/jbc.M505241200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16141199	hybrid			2022-12-27	WOS:000233044500056
J	Harvat, EM; Stevens, JM; Redfield, C; Ferguson, SJ				Harvat, EM; Stevens, JM; Redfield, C; Ferguson, SJ			Functional characterization of the C-terminal domain of the cytochrome c maturation protein CcmE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEME CHAPERONE CCME; ESCHERICHIA-COLI; ACTIVE-SITE; BIOGENESIS; SYSTEM; OVERPRODUCTION; APOCYTOCHROME; VARIANTS; REQUIRES; REVEALS	CcmE is a heme chaperone involved in the periplasmic maturation of c-type cytochromes in many bacteria and plant mitochondria. It binds heme covalently and subsequently transfers it to the apo form of cytochromes c. To examine the role of the C-terminal domain of CcmE in the binding of heme, in vitro heme binding to the apo form of a truncated ( immediately before Pro-136) version of the periplasmic domain of the heme chaperone from Escherichia coli was studied. Removal of the C-terminal domain dramatically altered the ligation of non-covalently bound heme in CcmE' ( the soluble form lacking the membrane anchor) but only slightly affected its affinity for protoporphyrin IX and 8-anilino-1-naphthalenesulfonate. This finding has significant mechanistic implications for in vivo holo-CcmE formation and indicates that the C-terminal region is not required for the recruitment and docking of heme into its binding site but is likely to contain amino acid(s) involved in heme iron axial coordination. Removal of the C-domain significantly impaired in vivo heme binding to CcmE and conversion of apocytochrome to holoprotein by a similar factor, suggesting that the C-terminal domain of the chaperone is primarily involved in heme binding to CcmE rather than in heme transfer to the apo cytochrome.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Univ Oxford, Dept Biochem, Oxford OX1 3TA, England; Univ Oxford, Oxford Ctr Mol Sci, Chem Res Lab, Oxford OX1 3TA, England	University of Oxford; University of Oxford; University of Oxford	Stevens, JM (corresponding author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.	julie.stevens@bioch.ox.ac.uk; stuart.ferguson@bioch.ox.ac.uk		Redfield, Christina/0000-0001-7297-7708				Allen JWA, 2003, J BIOL CHEM, V278, P52075, DOI 10.1074/jbc.M307196200; Allen JWA, 2003, PHILOS T ROY SOC B, V358, P255, DOI 10.1098/rstb.2002.1192; Allen JWA, 2002, J BIOL CHEM, V277, P33559, DOI 10.1074/jbc.M204963200; Arnesano F, 2002, BIOCHEMISTRY-US, V41, P13587, DOI 10.1021/bi026362w; Arslan E, 1998, BIOCHEM BIOPH RES CO, V251, P744, DOI 10.1006/bbrc.1998.9549; Baker HM, 2003, P NATL ACAD SCI USA, V100, P3579, DOI 10.1073/pnas.0637295100; BARKER PD, 1995, BIOCHEMISTRY-US, V34, P15191, DOI 10.1021/bi00046a027; Bartsch R. G., 1971, METHODS ENZYMOL, V23, P344, DOI [10.1016/S0076-6879(71)23110-4, DOI 10.1016/S0076-6879(71)23110-4]; BIRDSALL B, 1983, ANAL BIOCHEM, V132, P353, DOI 10.1016/0003-2697(83)90020-9; Daltrop O, 2002, P NATL ACAD SCI USA, V99, P9703, DOI 10.1073/pnas.152120699; Enggist E, 2003, J BACTERIOL, V185, P3821, DOI 10.1128/JB.185.13.3821-3827.2003; Enggist E, 2003, J BACTERIOL, V185, P175, DOI 10.1128/JB.185.1.175-183.2003; Enggist E, 2002, STRUCTURE, V10, P1551, DOI 10.1016/S0969-2126(02)00885-7; GOODHEW CF, 1986, BIOCHIM BIOPHYS ACTA, V852, P288, DOI 10.1016/0005-2728(86)90234-3; Lee DH, 2005, J AM CHEM SOC, V127, P3716, DOI 10.1021/ja044658e; Moore G. R., 1990, CYTOCHROMES C EVOLUT; Pettigrew G.W., 1987, CYTOCHROMES C BIOL A; Ren Q, 2002, J BIOL CHEM, V277, P7657, DOI 10.1074/jbc.M110979200; Ren Q, 2001, J BIOL CHEM, V276, P32591, DOI 10.1074/jbc.M103058200; SAMBONGI Y, 1994, FEBS LETT, V340, P65, DOI 10.1016/0014-5793(94)80174-6; Schulz H, 1998, SCIENCE, V281, P1197, DOI 10.1126/science.281.5380.1197; Schulz H, 1999, P NATL ACAD SCI USA, V96, P6462, DOI 10.1073/pnas.96.11.6462; SLAVIK J, 1982, BIOCHIM BIOPHYS ACTA, V694, P1, DOI 10.1016/0304-4157(82)90012-0; Spielewoy N, 2001, J BIOL CHEM, V276, P5491, DOI 10.1074/jbc.M008853200; Stevens JM, 2004, ACCOUNTS CHEM RES, V37, P999, DOI 10.1021/ar030266l; Stevens JM, 2004, FEBS LETT, V576, P81, DOI 10.1016/j.febslet.2004.08.067; Stevens JM, 2003, J BIOL CHEM, V278, P20500, DOI 10.1074/jbc.M212925200; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; Thony-Meyer L, 2003, BIOCHEMISTRY-US, V42, P13099, DOI 10.1021/bi035598c; Thony-Meyer L, 2002, BIOCHEM SOC T, V30, P633; THONYMEYER L, 1995, J BACTERIOL, V177, P4321; ThonyMeyer L, 1997, MICROBIOL MOL BIOL R, V61, P337; Uchida T, 2004, J BIOL CHEM, V279, P51981, DOI 10.1074/jbc.M408963200; Vu BC, 2002, J AM CHEM SOC, V124, P8544, DOI 10.1021/ja026569c	34	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36747	36753		10.1074/jbc.M508355200	http://dx.doi.org/10.1074/jbc.M508355200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16129669	hybrid			2022-12-27	WOS:000232901800028
J	Ren, J; Kotaka, M; Lockyer, M; Lamb, HK; Hawkins, AR; Stammers, DK				Ren, J; Kotaka, M; Lockyer, M; Lamb, HK; Hawkins, AR; Stammers, DK			GTP cyclohydrolase II structure and mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-DENSITY MAPS; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; BIOSYNTHESIS; ZINC; RIBOFLAVIN; ENZYME; METALLOENZYMES; TRIPHOSPHATE; INHIBITOR	GTP cyclohydrolase II converts GTP to 2,5-diamino-6-beta-ribosyl-4( 3H)-pyrimidinone 5'-phosphate, formate and pyrophosphate, the first step in riboflavin biosynthesis. The essential role of riboflavin in metabolism and the absence of GTP cyclohydrolase II in higher eukaryotes makes it a potential novel selective antimicrobial drug target. GTP cyclohydrolase II catalyzes a distinctive overall reaction from GTP cyclohydrolase I; the latter converts GTP to dihydroneopterin triphosphate, utilized in folate and tetrahydrobiopterin biosynthesis. The structure of GTP cyclohydrolase II determined at 1.54-angstrom resolution reveals both a different protein fold to GTP cyclohydrolase I and distinctive molecular recognition determinants for GTP; although in both enzymes there is a bound catalytic zinc. The GTP cyclohydrolase II center dot GMPCPP complex structure shows Arg(128) interacting with the alpha-phosphonate, and thus in the case of GTP, Arg(128) is positioned to act as the nucleophile for pyrophosphate release and formation of the proposed covalent guanylyl-GTP cyclohydrolase II intermediate. Tyr(105) is identified as playing a key role in GTP ring opening; it is hydrogen-bonded to the zinc-activated water molecule, the latter being positioned for nucleophilic attack on the guanine C-8 atom. Although GTP cyclohydrolase I and GTP cyclohydrolase II both use a zinc ion for the GTP ring opening and formate release, different residues are utilized in each case to catalyze this reaction step.	Univ Oxford, Wellcome Trust Ctr Human Genet, Div Struct Biol, Oxford OX3 7BN, England; Arrow Therapeut Ltd, Biol Sect, London SE1 1DA, England; Univ Newcastle Upon Tyne, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	University of Oxford; Wellcome Centre for Human Genetics; AstraZeneca; Newcastle University - UK	Stammers, DK (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Div Struct Biol, Roosevelt Dr, Oxford OX3 7BN, England.	daves@strubi.ox.ac.uk	Ren, Jingshan/AAT-7729-2021; Kotaka, Masayo/C-4483-2009	Ren, Jingshan/0000-0003-4015-1404; Kotaka, Masayo/0000-0001-9692-3843				Alberts IL, 1998, PROTEIN SCI, V7, P1700, DOI 10.1002/pro.5560070805; Auerbach G, 2000, P NATL ACAD SCI USA, V97, P13567, DOI 10.1073/pnas.240463497; Bacher A, 2000, ANNU REV NUTR, V20, P153, DOI 10.1146/annurev.nutr.20.1.153; Bracher A, 1999, J BIOL CHEM, V274, P16727, DOI 10.1074/jbc.274.24.16727; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Christianson DW, 1999, ANNU REV BIOCHEM, V68, P33, DOI 10.1146/annurev.biochem.68.1.33; CLEARY JD, 1986, DRUG INTEL CLIN PHAR, V20, P177, DOI 10.1177/106002808602000301; FOOR F, 1975, J BIOL CHEM, V250, P3545; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaiser J, 2002, EUR J BIOCHEM, V269, P5264, DOI 10.1046/j.1432-1033.2002.03239.x; Kobayashi M, 1998, J BIOL CHEM, V273, P26394, DOI 10.1074/jbc.273.41.26394; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lauble H, 2002, BIOCHEMISTRY-US, V41, P12043, DOI 10.1021/bi020300o; Lipscomb WN, 1996, CHEM REV, V96, P2375, DOI 10.1021/cr950042j; McCall KA, 2000, J NUTR, V130, p1437S, DOI 10.1093/jn/130.5.1437S; Morris RJ, 2003, METHOD ENZYMOL, V374, P229, DOI 10.1016/S0076-6879(03)74011-7; Nar H, 1995, P NATL ACAD SCI USA, V92, P12120, DOI 10.1073/pnas.92.26.12120; NAR H, 1995, STRUCTURE, V3, P459, DOI 10.1016/S0969-2126(01)00179-4; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rebelo J, 2003, J MOL BIOL, V326, P503, DOI 10.1016/S0022-2836(02)01303-7; RICHTER G, 1993, J BACTERIOL, V175, P4045, DOI 10.1128/JB.175.13.4045-4051.1993; Ritz H, 2001, J BIOL CHEM, V276, P22273, DOI 10.1074/jbc.M100752200; Rybak MJ, 2004, PHARMACOTHERAPY, V24, p203S, DOI 10.1592/phco.24.18.203S.52236; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Schramek N, 2002, J MOL BIOL, V316, P829, DOI 10.1006/jmbi.2001.5339; Schramek N, 2001, J BIOL CHEM, V276, P44157, DOI 10.1074/jbc.M107306200; Shuman S, 2004, CURR OPIN STRUC BIOL, V14, P757, DOI 10.1016/j.sbi.2004.10.006; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; Walter TS, 2005, ACTA CRYSTALLOGR D, V61, P651, DOI 10.1107/S0907444905007808; Zhou GF, 1998, P NATL ACAD SCI USA, V95, P8449, DOI 10.1073/pnas.95.15.8449	31	45	47	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36912	36919		10.1074/jbc.M507725200	http://dx.doi.org/10.1074/jbc.M507725200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16115872	hybrid			2022-12-27	WOS:000232901800047
J	Enkvetchakul, D; Jeliazkova, I; Nichols, CG				Enkvetchakul, D; Jeliazkova, I; Nichols, CG			Direct modulation of Kir channel gating by membrane phosphatidylinositol 4,5-bisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING K+ CHANNELS; ANIONIC PHOSPHOLIPIDS; PIP2 REGULATION; ATP CHANNELS; BINDING-SITE; ACTIVATION; DOMAIN; INHIBITION; DETERMINANTS	Multiple ion channels have now been shown to be regulated by phosphatidylinositol 4,5-bisphosphate (PIP2) at the cytoplasmic face of the membrane. However, direct evidence for a specific interaction between phosphoinositides and ion channels is critically lacking. We reconstituted pure KirBac1.1 and KcsA protein into liposomes of defined composition ( 3: 1 phosphatidylethanolamine: phosphatidylglycerol) and examined channel activity using a Rb-86(+) uptake assay. We demonstrate direct modulation by PIP2 of KirBac1.1 but not KcsA activity. In marked contrast to activation of eukaryotic Kir channels by PIP2, KirBac1.1 is inhibited by PIP2 incorporated in the membrane (K-1/2 = 0.3 mol %). The dependence of inhibition on the number of phosphate groups and requirement for a lipid tail matches that for activation of eukaryotic Kir channels, suggesting a fundamentally similar interaction mechanism. The data exclude the possibility of indirect modulation via cytoskeletal or other intermediary elements and establish a direct interaction of the channel with PIP2 in the membrane.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Renal Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Nichols, CG (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	cnichols@cellbio.wustl.edu	Nichols, Colin/D-6336-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK060086] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54171] Funding Source: Medline; NIDDK NIH HHS [DK60086] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antcliff JF, 2005, EMBO J, V24, P229, DOI 10.1038/sj.emboj.7600487; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; Bian JS, 2004, AM J PHYSIOL-HEART C, V287, pH2154, DOI 10.1152/ajpheart.00120.2004; Chemin J, 2005, EMBO J, V24, P44, DOI 10.1038/sj.emboj.7600494; Cukras CA, 2002, J GEN PHYSIOL, V120, P437, DOI 10.1085/jgp.20028621; DEUTSCH N, 1994, J GEN PHYSIOL, V104, P773, DOI 10.1085/jgp.104.4.773; Enkvetchakul D, 2004, J BIOL CHEM, V279, P47076, DOI 10.1074/jbc.C400417200; Enkvetchakul D, 2003, J GEN PHYSIOL, V122, P471, DOI 10.1085/jgp.200308878; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Furukawa T, 1996, PFLUG ARCH EUR J PHY, V431, P504, DOI 10.1007/s004240050028; Haider S, 2005, BIOPHYS J, V88, P3310, DOI 10.1529/biophysj.104.052019; Harvey J, 2000, J PHYSIOL-LONDON, V527, P95, DOI 10.1111/j.1469-7793.2000.00095.x; Hilgemann D W, 2001, Sci STKE, V2001, pre19, DOI 10.1126/stke.2001.111.re19; Hilgemann DW, 2004, SCIENCE, V304, P223, DOI 10.1126/science.1097439; Himmel B, 2004, EMBO REP, V5, P85, DOI 10.1038/sj.embor.7400034; Holz RW, 2000, J BIOL CHEM, V275, P17878, DOI 10.1074/jbc.M000925200; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; Liu D, 2003, P NATL ACAD SCI USA, V100, P15160, DOI 10.1073/pnas.2334159100; Lopes CMB, 2005, J PHYSIOL-LONDON, V564, P117, DOI 10.1113/jphysiol.2004.081935; Lopes CMB, 2002, NEURON, V34, P933, DOI 10.1016/S0896-6273(02)00725-0; MacGregor GG, 2002, P NATL ACAD SCI USA, V99, P2726, DOI 10.1073/pnas.042688899; McLaughlin S, 2002, ANNU REV BIOPH BIOM, V31, P151, DOI 10.1146/annurev.biophys.31.082901.134259; Nasuhoglu C, 2002, ANAL BIOCHEM, V301, P243, DOI 10.1006/abio.2001.5489; Nishida M, 2002, CELL, V111, P957, DOI 10.1016/S0092-8674(02)01227-8; Oliver D, 2004, SCIENCE, V304, P265, DOI 10.1126/science.1094113; Prescott ED, 2003, SCIENCE, V300, P1284, DOI 10.1126/science.1083646; Ptak CP, 2005, BIOCHEMISTRY-US, V44, P62, DOI 10.1021/bi048390f; Rohacs T, 2003, P NATL ACAD SCI USA, V100, P745, DOI 10.1073/pnas.0236364100; Rohacs T, 2002, METHOD ENZYMOL, V345, P71; Rohacs T, 1999, J BIOL CHEM, V274, P36065, DOI 10.1074/jbc.274.51.36065; Rohacs T, 2005, NAT NEUROSCI, V8, P626, DOI 10.1038/nn1451; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; Shyng SL, 2000, J GEN PHYSIOL, V116, P599, DOI 10.1085/jgp.116.5.599; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Soom M, 2001, FEBS LETT, V490, P49, DOI 10.1016/S0014-5793(01)02136-6; Suh BC, 2005, CURR OPIN NEUROBIOL, V15, P370, DOI 10.1016/j.conb.2005.05.005; Suh BC, 2002, NEURON, V35, P507, DOI 10.1016/S0896-6273(02)00790-0; Wu L, 2002, NATURE, V419, P947, DOI 10.1038/nature01118; Zhang HL, 1999, NAT CELL BIOL, V1, P183, DOI 10.1038/11103; Zhang HL, 2003, NEURON, V37, P963, DOI 10.1016/S0896-6273(03)00125-9	42	50	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35785	35788		10.1074/jbc.C500355200	http://dx.doi.org/10.1074/jbc.C500355200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16144841	hybrid			2022-12-27	WOS:000232726900002
J	Guo, J; Sheng, G; Warner, BW				Guo, J; Sheng, G; Warner, BW			Epidermal growth factor-induced rapid retinoblastoma phosphorylation at Ser(780) and Ser(795) is mediated by ERK1/2 in small intestine epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-BOWEL RESECTION; CYCLIN D1; DEPENDENT KINASE; PROTEIN; ACTIVATION; EXPRESSION; RB; ADAPTATION; MECHANISMS; RECEPTOR	The retinoblastoma protein Rb is critical for the regulation of mammalian cell cycle entry. Hypophosphorylated Rb is considered to be the active form and directs G(1) arrest, while hyperphosphorylated Rb permits the transition from G(1) to S phase for cell proliferation. Upon stimulation by various growth factors, Rb appears to be phosphorylated by a cascade of phosphorylation events mediated mainly by kinases associated with cyclins D and E. Here we report that in prototype small intestine crypt stem cells (RIEC-6), stimulation with either epidermal growth factor or fetal bovine serum results in an unexpected rapid and sustained Rb phosphorylation at sites Ser(780), Ser(795), and Thr(821) which precedes cyclin D1 expression, cyclin D1/cdk4 complex formation, and cdk4 kinase activity. Rb phosphorylation at Ser(780) and Ser(795) is prevented by MEK, but not phosphatidylinositol 3-kinase, inhibitors. In vitro, Rb is directly phosphorylated by active ERK1/2 as shown by [gamma-P-32] ATP labeling. The phosphorylation sites are further directed to Ser(780) and Ser(795) by kinase assays using recombined active ERK1/2 or immunoprecipitated phospho-ERK1/2 from mitogen stimulated cells. Pull-down assays revealed that Rb interacts with active ERK1/2 but not their inactive unphosphorylated forms. Upon EGF stimulation, phosphorylated ERK1/2 co-immunoprecipitates together with phosphorylated Rb. Collectively, these results demonstrate a novel rapid Rb phosphorylation at specific sites induced by mitogen stimulation in epithelial cells of the small intestine. These data specifically identify ERK1/2 as the kinase responsible for Rb phosphorylation targeted to sites Ser(780) and Ser(795). It appears that ERK1/2 could be an important link between a mitogenic signal directly to Rb, thereby providing a rapid response mechanism between mitogen stimulation and cell cycle machinery.	Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Dept Surg,Div Pediat Gen & Thorac Surg, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Warner, BW (corresponding author), Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Dept Surg,Div Pediat Gen & Thorac Surg, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	brad.warner@cchmc.org			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053234, T32DK064581] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32 DK064581, R0-1 DK53234] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adegbola O, 2005, J BIOL CHEM, V280, P15497, DOI 10.1074/jbc.M411382200; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; Buckley CT, 2004, J BIOL CHEM, V279, P41807, DOI 10.1074/jbc.M407851200; CHAET MS, 1994, J PEDIATR SURG, V29, P1035, DOI 10.1016/0022-3468(94)90274-7; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; Crossin KL, 2002, ANN NY ACAD SCI, V961, P159, DOI 10.1111/j.1749-6632.2002.tb03072.x; D'Abaco GM, 2002, J CELL SCI, V115, P4607, DOI 10.1242/jcs.00161; Dasgupta P, 2004, MOL CELL BIOL, V24, P9527, DOI 10.1128/MCB.24.21.9527-9541.2004; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; DYSON N, 1994, J CELL SCI, P81; Erwin CR, 1999, AM J PHYSIOL-GASTR L, V277, pG533, DOI 10.1152/ajpgi.1999.277.3.G533; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Garnovskaya MN, 2004, J BIOL CHEM, V279, P24899, DOI 10.1074/jbc.M311622200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Helmrath MA, 1997, J SURG RES, V69, P76, DOI 10.1006/jsre.1997.5033; Helmrath MA, 1998, J PEDIATR SURG, V33, P229, DOI 10.1016/S0022-3468(98)90437-7; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; O'Brien D P, 2001, Semin Pediatr Surg, V10, P56, DOI 10.1053/spsu.2001.22383; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Rivard N, 1999, AM J PHYSIOL-CELL PH, V277, pC652, DOI 10.1152/ajpcell.1999.277.4.C652; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Sheng H, 2003, GUT, V52, P1472, DOI 10.1136/gut.52.10.1472; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Wang S, 1998, MOL CELL BIOL, V18, P7487, DOI 10.1128/MCB.18.12.7487; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	39	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35992	35998		10.1074/jbc.M504583200	http://dx.doi.org/10.1074/jbc.M504583200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16126730	hybrid			2022-12-27	WOS:000232726900027
J	Redon, E; Loubiere, P; Cocaign-Bousquet, M				Redon, E; Loubiere, P; Cocaign-Bousquet, M			Role of mRNA stability during genome-wide adaptation of Lactococcus lactis to carbon starvation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; ESCHERICHIA-COLI; POSTTRANSCRIPTIONAL CONTROL; STREPTOCOCCUS-CREMORIS; METABOLIC-REGULATION; HALF-LIVES; E-CLEAVAGE; DECAY; DEGRADATION; BACTERIA	The stability of mRNA was investigated for the first time at the genomic scale during carbon starvation adaptation of Lactococcus lactis IL1403. In exponential phase, mRNA half-lives were correlated positively to open reading frame length. A polypurine sequence, AGGAG, was identified as a putative 5'-stabilizer and inverted repeated sequences as a 3'-destabilizer. These original findings suggested that multiple pathways of mRNA degradation should coexist: internal cleavage, endonuclease cleavage initiated at the 5'-end, and exonuclease attack at the 3'-end. During carbon starvation adaptation, mRNA stability globally increased, but specific mechanisms allowing a wide range of stabilization factors between genes and differential kinetic evolution were involved. A formal method allowing the quantification of the relative influences of transcription and degradation on the mRNA pool control was developed and applied in L. lactis. Gene expression was mostly controlled by altered transcription prior to carbon source exhaustion, while the influence of mRNA stability increased during the starvation phase. This study highlighted that stability modulation in response to adverse growth conditions can govern gene regulation to the same extent as transcription in bacteria.	CNRS, Unite Mixte Rech 5504, Lab Biotechnol Bioproc, F-31077 Toulouse, France; Inst Natl Sci Appl, INRA, Unite Mixte Rech 792, F-31077 Toulouse, France	Universite de Toulouse; Universite Federale Toulouse Midi-Pyrenees (ComUE); Institut National des Sciences Appliquees de Toulouse; Centre National de la Recherche Scientifique (CNRS); INRAE; Universite Federale Toulouse Midi-Pyrenees (ComUE); Universite de Toulouse; Institut National des Sciences Appliquees de Toulouse	Cocaign-Bousquet, M (corresponding author), CNRS, Unite Mixte Rech 5504, Lab Biotechnol Bioproc, 135 Ave Rangueil, F-31077 Toulouse, France.	cocaign@insa-toulouse.fr						Agaisse H, 1996, MOL MICROBIOL, V20, P633, DOI 10.1046/j.1365-2958.1996.5401046.x; ALBERTSON NH, 1990, J GEN MICROBIOL, V136, P2195; ALBERTSON NH, 1994, FEMS MICROBIOL LETT, V117, P181, DOI 10.1111/j.1574-6968.1994.tb06762.x; Amblar M, 2004, BIOCHEM BIOPH RES CO, V323, P884, DOI 10.1016/j.bbrc.2004.08.167; BELASCO JG, 1986, CELL, V46, P245, DOI 10.1016/0092-8674(86)90741-5; Bernhardt J, 2003, GENOME RES, V13, P224, DOI 10.1101/gr.905003; Bernstein JA, 2002, P NATL ACAD SCI USA, V99, P9697, DOI 10.1073/pnas.112318199; Betts JC, 2002, MOL MICROBIOL, V43, P717, DOI 10.1046/j.1365-2958.2002.02779.x; Bolotin A, 2001, GENOME RES, V11, P731, DOI 10.1101/gr.GR-1697R; Braun F, 1998, EMBO J, V17, P4790, DOI 10.1093/emboj/17.16.4790; Calin-Jageman I, 2003, NUCLEIC ACIDS RES, V31, P2381, DOI 10.1093/nar/gkg329; Coburn GA, 1999, PROG NUCLEIC ACID RE, V62, P55; COCAIGNBOUSQUET M, 1995, J APPL BACTERIOL, V79, P108, DOI 10.1111/j.1365-2672.1995.tb03131.x; Condon C, 2003, MICROBIOL MOL BIOL R, V67, P157, DOI 10.1128/MMBR.67.2.157-174.2003; DIMARI JF, 1993, MOL MICROBIOL, V7, P705; DREYFUS M, 2002, TRANSLATION MECH; Drider D, 2002, PLASMID, V47, P246, DOI 10.1016/S0147-619X(02)00010-0; Drider D, 2002, MOL MICROBIOL, V43, P1319, DOI 10.1046/j.1365-2958.2002.02830.x; Even S, 2005, NUCLEIC ACIDS RES, V33, P2141, DOI 10.1093/nar/gki505; Even S, 2002, MOL MICROBIOL, V45, P1143, DOI 10.1046/j.1365-2958.2002.03086.x; Even S, 2003, MICROBIOL-SGM, V149, P1935, DOI 10.1099/mic.0.26146-0; Farr GA, 1999, J BACTERIOL, V181, P7323, DOI 10.1128/JB.181.23.7323-7330.1999; Fontaine L, 2001, ANAL BIOCHEM, V298, P246, DOI 10.1006/abio.2001.5390; Grigull J, 2004, MOL CELL BIOL, V24, P5534, DOI 10.1128/MCB.24.12.5534-5547.2004; Gualerzi CO, 2003, J MOL BIOL, V331, P527, DOI 10.1016/S0022-2836(03)00732-0; Hambraeus G, 2003, MOL GENET GENOMICS, V269, P706, DOI 10.1007/s00438-003-0883-6; Hambraeus G, 2002, MICROBIOL-SGM, V148, P1795, DOI 10.1099/00221287-148-6-1795; HUE KK, 1995, J BACTERIOL, V177, P3465, DOI 10.1128/jb.177.12.3465-3471.1995; MCDOWALL KJ, 1994, J BIOL CHEM, V269, P10790; Meyer BJ, 1996, GENE, V179, P263, DOI 10.1016/S0378-1119(96)00377-0; Nickel M, 2004, MOL GENET GENOMICS, V272, P98, DOI 10.1007/s00438-004-1038-0; Nierlich DP, 1996, PROG NUCLEIC ACID RE, V52, P153, DOI 10.1016/S0079-6603(08)60967-8; OTTO R, 1983, FEMS MICROBIOL LETT, V16, P69, DOI 10.1111/j.1574-6968.1983.tb00261.x; POOLMAN B, 1988, J BACTERIOL, V170, P700, DOI 10.1128/jb.170.2.700-707.1988; Rauhut R, 1999, FEMS MICROBIOL REV, V23, P353, DOI 10.1016/S0168-6445(99)00012-1; Redon E, 2005, J BACTERIOL, V187, P3589, DOI 10.1128/JB.187.10.3589-3592.2005; Regnier P, 2000, BIOESSAYS, V22, P235; Selinger DW, 2003, GENOME RES, V13, P216, DOI 10.1101/gr.912603; Sharp JS, 2003, J BACTERIOL, V185, P5372, DOI 10.1128/JB.185.18.5372-5379.2003; Storz G, 2004, CURR OPIN MICROBIOL, V7, P140, DOI 10.1016/j.mib.2004.02.015; Takayama K, 2000, ENVIRON MICROBIOL, V2, P355, DOI 10.1046/j.1462-2920.2000.00119.x; ter Kuile BH, 2001, FEBS LETT, V500, P169, DOI 10.1016/S0014-5793(01)02613-8; van Helden J, 1998, J MOL BIOL, V281, P827, DOI 10.1006/jmbi.1998.1947; Wang YL, 2002, P NATL ACAD SCI USA, V99, P5860, DOI 10.1073/pnas.092538799; Wassarman KM, 2002, CELL, V109, P141, DOI 10.1016/S0092-8674(02)00717-1; WONG HC, 1986, P NATL ACAD SCI USA, V83, P3233, DOI 10.1073/pnas.83.10.3233	46	61	63	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36380	36385		10.1074/jbc.M506006200	http://dx.doi.org/10.1074/jbc.M506006200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16131490	Green Published, hybrid			2022-12-27	WOS:000232726900072
J	Tokumitsu, H; Hatano, N; Inuzuka, H; Sueyoshi, Y; Yokokura, S; Ichimura, T; Nozaki, N; Kobayashi, R				Tokumitsu, H; Hatano, N; Inuzuka, H; Sueyoshi, Y; Yokokura, S; Ichimura, T; Nozaki, N; Kobayashi, R			Phosphorylation of Numb family proteins - Possible involvement of Ca2+/calmodulin-dependent protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN NUMB; REGULATORY MECHANISM; TRANSCRIPTION FACTOR; CAENORHABDITIS-ELEGANS; CORTICAL NEUROGENESIS; MOLECULAR-CLONING; CDNA CLONING; IN-VIVO; CALMODULIN; ACTIVATION	To search for the substrates of Ca2+/calmodulin-dependent protein kinase I (CaM-KI), we performed affinity chromatography purification using either the unphosphorylated or phosphorylated (at Thr(177)) GST-fused CaM-KI catalytic domain (residues 1-293, K49E) as the affinity ligand. Proteomic analysis was then carried out to identify the interacting proteins. In addition to the detection of two known CaM-KI substrates (CREB and synapsin I), we identified two Numb family proteins (Numb and Numb1) from rat tissues. These proteins were unphosphorylated and were bound only to the Thr(177)-phosphorylated CaM-KI catalytic domain. This finding is consistent with the results demonstrating that Numb and Numb1 were efficiently and stoichiometrically phosphorylated in vitro at equivalent Ser residues (Ser(264) in Numb and Ser(304) in Numb1) by activated CaM-KI and also by two other CaM-Ks (CaM-KII and CaM-KIV). Using anti-phospho-Numb/Numb1 antibody, we observed the phosphorylation of Numb family proteins in various rat tissue extracts, and we also detected the ionomycin-induced phosphorylation of endogenous Numb at Ser(264) in COS-7 cells. The present results revealed that the Numb family proteins are phosphorylated in vivo as well as in vitro. Furthermore, we found that the recruitment of 14-3-3 proteins was the functional consequence of the phosphorylation of the Numb family proteins. Interaction of 14-3-3 protein with phosphorylated Numb1-blocked dephosphorylation of Ser(304). Taken together, these results indicate that the Numb family proteins may be intracellular targets for CaM-Ks, and they may also be regulated by phosphorylation-dependent interaction with 14-3-3 protein.	Kagawa Univ, Fac Med, Dept Signal Transduct Sci, Kagawa 7610793, Japan; Kagawa Univ, Fac Med, Dept Cell Physiol, Kagawa 7610793, Japan; Tokyo Metropolitan Univ, Grad Sch Sci, Dept Chem, Hachioji, Tokyo 1920397, Japan; Kanagawa Dent Coll, Dept Biochem & Mol Biol, Yokosuka, Kanagawa 2388580, Japan	Kagawa University; Kagawa University; Tokyo Metropolitan University; Kanagawa Dental College	Tokumitsu, H (corresponding author), Kagawa Univ, Fac Med, Dept Signal Transduct Sci, 1750-1 Miki Cho, Kagawa 7610793, Japan.	tokumit@med.kagawa-u.ac.jp	Hatano, Naoya/F-6147-2011; Tokumitsu, Hiroshi/M-3978-2015	Tokumitsu, Hiroshi/0000-0002-2193-6794				Adams JA, 2003, BIOCHEMISTRY-US, V42, P601, DOI 10.1021/bi020617o; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; CZERNIK AJ, 1987, P NATL ACAD SCI USA, V84, P7518, DOI 10.1073/pnas.84.21.7518; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Dho SE, 1999, J BIOL CHEM, V274, P33097, DOI 10.1074/jbc.274.46.33097; Eto K, 1999, J BIOL CHEM, V274, P22556, DOI 10.1074/jbc.274.32.22556; Frise E, 1996, P NATL ACAD SCI USA, V93, P11925, DOI 10.1073/pnas.93.21.11925; Hagopian JC, 2001, J BIOL CHEM, V276, P275, DOI 10.1074/jbc.M007337200; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; Hayashi N, 1998, PROTEIN EXPRES PURIF, V12, P25, DOI 10.1006/prep.1997.0807; Hook SS, 2001, ANNU REV PHARMACOL, V41, P471, DOI 10.1146/annurev.pharmtox.41.1.471; Ichimura T, 2005, J BIOL CHEM, V280, P13187, DOI 10.1074/jbc.M412884200; ICHIMURA T, 1995, J BIOL CHEM, V270, P28515, DOI 10.1074/jbc.270.48.28515; Ishikawa Y, 2003, FEBS LETT, V550, P57, DOI 10.1016/S0014-5793(03)00817-2; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Joseph JD, 2000, J BIOL CHEM, V275, P38230, DOI 10.1074/jbc.M006422200; Kahl CR, 2004, J BIOL CHEM, V279, P15411, DOI 10.1074/jbc.M312543200; Kikuchi M, 2004, J BIOL CHEM, V279, P421, DOI 10.1074/jbc.M305623200; KIMURA K, 1994, J BIOL CHEM, V269, P24523; Kimura Y, 2002, EMBO REP, V3, P962, DOI 10.1093/embo-reports/kvf191; LEE JC, 1994, P NATL ACAD SCI USA, V91, P6413, DOI 10.1073/pnas.91.14.6413; LEE JSC, 1994, J BIOL CHEM, V269, P2158; Lukas TJ, 1998, CALMODULIN AND SIGNAL TRANSDUCTION, P65; Matsushita M, 1998, J BIOL CHEM, V273, P21473, DOI 10.1074/jbc.273.34.21473; McGill MA, 2003, J BIOL CHEM, V278, P23196, DOI 10.1074/jbc.M302827200; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; Nishimura H, 2003, J NEUROCHEM, V85, P1216, DOI 10.1046/j.1471-4159.2003.01760.x; Nishimura T, 2003, NAT CELL BIOL, V5, P819, DOI 10.1038/ncb1039; Petersen PH, 2004, NAT NEUROSCI, V7, P803, DOI 10.1038/nn1289; Petersen PH, 2002, NATURE, V419, P929, DOI 10.1038/nature01124; PICCIOTTO MR, 1995, SYNAPSE, V20, P75, DOI 10.1002/syn.890200111; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; Prowse CN, 2001, J BIOL CHEM, V276, P99, DOI 10.1074/jbc.M008137200; Qin H, 2003, J BIOL CHEM, V278, P48570, DOI 10.1074/jbc.M308781200; Rasmussen CD, 2000, J BIOL CHEM, V275, P685, DOI 10.1074/jbc.275.1.685; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Spana EP, 1996, NEURON, V17, P21, DOI 10.1016/S0896-6273(00)80277-9; Suizu F, 2002, BIOCHEM J, V367, P335, DOI 10.1042/BJ20020536; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; Takemoto-Kimura S, 2003, J BIOL CHEM, V278, P18597, DOI 10.1074/jbc.M300578200; Tokumitsu H, 2000, J BIOL CHEM, V275, P20090, DOI 10.1074/jbc.M002193200; Tokumitsu H, 2004, J BIOL CHEM, V279, P40296, DOI 10.1074/jbc.M406534200; Tokumitsu H, 2004, J BIOL CHEM, V279, P42, DOI 10.1074/jbc.M309621200; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; Tokumitsu H, 2001, BIOCHEMISTRY-US, V40, P13925, DOI 10.1021/bi010863k; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; Ueda T, 1999, J NEUROCHEM, V73, P2119; Verdi J, 1996, CURR BIOL, V6, P1134, DOI 10.1016/S0960-9822(02)70680-5; Wayman GA, 2004, J NEUROSCI, V24, P3786, DOI 10.1523/JNEUROSCI.3294-03.2004; YOKOKURA H, 1995, J BIOL CHEM, V270, P23851, DOI 10.1074/jbc.270.40.23851; Yokokura H, 1997, BBA-PROTEIN STRUCT M, V1338, P8, DOI 10.1016/S0167-4838(97)00004-6; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhong WM, 1997, DEVELOPMENT, V124, P1887	57	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35108	35118		10.1074/jbc.M503912200	http://dx.doi.org/10.1074/jbc.M503912200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16105844	hybrid			2022-12-27	WOS:000232561200007
J	Tyson-Capper, AJ; Bailey, J; Krainer, AR; Robson, SC; Europe-Finner, GN				Tyson-Capper, AJ; Bailey, J; Krainer, AR; Robson, SC; Europe-Finner, GN			The switch in alternative splicing of cyclic AMP-response element modulator protein CREM tau(2)alpha (activator) to CREM alpha (repressor) in human myometrial cells is mediated by SRp40	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SR PROTEINS; TRANSCRIPTION FACTORS; ADENOSINE-MONOPHOSPHATE; SIGNAL-TRANSDUCTION; BINDING PROTEIN; PRETERM LABOR; IN-VIVO; IDENTIFICATION; EXPRESSION; GENE	The transcription factor cAMP-response element modulator (CREM) protein, plays a major role in cAMP-responsive gene regulation. Biological consequences resulting from the transcriptional stimuli of CREM are dictated by the expression of multiple protein isoforms generated by extensive alternative splicing of its precursor mRNA. We have previously shown that alternative splicing enables the expression of the CREM gene to be "switched" within the human myometrium during pregnancy from the production of CREM tau(2 alpha), a potent transcriptional activator to the synthesis of CREM alpha, a transcriptional repressor. Furthermore we have recently reported that this change in the expression of CREM spliced variants is likely to have important ramifications on the regulation of downstream cAMP-response element-responsive target genes involved in uterine activity during gestation. We have investigated the splicing factors involved in controlling the expression of myometrial CREM splice variants. Data presented here from transient transfections indicate that the switch in the synthesis of CREM tau(2)alpha to CREM alpha that occurs during pregnancy is regulated primarily by an SR protein family member, SRp40. We also show that expression of this splicing factor is tightly regulated in the myometrium during pregnancy. SRp40 regulates the splicing of CREM via its interactions with multiple ESE motifs present in the alternatively exons of CREM. In vitro splicing and electrophoretic mobility shift assays were employed to confirm the functionality of the SRp40-binding ESEs, thus providing a mechanistic explanation of how SRp40 regulates the switch in splicing from production of CREM tau(2)alpha to CREM alpha.	Newcastle Univ, Sch Med, Sch Surg & Reprod Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Newcastle University - UK; Cold Spring Harbor Laboratory	Tyson-Capper, AJ (corresponding author), Newcastle Univ, Sch Med, Sch Surg & Reprod Sci, 3rd Floor,William Leech Bldg, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	A.J.Tyson-Capper@ncl.ac.uk	Robson, Simon C./AAA-8537-2021; europe-finner, Nicholas/F-2569-2010	Krainer, Adrian/0000-0001-9024-9501	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bailey J, 2005, J MOL ENDOCRINOL, V34, P1, DOI 10.1677/jme.1.01594; Bailey J, 2002, J CLIN ENDOCR METAB, V87, P1717, DOI 10.1210/jcem.87.4.8360; Bailey J, 2000, MOL HUM REPROD, V6, P648, DOI 10.1093/molehr/6.7.648; BERNAL AL, 1995, TRENDS PHARMACOL SCI, V16, P129, DOI 10.1016/S0165-6147(00)89000-8; BORRELLI E, 1992, Critical Reviews in Oncogenesis, V3, P321; Bourgeois CF, 1999, MOL CELL BIOL, V19, P7347; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; CACERES JF, 1997, EUKARYOTIC MRNA PROC, P174; Caputi M, 2004, J VIROL, V78, P6517, DOI 10.1128/JVI.78.12.6517-6526.2004; Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616; Cooper TA, 2005, CELL, V120, P1, DOI 10.1016/j.cell.2004.12.030; Cowper AE, 2001, J BIOL CHEM, V276, P48908, DOI 10.1074/jbc.M103967200; DE CD, 1999, TRENDS BIOCHEM SCI, V24, P281; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; Don J, 2002, MOL CELL ENDOCRINOL, V187, P115, DOI 10.1016/S0303-7207(01)00696-7; Dong YL, 1999, J CLIN INVEST, V104, P559, DOI 10.1172/JCI6324; Elrick LL, 1998, MOL CELL BIOL, V18, P343, DOI 10.1128/MCB.18.1.343; EUROPEFINNER GN, 1993, ENDOCRINOLOGY, V132, P2484, DOI 10.1210/en.132.6.2484; EUROPEFINNER GN, 1994, J CLIN ENDOCR METAB, V79, P1835, DOI 10.1210/jc.79.6.1835; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Habener JF, 1995, VITAM HORM, V51, P1, DOI 10.1016/S0083-6729(08)61037-7; HAI TW, 1990, GENE DEV, V4, P682; Hanamura A, 1998, RNA, V4, P430; Hastings ML, 2001, CURR OPIN CELL BIOL, V13, P302, DOI 10.1016/S0955-0674(00)00212-X; Isoda T, 2003, FASEB J, V17, P144, DOI 10.1096/fj.01-0981com; KOFINAS AD, 1990, J REPROD MED, V35, P1045; Lam BJ, 2002, RNA, V8, P1233, DOI 10.1017/S1355838202028030; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; Mayeda A, 1999, MOL CELL BIOL, V19, P1853; Mayeda A, 1999, METH MOL B, V118, P315; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; PHANEUF S, 1993, J ENDOCRINOL, V136, P497, DOI 10.1677/joe.0.1360497; Pollard AJ, 2000, J CLIN ENDOCR METAB, V85, P1928, DOI 10.1210/jc.85.5.1928; Pollard AJ, 2002, J BIOL CHEM, V277, P15241, DOI 10.1074/jbc.M109046200; Sanborn BM, 1997, J ANDROL, V18, P62; Sanborn BM, 2000, ENDOCRINOLOGY, V141, P3921, DOI 10.1210/en.141.11.3921; Sassone-Corsi P, 1998, INT J BIOCHEM CELL B, V30, P27, DOI 10.1016/S1357-2725(97)00093-9; Schaal TD, 1999, MOL CELL BIOL, V19, P1705; Servillo G, 2002, EXP CELL RES, V275, P143, DOI 10.1006/excr.2002.5491; Servillo G, 1998, GENE DEV, V12, P3639, DOI 10.1101/gad.12.23.3639; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Stamm S, 2005, GENE, V344, P1, DOI 10.1016/j.gene.2004.10.022; SUN PQ, 1992, MOL ENDOCRINOL, V6, P1858, DOI 10.1210/me.6.11.1858; SUN Q, 1993, GENE DEV, V7, P2598, DOI 10.1101/gad.7.12b.2598; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; Tenbrock K, 2003, J IMMUNOL, V170, P2971, DOI 10.4049/jimmunol.170.6.2971; WANG J, 1995, RNA, V1, P335; Yang XJ, 1997, MOL ENDOCRINOL, V11, P1053, DOI 10.1210/me.11.8.1053; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G; ZUO J, 1994, J CLIN ENDOCR METAB, V79, P907, DOI 10.1210/jc.79.3.907	53	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34521	34529		10.1074/jbc.M505344200	http://dx.doi.org/10.1074/jbc.M505344200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16103121	hybrid			2022-12-27	WOS:000232403900020
J	Battaglia, V; Salvi, M; Toninello, A				Battaglia, V; Salvi, M; Toninello, A			Oxidative stress is responsible for mitochondrial permeability transition induction by salicylate in liver mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; REYES-SYNDROME; CYCLOSPORINE-A; COLON-CANCER; COMPLEX-I; MECHANISM; INHIBITION; APOPTOSIS; ASPIRIN; GLUTATHIONE	The interaction of salicylate with the respiratory chain of liver mitochondria generates hydrogen peroxide and, most probably, other reactive oxygen species, which in turn oxidize thiol groups and glutathione. This oxidative stress, confirmed by the prevention of action by antioxidant agents, leads to the induction of the mitochondrial permeability transition in the presence of Ca2+. This phenomenon induces further increase of oxidative damage resulting in impairment of oxidative phosphorylation and beta-oxidation, cardinal features of Reye's syndrome in the liver. Mitochondrial permeability transition induction also induces the release of cytochrome c and apoptotic inducing factor from mitochondria, suggesting that salicylate also behaves as a pro-apoptotic agent. The reactive group of salicylate for inducing oxidative stress is the hydroxyl group which, by interacting with a Fe-S cluster of mitochondrial Complex I, the so-called N-2(Fe-S) center, produces reactive oxygen species.	Univ Padua, Dipartimento Chim Biol, Ist Neurosci, CNR,Unita Studio Biomembrane, I-35121 Padua, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Padua	Toninello, A (corresponding author), Univ Padua, Dipartimento Chim Biol, Ist Neurosci, CNR,Unita Studio Biomembrane, Viale G Colombo 3, I-35121 Padua, Italy.	antonio.toninello@unipd.it		Salvi, Mauro/0000-0003-3448-6048				Adlam VJ, 2005, FASEB J, V19, P1088, DOI 10.1096/fj.05-3718com; BIBAN C, 1995, BIOCHEM PHARMACOL, V50, P497, DOI 10.1016/0006-2952(95)00165-V; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Cao GH, 1997, FREE RADICAL BIO MED, V22, P749, DOI 10.1016/S0891-5849(96)00351-6; CARPENTER KJ, 1950, BIOCHEM J, V46, P421, DOI 10.1042/bj0460421; Chernyak BV, 1996, EUR J BIOCHEM, V238, P623, DOI 10.1111/j.1432-1033.1996.0623w.x; Chung YM, 2003, FREE RADICAL BIO MED, V34, P434, DOI 10.1016/S0891-5849(02)01301-1; De Marchi U, 2003, BIOCHEM PHARMACOL, V66, P1749, DOI 10.1016/S0006-2952(03)00474-X; Fiore C, 2004, BBA-BIOENERGETICS, V1658, P195, DOI 10.1016/j.bbabio.2004.05.012; FLOWER RJ, 1985, PHARMACOL BASIS THER, P674; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; GORNALL AG, 1949, J BIOL CHEM, V177, P751; Grijalba MT, 1999, BIOCHEMISTRY-US, V38, P13279, DOI 10.1021/bi9828674; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121; LEMASTERS JJ, 1976, EUR J BIOCHEM, V67, P1, DOI 10.1111/j.1432-1033.1976.tb10625.x; Ligeret H, 2004, FREE RADICAL BIO MED, V36, P919, DOI 10.1016/j.freeradbiomed.2003.12.018; LOSCHEN G, 1973, FEBS LETT, V33, P84, DOI 10.1016/0014-5793(73)80165-6; MARTENS ME, 1984, BIOCHEM PHARMACOL, V33, P2869, DOI 10.1016/0006-2952(84)90209-0; MARTENS ME, 1986, ARCH BIOCHEM BIOPHYS, V244, P773, DOI 10.1016/0003-9861(86)90646-6; McStay GP, 2002, BIOCHEM J, V367, P541, DOI 10.1042/BJ20011672; Nulton-Persson AC, 2004, J CARDIOVASC PHARM, V44, P591, DOI 10.1097/00005344-200411000-00012; PARTIN JC, 1971, NEW ENGL J MED, V285, P1339, DOI 10.1056/NEJM197112092852402; Rigas B, 2000, MED HYPOTHESES, V54, P210, DOI 10.1054/mehy.1999.0023; ROOS I, 1980, EUR J BIOCHEM, V110, P319, DOI 10.1111/j.1432-1033.1980.tb04870.x; Salvi M, 2002, BBA-BIOENERGETICS, V1556, P187, DOI 10.1016/S0005-2728(02)00361-4; Santos AC, 1998, FREE RADICAL BIO MED, V24, P1455, DOI 10.1016/S0891-5849(98)00003-3; Sanz E, 2004, MED SCI MONITOR, V10, pBR477; Sawaoka H, 1998, AM J PHYSIOL-GASTR L, V274, pG1061, DOI 10.1152/ajpgi.1998.274.6.G1061; SCHNEIDER WC, 1950, J BIOL CHEM, V183, P123; SEGALMAN TY, 1995, ARCH BIOCHEM BIOPHYS, V317, P79; Sheng HM, 1998, CANCER RES, V58, P362; Shiff SJ, 1997, GASTROENTEROLOGY, V113, P1992, DOI 10.1016/S0016-5085(97)99999-6; Stark LA, 2001, FASEB J, V15, P1273, DOI 10.1096/fj.00-0529fje; STARKO KM, 1980, PEDIATRICS, V66, P859; Taketo MM, 1998, JNCI-J NATL CANCER I, V90, P1609, DOI 10.1093/jnci/90.21.1609; TETRUD JW, 1989, SCIENCE, V245, P519, DOI 10.1126/science.2502843; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TOMODA T, 1994, LIVER, V14, P103; TONSGARD JH, 1985, J CLIN INVEST, V76, P816, DOI 10.1172/JCI112039; Trost LC, 1997, TOXICOL APPL PHARM, V147, P431, DOI 10.1006/taap.1997.8313; TROST LC, 2001, MITOCHONDRIA PATHOGE, P425; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WALDMAN RJ, 1982, JAMA-J AM MED ASSOC, V247, P3089, DOI 10.1001/jama.247.22.3089; WEISS H, 1991, EUR J BIOCHEM, V197, P563, DOI 10.1111/j.1432-1033.1991.tb15945.x; WEISSMANN G, 1991, SCI AM, V264, P84, DOI 10.1038/scientificamerican0191-84; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	53	67	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33864	33872		10.1074/jbc.M502391200	http://dx.doi.org/10.1074/jbc.M502391200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16100122	hybrid			2022-12-27	WOS:000232229700023
J	Santelli, E; Leone, M; Li, CL; Fukushima, T; Preece, NE; Olson, AJ; Ely, KR; Reed, JC; Pellecchia, M; Liddington, RC; Matsuzawa, S				Santelli, E; Leone, M; Li, CL; Fukushima, T; Preece, NE; Olson, AJ; Ely, KR; Reed, JC; Pellecchia, M; Liddington, RC; Matsuzawa, S			Structural analysis of Siah1-Siah-interacting protein interactions and insights into the assembly of an E3 ligase multiprotein complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; MAMMALIAN HOMOLOGS; UBIQUITIN LIGASE; TRANSCRIPTIONAL REPRESSOR; PROTEASOME PATHWAY; SIAH-1; DEGRADATION; BINDING; ACTIVATION; REFINEMENT	Siah1 is the central component of a multiprotein E3 ubiquitin ligase complex that targets beta-catenin for destruction in response to p53 activation. The E3 complex comprises, in addition to Siah1, Siah-interacting protein ( SIP), the adaptor protein Skp1, and the F-box protein Ebi. Here we show that SIP engages Siah1 by means of two elements, both of which are required for mediating beta-catenin destruction in cells. An N-terminal dimerization domain of SIP sits across the saddle-shaped upper surface of Siah1, with two extended legs packing against the sides of Siah1 by means of a consensus PXAXVXP motif that is common to a family of Siah-binding proteins. The C-terminal domain of SIP, which binds to Skp1, protrudes from the lower surface of Siah1, and we propose that this surface provides the scaffold for bringing substrate and the E2 enzyme into apposition in the functional complex.	Burnham Inst, La Jolla, CA 92037 USA; Scripps Res Inst, La Jolla, CA 92037 USA; CNR, Ist Biostrutture & Bioimmagini, I-80134 Naples, Italy	Sanford Burnham Prebys Medical Discovery Institute; Scripps Research Institute; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biostrutture e Bioimmagini (IBB-CNR)	Matsuzawa, S (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	rlidding@burnham.org; smatsuzawa@burnham.org	Li, Chenglong/E-7182-2010; Pellecchia, Maurizio/Y-7072-2018	Li, Chenglong/0000-0003-3174-8719; LEONE, MARILISA/0000-0002-3811-6960				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Bhattacharya S, 2005, BIOCHEMISTRY-US, V44, P9462, DOI 10.1021/bi0502689; Boehm J, 2001, EMBO J, V20, P4153, DOI 10.1093/emboj/20.15.4153; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bursen A, 2004, ONCOGENE, V23, P6237, DOI 10.1038/sj.onc.1207837; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; Fanelli M, 2004, J BIOL CHEM, V279, P5374, DOI 10.1074/jbc.M306407200; Filipek A, 1996, BIOCHEM J, V320, P585, DOI 10.1042/bj3200585; Foadi J, 2000, ACTA CRYSTALLOGR D, V56, P1137, DOI 10.1107/S090744490000932X; FREIRE E, 1990, ANAL CHEM, V62, pA950, DOI 10.1021/ac00217a002; Germani A, 2003, ONCOGENE, V22, P8845, DOI 10.1038/sj.onc.1206994; Germani A, 1999, MOL CELL BIOL, V19, P3798; Germani A, 2000, ONCOGENE, V19, P5997, DOI 10.1038/sj.onc.1204002; Habelhah H, 2004, J BIOL CHEM, V279, P53782, DOI 10.1074/jbc.M410315200; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; House CM, 2003, P NATL ACAD SCI USA, V100, P3101, DOI 10.1073/pnas.0534783100; Hu G, 1999, MOL CELL BIOL, V19, P724; Hu G, 1997, GENOMICS, V46, P103, DOI 10.1006/geno.1997.4997; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; Isaacs AM, 2003, J NEUROSCI, V23, P1631; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim CJ, 2004, ONCOGENE, V23, P8591, DOI 10.1038/sj.onc.1208113; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li CL, 2002, STRUCTURE, V10, P403, DOI 10.1016/S0969-2126(02)00733-5; Li SH, 1997, CELL, V90, P469, DOI 10.1016/S0092-8674(00)80507-3; Liani E, 2004, P NATL ACAD SCI USA, V101, P5500, DOI 10.1073/pnas.0401081101; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Matsuzawa S, 2003, J BIOL CHEM, V278, P1837, DOI 10.1074/jbc.M210263200; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Moriyoshi K, 2004, P NATL ACAD SCI USA, V101, P8614, DOI 10.1073/pnas.0403042101; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nagano Y, 2003, J BIOL CHEM, V278, P51504, DOI 10.1074/jbc.M306347200; Nakayama K, 2004, CELL, V117, P941, DOI 10.1016/j.cell.2004.06.001; Okabe H, 2003, CANCER RES, V63, P3043; Oliver PL, 2004, P NATL ACAD SCI USA, V101, P14901, DOI 10.1073/pnas.0406196101; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park TJ, 2003, BIOCHEM BIOPH RES CO, V302, P671, DOI 10.1016/S0006-291X(03)00247-X; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pellecchia M, 2000, NAT STRUCT BIOL, V7, P298; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; Polekhina G, 2002, NAT STRUCT BIOL, V9, P68, DOI 10.1038/nsb743; Relaix F, 2000, P NATL ACAD SCI USA, V97, P2105, DOI 10.1073/pnas.040378897; Susini L, 2001, P NATL ACAD SCI USA, V98, P15067, DOI 10.1073/pnas.261571998; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Tang AH, 1997, CELL, V90, P459, DOI 10.1016/S0092-8674(00)80506-1; Tanikawa J, 2000, J BIOL CHEM, V275, P15578, DOI 10.1074/jbc.M000372200; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tiedt R, 2001, EMBO J, V20, P4143, DOI 10.1093/emboj/20.15.4143; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Venables JP, 2004, HUM MOL GENET, V13, P1525, DOI 10.1093/hmg/ddh165; Wheeler TC, 2002, J BIOL CHEM, V277, P10273, DOI 10.1074/jbc.M107857200; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775; Zhou HY, 2005, NUCLEIC ACIDS RES, V33, pW193, DOI 10.1093/nar/gki360	60	77	80	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34278	34287		10.1074/jbc.M506707200	http://dx.doi.org/10.1074/jbc.M506707200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16085652	hybrid			2022-12-27	WOS:000232229700070
J	McLeod, CJ; Aziz, A; Hoyt, RF; McCoy, JP; Sack, MN				McLeod, CJ; Aziz, A; Hoyt, RF; McCoy, JP; Sack, MN			Uncoupling proteins 2 and 3 function in concert to augment tolerance to cardiac ischemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISCHEMIA/REPERFUSION INJURY; TRANSGENIC MICE; PROTON LEAK; RAT-HEART; SUPEROXIDE; MITOCHONDRIA; OVEREXPRESSION; ANTIOXIDANTS; ACTIVATION; UCP2	Transient cardiac ischemia activates cell survival signaling, conferring subsequent ischemia tolerance to the heart. This biological phenomenon, termed ischemic preconditioning, results in improved clinical outcome and attenuated infarct size following myocardial infarction. To explore genomic modifications underpinning this ischemia tolerance, we delineated the regulation and function of the cardiac enriched mitochondrial uncoupling proteins 2 and 3 during delayed ischemic preconditioning in the rat. Cardiac transcripts of genes encoding uncoupling proteins 2 and 3 are upregulated in parallel with infarct size reduction in preconditioned hearts. Mitochondria isolated from preconditioned hearts exhibit an augmented inducible proton leak. In parallel, following anoxia-reoxygenation these mitochondria generate less hydrogen peroxide compared with non-preconditioned mitochondria. Preconditioning in rat cardiac derived myoblasts is abolished following uncoupling protein-2 depletion by RNA-interference. RNAi of uncoupling protein-3 partially attenuates the capacity to precondition these cells. Functional characterization of anoxia and reoxygenation tolerance following uncoupling protein 2 or 3 and combined 2 and 3 RNAi shows the largest reduction in viability follows depletion of both homologues. Uncoupling protein-2 depletion alone significantly attenuates anoxia-reoxygenation tolerance but uncoupling protein-3 depletion does not reduce anoxia tolerance. In parallel combined uncoupling protein depletion and isolated uncoupling protein-2 depletion augments ROS production in viable cardiomyocytes following anoxia-reoxygenation. Concurrent antioxidant administration ameliorates the uncoupling protein-depleted anoxia-susceptible phenotype. In conclusion, mitochondrial uncoupling proteins are necessary components of ischemia tolerance and function as components of the cellular antioxidant defense program. In the cytoprotective hierarchy, uncoupling protein-2 appears to play a greater role than uncoupling protein-3 in modulating ischemia/anoxia tolerance in heart-derived cells.	NHLBI, Cardiovasc Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Lab Anim Med & Surg, NIH, Bethesda, MD 20892 USA; NHLBI, Flow Cytometry Core, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Sack, MN (corresponding author), NHLBI, Cardiovasc Branch, NIH, Bldg 10 CRC,Rm 5-3150,10 Ctr Dr, Bethesda, MD 20892 USA.	sackm@nhlbi.nih.gov	mccoy, john philip/ABD-9348-2021		Intramural NIH HHS Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL005102, ZIAHL005102] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ardehali H, 2004, P NATL ACAD SCI USA, V101, P11880, DOI 10.1073/pnas.0401703101; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Bienengraeber M, 2003, J MOL CELL CARDIOL, V35, P861, DOI 10.1016/S0022-2828(03)00147-0; Chen ZY, 1998, J MOL CELL CARDIOL, V30, P2281, DOI 10.1006/jmcc.1998.0789; Considine MJ, 2003, J BIOL CHEM, V278, P22298, DOI 10.1074/jbc.M301075200; Couplan E, 2002, J BIOL CHEM, V277, P26268, DOI 10.1074/jbc.M202535200; de Bilbao F, 2004, J NEUROCHEM, V89, P1283, DOI 10.1111/j.1471-4159.2004.02432.x; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Echtay KS, 2002, J BIOL CHEM, V277, P47129, DOI 10.1074/jbc.M208262200; Fink BD, 2002, J BIOL CHEM, V277, P3918, DOI 10.1074/jbc.M107955200; Glantz L, 2005, EXP NEUROL, V192, P117, DOI 10.1016/j.expneurol.2004.11.012; Hoerter J, 2004, CIRCULATION, V110, P528, DOI 10.1161/01.CIR.0000137824.30476.0E; Jaburek M, 2004, J BIOL CHEM, V279, P53097, DOI 10.1074/jbc.M405339200; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; Krauss S, 2003, J CLIN INVEST, V112, P1831, DOI 10.1172/JCI200319774; Krauss S, 2005, NAT REV MOL CELL BIO, V6, P248, DOI 10.1038/nrm1592; Lee KU, 2005, CIRC RES, V96, P1200, DOI 10.1161/01.RES.0000170075.73039.5b; Maragos WF, 2004, J NEUROCHEM, V91, P257, DOI 10.1111/j.1471-4159.2004.02736.x; Marczin N, 2003, ARCH BIOCHEM BIOPHYS, V420, P222, DOI 10.1016/j.abb.2003.08.037; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; McCarthy J, 2005, J MOL CELL CARDIOL, V38, P697, DOI 10.1016/j.yjmcc.2005.02.010; McLeod CJ, 2004, CIRCULATION, V110, P534, DOI 10.1161/01.CIR.0000136997.53612.6C; Minners J, 2000, CARDIOVASC RES, V47, P68, DOI 10.1016/S0008-6363(00)00069-9; Minners J, 2001, CIRC RES, V89, P787, DOI 10.1161/hh2101.098372; Opie LH, 2002, J MOL CELL CARDIOL, V34, P1077, DOI 10.1006/jmcc.2002.2066; Oshima Y, 2005, CARDIOVASC RES, V65, P428, DOI 10.1016/j.cardiores.2004.10.021; Ozcan C, 2002, AM J PHYSIOL-HEART C, V282, pH531, DOI 10.1152/ajpheart.00552.2001; Schrauwen P, 2004, INT J OBESITY, V28, P824, DOI 10.1038/sj.ijo.0802629; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Sordahl L A, 1971, Methods Achiev Exp Pathol, V5, P287; St-Pierre J, 2003, J BIOL CHEM, V278, P26597, DOI 10.1074/jbc.M301850200; Talbot DA, 2003, BIOCHEM BIOPH RES CO, V312, P983, DOI 10.1016/j.bbrc.2003.11.022; Talbot DA, 2004, FEBS LETT, V556, P111, DOI 10.1016/S0014-5793(03)01386-3; Tang XL, 2002, AM J PHYSIOL-HEART C, V282, pH281, DOI 10.1152/ajpheart.2002.282.1.H281; Teshima Y, 2003, CIRC RES, V93, P192, DOI 10.1161/01.RES.0000085581.60197.4D; Yamashita N, 1998, J MOL CELL CARDIOL, V30, P1181, DOI 10.1006/jmcc.1998.0682; Yellon DM, 2003, PHYSIOL REV, V83, P1113, DOI 10.1152/physrev.00009.2003; Zackova M, 2003, J BIOL CHEM, V278, P20761, DOI 10.1074/jbc.M212850200	38	125	131	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33470	33476		10.1074/jbc.M505258200	http://dx.doi.org/10.1074/jbc.M505258200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16079144	hybrid			2022-12-27	WOS:000232058100046
J	Tiso, M; Konas, DW; Panda, K; Garcin, ED; Sharma, M; Getzoff, ED; Stuehr, DJ				Tiso, M; Konas, DW; Panda, K; Garcin, ED; Sharma, M; Getzoff, ED; Stuehr, DJ			C-terminal tail residue Arg(1400) enables NADPH to regulate electron transfer in neuronal nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CYTOCHROME-P450 REDUCTASE; AUTOINHIBITORY CONTROL ELEMENT; NO COMPLEX-FORMATION; FLAVIN DOMAIN; FERREDOXIN-NADP(+) REDUCTASE; COENZYME SPECIFICITY; CALMODULIN-BINDING; ENZYME ACTIVATION; STRUCTURAL BASIS; CALCIUM-BINDING	The neuronal nitric-oxide synthase (nNOS) flavoprotein domain (nNOSr) contains regulatory elements that repress its electron flux in the absence of bound calmodulin (CaM). The repression also requires bound NADP(H), but the mechanism is unclear. The crystal structure of a CaM-free nNOSr revealed an ionic interaction between Arg(1400) in the C-terminal tail regulatory element and the 2'-phosphate group of bound NADP( H). We tested the role of this interaction by substituting Ser and Glu for Arg1400 in nNOSr and in the full-length nNOS enzyme. The CaM-free nNOSr mutants had cytochrome c reductase activities that were less repressed than in wild-type, and this effect could be mimicked in wild-type by using NADH instead of NADPH. The nNOSr mutants also had faster flavin reduction rates, greater apparent Km for NADPH, and greater rates of flavin auto-oxidation. Single-turnover cytochrome c reduction data linked these properties to an inability of NADP(H) to cause shielding of the FMN module in the CaM-free nNOSr mutants. The full-length nNOS mutants had no NO synthesis in the CaM-free state and had lower steady-state NO synthesis activities in the CaM-bound state compared with wild-type. However, the mutants had faster rates of ferric heme reduction and ferrous heme-NO complex formation. Slowing down heme reduction in R1400E nNOS with CaM analogues brought its NO synthesis activity back up to normal level. Our studies indicate that the Arg(1400)-2'-phosphate interaction is a means by which bound NADP(H) represses electron transfer into and out of CaM-free nNOSr. This interaction enables the C-terminal tail to regulate a conformational equilibrium of the FMN module that controls its electron transfer reactions in both the CaM-free and CaM-bound forms of nNOS.	Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Pathobiol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University System of Ohio; Cleveland State University; Scripps Research Institute; Scripps Research Institute	Stuehr, DJ (corresponding author), Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, 9500 Euclid Ave,NB-30, Cleveland, OH 44195 USA.	stuehrd@ccf.org	Garcin, Elsa D/C-1556-2013; Panda, Koustubh/E-5273-2017	Garcin, Elsa D/0000-0003-0501-8421; Panda, Koustubh/0000-0002-4783-2221	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL005883] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL5883] Funding Source: Medline; NIGMS NIH HHS [GM51491] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbuSoud HM, 1997, BIOCHEMISTRY-US, V36, P10811, DOI 10.1021/bi971414g; ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; Adak S, 2002, P NATL ACAD SCI USA, V99, P13516, DOI 10.1073/pnas.192283399; Adak S, 2001, J BIOL CHEM, V276, P23246, DOI 10.1074/jbc.M102509200; Adak S, 2001, J BIOL CHEM, V276, P1244, DOI 10.1074/jbc.M006857200; Adak S, 1999, J BIOL CHEM, V274, P22313, DOI 10.1074/jbc.274.32.22313; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Aoyagi M, 2003, EMBO J, V22, P766, DOI 10.1093/emboj/cdg078; BATIE CJ, 1984, J BIOL CHEM, V259, P8832; BATIE CJ, 1986, J BIOL CHEM, V261, P1214; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Chen PF, 2000, J BIOL CHEM, V275, P13155, DOI 10.1074/jbc.275.17.13155; Craig DH, 2002, J BIOL CHEM, V277, P33987, DOI 10.1074/jbc.M203118200; Daff S, 1999, J BIOL CHEM, V274, P30589, DOI 10.1074/jbc.274.43.30589; Daff S, 2001, BIOCHEM SOC T, V29, P147, DOI 10.1042/0300-5127:0290147; de Montellano PRO, 1998, DRUG METAB DISPOS, V26, P1185; Deng Z, 1999, NAT STRUCT BIOL, V6, P847; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dunford AJ, 2004, EUR J BIOCHEM, V271, P2548, DOI 10.1111/j.1432-1033.2004.04185.x; Fulton D, 2002, J BIOL CHEM, V277, P4277, DOI 10.1074/jbc.M106302200; Gachhui R, 1997, BIOCHEMISTRY-US, V36, P5097, DOI 10.1021/bi970331x; Gachhui R, 1998, J BIOL CHEM, V273, P5451, DOI 10.1074/jbc.273.10.5451; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; Garcin ED, 2004, J BIOL CHEM, V279, P37918, DOI 10.1074/jbc.M406204200; Garnaud PE, 2004, BIOCHEMISTRY-US, V43, P11035, DOI 10.1021/bi049312v; GEORGE SE, 1993, J BIOL CHEM, V268, P25213; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; Guan ZW, 2003, J BIOL CHEM, V278, P30859, DOI 10.1074/jbc.M301929200; Guan ZW, 2003, ARCH BIOCHEM BIOPHYS, V412, P65, DOI 10.1016/S0003-9861(03)00009-2; Gutierrez A, 2003, EUR J BIOCHEM, V270, P2612, DOI 10.1046/j.1432-1033.2003.03633.x; Gutierrez A, 2001, BIOCHEMISTRY-US, V40, P1964, DOI 10.1021/bi001719m; Hurshman AR, 2002, BIOCHEMISTRY-US, V41, P3439, DOI 10.1021/bi012002h; Ignarro LJ, 2000, NITRIC OXIDE BIOL PA; Ignarro Louis J, 2005, Curr Diab Rep, V5, P17, DOI 10.1007/s11892-005-0062-8; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; Knight K, 2002, BIOCHEM J, V367, P19, DOI 10.1042/BJ20020667; Knudsen GM, 2003, J BIOL CHEM, V278, P31814, DOI 10.1074/jbc.M303267200; Konas DW, 2004, J BIOL CHEM, V279, P35412, DOI 10.1074/jbc.M400872200; Kondo R, 1999, J BIOL CHEM, V274, P36213, DOI 10.1074/jbc.274.51.36213; Lane P, 2002, J BIOL CHEM, V277, P19087, DOI 10.1074/jbc.M200258200; Martinez-Julvez M, 2005, BIOPHYS CHEM, V115, P219, DOI 10.1016/j.bpc.2004.12.034; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; Matsuda H, 1999, BBA-GEN SUBJECTS, V1473, P345, DOI 10.1016/S0304-4165(99)00193-2; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; MIZE RR, 1998, NITRIX OXIDE BRAIN D; Moncada S, 1999, J ROY SOC MED, V92, P164, DOI 10.1177/014107689909200402; Montgomery HJ, 2000, J BIOL CHEM, V275, P5052, DOI 10.1074/jbc.275.7.5052; Murataliev MB, 2004, BBA-PROTEINS PROTEOM, V1698, P1, DOI 10.1016/j.bbapap.2003.10.003; Neeli R, 2005, J BIOL CHEM, V280, P17634, DOI 10.1074/jbc.M413826200; Newman E, 2004, J BIOL CHEM, V279, P33547, DOI 10.1074/jbc.M403892200; Nishida CR, 2001, J BIOL CHEM, V276, P20116, DOI 10.1074/jbc.M101548200; Noble MA, 1999, BIOCHEMISTRY-US, V38, P16413, DOI 10.1021/bi992150w; Nogues I, 2004, BIOCHEMISTRY-US, V43, P6127, DOI 10.1021/bi049858h; Panda K, 2004, J BIOL CHEM, V279, P18323, DOI 10.1074/jbc.M310391200; Panda K, 2001, J BIOL CHEM, V276, P23349, DOI 10.1074/jbc.M100687200; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; Ricciardolo FLM, 2004, PHYSIOL REV, V84, P731, DOI 10.1152/physrev.00034.2003; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; Roman LJ, 2000, J BIOL CHEM, V275, P21914, DOI 10.1074/jbc.M002449200; Sagami I, 2001, J BIOL CHEM, V276, P30036, DOI 10.1074/jbc.M104123200; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; Santolini J, 2001, J BIOL CHEM, V276, P1233, DOI 10.1074/jbc.M006858200; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; Siddhanta U, 1996, J BIOL CHEM, V271, P7309, DOI 10.1074/jbc.271.13.7309; StevensTruss R, 1997, BIOCHEMISTRY-US, V36, P12337, DOI 10.1021/bi970973k; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Stuehr DJ, 1996, METHOD ENZYMOL, V268, P324; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; Stuehr DJ, 2004, J BIOL CHEM, V279, P36167, DOI 10.1074/jbc.R400017200; SU ZZ, 1995, J BIOL CHEM, V270, P29117, DOI 10.1074/jbc.270.49.29117; Tejero J, 2003, J BIOL CHEM, V278, P49203, DOI 10.1074/jbc.M307934200; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; Wei CC, 2003, CHEM REV, V103, P2365, DOI 10.1021/cr0204350; Zhang J, 2001, J BIOL CHEM, V276, P37506, DOI 10.1074/jbc.M105503200; ZHANG MJ, 1994, J BIOL CHEM, V269, P981	77	37	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39208	39219		10.1074/jbc.M507775200	http://dx.doi.org/10.1074/jbc.M507775200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16150731	hybrid			2022-12-27	WOS:000233362200037
J	Desire, L; Bourdin, J; Loiseau, N; Peillon, H; Picard, V; De Oliveira, C; Bachelot, F; Leblond, B; Taverne, T; Beausoleil, E; Lacombe, S; Drouin, D; Schweighoffer, F				Desire, L; Bourdin, J; Loiseau, N; Peillon, H; Picard, V; De Oliveira, C; Bachelot, F; Leblond, B; Taverne, T; Beausoleil, E; Lacombe, S; Drouin, D; Schweighoffer, F			RAC1 inhibition targets amyloid precursor protein processing by gamma-secretase and decreases A beta production in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; LIPID RAFTS; MEDIATED CLEAVAGE; ACTIVATION; CELLS; PRESENILIN-1; MICE; RHO; GENERATION; DOMAIN	beta-Amyloid peptides (A beta) that form the senile plaques of Alzheimer disease consist mainly of 40- and 42-amino acid (A beta 40 and A beta 42) peptides generated from the cleavage of the amyloid precursor protein (APP). Generation of A beta involves beta-secretase and gamma-secretase activities and is regulated by membrane trafficking of the proteins involved in A beta production. Here we describe a new small molecule, EHT1864, which blocks the Rac1 signaling pathways. In vitro, EHT 1864 blocks A beta 40 and A beta 42 production but does not impact sAPP alpha levels and does not inhibit beta-secretase. Rather, EHT 1864 modulates APP processing at the level of gamma-secretase to prevent A beta 40 and A beta 42 generation. This effect does not result from a direct inhibition of the gamma-secretase activity and is specific for APP cleavage, since EHT 1864 does not affect Notch cleavage. In vivo, EHT 1864 significantly reduces A beta 40 and A beta 42 levels in guinea pig brains at a threshold that is compatible with delaying plaque accumulation and/or clearing the existing plaque in brain. EHT 1864 is the first derivative of a new chemical series that consists of candidates for inhibiting A beta formation in the brain of AD patients. Our findings represent the first pharmacological validation of Rac1 signaling as a target for developing novel therapies for Alzheimer disease.	Exonhit Therapeut, F-75013 Paris, France		Desire, L (corresponding author), Exonhit Therapeut, 63 Bd Massena, F-75013 Paris, France.	laurent.desire@exonhit.com	Leblond, Bertrand/A-3076-2015	Leblond, Bertrand/0000-0003-2585-9834				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Andrau D, 2003, J BIOL CHEM, V278, P25859, DOI 10.1074/jbc.M302622200; Beck M, 2003, NEUROCHEM RES, V28, P637, DOI 10.1023/A:1022850113083; Blasko I, 1999, FASEB J, V13, P63, DOI 10.1096/fasebj.13.1.63; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; Chevallier N, 1997, BRIT J PHARMACOL, V121, P556, DOI 10.1038/sj.bjp.0701151; Cole SL, 2005, J BIOL CHEM, V280, P18755, DOI 10.1074/jbc.M413895200; Costa RM, 2003, CURR BIOL, V13, P1348, DOI 10.1016/S0960-9822(03)00492-5; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Ermolieff J, 2000, BIOCHEMISTRY-US, V39, P12450, DOI 10.1021/bi001494f; Field KA, 2000, MOL BIOL CELL, V11, P3661, DOI 10.1091/mbc.11.10.3661; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Gianni D, 2003, J BIOL CHEM, V278, P9290, DOI 10.1074/jbc.M211899200; Glogauer M, 2003, J IMMUNOL, V170, P5652, DOI 10.4049/jimmunol.170.11.5652; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Jaksits S, 2004, J IMMUNOL, V173, P1628, DOI 10.4049/jimmunol.173.3.1628; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Kukar T, 2005, NAT MED, V11, P545, DOI 10.1038/nm1235; Kumanogoh H, 2001, NEUROSCI RES, V39, P189, DOI 10.1016/S0168-0102(00)00211-X; Lanz TA, 2003, J PHARMACOL EXP THER, V305, P864, DOI 10.1124/jpet.102.048280; LEBLOND B, Patent No. 2004076445; Lee M, 2002, BIOCHEM J, V366, P937, DOI 10.1042/BJ20020453; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Lesne S, 2003, J BIOL CHEM, V278, P18408, DOI 10.1074/jbc.M300819200; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Liao JK, 2002, J CLIN INVEST, V110, P285, DOI 10.1172/JCI200216421; Liao YF, 2004, J BIOL CHEM, V279, P49523, DOI 10.1074/jbc.M402034200; Maccioni RB, 2001, EUR J BIOCHEM, V268, P1518, DOI 10.1046/j.1432-1327.2001.02024.x; Maillet M, 2003, NAT CELL BIOL, V5, P633, DOI 10.1038/ncb1007; O'Kane EM, 2004, NEUROPHARMACOLOGY, V46, P879, DOI 10.1016/j.neuropharm.2003.11.020; Pinnix I, 2001, J BIOL CHEM, V276, P481, DOI 10.1074/jbc.M005968200; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Takahashi Y, 2003, J BIOL CHEM, V278, P18664, DOI 10.1074/jbc.M301619200; van Leeuwen FN, 1999, NAT CELL BIOL, V1, P242, DOI 10.1038/12068; Vassar R, 2004, J MOL NEUROSCI, V23, P105, DOI 10.1385/JMN:23:1-2:105; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Vetrivel KS, 2005, J BIOL CHEM, V280, P25892, DOI 10.1074/jbc.M503570200; Wahrle S, 2002, NEUROBIOL DIS, V9, P11, DOI 10.1006/nbdi.2001.0470; Weidemann A, 1999, J BIOL CHEM, V274, P5823, DOI 10.1074/jbc.274.9.5823; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; Wolozin B, 2001, P NATL ACAD SCI USA, V98, P5371, DOI 10.1073/pnas.101123198; Wong GT, 2004, J BIOL CHEM, V279, P12876, DOI 10.1074/jbc.M311652200; Zambrano N, 2004, J BIOL CHEM, V279, P16161, DOI 10.1074/jbc.M311027200; Zhou Y, 2003, SCIENCE, V302, P1215, DOI 10.1126/science.1090154; Zhu XW, 2000, INT J DEV NEUROSCI, V18, P433, DOI 10.1016/S0736-5748(00)00010-1	55	102	115	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37516	37525		10.1074/jbc.M507913200	http://dx.doi.org/10.1074/jbc.M507913200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16150730	hybrid			2022-12-27	WOS:000233044500028
J	Bose, A; Guilherme, A; Huang, SH; Hubbard, AC; Lane, CR; Soriano, NA; Czech, MP				Bose, A; Guilherme, A; Huang, SH; Hubbard, AC; Lane, CR; Soriano, NA; Czech, MP			The v-SNARE Vti1a regulates insulin-stimulated glucose transport and Acrp30 secretion in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUT4-CONTAINING VESICLES; GLUT4 VESICLES; GOLGI NETWORK; COMPARTMENTS; TRAFFICKING; TRANSLOCATION; LOCALIZATION; SYNTAXIN-6; ENDOSOMES; MEMBRANE	Regulated exocytosis in adipocytes mediates key functions, exemplified by insulin-stimulated secretion of peptides such as adiponectin and recycling of intracellular membranes containing GLUT4 glucose transporters to the cell surface. Using a proteomics approach, the v-SNARE Vti1a (vps10p tail interacting 1a) was identified by mass spectrometry in purified GLUT4-containing membranes. Insulin treatment of 3T3-L1 adipocytes decreased the amounts of both Vti1a and GLUT4 in these membranes, confirming that Vti1a is a component of insulin-sensitive GLUT4-containing vesicles. In the basal state, endogenous Vti1a colocalizes exclusively with perinuclear GLUT4. Although Vti1a has previously been reported to be a v-SNARE localized in the trans-Golgi network, treatment with brefeldin A failed to significantly modify Vti1a or GLUT4 localization while completely dispersing Golgi and trans-Golgi network marker proteins. Furthermore, depletion of Vti1a protein in cultured adipocytes through small interfering RNA-based gene silencing significantly inhibited both adiponectin secretion and insulin-stimulated deoxyglucose uptake. Taken together, these results suggest that the v-SNARE Vti1a may regulate a step common to both GLUT4 and Acrp30 trafficking in 3T3-L1 adipocytes.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Czech, MP (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA.	Michael.Czech@umassmed.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030898, P30DK032520, R01DK060837, R01DK030898] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32520, DK30898, DK60837] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antonin W, 2000, J NEUROSCI, V20, P5724, DOI 10.1523/JNEUROSCI.20-15-05724.2000; Bogan JS, 1999, J CELL BIOL, V146, P609, DOI 10.1083/jcb.146.3.609; Bose A, 2002, NATURE, V420, P821, DOI 10.1038/nature01246; Bose A, 2001, MOL CELL BIOL, V21, P5262, DOI 10.1128/MCB.21.15.5262-5275.2001; CARRINGTON WA, 1995, SCIENCE, V268, P1483, DOI 10.1126/science.7770772; Guilherme A, 2000, J BIOL CHEM, V275, P38151, DOI 10.1074/jbc.M003432200; Hashiramoto M, 2000, MOL CELL BIOL, V20, P416, DOI 10.1128/MCB.20.1.416-427.2000; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; Jiang ZY, 2002, J BIOL CHEM, V277, P509, DOI 10.1074/jbc.M108280200; Jiang ZY, 2003, P NATL ACAD SCI USA, V100, P7569, DOI 10.1073/pnas.1332633100; Kandror KV, 1996, J BIOL CHEM, V271, P21703, DOI 10.1074/jbc.271.36.21703; Karylowski O, 2004, MOL BIOL CELL, V15, P870, DOI 10.1091/mbc.E03-07-0517; Katome T, 2003, J BIOL CHEM, V278, P28312, DOI 10.1074/jbc.M302094200; Kreykenbohm V, 2002, EUR J CELL BIOL, V81, P273, DOI 10.1078/0171-9335-00247; Kupriyanova TA, 2000, J BIOL CHEM, V275, P36263, DOI 10.1074/jbc.M002797200; Kupriyanova TA, 2002, J BIOL CHEM, V277, P9133, DOI 10.1074/jbc.M106999200; Mallard F, 2002, J CELL BIOL, V156, P653, DOI 10.1083/jcb.200110081; Martin S, 2000, J CELL SCI, V113, P3427; Martin S, 2000, TRAFFIC, V1, P652, DOI 10.1034/j.1600-0854.2000.010809.x; Millar CA, 1999, MOL BIOL CELL, V10, P3675, DOI 10.1091/mbc.10.11.3675; Perera HKI, 2003, MOL BIOL CELL, V14, P2946, DOI 10.1091/mbc.E02-11-0722; Ramm G, 2000, MOL BIOL CELL, V11, P4079, DOI 10.1091/mbc.11.12.4079; Shewan AM, 2003, MOL BIOL CELL, V14, P973, DOI 10.1091/mbc.E02-06-0315; vonMollard GF, 1997, J CELL BIOL, V137, P1511, DOI 10.1083/jcb.137.7.1511; Xu Y, 1998, J BIOL CHEM, V273, P21783, DOI 10.1074/jbc.273.34.21783; Xu Z, 2002, J BIOL CHEM, V277, P47972, DOI 10.1074/jbc.C200486200; Zeigerer A, 2002, MOL BIOL CELL, V13, P2421, DOI 10.1091/mbc.E02-02-0071	27	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36946	36951		10.1074/jbc.M508317200	http://dx.doi.org/10.1074/jbc.M508317200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16131485	hybrid			2022-12-27	WOS:000232901800051
J	O'Dowd, BF; Ji, XD; Alijaniaram, M; Rajaram, RD; Kong, MMC; Rashid, A; Nguyen, T; George, SR				O'Dowd, BF; Ji, XD; Alijaniaram, M; Rajaram, RD; Kong, MMC; Rashid, A; Nguyen, T; George, SR			Dopamine receptor oligomerization visualized in living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-LOCALIZATION; OPIOID RECEPTORS; PROTEIN; AGONIST; DIMERS; D1; HETEROOLIGOMERS; GENERATION; RHODOPSIN; SURFACE	G protein-coupled receptors occur as dimers within arrays of oligomers. We visualized ensembles of dopamine receptor oligomers in living cells and evaluated the contributions of receptor conformation to the dynamics of oligomer association and dissociation, using a strategy of trafficking a receptor to another cellular compartment. We incorporated a nuclear localization sequence into the D1 dopamine receptor, which translocated from the cell surface to the nucleus. Receptor inverse agonists blocked this translocation, retaining the modified receptor, D1-nuclear localization signal (NLS), at the cell surface. D1 co-translocated with D1-NLS to the nucleus, indicating formation of homooligomers. (+)-Butaclamol retained both receptors at the cell surface, and removal of the drug allowed translocation of both receptors to the nucleus. Agonist-nonbinding D1(S198A/S199A)-NLS, containing two substituted serine residues in transmembrane 5 also oligomerized with D1, and both were retained on the cell surface by (+)-butaclamol. Drug removal disrupted these oligomerized receptors so that D1 remained at the cell surface while D1(S198A/S199A)-NLS trafficked to the nucleus. Thus, receptor conformational differences permitted oligomer disruption and showed that ligand-binding pocket occupancy by the inverse agonist induced a conformational change. We demonstrated robust heterooligomerization between the D2 dopamine receptor and the D1 receptor. The heterooligomers could not be disrupted by inverse agonists targeting either one of the receptor constituents. However, D2 did not heterooligomerize with the structurally modified D1(S198A/S199A), indicating an impaired interface for their interaction. Thus, we describe a novel method showing that a homogeneous receptor conformation maintains the structural integrity of oligomers, whereas conformational heterogeneity disrupts it.	Univ Toronto, Dept Pharmacol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Ctr Addict & Mental Hlth, Toronto, ON M5T 1R8, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada	O'Dowd, BF (corresponding author), Univ Toronto, Dept Pharmacol, Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	brian.odowd@utoronto.ca	George, Susan R/P-9669-2018; George, Susan/W-7494-2019		NIDA NIH HHS [R01 DA007223] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007223] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Carrillo JJ, 2004, MOL PHARMACOL, V66, P1123, DOI 10.1124/mol.104.001586; Chen R, 2000, AM J PHYSIOL-RENAL, V279, pF440, DOI 10.1152/ajprenal.2000.279.3.F440; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Gales C, 2005, NAT METHODS, V2, P177, DOI 10.1038/NMETH743; George SR, 2000, J BIOL CHEM, V275, P26128, DOI 10.1074/jbc.M000345200; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; Gomes I, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-22-j0007.2000; Guo W, 2003, J BIOL CHEM, V278, P4385, DOI 10.1074/jbc.C200679200; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Jong YJI, 2005, J BIOL CHEM, V280, P30469, DOI 10.1074/jbc.M501775200; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Lee DK, 2004, J BIOL CHEM, V279, P7901, DOI 10.1074/jbc.M306377200; Lee SP, 2000, MOL PHARMACOL, V58, P120, DOI 10.1124/mol.58.1.120; Lee SP, 2004, J BIOL CHEM, V279, P35671, DOI 10.1074/jbc.M401923200; Lee SP, 2003, BIOCHEMISTRY-US, V42, P11023, DOI 10.1021/bi0345539; Levac BAR, 2002, CURR OPIN PHARMACOL, V2, P76, DOI 10.1016/S1471-4892(02)00124-8; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Lu D, 1998, ENDOCRINOLOGY, V139, P365, DOI 10.1210/en.139.1.365; MARCHESE A, 1998, REC BIOCH M, P1; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; Milligan G, 2004, MOL PHARMACOL, V66, P1, DOI 10.1124/mol.104.000497.; NG GYK, 1995, P NATL ACAD SCI USA, V92, P10157, DOI 10.1073/pnas.92.22.10157; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; Overton MC, 2002, J BIOL CHEM, V277, P41463, DOI 10.1074/jbc.M205368200; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; So CH, 2005, MOL PHARMACOL, V68, P568, DOI 10.1124/mol.105.012229; TOMIC M, 1993, BIOCHEM BIOPH RES CO, V191, P1020, DOI 10.1006/bbrc.1993.1319; Watson PH, 2000, BONE, V26, P221, DOI 10.1016/S8756-3282(99)00264-1; Zawarynski P, 1998, FEBS LETT, V441, P383, DOI 10.1016/S0014-5793(98)01588-9	32	50	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37225	37235		10.1074/jbc.M504562200	http://dx.doi.org/10.1074/jbc.M504562200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16115864	hybrid			2022-12-27	WOS:000232901800081
J	Tani, M; Igarashi, Y; Ito, M				Tani, M; Igarashi, Y; Ito, M			Involvement of neutral ceramidase in ceramide metabolism at the plasma membrane and in extracellular milieu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MOLECULAR-CLONING; SPHINGOSINE 1-PHOSPHATE; SECRETORY SPHINGOMYELINASE; ALKALINE CERAMIDASE; FUNCTIONAL-ANALYSIS; ACTIVATION; EXPRESSION; APOPTOSIS; RECEPTOR	Neutral ceramidase is a type II integral membrane protein, which is occasionally secreted into the extracellular milieu after the processing of its N-terminal anchor (Tani, M., Iida, H., and Ito, M. ( 2003) J. Biol. Chem. 278, 10523 - 10530). We found that when overexpressed in CHOP cells, neutral ceramidase hydrolyzed cell surface ceramide, which increased in amount after the treatment of cells with bacterial sphingomyelinase, leading to an increase in the cellular level of sphingosine and sphingosine 1-phosphate. On the other hand, knockdown of the endogenous enzyme by siRNA decreased the cellular level of both sphingolipid metabolites. The treatment of cells with bovine serum albumin significantly reduced the cellular level of sphingosine, but not sphingosine 1-phosphate, generated by overexpression of the enzyme. The cellular level of sphingosine 1-phosphate increased with overexpression of the cytosolic sphingosine kinase. These results suggest that sphingosine 1-phosphate is mainly produced inside of the cell after the incorporation of sphingosine generated on the plasma membranes. The enzyme also seems to participate in the hydrolysis of serum-derived ceramide in the vascular system. Significant amounts of sphingosine as well as sphingosine 1-phosphate were generated in the cell-free conditioned medium of ceramidase transfectants, compared with mock transfectants. No increase in these metabolites was observed if serum or bacterial sphingomyelinase was omitted from the conditioned medium, suggesting that the major source of ceramide is the serum-derived sphingomyelin. A sphingosine 1-phosphate receptor, S1P(1), was internalized much faster by the treatment of S1P(1)-overexpressing cells with conditioned medium of ceramidase transfectants than that of mock transfectants. Collectively, these results clearly indicate that the enzyme is involved in the metabolism of ceramide at the plasma membrane and in the extracellular milieu, which could regulate sphingosine 1-phosphate-mediated signaling through the generation of sphingosine.	Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Dept Biosci & Biotechnol, Higashi Ku, Fukuoka 8128581, Japan; Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biomembrane & Biofunct Chem, Kita Ku, Sapporo, Hokkaido 0600812, Japan	Kyushu University; Hokkaido University	Ito, M (corresponding author), Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Dept Biosci & Biotechnol, Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.	makotoi@agr.kyushu-u.ac.jp	Ito, Makoto/Q-6164-2019	ito, Makoto/0000-0003-3159-7818; Tani, Motohiro/0000-0003-4316-8260				Acharya U, 2004, P NATL ACAD SCI USA, V101, P1922, DOI 10.1073/pnas.0308693100; Acharya U, 2003, SCIENCE, V299, P1740, DOI 10.1126/science.1080549; Ancellin N, 2002, J BIOL CHEM, V277, P6667, DOI 10.1074/jbc.M102841200; Arakaki N, 2003, MOL CANCER RES, V1, P931; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bourbon NA, 2000, J BIOL CHEM, V275, P35617, DOI 10.1074/jbc.M007346200; Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; Cremesti AE, 2002, FEBS LETT, V531, P47, DOI 10.1016/S0014-5793(02)03489-0; Cuvillier O, 2002, BBA-MOL CELL BIOL L, V1585, P153, DOI 10.1016/S1388-1981(02)00336-0; Cuvillier O, 2001, CELL DEATH DIFFER, V8, P162, DOI 10.1038/sj.cdd.4400793; Di Bartolomeo S, 2000, J NEUROCHEM, V75, P532, DOI 10.1046/j.1471-4159.2000.0750532.x; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; Edsall LC, 2001, J NEUROCHEM, V76, P1573, DOI 10.1046/j.1471-4159.2001.00164.x; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; Fukuda Y, 2003, BIOCHEM BIOPH RES CO, V309, P155, DOI 10.1016/S0006-291X(03)01551-1; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; Hla T, 2003, PHARMACOL RES, V47, P401, DOI 10.1016/S1043-6618(03)00046-X; Huwiler A, 1998, BIOCHEMISTRY-US, V37, P14556, DOI 10.1021/bi981401i; Hwang YH, 2005, BIOCHEM BIOPH RES CO, V331, P37, DOI 10.1016/j.bbrc.2005.03.134; ITO M, 2003, CERAMIDE SIGNALING, P41; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Kihara A, 2002, J BIOL CHEM, V277, P30048, DOI 10.1074/jbc.M203385200; King CC, 2000, J BIOL CHEM, V275, P18108, DOI 10.1074/jbc.M909663199; Kohno T, 2002, FASEB J, V16, P983, DOI 10.1096/fj.01-0809com; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lang KS, 2004, CELL DEATH DIFFER, V11, P231, DOI 10.1038/sj.cdd.4401311; Lightle S, 2003, ARCH BIOCHEM BIOPHYS, V419, P120, DOI 10.1016/j.abb.2003.08.031; Linke T, 2001, J BIOL CHEM, V276, P5760, DOI 10.1074/jbc.M006846200; Liu CH, 1999, MOL BIOL CELL, V10, P1179, DOI 10.1091/mbc.10.4.1179; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Mao CG, 2003, J BIOL CHEM, V278, P31184, DOI 10.1074/jbc.M303875200; Marathe S, 1998, J BIOL CHEM, V273, P4081, DOI 10.1074/jbc.273.7.4081; Megidish T, 1998, J BIOL CHEM, V273, P21834, DOI 10.1074/jbc.273.34.21834; Michel C, 1997, J BIOL CHEM, V272, P22432, DOI 10.1074/jbc.272.36.22432; Min JK, 2002, ANAL BIOCHEM, V303, P167, DOI 10.1006/abio.2002.5579; Mitsutake S, 2001, J BIOL CHEM, V276, P26249, DOI 10.1074/jbc.M102233200; Monjusho H, 2003, BIOCHEM J, V376, P473, DOI 10.1042/BJ20030652; Newrzella D, 1996, J BIOL CHEM, V271, P32089, DOI 10.1074/jbc.271.50.32089; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; Ochi S, 2004, J BIOL CHEM, V279, P12181, DOI 10.1074/jbc.M307046200; Okino N, 1999, J BIOL CHEM, V274, P36616, DOI 10.1074/jbc.274.51.36616; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; RAINES MA, 1993, J BIOL CHEM, V268, P14572; Romiti E, 2000, BIOCHEM BIOPH RES CO, V275, P746, DOI 10.1006/bbrc.2000.3370; Schissel SL, 1998, J BIOL CHEM, V273, P2738, DOI 10.1074/jbc.273.5.2738; SEGERS RPAM, 1990, INFECT IMMUN, V58, P2177, DOI 10.1128/IAI.58.7.2177-2185.1990; Shakor ABA, 2004, J BIOL CHEM, V279, P36778, DOI 10.1074/jbc.M402170200; Spiegel S, 2002, LEUKEMIA, V16, P1596, DOI 10.1038/sj.leu.2402611; Tani M, 2000, J BIOL CHEM, V275, P11229, DOI 10.1074/jbc.275.15.11229; Tani M, 2003, J BIOL CHEM, V278, P10523, DOI 10.1074/jbc.M207932200; Tani M, 2000, J BIOL CHEM, V275, P3462, DOI 10.1074/jbc.275.5.3462; Tani M, 1998, ANAL BIOCHEM, V263, P183, DOI 10.1006/abio.1998.2781; Tseng HJ, 2004, BIOCHEM BIOPH RES CO, V314, P513, DOI 10.1016/j.bbrc.2003.12.125; Yatomi Y, 1997, J BIOL CHEM, V272, P5291, DOI 10.1074/jbc.272.8.5291; Yoshimura Y, 2004, J BIOL CHEM, V279, P44012, DOI 10.1074/jbc.M405598200; Yoshimura Y, 2002, J BIOCHEM, V132, P229, DOI 10.1093/oxfordjournals.jbchem.a003215	61	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36592	36600		10.1074/jbc.M506827200	http://dx.doi.org/10.1074/jbc.M506827200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16126722	hybrid			2022-12-27	WOS:000232901800009
J	Travassos, LH; Carneiro, LAM; Girardin, SE; Boneca, IG; Lemos, R; Bozza, MT; Domingues, RCP; Coyle, AJ; Bertin, J; Philpott, DJ; Plotkowski, MC				Travassos, LH; Carneiro, LAM; Girardin, SE; Boneca, IG; Lemos, R; Bozza, MT; Domingues, RCP; Coyle, AJ; Bertin, J; Philpott, DJ; Plotkowski, MC			Nod1 participates in the innate immune response to Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AIRWAY EPITHELIAL-CELLS; TOLL-LIKE RECEPTOR-5; NF-KAPPA-B; PEPTIDOGLYCAN RECOGNITION; HOST RESPONSE; EXOTOXIN-A; INFLAMMATION; ACTIVATION; FLAGELLIN; LIPOPOLYSACCHARIDE	The mammalian innate immune system recognizes pathogen-associated molecular patterns through pathogen recognition receptors. Nod1 has been described recently as a cytosolic receptor that detects specifically diaminopimelate-containing muropeptides from Gram-negative bacteria peptidoglycan. In the present study we investigated the potential role of Nod1 in the innate immune response against the opportunistic pathogen Pseudomonas aeruginosa. We demonstrate that Nod1 detects the P. aeruginosa peptidoglycan leading to NF-kappa B activation and that this activity is diminished in epithelial cells expressing a dominant-negative Nod1 construct or in mouse embryonic fibroblasts from Nod1 knock-out mice infected with P. aeruginosa. Finally, we demonstrate that the cytokine secretion kinetics and bacterial killing are altered in Nod1-deficient cells infected with P. aeruginosa in the early stages of infection.	Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Microbiol, BR-21941590 Rio De Janeiro, Brazil; Univ Estado Rio de Janeiro, Fac Ciencias Med, BR-20551030 Rio De Janeiro, Brazil; Inst Pasteur, Unite Pathogenie Microbienne Mol, F-75724 Paris, France; Inst Pasteur, Unite Pathogenie Bacterienne Muqueuses, F-75724 Paris, France; Inst Pasteur, Grp Immun Innee & Signalisat, F-75724 Paris, France; Millenium Pharmaceut, Cambridge, MA 02139 USA	Universidade Federal do Rio de Janeiro; Universidade do Estado do Rio de Janeiro; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Travassos, LH (corresponding author), Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Microbiol, Bloco 1,Prof Paulo de Goes Ctr Cidade Univ,Ilha F, BR-21941590 Rio De Janeiro, Brazil.	lhtravassos@ufrj.br	Carneiro, Leticia/T-8978-2019; Travassos, Leonardo/G-1925-2012; Boneca, Ivo G/H-1677-2014; Domingues, Regina/V-3046-2019	Carneiro, Leticia/0000-0001-5870-8288; Travassos, Leonardo/0000-0003-1323-3797; Boneca, Ivo G/0000-0001-8122-509X; Bozza, Marcelo/0000-0003-3683-7550				Agramonte-Hevia J, 2002, FEMS IMMUNOL MED MIC, V34, P255, DOI 10.1016/S0928-8244(02)00408-X; Athman R, 2004, CURR OPIN MICROBIOL, V7, P25, DOI 10.1016/j.mib.2003.12.013; CRIPPS AW, 1995, IMMUNOL CELL BIOL, V73, P418, DOI 10.1038/icb.1995.65; deBentzmann S, 1996, AM J RESP CRIT CARE, V154, pS155, DOI 10.1164/ajrccm/154.4_Pt_2.S155; Endlich B, 2002, J IMMUNOL, V168, P3586, DOI 10.4049/jimmunol.168.7.3586; Fritz JH, 2005, EUR J IMMUNOL, V35, P2459, DOI 10.1002/eji.200526286; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Girardin SE, 2003, J BIOL CHEM, V278, P41702, DOI 10.1074/jbc.M307198200; Girardin SE, 2004, EUR J IMMUNOL, V34, P1777, DOI 10.1002/eji.200425095; Girardin SE, 2003, EMBO REP, V4, P932, DOI 10.1038/sj.embor.embor940; Girardin SE, 2001, EMBO REP, V2, P736, DOI 10.1093/embo-reports/kve155; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Greene CM, 2005, J IMMUNOL, V174, P1638, DOI 10.4049/jimmunol.174.3.1638; Guillot L, 2004, J BIOL CHEM, V279, P2712, DOI 10.1074/jbc.M305790200; Hajjar AM, 2002, NAT IMMUNOL, V3, P354, DOI 10.1038/ni777; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; JOHNSON DA, 1982, AM REV RESPIR DIS, V126, P1070; Kim JG, 2004, INFECT IMMUN, V72, P1487, DOI 10.1128/IAI.72.3.1487-1495.2004; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Kooguchi K, 1998, INFECT IMMUN, V66, P3164, DOI 10.1128/IAI.66.7.3164-3169.1998; Park PW, 2001, NATURE, V411, P98, DOI 10.1038/35075100; Plotkowski MC, 2002, AM J RESP CELL MOL, V26, P617, DOI 10.1165/ajrcmb.26.5.4489; Plotkowski MC, 1999, AM J RESP CELL MOL, V20, P880, DOI 10.1165/ajrcmb.20.5.3408; Power MR, 2004, J BIOL CHEM, V279, P49315, DOI 10.1074/jbc.M402111200; Sato H, 2004, MOL MICROBIOL, V53, P1279, DOI 10.1111/j.1365-2958.2004.04194.x; Smith KD, 2003, NAT IMMUNOL, V4, P1247, DOI 10.1038/ni1011; Smith MF, 2003, J BIOL CHEM, V278, P32552, DOI 10.1074/jbc.M305536200; Travassos LH, 2004, EMBO REP, V5, P1000, DOI 10.1038/sj.embor.7400248; Tsai WC, 2000, INFECT IMMUN, V68, P4289, DOI 10.1128/IAI.68.7.4289-4296.2000; van Heel DA, 2005, EUR J IMMUNOL, V35, P2471, DOI 10.1002/eji.200526296; VANHEIJENOORT J, 1975, EUR J BIOCHEM, V58, P611; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; Wieland CW, 2002, INFECT IMMUN, V70, P1352, DOI 10.1128/IAI.70.3.1352-1358.2002; Zhang J, 2003, INVEST OPHTH VIS SCI, V44, P4247, DOI 10.1167/iovs.03-0219	36	118	124	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36714	36718		10.1074/jbc.M501649200	http://dx.doi.org/10.1074/jbc.M501649200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16150702	hybrid			2022-12-27	WOS:000232901800024
J	Zuin, A; Vivancos, AP; Sanso, M; Takatsume, Y; Ayte, J; Inoue, Y; Hidalgo, E				Zuin, A; Vivancos, AP; Sanso, M; Takatsume, Y; Ayte, J; Inoue, Y; Hidalgo, E			The glycolytic metabolite methylglyoxal activates Pap1 and Sty1 stress responses in Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR PAP1; NUCLEAR EXPORT FACTOR; MAP KINASE PATHWAY; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; OXIDATIVE STRESS; IDENTIFICATION; LOCALIZATION; MODULES	Methylglyoxal, a toxic metabolite synthesized in vivo during glycolysis, inhibits cell growth. One of the mechanisms protecting eukaryotic cells against its toxicity is the glyoxalase system, composed of glyoxalase I and II (glo1 and glo2), which converts methylglyoxal into D-lactic acid in the presence of glutathione. Here we have shown that the two principal oxidative stress response pathways of Schizosaccharomyces pombe, Sty1 and Pap1, are involved in the response to methylglyoxal toxicity. The mitogen-activated protein kinase Sty1 is phosphorylated and accumulates in the nucleus following methylglyoxal treatment. Moreover, glo2 expression is induced by methylglyoxal and environmental stresses in a Sty1-dependent manner. The transcription factor Pap1 also accumulates in the nucleus, activating the expression of its target genes following methylglyoxal treatment. Our studies showed that the C-terminal cysteine-rich domain of Pap1 is sufficient for methylglyoxal sensing. Furthermore, the redox status of Pap1 is not changed by methylglyoxal. We propose that methylglyoxal treatment triggers Pap1 and Sty1 nuclear accumulation, and we describe the molecular basis of such activation mechanisms. In addition, we discuss the potential physiological significance of these responses to a natural toxic metabolite.	Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Cell Signaling Unit, Barcelona 08003, Spain; Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Mol Microbiol Lab, Kyoto 6110011, Japan	Pompeu Fabra University; Kyoto University	Hidalgo, E (corresponding author), Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Cell Signaling Unit, C Dr Aiguader 80, Barcelona 08003, Spain.	elena.hidalgo@upf.edu	Vivancos, Ana/AAG-8331-2019; Ayte, Jose/L-5217-2014; Hidalgo, Elena/K-2919-2014	Vivancos, Ana/0000-0003-2888-6512; Ayte, Jose/0000-0002-6354-0536; Hidalgo, Elena/0000-0002-3768-6785; Takatsume, Yoshifumi/0000-0002-9467-2021				ALFA C, 1993, EXPT FISSION YEASTS; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Beisswenger PJ, 1999, DIABETES, V48, P198, DOI 10.2337/diabetes.48.1.198; Bito A, 1997, J BIOL CHEM, V272, P21509, DOI 10.1074/jbc.272.34.21509; Castillo EA, 2002, MOL MICROBIOL, V45, P243, DOI 10.1046/j.1365-2958.2002.03020.x; CASTILLO EA, 2003, RECENT DEV CELL RES, V1, P217; Chen DR, 2003, MOL BIOL CELL, V14, P214, DOI 10.1091/mbc.E02-08-0499; Degols G, 1996, MOL CELL BIOL, V16, P2870; Gaits F, 1998, GENE DEV, V12, P1464, DOI 10.1101/gad.12.10.1464; Leupold U., 1970, METHODS CELL PHYSL, V4, P169; LO TWC, 1994, J BIOL CHEM, V269, P32299; Maeta K, 2004, MOL CELL BIOL, V24, P8753, DOI 10.1128/MCB.24.19.8753-8764.2004; Maeta K, 2005, J BIOL CHEM, V280, P253, DOI 10.1074/jbc.M408061200; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Quinn J, 2002, MOL BIOL CELL, V13, P805, DOI 10.1091/mbc.01-06-0288; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Storz G, 1999, CURR OPIN MICROBIOL, V2, P188, DOI 10.1016/S1369-5274(99)80033-2; Takatsume Y, 2004, ARCH MICROBIOL, V181, P371, DOI 10.1007/s00203-004-0666-4; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; Toledano MB, 2004, TRENDS BIOCHEM SCI, V29, P351, DOI 10.1016/j.tibs.2004.05.005; Toone WM, 1998, GENE DEV, V12, P1453, DOI 10.1101/gad.12.10.1453; Vivancos AP, 2005, P NATL ACAD SCI USA, V102, P8875, DOI 10.1073/pnas.0503251102; Vivancos AP, 2004, MOL MICROBIOL, V52, P1427, DOI 10.1111/j.1365-2958.2004.04065.x; Wilkinson MG, 1996, GENE DEV, V10, P2289, DOI 10.1101/gad.10.18.2289	26	49	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36708	36713		10.1074/jbc.M508400200	http://dx.doi.org/10.1074/jbc.M508400200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16141205	hybrid			2022-12-27	WOS:000232901800023
J	David-Dufilho, M; Millanvoye-Ban Brussel, E; Topal, G; Walch, L; Brunet, A; Rendu, F				David-Dufilho, M; Millanvoye-Ban Brussel, E; Topal, G; Walch, L; Brunet, A; Rendu, F			Endothelial thrombomodulin induces Ca2+ signals and nitric oxide synthesis through epidermal growth factor receptor kinase and calmodulin kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; NO SYNTHASE ACTIVITY; SRC FAMILY KINASES; SOLUBLE THROMBOMODULIN; REGULATED KINASE; THROMBIN; PHOSPHORYLATION; HISTAMINE; MECHANISMS; CELLS	Endothelial membrane-bound thrombomodulin is a high affinity receptor for thrombin to inhibit coagulation. We previously demonstrated that the thrombin-thrombomodulin complex restrains cell proliferation mediated through protease-activated receptor (PAR)-1. We have now tested the hypothesis that thrombomodulin transduces a signal to activate the endothelial nitric-oxide synthase (NOS3) and to modulate G protein-coupled receptor signaling. Cultured human umbilical vein endothelial cells were stimulated with thrombin or a mutant of thrombin that binds to thrombomodulin and has no catalytic activity on PAR-1. Thrombin and its mutant dose dependently activated NO release at cell surface. Pretreatment with anti-thrombomodulin antibody suppressed NO response to the mutant and to low thrombin concentration and reduced by half response to high concentration. Thrombin receptor-activating peptide that only activates PAR-1 and high thrombin concentration induced marked biphasic Ca2+ signals with rapid phosphorylation of PLC beta 3 and NOS3 at both serine 1177 and threonine 495. The mutant thrombin evoked a Ca2+ spark and progressive phosphorylation of Src family kinases at tyrosine 416 and NOS3 only at threonine 495. It activated rapid phosphatidylinositol-3 kinase-dependent NO synthesis and phosphorylation of epidermal growth factor receptor and calmodulin kinase II. Complete epidermal growth factor receptor inhibition only partly reduced the activation of phospholipase C gamma(1) and NOS3. Prestimulation of thrombomodulin did not affect NO release but reduced Ca2+ responses to thrombin and histamine, suggesting cross-talks between thrombomodulin and G protein-coupled receptors. This is the first demonstration of an outside-in signal mediated by the cell surface thrombomodulin receptor to activate NOS3 through tyrosine kinase-dependent pathway. This signaling may contribute to thrombomodulin function in thrombosis, inflammation, and atherosclerosis.	Univ Paris 06, Dept Signalisat Cellulaire & Atherosclerose Preco, CNRS, UMR 7131, F-75014 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	David-Dufilho, M (corresponding author), Univ Paris 06, Dept Signalisat Cellulaire & Atherosclerose Preco, CNRS, UMR 7131, 102 Rue Didot, F-75014 Paris, France.	monique.dufilho@brs.aphp.fr		DAVID-DUFILHO, Monique/0000-0002-7479-075X				Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bhattacharya A, 2000, J PHARMACOL EXP THER, V295, P284; BROCK TA, 1988, J CELL PHYSIOL, V136, P54, DOI 10.1002/jcp.1041360107; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; Brouet A, 2001, J BIOL CHEM, V276, P32663, DOI 10.1074/jbc.M101371200; Bussolati B, 2001, AM J PATHOL, V159, P993, DOI 10.1016/S0002-9440(10)61775-0; Cha MS, 2001, BIOCHEM BIOPH RES CO, V282, P1061, DOI 10.1006/bbrc.2001.4682; Drew BG, 2004, P NATL ACAD SCI USA, V101, P6999, DOI 10.1073/pnas.0306266101; Esmon CT, 2003, CHEST, V124, p26S, DOI 10.1378/chest.124.3_suppl.26S; Fleming I, 2001, CIRC RES, V88, pE68, DOI 10.1161/hh1101.092677; Gu MF, 2000, J BIOL CHEM, V275, P11389, DOI 10.1074/jbc.275.15.11389; Hanafy K A, 2001, Med Sci Monit, V7, P801; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Hudmon A, 2002, BIOCHEM J, V364, P593, DOI 10.1042/BJ20020228; IOUZALEN L, 1995, EUR J PHARM-MOLEC PH, V289, P189, DOI 10.1016/0922-4106(95)90094-2; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Lafay M, 1998, THROMB HAEMOSTASIS, V79, P848, DOI 10.1055/s-0037-1615076; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; LANTOINE F, 1995, J ELECTROANAL CHEM, V392, P85, DOI 10.1016/0022-0728(95)04042-M; Lantoine F, 1998, BIOCHEM J, V330, P695, DOI 10.1042/bj3300695; Li HG, 2002, NITRIC OXIDE-BIOL CH, V7, P132, DOI 10.1016/S1089-8603(02)00127-1; Lin MI, 2003, J BIOL CHEM, V278, P44719, DOI 10.1074/jbc.M302836200; Lohi O, 2004, CURR BIOL, V14, P236, DOI 10.1016/j.cub.2004.01.025; Ludeman MJ, 2005, J BIOL CHEM, V280, P13122, DOI 10.1074/jbc.M410381200; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; McLaughlin JN, 2005, J BIOL CHEM, V280, P25048, DOI 10.1074/jbc.M414090200; Michell BJ, 2002, J BIOL CHEM, V277, P42344, DOI 10.1074/jbc.M205144200; Millanvoye-Van Brussel E, 2004, BIOCHEM J, V380, P533, DOI 10.1042/BJ20040069; Minami T, 2004, ARTERIOSCL THROM VAS, V24, P41, DOI 10.1161/01.ATV.0000099880.09014.7D; Nesheim M, 2003, CHEST, V124, p33S, DOI 10.1378/chest.124.3_suppl.33S; Olivot JM, 2001, CIRC RES, V88, P681, DOI 10.1161/hh0701.088769; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; Riewald M, 2005, J BIOL CHEM, V280, P19808, DOI 10.1074/jbc.M500747200; Sadler JE, 1997, THROMB HAEMOSTASIS, V78, P392; Salomaa V, 1999, LANCET, V353, P1729, DOI 10.1016/S0140-6736(98)09057-6; Schaeffer P, 1997, BIOCHEM PHARMACOL, V53, P487, DOI 10.1016/S0006-2952(96)00735-6; Shen BQ, 1999, J BIOL CHEM, V274, P33057, DOI 10.1074/jbc.274.46.33057; Shi CS, 2005, CIRCULATION, V111, P1627, DOI 10.1161/01.CIR.0000160364.05405.B5; Stephens LR, 2001, J BIOL CHEM, V276, P42767, DOI 10.1074/jbc.M107194200; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Thors B, 2004, FEBS LETT, V573, P175, DOI 10.1016/j.febslet.2004.07.078; Thors B, 2003, ATHEROSCLEROSIS, V168, P245, DOI 10.1016/S0021-9150(03)00127-8; Tkachenko E, 2005, CIRC RES, V96, P488, DOI 10.1161/01.RES.0000159708.71142.c8; Topal G, 2004, FREE RADICAL BIO MED, V36, P1532, DOI 10.1016/j.freeradbiomed.2004.03.019; Uchiba M, 2004, CIRC RES, V95, P34, DOI 10.1161/01.RES.0000133680.87668.FA; Van de Wouwer M, 2004, ARTERIOSCL THROM VAS, V24, P1374, DOI 10.1161/01.ATV.0000134298.25489.92; Wetzker R, 2003, NAT REV MOL CELL BIO, V4, P651, DOI 10.1038/nrm1173; Wu KK, 2003, CIRCULATION, V107, P1729, DOI 10.1161/01.CIR.0000064894.97094.4F; YE J, 1992, J BIOL CHEM, V267, P11023; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6	51	22	25	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35999	36006		10.1074/jbc.M506374200	http://dx.doi.org/10.1074/jbc.M506374200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16126727	hybrid, Green Published			2022-12-27	WOS:000232726900028
J	Gao, S; Steffen, J; Laughon, A				Gao, S; Steffen, J; Laughon, A			Dpp-responsive silencers are bound by a trimeric mad-medea complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; SMAD PROTEINS; DNA-BINDING; TRANSCRIPTIONAL REGULATION; STRUCTURAL BASIS; NUCLEAR-LOCALIZATION; MORPHOGEN GRADIENT; CRYSTAL-STRUCTURE; TUMOR-SUPPRESSOR; STEM-CELLS	Transcriptional regulation by transforming growth factor-beta signaling is mediated by the Smad family of transcription factors. It is generally accepted that Smads must interact with other transcription factors to bind to their targets. However, recently it has been shown that a complex of the Drosophila Smad proteins, Mad and Medea, binds with high affinity to silencer elements that repress brinker and bag of marbles in response to Dpp signaling. Here we report that these silencers are bound by a heterotrimer containing two Mad subunits and one Medea subunit. We found that the MH1 domains of all three subunits contributed directly to sequence-specific DNA contact, thus accounting for the exceptionally high stability of the Smad-silencer complex. The Medea MH1 domain binds to a canonical Smad box (GTCT), whereas the Mad MH1 domains bind to a GC-rich sequence resembling Mad binding sites previously identified in Dpp-responsive enhancer elements. The consensus for this sequence, GRCGNC, differs from that of the canonical Smad box, but we found that Mad binding nonetheless required the same beta-hairpin amino acids that mediate base-specific contact with GTCT. Binding was also affected by alanine substitutions in Mad and Med at a subset of basic residues within and flanking helix 2, indicating a contribution to binding of the GRCGNC and GTCT sites. The slight alteration of the Dpp silencers caused them to activate transcription in response to Dpp signaling, indicating that the potential for Smad complexes to recognize specific targets need not be limited to repression.	Univ Wisconsin, Genet Lab, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Laughon, A (corresponding author), Univ Wisconsin, Genet Lab, 445 Henry Mall, Madison, WI 53706 USA.	alaughon@wisc.edu						Affolter M, 2001, EMBO J, V20, P3298, DOI 10.1093/emboj/20.13.3298; Baird GS, 2000, P NATL ACAD SCI USA, V97, P11984, DOI 10.1073/pnas.97.22.11984; Campbell G, 1999, CELL, V96, P553, DOI 10.1016/S0092-8674(00)80659-5; Chacko BM, 2004, MOL CELL, V15, P813, DOI 10.1016/j.molcel.2004.07.016; Chacko BM, 2001, NAT STRUCT BIOL, V8, P248, DOI 10.1038/84995; Chai JJ, 2003, J BIOL CHEM, V278, P20327, DOI 10.1074/jbc.C300134200; Chen DH, 2003, CURR BIOL, V13, P1786, DOI 10.1016/j.cub.2003.09.033; Chen DH, 2003, DEVELOPMENT, V130, P1159, DOI 10.1242/dev.00325; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Dai H, 2000, DEV BIOL, V227, P373, DOI 10.1006/dbio.2000.9901; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Halfon MS, 2000, CELL, V103, P63, DOI 10.1016/S0092-8674(00)00105-7; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; Inman GJ, 2002, J BIOL CHEM, V277, P51008, DOI 10.1074/jbc.M208532200; Jayaraman L, 2000, J BIOL CHEM, V275, P40710, DOI 10.1074/jbc.M005799200; Jazwinska A, 1999, DEVELOPMENT, V126, P3323; Jazwinska A, 1999, CELL, V96, P563, DOI 10.1016/S0092-8674(00)80660-1; Johnson K, 1999, J BIOL CHEM, V274, P20709, DOI 10.1074/jbc.274.29.20709; Karaulanov E, 2004, EMBO J, V23, P844, DOI 10.1038/sj.emboj.7600101; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kirkpatrick H, 2001, J BIOL CHEM, V276, P18216, DOI 10.1074/jbc.M101365200; Knirr S, 2001, DEV BIOL, V238, P13, DOI 10.1006/dbio.2001.0397; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Kowanetz M, 2004, MOL CELL BIOL, V24, P4241, DOI 10.1128/MCB.24.10.4241-4254.2004; Kusanagi K, 2000, MOL BIOL CELL, V11, P555, DOI 10.1091/mbc.11.2.555; Kusanagi K, 2001, J BIOL CHEM, V276, P28155, DOI 10.1074/jbc.M103371200; Kwon C, 2004, DEVELOPMENT, V131, P2681, DOI 10.1242/dev.01127; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lee HH, 2005, DEVELOPMENT, V132, P1429, DOI 10.1242/dev.01687; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Lopez-Rovira T, 2002, J BIOL CHEM, V277, P3176, DOI 10.1074/jbc.M106826200; Marty T, 2000, NAT CELL BIOL, V2, P745, DOI 10.1038/35036383; Minami M, 1999, NATURE, V398, P242, DOI 10.1038/18451; Muller B, 2003, CELL, V113, P221, DOI 10.1016/S0092-8674(03)00241-1; NELSON HB, 1993, ROUX ARCH DEV BIOL, V202, P341, DOI 10.1007/BF00188733; Ohlstein B, 1997, DEVELOPMENT, V124, P3651; Pyrowolakis G, 2004, DEV CELL, V7, P229, DOI 10.1016/j.devcel.2004.07.008; Qin BY, 2001, MOL CELL, V8, P1303, DOI 10.1016/S1097-2765(01)00417-8; Raftery LA, 2003, TRENDS GENET, V19, P701, DOI 10.1016/j.tig.2003.10.009; Rushlow C, 2001, GENE DEV, V15, P340, DOI 10.1101/gad.861401; Saller E, 2001, EMBO REP, V2, P298, DOI 10.1093/embo-reports/kve068; SAWANO A, 2000, NUCLEIC ACIDS RES, V28, P78, DOI DOI 10.1093/NAR/28.16.E78; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Shi YG, 2001, BIOESSAYS, V23, P223, DOI 10.1002/1521-1878(200103)23:3<223::AID-BIES1032>3.3.CO;2-L; Sivasankaran R, 2000, EMBO J, V19, P6162, DOI 10.1093/emboj/19.22.6162; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Szuts D, 1998, GENE DEV, V12, P2022, DOI 10.1101/gad.12.13.2022; ten Dijke P, 2003, MOL CELL ENDOCRINOL, V211, P105, DOI 10.1016/j.mce.2003.09.016; Torres-Vazquez J, 2001, DEVELOPMENT, V128, P1657; Udagawa Y, 2000, GENES CELLS, V5, P359, DOI 10.1046/j.1365-2443.2000.00328.x; Vogel M, 2005, PROTEINS, V58, P478, DOI 10.1002/prot.20312; Waltzer L, 1999, EMBO J, V18, P1630, DOI 10.1093/emboj/18.6.1630; Wharton SJ, 2004, CURR BIOL, V14, P1550, DOI 10.1016/j.cub.2004.08.053; Wu JW, 2001, MOL CELL, V8, P1277, DOI 10.1016/S1097-2765(01)00421-X; Wu JW, 2001, J BIOL CHEM, V276, P20688, DOI 10.1074/jbc.M100174200; Xiao Z, 2000, P NATL ACAD SCI USA, V97, P7853, DOI 10.1073/pnas.97.14.7853; Xiao Z, 2001, J BIOL CHEM, V276, P39404, DOI 10.1074/jbc.M103117200; Xie T, 2000, SCIENCE, V290, P328, DOI 10.1126/science.290.5490.328; Xie T, 1998, CELL, V94, P251, DOI 10.1016/S0092-8674(00)81424-5; Xu M, 2005, DEVELOPMENT, V132, P1637, DOI 10.1242/dev.01722; Xu X, 1998, GENE DEV, V12, P2354, DOI 10.1101/gad.12.15.2354; Yeo CY, 1999, J BIOL CHEM, V274, P26584, DOI 10.1074/jbc.274.37.26584; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang HL, 2001, GENE DEV, V15, P261, DOI 10.1101/gad.861201; Zhang Y, 1998, NATURE, V396, P491, DOI 10.1038/24911; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	72	48	53	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36158	36164		10.1074/jbc.M506882200	http://dx.doi.org/10.1074/jbc.M506882200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16109720	hybrid			2022-12-27	WOS:000232726900047
J	Gordon, SM; Alon, N; Buchwald, M				Gordon, SM; Alon, N; Buchwald, M			FANCC, FANCE, and FANCD2 form a ternary complex essential to the integrity of the Fanconi anemia DNA damage response pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-COMPLEX; PROTEIN INTERACTIONS; UBIQUITIN LIGASE; YEAST 2-HYBRID; GENE; COMPLEMENTATION; ACCUMULATION; LOCALIZATION; SELECTION; INTERACT	Fanconi anemia ( FA) is a genetically heterogeneous disorder characterized by bone marrow failure, cancer predisposition, and increased cellular sensitivity to DNA-cross-linking agents. The products of seven of the nine identified FA genes participate in a protein complex required for monoubiquitination of the FANCD2 protein. Direct interaction of the FANCE protein with both fellow FA complex component FANCC and the downstream FANCD2 protein has been observed in the yeast two-hybrid system. Here, we demonstrate the ability of FANCE to mediate the interaction between FANCC and FANCD2 in the yeast three-hybrid system and confirm the FANCE-mediated association of FANCC with FANCD2 in human cells. A yeast two-hybrid system-based screen was devised to identify randomly mutagenized FANCE proteins capable of interaction with FANCC but not with FANCD2. Exogenous expression of these mutants in an FA-E cell line and subsequent evaluation of FANCD2 monoubiquitination and DNA crosslinker sensitivity indicated a critical role for the FANCE/FANCD2 interaction in maintaining FA pathway integrity. Three-hybrid experiments also demonstrated the ability of FANCE to mediate the interaction between FA core complex components FANCC and FANCF, indicating an additional role for FANCE in complex assembly. Thus, FANCE is shown to be a key mediator of protein interactions both in the architecture of the FA protein complex and in the connection of complex components to the putative downstream targets of complex activity.	Hosp Sick Children, Res Inst, Program Genet & Genom Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Gordon, SM (corresponding author), Hosp Sick Children, Res Inst, Program Genet & Genom Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	susan.gordon@utoronto.ca						Adachi D, 2002, HUM MOL GENET, V11, P3125, DOI 10.1093/hmg/11.25.3125; de Winter JP, 2000, NAT GENET, V24, P15, DOI 10.1038/71626; de Winter JP, 1998, NAT GENET, V20, P281, DOI 10.1038/3093; de Winter JP, 2000, AM J HUM GENET, V67, P1306, DOI 10.1016/S0002-9297(07)62959-0; de Winter JP, 2000, HUM MOL GENET, V9, P2665, DOI 10.1093/hmg/9.18.2665; Garcia-Higuera I, 2000, BLOOD, V96, P3224, DOI 10.1182/blood.V96.9.3224.h8003224_3224_3230; Garcia-Higuera I, 1999, MOL CELL BIOL, V19, P4866; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; GAVISH H, 1993, HUM MOL GENET, V2, P123, DOI 10.1093/hmg/2.2.123; Gordon SM, 2003, BLOOD, V102, P136, DOI 10.1182/blood-2002-11-3517; James P, 1996, GENETICS, V144, P1425; KIPPERT F, 1995, FEMS MICROBIOL LETT, V128, P201, DOI 10.1016/0378-1097(95)00113-J; Kupfer GM, 1997, NAT GENET, V17, P487, DOI 10.1038/ng1297-487; Leveille F, 2004, J BIOL CHEM, V279, P39421, DOI 10.1074/jbc.M407034200; Levitus M, 2004, BLOOD, V103, P2498, DOI 10.1182/blood-2003-08-2915; Lightfoot J, 1999, HUM MOL GENET, V8, P1007, DOI 10.1093/hmg/8.6.1007; LO TF, 1996, NAT GENET, V14, P320; Medhurst AL, 2001, HUM MOL GENET, V10, P423, DOI 10.1093/hmg/10.4.423; Meetei AR, 2003, MOL CELL BIOL, V23, P3417, DOI 10.1128/MCB.23.10.3417-3426.2003; Meetei AR, 2003, NAT GENET, V35, P165, DOI 10.1038/ng1241; Meetei AR, 2004, NAT GENET, V36, P1219, DOI 10.1038/ng1458; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Pace P, 2002, EMBO J, V21, P3414, DOI 10.1093/emboj/cdf355; Pause A, 1999, P NATL ACAD SCI USA, V96, P9533, DOI 10.1073/pnas.96.17.9533; Schild D, 2000, J BIOL CHEM, V275, P16443, DOI 10.1074/jbc.M001473200; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; Taniguchi T, 2002, BLOOD, V100, P2457, DOI 10.1182/blood-2002-03-0860; Thomashevski A, 2004, J BIOL CHEM, V279, P26201, DOI 10.1074/jbc.M400091200; Wang XZ, 2004, MOL CELL BIOL, V24, P5850, DOI 10.1128/MCB.24.13.5850-5862.2004; Yamashita T, 1998, P NATL ACAD SCI USA, V95, P13085, DOI 10.1073/pnas.95.22.13085; YOUSSOUFIAN H, 1994, P NATL ACAD SCI USA, V91, P7975, DOI 10.1073/pnas.91.17.7975	33	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36118	36125		10.1074/jbc.M507758200	http://dx.doi.org/10.1074/jbc.M507758200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16127171	hybrid			2022-12-27	WOS:000232726900042
J	Lange, Y; Ye, J; Steck, TL				Lange, Y; Ye, J; Steck, TL			Activation of membrane cholesterol by displacement from phospholipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-CELL MEMBRANE; LIPID-BILAYERS; MAXIMUM SOLUBILITY; HUMAN-FIBROBLASTS; STEROL STRUCTURE; SPHINGOMYELIN; MOVEMENT; MODEL; CYCLODEXTRIN; CALORIMETRY	We tested the hypothesis that certain membrane-intercalating agents increase the chemical activity of cholesterol by displacing it from its low activity association with phospholipids. Octanol, 1,2-dioctanoyl-sn- glycerol ( a diglyceride), and N-hexanoyl-D-erythrosphingosine ( a ceramide) were shown to increase both the rate of transfer and the extent of equilibrium partition of human red blood cell cholesterol to methyl-beta-cyclodextrin. These agents also promoted the interaction of the sterol with two cholesterol-specific probes, cholesterol oxidase and saponin. Expanding the pool of bilayer phospholipids with lysophosphatides countered these effects. The three intercalators also protected the red cells against lysis by cholesterol depletion as if substituting for the extracted sterol. As is the case for excess plasmamembrane cholesterol, treating human fibroblasts with octanol, diglyceride, or ceramide stimulated the rapid inactivation of their hydroxymethylglutaryl-CoA reductase, presumably through an increase in the pool of endoplasmic reticulum cholesterol. These data supported the stated hypothesis and point to competition between cholesterol and endogenous and exogenous intercalators for association with membrane phospholipids. We also describe simple screens using red cells in a microtiter well format to identify intercalating agents that increase or decrease the activity of membrane cholesterol.	Rush Univ, Med Ctr, Dept Pathol, Chicago, IL 60612 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	Rush University; University of Chicago	Lange, Y (corresponding author), Rush Univ, Med Ctr, Dept Pathol, 1653 W Congress Pkwy, Chicago, IL 60612 USA.	ylange@rush.edu	Lange, Yvonne/A-7794-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R55HL028448, R01HL028448] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 28448] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beattie ME, 2005, BIOPHYS J, V89, P1760, DOI 10.1529/biophysj.104.049635; BLOOM M, 1991, Q REV BIOPHYS, V24, P293, DOI 10.1017/S0033583500003735; Chen XY, 2000, BIOCHEMISTRY-US, V39, P13383, DOI 10.1021/bi001407j; Chiu SW, 2002, BIOPHYS J, V83, P1842, DOI 10.1016/S0006-3495(02)73949-0; COOPER RA, 1978, J SUPRAMOL STR CELL, V8, P413, DOI 10.1002/jss.400080404; Francis G, 2002, BRIT J NUTR, V88, P587, DOI 10.1079/BJN2002725; GUPTA AK, 1991, J LIPID RES, V32, P125; Holopainen JM, 2004, BIOPHYS J, V86, P1510, DOI 10.1016/S0006-3495(04)74219-8; Huang JY, 1999, BIOPHYS J, V76, P2142, DOI 10.1016/S0006-3495(99)77369-8; Huang JY, 1999, BBA-BIOMEMBRANES, V1417, P89, DOI 10.1016/S0005-2736(98)00260-0; Khelashvili GA, 2005, J CHEM PHYS, V123, DOI 10.1063/1.1943412; Lange Y, 2000, J BIOL CHEM, V275, P17468, DOI 10.1074/jbc.M000875200; Lange Y, 2004, P NATL ACAD SCI USA, V101, P11664, DOI 10.1073/pnas.0404766101; LANGE Y, 1991, J BIOL CHEM, V266, P21439; LANGE Y, 1984, BIOCHIM BIOPHYS ACTA, V769, P551, DOI 10.1016/0005-2736(84)90053-1; LANGE Y, 1980, J BIOL CHEM, V255, P9331; Lange Y, 1999, J LIPID RES, V40, P2264; LANGE Y, 1989, J BIOL CHEM, V264, P3786; London E, 2002, CURR OPIN STRUC BIOL, V12, P480, DOI 10.1016/S0959-440X(02)00351-2; London M, 2004, J BIOL CHEM, V279, P9997, DOI 10.1074/jbc.M309992200; Mannock DA, 2003, BIOPHYS J, V84, P1038, DOI 10.1016/S0006-3495(03)74920-0; McConnell HM, 2003, BBA-BIOMEMBRANES, V1610, P159, DOI 10.1016/S0005-2736(03)00015-4; NISHIKAWA M, 1984, J BIOCHEM-TOKYO, V96, P1231, DOI 10.1093/oxfordjournals.jbchem.a134941; OHNOIWASHITA Y, 1992, BIOCHIM BIOPHYS ACTA, V1109, P81, DOI 10.1016/0005-2736(92)90190-W; Radhakrishnan A, 2000, BIOCHEMISTRY-US, V39, P8119, DOI 10.1021/bi0005097; RIDGWAY ND, 1995, BBA-LIPID LIPID MET, V1256, P39, DOI 10.1016/0005-2760(95)00009-2; Rowe ES, 1998, BIOCHEMISTRY-US, V37, P2430, DOI 10.1021/bi9721602; Sever N, 2003, J BIOL CHEM, V278, P52479, DOI 10.1074/jbc.M310053200; Steck T L, 1974, Methods Enzymol, V31, P172; Steck TL, 2002, BIOPHYS J, V83, P2118, DOI 10.1016/S0006-3495(02)73972-6; Tsamaloukas A, 2005, BIOPHYS J, V89, P1109, DOI 10.1529/biophysj.105.061846; van Blitterswijk WJ, 2003, BIOCHEM J, V369, P199, DOI 10.1042/BJ20021528; Waheed AA, 2001, P NATL ACAD SCI USA, V98, P4926, DOI 10.1073/pnas.091090798; Xu XL, 2001, J BIOL CHEM, V276, P33540, DOI 10.1074/jbc.M104776200; Xu XL, 2000, BIOCHEMISTRY-US, V39, P843, DOI 10.1021/bi992543v; Yancey PG, 2003, ARTERIOSCL THROM VAS, V23, P712, DOI 10.1161/01.ATV.0000057572.97137.DD; YEAGLE PL, 1985, BIOCHIM BIOPHYS ACTA, V822, P267, DOI 10.1016/0304-4157(85)90011-5; Zitzer A, 2001, J BIOL CHEM, V276, P14628, DOI 10.1074/jbc.M100241200	38	69	69	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36126	36131		10.1074/jbc.M507149200	http://dx.doi.org/10.1074/jbc.M507149200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16129675	hybrid			2022-12-27	WOS:000232726900043
J	Lievremont, JP; Numaga, T; Vazquez, G; Lemonnier, L; Hara, Y; Mori, E; Trebak, M; Moss, SE; Bird, GS; Mori, Y; Putney, JW				Lievremont, JP; Numaga, T; Vazquez, G; Lemonnier, L; Hara, Y; Mori, E; Trebak, M; Moss, SE; Bird, GS; Mori, Y; Putney, JW			The role of canonical transient receptor potential 7 in B-cell receptor-activated channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CA2+ ENTRY; TRANSIENT RECEPTOR; CATION ENTRY; ENDOPLASMIC-RETICULUM; CALCIUM CURRENT; TRPC3 CHANNELS; RELEASE; EXPRESSION; PROTEIN; MOBILIZATION	Phospholipase C signaling stimulates Ca2+ entry across the plasma membrane through multiple mechanisms. Ca2+ store depletion stimulates store- operated Ca2+- selective channels, or alternatively, other phospholipase C- dependent events activate Ca2+- permeable non- selective cation channels. Transient receptor potential 7 ( TRPC7) is a non- selective cation channel that can be activated by both mechanisms when ectopically expressed, but the regulation of native TRPC7 channels is not known. We knocked out TRPC7 in DT40 B- cells, which expresses both forms of Ca2+ entry. No difference in the store- operated current I-crac was detected between TRPC7 (-/-) and wild- type cells. Wild- type cells demonstrated non-store-operated cation entry and currents in response to activation of the B- cell receptor or protease- activated receptor 2, intracellular dialysis with GTP gamma S, or application of the synthetic diacylglycerol oleyl- acetyl- glycerol. These responses were absent in TRPC7 (-/-) cells but could be restored by transfection with human TRPC7. In conclusion, in B- lymphocytes, TRPC7 appeared to participate in the formation of ion channels that could be activated by phospholipase C- linked receptors. This represents the first demonstration of a physiological function for endogenous TRPC7 channels.	NIEHS, Dept Hlth & Human Serv, NIH, Res Triangle Pk, NC 27709 USA; Kyoto Univ, Grad Sch Engn, Dept Synthet Chem & Biol Chem, Mol Biol Lab, Kyoto 6158510, Japan; UCL, Inst Ophthalmol, Div Cell Biol, London EC1V 9EL, England	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Kyoto University; University of London; University College London	Putney, JW (corresponding author), NIEHS, Dept Hlth & Human Serv, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	putney@niehs.nih.gov	Bird, Gary/AAI-8186-2021; Lemonnier, Loic/L-7289-2018; Putney, James W/F-7247-2019; Trebak, Mohamed/E-7405-2014	Bird, Gary/0000-0003-1389-8748; Lemonnier, Loic/0000-0001-6200-5382; Putney, James W/0000-0002-3379-4789; 	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090087, Z01ES090087] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Broad LM, 1996, BIOCHEM J, V316, P759, DOI 10.1042/bj3160759; Broad LM, 2001, J BIOL CHEM, V276, P15945, DOI 10.1074/jbc.M011571200; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; BYRON KL, 1995, J PHYSIOL-LONDON, V485, P455, DOI 10.1113/jphysiol.1995.sp020742; Grafton G, 2001, IMMUNOLOGY, V104, P119, DOI 10.1046/j.0019-2805.2001.01321.x; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Kiselyov K, 2001, BIOCHEM J, V360, P17, DOI 10.1042/0264-6021:3600017; KWAN CY, 1990, J BIOL CHEM, V265, P678; Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793; Lievremont JP, 2004, AM J PHYSIOL-CELL PH, V287, pC1709, DOI 10.1152/ajpcell.00350.2004; Mori Y, 2002, J EXP MED, V195, P673, DOI 10.1084/jem.20011758; Morita T, 2004, BIOCHEM J, V382, P793, DOI 10.1042/BJ20031970; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Patterson RL, 2002, CELL, V111, P529, DOI 10.1016/S0092-8674(02)01045-0; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Putney JW, 2004, TRENDS CELL BIOL, V14, P282, DOI 10.1016/j.tcb.2004.04.002; Riccio A, 2002, J BIOL CHEM, V277, P12302, DOI 10.1074/jbc.M112313200; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Trebak M, 2003, J BIOL CHEM, V278, P16244, DOI 10.1074/jbc.M300544200; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; Trepakova ES, 2001, J BIOL CHEM, V276, P7782, DOI 10.1074/jbc.M010104200; Turner H, 2003, BIOCHEM J, V371, P341, DOI 10.1042/BJ20021381; van Rossum DB, 2004, P NATL ACAD SCI USA, V101, P2323, DOI 10.1073/pnas.0308565100; Vazquez G, 2004, BBA-MOL CELL RES, V1742, P21, DOI 10.1016/j.bbamcr.2004.08.015; Vazquez G, 2003, J BIOL CHEM, V278, P21649, DOI 10.1074/jbc.M302162200; Vazquez G, 2002, EMBO J, V21, P4531, DOI 10.1093/emboj/cdf467; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Venkatachalam K, 2001, J BIOL CHEM, V276, P33980, DOI 10.1074/jbc.C100321200; Wisnoskey BJ, 2003, BIOCHEM J, V372, P517, DOI 10.1042/BJ20021574	31	44	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35346	35351		10.1074/jbc.M507606200	http://dx.doi.org/10.1074/jbc.M507606200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16123040	hybrid			2022-12-27	WOS:000232561200033
J	Wooten, MW; Geetha, T; Seibehener, ML; Babu, JR; Diaz-Meco, MT; Moscat, J				Wooten, MW; Geetha, T; Seibehener, ML; Babu, JR; Diaz-Meco, MT; Moscat, J			The p62 scaffold regulates nerve growth factor-induced NF-kappa B activation by influencing TRAF6 polyubiquitination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; P75 NEUROTROPHIN RECEPTOR; UBIQUITIN LIGASE ACTIVITY; BINDING-PROTEIN; PC12 CELLS; COMPLEX; IKK; DIFFERENTIATION; LOCALIZATION; CHANNELS	Sequestosome 1/p62 is a scaffolding protein with several interaction modules that include a PB1 dimerization domain, a TRAF6 (tumor necrosis factor receptor-associated factor 6) binding site, and a ubiquitin-associating (UBA) domain. Here, we report that p62 functions to facilitate K63-polyubiquitination of TRAF6 and thereby mediates nerve growth factor-induced activation of the NF-kappa B pathway. In brain of p62 knock-out mice we did not recover polyubiquitinated TRAF6. The UBA domain binds polyubiquitin chains and deletion of p62-UBA domain or mutation of F406V within the ubiquitin binding pocket of the UBA domain abolished TRAF6 polyubiquitination. Likewise, deletion of p62 N-terminal dimerization domain or the TRAF6 binding site had similar effects on both polyubiquitination and oligomerization of TRAF6. Nerve growth factor treatment of PC12 cells induced TRAF6 polyubiquitination along with formation of a p62-TRAF6-IKK beta-PKC iota signal complex, while inhibition of the p62/TRAF6 interaction had an opposite effect. These results provide evidence for a mechanism whereby p62 serves to regulate the NF-kappa B pathway.	Auburn Univ, Dept Biol Sci, Program Cell & Mol Biosci, Auburn, AL 36849 USA; Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Auburn University System; Auburn University; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Moscat, J (corresponding author), Auburn Univ, Dept Biol Sci, Program Cell & Mol Biosci, 331 Funchess Hall, Auburn, AL 36849 USA.	wootemw@auburn.edu	Thangiah, Geetha/W-6796-2019; Moscat, Jorge/A-7011-2009	Ramesh Babu, Jeganathan/0000-0002-3719-932X; Diaz-Meco, Maria/0000-0003-0147-0998	DS NIH HHS [NINDS 33661] Funding Source: Medline	DS NIH HHS		Badciong JC, 2002, J BIOL CHEM, V277, P49668, DOI 10.1074/jbc.M208593200; BHAKAR AL, 2002, J NEUROSCI, V22, P8465; Croci C, 2003, J BIOL CHEM, V278, P6128, DOI 10.1074/jbc.M205162200; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Duran A, 2004, DEV CELL, V6, P303, DOI 10.1016/S1534-5807(03)00403-9; Ea CK, 2004, P NATL ACAD SCI USA, V101, P15318, DOI 10.1073/pnas.0404132101; Feng YF, 2005, MOL CELL BIOL, V25, P4010, DOI 10.1128/MCB.25.10.4010-4022.2005; Foehr ED, 2000, J NEUROSCI, V20, P7556; Geetha T, 2002, FEBS LETT, V512, P19, DOI 10.1016/S0014-5793(02)02286-X; Gong JP, 1999, SCIENCE, V285, P1565, DOI 10.1126/science.285.5433.1565; Hocking LJ, 2004, J BONE MINER RES, V19, P1122, DOI 10.1359/JBMR.0403015; Hughes AL, 2001, J NEUROSCI RES, V63, P10, DOI 10.1002/1097-4547(20010101)63:1<10::AID-JNR2>3.0.CO;2-R; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Lamark T, 2003, J BIOL CHEM, V278, P34568, DOI 10.1074/jbc.M303221200; Mallery DL, 2002, EMBO J, V21, P6755, DOI 10.1093/emboj/cdf691; Mamidipudi V, 2002, J BIOL CHEM, V277, P28010, DOI 10.1074/jbc.M109730200; Moscat J, 2000, EMBO REP, V1, P399, DOI 10.1093/embo-reports/kvd098; ONEILL L, 1997, TRENDS NEUROSCI, V29, P252; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; RASSI S, 2005, NAT STRUCT MOL BIOL, V8, P708; Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1; Samuels IS, 2001, J CELL BIOCHEM, V82, P452, DOI 10.1002/jcb.1177; Sanchez P, 1998, MOL CELL BIOL, V18, P3069, DOI 10.1128/MCB.18.5.3069; Sanz L, 2000, EMBO J, V19, P1576, DOI 10.1093/emboj/19.7.1576; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Seibenhener ML, 2004, MOL CELL BIOL, V24, P8055, DOI 10.1128/MCB.24.18.8055-8068.2004; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wooten MW, 2001, J BIOL CHEM, V276, P7709, DOI 10.1074/jbc.C000869200; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888	33	165	183	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35625	35629		10.1074/jbc.C500237200	http://dx.doi.org/10.1074/jbc.C500237200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16079148	hybrid			2022-12-27	WOS:000232561200065
J	Han, SJ; Hamdan, FF; Kim, SK; Jacobson, KA; Bloodworth, LM; Li, B; Wess, J				Han, SJ; Hamdan, FF; Kim, SK; Jacobson, KA; Bloodworth, LM; Li, B; Wess, J			Identification of an agonist-induced conformational change occurring adjacent to the ligand-binding pocket of the M-3 muscarinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2) ADRENERGIC-RECEPTOR; SITE-DIRECTED MUTAGENESIS; TRANSMEMBRANE DOMAINS III; CROSS-LINKING STRATEGY; CONSTITUTIVE ACTIVATION; RHODOPSIN STRUCTURE; TYROSINE RESIDUES; CRYSTAL-STRUCTURE; M3-MUSCARINIC-RECEPTOR	To study the conformational changes that convert G protein-coupled receptors (GPCRs) from their resting to their active state, we used the M-3 muscarinic acetylcholine receptor, a prototypical class A GPCR, as a model system. Specifically, we employed a recently developed in situ disulfide cross-linking strategy that allows the formation of disulfide bonds in Cys-substituted mutant M-3 muscarinic receptors present in their native membrane environment. At present, little is known about the conformational changes that GPCR ligands induce in the immediate vicinity of the ligand-binding pocket. To address this issue, we generated 11 Cys-substituted mutant M-3 muscarinic receptors and characterized these receptors in transfected COS-7 cells. All analyzed mutant receptors contained an endogenous Cys residue (Cys-532(7.42)) located within the exofacial segment of transmembrane domain (TM) VII, close to the agonist-binding site. In addition, all mutant receptors harbored a second Cys residue that was introduced into the exofacial segment of TM III, within the sequence Leu-142(3.27)-Asn-152(3.37). Disulfide cross-linking studies showed that muscarinic agonists, but not antagonists, promoted the formation of a disulfide bond between S151(3.36)C and Cys-532. A three-dimensional model of the inactive state of the M-3 muscarinic receptor indicated that Cys-532 and Ser-151 face each other in the center of the TM receptor core. Our cross-linking data therefore support the concept that agonist activation pulls the exofacial segments of TMs VII and III closer to each other. This structural change may represent one of the early conformational events triggering the more pronounced structural reorganization of the intracellular receptor surface. To the best of our knowledge, this is the first direct demonstration of a conformational change occurring in the immediate vicinity of the binding site of a GPCR activated by a diffusible ligand.	NIDDK, Mol Signaling Sect, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Mol Recognit Sect, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Wess, J (corresponding author), NIDDK, Mol Signaling Sect, Bioorgan Chem Lab, NIH, Bldg 8A,Rm B1A-05,MSC 0810, Bethesda, MD 20892 USA.	jwess@helix.nih.gov	Han, Sung-Jun/B-9547-2012; Jacobson, Kenneth Alan/A-1530-2009	Jacobson, Kenneth Alan/0000-0001-8104-1493	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK032003] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allman K, 2000, MOL PHARMACOL, V58, P175, DOI 10.1124/mol.58.1.175; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; BARLOW RB, 1964, INTRODUCTION CHEMICA, P185; Bissantz C, 2003, J RECEPT SIG TRANSD, V23, P123, DOI 10.1081/RRS-120025192; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; CAREAGA CL, 1992, J MOL BIOL, V226, P1219, DOI 10.1016/0022-2836(92)91063-U; Elling CE, 1999, P NATL ACAD SCI USA, V96, P12322, DOI 10.1073/pnas.96.22.12322; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Foord SM, 2002, CURR OPIN PHARMACOL, V2, P561, DOI 10.1016/S1471-4892(02)00214-X; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; Furukawa H, 2002, MOL PHARMACOL, V62, P778, DOI 10.1124/mol.62.4.778; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; Gerber BO, 2001, J BIOL CHEM, V276, P3394, DOI 10.1074/jbc.M007748200; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; Halgren TA, 1999, J COMPUT CHEM, V20, P730, DOI 10.1002/(SICI)1096-987X(199905)20:7<730::AID-JCC8>3.0.CO;2-T; Hamdan FF, 2002, BIOCHEMISTRY-US, V41, P7647, DOI 10.1021/bi016029c; Han SJ, 2005, J BIOL CHEM, V280, P24870, DOI 10.1074/jbc.M500379200; Heitz F, 1999, EUR J PHARMACOL, V380, P183, DOI 10.1016/S0014-2999(99)00439-2; Holst B, 2000, MOL PHARMACOL, V58, P263, DOI 10.1124/mol.58.2.263; HOLTON P, 1949, BRIT J PHARM CHEMOTH, V4, P190, DOI 10.1111/j.1476-5381.1949.tb00535.x; Hubbell WL, 2003, ADV PROTEIN CHEM, V63, P243; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; Jensen AD, 2001, J BIOL CHEM, V276, P9279, DOI 10.1074/jbc.M004871200; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; JinsiParimoo A, 1997, ENDOCRINOLOGY, V138, P1471, DOI 10.1210/en.138.4.1471; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; Lu ZL, 1999, J BIOL CHEM, V274, P7309, DOI 10.1074/jbc.274.11.7309; Lu ZL, 2002, TRENDS PHARMACOL SCI, V23, P140, DOI 10.1016/S0165-6147(00)01973-8; Ma JC, 1997, CHEM REV, V97, P1303, DOI 10.1021/cr9603744; Meng EC, 2001, TRENDS PHARMACOL SCI, V22, P587, DOI 10.1016/S0165-6147(00)01825-3; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Rasmussen SGF, 1999, MOL PHARMACOL, V56, P175, DOI 10.1124/mol.56.1.175; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; Sakmar TP, 2002, ANNU REV BIOPH BIOM, V31, P443, DOI 10.1146/annurev.biophys.31.082901.134348; SCHADLOW VC, 1992, MOL BIOL CELL, V3, P941, DOI 10.1091/mbc.3.8.941; Scrutton NS, 1996, BIOCHEM J, V319, P1; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Shi L, 2002, ANNU REV PHARMACOL, V42, P437, DOI 10.1146/annurev.pharmtox.42.091101.144224; SRINIVASAN N, 1990, INT J PEPT PROT RES, V36, P147; STEWART JJP, 1990, J COMPUT AID MOL DES, V4, P1, DOI 10.1007/BF00128336; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Struthers M, 1999, BIOCHEMISTRY-US, V38, P6597, DOI 10.1021/bi9902384; Takeda S, 2002, FEBS LETT, V520, P97, DOI 10.1016/S0014-5793(02)02775-8; Ward SDC, 2002, J BIOL CHEM, V277, P2247, DOI 10.1074/jbc.M107647200; WESS J, 1992, J BIOL CHEM, V267, P19313; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x; Wess J, 1996, CRIT REV NEUROBIOL, V10, P69, DOI 10.1615/CritRevNeurobiol.v10.i1.40; WESS J, 1990, COMPREHENSIVE MED CH, V3, P423; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487; Zeng FY, 1999, J NEUROCHEM, V72, P2404, DOI 10.1046/j.1471-4159.1999.0722404.x; Zeng FY, 1999, J BIOL CHEM, V274, P16629, DOI 10.1074/jbc.274.23.16629	59	41	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34849	34858		10.1074/jbc.M506711200	http://dx.doi.org/10.1074/jbc.M506711200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16093246	hybrid			2022-12-27	WOS:000232403900057
J	Chattopadhyay, S; Santhamma, KR; Sengupta, S; McCue, B; Kinter, M; Sen, GC; Sen, I				Chattopadhyay, S; Santhamma, KR; Sengupta, S; McCue, B; Kinter, M; Sen, GC; Sen, I			Calmodulin binds to the cytoplasmic domain of angiotensin-converting enzyme and regulates its phosphorylation and cleavage secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; L-SELECTIN; PLASMA-MEMBRANE; CELL-SURFACE; PROTEIN; ECTODOMAIN; METALLOPROTEINASE; GROWTH; PRECURSOR; ADAM17	The rate of cleavage secretion of the enzymatically active ectodomain of angiotensin-converting enzyme ( ACE) is regulated by tyrosine phosphorylation of the protein and by the phorbol ester, phorbol 12-myristate 13-acetate (PMA), an activator of protein kinase C. Here, we report that both calmodulin inhibitor (CaMI) and calmodulin kinase inhibitor could also enhance cleavage secretion of ACE. This effect was accompanied by the dissociation of calmodulin from a specific region within the cytoplasmic domain of ACE to which it had been bound. The same domain of ACE was phosphorylated, and both CaMI and PMA caused dephosphorylation of ACE as well. Mass spectrometric and mutational analyses identified Ser(730) as the only phosphorylated residue in the cytoplasmic domain of ACE. The Ser(730) --> Ala mutant of ACE was not phosphorylated, but it still bound calmodulin, and its cleavage secretion was enhanced by both CaMI and PMA. Similarly, when Ser(730) was replaced by the phosphoserine mimetic, Asp, cleavage secretion of the resultant mutant remained susceptible to the enhancing effect of CaMI and PMA. These results demonstrate that, although CaMI and PMA can enhance both cleavage secretion of ACE and its dephosphorylation, the two effects are not mutually interdependent.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Genet, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Sen, I (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, NB50,9500 Euclid Ave, Cleveland, OH 44195 USA.	seni@ccf.org		Kinter, Michael/0000-0001-7409-8918	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048258, R01HL054297] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48258, HL54297] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allinson TMJ, 2004, EUR J BIOCHEM, V271, P2539, DOI 10.1111/j.1432-1033.2004.04184.x; Annabi B, 2001, BIOCHEM J, V359, P325, DOI 10.1042/0264-6021:3590325; Arribas J, 2003, CURR TOP DEV BIOL, V54, P125, DOI 10.1016/S0070-2153(03)54007-8; Arribas J, 2002, CHEM REV, V102, P4627, DOI 10.1021/cr010202t; Bauvois B, 2004, ONCOGENE, V23, P317, DOI 10.1038/sj.onc.1207124; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Blobel CP, 2002, INFLAMM RES, V51, P83, DOI 10.1007/BF02684007; Borrell-Pages M, 2003, EMBO J, V22, P1114, DOI 10.1093/emboj/cdg111; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Diaz-Rodriguez E, 2000, BIOCHEM J, V346, P359, DOI 10.1042/0264-6021:3460359; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; Ehlers M R, 1991, Protein Expr Purif, V2, P1, DOI 10.1016/1046-5928(91)90001-Y; Gardiner EE, 2004, BLOOD, V104, P3611, DOI 10.1182/blood-2004-04-1549; Gomez-Gaviro MV, 2002, J BIOL CHEM, V277, P38212, DOI 10.1074/jbc.M205142200; Hinkle CL, 2004, J BIOL CHEM, V279, P24179, DOI 10.1074/jbc.M312141200; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; Kahn J, 1998, CELL, V92, P809, DOI 10.1016/S0092-8674(00)81408-7; Kessler SP, 2003, J BIOL CHEM, V278, P21105, DOI 10.1074/jbc.M3023472000; KINTER M, 2000, PROTEIN SEQUENCING I, P166; Kohlstedt K, 2002, CIRC RES, V91, P749, DOI 10.1161/01.RES.0000038114.17939.C8; KUMAR RS, 1991, J BIOL CHEM, V266, P3854; Matala E, 2001, J IMMUNOL, V167, P1617, DOI 10.4049/jimmunol.167.3.1617; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Nagano O, 2004, J CELL BIOL, V165, P893, DOI 10.1083/jcb.200310024; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; RAMCHANDRAN R, 1995, BIOCHEMISTRY-US, V34, P12645, DOI 10.1021/bi00039a021; Ramchandran R, 1996, AM J PHYSIOL-HEART C, V271, pH744, DOI 10.1152/ajpheart.1996.271.2.H744; RAMCHANDRAN R, 1994, J BIOL CHEM, V269, P2125; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Sadhukhan R, 1999, J BIOL CHEM, V274, P10511, DOI 10.1074/jbc.274.15.10511; Sadhukhan R, 1998, P NATL ACAD SCI USA, V95, P138, DOI 10.1073/pnas.95.1.138; Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137; Santhamma KR, 2000, J BIOL CHEM, V275, P23253, DOI 10.1074/jbc.M000593200; Santhamma KR, 2004, J BIOL CHEM, V279, P40227, DOI 10.1074/jbc.M407176200; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Scarpati EM, 1996, J BIOL CHEM, V271, P3025, DOI 10.1074/jbc.271.6.3025; Schlondorff J, 1999, J CELL SCI, V112, P3603; SEN I, 1991, J BIOL CHEM, V266, P21985; SEN I, 1993, J BIOL CHEM, V268, P25748; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279	44	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33847	33855		10.1074/jbc.M501718200	http://dx.doi.org/10.1074/jbc.M501718200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16096279	hybrid			2022-12-27	WOS:000232229700021
J	Ishaq, M; DeGray, G; Natarajan, V				Ishaq, M; DeGray, G; Natarajan, V			Evidence for the involvement of tyrosine kinase ZAP 70 in nuclear retinoid receptor-dependent transactivation in T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; X-RECEPTOR; PROTEIN; ACTIVATION; PHOSPHORYLATION; PHOSPHATASES; THYMOCYTES; FAMILY; ALPHA	Retinoic acid receptors (RARs) and retinoid X receptors (RXRs) are transcription factors that control diverse cellular functions during development and homeostasis. The biochemical role of these proteins in T lymphocytes is not well known. Here we have studied the role of protein-tyrosine kinase ZAP70, a key enzyme involved in the proximal signaling events during T cell activation, in the modulation of RXRE- and RARE-dependent activation in T lymphocytes. Surprisingly, ZAP 70-negative Jurkat T cells showed considerable loss of both RXRE- and RARE-mediated transactivation as compared with wild type Jurkat cells. In addition, ZAP 70-negative cells failed to exhibit normal protein kinase C theta and calcineurin-induced transcriptional activity. ZAP 70-negative cells that were reconstituted with active ZAP 70 regained the transactivation function, whereas cells expressing kinase-dead form of ZAP 70 failed to do so. Defective transcriptional activation was also observed in actively proliferating human peripheral blood T lymphocytes in which RNA interference was used to induce loss of ZAP 70 expression. In addition, an Lck-deficient Jurkat cell line that cannot efficiently activate ZAP 70 was also found defective in RXRE- mediated transcription. Finally, RNA interference-induced loss of ZAP 70 or Lck protein in Jurkat cells resulted in significant decrease in the RXRE- dependent activation. Together, these results suggest a novel functional role for ZAP 70 in nuclear receptor-driven transactivation in T lymphocytes.	NCI, Mol Cell Biol Lab, SAIC, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Ishaq, M (corresponding author), NCI, Mol Cell Biol Lab, SAIC, NIH, Frederick, MD 21702 USA.	mishaq@nih.gov			NCI NIH HHS [N01-CO-12400] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alonso A, 2003, NAT IMMUNOL, V4, P44, DOI 10.1038/ni856; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; Elder ME, 1998, SEMIN HEMATOL, V35, P310; Herndon TM, 2001, J IMMUNOL, V166, P5654, DOI 10.4049/jimmunol.166.9.5654; Huang YP, 2004, J BIOL CHEM, V279, P28827, DOI 10.1074/jbc.R400012200; Ishaq M, 2000, J IMMUNOL, V165, P4217, DOI 10.4049/jimmunol.165.8.4217; Ishaq M, 2003, J BIOL CHEM, V278, P39296, DOI 10.1074/jbc.M302767200; Ishaq M, 2002, J IMMUNOL, V169, P732, DOI 10.4049/jimmunol.169.2.732; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Latour S, 2001, CURR OPIN IMMUNOL, V13, P299, DOI 10.1016/S0952-7915(00)00219-3; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; Pitcher LA, 2003, TRENDS IMMUNOL, V24, P554, DOI 10.1016/j.it.2003.08.003; Rastinejad F, 2001, CURR OPIN STRUC BIOL, V11, P33, DOI 10.1016/S0959-440X(00)00165-2; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; Saxena M, 2000, SEMIN IMMUNOL, V12, P387, DOI 10.1006/smim.2000.0219; SloanLancaster J, 1997, J EXP MED, V186, P1713, DOI 10.1084/jem.186.10.1713; vanOers NSC, 1996, J EXP MED, V183, P1053, DOI 10.1084/jem.183.3.1053; WANGE RL, 1995, J BIOL CHEM, V270, P944, DOI 10.1074/jbc.270.2.944; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388	23	6	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34152	34158		10.1074/jbc.M501547200	http://dx.doi.org/10.1074/jbc.M501547200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16096284	hybrid			2022-12-27	WOS:000232229700056
J	Zhou, R; Silverman, N; Hong, M; Liao, DS; Chung, Y; Chen, ZJJ; Maniatis, T				Zhou, R; Silverman, N; Hong, M; Liao, DS; Chung, Y; Chen, ZJJ; Maniatis, T			The role of ubiquitination in Drosophila innate immunity.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PEPTIDOGLYCAN RECOGNITION PROTEIN; SITE-SPECIFIC PHOSPHORYLATION; SIGNALING PATHWAYS; POLYUBIQUITIN CHAINS; PROTEASOME PATHWAY; KINASE-ACTIVITY; DEFICIENCY IMD; CASPASE DREDD; FACTOR RELISH	Infection of Drosophila by Gram-negative bacteria triggers a signal transduction pathway ( the IMD pathway) culminating in the expression of genes encoding antimicrobial peptides. A key component in this pathway is a Drosophila I kappa B kinase (DmIKK) complex, which stimulates the cleavage and activation of the NF-kappa B transcription factor Relish. Activation of the DmIKK complex requires the MAP3K dTAK1, but the mechanism of dTAK1 activation is not understood. In human cells, the activation of TAK1 and IKK requires the human ubiquitin-conjugating enzymes Ubc13 and UEV1a. Here we demonstrate that the Drosophila homologs of Ubc13 and UEV1a are similarly required for the activation of dTAK1 and the DmIKK complex. Surprisingly, we find that the Drosophila caspase DREDD and its partner dFADD are required for the activation of DmIKK and JNK, in addition to their role in Relish cleavage. These studies reveal an evolutionarily conserved role of ubiquitination in IKK activation, and provide new insights into the hierarchy of signaling components in the Drosophila antibacterial immunity pathway.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Univ Massachusetts, Sch Med, Dept Med, Div Infect Dis, Worcester, MA 01605 USA; Univ Texas, SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA	Harvard University; University of Massachusetts System; University of Massachusetts Worcester; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Maniatis, T (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 7 Divin Ave, Cambridge, MA 02138 USA.	maniatis@mcb.harvard.edu	Chen, Zhijian/C-6039-2012	Chen, Zhijian/0000-0002-8475-8251; Silverman, Neal/0000-0002-4259-456X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060025, R56AI060025] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063692, R01GM029379, R01GM059919] Funding Source: NIH RePORTER; NIAID NIH HHS [AI060025] Funding Source: Medline; NIGMS NIH HHS [GM29379, GM59919, GM63692] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boutros M, 2002, DEV CELL, V3, P711, DOI 10.1016/S1534-5807(02)00325-8; Cha GH, 2003, MOL CELL BIOL, V23, P7982, DOI 10.1128/MCB.23.22.7982-7991.2003; Chen W, 2002, J BIOL CHEM, V277, P49105, DOI 10.1074/jbc.M204934200; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Choe KM, 2005, P NATL ACAD SCI USA, V102, P1122, DOI 10.1073/pnas.0404952102; Choe KM, 2002, SCIENCE, V296, P359, DOI 10.1126/science.1070216; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Dimarcq JL, 1997, INSECT BIOCHEM MOLEC, V27, P877, DOI 10.1016/S0965-1748(97)00072-6; Georgel P, 2001, DEV CELL, V1, P503, DOI 10.1016/S1534-5807(01)00059-4; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Hoffmann JA, 1997, TRENDS CELL BIOL, V7, P309, DOI 10.1016/S0962-8924(97)01087-8; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Hu SM, 2000, J BIOL CHEM, V275, P30761, DOI 10.1074/jbc.C000341200; Hultmark D, 2003, CURR OPIN IMMUNOL, V15, P12, DOI 10.1016/S0952-7915(02)00005-5; Ishitani T, 2003, EMBO J, V22, P6277, DOI 10.1093/emboj/cdg605; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Kaneko T, 2004, IMMUNITY, V20, P637, DOI 10.1016/S1074-7613(04)00104-9; Lee TH, 2004, J BIOL CHEM, V279, P33185, DOI 10.1074/jbc.M404206200; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; LEMAITRE B, 1995, P NATL ACAD SCI USA, V92, P9465, DOI 10.1073/pnas.92.21.9465; Leulier F, 2000, EMBO REP, V1, P353, DOI 10.1093/embo-reports/kvd073; Leulier F, 2003, NAT IMMUNOL, V4, P478, DOI 10.1038/ni922; Leulier F, 2002, CURR BIOL, V12, P996, DOI 10.1016/S0960-9822(02)00873-4; Lu YR, 2001, GENE DEV, V15, P104, DOI 10.1101/gad.856901; MURALIDHAR MG, 1993, NEURON, V11, P253, DOI 10.1016/0896-6273(93)90182-Q; Naitza S, 2002, IMMUNITY, V17, P575, DOI 10.1016/S1074-7613(02)00454-5; OH CE, 1994, J NEUROSCI, V14, P3166; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Park JM, 2004, GENE DEV, V18, P584, DOI 10.1101/gad.1168104; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; Rutschmann S, 2000, NAT IMMUNOL, V1, P342, DOI 10.1038/79801; Shen BH, 2001, P NATL ACAD SCI USA, V98, P8596, DOI 10.1073/pnas.141235698; Silverman N, 2000, GENE DEV, V14, P2461, DOI 10.1101/gad.817800; Silverman N, 2003, J BIOL CHEM, V278, P48928, DOI 10.1074/jbc.M304802200; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Stoven S, 2000, EMBO REP, V1, P347, DOI 10.1093/embo-reports/kvd072; Stoven S, 2003, P NATL ACAD SCI USA, V100, P5991, DOI 10.1073/pnas.1035902100; Su H, 2005, SCIENCE, V307, P1465, DOI 10.1126/science.1104765; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; Vidal S, 2001, GENE DEV, V15, P1900, DOI 10.1101/gad.203301; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Weber ANR, 2003, NAT IMMUNOL, V4, P794, DOI 10.1038/ni955; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	48	103	107	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34048	34055		10.1074/jbc.M506655200	http://dx.doi.org/10.1074/jbc.M506655200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16081424	hybrid			2022-12-27	WOS:000232229700044
J	Hansen, M; Wind, T; Blouse, GE; Christensen, A; Petersen, HH; Kjelgaard, S; Mathiasen, L; Holtet, TL; Andreasen, PA				Hansen, M; Wind, T; Blouse, GE; Christensen, A; Petersen, HH; Kjelgaard, S; Mathiasen, L; Holtet, TL; Andreasen, PA			A urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P-2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIVE INHIBITORS; ONCOGENIC VIRUS; MOUSE CELLS; MECHANISM; SERINE; SPECIFICITY; MUTAGENESIS; TRANSITION; TRYPSIN; POTENT	To find new principles for inhibiting serine proteases, we screened phage-displayed random peptide repertoires with urokinase-type plasminogen activator (uPA) as the target. The most frequent of the isolated phage clones contained the disulfide bridge-constrained sequence CSWRGLENHRMC, which we designated upain-1. When expressed recombinantly with a protein fusion partner, upain-1 inhibited the enzymatic activity of uPA competitively with a temperature and pH-dependent K-i, which at 25 degrees C and pH 7.4 was similar to 500 nM. At the same conditions, the equilibrium dissociation constant K-D, monitored by displacement of p-aminobenzamidine from the specificity pocket of uPA, was similar to 400 nM. By an inhibitory screen against other serine proteases, including trypsin, upain-1 was found to be highly selective for uPA. The cyclical structure of upain-1 was indispensable for uPA binding. Alanine-scanning mutagenesis identified Arg(4) of upain-1 as the P-1 residue and indicated an extended binding interaction including the specificity pocket and the 37-, 60-, and 97-loops of uPA and the P-1, P-2, P-3', P-4', and the P-5' residues of upain-1. Substitution with alanine of the P-2 residue, Trp(3), converted upain-1 into a distinct, although poor, uPA substrate. Upain-1 represents a new type of uPA inhibitor that achieves selectivity by targeting uPA-specific surface loops. Most likely, the inhibitory activity depends on its cyclical structure and the unusual P2 residue preventing the scissile bond from assuming a tetrahedral geometry and thus from undergoing hydrolysis. Peptide-derived inhibitors such as upain-1 may provide novel mechanistic information about enzyme-inhibitor interactions and alternative methodologies for designing effective protease inhibitors.	Aarhus Univ, Dept Mol Biol, Lab Cellular Prot Sci, DK-8000 Aarhus, Denmark	Aarhus University	Andreasen, PA (corresponding author), Aarhus Univ, Dept Mol Biol, Lab Cellular Prot Sci, Gustav Wieds Vej 10C, DK-8000 Aarhus, Denmark.	pa@mb.au.dk						Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; BARRET AJ, 1998, HDB PROTEOLYTIC ENZY, P177; Blouse GE, 2002, BIOCHEMISTRY-US, V41, P11997, DOI 10.1021/bi025967p; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P231; Christensen L, 1996, INT J CANCER, V66, P441; Coombs GS, 1998, J BIOL CHEM, V273, P4323, DOI 10.1074/jbc.273.8.4323; Coombs GS, 1996, J BIOL CHEM, V271, P4461; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DANO K, 1980, BIOCHIM BIOPHYS ACTA, V613, P542, DOI 10.1016/0005-2744(80)90110-2; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DANO K, 1980, BIOCHIM BIOPHYS ACTA, V630, P146, DOI 10.1016/0304-4165(80)90146-4; Egelund R, 2001, EUR J BIOCHEM, V268, P673, DOI 10.1046/j.1432-1327.2001.01921.x; Hedstrom L, 2002, CHEM REV, V102, P4501, DOI 10.1021/cr000033x; Holtet TL, 1997, PROTEIN SCI, V6, P1511, DOI 10.1002/pro.5560060715; Jensen CM, 2005, J ORG CHEM, V70, P7512, DOI 10.1021/jo0505775; Jensen JK, 2002, FEBS LETT, V521, P91, DOI 10.1016/S0014-5793(02)02830-2; KALTOFT K, 1982, P NATL ACAD SCI-BIOL, V79, P3720, DOI 10.1073/pnas.79.12.3720; Katz BA, 2004, J MOL BIOL, V344, P527, DOI 10.1016/j.jmb.2004.09.032; Katz BA, 2003, J MOL BIOL, V329, P93, DOI 10.1016/S0022-2836(03)00399-1; Katz BA, 2001, CHEM BIOL, V8, P1107, DOI 10.1016/S1074-5521(01)00084-9; Klinghofer V, 2001, BIOCHEMISTRY-US, V40, P9125, DOI 10.1021/bi010186u; KOIVUNEN E, 1994, METHOD ENZYMOL, V245, P346; Krook M, 1998, MOL DIVERS, V3, P149; Kvassman JO, 1998, BIOCHEMISTRY-US, V37, P15491, DOI 10.1021/bi9814787; Laboissiere MCA, 2002, J BIOL CHEM, V277, P26623, DOI 10.1074/jbc.M203076200; Leinonen J, 2000, SCAND J CLIN LAB INV, V60, P59, DOI 10.1080/00365510050217726; LUND LR, 1988, MOL CELL ENDOCRINOL, V60, P43, DOI 10.1016/0303-7207(88)90118-9; Mackman RL, 2001, J MED CHEM, V44, P3856, DOI 10.1021/jm010244+; OLSON ST, 1995, J BIOL CHEM, V270, P30007; Petersen HH, 2001, EUR J BIOCHEM, V268, P4430, DOI 10.1046/j.1432-1327.2001.02365.x; Renatus M, 1998, J MED CHEM, V41, P5445, DOI 10.1021/jm981068g; ROBERTUS JD, 1972, BIOCHEMISTRY-US, V11, P4293, DOI 10.1021/bi00773a016; Salvesen, 1986, PROTEINASE INHIBITOR, P23; Schweinitz A, 2004, J BIOL CHEM, V279, P33613, DOI 10.1074/jbc.M314151200; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; Spencer JR, 2002, BIOORG MED CHEM LETT, V12, P2023, DOI 10.1016/S0960-894X(02)00312-8; Sperl S, 2000, P NATL ACAD SCI USA, V97, P5113, DOI 10.1073/pnas.97.10.5113; SPRAGGON G, 1995, STRUCTURE, V3, P681, DOI 10.1016/S0969-2126(01)00203-9; THOGERSEN HC, 1994, Patent No. 9418227; Wendt MD, 2004, J MED CHEM, V47, P303, DOI 10.1021/jm0300072; Wind T, 2003, EUR J BIOCHEM, V270, P1680, DOI 10.1046/j.1432-1033.2003.03524.x; Wu P, 2000, EUR J BIOCHEM, V267, P6212, DOI 10.1046/j.1432-1327.2000.01696.x; Zeslawska E, 2000, J MOL BIOL, V301, P465, DOI 10.1006/jmbi.2000.3966; Zeslawska E, 2003, J MOL BIOL, V328, P109, DOI 10.1016/S0022-2836(03)00267-5	46	48	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38424	38437		10.1074/jbc.M505933200	http://dx.doi.org/10.1074/jbc.M505933200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16141208	hybrid			2022-12-27	WOS:000233239800039
J	Su, M; Bansal, AK; Mantovani, R; Sodek, J				Su, M; Bansal, AK; Mantovani, R; Sodek, J			Recruitment of nuclear factor Y to the inverted CCAAT element (ICE) by c-Jun and E1A stimulates basal transcription of the bone sialoprotein gene in osteosarcoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; HUMAN HSP70 PROMOTER; BOX-BINDING FACTOR; NF-Y; HISTONE ACETYLTRANSFERASES; C/EBP-ALPHA; HUMAN BREAST; HA-RAS; EXPRESSION; ACTIVATION	Bone sialoprotein (BSP), a major protein in the extracellular matrix of bone, is expressed almost exclusively by bone cells and by cancer cells that have a propensity to metastasize to bone. Previous studies have shown that v-src stimulates basal transcription of bsp in osteosarcoma (ROS 17/2.8) cells by targeting the inverted CCAAT element ( ICE) in the proximal promoter. To identify possible downstream effectors of Src we studied the effects of the proto-oncogene c-jun, which functions downstream of Src, on basal transcription of bsp using transient transfection assays. Increased expression of endogenous c-Jun induced by the tumor promoter 12-O-tetradecanoyl-phorbol 13-acetate and ectopic expression of c-Jun increased basal transcription of chimeric reporter constructs encompassing the proximal promoter by 1.5-3-fold in ROS 17/2.8 osteosarcoma cells, with more modest effects in a normal bone cell line, RBMC-D8. The effects of c-Jun were abrogated by mutations in the ICE box and by co-expression of dominant negative nuclear factor Y, subunit A (NF-YA). The increase in bsp transcription did not require phosphorylation of c-Jun and was not altered by trichostatin treatment or by ectopic expression of p300/CREB-binding protein (CBP) or mutated forms lacking histone acetyltransferase ( HAT) activity. Similarly, ectopic expression of p300/CBP-associated factor (P/CAF), which transduces p300/ CBP effects, or of HAT-defective P/CAF did not influence the c-jun effects. Surprisingly, E1A, which competes with P/CAF binding to p300/ CBP, also stimulated BSP transcription through NF-Y independently of c-jun, p300/ CBP, and P/CAF. Collectively, these studies show that c-Jun and E1A regulate basal transcription of bsp in osteosarcoma cells by recruiting the NF-Y transcriptional complex to the ICE box in a mechanism that is independent of p300/ CBP and P/CAF HAT activities.	Univ Toronto, Fac Dent, Canadian Inst Hlth Res Grp Matrix Dynam, Toronto, ON M5S 3E2, Canada; Univ Toronto, Fac Med, Dept Biochem, Toronto, ON M5S 3E2, Canada; Univ Milan, Dipartimento Sci Biomol & Biotecnol, I-20143 Milan, Italy	University of Toronto; University of Toronto; University of Milan	Su, M (corresponding author), Univ Toronto, Fac Dent, Canadian Inst Hlth Res Grp Matrix Dynam, 234 FitzGerald Bldg,150 Coll St, Toronto, ON M5S 3E2, Canada.	m.su@utoronto.ca						AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Bellahcene A, 2000, CIRC RES, V86, P885, DOI 10.1161/01.RES.86.8.885; Bellahcene A, 1996, J BONE MINER RES, V11, P665; Bellorini M, 1997, NUCLEIC ACIDS RES, V25, P2174, DOI 10.1093/nar/25.11.2174; Besirli CG, 2003, J BIOL CHEM, V278, P22357, DOI 10.1074/jbc.M300742200; Bevilacqua MA, 1997, J BIOL CHEM, V272, P20736, DOI 10.1074/jbc.272.33.20736; Bolognese F, 1999, ONCOGENE, V18, P1845, DOI 10.1038/sj.onc.1202494; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Caretti G, 2003, J BIOL CHEM, V278, P30435, DOI 10.1074/jbc.M304606200; CHANG ZF, 1994, J BIOL CHEM, V269, P17893; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; Currie RA, 1998, J BIOL CHEM, V273, P1430, DOI 10.1074/jbc.273.3.1430; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; di Silvio A, 1999, NUCLEIC ACIDS RES, V27, P2578; DUTTA A, 1990, GENE DEV, V4, P243, DOI 10.1101/gad.4.2.243; Faniello MC, 1999, J BIOL CHEM, V274, P7623, DOI 10.1074/jbc.274.12.7623; Faniello MC, 2002, BIOCHEM J, V363, P53, DOI 10.1042/0264-6021:3630053; Farina A, 1999, ONCOGENE, V18, P2818, DOI 10.1038/sj.onc.1202472; Fedarko NS, 2004, FASEB J, V18, P734, DOI 10.1096/fj.03-0966fje; Fedarko NS, 2000, J BIOL CHEM, V275, P16666, DOI 10.1074/jbc.M001123200; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Ganss B, 1999, CRIT REV ORAL BIOL M, V10, P79, DOI 10.1177/10454411990100010401; Good LF, 1996, BIOL SIGNAL, V5, P163; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Imbriano C, 2001, J BIOL CHEM, V276, P26332, DOI 10.1074/jbc.M101553200; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Kim RH, 1999, CANCER RES, V59, P565; KIM RH, 2000, CHEM BIOL MINERALIZE, P39; KITABAYASHI I, 1991, NUCLEIC ACIDS RES, V19, P649, DOI 10.1093/nar/19.3.649; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; LI JJ, 1995, BIOCHEM J, V310, P33, DOI 10.1042/bj3100033; Liu G, 2003, J BIOL CHEM, V278, P17557, DOI 10.1074/jbc.M210696200; Liu HT, 2003, BLOOD, V101, P3885, DOI 10.1182/blood-2002-07-2212; LUM LSY, 1992, MOL CELL BIOL, V12, P2599, DOI 10.1128/MCB.12.6.2599; LUM LSY, 1990, MOL CELL BIOL, V10, P6709, DOI 10.1128/MCB.10.12.6709; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Mao DYL, 2004, NUCLEIC ACIDS RES, V32, P3462, DOI 10.1093/nar/gkh669; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; Motta MC, 1999, J BIOL CHEM, V274, P1326, DOI 10.1074/jbc.274.3.1326; Munz C, 2003, J BIOL CHEM, V278, P21510, DOI 10.1074/jbc.M212764200; Naumann M, 1999, J BIOL CHEM, V274, P35297, DOI 10.1074/jbc.274.50.35297; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; Rangatia J, 2003, ONCOGENE, V22, P4760, DOI 10.1038/sj.onc.1206664; Reddy VA, 2002, BLOOD, V100, P483, DOI 10.1182/blood.V100.2.483; Robert F, 1998, MOL CELL, V2, P341, DOI 10.1016/S1097-2765(00)80278-6; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Sodek J, 1996, CONNECT TISSUE RES, V35, P23, DOI 10.3109/03008209609029171; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; Tanimoto A, 1998, CARCINOGENESIS, V19, P1735, DOI 10.1093/carcin/19.10.1735; Tye CE, 2003, J BIOL CHEM, V278, P7949, DOI 10.1074/jbc.M211915200; Tye CE, 2005, J BIOL CHEM, V280, P13487, DOI 10.1074/jbc.M408923200; Waltregny D, 2000, J BONE MINER RES, V15, P834, DOI 10.1359/jbmr.2000.15.5.834; Wang YN, 2003, J BIOL CHEM, V278, P45848, DOI 10.1074/jbc.M302630200; Weiss C, 2003, EMBO J, V22, P3686, DOI 10.1093/emboj/cdg364; WHITE E, 1993, P SOC EXP BIOL MED, V204, P30; WILLIAMS GT, 1989, MOL CELL BIOL, V9, P2574, DOI 10.1128/MCB.9.6.2574; Yamauchi M, 1996, MATRIX BIOL, V15, P119, DOI 10.1016/S0945-053X(96)90153-5; YAO KL, 1994, J BONE MINER RES, V9, P231; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966	68	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38365	38375		10.1074/jbc.M501609200	http://dx.doi.org/10.1074/jbc.M501609200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16087680	hybrid			2022-12-27	WOS:000233239800032
J	Chen, YR; Chen, CL; Zhang, LW; Green-Church, KB; Zweier, JL				Chen, YR; Chen, CL; Zhang, LW; Green-Church, KB; Zweier, JL			Superoxide generation from mitochondrial NADH dehydrogenase induces self-inactivation with specific protein radical formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; BOVINE HEART-MITOCHONDRIA; OXIDOREDUCTASE COMPLEX-I; CYTOCHROME C REDUCTASE; OXYGEN-FREE RADICALS; UBIQUINONE OXIDOREDUCTASE; QUINONE OXIDOREDUCTASE; PARKINSONS-DISEASE; ELECTRON-TRANSPORT; MASS-SPECTROMETRY	Mitochondrial superoxide (O-2(radical anion).) production is an important mediator of oxidative cellular injury. While NADH dehydrogenase (NDH) is a critical site of this O-2(radical anion) production; its mechanism of O-2(radical anion) generation is not known. Therefore, the catalytic function of NDH in the mediation of O-2(radical anion) generation was investigated by EPR spin-trapping. In the presence of NADH, O-2(radical anion) generation from NDH was observed and was inhibited by diphenyleneiodinium chloride (DPI), indicating involvement of the FMN-binding site of NDH. Addition of FMN increased O-2(radical anion) production. Destruction of the cysteine ligands of iron-sulfur clusters decreased O-2(radical anion) generation, suggesting a secondary role of this site. This inhibitory effect was reversed by addition of FMN. However, FMN addition could not reverse the inhibition of NDH by either DPI or heat denaturation, demonstrating involvement of both FMN and its FMN-binding protein moiety in the catalysis of O-2(radical anion) generation. O-2(radical anion) production by NDH also induced self-inactivation. Immunospin-trapping with anti-DMPO antibody and subsequent mass spectrometry was used to define the sites of oxidative damage of NDH. A DMPO adduct was detected on the 51-kDa subunit and was O-2(radical anion)-dependent. Alkylation of the cysteine residues of NDH significantly inhibited NDH-DMPO spin adduct formation, indicating involvement of protein thiyl radicals. LC/MS/MS analysis of a tryptic digest of the 51-kDa polypeptide revealed that cysteine (Cys(206)) and tyrosine (Tyr(177)) were specific sites of NDH-derived protein radical formation. Thus, two domains of the 51-kDa subunit, Gly(200-) Ala-Gly-Ala-Tyr-Ile-Cys(206)- Gly-Glu-Glu- Thr-Ala-Leu-Ile-Glu-Ser-Ile-Glu-Gly-Lys(219) and Ala(176)-Tyr(177)- Glu-Ala-Gly-Leu-Ile-Gly-Lys(184), were demonstrated to be susceptible to oxidative attack, and their oxidative modification results in decreased electron transfer activity.	Ohio State Univ, Dept Internal Med, Davis Heart & Lung Res Inst, Div Cardiovasc Med, Columbus, OH 43210 USA; Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Ohio State Univ, Campus Chem Instrument Ctr, Proteom & Mass Spectrometry Facil, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Chen, YR (corresponding author), Ohio State Univ, Davis Heart & Lung Res Inst 607, 473 W 12th Ave, Columbus, OH 43210 USA.	yeong-renn.chen@osumc.edu	Zhang, Liwen/P-1111-2016; Green, Kari B/H-3541-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL083237, R29HL038324, P01HL065608, R01HL038324, R01HL063744] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K22ES011031] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38324, HL65608, HL63744, R01 HL083237] Funding Source: Medline; NIEHS NIH HHS [K22 ES011031, ES11031] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMBROSIO G, 1993, J BIOL CHEM, V268, P18532; ANDERSON RF, 1995, INT J RADIAT BIOL, V68, P535, DOI 10.1080/09553009514551521; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; Brand MD, 2004, FREE RADICAL BIO MED, V37, P755, DOI 10.1016/j.freeradbiomed.2004.05.034; Bugiani M, 2004, BBA-BIOENERGETICS, V1659, P136, DOI 10.1016/j.bbabio.2004.09.006; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; Cardounel AJ, 2005, J BIOL CHEM, V280, P7540, DOI 10.1074/jbc.M410241200; Carroll J, 2003, MOL CELL PROTEOMICS, V2, P117, DOI 10.1074/mcp.M300014-MCP200; Chen YR, 1999, J BIOL CHEM, V274, P3308, DOI 10.1074/jbc.274.6.3308; Chen YR, 2004, FREE RADICAL BIO MED, V37, P1591, DOI 10.1016/j.freeradbiomed.2004.07.013; Chen YR, 2000, BIOCHEMISTRY-US, V39, P4415, DOI 10.1021/bi992652+; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; DAVIES MJ, 1993, FREE RADICAL RES COM, V18, P353, DOI 10.3109/10715769309147502; Deterding LJ, 2004, J BIOL CHEM, V279, P11600, DOI 10.1074/jbc.M310704200; DULING DR, 1994, J MAGN RESON SER B, V104, P105, DOI 10.1006/jmrb.1994.1062; ELLIS JA, 1988, BIOCHEM J, V251, P887, DOI 10.1042/bj2510887; Feldkamp T, 2004, AM J PHYSIOL-RENAL, V286, pF749, DOI 10.1152/ajprenal.00276.2003; FREJAVILLE C, 1995, J MED CHEM, V38, P258, DOI 10.1021/jm00002a007; Galkin A, 2005, J BIOL CHEM, V280, P30129, DOI 10.1074/jbc.M504709200; Hatefi Y, 1978, Methods Enzymol, V53, P11; Hirst J, 2003, BBA-BIOENERGETICS, V1604, P135, DOI 10.1016/S0005-2728(03)00059-8; Kudin AP, 2004, J BIOL CHEM, V279, P4127, DOI 10.1074/jbc.M310341200; Lambert AJ, 2004, J BIOL CHEM, V279, P39414, DOI 10.1074/jbc.M406576200; Lee C, 2000, J BIOL CHEM, V275, P38965, DOI 10.1074/jbc.M006341200; Lee CI, 2000, J BIOL CHEM, V275, P9369, DOI 10.1074/jbc.275.13.9369; Lenaz G, 2002, ANN NY ACAD SCI, V959, P199, DOI 10.1111/j.1749-6632.2002.tb02094.x; Li YB, 1998, BIOCHEM BIOPH RES CO, V253, P295, DOI 10.1006/bbrc.1998.9729; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mason RP, 2004, FREE RADICAL BIO MED, V36, P1214, DOI 10.1016/j.freeradbiomed.2004.02.077; NOHL H, 1986, BIOCHEM BIOPH RES CO, V138, P533, DOI 10.1016/S0006-291X(86)80529-0; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; Ohnishi ST, 2005, J BIOENERG BIOMEMBR, V37, P1, DOI 10.1007/s10863-005-4117-y; Ohnishi T, 1998, BBA-BIOENERGETICS, V1364, P186, DOI 10.1016/S0005-2728(98)00027-9; Paradies G, 2004, CIRC RES, V94, P53, DOI 10.1161/01.RES.0000109416.56608.64; Prutz W A, 1986, Free Radic Res Commun, V2, P69, DOI 10.3109/10715768609088056; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; REDFEARN ER, 1966, BIOCHIM BIOPHYS ACTA, V118, P413, DOI 10.1016/S0926-6593(66)80050-4; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SANDERS SP, 1993, J CLIN INVEST, V91, P46, DOI 10.1172/JCI116198; Schapira AHV, 1999, BBA-BIOENERGETICS, V1410, P159, DOI 10.1016/S0005-2728(98)00164-9; Song Y, 2002, BIOCHEMISTRY-US, V41, P10616, DOI 10.1021/bi026060u; Taylor ER, 2003, J BIOL CHEM, V278, P19603, DOI 10.1074/jbc.M209359200; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Vinogradov A D, 1979, Methods Enzymol, V55, P118; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; Wever RMF, 1997, BIOCHEM BIOPH RES CO, V237, P340, DOI 10.1006/bbrc.1997.7069; Xia Y, 1998, J BIOL CHEM, V273, P22635, DOI 10.1074/jbc.273.35.22635; Yagi T, 2003, BIOCHEMISTRY-US, V42, P2266, DOI 10.1021/bi027158b; YANO T, 1994, FEBS LETT, V354, P160, DOI 10.1016/0014-5793(94)01107-9; Yano T, 2005, BIOCHEMISTRY-US, V44, P1744, DOI 10.1021/bi048132i; Zhang L, 1998, J BIOL CHEM, V273, P33972, DOI 10.1074/jbc.273.51.33972; Zhang Z, 1998, FREE RADICAL RES, V28, P151, DOI 10.3109/10715769809065801; Zhao X, 2005, CIRCULATION, V111, P2966, DOI 10.1161/CIRCULATIONAHA.104.527226; ZHU J, 2004, THESIS OKLAHOMA STAT; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404; ZWEIER JL, 1989, J BIOL CHEM, V264, P18890	60	108	111	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37339	37348		10.1074/jbc.M503936200	http://dx.doi.org/10.1074/jbc.M503936200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16150735	hybrid			2022-12-27	WOS:000233044500007
J	San Miguel, SM; Namdar-Attar, M; Noh, T; Frenkel, B; Bab, I				San Miguel, SM; Namdar-Attar, M; Noh, T; Frenkel, B; Bab, I			ERK1/2-activated de novo Mapkapk2 synthesis is essential for osteogenic growth peptide mitogenic signaling in osteoblastic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ELEMENT-BINDING PROTEIN; C-TERMINAL PENTAPEPTIDE; TRANSCRIPTION FACTOR; MAP KINASE; PARATHYROID-HORMONE; MECHANICAL STRAIN; IN-VITRO; PROLIFERATION; DIFFERENTIATION	In osteoblasts, the mitogen-activated protein kinases ERK1/2 and p38 as well as the cAMP-response element-binding protein ( CREB) have been implicated in the regulation of proliferation and differentiation. The osteogenic growth peptide (OGP) is a 14-mer bone cell mitogen that increases bone formation and trabecular bone density and stimulates fracture healing. OGP-(10-14) is the physiologically active form of OGP. Using gene array analysis, real-time reverse transcription-PCR, and immunoblot and DNA synthesis assays we show here that in MC3T3E1 and newborn mouse calvarial osteoblastic cultures the OGP-( 10 - 14) mitogenic signaling is critically dependent on de novo synthesis of mitogen-activated protein kinase-activated protein kinase 2 (Mapkapk2) mRNA and protein. The increase in Mapkapk2 occurs following short term ( 5 - 60 min) stimulation of ERK1/2 activity by OGP-( 10 - 14); phosphorylation of p38 remains unaffected. Downstream of Mapkapk2, CREB is phosphorylated on Ser133 leading to its enhanced transcriptional activity. That these events are critical for the OGP-( 10 - 14) mitogenic signaling is demonstrated by blocking the effects of OGP( 10 - 14) on the ERK1/2 pathway, Mapkapk2, CREB, and DNA synthesis using the MEK inhibitor PD098059. The OGP-( 10 - 14) stimulation of CREB transcriptional activity and DNA synthesis is also blocked by Mapkapk2 siRNA. These data define a novel mitogenic signaling pathway in osteoblasts whereby ERK1/2 stimulation of CREB phosphorylation and transcriptional activity as well as DNA synthesis are critically dependent on de novo Mapkapk2 synthesis.	Hebrew Univ Jerusalem, Bone Lab, IL-91120 Jerusalem, Israel; Univ So Calif, Keck Sch Med, Inst Med Genet, Dept Orthoped Surg, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Inst Med Genet, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA	Hebrew University of Jerusalem; University of Southern California; University of Southern California	Bab, I (corresponding author), Hebrew Univ Jerusalem, Bone Lab, POB 12272, IL-91120 Jerusalem, Israel.	babi@cc.huji.ac.il						ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bab I, 2002, BIOPOLYMERS, V66, P33, DOI 10.1002/bip.10202; Bab I, 1999, J PEPT RES, V54, P408, DOI 10.1034/j.1399-3011.1999.00135.x; BAB I, 1992, EMBO J, V11, P1867, DOI 10.1002/j.1460-2075.1992.tb05238.x; BENLEVY R, 1995, EMBO J, V14, P5920, DOI 10.1002/j.1460-2075.1995.tb00280.x; Bond CT, 1999, ANN NY ACAD SCI, V868, P370, DOI 10.1111/j.1749-6632.1999.tb11298.x; Chen C, 2004, J BIOL CHEM, V279, P29121, DOI 10.1074/jbc.M313000200; Chen YC, 2002, J MED CHEM, V45, P1624, DOI 10.1021/jm010479l; Cheng TJ, 1998, J CELL BIOCHEM, V71, P169; Clerk A, 1998, J CELL BIOL, V142, P523, DOI 10.1083/jcb.142.2.523; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369; Gabarin N, 2001, J CELL BIOCHEM, V81, P594, DOI 10.1002/jcb.1083; Gabet Y, 2004, BONE, V35, P65, DOI 10.1016/j.bone.2004.03.025; Gavish H, 1997, BIOCHEMISTRY-US, V36, P14883, DOI 10.1021/bi971670t; Ghayor C, 2005, BONE, V36, P93, DOI 10.1016/j.bone.2004.10.007; GREENBERG Z, 1993, BIOCHIM BIOPHYS ACTA, V1178, P273, DOI 10.1016/0167-4889(93)90204-3; Greenberg Z, 1997, J CELL BIOCHEM, V65, P359, DOI 10.1002/(SICI)1097-4644(19970601)65:3<359::AID-JCB6>3.0.CO;2-R; Guicheux J, 2003, J BONE MINER RES, V18, P2060, DOI 10.1359/jbmr.2003.18.11.2060; Gurevitch O, 1996, BLOOD, V88, P4719, DOI 10.1182/blood.V88.12.4719.bloodjournal88124719; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Hipskind Robert A., 1998, Frontiers in Bioscience, V3, pD804; Huang ZM, 2001, J BIOL CHEM, V276, P21351, DOI 10.1074/jbc.M010921200; Jessop HL, 2002, BONE, V31, P186, DOI 10.1016/S8756-3282(02)00797-4; Jessop HL, 2001, J BONE MINER RES, V16, P1045, DOI 10.1359/jbmr.2001.16.6.1045; Kato C, 2005, BIOCHEM BIOPH RES CO, V326, P147, DOI 10.1016/j.bbrc.2004.11.010; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matsuda N, 1998, BIOCHEM BIOPH RES CO, V249, P350, DOI 10.1006/bbrc.1998.9151; Mattii L, 2004, J CELL BIOCHEM, V93, P1231, DOI 10.1002/jcb.20248; Mehrotra M, 2004, J CELL BIOCHEM, V93, P741, DOI 10.1002/jcb.20138; Ogasawara A, 2001, J BIOL CHEM, V276, P7048, DOI 10.1074/jbc.M008070200; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; ROBINSON D, 1995, J BONE MINER RES, V10, P690; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Samoto H, 2003, J BIOL CHEM, V278, P28659, DOI 10.1074/jbc.M300671200; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shimoaka T, 2002, J BIOL CHEM, V277, P7493, DOI 10.1074/jbc.M108653200; Smith E, 2005, NUCLEIC ACIDS RES, V33, P1298, DOI 10.1093/nar/gki248; STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Swarthout JT, 2002, J BONE MINER RES, V17, P1401, DOI 10.1359/jbmr.2002.17.8.1401; Swarthout JT, 2001, J BIOL CHEM, V276, P7586, DOI 10.1074/jbc.M007400200; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; ter Haar E, 2003, STRUCTURE, V11, P611, DOI 10.1016/S0969-2126(03)00104-7; Vician LJ, 2004, J NEUROSCI RES, V78, P315, DOI 10.1002/jnr.20251; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8	51	38	44	3	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37495	37502		10.1074/jbc.M503861200	http://dx.doi.org/10.1074/jbc.M503861200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16150701	hybrid			2022-12-27	WOS:000233044500026
J	Rubi, B; Ljubicic, S; Pournourmohammadi, S; Carobbio, S; Armanet, M; Bartley, C; Maechler, P				Rubi, B; Ljubicic, S; Pournourmohammadi, S; Carobbio, S; Armanet, M; Bartley, C; Maechler, P			Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+ CHANNEL; L-DOPA; POTASSIUM CHANNELS; DIABETES-MELLITUS; HORMONE-SECRETION; CA2+ CURRENTS; B-CELLS; GLUCOSE; PROTEIN; D2	Dopamine signaling is mediated by five cloned receptors, grouped into D1-like (D1 and D5) and D2-like (D2, D3 and D4) families. We identified by reverse transcription-PCR the presence of dopamine receptors from both families in INS-1E insulin-secreting cells as well as in rodent and human isolated islets. D2 receptor expression was confirmed by immunodetection revealing localization on insulin secretory granules of INS-1E and primary rodent and human beta cells. We then tested potential effects mediated by the identified receptors on beta cell function. Dopamine ( 10 mu M) and the D2-like receptor agonist quinpirole ( 5 mu M) inhibited glucose-stimulated insulin secretion tested in several models, i.e. INS-1E beta cells, fluorescence-activated cell-sorted primary rat beta cells, and pancreatic islets of rat, mouse, and human origin. Insulin exocytosis is controlled by metabolism coupled to cytosolic calcium changes. Measurements of glucose-induced mitochondrial hyperpolarization and ATP generation showed that dopamine and D2-like agonists did not inhibit glucose metabolism. On the other hand, dopamine decreased cell membrane depolarization as well as cytosolic calcium increases evoked by glucose stimulation in INS-1E beta cells. These results show for the first time that dopamine receptors are expressed in pancreatic beta cells. Dopamine inhibited glucose-stimulated insulin secretion, an effect that could be ascribed to D2-like receptors. Regarding the molecular mechanisms implicated in dopamine-mediated inhibition of insulin release, our results point to distal steps in metabolism-secretion coupling. Thus, the role played by dopamine in glucose homeostasis might involve dopamine receptors, expressed in pancreatic beta cells, modulating insulin release.	Univ Geneva, Med Ctr, Dept Cell Physiol & Metab, CH-1211 Geneva, Switzerland; Univ Hosp Geneva, Dept Surg, Cell Isolat & Transplantat Ctr, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva	Rubi, B (corresponding author), Univ Geneva, Med Ctr, Dept Cell Physiol & Metab, 1 Rue Michel Servet, CH-1211 Geneva, Switzerland.	rubiweiss@yahoo.com	carobbio, stefania/E-7095-2018	Maechler, Pierre/0000-0002-2005-1433				Ahren B, 2000, DIABETOLOGIA, V43, P393, DOI 10.1007/s001250051322; AHREN B, 1985, PHARMACOLOGY, V30, P71, DOI 10.1159/000138053; Ananth Jambur, 2004, Ann Clin Psychiatry, V16, P75, DOI 10.1080/10401230490453293; ARNERIC SP, 1984, DIABETES, V33, P888, DOI 10.2337/diabetes.33.9.888; Barg S, 2002, NEURON, V33, P287, DOI 10.1016/S0896-6273(02)00563-9; Binda AV, 2002, MOL PHARMACOL, V62, P507, DOI 10.1124/mol.62.3.507; Borelli MI, 1997, DIABETES METAB, V23, P161; BOUNDY VA, 1993, MOL PHARMACOL, V43, P666; Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122; Budman CL, 2001, AM J PSYCHIAT, V158, P500, DOI 10.1176/appi.ajp.158.3.500-a; Callier S, 2003, BIOL CELL, V95, P489, DOI 10.1016/S0248-4900(03)00089-3; Citrome LL, 2004, DRUG TODAY, V40, P445, DOI 10.1358/dot.2004.40.5.850492; DEBUYSER A, 1991, PFLUG ARCH EUR J PHY, V419, P131, DOI 10.1007/BF00372998; Derouiche A, 1999, EUR J NEUROSCI, V11, P1391, DOI 10.1046/j.1460-9568.1999.00557.x; ERICSON LE, 1977, DIABETOLOGIA, V13, P117, DOI 10.1007/BF00745138; FERRER J, 1995, J BIOL CHEM, V270, P26086, DOI 10.1074/jbc.270.44.26086; Freeman ME, 2000, PHYSIOL REV, V80, P1523, DOI 10.1152/physrev.2000.80.4.1523; Guo W, 2003, J BIOL CHEM, V278, P4385, DOI 10.1074/jbc.C200679200; HAVRANKOVA J, 1981, DIABETOLOGIA, V20, P268, DOI 10.1007/BF00254492; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; Hernandez-Lopez S, 2000, J NEUROSCI, V20, P8987; Hoglinger GU, 2004, NAT NEUROSCI, V7, P726, DOI 10.1038/nn1265; Ishihara H, 2003, NAT CELL BIOL, V5, P330, DOI 10.1038/ncb951; Kuzhikandathil EV, 1998, MOL CELL NEUROSCI, V12, P390, DOI 10.1006/mcne.1998.0722; LACEY MG, 1987, J PHYSIOL-LONDON, V392, P397, DOI 10.1113/jphysiol.1987.sp016787; Lang JC, 1999, EUR J BIOCHEM, V259, P3, DOI 10.1046/j.1432-1327.1999.00043.x; Lavine N, 2002, J BIOL CHEM, V277, P46010, DOI 10.1074/jbc.M205035200; Lee SP, 2003, BIOCHEMISTRY-US, V42, P11023, DOI 10.1021/bi0345539; Lin RW, 2001, P NATL ACAD SCI USA, V98, P5258, DOI 10.1073/pnas.011538198; Maechler P, 1998, FEBS LETT, V422, P328, DOI 10.1016/S0014-5793(97)01618-9; Marder SR, 2004, AM J PSYCHIAT, V161, P1334, DOI 10.1176/appi.ajp.161.8.1334; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; MEMO M, 1982, P NATL ACAD SCI-BIOL, V79, P4456, DOI 10.1073/pnas.79.14.4456; Merglen A, 2004, ENDOCRINOLOGY, V145, P667, DOI 10.1210/en.2003-1099; Mezey E, 1996, P NATL ACAD SCI USA, V93, P10377, DOI 10.1073/pnas.93.19.10377; Nowicki S, 2000, AM J PHYSIOL-CELL PH, V279, pC1812, DOI 10.1152/ajpcell.2000.279.6.C1812; Okada Y, 2003, BRAIN RES, V968, P248, DOI 10.1016/S0006-8993(03)02267-4; OOMURA Y, 1981, DIABETOLOGIA, V20, P290, DOI 10.1007/BF00254495; Pijl H, 2003, EUR J PHARMACOL, V480, P125, DOI 10.1016/j.ejphar.2003.08.100; Prou D, 2001, J CELL SCI, V114, P3517; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rorsman P, 2003, DIABETOLOGIA, V46, P1029, DOI 10.1007/s00125-003-1153-1; RORSMAN P, 1991, NATURE, V349, P77, DOI 10.1038/349077a0; Rorsman P, 1997, DIABETOLOGIA, V40, P487, DOI 10.1007/s001250050706; ROSATI G, 1976, EUR NEUROL, V14, P229, DOI 10.1159/000114744; Rubi B, 2004, J BIOL CHEM, V279, P55659, DOI 10.1074/jbc.M409303200; Salamone JD, 2003, J PHARMACOL EXP THER, V305, P1, DOI 10.1124/jpet.102.035063; Sandyk R, 1993, Int J Neurosci, V69, P125; Scarselli M, 2001, J BIOL CHEM, V276, P30308, DOI 10.1074/jbc.M102297200; SCHMIDT A, 1991, J BIOL CHEM, V266, P18025; SHOBACK DM, 1984, P NATL ACAD SCI-BIOL, V81, P3113, DOI 10.1073/pnas.81.10.3113; Sieg A, 2004, AM J PHYSIOL-ENDOC M, V286, pE463, DOI 10.1152/ajpendo.00365.2003; Sowell MO, 2002, J CLIN ENDOCR METAB, V87, P2918, DOI 10.1210/jc.87.6.2918; STRICKER EM, 1975, SCIENCE, V189, P895, DOI 10.1126/science.1154028; Strowski MZ, 2003, MOL ENDOCRINOL, V17, P93, DOI 10.1210/me.2001-0035; Takahashi N, 2002, SCIENCE, V297, P1349, DOI 10.1126/science.1073806; Takayanagi M, 1996, TISSUE CELL, V28, P17, DOI 10.1016/S0040-8166(96)80040-1; Takeuchi Y, 2003, J NEUROCHEM, V85, P1064, DOI 10.1046/j.1471-4159.2003.01763.x; Uchida S, 2000, NEUROPHARMACOLOGY, V39, P191, DOI 10.1016/S0028-3908(99)00111-2; ULLRICH S, 1988, J BIOL CHEM, V263, P8615; VANWOERT MH, 1971, CLIN PHARMACOL THER, V12, P360; Vaughn J, 2000, BIOCHEM BIOPH RES CO, V274, P302, DOI 10.1006/bbrc.2000.3136; ZERN RT, 1980, DIABETOLOGIA, V18, P341	63	177	187	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36824	36832		10.1074/jbc.M505560200	http://dx.doi.org/10.1074/jbc.M505560200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16129680	hybrid			2022-12-27	WOS:000232901800037
J	Soares, JA; Zhang, LW; Pitsch, RL; Kleinholz, NM; Jones, RB; Wolff, JJ; Amster, J; Green-Church, KB; Krzycki, JA				Soares, JA; Zhang, LW; Pitsch, RL; Kleinholz, NM; Jones, RB; Wolff, JJ; Amster, J; Green-Church, KB; Krzycki, JA			The residue mass of L-pyrrolysine in three distinct methylamine methyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHANOSARCINA-BARKERI; CORRINOID PROTEIN; METHIONINE SYNTHASE; TRANSFER-RNA; AMINO-ACID; GENE; MONOMETHYLAMINE; METHANOGENESIS; RECONSTITUTION; SPECTROMETRY	Single in-frame amber (UAG) codons are found in the genes encoding MtmB, MtbB, or MttB, the methyltransferases initiating methane formation from monomethylamine, dimethylamine, or trimethylamine, respectively, in certain Archaea. The crystal structure of MtmB demonstrated that the amber codon codes for pyrrolysine, the 22nd genetically encoded amino acid found in nature. Previous attempts to visualize the amber-encoded residue by mass spectrometry identified only lysine, leaving information on the existence and structure of pyrrolysine resting entirely on crystallography of a single protein. Here we report successful mass spectral characterization of naturally occurring pyrrolysine and the first demonstration of the amber-encoded residue in proteins other than MtmB. The sequencing of chymotryptic fragments from acetonitrile-denatured proteins by tandem mass spectrometry revealed the mass of the amber-encoded residue in MtmB, MtbB, and MttB as 237.2 +/- 0.2 Da. Fourier transform ion cyclotron resonance mass spectrometry produced an accurate measurement for the pyrrolysyl-residue as 237.1456 Da, within error limits of the predicted mass based on the empirical formula C12H19N3O2. These measurements support the structure of pyrrolysine in MtmB as 4-methylpyrroline-5- carboxylate in amide linkage with the N-epsilon of lysine but not the alternative structure in which the 4-substituent of the pyrroline ring is an amine group. The presence of pyrrolysine with statistically identical mass in all three methyltransferases is in keeping with the proposed direct incorporation of pyrrolysine into protein during translation of the UAG codon and suggests that MtbB and MttB may exploit the unusual electrophilicity of pyrrolysine during catalysis.	Ohio State Univ, Mass Spectrometry & Proteom Facil, Fontana Labs 243, Campus Chem Instrument Ctr, Columbus, OH 43210 USA; Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; Ohio State Univ, Biochem Program, Columbus, OH 43210 USA; Univ Georgia, Dept Chem, Athens, GA 30602 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Georgia; University of Georgia	Krzycki, JA (corresponding author), Ohio State Univ, Mass Spectrometry & Proteom Facil, Fontana Labs 243, Campus Chem Instrument Ctr, 116 W 19th Ave, Columbus, OH 43210 USA.	Krzycki.1@osu.edu	Green, Kari B/H-3541-2011; Amster, Jon/D-6957-2011; Zhang, Liwen/P-1111-2016	Amster, Jon/0000-0001-7523-5144; Pitsch, Rhonda/0000-0002-9218-274X				Atkins JF, 2002, SCIENCE, V296, P1409, DOI 10.1126/science.1073339; Blight SK, 2004, NATURE, V431, P333, DOI 10.1038/nature02895; Breaux GA, 2000, ANAL CHEM, V72, P1169, DOI 10.1021/ac9907282; Burke SA, 1997, J BIOL CHEM, V272, P16570, DOI 10.1074/jbc.272.26.16570; Burke SA, 1998, J BACTERIOL, V180, P3432, DOI 10.1128/JB.180.13.3432-3440.1998; BURKE SA, 1995, J BACTERIOL, V177, P4410, DOI 10.1128/jb.177.15.4410-4416.1995; Commans S, 1999, FEMS MICROBIOL REV, V23, P335, DOI 10.1111/j.1574-6976.1999.tb00403.x; Deppenmeier U, 2002, J MOL MICROB BIOTECH, V4, P453; Deppenmeier U, 2004, J BIOENERG BIOMEMBR, V36, P55, DOI 10.1023/B:JOBB.0000019598.64642.97; DRENNAN CL, 1994, SCIENCE, V266, P1669, DOI 10.1126/science.7992050; Driscoll DM, 2003, ANNU REV NUTR, V23, P17, DOI 10.1146/annurev.nutr.23.011702.073318; Evans JC, 2004, P NATL ACAD SCI USA, V101, P3729, DOI 10.1073/pnas.0308082100; Ferguson DJ, 1997, J BACTERIOL, V179, P846, DOI 10.1128/jb.179.3.846-852.1997; Ferguson DJ, 1996, J BIOL CHEM, V271, P5189; Ferguson DJ, 2000, J BIOL CHEM, V275, P29053, DOI 10.1074/jbc.M910218199; Galagan JE, 2002, GENOME RES, V12, P532, DOI 10.1101/gr.223902; Goodchild A, 2004, MOL MICROBIOL, V53, P309, DOI 10.1111/j.1365-2958.2004.04130.x; Hao B, 2004, CHEM BIOL, V11, P1317, DOI 10.1016/j.chembiol.2004.07.011; Hao B, 2002, SCIENCE, V296, P1462, DOI 10.1126/science.1069556; James CM, 2001, J BIOL CHEM, V276, P34252, DOI 10.1074/jbc.M102929200; Krzycki JA, 2004, CURR OPIN CHEM BIOL, V8, P484, DOI 10.1016/j.cbpa.2004.08.012; KRZYCKI JA, 1989, J BIOL CHEM, V264, P7217; Namy O, 2004, MOL CELL, V13, P157, DOI 10.1016/S1097-2765(04)00031-0; Paul L, 1996, J BACTERIOL, V178, P6599, DOI 10.1128/jb.178.22.6599-6607.1996; Paul L, 2000, J BACTERIOL, V182, P2520, DOI 10.1128/JB.182.9.2520-2529.2000; PAUL L, 2000, THESIS OHIO STATE U; Polycarpo C, 2004, P NATL ACAD SCI USA, V101, P12450, DOI 10.1073/pnas.0405362101; Retey J, 2003, BBA-PROTEINS PROTEOM, V1647, P179, DOI 10.1016/S1570-9639(03)00091-8; Russell WK, 2001, ANAL CHEM, V73, P2682, DOI 10.1021/ac001332p; Srinivasan G, 2002, SCIENCE, V296, P1459, DOI 10.1126/science.1069588; Thauer RK, 1998, MICROBIOL-UK, V144, P2377, DOI 10.1099/00221287-144-9-2377; Theobald-Dietrich A, 2004, NUCLEIC ACIDS RES, V32, P1091, DOI 10.1093/nar/gkh266; Zhang Y, 2005, J BIOL CHEM, V280, P20740, DOI 10.1074/jbc.M501458200	33	47	52	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36962	36969		10.1074/jbc.M506402200	http://dx.doi.org/10.1074/jbc.M506402200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16096277	hybrid			2022-12-27	WOS:000232901800053
J	Beringer, M; Bruell, C; Xiong, LQ; Pfister, P; Bieling, P; Katunin, VI; Mankin, AS; Bottger, EC; Rodnina, MV				Beringer, M; Bruell, C; Xiong, LQ; Pfister, P; Bieling, P; Katunin, VI; Mankin, AS; Bottger, EC; Rodnina, MV			Essential mechanisms in the catalysis of peptide bond formation on the ribosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYLTRANSFERASE ACTIVE-SITE; ELONGATION-FACTOR TU; TRANSFERASE CENTER; AMINOGLYCOSIDE RESISTANCE; STRUCTURAL BASIS; BASE-PAIR; RNA; MUTATIONS; SUBUNIT; ROLES	Peptide bond formation is the main catalytic function of the ribosome. The mechanism of catalysis is presumed to be highly conserved in all organisms. We tested the conservation by comparing mechanistic features of the peptidyl transfer reaction on ribosomes from Escherichia coli and the Gram-positive bacterium Mycobacterium smegmatis. In both cases, the major contribution to catalysis was the lowering of the activation entropy. The rate of peptide bond formation was pH independent with the natural substrate, amino-acyl-tRNA, but was slowed down 200-fold with decreasing pH when puromycin was used as a substrate analog. Mutation of the conserved base A2451 of 23 SrRNA to U did not abolish the pH dependence of the reaction with puromycin in M. smegmatis, suggesting that A2451 did not confer the pH dependence. However, the A2451U mutation alters the structure of the peptidyl transferase center and changes the pattern of pH-dependent rearrangements, as probed by chemical modification of 23 S rRNA. A2451 seems to function as a pivot point in ordering the structure of the peptidyl transferase center rather than taking part in chemical catalysis.	Univ Witten Herdecke, Inst Phys Biochem, D-58448 Witten, Germany; Univ Zurich, Inst Med Microbiol, CH-8006 Zurich, Switzerland; Univ Illinois, Ctr Pharmaceut Biotechnol, Chicago, IL 60607 USA; Russian Acad Sci, Petersburg Nucl Phys Inst, Gatchina 188350, Russia	Witten Herdecke University; University of Zurich; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; National Research Centre - Kurchatov Institute; Petersburg Nuclear Physics Institute; Russian Academy of Sciences	Rodnina, MV (corresponding author), Univ Witten Herdecke, Inst Phys Biochem, Stockumer Str 10, D-58448 Witten, Germany.	rodnina@uni-wh.de	Beringer, Malte/N-3766-2015; Rodnina, Marina V./AAD-4667-2019; Beringer, Malte/AAC-5734-2020; Böttger, Erik C./F-6175-2011	Beringer, Malte/0000-0003-1958-9786; Rodnina, Marina V./0000-0003-0105-3879; Bieling, Peter/0000-0002-7458-4358	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059028] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM59028] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; BARTA A, 1996, RIBOSOMAL RNA GROUP, P35; Bashan A, 2003, MOL CELL, V11, P91, DOI 10.1016/S1097-2765(03)00009-1; Bayfield MA, 2004, NUCLEIC ACIDS RES, V32, P5512, DOI 10.1093/nar/gkh888; Bayfield MA, 2001, P NATL ACAD SCI USA, V98, P10096, DOI 10.1073/pnas.171319598; Beringer M, 2003, RNA, V9, P919, DOI 10.1261/rna.5600503; Bevilacqua PC, 2004, BIOPOLYMERS, V73, P90, DOI 10.1002/bip.10519; Erlacher MD, 2005, NUCLEIC ACIDS RES, V33, P1618, DOI 10.1093/nar/gki308; GUTELL RR, 1985, PROG NUCLEIC ACID RE, V32, P155, DOI 10.1016/S0079-6603(08)60348-7; Hansen JL, 2002, P NATL ACAD SCI USA, V99, P11670, DOI 10.1073/pnas.172404099; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; Hesslein AE, 2004, NUCLEIC ACIDS RES, V32, P3760, DOI 10.1093/nar/gkh672; Katunin VI, 2002, MOL CELL, V10, P339, DOI 10.1016/S1097-2765(02)00566-X; KEARSEY SE, 1981, NATURE, V290, P607, DOI 10.1038/290607a0; LIEBERMAN KR, 1995, PROG NUCLEIC ACID RE, V50, P1, DOI 10.1016/S0079-6603(08)60809-0; MADEN BEH, 1968, EUR J BIOCHEM, V6, P309, DOI 10.1111/j.1432-1033.1968.tb00450.x; Merryman C, 1998, PRACT APPROACH SER, V192, P237; MISKIN R, 1968, BIOCHEM BIOPH RES CO, V33, P551, DOI 10.1016/0006-291X(68)90330-6; Muth GW, 2000, SCIENCE, V289, P947, DOI 10.1126/science.289.5481.947; Muth GW, 2001, RNA, V7, P1403; NIERHAUS KH, 1980, BIOCHEM INT, V1, P185; NOLLER HF, 1981, SCIENCE, V212, P403, DOI 10.1126/science.6163215; Pape T, 1998, EMBO J, V17, P7490, DOI 10.1093/emboj/17.24.7490; Parnell KM, 2002, P NATL ACAD SCI USA, V99, P11658, DOI 10.1073/pnas.182210099; Pfister P, 2005, J MOL BIOL, V346, P467, DOI 10.1016/j.jmb.2004.11.073; Pfister P, 2003, CHEMBIOCHEM, V4, P1078, DOI 10.1002/cbic.200300657; Polacek N, 2001, NATURE, V411, P498, DOI 10.1038/35078113; Prammananan T, 1999, ANTIMICROB AGENTS CH, V43, P447, DOI 10.1128/AAC.43.3.447; Rodnina MV, 1999, P NATL ACAD SCI USA, V96, P9586, DOI 10.1073/pnas.96.17.9586; RODNINA MV, 1995, P NATL ACAD SCI USA, V92, P1945, DOI 10.1073/pnas.92.6.1945; Sander P, 2002, MOL MICROBIOL, V46, P1295, DOI 10.1046/j.1365-2958.2002.03242.x; Sander P, 1996, MOL MICROBIOL, V22, P841, DOI 10.1046/j.1365-2958.1996.01532.x; Sievers A, 2004, P NATL ACAD SCI USA, V101, P7897, DOI 10.1073/pnas.0402488101; Thompson J, 2001, P NATL ACAD SCI USA, V98, P9002, DOI 10.1073/pnas.151257098; Weinger JS, 2004, NAT STRUCT MOL BIOL, V11, P1101, DOI 10.1038/nsmb841; WOLFENDEN R, 1963, BIOCHEMISTRY-US, V2, P1090, DOI 10.1021/bi00905a031; Xiong LQ, 2001, RNA, V7, P1365; Youngman EM, 2004, CELL, V117, P589, DOI 10.1016/S0092-8674(04)00411-8; [No title captured]	40	74	77	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36065	36072		10.1074/jbc.M507961200	http://dx.doi.org/10.1074/jbc.M507961200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16129670	Green Published, hybrid			2022-12-27	WOS:000232726900036
J	Kandel, S; Morant, M; Benveniste, I; Blee, E; Werck-Reichhart, D; Pinot, F				Kandel, S; Morant, M; Benveniste, I; Blee, E; Werck-Reichhart, D; Pinot, F			Cloning, functional expression, and characterization of CYP709C1, the first sub-terminal hydroxylase of long chain fatty acid in plants - Induction by chemicals and methyl jasmonate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPOXIDE HYDROLASE ACTIVITIES; LAURIC-ACID; OMEGA-HYDROXYLATION; CUTIN MONOMERS; MICROSOMAL CYTOCHROME-P450; IN-VITRO; YEAST; METABOLISM; WHEAT; MONOOXYGENASE	We cloned and characterized CYP709C1, a new plant cytochrome P450 belonging to the P450 family, that so far has no identified function except for clustering with a fatty acid metabolizing clade of P450 enzymes. We showed here that CYP709C1 is capable of hydroxylating fatty acids at the omega-1 and omega-2 positions. This work was performed after recoding and heterologous expression of a full-length cDNA isolated from a wheat cDNA library in an engineered yeast strain. Investigation on substrate specificity indicates that CYP709C1 metabolizes different fatty acids varying in their chain length (C12 to C18) and unsaturation. CYP709C1 is the first identified plant cytochrome P450 that can catalyze sub-terminal hydroxylation of C18 fatty acids. cis-9,10-Epoxystearic acid is metabolized with the highest efficiency, i.e. K-m(app) of 8 mu M and V-max(app) of 328 nmol/min/nmol P450. This, together with the fact that wheat possesses amicrosomal peroxygenase able to synthesize this compound from oleic acid, strongly suggests that it is a physiological substrate. Hydroxylated fatty acids are implicated in plant defense events. We postulated that CYP709C1 could be involved in plant defense by producing such compounds. This receives support from the observation that (i) sub-terminal hydroxylation of 9,10-epoxystearic acid is induced (15-fold after 3 h) in microsomes of wheat seedlings treated with the stress hormone methyl jasmonate and (ii) CYP709C1 is enhanced at the transcriptional level by this treatment. CYP709C1 transcript also accumulated after treatment with a combination of the safener naphthalic acid anhydride and phenobarbital. This indicates a possible detoxifying function for CYP709C1 that we discussed.	IBMP, CNRS,UPR 2357, Inst Bot, Dept Response Metab Environm Biot, F-67083 Strasbourg, France; Royal Vet & Agr Univ, Dept Plant Biol, DK-1871 Frederiksberg, Denmark	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Copenhagen	Pinot, F (corresponding author), IBMP, CNRS,UPR 2357, Inst Bot, Dept Response Metab Environm Biot, 28 Rue Goethe, F-67083 Strasbourg, France.	franck.pinot@bota-ulp.u-strasbg.fr	WERCK-REICHHART, Danièle/U-3713-2019	WERCK-REICHHART, Danièle/0000-0003-2869-4262; Kandel, Sylvie/0000-0002-8059-8035				Afitlhile MM, 2004, PHYTOCHEMISTRY, V65, P2679, DOI 10.1016/j.phytochem.2004.08.028; Benveniste I, 1998, BIOCHEM BIOPH RES CO, V243, P688, DOI 10.1006/bbrc.1998.8156; BENVENISTE I, 1982, PLANT PHYSIOL, V70, P122, DOI 10.1104/pp.70.1.122; BLEE E, 1990, J BIOL CHEM, V265, P12887; Blee E, 2002, TRENDS PLANT SCI, V7, P315, DOI 10.1016/S1360-1385(02)02290-2; Cabello-Hurtado F, 1998, J BIOL CHEM, V273, P7260, DOI 10.1074/jbc.273.13.7260; CAJACOB CA, 1988, J BIOL CHEM, V263, P18640; Capdevila JH, 2002, CELL MOL LIFE SCI, V59, P780, DOI 10.1007/s00018-002-8466-y; Carroll MA, 1996, AM J PHYSIOL-REG I, V271, pR863, DOI 10.1152/ajpregu.1996.271.4.R863; Chuang SS, 2004, J BIOL CHEM, V279, P6305, DOI 10.1074/jbc.M311830200; Corcos L, 2001, PHARMACOL TOXICOL, V89, P113, DOI 10.1034/j.1600-0773.2001.d01-144.x; CROSS JW, 1992, PESTIC BIOCHEM PHYS, V44, P28, DOI 10.1016/0048-3575(92)90006-L; Durst Francis, 1995, Drug Metabolism and Drug Interactions, V12, P189; EGLINTON G, 1968, ORG MASS SPECTROM, V1, P593, DOI 10.1002/oms.1210010413; Fauth M, 1998, PLANT PHYSIOL, V117, P1373, DOI 10.1104/pp.117.4.1373; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GIBSON GG, 1989, XENOBIOTICA, V19, P1123; HAMBERG M, 1992, BIOCHIM BIOPHYS ACTA, V1165, P1, DOI 10.1016/0005-2760(92)90069-8; Hehn A, 2002, METHOD ENZYMOL, V357, P343; Helvig C, 2004, BIOCHEM BIOPH RES CO, V325, P1495, DOI 10.1016/j.bbrc.2004.10.194; Holloway P. J., 1982, The plant cuticle, P45; Kahn RA, 2001, ARCH BIOCHEM BIOPHYS, V391, P180, DOI 10.1006/abbi.2001.2415; KATO T, 1985, TETRAHEDRON LETT, V26, P2357, DOI 10.1016/S0040-4039(00)95098-6; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; KOLATTUKUDY PE, 1980, SCIENCE, V208, P990, DOI 10.1126/science.208.4447.990; Kong L, 2005, GENOME, V48, P29, DOI 10.1139/G04-097; Lait CG, 2003, P NATL ACAD SCI USA, V100, P7027, DOI 10.1073/pnas.1232474100; Le Bouquin R, 2001, EUR J BIOCHEM, V268, P3083, DOI 10.1046/j.1432-1327.2001.02207.x; Maitra S, 1996, GENE, V180, P165, DOI 10.1016/S0378-1119(96)00446-5; MASUI H, 1989, PHYTOCHEMISTRY, V28, P2613, DOI 10.1016/S0031-9422(00)98051-8; MCFADDEN JJ, 1990, BIOCHEM BIOPH RES CO, V168, P206, DOI 10.1016/0006-291X(90)91695-O; McGiff JC, 1999, AM J PHYSIOL-REG I, V277, pR607, DOI 10.1152/ajpregu.1999.277.3.R607; MEIJER AH, 1993, PLANT MOL BIOL, V22, P379, DOI 10.1007/BF00014944; MEYER A, 1989, PHYTOCHEMISTRY, V28, P1007, DOI 10.1016/0031-9422(89)80173-6; Morant Marc, 2002, BMC Plant Biol, V2, P7, DOI 10.1186/1471-2229-2-7; Noverr MC, 2003, CLIN MICROBIOL REV, V16, P517, DOI 10.1128/CMR.16.3.517-533.2003; OHTA H, 1991, PLANT PHYSIOL, V97, P94, DOI 10.1104/pp.97.1.94; OMURA T, 1964, J BIOL CHEM, V239, P2370; Pare PW, 1998, P NATL ACAD SCI USA, V95, P13971, DOI 10.1073/pnas.95.23.13971; Pinot F, 1997, PLANT PHYSIOL BIOCH, V35, P103; Pinot F, 1998, PLANT PHYSIOL, V118, P1481, DOI 10.1104/pp.118.4.1481; PINOT F, 1994, BIOCHEM BIOPH RES CO, V198, P795, DOI 10.1006/bbrc.1994.1114; Pinot F, 1999, BIOCHEM J, V342, P27, DOI 10.1042/0264-6021:3420027; PINOT F, 1992, BIOCHEM BIOPH RES CO, V184, P183, DOI 10.1016/0006-291X(92)91176-Q; Pompon D, 1996, METHOD ENZYMOL, V272, P51, DOI 10.1016/S0076-6879(96)72008-6; Qu W, 2001, J BIOL CHEM, V276, P25467, DOI 10.1074/jbc.M100545200; SALAUN JP, 1978, EUR J BIOCHEM, V90, P155, DOI 10.1111/j.1432-1033.1978.tb12586.x; SALAUN JP, 1982, PHYSIOL VEG, V20, P613; SALAUN JP, 1986, LIPIDS, V21, P776, DOI 10.1007/BF02535411; Scheller U, 1996, ARCH BIOCHEM BIOPHYS, V328, P245, DOI 10.1006/abbi.1996.0170; Schweizer P, 1996, PHYSIOL MOL PLANT P, V49, P103, DOI 10.1006/pmpp.1996.0043; Simpson AECM, 1997, GEN PHARMACOL-VASC S, V28, P351, DOI 10.1016/S0306-3623(96)00246-7; Spector AA, 2004, PROG LIPID RES, V43, P55, DOI 10.1016/S0163-7827(03)00049-3; Summerer S, 2002, BIOCHEM J, V366, P471, DOI 10.1042/BJ20011778; Theodoulou F. L., 1999, Plant Physiology, V119, P1567, DOI 10.1104/pp.119.4.1567; Tijet N, 1998, BIOCHEM J, V332, P583, DOI 10.1042/bj3320583; Werck-Reichhart D, 2000, GENOME BIOL, V1, P1, DOI DOI 10.1186/GB-2000-1-6-REVIEWS3003; ZIMMERLIN A, 1992, PLANT PHYSIOL, V100, P874, DOI 10.1104/pp.100.2.874	58	46	66	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35881	35889		10.1074/jbc.M500918200	http://dx.doi.org/10.1074/jbc.M500918200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16120613	hybrid			2022-12-27	WOS:000232726900014
J	Musiek, ES; Gao, L; Milne, GL; Han, W; Everhart, MB; Wang, DZ; Backlund, MG; DuBois, RN; Zanoni, G; Vidari, G; Blackwell, TS; Morrow, JD				Musiek, ES; Gao, L; Milne, GL; Han, W; Everhart, MB; Wang, DZ; Backlund, MG; DuBois, RN; Zanoni, G; Vidari, G; Blackwell, TS; Morrow, JD			Cyclopentenone isoprostanes inhibit the inflammatory response in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NEURONAL OXIDATIVE DAMAGE; ACTIVATED RECEPTOR-GAMMA; NITRIC-OXIDE SYNTHASE; 1ST TOTAL-SYNTHESIS; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); IN-VIVO; GENE-EXPRESSION; MURINE MACROPHAGES; LIPID-PEROXIDATION	Although both inflammation and oxidative stress contribute to the pathogenesis of many disease states, the interaction between the two is poorly understood. Cyclopentenone isoprostanes (IsoPs), highly reactive structural isomers of the bioactive cyclopentenone prostaglandins PGA(2) and PGJ(2), are formed non-enzymatically as products of oxidative stress in vivo. We have, for the first time, examined the effects of synthetic 15-A(2)- and 15-J(2)-IsoPs, two groups of endogenous cyclopentenone IsoPs, on the inflammatory response in RAW264.7 and primary murine macrophages. Cyclopentenone IsoPs potently inhibited lipopolysaccharide-stimulated I kappa B alpha degradation and subsequent NF-kappa B nuclear translocation and transcriptional activity. Expression of inducible nitric-oxide synthase and cyclooxygenase-2 were also inhibited by cyclopentenone IsoPs as was nitrite and prostaglandin production (IC50 similar to 360 and 210 nM, respectively). 15-J(2)-IsoPs potently activated peroxisome proliferator-activated receptor gamma (PPAR gamma) nuclear receptors, whereas 15-A(2)-IsoP did not, although the anti-inflammatory effects of both molecules were PPAR gamma-independent. Interestingly 15-A(2)-IsoPs induced oxidative stress in RAW cells that was blocked by the antioxidant 4-hydroxy-TEMPO (TEMPOL) or the mitochondrial uncoupler carbonyl cyanide p-(trifluoromethoxy)phenylhydrazone. TEMPOL also abrogated the inhibitory effect of 15-A(2)-IsoPs on lipopolysaccharide- induced kappa F-kappa B activation, inducible nitric-oxide synthase expression, and nitrite production, suggesting that 15-A(2)-IsoPs inhibit the NF-kappa B pathway at least partially via a redox-dependent mechanism. 15-J(2)-IsoP, but not 15-A(2)-IsoP, also potently induced RAW cell apoptosis again via a PPAR gamma-independent mechanism. These findings suggest that cyclopentenone IsoPs may serve as negative feedback regulators of inflammation and have important implications for defining the role of oxidative stress in the inflammatory response.	Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA; Univ Pavia, Dept Organ Chem, I-27100 Pavia, Italy	Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Pavia	Morrow, JD (corresponding author), Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Dept Med, 526 RRB,23rd & Pierce Ave, Nashville, TN 37232 USA.	jason.morrow@vanderbilt.edu	DuBois, Raymond N./AAX-8869-2020; Milne, Ginger/D-7648-2014	Milne, Ginger/0000-0003-3890-151X; Musiek, Erik/0000-0002-8873-0360; Vidari, Giovanni/0000-0003-4606-2154	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015431, P01GM015431] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48831] Funding Source: Medline; NIGMS NIH HHS [GM15431] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alvarez-Maqueda M, 2004, J BIOL CHEM, V279, P21929, DOI 10.1074/jbc.M400492200; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BANERJEE M, 1992, AM J PHYSIOL, V263, pH660, DOI 10.1152/ajpheart.1992.263.3.H660; Basu S, 2001, ANN RHEUM DIS, V60, P627, DOI 10.1136/ard.60.6.627; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; Beal MF, 2003, ANN NY ACAD SCI, V991, P120; Byun MS, 2002, EXP MOL MED, V34, P332, DOI 10.1038/emm.2002.47; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; Cathcart MK, 2004, ARTERIOSCL THROM VAS, V24, P23, DOI 10.1161/01.ATV.0000097769.47306.12; Cernuda-Morollon E, 2001, J BIOL CHEM, V276, P35530, DOI 10.1074/jbc.M104518200; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Chen Y, 1999, J BIOL CHEM, V274, P10863, DOI 10.1074/jbc.274.16.10863; Chen Y, 1999, BBA-MOL CELL BIOL L, V1436, P550, DOI 10.1016/S0005-2760(98)00168-4; Cuzzocrea S, 2002, MOL PHARMACOL, V61, P997, DOI 10.1124/mol.61.5.997; Fam SS, 2002, J BIOL CHEM, V277, P36076, DOI 10.1074/jbc.M205638200; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gniwotta C, 1997, ARTERIOSCL THROM VAS, V17, P3236, DOI 10.1161/01.ATV.17.11.3236; Hortelano S, 2000, J IMMUNOL, V165, P6525, DOI 10.4049/jimmunol.165.11.6525; Ianaro A, 2003, MOL PHARMACOL, V64, P85, DOI 10.1124/mol.64.1.85; Ishii T, 2004, CHEM RES TOXICOL, V17, P1313, DOI 10.1021/tx049860+; Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5; Jaspers I, 2001, AM J RESP CELL MOL, V24, P769, DOI 10.1165/ajrcmb.24.6.4344; Ji C, 2001, J BIOL CHEM, V276, P18223, DOI 10.1074/jbc.M101266200; Khadaroo RG, 2003, J BIOL CHEM, V278, P47834, DOI 10.1074/jbc.M302660200; Klaunig JE, 2004, ANNU REV PHARMACOL, V44, P239, DOI 10.1146/annurev.pharmtox.44.101802.121851; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kondo M, 2001, J BIOL CHEM, V276, P12076, DOI 10.1074/jbc.M009630200; Korn SH, 2001, J BIOL CHEM, V276, P35693, DOI 10.1074/jbc.M104321200; Lee TS, 2003, J BIOL CHEM, V278, P19325, DOI 10.1074/jbc.M300498200; Lennon AM, 2002, J BIOL CHEM, V277, P29681, DOI 10.1074/jbc.M201517200; Li LY, 2001, J BIOL CHEM, V276, P38152; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; Liu YB, 1997, J NEUROCHEM, V69, P581, DOI 10.1046/j.1471-4159.1997.69020581.x; McLaughlin B, 2001, J NEUROSCI, V21, P3303, DOI 10.1523/JNEUROSCI.21-10-03303.2001; Milatovic D, 2003, J NEUROCHEM, V87, P1518, DOI 10.1046/j.1471-4159.2003.02120.x; Milne GL, 2004, CHEM RES TOXICOL, V17, P17, DOI 10.1021/tx034213o; Montine TJ, 2002, J NEUROCHEM, V83, P463, DOI 10.1046/j.1471-4159.2002.01157.x; Morrow JD, 1999, METHOD ENZYMOL, V300, P3; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; Negishi M, 2002, PROSTAG OTH LIPID M, V68-9, P611, DOI 10.1016/S0090-6980(02)00059-X; Newton R, 1997, BIOCHEM BIOPH RES CO, V237, P28, DOI 10.1006/bbrc.1997.7064; Nishi T, 2002, J BIOL CHEM, V277, P44548, DOI 10.1074/jbc.M202970200; Page S, 1999, J BIOL CHEM, V274, P11611, DOI 10.1074/jbc.274.17.11611; Park HS, 2004, J IMMUNOL, V173, P3589, DOI 10.4049/jimmunol.173.6.3589; Perez-Sala D, 2002, ANN NY ACAD SCI, V973, P533, DOI 10.1111/j.1749-6632.2002.tb04695.x; Petrova TV, 1999, P NATL ACAD SCI USA, V96, P4668, DOI 10.1073/pnas.96.8.4668; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Reich EE, 2001, AM J PATHOL, V158, P293, DOI 10.1016/S0002-9440(10)63968-5; Reynaert NL, 2004, P NATL ACAD SCI USA, V101, P8945, DOI 10.1073/pnas.0400588101; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Roberts LJ, 2002, CELL MOL LIFE SCI, V59, P808, DOI 10.1007/s00018-002-8469-8; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Rossi A, 1997, P NATL ACAD SCI USA, V94, P746, DOI 10.1073/pnas.94.2.746; Sadikot RT, 2004, J IMMUNOL, V172, P1801, DOI 10.4049/jimmunol.172.3.1801; Stocker R, 2004, PHYSIOL REV, V84, P1381, DOI 10.1152/physrev.00047.2003; Strassheim D, 2004, AM J PHYSIOL-CELL PH, V286, pC683, DOI 10.1152/ajpcell.00296.2003; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Straus DS, 2001, MED RES REV, V21, P185, DOI 10.1002/med.1006; Willoughby DA, 2000, NAT MED, V6, P137, DOI 10.1038/72224; XIE QW, 1994, J BIOL CHEM, V269, P4705; Yull FE, 2003, J HISTOCHEM CYTOCHEM, V51, P741, DOI 10.1177/002215540305100605; Zamamiri-Davis F, 2002, FREE RADICAL BIO MED, V32, P890, DOI 10.1016/S0891-5849(02)00775-X; Zanoni G, 2003, J ORG CHEM, V68, P6005, DOI 10.1021/jo034658h; Zanoni G, 2002, J ORG CHEM, V67, P4346, DOI 10.1021/jo025652f	66	77	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35562	35570		10.1074/jbc.M504785200	http://dx.doi.org/10.1074/jbc.M504785200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16100121	hybrid			2022-12-27	WOS:000232561200058
J	Armoni, M; Harel, C; Bar-Yoseph, F; Milo, S; Karnieli, E				Armoni, M; Harel, C; Bar-Yoseph, F; Milo, S; Karnieli, E			Free fatty acids repress the GLUT4 gene expression in cardiac muscle via novel response elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTORS; INDUCED INSULIN-RESISTANCE; GLUCOSE TRANSPORTERS; ARACHIDONIC-ACID; 3T3-L1 ADIPOCYTES; PPAR-GAMMA; RAT-HEART; MECHANISM; TRANSLOCATION; TRANSCRIPTION	Hyperlipidemia (HL) impairs cardiac glucose homeostasis, but the molecular mechanisms involved are yet unclear. We examined HL-regulated GLUT4 and peroxisome proliferator-activated receptor (PPAR) gamma gene expression in human cardiac muscle. Compared with control patients, GLUT4 protein levels were 30% lower in human cardiac muscle biopsies from patients with HL and/or type 2 diabetes mellitus, whereas GLUT4 mRNA levels were unchanged. PPAR gamma mRNA levels were 30 - 50% lower in patients with HL and/or diabetes mellitus type 2 than in controls. Reporter studies in H9C2 cardiomyotubes showed that HL in vitro, induced by high levels of arachidonic ( AA) stearic, linoleic, and oleic acids ( 24 h, 200 mu M) repressed transcription from the GLUT4 promoter; AA also repressed transcription from the PPAR gamma 1 and PPAR gamma 2 promoters. Co-expression of PPAR gamma 2 repressed GLUT4 promoter activity, and the addition of AA further enhanced this effect. 5'-Deletion analysis revealed three GLUT4 promoter regions that accounted for AA-mediated effects: two repression-mediating sequences at - 443/ - 423 bp and - 222/ - 197 bp, the deletion of either or both of which led to a partial derepression of promoter activity, and a third derepression-mediating sequence at - 612/ - 587 bp that was required for sustaining this derepression effect. Electromobility shift assay further shows that AA enhanced binding to two of the three regions of cardiac nuclear protein(s), the nature of which is still unknown. We propose that HL, exhibited as a high free fatty acid level, modulates GLUT4 gene expression in cardiac muscle via a complex mechanism that includes: ( a) binding of AA mediator proteins to three newly identified response elements on the GLUT4 promoter gene and (b) repression of GLUT4 and the PPAR gamma genes by AA.	Rambam Med Ctr, Inst Endocrinol Diabet & Metab, IL-31096 Haifa, Israel; Rambam Med Ctr, Dept Cardiac Surg, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel	Rambam Health Care Campus; Technion Israel Institute of Technology; Rambam Health Care Campus; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Karnieli, E (corresponding author), Rambam Med Ctr, Inst Endocrinol Diabet & Metab, POB 9602, IL-31096 Haifa, Israel.	eddy@tx.technion.ac.il						Abel ED, 1999, J CLIN INVEST, V104, P1703, DOI 10.1172/JCI7605; Armoni M, 2003, J BIOL CHEM, V278, P30614, DOI 10.1074/jbc.M304654200; Armoni M, 2002, J CLIN ENDOCR METAB, V87, P5312, DOI 10.1210/jc.2002-020318; ARMONI M, 1995, ENDOCRINOLOGY, V136, P3292, DOI 10.1210/en.136.8.3292; Boden G, 1999, P ASSOC AM PHYSICIAN, V111, P241, DOI 10.1046/j.1525-1381.1999.99220.x; Clarke SD, 2001, J NUTR, V131, P1129, DOI 10.1093/jn/131.4.1129; Duplus E, 2000, J BIOL CHEM, V275, P30749, DOI 10.1074/jbc.R000015200; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Gavin JR, 1999, DIABETES CARE, V22, pS5; Gilde AJ, 2003, ACTA PHYSIOL SCAND, V178, P425, DOI 10.1046/j.1365-201X.2003.01161.x; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Guan HP, 2005, GENE DEV, V19, P453, DOI 10.1101/gad.1263305; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; Hundal RS, 2002, J CLIN INVEST, V109, P1321, DOI 10.1172/JCI200214955; James David E., 1994, Trends in Cell Biology, V4, P120, DOI 10.1016/0962-8924(94)90066-3; KAHN BB, 1992, J CELL BIOCHEM, V48, P122, DOI 10.1002/jcb.240480203; KARNIELI E, 1981, J CLIN INVEST, V68, P811, DOI 10.1172/JCI110318; KARNIELI E, 1990, HORM RES, V33, P99, DOI 10.1159/000181491; Kim JK, 2001, J CLIN INVEST, V108, P437, DOI 10.1172/JCI11559; Kim YB, 2002, J BIOL CHEM, V277, P32915, DOI 10.1074/jbc.M204710200; KLIP A, 1987, FEBS LETT, V224, P224, DOI 10.1016/0014-5793(87)80452-0; Long SD, 1996, J BIOL CHEM, V271, P1138, DOI 10.1074/jbc.271.2.1138; NASCIMBEN L, 1995, CIRCULATION, V91, P1824, DOI 10.1161/01.CIR.91.6.1824; Nugent C, 2001, J BIOL CHEM, V276, P9149, DOI 10.1074/jbc.M009817200; OWEN P, 1990, CIRC RES, V66, P344, DOI 10.1161/01.RES.66.2.344; Pegorier J P, 1998, Curr Opin Clin Nutr Metab Care, V1, P329, DOI 10.1097/00075197-199807000-00003; Pegorier JP, 2004, J NUTR, V134, p2444S, DOI 10.1093/jn/134.9.2444S; REAVEN GM, 1993, ANNU REV MED, V44, P121, DOI 10.1146/annurev.me.44.020193.001005; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; SCHOPF G, 1986, BIOCHIM BIOPHYS ACTA, V884, P319, DOI 10.1016/0304-4165(86)90180-7; Sessler AM, 1998, J NUTR, V128, P923, DOI 10.1093/jn/128.6.923; SEYMOUR AML, 1990, BIOCHIM BIOPHYS ACTA, V1055, P107, DOI 10.1016/0167-4889(90)90110-Y; Stenbit AE, 2000, AM J PHYSIOL-HEART C, V279, pH313, DOI 10.1152/ajpheart.2000.279.1.H313; TAEGTMEYER H, 1994, CURR PROB CARDIOLOGY, V19, P61, DOI 10.1016/0146-2806(94)90008-6; TEBBEY PW, 1994, J BIOL CHEM, V269, P639; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; WAHLI W, 1995, CHEM BIOL, V2, P261, DOI 10.1016/1074-5521(95)90045-4; Wang CG, 2001, MOL CELL BIOL, V21, P3057, DOI 10.1128/MCB.21.9.3057-3070.2001; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620	40	61	66	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34786	34795		10.1074/jbc.M502740200	http://dx.doi.org/10.1074/jbc.M502740200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16096283	hybrid			2022-12-27	WOS:000232403900050
J	Hebert, RL; Carmosino, M; Saito, O; Yang, GR; Jackson, CA; Qi, ZH; Breyer, RM; Natarajan, C; Hata, AN; Zhang, YH; Guan, YF; Breyer, MD				Hebert, RL; Carmosino, M; Saito, O; Yang, GR; Jackson, CA; Qi, ZH; Breyer, RM; Natarajan, C; Hata, AN; Zhang, YH; Guan, YF; Breyer, MD			Characterization of a rabbit kidney prostaglandin F-2 alpha receptor exhibiting G(i)-restricted signaling that inhibits water absorption in the collecting duct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CA2+ MOBILIZATION; VASOPRESSIN-ELICITED WATER; PROSTANOID RECEPTORS; MESSENGER-RNA; G-PROTEIN; MOLECULAR-CLONING; SODIUM-TRANSPORT; PGF(2 ALPHA); FP RECEPTOR; EXPRESSION	PGF(2 alpha) is the most abundant prostaglandin detected in urine; however, its renal effects are poorly characterized. The present study cloned a PGF-prostanoid receptor (FP) from the rabbit kidney and determined the functional consequences of its activation. Nuclease protection assay showed that FP mRNA expression predominates in rabbit ovary and kidney. In situ hybridization revealed that renal FP expression predominates in the cortical collecting duct (CCD). Although FP receptor activation failed to increase intracellular Ca2+, it potently inhibited vasopressin-stimulated osmotic water permeability (L-p, 10(-7) cm/(atm.s)) in in vitro microperfused rabbit CCDs. Inhibition of Lp by the FP selective agonist latanoprost was additive to inhibition of vasopressin action by the EP selective agonist sulprostone. Inhibition of Lp by latanoprost was completely blocked by pertussis toxin, consistent with a G(i)-coupled mechanism. Heterologous transfection of the rabbit FPr into HEK293 cells also showed that latanoprost inhibited cAMP generation via a pertussis toxin-sensitive mechanism but did not increase cell Ca2+. These studies demonstrate a functional FP receptor on the basolateral membrane of rabbit CCDs. In contrast to the Ca2+ signal transduced by other FP receptors, this renal FP receptor signals via a PT-sensitive mechanism that is not coupled to cell Ca2+.	Vanderbilt Univ, Med Ctr, Div Nephrol, Nashville, TN 37232 USA; Univ Ottawa, Fac Med, Kidney Res Ctr, Dept Cellular, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Fac Med, Kidney Res Ctr, Dept Mol Med, Ottawa, ON K1H 8M5, Canada; Peking Univ, Hlth Sci Ctr, Dept Physiol, Beijing 100083, Peoples R China	Vanderbilt University; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; Peking University	Breyer, MD (corresponding author), Vanderbilt Univ, Med Ctr, Div Nephrol, Nashville, TN 37232 USA.	matthew.breyer@vanderbilt.edu	YANG, GUANGRUI/F-9693-2013; Carmosino, Monica/O-2594-2014	YANG, GUANGRUI/0000-0002-8310-8257; Carmosino, Monica/0000-0001-7600-8816; guan, youfei/0000-0002-5231-0209	NIDDK NIH HHS [DK46205, DK37097] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037097, R01DK046205] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abramovitz M, 2000, BBA-MOL CELL BIOL L, V1483, P285, DOI 10.1016/S1388-1981(99)00164-X; ABRAMOVITZ M, 1995, ADV PROSTAG THROMB L, V23, P499; ABRAMOVITZ M, 1994, J BIOL CHEM, V269, P2632; Anthony TL, 1998, INVEST OPHTH VIS SCI, V39, P315; Audoly LP, 1999, J PHARMACOL EXP THER, V289, P140; Boie Y, 1997, EUR J PHARMACOL, V340, P227, DOI 10.1016/S0014-2999(97)01383-6; Boonyaprakob U, 2003, REPRODUCTION, V125, P53, DOI 10.1530/reprod/125.1.53; BREYER MD, 1993, KIDNEY INT, V44, P1372, DOI 10.1038/ki.1993.391; Breyer MD, 2000, AM J PHYSIOL-RENAL, V279, pF12, DOI 10.1152/ajprenal.2000.279.1.F12; BREYER MD, 1990, AM J PHYSIOL, V259, pF553, DOI 10.1152/ajprenal.1990.259.4.F553; BREYER RM, 1994, J BIOL CHEM, V269, P6163; Bryer MD, 2001, ANNU REV PHYSIOL, V63, P579, DOI 10.1146/annurev.physiol.63.1.579; Carrasco MP, 1997, J REPROD FERTIL, V111, P309; DUBOIS R, 1976, KIDNEY INT, V10, P478; DUNCAN AMV, 1995, GENOMICS, V25, P740, DOI 10.1016/0888-7543(95)80022-E; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guan YF, 1998, J CLIN INVEST, V102, P194, DOI 10.1172/JCI2872; Hasumoto K, 1997, J REPROD FERTIL, V109, P45, DOI 10.1530/jrf.0.1090045; HEBERT RL, 1991, J CLIN INVEST, V87, P1992, DOI 10.1172/JCI115227; HEBERT RL, 1993, AM J PHYSIOL, V265, pF643, DOI 10.1152/ajprenal.1993.265.5.F643; HEBERT RL, 1990, AM J PHYSIOL, V259, pF318, DOI 10.1152/ajprenal.1990.259.2.F318; IRIE A, 1994, BIOCHEM BIOPH RES CO, V204, P303, DOI 10.1006/bbrc.1994.2460; Ishikawa TO, 1996, GENOMICS, V32, P285, DOI 10.1006/geno.1996.0118; JOHNSTON HH, 1967, AM J PHYSIOL, V213, P939, DOI 10.1152/ajplegacy.1967.213.4.939; Joost P, 2002, GENOME BIOL, V3; Kelly CR, 2003, J PHARMACOL EXP THER, V304, P238, DOI 10.1124/jpet.102.042556; Kiriyama M, 1997, BRIT J PHARMACOL, V122, P217, DOI 10.1038/sj.bjp.0701367; Knepper MA, 1997, AM J PHYSIOL-RENAL, V272, pF3, DOI 10.1152/ajprenal.1997.272.1.F3; Kunapuli P, 1997, J BIOL CHEM, V272, P27147, DOI 10.1074/jbc.272.43.27147; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; NARAYFEJESTOTH A, 1984, J CLIN INVEST, V74, P120, DOI 10.1172/JCI111391; Ocklind A, 1997, PROSTAG LEUKOTR ESS, V57, P527, DOI 10.1016/S0952-3278(97)90555-X; Pierce KL, 1997, J BIOL CHEM, V272, P883, DOI 10.1074/jbc.272.2.883; Saito O, 2003, AM J PHYSIOL-RENAL, V284, pF1164, DOI 10.1152/ajprenal.00441.2002; SAKAMOTO K, 1994, J BIOL CHEM, V269, P3881; Sakamoto K, 2002, DNA SEQUENCE, V13, P307, DOI 10.1080/1042517021000011645; Sands JM, 1998, AM J PHYSIOL-RENAL, V274, pF978, DOI 10.1152/ajprenal.1998.274.5.F978; SENKFOR SI, 1993, J CLIN INVEST, V92, P786, DOI 10.1172/JCI116651; Sharif NA, 2003, J OCUL PHARMACOL TH, V19, P501, DOI 10.1089/108076803322660422; Sharif NA, 2003, J OCUL PHARMACOL TH, V19, P437, DOI 10.1089/108076803322473006; Sharif NA, 2002, J OCUL PHARMACOL TH, V18, P313, DOI 10.1089/10807680260218489; Siragy HM, 1997, AM J PHYSIOL-REG I, V273, pR1103, DOI 10.1152/ajpregu.1997.273.3.R1103; SONNENBURG WK, 1988, J BIOL CHEM, V263, P6155; SONNENBURG WK, 1990, J BIOL CHEM, V265, P8479; STIER CT, 1987, J PHARMACOL EXP THER, V243, P487; Stjernschantz JW, 2001, INVEST OPHTH VIS SCI, V42, P1134; Stocco CO, 2000, J BIOL CHEM, V275, P37202, DOI 10.1074/jbc.M006016200; STOW JL, 1991, AM J PHYSIOL, V261, pF831, DOI 10.1152/ajprenal.1991.261.5.F831; SUGIMOTO Y, 1994, J BIOL CHEM, V269, P1356; Sugimoto Y, 1997, SCIENCE, V277, P681, DOI 10.1126/science.277.5326.681; Sugimoto Y, 2000, PROG LIPID RES, V39, P289, DOI 10.1016/S0163-7827(00)00008-4; Tabata H, 2002, BIOCHEM BIOPH RES CO, V298, P398, DOI 10.1016/S0006-291X(02)02455-5; TOH H, 1995, FEBS LETT, V361, P17, DOI 10.1016/0014-5793(95)00129-W; Tosun M, 1997, EUR J PHARMACOL, V340, P203, DOI 10.1016/S0014-2999(97)01415-5; Tsai SJ, 1998, J REPROD FERTIL, V114, P69, DOI 10.1530/jrf.0.1140069; Tsuboi K, 2002, PROSTAG OTH LIPID M, V68-9, P535, DOI 10.1016/S0090-6980(02)00054-0; Valenti G, 1998, J BIOL CHEM, V273, P22627, DOI 10.1074/jbc.273.35.22627; Vezza R, 2001, MOL PHARMACOL, V59, P1506, DOI 10.1124/mol.59.6.1506; Ward DT, 1999, ANNU REV PHYSIOL, V61, P683, DOI 10.1146/annurev.physiol.61.1.683; WOODWARD DF, 1994, BIOCHEM PHARMACOL, V47, P1567, DOI 10.1016/0006-2952(94)90533-9; Yew SF, 1998, CARDIOVASC RES, V40, P538; ZOOK TE, 1981, J PHARMACOL EXP THER, V217, P674	62	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					35028	35037		10.1074/jbc.M505852200	http://dx.doi.org/10.1074/jbc.M505852200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16096282	hybrid, Green Published			2022-12-27	WOS:000232403900076
J	Nagahara, N; Katayama, A				Nagahara, N; Katayama, A			Post-translational regulation of mercaptopyruvate sulfurtransferase via a low redox potential cysteine-sulfenate in the maintenance of redox homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE 1B; ACTIVE-SITE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; 3-MERCAPTOPYRUVATE SULFURTRANSFERASE; HYDROGEN-PEROXIDE; ENZYME CATALYSIS; NADH PEROXIDASE; SH-GROUPS; ACID; GLUTATHIONE	3-Mercaptopyruvate sulfurtransferase (MST) (EC 2.8.1.2), a multifunctional enzyme, catalyzes a transsulfuration from mercaptopyruvate to pyruvate in the degradation process of cysteine. A stoichiometric concentration of hydrogen peroxide and of tetrathionate (S4O62-) inhibited rat MST (k(i) = 3.3 min(-1), K-i = 120.5 mu M and k(i) = 2.5 min(-1), K-i = 178.6 mu M, respectively). The activity was completely restored by dithiothreitol or thioredoxin with a reducing system containing thioredoxin reductase and NADPH, but glutathione did not restore the activity. On the other hand, an excess molar ratio dose of hydrogen peroxide inactivated MST. Oxidation with a stoichiometric concentration of hydrogen peroxide protected the enzyme against reaction by iodoacetate, which modifies a catalytic Cys(247), suggesting that Cys(247) is a target of the oxidants. A matrix-assisted laser desorption/ionization - time-of-flight mass spectrometric analysis revealed that hydrogen peroxide- and tetrathionate-inhibited MSTs were increased in molecular mass consistent with the addition of atomic oxygen and with a thiosulfate (S2O3-), respectively. Treatment with dithiothreitol restored modified MST to the original mass. These findings suggested that there was no nearby cysteine with which to form a disulfide, and mild oxidation of MST resulted in formation of a sulfenate (SO-) atCys(247), which exhibited exceptional stability and a lower redox potential than that of glutathione. Oxidative stress decreases MST activity so as to increase the amount of cysteine, a precursor of thioredoxin or glutathione, and furthermore, these cellular reductants restore the activity. Thus the redox state regulates MST activity at the enzymatic level, and on the other hand, MST controls redox to maintain cellular redox homeostasis.	Nippon Med Coll, Dept Environm Med, Bunkyo Ku, Tokyo 1138602, Japan; Nippon Med Coll, Dept Biochem & Mol Biol, Tokyo 1138602, Japan	Nippon Medical School; Nippon Medical School	Nagahara, N (corresponding author), Nippon Med Coll, Dept Environm Med, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan.	noriyuki@nms.ac.jp						Alphey MS, 2003, J BIOL CHEM, V278, P48219, DOI 10.1074/jbc.M307187200; AMPOLA MG, 1969, AM J DIS CHILD, V117, P66, DOI 10.1001/archpedi.1969.02100030068007; Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; BENITEZ LV, 1974, J BIOL CHEM, V249, P6234; BIRKETT DJ, 1970, FEBS LETT, V6, P346, DOI 10.1016/0014-5793(70)80095-3; CANNELLA C, 1983, FEBS LETT, V162, P180, DOI 10.1016/0014-5793(83)81074-6; Carballal S, 2003, BIOCHEMISTRY-US, V42, P9906, DOI 10.1021/bi027434m; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; CLAIBORNE A, 1993, FASEB J, V7, P1483, DOI 10.1096/fasebj.7.15.8262333; CRAWHALL JC, 1969, AM J DIS CHILD, V117, P71, DOI 10.1001/archpedi.1969.02100030073008; CRAWHALL JC, 1971, BIOCHEM MED METAB B, V5, P109, DOI 10.1016/0006-2944(71)90080-9; CRAWHALL JC, 1968, SCIENCE, V160, P419, DOI 10.1126/science.160.3826.419; Das TN, 1999, J PHYS CHEM A, V103, P3581, DOI 10.1021/jp9900234; Dickinson DA, 2003, BIOL CHEM, V384, P527, DOI 10.1515/BC.2003.061; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P15013, DOI 10.1021/bi972191x; ENGLUND PT, 1968, BIOCHEMISTRY-US, V7, P163, DOI 10.1021/bi00841a021; Griffiths SW, 2002, J BIOL CHEM, V277, P25486, DOI 10.1074/jbc.M203089200; HANNESTAD U, 1981, BIOCHEM MED METAB B, V26, P106, DOI 10.1016/0006-2944(81)90035-1; HOROWITZ PM, 1989, J BIOL CHEM, V264, P3311; Isom GE, 1997, COMPREHENSIVE TOXICO, P477; Jones DP, 2004, FASEB J, V18, P1246, DOI 10.1096/fj.03-0971fje; KITZ R, 1962, J BIOL CHEM, V237, P3245; KRIETER PA, 1984, MOL PHARMACOL, V26, P122; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; LIU TY, 1967, J BIOL CHEM, V242, P4029; Mallett TC, 1999, BIOCHEMISTRY-US, V38, P3000, DOI 10.1021/bi9817717; Mosharov E, 2000, BIOCHEMISTRY-US, V39, P13005, DOI 10.1021/bi001088w; Nagahara N, 2004, BBA-GENE STRUCT EXPR, V1680, P176, DOI 10.1016/j.bbaexp.2004.09.007; NAGAHARA N, 1995, J BIOL CHEM, V270, P16230, DOI 10.1074/jbc.270.27.16230; Nagahara N, 1996, J BIOL CHEM, V271, P27395, DOI 10.1074/jbc.271.44.27395; Nagahara N, 1998, HISTOCHEM CELL BIOL, V110, P243, DOI 10.1007/s004180050286; Nagahara N, 1999, HISTOL HISTOPATHOL, V14, P1277, DOI 10.14670/HH-14.1277; Nandi DL, 2000, INT J BIOCHEM CELL B, V32, P465, DOI 10.1016/S1357-2725(99)00035-7; NIEDERWI.A, 1973, CLIN CHIM ACTA, V43, P405, DOI 10.1016/0009-8981(73)90480-4; PARKER DJ, 1969, J BIOL CHEM, V244, P180; PIHL A, 1962, J BIOL CHEM, V237, P1356; POOLE LB, 1989, J BIOL CHEM, V264, P12330; Poole LB, 2002, METHOD ENZYMOL, V348, P122, DOI 10.1016/S0076-6879(02)48632-6; Rahman I, 2005, ANTIOXID REDOX SIGN, V7, P42, DOI 10.1089/ars.2005.7.42; Salmeen A, 2003, NATURE, V423, P769, DOI 10.1038/nature01680; Skorey K, 1997, J BIOL CHEM, V272, P22472, DOI 10.1074/jbc.272.36.22472; VAIDYANATHAN VV, 1993, MOL CELL BIOCHEM, V129, P57, DOI 10.1007/BF00926576; van Montfort RLM, 2003, NATURE, V423, P773, DOI 10.1038/nature01681; Williams RAM, 2003, J BIOL CHEM, V278, P1480, DOI 10.1074/jbc.M209395200; Yeh JI, 1996, BIOCHEMISTRY-US, V35, P9951, DOI 10.1021/bi961037s	45	84	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34569	34576		10.1074/jbc.M505643200	http://dx.doi.org/10.1074/jbc.M505643200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16107337	hybrid			2022-12-27	WOS:000232403900025
J	Cassuto, H; Kochan, K; Chakravarty, K; Cohen, H; Blum, B; Olswang, Y; Hakimi, P; Xu, C; Massillon, D; Hanson, RW; Reshef, L				Cassuto, H; Kochan, K; Chakravarty, K; Cohen, H; Blum, B; Olswang, Y; Hakimi, P; Xu, C; Massillon, D; Hanson, RW; Reshef, L			Glucocorticoids regulate transcription of the gene for phosphoenolpyruvate carboxykinase in the liver via an extended glucocorticoid regulatory unit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC NUCLEAR FACTOR-3; ACTIVATED RECEPTOR-GAMMA; GTP GENE; ACCESSORY FACTORS; BINDING PROTEIN; RESPONSE UNIT; ADIPOSE EXPRESSION; MESSENGER-RNA; PPAR-ALPHA; COUP-TF	The hepatic transcriptional regulation by glucocorticoids of the cytosolic form of phosphoenolpyruvate carboxykinase (PEPCK-C) gene is coordinated by interactions of specific transcription factors at the glucocorticoid regulatory unit (GRU). We propose an extended GRU that consists of four accessory sites, two proximal AF1 and AF2 sites and their distal counterpart dAF1 ( - 993) and a new site, dAF2 ( - 1365); together, these four sites form a palindrome. Sequencing and gel shift binding assays of hepatic nuclear proteins interacting with these sites indicated similarity of dAF1 and dAF2 sites to the GRU proximal AF1 and AF2 sites. Chromatin immunoprecipitation assays demonstrated that glucocorticoids enhanced the binding of FOXO1 and peroxisome proliferator-activated receptor-alpha to AF2 and dAF2 sites and not to dAF1 site but enhanced the binding of hepatic nuclear transcription factor-4 alpha only to the dAF1 site. Insulin inhibited the binding of these factors to their respective sites but intensified the binding of phosphorylated FOXO1. Transient transfections in HepG2 human hepatoma cells showed that glucocorticoid receptor interacts with several non-steroid nuclear receptors, yielding a synergistic response of the PEPCK-C gene promoter to glucocorticoids. The synergistic stimulation by glucocorticoid receptor together with peroxisome proliferator-activated receptor-alpha or hepatic nuclear transcription factor-4 alpha requires all four accessory sites, i.e. a mutation of each of these markedly affects the synergistic response. Mice with a targeted mutation of the dAF1 site confirmed this requirement. This mutation inhibited the full response of hepatic PEPCK-C gene to diabetes by reducing PEPCK-C mRNA level by 3.5-fold and the level of circulating glucose by 25%.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Dev Biochem, IL-91120 Jerusalem, Israel; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Nutr, Cleveland, OH 44106 USA	Hebrew University of Jerusalem; Case Western Reserve University; Case Western Reserve University	Reshef, L (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, POB 12272, IL-91120 Jerusalem, Israel.	reshef@cc.huji.ac.il	Hakimi, Parvin/AAB-1643-2021	Blum, Barak/0000-0002-5308-4194	NIDDK NIH HHS [DK22541] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEALE EG, 1985, J BIOL CHEM, V260, P748; Bernal-Mizrachi C, 2003, NAT MED, V9, P1069, DOI 10.1038/nm898; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Cassuto H, 1997, FEBS LETT, V412, P597, DOI 10.1016/S0014-5793(97)00867-3; Cassuto H, 2003, GENE, V318, P177, DOI 10.1016/S0378-1119(03)00775-3; Cassuto H, 1999, FEBS LETT, V457, P441, DOI 10.1016/S0014-5793(99)01080-7; Chakravarthy MV, 2005, CELL METAB, V1, P309, DOI 10.1016/j.cmet.2005.04.002; Chakravarty K, 2004, J BIOL CHEM, V279, P15385, DOI 10.1074/jbc.M309905200; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cissell MA, 1999, BBA-GENE STRUCT EXPR, V1445, P299, DOI 10.1016/S0167-4781(99)00049-4; Curthoys NP, 2001, AM J PHYSIOL-RENAL, V281, pF381, DOI 10.1152/ajprenal.2001.281.3.F381; De Martino MU, 2004, MOL ENDOCRINOL, V18, P820, DOI 10.1210/me.2003-0341; Devine JH, 1999, J BIOL CHEM, V274, P13604, DOI 10.1074/jbc.274.19.13604; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Duong DT, 2002, J BIOL CHEM, V277, P32234, DOI 10.1074/jbc.M204873200; EISENBERGER CL, 1992, MOL CELL BIOL, V12, P1396, DOI 10.1128/MCB.12.3.1396; FRIEDMAN JE, 1993, J BIOL CHEM, V268, P12952; Ghosh AK, 2001, J BIOL CHEM, V276, P8507, DOI 10.1074/jbc.M008541200; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HALL RK, 1992, MOL CELL BIOL, V12, P5527, DOI 10.1128/MCB.12.12.5527; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Holcomb T, 1996, AM J PHYSIOL-RENAL, V271, pF340, DOI 10.1152/ajprenal.1996.271.2.F340; IMAI E, 1993, J BIOL CHEM, V268, P5353; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; IP YT, 1989, MOL CELL BIOL, V9, P1289, DOI 10.1128/MCB.9.3.1289; Lechner PS, 2001, J BIOL CHEM, V276, P22675, DOI 10.1074/jbc.M102422200; Leffert H L, 1979, Methods Enzymol, V58, P536; LIU JS, 1990, BIOTECHNIQUES, V9, P738; MACDOUGALD OA, 1994, J BIOL CHEM, V269, P19041; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Massillon D, 2003, J BIOL CHEM, V278, P40694, DOI 10.1074/jbc.M303182200; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MEISNER H, 1985, BIOCHEMISTRY-US, V24, P421, DOI 10.1021/bi00323a027; MITCHELL J, 1994, MOL ENDOCRINOL, V8, P585, DOI 10.1210/me.8.5.585; NECHUSHTAN H, 1987, NUCLEIC ACIDS RES, V15, P6405, DOI 10.1093/nar/15.16.6405; OBrien RM, 1995, BBA-GENE STRUCT EXPR, V1264, P284, DOI 10.1016/0167-4781(95)00194-8; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; Odom DT, 2004, SCIENCE, V303, P1378, DOI 10.1126/science.1089769; Olswang Y, 2003, J BIOL CHEM, V278, P12929, DOI 10.1074/jbc.M300263200; Olswang Y, 2002, P NATL ACAD SCI USA, V99, P625, DOI 10.1073/pnas.022616299; Owen O.E., 1976, GLUCONEOGENESIS ITS, P533; PATEL YM, 1994, J BIOL CHEM, V269, P5619; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Reshef L, 2003, J BIOL CHEM, V278, P30413, DOI 10.1074/jbc.R300017200; Scott DK, 1998, MOL ENDOCRINOL, V12, P482, DOI 10.1210/me.12.4.482; Scott DK, 1996, J BIOL CHEM, V271, P31909, DOI 10.1074/jbc.271.50.31909; Sengupta S, 2001, GENE DEV, V15, P2367, DOI 10.1101/gad.202201; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; SLADEK FM, 1993, RECEPTOR, V3, P223; Stafford JM, 2001, J BIOL CHEM, V276, P39885, DOI 10.1074/jbc.M105370200; Stafford JM, 2001, J BIOL CHEM, V276, P3811, DOI 10.1074/jbc.M009389200; Sugiyama T, 1998, MOL ENDOCRINOL, V12, P1487, DOI 10.1210/me.12.10.1487; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TRUS M, 1990, MOL CELL BIOL, V10, P2418, DOI 10.1128/MCB.10.5.2418; Tsai WC, 2003, ENDOCRINOLOGY, V144, P5615, DOI 10.1210/en.2003-0481; Wang JC, 2000, J BIOL CHEM, V275, P14717, DOI 10.1074/jbc.275.19.14717; Wang JC, 1999, MOL ENDOCRINOL, V13, P604, DOI 10.1210/me.13.4.604; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794; Williams CP, 1999, MOL CELL ENDOCRINOL, V148, P67, DOI 10.1016/S0303-7207(98)00234-2; Wolfrum C, 2004, NATURE, V432, P1027, DOI 10.1038/nature03047; YANUKAKASHLES O, 1994, MOL CELL BIOL, V14, P7124, DOI 10.1128/MCB.14.11.7124; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	66	78	80	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33873	33884		10.1074/jbc.M504119200	http://dx.doi.org/10.1074/jbc.M504119200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16100117	hybrid			2022-12-27	WOS:000232229700024
J	Jiang, SX; Lertvorachon, J; Hou, ST; Konishi, Y; Webster, J; Mealing, G; Brunette, E; Tauskela, J; Preston, E				Jiang, SX; Lertvorachon, J; Hou, ST; Konishi, Y; Webster, J; Mealing, G; Brunette, E; Tauskela, J; Preston, E			Chlortetracycline and demeclocycline inhibit calpains and protect mouse neurons against glutamate toxicity and cerebral ischemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMDA-RECEPTOR; TETRACYCLINE DERIVATIVES; PARKINSONS-DISEASE; CORTICAL-NEURONS; FOCAL ISCHEMIA; BRAIN-INJURY; MINOCYCLINE; NEUROPROTECTION; PROTEOLYSIS; ACTIVATION	Minocycline is a potent neuroprotective tetracycline in animal models of cerebral ischemia. We examined the protective properties of chlortetracycline (CTC) and demeclocycline (DMC) and showed that these two tetracyclines were also potent neuroprotective against glutamate-induced neuronal death in vitro and cerebral ischemia in vivo. However, CTC and DMC appeared to confer neuroprotection through a unique mechanism compared with minocycline. Rather than inhibiting microglial activation and caspase, CTC and DMC suppressed calpain activities. In addition, CTC and DMC only weakly antagonized N-methyl-D-aspartate ( NMDA) receptor activities causing 16 and 14%, respectively, inhibition of NMDA-induced whole cell currents and partially blocked NMDA-induced Ca2+ influx, commonly regarded as the major trigger of neuronal death. In vitro and in vivo experiments demonstrated that the two compounds selectively inhibited the activities of calpain I and II activated following glutamate treatment and cerebral ischemia. In contrast, minocycline did not significantly inhibit calpain activity. Taken together, these results suggested that CTC and DMC provide neuroprotection through suppression of a rise in intracellular Ca2+ and inhibition of calpains.	Natl Res Council Canada, NRC Inst Biol Sci, Neurophysiol Grp, Ottawa, ON K1A 0R6, Canada; Natl Res Council Canada, Biotechnol Res Inst, Chem Biol Grp, Montreal, PQ H4P 2R2, Canada	National Research Council Canada; National Research Council Canada	Hou, ST (corresponding author), Natl Res Council Canada, NRC Inst Biol Sci, Neurophysiol Grp, 1200 Montreal Rd Bldg,M54, Ottawa, ON K1A 0R6, Canada.	sheng.hou@nrc-cnrc.gc.ca	Hou, Sheng Tao/O-3202-2018; Hou, Sheng Tao/AAM-7756-2020	Hou, Sheng Tao/0000-0001-9736-342X				AKAMATSU H, 1992, ACTA DERM-VENEREOL, V72, P178; Baptiste DC, 2004, MOL PHARMACOL, V66, P1113, DOI 10.1124/mol.104.001081; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Domercq M, 2004, TRENDS PHARMACOL SCI, V25, P609, DOI 10.1016/j.tips.2004.10.001; Donkor IO, 2000, CURR MED CHEM, V7, P1171, DOI 10.2174/0929867003374129; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Fagan SC, 2004, EXP NEUROL, V186, P248, DOI 10.1016/j.expneurol.2003.12.006; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hewitt KE, 1998, J NEUROSCI RES, V54, P223, DOI 10.1002/(SICI)1097-4547(19981015)54:2<223::AID-JNR10>3.0.CO;2-5; HONG SC, 1994, STROKE, V25, P663, DOI 10.1161/01.STR.25.3.663; HONG SC, 1994, BRAIN RES, V661, P43, DOI 10.1016/0006-8993(94)91178-9; Hou ST, 2002, J BIOL CHEM, V277, P48764, DOI 10.1074/jbc.M206336200; Hou ST, 2002, INT REV CYTOL, V221, P93; Hoyte L, 2004, CURR MOL MED, V4, P131, DOI 10.2174/1566524043479248; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; Inserte J, 2004, CARDIOVASC RES, V64, P105, DOI 10.1016/j.cardiores.2004.06.001; KLEIN NC, 1995, MED CLIN N AM, V79, P789, DOI 10.1016/S0025-7125(16)30039-6; Klein NC, 2001, MED CLIN N AM, V85, P125, DOI 10.1016/S0025-7125(05)70307-2; Koistinaho J, 2004, E SCHERING RES FDN W, V47, P101; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; MacManus JP, 2003, J CEREBR BLOOD F MET, V23, P1020, DOI 10.1097/01.WCB.0000084249.20114.FA; Mealing GAR, 2001, J PHARMACOL EXP THER, V297, P906; Patzke H, 2002, J BIOL CHEM, V277, P8054, DOI 10.1074/jbc.M109645200; Popovic N, 2002, ANN NEUROL, V51, P215, DOI 10.1002/ana.10092; Preston E, 2000, J NEUROSCI METH, V94, P187, DOI 10.1016/S0165-0270(99)00146-6; Rami A, 2003, NEUROBIOL DIS, V13, P75, DOI 10.1016/S0969-9961(03)00018-4; RAMI A, 1993, BRAIN RES, V609, P67, DOI 10.1016/0006-8993(93)90856-I; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Ryan M E, 1998, Adv Dent Res, V12, P152; SEUBERT P, 1989, BRAIN RES, V492, P366, DOI 10.1016/0006-8993(89)90921-9; Smith RA, 2003, MOL BRAIN RES, V116, P70, DOI 10.1016/S0169-328X(03)00253-5; Tauskela JS, 2003, AM J PHYSIOL-CELL PH, V285, pC899, DOI 10.1152/ajpcell.00110.2003; Thomas M, 2004, CURR PHARM DESIGN, V10, P679, DOI 10.2174/1381612043453162; Vanderklish PW, 2000, INT J EXP PATHOL, V81, P323, DOI 10.1046/j.1365-2613.2000.00169.x; Weaver JGR, 2005, J CLIN INVEST, V115, P1828, DOI 10.1172/JCI22954; Wells JEA, 2003, BRAIN, V126, P1628, DOI 10.1093/brain/awg178; Xiong ZG, 2004, CELL, V118, P687, DOI 10.1016/j.cell.2004.08.026; Xu L, 2004, BMC NEUROL, V4, DOI 10.1186/1471-2377-4-7; Yamashima T, 2004, CELL CALCIUM, V36, P285, DOI 10.1016/j.ceca.2004.03.001; Yokota M, 2003, BRAIN RES, V984, P122, DOI 10.1016/S0006-8993(03)03121-4; Yokota M, 1999, BRAIN RES, V819, P8, DOI 10.1016/S0006-8993(98)01334-1; Young KW, 2004, J NEUROCHEM, V89, P1537, DOI 10.1111/j.1471-4159.2004.02458.x; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Zhang C, 2002, NEUROBIOL DIS, V10, P289, DOI 10.1006/nbdi.2002.0526; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	48	57	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33811	33818		10.1074/jbc.M503113200	http://dx.doi.org/10.1074/jbc.M503113200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16091365	hybrid			2022-12-27	WOS:000232229700017
J	Kragt, A; Voorn-Brouwer, T; van den Berg, M; Distel, B				Kragt, A; Voorn-Brouwer, T; van den Berg, M; Distel, B			Endoplasmic reticulum-directed pex3p routes to peroxisomes and restores peroxisome formation in a Saccharomyces cerevisiae pex3 Delta strain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN PEX13P; TAIL-ANCHORED PROTEIN; SACCHAROMYCES-CEREVISIAE; ZELLWEGER-SYNDROME; TARGETING SIGNALS; FARNESYLATED PROTEIN; PICHIA-PASTORIS; SH3 DOMAIN; BIOGENESIS; IMPORT	Recent studies on the sorting of peroxisomal membrane proteins challenge the long-standing model in which peroxisomes are considered to be autonomous organelles that multiply by growth and division. Here, we present data lending support to the idea that the endoplasmic reticulum ( ER) is involved in sorting of the peroxisomal membrane protein Pex3p, a protein required early in peroxisome biogenesis. First, we show that the introduction of an artificial glycosylation site into the N terminus of Pex3p leads to partial N-linked core glycosylation, indicative of insertion into the ER membrane. Second, when FLAG-tagged Pex3p is equipped with an ER targeting signal, it can restore peroxisome formation in pex3 Delta cells. Importantly, FLAG antibodies that specifically recognize the processed Pex3p show that the signal peptide of the fusion protein is efficiently cleaved off and that the processed protein localizes to peroxisomes. In contrast, a Pex3p construct in which cleavage of the signal peptide is blocked by a mutation localizes to the ER and the cytosol and cannot complement pex3 Delta cells. Together, these results strongly suggest that ER-targeted Pex3p indeed routes via the ER to peroxisomes, and we hypothesize that this pathway is also used by endogenous Pex3p.	Univ Amsterdam, Acad Med Ctr, Dept Med Biochem, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Distel, B (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Med Biochem, Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.	b.distel@amc.uva.nl						Baerends RJS, 1996, J BIOL CHEM, V271, P8887, DOI 10.1074/jbc.271.15.8887; Bascom RA, 2003, MOL BIOL CELL, V14, P939, DOI 10.1091/mbc.E02-10-0633; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Biermanns M, 2001, BIOCHEM BIOPH RES CO, V285, P649, DOI 10.1006/bbrc.2001.5220; Bottger G, 2000, MOL BIOL CELL, V11, P3963, DOI 10.1091/mbc.11.11.3963; Brosius U, 2002, J BIOL CHEM, V277, P774, DOI 10.1074/jbc.M108155200; Coligan JE, 1995, CURRENT PROTOCOLS PR; Dammai V, 2001, CELL, V105, P187, DOI 10.1016/S0092-8674(01)00310-5; Distel B, 1996, J CELL BIOL, V135, P1, DOI 10.1083/jcb.135.1.1; Dyer JM, 1996, J CELL BIOL, V133, P269, DOI 10.1083/jcb.133.2.269; Eitzen GA, 1997, J CELL BIOL, V137, P1265, DOI 10.1083/jcb.137.6.1265; Elgersma Y, 1997, EMBO J, V16, P7326, DOI 10.1093/emboj/16.24.7326; Elgersma Y, 1996, J CELL BIOL, V135, P97, DOI 10.1083/jcb.135.1.97; Elgersma Y, 1996, J BIOL CHEM, V271, P26375, DOI 10.1074/jbc.271.42.26375; Erdmann R, 2002, METHOD ENZYMOL, V351, P365; Faber KN, 2002, J BIOL CHEM, V277, P11026, DOI 10.1074/jbc.M112347200; Fang Y, 2004, J CELL BIOL, V164, P863, DOI 10.1083/jcb.200311131; Geuze HJ, 2003, MOL BIOL CELL, V14, P2900, DOI 10.1091/mbc.E02-11-0734; Ghaedi K, 2000, MOL BIOL CELL, V11, P2085, DOI 10.1091/mbc.11.6.2085; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gotte K, 1998, MOL CELL BIOL, V18, P616; Hettema EH, 2000, EMBO J, V19, P223, DOI 10.1093/emboj/19.2.223; Hettema EH, 1998, J CELL BIOL, V142, P421, DOI 10.1083/jcb.142.2.421; Hoepfner D, 2005, CELL, V122, P85, DOI 10.1016/j.cell.2005.04.025; HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167; Honsho M, 1998, AM J HUM GENET, V63, P1622, DOI 10.1086/302161; Honsho M, 2002, J BIOL CHEM, V277, P44513, DOI 10.1074/jbc.M206139200; JAMES GL, 1994, J BIOL CHEM, V269, P14182; Jones JM, 2004, J CELL BIOL, V164, P57, DOI 10.1083/jcb.200304111; Jones JM, 2001, J CELL BIOL, V153, P1141, DOI 10.1083/jcb.153.6.1141; Kalish JE, 1996, EMBO J, V15, P3275, DOI 10.1002/j.1460-2075.1996.tb00692.x; Kammerer S, 1998, FEBS LETT, V429, P53, DOI 10.1016/S0014-5793(98)00557-2; Kammerer S, 1997, GENOMICS, V45, P200, DOI 10.1006/geno.1997.4914; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116; Mullen RT, 1999, PLANT CELL, V11, P2167, DOI 10.1105/tpc.11.11.2167; Muntau AC, 2000, AM J HUM GENET, V67, P967, DOI 10.1086/303071; Purdue PE, 2001, ANNU REV CELL DEV BI, V17, P701, DOI 10.1146/annurev.cellbio.17.1.701; RACCHI M, 1993, J BIOL CHEM, V268, P5735; Sacksteder KA, 2000, J CELL BIOL, V148, P931, DOI 10.1083/jcb.148.5.931; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shimozawa N, 2000, HUM MOL GENET, V9, P1995, DOI 10.1093/hmg/9.13.1995; Shimozawa N, 1998, BIOCHEM BIOPH RES CO, V243, P368, DOI 10.1006/bbrc.1997.8067; Snyder WB, 1999, MOL BIOL CELL, V10, P1745, DOI 10.1091/mbc.10.6.1745; South ST, 2000, J CELL BIOL, V149, P1345, DOI 10.1083/jcb.149.7.1345; South ST, 1999, J CELL BIOL, V144, P255, DOI 10.1083/jcb.144.2.255; South ST, 2001, P NATL ACAD SCI USA, V98, P12027, DOI 10.1073/pnas.221289498; Steel GJ, 2002, BIOCHEMISTRY-US, V41, P11914, DOI 10.1021/bi026105r; Stroobants AK, 1999, FEBS LETT, V453, P210, DOI 10.1016/S0014-5793(99)00721-8; Tabak HF, 2003, TRAFFIC, V4, P512, DOI 10.1034/j.1600-0854.2003.00110.x; Titorenko VI, 1998, MOL CELL BIOL, V18, P2789, DOI 10.1128/MCB.18.5.2789; Vizeacoumar FJ, 2004, MOL BIOL CELL, V15, P665, DOI 10.1091/mbc.E03-09-0681; Voorn-Brouwer T, 2001, J CELL SCI, V114, P2199; Wang XD, 2001, J BIOL CHEM, V276, P10897, DOI 10.1074/jbc.M010883200; Wiemer EAC, 1996, J BIOL CHEM, V271, P18973, DOI 10.1074/jbc.271.31.18973; Yabal M, 2003, J BIOL CHEM, V278, P3489, DOI 10.1074/jbc.M210253200	56	98	99	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34350	34357		10.1074/jbc.M505432200	http://dx.doi.org/10.1074/jbc.M505432200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16100114	hybrid			2022-12-27	WOS:000232229700078
J	Wei, S; Kashiwagi, M; Kota, S; Xie, ZH; Nagase, H; Brew, K				Wei, S; Kashiwagi, M; Kota, S; Xie, ZH; Nagase, H; Brew, K			Reactive site mutations in tissue inhibitor of metalloproteinase-3 disrupt inhibition of matrix metalloproteinases but not tumor necrosis factor-alpha-converting enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; POTENT INHIBITOR; ADAM FAMILY; TIMP-1; DOMAIN; TNF; TACE; EXPRESSION; MECHANISM	Tissue inhibitor of metalloproteinase-3 (TIMP-3) is a dual inhibitor of the matrix metalloproteinases (MMPs) and some adamalysins, two families of extracellular and cell surface metalloproteinases that function in extracellular matrix turnover and the shedding of cell surface proteins. The mechanism of inhibition of MMPs by TIMPs has been well characterized, and since the catalytic domains of MMPs and adamalysins are homologous, it was assumed that the interaction of TIMP-3 with adamalysins is closely similar. Here we report that the inhibition of the extracellular region of ADAM-17 (tumor necrosis factor alpha-converting enzyme (TACE)) by the inhibitory domain of TIMP-3 (N-TIMP-3) shows positive cooperativity. Also, mutations in the core of the MMP interaction surface of N-TIMP-3 dramatically reduce the binding affinity for MMPs but have little effect on the inhibitory activity for TACE. These results suggest that the mechanism of inhibition of ADAM-17 by TIMP-3 may be distinct from that for MMPs. The mutant proteins are also effective inhibitors of tumor necrosis factor alpha(TNF-alpha) release from phorbol ester-stimulated cells, indicating that they provide a lead for engineering TACE-specific inhibitors that may reduce side effects arising from MMP inhibition and are possibly useful for treatment of diseases associated with excessive TNF-alpha levels such as rheumatoid arthritis.	Florida Atlantic Univ, Dept Biomed Sci, Boca Raton, FL 33431 USA; Univ London Imperial Coll Sci Technol & Med, Div Rheumatol, Kennedy Inst, Fac Med, London W6 8LH, England	State University System of Florida; Florida Atlantic University; Imperial College London; University of Oxford	Brew, K (corresponding author), Florida Atlantic Univ, Dept Biomed Sci, Boca Raton, FL 33431 USA.	kbrew@fau.edu	Brew, Keith/A-6746-2009; Brew, Keith/W-1643-2019	Brew, Keith/0000-0003-1306-1032; Wei, Shuo/0000-0001-8203-4922	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040994] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40994] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Coeshott C, 1999, P NATL ACAD SCI USA, V96, P6261, DOI 10.1073/pnas.96.11.6261; Condon TP, 2001, ANTISENSE NUCLEIC A, V11, P107, DOI 10.1089/108729001750171353; Cortes A, 2001, BIOCHEM J, V357, P263, DOI 10.1042/0264-6021:3570263; ENGELBERTS I, 1991, LYMPHOKINE CYTOK RES, V10, P69; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Gonzales PE, 2004, J BIOL CHEM, V279, P31638, DOI 10.1074/jbc.M401311200; Haro H, 2000, J CLIN INVEST, V105, P143, DOI 10.1172/JCI7091; Higashi S, 1999, J BIOL CHEM, V274, P10497, DOI 10.1074/jbc.274.15.10497; Holmbeck K, 2005, J CELL SCI, V118, P147, DOI 10.1242/jcs.01581; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Jin GX, 2002, ANAL BIOCHEM, V302, P269, DOI 10.1006/abio.2001.5549; Kashiwagi M, 2001, J BIOL CHEM, V276, P12501, DOI 10.1074/jbc.C000848200; Kopp J, 2004, NUCLEIC ACIDS RES, V32, pD230, DOI 10.1093/nar/gkh008; Lee MH, 2005, J BIOL CHEM, V280, P15967, DOI 10.1074/jbc.M500897200; Lee MH, 2004, J BIOL CHEM, V279, P45121, DOI 10.1074/jbc.M406611200; Lee MH, 2003, J BIOL CHEM, V278, P40224, DOI 10.1074/jbc.M305678200; Lee MH, 2003, BIOCHEM J, V371, P369, DOI 10.1042/BJ20021538; Lee MH, 2002, PROTEIN SCI, V11, P2493, DOI 10.1110/ps.0216202; Lee MH, 2002, BIOCHEM J, V364, P227, DOI 10.1042/bj3640227; Lee MH, 2002, FEBS LETT, V520, P102, DOI 10.1016/S0014-5793(02)02776-X; Loechel F, 2000, BIOCHEM BIOPH RES CO, V278, P511, DOI 10.1006/bbrc.2000.3835; Lunn CA, 1997, FEBS LETT, V400, P333, DOI 10.1016/S0014-5793(96)01410-X; Martel-Pelletier J, 2001, BEST PRACT RES CL RH, V15, P805, DOI 10.1053/berh.2001.0195; Martignetti JA, 2001, NAT GENET, V28, P261, DOI 10.1038/90100; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; Meng Q, 1999, J BIOL CHEM, V274, P10184, DOI 10.1074/jbc.274.15.10184; Milla ME, 1999, J BIOL CHEM, V274, P30563, DOI 10.1074/jbc.274.43.30563; Mohammed FF, 2004, NAT GENET, V36, P969, DOI 10.1038/ng1413; Moss ML, 2004, BIOCHEMISTRY-US, V43, P7227, DOI 10.1021/bi049677f; Nagase H, 2003, BIOCHEM SOC SYMP, V70, P201, DOI 10.1042/bss0700201; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Qi JH, 2003, ADV EXP MED BIOL, V533, P97; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Rosendahl MS, 1997, J BIOL CHEM, V272, P24588, DOI 10.1074/jbc.272.39.24588; Smith KM, 2002, J CELL BIOL, V159, P893, DOI 10.1083/jcb.200206023; Troeberg L, 2002, BIOCHEMISTRY-US, V41, P15025, DOI 10.1021/bi026454l; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352; Wei S, 2003, BIOCHEMISTRY-US, V42, P12200, DOI 10.1021/bi035358x; Wei S, 2003, J BIOL CHEM, V278, P9831, DOI 10.1074/jbc.M211793200; Wingfield PT, 1999, J BIOL CHEM, V274, P21362, DOI 10.1074/jbc.274.30.21362; Woessner J.F., 2000, PROTEIN PROFILE SER; Zheng YF, 2004, J BIOL CHEM, V279, P42898, DOI 10.1074/jbc.M403193200	49	48	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32877	32882		10.1074/jbc.C500220200	http://dx.doi.org/10.1074/jbc.C500220200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16079149	hybrid			2022-12-27	WOS:000231920300041
J	Glascock, MC; Ballou, DP; Dawson, JH				Glascock, MC; Ballou, DP; Dawson, JH			Direct observation of a novel perturbed oxyferrous catalytic intermediate during reduced putidaredoxin-initiated turnover of cytochrome P-450-CAM - Probing the effector role of putidaredoxin in catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC CIRCULAR-DICHROISM; HEME-CONTAINING OXYGENASES; COMPOUND-I FORMATION; ELECTRON-TRANSFER; THIOLATE LIGATION; MECHANISTIC IMPLICATIONS; KINETIC CHARACTERIZATION; STRUCTURAL-CHANGES; CRYSTAL-STRUCTURE; COMPLEX-FORMATION	The single turnover of ( 1R)(+)-camphor-bound oxyferrous cytochrome P450-CAM with one equivalent of dithionite-reduced putidaredoxin ( Pdx) was monitored for the appearance of transient intermediates at 3 degrees C by double mixing rapid scanning stopped-flow spectroscopy. With excess camphor, three successive species were observed after generating oxyferrous P450-CAM and reacting versus reduced Pdx: a perturbed oxyferrous derivative, as species that was a mixture of high and low spin Fe( III), and high spin ferric camphor-bound enzyme. The rates of the first two steps, similar to 140 and similar to 85 s(-1), were assigned to formation of the perturbed oxyferrous intermediate and to electron transfer from reduced Pdx, respectively. In the presence of stoichiometric substrate, three phases with similar rates were seen even though the final state is low spin ferric P450-CAM. This is consistent with substrate being hydroxylated during the reaction. The single turnover reaction initiated by adding dioxygen to a preformed reduced P450-CAM center dot Pdx complex with excess camphor also led to phases with similar rates. It is proposed that formation of the perturbed oxyferrous intermediate reflects alteration of H-bonding to the proximal Cys, increasing the reduction potential of the oxyferrous state and triggering electron transfer from reduced Pdx. This species may be a direct spectral signature of the effector role of Pdx on P450-CAM reactivity ( i.e. during catalysis). The substrate-free oxyferrous enzyme also reacted readily with reduced Pdx, showing that the inability of substrate-free P450-CAM to accept electrons from reduced Pdx and function as an NADH oxidase is completely due to the incapacity of reduced Pdx to deliver the first but not the second electron.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA; Univ S Carolina, Sch Med, Columbia, SC 29208 USA	University of Michigan System; University of Michigan; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Ballou, DP (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.	dballou@umich.edu; dawson@sc.edu	dballou@umich.edu, David P/A-1298-2007; Dawson, John/HDM-6702-2022	Dawson, John H/0000-0002-4902-4295	NIGMS NIH HHS [GM 20877, GM 26730] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026730, R37GM020877, R01GM020877] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benson DE, 1997, BIOCHEMISTRY-US, V36, P5104, DOI 10.1021/bi963170q; Brazeau BJ, 2003, BIOCHEM BIOPH RES CO, V312, P143, DOI 10.1016/j.bbrc.2003.09.242; BREWER CB, 1988, J BIOL CHEM, V263, P791; Davydov R, 1999, J AM CHEM SOC, V121, P10654, DOI 10.1021/ja9918829; Davydov R, 2001, J AM CHEM SOC, V123, P1403, DOI 10.1021/ja003583l; Dawson JH, 2002, BIOPOLYMERS, V67, P200, DOI 10.1002/bip.10087; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; DAWSON JH, 1987, CHEM REV, V87, P1255, DOI 10.1021/cr00081a015; DAWSON JH, 1982, J BIOL CHEM, V257, P3606; DAWSON JH, 1976, J AM CHEM SOC, V98, P3707, DOI 10.1021/ja00428a054; EBLE KS, 1984, J BIOL CHEM, V259, P4389; EGAWA T, 1994, BIOCHEM BIOPH RES CO, V201, P1464, DOI 10.1006/bbrc.1994.1868; Gunsalus I C, 1978, Methods Enzymol, V52, P166; HITCHMAN ML, 1978, MEASUREMENT DISSOLVE, P7; Hoa G H, 1978, Biochemistry, V17, P2835; KADKHODAYAN S, 1995, J BIOL CHEM, V270, P28042; Kellner DG, 2002, J BIOL CHEM, V277, P9641, DOI 10.1074/jbc.C100745200; LI HY, 1995, J AM CHEM SOC, V117, P6297, DOI 10.1021/ja00128a019; LIPSCOMB JD, 1980, BIOCHEMISTRY-US, V19, P3590, DOI 10.1021/bi00556a027; LIPSCOMB JD, 1976, J BIOL CHEM, V251, P1116; MOMENTEAU M, 1994, CHEM REV, V94, P659, DOI 10.1021/cr00027a006; Mouro C, 1999, FEBS LETT, V455, P302, DOI 10.1016/S0014-5793(99)00898-4; Nagano S, 2003, BIOCHEMISTRY-US, V42, P14507, DOI 10.1021/bi035410p; Nagano S, 2004, J BIOL CHEM, V279, P42844, DOI 10.1074/jbc.M404217200; Ogliaro F, 2000, J AM CHEM SOC, V122, P12892, DOI 10.1021/ja005619f; PALCIC MM, 1980, BIOCHEM BIOPH RES CO, V94, P1123, DOI 10.1016/0006-291X(80)90535-5; PEDERSON TC, 1977, MICROSOMES DRUG OXID, P275; Pochapsky SS, 2003, BIOCHEMISTRY-US, V42, P5649, DOI 10.1021/bi034263s; Purdy MM, 2004, BIOCHEMISTRY-US, V43, P271, DOI 10.1021/bi0356045; Roach MP, 1999, J AM CHEM SOC, V121, P12088, DOI 10.1021/ja9915504; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; Schunemann V, 2002, J INORG BIOCHEM, V91, P586, DOI 10.1016/S0162-0134(02)00476-2; Schunemann V, 2000, FEBS LETT, V479, P149, DOI 10.1016/S0014-5793(00)01886-X; Shimada H, 2001, J INORG BIOCHEM, V83, P255, DOI 10.1016/S0162-0134(00)00173-2; Shimada H, 1999, J BIOL CHEM, V274, P9363, DOI 10.1074/jbc.274.14.9363; Sjodin T, 2001, BIOCHEMISTRY-US, V40, P6852, DOI 10.1021/bi002510b; SONO M, 1985, J BIOL CHEM, V260, P5530; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; Spolitak T, 2005, J BIOL CHEM, V280, P20300, DOI 10.1074/jbc.M501761200; Suzuki N, 1999, J AM CHEM SOC, V121, P11571, DOI 10.1021/ja992511v; Tosha T, 2002, BIOCHEMISTRY-US, V41, P13883, DOI 10.1021/bi0261037; Tosha T, 2003, J BIOL CHEM, V278, P39809, DOI 10.1074/jbc.M304265200; Tosha T, 2004, J BIOL CHEM, V279, P42836, DOI 10.1074/jbc.M404216200; UNGER BP, 1986, J BIOL CHEM, V261, P1158; Unno M, 1997, J AM CHEM SOC, V119, P6614, DOI 10.1021/ja963785a; Unno M, 2002, J BIOL CHEM, V277, P2547, DOI 10.1074/jbc.M108917200; Unno M, 1996, J BIOL CHEM, V271, P17869, DOI 10.1074/jbc.271.30.17869; Yoshioka S, 2002, J AM CHEM SOC, V124, P14571, DOI 10.1021/ja0265409; Yoshioka S, 2000, J INORG BIOCHEM, V81, P141, DOI 10.1016/S0162-0134(00)00097-0; Zhang HM, 2003, BIOCHEMISTRY-US, V42, P11594, DOI 10.1021/bi034968u	50	26	26	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42134	42141		10.1074/jbc.M505426200	http://dx.doi.org/10.1074/jbc.M505426200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16115886	hybrid			2022-12-27	WOS:000233992700040
J	Janiszewski, M; Lopes, LR; Carmo, AO; Pedro, MA; Brandes, RP; Santos, CXC; Laurindo, FRM				Janiszewski, M; Lopes, LR; Carmo, AO; Pedro, MA; Brandes, RP; Santos, CXC; Laurindo, FRM			Regulation of NAD(P)H oxidase by associated protein disulfide isomerase in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-II; NADPH OXIDASE; SUPEROXIDE GENERATION; CELLULAR GLUTATHIONE; PHENYLARSINE OXIDE; PLASMA-MEMBRANE; ACTIVATION; IDENTIFICATION; SUBUNIT; THIOREDOXIN	NAD( P) H oxidase, the main source of reactive oxygen species in vascular cells, is known to be regulated by redox processes and thiols. However, the nature of thiol-dependent regulation has not been established. Protein disulfide isomerase (PDI) is a dithiol/disulfide oxidoreductase chaperone of the thioredoxin superfamily involved in protein processing and translocation. We postulated that PDI regulates NAD( P) H oxidase activity of rabbit aortic smooth muscle cells ( VSMCs). Western blotting confirmed robust PDI expression and shift to membrane fraction after incubation with angiotensin II (AII, 100 nM, 6 h). In VSMC membrane fraction, PDI antagonism with bacitracin, scrambled RNase, or neutralizing antibody led to 26 - 83% inhibition (p < 0.05) of oxidase activity. AII incubation led to significant increase in oxidase activity, accompanied by a 6-fold increase in PDI refolding isomerase activity. AII-induced NAD( P) H oxidase activation was inhibited by 57 - 71% with antisense oligonucleotide against PDI ( PDIasODN). Dihydroethidium fluorescence showed decreased superoxide generation due to PDIasODN. Confocal microscopy showed co-localization between PDI and the oxidase subunits p22phox, Nox1, and Nox4. Co-immunoprecipitation assays supported spatial association between PDI and oxidase subunits p22phox, Nox1, and Nox4 in VSMCs. Moreover, in HEK293 cells transfected with green fluorescent protein constructs for Nox1, Nox2, and Nox4, each of these subunits co- immunoprecipitated with PDI. Akt phosphorylation, a known downstream pathway of AII- driven oxidase activation, was significantly reduced by PDIasODN. These results suggest that PDI closely associates with NAD( P) H oxidase and acts as a novel redoxsensitive regulatory protein of such enzyme complex, potentially affecting subunit traffic/assembling.	Univ Sao Paulo, Sch Med, Vasc Biol Lab, Heart Inst,Inst Coracao, BR-05403000 Sao Paulo, Brazil; Goethe Univ Frankfurt, Inst Kardiovaskulare Physiol, D-60596 Frankfurt, Germany; Univ Sao Paulo, Inst Biomed Sci, Dept Pharmacol, BR-05508900 Sao Paulo, Brazil; Hosp Israelita Albert Einstein, BR-05651901 Sao Paulo, Brazil	Universidade de Sao Paulo; Goethe University Frankfurt; Universidade de Sao Paulo; Hospital Israelita Albert Einstein	Laurindo, FRM (corresponding author), Univ Sao Paulo, Sch Med, Vasc Biol Lab, Heart Inst,Inst Coracao, Av Eneas Carvalho Aguiar,44 Subsolo, BR-05403000 Sao Paulo, Brazil.	expfrancisco@incor.usp.br	Laurindo, Francisco R/J-6575-2015; Lopes, Lucia R/B-9063-2012; Brandes, Ralf P/L-3058-2017	Lopes, Lucia R/0000-0003-0530-7805; Brandes, Ralf P/0000-0002-8035-0048				Ambasta RK, 2004, J BIOL CHEM, V279, P45935, DOI 10.1074/jbc.M406486200; Arrigo AP, 1999, FREE RADICAL BIO MED, V27, P936, DOI 10.1016/S0891-5849(99)00175-6; BARDWELL JCA, 1993, CELL, V74, P769, DOI 10.1016/0092-8674(93)90455-Y; Bennett TA, 2000, J IMMUNOL, V164, P4120, DOI 10.4049/jimmunol.164.8.4120; Brandes RP, 2005, CARDIOVASC RES, V65, P16, DOI 10.1016/j.cardiores.2004.08.007; BUONASSISI V, 1976, P NATL ACAD SCI USA, V73, P1612, DOI 10.1073/pnas.73.5.1612; Catz SD, 2002, P NATL ACAD SCI USA, V99, P11652, DOI 10.1073/pnas.172382799; Clissold PM, 2003, BIOESSAYS, V25, P603, DOI 10.1002/bies.10287; Colston JT, 2005, FEBS LETT, V579, P2533, DOI 10.1016/j.febslet.2005.03.057; Delom F, 2001, J BIOL CHEM, V276, P21337, DOI 10.1074/jbc.M101086200; Djordjevic T, 2005, FREE RADICAL BIO MED, V38, P616, DOI 10.1016/j.freeradbiomed.2004.09.036; Doussiere J, 1998, EUR J BIOCHEM, V251, P649, DOI 10.1046/j.1432-1327.1998.2510649.x; Essex DW, 1999, BRIT J HAEMATOL, V104, P448, DOI 10.1046/j.1365-2141.1999.01197.x; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Gallina A, 2002, J BIOL CHEM, V277, P50579, DOI 10.1074/jbc.M204547200; Gilbert HF, 1998, METHOD ENZYMOL, V290, P26, DOI 10.1016/S0076-6879(98)90005-2; Go YM, 2004, J BIOL CHEM, V279, P5837, DOI 10.1074/jbc.M307547200; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; Inanami O, 1998, ARCH BIOCHEM BIOPHYS, V350, P36, DOI 10.1006/abbi.1997.0484; Janiszewski M, 2000, FREE RADICAL BIO MED, V29, P889, DOI 10.1016/S0891-5849(00)00393-2; Janiszewski M, 2002, FREE RADICAL BIO MED, V32, P446, DOI 10.1016/S0891-5849(01)00828-0; Jiang XM, 1999, J BIOL CHEM, V274, P2416, DOI 10.1074/jbc.274.4.2416; Kim JR, 2000, ANAL BIOCHEM, V283, P214, DOI 10.1006/abio.2000.4623; Kimura T, 2005, BIOCHEM BIOPH RES CO, V331, P224, DOI 10.1016/j.bbrc.2005.03.147; Klappa P, 1997, EUR J BIOCHEM, V248, P37, DOI 10.1111/j.1432-1033.1997.t01-1-00037.x; Kobayashi T, 1998, J CELL SCI, V111, P81; Lahav J, 2003, BLOOD, V102, P2085, DOI 10.1182/blood-2002-06-1646; Lassegue B, 2003, AM J PHYSIOL-REG I, V285, pR277, DOI 10.1152/ajpregu.00758.2002; Laurindo FRM, 2002, METHOD ENZYMOL, V352, P432; Li JM, 2003, J BIOL CHEM, V278, P12094, DOI 10.1074/jbc.M209793200; Lumb RA, 2002, EMBO J, V21, P6763, DOI 10.1093/emboj/cdf685; MANDEL R, 1993, P NATL ACAD SCI USA, V90, P4112, DOI 10.1073/pnas.90.9.4112; Miller FJ, 1998, CIRC RES, V82, P1298, DOI 10.1161/01.RES.82.12.1298; MURPHY JK, 1995, FREE RADICAL BIO MED, V18, P37, DOI 10.1016/0891-5849(94)00101-O; Noiva R, 1999, SEMIN CELL DEV BIOL, V10, P481, DOI 10.1006/scdb.1999.0319; Orlandi PA, 1997, J BIOL CHEM, V272, P4591; Ramachandran N, 2001, P NATL ACAD SCI USA, V98, P9539, DOI 10.1073/pnas.171180998; RAO ASMK, 1993, P NATL ACAD SCI USA, V90, P2950, DOI 10.1073/pnas.90.7.2950; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Seshiah PN, 2002, CIRC RES, V91, P406, DOI 10.1161/01.RES.0000033523.08033.16; Souza HP, 2002, AM J PHYSIOL-HEART C, V282, pH466, DOI 10.1152/ajpheart.00482.2001; Touyz RM, 2003, ARTERIOSCL THROM VAS, V23, P981, DOI 10.1161/01.ATV.0000069236.27911.68; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Wang DT, 2005, J BIOL CHEM, V280, P3096, DOI 10.1074/jbc.M407709200; Wilkinson B, 2004, BBA-PROTEINS PROTEOM, V1699, P35, DOI 10.1016/j.bbapap.2004.02.017; Xiao RY, 2005, J BIOL CHEM, V280, P21099, DOI 10.1074/jbc.M411476200; Yamawaki H, 2003, CIRC RES, V93, P1029, DOI 10.1161/01.RES.0000102869.39150.23; Yellaturu CR, 2002, J BIOL CHEM, V277, P40148, DOI 10.1074/jbc.M206376200; Zai A, 1999, J CLIN INVEST, V103, P393, DOI 10.1172/JCI4890	53	168	172	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40813	40819		10.1074/jbc.M509255200	http://dx.doi.org/10.1074/jbc.M509255200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16150729	hybrid			2022-12-27	WOS:000233666600052
J	Hajishengallis, G; Ratti, P; Harokopakis, E				Hajishengallis, G; Ratti, P; Harokopakis, E			Peptide mapping of bacterial fimbrial epitopes interacting with pattern recognition receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTORS; PORPHYROMONAS-GINGIVALIS INVASION; HEAT-LABILE ENTEROTOXINS; MAC-1 CD11B/CD18; EPITHELIAL-CELLS; BINDING; INNATE; CD14; ACTIVATION; LIPOPOLYSACCHARIDE	The fimbriae of the oral pathogen Porphyromonas gingivalis induce Toll-like receptor 2 (TLR2)-dependent macrophage activation upon their recognition by CD14 and the beta 2 integrin CD11b/CD18. To map functional epitopes of fimbriae that interact with these pattern recognition receptors (PRRs), we examined 20 synthetic peptides covering the entire length of the 41-kDa fimbrillin subunit. Using direct or competitive inhibition assays for receptor binding or cell activation, the CD14 binding activity of fimbriae was localized to residues 69 - 90 and was essential for TLR2-dependent cytokine induction. The CD11b/CD18 binding activity of fimbriae was localized to two neighboring epitopes defined by residues 166-185 and 206-225. Unlike epitope 69-90 that constitutively bound CD14, the CD11b/CD18 binding activity of epitopes 166-185 and 206-225 was inducible by integrin activators. The CD11b/CD18 binding activity played a contributory role to TLR2-dependent induction of tumor necrosis factor-alpha by fimbriae but was involved in specific down-regulation of interleukin-12. Cell activation by a combination of fimbrillin peptides corresponding to the CD14 and CD11b/CD18 binding activities resulted in higher tumor necrosis factor-alpha responses than would be expected from a simply additive effect, attributable to CD14-dependent inside-out signaling leading to enhanced binding interactions with CD11b/CD18. These data suggest that P. gingivalis fimbriae display a modular structure that interacts through discrete epitopes and in a regulated mode with distinct PRRs, which in turn differentially modulate the state of cell activation. Elucidation of pathogen interactions with PRRs at the molecular level may glean insight into host defense mechanisms as well as into microbial strategies that subvert innate immunity.	Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol & Immunol, New Orleans, LA 70119 USA; Louisiana State Univ, Hlth Sci Ctr, Ctr Excellence Oral & Craniofacial Biol, New Orleans, LA 70119 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Hajishengallis, G (corresponding author), Univ Louisville, Sch Dent, Oral Hlth & Syst Dis Res Ctr, Dept Periodont & Endodont, Rm 206,501 S Preston St, Louisville, KY 40202 USA.	g0haji01@louisville.edu	Hajishengallis, George N./K-1117-2019	Hajishengallis, George N./0000-0001-7392-8852	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE015254] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE015254] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Amano A, 1996, INFECT IMMUN, V64, P1631, DOI 10.1128/IAI.64.5.1631-1637.1996; Chun YHP, 2005, J PERIODONTAL RES, V40, P87, DOI 10.1111/j.1600-0765.2004.00771.x; Coxon A, 1996, IMMUNITY, V5, P653, DOI 10.1016/S1074-7613(00)80278-2; Cunningham MD, 1996, INFECT IMMUN, V64, P3601, DOI 10.1128/IAI.64.9.3601-3608.1996; Delima AJ, 2003, PERIODONTOL 2000, V31, P55, DOI 10.1034/j.1600-0757.2003.03105.x; Deshpande RG, 1998, INFECT IMMUN, V66, P5337, DOI 10.1128/IAI.66.11.5337-5343.1998; Desvarieux M, 2005, CIRCULATION, V111, P576, DOI 10.1161/01.CIR.0000154582.37101.15; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DICKINSON DP, 1988, J BACTERIOL, V170, P1658, DOI 10.1128/jb.170.4.1658-1665.1988; Ernst JD, 1998, INFECT IMMUN, V66, P1277, DOI 10.1128/IAI.66.4.1277-1281.1998; Gibson FC, 2004, CIRCULATION, V109, P2801, DOI 10.1161/01.CIR.0000129769.17895.F0; GLACONA MB, 2004, FEMS MICROBIOL LETT, V241, P95; Hajishengallis G, 2005, INFECT IMMUN, V73, P1343, DOI 10.1128/IAI.73.3.1343-1349.2005; Hajishengallis G, 2004, INFECT IMMUN, V72, P6351, DOI 10.1128/IAI.72.11.6351-6358.2004; Hajishengallis G, 2004, INFECT IMMUN, V72, P1188, DOI 10.1128/IAI.72.2.1188-1191.2004; Hajishengallis G, 2002, INFECT IMMUN, V70, P6658, DOI 10.1128/IAI.70.12.6658-6664.2002; Hajishengallis G, 2002, CLIN DIAGN LAB IMMUN, V9, P403, DOI 10.1128/CDLI.9.2.403-411.2002; Hajishengallis George, 2002, Ann Periodontol, V7, P72, DOI 10.1902/annals.2002.7.1.72; Haraszthy VI, 2000, J PERIODONTOL, V71, P1554, DOI 10.1902/jop.2000.71.10.1554; Harokopakis E, 2005, EUR J IMMUNOL, V35, P1201, DOI 10.1002/eji.200425883; Jotwani R, 2004, INFECT IMMUN, V72, P1725, DOI 10.1128/IAI.72.3.1725-1732.2004; Kim JI, 2005, J BIOL CHEM, V280, P11347, DOI 10.1074/jbc.M414607200; LAMONT RJ, 1995, INFECT IMMUN, V63, P3878, DOI 10.1128/IAI.63.10.3878-3885.1995; LEE JY, 1995, PROTEIN EXPRES PURIF, V6, P496, DOI 10.1006/prep.1995.1066; Levitz SM, 1997, INFECT IMMUN, V65, P931, DOI 10.1128/IAI.65.3.931-935.1997; MALEK R, 1994, J BACTERIOL, V176, P1052, DOI 10.1128/JB.176.4.1052-1059.1994; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Moore KJ, 2000, J IMMUNOL, V165, P4272, DOI 10.4049/jimmunol.165.8.4272; Muthukuru M, 2005, INFECT IMMUN, V73, P687, DOI 10.1128/IAI.73.2.687-694.2005; NAITO Y, 1993, ORAL MICROBIOL IMMUN, V8, P195, DOI 10.1111/j.1399-302X.1993.tb00559.x; Ogawa T, 2002, EUR J IMMUNOL, V32, P2543, DOI 10.1002/1521-4141(200209)32:9<2543::AID-IMMU2543>3.0.CO;2-2; Perera PY, 2001, J IMMUNOL, V166, P574, DOI 10.4049/jimmunol.166.1.574; Pugin J, 1998, INFECT IMMUN, V66, P1174, DOI 10.1128/IAI.66.3.1174-1180.1998; Seong SY, 2004, NAT REV IMMUNOL, V4, P469, DOI 10.1038/nri1372; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; SOJAR HT, 1995, BIOCHEM BIOPH RES CO, V216, P785, DOI 10.1006/bbrc.1995.2690; STOCKL J, 1995, J IMMUNOL, V154, P5452; Triantafilou M, 2002, CRIT REV IMMUNOL, V22, P251; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Underhill DM, 2003, EUR J IMMUNOL, V33, P1767, DOI 10.1002/eji.200324037; WATANABE K, 1992, ORAL MICROBIOL IMMUN, V7, P357, DOI 10.1111/j.1399-302X.1992.tb00636.x; Weinberg A, 1997, INFECT IMMUN, V65, P313, DOI 10.1128/IAI.65.1.313-316.1997; Wooten RM, 2002, J IMMUNOL, V168, P348, DOI 10.4049/jimmunol.168.1.348; Yilmaz O, 2002, CELL MICROBIOL, V4, P305, DOI 10.1046/j.1462-5822.2002.00192.x; ZAMBON JJ, 1994, MOLECULAR PATHOGENESIS OF PERIODONTAL DISEASE, P3; Zhou Q, 2005, INFECT IMMUN, V73, P935, DOI 10.1128/IAI.73.2.935-943.2005	48	60	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					38902	38913		10.1074/jbc.M507326200	http://dx.doi.org/10.1074/jbc.M507326200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16129673	hybrid			2022-12-27	WOS:000233362200003
J	Labunskyy, VM; Ferguson, AD; Fomenko, DE; Chelliah, Y; Hatfield, DL; Gladyshev, VN				Labunskyy, VM; Ferguson, AD; Fomenko, DE; Chelliah, Y; Hatfield, DL; Gladyshev, VN			A novel cysteine-rich domain of Sep15 mediates the interaction with UDP-glucose : glycoprotein glucosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALRETICULIN P-DOMAIN; ENDOPLASMIC-RETICULUM; 15-KDA SELENOPROTEIN; QUALITY-CONTROL; RIBONUCLEASE B; PROTEIN; CALNEXIN; SELENIUM; EXPRESSION; CHAPERONE	Selenium is an essential trace element with potent cancer prevention activity in mammals. The 15-kDa selenoprotein (Sep15) has been implicated in the chemopreventive effect of dietary selenium. Although the precise function of Sep15 remains elusive, Sep15 co-purifies with UDP-glucose: glycoprotein glucosyltransferase (GT), an essential regulator of quality control mechanisms within the endoplasmic reticulum. Recent studies identified two GT and two Sep15 homologues in mammals. We characterize interactions between these protein families in this report. Sep15 and GT form a tight 1: 1 complex, and these interactions are conserved between mammals and fruit flies. In mammalian cells, Sep15 co-immunoprecipitates with both GT isozymes. In contrast, a Sep15 homologue, designated selenoprotein M(SelM), does not form a complex with GT. Sequence analysis of members of the Sep15 family identified a novel N-terminal cysteine-rich domain in Sep15 that is absent in SelM. This domain contains six conserved cysteine residues that form two CxxC motifs that do not coordinate metal ions. If this domain is deleted or the cysteines are mutated, Sep15 no longer forms a complex with GT. Conversely, if the cysteine-rich domain of Sep15 is fused to the N-terminus of SelM, the resulting chimera is capable of binding GT. These data indicate that the cysteine-rich domain of Sep15 exclusively mediates protein-protein interactions with GT.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; NCI, NIH, Bethesda, MD 20892 USA	University of Nebraska System; University of Nebraska Lincoln; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gladyshev, VN (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.	vgladyshev1@unl.edu	Gladyshev, Vadim N/A-9894-2013; Gladyshev, Vadim N/J-6187-2013; Labunskyy, Vyacheslav/AAC-8489-2020	Gladyshev, Vadim/0000-0002-0372-7016; Labunskyy, Vyacheslav/0000-0001-9317-1076	NCI NIH HHS [CA080946] Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIABC005317, R01CA080946, Z01BC005317] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Apostolou S, 2004, ONCOGENE, V23, P5032, DOI 10.1038/sj.onc.1207683; Apostolou S, 1999, CELL, V97, P684, DOI 10.1016/S0092-8674(02)09765-9; Arac D, 2003, BIOCHEMISTRY-US, V42, P2774, DOI 10.1021/bi0272050; Arnold SM, 2000, BIOCHEMISTRY-US, V39, P2149, DOI 10.1021/bi9916473; Arnold SM, 2003, J BIOL CHEM, V278, P43320, DOI 10.1074/jbc.M305800200; Caramelo JJ, 2004, J BIOL CHEM, V279, P46280, DOI 10.1074/jbc.M408404200; Caramelo JJ, 2003, P NATL ACAD SCI USA, V100, P86, DOI 10.1073/pnas.262661199; Cheung TH, 1999, CANCER-AM CANCER SOC, V86, P1294, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1294::AID-CNCR26>3.3.CO;2-F; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; Daniels R, 2003, MOL CELL, V11, P79, DOI 10.1016/S1097-2765(02)00821-3; Ellgaard L, 2001, P NATL ACAD SCI USA, V98, P3133, DOI 10.1073/pnas.051630098; Frickel EM, 2002, P NATL ACAD SCI USA, V99, P1954, DOI 10.1073/pnas.042699099; Gladyshev VN, 1998, J BIOL CHEM, V273, P8910, DOI 10.1074/jbc.273.15.8910; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hu YJ, 2001, CANCER RES, V61, P2307; Ip C, 2002, CANCER METAST REV, V21, P281, DOI 10.1023/A:1021263027659; Kapoor M, 2003, J BIOL CHEM, V278, P6194, DOI 10.1074/jbc.M209132200; Keith N, 2005, J BIOL CHEM, V280, P18138, DOI 10.1074/jbc.M501710200; Korotkov KV, 2002, MOL CELL BIOL, V22, P1402, DOI 10.1128/MCB.22.5.1402-1411.2002; Korotkov KV, 2001, J BIOL CHEM, V276, P15330, DOI 10.1074/jbc.M009861200; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Kumaraswamy E, 2000, J BIOL CHEM, V275, P35540, DOI 10.1074/jbc.M004014200; Kumaraswamy E, 2002, METHOD ENZYMOL, V347, P187; Leach MR, 2002, J BIOL CHEM, V277, P29686, DOI 10.1074/jbc.M202405200; Molinari M, 2000, SCIENCE, V288, P331, DOI 10.1126/science.288.5464.331; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; PARKER CG, 1995, EMBO J, V14, P1294, DOI 10.1002/j.1460-2075.1995.tb07115.x; Pelletier MF, 2000, GLYCOBIOLOGY, V10, P815, DOI 10.1093/glycob/10.8.815; Ritter C, 2005, EMBO J, V24, P1730, DOI 10.1038/sj.emboj.7600645; Ritter C, 2000, NAT STRUCT BIOL, V7, P278; Schrag JD, 2001, MOL CELL, V8, P633, DOI 10.1016/S1097-2765(01)00318-5; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Taylor SC, 2004, NAT STRUCT MOL BIOL, V11, P128, DOI 10.1038/nsmb715; Taylor SC, 2003, EMBO REP, V4, P405, DOI 10.1038/sj.embor.embor797; Trombetta ES, 2000, J CELL BIOL, V148, P1123, DOI 10.1083/jcb.148.6.1123; TROMBETTA SE, 1992, J BIOL CHEM, V267, P9236; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009; Zhang ZH, 1997, BIOL TRACE ELEM RES, V57, P147, DOI 10.1007/BF02778198	40	64	66	4	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37839	37845		10.1074/jbc.M508685200	http://dx.doi.org/10.1074/jbc.M508685200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16129668	hybrid, Green Submitted			2022-12-27	WOS:000233044500064
J	Sato, H; Shiiya, A; Kimata, M; Maebara, K; Tamba, M; Sakakura, Y; Makino, N; Sugiyama, F; Yagami, K; Moriguchi, T; Takahashi, S; Bannai, S				Sato, H; Shiiya, A; Kimata, M; Maebara, K; Tamba, M; Sakakura, Y; Makino, N; Sugiyama, F; Yagami, K; Moriguchi, T; Takahashi, S; Bannai, S			Redox imbalance in cystine/glutamate transporter-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PERITONEAL-MACROPHAGES; HUMAN PLASMA; EXCHANGE TRANSPORTER; BACTERIAL LIPOPOLYSACCHARIDE; HUMAN-FIBROBLASTS; CYSTINE; GLUTATHIONE; CYSTEINE; INDUCTION; STATE	Cystine/glutamate transporter, designated as system x(c)(-), mediates cystine entry in exchange for intracellular glutamate in mammalian cells. This transporter consists of two protein components, xCT and 4F2 heavy chain, and the former is predicted to mediate the transport activity. This transporter plays a pivotal role for maintaining the intracellular GSH levels and extracellular cystine/ cysteine redox balance in cultured cells. To clarify the physiological roles of this transporter in vivo, we generated and characterized mice lacking xCT. The xCT(-/-) mice were healthy in appearance and fertile. However, cystine concentration in plasma was significantly higher in these mice, compared with that in the littermate xCT(-/-) mice, while there was no significant difference in plasma cysteine concentration. Plasma GSH level in xCT(-/-) mice was lower than that in the xCT(+/+) mice. The embryonic fibroblasts derived from xCT(-/-) mice failed to survive in routine culture medium, and 2-mercaptoethanol was required for survival and growth. When 2-mercaptoethanol was removed from the culture medium, cysteine and GSH in these cells dramatically decreased, and cells started to die within 24 h. N-Acetyl cysteine also rescued xCT(-/-)- derived cells and permitted growth. These results demonstrate that system x(c)(-) contributes to maintaining the plasma redox balance in vivo but is dispensable in mammalian development, although it is vitally important to cells in vitro.	Yamagata Univ, Fac Agr, Dept Bioresource Engn, Yamagata 9978555, Japan; Univ Tsukuba, Inst Basic Med Sci, Dept Biochem, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Inst Basic Med Sci, Dept Anat & Dev, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Lab Anim Resource Ctr, Tsukuba, Ibaraki 3058575, Japan; Ibaraki Prefectural Univ Hlth Sci, Ctr Humanity & Sci, Ami, Ibaraki 3000394, Japan	Yamagata University; University of Tsukuba; University of Tsukuba; University of Tsukuba	Sato, H (corresponding author), Yamagata Univ, Fac Agr, Dept Bioresource Engn, Yamagata 9978555, Japan.	shideyo@tds1.tr.yamagata-u.ac.jp						BANNAI S, 1986, J MEMBRANE BIOL, V89, P1, DOI 10.1007/BF01870891; BANNAI S, 1991, BIOCHIM BIOPHYS ACTA, V1092, P175, DOI 10.1016/0167-4889(91)90153-O; BANNAI S, 1989, J BIOL CHEM, V264, P18480; BANNAI S, 1984, J BIOL CHEM, V259, P2435; BANNAI S, 1980, J BIOL CHEM, V255, P2372; BANNAI S, 1984, BIOCHIM BIOPHYS ACTA, V779, P289, DOI 10.1016/0304-4157(84)90014-5; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; COTGREAVE IA, 1986, J BIOCHEM BIOPH METH, V13, P231, DOI 10.1016/0165-022X(86)90102-8; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Hack V, 1997, FASEB J, V11, P84, DOI 10.1096/fasebj.11.1.9034170; Hack V, 1998, BLOOD, V92, P59, DOI 10.1182/blood.V92.1.59.413a05_59_67; Hildebrandt W, 2002, MECH AGEING DEV, V123, P1269, DOI 10.1016/S0047-6374(02)00013-1; Hildebrandt W, 2002, BLOOD, V99, P1552, DOI 10.1182/blood.V99.5.1552; ISHII T, 1981, J BIOL CHEM, V256, P2387; Jones DP, 2000, FREE RADICAL BIO MED, V28, P625, DOI 10.1016/S0891-5849(99)00275-0; Jones DP, 2002, FREE RADICAL BIO MED, V33, P1290, DOI 10.1016/S0891-5849(02)01040-7; MANSOOR MA, 1992, ANAL BIOCHEM, V200, P218, DOI 10.1016/0003-2697(92)90456-H; Moriarty SE, 2003, FREE RADICAL BIO MED, V35, P1582, DOI 10.1016/j.freeradbiomed.2003.09.006; SAGARA J, 1993, J NEUROCHEM, V61, P1667, DOI 10.1111/j.1471-4159.1993.tb09801.x; Sasaki H, 2002, J BIOL CHEM, V277, P44765, DOI 10.1074/jbc.M208704200; Sato H, 2004, BIOCHEM BIOPH RES CO, V325, P109, DOI 10.1016/j.bbrc.2004.10.009; SATO H, 1995, BIOCHEM J, V310, P547, DOI 10.1042/bj3100547; Sato H, 2002, J NEUROSCI, V22, P8028; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Sato H, 2001, J BIOL CHEM, V276, P10407, DOI 10.1074/jbc.M007216200; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; WATANABE H, 1987, J EXP MED, V165, P628, DOI 10.1084/jem.165.3.628; WILCKEN DEL, 1980, CLIN SCI, V58, P427, DOI 10.1042/cs0580427; Wlodek PJ, 2001, CLIN CHIM ACTA, V304, P9, DOI 10.1016/S0009-8981(00)00369-7	29	277	296	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37423	37429		10.1074/jbc.M506439200	http://dx.doi.org/10.1074/jbc.M506439200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16144837	hybrid			2022-12-27	WOS:000233044500017
J	Lin, C; Gates, CA; Rao, BG; Brennan, DL; Fulghum, JR; Luong, YP; Frantz, JD; Lin, K; Ma, S; Wei, YY; Perni, RB; Kwong, AD				Lin, C; Gates, CA; Rao, BG; Brennan, DL; Fulghum, JR; Luong, YP; Frantz, JD; Lin, K; Ma, S; Wei, YY; Perni, RB; Kwong, AD			In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NS3 PROTEASE; CRYSTAL-STRUCTURE; PLUS RIBAVIRIN; NS4A COFACTOR; PROTEINASE; CLEAVAGE; RNA; REPLICATION; VARIANTS; THERAPY	VX-950 is a potent, small molecule, peptidomimetic inhibitor of the hepatitis C virus (HCV) NS3 center dot 4A serine protease and has recently been shown to possess antiviral activity in a phase I trial in patients chronically infected with genotype 1 HCV. In a previous study, we described in vitro resistance mutations against either VX-950 or another HCV NS3 center dot 4A protease inhibitor, BILN 2061 (Lin, C., Lin, K., Luong, Y.- P., Rao, B. G., Wei, Y.- Y., Brennan, D. L., Fulghum, J. R., Hsiao, H.-M., Ma, S., Maxwell, J. P., Cottrell, K. M., Perni, R. B., Gates, C. A., and Kwong, A. D. ( 2004) J. Biol. Chem. 279, 17508 17514). Single amino acid substitutions that conferred drug resistance ( distinct for either inhibitor) were identified in the HCV NS3 serine protease domain. The dominant VX-950-resistant mutant (A156S) remains sensitive to BILN 2061. The major BILN 2061-resistant mutants (D168V and D168A) are fully susceptible to VX-950. Modeling analysis suggested that there are different mechanisms of resistance for these mutations induced by VX-950 or BILN 2061. In this study, we identified mutants that are cross-resistant to both HCV protease inhibitors. The cross-resistance conferred by substitution of Ala(156) with either Val or Thr was confirmed by characterization of the purified enzymes and reconstituted replicon cells containing the single amino acid substitution A156V or A156T. Both cross-resistance mutations ( A156V and A156T) displayed significantly diminished fitness ( or replication capacity) in a transient replicon cell system.	Vertex Pharmaceut Inc, Dept Infect Dis Biol, Cambridge, MA 02139 USA	Vertex Pharmaceuticals	Lin, C (corresponding author), Vertex Pharmaceut Inc, Dept Infect Dis Biol, 130 Waverly St, Cambridge, MA 02139 USA.	chao_lin@vrtx.com						Alter HJ, 2000, SEMIN LIVER DIS, V20, P17, DOI 10.1055/s-2000-9505; BARTENSCHLAGER R, 1993, J VIROL, V67, P3835, DOI 10.1128/JVI.67.7.3835-3844.1993; BARTENSCHLAGER R, 1995, J VIROL, V69, P7519, DOI 10.1128/JVI.69.12.7519-7528.1995; Blight KJ, 1998, ANTIVIR THER, V3, P71; Chander G, 2002, HEPATOLOGY, V36, pS135, DOI 10.1053/jhep.2002.37146; De Francesco R, 2003, ANTIVIR RES, V58, P1, DOI 10.1016/S0166-3542(03)00028-7; FAILLA C, 1995, J VIROL, V69, P1769, DOI 10.1128/JVI.69.3.1769-1777.1995; Foy E, 2005, P NATL ACAD SCI USA, V102, P2986, DOI 10.1073/pnas.0408707102; Foy E, 2003, SCIENCE, V300, P1145, DOI 10.1126/science.1082604; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; GRAKOUI A, 1993, J VIROL, V67, P2832, DOI 10.1128/JVI.67.5.2832-2843.1993; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; HIJIKATA M, 1993, P NATL ACAD SCI USA, V90, P10773, DOI 10.1073/pnas.90.22.10773; Hirsch MS, 2003, CLIN INFECT DIS, V37, P113, DOI 10.1086/375597; Kenny-Walsh E, 2001, Clin Liver Dis, V5, P969, DOI 10.1016/S1089-3261(05)70204-X; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; Kolykhalov AA, 2000, J VIROL, V74, P2046, DOI 10.1128/JVI.74.4.2046-2051.2000; Lai CL, 2003, CLIN INFECT DIS, V36, P687, DOI 10.1086/368083; Lamarre D, 2003, NATURE, V426, P186, DOI 10.1038/nature02099; Landro JA, 1997, BIOCHEMISTRY-US, V36, P9340, DOI 10.1021/bi963054n; Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102; Lin C, 2004, J BIOL CHEM, V279, P17508, DOI 10.1074/jbc.M313020200; LIN C, 1995, J VIROL, V69, P4373, DOI 10.1128/JVI.69.7.4373-4380.1995; LIN C, 1995, P NATL ACAD SCI USA, V92, P7622, DOI 10.1073/pnas.92.17.7622; Lin K, 2004, ANTIMICROB AGENTS CH, V48, P4784, DOI 10.1128/AAC.48.12.4784-4792.2004; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Lu LJ, 2004, ANTIMICROB AGENTS CH, V48, P2260, DOI 10.1128/AAC.48.6.2260-2266.2004; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; Migliaccio G, 2003, J BIOL CHEM, V278, P49164, DOI 10.1074/jbc.M305041200; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; Neumann AU, 1998, SCIENCE, V282, P103, DOI 10.1126/science.282.5386.103; Nguyen TT, 2003, ANTIMICROB AGENTS CH, V47, P3525, DOI 10.1128/AAC.47.11.3525-3530.2003; Perni RB, 2003, HEPATOLOGY, V38, p624A; Strader DB, 2004, HEPATOLOGY, V39, P1147, DOI 10.1002/hep.20119; Taliani M, 1996, ANAL BIOCHEM, V240, P60, DOI 10.1006/abio.1996.0331; TANJI Y, 1995, J VIROL, V69, P1575, DOI 10.1128/JVI.69.3.1575-1581.1995; TOMEI L, 1993, J VIROL, V67, P4017, DOI 10.1128/JVI.67.7.4017-4026.1993; Trozzi C, 2003, J VIROL, V77, P3669, DOI 10.1128/JVI.77.6.3669-3679.2003; Wasley A, 2000, SEMIN LIVER DIS, V20, P1, DOI 10.1055/s-2000-9506; Yao NH, 1999, STRUCTURE, V7, P1353, DOI 10.1016/S0969-2126(00)80025-8	40	188	208	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36784	36791		10.1074/jbc.M506462200	http://dx.doi.org/10.1074/jbc.M506462200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16087668	hybrid			2022-12-27	WOS:000232901800032
J	van Lummel, M; Pennings, MTT; Derksen, RHWM; Urbanus, RT; Lutters, BCH; Kaldenhoven, N; de Grott, PG				van Lummel, M; Pennings, MTT; Derksen, RHWM; Urbanus, RT; Lutters, BCH; Kaldenhoven, N; de Grott, PG			The binding site in beta(2)-glycoprotein I for ApoER2 ' on platelets is located in domain V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; ANTIPHOSPHOLIPID SYNDROME; RECEPTOR FAMILY; APOLIPOPROTEIN-H; CRYPTIC EPITOPE; MESSENGER-RNA; IN-VITRO; ANTIBODIES; PHOSPHOLIPIDS; EXPRESSION	The antiphospholipid syndrome is caused by autoantibodies directed against beta(2)-glycoprotein I (beta(2)GPI). Dimerization of beta(2)GPI results in an increased platelet deposition to collagen. We found that apolipoprotein E receptor 2' (apoER2'), a member of the low density lipoprotein receptor family, is involved in activation of platelets by dimeric beta(2)GPI. To identify which domain of dimeric beta(2)GPI interacts with apoER2', we have constructed domain deletion mutants of dimeric beta(2)GPI, lacking domain I ( Delta I), II (Delta II), or V (Delta V), and a mutant with a W316S substitution in the phospholipid (PL)-insertion loop of domain V. Delta I and Delta II prolonged the clotting time, as did full-length dimeric beta(2)GPI; Delta V had no effect on the clotting time. Second, Delta I and Delta II bound to anionic PL, comparable with full-length dimeric beta(2)GPI. Delta V and the W316S mutant bound with decreased affinity to anionic PL. Platelet adhesion to collagen increased significantly when full-length dimeric beta(2)GPI, Delta I, or Delta II ( mean increase 150%) were added to whole blood. No increase was found with plasma beta(2)GPI, Delta V, or the W316S mutant. Immunoprecipitation indicated that full-length dimeric beta(2)GPI, Delta I, Delta II, and the W316S mutant can interact with apoER2' on platelets. Delta V did not associate with apoER2'. We conclude that domain V is involved in both binding beta(2)GPI to anionic PL and in interaction with apoER2' and subsequent activation of platelets. The binding site in beta(2)GPI for interaction with apoER2' does not overlap with the hydrophobic insertion loop in domain V.	Univ Med Ctr, Dept Haematol & Rheumatol, NL-3508 GA Utrecht, Netherlands; Univ Med Ctr, Dept Clin Immunol, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Inst Biomembranes, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, ABC Prot Express Ctr, Dept Crystal & Struct Chem, NL-3584 CH Utrecht, Netherlands; Leiden Univ, Ctr Drug Res, Div Biopharmaceut, NL-2300 RA Leiden, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University; Leiden University; Leiden University - Excl LUMC	de Grott, PG (corresponding author), Univ Med Ctr Utrecht, Dept Haematol, Thrombosis & Haemostasis Lab, G-03-647,POB 85500, NL-3508 GA Utrecht, Netherlands.	ph.g.degroot@azu.nl	Urbanus, Rolf/AAG-7933-2020	Urbanus, Rolf/0000-0002-1601-9393				Andersen OM, 2003, BIOCHEMISTRY-US, V42, P9355, DOI 10.1021/bi034475p; ARFORS L, 1990, EUR J CLIN INVEST, V20, P607, DOI 10.1111/j.1365-2362.1990.tb01908.x; Averna M, 1997, INT J CLIN LAB RES, V27, P207, DOI 10.1007/BF02912460; Bouma B, 1999, EMBO J, V18, P5166, DOI 10.1093/emboj/18.19.5166; Brandes C, 2001, J BIOL CHEM, V276, P22160, DOI 10.1074/jbc.M102662200; BRUNNER J, 1976, BIOCHIM BIOPHYS ACTA, V455, P322, DOI 10.1016/0005-2736(76)90308-4; Caronti B, 1999, CLIN EXP IMMUNOL, V115, P214; Cervera R, 2002, ARTHRITIS RHEUM-US, V46, P1019, DOI 10.1002/art.10187; Chamley LW, 1997, PLACENTA, V18, P403, DOI 10.1016/S0143-4004(97)80040-9; Chung NS, 2004, ADV DRUG DELIVER REV, V56, P1315, DOI 10.1016/j.addr.2003.12.003; de Groot PG, 2004, THROMB RES, V114, P455, DOI 10.1016/j.thromres.2004.06.015; de Laat HB, 2004, CLIN IMMUNOL, V112, P161, DOI 10.1016/j.clim.2004.02.012; den Dekker E, 2001, BBA-MOL CELL RES, V1539, P243, DOI 10.1016/S0167-4889(01)00112-4; Derksen RHWM, 2004, ARTHRITIS RHEUM-US, V50, P1028, DOI 10.1002/art.20105; Durocher Y, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e9; Forastiero R, 1998, THROMB HAEMOSTASIS, V79, P42, DOI 10.1055/s-0037-1614216; GALLI M, 1990, LANCET, V335, P1544, DOI 10.1016/0140-6736(90)91374-J; HAGIHARA Y, 1995, J BIOCHEM-TOKYO, V118, P129, DOI 10.1093/oxfordjournals.jbchem.a124867; Hammel M, 2001, BIOCHEMISTRY-US, V40, P14173, DOI 10.1021/bi0114372; Hong DP, 2001, BIOCHEMISTRY-US, V40, P8092, DOI 10.1021/bi010196v; Horbach DA, 1998, THROMB HAEMOSTASIS, V80, P791; Horbach DA, 1996, THROMB HAEMOSTASIS, V76, P916; HUNT JE, 1993, P NATL ACAD SCI USA, V90, P2141, DOI 10.1073/pnas.90.6.2141; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; Korporaal SJA, 2004, J BIOL CHEM, V279, P52526, DOI 10.1074/jbc.M407407200; Kuwana M, 2005, BLOOD, V105, P1552, DOI 10.1182/blood-2004-08-3145; Leahy DJ, 2000, PROTEIN EXPRES PURIF, V20, P500, DOI 10.1006/prep.2000.1331; Lutters BCH, 2003, J BIOL CHEM, V278, P33831, DOI 10.1074/jbc.M212655200; Lutters BCH, 2001, J BIOL CHEM, V276, P3060, DOI 10.1074/jbc.M008224200; MATSUURA E, 1994, J EXP MED, V179, P457, DOI 10.1084/jem.179.2.457; MATSUURA E, 1990, LANCET, V336, P177, DOI 10.1016/0140-6736(90)91697-9; MEIJERS JCM, 1992, BLOOD, V79, P1435; Melman L, 2001, J BIOL CHEM, V276, P29338, DOI 10.1074/jbc.M103717200; Opara R, 2003, J RHEUMATOL, V30, P55; PENGO V, 1995, THROMB HAEMOSTASIS, V73, P29; Perez-Garcia CG, 2004, EUR J NEUROSCI, V20, P2827, DOI 10.1111/j.1460-9568.2004.03733.x; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; Strasser V, 2004, MOL CELL BIOL, V24, P1378, DOI 10.1128/MCB.24.3.1378-1386.2004; vanWijnen M, 1996, THROMB HAEMOSTASIS, V76, P397; Visvanathan S, 2000, J IMMUNOL, V165, P2258, DOI 10.4049/jimmunol.165.4.2258; Wang SX, 2000, BIOCHEM J, V348, P103, DOI 10.1042/0264-6021:3480103; Wilson WA, 1999, ARTHRITIS RHEUM, V42, P1309, DOI 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F	44	47	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36729	36736		10.1074/jbc.M504172200	http://dx.doi.org/10.1074/jbc.M504172200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16091370	hybrid			2022-12-27	WOS:000232901800026
J	Banci, L; Bertini, I; D'Amelio, N; Gaggelli, E; Libralesso, E; Matecko, I; Turano, P; Valentine, JS				Banci, L; Bertini, I; D'Amelio, N; Gaggelli, E; Libralesso, E; Matecko, I; Turano, P; Valentine, JS			Fully metallated S134NCu,Zn-superoxide dismutase displays abnormal mobility and intermolecular contacts in solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; ZINC SUPEROXIDE-DISMUTASE; MOLECULAR-WEIGHT COMPLEXES; MOTOR-NEURON DEGENERATION; MONOMERIC MUTANT; WILD-TYPE; PROTEINS; DYNAMICS; DISEASE; SOD1	S134N copper-zinc superoxide dismutase (SOD1) is one of the many mutant SOD1 proteins known to cause familial amyotrophic lateral sclerosis. Earlier studies demonstrated that partially metal-deficient S134N SOD1 crystallized in filament-like arrays with abnormal contacts between the individual protein molecules. Because protein aggregation is implicated in SOD1-linked familial amyotrophic lateral sclerosis, abnormal intermolecular interactions between mutant SOD1 proteins could be relevant to the mechanism of pathogenesis in the disease. We have therefore applied NMR methods to ascertain whether abnormal contacts also form between S134N SOD1 molecules in solution and whether Cys-6 or Cys-111 plays any role in the aggregation. Our studies demonstrate that the behavior of fully metallated S134N SOD1 is dramatically different from that of fully metallated wild type SOD1 with a region of subnanosecond mobility located close to the site of the mutation. Such a high degree of mobility is usually seen only in the apo form of wild type SOD1, because binding of zinc to the zinc site normally immobilizes that region. In addition, concentration-dependent chemical shift differences were observed for S134N SOD1 that were not observed for wild type SOD1, indicative of abnormal intermolecular contacts in solution. We have here also established that the two free cysteines ( 6 and 111) do not play a role in this behavior.	Univ Florence, Magnet Resonance Ctr, I-50019 Sesto Fiorentino, Italy; Univ Florence, Dept Chem, I-50019 Sesto Fiorentino, Italy; FiorGen Fdn, I-50019 Sesto Fiorentino, Italy; Univ Siena, Dept Chem, I-53100 Siena, Italy; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	University of Florence; University of Florence; University of Siena; University of California System; University of California Los Angeles	Bertini, I (corresponding author), Univ Florence, Magnet Resonance Ctr, Via Luigi Sacconi 6, I-50019 Sesto Fiorentino, Italy.	ivanobertini@cerm.unifi.it	Valentine, Joan S/B-6665-2008; Turano, Paola/F-9089-2011; D'Amelio, Nicola/AAJ-4369-2021	Valentine, Joan S/0000-0002-7174-925X; Turano, Paola/0000-0002-7683-8614; BANCI, LUCIA/0000-0003-0562-5774; D'Amelio, Nicola/0000-0002-4400-2222	NIGMS NIH HHS [GM28222] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028222] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antonyuk S, 2005, PROTEIN SCI, V14, P1201, DOI 10.1110/ps.041256705; Arnesano F, 2004, J BIOL CHEM, V279, P47998, DOI 10.1074/jbc.M406021200; Arnesano F, 2001, J BIOL CHEM, V276, P41365, DOI 10.1074/jbc.M104807200; Banci L, 2003, BIOCHEMISTRY-US, V42, P9543, DOI 10.1021/bi034324m; Banci L, 2000, BIOCHEMISTRY-US, V39, P9108, DOI 10.1021/bi000067z; Banci L, 1995, EUR J BIOCHEM, V234, P855, DOI 10.1111/j.1432-1033.1995.855_a.x; BANCI L, 1991, EUR J BIOCHEM, V196, P123, DOI 10.1111/j.1432-1033.1991.tb15794.x; Banci L, 2002, PROTEIN SCI, V11, P2479, DOI 10.1110/ps.0210802; Banci L, 2002, EUR J BIOCHEM, V269, P1905, DOI 10.1046/j.1432-1033.2002.02840.x; Banci L, 1997, MAGN RESON CHEM, V35, P845, DOI 10.1002/(SICI)1097-458X(199712)35:12<845::AID-OMR183>3.0.CO;2-O; BEEM KM, 1974, J BIOL CHEM, V249, P7298; Bertini I, 2000, MAGN RESON CHEM, V38, P543, DOI 10.1002/1097-458X(200007)38:7<543::AID-MRC722>3.0.CO;2-#; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; Elam JS, 2003, NAT STRUCT BIOL, V10, P461, DOI 10.1038/nsb935; GETZOFF ED, 1992, NATURE, V358, P347, DOI 10.1038/358347a0; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; Hart PJ, 1998, PROTEIN SCI, V7, P545; Hayward LJ, 2002, J BIOL CHEM, V277, P15923, DOI 10.1074/jbc.M112087200; Hough MA, 2004, P NATL ACAD SCI USA, V101, P5976, DOI 10.1073/pnas.0305143101; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Johnston JA, 2004, PROG NEUROBIOL, V73, P227, DOI 10.1016/j.pneurobio.2004.05.004; Kirkitadze MD, 2002, J NEUROSCI RES, V69, P567, DOI 10.1002/jnr.10328; Kneller JM, 2002, J AM CHEM SOC, V124, P1852, DOI 10.1021/ja017461k; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Lindberg MJ, 2002, P NATL ACAD SCI USA, V99, P16607, DOI 10.1073/pnas.262527099; Morrison BM, 1998, J EXP ZOOL, V282, P32; PARGE HE, 1992, P NATL ACAD SCI USA, V89, P6109, DOI 10.1073/pnas.89.13.6109; Ray SS, 2005, P NATL ACAD SCI USA, V102, P3639, DOI 10.1073/pnas.0408277102; Rowland LP, 2001, NEW ENGL J MED, V344, P1688, DOI 10.1056/NEJM200105313442207; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Shipp EL, 2003, BIOCHEMISTRY-US, V42, P1890, DOI 10.1021/bi026704y; Valentine JS, 2003, P NATL ACAD SCI USA, V100, P3617, DOI 10.1073/pnas.0730423100; Valentine JS, 2005, ANNU REV BIOCHEM, V74, P563, DOI 10.1146/annurev.biochem.72.121801.161647; Wang J, 2002, NEUROBIOL DIS, V10, P128, DOI 10.1006/nbdi.2002.0498; Wang J, 2002, NEUROBIOL DIS, V9, P139, DOI 10.1006/nbdi.2001.0471	39	54	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35815	35821		10.1074/jbc.M506637200	http://dx.doi.org/10.1074/jbc.M506637200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16105836	hybrid			2022-12-27	WOS:000232726900007
J	Chou, WK; Dick, S; Wakarchuk, WW; Tanner, ME				Chou, WK; Dick, S; Wakarchuk, WW; Tanner, ME			Identification and characterization of NeuB3 from Campylobacter jejuni as a pseudaminic acid synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-SPECIFIC POLYSACCHARIDE; PNEUMOPHILA SEROGROUP-1 LIPOPOLYSACCHARIDE; PSEUDOMONAS-AERUGINOSA; HELICOBACTER-PYLORI; SIALIC ACIDS; NEISSERIA-MENINGITIDIS; BISUBSTRATE INHIBITOR; ESCHERICHIA-COLI; SOMATIC ANTIGENS; KDO8P SYNTHASE	Campylobacter jejuni and Campylobacter coli are the main causes of bacterial diarrhea worldwide, and Helicobacter pylori is known to cause duodenal ulcers. In all of these pathogenic organisms, the flagellin proteins are heavily glycosylated with a 2-keto-3-deoxy acid, pseudaminic acid (5,7-diacetamido-3,5,7,9-tetradeoxy-L-glycero-L- manno-nonulosonic acid). The presence of pseudaminic acid is required for the proper development of the flagella and is thereby necessary for motility in, and invasion of, the host. In this study we report the first characterization of NeuB3 from C. jejuni as a pseudaminic acid synthase; the enzyme directly responsible for the biosynthesis of pseudaminic acid. Pseudaminic acid synthase catalyzes the condensation of phosphoenolpyruvate ( PEP) with the hexose, 2,4-diacetamido-2,4,6- trideoxy-L-altrose (6-deoxy-AltdiNAc), to form pseudaminic acid and phosphate. The enzymatic activity was monitored using H-1 and P-31 NMR spectroscopy, and the product was isolated and characterized. Kinetic analysis reveals that pseudaminic acid synthase requires the presence of a divalent metal ion for catalysis and that optimal catalysis occurs at pH 7.0. A coupled enzymatic assay gave the values for k(cat) of 0.65 +/- 0.01 s(-1), KmPEP of 6.5 +/- 0.4 mu M, and K(m)6-deoxy- AltdiNAc of 9.5 +/- 0.7 mu M. A mechanistic study on pseudaminic acid synthase, using[2-O-18] PEP, shows that catalysis proceeds through a C-O bond cleavage mechanism similar to other PEP condensing synthases such as sialic acid synthase.	Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	University of British Columbia; National Research Council Canada	Tanner, ME (corresponding author), Univ British Columbia, Dept Chem, 2036 Main Mall, Vancouver, BC V6T 1Z1, Canada.	mtanner@chem.ubc.ca	Wakarchuk, Warren/AAO-2774-2020; Wakarchuk, Warren/Q-9514-2017	Wakarchuk, Warren/0000-0002-1539-1679; Wakarchuk, Warren/0000-0002-1539-1679				Angata T, 2002, CHEM REV, V102, P439, DOI 10.1021/cr000407m; Asojo O, 2001, BIOCHEMISTRY-US, V40, P6326, DOI 10.1021/bi010339d; BARTLETT PA, 1983, J ORG CHEM, V48, P3854, DOI 10.1021/jo00169a064; BLACK RE, 1988, J INFECT DIS, V157, P472, DOI 10.1093/infdis/157.3.472; BLACKLOW RS, 1962, J BIOL CHEM, V237, P3520; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTZLER JP, 1979, CLIN GASTROENTEROL, V8, P737; CALDWELL MB, 1985, INFECT IMMUN, V50, P941, DOI 10.1128/IAI.50.3.941-943.1985; COHN M, 1978, P NATL ACAD SCI USA, V75, P200, DOI 10.1073/pnas.75.1.200; COVER TL, 1992, ANNU REV MED, V43, P135, DOI 10.1146/annurev.me.43.020192.001031; DELEO AB, 1968, BIOCHEM BIOPH RES CO, V32, P873, DOI 10.1016/0006-291X(68)90322-7; *ER SOFTW LTD, 2003, GRAFIT; FLOWERS HM, 1967, CARBOHYD RES, P189; Furdui C, 2004, J BIOL CHEM, V279, P45618, DOI 10.1074/jbc.M404753200; GORE MP, 1990, J ORG CHEM, V55, P758, DOI 10.1021/jo00289a063; Gunawan J, 2005, J BIOL CHEM, V280, P3555, DOI 10.1074/jbc.M411942200; HEDSTROM L, 1988, BIOCHEM BIOPH RES CO, V157, P816, DOI 10.1016/S0006-291X(88)80322-X; HOLBEIN BE, 1983, J BACTERIOL, P728; JOSENHANS C, 1995, J BACTERIOL, V177, P3010, DOI 10.1128/jb.177.11.3010-3020.1995; Kaustov L, 2003, J AM CHEM SOC, V125, P4662, DOI 10.1021/ja028688y; Kenne L, 1988, CARBOHYD RES, V180, P285, DOI 10.1016/0008-6215(88)80085-5; KNIREL YA, 1994, EUR J BIOCHEM, V221, P239, DOI 10.1111/j.1432-1033.1994.tb18734.x; KNIREL YA, 1987, EUR J BIOCHEM, V163, P627, DOI 10.1111/j.1432-1033.1987.tb10912.x; KNIREL YA, 1984, CARBOHYD RES, V133, pC5, DOI 10.1016/0008-6215(84)85213-1; KNIREL YA, 1987, EUR J BIOCHEM, V163, P639, DOI 10.1111/j.1432-1033.1987.tb10913.x; Knirel YA, 1997, CARBOHYD RES, V304, P77, DOI 10.1016/S0008-6215(97)00211-5; Kondakova AN, 2001, CARBOHYD RES, V333, P241, DOI 10.1016/S0008-6215(01)00145-8; LEVIN DH, 1959, J BIOL CHEM, V234, P2532; LIAV AL, 1973, CARBOHYD RES, V30, P109, DOI 10.1016/S0008-6215(00)82178-3; Linton D, 2000, MOL MICROBIOL, V35, P1120, DOI 10.1046/j.1365-2958.2000.01780.x; Logan SM, 2002, MOL MICROBIOL, V46, P587, DOI 10.1046/j.1365-2958.2002.03185.x; Matte A, 1997, J BIOL CHEM, V272, P8105, DOI 10.1074/jbc.272.13.8105; MOROOKA T, 1985, J GEN MICROBIOL, V131, P1973; Schirm M, 2003, MOL MICROBIOL, V48, P1579, DOI 10.1046/j.1365-2958.2003.03527.x; SEEHOLZER SH, 1991, BIOCHEMISTRY-US, V30, P727, DOI 10.1021/bi00217a022; Shulami S, 2004, J BIOL CHEM, V279, P45110, DOI 10.1074/jbc.M404561200; Sundaram AK, 2004, BIOCHEM J, V383, P83, DOI 10.1042/BJ20040218; Szymanski CM, 2005, NAT REV MICROBIOL, V3, P225, DOI 10.1038/nrmicro1100; Thibault P, 2001, J BIOL CHEM, V276, P34862, DOI 10.1074/jbc.M104529200; Tsvetkov YE, 2001, CARBOHYD RES, V331, P233, DOI 10.1016/S0008-6215(01)00041-6; WAKARCHUK WW, 1994, PROTEIN SCI, V3, P467; Wang J, 2001, BIOCHEMISTRY-US, V40, P15676, DOI 10.1021/bi015568e; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884	43	62	65	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35922	35928		10.1074/jbc.M507483200	http://dx.doi.org/10.1074/jbc.M507483200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16120604	hybrid			2022-12-27	WOS:000232726900019
J	Deng, Q; Sun, JJ; Barbieri, JT				Deng, Q; Sun, JJ; Barbieri, JT			Uncoupling Crk signal transduction by Pseudomonas exoenzyme T	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; FAMILY ADAPTER PROTEINS; GROWTH-FACTOR RECEPTOR; C-ABL KINASE; TYROSINE PHOSPHORYLATION; CELL-MIGRATION; MAMMALIAN-CELLS; AERUGINOSA EXOT; IN-VIVO; EPITHELIAL-CELLS	Exoenzyme T (ExoT) is a bifunctional type III cytotoxin of Pseudomonas aeruginosa that possesses both Rho GTPase-activating protein and ADP-ribosyltransferase activities. The ADP-ribosyltransferase activity of ExoT stimulated depolymerization of the actin cytoskeleton independent of Rho GTPase-activating protein function, and ExoT was subsequently shown to ADP-ribosylate Crk (CT10 regulator of kinase)-I and Crk-II. Crk proteins are eukaryotic adaptor proteins comprising SH2 and SH3 domains that are components of the integrin signaling pathway leading to Rac1 and Rap1 functions. Mass spectroscopic analysis identified Arg(20) as the site of ADP-ribosylation by ExoT. Arg(20) is a conserved residue located within the SH2 domain that is required for interactions with upstream signaling molecules such as paxillin and p130(cas). Glutathione S-transferase pull-down and far Western assays showed that ADP-ribosylated Crk-I or Crk-I(R20K) failed to bind p130cas or paxillin. This indicates that ADP-ribosylation inhibited the direct interaction of Crk with these focal adhesion proteins. Overexpression of wild-type Crk-I reduced cell rounding by ExoT, whereas expression of dominant-active Rac1 interfered with the ability of ExoT to round cells. Thus, the ADP-ribosylation of Crk uncouples integrin signaling by direct inhibition of the binding of Crk to focal adhesion proteins.	Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Barbieri, JT (corresponding author), Med Coll Wisconsin, Dept Microbiol & Mol Genet, 8701 watertown Plank Rd, Milwaukee, WI 53226 USA.	jtb01@mcw.edu	Deng, Qing/AAC-1123-2020; Deng, Qing/G-3923-2011	Deng, Qing/0000-0002-9254-9951; 	NIAID NIH HHS [R01 AI30162] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030162] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Barbieri JT, 2005, REV PHYSIOL BIOCH P, V152, P79, DOI 10.1007/s10254-004-0031-7; Black DS, 2000, CELL MICROBIOL, V2, P401, DOI 10.1046/j.1462-5822.2000.00061.x; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; Buday L, 1999, BBA-REV BIOMEMBRANES, V1422, P187, DOI 10.1016/S0304-4157(99)00005-2; Burton EA, 2003, EMBO J, V22, P5471, DOI 10.1093/emboj/cdg512; CARY LA, 1999, FRONT BIOSCI, V4, P102; Chen HY, 2004, MOL CELL BIOL, V24, P10558, DOI 10.1128/MCB.24.24.10558-10572.2004; COBURN J, 1989, INFECT IMMUN, V57, P996, DOI 10.1128/IAI.57.3.996-998.1989; COBURN J, 1991, J BIOL CHEM, V266, P6438; Donaldson LW, 2002, P NATL ACAD SCI USA, V99, P14053, DOI 10.1073/pnas.212518799; Escalante M, 2000, J BIOL CHEM, V275, P24787, DOI 10.1074/jbc.M000711200; Evans DJ, 2002, MICROB PATHOGENESIS, V33, P135, DOI 10.1006/mpat.2002.0521; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Feltman H, 2001, MICROBIOL-SGM, V147, P2659, DOI 10.1099/00221287-147-10-2659; Frank DW, 1997, MOL MICROBIOL, V26, P621, DOI 10.1046/j.1365-2958.1997.6251991.x; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; Garrity-Ryan L, 2000, INFECT IMMUN, V68, P7100, DOI 10.1128/IAI.68.12.7100-7113.2000; Gesbert F, 1998, J BIOL CHEM, V273, P18273, DOI 10.1074/jbc.273.29.18273; Goehring UM, 1999, J BIOL CHEM, V274, P36369, DOI 10.1074/jbc.274.51.36369; Goldberg GS, 2003, J BIOL CHEM, V278, P46533, DOI 10.1074/jbc.M307526200; Gu JG, 2001, J BIOL CHEM, V276, P27090, DOI 10.1074/jbc.M102284200; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Hashimoto Y, 1998, J BIOL CHEM, V273, P17186, DOI 10.1074/jbc.273.27.17186; Kain KH, 2001, J BIOL CHEM, V276, P16185, DOI 10.1074/jbc.M100095200; Kazmierczak BI, 2002, INFECT IMMUN, V70, P2198, DOI 10.1128/IAI.70.4.2198-2205.2002; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; Koval AP, 1998, BIOCHEM J, V330, P923; Krall R, 2000, INFECT IMMUN, V68, P6066, DOI 10.1128/IAI.68.10.6066-6068.2000; Krall R, 2004, J BIOL CHEM, V279, P2747, DOI 10.1074/jbc.M301963200; Krall R, 2002, INFECT IMMUN, V70, P360, DOI 10.1128/IAI.70.1.360-367.2002; Lamorte L, 2003, MOL BIOL CELL, V14, P2818, DOI 10.1091/mbc.E02-08-0497; Lamorte L, 2002, MOL BIOL CELL, V13, P1449, DOI 10.1091/mbc.01-10-0477; Ling P, 1999, MOL CELL BIOL, V19, P1359; Ling P, 2001, J BIOL CHEM, V276, P18908, DOI 10.1074/jbc.M101485200; Maresso AW, 2004, J BIOL CHEM, V279, P38402, DOI 10.1074/jbc.M405707200; Matsuda M, 1996, CELL SIGNAL, V8, P335, DOI 10.1016/0898-6568(96)00067-8; MATSUDA M, 1992, J VIROL, V66, P115, DOI 10.1128/JVI.66.1.115-121.1992; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; Nagashima KI, 2002, MOL BIOL CELL, V13, P4231, DOI 10.1091/mbc.E02-04-0181; Nakashima K, 1999, J BIOL CHEM, V274, P27786, DOI 10.1074/jbc.274.39.27786; Nasertorabi F, 2004, BIOCHEM BIOPH RES CO, V324, P993, DOI 10.1016/j.bbrc.2004.09.148; Oehrl W, 1998, ONCOGENE, V17, P1893, DOI 10.1038/sj.onc.1202108; Okada S, 1997, J BIOL CHEM, V272, P28179, DOI 10.1074/jbc.272.45.28179; Okada S, 1998, EMBO J, V17, P2554, DOI 10.1093/emboj/17.9.2554; Persson C, 1997, EMBO J, V16, P2307, DOI 10.1093/emboj/16.9.2307; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sato H, 2003, EMBO J, V22, P2959, DOI 10.1093/emboj/cdg290; Sattler M, 2001, J BIOL CHEM, V276, P2451, DOI 10.1074/jbc.M006250200; Sattler M, 1997, J BIOL CHEM, V272, P14320, DOI 10.1074/jbc.272.22.14320; Shi CS, 2000, BLOOD, V95, P776, DOI 10.1182/blood.V95.3.776.003k23_776_782; Shin NY, 2004, J BIOL CHEM, V279, P38331, DOI 10.1074/jbc.M404675200; Shishido T, 2001, GENES CELLS, V6, P431, DOI 10.1046/j.1365-2443.2001.00431.x; Sun JJ, 2003, J BIOL CHEM, V278, P32794, DOI 10.1074/jbc.M304290200; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tosello-Trampont AC, 2001, J BIOL CHEM, V276, P13797, DOI 10.1074/jbc.M011238200; Van Delden C, 1998, EMERG INFECT DIS, V4, P551, DOI 10.3201/eid0404.980405; Weidow CL, 2000, CELL MICROBIOL, V2, P549, DOI 10.1046/j.1462-5822.2000.00079.x; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4; Yahr TL, 1998, P NATL ACAD SCI USA, V95, P13899, DOI 10.1073/pnas.95.23.13899; Yang LT, 2002, J BIOL CHEM, V277, P17406, DOI 10.1074/jbc.M111902200; Yano H, 2000, J NEUROSCI RES, V59, P356, DOI 10.1002/(SICI)1097-4547(20000201)59:3<356::AID-JNR9>3.0.CO;2-G; Zamir E, 2001, J CELL SCI, V114, P3583; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	68	29	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35953	35960		10.1074/jbc.M504901200	http://dx.doi.org/10.1074/jbc.M504901200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16123042	hybrid			2022-12-27	WOS:000232726900022
J	Greive, SJ; Lins, AF; von Hippel, PH				Greive, SJ; Lins, AF; von Hippel, PH			Assembly of an RNA-protein complex - Binding of NusB and NusE (S10) proteins to boxA RNA nucleates the formation of the antitermination complex involved in controlling rRNA transcription in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEDIMENTATION-VELOCITY ANALYSIS; COEFFICIENT DISTRIBUTIONS C(S); ELONGATION-FACTOR-NUSA; LAMBDA N PROTEIN; PHAGE-LAMBDA; BACTERIOPHAGE-LAMBDA; DEFECTIVE ANTITERMINATION; INTRINSIC TERMINATORS; ANTI-TERMINATION; GENE-EXPRESSION	Analytical ultracentrifugation and fluorescence anisotropy methods have been used to measure the equilibrium parameters that control the formation of the core subcomplex of NusB and NusE proteins and boxA RNA. This subcomplex, in turn, nucleates the assembly of the antitermination complex that is involved in controlling the synthesis of ribosomal RNA in Escherichia coli and that also participates in forming the N protein-dependent antitermination complex in lambdoid phage synthesis. In this study we determined the dissociation constants (K-d values) for the individual binary interactions that participate in the assembly of the ternary NusB-NusE-boxA RNA subassembly, and we showed that multiple equilibria, involving both specific and nonspecific binding, are involved in the assembly pathway of this protein-RNA complex. The measured Kd values were used to model the in vitro assembly reaction and combined with in vivo concentration data to simulate the overall control of the assembly of this complex in E. coli at two different cellular growth rates. The results showed that at both growth rates assembly proceeds via the initial formation of a weak but specific NusB-boxA complex, which is then stabilized by NusE binding. We showed that NusE also binds nonspecifically to available single-stranded RNA sequences and that such nonspecific protein binding to RNA can help to regulate crucial interactions in the assembly of the various macromolecular machines of gene expression.	Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; Univ Oregon, Dept Chem, Eugene, OR 97403 USA	University of Oregon; University of Oregon	von Hippel, PH (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.	petevh@molbio.uoregon.edu		von Hippel, Peter H./0000-0003-2512-8097	NIGMS NIH HHS [GM-29158, GM-15792] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029158, R37GM015792, R01GM015792] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG KL, 1989, J MOL BIOL, V209, P345, DOI 10.1016/0022-2836(89)90002-8; Berglechner F, 1997, EUR J BIOCHEM, V248, P338, DOI 10.1111/j.1432-1033.1997.00338.x; Bonifacio GF, 1997, BIOPHYS J, V73, P1532, DOI 10.1016/S0006-3495(97)78185-2; Bremer H, 1996, ESCHERICHIA COLI SAL; COHEN G, 1968, BIOPOLYMERS, V6, P1077, DOI 10.1002/bip.1968.360060805; CONDON C, 1995, MICROBIOL REV, V59, P623, DOI 10.1128/MMBR.59.4.623-645.1995; COURT DL, 1995, J BACTERIOL, V177, P2589, DOI 10.1128/jb.177.9.2589-2591.1995; Culver GM, 1999, RNA, V5, P832, DOI 10.1017/S1355838299990714; Dam J, 2005, BIOPHYS J, V89, P619, DOI 10.1529/biophysj.105.059568; Dam J, 2005, BIOPHYS J, V89, P651, DOI 10.1529/biophysj.105.059584; Demeler B, 2004, ANAL BIOCHEM, V335, P279, DOI 10.1016/j.ab.2004.08.039; DEVITO J, 1994, P NATL ACAD SCI USA, V91, P8660, DOI 10.1073/pnas.91.18.8660; DODD J, 1991, BIOCHIMIE, V73, P757, DOI 10.1016/0300-9084(91)90055-6; GAUSING K, 1977, J MOL BIOL, V115, P335, DOI 10.1016/0022-2836(77)90158-9; GILL SC, 1991, J MOL BIOL, V220, P307, DOI 10.1016/0022-2836(91)90015-X; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gopal B, 2001, BIOCHEMISTRY-US, V40, P920, DOI 10.1021/bi0018279; GREENBLATT J, 1981, J MOL BIOL, V147, P11, DOI 10.1016/0022-2836(81)90076-0; Greive SJ, 2005, NAT REV MOL CELL BIO, V6, P221, DOI 10.1038/nrm1588; HEINRICH T, 1995, J BACTERIOL, V177, P3793, DOI 10.1128/jb.177.13.3793-3800.1995; HELD WA, 1974, J BIOL CHEM, V249, P3103; Koch A L, 1970, J Theor Biol, V28, P201; Komissarova N, 2002, MOL CELL, V10, P1151, DOI 10.1016/S1097-2765(02)00738-4; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Lakowicz J., 1999, PRINCIPLES FLUORESCE, P302; LI J, 1992, J BIOL CHEM, V267, P6012; Lucast LJ, 2001, BIOTECHNIQUES, V30, P544, DOI 10.2144/01303st06; Luttgen H, 2002, J MOL BIOL, V316, P875, DOI 10.1006/jmbi.2001.5388; Mah TF, 1999, MOL MICROBIOL, V34, P523, DOI 10.1046/j.1365-2958.1999.01618.x; MASON SW, 1991, GENE DEV, V5, P1504, DOI 10.1101/gad.5.8.1504; MASON SW, 1992, J MOL BIOL, V223, P55, DOI 10.1016/0022-2836(92)90715-V; MIZUSHIMA S, 1970, NATURE, V226, P1214, DOI 10.1038/2261214a0; Mogridge J, 1998, J BIOL CHEM, V273, P4143, DOI 10.1074/jbc.273.7.4143; NODWELL JR, 1993, CELL, V72, P261, DOI 10.1016/0092-8674(93)90665-D; NODWELL JR, 1991, GENE DEV, V5, P2141, DOI 10.1101/gad.5.11.2141; Pellizzoni L, 2002, SCIENCE, V298, P1775, DOI 10.1126/science.1074962; Pfeiffer T, 1997, J MOL BIOL, V265, P385, DOI 10.1006/jmbi.1996.0744; Rees WA, 1997, J MOL BIOL, V273, P797, DOI 10.1006/jmbi.1997.1327; Richardson JP, 2003, CELL, V114, P157, DOI 10.1016/S0092-8674(03)00554-3; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SHARROCK RA, 1985, P NATL ACAD SCI USA, V82, P5275, DOI 10.1073/pnas.82.16.5275; Stoylov SP, 1997, BIOPOLYMERS, V41, P301, DOI 10.1002/(SICI)1097-0282(199703)41:3&lt;301::AID-BIP5&gt;3.0.CO;2-W; SWINDLE J, 1988, J BIOL CHEM, V263, P10229; Torres M, 2001, EMBO J, V20, P3811, DOI 10.1093/emboj/20.14.3811; Van Gilst M, 1995, NUCL ACIDS S SER, V33, P145; Van Gilst MR, 2000, METHOD ENZYMOL, V323, P1; VanGilst MR, 1997, BIOCHEMISTRY-US, V36, P1514, DOI 10.1021/bi961920q; VanGilst MR, 1997, J MOL BIOL, V274, P160, DOI 10.1006/jmbi.1997.1389; VONHIPPEL PH, 1982, J MOL BIOL, V162, P795, DOI 10.1016/0022-2836(82)90548-4; Weisberg RA, 1999, J BACTERIOL, V181, P359, DOI 10.1128/JB.181.2.359-367.1999; WHALEN W A, 1990, New Biologist, V2, P975; WILSON KS, 1995, P NATL ACAD SCI USA, V92, P8793, DOI 10.1073/pnas.92.19.8793; YAGUCHI M, 1980, FEBS LETT, V121, P113, DOI 10.1016/0014-5793(80)81277-4	53	50	52	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36397	36408		10.1074/jbc.M507146200	http://dx.doi.org/10.1074/jbc.M507146200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16109710	hybrid			2022-12-27	WOS:000232726900074
J	Huang, LQ; Cao, J; Wang, H; Vo, LA; Brand, JG				Huang, LQ; Cao, J; Wang, H; Vo, LA; Brand, JG			Identification and functional characterization of a voltage-gated chloride channel and its novel splice variant in taste bud cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-CELLS; BITTER TASTE; SWEET TASTE; ALPHA-GUSTDUCIN; MESSENGER-RNA; SOUR TASTE; SYNAPTIC VESICLES; ACTION-POTENTIALS; EXPRESSION LEVELS; MUS-SPRETUS	Taste bud cells are epithelial cells with neuronal properties. Voltage-dependent ion channels have been physiologically described in these cells. Here, we report the molecular identification and functional characterization of a voltage-gated chloride channel (ClC-4) and its novel splice variant (ClC-4A) from taste bud cells. ClC-4A skipped an exon near its 5'-end, incurring the loss of 60 amino acids at the N terminus. In situ hybridization and immunohistochemistry localized these two channels' transcripts and proteins to a subset of taste bud cells. Electrophysiological recordings of the heterologously expressed channels in Xenopus oocytes showed that ClC-4 and ClC-4A have opposite sensitivity to pH and unique ion selectivity. The chloride channel blockers niflumic acid and 5-nitro-2-(3-phenylpropylamino) benzoic acid had a slight or no inhibitory effect on the conductance of ClC-4, but both blockers inhibited ClC-4A, suggesting that ClC-4A is a candidate channel for an acid-induced 5-nitro-2-( 3-phenylpropylamino) benzoic acid-sensitive current. Furthermore, these two channels may play a role in bitter-, sweet-, and umami-mediated taste transmission by regulating transmitter uptake into synaptic vesicles.	Monell Chem Senses Ctr, Philadelphia, PA 19104 USA; Univ Penn, Vet Affairs Med Ctr, Philadelphia, PA 19104 USA; Univ Penn, Dept Biochem, Philadelphia, PA 19104 USA	Monell Chemical Senses Center; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; University of Pennsylvania	Huang, LQ (corresponding author), Monell Chem Senses Ctr, 3500 Market St, Philadelphia, PA 19104 USA.	lhuang@monell.org		Huang, Liquan/0000-0003-3400-0685; Wang, Hong/0000-0003-4130-8741	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R03DC005154] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Adler DA, 1997, P NATL ACAD SCI USA, V94, P9244, DOI 10.1073/pnas.94.17.9244; Adler E, 2000, CELL, V100, P693, DOI 10.1016/S0092-8674(00)80705-9; AVENET P, 1991, J MEMBRANE BIOL, V124, P33, DOI 10.1007/BF01871362; Bachmanov AA, 2001, CHEM SENSES, V26, P925, DOI 10.1093/chemse/26.7.925; BEHE P, 1990, J GEN PHYSIOL, V96, P1061, DOI 10.1085/jgp.96.5.1061; Behrens M, 2004, BIOCHEM BIOPH RES CO, V319, P479, DOI 10.1016/j.bbrc.2004.05.019; Bufe B, 2002, NAT GENET, V32, P397, DOI 10.1038/ng1014; Caicedo A, 2003, J NEUROSCI, V23, P9947; Campos-Xavier AB, 2003, HUM GENET, V112, P186, DOI 10.1007/s00439-002-0861-9; Chandrashekar J, 2000, CELL, V100, P703, DOI 10.1016/S0092-8674(00)80706-0; Charlet-B N, 2002, MOL CELL, V10, P45, DOI 10.1016/S1097-2765(02)00572-5; Chaudhari N, 1998, ANN NY ACAD SCI, V855, P398, DOI 10.1111/j.1749-6632.1998.tb10598.x; Chen L, 2004, MUSCLE NERVE, V29, P670, DOI 10.1002/mus.20005; Chen YH, 1997, PFLUG ARCH EUR J PHY, V434, P215, DOI 10.1007/s004240050388; Chen YS, 1996, J NEUROPHYSIOL, V75, P820, DOI 10.1152/jn.1996.75.2.820; Chu SJ, 1996, NUCLEIC ACIDS RES, V24, P3453, DOI 10.1093/nar/24.17.3453; Chu SJ, 1997, NUCLEIC ACIDS RES, V25, P4153, DOI 10.1093/nar/25.20.4153; Clapp TR, 2001, BMC NEUROSCI, V2, DOI 10.1186/1471-2202-2-6; CUMMINGS TA, 1993, J NEUROPHYSIOL, V70, P2326, DOI 10.1152/jn.1993.70.6.2326; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Eggermont J, 1997, BIOCHEM J, V325, P269, DOI 10.1042/bj3250269; Forino M, 2004, J HUM GENET, V49, P53, DOI 10.1007/s10038-003-0108-1; Friedrich T, 1999, J BIOL CHEM, V274, P896, DOI 10.1074/jbc.274.2.896; Ghiaroni V, 2003, CHEM SENSES, V28, P827, DOI 10.1093/chemse/bjg076; GILBERTSON TA, 1992, J GEN PHYSIOL, V100, P803, DOI 10.1085/jgp.100.5.803; Gilbertson TA, 2000, CURR OPIN NEUROBIOL, V10, P519, DOI 10.1016/S0959-4388(00)00118-5; Gilbertson TA, 2002, CHEM SENSES, V27, P383, DOI 10.1093/chemse/27.4.383; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P279; Hara-Chikuma M, 2005, BIOCHEM BIOPH RES CO, V329, P941, DOI 10.1016/j.bbrc.2005.02.060; Herness MS, 1999, J NEUROPHYSIOL, V82, P260, DOI 10.1152/jn.1999.82.1.260; HERNESS MS, 1995, J MEMBRANE BIOL, V146, P73; Hofmann T, 2003, CURR BIOL, V13, P1153, DOI 10.1016/S0960-9822(03)00431-7; Hoon MA, 1999, CELL, V96, P541, DOI 10.1016/S0092-8674(00)80658-3; Huang LQ, 1999, NAT NEUROSCI, V2, P1055, DOI 10.1038/15981; KASHIWAYANAGI M, 1983, AM J PHYSIOL, V244, pC82, DOI 10.1152/ajpcell.1983.244.1.C82; Kawasaki Masanobu, 1999, American Journal of Physiology, V277, pC948; KINNAMON SC, 1988, P NATL ACAD SCI USA, V85, P7023, DOI 10.1073/pnas.85.18.7023; Kitagawa M, 2001, BIOCHEM BIOPH RES CO, V283, P236, DOI 10.1006/bbrc.2001.4760; Li XD, 2002, P NATL ACAD SCI USA, V99, P4692, DOI 10.1073/pnas.072090199; Lin WH, 2002, J NEUROPHYSIOL, V88, P133, DOI 10.1152/jn.2002.88.1.133; Lin WH, 1999, J COMP NEUROL, V405, P406, DOI 10.1002/(SICI)1096-9861(19990315)405:3<406::AID-CNE10>3.0.CO;2-F; Lindemann B, 1996, PHYSIOL REV, V76, P719, DOI 10.1152/physrev.1996.76.3.719; Liu D, 2003, P NATL ACAD SCI USA, V100, P15160, DOI 10.1073/pnas.2334159100; Liu LJ, 2001, BRAIN RES, V923, P58, DOI 10.1016/S0006-8993(01)03190-0; Loewen ME, 2000, BBA-GENE STRUCT EXPR, V1493, P284, DOI 10.1016/S0167-4781(00)00181-0; Lyall V, 2002, J NEUROPHYSIOL, V87, P399, DOI 10.1152/jn.00331.2001; Lyall V, 2001, AM J PHYSIOL-CELL PH, V281, pC1005, DOI 10.1152/ajpcell.2001.281.3.C1005; Matsunami H, 2000, NATURE, V404, P601, DOI 10.1038/35007072; Max M, 2001, NAT GENET, V28, P58, DOI 10.1038/88270; MCLAUGHLIN SK, 1994, PHYSIOL BEHAV, V56, P1157, DOI 10.1016/0031-9384(94)90360-3; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Middleton RE, 1996, NATURE, V383, P337, DOI 10.1038/383337a0; Miyamoto T, 1998, J NEUROPHYSIOL, V80, P1852, DOI 10.1152/jn.1998.80.4.1852; Mohammad-Panah R, 2003, J BIOL CHEM, V278, P29267, DOI 10.1074/jbc.M304357200; Mohammad-Panah R, 2002, J BIOL CHEM, V277, P566, DOI 10.1074/jbc.M106968200; Montmayeur JP, 2001, NAT NEUROSCI, V4, P492, DOI 10.1038/87440; Nelson G, 2002, NATURE, V416, P199, DOI 10.1038/nature726; Nelson G, 2001, CELL, V106, P381, DOI 10.1016/S0092-8674(01)00451-2; Ogura T, 2002, FASEB J, V16, P863, DOI 10.1096/fj.01-0845fje; Perez CA, 2002, NAT NEUROSCI, V5, P1169, DOI 10.1038/nn952; Prawitt D, 2003, P NATL ACAD SCI USA, V100, P15166, DOI 10.1073/pnas.2334624100; PUSCH M, 1995, NATURE, V373, P527, DOI 10.1038/373527a0; Robinson NC, 2004, J PHYSIOL-LONDON, V556, P353, DOI 10.1113/jphysiol.2003.058032; ROPER S, 1983, SCIENCE, V220, P1311, DOI 10.1126/science.6857254; Rossler P, 2000, CHEM SENSES, V25, P413, DOI 10.1093/chemse/25.4.413; Rossler P, 1998, EUR J CELL BIOL, V77, P253; RUGARLI EI, 1995, NAT GENET, V10, P466, DOI 10.1038/ng0895-466; Ruiz CJ, 2003, CHEM SENSES, V28, P573, DOI 10.1093/chemse/bjg049; Sainz E, 2001, J NEUROCHEM, V77, P896, DOI 10.1046/j.1471-4159.2001.00292.x; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Shimada K, 2000, AM J PHYSIOL-GASTR L, V279, pG268, DOI 10.1152/ajpgi.2000.279.2.G268; Stevens DR, 2001, NATURE, V413, P631, DOI 10.1038/35098087; Stobrawa SM, 2001, NEURON, V29, P185, DOI 10.1016/S0896-6273(01)00189-1; Sun XD, 1996, AM J PHYSIOL-CELL PH, V271, pC1221, DOI 10.1152/ajpcell.1996.271.4.C1221; Ugawa S, 1998, NATURE, V395, P555, DOI 10.1038/26882; Van der Kloot W, 2003, BRAIN RES, V961, P287, DOI 10.1016/S0006-8993(02)03954-9; Vanoye CG, 2002, J PHYSIOL-LONDON, V539, P373, DOI 10.1113/jphysiol.2001.013115; Varkevisser B, 2001, CHEM SENSES, V26, P499, DOI 10.1093/chemse/26.5.499; Wladkowski SL, 1998, J MEMBRANE BIOL, V164, P91, DOI 10.1007/s002329900396; Wong GT, 1996, NATURE, V381, P796, DOI 10.1038/381796a0; Yan WT, 2001, AM J PHYSIOL-CELL PH, V280, pC742, DOI 10.1152/ajpcell.2001.280.4.C742; Zhang YF, 2003, CELL, V112, P293, DOI 10.1016/S0092-8674(03)00071-0	82	18	20	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36150	36157		10.1074/jbc.M507706200	http://dx.doi.org/10.1074/jbc.M507706200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16129671	Green Accepted, hybrid			2022-12-27	WOS:000232726900046
J	Svegliati, S; Cancello, R; Sambo, P; Luchetti, M; Paroncini, P; Orlandini, G; Discepoli, G; Paterno, R; Santillo, M; Cuozzo, C; Cassano, S; Avvedimento, EV; Gabrielli, A				Svegliati, S; Cancello, R; Sambo, P; Luchetti, M; Paroncini, P; Orlandini, G; Discepoli, G; Paterno, R; Santillo, M; Cuozzo, C; Cassano, S; Avvedimento, EV; Gabrielli, A			Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2 - Amplification of ROS and Ras in systemic sclerosis fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADPH OXIDASE COMPLEX; OXIDATIVE STRESS; EPITHELIAL-CELLS; SCLERODERMA; GENERATION	The levels of Ras proteins in human primary fibroblasts are regulated by PDGF (platelet-derived growth factor). PDGF induced post-transcriptionally Ha-Ras by stimulating reactive oxygen species (ROS) and ERK1/2. Activation of ERK1/2 and high ROS levels stabilize Ha-Ras protein, by inhibiting proteasomal degradation. We found a remarkable example in vivo of amplification of this circuitry in fibroblasts derived from systemic sclerosis ( scleroderma) lesions, producing vast excess of ROS and undergoing rapid senescence. High ROS, Ha-Ras, and active ERK1/2 stimulated collagen synthesis, DNA damage, and accelerated senescence. Conversely ROS or Ras inhibition interrupted the signaling cascade and restored the normal phenotype. We conclude that in primary fibroblasts stabilization of Ras protein by ROS and ERK1/2 amplifies the response of the cells to growth factors and in systemic sclerosis represents a critical factor in the onset and progression of the disease.	Univ Ancona, Ist Clin Med Gen Ematol & Immunol Clin, I-60020 Ancona, Italy; Univ Parma, Dipartimento Med Sperimentale, Sez Istol, I-43100 Parma, Italy; Osped G Salesi, Lab Citogenet, I-60020 Ancona, Italy; Univ Naples Federico II, Dipartimento Med Clin & Sperimentale, I-80131 Naples, Italy; Univ Naples Federico II, Dipartimento Neurosci, Sez Fisiol, I-80131 Naples, Italy; Univ Naples Federico II, CNR, Ist Endocrinol & Oncol Seprimentale, Dipartimento Biol & Patol Mol & Cellulare, I-80131 Naples, Italy	Marche Polytechnic University; University of Parma; University of Naples Federico II; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II	Avvedimento, EV (corresponding author), Dept Biol Pat Mol Cell, Via S Pansini 5, I-80121 Naples, Italy.	avvedim@unina.it; a.gabrielli@univpm.it	Gabrielli, Armando/AAC-3173-2019; Svegliati, Silvia/L-2614-2016; Luchetti, Michele Maria/J-6955-2019	Svegliati, Silvia/0000-0001-6863-2600; Luchetti, Michele Maria/0000-0001-9132-7401; CASSANO, SILVANA/0000-0001-9868-7936				Alarcon-Vargas D, 2002, ONCOGENE, V21, P4384, DOI 10.1038/sj.onc.1205543; Bonvini P, 1998, ONCOGENE, V16, P1131, DOI 10.1038/sj.onc.1201625; Chang H, 2003, FREE RADICAL RES, V37, P655, DOI 10.1080/1071576031000094907; Chen KCW, 2004, EXP EYE RES, V78, P1057, DOI 10.1016/j.exer.2004.02.004; Cuda G, 2002, CIRCULATION, V105, P968, DOI 10.1161/hc0802.104324; Feliciello A, 2000, J BIOL CHEM, V275, P303, DOI 10.1074/jbc.275.1.303; Hlavata L, 2003, EMBO J, V22, P3337, DOI 10.1093/emboj/cdg314; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; KAHARI VM, 1984, BIOCHIM BIOPHYS ACTA, V781, P183, DOI 10.1016/0167-4781(84)90136-2; Kreuzer J, 2002, FASEB J, V16, P38, DOI 10.1096/fj.01-1036fje; Ohtsuka T, 1998, DERMATOLOGY, V196, P204, DOI 10.1159/000017899; Orlandini G, 1999, METHOD ENZYMOL, V307, P340; Pani G, 2000, J BIOL CHEM, V275, P38891, DOI 10.1074/jbc.M007319200; Piccinini G, 1999, J INVEST DERMATOL, V112, P191, DOI 10.1046/j.1523-1747.1999.00485.x; Prior IA, 2001, J CELL SCI, V114, P1603; Sambo P, 2001, ARTHRITIS RHEUM-US, V44, P2653, DOI 10.1002/1529-0131(200111)44:11<2653::AID-ART445>3.0.CO;2-1; Sambo P, 1999, J INVEST DERMATOL, V112, P78, DOI 10.1046/j.1523-1747.1999.00476.x; Santillo M, 2001, CURR BIOL, V11, P614, DOI 10.1016/S0960-9822(01)00159-2; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Seru R, 2004, J NEUROCHEM, V91, P613, DOI 10.1111/j.1471-4159.2004.02754.x; SUN JY, 1994, J BIOL CHEM, V269, P18638; Suzukawa K, 2000, J BIOL CHEM, V275, P13175, DOI 10.1074/jbc.275.18.13175; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; VALLETTA EA, 1987, J IMMUNOL, V138, P4366; Yan ZF, 1997, J BIOL CHEM, V272, P30928, DOI 10.1074/jbc.272.49.30928	25	140	147	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36474	36482		10.1074/jbc.M502851200	http://dx.doi.org/10.1074/jbc.M502851200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16081426	hybrid			2022-12-27	WOS:000232726900081
J	Dreier, B; Fuller, RP; Segal, DJ; Lund, CV; Blancafort, P; Huber, A; Koksch, B; Barbas, CF				Dreier, B; Fuller, RP; Segal, DJ; Lund, CV; Blancafort, P; Huber, A; Koksch, B; Barbas, CF			Development of zinc finger domains for recognition of the 5 '-CNN-3 ' family DNA sequences and their use in the construction of artificial transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMBINATORIAL ANTIBODY LIBRARIES; CONTROLLING GENE-EXPRESSION; CRYSTAL-STRUCTURE; BINDING PROTEINS; PHAGE DISPLAY; FACTOR IIIA; COMPLEX; DESIGN; SPECIFICITY; ACTIVATION	Considerable progress has been made in recent years in the design of transcription factors for the directed regulation of endogenous genes. Although many strategies involve selection methods that must be applied for each new target sequence, we have developed an approach based on linkage of predefined zinc finger domains that each recognize a three-base pair DNA sequence to construct artificial transcription factors that bind to a desired sequence. These domains can be assembled to recognize unique 18-base pair DNA sequences with high specificity. Here we report the development and characterization of zinc finger domains that bind to 15 of the 16 5'-CNN-3' subsites. These domains were created through a combination of phage display selection, site-directed mutagenesis, and de novo design. Furthermore, these domains were used to generate a highly specific six-finger protein targeting the ERBB-2 promoter. When fused to regulatory domains, this protein was capable of up- and down-regulating the expression of the endogenous ERBB-2 gene. With the addition of this collection of predefined zinc finger domains, most 5'-CNN-3'-, 5'-GNN-3'-, and 5'-ANN-3'-containing sequences can now be rapidly targeted for directed gene regulation and nuclease cleavage.	Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Univ Calif Davis, Genome Ctr, Davis, CA 95616 USA; Univ Calif Davis, Dept Med Pharmacol, Davis, CA 95616 USA; Univ Calif Davis, Dept Toxicol, Davis, CA 95616 USA; Free Univ Berlin, Inst Chem, D-14195 Berlin, Germany	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; Free University of Berlin	Barbas, CF (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.	carlos@scripps.edu	Segal, David/B-6646-2013; Blancafort, Pilar/K-9029-2012; Segal, David/V-9126-2019	Segal, David/0000-0001-8962-3105; Segal, David/0000-0001-8962-3105; Blancafort, Pilar/0000-0002-3881-7396	NCI NIH HHS [CA086258] Funding Source: Medline; NIGMS NIH HHS [GM065059] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086258] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065059] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BARBAS CF, 1991, METHODS COMPANION ME, V2, P119; Beerli RR, 2000, J BIOL CHEM, V275, P32617, DOI 10.1074/jbc.M005108200; Beerli RR, 1998, P NATL ACAD SCI USA, V95, P14628, DOI 10.1073/pnas.95.25.14628; Beerli RR, 2000, P NATL ACAD SCI USA, V97, P1495, DOI 10.1073/pnas.040552697; Beerli RR, 2002, NAT BIOTECHNOL, V20, P135, DOI 10.1038/nbt0202-135; Bibikova M, 2003, SCIENCE, V300, P764, DOI 10.1126/science.1079512; Blancafort P, 2004, MOL PHARMACOL, V66, P1361, DOI 10.1124/mol.104.002758; Blancafort P, 2003, NAT BIOTECHNOL, V21, P269, DOI 10.1038/nbt794; Dreier B, 2001, J BIOL CHEM, V276, P29466, DOI 10.1074/jbc.M102604200; Dreier B, 2000, J MOL BIOL, V303, P489, DOI 10.1006/jmbi.2000.4133; ElrodErickson M, 1996, STRUCTURE, V4, P1171, DOI 10.1016/S0969-2126(96)00125-6; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; Graslund T, 2005, J BIOL CHEM, V280, P3707, DOI 10.1074/jbc.M406809200; Guan X, 2002, P NATL ACAD SCI USA, V99, P13296, DOI 10.1073/pnas.192412899; HARWERTH IM, 1992, J BIOL CHEM, V267, P15160; Havranek JJ, 2004, J MOL BIOL, V344, P59, DOI 10.1016/j.jmb.2004.09.029; Houbaviy HB, 1996, P NATL ACAD SCI USA, V93, P13577, DOI 10.1073/pnas.93.24.13577; HUDSON LG, 1990, J BIOL CHEM, V265, P4389; Isalan M, 1997, P NATL ACAD SCI USA, V94, P5617, DOI 10.1073/pnas.94.11.5617; Jantz D, 2004, CHEM REV, V104, P789, DOI 10.1021/cr020603o; Kim CA, 1996, NAT STRUCT BIOL, V3, P940, DOI 10.1038/nsb1196-940; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; Liu PQ, 2001, J BIOL CHEM, V276, P11323, DOI 10.1074/jbc.M011172200; Liu Q, 1997, P NATL ACAD SCI USA, V94, P5525, DOI 10.1073/pnas.94.11.5525; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; Nolte RT, 1998, P NATL ACAD SCI USA, V95, P2938, DOI 10.1073/pnas.95.6.2938; Pabo CO, 2000, J MOL BIOL, V301, P597, DOI 10.1006/jmbi.2000.3918; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Porteus MH, 2005, NAT BIOTECHNOL, V23, P967, DOI 10.1038/nbt1125; Rader C, 1997, CURR OPIN BIOTECH, V8, P503, DOI 10.1016/S0958-1669(97)80075-4; Segal DJ, 1999, P NATL ACAD SCI USA, V96, P2758, DOI 10.1073/pnas.96.6.2758; Segal DJ, 2003, BIOCHEMISTRY-US, V42, P2137, DOI 10.1021/bi026806o; Tan SY, 2003, P NATL ACAD SCI USA, V100, P11997, DOI 10.1073/pnas.2035056100; Trauger JW, 2001, METHOD ENZYMOL, V340, P450; Wolfe SA, 1999, J MOL BIOL, V285, P1917, DOI 10.1006/jmbi.1998.2421; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183; WU H, 1995, P NATL ACAD SCI USA, V92, P344, DOI 10.1073/pnas.92.2.344; Wuttke DS, 1997, J MOL BIOL, V273, P183, DOI 10.1006/jmbi.1997.1291; Zhang L, 2000, J BIOL CHEM, V275, P33850, DOI 10.1074/jbc.M005341200	42	142	186	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35588	35597		10.1074/jbc.M506654200	http://dx.doi.org/10.1074/jbc.M506654200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16107335	hybrid			2022-12-27	WOS:000232561200061
J	Kim, K; Kim, JH; Lee, J; Jin, HM; Lee, SH; Fisher, DE; Kook, H; Kim, KK; Choi, YW; Kim, NS				Kim, K; Kim, JH; Lee, J; Jin, HM; Lee, SH; Fisher, DE; Kook, H; Kim, KK; Choi, YW; Kim, NS			Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROPHTHALMIA TRANSCRIPTION FACTOR; FCR-GAMMA; KAPPA-B; TERMINAL DIFFERENTIATION; SIGNAL-TRANSDUCTION; BONE-RESORPTION; PROTEIN-KINASE; FACTOR FAMILY; LIGAND; OSTEOPETROSIS	Osteoclast differentiation from hematopoietic precursors is controlled by the tumor necrosis factor family member tumor necrosis factor-related activation-induced cytokine (TRANCE) via induction of various transcription factors, including nuclear factor of activated T cells (NFAT) c1. During osteoclast differentiation, NFATc1 is further activated via calcium signaling when costimulatory receptors expressed on osteoclast precursors, such as osteoclast-associated receptor (OSCAR), are stimulated. Here we show that NFATc1 expression precedes that of OSCAR during TRANCE-mediated osteoclastogenesis and that inhibition of NFATc1 by cyclosporin A abolishes TRANCE-induced OSCAR expression and subsequent osteoclast differentiation. Moreover, we show that the 1.0-kb promoter region of the OSCAR gene contains three potential NFATc1-binding sites. Induction of an OSCAR promoter-luciferase reporter is significantly increased when transiently transfected into 293T cells in combination with NFATc1 expression plasmid. Deletion and site-directed mutant constructs confirmed that NFATc1-binding sites are both functional and NFATc1-specific. Furthermore, NFATc1 synergistically activates an OSCAR reporter construct together with microphthalmia transcription factor and PU.1, transcription factors previously shown to be critical for osteoclast differentiation. In addition, a plasmid expressing constitutively active MAP kinase kinase 6 enhances the transactivation activity of NFATc1/microphthalmia transcription factor/PU.1 on the OSCAR promoter. Taken together, our results indicate that NFATc1 is an important transcription factor in the induction of OSCAR during osteoclastogenesis. Elucidation of NFATc1 as a transcription factor for OSCAR expression implies the presence of a positive feedback circuit of TRANCE-induced activation of NFATc1, involving NFATc1-mediated OSCAR expression and its subsequent activation of NFATc1, necessary for efficient differentiation of osteoclasts.	Chonnam Natl Univ, Sch Med, Med Res Ctr Gene Regulat, Dong Ku 501746, Gwangju, South Korea; Univ Penn, Sch Med, Dept Pathol & Lab Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA	Chonnam National University; University of Pennsylvania; Pennsylvania Medicine; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kim, NS (corresponding author), Chonnam Natl Univ, Sch Med, Med Res Ctr Gene Regulat, Hak Dong 5, Dong Ku 501746, Gwangju, South Korea.	nacksung@jnu.ac.kr	Kook, Hyun/AAR-5405-2021	Kook, Hyun/0000-0002-0740-1806	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049078, R01AR048521] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR48521, AR49078] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hayman AR, 1996, DEVELOPMENT, V122, P3151; Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200; Hock MB, 2003, J BIOL CHEM, V278, P26695, DOI 10.1074/jbc.M301007200; Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200; Ishikawa S, 2004, INT IMMUNOL, V16, P1019, DOI 10.1093/intimm/dxh103; Kim N, 2000, P NATL ACAD SCI USA, V97, P10905, DOI 10.1073/pnas.200294797; Kim N, 2002, J EXP MED, V195, P201, DOI 10.1084/jem.20011681; Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006-291X(03)00695-8; Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105; Luchin A, 2001, J BIOL CHEM, V276, P36703, DOI 10.1074/jbc.M106418200; Luchin A, 2000, J BONE MINER RES, V15, P451, DOI 10.1359/jbmr.2000.15.3.451; Mansky KC, 2002, J BIOL CHEM, V277, P11077, DOI 10.1074/jbc.M111696200; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200; Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200; Merck E, 2004, BLOOD, V104, P1386, DOI 10.1182/blood-2004-03-0850; Mocsai A, 2004, P NATL ACAD SCI USA, V101, P6158, DOI 10.1073/pnas.0401602101; Motyckova G, 2001, P NATL ACAD SCI USA, V98, P5798, DOI 10.1073/pnas.091479298; Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453; So H, 2003, J BIOL CHEM, V278, P24209, DOI 10.1074/jbc.M302940200; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Takami M, 2002, J IMMUNOL, V169, P1516, DOI 10.4049/jimmunol.169.3.1516; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109-004-0612-6; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Yang XL, 2002, TRENDS MOL MED, V8, P340, DOI 10.1016/S1471-4914(02)02340-7; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	32	199	206	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35209	35216		10.1074/jbc.M505815200	http://dx.doi.org/10.1074/jbc.M505815200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16109714	hybrid			2022-12-27	WOS:000232561200018
J	Chen, CL; Deutscher, MP				Chen, CL; Deutscher, MP			Elevation of RNase R in response to multiple stress conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI POLYNUCLEOTIDE PHOSPHORYLASE; ESCHERICHIA-COLI; QUALITY-CONTROL; DEGRADATION; DEGRADOSOME; INDUCTION; HELICASE; DECAY; SHOCK	Cells respond to adverse environmental conditions by synthesizing new proteins or elevating the levels of pre-existing ones that are needed to cope with the particular stress situation. We show here that Escherichia coli RNase R, a processive 3'- to 5'-exoribonuclease, is dramatically increased in response to a variety of different stress conditions. Elevation of RNase R activity by as much as 10-fold was observed in response to entry into stationary phase, starvation, and cold shock, and a similar to 3-fold increase was seen during growth in minimal medium compared with rich medium. The elevation in RNase R activity was associated primarily with an increase in RNase R protein. RNase R was previously implicated in quality control of rRNA and tRNA and in the decay of mRNAs with extensive secondary structure. Its dramatic increase under multiple stress conditions suggests extensive remodeling of structured RNA in response to the altered environment.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami	Deutscher, MP (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, POB 016129, Miami, FL 33101 USA.	mdeutsch@med.miami.edu			NIGMS NIH HHS [GM16317] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beran RK, 2001, MOL MICROBIOL, V39, P112, DOI 10.1046/j.1365-2958.2001.02216.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bremer H, 1996, ESCHERICHIA COLI SAL; Cairrao F, 2003, MOL MICROBIOL, V50, P1349, DOI 10.1046/j.1365-2958.2003.03766.x; Cheng ZF, 2005, MOL CELL, V17, P313, DOI 10.1016/j.molcel.2004.11.048; Cheng ZF, 2003, P NATL ACAD SCI USA, V100, P6388, DOI 10.1073/pnas.1231041100; Cheng ZF, 2002, J BIOL CHEM, V277, P21624, DOI 10.1074/jbc.M202942200; Cheng ZF, 1998, J BIOL CHEM, V273, P14077, DOI 10.1074/jbc.273.23.14077; Coburn GA, 1999, GENE DEV, V13, P2594, DOI 10.1101/gad.13.19.2594; Deutscher MP, 2003, J BIOL CHEM, V278, P45041, DOI 10.1074/jbc.R300031200; Hong SJ, 2005, MOL MICROBIOL, V57, P565, DOI 10.1111/j.1365-2958.2005.04709.x; Khemici V, 2004, MOL MICROBIOL, V51, P777, DOI 10.1046/j.1365-2958.2003.03862.x; Li ZW, 2002, EMBO J, V21, P1132, DOI 10.1093/emboj/21.5.1132; Mathy N, 2001, J BACTERIOL, V183, P3848, DOI 10.1128/JB.183.13.3848-3854.2001; Purusharth RI, 2005, J BIOL CHEM, V280, P14572, DOI 10.1074/jbc.M413507200; Takayama K, 2000, ENVIRON MICROBIOL, V2, P355, DOI 10.1046/j.1462-2920.2000.00119.x; Thieringer HA, 1998, BIOESSAYS, V20, P49; Yamanaka Kunitoshi, 1999, Journal of Molecular Microbiology and Biotechnology, V1, P193; Zangrossi S, 2000, MOL MICROBIOL, V36, P1470, DOI 10.1046/j.1365-2958.2000.01971.x	19	72	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34393	34396		10.1074/jbc.C500333200	http://dx.doi.org/10.1074/jbc.C500333200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16135521	hybrid			2022-12-27	WOS:000232403900004
J	Levrand, S; Pesse, B; Feihl, F; Waeber, B; Pacher, P; Rolli, J; Schaller, MD; Liaudet, L				Levrand, S; Pesse, B; Feihl, F; Waeber, B; Pacher, P; Rolli, J; Schaller, MD; Liaudet, L			Peroxynitrite is a potent inhibitor of NF-kappa B activation triggered by inflammatory stimuli in cardiac and endothelial cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOTOXIN-BETA-RECEPTOR; NITRIC-OXIDE; IKK-ALPHA; MYOCARDIAL DYSFUNCTION; SYSTEMIC INFLAMMATION; HYDROGEN-PEROXIDE; GENE-EXPRESSION; KINASE-ACTIVITY; PHOSPHORYLATION; DEGRADATION	Peroxynitrite is a potent oxidant and nitrating species proposed as a direct effector of myocardial damage in numerous cardiac pathologies. Whether peroxynitrite also acts indirectly, by modulating cell signal transduction in the myocardium, has not been investigated. Therefore, we examined a possible role for peroxynitrite on the activation of NF-kappa B, a crucial pro-inflammatory transcription factor, in cultured H9C2 cardiomyocytes. H9C2 cells were stimulated with tumor necrosis factor-alpha or lipopolysaccharide following a brief (20-min) exposure to peroxynitrite. NF-kappa B activation ( phosphorylation and degradation of its inhibitor I kappa B alpha, nuclear translocation of NF-kappa B p65, and NF-kappa B DNA binding) triggered by lipopolysaccharide or tumor necrosis factor-alpha was abrogated by peroxynitrite. Peroxynitrite also inhibited NF-kappa B in two human endothelial cell lines activated with tumor necrosis factor-alpha or interleukin-1 beta. These effects were related to oxidative but not nitrative chemistry and were still being observed while nitration was suppressed by epicatechin. The mechanism of NF-kappa B inhibition by peroxynitrite was a complete blockade of phosphorylation and activation of the upstream kinase I kappa B kinase (IKK) beta, required for canonical, pro-inflammatory NF-kappa B activation. At the same time, peroxynitrite activated phosphorylation of NF-kappa B-inducing kinase and IKK alpha, considered as part of an alternative, noncanonical NF-kappa B activation pathway. Suppression of IKK beta-dependent NF-kappa B activation translated into a marked inhibition of the transcription of NF-kappa B-dependent genes by peroxynitrite. Thus, peroxynitrite has a dual effect on NF-kappa B, inhibiting canonical IKK beta-dependent NF-kappa B activation while activating NF-kappa B-inducing kinase and IKK alpha phosphorylation, which suggests its involvement in an alternative pathway of NF-kappa B activation. These findings offer new perspectives for the understanding of the relationships between redox stress and inflammation.	Univ Lausanne Hosp, Dept Internal Med, Div Crit Care, CH-1011 Lausanne, Switzerland; Univ Lausanne Hosp, Dept Internal Med, Div Clin Pathophysiol, CH-1011 Lausanne, Switzerland; NIAAA, Lab Physiol Studies, Bethesda, MD 20892 USA	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Liaudet, L (corresponding author), Univ Lausanne Hosp, Dept Internal Med, Div Crit Care, CH-1011 Lausanne, Switzerland.	Lucas.Liaudet@chuv.hospvd.ch	Pacher, Pal/B-6378-2008; Liaudet, Lucas/E-1322-2017	Pacher, Pal/0000-0001-7036-8108; Liaudet, Lucas/0000-0003-2670-4930	Intramural NIH HHS [Z01 AA000375-02] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000375] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bonizzi G, 2004, EMBO J, V23, P4202, DOI 10.1038/sj.emboj.7600391; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Chen LW, 2003, NAT MED, V9, P575, DOI 10.1038/nm849; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Drayton DL, 2004, J IMMUNOL, V173, P6161, DOI 10.4049/jimmunol.173.10.6161; Eaves-Pyles T, 2001, J IMMUNOL, V166, P1248, DOI 10.4049/jimmunol.166.2.1248; Egan LJ, 2004, P NATL ACAD SCI USA, V101, P2452, DOI 10.1073/pnas.0306734101; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Hayakawa M, 2003, EMBO J, V22, P3356, DOI 10.1093/emboj/cdg332; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P451; Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5; Kamata H, 2002, FEBS LETT, V519, P231, DOI 10.1016/S0014-5793(02)02712-6; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; Klotz LO, 2002, FREE RADICAL BIO MED, V33, P737, DOI 10.1016/S0891-5849(02)00892-4; Klotz LO, 2000, BIOCHEM J, V352, P219, DOI 10.1042/0264-6021:3520219; Korn SH, 2001, J BIOL CHEM, V276, P35693, DOI 10.1074/jbc.M104321200; Kumar A, 2000, CRIT CARE CLIN, V16, P251, DOI 10.1016/S0749-0704(05)70110-X; Lancel S, 2004, J AM COLL CARDIOL, V43, P2348, DOI 10.1016/j.jacc.2004.01.047; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Liaudet L, 2000, CRIT CARE MED, V28, pN37, DOI 10.1097/00003246-200004001-00005; Liaudet L, 2001, MOL MED, V7, P406, DOI 10.1007/BF03402187; Matsushima A, 2001, J EXP MED, V193, P631, DOI 10.1084/jem.193.5.631; Pacher P, 2003, CIRCULATION, V107, P896, DOI 10.1161/01.CIR.0000048192.52098.DD; Pacher P, 2002, J AM COLL CARDIOL, V40, P1006, DOI 10.1016/S0735-1097(02)02062-4; Pesse B, 2005, J MOL CELL CARDIOL, V38, P765, DOI 10.1016/j.yjmcc.2005.02.020; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schroeder P, 2001, BIOCHEM BIOPH RES CO, V285, P782, DOI 10.1006/bbrc.2001.5210; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; TorreAmione G, 1996, CIRCULATION, V93, P704, DOI 10.1161/01.CIR.93.4.704; Upmacis RK, 2004, AM J PHYSIOL-CELL PH, V286, pC1271, DOI 10.1152/ajpcell.00143.2003; Uppu RM, 1996, METHOD ENZYMOL, V269, P322; van der Vliet A, 1998, J BIOL CHEM, V273, P31860, DOI 10.1074/jbc.273.48.31860; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Zhang P, 2000, J BIOL CHEM, V275, P22479, DOI 10.1074/jbc.M910425199	41	61	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34878	34887		10.1074/jbc.M501977200	http://dx.doi.org/10.1074/jbc.M501977200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16079150	hybrid, Green Accepted, Green Submitted			2022-12-27	WOS:000232403900060
J	Zhou, QS; Ben-Efraim, I; Bigcas, JL; Junqueira, D; Wiedmer, T; Sims, PJ				Zhou, QS; Ben-Efraim, I; Bigcas, JL; Junqueira, D; Wiedmer, T; Sims, PJ			Phospholipid scramblase 1 binds to the promoter region of the inositol 1,4,5-triphosphate receptor type 1 gene to enhance its expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSBILAYER MOVEMENT; MEMBRANE PROTEIN; PHOSPHATIDYLSERINE; CELLS; MICE; TRANSCRIPTION; APOPTOSIS; INTERACTS; MELANOMA; NUCLEUS	Phospholipid scramblase 1 (PLSCR1) is a multiply palmitoylated, endofacial membrane protein originally identified based on its capacity to promote accelerated transbilayer phospholipid movement in response to Ca2+. Recent evidence suggests that this protein also participates in cell response to various growth factors and cytokines, influencing myeloid differentiation, tumor growth, and the antiviral activity of interferon. Whereas plasma membrane PLSCR1 was shown to be required for normal recruitment and activation of Src kinase by stimulated cell surface growth factor receptors, PLSCR1 was also found to traffic into the nucleus and to tightly bind to genomic DNA, suggesting a possible additional nuclear function. We now report evidence that PLSCR1 directly binds to the 5'-promoter region of the inositol 1,4,5-triphosphate receptor type 1 gene (IP3R1) to enhance expression of the receptor. Probing a CpG island genomic library with PLSCR1 as bait identified four clones with avidity for PLSCR1, including a 191-bp fragment of the IP3R1 promoter. Using electrophoretic mobility shift and transcription reporter assays, the PLSCR1-binding site in IP3R1 was mapped to residues(-101)GTAACCATGTGGA(-89), and the segment spanning Met(86)-Glu(118) in PLSCR1 was identified to mediate its transcriptional activity. The significance of this interaction between PLSCR1 and IP3R1 in situ was confirmed by comparing levels of IP3R1 mRNA and protein in matched cells that either expressed or were deficient in PLSCR1. These data suggest that in addition to its role at the plasma membrane, effects of PLSCR1 on cell proliferative and maturational responses may also relate to alterations in expression of cellular IP3 receptors.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Sims, PJ (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, MEM-275,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	psims@scripps.edu	Bigcas, Jo-Lawrence/GOE-4097-2022	Zhou, Quansheng/0000-0003-4712-0731	NHLBI NIH HHS [HL63819, HL76215, HL36946] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036946, R01HL063819, R01HL076215] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Basse F, 1996, J BIOL CHEM, V271, P17205, DOI 10.1074/jbc.271.29.17205; Ben-Efraim I, 2004, BIOCHEMISTRY-US, V43, P3518, DOI 10.1021/bi0356911; Bertolotto C, 1996, J CELL BIOL, V134, P747, DOI 10.1083/jcb.134.3.747; Bradford Peter G., 2000, Molecular Cell Biology Research Communications, V3, P73, DOI 10.1006/mcbr.2000.0194; Dong BH, 2004, J VIROL, V78, P8983, DOI 10.1128/JVI.78.17.8983-8993.2004; Fadeel B, 1999, BIOCHEM BIOPH RES CO, V266, P504, DOI 10.1006/bbrc.1999.1820; Frasch SC, 2004, J BIOL CHEM, V279, P17625, DOI 10.1074/jbc.M313414200; Furutama D, 1996, J NEUROCHEM, V66, P1793; Goding CR, 2000, GENE DEV, V14, P1712; Grayson TH, 2004, CELL CALCIUM, V36, P447, DOI 10.1016/j.ceca.2004.04.005; Kasukabe T, 1998, BIOCHEM BIOPH RES CO, V249, P449, DOI 10.1006/bbrc.1998.9190; Konishi Y, 1999, J NEUROCHEM, V72, P1717, DOI 10.1046/j.1471-4159.1999.721717.x; Matsumoto M, 1999, J MOL MED, V77, P406, DOI 10.1007/s001090050370; Matsumoto M, 1996, NATURE, V379, P168, DOI 10.1038/379168a0; Nakamaki T, 2002, EXP HEMATOL, V30, P421, DOI 10.1016/S0301-472X(02)00779-8; Nanjundan M, 2003, J BIOL CHEM, V278, P37413, DOI 10.1074/jbc.M306182200; Ohkawa N, 1999, GENE, V229, P11, DOI 10.1016/S0378-1119(99)00048-7; Patterson RL, 2004, ANNU REV BIOCHEM, V73, P437, DOI 10.1146/annurev.biochem.73.071403.161303; Powell LM, 2004, MOL CELL BIOL, V24, P9517, DOI 10.1128/MCB.24.21.9517-9526.2004; Silverman RH, 2002, CANCER RES, V62, P397; Sun J, 2002, BIOCHEMISTRY-US, V41, P6338, DOI 10.1021/bi025610l; Sun J, 2001, J BIOL CHEM, V276, P28984, DOI 10.1074/jbc.M102505200; Vermassen E, 2004, BIOL CELL, V96, P3, DOI 10.1016/j.biolcel.2003.11.004; Wiedmer T, 2000, BBA-BIOMEMBRANES, V1467, P244, DOI 10.1016/S0005-2736(00)00236-4; Wiedmer T, 2004, P NATL ACAD SCI USA, V101, P13296, DOI 10.1073/pnas.0405354101; Wiedmer T, 2003, BIOCHEMISTRY-US, V42, P1227, DOI 10.1021/bi026679w; YAMADA N, 1994, BIOCHEM J, V302, P781, DOI 10.1042/bj3020781; Yasumoto K, 1997, J BIOL CHEM, V272, P503; Yokoyama A, 2004, LEUKEMIA RES, V28, P149, DOI 10.1016/S0145-2126(03)00189-9; Yu A, 2003, J BIOL CHEM, V278, P9706, DOI 10.1074/jbc.M204614200; Zhao J, 1998, J BIOL CHEM, V273, P6603, DOI 10.1074/jbc.273.12.6603; Zhao KW, 2004, BLOOD, V104, P3731, DOI 10.1182/blood-2004-04-1630; Zhou QS, 2000, BLOOD, V95, P2593, DOI 10.1182/blood.V95.8.2593.008k32_2593_2599; Zhou QS, 2002, BLOOD, V99, P4030, DOI 10.1182/blood-2001-12-0271; Zhou QS, 1997, J BIOL CHEM, V272, P18240, DOI 10.1074/jbc.272.29.18240	35	74	77	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					35062	35068		10.1074/jbc.M504821200	http://dx.doi.org/10.1074/jbc.M504821200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16091359	hybrid			2022-12-27	WOS:000232403900079
J	Nyman, U; Sobczak-Pluta, A; Vlachos, P; Perlmann, T; Zhivotovsky, B; Joseph, B				Nyman, U; Sobczak-Pluta, A; Vlachos, P; Perlmann, T; Zhivotovsky, B; Joseph, B			Full-length p73 alpha represses drug-induced apoptosis in small cell lung carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P73; PHYSICAL INTERACTION; SPONTANEOUS TUMORS; SPLICING VARIANTS; C-MYC; P53; DELTA-NP73; EXPRESSION; CANCER; PUMA	The p73 gene, a member of the p53 family, encodes several variants through differential splicing and use of alternative promoters. At the NH2 terminus, two different promoters generate the full-length and the Delta N isoforms, with or without the transactivating domain. At the COOH terminus, seven isoforms generated through alternative splicing have been cloned. Previous studies have demonstrated that Delta Np73 isoforms exert a dominant-negative effect on p73 by blocking their transactivation activity and hence the ability to induce apoptosis. Considerable efforts are made to identify the functional diversity of the COOH-terminal p73 variants. In this study, we found that p73 alpha inhibited drug-induced apoptosis in small cell lung carcinoma cells, whereas p73 beta promoted it. p73 alpha prevented Bax activation, mitochondrial dysfunction, and caspase activation. In addition, p73 alpha was also able to reduce apoptosis induced by the BH3-only protein PUMA ( p53 up-regulated modulator of apoptosis). Furthermore, we discovered that p73 alpha is able to inhibit the pro-apoptotic effect of p73 alpha, demonstrating the existence of equilibrium between these two p73 isoforms. In conclusion, the reported overexpression of p73 alpha in certain tumor types, and our findings that p73 alpha exerts anti-apoptotic functions, indicate a potential oncogenic activity for p73.	Karolinska Inst, Inst Environm Med, S-17177 Stockholm, Sweden; Ludwig Inst Canc Res, S-17177 Stockholm, Sweden	Karolinska Institutet; Ludwig Institute for Cancer Research	Joseph, B (corresponding author), Karolinska Inst, Inst Environm Med, Box 210, S-17177 Stockholm, Sweden.	Bertrand.Joseph@imm.ki.se	Zhivotovsky, Boris/A-4346-2014; Nyman, Ulrika/D-3708-2013	Zhivotovsky, Boris/0000-0002-2238-3482; Joseph, Bertrand/0000-0001-5655-9979				Billon N, 2004, DEVELOPMENT, V131, P1211, DOI 10.1242/dev.01035; Cande C, 2002, J CELL SCI, V115, P4727, DOI 10.1242/jcs.00210; Cartron PF, 2004, MOL CELL, V16, P807, DOI 10.1016/j.molcel.2004.10.028; Casciano I, 2002, CELL DEATH DIFFER, V9, P246, DOI 10.1038/sj.cdd.4400993; Chi SW, 1999, EMBO J, V18, P4438, DOI 10.1093/emboj/18.16.4438; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Deb D, 2001, INT J ONCOL, V18, P401; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Frasca F, 2003, CANCER RES, V63, P5829; Hackzell A, 2002, J BIOL CHEM, V277, P39769, DOI 10.1074/jbc.M204483200; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Ishimoto O, 2002, CANCER RES, V62, P636; Joseph B, 2002, ONCOGENE, V21, P65, DOI 10.1038/sj/onc/1205018; Joseph B, 2001, ONCOGENE, V20, P2877, DOI 10.1038/sj.onc.1204402; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kang MJ, 2000, CLIN CANCER RES, V6, P1767; Khan QA, 2001, TOXICOL APPL PHARM, V173, P105, DOI 10.1006/taap.2001.9172; Li CY, 2005, J BIOL CHEM, V280, P2159, DOI 10.1074/jbc.M411194200; Liu FT, 2003, BIOCHEM BIOPH RES CO, V310, P956, DOI 10.1016/j.bbrc.2003.09.109; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2004, J BIOL CHEM, V279, P8076, DOI 10.1074/jbc.M307469200; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Moll UM, 2001, BBA-REV CANCER, V1552, P47, DOI 10.1016/S0304-419X(01)00036-1; Niyazi Maynur, 2003, Journal of Nippon Medical School, V70, P234; Novak U, 2001, ANN ONCOL, V12, P981, DOI 10.1023/A:1011153206003; Nozaki M, 2001, BRAIN PATHOL, V11, P296; Ozaki T, 2003, ONCOGENE, V22, P3231, DOI 10.1038/sj.onc.1206382; Petrenko O, 2003, MOL CELL BIOL, V23, P5540, DOI 10.1128/MCB.23.16.5540-5555.2003; Saelens X, 2004, ONCOGENE, V23, P2861, DOI 10.1038/sj.onc.1207523; Sirzen F, 1999, EUR J CANCER, V35, P111, DOI 10.1016/S0959-8049(98)00289-5; Stiewe T, 2002, CELL DEATH DIFFER, V9, P237, DOI 10.1038/sj.cdd.4400995; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Ueda Y, 2001, BIOCHEM J, V356, P859, DOI 10.1042/0264-6021:3560859; Ugur H, 2004, ONCOL REP, V11, P1337; Vikhanskaya F, 2001, CANCER RES, V61, P935; Viktorsson K, 2003, EXP CELL RES, V289, P256, DOI 10.1016/S0014-4827(03)00264-7; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Watanabe K, 2002, J BIOL CHEM, V277, P15113, DOI 10.1074/jbc.M111281200; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zaika AI, 1999, CANCER RES, V59, P3257; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zamzami N, 2003, CURR BIOL, V13, pR71, DOI 10.1016/S0960-9822(02)01433-1	52	25	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34159	34169		10.1074/jbc.M500394200	http://dx.doi.org/10.1074/jbc.M500394200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16087678	hybrid			2022-12-27	WOS:000232229700057
J	Santaguida, M; Nepveu, A				Santaguida, M; Nepveu, A			Differential regulation of CDP/Cux p110 by cyclin A/Cdk2 and cyclin A/Cdk1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT DISPLACEMENT PROTEIN; FACTOR HINF-D; DEPENDENT KINASE 2; TRANSCRIPTION FACTOR; DNA-BINDING; HOMEODOMAIN PROTEIN; CUT HOMEODOMAIN; GENE PROMOTER; S-PHASE; RETINOBLASTOMA PROTEIN	Previous experiments with peptide fusion proteins suggested that cyclin A/Cdk1 and Cdk2 might exhibit similar yet distinct phosphorylation specificities. Using a physiological substrate, CDP/Cux, our study confirms this notion. Proteolytic processing of CDP/Cux by cathepsin L generates the CDP/Cux p110 isoform at the beginning of S phase. CDP/Cux p110 makes stable interactions with DNA during S phase but is inhibited in G(2) following the phosphorylation of serine 1237 by cyclin A/Cdk1. In this study, we propose that differential phosphorylation by cyclin A/Cdk1 and cyclin A/Cdk2 enables CDP/Cux p110 to exert its function as a transcriptional regulator specifically during S phase. We found that like cyclin A/Cdk1, cyclin A/Cdk2 interacted efficiently with recombinant CDP/Cux proteins that contain the Cut homeodomain and an adjacent cyclin-binding motif (Cy). In contrast to cyclin A/Cdk1, however, cyclin A/Cdk2 did not efficiently phosphorylate CDP/Cux p110 on serine 1237 and did not inhibit its DNA binding activity in vitro. Accordingly, co-expression with cyclin A/Cdk2 in cells did not inhibit the DNA binding and transcriptional activities of CDP/Cux p110. To confirm that the sequence surrounding serine 1237 was responsible for the differential regulation by Cdk1 and Cdk2, we replaced 4 amino acids flanking the phosphorylation site to mimic a known Cdk2 phosphorylation site present in the Cdc6 protein. Both cyclin A/Cdk2 and Cdk1 efficiently phosphorylated the CDP/Cux(Cdc6) mutant and inhibited its DNA binding activity. Altogether our results help explain why the DNA binding activity of CDP/Cux p110 is maximal during S phase and decreases in G2 phase.	McGill Univ, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hlth, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada	McGill University; McGill University; McGill University; McGill University; McGill University	Nepveu, A (corresponding author), 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	alain.nepveu@mcgill.ca	/AAB-8315-2020					Adams PD, 1999, MOL CELL BIOL, V19, P1068; ANDRES V, 1994, GENE DEV, V8, P245, DOI 10.1101/gad.8.2.245; AUFIERO B, 1994, P NATL ACAD SCI USA, V91, P7757, DOI 10.1073/pnas.91.16.7757; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; Coqueret O, 1998, EMBO J, V17, P4680, DOI 10.1093/emboj/17.16.4680; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DESAI D, 1995, MOL CELL BIOL, V15, P345, DOI 10.1128/MCB.15.1.345; Gaiddon C, 2003, J BIOL CHEM, V278, P27421, DOI 10.1074/jbc.M300251200; Goulet B, 2004, MOL CELL, V14, P207, DOI 10.1016/S1097-2765(04)00209-6; Gupta S, 2003, J CELL PHYSIOL, V196, P541, DOI 10.1002/jcp.10335; Haidweger E, 2001, J MOL BIOL, V306, P201, DOI 10.1006/jmbi.2000.4406; HARADA R, 1994, J BIOL CHEM, V269, P2062; Henneke G, 2003, ONCOGENE, V22, P4301, DOI 10.1038/sj.onc.1206606; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; Howcroft TK, 1997, ANAL BIOCHEM, V244, P22, DOI 10.1006/abio.1996.9868; Ishimi Y, 2000, J BIOL CHEM, V275, P16235, DOI 10.1074/jbc.M909040199; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LI Y, 1994, MOL CELL BIOL, V14, P1861, DOI 10.1128/MCB.14.3.1861; Liu D, 1998, NAT GENET, V20, P377, DOI 10.1038/3855; Luciani MG, 2000, J MOL BIOL, V300, P503, DOI 10.1006/jmbi.2000.3830; Luo W, 1996, J BIOL CHEM, V271, P18203, DOI 10.1074/jbc.271.30.18203; Luong MX, 2002, MOL CELL BIOL, V22, P1424, DOI 10.1128/MCB.22.5.1424-1437.2002; Moon NS, 2000, J BIOL CHEM, V275, P31325, DOI 10.1074/jbc.M002912200; Moon NS, 2001, MOL CELL BIOL, V21, P6332, DOI 10.1128/MCB.21.18.6332-6345.2001; Murphy M, 1997, NAT GENET, V15, P83, DOI 10.1038/ng0197-83; Nepveu A, 2001, GENE, V270, P1, DOI 10.1016/S0378-1119(01)00485-1; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; Ohtoshi A, 2000, BIOCHEM BIOPH RES CO, V268, P530, DOI 10.1006/bbrc.2000.2167; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Ruffner H, 1999, MOL CELL BIOL, V19, P4843; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Santaguida M, 2001, J BIOL CHEM, V276, P45780, DOI 10.1074/jbc.M107978200; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; Sorensen CS, 2001, MOL CELL BIOL, V21, P3692, DOI 10.1128/MCB.21.11.3692-3703.2001; Sugimoto N, 2004, J BIOL CHEM, V279, P19691, DOI 10.1074/jbc.M313175200; Takeda DY, 2001, J BIOL CHEM, V276, P1993, DOI 10.1074/jbc.M005719200; Truscott M, 2003, MOL CELL BIOL, V23, P3013, DOI 10.1128/MCB.23.8.3013-3028.2003; VALARCHE I, 1993, DEVELOPMENT, V119, P881; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; vanWijnen AJ, 1996, P NATL ACAD SCI USA, V93, P11516, DOI 10.1073/pnas.93.21.11516; VANWIJNEN AJ, 1994, P NATL ACAD SCI USA, V91, P12882, DOI 10.1073/pnas.91.26.12882; VANWIJNEN AJ, 1991, J CELL BIOCHEM, V46, P174, DOI 10.1002/jcb.240460211; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WRIGHT KL, 1992, BIOCHEMISTRY-US, V31, P2812, DOI 10.1021/bi00125a023; Yang R, 1997, CANCER RES, V57, P913; YOON SO, 1994, J BIOL CHEM, V269, P18453; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	57	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32712	32721		10.1074/jbc.M505417200	http://dx.doi.org/10.1074/jbc.M505417200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16081423	hybrid			2022-12-27	WOS:000231920300021
J	Chami, M; Guilvout, I; Gregorini, M; Remigy, HW; Muller, SA; Valerio, M; Engel, A; Pugsley, AP; Bayan, N				Chami, M; Guilvout, I; Gregorini, M; Remigy, HW; Muller, SA; Valerio, M; Engel, A; Pugsley, AP; Bayan, N			Structural insights into the secretin PulD and its trypsin-resistant core	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; PHAGE PIV MULTIMER; C-TERMINAL DOMAIN; ESCHERICHIA-COLI; NEISSERIA-MENINGITIDIS; PILQ SECRETIN; FUNCTIONAL-CHARACTERIZATION; PULLULANASE SECRETION; ELECTRON-MICROSCOPY; CRYSTAL-STRUCTURE	Limited proteolysis, secondary structure and biochemical analyses, mass spectrometry, and mass measurements by scanning transmission electron microscopy were combined with cryo-electron microscopy to generate a three-dimensional model of the homomultimeric complex formed by the outer membrane secretin PulD, an essential channel-forming component of the type II secretion system from Klebsiella oxytoca. The complex is a dodecameric structure composed of two rings that sandwich a closed disc. The two rings form chambers on either side of a central plug that is part of the middle disc. The PulD polypeptide comprises two major, structurally quite distinct domains; an N domain, which forms the walls of one of the chambers, and a trypsin-resistant C domain, which contributes to the outer chamber, the central disc, and the plug. The C domain contains a lower proportion of potentially transmembrane beta-structure than classical outer membrane proteins, suggesting that only a small part of it is embedded within the outer membrane. Indeed, the C domain probably extends well beyond the confines of the outer membrane bilayer, forming a centrally plugged channel that penetrates both the peptidoglycan on the periplasmic side and the lipopolysaccharide and capsule layers on the cell surface. The inner chamber is proposed to constitute a docking site for the secreted exoprotein pullulanase, whereas the outer chamber could allow displacement of the plug to open the channel and permit the exoprotein to escape.	Inst Pasteur, CNRS, URA 2175, Mol Genet Unit, F-75724 Paris, France; Univ Basel, Biozentrum, ME Muller Inst, CH-4056 Basel, Switzerland; Univ Paris 11, Lab Modelisat & Ingn Prot, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Basel; UDICE-French Research Universities; Universite Paris Saclay	Pugsley, AP (corresponding author), Inst Pasteur, CNRS, URA 2175, Mol Genet Unit, 25 Rue Dr Roux, F-75724 Paris, France.	max@pasteur.fr	Bayan, Nicolas/AAI-5034-2020	Bayan, Nicolas/0000-0001-7760-0811				BAICHWAL V, 1993, P NATL ACAD SCI USA, V90, P620, DOI 10.1073/pnas.90.2.620; BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; Beis K, 2004, J BIOL CHEM, V279, P28227, DOI 10.1074/jbc.M402913200; Bitter W, 1998, MOL MICROBIOL, V27, P209, DOI 10.1046/j.1365-2958.1998.00677.x; Bleves S, 1999, J BACTERIOL, V181, P4012, DOI 10.1128/JB.181.13.4012-4019.1999; Boulanger P, 1996, BIOCHEMISTRY-US, V35, P14216, DOI 10.1021/bi9608673; Brok R, 1999, J MOL BIOL, V294, P1169, DOI 10.1006/jmbi.1999.3340; Burghout P, 2004, J BACTERIOL, V186, P4645, DOI 10.1128/JB.186.14.4645-4654.2004; Chen CJ, 2004, J BACTERIOL, V186, P730, DOI 10.1128/JB.186.3.730-739.2004; Collins RF, 2005, J BIOL CHEM, V280, P18923, DOI 10.1074/jbc.M411603200; Collins RF, 2004, J BIOL CHEM, V279, P39750, DOI 10.1074/jbc.M405971200; Collins RF, 2003, J BACTERIOL, V185, P2611, DOI 10.1128/JB.185.8.2611-2617.2003; Collins RF, 2001, J BACTERIOL, V183, P3825, DOI 10.1128/JB.183.13.3825-3832.2001; CROWTHER RA, 1971, J MOL BIOL, V60, P123, DOI 10.1016/0022-2836(71)90452-9; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; Daefler S, 1997, MOL MICROBIOL, V24, P465, DOI 10.1046/j.1365-2958.1997.3531727.x; Daefler S, 1997, J MOL BIOL, V266, P978, DOI 10.1006/jmbi.1996.0866; DENFERT C, 1987, EMBO J, V6, P3531, DOI 10.1002/j.1460-2075.1987.tb02679.x; Faller M, 2004, SCIENCE, V303, P1189, DOI 10.1126/science.1094114; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Gohlke U, 2005, P NATL ACAD SCI USA, V102, P10482, DOI 10.1073/pnas.0503558102; Guilvout I, 1999, J BACTERIOL, V181, P7212, DOI 10.1128/JB.181.23.7212-7220.1999; Hardie KR, 1996, MOL MICROBIOL, V22, P967, DOI 10.1046/j.1365-2958.1996.01539.x; Hardie KR, 1996, EMBO J, V15, P978, DOI 10.1002/j.1460-2075.1996.tb00434.x; Koebnik R, 2000, MOL MICROBIOL, V37, P239, DOI 10.1046/j.1365-2958.2000.01983.x; Kohler R, 2004, MOL MICROBIOL, V54, P647, DOI 10.1111/j.1365-2958.2004.04307.x; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; Koster M, 1997, MOL MICROBIOL, V26, P789, DOI 10.1046/j.1365-2958.1997.6141981.x; Lario PI, 2005, EMBO J, V24, P1111, DOI 10.1038/sj.emboj.7600610; Lee MS, 2005, J BIOL CHEM, V280, P4585, DOI 10.1074/jbc.M409362200; Letellier L, 1997, J BIOL CHEM, V272, P11109; Linderoth NA, 1997, SCIENCE, V278, P1635, DOI 10.1126/science.278.5343.1635; Linderoth NA, 1996, J BACTERIOL, V178, P1962, DOI 10.1128/jb.178.7.1962-1970.1996; Lobley A, 2002, BIOINFORMATICS, V18, P211, DOI 10.1093/bioinformatics/18.1.211; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Marabini R, 1996, J STRUCT BIOL, V116, P237, DOI 10.1006/jsbi.1996.0036; Marciano DK, 1999, SCIENCE, V284, P1516, DOI 10.1126/science.284.5419.1516; Marciano DK, 2001, P NATL ACAD SCI USA, V98, P9359, DOI 10.1073/pnas.161170398; Marlovits TC, 2004, SCIENCE, V306, P1040, DOI 10.1126/science.1102610; MICHAELIS S, 1985, J BACTERIOL, V164, P633, DOI 10.1128/JB.164.2.633-638.1985; MILLER JH, 1992, SHORT COURSE BACTERI, P437; MULLER SA, 1992, ULTRAMICROSCOPY, V46, P317, DOI 10.1016/0304-3991(92)90022-C; Nouwen N, 2000, EMBO J, V19, P2229, DOI 10.1093/emboj/19.10.2229; Nouwen N, 1999, P NATL ACAD SCI USA, V96, P8173, DOI 10.1073/pnas.96.14.8173; Opalka N, 2003, J MOL BIOL, V325, P461, DOI 10.1016/S0022-2836(02)01246-9; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; Possot OM, 1997, MOL MICROBIOL, V24, P457, DOI 10.1046/j.1365-2958.1997.3451726.x; Possot OM, 2000, J BACTERIOL, V182, P2142, DOI 10.1128/JB.182.8.2142-2152.2000; Possot OM, 1999, J BACTERIOL, V181, P4004, DOI 10.1128/JB.181.13.4004-4011.1999; Pugsley AP, 2001, J BACTERIOL, V183, P1312, DOI 10.1128/JB.183.4.1312-1319.2001; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; PUGSLEY AP, 1991, MOL MICROBIOL, V5, P343, DOI 10.1111/j.1365-2958.1991.tb02115.x; Sandkvist M, 2001, MOL MICROBIOL, V40, P271, DOI 10.1046/j.1365-2958.2001.02403.x; Sauvonnet N, 2000, EMBO J, V19, P2221, DOI 10.1093/emboj/19.10.2221; Shevchik VE, 1998, MICROBIOL-UK, V144, P3219, DOI 10.1099/00221287-144-11-3219; Shevchik VE, 1997, EMBO J, V16, P3007, DOI 10.1093/emboj/16.11.3007; Vignon G, 2003, J BACTERIOL, V185, P3416, DOI 10.1128/JB.185.11.3416-3428.2003; Voulhoux R, 2001, EMBO J, V20, P6735, DOI 10.1093/emboj/20.23.6735; Whitmore L, 2004, NUCLEIC ACIDS RES, V32, pW668, DOI 10.1093/nar/gkh371; Zhao SQ, 2005, MOL MICROBIOL, V57, P1238, DOI 10.1111/j.1365-2958.2005.04752.x	61	115	119	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37732	37741		10.1074/jbc.M504463200	http://dx.doi.org/10.1074/jbc.M504463200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16129681	hybrid			2022-12-27	WOS:000233044500051
J	Daujat, S; Zeissler, U; Waldmann, T; Happel, N; Schneider, R				Daujat, S; Zeissler, U; Waldmann, T; Happel, N; Schneider, R			HP1 binds specifically to Lys(26)-methylated histone H1.4, whereas simultaneous Ser(27) phosphorylation blocks HP1 binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSINE 9; H3; CHROMATIN; METHYLATION; EXPRESSION; PROTEINS; DEPHOSPHORYLATION; RECRUITMENT; MAINTENANCE; NUCLEOSOME	Histone lysine methylation can have positive or negative effects on transcription, depending on the precise methylation site. According to the "histone code" hypothesis these methylation marks can be read by proteins that bind them specifically and then regulate downstream events. Hetero-chromatin protein 1 (HP1), an essential component of heterochromatin, binds specifically to methylated Lys(9) of histone H3 (K9/H3). The linker histone H1.4 is methylated on Lys(26) (K26/H1.4), but the role of this methylation in downstream events remains unknown. Here we identify HP1 as a protein specifically recognizing and binding to methylated K26/ H1.4. We demonstrate that the Chromo domain of HP1 is mediating this binding and that phosphorylation of Ser(27) on H1.4 (S27/ H1.4) prevents HP1 from binding. We suggest that methylation of K26/ H1.4 could have a role in tethering HP1 to chromatin and that this could also explain how HP1 is targeted to those regions of chromatin where it does not colocalize with methylated K9/H3. Our results provide the first experimental evidence for a "phospho switch" model in which neighboring phosphorylation reverts the effect of histone lysine methylation.	Max Planck Inst Immunbiol, D-79108 Freiburg, Germany; Univ Gottingen, Inst Biochem & Mol Cell Biol, D-37073 Gottingen, Germany	Max Planck Society; University of Gottingen	Schneider, R (corresponding author), Max Planck Inst Immunbiol, D-79108 Freiburg, Germany.	schneiderr@immunbio.mpg.de	Waldmann, Tanja/A-5145-2010; Daujat, Sylvain/A-6070-2017	Waldmann, Tanja/0000-0001-9276-1592; Daujat, Sylvain/0000-0001-5107-119X				Albig W, 1998, FEBS LETT, V435, P245, DOI 10.1016/S0014-5793(98)01084-9; Alexandrow MG, 2005, J CELL BIOL, V168, P875, DOI 10.1083/jcb.200409055; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bustin M, 2005, MOL CELL, V17, P617, DOI 10.1016/j.molcel.2005.02.019; Cheutin T, 2003, SCIENCE, V299, P721, DOI 10.1126/science.1078572; Dou YL, 2000, MOL CELL, V6, P225, DOI 10.1016/S1097-2765(00)00024-1; Dou YL, 2002, J CELL BIOL, V158, P1161, DOI 10.1083/jcb.200202131; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Garcia BA, 2004, J PROTEOME RES, V3, P1219, DOI 10.1021/pr0498887; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; Khochbin S, 2001, GENE, V271, P1, DOI 10.1016/S0378-1119(01)00495-4; Kratzmeier M, 2000, J BIOL CHEM, V275, P30478, DOI 10.1074/jbc.M003956200; Kuzmichev A, 2005, P NATL ACAD SCI USA, V102, P1859, DOI 10.1073/pnas.0409875102; Kuzmichev A, 2004, MOL CELL, V14, P183, DOI 10.1016/S1097-2765(04)00185-6; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lever MA, 2000, NATURE, V408, P873, DOI 10.1038/35048603; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Maison C, 2004, NAT REV MOL CELL BIO, V5, P296, DOI 10.1038/nrm1355; Mateescu B, 2004, EMBO REP, V5, P490, DOI 10.1038/sj.embor.7400139; Meergans T, 1997, DNA CELL BIOL, V16, P1041, DOI 10.1089/dna.1997.16.1041; Muchardt C, 2002, EMBO REP, V3, P975, DOI 10.1093/embo-reports/kvf194; Nielsen AL, 2001, MOL CELL, V7, P729, DOI 10.1016/S1097-2765(01)00218-0; Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; Stewart MD, 2005, MOL CELL BIOL, V25, P2525, DOI 10.1128/MCB.25.7.2525-2538.2005; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; Van Holde KE, 1988, SPRINGER SERIES MOL; Yamamoto K, 2004, J BIOL CHEM, V279, P401, DOI 10.1074/jbc.M307344200	29	185	187	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					38090	38095		10.1074/jbc.C500229200	http://dx.doi.org/10.1074/jbc.C500229200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16127177	hybrid			2022-12-27	WOS:000233044500092
J	Katsanakis, KD; Pillay, TS				Katsanakis, KD; Pillay, TS			Cross-talk between the two divergent insulin signaling pathways is revealed by the protein kinase B (Akt)-mediated phosphorylation of adapter protein APS on serine 588	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUT4 TRANSLOCATION; C-CBL; GLUCOSE-TRANSPORT; RECEPTOR; RECRUITMENT; ADIPOCYTES; SUBSTRATE; CELLS; IDENTIFICATION; DEGUELIN	The APS adapter protein is recruited to the autophosphorylated kinase domain of the insulin receptor and initiates the phosphatidylinositol 3-kinase (PI3K)-independent pathway of insulin-stimulated glucose transport by recruiting CAP and c-Cbl. In this study, we have identified APS as a novel substrate for protein kinase B/Akt using an antibody that exhibits insulin-dependent immunoreactivity with a phosphospecific antibody raised against the protein kinase B substrate consensus sequence RXRXX(pS/pT) and a phosphospecific antibody that recognizes serine 21/9 of glycogen synthase kinase-3 alpha/beta. This phosphorylation of APS is observed in both 3T3-L1 adipocytes and transfected cells. The insulin-stimulated serine phosphorylation of APS was inhibited by a PI3-kinase inhibitor, LY290004, a specific protein kinase B (PKB) inhibitor, deguelin, and knockdown of Akt. Serine 588 of APS is contained in a protein kinase B consensus sequence for phosphorylation conserved in APS across multiple species but not found in other members of this family, including SH2-B and Lnk. Mutation of serine 588 to alanine abolished the insulin-stimulated serine phosphorylation of APS and prevented the localization of APS to membrane ruffles. A glutathione S-transferase fusion protein containing amino acids 534 - 621 of APS was phosphorylated by purified PKB in vitro, and mutation of serine 588 abolished the PKB-mediated phosphorylation of APS in vitro. Taken together, this study identifies APS as a novel physiological substrate for PKB and the first serine phosphorylation site on APS. These data therefore reveal the molecular cross-talk between the insulin-activated PI3-kinase-dependent and - independent pathways previously thought to be distinct and divergent.	Univ Nottingham, Sch Med, Inst Cell Signaling, Nottingham NG7 2UH, England; Univ Nottingham, Sch Med, Sch Biomed Sci, Nottingham NG7 2UH, England	University of Nottingham; University of Nottingham	Pillay, TS (corresponding author), Univ Nottingham, Sch Med, Inst Cell Signaling, Nottingham NG7 2UH, England.	tpillay@nottingham.ac.uk		pillay, tahir/0000-0002-9982-9710	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ahmed Z, 2000, FEBS LETT, V475, P31, DOI 10.1016/S0014-5793(00)01621-5; Ahmed Z, 2003, BIOCHEM J, V371, P405, DOI 10.1042/BJ20021589; Ahn MY, 2004, J BIOL CHEM, V279, P21526, DOI 10.1074/jbc.M307740200; Berwick DC, 2004, TRENDS BIOCHEM SCI, V29, P227, DOI 10.1016/j.tibs.2004.03.004; Berwick DC, 2002, J BIOL CHEM, V277, P33895, DOI 10.1074/jbc.M204681200; Bortul R, 2005, BRIT J HAEMATOL, V129, P677, DOI 10.1111/j.1365-2141.2005.05504.x; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Chang L, 2002, P NATL ACAD SCI USA, V99, P12835, DOI 10.1073/pnas.202495599; Chiang SH, 2003, EMBO J, V22, P2679, DOI 10.1093/emboj/cdg262; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; CHIANG SH, 2002, J BIOL CHEM, V30, P30; Chun KH, 2003, JNCI-J NATL CANCER I, V95, P291, DOI 10.1093/jnci/95.4.291; Hu JJ, 2005, J BIOL CHEM, V280, P18943, DOI 10.1074/jbc.M414157200; Hu JJ, 2003, MOL CELL, V12, P1379, DOI 10.1016/S1097-2765(03)00487-8; Jiang ZY, 2005, J BIOL CHEM, V280, P21622, DOI 10.1074/jbc.m414464200; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; Lawlor MA, 2001, J CELL SCI, V114, P2903; Liu J, 2003, J BIOL CHEM, V278, P36754, DOI 10.1074/jbc.M300664200; Liu J, 2002, MOL CELL BIOL, V22, P3599, DOI 10.1128/MCB.22.11.3599-3609.2002; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Welsh GL, 2005, BIOCHEM SOC T, V33, P346, DOI 10.1042/BST0330346; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Wilcox A, 2004, J BIOL CHEM, V279, P38881, DOI 10.1074/jbc.M406101200; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737	25	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37827	37832		10.1074/jbc.M505959200	http://dx.doi.org/10.1074/jbc.M505959200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16141217	hybrid			2022-12-27	WOS:000233044500062
J	Odell, AF; Scott, JL; Van Helden, DF				Odell, AF; Scott, JL; Van Helden, DF			Epidermal growth factor induces tyrosine phosphorylation, membrane insertion, and activation of transient receptor potential channel 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCHANGER REGULATORY FACTOR; OPERATED CA2+ ENTRY; SURFACE EXPRESSION; PLASMA-MEMBRANE; CATION CHANNELS; TRPC6 CHANNEL; CALCIUM-ENTRY; PDZ-DOMAIN; PROTEIN; CELLS	Various members of the canonical family of transient receptor potential channels (TRPCs) exhibit increased cation influx following receptor stimulation or Ca2+ store depletion. Tyrosine phosphorylation of TRP family members also results in increased channel activity; however, the link between the two events is unclear. We report that two tyrosine residues in the C terminus of human TRPC4 (hTRPC4), Tyr-959 and Tyr-972, are phosphorylated following epidermal growth factor (EGF) receptor stimulation of COS-7 cells. This phosphorylation was mediated by Src family tyrosine kinases (STKs), with Fyn appearing to be the dominant kinase. In addition, EGF receptor stimulation induced the exocytotic insertion of hTRPC4 into the plasma membrane dependent on the activity of STKs and was accompanied by a phosphorylation-dependent increase in the association of hTRPC4 with Na+/H+ exchanger regulatory factor. Furthermore, this translocation and association was defective upon mutation of Tyr-959 and Tyr-972 to phenylalanine. Significantly, inhibition of STKs was concomitant with a reduction in Ca2+ influx in both native COS-7 cells and hTRPC4-expressing HEK293 cells, with cells expressing the Y959F/Y972F mutant exhibiting a reduced EGF response. These findings represent the first demonstration of a mechanism for phosphorylation to modulate TRPC channel function.	Univ Newcastle, Sch Biomed Sci, Callaghan, NSW 2308, Australia	University of Newcastle	Odell, AF (corresponding author), Univ Newcastle, Sch Biomed Sci, Level 5 MSB,Univ Dr, Callaghan, NSW 2308, Australia.	adam.odell@newcastle.edu.au	Odell, Adam/J-1386-2012					Alessandri-Haber N, 2004, J NEUROSCI, V24, P4444, DOI 10.1523/JNEUROSCI.0242-04.2004; Babnigg G, 1997, J BIOL CHEM, V272, P29434, DOI 10.1074/jbc.272.47.29434; Bahner M, 2002, NEURON, V34, P83, DOI 10.1016/S0896-6273(02)00630-X; Berridge MJ, 2001, NOVART FDN SYMP, V239, P52; Berridge MJ, 2004, BBA-MOL CELL RES, V1742, P3, DOI 10.1016/j.bbamcr.2004.08.012; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Bezzerides VJ, 2004, NAT CELL BIOL, V6, P709, DOI 10.1038/ncb1150; Boels K, 2001, J CELL SCI, V114, P3599; Bootman MD, 2002, CURR BIOL, V12, pR563, DOI 10.1016/S0960-9822(02)01055-2; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Cayouette S, 2004, J BIOL CHEM, V279, P7241, DOI 10.1074/jbc.M312042200; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; FLOCKERZI V, 2005, IN PRESS PFLUGERS AR; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hildreth KL, 2004, J BIOL CHEM, V279, P41775, DOI 10.1074/jbc.M403274200; Hisatsune C, 2004, J BIOL CHEM, V279, P18887, DOI 10.1074/jbc.M311274200; Itagaki K, 2004, J IMMUNOL, V172, P601, DOI 10.4049/jimmunol.172.1.601; Jiang XP, 2003, J BIOL CHEM, V278, P42867, DOI 10.1074/jbc.M304487200; Jung S, 2003, J BIOL CHEM, V278, P3562, DOI 10.1074/jbc.M211484200; Kanzaki M, 1999, NAT CELL BIOL, V1, P165, DOI 10.1038/11086; Lazar CS, 2004, MOL BIOL CELL, V15, P5470, DOI 10.1091/mbc.E04-03-0239; McKay RR, 2000, BIOCHEM J, V351, P735, DOI 10.1042/0264-6021:3510735; Mery L, 2002, J CELL SCI, V115, P3497; Misonou H, 2004, CRIT REV BIOCHEM MOL, V39, P125, DOI 10.1080/10409230490475417; Misonou H, 2004, NAT NEUROSCI, V7, P711, DOI 10.1038/nn1260; Missiaen L, 2000, CELL CALCIUM, V28, P1, DOI 10.1054/ceca.2000.0131; Obukhov AG, 2004, J CELL PHYSIOL, V201, P227, DOI 10.1002/jcp.20057; Ong HL, 2002, BIOCHEM J, V364, P641, DOI 10.1042/BJ20020061; Redondo PC, 2003, BIOCHEM J, V370, P255, DOI 10.1042/BJ20021505; Rizzuto R, 2003, NAT GENET, V34, P135, DOI 10.1038/ng0603-135; Rosado JA, 2000, BIOCHEM J, V351, P429, DOI 10.1042/0264-6021:3510429; Saavedra FR, 2004, ARCH BIOCHEM BIOPHYS, V432, P261, DOI 10.1016/j.abb.2004.09.034; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; Singh BB, 2004, MOL CELL, V15, P635, DOI 10.1016/j.molcel.2004.07.010; SOTIRELLIS N, 1995, J BIOL CHEM, V270, P29773; TAKEUCHI M, 1993, J BIOL CHEM, V268, P27413; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; Tiruppathi C, 2002, CIRC RES, V91, P70, DOI 10.1161/01.RES.0000023391.40106.A8; van Rossum DB, 2005, NATURE, V434, P99, DOI 10.1038/nature03340; Vazquez G, 2004, J BIOL CHEM, V279, P40521, DOI 10.1074/jbc.M405280200; Voltz JW, 2001, ONCOGENE, V20, P6309, DOI 10.1038/sj.onc.1204774; Walker F, 1998, GROWTH FACTORS, V16, P53, DOI 10.3109/08977199809017491; Walker RL, 2002, AM J PHYSIOL-CELL PH, V283, pC1637, DOI 10.1152/ajpcell.00266.2002; Wu XY, 2002, J BIOL CHEM, V277, P13597, DOI 10.1074/jbc.M110881200; Xu HS, 2003, J BIOL CHEM, V278, P11520, DOI 10.1074/jbc.M211061200; Yang H, 2005, J BIOL CHEM, V280, P32230, DOI 10.1074/jbc.M504553200; Zeng FN, 2004, J PHYSIOL-LONDON, V559, P739, DOI 10.1113/jphysiol.2004.065391	49	89	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37974	37987		10.1074/jbc.M503646200	http://dx.doi.org/10.1074/jbc.M503646200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16144838	hybrid			2022-12-27	WOS:000233044500080
J	Blau, CA; Barbas, CF; Bomhoff, AL; Neades, R; Yan, J; Navas, PA; Peterson, KR				Blau, CA; Barbas, CF; Bomhoff, AL; Neades, R; Yan, J; Navas, PA; Peterson, KR			gamma-globin gene expression in chemical inducer of dimerization (CID)-dependent multipotential cells established from human beta-globin locus yeast artificial chromosome (beta-YAC) transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FETAL-HEMOGLOBIN; THALASSEMIA; INDUCTION; NF-E4	Identification of trans-acting factors or drugs capable of reactivating gamma-globin gene expression is complicated by the lack of suitable cell lines. Human K562 cells co-express epsilon- and gamma-globin but not beta-globin; transgenic mouse erythroleukemia 585 cells express predominantly human beta-globin but also gamma-globin; and transgenic murine GM979 cells co-express human gamma- and beta-globin. Human beta-globin locus yeast artificial chromosome transgenic mice display correct developmental regulation of beta-like globin gene expression. We rationalized that cells established from the adult bone marrow of these mice might express exclusively beta-globin and therefore could be employed to select or screen inducers of gamma-globin expression. A thrombopoietin receptor derivative that brings the proliferative status of primary mouse bone marrow cells under control of a chemical inducer of dimerization was employed to institute and maintain these cell populations. Human beta-globin was expressed, but gamma-globin was not; a similar expression pattern was observed in cells derived from fetal liver. gamma-Globin expression was induced upon exposure to 5-azacytidine, in cells derived from - 117 Greek hereditary persistence of fetal hemoglobin human beta-globin locus yeast artificial chromosome (beta-YAC) mice, showing that the hereditary persistence of fetal hemoglobin (HPFH) phenotype was maintained in these cells or was reactivated by an artificial zinc finger-gamma-globin transcription factor and the previously identified fetal globin transactivators fetal Kruppel-like factor ( FKLF) and fetal globin-increasing factor (FGIF). These cells may be useful for identifying transcription factors that reactivate gamma-globin synthesis or screening gamma-globin inducers for the treatment of sickle cell disease or beta-thalassemia.	Univ Washington, Med Ctr, Dept Med, Div Hematol, Seattle, WA 98195 USA; Univ Washington, Med Ctr, Dept Med, Div Med Genet, Seattle, WA 98195 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66213 USA; Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66213 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Scripps Research Institute; Scripps Research Institute; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Peterson, KR (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, MS 3030,3901 Rainbow Blvd, Kansas City, KS 66160 USA.	kpeterson@kumc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL067336, P01HL053750, R01HL067336] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052997, R01DK061804, R01DK061803] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53750, HL67336] Funding Source: Medline; NIDDK NIH HHS [DK61803, DK61804, DK52997, DK53510] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asano H, 1999, MOL CELL BIOL, V19, P3571; Asano H, 2000, BLOOD, V95, P3578, DOI 10.1182/blood.V95.11.3578.011k48_3578_3584; Blau CA, 1997, P NATL ACAD SCI USA, V94, P3076, DOI 10.1073/pnas.94.7.3076; CONSTANTOULAKIS P, 1989, BLOOD, V74, P1963; DESIMONE J, 1982, P NATL ACAD SCI-BIOL, V79, P4428, DOI 10.1073/pnas.79.14.4428; FIBACH E, 1993, BLOOD, V82, P2203, DOI 10.1182/blood.V82.7.2203.bloodjournal8272203; Graslund T, 2005, J BIOL CHEM, V280, P3707, DOI 10.1074/jbc.M406809200; Harju S, 2001, BIOTECHNIQUES, V30, P1198, DOI 10.2144/01306bm02; Jin LQ, 1998, P NATL ACAD SCI USA, V95, P8093, DOI 10.1073/pnas.95.14.8093; Jin LQ, 2000, NAT GENET, V26, P64, DOI 10.1038/79194; LEY TJ, 1982, NEW ENGL J MED, V307, P1469, DOI 10.1056/NEJM198212093072401; Neff T, 2001, BLOOD, V97, P2535, DOI 10.1182/blood.V97.9.2535; Papayannopoulou T, 2000, BLOOD, V95, P1274, DOI 10.1182/blood.V95.4.1274.004k45_1274_1282; PAPAYANNOPOULOU T, 1986, CELL, V46, P469, DOI 10.1016/0092-8674(86)90667-7; Peterson K R, 1997, Genet Eng (N Y), V19, P235; Peterson KR, 2004, GENESIS, V39, P1, DOI 10.1002/gene.20020; PETERSON KR, 1995, P NATL ACAD SCI USA, V92, P5655, DOI 10.1073/pnas.92.12.5655; PETERSON KR, 1993, P NATL ACAD SCI USA, V90, P7593, DOI 10.1073/pnas.90.16.7593; Peterson KR, 1998, HUM MOL GENET, V7, P2079, DOI 10.1093/hmg/7.13.2079; PETERSON KR, 1993, P NATL ACAD SCI USA, V90, P11207, DOI 10.1073/pnas.90.23.11207; Skarpidi E, 1998, BLOOD, V92, P3416, DOI 10.1182/blood.V92.9.3416.421k16_3416_3421; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; Stamatoyannopoulos G., 2001, MOL BASIS BLOOD DIS, Vthird, P135; Swank RA, 1998, CURR OPIN GENET DEV, V8, P366, DOI 10.1016/S0959-437X(98)80095-6; Vassilopoulos G, 1999, BLOOD, V93, P703, DOI 10.1182/blood.V93.2.703.402k07_703_712; Yang Y, 2001, BLOOD CELL MOL DIS, V27, P1, DOI 10.1006/bcmd.2000.0344; Zeng H, 2001, BLOOD, V98, P328, DOI 10.1182/blood.V98.2.328; Zhou WL, 2004, J BIOL CHEM, V279, P26227, DOI 10.1074/jbc.M402191200; Zhou WL, 2000, MOL CELL BIOL, V20, P7662, DOI 10.1128/MCB.20.20.7662-7672.2000	29	22	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36642	36647		10.1074/jbc.M504402200	http://dx.doi.org/10.1074/jbc.M504402200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16131492	hybrid			2022-12-27	WOS:000232901800015
J	Santoso, S; Orlova, VV; Song, KM; Sachs, UJ; Andrei-Selmer, CL; Chavakis, T				Santoso, S; Orlova, VV; Song, KM; Sachs, UJ; Andrei-Selmer, CL; Chavakis, T			The homophilic binding of junctional adhesion molecule-C mediates tumor cell-endothelial cell interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN SUPERFAMILY; JAM FAMILY; TRANSENDOTHELIAL MIGRATION; HUMAN PLATELETS; LIGAND; COUNTERRECEPTOR; EXPRESSION; INTEGRINS; RECEPTOR; MEMBER	The junctional adhesion molecule C(JAM-C) was recently shown to undergo a heterophilic interaction with the leukocyte beta 2 integrin Mac-1, thereby mediating interactions between vascular cells in inflammatory cell recruitment. Here, the homophilic interaction of JAM-C is presented and functionally characterized to mediate tumor cell-endothelial cell interactions. Recombinant soluble JAM-C in fluid phase bound to immobilized JAM-C as assessed in a purified system; moreover, JAM-C-transfected Chinese hamster ovary (CHO) cells adhered to immobilized JAM-C. The homophilic interaction of JAM-C was mediated by the isolated amino-terminal Ig domain (D1), but not the carboxyl-terminal Ig domain (D2), of the molecule. Dimerization of JAM-A is dependent on the sequence RVE in the amino-terminal Ig domain. This motif is conserved in JAM-C (Arg(64)-Ile(65)-Glu(66)), and a single amino acid mutation in this motif (E66R) abolished the homophilic interaction of JAM-C. The lung carcinoma cell line NCI-H522 was found to express JAM-C. NCI-H522 cells adhered to immobilized JAM-C, as well as to JAM-C-transfected CHO cells, but not to mock-transfected CHO cells or to CHO cells transfected with the JAM-Cmutant ( E66R). Adhesion of NCI-H522 cells to JAM-C protein or JAM-C-transfected CHO cells was abolished in the presence of soluble JAM-C or the isolated D1. Furthermore, the adhesion of NCI-H522 cells to endothelial cells was significantly blocked by soluble JAM-C or the isolated D1. Thus, JAM-C undergoes a homophilic interaction via the Arg(64)Ile(65)-Glu(66) motif on the membrane-distal Ig domain of the molecule. The homophilic interaction of JAM-C can mediate tumor cell-endothelial cell interactions and may thereby be involved in the process of tumor cell metastasis.	NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; Univ Giessen, Inst Clin Immunol & Transfus Med, D-35392 Giessen, Germany	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Justus Liebig University Giessen	Chavakis, T (corresponding author), NCI, Expt Immunol Branch, NIH, 10 Ctr Dr,Rm 4B17, Bethesda, MD 20892 USA.	chavakist@mail.nih.gov	Orlova, Valeria V/C-6065-2014; Sachs, Ulrich/GSI-7824-2022; Chavakis, Triantafyllos/ABE-8845-2020	Orlova, Valeria V/0000-0002-1169-2802; 				Aurrand-Lions M, 2001, BLOOD, V98, P3699, DOI 10.1182/blood.V98.13.3699; Aurrand-Lions M, 2001, J BIOL CHEM, V276, P2733, DOI 10.1074/jbc.M005458200; Bazzoni G, 2000, J BIOL CHEM, V275, P30970, DOI 10.1074/jbc.M003946200; Bazzoni G, 2003, CURR OPIN CELL BIOL, V15, P525, DOI 10.1016/S0955-0674(03)00104-2; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chavakis T, 2004, J BIOL CHEM, V279, P55602, DOI 10.1074/jbc.M404676200; Chavakis T, 2003, J EXP MED, V198, P1507, DOI 10.1084/jem.20030800; Chavakis T, 2003, THROMB HAEMOSTASIS, V89, P13; Cunningham SA, 2000, J BIOL CHEM, V275, P34750, DOI 10.1074/jbc.M002718200; Cunningham SA, 2002, J BIOL CHEM, V277, P27589, DOI 10.1074/jbc.C200331200; Ebnet K, 2003, J CELL SCI, V116, P3879, DOI 10.1242/jcs.00704; Ebnet K, 2004, J CELL SCI, V117, P19, DOI 10.1242/jcs.00930; Engers R, 2000, J CANCER RES CLIN, V126, P682, DOI 10.1007/s004320000148; GIAVAZZI R, 1993, J CLIN INVEST, V92, P3038, DOI 10.1172/JCI116928; Johnson-Leger CA, 2002, BLOOD, V100, P2479, DOI 10.1182/blood-2001-11-0098; Keiper T, 2005, HISTOL HISTOPATHOL, V20, P197, DOI 10.14670/HH-20.197; KORNECKI E, 1990, J BIOL CHEM, V265, P10042; Kostrewa D, 2001, EMBO J, V20, P4391, DOI 10.1093/emboj/20.16.4391; Liu Y, 2000, J CELL SCI, V113, P2363; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Ostermann G, 2002, NAT IMMUNOL, V3, P151, DOI 10.1038/ni755; Palmeri D, 2000, J BIOL CHEM, V275, P19139, DOI 10.1074/jbc.M003189200; Peterson JA, 1998, BLOOD, V92, P2053, DOI 10.1182/blood.V92.6.2053.418k14_2053_2063; Roschke AV, 2003, CANCER RES, V63, P8634; Santoso S, 2002, J EXP MED, V196, P679, DOI 10.1084/jem.20020267; Seftor REB, 1999, CANCER METAST REV, V18, P359, DOI 10.1023/A:1006317125454; Sobocka MB, 2000, BLOOD, V95, P2600; Yoshimasu T, 2004, CANCER SCI, V95, P142, DOI 10.1111/j.1349-7006.2004.tb03195.x; Zen K, 2004, MOL BIOL CELL, V15, P3926, DOI 10.1091/mbc.E04-04-0317	29	63	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36326	36333		10.1074/jbc.M505059200	http://dx.doi.org/10.1074/jbc.M505059200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16118203	hybrid			2022-12-27	WOS:000232726900066
J	Antoniv, TT; Tanaka, S; Sudan, B; De Val, S; Liu, K; Wang, L; Wells, DJ; Bou-Gharios, G; Ramirez, F				Antoniv, TT; Tanaka, S; Sudan, B; De Val, S; Liu, K; Wang, L; Wells, DJ; Bou-Gharios, G; Ramirez, F			Identification of a repressor in the first intron of the human alpha 2(I) collagen gene (COL1A2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN GENE-EXPRESSION; FAR-UPSTREAM ENHANCER; REPORTER GENES; PROMOTER; PRO-ALPHA-1(I); TRANSCRIPTION; ELEMENTS; SEQUENCE; PROTEIN; REGION	The human and mouse genes that code for the alpha 2 chain of collagen I ( COL1A2 and Col1a2, respectively) share a common chromatin structure and nearly identical proximal promoter and far upstream enhancer sequences. Despite these homologies, species-specific differences have been reported regarding the function of individual cis- acting elements, such as the first intron sequence. In the present study, we have investigated the transcriptional contribution of the unique open chromatin site in the first intron of COL1A2 using a transgenic mouse model. DNase I footprinting identified a cluster of three distinct areas of nuclease protection ( FI1 - 3) that span from nucleotides + 647 to + 760, relative to the transcription start site, and which contain consensus sequences for GATA and interferon regulatory factor ( IRF) transcription factors. Gel mobility shift and chromatin immunoprecipitation assays corroborated this last finding by documenting binding of GATA- 4 and IRF- 1 and IRF- 2 to the first intron sequence. Moreover, a short sequence encompassing the three footprints was found to inhibit expression of transgenic constructs containing the COL1A2 proximal promoter and far upstream enhancer in a position- independent manner. Mutations inserted into each of the footprints restored transgenic expression to different extents. These results therefore indicated that the unique open chromatin site of COL1A2 corresponds to a repressor, the activity of which seems to be mediated by the concerted action of GATA and IRF proteins. More generally, the study reiterated the existence of species- specific difference in the regulatory networks of the mammalian alpha 2( I) collagen coding genes.	Hosp Special Surg, Lab Genet & Organogenesis, Div Res, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Physiol & Biophys, New York, NY 10021 USA; Charing Cross Hosp, Imperial Coll Sch Med, Div Neurosci & Mental Hlth, Gene Targeting Unit, London W6 8RP, England; Imperial Coll Sch Med, London W12 ONN, England; CEINGE Biotecnol Avanzate, I-80131 Naples, Italy	Cornell University; Imperial College London; Imperial College London; CEINGE Biotecnologie Avanzate	Ramirez, F (corresponding author), Hosp Special Surg, Lab Genet & Organogenesis, Div Res, 535 E 70th St, New York, NY 10021 USA.	ramirezf@hss.edu		Wells, Dominic/0000-0002-1425-6344	NCRR NIH HHS [C06-RR12538-01] Funding Source: Medline; NIAMS NIH HHS [AR386481] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR012538] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Antoniv TT, 2001, J BIOL CHEM, V276, P21754, DOI 10.1074/jbc.M101397200; BouGharios G, 1996, J CELL BIOL, V134, P1333, DOI 10.1083/jcb.134.5.1333; De Val S, 2002, J BIOL CHEM, V277, P9286, DOI 10.1074/jbc.M111040200; DICKSON LA, 1985, NUCLEIC ACIDS RES, V13, P3427, DOI 10.1093/nar/13.10.3427; Ghosh AK, 2002, EXP BIOL MED, V227, P301, DOI 10.1177/153537020222700502; HAY ED, 1995, CELL BIOL EXTRACELLU, P419; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; NAGY A, 2003, MANIPULATING MOUSE E, P289; Ogbourne S, 1998, BIOCHEM J, V331, P1; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; Rossert JA, 1996, P NATL ACAD SCI USA, V93, P1027, DOI 10.1073/pnas.93.3.1027; ROSSI P, 1987, P NATL ACAD SCI USA, V84, P5590, DOI 10.1073/pnas.84.16.5590; Senger K, 2000, MOL CELL, V6, P931, DOI 10.1016/S1097-2765(05)00081-X; SHERWOOD AL, 1990, GENE, V89, P239, DOI 10.1016/0378-1119(90)90011-F; Smaldone S, 2004, MOL CELL BIOL, V24, P1058, DOI 10.1128/MCB.24.3.1058-1069.2004; Tanaka S, 2004, J BIOL CHEM, V279, P56024, DOI 10.1074/jbc.M411406200; Terraz C, 2002, J BIOL CHEM, V277, P19019, DOI 10.1074/jbc.M200125200; Terraz C, 2001, J BIOL CHEM, V276, P37011, DOI 10.1074/jbc.M104185200; Trojanowska M, 2002, FRONT BIOSCI-LANDMRK, V7, pD608, DOI 10.2741/trojan; TRUTER S, 1992, J BIOL CHEM, V267, P25389; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VARGA J, 1995, ANN INTERN MED, V122, P60, DOI 10.7326/0003-4819-122-1-199501010-00010; VUUST J, 1985, EUR J BIOCHEM, V151, P449, DOI 10.1111/j.1432-1033.1985.tb09122.x; Wang L, 2005, MATRIX BIOL, V24, P333, DOI 10.1016/j.matbio.2005.06.001	27	12	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35417	35423		10.1074/jbc.M502681200	http://dx.doi.org/10.1074/jbc.M502681200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16091368	hybrid			2022-12-27	WOS:000232561200041
J	Inuzuka, M; Hayakawa, M; Ingi, T				Inuzuka, M; Hayakawa, M; Ingi, T			Serinc, an activity-regulated protein family, incorporates serine into membrane lipid synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; EXPRESSION; RAFTS; GENE; IDENTIFICATION; PURIFICATION; PLASTICITY; SEQUENCE; BRAIN; RGS2	Cell membranes contain various transporter proteins, some of which are responsible for transferring amino acids across membrane. In this study, we report another class of carrier proteins, termed Serinc1 - 5, that incorporates a polar amino acid serine into membranes and facilitates the synthesis of two serine- derived lipids, phosphatidylserine and sphingolipids. Serinc is a unique protein family that shows no amino acid homology to other proteins but is highly conserved among eukaryotes. The members contain 11 transmembrane domains, and rat Serinc1 protein co- localizes with lipid biosynthetic enzymes in endoplasmic reticulum membranes. A Serinc protein forms an intracellular complex with key enzymes involved in serine and sphingolipid biosyntheses, and both functions, serine synthesis and membrane incorporation, are linked to each other. In the rat brain, expression of Serinc1 and Serinc2 mRNA was rapidly up- regulated by kainate- induced seizures in neuronal cell layers of the hippocampus. In contrast, myelin throughout the brain is enriched with Serinc5, which was down-regulated in the hippocampus by seizures. These results indicate a novel mechanism linking neural activity and lipid biosynthesis.	Niigata Univ, Brain Res Inst, Dept Neurophysiol, Niigata 9518585, Japan	Niigata University	Ingi, T (corresponding author), Niigata Univ, Brain Res Inst, Dept Neurophysiol, 1 Asahi Machi, Niigata 9518585, Japan.	tingi@bri.niigata-u.ac.jp						BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bossolasco M, 1999, MOL CARCINOGEN, V26, P189, DOI 10.1002/(SICI)1098-2744(199911)26:3<189::AID-MC8>3.0.CO;2-T; Cagney G, 2000, METHOD ENZYMOL, V328, P3, DOI 10.1016/S0076-6879(00)28386-9; CARMAN GM, 1992, METHOD ENZYMOL, V209, P298; De Hertogh Benoit, 2002, Funct Integr Genomics, V2, P154; DESTRUELLE M, 1994, MOL CELL BIOL, V14, P2740, DOI 10.1128/MCB.14.4.2740; Dickson RC, 1998, ANNU REV BIOCHEM, V67, P27, DOI 10.1146/annurev.biochem.67.1.27; DOWHAN W, 1992, METHOD ENZYMOL, V209, P287; DOWHAN W, 1974, J BIOL CHEM, V249, P3079; Grossman TR, 2000, J EXP BIOL, V203, P447; Guirland C, 2004, NEURON, V42, P51, DOI 10.1016/S0896-6273(04)00157-6; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P225, DOI 10.1073/pnas.012540899; Ingi T, 2002, EUR J NEUROSCI, V15, P929, DOI 10.1046/j.1460-9568.2002.01925.x; Ingi T, 2001, EUR J NEUROSCI, V13, P1459, DOI 10.1046/j.0953-816x.2001.01529.x; Ingi T, 1998, J NEUROSCI, V18, P7178; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; KANFER JN, 1992, METHOD ENZYMOL, V209, P341; Krueger WHH, 1997, J NEUROCHEM, V69, P1343; LAW DTS, 1988, MOL CELL BIOL, V8, P912, DOI 10.1128/MCB.8.2.912; LEBEL M, 1994, DNA SEQUENCE, V5, P31, DOI 10.3109/10425179409039702; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MERRILL AH, 1992, METHOD ENZYMOL, V209, P427; NEDIVI E, 1993, NATURE, V363, P718, DOI 10.1038/363718a0; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Tsui-Pierchala BA, 2002, TRENDS NEUROSCI, V25, P412, DOI 10.1016/S0166-2236(02)02215-4; WILLIAMS RD, 1984, ARCH BIOCHEM BIOPHYS, V228, P282, DOI 10.1016/0003-9861(84)90069-9	28	121	129	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35776	35783		10.1074/jbc.M505712200	http://dx.doi.org/10.1074/jbc.M505712200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16120614	hybrid			2022-12-27	WOS:000232561200081
J	Jones, AL; Poon, IKH; Hulett, MD; Parish, CR				Jones, AL; Poon, IKH; Hulett, MD; Parish, CR			Histidine-rich glycoprotein specifically binds to necrotic cells via its amino-terminal domain and facilitates necrotic cell phagocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSOLUBLE IMMUNE-COMPLEXES; APOPTOTIC CELLS; PLASMINOGEN ACTIVATION; PLASMA-PROTEIN; HIGH-AFFINITY; HUMAN-IGG; SURFACE; DEATH; INHIBITION; THROMBOSPONDIN	Cells that become necrotic or apoptotic through tissue damage or during normal cellular turnover are usually rapidly cleared from the circulation and tissues by phagocytic cells. A number of soluble proteins have been identified that facilitate the phagocytosis of apoptotic cells, but few proteins have been defined that selectively opsonize necrotic cells. Previous studies have shown that histidine-rich glycoprotein ( HRG), an abundant ( similar to 100 mu g/ ml) 75- kDa plasma glycoprotein, binds to cell surface heparan sulfate on viable cells and cross- links other ligands, such as plasminogen, to the cell surface. In this study we have demonstrated that HRG also binds very strongly, in a heparan sulfate- independent manner, to cytoplasmic ligand( s) exposed in necrotic cells. This interaction is mediated by the amino- terminal domain of HRG and results in enhanced phagocytosis of the necrotic cells by a monocytic cell line. In contrast, it was found that HRG binds poorly to and does not opsonize early stage apoptotic cells. Thus, HRG has the unique property of selectively recognizing necrotic cells and may play an important physiological role in vivo by facilitating the uptake and clearance of necrotic, but not apoptotic, cells by phagocytes.	Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Genet, Canc & Vasc Biol Grp, Canberra, ACT 0200, Australia; Univ Uppsala, Ctr Biomed, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden	Australian National University; John Curtin School of Medical Research; Uppsala University	Parish, CR (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Genet, Canc & Vasc Biol Grp, Bldg 54,Mills Rd, Canberra, ACT 0200, Australia.	christopher.parish@anu.edu.au	Hulett, Mark D/C-4160-2012	Hulett, Mark/0000-0003-2072-5968; Poon, Ivan/0000-0002-9119-7173; Parish, Christopher/0000-0001-7740-0430				Borza DB, 1997, J BIOL CHEM, V272, P5718, DOI 10.1074/jbc.272.9.5718; Borza DB, 2004, BLOOD COAGUL FIBRIN, V15, P663, DOI 10.1097/00001721-200412000-00006; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Dijstelbloem HM, 2001, TRENDS IMMUNOL, V22, P510, DOI 10.1016/S1471-4906(01)02014-2; Donate F, 2004, CANCER RES, V64, P5812, DOI 10.1158/0008-5472.CAN-04-0440; ESKO JD, 1986, J BIOL CHEM, V261, P5725; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Fishelson Z, 2001, MOL IMMUNOL, V38, P207, DOI 10.1016/S0161-5890(01)00055-4; Franc NC, 1999, CURR OPIN IMMUNOL, V11, P47, DOI 10.1016/S0952-7915(99)80009-0; Gaipl US, 2004, ARTHRITIS RHEUM-US, V50, P640, DOI 10.1002/art.20034; Gorgani NN, 1999, IMMUNOLOGY, V98, P456, DOI 10.1046/j.1365-2567.1999.00885.x; Gorgani NN, 1999, J BIOL CHEM, V274, P29633, DOI 10.1074/jbc.274.42.29633; Gorgani NN, 1997, BIOCHEMISTRY-US, V36, P6653, DOI 10.1021/bi962573n; Gorgani NN, 1999, INT IMMUNOL, V11, P1275, DOI 10.1093/intimm/11.8.1275; Gorgani NN, 2002, J IMMUNOL, V169, P4745, DOI 10.4049/jimmunol.169.9.4745; Guan XJ, 2004, THROMB HAEMOSTASIS, V92, P403, DOI 10.1160/TH04-02-0073; Harvey KJ, 2000, J CELL BIOL, V148, P59, DOI 10.1083/jcb.148.1.59; HEIMBURGER N, 1972, H-S Z PHYSIOL CHEM, V353, P1133, DOI 10.1515/bchm2.1972.353.2.1133; Hulett MD, 2000, IMMUNOL CELL BIOL, V78, P280, DOI 10.1046/j.1440-1711.2000.00940.x; Huynh MLN, 2002, J CLIN INVEST, V109, P41, DOI 10.1172/JCI11638; IERINO FL, 1993, J EXP MED, V178, P1617, DOI 10.1084/jem.178.5.1617; Jones AL, 2005, IMMUNOL CELL BIOL, V83, P106, DOI 10.1111/j.1440-1711.2005.01320.x; Jones AL, 2004, J BIOL CHEM, V279, P38267, DOI 10.1074/jbc.M406027200; Jones AL, 2004, J BIOL CHEM, V279, P30114, DOI 10.1074/jbc.M401996200; Juarez JC, 2002, CANCER RES, V62, P5344; Kagi D, 1995, EUR J IMMUNOL, V25, P3256, DOI 10.1002/eji.1830251209; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; KLUFT C, 1988, THROMB HAEMOSTASIS, V60, P411; KOIDE T, 1986, BIOCHEMISTRY-US, V25, P2220, DOI 10.1021/bi00356a055; Krysko DV, 2003, J MORPHOL, V258, P336, DOI 10.1002/jmor.10161; LEUNG LLK, 1986, J CLIN INVEST, V77, P1305, DOI 10.1172/JCI112435; LIJNEN HR, 1983, THROMB HAEMOSTASIS, V50, P560; Nauta AJ, 2003, EUR J IMMUNOL, V33, P2853, DOI 10.1002/eji.200323888; Olsson AK, 2004, CANCER RES, V64, P599, DOI 10.1158/0008-5472.CAN-03-1941; Proskuryakov SY, 2003, EXP CELL RES, V283, P1, DOI 10.1016/S0014-4827(02)00027-7; RYLATT DB, 1981, EUR J BIOCHEM, V119, P641, DOI 10.1111/j.1432-1033.1981.tb05655.x; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Shacter E, 2000, BLOOD, V96, P307, DOI 10.1182/blood.V96.1.307.013k47_307_313; SILVERSTEIN RL, 1985, J CLIN INVEST, V75, P2065, DOI 10.1172/JCI111926; Simantov R, 2001, J CLIN INVEST, V107, P45, DOI 10.1172/JCI9061; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; WALZ DA, 1987, SEMIN THROMB HEMOST, V13, P317, DOI 10.1055/s-2007-1003507; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; Zwart B, 2004, AUTOIMMUNITY, V37, P95, DOI 10.1080/0891693042000196183	44	28	31	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35733	35741		10.1074/jbc.M504384200	http://dx.doi.org/10.1074/jbc.M504384200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16107330	hybrid			2022-12-27	WOS:000232561200076
J	Hiniker, A; Collet, JF; Bardwell, JCA				Hiniker, A; Collet, JF; Bardwell, JCA			Copper stress causes an in vivo requirement for the Escherichia coli disulfide isomerase DsbC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOND FORMATION; PROTEIN; IDENTIFICATION; HOMEOSTASIS; EXPRESSION; REDUCTION; MUTATIONS; CYSTEINE; MUTANTS; OXIDASE	In Escherichia coli, the periplasmic disulfide oxidoreductase DsbA is thought to be a powerful but nonspecific oxidant, joining cysteines together the moment they enter the periplasm. DsbC, the primary disulfide isomerase, likely resolves incorrect disulfides. Given the reliance of protein function on correct disulfide bonds, it is surprising that no phenotype has been established for null mutations in dsbC. Here we demonstrate that mutations in the entire DsbC disulfide isomerization pathway cause an increased sensitivity to the redox-active metal copper. We find that copper catalyzes periplasmic disulfide bond formation under aerobic conditions and that copper catalyzes the formation of disulfide-bonded oligomers in vitro, which DsbC can resolve. Our data suggest that the copper sensitivity of dsbC(-) strains arises from the inability of the cell to rearrange copper-catalyzed non-native disulfides in the absence of functional DsbC. Absence of functional DsbA augments the deleterious effects of copper on a dsbC(-) strain, even though the dsbA(-) single mutant is unaffected by copper. This may indicate that DsbA successfully competes with copper and forms disulfide bonds more accurately than copper does. These findings lead us to a model in which DsbA may be significantly more accurate in disulfide oxidation than previously thought, and in which the primary role of DsbC may be to rearrange incorrect disulfide bonds that are formed during certain oxidative stresses.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Program Mol & Cellular Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Med Scientist Training Program, Ann Arbor, MI 48109 USA; Catholic Univ Louvain, Christian de Duve Inst Cellular Pathol, B-1200 Brussels, Belgium	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Universite Catholique Louvain	Bardwell, JCA (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, 4007 Krauss Nat Sci Bldg,830 N Univ, Ann Arbor, MI 48109 USA.	jbardwel@umich.edu	Collet, Jean Francois/F-2105-2010	Collet, Jean-Francois/0000-0001-8069-7036	NIGMS NIH HHS [GM064662] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064662] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALKSNE LE, 1995, J BACTERIOL, V177, P462, DOI 10.1128/jb.177.2.462-464.1995; Bader MW, 2000, J BIOL CHEM, V275, P26082, DOI 10.1074/jbc.M003850200; Bader MW, 2001, EMBO J, V20, P1555, DOI 10.1093/emboj/20.7.1555; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BERKMEN M, 2005, J BIOL CHEM; Bessette PH, 1999, J BIOL CHEM, V274, P7784, DOI 10.1074/jbc.274.12.7784; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cecconi I, 1998, BIOCHEMISTRY-US, V37, P14167, DOI 10.1021/bi981159f; DAILEY FE, 1993, P NATL ACAD SCI USA, V90, P1043, DOI 10.1073/pnas.90.3.1043; Dartigalongue C, 2001, J BIOL CHEM, V276, P20866, DOI 10.1074/jbc.M100464200; Hiniker A, 2004, J BIOL CHEM, V279, P12967, DOI 10.1074/jbc.M311391200; Kachur AV, 1999, FREE RADICAL RES, V31, P23, DOI 10.1080/10715769900300571; Kadokura H, 2004, SCIENCE, V303, P534, DOI 10.1126/science.1091724; Kershaw CJ, 2005, MICROBIOL-SGM, V151, P1187, DOI 10.1099/mic.0.27650-0; Lee ISM, 2000, ARCH BIOCHEM BIOPHYS, V374, P137, DOI 10.1006/abbi.1999.1595; Metheringham R, 1996, MOL GEN GENET, V253, P95; MISSIAKAS D, 1993, P NATL ACAD SCI USA, V90, P7084, DOI 10.1073/pnas.90.15.7084; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; MISSIAKAS D, 1995, EMBO J, V14, P3415, DOI 10.1002/j.1460-2075.1995.tb07347.x; Pogliano J, 1997, GENE DEV, V11, P1169, DOI 10.1101/gad.11.9.1169; Porat A, 2004, RES MICROBIOL, V155, P617, DOI 10.1016/j.resmic.2004.05.005; Rensing C, 2003, FEMS MICROBIOL REV, V27, P197, DOI 10.1016/S0168-6445(03)00049-4; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Rietsch A, 1997, J BACTERIOL, V179, P6602, DOI 10.1128/jb.179.21.6602-6608.1997; Rietsch A, 1996, P NATL ACAD SCI USA, V93, P13048, DOI 10.1073/pnas.93.23.13048; Roberts SA, 2002, P NATL ACAD SCI USA, V99, P2766, DOI 10.1073/pnas.052710499; SILHAVY TJ, 1976, P NATL ACAD SCI USA, V73, P3423, DOI 10.1073/pnas.73.10.3423; Sone M, 1997, J BIOL CHEM, V272, P10349; TAKEMOTO LJ, 1982, INVEST OPHTH VIS SCI, V22, P336; Tian HP, 2000, P NATL ACAD SCI USA, V97, P4730, DOI 10.1073/pnas.090087297; WATARAI M, 1995, P NATL ACAD SCI USA, V92, P4927, DOI 10.1073/pnas.92.11.4927; Wedemeyer WJ, 2000, BIOCHEMISTRY-US, V39, P7032, DOI 10.1021/bi005111p; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019; Zheng M, 2001, J BACTERIOL, V183, P4571, DOI 10.1128/JB.183.15.4571-4579.2001	34	120	122	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33785	33791		10.1074/jbc.M505742200	http://dx.doi.org/10.1074/jbc.M505742200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16087673	hybrid			2022-12-27	WOS:000232229700014
J	Collins, XH; Harmon, SD; Kaduce, TL; Berst, KB; Fang, X; Moore, SA; Raju, TV; Falck, JR; Weintraub, NL; Duester, G; Plapp, BV; Spector, AA				Collins, XH; Harmon, SD; Kaduce, TL; Berst, KB; Fang, X; Moore, SA; Raju, TV; Falck, JR; Weintraub, NL; Duester, G; Plapp, BV; Spector, AA			omega-Oxidation of 20-hydroxyeicosatetraenoic acid (20-HETE) in cerebral microvascular smooth muscle and endothelium by alcohol dehydrogenase 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IV ALCOHOL-DEHYDROGENASE; THICK ASCENDING LIMB; ARACHIDONIC-ACID; SUBSTRATE-SPECIFICITY; ETHANOL-METABOLISM; KINETIC MECHANISM; CYTOCHROME-P450 METABOLITES; RETINOL DEHYDROGENASE; HYDROXYFATTY ACIDS; PROSTAGLANDIN E-2	20-Carboxyeicosatetraenoic acid (20-COOH-AA) is a bioactive metabolite of 20-hydroxyeicosatetraenoic acid (20-HETE), an eicosanoid that produces vasoconstriction in the cerebral circulation. We found that smooth muscle (MSMC) and endothelial (MEC) cultures obtained from mouse brain microvessels convert [H-3] 20-HETE to 20-COOH-AA, indicating that the cerebral vasculature can produce this metabolite. The [H-3] 20-COOH-AA accumulated primarily in the culture medium, together with additional radiolabeled metabolites identified as the chain-shortened dicarboxylic acids 18-COOH-18: 4, 18-COOH-18: 3, and 16-COOH-16: 3. N-Heptylformamide, a potent inhibitor of alcohol dehydrogenase (ADH), decreased the conversion of [H-3] 20-HETE to 20-COOH-AA by the MSMC and MEC and also by isolated mouse brain microvessels. Purified mouse and human ADH4, human ADH3, and horse liver ADH1 efficiently oxidized 20-HETE, and ADH4 and ADH3 were detected in MSMC and MEC by Western blotting. N-Heptylformamide inhibited the oxidation of 20-HETE by mouse and human ADH4 but not by ADH3. These results demonstrated that cerebral microvessels convert 20-HETE to 20-COOH-AA and that ADH catalyzes the reaction. Although ADH4 and ADH3 are expressed in MSMC and MEC, the inhibition produced by N-heptylformamide suggests that ADH4 is primarily responsible for 20-COOH-AA formation in the cerebral microvasculature.	Univ Iowa, Carver Coll Med, Dept Biochem, Iowa City, IA 52242 USA; Univ Iowa, Carver Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Carver Coll Med, Dept Pathol, Iowa City, IA 52242 USA; Vet Affairs Med Ctr, Iowa City, IA 52242 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Burnham Inst, La Jolla, CA 92037 USA	University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Sanford Burnham Prebys Medical Discovery Institute	Spector, AA (corresponding author), Univ Iowa, Carver Coll Med, Dept Biochem, 4-403 BSB, Iowa City, IA 52242 USA.	arthur-spector@uiowa.edu	Plapp, Bryce V/F-6353-2010; Spector, Arthur/AAG-9860-2020	Weintraub, Neal/0000-0002-5138-3705; Falck, John/0000-0002-9219-7845; Moore, Steven/0000-0002-6353-7900	NCRR NIH HHS [RR13799] Funding Source: Medline; NHLBI NIH HHS [HL76684, HL72845, HL70860, HL62984] Funding Source: Medline; NIAAA NIH HHS [AA09731, AA00279] Funding Source: Medline; NIGMS NIH HHS [GM31278] Funding Source: Medline; NINDS NIH HHS [NS24621] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR013799] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072845, P01HL062984, R01HL076684, R01HL070860] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS024621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009731] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Allali-Hassani A, 1998, FEBS LETT, V426, P362, DOI 10.1016/S0014-5793(98)00374-3; AllaliHassani A, 1997, FEBS LETT, V405, P26, DOI 10.1016/S0014-5793(97)00151-8; BAUMERT T, 1989, EUR J BIOCHEM, V182, P223, DOI 10.1111/j.1432-1033.1989.tb14821.x; BOLEDA MD, 1993, ARCH BIOCHEM BIOPHYS, V307, P85, DOI 10.1006/abbi.1993.1564; BOLEDA MD, 1989, ARCH BIOCHEM BIOPHYS, V274, P74, DOI 10.1016/0003-9861(89)90416-5; Capdevila JH, 2001, BIOCHEM BIOPH RES CO, V285, P571, DOI 10.1006/bbrc.2001.5167; Capdevila JH, 2000, J LIPID RES, V41, P163; CARROLL MA, 1991, J BIOL CHEM, V266, P12306; Chou CF, 2002, J BIOL CHEM, V277, P25209, DOI 10.1074/jbc.M201947200; Cleland W W, 1979, Methods Enzymol, V63, P103; Crosas B, 2000, J BIOL CHEM, V275, P25180, DOI 10.1074/jbc.M910040199; Deltour L, 1999, DEV GENET, V25, P1, DOI 10.1002/(SICI)1520-6408(1999)25:1<1::AID-DVG1>3.0.CO;2-W; ESCALANTE B, 1991, SCIENCE, V251, P799, DOI 10.1126/science.1846705; ESCALANTE B, 1993, J CARDIOVASC PHARM, V22, pS106, DOI 10.1097/00005344-199322002-00034; ESCALANTE B, 1996, AM J PHYSIOL, V266, pC1775; Fang X, 1998, AM J PHYSIOL-HEART C, V275, pH2113, DOI 10.1152/ajpheart.1998.275.6.H2113; Fang X, 2000, J NEUROCHEM, V75, P614, DOI 10.1046/j.1471-4159.2000.0750614.x; Gebremedhin D, 1998, J PHYSIOL-LONDON, V507, P771, DOI 10.1111/j.1469-7793.1998.771bs.x; Gebremedhin D, 2000, CIRC RES, V87, P60, DOI 10.1161/01.RES.87.1.60; Han CL, 1998, EUR J BIOCHEM, V254, P25, DOI 10.1046/j.1432-1327.1998.2540025.x; Hankin JA, 1998, J PHARMACOL EXP THER, V285, P155; HARDER DR, 1995, J VASC RES, V32, P79, DOI 10.1159/000159080; HARDER DR, 1994, AM J PHYSIOL, V266, pH2098, DOI 10.1152/ajpheart.1994.266.5.H2098; Haselbeck RJ, 1997, ALCOHOL CLIN EXP RES, V21, P1484; HATZELMANN A, 1988, EUR J BIOCHEM, V173, P445, DOI 10.1111/j.1432-1033.1988.tb14019.x; HENEHAN GTM, 1993, BIOCHEMISTRY-US, V32, P736, DOI 10.1021/bi00054a001; Hur M W, 1992, DNA Seq, V3, P167, DOI 10.3109/10425179209034012; Kaduce TL, 2004, J BIOL CHEM, V279, P2648, DOI 10.1074/jbc.M306849200; Kedishvili NY, 1998, BIOCHEM BIOPH RES CO, V249, P191, DOI 10.1006/bbrc.1998.9105; KEDISHVILI NY, 1995, J BIOL CHEM, V270, P3625, DOI 10.1074/jbc.270.8.3625; Kroetz DL, 2002, CURR OPIN LIPIDOL, V13, P273, DOI 10.1097/00041433-200206000-00007; Lange A, 1997, J BIOL CHEM, V272, P27345, DOI 10.1074/jbc.272.43.27345; MA YH, 1993, CIRC RES, V72, P126, DOI 10.1161/01.RES.72.1.126; Maier KG, 2001, CURR OPIN NEPHROL HY, V10, P81, DOI 10.1097/00041552-200101000-00013; MANNA S, 1983, TETRAHEDRON LETT, V24, P33, DOI 10.1016/S0040-4039(00)81319-2; Martinez SE, 2001, EUR J BIOCHEM, V268, P5045; Martras S, 2004, ARCH BIOCHEM BIOPHYS, V430, P210, DOI 10.1016/j.abb.2004.07.002; McGiff JC, 1999, AM J PHYSIOL-REG I, V277, pR607, DOI 10.1152/ajpregu.1999.277.3.R607; MOORE SA, 1988, AM J PHYSIOL, V254, pC37, DOI 10.1152/ajpcell.1988.254.1.C37; MOORE SA, 1989, J NEUROCHEM, V53, P376, DOI 10.1111/j.1471-4159.1989.tb07345.x; Moreno C, 2001, AM J HYPERTENS, V14, p90S, DOI 10.1016/S0895-7061(01)02075-1; PLAPP BV, 1970, J BIOL CHEM, V245, P1727; Plapp BV, 2001, CHEM-BIOL INTERACT, V130, P445, DOI 10.1016/S0009-2797(00)00284-2; PLAPP BV, 2005, ENZYMOLOGY MOL BIOL, V12, P187; Roman RJ, 2000, CLIN EXP PHARMACOL P, V27, P855, DOI 10.1046/j.1440-1681.2000.03349.x; Roman RJ, 2002, PHYSIOL REV, V82, P131, DOI 10.1152/physrev.00021.2001; Roman RJ, 1997, AM J HYPERTENS, V10, pS63; Sanghani PC, 2000, BIOCHEMISTRY-US, V39, P10720, DOI 10.1021/bi9929711; Schindler JF, 1998, J MED CHEM, V41, P1696, DOI 10.1021/jm9707380; SHEARER GL, 1993, BIOCHEMISTRY-US, V32, P11186, DOI 10.1021/bi00092a031; Sun CW, 1999, HYPERTENSION, V33, P414, DOI 10.1161/01.HYP.33.1.414; Venkataramaiah TH, 2003, J BIOL CHEM, V278, P36699, DOI 10.1074/jbc.M305419200; WANG WH, 1995, J GEN PHYSIOL, V106, P727, DOI 10.1085/jgp.106.4.727; Xie PG, 1997, J BIOL CHEM, V272, P18558, DOI 10.1074/jbc.272.30.18558; ZGOMBICKNIGHT M, 1995, J BIOL CHEM, V270, P10868, DOI 10.1074/jbc.270.18.10868	55	37	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33157	33164		10.1074/jbc.M504055200	http://dx.doi.org/10.1074/jbc.M504055200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16081420	hybrid			2022-12-27	WOS:000232058100010
J	Duncan, MJ; Mann, EL; Cohen, MS; Ofek, I; Sharon, N; Abraham, SN				Duncan, MJ; Mann, EL; Cohen, MS; Ofek, I; Sharon, N; Abraham, SN			The distinct binding specificities exhibited by enterobacterial type 1 fimbriae are determined by their fimbrial shafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; FIMH ADHESIN; SALMONELLA-TYPHIMURIUM; KLEBSIELLA-PNEUMONIAE; RECOMBINANT PLASMIDS; NUCLEOTIDE-SEQUENCE; FAMILY ENTEROBACTERIACEAE; CARBOHYDRATE SPECIFICITY; MONOCLONAL-ANTIBODIES; EPITHELIAL-CELLS	Type 1 fimbriae of enterobacteria are heteropolymeric organelles of adhesion composed of FimH, a mannose-binding lectin, and a shaft composed primarily of FimA. We compared the binding activities of recombinant clones expressing type 1 fimbriae from Escherichia coli, Klebsiella pneumoniae, and Salmonella typhimurium for gut and uroepithelial cells and for various soluble mannosylated proteins. Each fimbria was characterized by its capacity to bind particular epithelial cells and to aggregate mannoproteins. However, when each respective FimH subunit was cloned and expressed in the absence of its shaft as a fusion protein with MalE, each FimH bound a wide range of mannose-containing compounds. In addition, we found that expression of FimH on a heterologous fimbrial shaft, e. g. K. pneumoniae FimH on the E. coli fimbrial shaft or vice versa, altered the binding specificity of FimH such that it closely resembled that of the native heterologous type 1 fimbriae. Furthermore, attachment to and invasion of bladder epithelial cells, which were mediated much better by native E. coli type 1 fimbriae compared with native K. pneumoniae type 1 fimbriae, were found to be dependent on the background of the fimbrial shaft ( E. coli versus K. pneumoniae) rather than the background of the FimH expressed. Thus, the distinct binding specificities of different enterobacterial type 1 fimbriae cannot be ascribed solely to the primary structure of their respective FimH subunits, but are also modulated by the fimbrial shaft on which each FimH subunit is presented, possibly through conformational constraints imposed on FimH by the fimbrial shaft. The capacity of type 1 fimbrial shafts to modulate the tissue tropism of different enterobacterial species represents a novel function for these highly organized structures.	Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA; Tel Aviv Univ, Sackler Fac Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Duke University; Duke University; Tel Aviv University; Sackler Faculty of Medicine; Weizmann Institute of Science	Abraham, SN (corresponding author), Duke Univ, Med Ctr, Dept Pathol, Campus Box 3020, Durham, NC 27710 USA.	soman.abraham@duke.edu	Ofek, Itzhak/L-4616-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI056101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK050814, R01DK050814] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 056101, AI150021] Funding Source: Medline; NIDDK NIH HHS [DK050814] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM SN, 1987, J BACTERIOL, V169, P5530, DOI 10.1128/jb.169.12.5530-5536.1987; ABRAHAM SN, 1988, NATURE, V336, P682, DOI 10.1038/336682a0; ADEGBOLA RA, 1987, J MED MICROBIOL, V24, P21, DOI 10.1099/00222615-24-1-21; BIRK HW, 1987, ANAL BIOCHEM, V164, P12, DOI 10.1016/0003-2697(87)90360-5; BRINTON CC, 1965, T NEW YORK ACAD SCI, V27, P1003, DOI 10.1111/j.2164-0947.1965.tb02342.x; Chandra NR, 1999, J MOL BIOL, V285, P1157, DOI 10.1006/jmbi.1998.2353; Choudhury D, 1999, SCIENCE, V285, P1061, DOI 10.1126/science.285.5430.1061; CLEGG S, 1987, J BACTERIOL, V169, P934, DOI 10.1128/jb.169.3.934-938.1987; CLEGG S, 1985, INFECT IMMUN, V48, P275, DOI 10.1128/IAI.48.2.275-279.1985; DODD DC, 1982, INFECT IMMUN, V38, P764, DOI 10.1128/IAI.38.2.764-773.1982; Duncan MJ, 2004, J BIOL CHEM, V279, P18944, DOI 10.1074/jbc.M400769200; EDEN CS, 1984, INFECT IMMUN, V44, P672; FEUTRIER J, 1986, J BACTERIOL, V168, P221, DOI 10.1128/jb.168.1.221-227.1986; FIRON N, 1983, CARBOHYD RES, V120, P235, DOI 10.1016/0008-6215(83)88019-7; FIRON N, 1984, INFECT IMMUN, V43, P1088, DOI 10.1128/IAI.43.3.1088-1090.1984; GERLACH GF, 1989, J BACTERIOL, V171, P1262, DOI 10.1128/jb.171.3.1262-1270.1989; GERLACH GF, 1989, INFECT IMMUN, V57, P764, DOI 10.1128/IAI.57.3.764-770.1989; GHOSH S, 1994, FEMS MICROBIOL LETT, V115, P229; HANSON MS, 1988, NATURE, V332, P265, DOI 10.1038/332265a0; HANSON MS, 1983, THESIS U PITTSBURGH; Harris SL, 2001, J BACTERIOL, V183, P4099, DOI 10.1128/JB.183.13.4099-4102.2001; JONES CH, 1995, P NATL ACAD SCI USA, V92, P2081, DOI 10.1073/pnas.92.6.2081; KLEMM P, 1987, MOL GEN GENET, V208, P439, DOI 10.1007/BF00328136; KLEMM P, 1984, EUR J BIOCHEM, V143, P395, DOI 10.1111/j.1432-1033.1984.tb08386.x; KROGFELT KA, 1988, MICROB PATHOGENESIS, V4, P231, DOI 10.1016/0882-4010(88)90073-3; KROGFELT KA, 1990, INFECT IMMUN, V58, P1995, DOI 10.1128/IAI.58.6.1995-1998.1990; MADISON B, 1994, INFECT IMMUN, V62, P843, DOI 10.1128/IAI.62.3.843-848.1994; Marc D, 1996, J MED MICROBIOL, V44, P444, DOI 10.1099/00222615-44-6-444; Martinez JJ, 2000, EMBO J, V19, P2803, DOI 10.1093/emboj/19.12.2803; MAURER L, 1987, J BACTERIOL, V169, P640, DOI 10.1128/jb.169.2.640-645.1987; MAY AK, 1993, INFECT IMMUN, V61, P1667, DOI 10.1128/IAI.61.5.1667-1673.1993; MINION FC, 1986, J BACTERIOL, V165, P1033, DOI 10.1128/jb.165.3.1033-1036.1986; MULLER KH, 1991, J BACTERIOL, V173, P4765; Mulvey MA, 1998, SCIENCE, V282, P1494, DOI 10.1126/science.282.5393.1494; Muro MD, 1996, J INVEST ALLERG CLIN, V6, P166; MUSCAS P, 1994, MICROBIOL IMMUNOL, V38, P353, DOI 10.1111/j.1348-0421.1994.tb01790.x; NICHOLS WA, 1990, MOL MICROBIOL, V4, P2119, DOI 10.1111/j.1365-2958.1990.tb00573.x; OFEK I, 1977, NATURE, V265, P623, DOI 10.1038/265623a0; Ofek I, 2000, ADV EXP MED BIOL, V485, P183; ORNDORFF PE, 1984, J BACTERIOL, V159, P736, DOI 10.1128/JB.159.2.736-744.1984; ORNDORFF PE, 1985, J BACTERIOL, V162, P454, DOI 10.1128/JB.162.1.454-457.1985; PONNIAH S, 1991, J BACTERIOL, V173, P4195, DOI 10.1128/jb.173.13.4195-4202.1991; PURCELL BK, 1983, INFECT IMMUN, V39, P1122, DOI 10.1128/IAI.39.3.1122-1127.1983; ROSENBAUM LC, 1989, ANAL BIOCHEM, V183, P250, DOI 10.1016/0003-2697(89)90475-2; SALIT IE, 1977, J EXP MED, V146, P1169, DOI 10.1084/jem.146.5.1169; Schembri MA, 2000, INFECT IMMUN, V68, P2638, DOI 10.1128/IAI.68.5.2638-2646.2000; Schembri MA, 1996, FEMS MICROBIOL LETT, V137, P257, DOI 10.1016/0378-1097(96)00067-5; Schembri MA, 2001, J INFECT DIS, V183, pS28, DOI 10.1086/318847; Sokurenko EV, 1997, J BIOL CHEM, V272, P17880, DOI 10.1074/jbc.272.28.17880; SOKURENKO EV, 1995, J BACTERIOL, V177, P3680, DOI 10.1128/jb.177.13.3680-3686.1995; Sokurenko EV, 1998, P NATL ACAD SCI USA, V95, P8922, DOI 10.1073/pnas.95.15.8922; Sokurenko EV, 2001, MOL MICROBIOL, V41, P675, DOI 10.1046/j.1365-2958.2001.02545.x; Sukupolvi S, 1997, INFECT IMMUN, V65, P5320, DOI 10.1128/IAI.65.12.5320-5325.1997; TAM JP, 1989, P NATL ACAD SCI USA, V86, P9084, DOI 10.1073/pnas.86.23.9084; TEWARI R, 1993, J BIOL CHEM, V268, P3009; Thankavel K, 1999, J BIOL CHEM, V274, P5797, DOI 10.1074/jbc.274.9.5797; Thankavel K, 1997, J CLIN INVEST, V100, P1123, DOI 10.1172/JCI119623	58	62	68	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37707	37716		10.1074/jbc.M501249200	http://dx.doi.org/10.1074/jbc.M501249200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16118220	hybrid			2022-12-27	WOS:000233044500048
J	Li, JQ; Dai, ZP; Jana, D; Callaway, DJE; Bu, ZM				Li, JQ; Dai, ZP; Jana, D; Callaway, DJE; Bu, ZM			Ezrin controls the macromolecular complexes formed between an adapter protein Na+/H+ exchanger regulatory factor and the cystic fibrosis transmembrane conductance regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-MEDIATED INTERACTION; CARBOXYL-TERMINAL REGION; X-RAY-SCATTERING; PDZ-DOMAIN; ERM PROTEINS; BETA(2)-ADRENERGIC RECEPTOR; BIOLOGICAL MACROMOLECULES; PARATHYROID-HORMONE; ION-TRANSPORT; BINDING-SITE	Na+/H+ exchanger regulatory factor ( NHERF) is an adapter protein that is responsible for organizing a number of cell receptors and channels. NHERF contains two amino-terminal PDZ ( postsynaptic density 95/disk-large/zonula occluden-1) domains that bind to the cytoplasmic domains of a number of membrane channels or receptors. The carboxyl terminus of NHERF interacts with the FERM domain ( a domain shared by protein 4.1, ezrin, radixin, and moesin) of a family of actin-binding proteins, ezrin-radixin-moesin. NHERF was shown previously to be capable of enhancing the channel activities of cystic fibrosis transmembrane conductance regulator ( CFTR). Here we show that binding of the FERM domain of ezrin to NHERF regulates the cooperative binding of NHERF to bring two cytoplasmic tails of CFTR into spatial proximity to each other. We find that ezrin binding activates the second PDZ domain of NHERF to interact with the cytoplasmic tails of CFTR (C-CFTR), so as to form a specific 2: 1: 1 (CCFTR)(2) center dot NHERF center dot ezrin ternary complex. Without ezrin binding, the cytoplasmic tail of CFTR only interacts strongly with the first amino-terminal PDZ domain to form a 1: 1 C-CFTR center dot NHERF complex. Immunoprecipitation and immunoblotting confirm the specific interactions of NHERF with the full-length CFTR and with ezrin in vivo. Because of the concentrated distribution of ezrin and NHERF in the apical membrane regions of epithelial cells and the diverse binding partners for the NHERF PDZ domains, the regulation of NHERF by ezrin may be employed as a general mechanism to assemble channels and receptors in the membrane cytoskeleton.	Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Bu, ZM (corresponding author), Fox Chase Canc Ctr, Reimann 414,333 Cottman Ave, Philadelphia, PA 19111 USA.	Zimei.Bu@fccc.edu			NCI NIH HHS [CA06927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; Benharouga M, 2003, J BIOL CHEM, V278, P22079, DOI 10.1074/jbc.M301030200; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Brone B, 2005, AM J PHYSIOL-CELL PH, V288, pC20, DOI 10.1152/ajpcell.00368.2004; Bu ZM, 1999, BIOPHYS J, V77, P1064, DOI 10.1016/S0006-3495(99)76956-0; Bu ZM, 1998, J APPL CRYSTALLOGR, V31, P533, DOI 10.1107/S0021889897015422; Dai JL, 2004, ONCOGENE, V23, P8681, DOI 10.1038/sj.onc.1207962; Eskandari S, 1998, P NATL ACAD SCI USA, V95, P11235, DOI 10.1073/pnas.95.19.11235; Finnerty CM, 2004, J CELL SCI, V117, P1547, DOI 10.1242/jcs.01038; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Gautreau A, 2002, CURR OPIN CELL BIOL, V14, P104, DOI 10.1016/S0955-0674(01)00300-3; GLATTER O, 1982, SMALL ANGLE XRAY SCA, P15; Guggino WB, 2004, AM J RESP CRIT CARE, V170, P815, DOI 10.1164/rccm.200403-381WS; Haardt M, 1999, J BIOL CHEM, V274, P21873, DOI 10.1074/jbc.274.31.21873; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1999, J BIOL CHEM, V274, P24328, DOI 10.1074/jbc.274.34.24328; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Herr AB, 2003, J MOL BIOL, V327, P645, DOI 10.1016/S0022-2836(03)00149-9; Ho DL, 2004, J BIOL CHEM, V279, P39146, DOI 10.1074/jbc.M404565200; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Hwang JI, 2000, J BIOL CHEM, V275, P16632, DOI 10.1074/jbc.M001410200; Karthikeyan S, 2002, J BIOL CHEM, V277, P18973, DOI 10.1074/jbc.M201507200; Karthikeyan S, 2001, J BIOL CHEM, V276, P19683, DOI 10.1074/jbc.C100154200; Karthikeyan S, 2001, J MOL BIOL, V308, P963, DOI 10.1006/jmbi.2001.4634; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KRIEG J, 1992, J BIOL CHEM, V267, P19258; Ladias JAA, 2003, J MEMBRANE BIOL, V192, P79, DOI 10.1007/s00232-002-1065-x; Li JG, 2002, J BIOL CHEM, V277, P27545, DOI 10.1074/jbc.M200058200; Mahon MJ, 2002, NATURE, V417, P858, DOI 10.1038/nature00816; Mahon MJ, 2004, J BIOL CHEM, V279, P23550, DOI 10.1074/jbc.M313229200; Masters Shane C, 2004, Methods Mol Biol, V261, P337; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Maudsley S, 2000, MOL CELL BIOL, V20, P8352, DOI 10.1128/MCB.20.22.8352-8363.2000; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; Naren AP, 2003, P NATL ACAD SCI USA, V100, P342, DOI 10.1073/pnas.0135434100; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Ogura T, 2002, FASEB J, V16, P863, DOI 10.1096/fj.01-0845fje; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Pietromonaco SF, 1998, J BIOL CHEM, V273, P7594, DOI 10.1074/jbc.273.13.7594; Prat AG, 1999, AM J PHYSIOL-CELL PH, V277, pC1160, DOI 10.1152/ajpcell.1999.277.6.C1160; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Raghuram V, 2003, P NATL ACAD SCI USA, V100, P9620, DOI 10.1073/pnas.1633250100; Reczek D, 2001, J CELL BIOL, V153, P191, DOI 10.1083/jcb.153.1.191; Reczek D, 1998, J BIOL CHEM, V273, P18452, DOI 10.1074/jbc.273.29.18452; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X; Shenolikar S, 2004, PHYSIOLOGY, V19, P362, DOI 10.1152/physiol.00020.2004; Sheppard DN, 1999, PHYSIOL REV, V79, P23; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Sneddon WB, 2003, J BIOL CHEM, V278, P43787, DOI 10.1074/jbc.M306019200; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; VANHOLDE KE, 1998, PRINCIPLES PHYS BIOC, P325; Voltz JW, 2001, ONCOGENE, V20, P6309, DOI 10.1038/sj.onc.1204774; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; Weinman EJ, 2000, BIOCHEMISTRY-US, V39, P6123, DOI 10.1021/bi000064m; Weinman EJ, 2001, AM J PHYSIOL-RENAL, V281, pF374, DOI 10.1152/ajprenal.2001.281.2.F374; WEINMAN EJ, 1993, J CLIN INVEST, V91, P2097, DOI 10.1172/JCI116433; Wriggers W, 2001, J APPL CRYSTALLOGR, V34, P773, DOI 10.1107/S0021889801012869; Yoo D, 2004, J BIOL CHEM, V279, P6863, DOI 10.1074/jbc.M311599200; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	65	64	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37634	37643		10.1074/jbc.M502305200	http://dx.doi.org/10.1074/jbc.M502305200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16129695	hybrid			2022-12-27	WOS:000233044500040
J	Nakashima, A; Katagiri, T; Tamura, M				Nakashima, A; Katagiri, T; Tamura, M			Cross-talk between Wnt and bone morphogenetic protein 2 (BMP-2) signaling in differentiation pathway of C2C12 myoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; BETA-CATENIN; OSTEOBLAST DIFFERENTIATION; MESSENGER-RNA; DNA-BINDING; GENE; EXPRESSION; IDENTIFICATION; MOUSE; ACTIVATION	Loss of function of the Wnt co-receptor, lipoprotein receptor-related protein 5, decreases bone formation, and a point mutation in this gene results in high bone mass, indicating the importance of this signaling pathway in bone formation. However, the exact mechanism is currently unknown. We examined a potential role for Wnt signaling and functional cross-talk of bone morphogenetic protein 2 (BMP-2) in osteoblast differentiation. To assess the contribution of Wnt, we generated C2C12 cells over-expressing Wnt3a or Wnt5a and treated these with BMP-2. We showed that expression of matrix extracellular phosphoglycoprotein was induced by BMP-2 in Wnt3a over-expressing C2C12 cells but not in Wnt5a over-expressing C2C12 cells. Over-expression of Wnt3a blocked BMP-2-induced inhibition of myotube formation in C2C12 cells when switched to low mitogen medium. In these cultures, expression of inhibitor of DNA binding/differentiation ( Id) 1, a helix-loop-helix protein induced by BMP-2, decreased in stable Wnt3a- but not in Wnt5a-expressing cells. This suppression is mediated by a GC-rich region of the BMP-2-responsive element of the Id1 gene promoter, and interaction between Smad1/4 and beta-catenin is crucial for Wnt-mediated suppression of the BMP-2 response in C2C12 cells. Overexpression of the inhibitor of canonical Wnt signaling, Dickkopf, inhibits this suppression. In contrast, BMP-2 or Smad1/4 up-regulated Wnt3a or activated beta-catenin-induced lymphoid-enhancing factor 1/T cell factor-dependent transcriptional activity. These findings identify functional cross-talk of Id1 expression between Wnt and BMP signaling and demonstrate a novel mechanism for Wnt regulation of the BMP-2 response, linking Id1 expression to Wnt/beta-catenin signaling.	Hokkaido Univ, Grad Sch Dent Med, Dept Biochem & Mol Biol, Sapporo, Hokkaido 0608586, Japan; Saitama Med Sch, Res Ctr Genom Med, Div Pathophysiol, Hidaka 3501241, Japan	Hokkaido University; Saitama Medical University	Tamura, M (corresponding author), Hokkaido Univ, Grad Sch Dent Med, Dept Biochem & Mol Biol, N 13,W 7, Sapporo, Hokkaido 0608586, Japan.	mtamura@den.hokudai.ac.jp	tamura, masato/B-7304-2009	tamura, masato/0000-0003-3700-5203				Aubin J E, 2001, Rev Endocr Metab Disord, V2, P81, DOI 10.1023/A:1010011209064; Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960; Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006-291X(02)02951-0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; BUSKIN JN, 1985, J MOL EVOL, V22, P334, DOI 10.1007/BF02115689; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; Capdevila J, 2001, ANNU REV CELL DEV BI, V17, P87, DOI 10.1146/annurev.cellbio.17.1.87; CELESTE AJ, 1986, EMBO J, V5, P1885, DOI 10.1002/j.1460-2075.1986.tb04440.x; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; Fisher LW, 2003, CONNECT TISSUE RES, V44, P33, DOI 10.1080/03008200390152061; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; Ghosh AK, 2004, J BIOL CHEM, V279, P47455, DOI 10.1074/jbc.M403477200; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Gowen LC, 2003, J BIOL CHEM, V278, P1998, DOI 10.1074/jbc.M203250200; Grotewold L, 2002, EMBO J, V21, P966, DOI 10.1093/emboj/21.5.966; Hadjiargyrou M, 2002, J BIOL CHEM, V277, P30177, DOI 10.1074/jbc.M203171200; Haegele L, 2003, MOL CELL NEUROSCI, V24, P696, DOI 10.1016/S1044-7431(03)00232-X; Hu MC, 2005, DEVELOPMENT, V132, P215, DOI 10.1242/dev.01573; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089; Hussein SM, 2003, J BIOL CHEM, V278, P48805, DOI 10.1074/jbc.M305472200; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131-139.2003; Iwasaki S, 1999, J BIOL CHEM, V274, P26503, DOI 10.1074/jbc.274.37.26503; Kahler RA, 2003, J BIOL CHEM, V278, P11937, DOI 10.1074/jbc.M211443200; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Katagiri T, 2002, GENES CELLS, V7, P949, DOI 10.1046/j.1365-2443.2002.00573.x; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Mbalaviele G, 2005, J CELL BIOCHEM, V94, P403, DOI 10.1002/jcb.20253; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Miyazono Kohei, 2002, Sci STKE, V2002, ppe40, DOI 10.1126/stke.2002.151.pe40; MULLER MM, 1989, NUCLEIC ACIDS RES, V17, P6420, DOI 10.1093/nar/17.15.6420; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/s0092-8674(01)00622-5; Norton JD, 2000, J CELL SCI, V113, P3897; Nusse R, 2003, DEVELOPMENT, V130, P5297, DOI 10.1242/dev.00821; Obama H, 1997, J BIOL CHEM, V272, P11017; Peng Y, 2004, J BIOL CHEM, V279, P32941, DOI 10.1074/jbc.M403344200; Quarles LD, 2003, AM J PHYSIOL-ENDOC M, V285, pE1, DOI 10.1152/ajpendo.00016.2003; Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842; ROELINK H, 1991, GENE DEV, V5, P381, DOI 10.1101/gad.5.3.381; Rowe PSN, 2000, GENOMICS, V67, P54, DOI 10.1006/geno.2000.6235; SABATH DE, 1990, GENE, V91, P185, DOI 10.1016/0378-1119(90)90087-8; Takizawa T, 2003, NUCLEIC ACIDS RES, V31, P5723, DOI 10.1093/nar/gkg778; TAMURA M, 1994, J CELL BIOL, V126, P773, DOI 10.1083/jcb.126.3.773; Vinals F, 2004, EMBO J, V23, P3527, DOI 10.1038/sj.emboj.7600360; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393; Zhang GX, 2004, ENDOCRINE, V24, P15, DOI 10.1385/ENDO:24:1:015; Zhao GQ, 2003, GENESIS, V35, P43, DOI 10.1002/gene.10167	55	117	141	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37660	37668		10.1074/jbc.M504612200	http://dx.doi.org/10.1074/jbc.M504612200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16150699	Green Submitted, hybrid			2022-12-27	WOS:000233044500043
J	Anthony, AC; Ushkaryov, YA				Anthony, AC; Ushkaryov, YA			Properties of synaptic vesicle pools in mature central nerve terminals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							READILY RELEASABLE POOL; FROG NEUROMUSCULAR-JUNCTION; PROTEIN-KINASE-C; HIPPOCAMPAL SYNAPSES; TRANSMITTER RELEASE; ALPHA-LATROTOXIN; MEDIATED ENDOCYTOSIS; EXOCYTOSIS; NEURONS; CA2+	Readily releasable and reserve pools of synaptic vesicles play different roles in neurotransmission, and it is important to understand their recycling and interchange in mature central synapses. Using adult rat cerebrocortical synaptosomes, we have shown that 100 mosM hypertonic sucrose caused complete exocytosis of only the readily releasable pool (RRP) of synaptic vesicles containing glutamate or gamma-aminobutyric acid. Repetitive hypertonic stimulations revealed that this pool recycled (and reloaded the neurotransmitter from the cytosol) fully in <30 s and did so independently of the reserve pool. Multiple rounds of exocytosis could occur in the constant absence of extracellular Ca2+. However, although each vesicle cycle includes a Ca2+-independent exocytotic step, some other stage(s) critically require an elevation of cytosolic [Ca2+], and this is supplied by intracellular stores. Repetitive recycling also requires energy, but not the activity of phosphatidylinositol 4-kinase, which maintains the normal level of phosphoinositides. By varying the length of hypertonic stimulations, we found that similar to 70% of the RRP vesicles fused completely with the plasmalemma during exocytosis and could then enter silent pools, probably outside active zones. The rest of the RRP vesicles underwent very fast local recycling (possibly by kiss-and-run) and did not leave active zones. Forcing the fully fused RRP vesicles into the silent pool enabled us to measure the transfer of reserve vesicles to the RRP and to show that this process requires intact phosphatidylinositol 4-kinase and actin microfilaments. Our findings also demonstrate that respective vesicle pools have similar characteristics and requirements in excitatory and inhibitory nerve terminals.	Univ London Imperial Coll Sci Technol & Med, Div Cell & Mol Biol, Dept Biol Sci, London SW7 2AZ, England; Univ Cent Lancashire, Dept Biol Sci, Preston PR1 2HE, Lancs, England	Imperial College London; University of Central Lancashire	Ushkaryov, YA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Cell & Mol Biol, Dept Biol Sci, London SW7 2AZ, England.	y.ushkaryov@imperial.ac.uk	Ushkaryov, Yuri/AAQ-2985-2020	Ushkaryov, Yuri/0000-0002-5712-8297	Biotechnology and Biological Sciences Research Council [BB/D523078/1] Funding Source: Medline; Wellcome Trust [074359] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		ARTALEJO CR, 1995, P NATL ACAD SCI USA, V92, P8328, DOI 10.1073/pnas.92.18.8328; Ashton AC, 2000, J NEUROCHEM, V74, P1979, DOI 10.1046/j.1471-4159.2000.0741979.x; Ashton AC, 2001, J BIOL CHEM, V276, P44695, DOI 10.1074/jbc.M108088200; BRADFORD HF, 1986, CHEM NEUROBIOLOGY; BROSIUS DC, 1992, J NEUROPHYSIOL, V68, P1229, DOI 10.1152/jn.1992.68.4.1229; Bykhovskaia M, 2001, J PHYSIOL-LONDON, V537, P179, DOI 10.1111/j.1469-7793.2001.0179k.x; Capogna M, 2003, J NEUROSCI, V23, P4044; Caroni P, 2001, EMBO J, V20, P4332, DOI 10.1093/emboj/20.16.4332; Chawla S, 2001, J PHYSIOL-LONDON, V536, P351, DOI 10.1111/j.1469-7793.2001.0351c.xd; Cole JC, 2000, J PHYSIOL-LONDON, V525, P579, DOI 10.1111/j.1469-7793.2000.t01-2-00579.x; Cousin MA, 2000, J NEUROCHEM, V75, P1645, DOI 10.1046/j.1471-4159.2000.0751645.x; Cremona O, 2001, J CELL SCI, V114, P1041; Cseresnyes Z, 1997, NEURON, V19, P403, DOI 10.1016/S0896-6273(00)80949-6; Di Paolo G, 2002, NEURON, V33, P789, DOI 10.1016/S0896-6273(02)00601-3; ELMQVIST D, 1965, J PHYSIOL-LONDON, V178, P505, DOI 10.1113/jphysiol.1965.sp007639; Gad H, 1998, NEURON, V21, P607, DOI 10.1016/S0896-6273(00)80570-X; Gandhi SP, 2003, NATURE, V423, P607, DOI 10.1038/nature01677; GIBSON AE, 1989, AM J PHYSIOL, V257, pC182, DOI 10.1152/ajpcell.1989.257.2.C182; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANO T, 1989, HYPERTENSION, V13, P250, DOI 10.1161/01.HYP.13.3.250; Harata N, 2001, TRENDS NEUROSCI, V24, P637, DOI 10.1016/S0166-2236(00)02030-0; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; KAUPPINEN RA, 1988, NEUROSCIENCE, V27, P175, DOI 10.1016/0306-4522(88)90228-X; Khvotchev M, 1998, J BIOL CHEM, V273, P21451, DOI 10.1074/jbc.273.34.21451; Khvotchev M, 2000, NEUROSCIENCE, V101, P793, DOI 10.1016/S0306-4522(00)00378-X; Kuromi H, 2002, NEURON, V35, P333, DOI 10.1016/S0896-6273(02)00777-8; Lee MC, 2002, SYNAPSE, V43, P102, DOI 10.1002/syn.10014; Leenders AGM, 2002, NEUROSCIENCE, V109, P195, DOI 10.1016/S0306-4522(01)00450-X; Lonart G, 2000, J BIOL CHEM, V275, P27703; Moskowitz HS, 2003, MOL BIOL CELL, V14, P4437, DOI 10.1091/mbc.e03-04-0230; NICHOLLS DG, 1993, EUR J BIOCHEM, V212, P613, DOI 10.1111/j.1432-1033.1993.tb17700.x; OJA SS, 1988, NEUROCHEM RES, V13, P923, DOI 10.1007/BF00970763; Olsen HL, 2003, P NATL ACAD SCI USA, V100, P5187, DOI 10.1073/pnas.0931282100; Otsu Y, 2004, J NEUROSCI, V24, P9076, DOI 10.1523/JNEUROSCI.2060-04.2004; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; Pyle JL, 2000, NEURON, V28, P221, DOI 10.1016/S0896-6273(00)00098-2; Richards DA, 2005, J CELL BIOL, V168, P929, DOI 10.1083/jcb.200407148; Richards DA, 2004, J PHYSIOL-LONDON, V557, P77, DOI 10.1113/jphysiol.2004.062158; Richards DA, 2003, NEURON, V39, P529, DOI 10.1016/S0896-6273(03)00405-7; Richards DA, 2000, NEURON, V27, P551, DOI 10.1016/S0896-6273(00)00065-9; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; Rosenmund C, 1997, J NEUROSCI METH, V76, P1, DOI 10.1016/S0165-0270(97)00061-7; Sakaba T, 2003, J NEUROSCI, V23, P837; Sara Y, 2002, J NEUROSCI, V22, P1608, DOI 10.1523/JNEUROSCI.22-05-01608.2002; Schoch S, 2001, SCIENCE, V294, P1117, DOI 10.1126/science.1064335; Smith SM, 2004, NEURON, V41, P243, DOI 10.1016/S0896-6273(03)00837-7; Stevens CF, 1998, NEURON, V21, P885, DOI 10.1016/S0896-6273(00)80603-0; Stevens CF, 1999, NEURON, V24, P1017, DOI 10.1016/S0896-6273(00)81047-8; Stevens CF, 1998, NEURON, V21, P415, DOI 10.1016/S0896-6273(00)80550-4; Suzuki K, 2002, J PHYSIOL-LONDON, V538, P103, DOI 10.1113/jphysiol.2001.012901; Troyer KP, 2002, J BIOL CHEM, V277, P29101, DOI 10.1074/jbc.M202856200; Walker JKL, 1999, J BIOL CHEM, V274, P31515, DOI 10.1074/jbc.274.44.31515; Werbonat Y, 2000, J BIOL CHEM, V275, P21969, DOI 10.1074/jbc.M001736200; WHITTAKER VP, 1993, J NEUROCYTOL, V22, P735, DOI 10.1007/BF01181319; WILKINSON RJ, 1989, NEUROCHEM INT, V15, P191, DOI 10.1016/0197-0186(89)90100-9; Wu XS, 2001, J NEUROSCI, V21, P7928, DOI 10.1523/JNEUROSCI.21-20-07928.2001; Zhou Q, 2000, J PHYSIOL-LONDON, V525, P195, DOI 10.1111/j.1469-7793.2000.t01-1-00195.x	57	27	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37278	37288		10.1074/jbc.M504137200	http://dx.doi.org/10.1074/jbc.M504137200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16148008	hybrid			2022-12-27	WOS:000232901800086
J	Hiriart, E; Gruffat, H; Buisson, M; Mikaelian, I; Keppler, S; Meresse, P; Mercher, T; Bernard, OA; Sergeant, A; Manet, E				Hiriart, E; Gruffat, H; Buisson, M; Mikaelian, I; Keppler, S; Meresse, P; Mercher, T; Bernard, OA; Sergeant, A; Manet, E			Interaction of the Epstein-Barr virus mRNA export factor EB2 with human spen proteins SHARP, OTT1, and a novel member of the family, OTT3, links spen proteins with splicing regulation and mRNA export	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT; IN-VIVO; SIGNALING PATHWAY; BINDING-PROTEIN; GENE-EXPRESSION; SPLIT-ENDS; SM PROTEIN; J-KAPPA; TRANSCRIPTION; RECEPTOR	The Epstein-Barr virus early protein EB2 ( also called BMLF1, Mta, or SM), a protein absolutely required for the production of infectious virions, shares properties with mRNA export factors. By using a yeast two-hybrid screen, we have identified the human protein OTT3 as an EB2-interacting factor. OTT3 is a new member of the Spen ( split end) family of proteins (huSHARP, huOTT1, DmSpen, and muMINT), which are characterized by several N-terminal RNA recognition motifs and a highly conserved C-terminal SPOC ( Spen Paralog and Ortholog C-terminal) domain that, in the case of SHARP, has been shown to interact with SMRT/NCoR co-repressors. OTT3 is ubiquitously expressed as a 120-kDa protein. Transfected OTT3 is a nonshuttling nuclear protein that co-localizes with co-transfected EB2. We also showed that EB2 interacts with the SPOC domains of both OTT1 and SHARP proteins. Although the OTT3 interaction domain maps within the 40 N-terminal amino acids of EB2, OTT1 and SHARP interact within the C-terminal half of the protein. Furthermore, we demonstrated that the capacity of the OTT3 and OTT1 SPOC domains to interact with SMRT and repress transcription is far weaker than that of SHARP. Thus there is no evidence for a role of OTT3 in transcriptional regulation. Most interestingly, however, we have found that OTT3 has a role in splicing regulation; OTT3 represses accumulation of the alternatively spliced beta-thalassemia mRNAs, but it has no effect on the beta-globin constitutively spliced mRNA. Thus our results suggested a new function for Spen proteins related to mRNA export and splicing.	Ecole Normale Super Lyon, INSERM, U412, IFR Biosci Lyon Gerland 128,Lab Virol Humaine, F-69364 Lyon, France; UJR Lab Virol Mol & Struct, CNRS, FRE 2854, F-38706 La Tronche, France; Hop Necker Enfants Malad, INSERM E0210, F-75743 Paris, France	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Manet, E (corresponding author), Ecole Normale Super Lyon, INSERM, U412, IFR Biosci Lyon Gerland 128,Lab Virol Humaine, 46 Allee Italie, F-69364 Lyon, France.	evelyne.manet@ens-lyon.fr	Gruffat, Henri/I-2407-2016; Bernard, Olivier A./E-5721-2016; Mercher, Thomas/J-2446-2014; MANET, Evelyne/G-5644-2019	Gruffat, Henri/0000-0002-4735-6894; Mercher, Thomas/0000-0003-1552-087X; MANET, Evelyne/0000-0001-7619-9982; Bernard, Olivier/0000-0002-0463-9747; Keppler, Selina Jessica/0000-0002-9010-8044				Ariyoshi M, 2003, GENE DEV, V17, P1909, DOI 10.1101/gad.266203; Auboeuf D, 2005, MOL CELL BIOL, V25, P5307, DOI 10.1128/MCB.25.13.5307-5316.2005; Boyle SM, 1999, J VIROL, V73, P6872, DOI 10.1128/JVI.73.8.6872-6881.1999; Buisson M, 1999, J VIROL, V73, P4090, DOI 10.1128/JVI.73.5.4090-4100.1999; BUISSON M, 1989, J VIROL, V63, P5276, DOI 10.1128/JVI.63.12.5276-5284.1989; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cullen BR, 2003, TRENDS BIOCHEM SCI, V28, P419, DOI 10.1016/S0968-0004(03)00142-7; Dimaano C, 2004, MOL CELL BIOL, V24, P3069, DOI 10.1128/MCB.24.8.3069-3076.2004; Farago M, 2003, MOL BIOL CELL, V14, P2744, DOI 10.1091/mbc.E02-11-0740; Farjot G, 2000, J VIROL, V74, P6068, DOI 10.1128/JVI.74.13.6068-6076.2000; Gruffat H, 2002, J VIROL, V76, P9635, DOI 10.1128/JVI.76.19.9635-9644.2002; HIKADA M, 1988, EMBO J, V7, P519; Hiriart E, 2003, J BIOL CHEM, V278, P37790, DOI 10.1074/jbc.M305925200; Hiriart E, 2003, J BIOL CHEM, V278, P335, DOI 10.1074/jbc.M208656200; Huang YQ, 2003, MOL CELL, V11, P837, DOI 10.1016/S1097-2765(03)00089-3; Huang YQ, 2001, MOL CELL, V7, P899, DOI 10.1016/S1097-2765(01)00233-7; INOUE JI, 1986, FEBS LETT, V209, P187, DOI 10.1016/0014-5793(86)81108-5; Kuang B, 2000, DEVELOPMENT, V127, P1517; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Le Hir H, 2001, EMBO J, V20, P4987, DOI 10.1093/emboj/20.17.4987; Lei EP, 2001, GENE DEV, V15, P1771, DOI 10.1101/gad.892401; Lei EP, 2002, GENE DEV, V16, P2761, DOI 10.1101/gad.1032902; Lin HV, 2003, DEVELOPMENT, V130, P3125, DOI 10.1242/dev.00527; Luo MJ, 2001, NATURE, V413, P644, DOI 10.1038/35098106; Luo MJ, 1999, P NATL ACAD SCI USA, V96, P14937, DOI 10.1073/pnas.96.26.14937; Ma ZG, 2001, NAT GENET, V28, P220, DOI 10.1038/90054; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; Masuda S, 2005, GENE DEV, V19, P1512, DOI 10.1101/gad.1302205; Mercher T, 2001, P NATL ACAD SCI USA, V98, P5776, DOI 10.1073/pnas.101001498; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Newberry EP, 1999, BIOCHEMISTRY-US, V38, P10678, DOI 10.1021/bi990967j; Oswald F, 2002, EMBO J, V21, P5417, DOI 10.1093/emboj/cdf549; Raijmakers R, 2004, EUR J CELL BIOL, V83, P175, DOI 10.1078/0171-9335-00385; Rebay I, 2000, GENETICS, V154, P695; Reed R, 2003, CURR OPIN CELL BIOL, V15, P326, DOI 10.1016/S0955-0674(03)00048-6; Rodrigues JP, 2001, P NATL ACAD SCI USA, V98, P1030, DOI 10.1073/pnas.98.3.1030; Rodriguez MS, 2004, BIOL CELL, V96, P639, DOI 10.1016/j.biolcel.2004.04.014; Ruvolo V, 2001, J VIROL, V75, P6033, DOI 10.1128/JVI.75.13.6033-6041.2001; Santos-Rosa H, 1998, MOL CELL BIOL, V18, P6826, DOI 10.1128/MCB.18.11.6826; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Semmes OJ, 1998, J VIROL, V72, P9526, DOI 10.1128/JVI.72.12.9526-9534.1998; Shi YH, 2001, GENE DEV, V15, P1140, DOI 10.1101/gad.871201; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; Sokolowski M, 2003, J BIOL CHEM, V278, P33540, DOI 10.1074/jbc.M302063200; Strasser K, 2001, NATURE, V413, P648, DOI 10.1038/35098113; Strasser K, 2000, EMBO J, V19, P410, DOI 10.1093/emboj/19.3.410; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Stutz F, 2003, TRENDS CELL BIOL, V13, P319, DOI 10.1016/S0962-8924(03)00106-5; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Waltzer L, 1996, J VIROL, V70, P5909, DOI 10.1128/JVI.70.9.5909-5915.1996; WEBSTER NJG, 1989, EMBO J, V8, P1441, DOI 10.1002/j.1460-2075.1989.tb03526.x; Zenklusen D, 2002, MOL CELL BIOL, V22, P8241, DOI 10.1128/MCB.22.23.8241-8253.2002; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031; Zolotukhin AS, 2002, J BIOL CHEM, V277, P3935, DOI 10.1074/jbc.M107598200	55	58	65	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36935	36945		10.1074/jbc.M501725200	http://dx.doi.org/10.1074/jbc.M501725200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16129689	Green Published, hybrid			2022-12-27	WOS:000232901800050
J	Muenster, U; Harrison, CA; Donaldson, C; Vale, W; Fischer, WH				Muenster, U; Harrison, CA; Donaldson, C; Vale, W; Fischer, WH			An activin-A/C chimera exhibits activin and myostatin antagonistic properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II RECEPTORS; BETA-C; BINDING; COMPLEX; CELLS; GROWTH; BMP-2; DIFFERENTIATION; BETA(C)-SUBUNIT; HETERODIMERS	Activins are involved in many physiological and pathological processes and, like other members of the transforming growth factor-beta superfamily, signal via type II and I receptor serine kinases. Ligand residues involved in type II receptor binding are located in the two anti-parallel beta strands of the TGF-beta proteins, also known as the fingers. Activin-A mutants able to bind ActRII but unable to bind the activin type I receptor ALK4 define ligand residues involved in ALK4 binding and could potentially act as antagonists. Therefore, a series of FLAG-tagged activin-A/C chimeras were constructed, in each of which eight residues in the wrist loop and helix region (A/C 46 - 53, 54 - 61, 62 - 69, and 70 - 78) were replaced. Additionally, a chimera was generated in which the entire wrist region ( A/ C 46 - 78) was changed from activin-A to activin-C. The chimeras were assessed for ActRII binding, activin bioactivity, as well as antagonistic properties. All five chimeras retained high affinity for mouse ActRII. Of these, only A/ C 46 - 78 was devoid of significant activin bioactivity in an A3 Lux reporter assay in 293T cells at concentrations up to 40 nM. A/C 46 - 53, 54 - 61, 62 - 69, and 70 - 78 showed activity comparable with wild type activin- A. When tested for the ability to antagonize ligands that signal via activin type II receptors, such as activin- A and myostatin, only the A/ C 46 - 78 chimera showed antagonism (IC50, 1 - 10 nM). Additionally, A/ C 46 - 78 decreased follicle-stimulating hormone release from the L beta T2 cell line and rat anterior pituitary cells in primary culture in a concentration-dependent manner. These data indicate that activin residues in the wrist are involved in ALK4-mediated signaling. The activin antagonist A/ C 46 - 78 may be useful for the study and modulation of activin- dependent processes.	Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA; Monash Med Ctr, Prince Henrys Inst Med Res, Clayton, Vic 3168, Australia	Salk Institute; Monash University; Prince Henry's Institute of Medical Research	Fischer, WH (corresponding author), Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	fischer@salk.edu		Harrison, Craig/0000-0003-1059-3682	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD013527] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-13527] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Attisano L, 1996, MOL CELL BIOL, V16, P1066; Butler CM, 2005, CYTOKINE GROWTH F R, V16, P377, DOI 10.1016/j.cytogfr.2005.04.005; Chabicovsky M, 2003, ENDOCRINOLOGY, V144, P3497, DOI 10.1210/en.2003-0388; Chen YG, 2002, EXP BIOL MED, V227, P75, DOI 10.1177/153537020222700201; Durocher Y, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e9; Fischer WH, 2003, J ENDOCRINOL, V176, P61, DOI 10.1677/joe.0.1760061; Greenwald J, 2004, MOL CELL, V15, P485, DOI 10.1016/j.molcel.2004.07.011; Greenwald J, 2003, MOL CELL, V11, P605, DOI 10.1016/S1097-2765(03)00094-7; Harrison CA, 2004, J BIOL CHEM, V279, P28036, DOI 10.1074/jbc.M402782200; Keller S, 2004, NAT STRUCT MOL BIOL, V11, P481, DOI 10.1038/nsmb756; Kirsch T, 2000, EMBO J, V19, P3314, DOI 10.1093/emboj/19.13.3314; Kirsch T, 2000, NAT STRUCT BIOL, V7, P492; Knaus P, 2001, BIOL CHEM, V382, P1189, DOI 10.1515/BC.2001.149; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; Lau AL, 2000, MOL CELL BIOL, V20, P6127, DOI 10.1128/MCB.20.16.6127-6137.2000; Lebrun JJ, 1997, MOL CELL BIOL, V17, P1682, DOI 10.1128/MCB.17.3.1682; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mellor SL, 2000, J CLIN ENDOCR METAB, V85, P4851, DOI 10.1210/jc.85.12.4851; Mellor SL, 2003, ENDOCRINOLOGY, V144, P4410, DOI 10.1210/en.2003-0225; Phillips DJ, 2000, BIOESSAYS, V22, P689, DOI 10.1002/1521-1878(200008)22:8<689::AID-BIES2>3.0.CO;2-5; Rebbapragada A, 2003, MOL CELL BIOL, V23, P7230, DOI 10.1128/MCB.23.20.7230-7242.2003; Risbridger GP, 2001, ENDOCR REV, V22, P836, DOI 10.1210/er.22.6.836; Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126; Schuelke M, 2004, NEW ENGL J MED, V350, P2682, DOI 10.1056/NEJMoa040933; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Thompson TB, 2003, EMBO J, V22, P1555, DOI 10.1093/emboj/cdg156; VALE W, 1983, METHOD ENZYMOL, V103, P565; Vejda S, 2002, J MOL ENDOCRINOL, V28, P137, DOI 10.1677/jme.0.0280137; Vejda S, 2003, CARCINOGENESIS, V24, P1801, DOI 10.1093/carcin/bgg154; Vitt UA, 2001, MOL ENDOCRINOL, V15, P681, DOI 10.1210/me.15.5.681; Wada W, 2004, AM J PHYSIOL-ENDOC M, V287, pE247, DOI 10.1152/ajpendo.00390.2003; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; Wuytens G, 1999, J BIOL CHEM, V274, P9821, DOI 10.1074/jbc.274.14.9821	34	17	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36626	36632		10.1074/jbc.M507236200	http://dx.doi.org/10.1074/jbc.M507236200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16129674	hybrid			2022-12-27	WOS:000232901800013
J	Newcomb, DC; Sajjan, U; Nanua, S; Jia, Y; Goldsmith, AM; Bentley, JK; Hershenson, MB				Newcomb, DC; Sajjan, U; Nanua, S; Jia, Y; Goldsmith, AM; Bentley, JK; Hershenson, MB			Phosphatidylinositol 3-kinase is required for rhinovirusinduced airway epithelial cell interleukin-8 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; OBSTRUCTIVE PULMONARY-DISEASE; ACTIVATED PROTEIN-KINASE; FOCAL ADHESION KINASE; PHOSPHOINOSITIDE 3-KINASE; RESPIRATORY VIRUSES; ASTHMATIC SUBJECTS; IN-VIVO; INFLAMMATORY MARKERS; ACUTE EXACERBATIONS	Rhinovirus (RV) is a common cause of asthma exacerbations. The signaling mechanisms regulating RV-induced airway epithelial cell responses have not been well studied. We examined the role of phosphatidylinositol ( PI) 3-kinase in RV-induced interleukin (IL)-8 expression. Infection of 16HBE14o - human bronchial epithelial cells with RV39 induced rapid activation of PI 3-kinase and phosphorylation of Akt, a downstream effector of PI 3-kinase. RV39 also colocalized with cit-Akt-PH, a citrogen-tagged fluorescent fusion protein encoding the pleckstrin homology domain of Akt, indicating that 3-phosphorylated PI accumulates at the site of RV infection. Inhibition of PI 3-kinase and Akt attenuated RV39-induced NF-kappa B transactivation and IL-8 expression. Inhibition of PI 3-kinase also blocked internalization of labeled RV39 into 16HBE14o - cells, suggesting that the requirement of PI 3-kinase for RV39-induced IL-8 expression, at least in part, relates to its role in viral endocytosis.	Univ Michigan, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Hershenson, MB (corresponding author), Univ Michigan, Dept Pediat & Communicable Dis, 1150 W Med Ctr Dr,Rm 3570,MSRBII,Box 0688, Ann Arbor, MI 48109 USA.	mhershen@umich.edu		Bentley, John Kelley/0000-0001-8865-7979	NHLBI NIH HHS [HL56399, HL82550] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056399, R01HL082550] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aaron SD, 2001, AM J RESP CRIT CARE, V163, P349, DOI 10.1164/ajrccm.163.2.2003122; Baravalle G, 2004, J VIROL, V78, P2729, DOI 10.1128/JVI.78.6.2729-2737.2004; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; Denning GM, 1998, INFECT IMMUN, V66, P5777, DOI 10.1128/IAI.66.12.5777-5784.1998; Etienne S, 1998, J IMMUNOL, V161, P5755; Etienne-Manneville S, 2000, J IMMUNOL, V165, P3375, DOI 10.4049/jimmunol.165.6.3375; Fleming HE, 1999, AM J RESP CRIT CARE, V160, P100, DOI 10.1164/ajrccm.160.1.9808074; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Funkhouser AW, 2004, PEDIATR RES, V55, P13, DOI 10.1203/01.PDR.0000099801.06360.AB; Futter CE, 2001, J CELL BIOL, V155, P1251, DOI 10.1083/jcb.200108152; Gaidarov I, 2001, MOL CELL, V7, P443, DOI 10.1016/S1097-2765(01)00191-5; Gern JE, 2003, AM J RESP CELL MOL, V28, P731, DOI 10.1165/rcmb.2002-0055OC; Gern JE, 2000, AM J RESP CRIT CARE, V162, P2226, DOI 10.1164/ajrccm.162.6.2003019; Gompertz S, 2001, EUR RESPIR J, V17, P1112, DOI 10.1183/09031936.01.99114901; Griego SD, 2000, J IMMUNOL, V165, P5211, DOI 10.4049/jimmunol.165.9.5211; Grunberg K, 1997, AM J RESP CRIT CARE, V156, P609; Grunberg K, 1997, CLIN EXP ALLERGY, V27, P36, DOI 10.1111/j.1365-2222.1997.tb00670.x; Grunert HP, 1997, MED MICROBIOL IMMUN, V186, P1, DOI 10.1007/s004300050039; HAEFNER B, 1995, J BIOL CHEM, V270, P7937, DOI 10.1074/jbc.270.14.7937; HALPERIN SA, 1983, AM REV RESPIR DIS, V128, P806; Hoppe AD, 2004, MOL BIOL CELL, V15, P3509, DOI 10.1091/mbc.E03-11-0847; Huber M, 2001, TRAFFIC, V2, P727, DOI 10.1034/j.1600-0854.2001.21007.x; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Johnston SL., 1997, DIAGNOSTIC PROCEDURE, P553; Kim J, 2000, J IMMUNOL, V165, P3384, DOI 10.4049/jimmunol.165.6.3384; Li EG, 1998, J VIROL, V72, P2055, DOI 10.1128/JVI.72.3.2055-2061.1998; Li J, 2003, AM J PHYSIOL-LUNG C, V284, pL307, DOI 10.1152/ajplung.00086.2002; Lopez-Souza N, 2004, AM J PHYSIOL-LUNG C, V286, pL373, DOI 10.1152/ajplung.00300.2003; Marshall JG, 2001, J CELL BIOL, V153, P1369, DOI 10.1083/jcb.153.7.1369; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Norzila MZ, 2000, AM J RESP CRIT CARE, V161, P769, DOI 10.1164/ajrccm.161.3.9809071; Ordonez CL, 2000, AM J RESP CRIT CARE, V161, P1185, DOI 10.1164/ajrccm.161.4.9812061; Papi A, 1999, J BIOL CHEM, V274, P30041, DOI 10.1074/jbc.274.42.30041; Papi A, 1999, J BIOL CHEM, V274, P9707, DOI 10.1074/jbc.274.14.9707; Pizzichini MMM, 1998, AM J RESP CRIT CARE, V158, P1178, DOI 10.1164/ajrccm.158.4.9712082; Qiu YS, 2003, AM J RESP CRIT CARE, V168, P968, DOI 10.1164/rccm.200208-794OC; Rohde G, 2003, THORAX, V58, P37, DOI 10.1136/thorax.58.1.37; Sajjan U, 2004, INFECT IMMUN, V72, P4188, DOI 10.1128/IAI.72.7.4188-4199.2004; Sanlioglu S, 2000, J VIROL, V74, P9184, DOI 10.1128/JVI.74.19.9184-9196.2000; Seemungal T, 2001, AM J RESP CRIT CARE, V164, P1618, DOI 10.1164/ajrccm.164.9.2105011; SUBAUSTE MC, 1995, J CLIN INVEST, V96, P549, DOI 10.1172/JCI118067; Suzuki T, 2001, AM J PHYSIOL-LUNG C, V280, pL1115, DOI 10.1152/ajplung.2001.280.6.L1115; Terajima M, 1997, AM J PHYSIOL-LUNG C, V273, pL749, DOI 10.1152/ajplung.1997.273.4.L749; Thomas KW, 2002, J BIOL CHEM, V277, P492, DOI 10.1074/jbc.M108107200; Vojtek AB, 2003, MOL CELL BIOL, V23, P4417, DOI 10.1128/MCB.23.13.4417-4427.2003; Wang Q, 2003, J BIOL CHEM, V278, P47731, DOI 10.1074/jbc.M308466200; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC1033, DOI 10.1152/ajpcell.1989.256.5.C1033; Wymann MP, 2003, TRENDS PHARMACOL SCI, V24, P366, DOI 10.1016/S0165-6147(03)00163-9; Yamaya M, 1999, AM J PHYSIOL-LUNG C, V277, pL362, DOI 10.1152/ajplung.1999.277.2.L362; Zhu Z, 1996, J CLIN INVEST, V97, P421, DOI 10.1172/JCI118431; Zhu Z, 1997, AM J PHYSIOL-LUNG C, V273, pL814, DOI 10.1152/ajplung.1997.273.4.L814	57	79	86	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36952	36961		10.1074/jbc.M502449200	http://dx.doi.org/10.1074/jbc.M502449200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16120607	hybrid			2022-12-27	WOS:000232901800052
J	Thoden, JB; Sellick, CA; Timson, DJ; Reece, RJ; Holden, HM				Thoden, JB; Sellick, CA; Timson, DJ; Reece, RJ; Holden, HM			Molecular structure of Saccharomyces cerevisiae Gal1p, a bifunctional galactokinase and transcriptional inducer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; MACROMOLECULAR STRUCTURES; GAL80P; YEAST; ACTIVATION; COMPLEX; PROTEIN; GAL3P; REFINEMENT; INDUCTION	Gal1p of Saccharomyces cerevisiae is capable of performing two independent cellular functions. First, it is a key enzyme in the Leloir pathway for galactose metabolism where it catalyzes the conversion of -D-galactose to galactose 1-phosphate. Second, it has the capacity to induce the transcription of the yeast GAL genes in response to the organism being challenged with galactose as the sole source of carbon. This latter function is normally performed by a highly related protein, Gal3p, but in its absence Gal1p can induce transcription, albeit inefficiently, both in vivo and in vitro. Here we report the x-ray structure of Gal1p in complex with alpha-D-galactose and Mg-adenosine 5'-(beta,gamma-imido) triphosphate ( AMPPNP) determined to 2.4 angstrom resolution. Overall, the enzyme displays a marked bilobal appearance with the active site being wedged between distinct N- and C-terminal domains. Despite being considerably larger than other galactokinases, Gal1p shares a similar molecular architecture with these enzymes as well as with other members of the GHMP superfamily. The extraordinary levels of similarity between Gal1p and Gal3p ( similar to 70% amino acid identity and similar to 90% similarity) have allowed a model for Gal3p to be constructed. By identifying the locations of mutations of Gal3p that result in altered transcriptional properties, we suggest potential models for Gal3p function and mechanisms for its interaction with the transcriptional inhibitor Gal80p. The GAL genetic switch has long been regarded as a paradigm for the control of gene expression in eukaryotes. Understanding the manner in which two of the proteins that function in transcriptional regulation interact with one another is an important step in determining the overall molecular mechanism of this switch.	Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Queens Univ Belfast, Sch Biol & Biochem, Ctr Med Biol, Belfast BT9 7BL, Antrim, North Ireland	University of Manchester; University of Wisconsin System; University of Wisconsin Madison; Queens University Belfast	Reece, RJ (corresponding author), Univ Manchester, Fac Life Sci, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	Richard.Reece@manchester.ac.uk; Hazel_Holden@biochem.wisc.edu	Timson, David/I-4014-2019	Timson, David/0000-0002-0985-8818	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047814, R56DK047814] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47814] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMS BG, 1977, BIOCHEM BIOPH RES CO, V74, P1348, DOI 10.1016/0006-291X(77)90590-3; BHAT PJ, 1990, GENETICS, V125, P281; BHAT PJ, 1992, MOL CELL BIOL, V12, P2701, DOI 10.1128/MCB.12.6.2701; Blank TE, 1997, MOL CELL BIOL, V17, P2566, DOI 10.1128/MCB.17.5.2566; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; Hartley A, 2004, J MOL BIOL, V337, P387, DOI 10.1016/j.jmb.2004.01.043; Holden HM, 2003, J BIOL CHEM, V278, P43885, DOI 10.1074/jbc.R300025200; LOHR D, 1995, FASEB J, V9, P777, DOI 10.1096/fasebj.9.9.7601342; Menezes RA, 2003, J MOL BIOL, V333, P479, DOI 10.1016/j.jmb.2003.08.034; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Platt A, 2000, P NATL ACAD SCI USA, V97, P3154, DOI 10.1073/pnas.97.7.3154; Platt A, 1998, EMBO J, V17, P4086, DOI 10.1093/emboj/17.14.4086; Reece RJ, 2000, CELL MOL LIFE SCI, V57, P1161, DOI 10.1007/PL00000756; ROTMAN B, 1953, J BACTERIOL, V66, P492, DOI 10.1128/JB.66.4.492-497.1953; ROUSSEL A, 1990, ACTA CRYSTALLOGR A, V4, P66; Sellick CA, 2005, TRENDS BIOCHEM SCI, V30, P405, DOI 10.1016/j.tibs.2005.05.007; SHERMAN JR, 1963, J BIOL CHEM, V238, P873; SuzukiFujimoto T, 1996, MOL CELL BIOL, V16, P2504; Thoden JB, 2005, J BIOL CHEM, V280, P32784, DOI 10.1074/jbc.M505730200; Thoden JB, 2005, J BIOL CHEM, V280, P9662, DOI 10.1074/jbc.M412916200; Thoden JB, 2003, J BIOL CHEM, V278, P33305, DOI 10.1074/jbc.M304789200; Timson DJ, 2002, BIOCHEM J, V363, P515, DOI 10.1042/0264-6021:3630515; Timson DJ, 2002, BIOCHIMIE, V84, P265, DOI 10.1016/S0300-9084(02)01399-8; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; Vollenbroich V, 1999, MOL GEN GENET, V261, P495, DOI 10.1007/s004380050993; Yang D, 2002, J BIOL CHEM, V277, P9462, DOI 10.1074/jbc.M110787200; YOUNT RG, 1971, BIOCHEMISTRY-US, V10, P2484, DOI 10.1021/bi00789a009; Zenke FT, 1996, SCIENCE, V272, P1662, DOI 10.1126/science.272.5268.1662	28	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36905	36911		10.1074/jbc.M508446200	http://dx.doi.org/10.1074/jbc.M508446200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16115868	hybrid			2022-12-27	WOS:000232901800046
J	Hamelin, E; Theriault, C; Laroche, G; Parent, JL				Hamelin, E; Theriault, C; Laroche, G; Parent, JL			The intracellular trafficking of the G protein-coupled receptor TP beta depends on a direct interaction with Rab11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBOXANE A(2) RECEPTOR; ENDOCYTIC RECYCLING SIGNAL; HUMAN LUTROPIN RECEPTOR; MEMBRANE TRAFFICKING; MYOSIN VB; MEDIATED ENDOCYTOSIS; EFFECTOR PROTEIN; GTP-BINDING; GTPASES; IDENTIFICATION	Intracellular trafficking pathways of cell surface receptors following their internalization are the subject of intense research efforts. However, the mechanisms by which they recycle back to the cell surface are still poorly defined. We have recently demonstrated that the small Rab11 GTPase protein is a determinant factor in controlling the recycling to the cell surface of the beta-isoform of the thromboxane A(2) receptor (TP beta) following its internalization. Here, we demonstrate with co-immunoprecipitation studies in HEK293 cells that there is a Rab11-TP beta association occurring in the absence of agonist, which is not modulated by stimulation of TP beta. We show with purified TP beta intracellular domains fused to GST and HIS-Rab11 proteins that Rab11 interacts directly with the first intracellular loop and the C-tail of TP beta. Amino acids 335 - 344 of the TP beta C-tail were determined to be essential for the interaction of Rab11 with this receptor domain. This identified sequence appears to be important in directing the intracellular trafficking of the receptor from the Rab5-positive intracellular compartment to the perinuclear recycling endosome. Interestingly, our data indicate that TP beta interacts with the GDP-bound form, and not the GTP-bound form, of Rab11 which is necessary for recycling of the receptor back to the cell surface. To our knowledge, this is the first demonstration of a direct interaction between Rab11 and a transmembrane receptor.	Univ Sherbrooke, Fac Med, Serv Rhumatol, Sherbrooke, PQ J1H 5N4, Canada; Univ Sherbrooke, CHUS, Ctr Rech Clin, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke; University of Sherbrooke	Parent, JL (corresponding author), Univ Sherbrooke, Fac Med, Serv Rhumatol, 3001 12E Ave Nord, Fleurimont, PQ J1H 5N4, Canada.	jean-luc.parent@USherbrooke.ca						Bartz R, 2003, BIOCHEM BIOPH RES CO, V312, P663, DOI 10.1016/j.bbrc.2003.10.172; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Claing A, 2001, J BIOL CHEM, V276, P42509, DOI 10.1074/jbc.M108399200; Dale LB, 2004, J BIOL CHEM, V279, P13110, DOI 10.1074/jbc.M313333200; DORN GW, 1990, CIRCULATION, V81, P212, DOI 10.1161/01.CIR.81.1.212; Fan GH, 2004, MOL BIOL CELL, V15, P2456, DOI 10.1091/mbc.E03-09-0706; Fan GH, 2003, BLOOD, V101, P2115, DOI 10.1182/blood-2002-07-1965; Fischer D, 1999, PROTEINS, P209; FITZGERALD DJ, 1990, LANCET, V335, P751, DOI 10.1016/0140-6736(90)90869-7; Galet C, 2004, MOL ENDOCRINOL, V18, P434, DOI 10.1210/me.2003-0293; Galet C, 2003, MOL ENDOCRINOL, V17, P411, DOI 10.1210/me.2002-0161; Habib A, 1997, J BIOL CHEM, V272, P7191, DOI 10.1074/jbc.272.11.7191; Hales CM, 2001, J BIOL CHEM, V276, P39067, DOI 10.1074/jbc.M104831200; Hata AN, 2004, PHARMACOL THERAPEUT, V103, P147, DOI 10.1016/j.pharmthera.2004.06.003; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; Hirata T, 1996, J CLIN INVEST, V97, P949, DOI 10.1172/JCI118518; Huang JS, 2004, CELL SIGNAL, V16, P521, DOI 10.1016/j.cellsig.2003.10.008; Innamorati G, 2001, J BIOL CHEM, V276, P13096, DOI 10.1074/jbc.M009780200; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; KELLEY LA, 1999, RECOMB 99 P 3 ANN C, P218; Kinsella BT, 2001, BIOCHEM SOC T, V29, P641, DOI 10.1042/BST0290641; Kreuzer OJ, 2001, J NEUROENDOCRINOL, V13, P279, DOI 10.1046/j.1365-2826.2001.00630.x; Lapierre LA, 2001, MOL BIOL CELL, V12, P1843, DOI 10.1091/mbc.12.6.1843; Lefkowitz RJ, 2004, TRENDS PHARMACOL SCI, V25, P413, DOI 10.1016/j.tips.2004.06.006; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; Lindsay AJ, 2002, J BIOL CHEM, V277, P27193, DOI 10.1074/jbc.M200757200; Lindsay AJ, 2002, J BIOL CHEM, V277, P12190, DOI 10.1074/jbc.M108665200; Lock JG, 2005, MOL BIOL CELL, V16, P1744, DOI 10.1091/mbc.E04-10-0867; Miggin SM, 2002, MOL PHARMACOL, V61, P817, DOI 10.1124/mol.61.4.817; Mitchell H, 2004, MOL BIOL CELL, V15, P4166, DOI 10.1091/mbc.E04-03-0245; MORINELLI TA, 1991, ADV PROSTAG THROMB L, V21, P331; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; OATES JA, 1988, NEW ENGL J MED, V319, P761, DOI 10.1056/NEJM198809223191206; OGLETREE ML, 1987, FED PROC, V46, P133; Olkkonen VM, 1997, INT REV CYTOL, V176, P1, DOI 10.1016/S0074-7696(08)61608-3; Parent JL, 2001, J BIOL CHEM, V276, P7079, DOI 10.1074/jbc.M009375200; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; Prekeris R, 2001, J BIOL CHEM, V276, P38966, DOI 10.1074/jbc.M106133200; Prekeris R, 2000, MOL CELL, V6, P1437, DOI 10.1016/S1097-2765(00)00140-4; Prekeris Rytis, 2003, ScientificWorldJournal, V3, P870; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; Rochdi MD, 2004, J BIOL CHEM, V279, P18981, DOI 10.1074/jbc.M312621200; Rochdi MD, 2003, J BIOL CHEM, V278, P17827, DOI 10.1074/jbc.M210319200; Rochdi MD, 2002, J BIOL CHEM, V277, P40751, DOI 10.1074/jbc.M207910200; Roosterman D, 2004, J BIOL CHEM, V279, P30670, DOI 10.1074/jbc.M402479200; Roosterman D, 2003, AM J PHYSIOL-CELL PH, V284, pC1319, DOI 10.1152/ajpcell.00540.2002; Rosenfeld JL, 2002, RECEPTOR CHANNEL, V8, P87, DOI 10.1080/10606820212398; Seachrist JL, 2003, LIFE SCI, V74, P225, DOI 10.1016/j.lfs.2003.09.009; Seachrist JL, 2002, J BIOL CHEM, V277, P679, DOI 10.1074/jbc.M109022200; Spurney RF, 2001, J PHARMACOL EXP THER, V296, P592; Tanowitz M, 2003, J BIOL CHEM, V278, P45978, DOI 10.1074/jbc.M304504200; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; URBE S, 1993, FEBS LETT, V334, P175, DOI 10.1016/0014-5793(93)81707-7; Vargas GA, 2004, J BIOL CHEM, V279, P37461, DOI 10.1074/jbc.M401034200; Volpicelli LA, 2002, J NEUROSCI, V22, P9776, DOI 10.1523/jneurosci.22-22-09776.2002; von Zastrow M, 2003, LIFE SCI, V74, P217, DOI 10.1016/j.lfs.2003.09.008; Wallace DME, 2002, BIOCHEM BIOPH RES CO, V299, P770, DOI 10.1016/S0006-291X(02)02720-1; Walsh MT, 2000, J BIOL CHEM, V275, P20412, DOI 10.1074/jbc.M907881199; Ward ES, 2005, MOL BIOL CELL, V16, P2028, DOI 10.1091/mbc.E04-08-0735; Zeng JB, 1999, P NATL ACAD SCI USA, V96, P2840, DOI 10.1073/pnas.96.6.2840; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhang XM, 2004, J BIOL CHEM, V279, P43027, DOI 10.1074/jbc.M402264200	62	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36195	36205		10.1074/jbc.M503438200	http://dx.doi.org/10.1074/jbc.M503438200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16126723	hybrid			2022-12-27	WOS:000232726900051
J	Tsukamoto, K; Kohda, T; Mukamoto, M; Takeuchi, K; Ihara, H; Saito, M; Kozaki, S				Tsukamoto, K; Kohda, T; Mukamoto, M; Takeuchi, K; Ihara, H; Saito, M; Kozaki, S			Binding of Clostridium botulinum type C and D neurotoxins to ganglioside and phospholipid - Novel insights into the receptor for clostridial neurotoxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN SYNAPTOSOMES; FREE FATTY-ACIDS; B NEUROTOXIN; HELICOBACTER-PYLORI; SYNAPTOTAGMIN-I; CELLS; PHOSPHATIDYLETHANOLAMINE; TOXIN; EXOCYTOSIS; GENE	Clostridium botulinum neurotoxins (BoNTs) act on nerve endings to block acetylcholine release. Their potency is due to their enzymatic activity and selective high affinity binding to neurons. Although there are many pieces of data available on the receptor for BoNT, little attempt has been made to characterize the receptors for BoNT/C and BoNT/D. For this purpose, we prepared the recombinant carboxyl-terminal domain of the heavy chain (H-C) and then examined its binding capability to rat brain synaptosomes treated with enzymes and heating. Synaptosomes treated with proteinase K or heating retained binding capability to both H-C/C and H-C/D, suggesting that a proteinaceous substance does not constitute the receptor component. We next performed a thin layer chromatography overlay assay of HC with a lipid extract of synaptosomes. Under physiological or higher ionic strengths, H-C/C bound to gangliosides GD1b and GT1b. These data are in accord with results showing that neuraminidase and endoglycoceramidase treatment decreased H-C/C binding to synaptosomes. On the other hand, H-C/D interacted with phosphatidylethanolamine but not with any ganglioside. Using cerebellar granule cells obtained from GM3 synthase knock-out mice, we found that BoNT/C did not elicit a toxic effect but that BoNT/D still inhibited glutamate release to the same extent as in granule cells from wild type mice. These observations suggested that BoNT/C recognized GD1b and GT1b as functional receptors, whereas BoNT/D induced toxicity in a ganglioside-independent manner, possibly through binding to phosphatidylethanolamine. Our results provide novel insights into the receptor for clostridial neurotoxin.	Osaka Prefecture Univ, Grad Sch Life & Environm Sci, Dept Vet Sci, Osaka 5998531, Japan; Osaka Prefecture Univ, Grad Sch Sci, Dept Biol Sci, Osaka 5998531, Japan; Meiji Pharmaceut Univ, Dept Oncol & Pharmacodynam, Tokyo 2048588, Japan	Osaka Metropolitan University; Osaka Metropolitan University; Meiji Pharmaceutical University	Kozaki, S (corresponding author), Osaka Prefecture Univ, Grad Sch Life & Environm Sci, Dept Vet Sci, 1-1 Gakuen Cho, Osaka 5998531, Japan.	kozaki@center.osakafu-u.ac.jp	Taylor, Graham/A-4027-2012; Tsukamoto, Kentaro/AFQ-2771-2022	Tsukamoto, Kentaro/0000-0002-9254-4632				AIZAWA S, 1990, EMBO J, V9, P2107, DOI 10.1002/j.1460-2075.1990.tb07379.x; AMINOFF D, 1959, VIROLOGY, V7, P355, DOI 10.1016/0042-6822(59)90207-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Busse J, 1997, J INFECT DIS, V175, P77, DOI 10.1093/infdis/175.1.77; Chapman ER, 2002, NAT REV MOL CELL BIO, V3, P498, DOI 10.1038/nrm855; Coffield JA, 1997, J PHARMACOL EXP THER, V280, P1489; Collins MD, 1998, J APPL MICROBIOL, V84, P5, DOI 10.1046/j.1365-2672.1997.00313.x; Dong M, 2003, J CELL BIOL, V162, P1293, DOI 10.1083/jcb.200305098; Foran P, 1996, BIOCHEMISTRY-US, V35, P2630, DOI 10.1021/bi9519009; Foster DB, 1999, MICROB PATHOGENESIS, V27, P289, DOI 10.1006/mpat.1999.0305; GOLD BD, 1993, INFECT IMMUN, V61, P2632, DOI 10.1128/IAI.61.6.2632-2638.1993; GROSS WB, 1971, AVIAN DIS, V15, P716, DOI 10.2307/1588859; Ihara H, 2003, BBA-GENE STRUCT EXPR, V1625, P19, DOI 10.1016/S0167-4781(02)00537-7; Iwamori M, 2004, BIOCHEM J, V380, P75, DOI 10.1042/BJ20031668; Jeannotte ME, 2003, INFECT IMMUN, V71, P4657, DOI 10.1128/IAI.71.8.4657-4663.2003; KAMATA Y, 1986, BIOCHEM BIOPH RES CO, V140, P1015, DOI 10.1016/0006-291X(86)90736-9; KITAMURA M, 1987, BIOCHEM BIOPH RES CO, V143, P928, DOI 10.1016/0006-291X(87)90339-1; KNIGHT DE, 1985, NATURE, V317, P719, DOI 10.1038/317719a0; Koga T, 2002, BRAIN RES, V952, P282, DOI 10.1016/S0006-8993(02)03253-5; Kohda T, 2000, J VET MED SCI, V62, P1133, DOI 10.1292/jvms.62.1133; KONDO H, 1984, JPN J MED SCI BIOL, V37, P131, DOI 10.7883/yoken1952.37.131; Kozaki S, 1998, MICROB PATHOGENESIS, V25, P91, DOI 10.1006/mpat.1998.0214; KOZAKI S, 1979, N-S ARCH PHARMACOL, V308, P67, DOI 10.1007/BF00499721; KRIVAN HC, 1991, BIOCHEM BIOPH RES CO, V175, P1082, DOI 10.1016/0006-291X(91)91676-4; KURAZONO H, 1985, FEMS MICROBIOL LETT, V30, P47; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINGWOOD CA, 1992, INFECT IMMUN, V60, P2470, DOI 10.1128/IAI.60.6.2470-2474.1992; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MONTECUCCO C, 1994, MOL MICROBIOL, V13, P1, DOI 10.1111/j.1365-2958.1994.tb00396.x; Moriishi K, 1996, APPL ENVIRON MICROB, V62, P662, DOI 10.1128/AEM.62.2.662-667.1996; Moriishi K, 1996, BBA-GENE STRUCT EXPR, V1307, P123, DOI 10.1016/0167-4781(96)00006-1; Niemann Heiner, 1994, Trends in Cell Biology, V4, P179, DOI 10.1016/0962-8924(94)90203-8; Nishiki T, 1996, FEBS LETT, V378, P253, DOI 10.1016/0014-5793(95)01471-3; NISHIKI T, 1994, J BIOL CHEM, V269, P10498; OCHANDA JO, 1986, J BIOCHEM-TOKYO, V100, P27, DOI 10.1093/oxfordjournals.jbchem.a121702; OGASAWARA J, 1991, FEMS MICROBIOL LETT, V79, P351, DOI 10.1111/j.1574-6968.1991.tb04554.x; OGUMA K, 1984, INFECT IMMUN, V43, P584, DOI 10.1128/IAI.43.2.584-588.1984; OPDENKAMP JAF, 1979, ANNU REV BIOCHEM, V48, P47, DOI 10.1146/annurev.bi.48.070179.000403; REED L. J., 1938, AMER JOUR HYG, V27, P493; Rummel A, 2004, J BIOL CHEM, V279, P30865, DOI 10.1074/jbc.M403945200; Simpson LL, 2004, ANNU REV PHARMACOL, V44, P167, DOI 10.1146/annurev.pharmtox.44.101802.121554; Svennerholm L, 1980, Adv Exp Med Biol, V125, P11; SVENNERHOLM L, 1968, J LIPID RES, V9, P570; TAKAMIZAWA K, 1986, FEBS LETT, V201, P229, DOI 10.1016/0014-5793(86)80614-7; Takeda M, 2005, AVIAN DIS, V49, P376, DOI 10.1637/7347-022305R1.1; WHITTAKER VP, 1959, BIOCHEM J, V72, P694, DOI 10.1042/bj0720694; Williamson P, 2002, BBA-MOL CELL BIOL L, V1585, P53, DOI 10.1016/S1388-1981(02)00324-4; YABUUCHI H, 1968, J LIPID RES, V9, P65; Yamashita T, 2003, P NATL ACAD SCI USA, V100, P3445, DOI 10.1073/pnas.0635898100; Yowler BC, 2004, BIOCHEMISTRY-US, V43, P9725, DOI 10.1021/bi0494673; ZWAAL RFA, 1973, BIOCHIM BIOPHYS ACTA, V300, P159	51	106	112	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35164	35171		10.1074/jbc.M507596200	http://dx.doi.org/10.1074/jbc.M507596200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16115873	hybrid			2022-12-27	WOS:000232561200013
J	Yu, XP; Zhu, XG; Pi, WH; Ling, JH; Ko, L; Takeda, Y; Tuan, D				Yu, XP; Zhu, XG; Pi, WH; Ling, JH; Ko, L; Takeda, Y; Tuan, D			The long terminal repeat (LTR) of ERV-9 human endogenous retrovirus binds to NF-Y in the assembly of an active LTR enhancer complex NF-Y/MZF1/GATA-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLOBIN LOCUS; ZINC-FINGER GENE; 5' BOUNDARY AREA; DNA-BINDING; TRANSCRIPTIONAL REGULATION; CONTROL REGION; CHAIN GENE; IN-VIVO; EXPRESSION; ACTIVATION	The solitary ERV-9 long terminal repeat (LTR) located upstream of the HS5 site in the human beta-globin locus control region exhibits prominent enhancer activity in embryonic and erythroid cells. The LTR enhancer contains 14 tandemly repeated subunits with recurrent CCAAT, GTGGGGA, and GATA motifs. Here we showed that in erythroid K562 cells these DNA motifs bound the following three transcription factors: ubiquitous NF-Y and hematopoietic MZF1 and GATA-2. These factors and their target DNA motifs exhibited a hierarchy of DNA/protein and protein/protein binding affinities: NF-Y/CCAAT > NF-Y/GATA-2 > NF-Y/MZF1 > MZF1/GTGGGGA; GATA-2/GATA. Through protein/protein interactions, NF-Y bound at the CCAAT motif recruited MZF1 and GATA-2, but not Sp1 and GATA-1, and stabilized their binding to the neighboring GTGGGGA and GATA sites to assemble a novel LTR enhancer complex, NF-Y/MZF1/GATA-2. In the LTR-HS5-epsilon p-GFP plasmid integrated into K562 cells, mutation of the CCAAT motif in the LTR enhancer to abolish NF-Y binding inactivated the enhancer, closed down the chromatin structure of the epsilon-globin promoter, and silenced transcription of the green fluorescent protein gene. The results indicated that NF-Y bound at the CCAAT motifs assembled a robust LTR enhancer complex, which could act over the intervening DNA to remodel the chromatin structure and to stimulate the transcription of the downstream gene locus.	Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	Tuan, D (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.	dtuanlo@mcg.edu		Yu, Xiuping/0000-0003-2844-7026	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062308] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62308] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anguita E, 2004, EMBO J, V23, P2841, DOI 10.1038/sj.emboj.7600274; Bi WM, 1997, J BIOL CHEM, V272, P26562, DOI 10.1074/jbc.272.42.26562; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Britten RJ, 1996, P NATL ACAD SCI USA, V93, P9374, DOI 10.1073/pnas.93.18.9374; Caretti G, 1999, MOL CELL BIOL, V19, P8591; CHUNG J, 1983, CELL, V74, P505; DICRISTOFANO A, 1995, VIROLOGY, V213, P271, DOI 10.1006/viro.1995.1570; DOOLITTLE WF, 1980, NATURE, V284, P601, DOI 10.1038/284601a0; Duan ZJ, 2001, MOL CELL BIOL, V21, P3083, DOI 10.1128/MCB.21.9.3083-3095.2001; Farina A, 1999, ONCOGENE, V18, P2818, DOI 10.1038/sj.onc.1202472; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; Henikoff S, 1997, SCIENCE, V278, P609, DOI 10.1126/science.278.5338.609; HENTHORN PS, 1986, P NATL ACAD SCI USA, V83, P5194, DOI 10.1073/pnas.83.14.5194; HORTON MA, 1983, GLOBIN GENE EXPRESSI, P305; HROMAS R, 1991, J BIOL CHEM, V266, P14183; Hromas R, 1996, CURR TOP MICROBIOL, V211, P159; Huang DY, 2004, NUCLEIC ACIDS RES, V32, P3935, DOI 10.1093/nar/gkh719; Jackson SM, 1998, J LIPID RES, V39, P767; Johnson KD, 2002, METHODS, V26, P27, DOI 10.1016/S1046-2023(02)00005-1; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; LAMANTIA G, 1991, NUCLEIC ACIDS RES, V19, P1513; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li Q, 1998, EMBO J, V17, P6300, DOI 10.1093/emboj/17.21.6300; LI QL, 1994, BLOOD, V84, P1399; Liberati C, 1998, J BIOL CHEM, V273, P16880, DOI 10.1074/jbc.273.27.16880; Ling JH, 2003, NUCLEIC ACIDS RES, V31, P4582, DOI 10.1093/nar/gkg646; Ling JH, 2002, J VIROL, V76, P2410, DOI 10.1128/JVI.76.5.2410-2423.2002; Long QM, 1998, GENOMICS, V54, P542, DOI 10.1006/geno.1998.5608; Lower R, 1996, P NATL ACAD SCI USA, V93, P5177, DOI 10.1073/pnas.93.11.5177; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; Medstrand P, 2001, J BIOL CHEM, V276, P1896, DOI 10.1074/jbc.M006557200; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; Moran JV, 1999, SCIENCE, V283, P1530, DOI 10.1126/science.283.5407.1530; MORRIS JF, 1994, MOL CELL BIOL, V14, P1786, DOI 10.1128/MCB.14.3.1786; Motta MC, 1999, J BIOL CHEM, V274, P1326, DOI 10.1074/jbc.274.3.1326; ORKIN SH, 1992, BLOOD, V80, P575; Peterson MJ, 2000, GENE, V254, P105, DOI 10.1016/S0378-1119(00)00281-X; Phair RD, 2004, MOL CELL BIOL, V24, P6393, DOI 10.1128/MCB.24.14.6393-6402.2004; Pi WH, 2004, P NATL ACAD SCI USA, V101, P805, DOI 10.1073/pnas.0307698100; Ramchandran R, 2000, AM J HEMATOL, V65, P14, DOI 10.1002/1096-8652(200009)65:1<14::AID-AJH3>3.0.CO;2-F; Reik A, 1998, MOL CELL BIOL, V18, P5992, DOI 10.1128/MCB.18.10.5992; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Romier C, 2003, J BIOL CHEM, V278, P1336, DOI 10.1074/jbc.M209635200; Sambrook J., 2001, MOL CLONING LAB MANU, V3; Schulte AM, 1996, P NATL ACAD SCI USA, V93, P14759, DOI 10.1073/pnas.93.25.14759; Speck NA, 2001, CURR OPIN HEMATOL, V8, P192, DOI 10.1097/00062752-200107000-00002; Strazzullo M, 1998, GENE, V206, P77, DOI 10.1016/S0378-1119(97)00568-4; SVENSSON AC, 1995, IMMUNOGENETICS, V41, P74; TEMIN HM, 1981, CELL, V27, P1, DOI 10.1016/0092-8674(81)90353-6; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; TING CN, 1992, GENE DEV, V6, P1457, DOI 10.1101/gad.6.8.1457; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; ZEUTHEN J, 1980, INT J CANCER, V25, P19, DOI 10.1002/ijc.2910250104; Zhong ZD, 2000, J BIOL CHEM, V275, P18602, DOI 10.1074/jbc.M001389200; Zhu J, 2003, BLOOD, V102, P2420, DOI 10.1182/blood-2003-01-0251; ZON LI, 1993, BLOOD, V81, P3234	61	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35184	35194		10.1074/jbc.M508138200	http://dx.doi.org/10.1074/jbc.M508138200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16105833	hybrid			2022-12-27	WOS:000232561200015
J	Kenski, DM; Zhang, C; von Zastrow, M; Shokat, KM				Kenski, DM; Zhang, C; von Zastrow, M; Shokat, KM			Chemical genetic engineering of G protein-coupled receptor kinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MU-OPIOID RECEPTOR; BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; TYROSINE KINASE; MEDIATED DESENSITIZATION; MEMBRANE TRAFFICKING; DOWN-REGULATION; PHOSPHORYLATION; INTERNALIZATION; MORPHINE	G protein-coupled receptor kinases (GRKs) play a pivotal role in receptor regulation. Efforts to study the acute effects of GRKs in intact cells have been limited by a lack of specific inhibitors. In the present study we have developed an engineered version of GRK2 that is specifically and reversibly inhibited by the substituted nucleotide analog 1-naphthyl-PP1 (1Na-PP1), and we explored GRK2 function in regulated internalization of the mu-opioid receptor (mu OR). A previously described method that conferred analog sensitivity on various kinases, by introducing a space-creating mutation in the conserved active site, failed when applied to GRK2 because the corresponding mutation (L271G) rendered the mutant kinase (GRK2-as1) catalytically inactive. A sequence homology-based approach was used to design second-site suppressor mutations. A C221V second-site mutation produced a mutant kinase (GRK2-as5) with full functional activity and analog sensitivity as compared with wild-type GRK2 in vitro and in intact cells. The role of GRK2-as5 activity in the membrane trafficking of the mu OR was also characterized. Morphine-induced internalization was completely blocked when GRK2-as5 activity was inhibited before morphine application. However, inhibition of GRK2-as5 during recycling and reinternalization of the mu OR did not attenuate these processes. These results suggest there is a difference in the GRK requirement for initial ligand-induced internalization of a G protein-coupled receptor compared with subsequent rounds of reinternalization.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Chem & Chem Biol Grad Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Shokat, KM (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, 600 16th St, San Francisco, CA 94143 USA.	shokat@cmp.ucsf.edu			NIAID NIH HHS [AI44009] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044009] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARDEN JR, 1995, J NEUROCHEM, V65, P1636; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; Bishop AC, 2000, NATURE, V407, P395, DOI 10.1038/35030148; Bishop AC, 1998, CURR BIOL, V8, P257, DOI 10.1016/S0960-9822(98)70198-8; Bishop AC, 1999, J AM CHEM SOC, V121, P627, DOI 10.1021/ja983267v; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buzko O, 2002, BIOINFORMATICS, V18, P1274, DOI 10.1093/bioinformatics/18.9.1274; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; Celver JP, 2001, J BIOL CHEM, V276, P4894, DOI 10.1074/jbc.M007437200; Chakrabarti S, 1998, J NEUROCHEM, V71, P231; Chen X, 2005, NEURON, V46, P13, DOI 10.1016/j.neuron.2005.03.009; Diviani D, 1997, J BIOL CHEM, V272, P28712, DOI 10.1074/jbc.272.45.28712; Erdtmann-Vourliotis M, 2001, MOL BRAIN RES, V95, P129, DOI 10.1016/S0006-8993(01)03046-3; Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; Fukuto HS, 2004, NEURON, V42, P581, DOI 10.1016/S0896-6273(04)00252-1; Gage RM, 2001, J BIOL CHEM, V276, P44712, DOI 10.1074/jbc.M107417200; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Garby Lars, 1995, BIOENERGETICS ITS TH; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Haberstock-Debic H, 2003, J NEUROSCI, V23, P4324; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hasbi A, 2000, J PHARMACOL EXP THER, V293, P237; Ignatova EG, 1999, J NEUROSCI, V19, P56, DOI 10.1523/JNEUROSCI.19-01-00056.1999; KAUFMAN DL, 1994, GENOMICS, V19, P405, DOI 10.1006/geno.1994.1087; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; KIM CM, 1993, RECEPTOR, V3, P39; Koch T, 1997, J NEUROCHEM, V69, P1767; Krasel C, 2005, J BIOL CHEM, V280, P9528, DOI 10.1074/jbc.M413078200; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Liu Y, 1999, CHEM BIOL, V6, P671, DOI 10.1016/S1074-5521(99)80118-5; Liu Y, 2000, BIOCHEMISTRY-US, V39, P14400, DOI 10.1021/bi000437j; Lodowski DT, 2003, SCIENCE, V300, P1256, DOI 10.1126/science.1082348; McLaughlin JP, 2001, MOL PHARMACOL, V59, P1360, DOI 10.1124/mol.59.6.1360; MESTEK A, 1995, J NEUROSCI, V15, P2396, DOI 10.1523/JNEUROSCI.15-03-02396.1995; Niswender CM, 2002, J BIOL CHEM, V277, P28916, DOI 10.1074/jbc.M203327200; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; Pitcher JA, 1998, J BIOL CHEM, V273, P12316, DOI 10.1074/jbc.273.20.12316; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Polakiewicz RD, 1998, J BIOL CHEM, V273, P12402, DOI 10.1074/jbc.273.20.12402; Qiu Y, 2003, J BIOL CHEM, V278, P36733, DOI 10.1074/jbc.M305857200; Schulz S, 2004, EMBO J, V23, P3282, DOI 10.1038/sj.emboj.7600334; Shah K, 1997, P NATL ACAD SCI USA, V94, P3565, DOI 10.1073/pnas.94.8.3565; Shen J, 2000, SYNAPSE, V38, P322, DOI 10.1002/1098-2396(20001201)38:3<322::AID-SYN11>3.0.CO;2-1; Sreenivasan A, 2003, MOL CELL BIOL, V23, P6327, DOI 10.1128/MCB.23.17.6327-6337.2003; Tanowitz M, 2003, J BIOL CHEM, V278, P45978, DOI 10.1074/jbc.M304504200; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; von Zastrow M, 2003, LIFE SCI, V74, P217, DOI 10.1016/j.lfs.2003.09.008; Wang H, 2003, P NATL ACAD SCI USA, V100, P4287, DOI 10.1073/pnas.0636870100; Wang Q, 2004, SCIENCE, V304, P1940, DOI 10.1126/science.1098274; Weiss EL, 2002, J CELL BIOL, V158, P885, DOI 10.1083/jcb.200203094; Weiss EL, 2000, NAT CELL BIOL, V2, P677, DOI 10.1038/35036300; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Zhang C, 2005, NAT METHODS, V2, P435, DOI 10.1038/NMETH764; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang L, 1996, J BIOL CHEM, V271, P11449, DOI 10.1074/jbc.271.19.11449	59	23	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					35051	35061		10.1074/jbc.M507594200	http://dx.doi.org/10.1074/jbc.M507594200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16081410	hybrid			2022-12-27	WOS:000232403900078
J	Piccini, A; Russo, C; Gliozzi, A; Relini, A; Vitali, A; Borghi, R; Giliberto, L; Armirotti, A; D'Arrigo, C; Bachi, A; Cattaneo, A; Canale, C; Torrassa, S; Saido, TC; Markesbery, W; Gambetti, P; Tabaton, M				Piccini, A; Russo, C; Gliozzi, A; Relini, A; Vitali, A; Borghi, R; Giliberto, L; Armirotti, A; D'Arrigo, C; Bachi, A; Cattaneo, A; Canale, C; Torrassa, S; Saido, TC; Markesbery, W; Gambetti, P; Tabaton, M			beta-amyloid is different in normal aging and in Alzheimer disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOWNS-SYNDROME; MISFOLDING DISEASES; COMMON MECHANISM; SENILE PLAQUES; A-BETA; PROTEIN; PEPTIDE; BRAIN; NEPRILYSIN; DEPOSITION	The mechanism of neurodegeneration caused by beta-amyloid in Alzheimer disease is controversial. Neuronal toxicity is exerted mostly by various species of soluble beta-amyloid oligomers that differ in their N- and C-terminal domains. However, abundant accumulation of beta-amyloid also occurs in the brains of cognitively normal elderly people, in the absence of obvious neuronal dysfunction. We postulated that neuronal toxicity depends on the molecular composition, rather than the amount, of the soluble beta-amyloid oligomers. Here we show that soluble beta-amyloid aggregates that accumulate in Alzheimer disease are different from those of normal aging in regard to the composition as well as the aggregation and toxicity properties.	Univ Genoa, Dept Neurosci Ophthalmol & Genet, I-16132 Genoa, Italy; Univ Genoa, Dept Oncol Biol & Genet, I-16132 Genoa, Italy; Univ Genoa, Dept Phys, I-16132 Genoa, Italy; Univ Genoa, Ctr Excellence Biomed Res, Dept Expt Med, I-16132 Genoa, Italy; CNR, Inst Macromol Res, I-16149 Genoa, Italy; San Raffaele Fdn, Dept Biotechnol, I-20132 Milan, Italy; RIKEN Brain Sci Inst, Saitama 3510198, Japan; Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA	University of Genoa; University of Genoa; University of Genoa; University of Genoa; Consiglio Nazionale delle Ricerche (CNR); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; RIKEN; University of Kentucky; Case Western Reserve University	Tabaton, M (corresponding author), Univ Genoa, Dept Neurosci Ophthalmol & Genet, Via A De Toni 5, I-16132 Genoa, Italy.	mtabaton@neurologia.unige.it	Saido, Takaomi C/N-5472-2015; Russo, Claudio/AIA-1429-2022; Relini, Annalisa/AHC-3105-2022; Armirotti, Andrea/AAB-3284-2019; Sado, Takaomi/AAN-2759-2021; bachi, angela/B-3527-2015	Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903; bachi, angela/0000-0003-4842-6556; russo, claudio/0000-0002-2520-2958; D'Arrigo, Cristina/0000-0002-5352-5287; RELINI, ANNALISA/0000-0002-4040-9279; Armirotti, Andrea/0000-0002-3766-8755; Canale, Claudio/0000-0002-7582-6849				Akiyama H, 1997, NEUROCHEM RES, V22, P1499, DOI 10.1023/A:1021910729963; Alonzo NC, 1998, J NEUROPATH EXP NEUR, V57, P353, DOI 10.1097/00005072-199804000-00008; Armstrong RA, 1996, NEURODEGENERATION, V5, P35; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Carson JA, 2002, J NEUROCHEM, V81, P1, DOI 10.1046/j.1471-4159.2002.00855.x; Casas C, 2004, AM J PATHOL, V165, P1289, DOI 10.1016/S0002-9440(10)63388-3; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; DICKSON DW, 1992, NEUROBIOL AGING, V13, P179, DOI 10.1016/0197-4580(92)90027-U; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Harigaya Y, 2000, BIOCHEM BIOPH RES CO, V276, P422, DOI 10.1006/bbrc.2000.3490; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Liu KN, 2002, BIOCHEMISTRY-US, V41, P3128, DOI 10.1021/bi015800g; Relini A, 2004, J MOL BIOL, V338, P943, DOI 10.1016/j.jmb.2004.03.054; Russo C, 2000, NATURE, V405, P531, DOI 10.1038/35014735; Russo C, 1997, FEBS LETT, V409, P411, DOI 10.1016/S0014-5793(97)00564-4; Saido TC, 1996, NEUROSCI LETT, V215, P173, DOI 10.1016/0304-3940(96)12970-0; Saido TC, 1998, NEUROBIOL AGING, V19, pS69, DOI 10.1016/S0197-4580(98)00033-5; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Shirotani K, 2001, J BIOL CHEM, V276, P21895, DOI 10.1074/jbc.M008511200; Shirotani K, 2002, NEUROSCI LETT, V327, P25, DOI 10.1016/S0304-3940(02)00351-8; Smirnov IP, 2004, ANAL CHEM, V76, P2958, DOI 10.1021/ac035331j; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Stine WB, 2003, J BIOL CHEM, V278, P11612, DOI 10.1074/jbc.M210207200; TABATON M, 1994, BIOCHEM BIOPH RES CO, V200, P1598, DOI 10.1006/bbrc.1994.1634; Takaki Y, 2000, J BIOCHEM-TOKYO, V128, P897, DOI 10.1093/oxfordjournals.jbchem.a022839; Tekirian TL, 1999, J NEUROCHEM, V73, P1584, DOI 10.1046/j.1471-4159.1999.0731584.x; Teller JK, 1996, NAT MED, V2, P93, DOI 10.1038/nm0196-93; Turner PR, 2003, PROG NEUROBIOL, V70, P1, DOI 10.1016/S0301-0082(03)00089-3; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Yamaguchi H, 1998, ACTA NEUROPATHOL, V95, P217, DOI 10.1007/s004010050790; Yasojima K, 2001, NEUROSCI LETT, V297, P97, DOI 10.1016/S0304-3940(00)01675-X	37	162	167	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34186	34192		10.1074/jbc.M501694200	http://dx.doi.org/10.1074/jbc.M501694200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16103127	hybrid			2022-12-27	WOS:000232229700060
J	Horvath, AJ; Irving, JA; Rossjohn, J; Law, RH; Bottomley, SP; Quinsey, NS; Pike, RN; Coughlin, PB; Whisstock, JC				Horvath, AJ; Irving, JA; Rossjohn, J; Law, RH; Bottomley, SP; Quinsey, NS; Pike, RN; Coughlin, PB; Whisstock, JC			The murine orthologue of human antichymotrypsin - A structural paradigm for CLADE A3 serpins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-1-ANTICHYMOTRYPSIN; PROTEASE INHIBITOR; REACTIVE LOOP; DNA-BINDING; CATHEPSIN-G; ALPHA(1)-ANTICHYMOTRYPSIN; IDENTIFICATION; ANTITHROMBIN; ASSOCIATION; MECHANISM	Antichymotrypsin (SERPINA3) is a widely expressed member of the serpin superfamily, required for the regulation of leukocyte proteases released during an inflammatory response and with a permissive role in the development of amyloid encephalopathy. Despite its biological significance, there is at present no available structure of this serpin in its native, inhibitory state. We present here the first fully refined structure of a murine antichymotrypsin orthologue to 2.1 angstrom, which we propose as a template for other antichymotrypsin-like serpins. A most unexpected feature of the structure of murine serpina3n is that it reveals the reactive center loop (RCL) to be partially inserted into the A beta-sheet, a structural motif associated with ligand-dependent activation in other serpins. The RCL is, in addition, stabilized by salt bridges, and its plane is oriented at 90 to the RCL of antitrypsin. A biochemical and biophysical analysis of this serpin demonstrates that it is a fast and efficient inhibitor of human leukocyte elastase (k(a):4 +/- 0.9 x 10(6) M-1 s(-1)) and cathepsin G (ka: 7.9 +/- 0.9 x 10(5) M-1 s(-1)) giving a spectrum of activity intermediate between that of human antichymotrypsin and human antitrypsin. An evolutionary analysis reveals that residues subject to positive selection and that have contributed to the diversity of sequences in this sub-branch (A3) of the serpin superfamily are essentially restricted to the P-4 - P-6' region of the RCL, the distal hinge, and the loop between strands 4B and 5B.	Monash Univ, Australian Ctr Blood Dis, Alfred Med Res Precinct, Prahran, Vic 3181, Australia; Monash Univ, Prot Crystallog Unit, Monash Ctr Synchrotron Sci, Clayton, Vic 3800, Australia; Monash Univ, Dept Biochem & Mol Biol, Sch Biomed Sci, Clayton, Vic 3800, Australia; Monash Univ, Victorian Bioinformat Consortium, Clayton, Vic 3800, Australia; Monash Univ, Australian Res Council Ctr Struct & Funct Microbi, Clayton, Vic 3800, Australia	Monash University; Monash University; Monash University; Monash University; Monash University	Coughlin, PB (corresponding author), Monash Univ, Australian Ctr Blood Dis, Alfred Med Res Precinct, Commercial Rd,6th Floor,Macfarlane Burnet Bldg, Prahran, Vic 3181, Australia.	Paul.Coughlin@med.monash.edu.au; James.Whisstock@med.monash.edu.au	Irving, James/P-3860-2019; Irving, James A/I-8467-2015; Rossjohn, Jamie/F-9032-2013	Irving, James/0000-0003-3204-6356; Rossjohn, Jamie/0000-0002-2020-7522; law, ruby/0000-0001-5432-5781; Whisstock, James/0000-0003-4200-5611; Pike, Robert/0000-0002-2083-0269	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abraham CR, 2001, NEUROBIOL AGING, V22, P931, DOI 10.1016/S0197-4580(01)00302-5; ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; Adachi J., 1996, MOLPHY PROGRAMS MOL; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barbour KW, 2002, GENOMICS, V80, P515, DOI [10.1016/S0888-7543(02)96864-3, 10.1006/geno.2002.6864]; Barbour KW, 2002, MOL BIOL EVOL, V19, P718, DOI 10.1093/oxfordjournals.molbev.a004130; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BEATTY K, 1980, J BIOL CHEM, V255, P3931; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chaillan-Huntington CE, 1998, J BIOL CHEM, V273, P4569, DOI 10.1074/jbc.273.8.4569; CHANDRA T, 1983, BIOCHEMISTRY-US, V22, P5055, DOI 10.1021/bi00291a001; Chang WSW, 1997, PROTEIN SCI, V6, P89; Cheung J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-8-r47; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CICHY J, 1995, J CLIN INVEST, V95, P2729, DOI 10.1172/JCI117975; DICKSON I, 1974, CLIN CHIM ACTA, V54, P381, DOI 10.1016/0009-8981(74)90257-5; Dunstone MA, 2000, PROTEIN SCI, V9, P417; Duranton J, 1998, BIOCHEMISTRY-US, V37, P11239, DOI 10.1021/bi980223q; Elliott PR, 1998, J MOL BIOL, V275, P419, DOI 10.1006/jmbi.1997.1458; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; FABER JP, 1993, J HEPATOL, V18, P313, DOI 10.1016/S0168-8278(05)80275-2; Forsyth S, 2003, GENOMICS, V81, P336, DOI 10.1016/S0888-7543(02)00041-1; Gooptu B, 2000, P NATL ACAD SCI USA, V97, P67, DOI 10.1073/pnas.97.1.67; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HOPKINS PCR, 1993, BIOCHEMISTRY-US, V32, P7650, DOI 10.1021/bi00081a008; Horvath AJ, 2004, J MOL EVOL, V59, P488, DOI 10.1007/s00239-004-2640-9; Hwang SR, 1999, J BIOL CHEM, V274, P1821, DOI 10.1074/jbc.274.3.1821; INGLIS JD, 1991, EMBO J, V10, P255, DOI 10.1002/j.1460-2075.1991.tb07945.x; Irving JA, 2004, METHODS, V32, P73, DOI 10.1016/S1046-2023(03)00200-7; Irving JA, 2002, MOL BIOL EVOL, V19, P1881, DOI 10.1093/oxfordjournals.molbev.a004012; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kaiserman D, 2002, GENOMICS, V79, P349, DOI 10.1006/geno.2002.6716; KAMBOH MI, 1995, NAT GENET, V10, P486, DOI 10.1038/ng0895-486; KLEYWEGT GJ, 1995, STRUCTURE, V3, P535, DOI 10.1016/S0969-2126(01)00187-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; LEBONNIEC BF, 1995, BIOCHEMISTRY-US, V34, P12241, DOI 10.1021/bi00038a019; LOMAS DA, 1995, J BIOL CHEM, V270, P23437, DOI 10.1074/jbc.270.40.23437; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAIDOO N, 1995, J BIOL CHEM, V270, P14548, DOI 10.1074/jbc.270.24.14548; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nielsen R, 1998, GENETICS, V148, P929; O'Keeffe D, 2004, J BIOL CHEM, V279, P50267, DOI 10.1074/jbc.M408774200; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Plotnick MI, 1997, BIOCHEMISTRY-US, V36, P14601, DOI 10.1021/bi971530j; POLLER W, 1993, GENOMICS, V17, P740, DOI 10.1006/geno.1993.1396; Quinsey NS, 2002, J BIOL CHEM, V277, P15971, DOI 10.1074/jbc.M108131200; ROVELLI G, 1992, BIOCHEMISTRY-US, V31, P3542, DOI 10.1021/bi00128a031; RUBIN H, 1994, BIOCHEMISTRY-US, V33, P7627, DOI 10.1021/bi00190a016; SCHECHTER NM, 1993, J BIOL CHEM, V268, P23626; SIDDIQUI AA, 1980, BIOCHEM BIOPH RES CO, V95, P1737, DOI 10.1016/S0006-291X(80)80099-4; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; TRAVIS J, 1978, BIOCHEMISTRY-US, V17, P5651, DOI 10.1021/bi00619a011; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; Whisstock J, 1998, TRENDS BIOCHEM SCI, V23, P63, DOI 10.1016/S0968-0004(97)01172-9; Yamada M, 1998, ANN NEUROL, V44, P129, DOI 10.1002/ana.410440120; Yang ZH, 1998, MOL BIOL EVOL, V15, P568, DOI 10.1093/oxfordjournals.molbev.a025957	67	85	87	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					43168	43178		10.1074/jbc.M505598200	http://dx.doi.org/10.1074/jbc.M505598200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16141197	hybrid			2022-12-27	WOS:000234200800083
J	Karamyshev, AL; Johnson, AE				Karamyshev, AL; Johnson, AE			Selective SecA association with signal sequences in ribosome-bound nascent chains - A potential role for SecA in ribosome targeting to the bacterial membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOGNITION PARTICLE BINDS; ESCHERICHIA-COLI; TRIGGER FACTOR; PROTEIN-TRANSLOCATION; PLASMA-MEMBRANE; ATPASE ACTIVITY; INNER MEMBRANE; ER MEMBRANE; INTEGRATION; PEPTIDE	The role of SecA in selecting bacterial proteins for export was examined using a heterologous system that lacks endogenous SecA and other bacterial proteins. This approach allowed us to assess the interaction of SecA with ribosome-bound photoreactive nascent chains in the absence of trigger factor, SecB, Ffh ( the bacterial protein component of the signal recognition particle), and the SecYEG translocon in the bacterial plasma membrane. In the absence of membranes, SecA photocross-linked efficiently to nascent translocation substrate OmpA in ribosome-nascent chain (RNC) complexes in an interaction that was independent of both ATP and SecB. However, no photocross-linking to a nascent membrane protein that is normally targeted by a signal recognition particle was observed. Modification of the signal sequence revealed that its affinity for SecA and Ffh varied inversely. Gel filtration showed that SecA binds tightly to both translating and non-translating ribosomes. When purified SecA center dot RNC complexes containing nascent OmpA were exposed to inner membrane vesicles lacking functional SecA, the nascent chains were successfully targeted to SecYEG translocons. However, purified RNCs lacking SecA were unable to target to the same membranes. Taken together, these data strongly suggest that cytosolic SecA participates in the selection of proteins for export by co-translationally binding to the signal sequences of non-membrane proteins and directing those nascent chains to the translocon.	Texas A&M Univ Syst Hlth Sci Ctr, Coll Med, Dept Med Biochem & Genet, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Johnson, AE (corresponding author), Texas A&M Univ Syst Hlth Sci Ctr, Coll Med, Dept Med Biochem & Genet, TAMU 1114,116 Reynolds Med Bldg, College Stn, TX 77843 USA.	ajohnson@medicine.tamhsc.edu	Johnson, Arthur E/G-3457-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026494] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 26494] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKITA M, 1990, J BIOL CHEM, V265, P8164; AKIYAMA Y, 1990, BIOCHEM BIOPH RES CO, V167, P711, DOI 10.1016/0006-291X(90)92083-C; AKIYAMA Y, 1986, EUR J BIOCHEM, V159, P263, DOI 10.1111/j.1432-1033.1986.tb09862.x; Beck K, 2000, EMBO J, V19, P134, DOI 10.1093/emboj/19.1.134; Behrmann M, 1998, J BIOL CHEM, V273, P13898, DOI 10.1074/jbc.273.22.13898; Buskiewicz I, 2004, P NATL ACAD SCI USA, V101, P7902, DOI 10.1073/pnas.0402231101; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; Chou YT, 2005, J BIOL CHEM, V280, P32753, DOI 10.1074/jbc.M507532200; CHUN SY, 1994, J BACTERIOL, V176, P4197, DOI 10.1128/jb.176.14.4197-4203.1994; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; Dalbey RE, 2004, J CELL BIOL, V166, P769, DOI 10.1083/jcb.200405161; de Keyzer J, 2003, CELL MOL LIFE SCI, V60, P2034, DOI 10.1007/s00018-003-3006-y; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; Eichler J, 1998, J BIOL CHEM, V273, P21675, DOI 10.1074/jbc.273.34.21675; Eisner G, 2003, J CELL BIOL, V163, P35, DOI 10.1083/jcb.200306069; Flanagan JJ, 2003, J BIOL CHEM, V278, P18628, DOI 10.1074/jbc.M300173200; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; Gu SQ, 2003, RNA, V9, P566, DOI 10.1261/rna.2196403; Houben ENG, 2000, FEBS LETT, V476, P229, DOI 10.1016/S0014-5793(00)01735-X; JOHNSON AE, 1976, BIOCHEMISTRY-US, V15, P569, DOI 10.1021/bi00648a018; Kebir MO, 2002, BIOCHEMISTRY-US, V41, P5573, DOI 10.1021/bi015798t; Knoblauch NTM, 1999, J BIOL CHEM, V274, P34219, DOI 10.1074/jbc.274.48.34219; Koch HG, 1999, MOL BIOL CELL, V10, P2163, DOI 10.1091/mbc.10.7.2163; Kramer G, 2002, NATURE, V419, P171, DOI 10.1038/nature01047; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; Lee HC, 2001, P NATL ACAD SCI USA, V98, P3471, DOI 10.1073/pnas.051484198; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; MACFARLANE J, 1995, EUR J BIOCHEM, V233, P766, DOI 10.1111/j.1432-1033.1995.766_3.x; McCallum CD, 2000, J CELL BIOL, V149, P591, DOI 10.1083/jcb.149.3.591; McCormick PJ, 2003, MOL CELL, V12, P329, DOI 10.1016/S1097-2765(03)00304-6; Miller A, 1998, J BIOL CHEM, V273, P11409, DOI 10.1074/jbc.273.19.11409; Mori H, 2001, TRENDS MICROBIOL, V9, P494, DOI 10.1016/S0966-842X(01)02174-6; Muller M, 2001, PROG NUCLEIC ACID RE, V66, P107; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; Peluso P, 2001, BIOCHEMISTRY-US, V40, P15224, DOI 10.1021/bi011639y; Plath K, 1998, CELL, V94, P795, DOI 10.1016/S0092-8674(00)81738-9; Raine A, 2004, BIOCHIMIE, V86, P495, DOI 10.1016/j.biochi.2004.05.004; RANDALL LL, 1990, SCIENCE, V248, P860, DOI 10.1126/science.2188362; Randall LL, 2005, J MOL BIOL, V348, P479, DOI 10.1016/j.jmb.2005.02.036; Randall LL, 2002, CELL MOL LIFE SCI, V59, P1617, DOI 10.1007/PL00012488; TAI PC, 1991, METHOD CELL BIOL, V34, P167; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; Ullers RS, 2003, J CELL BIOL, V161, P679, DOI 10.1083/jcb.200302130; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; van der Laan M, 2004, J CELL BIOL, V165, P213, DOI 10.1083/jcb.200402100; Veenendaal AKJ, 2004, BBA-MOL CELL RES, V1694, P81, DOI 10.1016/j.bbamcr.2004.02.009; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Vrontou E, 2004, BBA-MOL CELL RES, V1694, P67, DOI 10.1016/j.bbamcr.2004.06.003; WALTER P, 1983, METHOD ENZYMOL, V96, P682; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511	57	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37930	37940		10.1074/jbc.M509100200	http://dx.doi.org/10.1074/jbc.M509100200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16120599	hybrid			2022-12-27	WOS:000233044500075
J	Kim, IM; Zhou, Y; Ramakrishna, S; Hughes, DE; Solway, J; Costa, RH; Kalinichenko, VV				Kim, IM; Zhou, Y; Ramakrishna, S; Hughes, DE; Solway, J; Costa, RH; Kalinichenko, VV			Functional characterization of evolutionarily conserved DNA regions in Forkhead Box f1 gene locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WINGED HELIX PROTEINS; NUCLEAR FACTOR 3-BETA; TRANSCRIPTION FACTOR; PULMONARY VASCULATURE; EMBRYONIC-DEVELOPMENT; LIVER-REGENERATION; SONIC HEDGEHOG; MOUSE EMBRYOS; EXPRESSION; LUNG	The Forkhead Box f1 (Foxf1) transcription factor ( previously known as HFH-8 or Freac-1) is expressed in the septum transversum and splanchnic ( visceral) mesoderm and is required for proper development of gut-derived organs. Sequence comparisons of mouse and human Foxf1 genes have revealed highly conserved DNA sequences located within the -5.3-kb Foxf1 promoter region and the 400-nucleotide regulatory element located 1 kb 3' to the Foxf1 gene (3'RE). To examine their transcriptional activity during mouse embryonic development, we generated transgenic mice in which the expression of the beta-galactosidase transgene was controlled by the - 2.7- kb Foxf1 promoter region, the - 5.3-kb Foxf1 promoter region, or the - 5.3-kb Foxf1 promoter region fused to the 3' RE. The - 5.3-kb Foxf1 promoter sequences induced appropriate transgene expression in the midgut and developing intestine, whereas the - 2.7-kb Foxf1 promoter region was transcriptionally inactive. Addition of 3' RE to the - 5.3-kb Foxf1 promoter restored proper transgene expression in the foregut, liver, and lung mesenchyme and prevented ectopic transgene expression in the developing nervous system. Cotransfection studies demonstrated that FoxA2 protein bound to the 3' RE region (+ 4506/+4529 bp) and was sufficient to inhibit expression of the -5.3-kb Foxf1 promoter. Furthermore, C/EBP beta and HNF-6 proteins bound to the 3' RE region (+ 4647/ + 4694 bp) and provided synergistic transcriptional activation of the - 5.3-kb Foxf1 promoter in cotransfection assays. These studies demonstrated that the conserved Foxf1 3' RE region is essential for proper tissue-specific regulation of the Foxf1 promoter region during mouse embryogenesis.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Comm Dev Biol, Chicago, IL 60637 USA; Univ Illinois, Coll Med, Dept Biochem & Mol Genet, Chicago, IL 60607 USA	University of Chicago; University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kalinichenko, VV (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave,MC 6076, Chicago, IL 60637 USA.	vkalin@medicine.bsd.uchicago.edu	Solway, Julian/B-1116-2008	Solway, Julian/0000-0002-0898-8530; Kim, Il-man/0000-0002-9268-8337; Ramakrishna, Sneha/0000-0001-7445-3190	NHLBI NIH HHS [HL 62446] Funding Source: Medline; NIDDK NIH HHS [DK 54687-06] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062446] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054687] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Attard FA, 2000, ARCH BIOCHEM BIOPHYS, V378, P57, DOI 10.1006/abbi.2000.1803; Barr FG, 2001, ONCOGENE, V20, P5736, DOI 10.1038/sj.onc.1204599; Baxter RM, 2002, J INVEST DERMATOL, V118, P303, DOI 10.1046/j.0022-202x.2001.01662.x; Beck F, 2002, GUT, V51, P450, DOI 10.1136/gut.51.3.450; Chang VWH, 2001, GENE, V267, P201, DOI 10.1016/S0378-1119(01)00400-0; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Costa RH, 2003, HEPATOLOGY, V38, P1331, DOI 10.1016/j.hep.2003.09.034; Costa RH, 2001, AM J PHYSIOL-LUNG C, V280, pL823, DOI 10.1152/ajplung.2001.280.5.L823; Duncan SA, 2003, MECH DEVELOP, V120, P19, DOI 10.1016/S0925-4773(02)00328-3; Garry DJ, 1997, DEV BIOL, V188, P280, DOI 10.1006/dbio.1997.8657; Gerrish K, 2000, J BIOL CHEM, V275, P3485, DOI 10.1074/jbc.275.5.3485; Kaestner KH, 2000, TRENDS ENDOCRIN MET, V11, P281, DOI 10.1016/S1043-2760(00)00271-X; Kalinichenko VV, 2003, HEPATOLOGY, V37, P107, DOI 10.1053/jhep.2003.50005; Kalinichenko VV, 2002, J BIOL CHEM, V277, P12369, DOI 10.1074/jbc.M112162200; Kalinichenko VV, 2002, AM J PHYSIOL-LUNG C, V282, pL1253, DOI 10.1152/ajplung.00463.2001; Kalinichenko VV, 2001, DEV BIOL, V235, P489, DOI 10.1006/dbio.2001.0322; Kalinichenko VV, 2001, AM J PHYSIOL-LUNG C, V280, pL695, DOI 10.1152/ajplung.2001.280.4.L695; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Kim IM, 2005, J BIOL CHEM, V280, P22278, DOI 10.1074/jbc.M500936200; Kunath M, 2002, MECH DEVELOP, V119, pS117, DOI 10.1016/S0925-4773(03)00103-5; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; Landry C, 1997, DEV BIOL, V192, P247, DOI 10.1006/dbio.1997.8757; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Lim L, 2002, AM J PHYSIOL-LUNG C, V282, pL1012, DOI 10.1152/ajplung.00371.2001; Mahlapuu M, 1998, DEV BIOL, V202, P183, DOI 10.1006/dbio.1998.9010; Mahlapuu M, 2001, DEVELOPMENT, V128, P2397; Mahlapuu M, 2001, DEVELOPMENT, V128, P155; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; Morrisey EE, 1997, DEV BIOL, V183, P21, DOI 10.1006/dbio.1996.8485; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Nervi C, 2001, CANCER RES, V61, P1247; Peterson RS, 1997, MECH DEVELOP, V69, P53, DOI 10.1016/S0925-4773(97)00153-6; Rausa F, 1997, DEV BIOL, V192, P228, DOI 10.1006/dbio.1997.8744; Rausa FM, 2000, MOL CELL BIOL, V20, P8264, DOI 10.1128/MCB.20.21.8264-8282.2000; Rausa FM, 2003, MOL CELL BIOL, V23, P437, DOI 10.1128/MCB.23.2.437-449.2003; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Tan YJ, 2001, GENE EXPRESSION, V9, P237, DOI 10.3727/000000001783992542; Tremblay JJ, 2002, ENDOCRINOLOGY, V143, P3935, DOI 10.1210/en.2002-220413; Tseng HT, 2004, DEVELOPMENT, V131, P3637, DOI 10.1242/dev.01234; Vogt PK, 1997, VIROLOGY, V238, P1, DOI 10.1006/viro.1997.8846; Wang XH, 2002, P NATL ACAD SCI USA, V99, P16881, DOI 10.1073/pnas.252570299; Warburton D, 2000, MECH DEVELOP, V92, P55, DOI 10.1016/S0925-4773(99)00325-1; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5; Winnier GE, 1997, GENE DEV, V11, P926, DOI 10.1101/gad.11.7.926; Yamaguchi Y, 1999, BLOOD, V94, P1429, DOI 10.1182/blood.V94.4.1429.416k13_1429_1439; Zaret KS, 2002, NAT REV GENET, V3, P499, DOI 10.1038/nrg837	46	47	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37908	37916		10.1074/jbc.M506531200	http://dx.doi.org/10.1074/jbc.M506531200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16144835	hybrid			2022-12-27	WOS:000233044500072
J	Kumar, A; Mohan, S; Newton, J; Rehage, M; Tran, K; Baylink, DJ; Qin, XZ				Kumar, A; Mohan, S; Newton, J; Rehage, M; Tran, K; Baylink, DJ; Qin, XZ			Pregnancy-associated plasma protein-A regulates myoblast proliferation and differentiation through an insulin-like growth factor-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING-PROTEINS; IGF-I; MYOGENIC DIFFERENTIATION; PAPP-A; PROTEOLYTIC ACTIVITY; GENE-EXPRESSION; SERUM; (IGFBP)-4; MICE; IDENTIFICATION	Pregnancy-associated plasma protein-A (PAPP-A), a member of the metalloproteinase superfamily, is an important regulator of mammalian growth and development. However, the role of PAPP-A and its mechanism of action in various cellular processes remain unknown. In this study, we have investigated the role of PAPP-A in skeletal myogenesis using C2C12 myoblasts. Recombinant PAPP-A was purified from the conditioned medium of HT1080 cells overexpressing PAPP-A. Treatment of C2C12 myoblasts with PAPP-A increased their proliferation in a dose- and time-dependent manner. Addition of exogenous PAPP-A also increased the myotube formation and the activity of creatine kinase in C2C12 cultures. Transient overexpression of the full-length PAPP-A-( 1 - 1547), but not truncated protease-inactive N-terminal PAPP-A-( 1 - 920) or C-terminal PAPP-A-( 1100 - 1547), significantly enhanced the proliferation of C2C12 myoblasts. In vitro and in situ experiments demonstrated that PAPP-A cleaves insulin-like growth factor-binding protein ( IGFBP)- 2, but not IGFBP-3, in the conditioned medium of C2C12 myoblasts. Overexpression of PAPP-A led to degradation of the IGFBP-2 produced by C2C12 myoblasts and increased free IGF-I concentrations without affecting total IGF-I concentrations. Addition of protease-resistant IGFBP-4 completely abolished the PAPP-A- induced proliferation of C2C12 myoblasts. Our results demonstrate that 1) PAPP-A increases the proliferation and differentiation of myoblasts, 2) the stimulatory effect of PAPP-A on myogenesis is governed by its proteolytic activity, and 3) PAPP-A promotes skeletal myogenesis by increasing the amount of free IGFs via specific degradation of IGFBP-2 produced by myoblasts.	JL Pettis Mem Vet Affairs Med Ctr, Musculoskeletal Dis Ctr, Loma Linda, CA 92357 USA; Loma Linda Univ, Dept Med, Loma Linda, CA 92357 USA; Loma Linda Univ, Dept Biochem, Loma Linda, CA 92357 USA; Loma Linda Univ, Dept Physiol, Loma Linda, CA 92357 USA	Loma Linda University; Loma Linda University; Loma Linda University	Qin, XZ (corresponding author), JL Pettis Mem Vet Affairs Med Ctr, Musculoskeletal Dis Ctr, 151,11201 Benton St, Loma Linda, CA 92357 USA.	Xuezhong.Qin@med.va.gov		Kumar, Ashok/0000-0001-8571-2848	NIAMS NIH HHS [R01 AR45210, R01 AR031062, R01 AR045210, R01 AR031062-21, R01 AR31062] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045210, R01AR031062] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Amin S, 2004, J BONE MINER RES, V19, P1075, DOI 10.1359/JBMR.040301; Barton ER, 2002, J CELL BIOL, V157, P137, DOI 10.1083/jcb.200108071; Barton-Davis ER, 1998, P NATL ACAD SCI USA, V95, P15603, DOI 10.1073/pnas.95.26.15603; Byun DW, 2001, J CLIN ENDOCR METAB, V86, P847, DOI 10.1210/jc.86.2.847; Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003; Clemmons David R., 1997, Cytokine and Growth Factor Reviews, V8, P45, DOI 10.1016/S1359-6101(96)00053-6; Conover CA, 2004, DEVELOPMENT, V131, P1187, DOI 10.1242/dev.00997; Damon SE, 1998, J CELL PHYSIOL, V175, P109, DOI 10.1002/(SICI)1097-4652(199804)175:1<109::AID-JCP12>3.0.CO;2-6; Delgado I, 2003, GENOMICS, V82, P109, DOI 10.1016/S0888-7543(03)00104-6; ERNST CW, 1992, ENDOCRINOLOGY, V130, P607, DOI 10.1210/en.130.2.607; Ernst CW, 1996, J ENDOCRINOL, V149, P417, DOI 10.1677/joe.0.1490417; Ernst CW, 1996, DIFFERENTIATION, V61, P25, DOI 10.1046/j.1432-0436.1996.6110025.x; Ewton DZ, 1998, J CELL PHYSIOL, V177, P47, DOI 10.1002/(SICI)1097-4652(199810)177:1<47::AID-JCP5>3.0.CO;2-E; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; FUNSTON RN, 1995, ENDOCRINOLOGY, V136, P62, DOI 10.1210/en.136.1.62; Gustafsson T, 1999, J ENDOCRINOL, V161, P245, DOI 10.1677/joe.0.1610245; Haugk KL, 2000, ENDOCRINOLOGY, V141, P100, DOI 10.1210/en.141.1.100; Husmann Irene, 1996, Cytokine and Growth Factor Reviews, V7, P249, DOI 10.1016/S1359-6101(96)00029-9; Hwa V, 1999, ENDOCR REV, V20, P761, DOI 10.1210/er.20.6.761; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KRISTENSEN T, 1994, BIOCHEMISTRY-US, V33, P1592, DOI 10.1021/bi00172a040; Langen RCJ, 2004, FASEB J, V18, P227, DOI 10.1096/fj.03-0251com; Langen RCJ, 2001, FASEB J, V15, P1169, DOI 10.1096/fj.00-0463; Laursen LS, 2002, J BIOL CHEM, V277, P47225, DOI 10.1074/jbc.M209155200; Laursen LS, 2001, FEBS LETT, V504, P36, DOI 10.1016/S0014-5793(01)02760-0; Lawrence JB, 1999, P NATL ACAD SCI USA, V96, P3149, DOI 10.1073/pnas.96.6.3149; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P2827, DOI 10.1210/endo-123-6-2827; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; Miyakoshi N, 2001, J CLIN INVEST, V107, P73, DOI 10.1172/JCI10459; MOHAN S, 1995, J CLIN ENDOCR METAB, V80, P2638, DOI 10.1210/jc.80.9.2638; Monget P, 2003, BIOL REPROD, V68, P77, DOI 10.1095/biolreprod.102.007609; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; ORLOWSKI CC, 1990, ENDOCRINOLOGY, V126, P644, DOI 10.1210/endo-126-1-644; Perry RLS, 2000, FRONT BIOSCI, V5, pD750, DOI 10.2741/Perry; POWELLBRAXTON L, 1993, GENE DEV, V7, P2609, DOI 10.1101/gad.7.12b.2609; Qin XZ, 1999, J BONE MINER RES, V14, P2079, DOI 10.1359/jbmr.1999.14.12.2079; Qin XZ, 2000, ARCH BIOCHEM BIOPHYS, V379, P209, DOI 10.1006/abbi.2000.1872; Qin XZ, 2002, GROWTH HORM IGF RES, V12, P359, DOI 10.1016/S1096-6374(02)00046-1; Qin XZ, 1998, J BIOL CHEM, V273, P23509, DOI 10.1074/jbc.273.36.23509; Rajaram S, 1997, ENDOCR REV, V18, P801, DOI 10.1210/er.18.6.801; ROSEN CJ, 1994, P SOC EXP BIOL MED, V206, P83; Salih DAM, 2004, P NATL ACAD SCI USA, V101, P4314, DOI 10.1073/pnas.0400230101; Sivanandam AS, 2004, BIOCHEM J, V379, P57, DOI 10.1042/BJ20030937; Sivanandam AS, 2004, ARCH BIOCHEM BIOPHYS, V423, P343, DOI 10.1016/j.abb.2004.01.005; SKAAR TC, 1994, J ANIM SCI, V72, P421, DOI 10.2527/1994.722421x; Thomas M, 2000, J BIOL CHEM, V275, P40235, DOI 10.1074/jbc.M004356200; Tomczak KK, 2003, FASEB J, V17, P403, DOI 10.1096/f.03-0568fje; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; van den Beld AW, 2003, EUR J ENDOCRINOL, V148, P627, DOI 10.1530/eje.0.1480627; Xi G, 2004, J CELL PHYSIOL, V200, P387, DOI 10.1002/jcp.20068; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3	53	37	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37782	37789		10.1074/jbc.M505278200	http://dx.doi.org/10.1074/jbc.M505278200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16115888	hybrid, Green Accepted			2022-12-27	WOS:000233044500057
J	Weigert, C; Hennige, AM; Brischmann, T; Beck, A; Moeschel, K; Schauble, M; Brodbeck, K; Haring, HU; Schleicher, ED; Lehmann, R				Weigert, C; Hennige, AM; Brischmann, T; Beck, A; Moeschel, K; Schauble, M; Brodbeck, K; Haring, HU; Schleicher, ED; Lehmann, R			The phosphorylation of Ser(318) of insulin receptor substrate 1 is not per se inhibitory in skeletal muscle cells but is necessary to trigger the attenuation of the insulin-stimulated signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GLUCOSE-TRANSPORT; PKC-ZETA; PHOSPHATIDYLINOSITOL 3-KINASE; REGULATORY ROLE; IRS-1; ACTIVATION; ALPHA; PROLIFERATION; PATHOGENESIS	The Ser/Thr phosphorylation of insulin receptor substrate 1 (IRS) is one key mechanism to stimulate and/or attenuate insulin signal transduction. Using a phospho-specific polyclonal antibody directed against phosphorylated Ser(318) of IRS-1, we found a rapid and transient insulin-stimulated phosphorylation of Ser(318) in human and rodent skeletal muscle cell models and in muscle tissue of insulin-treated mice. None of the investigated insulin resistance-associated factors ( e. g. high glucose, tumor necrosis factor-alpha, adrenaline) stimulated the phosphorylation of Ser(318). Studying the function of this phosphorylation, we found that replacing Ser(318) by alanine completely prevented both the attenuation of insulin-stimulated Akt/protein kinase B Ser(473) phosphorylation and glucose uptake after 60 min of insulin stimulation. Unexpectedly, after acute insulin stimulation, we observed that phosphorylation of Ser(318) is not inhibitory but rather enhances insulin signal transduction because introduction of Ala(318) led to a reduction of the insulin-stimulated Akt/protein kinase B phosphorylation. Furthermore, replacing Ser(318) by glutamate, i.e. mimicking phosphorylation, improved glucose uptake after acute insulin stimulation. These data suggest that phosphorylation of Ser(318) is not per se inhibitory but is necessary to trigger the attenuation of the insulin-stimulated signal in skeletal muscle cells. Investigating the molecular mechanism of insulin-stimulated Ser(318) phosphorylation, we found that phosphatidylinositol 3-kinase-mediated activation of atypical protein kinase C-zeta and recruitment of protein kinase C-zeta to IRS-1 was responsible for this phosphorylation. We conclude that Ser(318) phosphorylation of IRS-1 is an early physiological event in insulin-stimulated signal transduction, which attenuates the continuing action of insulin.	Univ Tubingen Hosp, Dept Internal Med Endocrinol Metab Pathobiochem &, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Lehmann, R (corresponding author), Univ Tubingen Hosp, Dept Internal Med Endocrinol Metab Pathobiochem &, Otfried Muller Str 10, D-72076 Tubingen, Germany.	rainer.lehmann@med.uni-tuebingen.de	Lehmann, Rainer/AAF-4281-2019	Lehmann, Rainer/0000-0003-1218-6810				Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Bandyopadhyay G, 1997, ENDOCRINOLOGY, V138, P4721, DOI 10.1210/en.138.11.4721; Beck A, 2003, J AM SOC MASS SPECTR, V14, P401, DOI 10.1016/S1044-0305(03)00122-3; Braun MU, 2003, J MOL CELL CARDIOL, V35, P895, DOI 10.1016/S0022-2828(03)00142-1; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DeFronzo RA, 2004, MED CLIN N AM, V88, P787, DOI 10.1016/j.mcna.2004.04.013; Farese RV, 2002, AM J PHYSIOL-ENDOC M, V283, pE1, DOI 10.1152/ajpendo.00045.2002; Giraud J, 2004, J BIOL CHEM, V279, P3447, DOI 10.1074/jbc.M308631200; Greene MW, 2002, BIOCHEMISTRY-US, V41, P7082, DOI 10.1021/bi015992f; Gual P, 2005, BIOCHIMIE, V87, P99, DOI 10.1016/j.biochi.2004.10.019; Hennige AM, 2003, J CLIN INVEST, V112, P1521, DOI 10.1172/JCI200318581; Horike N, 2003, J BIOL CHEM, V278, P18440, DOI 10.1074/jbc.M211770200; Huang C, 2005, J BIOL CHEM, V280, P19426, DOI 10.1074/jbc.M412317200; Jakobsen SN, 2001, J BIOL CHEM, V276, P46912, DOI 10.1074/jbc.C100483200; Kellerer M, 1998, DIABETOLOGIA, V41, P833, DOI 10.1007/s001250050995; KOIVISTO UM, 1991, J BIOL CHEM, V266, P2615; KOTLIAR N, 1992, MOL ENDOCRINOL, V6, P337, DOI 10.1210/me.6.3.337; Krutzfeldt J, 2000, DIABETES, V49, P992, DOI 10.2337/diabetes.49.6.992; LEHMANN R, 2002, SIGN TRANSDUCT, V1, P40; Liu YF, 2004, MOL CELL BIOL, V24, P9668, DOI 10.1128/MCB.24.21.9668-9681.2004; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; MACIEJEWSKI PM, 1995, J BIOL CHEM, V270, P27661, DOI 10.1074/jbc.270.46.27661; Moeschel K, 2004, J BIOL CHEM, V279, P25157, DOI 10.1074/jbc.M402477200; Olefsky JM, 1999, J BIOL CHEM, V274, P1863, DOI 10.1074/jbc.274.4.1863; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; Petersen KF, 2002, AM J CARDIOL, V90, p11G; Pirola L, 2004, DIABETOLOGIA, V47, P170, DOI 10.1007/s00125-003-1313-3; Qiao LY, 2002, J BIOL CHEM, V277, P26530, DOI 10.1074/jbc.M201494200; Ravichandran LV, 2001, J BIOL CHEM, V276, P3543, DOI 10.1074/jbc.M007231200; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Standaert ML, 2001, BIOCHEMISTRY-US, V40, P249, DOI 10.1021/bi0018234; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; WALKER PS, 1989, J BIOL CHEM, V264, P6587; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Werner ED, 2004, J BIOL CHEM, V279, P35298, DOI 10.1074/jbc.M405203200; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; Yano KJ, 1999, ENDOCRINOLOGY, V140, P4622, DOI 10.1210/en.140.10.4622; ZHANG B, 1991, J BIOL CHEM, V266, P990; Zheng WH, 2000, J BIOL CHEM, V275, P13377, DOI 10.1074/jbc.275.18.13377; Zick Y, 2004, BIOCHEM SOC T, V32, P812, DOI 10.1042/BST0320812	41	33	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37393	37399		10.1074/jbc.M506134200	http://dx.doi.org/10.1074/jbc.M506134200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16129678	hybrid			2022-12-27	WOS:000233044500013
J	den Englesman, J; Gerrits, D; de Jong, WW; Robbins, J; Kato, K; Boelens, WC				den Englesman, J; Gerrits, D; de Jong, WW; Robbins, J; Kato, K; Boelens, WC			Nuclear import of alpha B-crystallin is phosphorylation-dependent and hampered by hyperphosphorylation of the myopathy-related mutant R120G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESMIN-RELATED MYOPATHY; HEAT-SHOCK PROTEINS; MIMICKING PHOSPHORYLATION; CHAPERONE FUNCTION; COILED BODIES; MUTATION; EXPRESSION; MITOSIS; SNRNPS; CARDIOMYOPATHY	Phosphorylation modulates the functioning of alpha B-crystallin as a molecular chaperone. We here explore the role of phosphorylation in the nuclear import and cellular localization of alpha B-crystallin in HeLa cells. Inhibition of nuclear export demonstrated that phosphorylation of alpha B-crystallin is required for import into the nucleus. As revealed by mutant analysis, phosphorylation at Ser-59 is crucial for nuclear import, and phosphorylation at Ser-45 is required for speckle localization. Co-immunoprecipitation experiments suggested that the import of alpha B-crystallin is possibly regulated by its phosphorylation-dependent interaction with the survival motor neuron (SMN) protein, an important factor in small nuclear ribonucleoprotein nuclear import and assembly. This interaction was supported by co-localization of endogenous phosphorylated alpha B-crystallin with SMN in nuclear structures. The cardiomyopathy-causing alpha B-crystallin mutant R120G was found to be excessively phosphorylated, which disturbed SMN interaction and nuclear import, and resulted in the formation of cytoplasmic inclusions. Like for other protein aggregation disorders, hyperphosphorylation appears as an important aspect of the pathogenicity of alpha B-crystallin R120G.	Radboud Univ Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Biochem 161, NL-6500 HB Nijmegen, Netherlands; Childrens Hosp Med Ctr, Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA; Aichi Human Serv Ctr, Inst Dev Res, Aichi 4800392, Japan	Radboud University Nijmegen; Cincinnati Children's Hospital Medical Center	Boelens, WC (corresponding author), Radboud Univ Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Biochem 161, POB 9101, NL-6500 HB Nijmegen, Netherlands.	W.Boelens@ncmls.ru.nl	Boelens, Wilbert/D-8877-2012					Aquilina JA, 2004, J BIOL CHEM, V279, P28675, DOI 10.1074/jbc.M403348200; Arrigo A.-P., 2002, SMALL STRESS PROTEIN; Boelens WC, 2001, BBA-PROTEIN STRUCT M, V1544, P311, DOI 10.1016/S0167-4838(00)00243-0; Bova MP, 1999, P NATL ACAD SCI USA, V96, P6137, DOI 10.1073/pnas.96.11.6137; Caron A, 1999, MUSCLE NERVE, V22, P1122, DOI 10.1002/(SICI)1097-4598(199908)22:8<1122::AID-MUS17>3.0.CO;2-T; den Engelsman J, 2004, EUR J BIOCHEM, V271, P4195, DOI 10.1111/j.1432-1033.2004.04359.x; den Engelsman J, 2003, J BIOL CHEM, V278, P4699, DOI 10.1074/jbc.M211403200; Der Perng M, 1999, J BIOL CHEM, V274, P33235, DOI 10.1074/jbc.274.47.33235; Djabali K, 1999, EXP CELL RES, V253, P649, DOI 10.1006/excr.1999.4679; FERREIRA JA, 1994, J CELL BIOL, V126, P11, DOI 10.1083/jcb.126.1.11; Fujita Y, 2004, J CELL SCI, V117, P1719, DOI 10.1242/jcs.01021; Gaestel M, 2002, Prog Mol Subcell Biol, V28, P151; Gangalum RK, 2004, J BIOL CHEM, V279, P43374, DOI 10.1074/jbc.C400371200; Goebel HH, 2000, MOL GENET METAB, V71, P267, DOI 10.1006/mgme.2000.3064; Goldbaum O, 2004, J NEUROSCI, V24, P5748, DOI 10.1523/JNEUROSCI.1307-04.2004; Haslbeck Martin, 2002, Prog Mol Subcell Biol, V28, P37; INAGUMA Y, 1995, J BIOCHEM-TOKYO, V117, P1238, DOI 10.1093/oxfordjournals.jbchem.a124850; Inaguma Y, 2001, EUR J CELL BIOL, V80, P741, DOI 10.1078/0171-9335-00203; Ito H, 2003, CELL MOL LIFE SCI, V60, P1217, DOI 10.1007/s00018-003-3024-9; Ito H, 1997, J BIOL CHEM, V272, P29934, DOI 10.1074/jbc.272.47.29934; Ito H, 2002, J BIOCHEM, V131, P593, DOI 10.1093/oxfordjournals.jbchem.a003139; Ito K, 2001, J BIOL CHEM, V276, P5346, DOI 10.1074/jbc.M009004200; Kamradt MC, 2002, J BIOL CHEM, V277, P38731, DOI 10.1074/jbc.M201770200; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; Kato K, 1998, J BIOL CHEM, V273, P28346, DOI 10.1074/jbc.273.43.28346; Kato K, 2002, FASEB J, V16, P1432, DOI 10.1096/fj.02-0129fje; Kato K, 2001, J NEUROCHEM, V76, P730, DOI 10.1046/j.1471-4159.2001.00038.x; Kato Kanefusa, 2002, Prog Mol Subcell Biol, V28, P129; Kumar LVS, 1999, J BIOL CHEM, V274, P24137, DOI 10.1074/jbc.274.34.24137; Lamond AI, 2003, NAT REV MOL CELL BIO, V4, P605, DOI 10.1038/nrm1172; LESER GP, 1989, EUR J CELL BIOL, V50, P376; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; Massenet S, 2002, MOL CELL BIOL, V22, P6533, DOI 10.1128/MCB.22.18.6533-6541.2002; Meister G, 2002, TRENDS CELL BIOL, V12, P472, DOI 10.1016/S0962-8924(02)02371-1; Morrison LE, 2003, CIRC RES, V92, P203, DOI 10.1161/01.RES.0000052989.83995.A5; Narayanan U, 2004, MOL CELL, V16, P223, DOI 10.1016/j.molcel.2004.09.024; Nedellec P, 2002, NEUROMUSCULAR DISORD, V12, P457, DOI 10.1016/S0960-8966(01)00306-6; Perng MD, 2004, MOL BIOL CELL, V15, P2335, DOI 10.1091/mbc.E03-12-0893; Pruijn GJM, 1997, J AUTOIMMUN, V10, P127, DOI 10.1006/jaut.1996.0123; Quinlan Roy, 2002, Prog Mol Subcell Biol, V28, P219; RAPPAPORT L, 1988, FEBS LETT, V231, P421, DOI 10.1016/0014-5793(88)80863-9; Sanbe A, 2004, P NATL ACAD SCI USA, V101, P10132, DOI 10.1073/pnas.0401900101; Sleeman JE, 1999, CURR BIOL, V9, P1065, DOI 10.1016/S0960-9822(99)80475-8; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; Treweek TM, 2005, FEBS J, V272, P711, DOI 10.1111/j.1742-4658.2004.04507.x; van den IJssel P, 2003, EXP CELL RES, V287, P249, DOI 10.1016/S0014-4827(03)00092-2; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; van Rijk AF, 2003, EUR J CELL BIOL, V82, P361, DOI 10.1078/0171-9335-00321; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Wang XJ, 2001, CIRC RES, V89, P84, DOI 10.1161/hh1301.092688; Will CL, 2001, CURR OPIN CELL BIOL, V13, P290, DOI 10.1016/S0955-0674(00)00211-8; Yong JS, 2004, TRENDS CELL BIOL, V14, P226, DOI 10.1016/j.tcb.2004.03.010; Zobel ATC, 2003, HUM MOL GENET, V12, P1609, DOI 10.1093/hmg/ddg173	53	64	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37139	37148		10.1074/jbc.M504106200	http://dx.doi.org/10.1074/jbc.M504106200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16129694	hybrid			2022-12-27	WOS:000232901800072
J	Goto, M; Miyahara, I; Hirotsu, K; Conway, M; Islam, MM; Hutson, SM				Goto, M; Miyahara, I; Hirotsu, K; Conway, M; Islam, MM; Hutson, SM			Structural determinants for branched-chain aminotransferase isozyme-specific inhibition by the anticonvulsant drug gabapentin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID AMINOTRANSFERASE; COLI ASPARTATE-AMINOTRANSFERASE; ESCHERICHIA-COLI; HUMAN MITOCHONDRIAL; NEUROTRANSMITTER METABOLISM; 3-DIMENSIONAL STRUCTURE; SUBSTRATE RECOGNITION; GLUTAMATE SYNTHESIS; CRYSTAL-STRUCTURES; RAT-TISSUES	This study presents the first three-dimensional structures of human cytosolic branched-chain aminotransferase (hBCATc) isozyme complexed with the neuroactive drug gabapentin, the hBCATc Michaelis complex with the substrate analog, 4-methylvalerate, and the mitochondrial isozyme (hBCATm) complexed with gabapentin. The branched-chain aminotransferases (BCAT) reversibly catalyze transamination of the essential branched-chain amino acids (leucine, isoleucine, valine) to alpha-ketoglutarate to form the respective branched-chain alpha-keto acids and glutamate. The cytosolic isozyme is the predominant BCAT found in the nervous system, and only hBCATc is inhibited by gabapentin. Pre-steady state kinetics show that 1.3 mM gabapentin can completely inhibit the binding of leucine to reduced hBCATc, whereas 65.4 mM gabapentin is required to inhibit leucine binding to hBCATm. Structural analysis shows that the bulky gabapentin is enclosed in the active-site cavity by the shift of a flexible loop that enlarges the active-site cavity. The specificity of gabapentin for the cytosolic isozyme is ascribed at least in part to the location of the interdomain loop and the relative orientation between the small and large domain which is different from these relationships in the mitochondrial isozyme. Both isozymes contain a CXXC center and form a disulfide bond under oxidizing conditions. The structure of reduced hBCATc was obtained by soaking the oxidized hBCATc crystals with dithiothreitol. The close similarity in active-site structures between cytosolic enzyme complexes in the oxidized and reduced states is consistent with the small effect of oxidation on pre-steady state kinetics of the hBCATc first half-reaction. However, these kinetic data do not explain the inactivation of hBCATm by oxidation of the CXXC center. The structural data suggest that there is a larger effect of oxidation on the interdomain loop and residues surrounding the CXXC center in hBCATm than in hBCATc.	Osaka City Univ, Grad Sch Sci, Dept Chem, Osaka 5588585, Japan; Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem & Mol Biol, Winston Salem, NC 27157 USA; Penn State Univ, Dept Biochem & Mol Biol, Althouse Lab, University Pk, PA 16802 USA	Osaka Metropolitan University; Wake Forest University; Wake Forest Baptist Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Hirotsu, K (corresponding author), Osaka City Univ, Grad Sch Sci, Dept Chem, Osaka 5588585, Japan.	hirotsu@sci.osaka-cu.ac.jp			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK034738, R01DK034738] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34738] Funding Source: Medline; NINDS NIH HHS [NS3864] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDREWS J, 1990, LANCET, V335, P1114; Bergey GK, 1997, NEUROLOGY, V49, P739, DOI 10.1212/WNL.49.3.739; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHRISTEN P, 1985, TRANSAMINASES, V2, P430; Conway ME, 2000, METHOD ENZYMOL, V324, P355; Conway ME, 2004, BIOCHEMISTRY-US, V43, P7356, DOI 10.1021/bi0498050; Conway ME, 2002, BIOCHEMISTRY-US, V41, P9070, DOI 10.1021/bi020200i; Davoodi J, 1998, J BIOL CHEM, V273, P4982, DOI 10.1074/jbc.273.9.4982; DeLano WL, 2002, PYMOL USERS MANUAL; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GOLDBERG JM, 1991, BIOCHEMISTRY-US, V30, P305, DOI 10.1021/bi00215a041; GOTO M, 1977, GANN, V68, P663; Goto M, 2003, BIOCHEMISTRY-US, V42, P3725, DOI 10.1021/bi026722f; HALL TR, 1993, J BIOL CHEM, V268, P3092; Hutson S, 2001, PROG NUCLEIC ACID RE, V70, P175, DOI 10.1016/S0079-6603(01)70017-7; HUTSON SM, 1992, J BIOL CHEM, V267, P15681; HUTSON SM, 1988, J BIOL CHEM, V263, P3618; HUTSON SM, 1988, J NUTR, V118, P1475, DOI 10.1093/jn/118.12.1475; Hutson SM, 1998, J NEUROCHEM, V71, P863; ICHIHARA A, 1966, J BIOCHEM-TOKYO, V59, P160, DOI 10.1093/oxfordjournals.jbchem.a128277; ICHIHARA A, 1985, TRANSAMINASES, V2, P430; Jansonius JN, 1998, CURR OPIN STRUC BIOL, V8, P759, DOI 10.1016/S0959-440X(98)80096-1; Jhee KH, 2000, J BIOCHEM-TOKYO, V128, P679, DOI 10.1093/oxfordjournals.jbchem.a022801; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAMITORI S, 1989, J BIOCHEM-TOKYO, V105, P671, DOI 10.1093/oxfordjournals.jbchem.a122723; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P208, DOI 10.1016/S0076-6879(97)77013-7; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LaNoue KF, 2001, J NEUROSCI RES, V66, P914, DOI 10.1002/jnr.10064; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lieth E, 2001, J NEUROCHEM, V76, P1712, DOI 10.1046/j.1471-4159.2001.00156.x; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCLEAN MJ, 1997, NEUROLOGY, V43, P2292; Nakai T, 2000, J BIOCHEM, V128, P29, DOI 10.1093/oxfordjournals.jbchem.a022727; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Okada K, 2001, BIOCHEMISTRY-US, V40, P7453, DOI 10.1021/bi010384l; Okada K, 1997, J BIOCHEM-TOKYO, V121, P637; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peisach D, 1998, BIOCHEMISTRY-US, V37, P4958, DOI 10.1021/bi972884d; Rogawski MA, 2004, NAT MED, V10, P685, DOI 10.1038/nm1074; SUGIO S, 1995, BIOCHEMISTRY-US, V34, P9661, DOI 10.1021/bi00030a002; Sweatt AJ, 2004, J COMP NEUROL, V477, P360, DOI 10.1002/cne.20200; Sweatt AJ, 2004, AM J PHYSIOL-ENDOC M, V286, pE64, DOI 10.1152/ajpendo.00276.2003; TAYLOR RT, 1966, J BIOL CHEM, V241, P4396; WELTY DF, 1995, ANN PHARMACOTHER, V29, P1164, DOI 10.1177/106002809502901118; YANO T, 1992, BIOCHEMISTRY-US, V31, P5878, DOI 10.1021/bi00140a025; YANO T, 1993, J MOL BIOL, V234, P1218, DOI 10.1006/jmbi.1993.1672; Yennawar N, 2001, ACTA CRYSTALLOGR D, V57, P506, DOI 10.1107/S0907444901001925; Yennawar NH, 2002, BIOCHEMISTRY-US, V41, P11592, DOI 10.1021/bi020221c; YOSHIMURA T, 1993, J AM CHEM SOC, V115, P3897, DOI 10.1021/ja00063a007	51	60	65	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37246	37256		10.1074/jbc.M506486200	http://dx.doi.org/10.1074/jbc.M506486200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16141215	hybrid			2022-12-27	WOS:000232901800083
J	Liu, ML; Tarsio, M; Charsky, CMH; Kane, PM				Liu, ML; Tarsio, M; Charsky, CMH; Kane, PM			Structural and functional separation of the N- and C-terminal domains of the yeast V-ATPase subunit H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED CROSS-LINKING; COLI F1F0-ATP SYNTHASE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; VACUOLAR-ATPASE; 3-DIMENSIONAL STRUCTURE; TRANSLOCATING ATPASE; CRYSTAL-STRUCTURE; MANDUCA-SEXTA; BINDING-SITE	The H subunit of the yeast V-ATPase is an extended structure with two relatively independent domains, an N-terminal domain consisting of amino acids 1 - 348 and a C-terminal domain consisting of amino acids 352 - 478 (Sagermann, M., Stevens, T. H., and Matthews, B. W. ( 2001) Proc. Natl. Acad. Sci. U. S. A. 98, 7134 7139). We have expressed these two domains independently and together in a yeast strain lacking the H subunit (vma13 Delta mutant). The N-terminal domain partially complements the growth defects of the mutant and supports similar to 25% of the wild-type Mg2+-dependent ATPase activity in isolated vacuolar vesicles, but surprisingly, this activity is both largely concanamycin-insensitive and uncoupled from proton transport. The C-terminal domain does not complement the growth defects, and supports no ATP hydrolysis or proton transport, even though it is recruited to the vacuolar membrane. Expression of both domains in a vma13 Delta strain gives better complementation than either fragment alone and results in higher concanamycin-sensitive ATPase activity and ATP-driven proton pumping than the N-terminal domain alone. Thus, the two domains make complementary contributions to structural and functional coupling of the peripheral V-1 and membrane V-o sectors of the V-ATPase, but this coupling does not require that they be joined covalently. The N-terminal domain alone is sufficient for activation of ATP hydrolysis in V-1, but the C-terminal domain is essential for proper communication between the V-1 and V-o sectors.	SUNy Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Kane, PM (corresponding author), SUNy Upstate Med Univ, Dept Biochem & Mol Biol, 750 E Adams St, Syracuse, NY 13210 USA.	kanepm@upstate.edu			NIGMS NIH HHS [1R01GM50322, R01 GM050322] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050322] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arata Y, 2002, BIOCHEMISTRY-US, V41, P11301, DOI 10.1021/bi0262449; Arata Y, 2002, J BIOL CHEM, V277, P3357, DOI 10.1074/jbc.M109967200; Bowman BJ, 2002, J BIOL CHEM, V277, P3965, DOI 10.1074/jbc.M109756200; Bowman EJ, 2004, J BIOL CHEM, V279, P33131, DOI 10.1074/jbc.M404638200; Caviston TL, 1998, FEBS LETT, V429, P201, DOI 10.1016/S0014-5793(98)00597-3; Chaban YL, 2004, J BIOL CHEM, V279, P47866, DOI 10.1074/jbc.M408460200; Crider BP, 2003, J BIOL CHEM, V278, P44281, DOI 10.1074/jbc.M307372200; Curtis KK, 2002, J BIOL CHEM, V277, P8979, DOI 10.1074/jbc.M111708200; CURTIS KK, 2001, J BIOL CHEM, V20, P20; Dunn SD, 2000, BBA-BIOENERGETICS, V1458, P356, DOI 10.1016/S0005-2728(00)00086-4; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; FENG Y, 1992, J BIOL CHEM, V267, P5817; FENG Y, 1994, J BIOL CHEM, V269, P13224; Fethiere J, 2004, J BIOL CHEM, V279, P40670, DOI 10.1074/jbc.M407086200; Gruber G, 2000, BIOCHEMISTRY-US, V39, P8609, DOI 10.1021/bi000103u; HAZARD AL, 1994, J BIOL CHEM, V269, P418; HAZARD AL, 1994, J BIOL CHEM, V269, P427; Hirata T, 2003, J BIOL CHEM, V278, P23714, DOI 10.1074/jbc.M302756200; HO MN, 1993, J BIOL CHEM, V268, P18286; Huss M, 2002, J BIOL CHEM, V277, P40544, DOI 10.1074/jbc.M207345200; Imamura H, 2003, P NATL ACAD SCI USA, V100, P2312, DOI 10.1073/pnas.0436796100; Inoue T, 2005, J BIOL CHEM, V280, P27896, DOI 10.1074/jbc.M504890200; Iwata M, 2004, P NATL ACAD SCI USA, V101, P59, DOI 10.1073/pnas.0305165101; Jones RPO, 2005, BIOCHEMISTRY-US, V44, P3933, DOI 10.1021/bi048402x; Kane PM, 2003, J BIOENERG BIOMEMBR, V35, P313, DOI 10.1023/A:1025724814656; KANE PM, 1995, J BIOL CHEM, V270, P17025; Kane PM, 2000, J EXP BIOL, V203, P81; KANE PM, 1992, J BIOL CHEM, V267, P447; Landolt-Marticorena C, 2000, J BIOL CHEM, V275, P15449, DOI 10.1074/jbc.M000207200; MCCORMICK KA, 1993, J BIOL CHEM, V268, P24683; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; OHYA Y, 1994, GENETICS, V138, P1041; Parra KJ, 2000, J BIOL CHEM, V275, P21761, DOI 10.1074/jbc.M002305200; Parra KJ, 1998, MOL CELL BIOL, V18, P7064, DOI 10.1128/MCB.18.12.7064; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Sagermann M, 2001, P NATL ACAD SCI USA, V98, P7134, DOI 10.1073/pnas.131192798; Sambade M, 2004, J BIOL CHEM, V279, P17361, DOI 10.1074/jbc.M314104200; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; Shao E, 2004, J BIOL CHEM, V279, P48663, DOI 10.1074/jbc.M408278200; Sherman F., 1982, METHODS YEAST GENETI; Smardon AM, 2002, J BIOL CHEM, V277, P13831, DOI 10.1074/jbc.M200682200; Sorgen PL, 1998, J BIOL CHEM, V273, P27873, DOI 10.1074/jbc.273.43.27873; Wieczorek H, 1999, BIOESSAYS, V21, P637, DOI 10.1002/(SICI)1521-1878(199908)21:8<637::AID-BIES3>3.3.CO;2-N; Wieczorek H, 2000, J EXP BIOL, V203, P127; Wilkens S, 2004, J BIOL CHEM, V279, P41942, DOI 10.1074/jbc.M407821200; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; XIE XS, 1994, J BIOL CHEM, V269, P25809; Xu T, 2000, J BIOL CHEM, V275, P22075, DOI 10.1074/jbc.M002983200; Yokoyama K, 2003, J BIOL CHEM, V278, P42686, DOI 10.1074/jbc.M305853200	51	44	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36978	36985		10.1074/jbc.M505296200	http://dx.doi.org/10.1074/jbc.M505296200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16141210	Green Accepted, hybrid			2022-12-27	WOS:000232901800055
J	Ma, B; Lau, LH; Palcic, MM; Hazes, B; Taylor, DE				Ma, B; Lau, LH; Palcic, MM; Hazes, B; Taylor, DE			A single aromatic amino acid at the carboxyl terminus of Helicobacter pylori alpha 1,3/4 fucosyltransferase determines substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SIALYL-LEWIS-X; PHASE VARIATION; MOLECULAR-CLONING; ALPHA(1,3)-FUCOSYL-TRANSFERASE GENE; ACCEPTOR SPECIFICITY; GASTRIC EPITHELIUM; EXPRESSION; OLIGOSACCHARIDES; ENZYME	Fucosyltransferases ( FucT) from different Helicobacter pylori strains display distinct Type I (Gal beta 1,3GlcNAc) or Type II (Gal beta 1,4GlcNAc) substrate specificity. FucT from strain UA948 can transfer fucose to the OH-3 of Type II acceptors as well as to the OH-4 of Type I acceptors on the GlcNAc moiety, so it has both alpha 1,3 and alpha 1,4 activities. In contrast, FucT from strain NCTC11639 has exclusive alpha 1,3 activity. Our domain swapping study (Ma, B., Wang, G., Palcic, M. M., Hazes, B., and Taylor, D. E. ( 2003) J. Biol. Chem. 278, 21893 - 21900) demonstrated that exchange of the hypervariable loops, (DNPFIFC353)-D-347 in 11639FucT and (345)CNDAHYSALH(354) in UA948FucT, were sufficient to either confer or abolish alpha 1,4 activity. Here we performed alanine scanning site-directed mutagenesis to identify which amino acids within (345)CNDAHYSALH(354) of UA948FucT confer Type I substrate specificity. The Tyr(350) --> Ala mutation dramatically reduced alpha 1,4 activity without lowering alpha 1,3 activity. None of the other alanine substitutions selectively eliminated alpha 1,4 activity. To elucidate how Tyr(350) determines alpha 1,4 specificity, mutants Tyr(350) --> Phe, Tyr(350) --> Trp, and Tyr(350) --> Gly were constructed in UA948FucT. These mutations did not decrease alpha 1,3 activity but reduced the alpha 1,4 activity to 61.8%, 78.5%, and 4.7% of wild type level, respectively. Apparently the aromatic nature, but not the hydroxyl group of Tyr(350), is essential for alpha 1,4 activity. Our data demonstrate that a single amino acid ( Tyr350) in the C-terminal hypervariable region of UA948FucT determines Type I acceptor specificity. Notably, a single aromatic residue ( Trp) has also been implicated in controlling Type I acceptor preference for human FucT III, but it is located in an N-terminal hypervariable stem domain.	Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada	University of Alberta; University of Alberta	Taylor, DE (corresponding author), Univ Alberta, Dept Med Microbiol & Immunol, 1-63 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	diane.taylor@ualberta.ca						Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Appelmelk BJ, 2000, INFECT IMMUN, V68, P5928, DOI 10.1128/IAI.68.10.5928-5932.2000; Appelmelk BJ, 1999, INFECT IMMUN, V67, P5361, DOI 10.1128/IAI.67.10.5361-5366.1999; Azurmendi HF, 2002, BIOPOLYMERS, V63, P89, DOI 10.1002/bip.10015; BISWAS M, 1980, BIOPOLYMERS, V19, P1555, DOI 10.1002/bip.1980.360190811; BOURNE Y, 1992, J BIOL CHEM, V267, P197; Bush CA, 1999, ANNU REV BIOPH BIOM, V28, P269, DOI 10.1146/annurev.biophys.28.1.269; CHAN NWC, 1995, GLYCOBIOLOGY, V5, P683, DOI 10.1093/glycob/5.7.683; Costache M, 1997, J BIOL CHEM, V272, P29721, DOI 10.1074/jbc.272.47.29721; DEVRIES T, 1995, J BIOL CHEM, V270, P8712, DOI 10.1074/jbc.270.15.8712; DeVries T, 1997, GLYCOBIOLOGY, V7, P921, DOI 10.1093/glycob/7.7.921; Dupuy F, 1999, J BIOL CHEM, V274, P12257, DOI 10.1074/jbc.274.18.12257; Dupuy F, 2004, GLYCOBIOLOGY, V14, P347, DOI 10.1093/glycob/cwh053; Dwek RA, 1996, CHEM REV, V96, P683, DOI 10.1021/cr940283b; Edwards NJ, 2000, MOL MICROBIOL, V35, P1530, DOI 10.1046/j.1365-2958.2000.01823.x; Endo T, 2000, CURR OPIN STRUC BIOL, V10, P536, DOI 10.1016/S0959-440X(00)00127-5; Ge ZM, 1997, J BIOL CHEM, V272, P21357, DOI 10.1074/jbc.272.34.21357; Gosselin S, 1996, BIOORGAN MED CHEM, V4, P2023, DOI 10.1016/S0968-0896(97)81455-1; Guo ZM, 1997, APPL BIOCHEM BIOTECH, V68, P1, DOI 10.1007/BF02785977; HOMANS SW, 1993, GLYCOBIOLOGY, V3, P551, DOI 10.1093/glycob/3.6.551; Johnson KF, 1999, GLYCOCONJUGATE J, V16, P141, DOI 10.1023/A:1026440509859; KHARE DP, 1985, CARBOHYD RES, V136, P285, DOI 10.1016/0008-6215(85)85204-6; Krylov SN, 2000, ANAL BIOCHEM, V283, P133, DOI 10.1006/abio.2000.4648; LEGAULT DJ, 1995, J BIOL CHEM, V270, P20987, DOI 10.1074/jbc.270.36.20987; LEMIEUX RU, 1980, CAN J CHEM, V58, P631, DOI 10.1139/v80-098; Lozniewski A, 2003, INFECT IMMUN, V71, P2902, DOI 10.1128/IAI.71.5.2902-2906.2003; Ma B, 2003, J BIOL CHEM, V278, P21893, DOI 10.1074/jbc.M301704200; Mahdavi J, 2003, INFECT IMMUN, V71, P2876, DOI 10.1128/IAI.71.5.2876-2880.2003; Martin SL, 1997, J BIOL CHEM, V272, P21349, DOI 10.1074/jbc.272.34.21349; Monteiro MA, 2000, EUR J BIOCHEM, V267, P305, DOI 10.1046/j.1432-1327.2000.01007.x; Monteiro MA, 1998, J BIOL CHEM, V273, P11533, DOI 10.1074/jbc.273.19.11533; Moran AP, 1996, FEMS IMMUNOL MED MIC, V16, P105, DOI 10.1111/j.1574-695X.1996.tb00127.x; Moran AP, 2002, J BIOL CHEM, V277, P5785, DOI 10.1074/jbc.M108574200; Nguyen AT, 1998, J BIOL CHEM, V273, P25244, DOI 10.1074/jbc.273.39.25244; Oriol R, 1999, GLYCOBIOLOGY, V9, P323, DOI 10.1093/glycob/9.4.323; Oulmouden A, 1997, J BIOL CHEM, V272, P8764, DOI 10.1074/jbc.272.13.8764; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; Qasba PK, 2005, TRENDS BIOCHEM SCI, V30, P53, DOI 10.1016/j.tibs.2004.11.005; Qiao L, 1996, J AM CHEM SOC, V118, P7653, DOI 10.1021/ja960274f; RABBANI S, 2005, IN PRESS GLYCOBIOLOG; Rasko DA, 2000, EUR J BIOCHEM, V267, P6059, DOI 10.1046/j.1432-1327.2000.01683.x; Rasko DA, 2000, J BIOL CHEM, V275, P4988, DOI 10.1074/jbc.275.7.4988; RASKO DA, 2000, THESIS U ALBERTA EDM, P220; Suresh MR, 2000, J PHARM PHARM SCI, V3, P259; Takata T, 2002, INFECT IMMUN, V70, P3073, DOI 10.1128/IAI.70.6.3073-3079.2002; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Wang G, 1999, MICROBIOL-SGM, V145, P3245, DOI 10.1099/00221287-145-11-3245; Wang G, 1999, MOL MICROBIOL, V31, P1265, DOI 10.1046/j.1365-2958.1999.01268.x; Wang G, 2000, MOL MICROBIOL, V36, P1187, DOI 10.1046/j.1365-2958.2000.01934.x; Watt GM, 1997, CURR OPIN STRUC BIOL, V7, P652, DOI 10.1016/S0959-440X(97)80074-7; WESTON BW, 1992, J BIOL CHEM, V267, P24575; Wirth HP, 1996, INFECT IMMUN, V64, P4598, DOI 10.1128/IAI.64.11.4598-4605.1996; ZHANG YN, 1995, ANAL BIOCHEM, V227, P368, DOI 10.1006/abio.1995.1293	53	13	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36848	36856		10.1074/jbc.M504415200	http://dx.doi.org/10.1074/jbc.M504415200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16150700	hybrid			2022-12-27	WOS:000232901800040
J	Martinez-Arca, S; Bech-Serra, JJ; Hurtado-Kuttner, M; Borroto, A; Arribas, J				Martinez-Arca, S; Bech-Serra, JJ; Hurtado-Kuttner, M; Borroto, A; Arribas, J			Recycling of cell surface pro-transforming growth factor-alpha regulates epidermal growth factor receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; TGF-ALPHA; PROTEIN; MEMBRANE; PRECURSOR; TRANSPORT; PATHWAY	Impairments in signal transduction, leading to the regulation of cell proliferation, differentiation, or migration are frequently the cause of cancer. Since the accurate spatial and temporal location of their components is crucial to ensure the correct regulation of these signaling pathways, it could be anticipated that defects in intracellular trafficking are at the base of certain neoplasias. However, the trafficking of many components of pathways frequently up-regulated in cancers, such as the epidermal growth factor receptor ( EGFR) pathway, are largely unknown. Here, we show that the protransforming growth factor-alpha (pro-TGF-alpha), a prototypical EGFR ligand, is endocytosed from the cell surface via a clathrin-dependent pathway. Internalized pro-TGF-alpha does not progress to the lysosome; instead, it is delivered to the cell surface via recycling endosomes. To analyze the functional meaning of the internalization of pro-TGF-alpha, we used a deletion construct that is normally transported to the cell surface but is deficiently endocytosed. Due to this impairment, the levels of this construct at the cell surface are dramatically augmented. Consequently, the deletion construct displays a higher EGFR-activating ability, revealing a link between the trafficking of pro-TGF-alpha and the signaling by the EGFR and opening the possibility that defects in the trafficking of the growth factor may contribute to the development of tumors.	Vall dHebron Res Inst Univ Hosp, Med Oncol Res Program, Barcelona 08035, Spain		Arribas, J (corresponding author), Vall dHebron Res Inst Univ Hosp, Med Oncol Res Program, 119-129 Psg Vall dHebron, Barcelona 08035, Spain.	jarribas@vhebron.net	Bech-Serra, Joan Josep/AAA-2330-2020; Arribas, Joaquin/M-4482-2014	Bech-Serra, Joan Josep/0000-0003-3486-781X; Arribas, Joaquin/0000-0002-0504-0664				Aridor M, 2002, TRAFFIC, V3, P537, DOI 10.1034/j.1600-0854.2002.30804.x; Arribas J, 2002, CHEM REV, V102, P4627, DOI 10.1021/cr010202t; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Bache KG, 2004, EMBO J, V23, P2707, DOI 10.1038/sj.emboj.7600292; Benmerah A, 1999, J CELL SCI, V112, P1303; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Borrell-Pages M, 2003, EMBO J, V22, P1114, DOI 10.1093/emboj/cdg111; Briley GP, 1997, MOL BIOL CELL, V8, P1619, DOI 10.1091/mbc.8.8.1619; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; Dempsey PJ, 2003, EXP CELL RES, V285, P159, DOI 10.1016/S0014-4827(03)00035-1; DEMPSEY PJ, 1994, J BIOL CHEM, V269, P16878; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; Floyd S, 1998, TRENDS CELL BIOL, V8, P299, DOI 10.1016/S0962-8924(98)01316-6; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; Huang FT, 2004, J BIOL CHEM, V279, P16657, DOI 10.1074/jbc.C400046200; Kuo A, 2000, EMBO J, V19, P6427, DOI 10.1093/emboj/19.23.6427; Lee JR, 2001, CELL, V107, P161, DOI 10.1016/S0092-8674(01)00526-8; Li CX, 2004, P NATL ACAD SCI USA, V101, P5571, DOI 10.1073/pnas.0401294101; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Martinez-Arca S, 2003, J CELL SCI, V116, P2805, DOI 10.1242/jcs.00467; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; Mitchell H, 2004, MOL BIOL CELL, V15, P4166, DOI 10.1091/mbc.E04-03-0245; Normanno N, 2001, FRONT BIOSCI-LANDMRK, V6, pD685, DOI 10.2741/Normano; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Shorter J, 1999, EMBO J, V18, P4949, DOI 10.1093/emboj/18.18.4949; SHUM L, 1994, J CELL BIOL, V125, P903, DOI 10.1083/jcb.125.4.903; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; Szymkiewicz I, 2004, BIOCHEM J, V383, P1, DOI 10.1042/BJ20040913; Urena JM, 1999, J CELL SCI, V112, P773; Yarden Y, 2001, EUR J CANCER, V37, pS3; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	33	9	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36970	36977		10.1074/jbc.M504425200	http://dx.doi.org/10.1074/jbc.M504425200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16129682	hybrid			2022-12-27	WOS:000232901800054
J	Schertzer, JW; Bhavsar, AP; Brown, ED				Schertzer, JW; Bhavsar, AP; Brown, ED			Two conserved histidine residues are critical to the function of the TagF-like family of enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCEROL 3-PHOSPHATE CYTIDYLYLTRANSFERASE; WALL TEICHOIC-ACID; SIMILAR-TO-P; BACILLUS-SUBTILIS; CTPGLYCEROL-3-PHOSPHATE CYTIDYLYLTRANSFERASE; GLYCEROL-3-PHOSPHATE CYTIDYLYLTRANSFERASE; STRUCTURAL-CHANGES; CDP-GLYCEROL; BACILLUS-SUBTILIS-168; EXPRESSION	The TagF protein from Bacillus subtilis 168 is the poly( glycerol phosphate) polymerase responsible for the synthesis of wall teichoic acid and is the prototype member of a poorly understood family of similar teichoic acid synthetic enzymes. Here we describe in vitro and in vivo characterization of TagF, which localizes the active site to the carboxyl terminus of the protein and identifies residues that are critical for catalysis. We also establish the first mechanistic link among TagF and similar proteins by demonstrating that the identified residues are also critical in the function of TagB, a homologous enzyme implicated as the glycerophosphotransferase responsible for priming poly( glycerol phosphate) synthesis (Bhavsar, A. P., Truant, R., and Brown, E. D. (Sept. 2, 2005) J. Biol. Chem. 36691 - 36700). We investigated the dependence of TagF activity on pH and showed that deprotonation of a residue with a pK(a) near neutral is critical for proper function. Alteration of histidine residues 474 and 612 by site-directed mutagenesis abolished TagF activity in vitro ( 5000-fold reduction in k(cat)/K-m) while variants in four other conserved acidic residues showed minimal loss of activity. Complementation using H474A and H612A mutant alleles failed to suppress a lethal temperature-sensitive tagF defect in vivo despite confirmation of robust expression by Western blot. When corresponding mutations were made to the homologous tagB gene, these alleles were unable to suppress a tagB temperature-sensitive lethal phenotype. These results extend the mechanistic observations for TagF across a wider family of enzymes and provide the first biochemical evidence for the relatedness of these two enzymes.	McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Antimicrobial Res Ctr, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University	Brown, ED (corresponding author), McMaster Univ, Dept Biochem & Biomed Sci, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	ebrown@mcmaster.ca	Schertzer, Jonathan/P-3395-2017	Schertzer, Jonathan/0000-0002-1547-5856; Bhavsar, Amit/0000-0003-3336-9288				Badurina DS, 2003, BBA-PROTEINS PROTEOM, V1646, P196, DOI 10.1016/S1570-9639(03)00019-0; Bhavsar AP, 2005, J BIOL CHEM, V280, P36691, DOI 10.1074/jbc.M507154200; Bhavsar AP, 2004, J BACTERIOL, V186, P7865, DOI 10.1128/JB.186.23.7865-7873.2004; Bhavsar AP, 2001, J BACTERIOL, V183, P6688, DOI 10.1128/JB.183.22.6688-6693.2001; Bhavsar AP, 2001, APPL ENVIRON MICROB, V67, P403, DOI 10.1128/AEM.67.1.403-410.2001; Breyer WA, 2001, PROTEIN SCI, V10, P1699, DOI 10.1110/ps.10301; BRIEHL M, 1989, J GEN MICROBIOL, V135, P1325; BRUCKNER R, 1992, GENE, V122, P187, DOI 10.1016/0378-1119(92)90048-T; BURGER MM, 1964, J BIOL CHEM, V239, P3168; CUTTING SM, 1990, MOL BIOL METHODS BAC, P175; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Glusker J.P., 1999, RIGAKU J, V16, P8, DOI DOI 10.1201/9781482289893; HONEYMAN AL, 1989, MOL MICROBIOL, V3, P1257, DOI 10.1111/j.1365-2958.1989.tb00276.x; JONES MD, 1986, BIOCHEMISTRY-US, V25, P1887, DOI 10.1021/bi00356a008; KARAMATA D, 1970, MOL GEN GENET, V108, P277, DOI 10.1007/BF00283358; KARAMATA D, 1972, J BACTERIOL, V11, P73, DOI 10.1128/JB.111.1.73-79.1972; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lazarevic V, 2002, MICROBIOL-SGM, V148, P815, DOI 10.1099/00221287-148-3-815; LAZAREVIC V, 1995, MICROBIOL-SGM, V141, P329, DOI 10.1099/13500872-141-2-329; LAZAREVIC V, 1995, MOL MICROBIOL, V16, P345, DOI 10.1111/j.1365-2958.1995.tb02306.x; Liu W, 1998, J BACTERIOL, V180, P753, DOI 10.1128/JB.180.3.753-758.1998; MAUCK J, 1972, P NATL ACAD SCI USA, V69, P2386, DOI 10.1073/pnas.69.9.2386; MAUEL C, 1991, J GEN MICROBIOL, V137, P929, DOI 10.1099/00221287-137-4-929; MAUEL C, 1989, MOL GEN GENET, V215, P388, DOI 10.1007/BF00427034; MAUEL C, 1994, MICROBIOL-UK, V140, P2279, DOI 10.1099/13500872-140-9-2279; Park YS, 1997, J BIOL CHEM, V272, P15161, DOI 10.1074/jbc.272.24.15161; PARK YS, 1993, J BIOL CHEM, V268, P16648; Pattridge KA, 2003, J BIOL CHEM, V278, P51863, DOI 10.1074/jbc.M306174200; Paulsen IT, 1997, MICROBIOL-SGM, V143, P2685, DOI 10.1099/00221287-143-8-2685; POOLEY HM, 1992, J BACTERIOL, V174, P646, DOI 10.1128/jb.174.2.646-649.1992; Qi Y, 1998, J BACTERIOL, V180, P4007, DOI 10.1128/JB.180.15.4007-4010.1998; ROGERS HJ, 1970, J GEN MICROBIOL, V61, P155, DOI 10.1099/00221287-61-2-155; ROUVINEN J, 1990, SCIENCE, V249, P380, DOI 10.1126/science.2377893; Sambrook J., 1989, MOL CLONING, pA1; Sanker S, 2001, J BIOL CHEM, V276, P37922; Schertzer JW, 2003, J BIOL CHEM, V278, P18002, DOI 10.1074/jbc.M300706200; Soldo B, 2002, MICROBIOL-SGM, V148, P2079, DOI 10.1099/00221287-148-7-2079; Tipton K F, 1979, Methods Enzymol, V63, P183; Varrot A, 1999, BIOCHEMISTRY-US, V38, P8884, DOI 10.1021/bi9903998; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Weber CH, 1999, STRUCTURE, V7, P1113, DOI 10.1016/S0969-2126(99)80178-6; Williams JG, 1998, J BIOL CHEM, V273, P13482, DOI 10.1074/jbc.273.22.13482	42	18	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36683	36690		10.1074/jbc.M507153200	http://dx.doi.org/10.1074/jbc.M507153200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16141206	hybrid			2022-12-27	WOS:000232901800020
J	Berger, F; Lau, C; Dahlmann, M; Ziegler, M				Berger, F; Lau, C; Dahlmann, M; Ziegler, M			Subcellular compartmentation and differential catalytic properties of the three human nicotinamide mononucleotide adenylyltransferase isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMN ADENYLYLTRANSFERASE; POLY(ADP-RIBOSE) POLYMERASE; NAD BIOSYNTHESIS; NUCLEAR ENZYME; LIFE-SPAN; IDENTIFICATION; EXPRESSION; PROTEIN; CLONING; PURIFICATION	Nicotinamide mononucleotide adenylyltransferase (NMNAT) is the central enzyme of the NAD biosynthetic pathway. Three human NMNAT isoforms have recently been identified, but isoform-specific functions are presently unknown, although a tissue-specific role has been suggested. Analyses of the subcellular localization confirmed NMNAT1 to be a nuclear protein, whereas NMNAT2 and -3 were localized to the Golgi complex and the mitochondria, respectively. This differential subcellular localization points to an organelle-specific, nonredundant function of each of the three proteins. Comparison of the kinetic properties showed that particularly NMNAT3 exhibits a high tolerance toward substrate modifications. Moreover, as opposed to preferred NAD(+) synthesis by NMNAT1, the other two isoforms could also form NADH directly from the reduced nicotinamide mononucleotide, supporting a hitherto unknown pathway of NAD generation. A variety of physiological intermediates was tested and exerted only minor influence on the catalytic activities of the NMNATs. However, gallotannin was found to be a potent inhibitor, thereby compromising its use as a specific inhibitor of poly-ADP-ribose glycohydrolase. The presence of substrate-specific and independent nuclear, mitochondrial, and Golgi-specific NAD biosynthetic pathways is opposed to the assumption of a general cellular NAD pool. Their existence appears to be consistent with important compartment-specific functions rather than to reflect simple functional redundance.	Univ Bergen, Inst Mol Biol, N-5020 Bergen, Norway; Free Univ Berlin, Inst Biochem, D-14195 Berlin, Germany	University of Bergen; Free University of Berlin	Ziegler, M (corresponding author), Univ Bergen, Inst Mol Biol, Thormohlensgt 55, N-5020 Bergen, Norway.	Mathias.Ziegler@mbi.uib.no		Dahlmann, Mathias/0000-0002-0036-5283; Lau, Corinna/0000-0003-1750-8065; Ziegler, Mathias/0000-0001-6961-2396				Abdelraheim SR, 2003, BIOCHEM J, V374, P329, DOI 10.1042/BJ20030441; Anderson RM, 2002, J BIOL CHEM, V277, P18881, DOI 10.1074/jbc.M111773200; AOKI K, 1993, BIOCHIM BIOPHYS ACTA, V1158, P251, DOI 10.1016/0304-4165(93)90022-Z; Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Bakondi E, 2004, EXP DERMATOL, V13, P170, DOI 10.1111/j.0906-6705.2004.0150.x; Barile M, 1996, BIOCHEM MOL BIOL INT, V38, P297; Bedalov A, 2004, SCIENCE, V305, P954, DOI 10.1126/science.1102497; Berger F, 2004, TRENDS BIOCHEM SCI, V29, P111, DOI 10.1016/j.tibs.2004.01.007; Bieganowski P, 2004, CELL, V117, P495, DOI 10.1016/S0092-8674(04)00416-7; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Chi NW, 2000, J BIOL CHEM, V275, P38437, DOI 10.1074/jbc.M007635200; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; Conforti L, 2000, P NATL ACAD SCI USA, V97, P11377, DOI 10.1073/pnas.97.21.11377; Corda D, 2003, EMBO J, V22, P1953, DOI 10.1093/emboj/cdg209; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Di Lisa F, 2001, FEBS LETT, V492, P4, DOI 10.1016/S0014-5793(01)02198-6; Emanuelli M, 2001, J BIOL CHEM, V276, P406, DOI 10.1074/jbc.M008700200; Emanuelli M, 1999, FEBS LETT, V455, P13, DOI 10.1016/S0014-5793(99)00852-2; EMANUELLI M, 1992, ARCH BIOCHEM BIOPHYS, V298, P29, DOI 10.1016/0003-9861(92)90089-F; Fernando FS, 2002, GENE, V284, P23, DOI 10.1016/S0378-1119(02)00394-3; Galione A, 2000, Sci STKE, V2000, ppe1; Garavaglia S, 2002, J BIOL CHEM, V277, P8524, DOI 10.1074/jbc.M111589200; Guse AH, 2004, CURR MED CHEM, V11, P847, DOI 10.2174/0929867043455602; HOGEBOOM GH, 1952, NATURE, V170, P374, DOI 10.1038/170374a0; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Keil C, 2004, ARCH BIOCHEM BIOPHYS, V425, P115, DOI 10.1016/j.abb.2004.02.024; Lee HC, 2004, CURR MOL MED, V4, P227, DOI 10.2174/1566524043360753; Lerner F, 2001, BIOCHEM BIOPH RES CO, V288, P69, DOI 10.1006/bbrc.2001.5735; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Magni G, 1997, METHOD ENZYMOL, V280, P241; Magni G, 1999, ADV ENZYMOL RAMB, V73, P135, DOI 10.1002/9780470123195.ch5; Oei SL, 2000, J BIOL CHEM, V275, P23234, DOI 10.1074/jbc.M002429200; Outten CE, 2003, EMBO J, V22, P2015, DOI 10.1093/emboj/cdg211; PREISS J, 1957, J BIOL CHEM, V225, P759; Raffaelli N, 2002, BIOCHEM BIOPH RES CO, V297, P835, DOI 10.1016/S0006-291X(02)02285-4; Raffaelli N, 1999, MOL CELL BIOCHEM, V193, P99, DOI 10.1023/A:1006968328186; Raffaelli N, 1999, J BACTERIOL, V181, P5509, DOI 10.1128/JB.181.17.5509-5511.1999; Raffaelli N, 2001, METHOD ENZYMOL, V331, P292; Raffaelli N, 2001, METHOD ENZYMOL, V331, P281; Schweiger M, 2001, FEBS LETT, V492, P95, DOI 10.1016/S0014-5793(01)02180-9; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; TSAI YJ, 1992, J BIOL CHEM, V267, P14436; Turner WL, 2004, PLANT PHYSIOL, V135, P1243, DOI 10.1104/pp.104.040428; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Werner E, 2002, FEBS LETT, V516, P239, DOI 10.1016/S0014-5793(02)02556-5; Yalowitz JA, 2004, BIOCHEM J, V377, P317, DOI 10.1042/BJ20030518; Ying WH, 2001, P NATL ACAD SCI USA, V98, P12227, DOI 10.1073/pnas.211202598; Ying WH, 2000, NEUROREPORT, V11, P1385, DOI 10.1097/00001756-200005150-00007; Zhang XJ, 2003, J BIOL CHEM, V278, P13503, DOI 10.1074/jbc.M300073200; Zhou TJ, 2002, J BIOL CHEM, V277, P13148, DOI 10.1074/jbc.M111469200	51	355	367	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36334	36341		10.1074/jbc.M508660200	http://dx.doi.org/10.1074/jbc.M508660200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16118205	hybrid			2022-12-27	WOS:000232726900067
J	Grimm, SL; Contreras, A; Barcellos-Hoff, MH; Rosen, JM				Grimm, SL; Contreras, A; Barcellos-Hoff, MH; Rosen, JM			Cell cycle defects contribute to a block in hormone-induced mammary gland proliferation in CCAAT/enhancer-binding protein (C/EBP beta)-null mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; ESTROGEN-RECEPTOR-ALPHA; HUMAN BREAST-CANCER; C/EBP-BETA; PROGESTERONE-RECEPTOR; EPITHELIAL-CELLS; TRANSFORMING GROWTH-FACTOR-BETA-1; TGF-BETA-1 EXPRESSION; DUCTAL MORPHOGENESIS; PARTIAL-HEPATECTOMY	In contrast to hormone-dependent breast cancer, steroid hormone-induced proliferation in the normal mammary gland does not occur in the steroid-receptor positive cells but rather in adjacent cells via paracrine signaling involving several local growth factors. To help elucidate the mechanisms involved in the block in proliferation in hormone-receptor positive cells, we have utilized a CCAAT/enhancer binding protein (C/EBP beta)-null mouse model. Loss of this transcription factor results in increased steroid and prolactin receptor expression concomitant with a 10-fold decrease in proliferation in response to pregnancy hormones. To determine the basis for this decrease, several markers of cell cycle progression were analyzed in wild type and C/EBP beta-null mammary epithelial cells (MECs). These studies indicated that cell cycle progression in C/EBP beta-null MECs is blocked at the G(1)/S transition. C/EBP beta-null mammary glands display substantially increased levels of the activated form of transforming growth factor beta, a potent inhibitor of epithelial cell proliferation, as well as increased downstream Smad2 expression and signaling. While cyclin D1 levels were equivalent, cyclin E expression was markedly reduced in C/EBP beta-null as compared with wildtype MECs. In addition, increased p27 stability and retention in the nucleus and decreased levels of the cdc25a phosphatase contributed to a significant loss of cdk2 kinase activity. Collectively, these changes prevent C/EBP beta-null mammary epithelial cells from responding to hormone-induced proliferative signals.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94710 USA	Baylor College of Medicine; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Rosen, JM (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	jrosen@bcm.tmc.edu			NATIONAL CANCER INSTITUTE [R01CA016303, R37CA016303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM056929] Funding Source: NIH RePORTER; NCI NIH HHS [CA16303] Funding Source: Medline; NIGMS NIH HHS [R25 GM056929] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akli S, 2004, CANCER RES, V64, P3198, DOI 10.1158/0008-5472.CAN-03-3672; Barcellos-Hoff MH, 2000, BREAST CANCER RES, V2, P92, DOI 10.1186/bcr40; Berger C, 2005, CELL CYCLE, V4, P422, DOI 10.4161/cc.4.3.1524; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Boulanger CA, 2005, ONCOGENE, V24, P552, DOI 10.1038/sj.onc.1208185; Cangi MG, 2000, J CLIN INVEST, V106, P753, DOI 10.1172/JCI9174; Clarke RB, 2005, DEV BIOL, V277, P443, DOI 10.1016/j.ydbio.2004.07.044; Clarke RB, 1997, CANCER RES, V57, P4987; Clarysse W, 2000, STUD HELLENIST, V36, P29; Contreras A, 2003, MOL CELL BIOL, V23, P8626, DOI 10.1128/MCB.23.23.8626-8636.2003; DANIEL CW, 1995, DEV BIOL, V169, P511, DOI 10.1006/dbio.1995.1165; Donzelli M, 2003, EMBO REP, V4, P671, DOI 10.1038/sj.embor.embor887; Ewan KB, 2002, AM J PATHOL, V160, P2081, DOI 10.1016/S0002-9440(10)61158-3; Ewan KBR, 2005, AM J PATHOL, V167, P409, DOI 10.1016/S0002-9440(10)62985-9; GERDES J, 1984, J IMMUNOL, V133, P1710; Greenbaum LE, 1998, J CLIN INVEST, V102, P996, DOI 10.1172/JCI3135; Grimm SL, 2003, J MAMMARY GLAND BIOL, V8, P191, DOI 10.1023/A:1025900908026; Grimm SL, 2002, MOL ENDOCRINOL, V16, P2675, DOI 10.1210/me.2002-0239; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; KEYOMARSI K, 1994, CANCER RES, V54, P380; KORDON EC, 1995, DEV BIOL, V168, P47, DOI 10.1006/dbio.1995.1060; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Liu F, 2003, FRONT BIOSCI-LANDMRK, V8, pS1280, DOI 10.2741/1149; Loffler H, 2003, ONCOGENE, V22, P8063, DOI 10.1038/sj.onc.1206976; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Matsumoto Y, 2004, SCIENCE, V306, P885, DOI 10.1126/science.1103544; Medina D, 2002, FASEB J, V16, P881, DOI 10.1096/fj.01-0885fje; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Miyoshi K, 2002, MOL ENDOCRINOL, V16, P2892, DOI 10.1210/me.2002-0128; Mo XM, 2004, MOL CELL, V13, P241, DOI 10.1016/S1097-2765(03)00521-5; Mulac-Jericevic B, 2003, P NATL ACAD SCI USA, V100, P9744, DOI 10.1073/pnas.1732707100; Nakano K, 2001, BIOCHEM BIOPH RES CO, V280, P640, DOI 10.1006/bbrc.2000.4185; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; Polesello C, 2004, TRENDS CELL BIOL, V14, P294, DOI 10.1016/j.tcb.2004.04.003; Pullan Shirley E., 1996, P97; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; Ray D, 2005, MOL CELL BIOL, V25, P3338, DOI 10.1128/MCB.25.8.3338-3347.2005; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; Russo J, 1999, BREAST CANCER RES TR, V53, P217, DOI 10.1023/A:1006186719322; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; Seagroves TN, 2000, MOL ENDOCRINOL, V14, P359, DOI 10.1210/me.14.3.359; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Shoker BS, 1999, AM J PATHOL, V155, P1811, DOI 10.1016/S0002-9440(10)65498-3; Shuman JD, 2004, MOL CELL BIOL, V24, P7380, DOI 10.1128/MCB.24.17.7380-7391.2004; Sicinski P, 1997, J MAMMARY GLAND BIOL, V2, P335, DOI 10.1023/A:1026391128117; Sutherland RL, 2004, J MAMMARY GLAND BIOL, V9, P95, DOI 10.1023/B:JOMG.0000023591.45568.77; Talasz H, 1996, BIOCHEMISTRY-US, V35, P1761, DOI 10.1021/bi951914e; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Wagner KU, 2002, DEVELOPMENT, V129, P1377; Zahnow CA, 2001, CANCER RES, V61, P261; Zhu SY, 2002, P NATL ACAD SCI USA, V99, P207, DOI 10.1073/pnas.012437299	53	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36301	36309		10.1074/jbc.M508167200	http://dx.doi.org/10.1074/jbc.M508167200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16120603	hybrid			2022-12-27	WOS:000232726900063
J	Lazarus, BD; Roos, MD; Hanover, JA				Lazarus, BD; Roos, MD; Hanover, JA			Mutational analysis of the catalytic domain of O-linked N-acetylglucosaminyl transferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; GIBBERELLIN SIGNAL-TRANSDUCTION; GLCNAC TRANSFERASE; INSULIN-RESISTANCE; TETRATRICOPEPTIDE REPEATS; NUCLEAR-PORE; CRYSTAL-STRUCTURE; BETA-GLUCOSYLTRANSFERASE; SUBSTRATE-SPECIFICITY; CYTOSOLIC PROTEINS	O-Linked N-acetylglucosaminyltransferase (OGT) catalyzes the transfer of O-linked GlcNAc to serine/threonine residues of a variety of target proteins, many of which have been implicated in such diseases as diabetes and neurodegeneration. The addition of O-GlcNAc to proteins occurs in response to fluctuations in cellular concentrations of UDP-GlcNAc, which result from nutrients entering the hexosamine biosynthetic pathway. However, the molecular mechanisms involved in sugar nucleotide recognition and transfer to protein are poorly understood. We employed site-directed mutagenesis to target potentially important amino acid residues within the two conserved catalytic domains of OGT(CDI and CDII), followed by an in vitro glycosylation assay to evaluate N-acetylglucosaminyltransferase activity after bacterial expression. Although many of the amino acid substitutions caused inactivation of the enzyme, we identified three amino acid residues ( two in CD I and one in CD II) that produced viable enzymes when mutated. Structure-based homology modeling revealed that these permissive mutants may be either in or near the sugar nucleotide-binding site. Our findings suggest a model in which the two conserved regions of the catalytic domain, CDI and CDII, contribute to the formation of a UDP-GlcNAc-binding pocket that catalyzes the transfer of O-GlcNAc to substrate proteins. Identification of viable OGT mutants may facilitate examination of its role in nutrient sensing and signal transduction cascades.	NIDDK, Lab Cell Biol & Biochem, NIH, Bethesda, MD 20897 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Hanover, JA (corresponding author), NIDDK, Lab Cell Biol & Biochem, NIH, Bldg 8,Rm 402,9000 Rockville Pike, Bethesda, MD 20897 USA.	jah@helix.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK060000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnold CS, 1996, J BIOL CHEM, V271, P28741, DOI 10.1074/jbc.271.46.28741; Beattie BK, 1996, BIOCHEMISTRY-US, V35, P15134, DOI 10.1021/bi961985t; Breton C, 1999, CURR OPIN STRUC BIOL, V9, P563, DOI 10.1016/S0959-440X(99)00006-8; Buse MG, 2002, AM J PHYSIOL-ENDOC M, V283, pE241, DOI 10.1152/ajpendo.00060.2002; Campbell RE, 2000, BIOCHEMISTRY-US, V39, P14993, DOI 10.1021/bi001627x; Cervoni L, 1997, FEBS LETT, V417, P227, DOI 10.1016/S0014-5793(97)01285-4; CHOU TY, 1995, P NATL ACAD SCI USA, V92, P4417, DOI 10.1073/pnas.92.10.4417; Cid E, 2000, J BIOL CHEM, V275, P33614, DOI 10.1074/jbc.M005358200; Cole RN, 1999, J NEUROCHEM, V73, P418, DOI 10.1046/j.1471-4159.1999.0730418.x; Comer FI, 2001, BIOCHEMISTRY-US, V40, P7845, DOI 10.1021/bi0027480; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; DAVIS LI, 1987, P NATL ACAD SCI USA, V84, P7552, DOI 10.1073/pnas.84.21.7552; Ding M, 1996, J BIOL CHEM, V271, P12555, DOI 10.1074/jbc.271.21.12555; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; Hagen FK, 1999, J BIOL CHEM, V274, P6797, DOI 10.1074/jbc.274.10.6797; Haltiwanger RS, 1997, BIOCHEM BIOPH RES CO, V231, P237, DOI 10.1006/bbrc.1997.6110; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; HANOVER JA, 1987, J BIOL CHEM, V262, P9887; Hanover JA, 2003, ARCH BIOCHEM BIOPHYS, V409, P287, DOI 10.1016/S0003-9861(02)00578-7; Hanover JA, 2001, FASEB J, V15, P1865, DOI 10.1096/fj.01-0094rev; Hawkins M, 1997, J CLIN INVEST, V99, P2173, DOI 10.1172/JCI119390; Hawkins M, 1996, DIABETES, V45, P1734, DOI 10.2337/diabetes.45.12.1734; Hazel M, 2004, ENDOCRINOLOGY, V145, P2118, DOI 10.1210/en.2003-0812; Hedden P, 2000, TRENDS PLANT SCI, V5, P523, DOI 10.1016/S1360-1385(00)01790-8; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; Hu YN, 2003, P NATL ACAD SCI USA, V100, P845, DOI 10.1073/pnas.0235749100; Iyer SPN, 2003, J BIOL CHEM, V278, P24608, DOI 10.1074/jbc.M300036200; Iyer SPN, 2003, J BIOL CHEM, V278, P5399, DOI 10.1074/jbc.M209384200; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; Jacobsen SE, 1996, P NATL ACAD SCI USA, V93, P9292, DOI 10.1073/pnas.93.17.9292; JACOBSEN SE, 1993, PLANT CELL, V5, P887, DOI 10.1105/tpc.5.8.887; Jinek M, 2004, NAT STRUCT MOL BIOL, V11, P1001, DOI 10.1038/nsmb833; Kamemura K, 2002, J BIOL CHEM, V277, P19229, DOI 10.1074/jbc.M201729200; KELLY WG, 1993, J BIOL CHEM, V268, P10416; Kreppel LK, 1999, J BIOL CHEM, V274, P32015, DOI 10.1074/jbc.274.45.32015; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; Liu FH, 1999, J BIOL CHEM, V274, P34425, DOI 10.1074/jbc.274.48.34425; Lubas WA, 2000, J BIOL CHEM, V275, P10983, DOI 10.1074/jbc.275.15.10983; LUBAS WA, 1995, BIOCHEMISTRY-US, V34, P1686, DOI 10.1021/bi00005a025; Lubas WA, 1997, J BIOL CHEM, V272, P9316; LUTHI T, 1991, J NEUROCHEM, V56, P1493; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; McClain DA, 2002, P NATL ACAD SCI USA, V99, P10695, DOI 10.1073/pnas.152346899; Medina L, 1998, GLYCOBIOLOGY, V8, P383, DOI 10.1093/glycob/8.4.383; Miller MW, 1999, ARCH BIOCHEM BIOPHYS, V367, P51, DOI 10.1006/abbi.1999.1237; Morera S, 1999, J MOL BIOL, V292, P717, DOI 10.1006/jmbi.1999.3094; Persson K, 2001, NAT STRUCT BIOL, V8, P166, DOI 10.1038/84168; Robertson M, 1998, PLANT CELL, V10, P995, DOI 10.1105/tpc.10.6.995; ROBINSON KA, 1995, DIABETES, V44, P1438, DOI 10.2337/diabetes.44.12.1438; Roos MD, 2000, BIOCHEM BIOPH RES CO, V271, P275, DOI 10.1006/bbrc.2000.2600; ROSSETTI L, 1995, J CLIN INVEST, V96, P132, DOI 10.1172/JCI118013; Shafi R, 2000, P NATL ACAD SCI USA, V97, P5735, DOI 10.1073/pnas.100471497; Shaw P, 1996, ONCOGENE, V12, P921; Takahashi M, 1999, ACTA NEUROPATHOL, V97, P635, DOI 10.1007/s004010051040; Tenno M, 2002, J BIOL CHEM, V277, P47088, DOI 10.1074/jbc.M207369200; VRIELINK A, 1994, EMBO J, V13, P3413, DOI 10.1002/j.1460-2075.1994.tb06646.x; Wells L, 2003, CELL MOL LIFE SCI, V60, P222, DOI 10.1007/s000180300017; Wells L, 2003, FEBS LETT, V546, P154, DOI 10.1016/S0014-5793(03)00641-0; Wrabl JO, 2001, J MOL BIOL, V314, P365, DOI 10.1006/jmbi.2001.5151; Yang XY, 2001, P NATL ACAD SCI USA, V98, P6611, DOI 10.1073/pnas.111099998; Zhang FX, 2003, CELL, V115, P715, DOI 10.1016/S0092-8674(03)00974-7; Zhang YN, 1999, GLYCOBIOLOGY, V9, P815, DOI 10.1093/glycob/9.8.815	62	27	31	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35537	35544		10.1074/jbc.M504948200	http://dx.doi.org/10.1074/jbc.M504948200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16105839	hybrid			2022-12-27	WOS:000232561200055
J	Robinson, MA; Park, S; Sun, ZYJ; Silver, PA; Wagner, G; Hogle, JM				Robinson, MA; Park, S; Sun, ZYJ; Silver, PA; Wagner, G; Hogle, JM			Multiple conformations in the ligand-binding site of the yeast nuclear pore-targeting domain of Nup116p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROMOLECULAR STRUCTURE; NUCLEOPORIN NUP145P; BIOGENESIS PATHWAY; PROTEIN STRUCTURES; COMPLEX; NUP98; NMR; DYNAMICS; PROGRAM; ARCHITECTURE	The yeast nucleoporin Nup116p plays an important role in mRNA export and protein transport. We have determined the solution structure of the C- terminal 147 residues of this protein, the region responsible for targeting the protein to the nuclear pore complex ( NPC). The structure of Nup116p- C consists of a large beta- sheet sandwiched against a smaller one, flanked on both sides by alpha- helical stretches, similar to the structure of its human homolog, NUP98. In unliganded form, Nup116p- C exhibits evidence of exchange among multiple conformations, raising the intriguing possibility that it may adopt distinct conformations when bound to different partners in the NPC. We have additionally shown that a peptide from the N terminus of the nucleoporin Nup145p- C binds Nup116p- C. This previously unknown interaction may explain the unusual asymmetric localization pattern of Nup116p in the NPC. Strikingly, the exchange phenomenon observed in the unbound state is greatly reduced in the corresponding spectra of peptide-bound Nup116p- C, suggesting that the binding interaction stabilizes the domain conformation. This study offers a high resolution view of a yeast nucleoporin structural domain and may provide insights into NPC architecture and function.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Comm Higher Degrees Biophys, Cambridge, MA 02138 USA; Inha Univ, Coll Med, Dept Biochem, Inchon 400712, South Korea	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Inha University	Wagner, G (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.	gerhard_wagner@hms.harvard.edu; james_hogle@hms.harvard.edu	Hogle, James/HIG-9121-2022	Hogle, James/0000-0002-3655-1504	NATIONAL CANCER INSTITUTE [R01CA068262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036373, R01GM036373, P01GM047467] Funding Source: NIH RePORTER; NCI NIH HHS [CA68262] Funding Source: Medline; NIGMS NIH HHS [GM36373, GM47467] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen TD, 2000, J CELL SCI, V113, P1651; Bailer SM, 2000, J BIOL CHEM, V275, P23540, DOI 10.1074/jbc.M001963200; Bailer SM, 1998, EMBO J, V17, P1107, DOI 10.1093/emboj/17.4.1107; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cavanagh J., 1995, PROTEIN NMR SPECTROS; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Emtage JLT, 1997, J CELL SCI, V110, P911; Fabre E, 1997, ANNU REV GENET, V31, P277, DOI 10.1146/annurev.genet.31.1.277; Ferentz AE, 2000, Q REV BIOPHYS, V33, P29, DOI 10.1017/S0033583500003589; Fontoura BMA, 1999, J CELL BIOL, V144, P1097, DOI 10.1083/jcb.144.6.1097; Fontoura BMA, 2001, P NATL ACAD SCI USA, V98, P3208, DOI 10.1073/pnas.061014698; Goh CS, 2004, CURR OPIN STRUC BIOL, V14, P104, DOI 10.1016/j.sbi.2004.01.005; Griffis ER, 2003, MOL BIOL CELL, V14, P600, DOI 10.1091/mbc.E02-09-0582; Griffis ER, 2002, MOL BIOL CELL, V13, P1282, DOI 10.1091/mbc.01-11-0538; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Ho AK, 2000, MOL CELL BIOL, V20, P5736, DOI 10.1128/MCB.20.15.5736-5748.2000; Hodel AE, 2002, MOL CELL, V10, P347, DOI 10.1016/S1097-2765(02)00589-0; HURWITZ ME, 1995, J CELL BIOL, V130, P1275, DOI 10.1083/jcb.130.6.1275; Hyberts SG, 2003, J BIOMOL NMR, V26, P335, DOI 10.1023/A:1024078926886; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; James LC, 2003, SCIENCE, V299, P1362, DOI 10.1126/science.1079731; James LC, 2003, TRENDS BIOCHEM SCI, V28, P361, DOI 10.1016/S0968-0004(03)00135-X; Johnson Bruce A, 2004, Methods Mol Biol, V278, P313; Kiseleva E, 2000, CRIT REV EUKAR GENE, V10, P101; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Ma BY, 2002, PROTEIN SCI, V11, P184, DOI 10.1110/ps.21302; NILGES M, 1993, PROTEINS, V17, P297, DOI 10.1002/prot.340170307; Rosenblum JS, 1999, P NATL ACAD SCI USA, V96, P11370, DOI 10.1073/pnas.96.20.11370; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Stoffler D, 1999, CURR OPIN CELL BIOL, V11, P391, DOI 10.1016/S0955-0674(99)80055-6; Strawn LA, 2001, J BIOL CHEM, V276, P6445, DOI 10.1074/jbc.M008311200; Teixeira MT, 1999, J BIOL CHEM, V274, P32439, DOI 10.1074/jbc.274.45.32439; Teixeira MT, 1997, EMBO J, V16, P5086, DOI 10.1093/emboj/16.16.5086; Tsai CJ, 1999, PROTEIN SCI, V8, P1181, DOI 10.1110/ps.8.6.1181; WENTE SR, 1993, J CELL BIOL, V123, P275, DOI 10.1083/jcb.123.2.275; WENTE SR, 1992, J CELL BIOL, V119, P705, DOI 10.1083/jcb.119.4.705	40	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35723	35732		10.1074/jbc.M505068200	http://dx.doi.org/10.1074/jbc.M505068200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16105837	hybrid			2022-12-27	WOS:000232561200075
J	Ryer, EJ; Sakakibara, K; Wang, C; Sarkar, D; Fisher, PB; Faries, PL; Kent, KC; Liu, B				Ryer, EJ; Sakakibara, K; Wang, C; Sarkar, D; Fisher, PB; Faries, PL; Kent, KC; Liu, B			Protein kinase C delta induces apoptosis of vascular smooth muscle cells through induction of the tumor suppressor p53 by both p38-dependent and p38-independent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53 GENE-TRANSFER; DNA-DAMAGE; KAPPA-B; MAP KINASES; PKC-DELTA; PROLIFERATION; ACTIVATION; EXPRESSION; ATHEROSCLEROSIS; VEIN	Apoptotic death of vascular smooth muscle cells ( SMCs) is a prominent feature of blood vessel remodeling. In the present study, we examined the novel PKC isoform protein kinase C delta ( PKC delta) and its role in vascular SMC apoptosis. In A10 SMCs, overexpression of PKC delta was sufficient to induce apoptosis, whereas inhibition of PKC delta diminished H2O2- induced apoptosis. Moreover, evidence is provided that the tumor suppressor p53 is an essential mediator of PKC delta- induced apoptosis in SMCs. Activation of PKC delta led to accumulation as well as phosphorylation of p53 in SMCs; this induction correlated with apoptosis. Furthermore, blocking p53 induction with small interference RNA or targeted gene deletion prevented PKC delta- induced apoptosis, whereas restoring p53 expression rescued the ability of PKC delta to induce apoptosis in p53 null SMCs. We also establish that PKC delta regulates p53 at both transcriptional and post- translational levels. Specifically, the transcriptional regulation required p38 MAPK, whereas the post- translational modification, at least for serine 46, did not involve MAPK. Additionally, PKC delta, p38 MAPK, and p53 co- associate in cells under conditions favoring apoptosis. Together, our data suggest that SMC apoptosis proceeds through a pathway that involves PKC delta, the intermediary p38 MAPK, and the downstream target tumor suppressor p53.	New York Presbyterian Hosp, Dept Surg, Div Vasc Surg, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, New York, NY 10021 USA; Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Neurosurg, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Urol, New York, NY 10032 USA	NewYork-Presbyterian Hospital; Cornell University; Columbia University; Columbia University; Columbia University	Liu, B (corresponding author), New York Presbyterian Hosp, Dept Surg, Div Vasc Surg, 525 E 68th St,Payson 707, New York, NY 10021 USA.	bol2001@med.cornell.edu			NATIONAL CANCER INSTITUTE [T32CA068971] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068673] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA68971-07] Funding Source: Medline; NHLBI NIH HHS [HL-68673] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbas T, 2004, J BIOL CHEM, V279, P9970, DOI 10.1074/jbc.M306979200; Basu A, 2001, CELL DEATH DIFFER, V8, P899, DOI 10.1038/sj.cdd.4400885; Bauriedel G, 1998, ARTERIOSCL THROM VAS, V18, P1132, DOI 10.1161/01.ATV.18.7.1132; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; BODHATONPIALLAT M, 1995, AM J PATHOL, V146, P1059; CLOWES MM, 1994, J CLIN INVEST, V93, P644, DOI 10.1172/JCI117016; Cross T, 2000, ONCOGENE, V19, P2331, DOI 10.1038/sj.onc.1203555; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Durland-Busbice S, 2002, LEUKEMIA, V16, P2165, DOI 10.1038/sj.leu.2402647; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Franklin RA, 2000, LEUKEMIA, V14, P2019, DOI 10.1038/sj.leu.2401967; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; GENG YJ, 1995, AM J PATHOL, V147, P251; George SJ, 2001, GENE THER, V8, P668, DOI 10.1038/sj.gt.3301431; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; HAN DKM, 1995, AM J PATHOL, V147, P267; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hollenbeck ST, 2004, BIOCHEM BIOPH RES CO, V325, P328, DOI 10.1016/j.bbrc.2004.10.031; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; ISNER JM, 1995, CIRCULATION, V91, P2703, DOI 10.1161/01.CIR.91.11.2703; Itoh H, 2001, AM J PHYSIOL-HEART C, V281, pH359, DOI 10.1152/ajpheart.2001.281.1.H359; Johnson CL, 2002, MOL CANCER THER, V1, P861; Jorgensen K, 2005, BIOCHEM BIOPH RES CO, V329, P266, DOI 10.1016/j.bbrc.2005.01.143; Kerr J. F., 1991, APOPTOSIS MOL BASIS, V3, P5; Kim SJ, 2002, J BIOL CHEM, V277, P33501, DOI 10.1074/jbc.M202862200; Kockx MM, 1998, ARTERIOSCL THROM VAS, V18, P1519, DOI 10.1161/01.ATV.18.10.1519; Kokontis JM, 2001, ONCOGENE, V20, P659, DOI 10.1038/sj.onc.1204139; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kubota K, 2003, J SURG RES, V109, P43, DOI 10.1016/S0022-4804(02)00037-9; Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177; Lee YJ, 2002, CELL GROWTH DIFFER, V13, P237; Leirdal M, 1999, BRIT J CANCER, V80, P1558, DOI 10.1038/sj.bjc.6690560; Leitges M, 2001, J CLIN INVEST, V108, P1505; Li LW, 1999, MOL CELL BIOL, V19, P8547; Li PF, 1999, CIRCULATION, V100, P967, DOI 10.1161/01.CIR.100.9.967; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Mayr U, 2002, CIRC RES, V90, P197, DOI 10.1161/hh0202.103715; Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a; Newby AC, 1996, CURR OPIN CARDIOL, V11, P574, DOI 10.1097/00001573-199611000-00004; Niwa K, 2002, FREE RADICAL RES, V36, P1147, DOI 10.1080/1071576021000016409; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Reisman D, 1996, GENOMICS, V38, P364, DOI 10.1006/geno.1996.0639; Ren J, 2002, J BIOL CHEM, V277, P33758, DOI 10.1074/jbc.M110667200; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sakakibara K, 2005, J BIOL CHEM, V280, P25470, DOI 10.1074/jbc.M502320200; Sarkar D, 2002, P NATL ACAD SCI USA, V99, P10054, DOI 10.1073/pnas.152327199; Satoh A, 2004, AM J PHYSIOL-GASTR L, V287, pG582, DOI 10.1152/ajpgi.00087.2004; Sauane M, 2003, J CELL PHYSIOL, V196, P334, DOI 10.1002/jcp.10309; Scheinman M, 1999, J VASC SURG, V29, P360, DOI 10.1016/S0741-5214(99)70389-7; Scheinman M, 1999, SURGERY, V126, P863, DOI 10.1016/S0039-6060(99)70027-9; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Wada T, 2001, AM J KIDNEY DIS, V38, P1169, DOI 10.1053/ajkd.2001.29206; Wang QD, 2003, J BIOL CHEM, V278, P51091, DOI 10.1074/jbc.M306541200; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; WYLLIE AH, 1992, CANCER METAST REV, V11, P95, DOI 10.1007/BF00048057; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu QB, 2000, TRENDS CARDIOVAS MED, V10, P35, DOI 10.1016/S1050-1738(00)00042-6; Yonemitsu Y, 1998, CIRC RES, V82, P147; Zhao TC, 2003, AM J PHYSIOL-HEART C, V285, pH434, DOI 10.1152/ajpheart.00095.2003	64	50	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35310	35317		10.1074/jbc.M507187200	http://dx.doi.org/10.1074/jbc.M507187200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16118209	hybrid			2022-12-27	WOS:000232561200029
J	Pan, YX; Chen, H; Kilberg, MS				Pan, YX; Chen, H; Kilberg, MS			Interaction of RNA-binding proteins HuR and AUF1 with the human ATF3 mRNA 3 '-untranslated region regulates its amino acid limitation-induced stabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING TRANSCRIPTION FACTOR-3; ASPARAGINE SYNTHETASE GENE; RICH ELEMENT; NUTRITIONAL REGULATION; GENOMIC ORGANIZATION; MAMMALIAN-CELLS; STRESS-RESPONSE; HEPATOMA-CELLS; KINASE; EXPRESSION	ATF3 expression is induced in cells exposed to a variety of stress conditions, including nutrient limitation. Here we demonstrated that the mechanism by which the ATF3 mRNA content is increased following amino acid limitation of human HepG2 hepatoma cells is mRNA stabilization. Analysis of ATF3 mRNA turnover revealed that the half-life was increased from about 1 h in control cells to greater than 8 h in the histidine-deprived state, demonstrating mRNA stabilization in response to nutrient deprivation. Treatment of HepG2 cells with thapsigargin, which causes endoplasmic reticulum stress, also increased the half-life of ATF3 mRNA. HuR is an RNA-binding protein that regulates both the stability and cytoplasmic/ nuclear localization of mRNA species containing AU-rich elements. Another RNA-binding protein, AUF1, regulates target mRNA molecules by enhancing their decay. Amino acid limitation caused a slightly elevated mRNA level for HuR and AUF1 mRNA. The nuclear HuR protein content was unchanged, and AUF1 protein increased slightly after amino acid limitation, whereas the cytoplasmic levels of both HuR and AUF1 protein increased. Immunoprecipitation of HuR-RNA complexes followed by reverse transcriptase-PCR analysis showed that HuR interacted with ATF3 mRNA in vivo and that this interaction increased following amino acid limitation. In contrast, the interaction of AUF1 with the ATF3 mRNA is decreased in histidine-deprived cells relative to control cells. Suppression of HuR expression by RNA interference partially blocked the accumulation of ATF3 mRNA following amino acid deprivation. The results demonstrated that coordinated regulation of mRNA stability by HuR and AUF1 proteins contributes to the observed increase in ATF3 expression following amino acid limitation.	Univ Florida, Coll Med, Dept Biochem & Mol Biol, Genet Inst, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Shands Canc Ctr, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Kilberg, MS (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, Genet Inst, Box 100245, Gainesville, FL 32610 USA.	mkilberg@ufl.edu	Pan, Yuan-Xiang/C-6576-2019	Pan, Yuan-Xiang/0000-0003-3219-4367	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052064, R01DK059315] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-59315, DK-52064, R01 DK059315, R01 DK052064] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aslanian AM, 2001, BIOCHEM J, V357, P321, DOI 10.1042/0264-6021:3570321; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Bruhat A, 1997, J BIOL CHEM, V272, P17588, DOI 10.1074/jbc.272.28.17588; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; Chen H, 2004, J BIOL CHEM, V279, P50829, DOI 10.1074/jbc.M409173200; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; Giles KM, 2003, J BIOL CHEM, V278, P2937, DOI 10.1074/jbc.M208439200; Hai T, 1999, GENE EXPRESSION, V7, P321; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hartman MG, 2004, MOL CELL BIOL, V24, P5721, DOI 10.1128/MCB.24.13.5721-5732.2004; Hashimoto Y, 2002, NUCLEIC ACIDS RES, V30, P2398, DOI 10.1093/nar/30.11.2398; HOFFER LJ, 1993, CAN J PHYSIOL PHARM, V71, P633, DOI 10.1139/y93-092; Jiang HY, 2004, MOL CELL BIOL, V24, P1365, DOI 10.1128/MCB.24.3.1365-1377.2004; Jing Q, 2005, CELL, V120, P623, DOI 10.1016/j.cell.2004.12.038; Kilberg Michael S., 2003, P105, DOI 10.1079/9780851996790.0105; Lal A, 2004, EMBO J, V23, P3092, DOI 10.1038/sj.emboj.7600305; Leung-Pineda V, 2004, BIOCHEM J, V379, P79, DOI 10.1042/BJ20031383; Liang GN, 2004, P NATL ACAD SCI USA, V101, P7357, DOI 10.1073/pnas.0401866101; Liang GS, 1996, J BIOL CHEM, V271, P1695, DOI 10.1074/jbc.271.3.1695; Lu JY, 2004, J BIOL CHEM, V279, P12974, DOI 10.1074/jbc.M310433200; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; Ming XF, 2001, MOL CELL BIOL, V21, P5778, DOI 10.1128/MCB.21.17.5778-5789.2001; Mizock BA, 1999, NUTRITION, V15, P220, DOI 10.1016/S0899-9007(98)00191-9; Pan YX, 2003, J BIOL CHEM, V278, P38402, DOI 10.1074/jbc.M304574200; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Raineri I, 2004, NUCLEIC ACIDS RES, V32, P1279, DOI 10.1093/nar/gkh282; Sarkar B, 2003, MOL CELL BIOL, V23, P6685, DOI 10.1128/MCB.23.18.6685-6693.2003; Siu F, 2002, J BIOL CHEM, V277, P24120, DOI 10.1074/jbc.M201959200; Straus DS, 2002, CLIN CHEM LAB MED, V40, P1274, DOI 10.1515/CCLM.2002.221; STRAUS DS, 1994, FASEB J, V8, P6, DOI 10.1096/fasebj.8.1.8299891; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; Wang J, 2003, J BIOL CHEM, V278, P32899, DOI 10.1074/jbc.M305456200; Winzen R, 2004, MOL CELL BIOL, V24, P4835, DOI 10.1128/MCB.24.11.4835-4847.2004; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Yaman I, 2003, CELL, V113, P519, DOI 10.1016/S0092-8674(03)00345-3; Yaman I, 2002, J BIOL CHEM, V277, P41539, DOI 10.1074/jbc.M204850200; Zhan K, 2002, MOL CELL BIOL, V22, P7134, DOI 10.1128/MCB.22.20.7134-7146.2002; Zhang F, 2001, J BIOL CHEM, V276, P24946, DOI 10.1074/jbc.M102108200; Zhang PC, 2002, MOL CELL BIOL, V22, P6681, DOI 10.1128/MCB.22.19.6681-6688.2002	45	59	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34609	34616		10.1074/jbc.M507802200	http://dx.doi.org/10.1074/jbc.M507802200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16109718	Green Accepted, hybrid			2022-12-27	WOS:000232403900029
J	Schmidt, A; Echtermeyer, F; Alozie, A; Brands, K; Buddecke, E				Schmidt, A; Echtermeyer, F; Alozie, A; Brands, K; Buddecke, E			Plasmin- and thrombin-accelerated shedding of syndecan-4 ectodomain generates cleavage sites at Lys(114)-Arg(115) and Lys(129)-Val(130) bonds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; FIBROBLAST-GROWTH-FACTOR; CELL-SURFACE; CORE PROTEIN; BINDING; GLYCOSAMINOGLYCANS; SELECTIN; ADHESION; DOMAINS	Syndecans are transmembranous heparan sulfate proteoglycans abundant in the surface of all adherent mammalian cells and involved in vital cellular functions. In this study, we found syndecan-1, - 2, - 3, and - 4 to be constitutively expressed by human umbilical vein endothelial cells. The exposure of the ectodomains of syndecan-1 and - 4 to the cell surface and their constitutive shedding into the extracellular compartment was measured by immunoassays. In the presence of plasmin and thrombin, shedding was accelerated and monitored by detection and identification of S-35-labeled proteoglycans. To elucidate the cleavage site of the syndecan ectodomains, we used a cell-free in vitro system with enzyme and substrate as the only reactants. For this purpose, we constructed recombinant fusion proteins of the syndecan-1 and - 4 ectodomain together with maltose-binding protein and enhanced yellow fluorescent protein as reporter proteins attached to the N and C termini via oligopeptide linkers. After protease treatment of the fusion proteins, the electrophoretically resolved split products were sequenced and cleavage sites of the ectodomain were identified. Plasmin generated cleavage sites at Lys(114) down arrow Arg(115\) and Lys(129) down arrow Val(130) in the ectodomain of syndecan-4. In thrombin proteolysates of the syndecan-4 ectodomain, the cleavage site Lys(114) down arrow Arg(115) was also identified. The cleavage sites for plasmin and thrombin within the syndecan-4 ectodomain were not present in the syndecan-1 ectodomain. Cleavage of the syndecan-1 fusion protein by thrombin occurred only at a control cleavage site ( Arg down arrow Gly) introduced into the linker region connecting the ectodomain with the enhanced yellow fluorescent protein. Because both plasmin and thrombin are involved in thrombogenic and thrombolytic processes in the course of the pathogenesis of arteriosclerosis, the detachment of heparan sulfate-bearing ectodomains could be relevant for the development of arteriosclerotic plaques and recruitment of mononuclear blood cells to the plaque.	Univ Munster, Leibniz Inst Arteriosclerosis Res 1, D-48149 Munster, Germany; Univ Munster, Inst Physiol Chem & Pathobiochem, D-48149 Munster, Germany	University of Munster; University of Munster	Schmidt, A (corresponding author), Univ Munster, Inst Arteriosclerosis Res, Dept Mol Cardiol, Domagkstr 3, D-48149 Munster, Germany.	annschm@uni-muenster.de		Locher, Kerstin/0000-0002-0175-3747				AVIEZER D, 1994, J BIOL CHEM, V269, P114; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Carey DJ, 1997, BIOCHEM J, V327, P1; CizmeciSmith G, 1997, ARTERIOSCL THROM VAS, V17, P172, DOI 10.1161/01.ATV.17.1.172; Echtermeyer F, 1999, J CELL SCI, V112, P3433; Echtermeyer F, 2001, J CLIN INVEST, V107, pR9, DOI 10.1172/JCI10559; Endo K, 2003, J BIOL CHEM, V278, P40764, DOI 10.1074/jbc.M306736200; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; Giuffre L, 1997, J CELL BIOL, V136, P945, DOI 10.1083/jcb.136.4.945; Gotte M, 2003, FASEB J, V17, P575, DOI 10.1096/fj.02-0739rev; Gotte Martin, 2003, ScientificWorldJournal, V3, P1327; Halden Y, 2004, BIOCHEM J, V377, P533, DOI 10.1042/BJ20030729; Horowitz A, 1998, J BIOL CHEM, V273, P10914, DOI 10.1074/jbc.273.18.10914; Horowitz A, 2002, J CELL BIOL, V157, P715, DOI 10.1083/jcb.200112145; Houston M, 2005, AM J PHYSIOL-CELL PH, V288, pC458, DOI 10.1152/ajpcell.00001.2004; Ishiguro K, 2001, J BIOL CHEM, V276, P47483, DOI 10.1074/jbc.M106268200; JAAKKOLA P, 2000, PROTEOGLYCANS STRUCT, P115; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JALKANEN M, 1987, J CELL BIOL, V105, P3087, DOI 10.1083/jcb.105.6.3087; Kainulainen V, 1998, J BIOL CHEM, V273, P11563, DOI 10.1074/jbc.273.19.11563; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; Koenig A, 1998, J CLIN INVEST, V101, P877, DOI 10.1172/JCI1509; Levi E, 1996, P NATL ACAD SCI USA, V93, P7069, DOI 10.1073/pnas.93.14.7069; Li QL, 2002, CELL, V111, P635, DOI 10.1016/S0092-8674(02)01079-6; Mead JR, 1999, FEBS LETT, V462, P1, DOI 10.1016/S0014-5793(99)01495-7; MERTENS G, 1992, J BIOL CHEM, V267, P20435; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; Park PW, 2004, J BIOL CHEM, V279, P251, DOI 10.1074/jbc.M308537200; Park PW, 2000, J BIOL CHEM, V275, P3057, DOI 10.1074/jbc.275.5.3057; Rapraeger AC, 2000, J CELL BIOL, V149, P995, DOI 10.1083/jcb.149.5.995; Rioux V, 2002, J LIPID RES, V43, P167; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SCHMIDT A, 1992, J BIOL CHEM, V267, P19242; Schmidt A, 2002, ATHEROSCLEROSIS, V164, P57, DOI 10.1016/S0021-9150(02)00053-9; SCHMIDT A, 1992, EUR J CELL BIOL, V59, P322; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; Tumova S, 2000, INT J BIOCHEM CELL B, V32, P269, DOI 10.1016/S1357-2725(99)00116-8; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; Zimmermann P, 1999, FASEB J, V13, pS91	41	50	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34441	34446		10.1074/jbc.M501903200	http://dx.doi.org/10.1074/jbc.M501903200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16087677	hybrid			2022-12-27	WOS:000232403900010
J	Vicente, JB; Teixeira, M				Vicente, JB; Teixeira, M			Redox and spectroscopic properties of the Escherichia coli nitric oxide-detoxifying system involving flavorubredoxin and its NADH-oxidizing redox partner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOOXYGENASE HYDROXYLASE COMPONENT; METHYLOCOCCUS-CAPSULATUS BATH; MOLECULAR-WEIGHT RUBREDOXIN; OXIDATIVE STRESS PROTECTION; METHANE MONOOXYGENASE; ELECTRON-TRANSFER; DESULFOVIBRIO-VULGARIS; NAD(P)H-RUBREDOXIN OXIDOREDUCTASE; PSEUDOMONAS-OLEOVORANS; MOORELLA-THERMOACETICA	Under anaerobic conditions, the flavodiiron NO-reductase from Escherichia coli ( flavorubredoxin, FlRd) constitutes one of the major protective enzymes against nitric oxide. The redox and spectroscopic properties of the rubredoxin (Rd), non-heme diiron, and FMN sites of flavorubredoxin were determined, which was complemented by the study of truncated versions of FlRd: one consisting only of its rubredoxin module, and another consisting of its flavodiiron structural core ( lacking the Rd domain). The studies here reported were performed by a combination of potentiometry with visible and EPR spectroscopies. Moreover, we present the first direct EPR evidence for the presence of the non-heme diiron site in the flavodiiron proteins family. Also, the redox properties of the FlRd physiological partner, the NADH: flavorubredoxin oxidoreductase (FlRd-Red), were determined. It is further shown that the redox properties of this complex electron transfer system are fine-tuned upon interaction of the two enzymes.	Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2781901 Oeiras, Portugal	Universidade Nova de Lisboa	Teixeira, M (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Av Republ,Apt 127, P-2781901 Oeiras, Portugal.	miguel@itqb.unl.pt	Vicente, João B/B-9623-2014; Vicente, Joao B/L-8732-2016; Teixeira, Miguel/M-1509-2019; Teixeira, Miguel/A-9098-2011	Vicente, João B/0000-0003-3919-8280; Teixeira, Miguel/0000-0003-4124-6237; Teixeira, Miguel/0000-0003-4124-6237; Vicente, Joao/0000-0001-5244-8059				Alric J, 2004, J BIOL CHEM, V279, P47849, DOI 10.1074/jbc.M408888200; ATTA M, 1994, J AM CHEM SOC, V116, P6429, DOI 10.1021/ja00093a051; Berthold DA, 2002, J BIOL CHEM, V277, P43608, DOI 10.1074/jbc.M206724200; Carlton JM, 2002, NATURE, V419, P512, DOI 10.1038/nature01099; Coulter ED, 2001, ARCH BIOCHEM BIOPHYS, V394, P76, DOI 10.1006/abbi.2001.2531; da Costa PN, 2001, MOL MICROBIOL, V41, P217, DOI 10.1046/j.1365-2958.2001.02509.x; Das A, 2001, J BACTERIOL, V183, P1560, DOI 10.1128/JB.183.5.1560-1567.2001; deMare F, 1996, NAT STRUCT BIOL, V3, P539, DOI 10.1038/nsb0696-539; EGGINK G, 1990, J MOL BIOL, V212, P135, DOI 10.1016/0022-2836(90)90310-I; Eidsness MK, 1999, BIOCHEMISTRY-US, V38, P14803, DOI 10.1021/bi991661f; FISCHER DS, 1964, CLIN CHEM, V10, P21, DOI 10.1016/0009-8981(64)90210-4; FOX BG, 1988, J BIOL CHEM, V263, P10553; FOX BG, 1988, BIOCHEM BIOPH RES CO, V154, P165, DOI 10.1016/0006-291X(88)90665-1; Frazao C, 2000, NAT STRUCT BIOL, V7, P1041; Frey AD, 2002, APPL ENVIRON MICROB, V68, P4835, DOI 10.1128/AEM.68.10.4835-4840.2002; Gardner AM, 2002, J BIOL CHEM, V277, P8172, DOI 10.1074/jbc.M110471200; GHISLA S, 2001, ENCY LIFE SCI; Gomes CM, 1997, J BIOL CHEM, V272, P22502, DOI 10.1074/jbc.272.36.22502; Gomes CM, 2002, J BIOL CHEM, V277, P25273, DOI 10.1074/jbc.M203886200; Gomes CM, 2000, BIOCHEMISTRY-US, V39, P16230, DOI 10.1021/bi001844y; HENDRICH MP, 1990, J AM CHEM SOC, V112, P5861, DOI 10.1021/ja00171a029; Justino MC, 2005, J BIOL CHEM, V280, P2636, DOI 10.1074/jbc.M411070200; Kummerle R, 1997, BIOCHEMISTRY-US, V36, P15983, DOI 10.1021/bi971636e; Kurtz DM, 1997, J BIOL INORG CHEM, V2, P159, DOI 10.1007/s007750050120; Lee HJ, 1998, BIOCHEMISTRY-US, V37, P15513, DOI 10.1021/bi981853v; Lee NR, 1996, BIOCHEM BIOPH RES CO, V218, P17, DOI 10.1006/bbrc.1996.0004; LIU KE, 1991, J BIOL CHEM, V266, P12836; Lumppio HL, 2001, J BACTERIOL, V183, P101, DOI 10.1128/JB.183.1.101-108.2001; Ma K, 2001, METHOD ENZYMOL, V334, P55; Ma K, 1999, J BACTERIOL, V181, P5530, DOI 10.1128/JB.181.17.5530-5533.1999; Meyer J., 2001, HDB METALLOPROTEINS, V1, P505; PAULSEN KE, 1994, BIOCHEMISTRY-US, V33, P713, DOI 10.1021/bi00169a013; PETITDEMANGE H, 1981, ANAL BIOCHEM, V116, P564, DOI 10.1016/0003-2697(81)90403-6; Poole RK, 2000, MOL MICROBIOL, V36, P775, DOI 10.1046/j.1365-2958.2000.01889.x; Rodrigues JV, 2005, BIOCHEM BIOPH RES CO, V329, P1300, DOI 10.1016/j.bbrc.2005.02.114; Saraiva LM, 2004, ADV MICROB PHYSIOL, V49, P77, DOI 10.1016/S0065-2911(04)49002-X; Silaghi-Dumitrescu R, 2005, BIOCHEMISTRY-US, V44, P6492, DOI 10.1021/bi0473049; Silaghi-Dumitrescu R, 2003, BIOCHEMISTRY-US, V42, P2806, DOI 10.1021/bi027253k; Solomon EI, 2000, CHEM REV, V100, P235, DOI 10.1021/cr9900275; SUSIN S, 1993, J BIOL CHEM, V268, P20958; Teixeira VH, 2004, BIOPHYS J, V86, P2773, DOI 10.1016/S0006-3495(04)74331-3; van Beilen JB, 2002, J BACTERIOL, V184, P1722, DOI 10.1128/JB.184.6.1722-1732.2002; Wasserfallen A, 1998, EUR J BIOCHEM, V254, P325, DOI 10.1046/j.1432-1327.1998.2540325.x; Wastl J, 2000, FEBS LETT, V471, P191, DOI 10.1016/S0014-5793(00)01399-5; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WOODLAND MP, 1986, BIOCHIM BIOPHYS ACTA, V873, P237, DOI 10.1016/0167-4838(86)90050-6	46	40	41	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34599	34608		10.1074/jbc.M506349200	http://dx.doi.org/10.1074/jbc.M506349200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16100392	hybrid			2022-12-27	WOS:000232403900028
J	Gorin, Y; Block, K; Hernandez, J; Bhandari, B; Wagner, B; Barnes, JL; Abboud, HE				Gorin, Y; Block, K; Hernandez, J; Bhandari, B; Wagner, B; Barnes, JL; Abboud, HE			Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AKT/PROTEIN KINASE-B; OXIDATIVE STRESS; ANGIOTENSIN-II; NADPH OXIDASE; HIGH-GLUCOSE; MESANGIAL CELLS; EXTRACELLULAR-MATRIX; PROTEIN-SYNTHESIS; GENE-EXPRESSION; DNA-DAMAGE	Renal hypertrophy and extracellular matrix accumulation are early features of diabetic nephropathy. We investigated the role of the NAD(P) H oxidase Nox4 in generation of reactive oxygen species (ROS), hypertrophy, and fibronectin expression in a rat model of type 1 diabetes induced by streptozotocin. Phosphorothioated antisense (AS) or sense oligonucleotides for Nox4 were administered for 2 weeks with an osmotic minipump 72 h after streptozotocin treatment. Nox4 protein expression was increased in diabetic kidney cortex compared with non-diabetic controls and was down-regulated in AS-treated animals. AS oligonucleotides inhibited NADPH-dependent ROS generation in renal cortical and glomerular homogenates. ROS generation by intact isolated glomeruli from diabetic animals was increased compared with glomeruli isolated from AS-treated animals. AS treatment reduced whole kidney and glomerular hypertrophy. Moreover, the increased expression of fibronectin protein was markedly reduced in renal cortex including glomeruli of AS-treated diabetic rats. Akt/protein kinase B and ERK1/2, two protein kinases critical for cell growth and hypertrophy, were activated in diabetes, and AS treatment almost abolished their activation. In cultured mesangial cells, high glucose increased NADPH oxidase activity and fibronectin expression, effects that were prevented in cells transfected with AS oligonucleotides. These data establish a role for Nox4 as the major source of ROS in the kidneys during early stages of diabetes and establish that Nox4-derived ROS mediate renal hypertrophy and increased fibronectin expression.	Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol, San Antonio, TX 78229 USA; S Texas Vet Hlth Care Syst, Audie L Murphy Mem Hosp Div, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Abboud, HE (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol, MC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	abboud@uthsca.edu	Wagner, Brent/AAA-8291-2020	Wagner, Brent/0000-0002-7063-0142; Gorin, Yves/0000-0003-4048-6925	NIDDK NIH HHS [DK43988, DK33665] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033665, R37DK033665, R01DK043988] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABBOUD HE, 1982, J CLIN INVEST, V69, P327, DOI 10.1172/JCI110456; Abboud HE, 1997, KIDNEY INT, pS3; Ambasta RK, 2004, J BIOL CHEM, V279, P45935, DOI 10.1074/jbc.M406486200; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BILOUS RW, 1989, DIABETES, V38, P1142, DOI 10.2337/diabetes.38.9.1142; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; Carey RM, 2003, TRENDS ENDOCRIN MET, V14, P274, DOI 10.1016/S1043-2760(03)00111-5; Chen HC, 2000, J LAB CLIN MED, V135, P309, DOI 10.1067/mlc.2000.105616; Chen K, 2004, J BIOL CHEM, V279, P35079, DOI 10.1074/jbc.M404859200; Choudhury GG, 2004, CELL SIGNAL, V16, P31, DOI 10.1016/S0898-6568(03)00094-9; Choudhury GG, 1997, AM J PHYSIOL-RENAL, V273, pF931, DOI 10.1152/ajprenal.1997.273.6.F931; Crean JKG, 2002, J BIOL CHEM, V277, P44187, DOI 10.1074/jbc.M203715200; Cross AR, 2004, BBA-BIOENERGETICS, V1657, P1, DOI 10.1016/j.bbabio.2004.03.008; Cui XL, 1997, P NATL ACAD SCI USA, V94, P3771, DOI 10.1073/pnas.94.8.3771; DeRubertis FR, 2004, DIABETES, V53, P762, DOI 10.2337/diabetes.53.3.762; Etoh T, 2003, DIABETOLOGIA, V46, P1428, DOI 10.1007/s00125-003-1205-6; Forbes JM, 2002, DIABETES, V51, P3274, DOI 10.2337/diabetes.51.11.3274; Fujita H, 2004, AM J PHYSIOL-RENAL, V286, pF120, DOI 10.1152/ajprenal.00351.2002; Geiszt M, 2004, J BIOL CHEM, V279, P51715, DOI 10.1074/jbc.R400024200; Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897; Gorin Y, 2004, BIOCHEM J, V381, P231, DOI 10.1042/BJ20031614; Gorin Y, 2003, AM J PHYSIOL-RENAL, V285, pF219, DOI 10.1152/ajprenal.00414.2002; Gorin Y, 2001, FASEB J, V15, P1909, DOI 10.1096/fj..01-0165com; Green K, 2004, DIABETES, V53, pS110, DOI 10.2337/diabetes.53.2007.S110; HA HJ, 1994, FREE RADICAL BIO MED, V16, P271, DOI 10.1016/0891-5849(94)90152-X; Haneda M, 2003, J AM SOC NEPHROL, V14, P1374, DOI 10.1097/01.ASN.0000064500.89551.76; Hink U, 2001, CIRC RES, V88, pE14; Hinokio Y, 1999, DIABETOLOGIA, V42, P995, DOI 10.1007/s001250051258; Hixon ML, 2000, J CLIN INVEST, V106, P1011, DOI 10.1172/JCI8252; Hua H, 2003, J BIOL CHEM, V278, P33951, DOI 10.1074/jbc.M302823200; Inoguchi T, 2003, J AM SOC NEPHROL, V14, pS227, DOI 10.1097/01.ASN.0000077407.90309.65; Isono M, 2000, J AM SOC NEPHROL, V11, P2222, DOI 10.1681/ASN.V11122222; JONES SA, 1995, J AM SOC NEPHROL, V5, P1483; Kim IJ, 2003, DIABETES RES CLIN PR, V60, P11, DOI 10.1016/S0168-8227(02)00278-4; Kimura S, 2005, HYPERTENSION, V45, P860, DOI 10.1161/01.HYP.0000163462.98381.7f; Kiritoshi S, 2003, DIABETES, V52, P2570, DOI 10.2337/diabetes.52.10.2570; Kitada M, 2003, DIABETES, V52, P2603, DOI 10.2337/diabetes.52.10.2603; Koya D, 2003, J AM SOC NEPHROL, V14, pS250, DOI 10.1097/01.ASN.0000077412.07578.44; Kuroki T, 2003, J AM SOC NEPHROL, V14, pS216, DOI 10.1097/01.ASN.0000077405.07888.07; Lassegue B, 2003, AM J PHYSIOL-REG I, V285, pR277, DOI 10.1152/ajpregu.00758.2002; Lee HB, 2003, J AM SOC NEPHROL, V14, pS241, DOI 10.1097/01.ASN.0000077410.66390.0F; Li JM, 2003, J AM SOC NEPHROL, V14, pS221, DOI 10.1097/01.ASN.0000077406.67663.E7; Lin Y, 2005, J BIOL CHEM, V280, P4617, DOI 10.1074/jbc.M411863200; Martyn KD, 2006, CELL SIGNAL, V18, P69, DOI 10.1016/j.cellsig.2005.03.023; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Onozato ML, 2002, KIDNEY INT, V61, P186, DOI 10.1046/j.1523-1755.2002.00123.x; Petermann AT, 2005, KIDNEY INT, V67, P157, DOI 10.1111/j.1523-1755.2005.00066.x; Phillips Aled O, 2003, Curr Diab Rep, V3, P491, DOI 10.1007/s11892-003-0013-1; RAPPAPORT J, 1995, KIDNEY INT, V47, P1462, DOI 10.1038/ki.1995.205; Sano T, 1998, DIABETOLOGIA, V41, P1355, DOI 10.1007/s001250051076; Schafer M, 2003, CIRC RES, V92, P1010, DOI 10.1161/01.RES.0000070882.81508.FC; Schnackenberg CG, 2002, CURR OPIN PHARMACOL, V2, P121, DOI 10.1016/S1471-4892(02)00133-9; Servant MJ, 1996, J BIOL CHEM, V271, P16047, DOI 10.1074/jbc.271.27.16047; Sheu ML, 2004, MOL PHARMACOL, V66, P187, DOI 10.1124/mol.66.1.187; Shiose A, 2001, J BIOL CHEM, V276, P1417, DOI 10.1074/jbc.M007597200; Wolf G, 1999, KIDNEY INT, V56, P393, DOI 10.1046/j.1523-1755.1999.00590.x; Wolf G, 2004, HYPERTENSION, V43, P693, DOI 10.1161/01.HYP.0000120963.09029.ca; Wolf Gunter, 2003, Curr Diab Rep, V3, P485, DOI 10.1007/s11892-003-0012-2; Yamagishi S, 2001, DIABETES, V50, P1491, DOI 10.2337/diabetes.50.6.1491; ZIYADEH FN, 1993, AM J KIDNEY DIS, V22, P736, DOI 10.1016/S0272-6386(12)80440-9; Ziyadeh FN, 2000, P NATL ACAD SCI USA, V97, P8015, DOI 10.1073/pnas.120055097	62	421	444	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39616	39626		10.1074/jbc.M502412200	http://dx.doi.org/10.1074/jbc.M502412200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16135519	hybrid			2022-12-27	WOS:000233362200085
J	Duy, C; Fitter, J				Duy, C; Fitter, J			Thermostability of irreversible unfolding alpha-amylases analyzed by unfolding kinetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL SCANNING CALORIMETRY; PYRROLIDONE CARBOXYL PEPTIDASE; THERMAL-DENATURATION; THERMODYNAMIC STABILITY; TAKA-AMYLASE; MECHANISM; PROTEIN; HYPERTHERMOPHILE; COLD; STABILIZATION	For most multidomain proteins the thermal unfolding transitions are accompanied by an irreversible step, often related to aggregation at elevated temperatures. As a consequence the analysis of thermostabilities in terms of equilibrium thermodynamics is not applicable, at least not if the irreversible process is fast with respect the structural unfolding transition. In a comparative study we investigated aggregation effects and unfolding kinetics for five homologous alpha-amylases, all from mesophilic sources but with rather different thermostabilities. The results indicate that for all enzymes the irreversible process is fast and the precedent unfolding transition is the rate-limiting step. In this case the kinetic barrier toward unfolding, as measured by unfolding rates as function of temperature, is the key feature in thermostability. The investigated enzymes exhibit activation energies (E-a) between 208 and 364 kJ mol(-1) and pronounced differences in the corresponding unfolding rates. The most thermostable alpha-amylase from Bacillus licheniformis ( apparent transition temperature, T-1/2 similar to 100 degrees C) shows an unfolding rate which is four orders of magnitude smaller as compared with the alpha-amylase from pig pancreas (T-1/2 similar to 65 degrees C). Even with respect to two other alpha-amylases from Bacillus species (T-1/2 similar to 86 degrees C) the difference in unfolding rates is still two orders of magnitude.	Forschungszentrum Julich, Biol Strukturforsch, D-52425 Julich, Germany	Helmholtz Association; Research Center Julich	Fitter, J (corresponding author), Forschungszentrum Julich, Biol Strukturforsch, IBI-2, D-52425 Julich, Germany.	j.fitter@fz-juelich.de	Duy, Cihangir/AAD-7735-2022; Fitter, Joerg/J-3294-2013	Duy, Cihangir/0000-0001-9150-9379; Fitter, Joerg/0000-0002-4503-2079				Bachmann A, 2005, PROTEIN FOLDING HANDBOOK, P379; Cavagnero S, 1998, BIOCHEMISTRY-US, V37, P3369, DOI 10.1021/bi9721795; Cavagnero S, 1998, BIOCHEMISTRY-US, V37, P3377, DOI 10.1021/bi9721804; Collins T, 2003, J MOL BIOL, V328, P419, DOI 10.1016/S0022-2836(03)00287-0; Cunningham EL, 1999, P NATL ACAD SCI USA, V96, P11008, DOI 10.1073/pnas.96.20.11008; D'Amico S, 2003, J BIOL CHEM, V278, P7891, DOI 10.1074/jbc.M212508200; Declerck N, 1997, PROTEIN ENG, V10, P541, DOI 10.1093/protein/10.5.541; del Pino IMP, 2000, PROTEINS, V40, P58, DOI 10.1002/(SICI)1097-0134(20000701)40:1<58::AID-PROT80>3.0.CO;2-M; Feller G, 1999, BIOCHEMISTRY-US, V38, P4613, DOI 10.1021/bi982650+; Fitter J, 2005, CELL MOL LIFE SCI, V62, P1925, DOI 10.1007/s00018-005-5079-2; Fitter J, 2004, BIOCHEMISTRY-US, V43, P9589, DOI 10.1021/bi0493362; Fitter J, 2001, BIOCHEMISTRY-US, V40, P10723, DOI 10.1021/bi010808b; FUKADA H, 1987, BIOCHEMISTRY-US, V26, P4063, DOI 10.1021/bi00387a048; GALISTEO ML, 1991, BIOCHEMISTRY-US, V30, P2061, DOI 10.1021/bi00222a009; Georlette D, 2004, FEMS MICROBIOL REV, V28, P25, DOI 10.1016/j.femsre.2003.07.003; Hollien J, 2002, J MOL BIOL, V316, P327, DOI 10.1006/jmbi.2001.5346; Jaenicke R, 1998, CURR OPIN STRUC BIOL, V8, P738, DOI 10.1016/S0959-440X(98)80094-8; Kaushik JK, 2002, J MOL BIOL, V316, P991, DOI 10.1006/jmbi.2001.5355; Kawata Y, 1998, PROTEIN ENG, V11, P1293, DOI 10.1093/protein/11.12.1293; Khajeh K, 2001, BBA-PROTEIN STRUCT M, V1548, P229, DOI 10.1016/S0167-4838(01)00236-9; LADERMAN KA, 1993, J BIOL CHEM, V268, P24394; LASKIN AI, 1988, CRC HDB MICROBIOLOGY, P325; LEPOCK JR, 1992, BIOCHEMISTRY-US, V31, P12706, DOI 10.1021/bi00165a023; LUMRY R, 1954, J PHYS CHEM-US, V58, P110, DOI 10.1021/j150512a005; Machius M, 2003, J BIOL CHEM, V278, P11546, DOI 10.1074/jbc.M212618200; Mukaiyama A, 2004, BIOCHEMISTRY-US, V43, P13859, DOI 10.1021/bi0487645; Nielsen AD, 2003, BBA-PROTEINS PROTEOM, V1652, P52, DOI 10.1016/j.bbapap.2003.08.002; Ogasahara K, 1998, BIOCHEMISTRY-US, V37, P17537, DOI 10.1021/bi9814585; Ogasahara K, 1998, BIOCHEMISTRY-US, V37, P5939, DOI 10.1021/bi973172q; Perl D, 1998, NAT STRUCT BIOL, V5, P229, DOI 10.1038/nsb0398-229; Rosengarth A, 1999, EUR J BIOCHEM, V264, P989, DOI 10.1046/j.1432-1327.1999.00712.x; SANCHEZRUIZ JM, 1988, BIOCHEMISTRY-US, V27, P1648, DOI 10.1021/bi00405a039; Shin I, 2002, PROTEIN SCI, V11, P2022, DOI 10.1110/ps.0205102; Sterner R, 2001, CRIT REV BIOCHEM MOL, V36, P39, DOI 10.1080/20014091074174; Tanaka A, 2002, BIOCHEM J, V364, P635, DOI 10.1042/BJ20011436; TELLOSOLIS SR, 1995, BIOCHEM J, V311, P969, DOI 10.1042/bj3110969; TOMAZIC SJ, 1988, J BIOL CHEM, V263, P3092; TOMAZIC SJ, 1988, J BIOL CHEM, V263, P3086; Vieille C, 2001, MICROBIOL MOL BIOL R, V65, P1, DOI 10.1128/MMBR.65.1.1-43.2001; VIHINEN M, 1989, CRIT REV BIOCHEM MOL, V24, P329, DOI 10.3109/10409238909082556; VIOLET M, 1989, BIOCHEM J, V263, P665, DOI 10.1042/bj2630665; Vogl T, 1997, BIOCHEMISTRY-US, V36, P1657, DOI 10.1021/bi962163z; Wittung-Stafshede P, 2004, BBA-PROTEINS PROTEOM, V1700, P1, DOI 10.1016/j.bbapap.2004.04.002; Yazdanparast R, 2005, INT J BIOL MACROMOL, V35, P257, DOI 10.1016/j.ijbiomac.2005.02.007	44	74	74	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37360	37365		10.1074/jbc.M507530200	http://dx.doi.org/10.1074/jbc.M507530200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16150692	hybrid			2022-12-27	WOS:000233044500009
J	Girardin, EP; HajMohammadi, S; Birmele, B; Helisch, A; Shworak, NW; de Agostini, AI				Girardin, EP; HajMohammadi, S; Birmele, B; Helisch, A; Shworak, NW; de Agostini, AI			Synthesis of anticoagulantly active heparan sulfate proteoglycans by glomerular epithelial cells involves multiple 3-O-sulfotransferase isoforms and a limiting precursor pool	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX-VIRUS; D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE; ANTI-THROMBIN-III; BASEMENT-MEMBRANE; ANTITHROMBIN-BINDING; INCREASED PERMEABILITY; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; HIGH-AFFINITY; HUMAN CDNAS	Endothelial and other select cell types synthesize a subpopulation of heparan sulfate (HS) proteoglycans (HSPGs), anticoagulant HSPGs (aHSPGs) that bear aHS-HS chains with the cognate 3-O-sulfated pentasaccharide motif that can bind and activate antithrombin ( AT). Endothelial cells regulate aHSPG production by limiting levels of HS 3-O-sulfotransferase-1 (3-OST-1), which modifies a non-limiting pool of aHS-precursors. By probing kidney cryosections with I-125-AT and fluorescently tagged AT we found that the glomerular basement membrane contains aHSPGs, with the staining pattern implicating synthesis by glomerular epithelial cells (GECs). Indeed, cultured GECs synthesized aHS with high AT affinity that was comparable with the endothelial product. Disaccharide analyses of human GEC (hGEC) HS in conjunction with transcript analyses revealed that hGECs express predominantly 3-OST-1 and 3-OST-3A. aHS production has not been previously examined in cells expressing multiple 3-OST isoforms. This unusual situation appears to involve novel mechanisms to regulate aHS production, as HS structural analyses suggest hGECs exhibit excess levels of 3-OST-1 and an extremely limiting pool of aHS-precursor. A limiting aHS-precursor pool may serve to minimize aHS synthesis by non-3-OST-1 isoforms. Indeed, we show that high in vitro levels of 3-OST-3(A) can efficiently generate aHS. Non-3-OST-1 isoforms can generate aHS in vivo, as the probing of kidney sections from 3-OST-1-deficient mice revealed GEC synthesis of aHSPGs. Surprisingly, Hs3st1(-/-) kidney only expresses 3-OST isoforms having a low specificity for aHS synthesis. Thus, our analyses reveal a cell type that expresses multiple 3-OST isoforms and produces minimal amounts of aHS-precursor. In part, this mechanism should prevent aHS overproduction by non-3-OST-1 isoforms. Such a role may be essential, as 3-OST isoforms that have a low specificity for aHS synthesis can generate substantial levels of aHSPGs in vivo.	Univ Hosp Geneva, Dept Pediat, CH-1211 Geneva, Switzerland; Univ Hosp Geneva, Dept Obstet & Gynecol, CH-1211 Geneva, Switzerland; Dartmouth Coll Sch Med, Dept Med, Cardiol Sect, Lebanon, NH 03756 USA	University of Geneva; University of Geneva; Dartmouth College	Girardin, EP (corresponding author), Univ Hosp Geneva, Dept Pediat, CH-1211 Geneva, Switzerland.	Eric.girardin@hcuge.ch	Shworak, Nicholas/AAJ-6770-2020	Shworak, Nicholas/0000-0001-7783-4634; Helisch, Armin/0000-0002-6507-8226; Girardin, Eric/0000-0002-5443-3640	NCI NIH HHS [CA 23108, P30 CA023108] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023108] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belting M, 2003, TRENDS BIOCHEM SCI, V28, P145, DOI 10.1016/S0968-0004(03)00031-8; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Chen JH, 2003, GLYCOBIOLOGY, V13, P785, DOI 10.1093/glycob/cwg101; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; COLLIECJOUAULT S, 1994, J BIOL CHEM, V269, P24953; Cunningham MA, 2000, J EXP MED, V191, P455, DOI 10.1084/jem.191.3.455; Daniels RJ, 2001, HUM MOL GENET, V10, P339, DOI 10.1093/hmg/10.4.339; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; DEAGOSTINI AL, 1990, P NATL ACAD SCI USA, V87, P9784, DOI 10.1073/pnas.87.24.9784; EDGE ASB, 1990, J BIOL CHEM, V265, P15874; Edge ASB, 2000, DIABETOLOGIA, V43, P1056, DOI 10.1007/s001250051489; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; Groffen AJ, 1998, J HISTOCHEM CYTOCHEM, V46, P19, DOI 10.1177/002215549804600104; GUO YC, 1988, ANAL BIOCHEM, V168, P54, DOI 10.1016/0003-2697(88)90009-7; HajMohammadi S, 2003, J CLIN INVEST, V111, P989, DOI 10.1172/JCI200315809; HISCOCK DRR, 1995, BBA-GEN SUBJECTS, V1244, P104, DOI 10.1016/0304-4165(94)00206-D; Hosseini G, 1996, J BIOL CHEM, V271, P22090, DOI 10.1074/jbc.271.36.22090; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; Iozzo RV, 2001, J CLIN INVEST, V108, P165, DOI 10.1172/JCI13560; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096; KANWAR YS, 1983, EUR J CELL BIOL, V31, P290; KANWAR YS, 1980, J CELL BIOL, V86, P688, DOI 10.1083/jcb.86.2.688; KANWAR YS, 1981, RENAL PHYSIOL BIOCH, V4, P121; KINSELLA MG, 1988, BIOCHEMISTRY-US, V27, P2136, DOI 10.1021/bi00406a048; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; KRIZ W, 1995, KIDNEY INT, V48, P1435, DOI 10.1038/ki.1995.433; KUSCHE M, 1990, J BIOL CHEM, V265, P7292; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; LINHARDT RJ, 1992, J BIOL CHEM, V267, P2380; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; Liu J, 2002, J BIOL CHEM, V277, P33456, DOI 10.1074/jbc.M202034200; Liu JA, 1999, J BIOL CHEM, V274, P5185, DOI 10.1074/jbc.274.8.5185; LYON M, 1990, ANAL BIOCHEM, V185, P63, DOI 10.1016/0003-2697(90)90255-8; Mani K, 2000, GLYCOBIOLOGY, V10, P577, DOI 10.1093/glycob/10.6.577; MARCUM JA, 1986, EXP CELL RES, V166, P253, DOI 10.1016/0014-4827(86)90525-2; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; MARCUM JA, 1984, BIOCHEMISTRY-US, V23, P1730, DOI 10.1021/bi00303a023; MARCUM JA, 1983, AM J PHYSIOL, V245, pH725, DOI 10.1152/ajpheart.1983.245.5.H725; Miyamoto K, 2003, ONCOGENE, V22, P274, DOI 10.1038/sj.onc.1206146; MURDOCH AD, 1994, J HISTOCHEM CYTOCHEM, V42, P239, DOI 10.1177/42.2.7507142; Pahl MV, 1996, J AM SOC NEPHROL, V7, P2249; PEJLER G, 1987, BIOCHEM J, V248, P69, DOI 10.1042/bj2480069; PEJLER G, 1987, J BIOL CHEM, V262, P5036; Pfeiffer S, 2002, CURR BIOL, V12, P957, DOI 10.1016/S0960-9822(02)00867-9; Princivalle M, 2001, GLYCOBIOLOGY, V11, P183, DOI 10.1093/glycob/11.3.183; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; ROSENZWEIG LJ, 1982, LAB INVEST, V47, P177; RUEF C, 1990, KIDNEY INT, V38, P249, DOI 10.1038/ki.1990.193; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; SHEN GQ, 1995, ARCH BIOCHEM BIOPHYS, V321, P83, DOI 10.1006/abbi.1995.1371; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; SHWORAK NW, 1994, J BIOL CHEM, V269, P21204; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; SHWORAK NW, 1994, J BIOL CHEM, V269, P24941; Shworak NW, 1998, TRENDS GLYCOSCI GLYC, V10, P175, DOI 10.4052/tigg.10.175; SHWORAK NW, 1993, J BIOL CHEM, V268, P24460; Shworak NW, 1996, J BIOL CHEM, V271, P27063, DOI 10.1074/jbc.271.43.27063; STRIKER GE, 1985, LAB INVEST, V53, P122; TAKEUCHI Y, 1990, J BIOL CHEM, V265, P13661; Torry RJ, 1999, J HISTOCHEM CYTOCHEM, V47, P313, DOI 10.1177/002215549904700305; Torry RJ, 1998, TRANSPLANTATION, V66, P797, DOI 10.1097/00007890-199809270-00016; Wu ZLL, 2004, J BIOL CHEM, V279, P1861, DOI 10.1074/jbc.M311398200; Xia GQ, 2002, J BIOL CHEM, V277, P37912, DOI 10.1074/jbc.M204209200; Xu D, 2005, BIOCHEM J, V385, P451, DOI 10.1042/BJ20040908; XU YH, 1994, J HISTOCHEM CYTOCHEM, V42, P1365, DOI 10.1177/42.10.7930519; Yabe T, 2001, BIOCHEM J, V359, P235, DOI 10.1042/0264-6021:3590235; Ye S, 2001, BIOCHEMISTRY-US, V40, P14429, DOI 10.1021/bi011000u; Zhang LJ, 1999, J BIOL CHEM, V274, P5681, DOI 10.1074/jbc.274.9.5681; Zhang LJ, 1998, J BIOL CHEM, V273, P27998, DOI 10.1074/jbc.273.43.27998	74	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					38059	38070		10.1074/jbc.M507997200	http://dx.doi.org/10.1074/jbc.M507997200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16107334	hybrid			2022-12-27	WOS:000233044500089
J	Verlinden, L; Eelen, G; Beullens, I; Van Camp, M; Van Hummelen, P; Engelen, K; Van Hellemont, R; Marchal, K; De Moor, B; Foijer, F; Riele, HT; Beullens, M; Bollen, M; Mathieu, C; Bouillon, R; Verstuyf, A				Verlinden, L; Eelen, G; Beullens, I; Van Camp, M; Van Hummelen, P; Engelen, K; Van Hellemont, R; Marchal, K; De Moor, B; Foijer, F; Riele, HT; Beullens, M; Bollen, M; Mathieu, C; Bouillon, R; Verstuyf, A			Characterization of the condensin component Cnap1 and protein kinase Melk as novel E2F target genes down-regulated by 1,25-dihydroxyvitamin D-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; IN-VIVO; DNA-REPLICATION; FAMILY-MEMBER; EXPRESSION; TRANSCRIPTION; COMPLEX; PROFILES; PROLIFERATION; PROGRESSION	1,25-Dihydroxyvitamin D-3 (1,25(OH)(2)D-3) has potent antiproliferative effects characterized by a hampered G(1)/S transition. cDNA microarrays were used to monitor expression of 21,492 genes in MC3T3-E1 mouse osteoblasts at 1, 6, 12, 24, and 36 h after treatment with 1,25(OH)(2)D-3. Statistical analysis revealed a cluster of genes that were strongly down-regulated by 1,25(OH)(2)D-3 and which not only function in cell cycle regulation and DNA replication but also mediate checkpoint control, DNA repair, chromosome modifications, and mitosis. Because many of these genes were shown earlier to be regulated by the transcriptional repressor E2F4, the intergenic regions of these 1,25(OH)(2)D-3-down-regulated genes were searched for the presence of E2F binding sites. This led to the characterization of two novel E2F target genes, chromosome condensation-related SMC-associated protein 1 (Cnap1) and maternal embryonic leucine zipper kinase ( Melk). Transfection studies and site-directed mutagenesis confirmed Cnap1 and Melk to be bona fide E2F targets. Repression of Cnap1 and Melk by 1,25(OH)(2)D-3 was confirmed not only in MC3T3-E1 cells but also in several other bone-unrelated cell types. This down-regulation as well as the antiproliferative effect of 1,25( OH)(2)D-3 depended on the pocket proteins p107 and p130 because 1,25(OH)(2)D-3 failed to repress these E2F target genes and lost its antiproliferative action in p107(-/-); p130(-/-) cells but not in pRb(-/-) cells.	Katholieke Univ Leuven, Lab Expt Geneeskunde & Endocrinol, B-3000 Louvain, Belgium; Vlaams Interuniv Inst Biotechnol, Microarray Facil, B-3000 Louvain, Belgium; Katholieke Univ Leuven, ESAT SCD, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Afdeling Biochem, Louvain, Belgium; Netherlands Canc Inst, NL-1066 CX Amsterdam, Netherlands	KU Leuven; KU Leuven; KU Leuven; Netherlands Cancer Institute	Bouillon, R (corresponding author), Katholieke Univ Leuven, Lab Expt Geneeskunde & Endocrinol, B-3000 Louvain, Belgium.	Roger.Bouillon@med.kuleuven.be	Verlinden, Lieve/E-6517-2011; Marchal, Kathleen/O-7936-2017; mathieu, chantal/ABD-5505-2021; Marchal, Kathleen/B-5001-2013	Marchal, Kathleen/0000-0002-2169-4588; mathieu, chantal/0000-0002-4055-5233; Marchal, Kathleen/0000-0002-2169-4588; Verlinden, Lieve/0000-0002-9621-3662; Engelen, Kristof/0000-0001-6215-1689; van hummelen, paul/0000-0002-4801-8600; Verstuyf, Annemieke/0000-0003-3193-2698; Foijer, Floris/0000-0003-0989-3127				Attwooll C, 2005, J BIOL CHEM, V280, P1199, DOI 10.1074/jbc.M412509200; Audo I, 2003, INVEST OPHTH VIS SCI, V44, P4192, DOI 10.1167/iovs.02-1198; Ball AR, 2002, MOL CELL BIOL, V22, P5769, DOI 10.1128/MCB.22.16.5769-5781.2002; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Carroll JS, 2000, J BIOL CHEM, V275, P38221, DOI 10.1074/jbc.M004424200; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Cook JG, 2004, J BIOL CHEM, V279, P9625, DOI 10.1074/jbc.M311933200; De Smet F, 2002, BIOINFORMATICS, V18, P735, DOI 10.1093/bioinformatics/18.5.735; Eelen G, 2004, J BONE MINER RES, V19, P133, DOI 10.1359/JBMR.0301204; Engelen K, 2003, BIOINFORMATICS, V19, P893, DOI 10.1093/bioinformatics/btg085; Giangrande PH, 2004, GENE DEV, V18, P2941, DOI 10.1101/gad.1239304; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; Heyer BS, 1999, DEV DYNAM, V215, P344; Hofman K, 2001, BIOCHEM BIOPH RES CO, V283, P97, DOI 10.1006/bbrc.2001.4738; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Jensen SS, 2001, MOL ENDOCRINOL, V15, P1370, DOI 10.1210/me.15.8.1370; Kasprzyk A, 2004, GENOME RES, V14, P160, DOI 10.1101/gr.1645104; Kimura K, 2001, J BIOL CHEM, V276, P5417, DOI 10.1074/jbc.C000873200; Lee HY, 1998, J CLIN INVEST, V101, P1012, DOI 10.1172/JCI1329; Lenhard B, 2002, BIOINFORMATICS, V18, P1135, DOI 10.1093/bioinformatics/18.8.1135; Logan N, 2004, ONCOGENE, V23, P5138, DOI 10.1038/sj.onc.1207649; Maiti B, 2005, J BIOL CHEM, V280, P18211, DOI 10.1074/jbc.M501410200; Overbergh L, 1999, CYTOKINE, V11, P305, DOI 10.1006/cyto.1998.0426; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pD91, DOI 10.1093/nar/gkh012; Stevens C, 2003, ARCH BIOCHEM BIOPHYS, V412, P157, DOI 10.1016/S0003-9861(03)00054-7; Thijs G, 2002, BIOINFORMATICS, V18, P331, DOI 10.1093/bioinformatics/18.2.331; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Vaisanen S, 2004, J STEROID BIOCHEM, V89-90, P277, DOI 10.1016/j.jsbmb.2004.03.075; Verlinden L, 2000, CANCER RES, V60, P2673; Vulsteke V, 2004, J BIOL CHEM, V279, P8642, DOI 10.1074/jbc.M311466200; Wang QM, 1997, CANCER RES, V57, P2851; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Yoshida K, 2004, ONCOGENE, V23, P3802, DOI 10.1038/sj.onc.1207488	39	38	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37319	37330		10.1074/jbc.M503587200	http://dx.doi.org/10.1074/jbc.M503587200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16144839	hybrid, Green Published			2022-12-27	WOS:000233044500005
J	Hernandez, OM; Szczesna-Cordary, D; Knollmann, BC; Miller, T; Bell, M; Zhao, JJ; Sirenko, SG; Diaz, Z; Guzman, G; Xu, YY; Wang, Y; Kerrick, WGL; Potter, JD				Hernandez, OM; Szczesna-Cordary, D; Knollmann, BC; Miller, T; Bell, M; Zhao, JJ; Sirenko, SG; Diaz, Z; Guzman, G; Xu, YY; Wang, Y; Kerrick, WGL; Potter, JD			F110I and R278C troponin T mutations that cause familial hypertrophic cardiomyopathy affect muscle contraction in transgenic mice and reconstituted human cardiac fibers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIN FILAMENT; ALPHA-TROPOMYOSIN; TAIL DOMAIN; MOUSE MODEL; PREVALENCE; ATPASE; GENES	We have studied the physiological effects of the troponin T (TnT) F110I and R278C mutations associated with familial hypertrophic cardiomyopathy (FHC) in humans. Three to four-month-old transgenic (Tg) mice expressing F110I-TnT and R278C-TnT did not develop significant hypertrophy or ventricular fibrosis even after chronic exercise challenge. The F110I mutation impaired acute exercise tolerance, whereas R278C did not. Skinned papillary muscle fibers from transgenic mice expressing F110I-TnT demonstrated increased Ca2+ sensitivity of force and ATPase activity, and likewise an increased Ca2+ sensitivity of force was observed in F110I-TnT-reconstituted human cardiac muscle preparations. In contrast, no changes in force or the ATPase-pCa dependencies were observed in transgenic R278C fibers or in human fibers reconstituted with the R278C-TnT mutant. The maximal level of force development was dramatically decreased in both transgenic mice. However, the maximal ATPase was not different (R278C-TnT) or only slightly less (F110I-TnT) than that of non-Tg and WT-Tg littermates. Consequently, their ratios of ATPase/ force (energy cost) at all Ca2+ concentrations were dramatically higher compared with non-Tg and WT-Tg fibers. This increase in energy cost most likely results from a decrease in force per myosin cross-bridge, because forcing all cross-bridges into the force generating state by substitution of MgADP for MgATP in maximum contracting solutions resulted in the same increase in maximal force (15%) in all transgenic and non-transgenic preparations. The combination of increased Ca2+ sensitivity and energy cost in the F110I hearts may be responsible for the greater severity of this phenotype compared with the R278C mutation.	Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; Univ Miami, Miller Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA; Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA; Georgetown Univ, Med Ctr, Dept Pharmacol, Washington, DC 20057 USA	University of Miami; University of Miami; University of Miami; Georgetown University	Potter, JD (corresponding author), Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, 1600 NW 10th Ave, Miami, FL 33136 USA.	jdpotter@miami.edu		Knollmann, Bjorn/0000-0003-4956-9735	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL042325, R01HL071670, R01HL071778, R01HL042325, R01HL067415] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL67415, HL42325, HL071778, R01 HL071778, HL071670, R01 HL071778-02, R01 HL071778-01A1] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allen K, 2000, J APPL PHYSIOL, V88, P180, DOI 10.1152/jappl.2000.88.1.180; Anan R, 1998, CIRCULATION, V98, P391, DOI 10.1161/01.CIR.98.5.391; Ausubel FM, 1995, CURRENT PROTOCOLS MO, V1; Aziz T, 2005, BIOPHYS J, V88, p538A; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; Desai KH, 1997, AM J PHYSIOL-HEART C, V272, pH1053, DOI 10.1152/ajpheart.1997.272.2.H1053; Elliott PM, 1999, NEW ENGL J MED, V341, P1855, DOI 10.1056/NEJM199912093412416; FABIATO A, 1981, J GEN PHYSIOL, V78, P457, DOI 10.1085/jgp.78.5.457; Garcia-Castro M, 2003, CLIN CHEM, V49, P1279, DOI 10.1373/49.8.1279; GeisterferLowrance AAT, 1996, SCIENCE, V272, P731, DOI 10.1126/science.272.5262.731; Gomes AV, 2002, IUBMB LIFE, V54, P323, DOI 10.1080/15216540216037; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; GUTH K, 1986, PFLUG ARCH EUR J PHY, V407, P552, DOI 10.1007/BF00657515; Harada K, 2004, J BIOL CHEM, V279, P14488, DOI 10.1074/jbc.M309355200; Hinkle A, 2003, J BIOL CHEM, V278, P506, DOI 10.1074/jbc.M209194200; Knollmann BC, 2001, J BIOL CHEM, V276, P10039, DOI 10.1074/jbc.M006745200; Lin TL, 2000, CARDIOLOGY, V93, P155, DOI 10.1159/000007020; Miller T, 2001, J BIOL CHEM, V276, P3743, DOI 10.1074/jbc.M006746200; Redwood CS, 1999, CARDIOVASC RES, V44, P20, DOI 10.1016/S0008-6363(99)00213-8; Sambrook J., 1989, MOL CLONING LAB MANU, V1; Sola Francesco, 1997, Angiogenesis, V1, P102, DOI 10.1023/A:1018309200629; Szczesna D, 2000, J BIOL CHEM, V275, P624, DOI 10.1074/jbc.275.1.624; Szczesna Danuta, 2002, Results Probl Cell Differ, V36, P171; TAKASHI R, 1979, ANAL BIOCHEM, V92, P375, DOI 10.1016/0003-2697(79)90674-2; Takeda S, 2003, NATURE, V424, P35, DOI 10.1038/nature01780; Tardiff JC, 1999, J CLIN INVEST, V104, P469, DOI 10.1172/JCI6067; Tardiff JC, 1998, J CLIN INVEST, V101, P2800, DOI 10.1172/JCI2389; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; Tobacman LS, 1999, J BIOL CHEM, V274, P28363, DOI 10.1074/jbc.274.40.28363; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; Tobacman LS, 2002, J BIOL CHEM, V277, P27636, DOI 10.1074/jbc.M201768200; Torricelli F, 2003, AM J CARDIOL, V92, P1358, DOI 10.1016/j.amjcard.2003.08.031; Van Driest SL, 2003, CIRCULATION, V108, P445, DOI 10.1161/01.CIR.0000080896.52003.DF; Vinogradova MV, 2005, P NATL ACAD SCI USA, V102, P5038, DOI 10.1073/pnas.0408882102; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; Yanaga F, 1999, J BIOL CHEM, V274, P8806, DOI 10.1074/jbc.274.13.8806	36	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37183	37194		10.1074/jbc.M508114200	http://dx.doi.org/10.1074/jbc.M508114200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16115869	hybrid			2022-12-27	WOS:000232901800077
J	O'Gorman, W; Thomas, B; Kwek, KY; Furger, A; Akoulitchev, A				O'Gorman, W; Thomas, B; Kwek, KY; Furger, A; Akoulitchev, A			Analysis of U1 small nuclear RNA interaction with cyclin H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK-ACTIVATING KINASE; POLYMERASE-II TRANSCRIPTION; CARBOXYL-TERMINAL DOMAIN; P-TEFB; HIV-1 TAT; SUBSTRATE-SPECIFICITY; MASS-SPECTROMETRY; CROSS-LINKING; SMN COMPLEX; DNA-REPAIR	TFIIH is a general transcription and repair factor implicated in RNA polymerase II transcription, nucleotide excision repair, and transcription-coupled repair. Genetic defects in TFIIH lead to three distinct inheritable diseases: xeroderma pigmentosa, Cockayne syndrome, and trichothiodystrophy, with xeroderma pigmentosa patients being highly susceptible to skin cancer. Earlier data revealed that the cyclin H subunit of TFIIH associates with U1 small nuclear RNA, a core-splicing component. In addition to its role in RNA processing U1 small nuclear RNA also regulates diverse stages of transcription by RNA polymerase II both in vivo and in vitro, including abortive initiation and re-initiation. Here we identify structural components of U1 and cyclin H implicated in the direct interaction and show how they affect function. Because of unique features of cyclin H we have developed a new methodology for mapping RNA interaction with the full-length cyclin H polypeptide based on electrospray ionization tandem mass spectrometry. We also demonstrate the importance of U1 stem-loops 1 and 2 for the interaction with cyclin H. Functional assays implicate the identified interaction with U1 in regulation of the activity of the cyclin H associated kinase CDK7.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford; University of Oxford	Akoulitchev, A (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	alexandre.akoulitchev@pathology.ox.ac.uk			Medical Research Council [G0200452] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G0200452] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Andersen G, 1997, EMBO J, V16, P958, DOI 10.1093/emboj/16.5.958; Ashe MP, 2000, RNA, V6, P170, DOI 10.1017/S1355838200991957; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bieniasz PD, 1999, P NATL ACAD SCI USA, V96, P7791, DOI 10.1073/pnas.96.14.7791; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; Chen RC, 2004, J BIOL CHEM, V279, P4153, DOI 10.1074/jbc.M310044200; Costa RMA, 2003, BIOCHIMIE, V85, P1083, DOI 10.1016/j.biochi.2003.10.017; Douziech M, 2000, MOL CELL BIOL, V20, P8168, DOI 10.1128/MCB.20.21.8168-8177.2000; Dvir A, 2001, CURR OPIN GENET DEV, V11, P209, DOI 10.1016/S0959-437X(00)00181-7; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Furger A, 2002, GENE DEV, V16, P2792, DOI 10.1101/gad.983602; Garber ME, 1998, GENE DEV, V12, P3512, DOI 10.1101/gad.12.22.3512; Gilbert C, 2004, MOL CELL, V14, P457, DOI 10.1016/S1097-2765(04)00239-4; Gubitz AK, 2004, EXP CELL RES, V296, P51, DOI 10.1016/j.yexcr.2004.03.022; Hahn S, 2004, NAT STRUCT MOL BIOL, V11, P394, DOI 10.1038/nsmb763; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; Kim KK, 1996, NAT STRUCT BIOL, V3, P849, DOI 10.1038/nsb1096-849; Kim TK, 2000, SCIENCE, V288, P1418, DOI 10.1126/science.288.5470.1418; KROL A, 1990, NUCLEIC ACIDS RES, V18, P3803, DOI 10.1093/nar/18.13.3803; Kwek KY, 2002, NAT STRUCT BIOL, V9, P800, DOI 10.1038/nsb862; Marchler-Bauer A, 2005, NUCLEIC ACIDS RES, V33, pD192, DOI 10.1093/nar/gki069; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Martinez AM, 1997, EMBO J, V16, P343, DOI 10.1093/emboj/16.2.343; Michels AA, 2003, MOL CELL BIOL, V23, P4859, DOI 10.1128/MCB.23.14.4859-4869.2003; Nguyen VT, 2001, NATURE, V414, P322, DOI 10.1038/35104581; O'Sullivan JM, 2004, NAT GENET, V36, P1014, DOI 10.1038/ng1411; PALMITER RD, 1991, P NATL ACAD SCI USA, V88, P478, DOI 10.1073/pnas.88.2.478; Pellizzoni L, 2001, J CELL BIOL, V152, P75, DOI 10.1083/jcb.152.1.75; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Reese JC, 2003, CURR OPIN GENET DEV, V13, P114, DOI 10.1016/S0959-437X(03)00013-3; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; Rusconi F, 2002, MASS SPECTROM REV, V21, P305, DOI 10.1002/mas.10036; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Steen H, 2002, MASS SPECTROM REV, V21, P163, DOI 10.1002/mas.10024; Svejstrup JQ, 2002, NAT REV MOL CELL BIO, V3, P21, DOI 10.1038/nrm703; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Will CL, 2001, CURR OPIN CELL BIOL, V13, P290, DOI 10.1016/S0955-0674(00)00211-8; Yang ZY, 2001, NATURE, V414, P317, DOI 10.1038/35104575; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638; Yik JHN, 2003, MOL CELL, V12, P971, DOI 10.1016/S1097-2765(03)00388-5; Yong JS, 2002, EMBO J, V21, P1188, DOI 10.1093/emboj/21.5.1188; Yudkovsky N, 2000, NATURE, V408, P225, DOI 10.1038/35041603; Zhang J, 2000, J BIOL CHEM, V275, P34314, DOI 10.1074/jbc.M006804200; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	51	26	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36920	36925		10.1074/jbc.M505791200	http://dx.doi.org/10.1074/jbc.M505791200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16115885	hybrid			2022-12-27	WOS:000232901800048
J	Omueti, KO; Beyer, JM; Johnson, CM; Lyle, EA; Tapping, RI				Omueti, KO; Beyer, JM; Johnson, CM; Lyle, EA; Tapping, RI			Domain exchange between human Toll-like receptors 1 and 6 reveals a region required for lipopeptide discrimination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR ACTIVATION; CUTTING EDGE; BACTERIAL LIPOPROTEINS; SYNTHETIC LIPOPEPTIDES; LIPOTEICHOIC ACID; RECOGNITION; LIPOPOLYSACCHARIDE; CD14; CELLS; BINDING	Among the 10 human Toll-like receptors (TLRs), TLR2 appears to be unique in its requirement for cooperation with other TLRs, namely TLR1 and TLR6, to mediate cell signaling. Through reconstitution experiments, we have defined more precisely the function of these human TLRs. Human colonic epithelial cells cotransfected with TLR1 and - 2 preferentially respond to a synthetic tripalmitoylated bacterial lipopeptide analogue (Pam(3)CSK(4)). However, examination of a wide variety of lipopeptide derivatives indicates that recognition by human TLR1 and - 2 does not strictly correlate with the number or position of the acyl chains on the modified cysteine residue. Conversely, human TLR2 and - 6 exclusively respond to lipopeptides possessing a diacylglycerol group. Most surprisingly, we have found that an R stereoisomer of diacylated macrophage-activating lipopeptide 2 (MALP-2) exclusively activates epithelial cells through TLR6 and - 2 but not through TLR1 and - 2. These results suggest that the chirality of the central carbon of the diacylglycerol group of these agonists is a structural determinant for human TLR recognition. Examination of chimeric receptors, generated by domain exchange between TLR1 and - 6, has revealed that leucine-rich repeats 9 - 12 of the extracellular domain enable these receptors to discriminate between structurally similar lipopeptides. However, additional chimeric constructs reveal that this region alone is not sufficient to generate receptors that can functionally cooperate with TLR2. Our results support the idea that TLR1 and TLR6 diverged during evolution to differentially recognize natural lipoprotein structures and that this function has been conserved with respect to the human receptors.	Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Coll Med, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Tapping, RI (corresponding author), Univ Illinois, Dept Microbiol, B103 Chem & Life Sci Bldg,MC 110,601 S Goodwin, Urbana, IL 61801 USA.	tapping@life.uiuc.edu		, Katherine/0000-0002-8822-6607	NIAID NIH HHS [AI052344] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI052344, R01AI052344] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexopoulou L, 2002, NAT MED, V8, P878, DOI 10.1038/nm732; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498; Bell JK, 2003, TRENDS IMMUNOL, V24, P528, DOI 10.1016/S1471-4906(03)00242-4; BESSLER WG, 1985, J IMMUNOL, V135, P1900; BESSLER WG, 1992, RES IMMUNOL, V143, P548, DOI 10.1016/0923-2494(92)80067-U; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890; Bulut Y, 2001, J IMMUNOL, V167, P987, DOI 10.4049/jimmunol.167.2.987; Buwitt-Beckmann U, 2005, EUR J IMMUNOL, V35, P282, DOI 10.1002/eji.200424955; Campos MA, 2001, J IMMUNOL, V167, P416, DOI 10.4049/jimmunol.167.1.416; CHOE J, 2005, SCIENCE         0616, DOI DOI 10.1126/SCIENCE.1115253; Correia JD, 2002, J BIOL CHEM, V277, P1845, DOI 10.1074/jbc.M109910200; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Grabiec A, 2004, J BIOL CHEM, V279, P48004, DOI 10.1074/jbc.M405311200; Hajishengallis G, 2005, INFECT IMMUN, V73, P1343, DOI 10.1128/IAI.73.3.1343-1349.2005; Hajjar AM, 2001, J IMMUNOL, V166, P15, DOI 10.4049/jimmunol.166.1.15; Henneke P, 2001, J IMMUNOL, V167, P7069, DOI 10.4049/jimmunol.167.12.7069; Hoebe K, 2005, NATURE, V433, P523, DOI 10.1038/nature03253; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Jackson DC, 2004, P NATL ACAD SCI USA, V101, P15440, DOI 10.1073/pnas.0406740101; Jouault T, 2003, J INFECT DIS, V188, P165, DOI 10.1086/375784; Kawasaki K, 2000, J BIOL CHEM, V275, P2251, DOI 10.1074/jbc.275.4.2251; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Manukyan M, 2005, EUR J IMMUNOL, V35, P911, DOI 10.1002/eji.200425336; Massari P, 2002, J IMMUNOL, V168, P1533, DOI 10.4049/jimmunol.168.4.1533; Means TK, 1999, J IMMUNOL, V163, P3920; Meng GX, 2003, J BIOL CHEM, V278, P39822, DOI 10.1074/jbc.M304766200; METZGER J, 1991, INT J PEPT PROT RES, V37, P46; Morath S, 2002, J EXP MED, V195, P1635, DOI 10.1084/jem.20020322; Morr M, 2002, EUR J IMMUNOL, V32, P3337, DOI 10.1002/1521-4141(2002012)32:12<3337::AID-IMMU3337>3.0.CO;2-I; Muhlradt PF, 1997, J EXP MED, V185, P1951, DOI 10.1084/jem.185.11.1951; Nakao Y, 2005, J IMMUNOL, V174, P1566, DOI 10.4049/jimmunol.174.3.1566; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Poltorak A, 2000, P NATL ACAD SCI USA, V97, P2163, DOI 10.1073/pnas.040565397; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; Reschner A, 2003, EUR J IMMUNOL, V33, P2044, DOI 10.1002/eji.200323776; Sandor F, 2003, J CELL BIOL, V162, P1099, DOI 10.1083/jcb.200304093; SANKARAN K, 1994, J BIOL CHEM, V269, P19701; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Sellati TJ, 1998, J IMMUNOL, V160, P5455; Sing A, 2002, J EXP MED, V196, P1017, DOI 10.1084/jem.20020908; Spohn R, 2004, VACCINE, V22, P2494, DOI 10.1016/j.vaccine.2003.11.074; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeuchi O, 2000, J IMMUNOL, V164, P554, DOI 10.4049/jimmunol.164.2.554; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; Tapping RI, 1997, J BIOL CHEM, V272, P23157, DOI 10.1074/jbc.272.37.23157; Underhill DM, 1999, P NATL ACAD SCI USA, V96, P14459, DOI 10.1073/pnas.96.25.14459; Underhill DM, 2003, EUR J IMMUNOL, V33, P1767, DOI 10.1002/eji.200324037; van der Kleij D, 2002, J BIOL CHEM, V277, P48122, DOI 10.1074/jbc.M206941200; Vasselon T, 2004, J IMMUNOL, V173, P7401, DOI 10.4049/jimmunol.173.12.7401; Weber ANR, 2004, J BIOL CHEM, V279, P34589, DOI 10.1074/jbc.M403830200; Wetzler LM, 2003, VACCINE, V21, pS55, DOI 10.1016/S0264-410X(03)00201-9; Wooten RM, 1998, J IMMUNOL, V160, P5485; Wyllie DH, 2000, J IMMUNOL, V165, P7125, DOI 10.4049/jimmunol.165.12.7125	57	118	122	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36616	36625		10.1074/jbc.M504320200	http://dx.doi.org/10.1074/jbc.M504320200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16129684	hybrid			2022-12-27	WOS:000232901800012
J	Predescu, SA; Predescu, DN; Shimizu, K; Klein, IK; Malik, AB				Predescu, SA; Predescu, DN; Shimizu, K; Klein, IK; Malik, AB			Cholesterol-dependent syntaxin-4 and SNAP-23 clustering regulates caveolar fusion with the endothelial plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXOCYTOSIS; TRANSPORT; VESICLES; CELLS; MACHINERY; ENDOCYTOSIS; COMPLEXES; FISSION; DOCKING; SNARES	We determined the organization of target (t) SNARE proteins on the basolateral endothelial plasmamembrane ( PM) and their role in the mechanism of caveolar fusion. Studies were performed in a cell-free system involving endothelial PM sheets and isolated biotin-labeled caveolae. We monitored the fusion of caveolae with the PM by the detection of biotin-streptavidin complexes using correlative high resolution fluorescence microscopy and gold labeling electron microscopy on ultrathin sections of PM sheets. Imaging of PM sheets demonstrated and biochemical findings showed that the t-SNARE proteins present in endothelial cells (SNAP-23 and syntaxin-4) formed cholesterol-dependent clusters in discrete areas of the PM. Upon fusion of caveolae with the target PM, 50% of the caveolae co-localized with the t-SNARE clusters, indicating that these caveolae were at the peak of the fusion reaction. Fluorescent streptavidin staining of PM sheets correlated with the ultrastructure in the same area. These findings demonstrate that t-SNARE clusters in the endothelial target PM serve as the fusion sites for caveolae during exocytosis.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Ctr Lung & Vasc Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Malik, AB (corresponding author), Univ Illinois, Dept Pharmacol MC868, 835 S Wolcott Ave, Chicago, IL 60612 USA.	abmalik@uic.edu		Malik, Asrar/0000-0002-8205-7128; Predescu, Sanda/0000-0002-9386-6756	NHLBI NIH HHS [P01 HL60678] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL060678] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Avery J, 2000, J CELL BIOL, V148, P317, DOI 10.1083/jcb.148.2.317; Foster LJ, 1998, BIOCHEMISTRY-US, V37, P11089, DOI 10.1021/bi980253t; Heuser J, 2000, TRAFFIC, V1, P545, DOI 10.1034/j.1600-0854.2000.010704.x; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Lafont F, 1999, P NATL ACAD SCI USA, V96, P3734, DOI 10.1073/pnas.96.7.3734; Lang T, 2002, J CELL BIOL, V158, P751, DOI 10.1083/jcb.200203088; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Nichols BJ, 2002, NAT CELL BIOL, V4, P374, DOI 10.1038/ncb787; Niles WD, 1999, J MEMBRANE BIOL, V167, P85, DOI 10.1007/s002329900474; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; PALADE GE, 1968, J CELL BIOL, V37, P633, DOI 10.1083/jcb.37.3.633; PALADE GE, 1979, ACTA PHYSIOL SCAND, P11; PREDESCU AS, 1997, AM J PHYSIOL, V272, pH937; PREDESCU D, 1994, P NATL ACAD SCI USA, V91, P3014, DOI 10.1073/pnas.91.8.3014; Predescu SA, 2003, MOL BIOL CELL, V14, P4997, DOI 10.1091/mbc.e03-01-0041; Predescu SA, 2001, MOL BIOL CELL, V12, P1019, DOI 10.1091/mbc.12.4.1019; Rothman JE, 2002, NAT MED, V8, P1059, DOI 10.1038/nm770; Salaun C, 2004, TRAFFIC, V5, P255, DOI 10.1111/j.1600-0854.2004.0162.x; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; SIMIONESCU N, 1983, J CELL BIOL, V97, P1592, DOI 10.1083/jcb.97.5.1592; Zenisek D, 2000, NATURE, V406, P849, DOI 10.1038/35022500	21	72	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37130	37138		10.1074/jbc.M505659200	http://dx.doi.org/10.1074/jbc.M505659200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16118213	hybrid			2022-12-27	WOS:000232901800071
J	Kao, KC; Tran, LM; Liao, JC				Kao, KC; Tran, LM; Liao, JC			A global regulatory role of gluconeogenic genes in Escherichia coli revealed by transcriptome network analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA SYNTHETASE; PHOSPHORYLATION STATE; ACETATE OPERON; RNA-POLYMERASE; IN-VIVO; EXPRESSION; PROTEIN; SIGMA(S); GROWTH; IDENTIFICATION	In bacterial adaptation to the dynamic environment, metabolic genes are typically thought to be the executors, whereas global transcription regulators are regarded as the decision makers. Although the feedback from metabolic consequence is believed to be important, much less is understood. This work demonstrates that the gluconeogenic genes in Escherichia coli, ppsA, sfcA, and maeB, provide a feedback loop to the global regulator, cAMP receptor protein (CRP), in carbon source transition. Disruption of one of the gluconeogenic pathways has no phenotype in balanced growth, but causes a significant delay in the diauxic transition from glucose to acetate. To investigate the underlying mechanism, we measured the transcriptome profiles during the transition using DNA microarray, and network component analysis was employed to obtain the transcription factor activities. Results showed that one of the global regulators, CRP, was insufficiently activated during the transition in the ppsA deletion mutant. Indeed, addition of cAMP partially rescued the delay in transition. These results suggest that the gluconeogenic flux to phosphoenolpyruvate is important for full activation of adenylate cyclase through the phosphorylated enzyme IIA(glu) of the phosphotransferase system. Reduction of this flux causes insufficient activation of CRP and a global metabolic deficiency, which exemplifies a significant feedback interaction from metabolism to the a global regulatory system.	Univ Calif Los Angeles, Dept Chem & Biomol Engn, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Liao, JC (corresponding author), Univ Calif Los Angeles, Dept Chem & Biomol Engn, 420 Westwood Plaza, Los Angeles, CA 90095 USA.	liaoj@ucla.edu		Kao, Katy/0000-0002-1184-276X; Liao, James/0000-0002-4580-7276				Almeida Jonas S, 2003, Genome Inform, V14, P114; ALTUVIA S, 1994, MOL MICROBIOL, V13, P265, DOI 10.1111/j.1365-2958.1994.tb00421.x; Andersen JB, 1998, APPL ENVIRON MICROB, V64, P2240; Azam TA, 1999, J BACTERIOL, V181, P6361, DOI 10.1128/JB.181.20.6361-6370.1999; BALL CA, 1992, J BACTERIOL, V174, P8043, DOI 10.1128/JB.174.24.8043-8056.1992; Barker MM, 2001, J MOL BIOL, V305, P673, DOI 10.1006/jmbi.2000.4327; Beatty CM, 2003, J BACTERIOL, V185, P5148, DOI 10.1128/JB.185.17.5148-5157.2003; CORTAY JC, 1991, EMBO J, V10, P675, DOI 10.1002/j.1460-2075.1991.tb07996.x; Cozzone AJ, 1998, ANNU REV MICROBIOL, V52, P127, DOI 10.1146/annurev.micro.52.1.127; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; ELMANSI EMT, 1986, J GEN MICROBIOL, V132, P797; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GENTRY DR, 1993, J BACTERIOL, V175, P7982, DOI 10.1128/JB.175.24.7982-7989.1993; Gimenez R, 2003, J BACTERIOL, V185, P6448, DOI 10.1128/JB.185.21.6448-6455.2003; Hogema BM, 1998, MOL MICROBIOL, V30, P487, DOI 10.1046/j.1365-2958.1998.01053.x; Holms H, 1996, FEMS MICROBIOL REV, V19, P85, DOI 10.1111/j.1574-6976.1996.tb00255.x; Hyduke Daniel R., 2003, OMICS A Journal of Integrative Biology, V7, P227, DOI 10.1089/153623103322452369; Jishage M, 1996, J BACTERIOL, V178, P5447, DOI 10.1128/jb.178.18.5447-5451.1996; Kao KC, 2004, P NATL ACAD SCI USA, V101, P641, DOI 10.1073/pnas.0305287101; Kumari S, 2000, J BACTERIOL, V182, P4173, DOI 10.1128/JB.182.15.4173-4179.2000; LANGE R, 1994, GENE DEV, V8, P1600, DOI 10.1101/gad.8.13.1600; LAZZARINI RA, 1971, J BIOL CHEM, V246, P4381; Liao JC, 1996, BIOTECHNOL BIOENG, V52, P129, DOI 10.1002/(SICI)1097-0290(19961005)52:1<129::AID-BIT13>3.0.CO;2-J; Liao JC, 2003, P NATL ACAD SCI USA, V100, P15522, DOI 10.1073/pnas.2136632100; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Murray HD, 2003, MOL CELL, V12, P125, DOI 10.1016/S1097-2765(03)00266-1; Nair S, 2004, J BACTERIOL, V186, P4192, DOI 10.1128/JB.186.13.4192-4198.2004; Oh MK, 2000, BIOTECHNOL PROGR, V16, P278, DOI 10.1021/bp000002n; Oh MK, 2002, J BIOL CHEM, V277, P13175, DOI 10.1074/jbc.M110809200; PARK SJ, 1995, J BACTERIOL, V177, P6652, DOI 10.1128/jb.177.22.6652-6656.1995; PATNAIK R, 1992, J BACTERIOL, V174, P7527, DOI 10.1128/JB.174.23.7527-7532.1992; Pellicer MT, 1999, J BIOL CHEM, V274, P1745, DOI 10.1074/jbc.274.3.1745; Resnik E, 1996, J BACTERIOL, V178, P2715, DOI 10.1128/jb.178.9.2715-2717.1996; Salgado H, 2001, NUCLEIC ACIDS RES, V29, P72, DOI 10.1093/nar/29.1.72; Savageau M, 1976, BIOCH SYSTEMS ANAL S; Shin S, 1997, FEMS MICROBIOL LETT, V146, P103, DOI 10.1111/j.1574-6968.1997.tb10178.x; Starai VJ, 2004, J MOL BIOL, V340, P1005, DOI 10.1016/j.jmb.2004.05.010; Starai VJ, 2002, SCIENCE, V298, P2390, DOI 10.1126/science.1077650; Teich A, 1999, BIOTECHNOL PROGR, V15, P123, DOI 10.1021/bp980102h; Tran LM, 2005, METAB ENG, V7, P128, DOI 10.1016/j.ymben.2004.12.001; Tseng GC, 2001, NUCLEIC ACIDS RES, V29, P2549, DOI 10.1093/nar/29.12.2549; Wolfe AJ, 2005, MICROBIOL MOL BIOL R, V69, P12, DOI 10.1128/MMBR.69.1.12-50.2005; Yamamoto K, 2003, MOL MICROBIOL, V47, P183, DOI 10.1046/j.1365-2958.2003.03287.x; Zheng DL, 2004, NUCLEIC ACIDS RES, V32, P5874, DOI 10.1093/nar/gkh908	44	67	71	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36079	36087		10.1074/jbc.M508202200	http://dx.doi.org/10.1074/jbc.M508202200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16141204	hybrid, Green Published			2022-12-27	WOS:000232726900038
J	Okada, T; Ding, G; Sonoda, H; Kajimoto, T; Haga, Y; Khosrowbeygi, A; Gao, SY; Miwa, N; Jahangeer, S; Nakamura, S				Okada, T; Ding, G; Sonoda, H; Kajimoto, T; Haga, Y; Khosrowbeygi, A; Gao, SY; Miwa, N; Jahangeer, S; Nakamura, S			Involvement of N-terminal-extended form of sphingosine kinase 2 in serum-dependent regulation of cell proliferation and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; MOLECULAR-CLONING; KINASE TYPE-2; PROTEIN; SPHINGOSINE-1-PHOSPHATE; 1-PHOSPHATE; FTY720	Sphingosine kinase (SPHK) 1 is implicated in the regulation of cell proliferation and anti-apoptotic processes by catalyzing the formation of an important bioactive messenger, sphingosine 1-phosphate. Unlike the proliferative action of SPHK1, another isozyme, SPHK2, has been shown to possess anti-proliferative or pro-apoptotic action. Molecular mechanisms of SPHK2 action, however, are largely unknown. The present studies were undertaken to characterize the N-terminal-extended form of SPHK2 (SPHK2-L) by comparing it with the originally reported form, SPHK2-S. Real-time quantitative PCR analysis revealed that SPHK2-L mRNA is the major form in several human cell lines and tissues. From sequence analyses it was concluded that SPHK2-L is a species-specific isoform that is expressed in human but not in mouse. At the protein level it has been demonstrated by immunoprecipitation studies that SPHK2-L is the major isoform in human hepatoma HepG2 cells. SPHK2-L, when expressed in human embryonic kidney (HEK) 293 cells, did not show any inhibition of DNA synthesis in the presence of serum, whereas it showed marked inhibition in the absence of serum. Moreover, serum deprivation resulted in the translocation of SPHK2-L into the nuclei. In addition, serum deprivation induced SPHK2-L expression in HEK293 cells. Furthermore, suppression of SPHK2 by small interfering RNA treatment prevented serum deprivation- or drug-induced apoptosis in HEK293 cells. Taken together, these results indicate that a major form of SPHK2 splice variant, SPHK2-L, in human cells does not inhibit DNA synthesis under normal conditions and that SPHK2- L accumulation in the nucleus induced by serum deprivation may be involved in the cessation of cell proliferation or apoptosis depending on the cell type.	Kobe Univ, Grad Sch Med, Dept Mol & Cellular Biol, Div Biochem, Kobe, Hyogo 6500017, Japan	Kobe University	Nakamura, S (corresponding author), Kobe Univ, Grad Sch Med, Dept Mol & Cellular Biol, Div Biochem, Kobe, Hyogo 6500017, Japan.	snakamur@kobe-u.ac.jp		Sonoda, Hirofumi/0000-0003-3353-1783				Billich A, 2003, J BIOL CHEM, V278, P47408, DOI 10.1074/jbc.M307687200; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Fujita T, 2004, BIOCHEM J, V382, P717, DOI 10.1042/BJ20040141; Hayashi S, 2002, J BIOL CHEM, V277, P33319, DOI 10.1074/jbc.M201442200; Heringdorf DMZ, 1997, FEBS LETT, V410, P34, DOI 10.1016/S0014-5793(97)00320-7; Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200; Igarashi Y, 1997, J BIOCHEM-TOKYO, V122, P1080; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Le Stunff H, 2002, BBA-MOL CELL BIOL L, V1582, P8, DOI 10.1016/S1388-1981(02)00132-4; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200; MATTIE M, 1994, J BIOL CHEM, V269, P3181; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Paugh SW, 2003, FEBS LETT, V554, P189, DOI 10.1016/S0014-5793(03)01168-2; Pitson SM, 2005, J EXP MED, V201, P49, DOI 10.1084/jem.20040559; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Safadi-Chamberlain F, 2005, BIOCHEM J, V388, P827, DOI 10.1042/BJ20041726; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499; Yoshimoto T, 2003, J IMMUNOL, V171, P1352, DOI 10.4049/jimmunol.171.3.1352	19	128	144	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36318	36325		10.1074/jbc.M504507200	http://dx.doi.org/10.1074/jbc.M504507200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16103110	hybrid			2022-12-27	WOS:000232726900065
J	Tabner, BJ; El-Agnaf, OMA; Turnbull, S; German, MJ; Paleologou, KE; Hayashi, Y; Cooper, LJ; Fullwood, NJ; Allsop, D				Tabner, BJ; El-Agnaf, OMA; Turnbull, S; German, MJ; Paleologou, KE; Hayashi, Y; Cooper, LJ; Fullwood, NJ; Allsop, D			Hydrogen peroxide is generated during the very early stages of aggregation of the amyloid peptides implicated in Alzheimer disease and familial British dementia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-BETA; OXIDATIVE STRESS; PARKINSONS-DISEASE; ALPHA-SYNUCLEIN; CELL-DEATH; NEURODEGENERATIVE DISEASES; ABRI PEPTIDE; PROTEIN; REDUCTION; OLIGOMERS	Alzheimer disease and familial British dementia are neurodegenerative diseases that are characterized by the presence of numerous amyloid plaques in the brain. These lesions contain fibrillar deposits of the beta-amyloid peptide (A beta) and the British dementia peptide (ABri), respectively. Both peptides are toxic to cells in culture, and there is increasing evidence that early "soluble oligomers" are the toxic entity rather than mature amyloid fibrils. The molecular mechanisms responsible for this toxicity are not clear, but in the case of A beta, one prominent hypothesis is that the peptide can induce oxidative damage via the formation of hydrogen peroxide. We have developed a reliable method, employing electron spin resonance spectroscopy in conjunction with the spin-trapping technique, to detect any hydrogen peroxide generated during the incubation of A beta and other amyloidogenic peptides. Here, we monitored levels of hydrogen peroxide accumulation during different stages of aggregation of A beta-(1 - 40) and ABri and found that in both cases it was generated as a short "burst" early on in the aggregation process. Ultrastructural studies with both peptides revealed that structures resembling "soluble oligomers" or "protofibrils" were present during this early phase of hydrogen peroxide formation. Mature amyloid fibrils derived from A beta-( 1 - 40) did not generate hydrogen peroxide. We conclude that hydrogen peroxide formation during the early stages of protein aggregation may be a common mechanism of cell death in these ( and possibly other) neurodegenerative diseases.	Univ Lancaster, Dept Biol Sci, Lancaster LA1 4YQ, England; Univ Lancaster, Dept Phys, Lancaster LA1 4YQ, England; Univ Lancaster, Magnet Resonance Lab, Lancaster LA1 4YQ, England; United Arab Emirates Univ, Fac Med & Hlth Sci, Dept Biochem, Al Ain, U Arab Emirates	Lancaster University; Lancaster University; Lancaster University; United Arab Emirates University	Allsop, D (corresponding author), Univ Lancaster, Dept Biol Sci, Lancaster LA1 4YQ, England.	d.allsop@lancaster.ac.uk	German, Matt/R-5269-2018; Allsop, David/B-9725-2008	German, Matt/0000-0002-3910-6377; Allsop, David/0000-0002-0513-5575; Fullwood, Nigel James/0000-0002-9405-8515	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Antunes F, 2001, FREE RADICAL BIO MED, V30, P1008, DOI 10.1016/S0891-5849(01)00493-2; Atwood CS, 2003, BRAIN RES REV, V43, P1, DOI 10.1016/S0165-0173(03)00174-7; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Barnham KJ, 2004, FASEB J, V18, P1427, DOI 10.1096/fj.04-1890fje; Beal MF, 2002, FREE RADICAL BIO MED, V32, P797, DOI 10.1016/S0891-5849(02)00780-3; Bitan G, 2003, J BIOL CHEM, V278, P34882, DOI 10.1074/jbc.M300825200; Bitan G, 2003, P NATL ACAD SCI USA, V100, P330, DOI 10.1073/pnas.222681699; Butterfield DA, 2001, TRENDS MOL MED, V7, P548, DOI 10.1016/S1471-4914(01)02173-6; Chromy BA, 2003, BIOCHEMISTRY-US, V42, P12749, DOI 10.1021/bi030029q; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Curtain CC, 2001, J BIOL CHEM, V276, P20466, DOI 10.1074/jbc.M100175200; Dikalov SI, 2004, FREE RADICAL BIO MED, V36, P340, DOI 10.1016/j.freeradbiomed.2003.11.004; El-Agnaf OMA, 2001, J MOL BIOL, V310, P157, DOI 10.1006/jmbi.2001.4743; El-Agnaf OMA, 2001, BIOCHEMISTRY-US, V40, P3449, DOI 10.1021/bi002287i; HARPER JD, 1997, ANNU REV BIOCHEM, V66, P387; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Huang XD, 1999, J BIOL CHEM, V274, P37111, DOI 10.1074/jbc.274.52.37111; Kamsler A, 2004, MOL NEUROBIOL, V29, P167, DOI 10.1385/MN:29:2:167; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Lashuel HA, 2002, J MOL BIOL, V322, P1089, DOI 10.1016/S0022-2836(02)00735-0; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; Miranda S, 2000, PROG NEUROBIOL, V62, P633, DOI 10.1016/S0301-0082(00)00015-0; Moore SA, 2004, BIOCHEMISTRY-US, V43, P819, DOI 10.1021/bi035728h; Nelson TJ, 2005, J BIOL CHEM, V280, P7377, DOI 10.1074/jbc.M409071200; Opazo C, 2003, BIOMETALS, V16, P91, DOI 10.1023/A:1020795422185; Opazo C, 2002, J BIOL CHEM, V277, P40302, DOI 10.1074/jbc.M206428200; Sayre LM, 2001, CURR MED CHEM, V8, P721, DOI 10.2174/0929867013372922; Srinivasan R, 2003, J MOL BIOL, V333, P1003, DOI 10.1016/j.jmb.2003.09.001; Tabner BJ, 2002, FREE RADICAL BIO MED, V32, P1076, DOI 10.1016/S0891-5849(02)00801-8; Tabner Brian J., 2003, Current Medicinal Chemistry - Immunology Endocrine & Metabolic Agents, V3, P299, DOI 10.2174/1568013033483249; Tabner Brian J., 2001, Current Topics in Medicinal Chemistry, V1, P507, DOI 10.2174/1568026013394822; Turnbull S, 2003, NEUROSCI LETT, V336, P159, DOI 10.1016/S0304-3940(02)01254-5; Turnbull S, 2003, BIOCHEMISTRY-US, V42, P7675, DOI 10.1021/bi030036e; Turnbull S, 2001, FREE RADICAL BIO MED, V30, P1163, DOI 10.1016/S0891-5849(01)00513-5; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wogulis M, 2005, J NEUROSCI, V25, P1071, DOI 10.1523/JNEUROSCI.2381-04.2005; Yoshiike Y, 2001, J BIOL CHEM, V276, P32293, DOI 10.1074/jbc.M010706200	39	191	193	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35789	35792		10.1074/jbc.C500238200	http://dx.doi.org/10.1074/jbc.C500238200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16141213	hybrid			2022-12-27	WOS:000232726900003
J	Low, LY; Yang, C; Perego, M; Osterman, A; Liddington, RC				Low, LY; Yang, C; Perego, M; Osterman, A; Liddington, RC			Structure and lytic activity of a Bacillus anthracis prophage endolysin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL; STAPHYLOCOCCUS-AUREUS; BACTERIOPHAGE; RECOGNITION; HYDROLASES; LYSOZYME; HOMOLOGY; AMIDASE; PROGRAM; DOMAINS	We report a structural and functional analysis of the lambda prophage Ba02 endolysin ( PlyL) encoded by the Bacillus anthracis genome. We show that PlyL comprises two autonomously folded domains, an N- terminal catalytic domain and a C- terminal cell wall- binding domain. We determined the crystal structure of the catalytic domain; its three- dimensional fold is related to that of the cell wall amidase, T7 lysozyme, and contains a conserved zinc coordination site and other components of the catalytic machinery. We demonstrate that PlyL is an N- acetylmuramoyl- L- alanine amidase that cleaves the cell wall of several Bacillus species when applied exogenously. We show, unexpectedly, that the catalytic domain of PlyL cleaves more efficiently than the full- length protein, except in the case of Bacillus cereus, and using GFP- tagged cell wall- binding domain, we detected strong binding of the cell wall- binding domain to B. cereus but not to other species tested. We further show that a related endolysin ( Ply21) from the B. cereus phage, TP21, shows a similar pattern of behavior. To explain these data, and the species specificity of PlyL, we propose that the C- terminal domain inhibits the activity of the catalytic domain through intramolecular interactions that are relieved upon binding of the C- terminal domain to the cell wall. Furthermore, our data show that ( when applied exogenously) targeting of the enzyme to the cell wall is not a prerequisite of its lytic activity, which is inherently high. These results may have broad implications for the design of endolysins as therapeutic agents.	Burnham Inst, Infect & Inflammatory Dis Ctr, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, Div Cellular Biol, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute; Scripps Research Institute	Liddington, RC (corresponding author), Burnham Inst, Infect & Inflammatory Dis Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	rlidding@burnham.org						Baba T, 1996, EMBO J, V15, P4789, DOI 10.1002/j.1460-2075.1996.tb00859.x; BROWN ER, 1955, J INFECT DIS, V96, P34, DOI 10.1093/infdis/96.1.34; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHENG XD, 1994, P NATL ACAD SCI USA, V91, P4034, DOI 10.1073/pnas.91.9.4034; Ghuysen J-M., 1966, METHOD ENZYMOL, P685, DOI DOI 10.1016/0076-6879(66)08124-2; Inglesby TV, 2002, JAMA-J AM MED ASSOC, V287, P2236, DOI 10.1001/jama.287.17.2236; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim MS, 2003, NAT IMMUNOL, V4, P787, DOI 10.1038/ni952; Kleywegt GJ, 1996, STRUCTURE, V4, P897, DOI 10.1016/S0969-2126(96)00097-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Liepinsh E, 2003, J MOL BIOL, V327, P833, DOI 10.1016/S0022-2836(03)00185-2; Loessner MJ, 1999, J BACTERIOL, V181, P4452, DOI 10.1128/JB.181.15.4452-4460.1999; Loessner MJ, 1997, J BACTERIOL, V179, P2845, DOI 10.1128/jb.179.9.2845-2851.1997; Loessner MJ, 2002, MOL MICROBIOL, V44, P335, DOI 10.1046/j.1365-2958.2002.02889.x; Loessner MJ, 1998, FEMS MICROBIOL LETT, V162, P265, DOI 10.1016/S0378-1097(98)00131-1; Lopez R, 1997, MICROB DRUG RESIST, V3, P199, DOI 10.1089/mdr.1997.3.199; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Schuch R, 2002, NATURE, V418, P884, DOI 10.1038/nature01026; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876	22	133	140	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35433	35439		10.1074/jbc.M502723200	http://dx.doi.org/10.1074/jbc.M502723200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16103125	hybrid			2022-12-27	WOS:000232561200043
J	Vigil, D; Blumenthal, DK; Taylor, SS; Trewhella, J				Vigil, D; Blumenthal, DK; Taylor, SS; Trewhella, J			The conformationally dynamic C helix of the RI alpha subunit of protein kinase A mediates isoform-specific domain reorganization upon C subunit binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMIDE H/H-2 EXCHANGE; REGULATORY SUBUNIT; CATALYTIC SUBUNIT; I-ALPHA; CRYSTAL-STRUCTURE; BIOLOGICAL MACROMOLECULES; SOLUTION SCATTERING; DIMERIC COMPLEX; MOLECULAR-BASIS; CAMP	Different isoforms of the full- length protein kinase A ( PKA) regulatory subunit homodimer ( R-2) and the catalytic ( C) subunit-bound holoenzyme ( R2C2) have very different global structures despite similar molecular weights and domain organization within their primary sequences. To date, it has been the linker sequence between the R subunit dimerization/ docking domain and cAMP-binding domain A that has been implicated in modulating domain interactions to give rise to these differences in global structure. The small angle solution scattering data presented here for three different isoforms of PKA heterodimer ( Delta R- C) complexes reveal a role for another conformationally dynamic sequence in modulating inter-subunit and domain interactions, the C helix that connects the cAMP- binding domains A and B of the R subunit. The Delta R- C heterodimer complexes studied here were each formed with a monomeric N- terminal deletion mutant of the R subunit ( Delta R) that contains the inhibitor sequence and both cAMP- binding domains. The scattering data show that type II alpha and type II beta Delta R- C heterodimers are relatively compact and globular, with the C subunit contacting the inhibitor sequence and both cAMP- binding domains. In contrast, the type I alpha heterodimer is significantly more extended, with the C subunit interacting with the inhibitor sequence and cAMP-binding domain A, whereas domain B extends out such that its surface is almost completely solvent exposed. These data implicate the C helix of RI alpha in modulating isoform- specific interdomain communication in the PKA holoenzyme, adding another layer of structural complexity to our understanding of signaling dynamics in this multisubunit, multidomain protein kinase.	Univ Utah, Dept Chem, Salt Lake City, UT 84112 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92037 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Univ Utah, Dept Pharmacol & Toxicol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Biochem, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Trewhella, J (corresponding author), Univ Utah, Dept Chem, 315 S 1400 E,Rm 1124 HEB, Salt Lake City, UT 84112 USA.	Jill.Trewhella@chemistry.utah.edu		Blumenthal, Donald/0000-0002-8614-1167; Trewhella, Jill/0000-0002-8555-6766	NIGMS NIH HHS [GM34921-19A1, GM34921] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034921] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amieux PS, 2002, ANN NY ACAD SCI, V968, P75, DOI 10.1111/j.1749-6632.2002.tb04328.x; Anand GS, 2003, P NATL ACAD SCI USA, V100, P13264, DOI 10.1073/pnas.2232255100; Banky P, 2003, J MOL BIOL, V330, P1117, DOI 10.1016/S0022-2836(03)00552-7; Berman HM, 2005, P NATL ACAD SCI USA, V102, P45, DOI 10.1073/pnas.0408579102; Canaves JM, 2002, J MOL EVOL, V54, P17, DOI 10.1007/s00239-001-0013-1; Cheng XD, 2001, J BIOL CHEM, V276, P4102, DOI 10.1074/jbc.M006447200; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; Cummings DE, 1996, NATURE, V382, P622, DOI 10.1038/382622a0; Diller TC, 2001, STRUCTURE, V9, P73, DOI 10.1016/S0969-2126(00)00556-6; Gekko K, 2004, BIOCHEMISTRY-US, V43, P3844, DOI 10.1021/bi036271e; Guinier A., 1939, ANN PHYS, V12, P166; Hamuro Y, 2003, J MOL BIOL, V327, P1065, DOI 10.1016/S0022-2836(03)00234-1; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; Heller WT, 2004, J BIOL CHEM, V279, P19084, DOI 10.1074/jbc.M313405200; Heller WT, 2002, BIOCHEMISTRY-US, V41, P15654, DOI 10.1021/bi026687c; Herberg FW, 1996, BIOCHEMISTRY-US, V35, P2934, DOI 10.1021/bi951647c; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; KANDEL E, 2001, SCIENCE, V294, P5544; Kim C, 2005, SCIENCE, V307, P690, DOI 10.1126/science.1104607; Kirschner LS, 2000, NAT GENET, V26, P89, DOI 10.1038/79238; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Kozin MB, 2001, J APPL CRYSTALLOGR, V34, P33, DOI 10.1107/S0021889800014126; Laxminarayana D, 2000, INT IMMUNOL, V12, P1521, DOI 10.1093/intimm/12.11.1521; Newlon MG, 1999, NAT STRUCT BIOL, V6, P222; Porod G., 1982, SMALL ANGLE XRAY SCA, P18; Qin ZH, 2001, BIOPHYS J, V81, P2908, DOI 10.1016/S0006-3495(01)75931-0; Skalhegg BS, 2000, FRONT BIOSCI-LANDMRK, V5, pD678, DOI 10.2741/Skalhegg; SLICE LW, 1989, J BIOL CHEM, V264, P20940; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1988, ACTA CRYSTALLOGR A, V44, P244, DOI 10.1107/S0108767387011255; Tung CS, 2002, J BIOL CHEM, V277, P12423, DOI 10.1074/jbc.M110298200; Vigil D, 2004, J MOL BIOL, V337, P1183, DOI 10.1016/j.jmb.2004.02.028; Volkov VV, 2003, J APPL CRYSTALLOGR, V36, P860, DOI 10.1107/S0021889803000268; Wong W, 2004, NAT REV MOL CELL BIO, V5, P959, DOI 10.1038/nrm1527; Wu J, 2004, STRUCTURE, V12, P1057, DOI 10.1016/j.str.2004.03.022; Yu SN, 2004, BIOCHEMISTRY-US, V43, P1908, DOI 10.1021/bi0354435; Zhao JK, 1998, J BIOL CHEM, V273, P30448, DOI 10.1074/jbc.273.46.30448	40	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35521	35527		10.1074/jbc.M506769200	http://dx.doi.org/10.1074/jbc.M506769200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16109722	hybrid			2022-12-27	WOS:000232561200053
J	Cadoret, JC; Rousseau, B; Perewoska, I; Sicora, C; Cheregi, O; Vass, I; Houmard, J				Cadoret, JC; Rousseau, B; Perewoska, I; Sicora, C; Cheregi, O; Vass, I; Houmard, J			Cyclic nucleotides, the photosynthetic apparatus and response to a UV-B stress in the cyanobacterium Synechocystis sp PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II REACTION-CENTER; CAMP SIGNAL-TRANSDUCTION; PHOTOSYSTEM-II; ULTRAVIOLET-B; ADENYLATE-CYCLASE; ISOLATED THYLAKOIDS; RECEPTOR PROTEIN; ACCEPTOR-SIDE; CELL MOTILITY; SIGMA-FACTORS	Cyclic nucleotides cAMP and cGMP are ubiquitous signaling molecules that mediate many adaptative responses in eukaryotic cells. Cyanobacteria present the peculiarity among the prokaryotes of having the two types of cyclic nucleotide. Cellular homeostasis requires both cyclases (adenylyl/guanylyl, for their synthesis) and phosphodiesterases ( for their degradation). Fully segregated null mutants have been obtained for the two genes, sll1624 and slr2100, which encode putative cNMP phosphodiesterases. We present physiological evidence that the Synechocystis PCC 6803 open reading frame slr2100 could be a cGMP phosphodiesterase. In addition, we show that Slr2100, but not Sll1624, is required for the adaptation of the cells to a UV-B stress. UV-B radiation has deleterious effects for photosynthetic organisms, in particular on the photosystem II, through damaging the protein structure of the reaction center. Using biophysical and biochemical approaches, it was found that Slr2100 is involved in the signal transduction events which permit the repair of the UV-B-damaged photosystem II. This was confirmed by quantitative reverse transcriptase-PCR analyses. Altogether, the data point to an important role for cGMP in signal transduction and photoacclimation processes during a UV-B stress.	Ecole Normale Super, CNRS, FRE 2433, Dept Biol, F-75230 Paris, France; Biol Res Ctr, Inst Plant Biol, H-6701 Szeged, Hungary	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center	Houmard, J (corresponding author), Ecole Normale Super, CNRS, FRE 2433, Dept Biol, 46 Rue Ulm, F-75230 Paris, France.	jhoumard@biologie.ens.fr	Vass, Imre/AAS-6171-2021; Cheregi, Otilia/AAP-2474-2021	Vass, Imre/0000-0003-4987-7842; Cadoret, Jean-Charles/0000-0002-3827-5208				Abdollahi M, 2003, MOL CELL BIOCHEM, V252, P205, DOI 10.1023/A:1025568714217; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; Cann MJ, 2004, NEW PHYTOL, V161, P23, DOI 10.1046/j.1469-8137.2003.00916.x; de Alda JAGO, 2000, J BACTERIOL, V182, P3839, DOI 10.1128/JB.182.13.3839-3842.2000; de Alda JAGO, 2000, MICROBIOL-SGM, V146, P3183, DOI 10.1099/00221287-146-12-3183; DEMARSAC NT, 1993, FEMS MICROBIOL LETT, V104, P119; DOHLER G, 1994, Z NATURFORSCH C, V49, P607; ELMORJANI K, 1987, J GEN MICROBIOL, V133, P1685; FRISO G, 1994, BBA-BIOENERGETICS, V1184, P78, DOI 10.1016/0005-2728(94)90156-2; Galperin MY, 2001, FEMS MICROBIOL LETT, V205, P17, DOI 10.1016/S0378-1097(01)00424-4; Giacometti GM, 1996, EUR J BIOCHEM, V242, P799, DOI 10.1111/j.1432-1033.1996.0799r.x; GOLDEN SS, 1987, METHOD ENZYMOL, V153, P215; GREENBERG BM, 1989, P NATL ACAD SCI USA, V86, P6617, DOI 10.1073/pnas.86.17.6617; Grossman AR, 2001, J BIOL CHEM, V276, P11449, DOI 10.1074/jbc.R100003200; He YY, 2002, PHOTOCH PHOTOBIO SCI, V1, P729, DOI 10.1039/b110365m; HOUMARD J, 1990, P NATL ACAD SCI USA, V87, P2152, DOI 10.1073/pnas.87.6.2152; Huang LX, 2002, J BACTERIOL, V184, P6845, DOI 10.1128/JB.184.24.6845-6858.2002; Imamura S, 2003, FEBS LETT, V554, P357, DOI 10.1016/S0014-5793(03)01188-8; Kaneko T, 1996, DNA Res, V3, P185, DOI 10.1093/dnares/3.3.185; Katayama M, 1997, J BACTERIOL, V179, P3588, DOI 10.1128/jb.179.11.3588-3593.1997; Komenda J, 2002, EUR J BIOCHEM, V269, P610, DOI 10.1046/j.0014-2956.2001.02693.x; KULANDAIVELU G, 1983, PHYSIOL PLANTARUM, V58, P389, DOI 10.1111/j.1399-3054.1983.tb04199.x; Lao KQ, 1996, P NATL ACAD SCI USA, V93, P5258, DOI 10.1073/pnas.93.11.5258; Mate Z, 1998, J BIOL CHEM, V273, P17439, DOI 10.1074/jbc.273.28.17439; MOHAMED A, 1989, PLANT MOL BIOL, V13, P693, DOI 10.1007/BF00016024; Nakamura Y, 2000, NUCLEIC ACIDS RES, V28, P72, DOI 10.1093/nar/28.1.72; Nedunchezhian N, 1996, ACTA PHYSIOL PLANT, V18, P39; Ohmori M, 2004, PHOTOCH PHOTOBIO SCI, V3, P503, DOI 10.1039/b401623h; Ohmori M, 2002, PHOTOCHEM PHOTOBIOL, V75, P675, DOI 10.1562/0031-8655(2002)075<0675:ROCMPB>2.0.CO;2; Ohmori M, 2001, DNA RES, V8, P271, DOI 10.1093/dnares/8.6.271; Okamoto S, 2004, PHOTOCHEM PHOTOBIOL, V80, P429, DOI 10.1562/0031-8655(2004)080&lt;0429:APPATT&gt;2.0.CO;2; Omagari K, 2004, FEBS LETT, V563, P55, DOI 10.1016/S0014-5793(04)00248-0; PORRA RJ, 1974, ANAL BIOCHEM, V57, P255, DOI 10.1016/0003-2697(74)90071-2; Post A, 1996, PHOTOSYNTH RES, V49, P21, DOI 10.1007/BF00029424; RENGER G, 1989, PHOTOCHEM PHOTOBIOL, V49, P97, DOI 10.1111/j.1751-1097.1989.tb04083.x; RIPPKA R, 1988, METHOD ENZYMOL, V167, P3; SAKAMOTO T, 1991, PLANT CELL PHYSIOL, V32, P581; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sass L, 1997, PHOTOSYNTH RES, V54, P55, DOI 10.1023/A:1005895924892; SICORA C, 2005, IN PRESS PHYTOSYNTHE; Silva P, 2003, PLANT CELL, V15, P2152, DOI 10.1105/tpc.012609; Spetea C, 1996, PLANT SCI, V115, P207, DOI 10.1016/0168-9452(96)04347-6; TERAMURA AH, 1980, PLANT PHYSIOL, V65, P483, DOI 10.1104/pp.65.3.483; Terauchi K, 2004, MOL MICROBIOL, V52, P303, DOI 10.1111/j.1365-2958.2003.03980.x; Terauchi K, 1999, PLANT CELL PHYSIOL, V40, P248, DOI 10.1093/oxfordjournals.pcp.a029534; Tichy M, 2003, BBA-BIOENERGETICS, V1605, P55, DOI 10.1016/S0005-2728(03)00064-1; TREBST A, 1990, Z NATURFORSCH C, V45, P765; Trewavas AJ, 2002, CURR OPIN PLANT BIOL, V5, P425, DOI 10.1016/S1369-5266(02)00281-9; Tu CJ, 2004, J BACTERIOL, V186, P3889, DOI 10.1128/JB.186.12.3889-3902.2004; Tuominen I, 2003, J BACTERIOL, V185, P1116, DOI 10.1128/JB.185.3.1116-1119.2003; Unsal-Kacmaz K, 2002, P NATL ACAD SCI USA, V99, P6673, DOI 10.1073/pnas.102167799; Vass I, 1999, BIOCHEMISTRY-US, V38, P12786, DOI 10.1021/bi991094w; Vazquez-Bermudez MF, 2002, BBA-GENE STRUCT EXPR, V1578, P95, DOI 10.1016/S0167-4781(02)00506-7; VLADIMIROV YA, 1970, PHOTOCHEM PHOTOBIOL, V11, P227, DOI 10.1111/j.1751-1097.1970.tb05992.x; Yoshimura H, 2002, PLANT CELL PHYSIOL, V43, P460, DOI 10.1093/pcp/pcf050	55	31	36	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33935	33944		10.1074/jbc.M503153200	http://dx.doi.org/10.1074/jbc.M503153200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16096278	hybrid			2022-12-27	WOS:000232229700030
J	Huttenrach, F; Pollok-Kopp, B; Oppermann, M				Huttenrach, F; Pollok-Kopp, B; Oppermann, M			G protein-coupled receptor kinases promote phosphorylation and beta-arrestin-mediated internalization of CCR5 homo- and hetero-oligomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C5A ANAPHYLATOXIN RECEPTOR; CHEMOKINE RECEPTOR; CARBOXYL-TERMINUS; CRYSTAL-STRUCTURE; HIV-1 INFECTION; DOWN-REGULATION; IN-VIVO; DESENSITIZATION; DIMERIZATION; BINDING	Expression levels of the chemokine receptor, CC chemokine receptor 5 (CCR5), at the cell surface determine cell susceptibility to HIV entry and infection. Cellular activation by CCR5 itself, but also by unrelated receptors leads to cross-phosphorylation and cross-internalization of CCR5. This study addresses the underlying molecular mechanisms of homologous and heterologous CCR5 regulation. As shown by bioluminescence resonance energy transfer experiments, CCR5 formed constitutive homo- as well as heterooligomeric complexes together with C5aR but not with the unrelated AT(1a)R in living cells. Stimulation with CCL5 of RBL cells, which co-expressed CCR5 together with an N-terminally truncated CCR5-Delta NT mutant, resulted in both protein kinase C(PKC)- and G protein-coupled receptor (GPCR) kinase (GRK)-mediated cross-phosphorylation of the mutant unligated receptor, as determined by phosphosite-specific monoclonal antibody. Similarly, both PKC and GRK cross-phosphorylated CCR5 in a heterologous manner after C5a stimulation of RBL-CCR5/ C5aR cells, whereas AT(1a)R stimulation resulted only in classical PKC-mediated CCR5 phosphorylation. Co-expression of CCR5-Delta NT together with a phosphorylation-deficient CCR5 mutant that neither binds beta-arrestin nor undergoes internalization partially restored the CCL5-induced association of beta-arrestin with the homo- oligomeric receptor complex and augmented cellular uptake of I-125-CCL5. Co-expression of C5aR, but not of AT1aR, promoted CCR5 co-internalization upon agonist stimulation by a mechanism independent of CCR5 phosphorylation. Co-internalization of phosphorylated CCR5 was also observed in C5a-stimulated macrophages. Finally, co-expression of a constitutively internalized C5aR-US28(CT) mutant led to intracellular accumulation of CCR5 in the absence of ligand stimulation. These results show that GRKs and beta-arrestin are involved in heterologous receptor regulation by cross-phosphorylating and co-internalizing unligated receptors within homo- or hetero-oligomeric protein complexes.	Univ Gottingen, Dept Cellular & Mol Immunol, D-37073 Gottingen, Germany	University of Gottingen	Oppermann, M (corresponding author), Univ Gottingen, Dept Cellular & Mol Immunol, Humboldtallee 34, D-37073 Gottingen, Germany.	mopperm@gwdg.de						AbdAlla S, 1999, J BIOL CHEM, V274, P26079, DOI 10.1074/jbc.274.37.26079; Ali H, 1999, J BIOL CHEM, V274, P6027, DOI 10.1074/jbc.274.10.6027; ALI H, 1993, J BIOL CHEM, V268, P24247; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Ayoub M, 2001, N-S ARCH PHARMACOL, V363, pR53; Babcock GJ, 2003, J BIOL CHEM, V278, P3378, DOI 10.1074/jbc.M210140200; Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603; BENOVIC JL, 1990, BRIT J CLIN PHARMACO, V30, pS3, DOI 10.1111/j.1365-2125.1990.tb05462.x; Blanpain C, 1999, J BIOL CHEM, V274, P34719, DOI 10.1074/jbc.274.49.34719; Braun L, 2003, J BIOL CHEM, V278, P4277, DOI 10.1074/jbc.M210120200; Breit A, 2004, J BIOL CHEM, V279, P28756, DOI 10.1074/jbc.M313310200; Bunemann M, 1999, J PHYSIOL-LONDON, V517, P5, DOI 10.1111/j.1469-7793.1999.0005z.x; Chelli M, 2002, J BIOL CHEM, V277, P39388, DOI 10.1074/jbc.M205394200; Christophe T, 2000, J BIOL CHEM, V275, P1656, DOI 10.1074/jbc.275.3.1656; El-Asmar L, 2005, MOL PHARMACOL, V67, P460, DOI 10.1124/mol.104.003624; GIANNINI E, 1995, J BIOL CHEM, V270, P19166, DOI 10.1074/jbc.270.32.19166; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Hansen JL, 2004, J BIOL CHEM, V279, P24108, DOI 10.1074/jbc.M400092200; Hernanz-Falcon P, 2004, NAT IMMUNOL, V5, P216, DOI 10.1038/ni1027; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; Huttenrauch F, 2002, J BIOL CHEM, V277, P30769, DOI 10.1074/jbc.M204033200; Issafras H, 2002, J BIOL CHEM, V277, P34666, DOI 10.1074/jbc.M202386200; Kohout TA, 2003, MOL PHARMACOL, V63, P9, DOI 10.1124/mol.63.1.9; Kraft K, 2001, J BIOL CHEM, V276, P34408, DOI 10.1074/jbc.M102782200; Lagane B, 2005, MOL PHARMACOL, V67, P1966, DOI 10.1124/mol.104.009779; Langkabel P, 1999, EUR J IMMUNOL, V29, P3035, DOI 10.1002/(SICI)1521-4141(199909)29:09<3035::AID-IMMU3035>3.0.CO;2-Z; Lederman MM, 2004, SCIENCE, V306, P485, DOI 10.1126/science.1099288; Lemay J, 2005, NAT IMMUNOL, V6, P535, DOI 10.1038/ni0605-535a; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Lodowski DT, 2003, SCIENCE, V300, P1256, DOI 10.1126/science.1082348; Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215; Mesnier D, 2004, J BIOL CHEM, V279, P49664, DOI 10.1074/jbc.M404941200; MONTZ H, 1990, CELL IMMUNOL, V127, P337, DOI 10.1016/0008-8749(90)90137-G; Moser B, 2004, TRENDS IMMUNOL, V25, P75, DOI 10.1016/j.it.2003.12.005; Novi F, 2004, J BIOL CHEM, V279, P7476, DOI 10.1074/jbc.M306818200; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; Park PSH, 2004, J NEUROCHEM, V90, P537, DOI 10.1111/j.1471-4159.2004.02536.x; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; Pfeiffer M, 2002, J BIOL CHEM, V277, P19762, DOI 10.1074/jbc.M110373200; Pfeiffer M, 2003, J BIOL CHEM, V278, P51630, DOI 10.1074/jbc.M307095200; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Pollok-Kopp B, 2003, J BIOL CHEM, V278, P2190, DOI 10.1074/jbc.M209844200; Richardson RM, 2003, J BIOL CHEM, V278, P15867, DOI 10.1074/jbc.M211745200; Rothermel E, 1997, BBA-GENE STRUCT EXPR, V1351, P9, DOI 10.1016/S0167-4781(97)00006-7; Shen WP, 2000, BLOOD, V96, P2887, DOI 10.1182/blood.V96.8.2887.h8002887_2887_2894; Signoret N, 1998, J CELL SCI, V111, P2819; Szabo I, 2003, J LEUKOCYTE BIOL, V74, P1074, DOI 10.1189/jlb.0203067; Terrillon S, 2004, EMBO REP, V5, P30, DOI 10.1038/sj.embor.7400052; Terrillon S, 2004, P NATL ACAD SCI USA, V101, P1548, DOI 10.1073/pnas.0305322101; Terrillon S, 2004, EMBO J, V23, P3950, DOI 10.1038/sj.emboj.7600387; Vila-Coro AJ, 2000, P NATL ACAD SCI USA, V97, P3388, DOI 10.1073/pnas.050457797; Waldhoer M, 2005, P NATL ACAD SCI USA, V102, P9050, DOI 10.1073/pnas.0501112102; Waldhoer M, 2003, J BIOL CHEM, V278, P19473, DOI 10.1074/jbc.M213179200	57	64	69	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37503	37515		10.1074/jbc.M500535200	http://dx.doi.org/10.1074/jbc.M500535200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16144840	hybrid			2022-12-27	WOS:000233044500027
J	Song, LN; Gelmann, EP				Song, LN; Gelmann, EP			Interaction of beta-catenin and TIF2/GRIP1 in transcriptional activation by the androgen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROSTATE-CANCER; CRYSTAL-STRUCTURE; MUTATIONS; COMPLEX; GENE; COACTIVATORS; CELLS; RECOGNITION; PROGRESSION; INHIBITION	The multifunctional oncoprotein beta-catenin interacts with the activation function-2 domain of androgen receptor (AR) to stimulate androgen receptor transcriptional activity, increase sensitivity, and broaden specificity of ligand interactions. beta-Catenin interacts with androgen receptor in close proximity to the binding groove for P160 coactivators such as transcriptional intermediary factor-2 (TIF2)/glucocorticoid receptor interacting protein-1 (GRIP1). beta-Catenin can also bind directly to TIF2/GRIP1. Both N- and C-terminal regions of beta-catenin are needed for optimal interaction with TIF2/GRIP1. We show that distinct residues of beta-catenin are responsible for both binding and functional interactions with androgen receptor and with TCF4, thus allowing the introduction of missense mutations that selectively affect these interactions. beta-Catenin and TIF2/GRIP1 are each able to mediate binding between the other and androgen receptor in functional interactions that enhance ligand-dependent transcription. The data strongly imply that AR, beta-catenin, and TIF2/GRIP1 bind in a three-way interaction that mediates transcription. Lastly, we observed that a beta-catenin C-terminal peptide containing 229 amino acids can bind TIF2/GRIP1 and AR but has a profound dominant inhibitory effect on ligand-dependent transcription. We propose that beta-catenin may play an integral role in formation of the androgen-receptor transcriptional complex.	Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20007 USA; Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Med, Washington, DC 20007 USA	Georgetown University; Georgetown University	Gelmann, EP (corresponding author), Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, 3800 Reservoir Rd NW, Washington, DC 20007 USA.	Gelmanne@georgetown.edu			NATIONAL CANCER INSTITUTE [R01CA096854] Funding Source: NIH RePORTER; NCI NIH HHS [CA96854] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amir AL, 2003, J BIOL CHEM, V278, P30828, DOI 10.1074/jbc.M301208200; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Chesire DR, 2000, PROSTATE, V45, P323, DOI 10.1002/1097-0045(20001201)45:4<323::AID-PROS7>3.0.CO;2-W; Culig Z, 2004, J STEROID BIOCHEM, V92, P265, DOI 10.1016/j.jsbmb.2004.10.003; Gerstein AV, 2002, GENE CHROMOSOME CANC, V34, P9, DOI 10.1002/gcc.10037; Graham TA, 2000, CELL, V103, P885, DOI 10.1016/S0092-8674(00)00192-6; Graham TA, 2002, MOL CELL, V10, P563, DOI 10.1016/S1097-2765(02)00637-8; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Horvath LG, 2005, INT J CANCER, V113, P415, DOI 10.1002/ijc.20599; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Hur E, 2004, PLOS BIOL, V2, P1303, DOI 10.1371/journal.pbio.0020274; Lehrer S, 2000, CANCER GENET CYTOGEN, V122, P131, DOI 10.1016/S0165-4608(00)00291-0; Li HW, 2004, J BIOL CHEM, V279, P4212, DOI 10.1074/jbc.M311374200; Linja MJ, 2004, CLIN CANCER RES, V10, P1032, DOI 10.1158/1078-0432.CCR-0990-3; Miyamoto H, 1998, P NATL ACAD SCI USA, V95, P7379, DOI 10.1073/pnas.95.13.7379; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Mulholland DJ, 2003, ONCOGENE, V22, P5602, DOI 10.1038/sj.onc.1206802; Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200; Pawlowski JE, 2002, J BIOL CHEM, V277, P20702, DOI 10.1074/jbc.M200545200; Piedra J, 2001, J BIOL CHEM, V276, P20436, DOI 10.1074/jbc.M100194200; Rios-Doria J, 2004, CANCER RES, V64, P7237, DOI 10.1158/0008-5472.CAN-04-1048; SADI MV, 1991, CANCER, V67, P3057, DOI 10.1002/1097-0142(19910615)67:12<3057::AID-CNCR2820671221>3.0.CO;2-S; Shah S, 2003, J BIOL CHEM, V278, P48137, DOI 10.1074/jbc.M307154200; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Song LN, 2003, MOL CELL BIOL, V23, P1674, DOI 10.1128/MCB.23.5.1674-1687.2003; Tago K, 2000, GENE DEV, V14, P1741; Taplin ME, 1999, CANCER RES, V59, P2511; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Tilley WD, 1996, CLIN CANCER RES, V2, P277; Truica CI, 2000, CANCER RES, V60, P4709; Tyrrell CJ, 1998, EUR UROL, V33, P447, DOI 10.1159/000019634; Umar A, 2005, J CLIN ENDOCR METAB, V90, P507, DOI 10.1210/jc.2004-0057; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voeller HJ, 1998, CANCER RES, V58, P2520; von Kries JP, 2000, NAT STRUCT BIOL, V7, P800; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200	37	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37853	37867		10.1074/jbc.M503850200	http://dx.doi.org/10.1074/jbc.M503850200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16141201	hybrid			2022-12-27	WOS:000233044500066
J	Auerbach, SD; Johnson, KA				Auerbach, SD; Johnson, KA			Kinetic effects of kinesin switch I and switch II mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN MOTOR DOMAIN; X-RAY STRUCTURES; ATP HYDROLYSIS; CRYSTAL-STRUCTURE; ACTOMYOSIN SUBFRAGMENT-1; ESCHERICHIA-COLI; MOLECULAR MOTORS; DIMERIC KINESIN; GTP HYDROLYSIS; BINDING SITES	We have examined several mutants in the switch I, switch II region of rat kinesin. Pre-steady-state kinetic analysis of association and dissociation of an N256K mutant with nucleotides and microtubules demonstrates that the mutation blocks microtubule stimulation of nucleotide release and ATP hydrolysis without affecting other kinetic parameters. The results suggest that ADP release on one head may be coupled to structural changes on the other head to stimulate ATP hydrolysis. Mutations at Glu(237), a residue predicted to participate in a hydrogen-bond interaction critical for nucleotide processing, reduced or abolished microtubule-dependent ATPase activity with only minor effects on pre-steady-state rates of nucleotide release or binding. Mutations at Glu(200), a residue that could serve as an alternate electron acceptor in the above-mentioned hydrogen-bond interaction, had small effects on microtubule-dependent ATPase activity despite modestly reducing the rate at which microtubule-stimulated nucleotide release occurs. These results further clarify the pathway of coupling of ATP hydrolysis to force production.	Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Johnson, KA (corresponding author), Univ Texas, MBB 3-122,2500 Speedway A4800, Austin, TX 78735 USA.	kajohnson@mail.utexas.edu			NIGMS NIH HHS [GM-26726-25] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026726] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Auerbach SD, 2005, J BIOL CHEM, V280, P37048, DOI 10.1074/jbc.M502984200; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; Brune M, 1998, BIOCHEMISTRY-US, V37, P10370, DOI 10.1021/bi9804277; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; Farrell CM, 2002, J BIOL CHEM, V277, P17079, DOI 10.1074/jbc.M108793200; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; Gilbert SP, 1998, BIOCHEMISTRY-US, V37, P792, DOI 10.1021/bi971117b; Gulick AM, 1997, BIOCHEMISTRY-US, V36, P11619, DOI 10.1021/bi9712596; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HOYT MA, 1993, GENETICS, V135, P35; Kikkawa M, 2001, NATURE, V411, P439, DOI 10.1038/35078000; Klumpp LM, 2003, J BIOL CHEM, V278, P39059, DOI 10.1074/jbc.M304250200; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; Kull FJ, 2002, J CELL SCI, V115, P15; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13233, DOI 10.1021/bi00040a039; Minehardt TJ, 2001, BIOPHYS J, V80, P1151, DOI 10.1016/S0006-3495(01)76092-4; Moyer ML, 1998, BIOCHEMISTRY-US, V37, P800, DOI 10.1021/bi9711184; Muller J, 1999, BIOL CHEM, V380, P981, DOI 10.1515/BC.1999.122; Naber N, 2003, BIOPHYS J, V84, P3190, DOI 10.1016/S0006-3495(03)70043-5; Onishi H, 2004, BIOCHEMISTRY-US, V43, P3757, DOI 10.1021/bi040002m; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Sablin EP, 2001, CURR OPIN STRUC BIOL, V11, P716, DOI 10.1016/S0959-440X(01)00265-2; Sack S, 1999, EUR J BIOCHEM, V262, P1, DOI 10.1046/j.1432-1327.1999.00341.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Song HB, 1998, NATURE, V396, P587, DOI 10.1038/25153; Song YH, 2001, EMBO J, V20, P6213, DOI 10.1093/emboj/20.22.6213; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P; WOODWARD SKA, 1991, BIOCHEMISTRY-US, V30, P422, DOI 10.1021/bi00216a017; Xing J, 2000, J BIOL CHEM, V275, P35413, DOI 10.1074/jbc.M004232200; Yun MY, 2001, EMBO J, V20, P2611, DOI 10.1093/emboj/20.11.2611	39	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37061	37068		10.1074/jbc.M502985200	http://dx.doi.org/10.1074/jbc.M502985200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16118217	hybrid			2022-12-27	WOS:000232901800064
J	Beeser, A; Jaffer, ZM; Hofmann, C; Chernoff, J				Beeser, A; Jaffer, ZM; Hofmann, C; Chernoff, J			Role of group A p21-activated kinases in activation of extracellular-regulated kinase by growth factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; SERINE-338 PHOSPHORYLATION; DEPENDENT ACTIVATION; PROTEIN-KINASES; RAF ACTIVATION; B-RAF; PAK; ERK; TRANSFORMATION; FIBROBLASTS	The canonical extracellular-regulated kinase (ERK) signaling cascade, consisting of the Ras-Raf-Mek-ERK module, is critically important to many cellular functions. Although the general mechanism of activation of the ERK cascade is well established, additional noncanonical components greatly influence the activity of this pathway. Here, we focus on the group A p21-activated kinases (Paks), which have previously been implicated in regulating both c-Raf and Mek1 activity, by phosphorylating these proteins at Ser(338) and Ser(298), respectively. In NIH-3T3 cells, expression of an inhibitor of all three group A Paks reduced activation of ERK in response to platelet-derived growth factor ( PDGF) but not to epidermal growth factor (EGF). Similar results were obtained in HeLa cells using small interference RNA-mediated simultaneous knockdown of both Pak1 and Pak2 to reduce group A Pak function. Inhibition of Pak kinase activity dramatically decreased phosphorylation of Mek1 at Ser(298) in response to either PDGF or EGF, but this inhibition did not prevent Mek1 activation by EGF, suggesting that although Pak can phosphorylate Mek1 at Ser(298), this event is not required for Mek1 activation by growth factors. Inhibition of Pak reduced the Ser(338) phosphorylation of c-Raf in response to both PDGF and EGF; however, in the case of EGF, the reduction in Ser(338) phosphorylation was not accompanied by a significant decrease in c-Raf activity. These findings suggest that Paks are required for the phosphorylation of c-Raf at Ser(338) in response to either growth factor, but that the mechanisms by which EGF and PDGF activate c-Raf are fundamentally different.	Fox Chase Canc Ctr, Tumor Cell Biol Program, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Chernoff, J (corresponding author), Fox Chase Canc Ctr, Tumor Cell Biol Program, 333 Cottman Ave, Philadelphia, PA 19111 USA.	J_Chernoff@fccc.edu	Chernoff, Jonathan/I-7631-2014	Chernoff, Jonathan/0000-0002-4803-7836	NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054168] Funding Source: NIH RePORTER; NCI NIH HHS [CA-06927] Funding Source: Medline; NIGMS NIH HHS [GM54168] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BOKOCH GM, 2003, ANN REV BIOCH; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chiloeches A, 2001, MOL CELL BIOL, V21, P2423, DOI 10.1128/MCB.21.7.2423-2434.2001; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Chong HR, 2003, J BIOL CHEM, V278, P36269, DOI 10.1074/jbc.M212803200; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; DING JB, 1993, J BIOL CHEM, V268, P17326; Eblen ST, 2002, MOL CELL BIOL, V22, P6023, DOI 10.1128/MCB.22.17.6023-6033.2002; Edin ML, 2005, MOL CELL BIOL, V25, P4466, DOI 10.1128/MCB.25.11.4466-4475.2005; Fackler OT, 2000, MOL CELL BIOL, V20, P2619, DOI 10.1128/MCB.20.7.2619-2627.2000; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kratchmarova I, 2005, SCIENCE, V308, P1472, DOI 10.1126/science.1107627; Li WQ, 2001, J BIOL CHEM, V276, P34728, DOI 10.1074/jbc.M103496200; LU W, 1997, CURR BIOL, V7, P88; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Muller J, 2002, METHOD ENZYMOL, V345, P490; Nosaka Y, 2001, BIOCHEM BIOPH RES CO, V285, P675, DOI 10.1006/bbrc.2001.5222; Oehrl W, 2003, J BIOL CHEM, V278, P17819, DOI 10.1074/jbc.M209951200; Pullikuth A, 2005, MOL CELL BIOL, V25, P5119, DOI 10.1128/MCB.25.12.5119-5133.2005; Sells MA, 2000, J CELL BIOL, V151, P1449, DOI 10.1083/jcb.151.7.1449; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Tilbrook PA, 2001, ARCH BIOCHEM BIOPHYS, V396, P128, DOI 10.1006/abbi.2001.2577; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	38	105	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36609	36615		10.1074/jbc.M502306200	http://dx.doi.org/10.1074/jbc.M502306200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16129686	hybrid			2022-12-27	WOS:000232901800011
J	Bhavsar, AP; Truant, R; Brown, ED				Bhavsar, AP; Truant, R; Brown, ED			The TagB protein in Bacillus subtilis 168 is an intracellular peripheral membrane protein that can incorporate glycerol phosphate onto a membrane-bound acceptor in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WALL TEICHOIC-ACID; GRAM-POSITIVE BACTERIA; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; 3-PHOSPHATE CYTIDYLYLTRANSFERASE; CELL-WALL; MUTANT; BIOSYNTHESIS; LOCALIZATION; LIPOPROTEINS	Genes involved in the synthesis of poly( glycerol phosphate) wall teichoic acid have been identified in the tag locus of the model Gram-positive organism Bacillus subtilis 168. The functions of most of these gene products are predictable from sequence similarity to characterized proteins and have provided limited insight into the intracellular synthesis and translocation of wall teichoic acid. Nevertheless, critical steps of poly( glycerol phosphate) teichoic acid polymerization continue to be a puzzle. TagB and TagF, encoded in the tag locus, do not show sequence similarity to characterized proteins. We recently showed that recombinant TagF could catalyze glycerol phosphate polymerization in vitro. Based largely on homology to TagF, the TagB protein has been proposed to catalyze either an intracellular glycerophosphotransfer reaction or the extracellular teichoic acid/peptidoglycan ligation reaction. Here we have taken steps to characterize TagB, particularly through in vivo localization studies and in vitro biochemical assay, in order to make a case for either role in teichoic acid biogenesis. We have shown that TagB associates peripherally with the intracellular face of the cell membrane in vivo. We have also produced recombinant TagB and used it to demonstrate the enzymatic incorporation of labeled glycerol phosphate onto a membrane-bound acceptor. The data collected from this and the accompanying study (Schertzer, J. W., Bhavsar, A. P., and Brown, E. D. ( 2005) J. Biol. Chem. 280, 36683 36690) are strongly supportive of a role for TagB in B. subtilis 168 teichoic acid biogenesis as the CDP-glycerol:N-acetyl-beta-D-mannosaminyl-1,4-N- acetyl-D-glucosaminyldiphosphoundecaprenyl glycerophosphotransferase. Here we use the trivial name "Tag primase."	McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Antimicrobial Res Ctr, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University	Brown, ED (corresponding author), McMaster Univ, Dept Biochem & Biomed Sci, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	ebrown@mcmaster.ca		Bhavsar, Amit/0000-0003-3336-9288				Amer AO, 2002, MICROBIOL-SGM, V148, P571, DOI 10.1099/00221287-148-2-571; ANDERSON RG, 1972, BIOCHEM J, V127, P11, DOI 10.1042/bj1270011; Badurina DS, 2003, BBA-PROTEINS PROTEOM, V1646, P196, DOI 10.1016/S1570-9639(03)00019-0; Bhavsar AP, 2004, J BACTERIOL, V186, P7865, DOI 10.1128/JB.186.23.7865-7873.2004; Bhavsar AP, 2001, J BACTERIOL, V183, P6688, DOI 10.1128/JB.183.22.6688-6693.2001; BOYLAN RJ, 1969, J BACTERIOL, V100, P1316, DOI 10.1128/JB.100.3.1316-1321.1969; BOYLAN RJ, 1972, J BACTERIOL, V110, P281, DOI 10.1128/JB.110.1.281-290.1972; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITLING R, 1990, J BACTERIOL, V172, P1499, DOI 10.1128/jb.172.3.1499-1508.1990; BRIEHL M, 1989, J GEN MICROBIOL, V135, P1325; BRUCKNER R, 1992, GENE, V122, P187, DOI 10.1016/0378-1119(92)90048-T; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; Cutting Simon M., 1994, P348; Daniel RA, 2003, CELL, V113, P767, DOI 10.1016/S0092-8674(03)00421-5; HARRY EJ, 1995, J BACTERIOL, V177, P3386, DOI 10.1128/jb.177.12.3386-3393.1995; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Hu ZL, 2003, MOL MICROBIOL, V47, P345, DOI 10.1046/j.1365-2958.2003.03321.x; Jones LJF, 2001, CELL, V104, P913, DOI 10.1016/S0092-8674(01)00287-2; Kao MC, 2003, BIOCHEMISTRY-US, V42, P4534, DOI 10.1021/bi034166z; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Lazarevic V, 2002, MICROBIOL-SGM, V148, P815, DOI 10.1099/00221287-148-3-815; LAZAREVIC V, 1995, MOL MICROBIOL, V16, P345, DOI 10.1111/j.1365-2958.1995.tb02306.x; Levin PA, 1999, P NATL ACAD SCI USA, V96, P9642, DOI 10.1073/pnas.96.17.9642; Lin DCH, 1997, P NATL ACAD SCI USA, V94, P4721, DOI 10.1073/pnas.94.9.4721; MANOIL C, 1990, J BACTERIOL, V172, P1035, DOI 10.1128/jb.172.2.1035-1042.1990; MAUEL C, 1991, J GEN MICROBIOL, V137, P929, DOI 10.1099/00221287-137-4-929; MAUEL C, 1989, MOL GEN GENET, V215, P388, DOI 10.1007/BF00427034; MAUEL C, 1995, MICROBIOL-UK, V141, P2379, DOI 10.1099/13500872-141-10-2379; MCARTHUR HAI, 1980, FEBS LETT, V111, P317, DOI 10.1016/0014-5793(80)80818-0; NIELSEN JBK, 1982, J BACTERIOL, V152, P315; PARK YS, 1993, J BIOL CHEM, V268, P16648; Pichoff S, 2005, MOL MICROBIOL, V55, P1722, DOI 10.1111/j.1365-2958.2005.04522.x; POOLE HM, 1991, J GEN MICROBIOL, V137, P921, DOI 10.1099/00221287-137-4-921; POOLEY HM, 1992, J BACTERIOL, V174, P646, DOI 10.1128/jb.174.2.646-649.1992; POOLEY HM, 1994, BACTERIAL CELL WALL, P187; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schertzer JW, 2005, J BIOL CHEM, V280, P36683, DOI 10.1074/jbc.M507153200; Schertzer JW, 2003, J BIOL CHEM, V278, P18002, DOI 10.1074/jbc.M300706200; Soldo B, 2002, MICROBIOL-SGM, V148, P2079, DOI 10.1099/00221287-148-7-2079; Soldo B, 2002, J BACTERIOL, V184, P4316, DOI 10.1128/JB.184.15.4316-4320.2002; SUTCLIFFE IC, 1995, J BACTERIOL, V177, P1123, DOI 10.1128/jb.177.5.1123-1128.1995; Szeto TH, 2002, P NATL ACAD SCI USA, V99, P15693, DOI 10.1073/pnas.232590599; Tjalsma H, 1999, J BIOL CHEM, V274, P1698, DOI 10.1074/jbc.274.3.1698	44	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36691	36700		10.1074/jbc.M507154200	http://dx.doi.org/10.1074/jbc.M507154200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16150696	hybrid			2022-12-27	WOS:000232901800021
J	Eisses, JF; Kaplan, JH				Eisses, JF; Kaplan, JH			The mechanism of copper uptake mediated by human CTR1 - A mutational analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; TRANSPORTER CTR1; PLASMA-MEMBRANE; PROTEIN; TRAFFICKING; AFFINITY; PROVIDES; DOMAIN; HCTR1; CELLS	Cellular copper uptake is a prerequisite for the biosynthesis of many copper-dependent enzymes; disruption of copper uptake results in embryonic lethality. In humans, copper is transported into cells by hCTR1, a membrane protein, composed of 190 amino acids with only three trans-membrane segments. To provide insight into the mechanism of this unusual transporter, we characterized the functional properties of various hCTR1 mutants stably expressed in Sf9 cells. Most single amino acid substitutions involving charged and potential copper-coordinating residues have some influence on the V-max and K-m values for copper uptake but do not greatly alter hCTR1-mediated copper transport. However, there were two notable exceptions. Replacement of Tyr(156) with Ala greatly reduced the maximal transport rate without effect on the K-m value for copper. Also, replacement of His(139) in the second transmembrane segment with Arg caused a dramatic increase in the rate of copper uptake and a large increase in the K-m value for copper. This effect was not seen with an Ala replacement, pointing to the role of a positive charge in modulating copper exit from the pathway. Truncated mutants demonstrated that the deletion of a large portion of the N-terminal domain only slightly decreased the apparent K-m value for copper and decreased the rate of transport. Similar effects were observed with the removal of the last 11 C-terminal residues. The results suggested that the N and C termini, although nonessential for transport, may have an important role in facilitating the delivery of copper to and retrieving copper from, respectively, the translocation pathway. A model of how hCTR1 mediates copper entry into cells was proposed that included a rate-limiting site in the pore close to the intracellular exit.	Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kaplan, JH (corresponding author), Univ Illinois, Dept Biochem & Mol Genet, 900 S Ashland Ave, Chicago, IL 60607 USA.	kaplanj@uic.edu		Kaplan, Jack/0000-0002-7048-6574	NATIONAL CANCER INSTITUTE [R24CA086307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM067166] Funding Source: NIH RePORTER; NCI NIH HHS [R24 CA86307] Funding Source: Medline; NIGMS NIH HHS [P01 GM067166] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aller SG, 2004, J BIOL CHEM, V279, P53435, DOI 10.1074/jbc.M409421200; Arnesano F, 2003, P NATL ACAD SCI USA, V100, P3814, DOI 10.1073/pnas.0636904100; Eisses JF, 2005, J BIOL CHEM, V280, P9635, DOI 10.1074/jbc.M500116200; Eisses JF, 2002, J BIOL CHEM, V277, P29162, DOI 10.1074/jbc.M203652200; El Meskini R, 2003, J BIOL CHEM, V278, P12278, DOI 10.1074/jbc.M211413200; FRIEDEN E, 1986, CLIN PHYSIOL BIOCH, V4, P11; Harris ED, 2003, CRIT REV CL LAB SCI, V40, P547, DOI 10.1080/10408360390250649; HOLM L, 1987, EMBO J, V6, P2819, DOI 10.1002/j.1460-2075.1987.tb02578.x; Howard CM, 1998, THROMB RES, V91, P113, DOI 10.1016/S0049-3848(98)00060-7; Jaksch M, 2001, HUM MOL GENET, V10, P3025, DOI 10.1093/hmg/10.26.3025; Kuo YM, 2001, P NATL ACAD SCI USA, V98, P6836, DOI 10.1073/pnas.111057298; Lee J, 2002, J BIOL CHEM, V277, P4380, DOI 10.1074/jbc.M104728200; Lee LW, 2001, P NATL ACAD SCI USA, V98, P6842, DOI 10.1073/pnas.111058698; Lutsenko S, 2003, J MEMBRANE BIOL, V191, P1, DOI 10.1007/s00232-002-1040-6; Medeiros DM, 2002, J BIOENERG BIOMEMBR, V34, P389, DOI 10.1023/A:1021206220851; Pena MMO, 2000, J BIOL CHEM, V275, P33244, DOI 10.1074/jbc.M005392200; Petris MJ, 1999, HUM MOL GENET, V8, P2107, DOI 10.1093/hmg/8.11.2107; Petris MJ, 2000, HUM MOL GENET, V9, P2845, DOI 10.1093/hmg/9.19.2845; Puig S, 2002, J BIOL CHEM, V277, P26021, DOI 10.1074/jbc.M202547200; Richter OMH, 2003, REV PHYSIOL BIOCH P, V147, P47, DOI 10.1007/s10254-003-0006-0; Roelofsen H, 2000, GASTROENTEROLOGY, V119, P782, DOI 10.1053/gast.2000.17834; Sharp PA, 2003, INT J BIOCHEM CELL B, V35, P288, DOI 10.1016/S1357-2725(02)00134-6; Tandy S, 2000, J BIOL CHEM, V275, P1023, DOI 10.1074/jbc.275.2.1023; Whittaker JW, 2005, ARCH BIOCHEM BIOPHYS, V433, P227, DOI 10.1016/j.abb.2004.08.034; Xiao Z, 2002, CHEM COMMUN, V6, P588; Xiao ZG, 2004, J AM CHEM SOC, V126, P3081, DOI 10.1021/ja0390350	26	119	122	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37159	37168		10.1074/jbc.M508822200	http://dx.doi.org/10.1074/jbc.M508822200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16135512	hybrid			2022-12-27	WOS:000232901800074
J	Hamdane, D; Kiger, L; Hoa, GHB; Dewilde, S; Uzan, J; Burmester, T; Hankeln, T; Moens, L; Marden, MC				Hamdane, D; Kiger, L; Hoa, GHB; Dewilde, S; Uzan, J; Burmester, T; Hankeln, T; Moens, L; Marden, MC			High pressure enhances hexacoordination in neuroglobin and other globins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-MONOXIDE; LIGAND-BINDING; MYOGLOBIN; HEMOPROTEINS; HEMOGLOBIN; DYNAMICS; OXYGEN; STATE; PHOTOLYSIS; MECHANISM	The techniques of high applied pressure and flash photolysis have been combined to study ligand rebinding to neuroglobin (Ngb) and tomato Hb, globins that may display a His-Fe-His hexacoordination in the absence of external ligands. High pressure induces a moderate decrease in the His association rate and a large decrease in His dissociation rate, thus leading to an enhancement of the overall His affinity. The overall structural difference between penta- and hexacoordinated globins may be rather small and can be overcome by external modifications such as high pressure. Over the pressure range 0.1 - 700 MPa ( 7 kbar), the globins may show a loss of over a factor of 100 in the amplitude of the bimolecular rebinding phase after photodissociation. The kinetic data show that pressure induces a moderate increase of the rate for ligand binding from the correlated pair state ( just after photodissociation) and a large ( factor of 1000) decrease in rate for migration through the protein. The effect on the ligand migration phase was similar for both the external ligands ( such as oxygen) as for the internal ( histidine) ligand, suggesting the dominant role of protein fluctuations, rather than specific chemical barriers. Thus high pressure efficiently closes the protein migration channels; however, contrary to the effect of high viscosity, high pressure induces a greater decrease in rate for ligand migration toward the exterior ( heme to the solvent) versus inward migration, as if the presence of the ligand itself induces an additional steric constraint.	INSERM, U473, F-94275 Le Kremlin Bicetre, France; Univ Antwerp, Dept Biomed Sci, B-2610 Antwerp, Belgium; Johannes Gutenberg Univ Mainz, Inst Zool, D-55099 Mainz, Germany; Johannes Gutenberg Univ Mainz, Inst Mol Genet, D-55099 Mainz, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Antwerp; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Marden, MC (corresponding author), INSERM, U473, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France.	marden@kb.inserm.fr	Burmester, Thorsten/I-7225-2013; Marden, Michael/AAA-5923-2020; Kiger, Laurent/Q-1686-2018; Marden, Michael C/G-3139-2012	Burmester, Thorsten/0000-0002-5772-7863; Marden, Michael C/0000-0002-5254-6385				ADACHI S, 1989, J BIOL CHEM, V264, P18896; ALDEN RG, 1989, J BIOL CHEM, V264, P1933; ArredondoPeter R, 1997, PLANT PHYSIOL, V115, P1259, DOI 10.1104/pp.115.3.1259; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; BEECE D, 1980, BIOCHEMISTRY-US, V19, P5147, DOI 10.1021/bi00564a001; Burmester T, 2002, MOL BIOL EVOL, V19, P416, DOI 10.1093/oxfordjournals.molbev.a004096; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; Couture M, 2001, J BIOL CHEM, V276, P36377, DOI 10.1074/jbc.M103907200; Dewilde S, 2001, J BIOL CHEM, V276, P38949, DOI 10.1074/jbc.M106438200; Fenimore PW, 2002, P NATL ACAD SCI USA, V99, P16047, DOI 10.1073/pnas.212637899; FRAUENFELDER H, 1990, J PHYS CHEM-US, V94, P1024, DOI 10.1021/j100366a002; Hamdane D, 2003, J BIOL CHEM, V278, P51713, DOI 10.1074/jbc.M309396200; HASINOFF BB, 1974, BIOCHEMISTRY-US, V13, P3111, DOI 10.1021/bi00712a017; KEILIN J, 1949, BIOCHEM J, V45, P440, DOI 10.1042/bj0450440; MARDEN MC, 1988, BIOCHEMISTRY-US, V27, P1659, DOI 10.1021/bi00405a041; Mentre P, 2001, INT REV CYTOL, V201, P1, DOI 10.1016/S0074-7696(01)01001-4; MORISHIMA I, 1980, BIOCHEMISTRY-US, V19, P1569, DOI 10.1021/bi00549a006; NEUMAN RC, 1973, J PHYS CHEM-US, V77, P2687, DOI 10.1021/j100640a025; Pesce A, 2003, STRUCTURE, V11, P1087, DOI 10.1016/S0969-2126(03)00166-7; TAUBE DJ, 1990, J AM CHEM SOC, V112, P6880, DOI 10.1021/ja00175a023; Teeter MM, 2004, PROTEIN SCI, V13, P313, DOI 10.1110/ps.03334304; Trent JT, 2002, J BIOL CHEM, V277, P19538, DOI 10.1074/jbc.M201934200; UNNO M, 1991, BIOCHEMISTRY-US, V30, P10679, DOI 10.1021/bi00108a011; UNNO M, 1990, BIOCHEMISTRY-US, V29, P10199, DOI 10.1021/bi00496a007; UNNO M, 1994, BIOCHEMISTRY-US, V33, P9762, DOI 10.1021/bi00198a047; Uzan J, 2004, BIOPHYS J, V87, P1196, DOI 10.1529/biophysj.104.042168; Vallone B, 2004, PROTEINS, V56, P85, DOI 10.1002/prot.20113; Vallone B, 2004, P NATL ACAD SCI USA, V101, P17351, DOI 10.1073/pnas.0407633101; VEDAM R, 1968, J ACOUST SOC AM, V43, P108, DOI 10.1121/1.1910740; Wakasugi K, 2003, J BIOL CHEM, V278, P36505, DOI 10.1074/jbc.M305519200	31	26	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36809	36814		10.1074/jbc.M506253200	http://dx.doi.org/10.1074/jbc.M506253200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16100391	hybrid			2022-12-27	WOS:000232901800035
J	Marchesini, N; Vieira, M; Luo, SH; Moreno, SNJ; Docampo, R				Marchesini, N; Vieira, M; Luo, SH; Moreno, SNJ; Docampo, R			A malaria parasite-encoded vacuolar H+-ATPase is targeted to the host erythrocyte	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIA-RICH CELLS; RED-BLOOD-CELLS; PLASMODIUM-FALCIPARUM; TRYPANOSOMA-CRUZI; CHLORIDE CHANNEL; MAURERS CLEFTS; CYTOPLASMIC PH; TRANSPORT; MEMBRANE; ACIDOCALCISOMES	The asexual development of malaria parasites inside the erythrocyte is accompanied by changes in the composition, structure, and function of the host cell membrane and cytoplasm. The parasite exports a membrane network into the host cytoplasm and several proteins that are inserted into the erythrocyte membrane, although none of these proteins has been shown to have enzymatic activity. We report here that a functional malaria parasite-encoded vacuolar (V)-H+-ATPase is exported to the erythrocyte and localized in membranous structures and in the plasma membrane of the infected erythrocyte. This localization was determined by separation of parasite and erythrocyte membranes and determination of enzyme marker activities and by immunofluorescence microscopy assays using antibodies against the B subunit of the malarial V-H+ ATPase and erythrocyte ( spectrins) and parasite ( merozoite surface protein 1) markers. Our results suggest that this pump has a role in the maintenance of the intracellular pH (pH(i)) of the infected erythrocyte. Our results also indicate that although the pH(i) maintained by the V-H+-ATPase is important for maximum uptake of small metabolites at equilibrium, it does not appear to affect transport across the erythrocyte membrane and is, therefore, not involved in the previously described phenomenon of increased permeability of infected erythrocytes that is sensitive to chloride channel inhibitors ( new permeation pathway). This constitutes the first report of the presence of a functional enzyme of parasite origin in the plasma membrane of its host.	Univ Illinois, Dept Pathobiol, Urbana, IL 61802 USA; Univ Illinois, Ctr Zoonoses Res, Urbana, IL 61802 USA; Univ Georgia, Ctr Cellular Biol, Athens, GA 30602 USA; Univ Georgia, Ctr Trop & Global Emerging Dis, Athens, GA 30602 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Docampo, R (corresponding author), Univ Illinois, Dept Pathobiol, Urbana, IL 61802 USA.	rdocampo@uga.edu			NCRR NIH HHS [C06 RR16515-01] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR016515] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Allen RJW, 2004, J BIOL CHEM, V279, P11264, DOI 10.1074/jbc.M311110200; BENAIM G, 1991, BIOCHEM J, V280, P715, DOI 10.1042/bj2800715; BOOKCHIN RM, 1981, J PHYSIOL-LONDON, V312, P265, DOI 10.1113/jphysiol.1981.sp013628; Cheng HS, 1998, J MEMBRANE BIOL, V164, P155, DOI 10.1007/s002329900401; DEGUERCY A, 1990, MOL BIOCHEM PARASIT, V38, P233, DOI 10.1016/0166-6851(90)90026-I; Deitsch KW, 1996, MOL BIOCHEM PARASIT, V76, P1, DOI 10.1016/0166-6851(95)02575-8; Desai SA, 2000, NATURE, V406, P1001, DOI 10.1038/35023000; Docampo R, 2005, NAT REV MICROBIOL, V3, P251, DOI 10.1038/nrmicro1097; Drose S, 1997, J EXP BIOL, V200, P1; Drozdowicz YM, 2001, TRENDS PLANT SCI, V6, P206, DOI 10.1016/S1360-1385(01)01923-9; DUNN MJ, 1969, J CLIN INVEST, V48, P674, DOI 10.1172/JCI106025; GINSBURG H, 1985, MOL BIOCHEM PARASIT, V14, P313, DOI 10.1016/0166-6851(85)90059-3; GINSBURG H, 1983, BIOCHIM BIOPHYS ACTA, V729, P97, DOI 10.1016/0005-2736(83)90460-1; HARVEY BJ, 1992, J EXP BIOL, V172, P289; Hayashi M, 2000, J BIOL CHEM, V275, P34353, DOI 10.1074/jbc.M003323200; HIBBS AR, 1994, EXP PARASITOL, V79, P260, DOI 10.1006/expr.1994.1089; Hiller NL, 2004, SCIENCE, V306, P1934, DOI 10.1126/science.1102737; HOLDER AA, 1984, J EXP MED, V160, P624, DOI 10.1084/jem.160.2.624; HOLDER AA, 1982, J EXP MED, V156, P1528, DOI 10.1084/jem.156.5.1528; KARCZ SR, 1994, MOL BIOCHEM PARASIT, V65, P123, DOI 10.1016/0166-6851(94)90121-X; KIRK K, 1994, J BIOL CHEM, V269, P3339; KUTNER S, 1982, BIOCHIM BIOPHYS ACTA, V687, P113, DOI 10.1016/0005-2736(82)90178-X; KUTNER S, 1983, J CELL PHYSIOL, V114, P245, DOI 10.1002/jcp.1041140215; LARSEN EH, 1991, PHYSIOL REV, V71, P235, DOI 10.1152/physrev.1991.71.1.235; LARSEN EH, 1992, J PHYSIOL-LONDON, V450, P203, DOI 10.1113/jphysiol.1992.sp019124; Luo SH, 1999, FEBS LETT, V460, P217, DOI 10.1016/S0014-5793(99)01353-8; Marchesini N, 2000, BIOCHEM J, V347, P243, DOI 10.1042/0264-6021:3470243; Marti M, 2004, SCIENCE, V306, P1930, DOI 10.1126/science.1102452; McIntosh MT, 2001, MOL BIOCHEM PARASIT, V114, P183, DOI 10.1016/S0166-6851(01)00251-1; Moreno SNJ, 1998, BIOCHEM J, V330, P853; Oh SS, 2000, MOL BIOCHEM PARASIT, V108, P237, DOI 10.1016/S0166-6851(00)00227-9; ONKEN H, 1995, J EXP BIOL, V198, P767; Przyborski JM, 2003, MOL BIOCHEM PARASIT, V132, P17, DOI 10.1016/S0166-6851(03)00212-3; Rodrigues CO, 1999, MOL CELL BIOL, V19, P7712; Saliba KJ, 1999, J BIOL CHEM, V274, P33213, DOI 10.1074/jbc.274.47.33213; Schlesinger PH, 1997, J BIOL CHEM, V272, P18636, DOI 10.1074/jbc.272.30.18636; Seufferheld M, 2004, J BIOL CHEM, V279, P51193, DOI 10.1074/jbc.M406099200; Shahabuddin M, 1998, P NATL ACAD SCI USA, V95, P3385, DOI 10.1073/pnas.95.7.3385; UPSTON JM, 1995, BBA-BIOMEMBRANES, V1236, P249, DOI 10.1016/0005-2736(95)00055-8; Vanderheyden N, 1996, BIOCHEM J, V318, P103, DOI 10.1042/bj3180103; VANDERJAGT DL, 1982, J PARASITOL, V68, P1068, DOI 10.2307/3281093; Vincensini L, 2005, MOL CELL PROTEOMICS, V4, P582, DOI 10.1074/mcp.M400176-MCP200; WELTENS R, 1992, Cellular Physiology and Biochemistry, V2, P101, DOI 10.1159/000154630; ZEISKE W, 1992, J EXP BIOL, V172, P323	44	18	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36841	36847		10.1074/jbc.M507727200	http://dx.doi.org/10.1074/jbc.M507727200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16135514	hybrid			2022-12-27	WOS:000232901800039
J	Sano, T; Kihara, A; Kurotsu, F; Iwaki, S; Igarashi, Y				Sano, T; Kihara, A; Kurotsu, F; Iwaki, S; Igarashi, Y			Regulation of the sphingoid long-chain base kinase Lcb4p by ergosterol and heme - Studies in phytosphingosine-resistant mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTOPORPHYRINOGEN OXIDASE; KEY REGULATOR; YEAST-CELLS; HEAT-STRESS; GENE; PROTEIN; 1-PHOSPHATE; IDENTIFICATION; BIOSYNTHESIS	Sphingoid long-chain base 1-phosphates (LCBPs) are widely conserved, bioactive lipid molecules. In yeast, LCBPs are known to be involved in several cellular responses such as heat shock resistance and Ca2+ mobilization, although their target molecules and signaling pathways remain unclear. To identify genes involved in LCBP signaling and in regulation of LCBP synthesis, we performed transposon mutagenesis in cells lacking the LCBP lyase DPL1 and LCBP phosphatase LCB3 genes and screened for phytosphingosine-resistant clones. Further isolation and identification revealed eight genes (PBP1, HEM14, UFD4, HMG1, TPS1, KES1, WHI2, and ERG5), in addition to the previously characterized LCB4 and PDR5 genes, that are involved in phytosphingosine resistance. Of these eight, four are ergosterol-related genes ( HEM14, HMG1, KES1, and ERG5). We also demonstrated that protein expression of the long-chain base kinase Lcb4p was reduced in Delta hem14 and Delta hmg1 cells, likely as a consequence of decreased activity of the heme-dependent transcription factor Hap1p. In addition, phosphorylation of Lcb4p was decreased in all the ergosterol-related mutants isolated and other ergosterol mutants constructed (Delta erg2, Delta erg3, and Delta erg6). Finally, plasma membrane localization of Lcb4p was found to be reduced in Delta erg6 cells. These results suggest that changes in sterol composition affect the phosphorylation of Lcb4p because of the altered localization. The other genes isolated ( PBP1, UFD4, TPS1, and WHI2) may be involved in LCBP signaling.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biomembrane & Biofunct Chem, Kita Ku, Sapporo, Hokkaido 0600812, Japan	Hokkaido University	Kihara, A (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biomembrane & Biofunct Chem, Kita Ku, Kita 12 Jo,Nishi 6 Choume, Sapporo, Hokkaido 0600812, Japan.	kihara@pharm.hokudai.ac.jp	KIHARA, AKIO/A-3802-2012; Sano, Takamitsu/F-9410-2012	KIHARA, AKIO/0000-0001-5889-0788; 				ARGUELLES JC, 1994, FEBS LETT, V350, P266, DOI 10.1016/0014-5793(94)00786-1; BASSON ME, 1986, P NATL ACAD SCI USA, V83, P5563, DOI 10.1073/pnas.83.15.5563; Beh CT, 2001, GENETICS, V157, P1117; Birchwood CJ, 2001, J BIOL CHEM, V276, P11712, DOI 10.1074/jbc.M010221200; Camadro JM, 1996, J BIOL CHEM, V271, P9120, DOI 10.1074/jbc.271.15.9120; Cuvillier O, 2002, BBA-MOL CELL BIOL L, V1585, P153, DOI 10.1016/S1388-1981(02)00336-0; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Emter R, 2002, FEBS LETT, V521, P57, DOI 10.1016/S0014-5793(02)02818-1; Fukuda Y, 2004, BBA-MOL CELL BIOL L, V1636, P12, DOI 10.1016/j.bbalip.2003.11.006; Funato K, 2003, J BIOL CHEM, V278, P7325, DOI 10.1074/jbc.M209925200; Glerum DM, 1996, YEAST, V12, P1421; Grabinska K, 2002, FEMS YEAST RES, V2, P259, DOI 10.1016/S1567-1356(02)00110-1; Hait NC, 2002, FEBS LETT, V532, P97, DOI 10.1016/S0014-5793(02)03636-0; Hayashi S, 2002, J BIOL CHEM, V277, P33319, DOI 10.1074/jbc.M201442200; Heese-Peck A, 2002, MOL BIOL CELL, V13, P2664, DOI 10.1091/mbc.E02-04-0186; Igarashi Y, 1997, J BIOCHEM-TOKYO, V122, P1080; Iwaki S, 2005, J BIOL CHEM, V280, P6520, DOI 10.1074/jbc.M410908200; Jenkins GM, 2001, J BIOL CHEM, V276, P8574, DOI 10.1074/jbc.M007425200; Kaida D, 2002, GENES CELLS, V7, P543, DOI 10.1046/j.1365-2443.2002.00538.x; Kaiser C., 1994, METHODS YEAST GENETI; KALB VF, 1987, DNA-J MOLEC CELL BIO, V6, P529, DOI 10.1089/dna.1987.6.529; Kihara A, 2004, MOL BIOL CELL, V15, P4949, DOI 10.1091/mbc.E04-06-0458; Kihara A, 2002, J BIOL CHEM, V277, P30048, DOI 10.1074/jbc.M203385200; KIHARA A, 2005, IN PRESS MOL CELL BI; Kim S, 2000, GENETICS, V156, P1519; Kluk MJ, 2002, BBA-MOL CELL BIOL L, V1582, P72, DOI 10.1016/S1388-1981(02)00139-7; Kwast KE, 1998, J EXP BIOL, V201, P1177; Lacana E, 2002, J BIOL CHEM, V277, P32947, DOI 10.1074/jbc.M202841200; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; Mao CG, 1999, BIOCHEM J, V342, P667, DOI 10.1042/0264-6021:3420667; Moraes CT, 2004, BBA-BIOENERGETICS, V1659, P153, DOI 10.1016/j.bbabio.2004.09.002; Munn AL, 1999, MOL BIOL CELL, V10, P3943, DOI 10.1091/mbc.10.11.3943; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Saba JD, 1997, J BIOL CHEM, V272, P26087, DOI 10.1074/jbc.272.42.26087; Skaggs BA, 1996, GENE, V169, P105, DOI 10.1016/0378-1119(95)00770-9; Skrzypek MS, 1999, J BACTERIOL, V181, P1134, DOI 10.1128/JB.181.4.1134-1140.1999; Skrzypek MS, 1998, J BIOL CHEM, V273, P2829, DOI 10.1074/jbc.273.5.2829; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Swain E, 2002, J BIOL CHEM, V277, P36152, DOI 10.1074/jbc.M206624200; Swain E, 2002, J BIOL CHEM, V277, P26177, DOI 10.1074/jbc.M204115200; THORSNESS M, 1989, MOL CELL BIOL, V9, P5702, DOI 10.1128/MCB.9.12.5702; TURI TG, 1992, J BIOL CHEM, V267, P2046; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; Yatomi Y, 2000, BLOOD, V96, P3431; Zanolari B, 2000, EMBO J, V19, P2824, DOI 10.1093/emboj/19.12.2824; Zhang XP, 2001, CURR GENET, V40, P221, DOI 10.1007/s00294-001-0259-6	49	19	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36674	36682		10.1074/jbc.M503147200	http://dx.doi.org/10.1074/jbc.M503147200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16141212	hybrid			2022-12-27	WOS:000232901800019
J	Hawthorne, R; Lynch, JW				Hawthorne, R; Lynch, JW			A picrotoxin-specific conformational change in the glycine receptor M2-M3 loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL-LINING RESIDUES; NICOTINIC ACETYLCHOLINE-RECEPTOR; BETA-SUBUNIT; SURFACE ACCESSIBILITY; CHLORIDE CHANNELS; IDENTIFICATION; ACTIVATION; PORE; MECHANISM; BLOCK	The external loop linking the M2 and M3 transmembrane domains is crucial for coupling agonist binding to channel gating in the glycine receptor chloride channel (GlyR). A substituted cysteine accessibility scan previously showed that glycine activation increased the surface accessibility of 6 contiguous residues (Arg(271) Lys(276)) toward the N-terminal end of the homomeric alpha 1 GlyR M2 - M3 loop. In the present study we used a similar approach to determine whether the allosteric antagonist, picrotoxin, could impose conformational changes to this domain that cannot be induced by varying agonist concentrations alone. Picrotoxin slowed the reaction rate of a sulfhydryl-containing compound ( MTSET) with A272C, S273C, and L274C. Before interpreting this as a picrotoxin-specific conformational change, it was necessary to eliminate the possibility of steric competition between picrotoxin and MTSET. Accordingly, we showed that picrotoxin and the structurally unrelated blocker, bilobalide, were both trapped in the R271C GlyR in the closed state and that a point mutation to the pore-lining Thr(6') residue abolished inhibition by both compounds. We also demonstrated that the picrotoxin dissociation rate was linearly related to the channel open probability. These observations constitute a strong case for picrotoxin binding in the pore. We thus conclude that the picrotoxin-specific effects on the M2 - M3 loop are mediated allosterically. This suggests that the M2 - M3 loop responds differently to the occupation of different binding sites.	Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia	University of Queensland	Lynch, JW (corresponding author), Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia.	j.lynch@uq.edu.au	Lynch, Joseph/C-8636-2009					AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; AUERBACH A, 2003, SCI STKE, pRE11; Barry PH, 2005, IEEE T NANOBIOSCI, V4, P70, DOI 10.1109/TNB.2004.842497; Beato M, 2002, J GEN PHYSIOL, V119, P443, DOI 10.1085/jgp.20028530; Chang YC, 2002, NAT NEUROSCI, V5, P1163, DOI 10.1038/nn926; Dibas MI, 2002, J BIOL CHEM, V277, P9112, DOI 10.1074/jbc.M111356200; Etter A, 1999, J NEUROCHEM, V72, P318, DOI 10.1111/jnc.1999.72.1.318; FFRENCHCONSTANT RH, 1993, NATURE, V363, P449, DOI 10.1038/363449a0; Grosman C, 2000, NATURE, V403, P773, DOI 10.1038/35001586; GURLEY D, 1995, RECEPTOR CHANNEL, V3, P13; Holmgren M, 1997, J GEN PHYSIOL, V109, P527, DOI 10.1085/jgp.109.5.527; Horenstein J, 2001, NAT NEUROSCI, V4, P477, DOI 10.1038/87425; Ivic L, 2003, J BIOL CHEM, V278, P49279, DOI 10.1074/jbc.M304034200; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Kash TL, 2004, BIOCHEM SOC T, V32, P540, DOI 10.1042/BST0320540; Kash TL, 2003, NATURE, V421, P272, DOI 10.1038/nature01280; Kondratskaya EL, 2002, NEUROCHEM INT, V40, P647, DOI 10.1016/S0197-0186(01)00109-7; Legendre P, 1997, J NEUROPHYSIOL, V77, P2400, DOI 10.1152/jn.1997.77.5.2400; Legendre P, 2001, CELL MOL LIFE SCI, V58, P760, DOI 10.1007/PL00000899; Lynch JW, 1997, EMBO J, V16, P110, DOI 10.1093/emboj/16.1.110; LYNCH JW, 1995, J BIOL CHEM, V270, P13799, DOI 10.1074/jbc.270.23.13799; Lynch JW, 2001, J NEUROSCI, V21, P2589, DOI 10.1523/JNEUROSCI.21-08-02589.2001; Lynch JW, 2004, PHYSIOL REV, V84, P1051, DOI 10.1152/physrev.00042.2003; MILLER C, 1987, BIOPHYS J, V52, P123, DOI 10.1016/S0006-3495(87)83196-X; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; NEWLAND CF, 1992, J PHYSIOL-LONDON, V447, P191, DOI 10.1113/jphysiol.1992.sp018998; Panicker S, 2004, J BIOL CHEM, V279, P28149, DOI 10.1074/jbc.M403545200; Panicker S, 2002, J NEUROSCI, V22, P1629, DOI 10.1523/JNEUROSCI.22-05-01629.2002; Phillips LR, 2003, J GEN PHYSIOL, V122, P795, DOI 10.1085/jgp.200308953; PRIBILLA I, 1992, EMBO J, V11, P4305, DOI 10.1002/j.1460-2075.1992.tb05529.x; Qian HH, 2005, MOL PHARMACOL, V67, P470, DOI 10.1124/mol.104.003996; RUNDSTROM N, 1994, P NATL ACAD SCI USA, V91, P8950, DOI 10.1073/pnas.91.19.8950; Shan Q, 2002, J BIOL CHEM, V277, P44845, DOI 10.1074/jbc.M208647200; Shan Q, 2001, J NEUROCHEM, V76, P1109, DOI 10.1046/j.1471-4159.2001.00124.x; Unwin N, 2003, FEBS LETT, V555, P91, DOI 10.1016/S0014-5793(03)01084-6; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031; WANG TL, 1995, P NATL ACAD SCI USA, V92, P11751, DOI 10.1073/pnas.92.25.11751; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1; Xu M, 1995, BIOPHYS J, V69, P1858, DOI 10.1016/S0006-3495(95)80056-1; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; YOON KW, 1993, J PHYSIOL-LONDON, V464, P423, DOI 10.1113/jphysiol.1993.sp019643; ZHANG DX, 1995, P NATL ACAD SCI USA, V92, P11756, DOI 10.1073/pnas.92.25.11756; Zhorov BS, 2000, BIOPHYS J, V78, P1786, DOI 10.1016/S0006-3495(00)76729-4	44	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35836	35843		10.1074/jbc.M506645200	http://dx.doi.org/10.1074/jbc.M506645200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16109711	hybrid			2022-12-27	WOS:000232726900010
J	Navaneetham, D; Jin, L; Pandey, P; Strickler, JE; Babine, RE; Abdel-Meguid, SS; Walsh, PN				Navaneetham, D; Jin, L; Pandey, P; Strickler, JE; Babine, RE; Abdel-Meguid, SS; Walsh, PN			Structural and mutational analyses of the molecular interactions between the catalytic domain of factor XIa and the Kunitz protease inhibitor domain of protease nexin 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; COAGULATION-FACTOR-XIA; PANCREATIC TRYPSIN-INHIBITOR; ALZHEIMERS-DISEASE; HUMAN-PLATELETS; BLOOD-COAGULATION; BINDING-SITE; ACTIVATED PLATELETS; CRYSTAL-STRUCTURES; HAGEMAN-FACTOR	Factor XIa (FXIa) is a serine protease important for initiating the intrinsic pathway of blood coagulation. Protease nexin 2 (PN2) is a Kunitz-type protease inhibitor secreted by activated platelets and a physiologically important inhibitor of FXIa. Inhibition of FXIa by PN2 requires interactions between the two proteins that are confined to the catalytic domain of the enzyme and the Kunitz protease inhibitor (KPI) domain of PN2. Recombinant PN2KPI and a mutant form of the FXI catalytic domain (FXIac) were expressed in yeast, purified to homogeneity, co-crystallized, and the structure of the complex was solved at 2.6 angstrom ( Protein Data Bank code 1ZJD). In this complex, PN2KPI has a characteristic, disulfide-stabilized double loop structure that fits into the FXIac active site. To determine the contributions of residues within PN2KPI to its inhibitory activity, selected point mutations in PN2KPI loop 1 (11)TGPCRAMISR(20) and loop 2 (34)FYGGC(38) were tested for their ability to inhibit FXIa. The P1 site mutation R15A completely abolished its ability to inhibit FXIa. IC50 values for the wild type protein and the remaining mutants were as follows: PN2KPI WT, 1.28 nM; P13A, 5.92 nM; M17A, 1.62 nM; S19A, 1.86 nM; R20A, 5.67 nM; F34A, 9.85 nM. The IC50 values for the M17A and S19A mutants were not significantly different from those obtained with wild type PN2KPI. These functional studies and activated partial thromboplastin time analysis validate predictions made from the PN2KPI-FXIac co-crystal structure and implicate PN2KPI residues, in descending order of importance, Arg(15), Phe(34), Pro(13), and Arg(20) in FXIa inhibition by PN2KPI.	Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Med, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Daiichi Asubio Med Res Labs LLC, Cambridge, MA 02139 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Jin, L (corresponding author), 8 Harris Ave, Wellesley, MA 02481 USA.	leijin05@yahoo.com; pnw@temple.edu			NHLBI NIH HHS [HL46213, HL74124, HL70683, HL64943] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL074124, R01HL046213, P01HL064943, R01HL070683] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Badellino KO, 2000, BIOCHEMISTRY-US, V39, P4769, DOI 10.1021/bi9925468; Badellino KO, 2001, BIOCHEMISTRY-US, V40, P7569, DOI 10.1021/bi0027433; Baglia FA, 2000, J BIOL CHEM, V275, P20514, DOI 10.1074/jbc.M000464200; Baglia FA, 2003, J BIOL CHEM, V278, P21744, DOI 10.1074/jbc.M212991200; Baglia FA, 2002, J BIOL CHEM, V277, P1662, DOI 10.1074/jbc.M108319200; BAGLIA FA, 1995, J BIOL CHEM, V270, P6734, DOI 10.1074/jbc.270.12.6734; Baglia FA, 1996, J BIOL CHEM, V271, P3652; Baglia FA, 1998, BIOCHEMISTRY-US, V37, P2271, DOI 10.1021/bi972113+; Baird TR, 2002, J BIOL CHEM, V277, P38462, DOI 10.1074/jbc.M205902200; BUSH AI, 1990, J BIOL CHEM, V265, P15977; DAMUS PS, 1973, NATURE, V246, P355, DOI 10.1038/246355a0; DENNIS MS, 1995, J BIOL CHEM, V270, P25411, DOI 10.1074/jbc.270.43.25411; DENNIS MS, 1994, J BIOL CHEM, V269, P22137; Evin G, 2003, J NEUROSCI RES, V74, P386, DOI 10.1002/jnr.10745; FORBES CD, 1970, J LAB CLIN MED, V76, P809; GREENGARD JS, 1986, BIOCHEMISTRY-US, V25, P3884, DOI 10.1021/bi00361a022; Grzesiak A, 2000, J BIOL CHEM, V275, P33346, DOI 10.1074/jbc.M006085200; HECK LW, 1974, J EXP MED, V140, P1615, DOI 10.1084/jem.140.6.1615; Ho DH, 2000, BIOCHEMISTRY-US, V39, P316, DOI 10.1021/bi991851q; HYNES TR, 1990, BIOCHEMISTRY-US, V29, P10018, DOI 10.1021/bi00495a002; Jin L, 2005, J BIOL CHEM, V280, P4704, DOI 10.1074/jbc.M411309200; Knauer DJ, 2000, J BIOL CHEM, V275, P37340, DOI 10.1074/jbc.M003909200; LI QX, 1995, J BIOL CHEM, V270, P14140, DOI 10.1074/jbc.270.23.14140; LI QX, 1994, BLOOD, V84, P133, DOI 10.1182/blood.V84.1.133.133; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Radisky ES, 2002, P NATL ACAD SCI USA, V99, P10316, DOI 10.1073/pnas.112332899; SAITO H, 1979, P NATL ACAD SCI USA, V76, P2013, DOI 10.1073/pnas.76.4.2013; Scandura JM, 1997, BIOCHEMISTRY-US, V36, P412, DOI 10.1021/bi9612576; Scheidig AJ, 1997, PROTEIN SCI, V6, P1806, DOI 10.1002/pro.5560060902; SCOTT CF, 1982, J CLIN INVEST, V69, P844, DOI 10.1172/JCI110524; SINHA S, 1991, J BIOL CHEM, V266, P21011; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; Song HK, 1998, J MOL BIOL, V275, P347, DOI 10.1006/jmbi.1997.1469; vandeLocht A, 1997, EMBO J, V16, P2977, DOI 10.1093/emboj/16.11.2977; VANNOSTRAND WE, 1995, J BIOL CHEM, V270, P22827, DOI 10.1074/jbc.270.39.22827; VANNOSTRAND WE, 1990, SCIENCE, V248, P745, DOI 10.1126/science.2110384; VANNOSTRAND WE, 1990, J BIOL CHEM, V265, P9591; Walsh P. N., 2001, HEMOSTASIS THROMBOSI, P191; WALSH PN, 1981, BLOOD, V57, P106; Wuillemin WA, 1996, J BIOL CHEM, V271, P12913, DOI 10.1074/jbc.271.22.12913; Zhang E, 1999, J MOL BIOL, V285, P2089, DOI 10.1006/jmbi.1998.2452; Zhang Y, 1997, J BIOL CHEM, V272, P26139, DOI 10.1074/jbc.272.42.26139	43	53	63	5	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36165	36175		10.1074/jbc.M504990200	http://dx.doi.org/10.1074/jbc.M504990200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16085935	hybrid			2022-12-27	WOS:000232726900048
J	Arnoult, D; Grodet, A; Lee, YJ; Estaquier, J; Blackstone, C				Arnoult, D; Grodet, A; Lee, YJ; Estaquier, J; Blackstone, C			Release of OPA1 during apoptosis participates in the rapid and complete release of cytochrome c and subsequent mitochondrial fragmentation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; FUSION; FISSION; BAX; ASSOCIATION; DYSFUNCTION; DYNAMICS; DRP1	Mitochondria are important participants in apoptosis, releasing cytochrome c into the cytoplasm and undergoing extensive fragmentation. However, mechanisms underlying these processes remain unclear. Here, we demonstrate that cytochrome c release during apoptosis precedes mitochondrial fragmentation. Unexpectedly, OPA1, a dynamin- like GTPase of the mitochondrial intermembrane space important for maintaining cristae structure, is co-released with cytochrome c. To mimic the loss of OPA1 occurring after its release, we knocked down OPA1 expression using RNA interference. This triggered structural changes in the mitochondrial cristae and caused increased fragmentation by blocking mitochondrial fusion. Because cytochrome c is mostly sequestered within cristae folds but released rapidly and completely during apoptosis, we examined the effect of OPA1 loss on cytochrome c release, demonstrating that it is accelerated. Thus, our results suggest that an initial mitochondrial leak of OPA1 leads to cristae structural alterations and exposure of previously sequestered protein pools, permitting continued release in a feed- forward manner to completion. Moreover, our findings indicate that the resulting OPA1 depletion causes a block in mitochondrial fusion, providing a compelling mechanism for the prominent increase in mitochondrial fragmentation seen during apoptosis.	NINDS, Cellular Neurol Unit, NIH, Bethesda, MD 20892 USA; NINDS, Biochem Sect, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA; Inst Pasteur, Unite Physiopathol Infect Lentivirales, F-75724 Paris, France; Univ Paris 07, INSERM, U327, F-75018 Paris, France	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Blackstone, C (corresponding author), NINDS, Cellular Neurol Unit, NIH, Bethesda, MD 20892 USA.	blackstc@ninds.nih.gov	Arnoult, Damien/R-2032-2018; , ESTAQUIER/AAR-7799-2020	, ESTAQUIER/0000-0002-9432-8044	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS002992, Z01NS002992] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wellcome Trust(Wellcome TrustEuropean Commission)		BERNARDI P, 1981, J BIOL CHEM, V256, P7187; Bossy-Wetzel E, 2003, CURR OPIN CELL BIOL, V15, P706, DOI 10.1016/j.ceb.2003.10.015; Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200; Cipolat S, 2004, P NATL ACAD SCI USA, V101, P15927, DOI 10.1073/pnas.0407043101; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Esseiva AC, 2004, EMBO REP, V5, P268, DOI 10.1038/sj.embor.7400095; Eura Y, 2003, J BIOCHEM, V134, P333, DOI 10.1093/jb/mvg150; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Gao WH, 2001, J CELL SCI, V114, P2855; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Griparic L, 2004, J BIOL CHEM, V279, P18792, DOI 10.1074/jbc.M400920200; Hengartner M, 2005, NATURE, V433, P692, DOI 10.1038/433692a; Iverson SL, 2004, ARCH BIOCHEM BIOPHYS, V423, P37, DOI 10.1016/j.abb.2003.12.002; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jagasia R, 2005, NATURE, V433, P754, DOI 10.1038/nature03316; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; Karbowski M, 2004, J CELL BIOL, V164, P493, DOI 10.1083/jcb.200309082; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Sugioka R, 2004, J BIOL CHEM, V279, P52726, DOI 10.1074/jbc.M408910200; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wong ED, 2000, J CELL BIOL, V151, P341, DOI 10.1083/jcb.151.2.341; Zhu PP, 2003, J BIOL CHEM, V278, P49063, DOI 10.1074/jbc.M306702200	27	216	221	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35742	35750		10.1074/jbc.M505970200	http://dx.doi.org/10.1074/jbc.M505970200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16115883	hybrid			2022-12-27	WOS:000232561200077
J	Eckhart, L; Ballaun, C; Uthman, A; Kittel, C; Stichenwirth, M; Buchberger, M; Fischer, H; Sipos, W; Tschachler, E				Eckhart, L; Ballaun, C; Uthman, A; Kittel, C; Stichenwirth, M; Buchberger, M; Fischer, H; Sipos, W; Tschachler, E			Identification and characterization of a novel mammalian caspase with proapoptotic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIN DOMAIN; ACTIVATION; APOPTOSIS; ASC; DIFFERENTIATION; OLIGOMERIZATION; SPECIFICITY; PROTEIN	Caspases are essential proteases in programmed cell death and inflammation. Studies in murine and human cells have led to the characterization of 14 members of this enzyme family. Here we report the identification of caspase-15, a novel caspase that is expressed in various mammalian species including pig, dog, and cattle. The caspase-15 protein contains a catalytic domain with all amino acid residues critical for caspase activity and a prodomain that is predicted to fold into a pyrin domain structure, which is a unique feature among mammalian caspases. Recombinant porcine caspase-15 underwent autocatalytic processing into its subunits and cleaved both tetrapeptide caspase substrates and the apoptosis regulator protein Bid in vitro. Overexpression of caspase-15 in mammalian cells induced proenzyme maturation, cleavage of Bid, activation of caspase-3, and eventually cell death. Both the proteolytic and the pro-apoptotic activity of caspase-15 were abolished by mutation of the active site cysteine. Since a homolog of caspase-15 is absent in the human and the mouse genome, our results reveal an unexpected variability in the molecular apoptotic machinery of mammals.	Med Univ Vienna, Dept Dermatol, A-1090 Vienna, Austria; Univ Vet Med Vienna, Clin Dept Farm Anim & Herd Management, A-1210 Vienna, Austria	Medical University of Vienna; University of Veterinary Medicine Vienna	Tschachler, E (corresponding author), Med Univ Vienna, Dept Dermatol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	erwin.tschachler@meduniwien.ac.at	Fischer, Heinz/AAD-9950-2020; Sipos, Wolfgang/AGH-1464-2022	Eckhart, Leopold/0000-0002-5645-2036; Tschachler, Erwin/0000-0002-0248-1798; Fischer, Heinz/0000-0003-1280-0200				Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Eckhart L, 2000, J INVEST DERMATOL, V115, P1148, DOI 10.1046/j.1523-1747.2000.00205.x; Esposti MD, 2003, J BIOL CHEM, V278, P15749, DOI 10.1074/jbc.M209208200; Fischer H, 2002, BIOCHEM BIOPH RES CO, V293, P722, DOI 10.1016/S0006-291X(02)00289-9; Fuentes-Prior P, 2004, BIOCHEM J, V384, P201, DOI 10.1042/BJ20041142; Hiller S, 2003, STRUCTURE, V11, P1199, DOI 10.1016/j.str.2003.08.009; Kang TB, 2004, J IMMUNOL, V173, P2976, DOI 10.4049/jimmunol.173.5.2976; Koenig U, 2001, BIOCHEM BIOPH RES CO, V285, P1150, DOI 10.1006/bbrc.2001.5315; Lamkanfi M, 2002, CELL DEATH DIFFER, V9, P358, DOI 10.1038/sj.cdd.4400989; Liepinsh E, 2003, J MOL BIOL, V332, P1155, DOI 10.1016/j.jmb.2003.07.007; Lippens S, 2000, CELL DEATH DIFFER, V7, P1218, DOI 10.1038/sj.cdd.4400785; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martinon F, 2004, CELL, V117, P561, DOI 10.1016/j.cell.2004.05.004; Martinon F, 2001, CURR BIOL, V11, pR118, DOI 10.1016/S0960-9822(01)00056-2; Masumoto J, 2003, J BIOL CHEM, V278, P4268, DOI 10.1074/jbc.M203944200; Moriya M, 2005, BIOCHEMISTRY-US, V44, P575, DOI 10.1021/bi048374i; Saleh M, 2004, NATURE, V429, P75, DOI 10.1038/nature02451; Stennicke HR, 1999, METHODS, V17, P313, DOI 10.1006/meth.1999.0745; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Weber CH, 2001, TRENDS BIOCHEM SCI, V26, P475, DOI 10.1016/S0968-0004(01)01905-3; Woo M, 2003, NAT IMMUNOL, V4, P1016, DOI 10.1038/ni976	22	40	43	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35077	35080		10.1074/jbc.C500282200	http://dx.doi.org/10.1074/jbc.C500282200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16120609	hybrid			2022-12-27	WOS:000232561200002
J	McNicoll, F; Muller, M; Cloutier, S; Boilard, N; Rochette, A; Dube, M; Papadopoulou, B				McNicoll, F; Muller, M; Cloutier, S; Boilard, N; Rochette, A; Dube, M; Papadopoulou, B			Distinct 3 '-untranslated region elements regulate stage-specific mRNA accumulation and translation in Leishmania	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY ENCODING AMASTIN; 60S RIBOSOMAL-SUBUNIT; IN-VITRO MODEL; GENE-EXPRESSION; UNTRANSLATED REGIONS; AXENIC AMASTIGOTES; DONOVANI; PROTEIN; RESISTANCE; INFANTUM	We recently characterized a large developmentally regulated gene family in Leishmania encoding the amastin surface proteins. While studying the regulation of these genes, we identified a region of 770 nucleotides (nt) within the 2055-nt 3'-untranslated region (3'-UTR) that regulates stage-specific gene expression at the level of translation. An intriguing feature of this 3'-UTR regulatory region is the presence of a similar to 450-nt element that is highly conserved among several Leishmania mRNAs. Here we show, using a luciferase reporter system and polysome profiling experiments, that the 450-nt element stimulates translation initiation of the amastin mRNA in response to heat shock, which is the main environmental change that the parasite encounters upon its entry into the mammalian host. Deletional analyses depicted a second region of similar to 100 nucleotides located at the 3'-end of several amastin transcripts, which also activates translation in response to elevated temperature. Both 3'-UTR regulatory elements act in an additive manner to stimulate amastin mRNA translation. In addition, we show that acidic pH encountered in the phagolysosomes of macrophages, the location of parasitic differentiation, triggers the accumulation of amastin transcripts by a distinct mechanism that is independent of the 450-nt and 100-nt elements. Overall, these important findings support the notion that stage-specific post-transcriptional regulation of the amastin mRNAs in Leishmania is complex and involves the coordination of distinct mechanisms controlling mRNA stability and translation that are independently triggered by key environmental signals inducing differentiation of the parasite within macrophages.	Univ Laval, Res Ctr, Ctr Hosp, Infect Dis Res Ctr, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Dept Med Biol, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University	Papadopoulou, B (corresponding author), Univ Laval, Res Ctr, Ctr Hosp Univ Quebec, Infect Dis Res Ctr,Res Ctr,Ctr Hosp, 2705 Laurier Blvd, Quebec City, PQ G1V 4G2, Canada.	barbara.papadopoulou@crchul.ulaval.ca	Müller-McNicoll, Michaela/AAC-6125-2019	Müller-McNicoll, Michaela/0000-0002-7174-8310				Akopyants NS, 2004, MOL BIOCHEM PARASIT, V136, P71, DOI 10.1016/j.molbiopara.2004.03.002; ALY R, 1994, NUCLEIC ACIDS RES, V22, P2922, DOI 10.1093/nar/22.15.2922; Ashford RW, 2000, INT J PARASITOL, V30, P1269, DOI 10.1016/S0020-7519(00)00136-3; ASHFORD RW, 1992, PARASITOL TODAY, V8, P104, DOI 10.1016/0169-4758(92)90249-2; Barak E, 2005, MOL BIOCHEM PARASIT, V141, P99, DOI 10.1016/j.molbiopara.2005.02.004; Barends S, 2004, J VIROL, V78, P4003, DOI 10.1128/JVI.78.8.4003-4010.2004; Barends S, 2003, CELL, V112, P123, DOI 10.1016/S0092-8674(02)01256-4; BATES PA, 1994, PARASITOLOGY, V108, P1, DOI 10.1017/S0031182000078458; Bente M, 2003, PROTEOMICS, V3, P1811, DOI 10.1002/pmic.200300462; Boucher N, 2002, J BIOL CHEM, V277, P19511, DOI 10.1074/jbc.M200500200; Charest H, 1996, J BIOL CHEM, V271, P17081, DOI 10.1074/jbc.271.29.17081; Clayton CE, 2002, EMBO J, V21, P1881, DOI 10.1093/emboj/21.8.1881; Clemens MJ, 2001, J CELL MOL MED, V5, P221, DOI 10.1111/j.1582-4934.2001.tb00157.x; Diehl S, 2002, MOL BIOCHEM PARASIT, V123, P115, DOI 10.1016/S0166-6851(02)00138-X; El Fadili K, 2005, ANTIMICROB AGENTS CH, V49, P1988, DOI 10.1128/AAC.49.5.1988-1993.2005; El Fakhry Y, 2002, PROTEOMICS, V2, P1007, DOI 10.1002/1615-9861(200208)2:8<1007::AID-PROT1007>3.0.CO;2-G; Gebauer F, 2003, MOL CELL, V11, P1397, DOI 10.1016/S1097-2765(03)00176-X; Glaser B, 1998, TIERARZTL PRAX K H, V26, P55; Goyard S, 2003, MOL BIOCHEM PARASIT, V130, P31, DOI 10.1016/S0166-6851(03)00142-7; Guo L, 2001, MOL CELL, V7, P1103, DOI 10.1016/S1097-2765(01)00252-0; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Kaufman RJ, 2004, TRENDS BIOCHEM SCI, V29, P152, DOI 10.1016/j.tibs.2004.01.004; Khandjian EW, 1996, NAT GENET, V12, P91, DOI 10.1038/ng0196-91; Kundig C, 1999, EMBO J, V18, P2342, DOI 10.1093/emboj/18.9.2342; Larreta R, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-3; Ling J, 2002, MOL CELL BIOL, V22, P7853, DOI 10.1128/MCB.22.22.7853-7867.2002; MACFARLANE J, 1990, EUR J BIOCHEM, V190, P377, DOI 10.1111/j.1432-1033.1990.tb15586.x; Mangus DA, 1999, METHODS, V17, P28, DOI 10.1006/meth.1998.0704; Mangus DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-7-223; Mathews MB, 2000, COLD SPRING HARBOR M, V39, P1; Mazumder B, 2003, CELL, V115, P187, DOI 10.1016/S0092-8674(03)00773-6; Mazumder B, 2003, TRENDS BIOCHEM SCI, V28, P91, DOI 10.1016/S0968-0004(03)00002-1; Mishra KK, 2003, EUKARYOT CELL, V2, P1009, DOI 10.1128/EC.2.5.1009-1017.2003; Ostareck DH, 2001, CELL, V104, P281, DOI 10.1016/S0092-8674(01)00212-4; PAPADOPOULOU B, 1992, EMBO J, V11, P3601, DOI 10.1002/j.1460-2075.1992.tb05444.x; Papadopoulou B, 2002, INFECT IMMUN, V70, P62, DOI 10.1128/IAI.70.1.62-68.2002; PAPADOPOULOU B, 2003, J PARASITOL, V89, pS174; Rochette A, 2005, MOL BIOCHEM PARASIT, V140, P205, DOI 10.1016/j.molbiopara.2005.01.006; Roy G, 2000, MOL BIOCHEM PARASIT, V110, P195, DOI 10.1016/S0166-6851(00)00270-X; Saar Y, 1998, MOL BIOCHEM PARASIT, V95, P9, DOI 10.1016/S0166-6851(98)00062-0; Sachs A, 2000, COLD SPRING HARBOR M, V39, P447; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Saxena A, 2003, MOL BIOCHEM PARASIT, V129, P103, DOI 10.1016/S0166-6851(03)00100-2; Schneider RJ, 2000, COLD SPRING HARBOR M, V39, P581; Sereno D, 1998, ANTIMICROB AGENTS CH, V42, P3097, DOI 10.1128/AAC.42.12.3097; Sereno D, 1997, ANTIMICROB AGENTS CH, V41, P972, DOI 10.1128/AAC.41.5.972; Sereno D, 2001, ANTIMICROB AGENTS CH, V45, P1168, DOI 10.1128/AAC.45.4.1168-1173.2001; Shen RZ, 2004, J VIROL, V78, P4655, DOI 10.1128/JVI.78.9.4655-4664.2004; Sundar S, 2001, TROP MED INT HEALTH, V6, P849, DOI 10.1046/j.1365-3156.2001.00778.x; TEIXEIRA SMR, 1994, J BIOL CHEM, V269, P20509; TEIXEIRA SMR, 1995, J BIOL CHEM, V270, P22586, DOI 10.1074/jbc.270.38.22586; TURCO SJ, 1991, MOL BIOCHEM PARASIT, V45, P91, DOI 10.1016/0166-6851(91)90030-A; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7; Wilkie GS, 2003, TRENDS BIOCHEM SCI, V28, P182, DOI 10.1016/S0968-0004(03)00051-3; Wu Y, 2000, MOL BIOCHEM PARASIT, V110, P345, DOI 10.1016/S0166-6851(00)00290-5; Yaman I, 2003, CELL, V113, P519, DOI 10.1016/S0092-8674(03)00345-3; ZILBERSTEIN D, 1994, ANNU REV MICROBIOL, V48, P449, DOI 10.1146/annurev.mi.48.100194.002313; Zilka A, 2001, J BIOL CHEM, V276, P47922, DOI 10.1074/jbc.M108271200	59	76	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35238	35246		10.1074/jbc.M507511200	http://dx.doi.org/10.1074/jbc.M507511200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16115874	hybrid			2022-12-27	WOS:000232561200021
J	Monje, P; Hernandez-Losa, J; Lyons, RJ; Castellone, MD; Gutkind, JS				Monje, P; Hernandez-Losa, J; Lyons, RJ; Castellone, MD; Gutkind, JS			Regulation of the transcriptional activity of c-Fos by ERK: A novel role for the prolyl isomerase Pin1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION PATHWAYS; CELLULAR-TRANSFORMATION; GROWTH-FACTOR; JUN PROMOTER; PHOSPHORYLATION; AP-1; DOMAINS	The activation of the activating protein-1 (AP-1) family of transcription factors, including c-Fos and c-Jun family members, is one of the earliest nuclear events induced by growth factors that stimulate extracellular signal-regulated kinases (ERKs). In the case of c-Fos, the activation of ERK leads to an increased expression of c-fos mRNA. In turn, we have recently shown that ERK phosphorylates multiple residues within the carboxyl-terminal transactivation domain (TAD) of c-Fos, thus resulting in its increased transcriptional activity. However, how ERK-dependent phosphorylation regulates c-Fos function is still poorly understood. In this regard, it has been recently observed that the prolyl isomerase Pin1 can interact with proteins phosphorylated on serine or threonine residues that precede prolines (pS/T-P), such as the transcription factors p53 and c-Jun, thereby controlling their activity by promoting the cis-trans isomerization of these pS/T-P bonds. Here, we found that Pin1 binds c-Fos through specific pS/T-P sites within the c-Fos TAD, and that this interaction results in an enhanced transcriptional response of c-Fos to polypeptide growth factors that stimulate ERK. Our findings suggest that c-Fos represents a novel target for the isomerizing activity of Pin1 and support a role for Pin1 in the mechanism by which c-Jun and c-Fos can cooperate to regulate AP-1-dependent gene transcription upon phosphorylation by mitogen-activated kinase (MAPK) family members.	NIDCR, Oral & Pharyngeal Canc Branch, NIH, DHHS, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Gutkind, JS (corresponding author), NIDCR, Oral & Pharyngeal Canc Branch, NIH, DHHS, 30 Convent Dr,Bldg 30,Rm 211, Bethesda, MD 20892 USA.	sg39v@nih.gov	Gutkind, J. Silvio/A-1053-2009; Javier, Hernandez Losa/C-1173-2008; Gutkind, J. Silvio/J-1201-2016; Monje, Paula/AAB-9099-2020	Javier, Hernandez Losa/0000-0003-1526-3201; Gutkind, J. Silvio/0000-0002-5150-4482; CASTELLONE, MARIADOMENICA/0000-0003-0507-8037	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Lu KP, 2002, TRENDS CELL BIOL, V12, P164, DOI 10.1016/S0962-8924(02)02253-5; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; METZ R, 1994, MOL CELL BIOL, V14, P6021, DOI 10.1128/MCB.14.9.6021; Monje P, 2003, MOL CELL BIOL, V23, P7030, DOI 10.1128/MCB.23.19.7030-7043.2003; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106	17	214	219	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35081	35084		10.1074/jbc.C500353200	http://dx.doi.org/10.1074/jbc.C500353200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16123044	hybrid			2022-12-27	WOS:000232561200003
J	Nguyen, MTA; Satoh, H; Favelyukis, S; Babendure, JL; Imamura, T; Sbodio, JI; Zalevsky, J; Dahiyat, BI; Chi, NW; Olefsky, JM				Nguyen, MTA; Satoh, H; Favelyukis, S; Babendure, JL; Imamura, T; Sbodio, JI; Zalevsky, J; Dahiyat, BI; Chi, NW; Olefsky, JM			JNK and tumor necrosis factor-alpha mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C-LAMBDA/ZETA; KAPPA-B KINASE; ADIPOSE-TISSUE; TNF-ALPHA; SKELETAL-MUSCLE; RECEPTOR SUBSTRATE-1; 3T3-L1 ADIPOCYTES; ACTIVATION; OBESITY; SENSITIVITY	Lipid infusion and high fat feeding are established causes of systemic and adipose tissue insulin resistance. In this study, we treated 3T3- L1 adipocytes with a mixture of free fatty acids ( FFAs) to investigate the molecular mechanisms underlying fat- induced insulin resistance. FFA treatment impaired insulin receptor- mediated signal transduction and decreased insulin- stimulated GLUT4 translocation and glucose transport. FFAs activated the stress/ inflammatory kinases c- Jun N- terminal kinase ( JNK) and IKK beta, and the suppressor of cytokine signaling protein 3, increased secretion of the inflammatory cytokine tumor necrosis factor ( TNF)-alpha, and decreased secretion of adiponectin into the medium. RNA interference-mediated down- regulation of JNK blocked JNK activation and prevented most of the FFA- induced defects in insulin action. Blockade of TNF-alpha signaling with neutralizing antibodies to TNF-alpha or its receptors or with a dominant negative TNF-alpha peptide had a partial effect to inhibit FFA- induced cellular insulin resistance. We found that JNK activation by FFAs was not inhibited by blocking TNF-alpha signaling, whereas the FFA- induced increase in TNF-alpha secretion was inhibited by RNA interference- mediated JNK knockdown. Together, these results indicate that 1) JNK can be activated by FFAs through TNF-alpha- independent mechanisms, 2) activated JNK is a major contributor to FFA- induced cellular insulin resistance, and 3) TNF-alpha is an autocrine/ paracrine downstream effector of activated JNK that can also mediate insulin resistance.	Univ Calif San Diego, Div Endocrinol Metab, La Jolla, CA 92093 USA; Xencor, Monrovia, CA 91016 USA	University of California System; University of California San Diego	Olefsky, JM (corresponding author), Univ Calif San Diego, Div Endocrinol Metab, 9500 Gilman Dr, La Jolla, CA 92093 USA.	jolefsky@ucsd.edu	Nguyen, Minh Tho/N-9582-2019; Satoh, Hiroaki/E-9096-2017	Nguyen, Minh Tho/0000-0002-3803-0569; Satoh, Hiroaki/0000-0002-0353-5807	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033651, R01DK033651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Alarcon-Vargas D, 2004, J BIOL CHEM, V279, P5008, DOI 10.1074/jbc.M312054200; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Bays H, 2004, J CLIN ENDOCR METAB, V89, P463, DOI 10.1210/jc.2003-030723; BEUTLER BA, 1985, J IMMUNOL, V135, P3972; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; Chavez JA, 2003, ARCH BIOCHEM BIOPHYS, V419, P101, DOI 10.1016/j.abb.2003.08.020; Dai Y, 2005, BLOOD, V105, P1706, DOI 10.1182/blood-2004-07-2767; de Alvaro C, 2004, J BIOL CHEM, V279, P17070, DOI 10.1074/jbc.M312021200; Di Rocco P, 2004, OBES RES, V12, P734, DOI 10.1038/oby.2004.86; Egawa K, 1999, J BIOL CHEM, V274, P14306, DOI 10.1074/jbc.274.20.14306; Emanuelli B, 2001, J BIOL CHEM, V276, P47944, DOI 10.1074/jbc.M104602200; FLICK DA, 1986, J IMMUNOPHARMACOL, V8, P89; Gao ZG, 2004, MOL ENDOCRINOL, V18, P2024, DOI 10.1210/me.2003-0383; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; Grimble RF, 2002, CURR OPIN CLIN NUTR, V5, P551, DOI 10.1097/00075197-200209000-00015; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Kappes A, 2000, HORM METAB RES, V32, P548, DOI 10.1055/s-2007-978684; Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395; Kim YB, 2002, J BIOL CHEM, V277, P32915, DOI 10.1074/jbc.M204710200; Kim YB, 2003, DIABETES, V52, P1935, DOI 10.2337/diabetes.52.8.1935; Kraegen EW, 2001, EXP CLIN ENDOCR DIAB, V109, pS189, DOI 10.1055/s-2001-18581; KREBS DL, 2003, SCI STKE, pPE6; Miura A, 1999, BBA-MOL CELL RES, V1449, P227, DOI 10.1016/S0167-4889(99)00016-6; Ofei F, 1996, DIABETES, V45, P881, DOI 10.2337/diabetes.45.7.881; Peraldi P, 1998, MOL CELL BIOCHEM, V182, P169, DOI 10.1023/A:1006865715292; Perseghin G, 2003, INT J OBESITY, V27, pS6, DOI 10.1038/sj.ijo.0802491; Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314; Riccardi G, 2000, BRIT J NUTR, V83, pS143; Ruan H, 2003, CYTOKINE GROWTH F R, V14, P447, DOI 10.1016/S1359-6101(03)00052-2; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; Sasaki A, 2003, J BIOL CHEM, V278, P2432, DOI 10.1074/jbc.C200608200; Sewter CP, 1999, J ENDOCRINOL, V163, P33, DOI 10.1677/joe.0.1630033; Steed PM, 2003, SCIENCE, V301, P1895, DOI 10.1126/science.1081297; Subtil A, 2000, J BIOL CHEM, V275, P4787, DOI 10.1074/jbc.275.7.4787; Tremblay F, 2001, DIABETES, V50, P1901, DOI 10.2337/diabetes.50.8.1901; Ueki K, 2004, MOL CELL BIOL, V24, P5434, DOI 10.1128/MCB.24.12.5434-5446.2004; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Watson RT, 2001, EXP CELL RES, V271, P75, DOI 10.1006/excr.2001.5375; Worrall DS, 2002, MOL ENDOCRINOL, V16, P378, DOI 10.1210/me.16.2.378; Xu HY, 2002, DIABETES, V51, P1876, DOI 10.2337/diabetes.51.6.1876; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620; Zagariya A, 1998, MOL CELL BIOL, V18, P2815, DOI 10.1128/MCB.18.5.2815	45	316	339	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35361	35371		10.1074/jbc.M504611200	http://dx.doi.org/10.1074/jbc.M504611200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16085647	hybrid			2022-12-27	WOS:000232561200035
J	O'Byrne, SM; Wongsiriroj, N; Libien, J; Vogel, S; Goldberg, IJ; Baehr, W; Palczewski, K; Blaner, WS				O'Byrne, SM; Wongsiriroj, N; Libien, J; Vogel, S; Goldberg, IJ; Baehr, W; Palczewski, K; Blaner, WS			Retinoid absorption and storage is impaired in mice lacking lecithin : retinol acyltransferase (LRAT)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MICROSOMES; BINDING-PROTEIN; ACYL-COA; HEPATIC-FIBROSIS; STELLATE CELLS; ESTERIFICATION; ACID; EXPRESSION; METABOLISM; BIOSYNTHESIS	Lecithin: retinol acyltransferase (LRAT) is believed to be the predominant if not the sole enzyme in the body responsible for the physiologic esterification of retinol. We have studied Lrat-deficient (Lrat(-/-)) mice to gain a better understanding of how these mice take up and store dietary retinoids and to determine whether other enzymes may be responsible for retinol esterification in the body. Although the Lrat(-/-) mice possess only trace amounts of retinyl esters in liver, lung, and kidney, they possess elevated (by 2-3-fold) concentrations of retinyl esters in adipose tissue compared with wild type mice. These adipose retinyl ester depots are mobilized in times of dietary retinoid insufficiency. We further observed an up-regulation (3-4- fold) in the level of cytosolic retinol-binding protein type III (CRBPIII) in adipose tissue of Lrat(-/-) mice. Examination by electron microscopy reveals a striking total absence of large lipid-containing droplets that normally store hepatic retinoid within the hepatic stellate cells of Lrat(-/-) mice. Despite the absence of significant retinyl ester stores and stellate cell lipid droplets, the livers of Lrat(-/-) mice upon histologic analysis appear normal and show no histological signs of liver fibrosis. Lrat(-/-) mice absorb dietary retinol primarily as free retinol in chylomicrons; however, retinyl esters are also present within the chylomicron fraction obtained from Lrat(-/-) mice. The fatty acyl composition of these chylomicron retinyl esters suggests that they are synthesized via an acyl-CoA-dependent process suggesting the existence of a physiologically significant acyl-CoA: retinol acyltransferase.	Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Inst Human Nutr, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Univ Utah, Hlth Sci Ctr, Dept Ophthalmol, Salt Lake City, UT 84112 USA; Univ Washington, Dept Ophthalmol, Seattle, WA 98185 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98185 USA; Univ Washington, Dept Chem, Seattle, WA 98185 USA	Columbia University; Columbia University; Columbia University; Utah System of Higher Education; University of Utah; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Blaner, WS (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Med, 701 W 168th St, New York, NY 10032 USA.	wsb2@columbia.edu		Libien, Jenny/0000-0001-6291-4391	NEI NIH HHS [R01 EY009339, R01 EY008123, R01 EY09339, R01 EY08123] Funding Source: Medline; NIDDK NIH HHS [R01 DK068437, R01 DK067512, R01 DK061310] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009339, R01EY008123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068437, R01DK067512, R01DK061310] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balmer JE, 2002, J LIPID RES, V43, P1773, DOI 10.1194/jlr.R100015-JLR200; Batten ML, 2004, J BIOL CHEM, V279, P10422, DOI 10.1074/jbc.M312410200; Berriot-Varoqueaux N, 2000, ANNU REV NUTR, V20, P663, DOI 10.1146/annurev.nutr.20.1.663; Blaner William S., 1994, P229; BLANER WS, 1990, METHOD ENZYMOL, V189, P270; BLANER WS, 1994, J BIOL CHEM, V269, P16559; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHAMBON P, 1994, CELL BIOL, V5, P115; Dickman ED, 1997, DEVELOPMENT, V124, P3111; Duester G, 2000, EUR J BIOCHEM, V267, P4315, DOI 10.1046/j.1432-1327.2000.01497.x; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; Geerts A, 2001, SEMIN LIVER DIS, V21, P311, DOI 10.1055/s-2001-17550; Geerts Albert, 1994, P819; Goodman DS, 1984, RETINOIDS, P41, DOI DOI 10.1016/B978-0-12-658102-7.50008-7; Gudas Lorraine J., 1994, P443; Guo XJ, 2000, CARCINOGENESIS, V21, P1925, DOI 10.1093/carcin/21.11.1925; HERR FM, 1992, BIOCHEMISTRY-US, V31, P6748, DOI 10.1021/bi00144a014; Johnston TP, 2004, J CARDIOVASC PHARM, V43, P595, DOI 10.1097/00005344-200404000-00016; KURLANDSKY SB, 1995, J BIOL CHEM, V270, P17850, DOI 10.1074/jbc.270.30.17850; Kurlandsky SB, 1996, J BIOL CHEM, V271, P15346, DOI 10.1074/jbc.271.26.15346; Li D, 1999, J GASTROEN HEPATOL, V14, P618, DOI 10.1046/j.1440-1746.1999.01928.x; Liang JJ, 2004, J BIOL CHEM, V279, P44938, DOI 10.1074/jbc.M408507200; Mangelsdorf David J., 1994, P319; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; Molotkov A, 2002, J BIOL CHEM, V277, P13804, DOI 10.1074/jbc.M112039200; Moore T., 1957, VITAMIN; MORIWAKI H, 1988, J LIPID RES, V29, P1523; MULLER H, 1986, BRIT J NUTR, V55, P37, DOI 10.1079/BJN19860007; Napoli JL, 2000, PROG NUCLEIC ACID RE, V63, P139, DOI 10.1016/S0079-6603(08)60722-9; *NAT RES COUNC, 1996, GUID CAR US LAB AN; OBYRNE SM, 2005, CAROTENOIDS RETINOID, P1; ONG DE, 1988, J BIOL CHEM, V263, P5789; Piantedosi R, 2005, J BIOL CHEM, V280, P24286, DOI 10.1074/jbc.M503906200; RANDOLPH RK, 1991, ARCH BIOCHEM BIOPHYS, V288, P500, DOI 10.1016/0003-9861(91)90227-A; ROSS AC, 1982, J BIOL CHEM, V257, P2453; ROSS AC, 1982, J LIPID RES, V23, P133; Ruiz A, 1999, J BIOL CHEM, V274, P3834, DOI 10.1074/jbc.274.6.3834; SAARI JC, 1989, J BIOL CHEM, V264, P8636; Soprano Dianne Robert, 1994, P257; SUHARA A, 1990, J LIPID RES, V31, P1669; TSUTSUMI C, 1992, J BIOL CHEM, V267, P1805; VOGEL S, 1999, HANDB EXP PHARM, V139, P31; WALD G, 1968, NATURE, V219, P800, DOI 10.1038/219800a0; Wasan KM, 2003, J PHARM PHARM SCI, V6, P189; YAMADA M, 1987, HEPATOLOGY, V7, P1224, DOI 10.1002/hep.1840070609; Yen CLE, 2005, J LIPID RES, V46, P1502, DOI 10.1194/jlr.M500036-JLR200; YOST RW, 1988, J BIOL CHEM, V263, P18693; ZOVICH DC, 1992, J BIOL CHEM, V267, P13884	50	216	227	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35647	35657		10.1074/jbc.M507924200	http://dx.doi.org/10.1074/jbc.M507924200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16115871	Green Accepted, hybrid			2022-12-27	WOS:000232561200068
J	Sun, XJ; Wei, J; Wu, XY; Hu, M; Wang, L; Wang, HH; Zhang, QH; Chen, SJ; Huang, QH; Chen, Z				Sun, XJ; Wei, J; Wu, XY; Hu, M; Wang, L; Wang, HH; Zhang, QH; Chen, SJ; Huang, QH; Chen, Z			Identification and characterization of a novel human histone H3 lysine 36-specific methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTIONAL ACTIVATION DOMAINS; ACUTE MYELOID-LEUKEMIA; SET-DOMAIN; STEM/PROGENITOR CELLS; TERMINAL DOMAIN; SOTOS-SYNDROME; METHYLATION; PROTEINS; GENE	Histone methylation plays an important role in eukaryotic transcriptional regulation. A number of histone methyltransferases (HMTases) with distinct functions have been identified. The HSPC069/HYPB gene was originally isolated from the human hematopoietic stem/progenitor cells (HSPCs), and it was also identified as a huntingtin interacting protein, implicated in the pathogenesis of Huntington disease (HD). However, its biochemical function is poorly understood. Here we report the structural and functional characterization of the huntingtin interacting protein B (HYPB). 1) The triplicate AWS-SET-PostSET domains mediate a histone H3 lysine 36 specific HMTase activity. 2) A low charged region that is rich in glutamine and proline has been characterized as a novel transcriptional activation domain. The structural features of this region are evolutionarily conserved in vertebrates. 3) Coimmunoprecipitation assays indicate that HYPB protein associates with hyperphosphorylated RNA polymerase II (RNAPII) but not the unphosphorylated form. Furthermore, the RNAPII-association region of HYPB protein has been identified to encompass the C-terminal 142 amino acids. Thus, our results suggest that HYPB HMTase may coordinate histone methylation and transcriptional regulation in mammals and open perspective for the further study of the potential roles of HYPB protein in hematopoiesis and pathogenesis of HD.	Shanghai Med Univ 2, Ruijin Hosp, Shanghai Inst Hematol, State Key Lab Med Genom, Shanghai 200025, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Beijing 100864, Peoples R China; Shanghai Med Univ 2, Shanghai, Peoples R China; Chinese Acad Sci, Grad Sch, Shanghai 200025, Peoples R China	Chinese Academy of Sciences; Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Chinese Academy of Sciences	Chen, Z (corresponding author), Shanghai Med Univ 2, Ruijin Hosp, Shanghai Inst Hematol, State Key Lab Med Genom, 197 Ruijin Rd 2, Shanghai 200025, Peoples R China.	qiuhua_huang@etang.com; zchen@stn.sh.cn	Sun, Xiao-Jian/D-1560-2011	Sun, Xiao-Jian/0000-0001-8826-4614				Aagaard L, 2000, J CELL SCI, V113, P817; Abedi M, 2001, BMC Mol Biol, V2, P10, DOI 10.1186/1471-2199-2-10; Ayton PM, 2004, MOL CELL BIOL, V24, P10470, DOI 10.1128/MCB.24.23.10470-10478.2004; Bannister AJ, 2005, J BIOL CHEM, V280, P17732, DOI 10.1074/jbc.M500796200; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Baujat G, 2004, AM J HUM GENET, V74, P715, DOI 10.1086/383093; Blau J, 1996, MOL CELL BIOL, V16, P2044; Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; BRENDEL V, 1992, P NATL ACAD SCI USA, V89, P2002, DOI 10.1073/pnas.89.6.2002; BRENDEL V, 1989, P NATL ACAD SCI USA, V86, P5698, DOI 10.1073/pnas.86.15.5698; Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Dodge JE, 2004, MOL CELL BIOL, V24, P2478, DOI 10.1128/MCB.24.6.2478-2486.2004; Faber PW, 1998, HUM MOL GENET, V7, P1463, DOI 10.1093/hmg/7.9.1463; Fang J, 2004, METHOD ENZYMOL, V377, P213; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Huang NW, 1998, EMBO J, V17, P3398, DOI 10.1093/emboj/17.12.3398; Jaju RJ, 2001, BLOOD, V98, P1264, DOI 10.1182/blood.V98.4.1264; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; Kim KC, 2003, CANCER RES, V63, P7619; Kizer KO, 2005, MOL CELL BIOL, V25, P3305, DOI 10.1128/MCB.25.8.3305-3316.2005; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Krajewski WA, 2005, MOL CELL BIOL, V25, P1891, DOI 10.1128/MCB.25.5.1891-1899.2005; Krogan NJ, 2003, MOL CELL BIOL, V23, P4207, DOI 10.1128/MCB.23.12.4207-4218.2003; Kurotaki N, 2002, NAT GENET, V30, P365, DOI 10.1038/ng863; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Li B, 2003, J BIOL CHEM, V278, P8897, DOI 10.1074/jbc.M212134200; Li JX, 2002, J BIOL CHEM, V277, P49383, DOI 10.1074/jbc.M209294200; Mao M, 1998, P NATL ACAD SCI USA, V95, P8175, DOI 10.1073/pnas.95.14.8175; Miller W, 2004, ANNU REV GENOM HUM G, V5, P15, DOI 10.1146/annurev.genom.5.061903.180057; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Mizzen CA, 1999, METHOD ENZYMOL, V304, P675; Nagase T, 2000, DNA RES, V7, P347, DOI 10.1093/dnares/7.6.347; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Passani LA, 2000, HUM MOL GENET, V9, P2175, DOI 10.1093/hmg/9.14.2175; Pearson WR, 1998, J MOL BIOL, V276, P71, DOI 10.1006/jmbi.1997.1525; Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274; Rayasam GV, 2003, EMBO J, V22, P3153, DOI 10.1093/emboj/cdg288; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rega S, 2001, MOL CELL NEUROSCI, V18, P68, DOI 10.1006/mcne.2001.1004; Rosati R, 2002, BLOOD, V99, P3857, DOI 10.1182/blood.V99.10.3857; Sambrook J., 2001, MOL CLONING LAB MANU; Schaft D, 2003, NUCLEIC ACIDS RES, V31, P2475, DOI 10.1093/nar/gkg372; Schneider R, 2002, TRENDS BIOCHEM SCI, V27, P396, DOI 10.1016/S0968-0004(02)02141-2; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Song HD, 2004, P NATL ACAD SCI USA, V101, P16240, DOI 10.1073/pnas.0407241101; Stec I, 1998, HUM MOL GENET, V7, P1071, DOI 10.1093/hmg/7.7.1071; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Sugars KL, 2003, TRENDS GENET, V19, P233, DOI 10.1016/S0168-9525(03)00074-X; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Xiao TJ, 2003, GENE DEV, V17, P654, DOI 10.1101/gad.1055503; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610; Zhang QH, 2000, GENOME RES, V10, P1546, DOI 10.1101/gr.140200	66	174	184	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35261	35271		10.1074/jbc.M504012200	http://dx.doi.org/10.1074/jbc.M504012200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16118227	hybrid			2022-12-27	WOS:000232561200024
J	Hubmacher, D; Tiedemann, K; Bartels, R; Brinckmann, J; Vollbrandt, T; Batge, B; Notbohm, H; Reinhardt, DP				Hubmacher, D; Tiedemann, K; Bartels, R; Brinckmann, J; Vollbrandt, T; Batge, B; Notbohm, H; Reinhardt, DP			Modification of the structure and function of fibrillin-1 by homocysteine suggests a potential pathogenetic mechanism in homocystinuria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-LIKE DOMAINS; CALCIUM-BINDING PROPERTIES; GROWTH-FACTOR MODULES; MARFAN-SYNDROME; IN-VITRO; TERMINAL DOMAIN; PROTEIN; MUTATIONS; MICROFIBRILS; ORGANIZATION	Homocystinuria, a disorder originating in defects in the methionine metabolism, is characterized by an elevated plasma concentration of homocysteine. Most patients have a defect in the cystathionine-beta-synthase, the key enzyme in the conversion of homocysteine to cysteine. Many abnormalities in the connective tissue of patients with homocystinuria resemble those seen in Marfan syndrome, caused by mutations in fibrillin-1. These observations led to the hypothesis that the structure and function of fibrillin-1 is compromised in patients with homocystinuria. To test this hypothesis we produced recombinant human fibrillin-1 fragments spanning the central portion of the molecule (8-Cys/transforming growth factor-beta binding domain 3 to calcium binding EGF domain 22) and extensively analyzed the potential of homocysteine to modify structural and functional properties of these proteins. Circular dichroism spectroscopy revealed moderate changes of their secondary structures after incubation with homocysteine. Equilibrium dialysis demonstrated a number of high affinity calcium binding sites in the tandemly repeated calcium binding epidermal growth factor-like domains 11-22. Calcium binding of homocysteine-modified fragments was completely abolished. Incubation of the recombinant proteins with homocysteine rendered the analyzed calcium binding EGF domains as well as the 8-Cys/transforming growth factor-beta binding domain 3 significantly more susceptible to proteolytic degradation. Furthermore, data were obtained demonstrating that homocysteine can covalently modify fibrillin-1 via disulfide bonds. These data strongly suggest that structural and functional modifications as well as degradation processes of fibrillin-1 in the connective tissues of patients with homocystinuria play a major role in the pathogenesis of this disorder.	McGill Univ, Dept Anat & Cell Biol, Fac Med, Montreal, PQ H3A 2B2, Canada; McGill Univ, Fac Dent, Montreal, PQ H3A 2B2, Canada; Med Univ Lubeck, Dept Med Mol Biol, D-23538 Lubeck, Germany; Med Univ Lubeck, Dept Dermatol, D-23538 Lubeck, Germany; Forschungszentrum Borstel, D-23845 Borstel, Germany; Klinikum Neustadt, D-23730 Neustadt, Germany	McGill University; McGill University; University of Lubeck; University of Lubeck; Forschungszentrum Borstel	Reinhardt, DP (corresponding author), McGill Univ, Dept Anat & Cell Biol, Fac Med, Montreal, PQ H3A 2B2, Canada.	dieter.reinhardt@mcgill.ca	Hubmacher, Dirk/AAE-1875-2020; Reinhardt, Dieter P/A-3102-2008; Tiedemann, one/A-9739-2016	Reinhardt, Dieter P/0000-0001-6535-9872; Hubmacher, Dirk/0000-0003-1569-9451				Adam S, 1997, J MOL BIOL, V272, P226, DOI 10.1006/jmbi.1997.1244; Ashworth JL, 1999, BIOCHEM J, V340, P171, DOI 10.1042/0264-6021:3400171; Booms P, 2000, HUM GENET, V107, P216, DOI 10.1007/s004390000368; Collod-Beroud G, 2003, HUM MUTAT, V22, P199, DOI 10.1002/humu.10249; Corson GM, 2004, GENOMICS, V83, P461, DOI 10.1016/j.ygeno.2003.08.023; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; DUERRE JA, 1966, ANAL BIOCHEM, V17, P310, DOI 10.1016/0003-2697(66)90209-0; GLANVILLE RW, 1994, J BIOL CHEM, V269, P26630; HANDFORD P, 1995, J BIOL CHEM, V270, P6751, DOI 10.1074/jbc.270.12.6751; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; Hill CH, 2002, J NUTR, V132, P2143, DOI 10.1093/jn/132.8.2143; Hutchinson S, 2005, J MOL BIOL, V346, P833, DOI 10.1016/j.jmb.2004.11.038; Isogai Z, 2003, J BIOL CHEM, V278, P2750, DOI 10.1074/jbc.M209256200; Jensen SA, 2005, J BIOL CHEM, V280, P14076, DOI 10.1074/jbc.M412832200; Jensen SA, 2001, J BIOL CHEM, V276, P39661, DOI 10.1074/jbc.M104533200; Julenius K, 2005, GLYCOBIOLOGY, V15, P153, DOI 10.1093/glycob/cwh151; Kettle S, 1999, J MOL BIOL, V285, P1277, DOI 10.1006/jmbi.1998.2368; Knott V, 1996, J MOL BIOL, V255, P22, DOI 10.1006/jmbi.1996.0003; Lee SSJ, 2004, STRUCTURE, V12, P717, DOI 10.1016/j.str.2004.02.023; LENTZ SR, 1991, J CLIN INVEST, V88, P1906, DOI 10.1172/JCI115514; Lin GQ, 2002, J BIOL CHEM, V277, P50795, DOI 10.1074/jbc.M210611200; Majors AK, 2000, MOL GENET METAB, V70, P252, DOI 10.1006/mgme.2000.3024; Marson A, 2005, J BIOL CHEM, V280, P5013, DOI 10.1074/jbc.M409029200; McGettrick AJ, 2000, HUM MOL GENET, V9, P1987, DOI 10.1093/hmg/9.13.1987; Mecham R. P., 1994, EXTRACELLULAR MATRIX, P281; Nagase T, 2001, DNA RES, V8, P85, DOI 10.1093/dnares/8.2.85; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; Pyeritz R., 2002, CONNECTIVE TISSUE IT, P585, DOI [10.1002/0471221929.ch12, DOI 10.1002/0471221929.CH12]; Pyeritz RE, 2000, ANNU REV MED, V51, P481, DOI 10.1146/annurev.med.51.1.481; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; Reinhardt DP, 2000, J BIOL CHEM, V275, P2205, DOI 10.1074/jbc.275.3.2205; Reinhardt DP, 2000, J BIOL CHEM, V275, P12339, DOI 10.1074/jbc.275.16.12339; Reinhardt DP, 1996, J BIOL CHEM, V271, P19489, DOI 10.1074/jbc.271.32.19489; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; Reinhardt DP, 1997, J BIOL CHEM, V272, P1231, DOI 10.1074/jbc.272.2.1231; Reinhardt DP, 1997, J BIOL CHEM, V272, P7368, DOI 10.1074/jbc.272.11.7368; Ritty TM, 2003, BIOCHEM J, V375, P425, DOI 10.1042/BJ20030649; Ritty TM, 1999, J BIOL CHEM, V274, P8933, DOI 10.1074/jbc.274.13.8933; Robinson PN, 2002, HUM MUTAT, V20, P153, DOI 10.1002/humu.10113; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Schrijver I, 1999, AM J HUM GENET, V65, P1007, DOI 10.1086/302582; SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4; SKOVBY F, 2002, CONNECTIVE TISSUE IT, P627; Smallridge RS, 1999, J MOL BIOL, V286, P661, DOI 10.1006/jmbi.1998.2536; Tiedemann K, 2001, J BIOL CHEM, V276, P36035, DOI 10.1074/jbc.M104985200; Ueland PM., 1992, ATHEROSCLEROTIC CARD, P183; VANSTOKKUM IHM, 1990, ANAL BIOCHEM, V191, P110, DOI 10.1016/0003-2697(90)90396-Q; Vollbrandt T, 2004, J BIOL CHEM, V279, P32924, DOI 10.1074/jbc.M405239200; Whiteman P, 2003, HUM MOL GENET, V12, P727, DOI 10.1093/hmg/ddg081; Whiteman P, 1998, J BIOL CHEM, V273, P7807, DOI 10.1074/jbc.273.14.7807; Yuan XM, 1997, EMBO J, V16, P6659, DOI 10.1093/emboj/16.22.6659; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855	53	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34946	34955		10.1074/jbc.M504748200	http://dx.doi.org/10.1074/jbc.M504748200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16096271	hybrid, Green Published			2022-12-27	WOS:000232403900068
J	Ren, JG; Li, ZG; Crimmins, DL; Sacks, DB				Ren, JG; Li, ZG; Crimmins, DL; Sacks, DB			Self-association of IQGAP1 - Characterization and functional sequelae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; PROTEIN; CALMODULIN; CDC42; DIMERIZATION; IDENTIFICATION; TARGET; BINDS; RAC1	The scaffolding protein IQGAP1 participates in numerous cellular functions by binding to target proteins such as actin, calmodulin, E-cadherin, beta-catenin, Cdc42, Rac1, and CLIP-170. IQGAP1 regulates the cytoskeleton, promotes cell motility, and modulates E-cadherin-mediated cell-cell adhesion. However, how IQGAP1 exerts its functions in vivo is still unclear. In this study we investigate the self-association of IQGAP1 and its role in IQGAP1 function. Endogenous IQGAP1 co-immunoprecipitated from MCF-7 cells with IQGAP1 tagged with enhanced green fluorescent protein, indicating that IQGAP1 self-associates in cells. In vitro assays confirmed that IQGAP1 can self-associate and that this effect is mediated by the N-terminal half of the protein. Gel filtration analysis suggested that full-length IQGAP1 exists as a combination of monomers, dimers, and larger oligomers. Analysis performed with multiple fragments of IQGAP1 narrowed the self-association region to amino acids 763 - 863. In support of this observation, a peptide comprising residues 763 - 863 disrupted self-association of full-length IQGAP1 in a dose-dependent manner. Similarly, deleting this sequence from IQGAP1 abolished binding to full-length IQGAP1. In addition, the ability of IQGAP1 to increase the amount of active Cdc42 in cells is abrogated upon removal of this region. Consistent with these findings, transfection into cells of a peptide containing the self-association domain significantly reduced the amount of active Cdc42 in cell lysates. These observations define a sequence of IQGAP1 that is necessary for its oligomerization and demonstrate that self-association is required for the normal cellular function of IQGAP1.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Washington University (WUSTL)	Sacks, DB (corresponding author), Brigham & Womens Hosp, Dept Pathol, Thorn 530,75 Francis St, Boston, MA 02115 USA.	dsacks@rics.bwh.harvard.edu		Sacks, David/0000-0003-3100-0735				Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; Briggs MW, 2003, EMBO REP, V4, P571, DOI 10.1038/sj.embor.embor867; Briggs MW, 2003, FEBS LETT, V542, P7, DOI 10.1016/S0014-5793(03)00333-8; Briggs MW, 2002, J BIOL CHEM, V277, P7453, DOI 10.1074/jbc.M104315200; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Copeland JW, 2004, J BIOL CHEM, V279, P50250, DOI 10.1074/jbc.M404429200; FISH WW, 1969, J BIOL CHEM, V244, P4989; Fukata M, 2002, CELL, V109, P873, DOI 10.1016/S0092-8674(02)00800-0; Fukata M, 1997, J BIOL CHEM, V272, P29579, DOI 10.1074/jbc.272.47.29579; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Ho YD, 1999, J BIOL CHEM, V274, P464, DOI 10.1074/jbc.274.1.464; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Li ZG, 2003, J BIOL CHEM, V278, P4347, DOI 10.1074/jbc.M208579200; Li ZG, 1999, J BIOL CHEM, V274, P37885, DOI 10.1074/jbc.274.53.37885; Marianayagam NJ, 2004, TRENDS BIOCHEM SCI, V29, P618, DOI 10.1016/j.tibs.2004.09.006; Mataraza JM, 2003, J BIOL CHEM, V278, P41237, DOI 10.1074/jbc.M304838200; Mateer SC, 2003, CELL MOTIL CYTOSKEL, V55, P147, DOI 10.1002/cm.10118; Mateer SC, 2002, J BIOL CHEM, V277, P12324, DOI 10.1074/jbc.M109535200; Meller N, 2004, J BIOL CHEM, V279, P37470, DOI 10.1074/jbc.M404535200; Roy M, 2004, J BIOL CHEM, V279, P17329, DOI 10.1074/jbc.M308405200; So CW, 2003, CANCER CELL, V4, P99, DOI 10.1016/S1535-6108(03)00188-0; Sokol SY, 2001, J BIOL CHEM, V276, P48425, DOI 10.1074/jbc.M107975200; Swart-Mataraza JM, 2002, J BIOL CHEM, V277, P24753, DOI 10.1074/jbc.M111165200; Thornton C, 2004, J BIOL CHEM, V279, P31357, DOI 10.1074/jbc.M402316200; Veselovsky AV, 2002, J MOL RECOGNIT, V15, P405, DOI 10.1002/jmr.597; Wang YZ, 2004, J CELL BIOL, V164, P973, DOI 10.1083/jcb.200401010; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; Yablonski D, 1996, P NATL ACAD SCI USA, V93, P13864, DOI 10.1073/pnas.93.24.13864	31	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34548	34557		10.1074/jbc.M507321200	http://dx.doi.org/10.1074/jbc.M507321200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16105843	hybrid			2022-12-27	WOS:000232403900023
J	Sleeman, MC; Sorensen, JL; Batchelar, ET; McDonough, MA; Schofield, CJ				Sleeman, MC; Sorensen, JL; Batchelar, ET; McDonough, MA; Schofield, CJ			Structural and mechanistic studies on carboxymethylproline synthase (CarB), a unique member of the crotonase superfamily catalyzing the first step in carbapenem biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLAVULANIC ACID BIOSYNTHESIS; BETA-LACTAM SYNTHETASE; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; DELTA(3)-DELTA(2)-ENOYL-COA ISOMERASE; STREPTOMYCES-CLAVULIGERUS; MACROMOLECULAR STRUCTURES; COA HYDRATASE; FATTY-ACID; ENZYME	The first step in the biosynthesis of the medicinally important carbapenem family of beta-lactam antibiotics is catalyzed by carboxymethylproline synthase (CarB), a unique member of the crotonase superfamily. CarB catalyzes formation of (2S,5S)-carboxymethylproline [(2S,5S)-t-CMP] from malonyl-CoA and L-glutamate semialdehyde. In addition to using a cosubstrate, CarB catalyzes C-C and C-N bond formation processes as well as an acyl-coenzyme A hydrolysis reaction. We describe the crystal structure of CarB in the presence and absence of acetyl-CoA at 2.24 angstrom and 3.15 angstrom resolution, respectively. The structures reveal that CarB contains a conserved oxy-anion hole probably required for decarboxylation of malonyl-CoA and stabilization of the resultant enolate. Comparison of the structures reveals that conformational changes (involving His(229)) in the cavity predicted to bind L-glutamate semialdehyde occur on (co)substrate binding. Mechanisms for the formation of the carboxymethylproline ring are discussed in the light of the structures and the accompanying studies using isotopically labeled substrates; cyclization via 1,4-addition is consistent with the observed labeling results (providing that hydrogen exchange at the C-6 position of carboxymethylproline does not occur). The side chain of Glu(131) appears to be positioned to be involved in hydrolysis of the carboxymethylproline-CoA ester intermediate. Labeling experiments ruled out the possibility that hydrolysis proceeds via an anhydride in which water attacks a carbonyl derived from Glu(131), as proposed for 3-hydroxyisobutyryl-CoA hydrolase. The structural work will aid in mutagenesis studies directed at altering the selectivity of CarB to provide intermediates for the production of clinically useful carbapenems.	Univ Oxford, Dept Chem, Chem Res Lab, Oxford OX1 3TA, England; Univ Oxford, Oxford Ctr Mol Sci, Chem Res Lab, Oxford OX1 3TA, England	University of Oxford; University of Oxford	Schofield, CJ (corresponding author), Univ Oxford, Dept Chem, Chem Res Lab, Mansfield Rd, Oxford OX1 3TA, England.	christopher.schofield@chem.ox.ac.uk	McDonough, Michael/N-8913-2019; McDonough, Michael A/G-2744-2013	McDonough, Michael/0000-0003-4664-6942; McDonough, Michael A/0000-0003-4664-6942; Schofield, Christopher/0000-0002-0290-6565	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bachmann BO, 1998, P NATL ACAD SCI USA, V95, P9082, DOI 10.1073/pnas.95.16.9082; Baggaley KH, 1997, NAT PROD REP, V14, P309, DOI 10.1039/np9971400309; BALDWIN JE, 1976, J CHEM SOC CHEM COMM, P736, DOI 10.1039/c39760000736; Benning MM, 1996, BIOCHEMISTRY-US, V35, P8103, DOI 10.1021/bi960768p; Benning MM, 2000, BIOCHEMISTRY-US, V39, P4630, DOI 10.1021/bi9928896; *BRUK AXS INC, 2003, XPREP DAT PREP REC S; Carreras CW, 1997, TOP CURR CHEM, V188, P85; Cianci M, 2005, J SYNCHROTRON RADIAT, V12, P455, DOI 10.1107/S0909049505009131; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; COLLADO I, 1994, TETRAHEDRON LETT, V35, P8037; DOUGLAS KT, 1981, J CHEM SOC PERK T 2, P171, DOI 10.1039/p29810000171; DOUGLAS KT, 1986, ACCOUNTS CHEM RES, V19, P186, DOI 10.1021/ar00126a005; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Engel CK, 1998, J MOL BIOL, V275, P847, DOI 10.1006/jmbi.1997.1491; Engel CK, 1996, EMBO J, V15, P5135, DOI 10.1002/j.1460-2075.1996.tb00897.x; Gerratana B, 2004, BIOCHEMISTRY-US, V43, P15936, DOI 10.1021/bi0483662; Gerratana B, 2003, BIOCHEMISTRY-US, V42, P7836, DOI 10.1021/bi034361d; HODGSON JE, 1995, GENE, V166, P49, DOI 10.1016/0378-1119(95)00560-9; Holden HM, 2001, ACCOUNTS CHEM RES, V34, P145, DOI 10.1021/ar000053l; Jensen SE, 2000, ANTIMICROB AGENTS CH, V44, P720, DOI 10.1128/AAC.44.3.720-726.2000; Jensen SE, 1999, ANTON LEEUW INT J G, V75, P125, DOI 10.1023/A:1001755724055; Khaleeli N, 1999, J AM CHEM SOC, V121, P9223, DOI 10.1021/ja9923134; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Kurimoto K, 2001, STRUCTURE, V9, P1253, DOI 10.1016/S0969-2126(01)00686-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB; Li RF, 2000, J AM CHEM SOC, V122, P9296, DOI 10.1021/ja001723l; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; McDaniel R, 2005, CHEM REV, V105, P543, DOI 10.1021/cr0301189; McGowan SJ, 1996, MOL MICROBIOL, V22, P415, DOI 10.1046/j.1365-2958.1996.00125.x; McNaughton HJ, 1998, CHEM COMMUN, P2325, DOI 10.1039/a806713i; Modis Y, 1998, STRUCTURE, V6, P957, DOI 10.1016/S0969-2126(98)00098-7; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Mursula AM, 2004, FEBS LETT, V557, P81, DOI 10.1016/S0014-5793(03)01450-9; Mursula AM, 2001, J MOL BIOL, V309, P845, DOI 10.1006/jmbi.2001.4671; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAGE MI, 1992, CHEM BETA LACTAMS, P1; Schofield CJ, 1997, CURR OPIN STRUC BIOL, V7, P857, DOI 10.1016/S0959-440X(97)80158-3; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Sleeman MC, 2004, CHEMBIOCHEM, V5, P879, DOI 10.1002/cbic.200300908; Sleeman MC, 2004, J BIOL CHEM, V279, P6730, DOI 10.1074/jbc.M311824200; Sorensen JL, 2005, CHEM COMMUN, P1155, DOI 10.1039/b416423g; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Townsend CA, 2002, CURR OPIN CHEM BIOL, V6, P583, DOI 10.1016/S1367-5931(02)00392-7; Truglio JJ, 2003, J BIOL CHEM, V278, P42352, DOI 10.1074/jbc.M307399200; Verdonk ML, 2003, PROTEINS, V52, P609, DOI 10.1002/prot.10465; Walter TS, 2005, ACTA CRYSTALLOGR D, V61, P651, DOI 10.1107/S0907444905007808; Whittingham JL, 2003, J BIOL CHEM, V278, P1744, DOI 10.1074/jbc.M211188200; Wong BJ, 2003, J AM CHEM SOC, V125, P12076, DOI 10.1021/ja037652i; YAGGI NF, 1977, J AM CHEM SOC, V99, P4844, DOI 10.1021/ja00456a061	52	26	27	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34956	34965		10.1074/jbc.M507196200	http://dx.doi.org/10.1074/jbc.M507196200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16096274	hybrid			2022-12-27	WOS:000232403900069
J	Xu, BE; Stippec, S; Lazrak, A; Huang, CL; Cobb, MH				Xu, BE; Stippec, S; Lazrak, A; Huang, CL; Cobb, MH			WNK1 activates SGK1 by a phosphatidylinositol 3-kinase-dependent and non-catalytic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL SODIUM-CHANNEL; GLUCOCORTICOID-INDUCIBLE KINASE; PROTEIN-KINASE; NA+ CHANNEL; SIGNALING PATHWAY; BLOOD-PRESSURE; SERUM; EXPRESSION; PHOSPHORYLATION; CELLS	WNK1 ( with no lysine ( K) 1) is a protein-serine/threonine kinase with a unique catalytic site organization. Deletions in the first intron of the WNK1 gene were found in a group of hypertensive patients with pseudohypoaldosteronism type II. No changes in coding sequence of WNK1 were found, but its expression was increased severalfold. We have been investigating actions of WNK1 and have found that WNK1 activates the serum- and glucocorticoid-induced protein kinase SGK1, which impacts membrane expression of the epithelial sodium channel. Here we explore the role of WNK1 in SGK1 regulation. Activation of SGK1 by WNK1 is blocked by phosphatidylinositol 3-kinase inhibitors. Neither the catalytic activity nor the kinase domain of WNK1 is required; rather the N-terminal 220 residues of WNK1 are necessary and sufficient to activate SGK1. Phosphorylation of WNK1 on Thr-58 contributes to SGK1 activation. Finally, we show that WNK1 is required for the activation of SGK1 by insulin-like growth factor 1.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 6001 Forest Pk Rd, Dallas, TX 75390 USA.	Melanie.Cobb@UTSouthwestern.edu		Lazrak, Ahmed/0000-0002-4127-1937; Cobb, Melanie/0000-0003-0833-5473	NIDDK NIH HHS [DK54368, DK59530] Funding Source: Medline; NIGMS NIH HHS [GM53032] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054368, R01DK059530] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn YJ, 1999, AM J PHYSIOL-RENAL, V277, pF121, DOI 10.1152/ajprenal.1999.277.1.F121; Arteaga MF, 2005, AM J PHYSIOL-RENAL, V289, pF90, DOI 10.1152/ajprenal.00390.2004; Bell LM, 2000, J BIOL CHEM, V275, P25262, DOI 10.1074/jbc.M002076200; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; de la Rosa DA, 1999, J BIOL CHEM, V274, P37834, DOI 10.1074/jbc.274.53.37834; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Delaloy C, 2003, MOL CELL BIOL, V23, P9208, DOI 10.1128/MCB.23.24.9208-9221.2003; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Gonzalez-Robayna IJ, 2000, MOL ENDOCRINOL, V14, P1283, DOI 10.1210/me.14.8.1283; Hayashi M, 2001, J BIOL CHEM, V276, P8631, DOI 10.1074/jbc.C000838200; Jiang ZY, 2005, J BIOL CHEM, V280, P21622, DOI 10.1074/jbc.m414464200; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Lee BH, 2004, MOL CELL, V15, P741, DOI 10.1016/j.molcel.2004.07.018; Lenertz LY, 2005, J BIOL CHEM, V280, P26653, DOI 10.1074/jbc.M502598200; Leong MLL, 2003, J BIOL CHEM, V278, P5871, DOI 10.1074/jbc.M211649200; Min XS, 2004, STRUCTURE, V12, P1303, DOI 10.1016/j.str.2004.04.014; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Rotin D, 2000, CURR OPIN NEPHROL HY, V9, P529, DOI 10.1097/00041552-200009000-00012; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; Verissimo F, 2001, ONCOGENE, V20, P5562, DOI 10.1038/sj.onc.1204726; Vitari AC, 2004, BIOCHEM J, V378, P257, DOI 10.1042/BJ20031692; Wilson FH, 2001, SCIENCE, V293, P1107, DOI 10.1126/science.1062844; Xu BE, 2005, P NATL ACAD SCI USA, V102, P10315, DOI 10.1073/pnas.0504422102; Xu BE, 2004, J BIOL CHEM, V279, P7826, DOI 10.1074/jbc.M313465200; Xu BE, 2002, J BIOL CHEM, V277, P48456, DOI 10.1074/jbc.M207917200; Xu BE, 2000, J BIOL CHEM, V275, P16795, DOI 10.1074/jbc.275.22.16795; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029; Xu Q, 2002, NUCLEIC ACIDS RES, V30, P3754, DOI 10.1093/nar/gkf492; Zambrowicz BP, 2003, P NATL ACAD SCI USA, V100, P14109, DOI 10.1073/pnas.2336103100; Zeng WZ, 2003, J BIOL CHEM, V278, P16852, DOI 10.1074/jbc.M300619200	31	74	77	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34218	34223		10.1074/jbc.M505735200	http://dx.doi.org/10.1074/jbc.M505735200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16081417	hybrid			2022-12-27	WOS:000232229700064
J	Steet, R; Lee, WS; Kornfeld, S				Steet, R; Lee, WS; Kornfeld, S			Identification of the minimal lysosomal enzyme recognition domain in cathepsin D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASN-LINKED OLIGOSACCHARIDES; LYSINE-BASED STRUCTURE; MANNOSE PHOSPHORYLATION; PROCATHEPSIN-D; DNASE-I; AMINO; PHOSPHOTRANSFERASE; DETERMINANTS; MEDIATE; SITES	Specific recognition of lysosomal hydrolases by UDP-GlcNAc: lysosomal enzyme N-acetylglucosamine-1-phosphotransferase, the initial enzyme in the biosynthesis of mannose 6-phosphate residues, is governed by a common protein determinant. Previously, we generated a lysosomal enzyme recognition domain in the secretory protein glycopepsinogen by substituting in two regions ( lysine 203 and amino acids 265 - 293 of the beta loop) from cathepsin D, a highly related lysosomal protease. Here we show that substitution of just two lysines (Lys-203 and Lys-267) stimulates mannose phosphorylation 116-fold. Substitution of additional residues in the beta loop, particularly lysines, increased phosphorylation 4-fold further, approaching the level obtained with intact cathepsin D. All the phosphorylation occurred at the carboxyl lobe glycan, indicating that additional elements are required for phosphorylation of the amino lobe glycan. These data support the proposal that as few as two lysines in the correct orientation to each other and to the glycan can serve as the minimal elements of the lysosomal enzyme recognition domain. However, our findings show that the spacing between lysines is flexible and other residues contribute to the recognition marker.	Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA	Washington University (WUSTL)	Kornfeld, S (corresponding author), Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA.	skornfel@im.wustl.edu			NCI NIH HHS [CA08759] Funding Source: Medline; NHLBI NIH HHS [5T32-HL07088-30] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA008759, R01CA008759] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007088] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BARANSKI TJ, 1992, J BIOL CHEM, V267, P23342; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; CANTOR AB, 1992, J BIOL CHEM, V267, P23349; CANTOR AB, 1992, J BIOL CHEM, V267, P23357; Cuozzo JW, 1998, J BIOL CHEM, V273, P21067, DOI 10.1074/jbc.273.33.21067; CUOZZO JW, 1995, J BIOL CHEM, V270, P15611, DOI 10.1074/jbc.270.26.15611; Do H, 2002, J BIOL CHEM, V277, P29737, DOI 10.1074/jbc.M202369200; DUSTIN ML, 1995, J BIOL CHEM, V270, P170, DOI 10.1074/jbc.270.1.170; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Nishikawa A, 1999, J BIOL CHEM, V274, P19309, DOI 10.1074/jbc.274.27.19309; Nishikawa A, 1997, J BIOL CHEM, V272, P19408, DOI 10.1074/jbc.272.31.19408; Tikkanen R, 1997, EMBO J, V16, P6684, DOI 10.1093/emboj/16.22.6684; Warner JB, 2002, J BIOL CHEM, V277, P41897, DOI 10.1074/jbc.M203097200; Yaghootfam A, 2003, J BIOL CHEM, V278, P32653, DOI 10.1074/jbc.M304865200	16	28	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33318	33323		10.1074/jbc.M505994200	http://dx.doi.org/10.1074/jbc.M505994200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16081416	hybrid			2022-12-27	WOS:000232058100028
J	Movahed, P; Jonsson, BAG; Birnir, B; Wingstrand, JA; Jorgensen, TD; Ermund, A; Sterner, O; Zygmunt, PM; Hogestatt, ED				Movahed, P; Jonsson, BAG; Birnir, B; Wingstrand, JA; Jorgensen, TD; Ermund, A; Sterner, O; Zygmunt, PM; Hogestatt, ED			Endogenous unsaturated C18N-acylethanolamines are vanilloid receptor (TRPV1) agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED ION-CHANNEL; PROTEIN-KINASE-C; CAPSAICIN-RECEPTOR; CANNABINOID RECEPTOR; SENSORY NEURONS; ANANDAMIDE; RELEASE; ANALOGS; BRAIN; HEAT	The endogenous C18 N-acylethanolamines (NAEs) N-linolenoylethanolamine ( 18: 3 NAE), N-linoleoylethanolamine ( 18: 2 NAE), N-oleoylethanolamine ( 18: 1 NAE), and N-stearoylethanolamine ( 18: 0 NAE) are structurally related to the endocannabinoid anandamide ( 20: 4 NAE), but these lipids are poor ligands at cannabinoid CB1 receptors. Anandamide is also an activator of the transient receptor potential (TRP) vanilloid 1 (TRPV1) on primary sensory neurons. Here we show that C18 NAEs are present in rat sensory ganglia and vascular tissue. With the exception of 18: 3 NAE in rat sensory ganglia, the levels of C18 NAEs are equal to or substantially exceed those of anandamide. At submicromolar concentrations, 18: 3 NAE, 18: 2 NAE, and 18: 1 NAE, but not 18: 0 NAE and oleic acid, activate native rTRPV(1) on perivascular sensory nerves. 18: 1 NAE does not activate these nerves in TRPV1 gene knock-out mice. Only the unsaturated C18 NAEs elicit whole cell currents and fluorometric calcium responses in HEK293 cells expressing hTRPV(1). Molecular modeling revealed a low energy cluster of U-shaped unsaturated NAE conformers, sharing several pharmacophoric elements with capsaicin. Furthermore, one of the two major low energy conformational families of anandamide also overlaps with the cannabinoid CB1 receptor ligand HU210, which is in line with anandamide being a dual activator of TRPV1 and the cannabinoid CB1 receptor. This study shows that several endogenous non-cannabinoid NAEs, many of which are more abundant than anandamide in rat tissues, activate TRPV1 and thus may play a role as endogenous TRPV1 modulators.	Lund Univ, Dept Lab Med, SE-22185 Lund, Sweden; Lund Univ, Dept Expt Med Sci, SE-22184 Lund, Sweden; Lund Univ, Dept Organ Chem, SE-22100 Lund, Sweden; NeuroSearch AS, DK-2750 Ballerup, Denmark	Lund University; Lund University; Lund University	Zygmunt, PM (corresponding author), Univ Lund Hosp, Dept Lab Med, SE-22185 Lund, Sweden.	peter.zygmunt@med.lu.se	Ermund, Anna/AAG-3160-2020	Dyhring, Tino/0000-0002-9607-0577; Ermund, Anna/0000-0002-3233-043X; Movahed, Pouya/0000-0003-2041-3550; Jonsson, Bo/0000-0002-8767-0589; Zygmunt, Peter/0000-0002-5102-8199; Birnir, Bryndis/0000-0002-1763-0266				Ahern GP, 2003, J BIOL CHEM, V278, P30429, DOI 10.1074/jbc.M305051200; Ahluwalia J, 2003, J NEUROCHEM, V84, P585, DOI 10.1046/j.1471-4159.2003.01550.x; Appendino G, 2002, J MED CHEM, V45, P3739, DOI 10.1021/jm020844o; Bandell M, 2004, NEURON, V41, P849, DOI 10.1016/S0896-6273(04)00150-3; Bridges D, 2003, NEUROSCIENCE, V119, P803, DOI 10.1016/S0306-4522(03)00200-8; Busch-Petersen J, 1996, J MED CHEM, V39, P3790, DOI 10.1021/jm950934b; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Chuang HH, 2001, NATURE, V411, P957, DOI 10.1038/35082088; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; de Fonseca FR, 2001, NATURE, V414, P209, DOI 10.1038/35102582; De Petrocellis L, 2001, J NEUROCHEM, V77, P1660, DOI 10.1046/j.1471-4159.2001.00406.x; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; Dinis P, 2004, J NEUROSCI, V24, P11253, DOI 10.1523/JNEUROSCI.2657-04.2004; Evans RM, 2004, BRIT J PHARMACOL, V141, P1223, DOI 10.1038/sj.bjp.0705723; Gavva NR, 2004, J BIOL CHEM, V279, P20283, DOI 10.1074/jbc.M312577200; Gomez R, 2002, J NEUROSCI, V22, P9612; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; JANUSZ JM, 1993, J MED CHEM, V36, P2595, DOI 10.1021/jm00070a002; Jordt SE, 2002, CELL, V108, P421, DOI 10.1016/S0092-8674(02)00637-2; Jordt SE, 2004, NATURE, V427, P260, DOI 10.1038/nature02282; Jung J, 1999, J NEUROSCI, V19, P529; Kedei N, 2001, J BIOL CHEM, V276, P28613, DOI 10.1074/jbc.M103272200; Lin SY, 1998, J MED CHEM, V41, P5353, DOI 10.1021/jm970257g; Lopshire JC, 1998, J NEUROSCI, V18, P6081; Maccarrone M, 2002, MOL CELL NEUROSCI, V21, P126, DOI 10.1006/mcne.2002.1164; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; McVey DC, 2001, PEPTIDES, V22, P1439, DOI 10.1016/S0196-9781(01)00463-6; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; MOVAHED P, 2002, PHARMACOLOGIST, V44, pA152; Nagy I, 2004, EUR J PHARMACOL, V500, P351, DOI 10.1016/j.ejphar.2004.07.037; Okamoto Y, 2004, J BIOL CHEM, V279, P5298, DOI 10.1074/jbc.M306642200; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Premkumar LS, 2000, NATURE, V408, P985, DOI 10.1038/35050121; Reggio PH, 2002, PROSTAG LEUKOTR ESS, V66, P143, DOI 10.1054/plef.2001.0343; Schmid HHO, 2002, CHEM PHYS LIPIDS, V121, P111, DOI 10.1016/S0009-3084(02)00157-3; SCHMID PC, 1983, J BIOL CHEM, V258, P9302; SCHMID PC, 1995, FEBS LETT, V375, P117, DOI 10.1016/0014-5793(95)01194-J; SHENKIN PS, 1994, J COMPUT CHEM, V15, P899, DOI 10.1002/jcc.540150811; Sheskin T, 1997, J MED CHEM, V40, P659, DOI 10.1021/jm960752x; Shin J, 2002, P NATL ACAD SCI USA, V99, P10150, DOI 10.1073/pnas.152002699; Smart D, 2002, BRIT J PHARMACOL, V136, P452, DOI 10.1038/sj.bjp.0704732; Smith M, 2003, EUR J PHARMACOL, V478, P21, DOI 10.1016/j.ejphar.2003.08.034; Stella N, 2001, EUR J PHARMACOL, V425, P189, DOI 10.1016/S0014-2999(01)01182-7; Story GM, 2003, CELL, V112, P819, DOI 10.1016/S0092-8674(03)00158-2; Sun YX, 2004, BIOCHEM J, V380, P749, DOI 10.1042/BJ20040031; Szallasi A, 1999, PHARMACOL REV, V51, P159; Tian XY, 2005, J BIOL CHEM, V280, P29788, DOI 10.1074/jbc.M502925200; Tong WD, 1998, J MED CHEM, V41, P4207, DOI 10.1021/jm970239z; Vellani V, 2001, J PHYSIOL-LONDON, V534, P813, DOI 10.1111/j.1469-7793.2001.00813.x; Wang XB, 2005, J PHYSIOL-LONDON, V564, P541, DOI 10.1113/jphysiol.2004.081844; XIE XQ, 1994, J MED CHEM, V37, P1418, DOI 10.1021/jm00036a006; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761; Zygmunt PM, 2002, J NEUROSCI, V22, P4720, DOI 10.1523/JNEUROSCI.22-11-04720.2002	57	144	153	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38496	38504		10.1074/jbc.M507429200	http://dx.doi.org/10.1074/jbc.M507429200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16081411	hybrid			2022-12-27	WOS:000233239800047
J	Korenaga, M; Wang, T; Li, YC; Showalter, LA; Chan, TS; Sun, JR; Weinman, SA				Korenaga, M; Wang, T; Li, YC; Showalter, LA; Chan, TS; Sun, JR; Weinman, SA			Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE REDUCTASE; OXIDATIVE STRESS; HYDROGEN-PEROXIDE; RESPIRATORY-CHAIN; SUPEROXIDE ANION; PLUS RIBAVIRIN; COMPLEX-I; ER STRESS; LIVER; APOPTOSIS	Hepatitis C infection causes a state of chronic oxidative stress, which may contribute to fibrosis and carcinogenesis in the liver. Previous studies have shown that expression of the HCV core protein in hepatoma cells depolarized mitochondria and increased reactive oxygen species (ROS) production, but the mechanisms of these effects are unknown. In this study we examined the properties of liver mitochondria from transgenic mice expressing HCV core protein, and from normal liver mitochondria incubated with recombinant core protein. Liver mitochondria from transgenic mice expressing the HCV proteins core, E1 and E2 demonstrated oxidation of the glutathione pool and a decrease in NADPH content. In addition, there was reduced activity of electron transport complex I, and increased ROS production from complex I substrates. There were no abnormalities observed in complex II or complex III function. Incubation of control mitochondria in vitro with recombinant core protein also caused glutathione oxidation, selective complex I inhibition, and increased ROS production. Proteinase K digestion of either transgenic mitochondria or control mitochondria incubated with core protein showed that core protein associates strongly with mitochondria, remains associated with the outer membrane, and is not taken up across the outer membrane. Core protein also increased Ca2+ uptake into isolated mitochondria. These results suggest that interaction of core protein with mitochondria and subsequent oxidation of the glutathione pool and complex I inhibition may be an important cause of the oxidative stress seen in chronic hepatitis C.	Univ Texas, Med Branch, Dept Internal Med, Galveston, TX 77555 USA; Univ Texas, Med Branch, Ctr Hepatitis Res, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA; Yamaguchi Univ, Sch Med, Dept Gastroenterol & Hepatol, Yamaguchi 7558505, Japan	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Yamaguchi University	Weinman, SA (corresponding author), Univ Texas, Med Branch, Dept Internal Med, 301 Univ Blvd, Galveston, TX 77555 USA.	sweinman@utmb.edu	Korenaga, Masaaki/AAE-7479-2020; Weinman, Steven/E-7012-2011		NIAAA NIH HHS [AA12863] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA012863] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Adinolfi LE, 2001, HEPATOLOGY, V33, P1358, DOI 10.1053/jhep.2001.24432; Anderson M. E., 1989, GLUTATHIONE CHEM BIO, VA, P339; Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; Barbaro G, 1999, AM J GASTROENTEROL, V94, P2198, DOI 10.1111/j.1572-0241.1999.01294.x; Becker LB, 1999, AM J PHYSIOL-HEART C, V277, pH2240, DOI 10.1152/ajpheart.1999.277.6.H2240; Benali-Furet NL, 2005, ONCOGENE, V24, P4921, DOI 10.1038/sj.onc.1208673; Bianchi K, 2004, BBA-MOL CELL RES, V1742, P119, DOI 10.1016/j.bbamcr.2004.09.015; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Brookes PS, 2004, AM J PHYSIOL-CELL PH, V287, pC817, DOI 10.1152/ajpcell.00139.2004; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; Cerny A, 1999, HEPATOLOGY, V30, P595, DOI 10.1002/hep.510300312; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; Davis GL, 2000, GASTROENTEROLOGY, V118, pS104, DOI 10.1016/S0016-5085(00)70009-6; Estabrook R. W., 1967, METHODS ENZYMOLOGY, V10, P41, DOI DOI 10.1016/0076-6879(67)10010-4; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; Gong GZ, 2001, P NATL ACAD SCI USA, V98, P9599, DOI 10.1073/pnas.171311298; HANUKOGLU I, 1995, ENDOCR RES, V21, P231, DOI 10.3109/07435809509030439; Higuchi M, 1998, ONCOGENE, V17, P2515, DOI 10.1038/sj.onc.1202485; Honda M, 2000, HEPATOLOGY, V31, P1351, DOI 10.1053/jhep.2000.7985; Houglum K, 1997, GASTROENTEROLOGY, V113, P1069, DOI 10.1053/gast.1997.v113.pm9322499; Hussy P, 1996, VIROLOGY, V224, P93, DOI 10.1006/viro.1996.0510; Jarreta D, 2000, CARDIOVASC RES, V45, P860, DOI 10.1016/S0008-6363(99)00388-0; JOHONSON D, 1967, METHOD ENZYMOL, V10, P94; Kato N, 2000, HEPATOLOGY, V32, P405, DOI 10.1053/jhep.2000.9198; Kumar D, 2002, HEPATOLOGY, V36, P1266, DOI 10.1053/jhep.2002.36370; Kwong LK, 1998, ARCH BIOCHEM BIOPHYS, V350, P118, DOI 10.1006/abbi.1997.0489; Lau JYN, 1996, J HEPATOL, V24, P43; Lerat H, 2002, GASTROENTEROLOGY, V122, P352, DOI 10.1053/gast.2002.31001; Li YB, 1999, BIOCHEM BIOPH RES CO, V262, P80, DOI 10.1006/bbrc.1999.1174; Liu QY, 1997, J VIROL, V71, P657, DOI 10.1128/JVI.71.1.657-662.1997; Loguercio C, 2003, FREE RADICAL BIO MED, V34, P1, DOI 10.1016/S0891-5849(02)01167-X; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; Martin EJ, 2003, J PHARMACOL EXP THER, V304, P121, DOI 10.1124/jpet.102.041392; McLauchlan J, 2002, EMBO J, V21, P3980, DOI 10.1093/emboj/cdf414; Moradpour D, 1996, VIROLOGY, V222, P51, DOI 10.1006/viro.1996.0397; Moriya K, 2001, CANCER RES, V61, P4365; OKUDA M, 1992, ACTA PHYSIOL SCAND, V145, P159, DOI 10.1111/j.1748-1716.1992.tb09351.x; Okuda M, 2002, GASTROENTEROLOGY, V122, P366, DOI 10.1053/gast.2002.30983; OLAFSDOTTIR K, 1988, ARCH BIOCHEM BIOPHYS, V263, P226, DOI 10.1016/0003-9861(88)90631-5; Otani K, 2005, GASTROENTEROLOGY, V128, P96, DOI 10.1053/j.gastro.2004.10.045; Otsuka M, 2002, VIROLOGY, V296, P84, DOI 10.1006/viro.2002.1371; Ray RB, 2000, VIROLOGY, V271, P197, DOI 10.1006/viro.2000.0295; Rolo AP, 2002, TOXICOL APPL PHARM, V182, P20, DOI 10.1006/taap.2002.9434; Sabile A, 1999, HEPATOLOGY, V30, P1064, DOI 10.1002/hep.510300429; SANTOLINI E, 1994, J VIROL, V68, P3631, DOI 10.1128/JVI.68.6.3631-3641.1994; Schwer B, 2004, J VIROL, V78, P7958, DOI 10.1128/JVI.78.15.7958-7968.2004; Seeff LB, 2002, HEPATOLOGY, V36, pS35, DOI 10.1053/jhep.2002.36806; Suzuki R, 2005, J VIROL, V79, P1271, DOI 10.1128/JVI.79.2.1271-1281.2005; TAKESHIGE K, 1979, BIOCHEM J, V180, P129, DOI 10.1042/bj1800129; Tardif KD, 2005, TRENDS MICROBIOL, V13, P159, DOI 10.1016/j.tim.2005.02.004; Taylor ER, 2003, J BIOL CHEM, V278, P19603, DOI 10.1074/jbc.M209359200; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Valgimigli M, 2002, FREE RADICAL RES, V36, P939, DOI 10.1080/107156021000006653; Vrablic AS, 2001, FASEB J, V15, P1739, DOI 10.1096/fj.00-0300com; Watashi K, 2003, CANCER SCI, V94, P937, DOI 10.1111/j.1349-7006.2003.tb01381.x; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Wen F, 2004, J MED VIROL, V72, P230, DOI 10.1002/jmv.10567; Yasui K, 1998, J VIROL, V72, P6048, DOI 10.1128/JVI.72.7.6048-6055.1998; Young TA, 2002, ARCH BIOCHEM BIOPHYS, V405, P65, DOI 10.1016/S0003-9861(02)00338-7; Zhang ZQ, 2000, ANAL BIOCHEM, V285, P163, DOI 10.1006/abio.2000.4701; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998	63	313	324	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37481	37488		10.1074/jbc.M506412200	http://dx.doi.org/10.1074/jbc.M506412200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16150732	hybrid			2022-12-27	WOS:000233044500024
J	Singh, M; Krajewski, M; Mikolajka, A; Holak, TA				Singh, M; Krajewski, M; Mikolajka, A; Holak, TA			Molecular determinants for the complex formation between the retinoblastoma protein and LXCXE sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE T-ANTIGEN; CELL-CYCLE CONTROL; ONCOGENIC POINT MUTATIONS; TUMOR-SUPPRESSOR PROTEIN; HISTONE DEACETYLASE; RB FAMILY; FUNCTIONAL INTERACTIONS; REPRESS TRANSCRIPTION; VIRAL ONCOPROTEINS; STRUCTURAL BASIS	The retinoblastoma tumor suppressor protein (pRb) is a key negative regulator of cell proliferation that is frequently disregulated in human cancer. Many viral oncoproteins ( for example, HPV E7 and E1A) are known to bind to the pRb pocket domain via a LXCXE binding motif. There are also some 20 cellular proteins that contain a LXCXE motif and have been reported to associate with the pocket domain of pRb. Using NMR spectroscopy and isothermal calorimetry titration, we show that LXCXE peptides of viral oncoproteins bind strongly to the pocket domain of pRb. Additionally, we show that LXCXE-like peptides of HDAC1 bind to the same site on pRb with a weak ( micromolar) and transient association. Systematic substitution of residues other than conserved Leu, Cys, and Glu show that the residues flanking the LXCXE are important for the binding, whereas positively charged amino acids in the XLXCX-EXXX sequence significantly weaken the interaction.	Max Planck Inst Biochem, D-82152 Martinsried, Germany	Max Planck Society	Holak, TA (corresponding author), Max Planck Inst Biochem, D-82152 Martinsried, Germany.	holak@biochem.mpg.de						Ach RA, 1997, MOL CELL BIOL, V17, P5077, DOI 10.1128/MCB.17.9.5077; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brown VD, 2002, MOL CELL BIOL, V22, P1390, DOI 10.1128/MCB.22.5.1390-1401.2002; Chan HM, 2001, ONCOGENE, V20, P6152, DOI 10.1038/sj.onc.1204793; Chen TT, 2000, MOL CELL BIOL, V20, P5571, DOI 10.1128/MCB.20.15.5571-5580.2000; Cobrinik D, 1996, CURR TOP MICROBIOL, V208, P31; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; Darnell GA, 2003, MOL CELL BIOL, V23, P6520, DOI 10.1128/MCB.23.18.6520-6532.2003; Dick FA, 2000, MOL CELL BIOL, V20, P3715, DOI 10.1128/MCB.20.10.3715-3727.2000; Dick FA, 2002, J VIROL, V76, P6224, DOI 10.1128/JVI.76.12.6224-6234.2002; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Fan SJ, 2001, ONCOGENE, V20, P4827, DOI 10.1038/sj.onc.1204666; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Helt AM, 2003, CARCINOGENESIS, V24, P159, DOI 10.1093/carcin/24.2.159; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kang H, 2004, MOL CELL BIOL, V24, P1188, DOI 10.1128/MCB.24.3.1188-1199.2004; Kennedy BK, 2001, P NATL ACAD SCI USA, V98, P8720, DOI 10.1073/pnas.151240898; Kim HY, 2001, EMBO J, V20, P295, DOI 10.1093/emboj/20.1.295; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; KRATZKE RA, 1992, J BIOL CHEM, V267, P25998; Laj A, 1999, MOL CELL BIOL, V19, P6632; Ledl A, 2005, ONCOGENE, V24, P3810, DOI 10.1038/sj.onc.1208539; Lee C, 2002, GENE DEV, V16, P3199, DOI 10.1101/gad.1046102; Lee C, 2002, REV MED VIROL, V12, P81, DOI 10.1002/rmv.340; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Lu XW, 1998, CELL, V95, P981, DOI 10.1016/S0092-8674(00)81722-5; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Meyer B, 2003, ANGEW CHEM INT EDIT, V42, P864, DOI 10.1002/anie.200390233; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; ONADIM Z, 1992, P NATL ACAD SCI USA, V89, P6177, DOI 10.1073/pnas.89.13.6177; Pellecchia M, 2002, NAT REV DRUG DISCOV, V1, P211, DOI 10.1038/nrd748; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; Rehm T, 2002, STRUCTURE, V10, P1613, DOI 10.1016/S0969-2126(02)00894-8; Sambrook J., 2001, MOL CLONING; SCHNUCHEL A, 1993, NATURE, V364, P169, DOI 10.1038/364169a0; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WUTHRICH K, 1986, NMR PROTEINS NUCLEIC, P28; Xiao B, 2003, P NATL ACAD SCI USA, V100, P2363, DOI 10.1073/pnas.0436813100; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	57	61	64	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37868	37876		10.1074/jbc.M504877200	http://dx.doi.org/10.1074/jbc.M504877200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16118215	hybrid			2022-12-27	WOS:000233044500067
J	Walter, KU; Vamvaca, K; Hilvert, D				Walter, KU; Vamvaca, K; Hilvert, D			An active enzyme constructed from a 9-amino acid alphabet	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOFUNCTIONAL CHORISMATE MUTASE; NOVO PROTEIN DESIGN; COMBINATORIAL MUTAGENESIS; COMPUTATIONAL DESIGN; MOLTEN GLOBULE; CATALYSIS; SELECTION; STATE; EVOLUTION; FOLD	Nature employs a set of 20 amino acids to produce a repertoire of protein structures endowed with sophisticated functions. Here, we combined design and selection to create an enzyme composed entirely from a set of only 9 amino acids that can rescue auxotrophic cells lacking chorismate mutase. The simplified protein captures key structural features of its natural counterpart but appears to be somewhat less stable and more flexible. The potential of a dramatically reduced amino acid alphabet to produce an active catalyst supports the notion that primordial enzymes may have possessed low amino acid diversity and suggests that combinatorial engineering strategies, such as the one used here, may be generally applied to create enzymes with novel structures and functions.	ETH Honggerberg, Swiss Fed Inst Technol, Organ Chem Lab, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Hilvert, D (corresponding author), ETH Honggerberg, Swiss Fed Inst Technol, Organ Chem Lab, CH-8093 Zurich, Switzerland.	hilvert@org.chem.ethz.ch						Akanuma S, 2002, P NATL ACAD SCI USA, V99, P13549, DOI 10.1073/pnas.222243999; BARTLETT PA, 1985, J AM CHEM SOC, V107, P7792, DOI 10.1021/ja00311a111; BETZ SF, 1993, CURR OPIN STRUC BIOL, V3, P601, DOI 10.1016/0959-440X(93)90090-8; CHOOK YM, 1993, P NATL ACAD SCI USA, V90, P8600, DOI 10.1073/pnas.90.18.8600; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P171; Dahiyat BI, 1997, SCIENCE, V278, P82, DOI 10.1126/science.278.5335.82; DAVIDSON AR, 1995, NAT STRUCT BIOL, V2, P856, DOI 10.1038/nsb1095-856; Davis BK, 2002, PROG BIOPHYS MOL BIO, V79, P77, DOI 10.1016/S0079-6107(02)00012-3; Dwyer MA, 2004, SCIENCE, V304, P1967, DOI 10.1126/science.1098432; Firth AE, 2005, BIOINFORMATICS, V21, P3314, DOI 10.1093/bioinformatics/bti516; Harbury PB, 1998, SCIENCE, V282, P1462, DOI 10.1126/science.282.5393.1462; HAYNES MR, 1994, SCIENCE, V263, P646, DOI 10.1126/science.8303271; KAMTEKAR S, 1993, SCIENCE, V262, P1680, DOI 10.1126/science.8259512; Kast P, 1996, P NATL ACAD SCI USA, V93, P5043, DOI 10.1073/pnas.93.10.5043; Kuhlman B, 2003, SCIENCE, V302, P1364, DOI 10.1126/science.1089427; LEE AY, 1995, J AM CHEM SOC, V117, P3627, DOI 10.1021/ja00117a038; Looger LL, 2003, NATURE, V423, P185, DOI 10.1038/nature01556; MacBeath G, 1998, BIOTECHNIQUES, V24, P789, DOI 10.2144/98245st02; MacBeath G, 1998, BIOCHEMISTRY-US, V37, P10062, DOI 10.1021/bi980449t; MacBeath G, 1998, SCIENCE, V279, P1958, DOI 10.1126/science.279.5358.1958; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; REGAN L, 1988, SCIENCE, V241, P976, DOI 10.1126/science.3043666; Riddle DS, 1997, NAT STRUCT BIOL, V4, P805, DOI 10.1038/nsb1097-805; Schafmeister CE, 1997, NAT STRUCT BIOL, V4, P1039, DOI 10.1038/nsb1297-1039; Silverman JA, 2001, P NATL ACAD SCI USA, V98, P3092, DOI 10.1073/pnas.041613598; Smith DL, 1997, J MASS SPECTROM, V32, P135, DOI 10.1002/(SICI)1096-9888(199702)32:2<135::AID-JMS486>3.0.CO;2-M; STRYER L, 1968, SCIENCE, V162, P526, DOI 10.1126/science.162.3853.526; Taylor SV, 2001, ANGEW CHEM INT EDIT, V40, P3310, DOI 10.1002/1521-3773(20010917)40:18<3310::AID-ANIE3310>3.0.CO;2-P; Taylor SV, 2001, P NATL ACAD SCI USA, V98, P10596, DOI 10.1073/pnas.191159298; Vamvaca K, 2004, P NATL ACAD SCI USA, V101, P12860, DOI 10.1073/pnas.0404109101; Wang J, 1999, NAT STRUCT BIOL, V6, P1033; Zhang S, 1996, BIOORGAN MED CHEM, V4, P1015, DOI 10.1016/0968-0896(96)00099-5	32	76	79	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37742	37746		10.1074/jbc.M507210200	http://dx.doi.org/10.1074/jbc.M507210200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16144843	hybrid			2022-12-27	WOS:000233044500052
J	Zaremberg, V; Gajate, C; Cacharro, LM; Mollinedo, F; McMaster, CR				Zaremberg, V; Gajate, C; Cacharro, LM; Mollinedo, F; McMaster, CR			Cytotoxicity of an anti-cancer lysophospholipid through selective modification of lipid raft composition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE ATPASE; CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; SPHINGOID BASE SYNTHESIS; LIVING YEAST-CELLS; SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLCHOLINE SYNTHESIS; ET-18-OCH3 EDELFOSINE; DOMAINS RAFTS; CERAMIDE; APOPTOSIS	Edelfosine is a prototypical member of the alkylphosphocholine class of antitumor drugs. Saccharomyces cerevisiae was used to screen for genes that modulate edelfosine cytotoxicity and identified sterol and sphingolipid pathways as relevant regulators. Edelfosine addition to yeast resulted in the selective partitioning of the essential plasma membrane protein Pma1p out of lipid rafts. Microscopic analysis revealed that Pma1p moved from the plasma membrane to intracellular punctate regions and finally localized to the vacuole. Consistent with altered sterol and sphingolipid synthesis resulting in increased edelfosine sensitivity, mislocalization of Pma1p was preceded by the movement of sterols out of the plasma membrane. Cells with enfeebled endocytosis and vacuolar protease activities prevented edelfosine-mediated (i) mobilization of sterols, (ii) loss of Pma1p from lipid rafts, and (iii) cell death. The activities of proteins and signaling processes are meaningfully altered by changes in lipid raft biophysical properties. This study points to a novel mode of action for an anti-cancer drug through modification of plasma membrane lipid composition resulting in the displacement of an essential protein from lipid rafts.	Dalhousie Univ, Dept Pediat, Atlantic Res Ctr, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Dept Biochem & Mol Biol, Atlantic Res Ctr, Halifax, NS B3H 4H7, Canada; Univ Salamanca, Consejo Super Invest Cient, Inst Biol Mol & Celular Canc, Ctr Invest Canc, E-37007 Salamanca, Spain	Dalhousie University; Dalhousie University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	McMaster, CR (corresponding author), 5849 Univ Ave,Rm C302, Halifax, NS B3H 4H7, Canada.	Christopher.mcmaster@dal.ca		McMaster, Christopher/0000-0003-0822-5776; Gajate, Consuelo/0000-0003-0604-6459				AMES BN, 1960, J BIOL CHEM, V235, P769; Arthur G, 1998, BBA-LIPID LIPID MET, V1390, P85, DOI 10.1016/S0005-2760(97)00163-X; Baburina I, 1998, J BIOL CHEM, V273, P2169, DOI 10.1074/jbc.273.4.2169; Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; Bagnat M, 2001, MOL BIOL CELL, V12, P4129, DOI 10.1091/mbc.12.12.4129; Balguerie A, 2002, EUKARYOT CELL, V1, P1021, DOI 10.1128/EC.1.6.1021-1031.2002; Bammert GF, 2000, ANTIMICROB AGENTS CH, V44, P1255, DOI 10.1128/AAC.44.5.1255-1265.2000; Baudry K, 2001, J BIOL CHEM, V276, P12702, DOI 10.1074/jbc.M100274200; Beh CT, 2004, J CELL SCI, V117, P2983, DOI 10.1242/jcs.01157; BOGGS KP, 1995, J BIOL CHEM, V270, P7757, DOI 10.1074/jbc.270.13.7757; BOGGS KP, 1995, J BIOL CHEM, V270, P11612, DOI 10.1074/jbc.270.19.11612; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Cremesti AE, 2002, FEBS LETT, V531, P47, DOI 10.1016/S0014-5793(02)03489-0; Eisenkolb M, 2002, MOL BIOL CELL, V13, P4414, DOI 10.1091/mbc.E02-02-0116; Ferreira T, 2002, J BIOL CHEM, V277, P21027, DOI 10.1074/jbc.M112281200; Fyrst H, 1999, BIOCHEMISTRY-US, V38, P5864, DOI 10.1021/bi9824590; Gaigg B, 2005, J BIOL CHEM, V280, P22515, DOI 10.1074/jbc.M413472200; Gajate C, 2004, J EXP MED, V200, P353, DOI 10.1084/jem.20040213; Gajate C, 2002, CURR DRUG METAB, V3, P491, DOI 10.2174/1389200023337225; Gajate C, 2001, BLOOD, V98, P3860, DOI 10.1182/blood.V98.13.3860; Gong XH, 2001, P NATL ACAD SCI USA, V98, P9104, DOI 10.1073/pnas.161282998; Grassme H, 2003, NAT MED, V9, P322, DOI 10.1038/nm823; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; Hanson PK, 2003, J BIOL CHEM, V278, P36041, DOI 10.1074/jbc.M305263200; Howe AG, 2002, J BIOL CHEM, V277, P44100, DOI 10.1074/jbc.M206643200; Howe AG, 2001, BBA-MOL CELL BIOL L, V1534, P65, DOI 10.1016/S1388-1981(01)00181-0; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; Kubler E, 1996, J BIOL CHEM, V271, P32975, DOI 10.1074/jbc.271.51.32975; Lee MCS, 2002, J BIOL CHEM, V277, P22395, DOI 10.1074/jbc.M200450200; London M, 2004, J BIOL CHEM, V279, P9997, DOI 10.1074/jbc.M309992200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Malinska K, 2003, MOL BIOL CELL, V14, P4427, DOI 10.1091/mbc.E03-04-0221; Mollinedo F, 1997, CANCER RES, V57, P1320; Pichler H, 2004, BBA-BIOMEMBRANES, V1666, P51, DOI 10.1016/j.bbamem.2004.05.011; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Swain E, 2002, J BIOL CHEM, V277, P26177, DOI 10.1074/jbc.M204115200; Takeda T, 2004, NAT CELL BIOL, V6, P1142, DOI 10.1038/ncb1189; Tatchell K, 2002, METHOD ENZYMOL, V351, P661; Van der Luit AH, 2003, BIOCHEM J, V374, P747, DOI 10.1042/BJ20030179; van der Luit AH, 2002, J BIOL CHEM, V277, P39541, DOI 10.1074/jbc.M203176200; Wang QQ, 2002, P NATL ACAD SCI USA, V99, P12853, DOI 10.1073/pnas.202115499; Wieder T, 1998, J BIOL CHEM, V273, P11025, DOI 10.1074/jbc.273.18.11025; WU WI, 1995, J BIOL CHEM, V270, P13171, DOI 10.1074/jbc.270.22.13171; Xu XL, 2001, J BIOL CHEM, V276, P33540, DOI 10.1074/jbc.M104776200; Zanolari B, 2000, EMBO J, V19, P2824, DOI 10.1093/emboj/19.12.2824; Zaremberg V, 2002, J BIOL CHEM, V277, P39035, DOI 10.1074/jbc.M207753200; Zink S, 2005, EUKARYOT CELL, V4, P879, DOI 10.1128/EC.4.5.879-889.2005; Zurzolo C, 2003, EMBO REP, V4, P1117, DOI 10.1038/sj.embor.7400032	49	71	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					38047	38058		10.1074/jbc.M502849200	http://dx.doi.org/10.1074/jbc.M502849200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16155007	hybrid			2022-12-27	WOS:000233044500088
J	Park, C; Meng, L; Stanton, LH; Collins, RE; Mast, SW; Yi, XB; Strachan, H; Moremen, KW				Park, C; Meng, L; Stanton, LH; Collins, RE; Mast, SW; Yi, XB; Strachan, H; Moremen, KW			Characterization of a human core-specific lysosomal alpha 1,6-mannosidase involved in N-glycan catabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-MANNOSIDASE-II; SEQUENCE-BASED CLASSIFICATION; RETICULUM QUALITY-CONTROL; ENDOPLASMIC-RETICULUM; GLYCOSYL HYDROLASES; 135-KILODALTON PROTEIN; SUBSTRATE-SPECIFICITY; COMPLEX GLYCANS; MOUSE HOMOLOG; PURIFICATION	In humans and rodents, the lysosomal catabolism of core Man(3)GlcNAc(2) N-glycan structures is catalyzed by the concerted action of several exoglycosidases, including a broad specificity lysosomal alpha-mannosidase (LysMan), core-specific alpha 1,6-mannosidase, beta-mannosidase, and cleavage at the reducing terminus by a di-N-acetylchitobiase. We describe here the first cloning, expression, purification, and characterization of a novel human glycosylhydrolase family 38 alpha-mannosidase with catalytic characteristics similar to those established previously for the core-specific alpha 1,6-mannosidase (acidic pH optimum, inhibition by swainsonine and 1,4-dideoxy-1,4-imino-D-mannitol, and stimulation by Co2+ and Zn2+). Substrate specificity studies comparing the novel human alpha-mannosidase with human LysMan revealed that the former enzyme efficiently cleaved only the alpha 1-6mannose residue from Man(3)GlcNAc but not Man(3)GlcNAc(2) or other larger high mannose oligosaccharides, indicating a requirement for chitobiase action before alpha 1,6-mannosidase activity. In contrast, LysMan cleaved all of the alpha-linked mannose residues from high mannose oligosaccharides except the core alpha 1-6mannose residue. alpha 1,6-Mannosidase transcripts were ubiquitously expressed in human tissues, and expressed sequence tag searches identified homologous sequences in murine, porcine, and canine databases. No expressed sequence tags were identified for bovine alpha 1,6-mannosidase, despite the identification of two sequence homologs in the bovine genome. The lack of conservation in 5'-flanking sequences for the bovine alpha 1,6-mannosidase genes may lead to defective transcription similar to transcription defects in the bovine chitobiase gene. These results suggest that the chitobiase and alpha 1,6-mannosidase function in tandem for mammalian lysosomal N-glycan catabolism.	Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Moremen, KW (corresponding author), Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA.	moremen@uga.edu	Moremen, Kelley/AAD-4661-2019		NCI NIH HHS [CA91295, U01 CA091295] Funding Source: Medline; NCRR NIH HHS [RR05351, P41 RR005351] Funding Source: Medline; NIGMS NIH HHS [GM47533, R01 GM047533] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA091295] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR005351] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047533] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM D, 1983, BIOCHEM J, V215, P573, DOI 10.1042/bj2150573; ALDAHER S, 1991, BIOCHEM J, V277, P743, DOI 10.1042/bj2770743; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARONSON NN, 1989, FASEB J, V3, P2615, DOI 10.1096/fasebj.3.14.2531691; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Berg T, 1997, BIOCHEM J, V328, P863, DOI 10.1042/bj3280863; Berg T, 2001, MOL GENET METAB, V73, P18, DOI 10.1006/mgme.2001.3173; BURDITT LJ, 1980, BIOCHEM J, V189, P467, DOI 10.1042/bj1890467; Cacan R, 1998, BIOCHIMIE, V80, P59, DOI 10.1016/S0300-9084(98)80057-6; CARROLL M, 1972, BIOCHEM BIOPH RES CO, V49, P579, DOI 10.1016/0006-291X(72)90450-0; Crawley AC, 1999, PEDIATR RES, V46, P501, DOI 10.1203/00006450-199911000-00003; DANIEL PF, 1994, GLYCOBIOLOGY, V4, P551, DOI 10.1093/glycob/4.5.551; DANIEL PF, 1992, GLYCOBIOLOGY, V2, P327, DOI 10.1093/glycob/2.4.327; DEGASPERI R, 1991, J BIOL CHEM, V266, P16556; DEGASPERI R, 1992, J BIOL CHEM, V267, P9706; Ducret A, 1998, PROTEIN SCI, V7, P706, DOI 10.1002/pro.5560070320; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; HAEUW JF, 1994, BIOCHEM J, V297, P463, DOI 10.1042/bj2970463; Heikinheimo P, 2003, J MOL BIOL, V327, P631, DOI 10.1016/S0022-2836(03)00172-4; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; Henrissat B, 1998, BIOCHEM SOC T, V26, P153, DOI 10.1042/bst0260153; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Hiramoto S, 1997, BIOCHEM BIOPH RES CO, V241, P439, DOI 10.1006/bbrc.1997.7768; HOCKING JD, 1972, BIOCHEM J, V128, P69, DOI 10.1042/bj1280069; Karaveg K, 2005, J BIOL CHEM, V280, P16197, DOI 10.1074/jbc.M500119200; Karaveg K, 2005, J BIOL CHEM, V280, P29837, DOI 10.1074/jbc.M505130200; Lal A, 1998, GLYCOBIOLOGY, V8, P981, DOI 10.1093/glycob/8.10.981; Li B, 2004, CHEMBIOCHEM, V5, P1220, DOI 10.1002/cbic.200300842; Liao YF, 1996, J BIOL CHEM, V271, P28348, DOI 10.1074/jbc.271.45.28348; Liu B, 1999, GLYCOBIOLOGY, V9, P589, DOI 10.1093/glycob/9.6.589; MAIZEL JV, 1981, P NATL ACAD SCI-BIOL, V78, P7665, DOI 10.1073/pnas.78.12.7665; McIlvaine TC, 1921, J BIOL CHEM, V49, P183; Merkle RK, 1997, BBA-GEN SUBJECTS, V1336, P132, DOI 10.1016/S0304-4165(97)00023-8; MICHALSKI JC, 1990, EUR J BIOCHEM, V189, P369, DOI 10.1111/j.1432-1033.1990.tb15498.x; MISAGO M, 1995, P NATL ACAD SCI USA, V92, P11766, DOI 10.1073/pnas.92.25.11766; Moremen K., 2000, OLIGOSACCHARIDES CHE, VII, P81; MOREMEN KW, 1991, J CELL BIOL, V115, P1521, DOI 10.1083/jcb.115.6.1521; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; Nilssen O, 1997, HUM MOL GENET, V6, P717, DOI 10.1093/hmg/6.5.717; OKAMURA N, 1995, MOL REPROD DEV, V42, P141, DOI 10.1002/mrd.1080420203; OKAMURA N, 1992, BIOL REPROD, V47, P1040, DOI 10.1095/biolreprod47.6.1040; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Riise HMF, 1997, GENOMICS, V42, P200, DOI 10.1006/geno.1997.4668; Segel IH, 1975, ENZYME KINETICS BEHA; Siriwardena A, 2005, CHEMBIOCHEM, V6, P845, DOI 10.1002/cbic.200400397; Stinchi S, 1999, HUM MOL GENET, V8, P1365, DOI 10.1093/hmg/8.8.1365; Sun HC, 2001, EXP MOL MED, V33, P1; Tascou S, 2000, BIOCHEM BIOPH RES CO, V272, P951, DOI 10.1006/bbrc.2000.2868; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van den Elsen JMH, 2001, EMBO J, V20, P3008, DOI 10.1093/emboj/20.12.3008; Wilkinson J., 1986, PRACTICAL PROTEIN CH, P121; Winchester B, 2005, GLYCOBIOLOGY, V15, p1R, DOI 10.1093/glycob/cwi041; Wu Y, 2003, P NATL ACAD SCI USA, V100, P8229, DOI 10.1073/pnas.1430537100; YAMASHITA K, 1980, J BIOL CHEM, V255, P5126	59	32	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37204	37216		10.1074/jbc.M508930200	http://dx.doi.org/10.1074/jbc.M508930200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16115860	Green Accepted, hybrid			2022-12-27	WOS:000232901800079
J	Gao, XD; Tachikawa, H; Sato, T; Jigami, Y; Dean, N				Gao, XD; Tachikawa, H; Sato, T; Jigami, Y; Dean, N			Alg14 recruits alg13 to the cytoplasmic face of the endoplasmic reticulum to form a novel bipartite UDP-N-acetylglucosamine transferase required for the second step of N-linked glycosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST MUTANTS DEFICIENT; SACCHAROMYCES-CEREVISIAE; GENE DELETION; OLIGOSACCHARIDE; BIOSYNTHESIS; PATHWAY; CLONING; LOCUS; GLYCOSYLTRANSFERASES; GLUCOSYLATION	N-linked glycosylation requires the synthesis of an evolutionarily conserved lipid-linked oligosaccharide (LLO) precursor that is essential for glycoprotein folding and stability. Despite intense research, several of the enzymes required for LLO synthesis have not yet been identified. Here we show that two poorly characterized yeast proteins known to be required for the synthesis of the LLO precursor, GlcNAc(2)-PP-dolichol, interact to form an unusual hetero-oligomeric UDP-GlcNAc transferase. Alg13 contains a predicted catalytic domain, but lacks any membrane-spanning domains. Alg14 spans the membrane but lacks any sequences predicted to play a direct role in sugar catalysis. We show that Alg14 functions as a membrane anchor that recruits Alg13 to the cytosolic face of the ER, where catalysis of GlcNAc(2)-PP-dol occurs. Alg13 and Alg14 physically interact and under normal conditions, are associated with the ER membrane. Overexpression of Alg13 leads to its cytosolic partitioning, as does reduction of Alg14 levels. Concomitant Alg14 overproduction suppresses this cytosolic partitioning of Alg13, demonstrating that Alg14 is both necessary and sufficient for the ER localization of Alg13. Further evidence for the functional relevance of this interaction comes from our demonstration that the human ALG13 and ALG14 orthologues fail to pair with their yeast partners, but when co-expressed in yeast can functionally complement the loss of either ALG13 or ALG14. These results demonstrate that this novel UDP-GlcNAc transferase is a unique eukaryotic ER glycosyltransferase that is comprised of at least two functional polypeptides, one that functions in catalysis and the other as a membrane anchor.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Tsukuba, Ibaraki 3058566, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Fac Agr & Life Sci, Dept Appl Biol Chem,Lab Biol Chem,Bunkyo Ku, Tokyo 1138657, Japan	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; National Institute of Advanced Industrial Science & Technology (AIST); University of Tokyo	Dean, N (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	Neta.Dean@stonybrook.edu	Sato, Takashi/M-2577-2018	Sato, Takashi/0000-0002-9973-8923; TACHIKAWA, HIROYUKI/0000-0002-4815-9964				ABEIJON C, 1992, TRENDS BIOCHEM SCI, V17, P32, DOI 10.1016/0968-0004(92)90424-8; Aebi M, 2001, TRENDS CELL BIOL, V11, P136, DOI 10.1016/S0962-8924(01)01925-0; Aebi M, 1996, GLYCOBIOLOGY, V6, P439, DOI 10.1093/glycob/6.4.439; BARNES G, 1984, MOL CELL BIOL, V4, P2381, DOI 10.1128/MCB.4.11.2381; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Burda P, 1999, BBA-GEN SUBJECTS, V1426, P239, DOI 10.1016/S0304-4165(98)00127-5; Burda P, 1998, GLYCOBIOLOGY, V8, P455, DOI 10.1093/glycob/8.5.455; Burda P, 1996, P NATL ACAD SCI USA, V93, P7160, DOI 10.1073/pnas.93.14.7160; Burda P, 1999, GLYCOBIOLOGY, V9, P617, DOI 10.1093/glycob/9.6.617; Chantret I, 2005, J BIOL CHEM, V280, P9236, DOI 10.1074/jbc.M413941200; Cipollo JF, 2001, J BIOL CHEM, V276, P21828, DOI 10.1074/jbc.M010896200; COUTO JR, 1984, J BIOL CHEM, V259, P378; de Graffenried CL, 2004, CURR OPIN CELL BIOL, V16, P356, DOI 10.1016/j.ceb.2004.06.007; FRANK CG, 2005, IN PRESS GLYCOBIOLOG; Freeze HH, 2002, BBA-GEN SUBJECTS, V1573, P388, DOI 10.1016/S0304-4165(02)00408-7; Gao XD, 2000, J BIOL CHEM, V275, P17718, DOI 10.1074/jbc.M909946199; Gao XD, 2004, GLYCOBIOLOGY, V14, P559, DOI 10.1093/glycob/cwh072; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; Hebert DN, 2005, TRENDS CELL BIOL, V15, P364, DOI 10.1016/j.tcb.2005.05.007; Heesen S, 1994, EUR J BIOCHEM, V224, P71; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HUFFAKER TC, 1982, J BIOL CHEM, V257, P3203; HUFFAKER TC, 1983, P NATL ACAD SCI-BIOL, V80, P7466, DOI 10.1073/pnas.80.24.7466; JACKSON BJ, 1993, GLYCOBIOLOGY, V3, P357, DOI 10.1093/glycob/3.4.357; Kean EL, 1999, J BIOL CHEM, V274, P34072, DOI 10.1074/jbc.274.48.34072; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEHRMAN M A, 1991, Glycobiology, V1, P553, DOI 10.1093/glycob/1.6.553; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; PEREZ M, 1986, J BIOL CHEM, V261, P6822; Reiss G, 1996, GLYCOBIOLOGY, V6, P493, DOI 10.1093/glycob/6.5.493; Samuelson J, 2005, P NATL ACAD SCI USA, V102, P1548, DOI 10.1073/pnas.0409460102; SIKORSKI RS, 1989, GENETICS, V122, P19; SNIDER MD, 1984, CELL, V36, P753, DOI 10.1016/0092-8674(84)90355-6; STAGLJAR I, 1994, P NATL ACAD SCI USA, V91, P5977, DOI 10.1073/pnas.91.13.5977; THOMAS BJ, 1989, GENETICS, V123, P725; Yan AX, 2005, J BIOL CHEM, V280, P3121, DOI 10.1074/jbc.R400036200	37	79	86	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36254	36262		10.1074/jbc.M507569200	http://dx.doi.org/10.1074/jbc.M507569200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16100110	hybrid			2022-12-27	WOS:000232726900058
J	McKane, M; Wen, KK; Boldogh, IR; Ramcharan, S; Pon, LA; Rubenstein, PA				McKane, M; Wen, KK; Boldogh, IR; Ramcharan, S; Pon, LA; Rubenstein, PA			A mammalian actin substitution in yeast actin (H372R) causes a suppressible mitochondria/vacuole phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; F-ACTIN; BETA-ACTIN; CRYSTAL-STRUCTURE; ARP2/3 COMPLEX; CELL-DIVISION; BUDDING YEAST; BINDING SITE; MYOSIN; PROFILIN	To determine the reason for the inviability of Saccharomyces cerevisiae with skeletal muscle actin, we introduced into yeast actin the first variant muscle residue from the C-terminal end, H372R. Arg is also found at this position in non-yeast nonmuscle actins. The substitution caused retarded growth on glucose and an inability to use glycerol as a sole carbon source. The mitochondria were clumped and had lost their DNA, the vacuole appeared hypervesiculated, and the actin cytoskeleton became somewhat depolarized. Introduction of the second muscle actin-specific substitution, S365A, rescued these defects. Suppression was also achieved by introducing the four acidic N-terminal residues of muscle actin in place of the two found in yeast actin. The H372R substitution results in an increase in polymerization-dependent fluorescence of Cys-374 pyrene-labeled actin. H372R actin polymerizes slightly faster than wild-type (WT) actin. Yeast actin-related proteins 2 and 3 (Arp2/3) accelerates the polymerization of H372R actin to a much greater extent than WT actin. The two suppressors did not affect the rate of H372R actin polymerization in the absence of an Arp2/3 complex. In contrast, the S365A substitution dampened the rate of Arp2/3 complex-stimulated H372R actin polymerization, and the addition of the four acidic N-terminal residues caused this rate to decrease below that observed with WT actin in the presence of Arp2/3. Structural analysis of the mutations suggests the presence of stringent steric and ionic requirements for the bottom of actin subdomain 1 and also suggests that there is allosteric communication through subdomain 1 within the actin monomer between the N and C termini.	Univ Iowa, Carver Coll Med, Dept Biochem, Iowa City, IA 52242 USA; Columbia Univ Coll Phys & Surg, Dept Anat & Cell Biol, New York, NY 10032 USA	University of Iowa; Columbia University	Rubenstein, PA (corresponding author), Univ Iowa, Carver Coll Med, Dept Biochem, Iowa City, IA 52242 USA.	peter-rubenstein@uiowa.edu		Rubenstein, Peter/0000-0003-1225-4414	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045735, R01GM033689] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 66037, GM33689, GM45735] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASPENSTROM P, 1993, FEBS LETT, V329, P163, DOI 10.1016/0014-5793(93)80215-G; ASPENSTROM P, 1992, FEBS LETT, V303, P59, DOI 10.1016/0014-5793(92)80477-X; Belmont LD, 1999, P NATL ACAD SCI USA, V96, P29, DOI 10.1073/pnas.96.1.29; Blondin L, 2001, EUR J BIOCHEM, V268, P6426, DOI 10.1046/j.0014-2956.2001.02592.x; Boldogh IR, 2004, MOL BIOL CELL, V15, P3994, DOI 10.1091/mbc.E04-01-0053; Boldogh IR, 2003, MOL BIOL CELL, V14, P4618, DOI 10.1091/mbc.E03-04-0225; Boldogh IR, 2001, P NATL ACAD SCI USA, V98, P3162, DOI 10.1073/pnas.051494698; Bossy-Wetzel E, 2003, CURR OPIN CELL BIOL, V15, P706, DOI 10.1016/j.ceb.2003.10.015; Buzan JM, 1996, P NATL ACAD SCI USA, V93, P91, DOI 10.1073/pnas.93.1.91; COOK RK, 1992, J BIOL CHEM, V267, P9430; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; CROSBIE RH, 1994, BIOPHYS J, V67, P1957, DOI 10.1016/S0006-3495(94)80678-2; DASGUPTA G, 1991, BIOCHEMISTRY-US, V30, P9961, DOI 10.1021/bi00105a021; Dickinson RB, 2004, BIOPHYS J, V87, P2838, DOI 10.1529/biophysj.104.045211; Dickinson RB, 2002, BIOPHYS J, V82, P605, DOI 10.1016/S0006-3495(02)75425-8; DRUBIN DG, 1993, MOL BIOL CELL, V4, P1277, DOI 10.1091/mbc.4.12.1277; Eads JC, 1998, BIOCHEMISTRY-US, V37, P11171, DOI 10.1021/bi9720033; Eichinger L, 2005, NATURE, V435, P43, DOI 10.1038/nature03481; Eitzen G, 2002, J CELL BIOL, V158, P669, DOI 10.1083/jcb.200204089; ERBA HP, 1986, NUCLEIC ACIDS RES, V14, P5275, DOI 10.1093/nar/14.13.5275; Fehrenbacher KL, 2004, CURR BIOL, V14, P1996, DOI 10.1016/j.cub.2004.11.004; Feng L, 1997, J BIOL CHEM, V272, P16829, DOI 10.1074/jbc.272.27.16829; Fratti RA, 2004, J CELL BIOL, V167, P1087, DOI 10.1083/jcb.200409068; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P5901, DOI 10.1073/pnas.79.19.5901; Head JF, 2002, BIOCHEMISTRY-US, V41, P9015, DOI 10.1021/bi026054y; Hill KL, 1996, J CELL BIOL, V135, P1535, DOI 10.1083/jcb.135.6.1535; Holmes KC, 2003, NATURE, V425, P423, DOI 10.1038/nature02005; HOLMES KC, 1993, ADV EXP MED BIOL, V332, P15; Ishikawa K, 2003, J CELL BIOL, V160, P887, DOI 10.1083/jcb.200210139; JOHANNES FJ, 1991, EMBO J, V10, P3951, DOI 10.1002/j.1460-2075.1991.tb04965.x; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Kaksonen M, 2003, CELL, V115, P475, DOI 10.1016/S0092-8674(03)00883-3; Kim E, 2000, J MOL BIOL, V299, P421, DOI 10.1006/jmbi.2000.3727; Kuang B, 1997, J BIOL CHEM, V272, P4412, DOI 10.1074/jbc.272.7.4412; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; Moseley JB, 2005, J BIOL CHEM, V280, P28023, DOI 10.1074/jbc.M503094200; ODONOGHUE SI, 1992, ARCH BIOCHEM BIOPHYS, V293, P110, DOI 10.1016/0003-9861(92)90372-4; Okamoto K, 2001, METHOD CELL BIOL, V65, P277, DOI 10.1016/S0091-679X(01)65017-9; Otomo T, 2005, NATURE, V433, P488, DOI 10.1038/nature03251; Otterbein LR, 2001, SCIENCE, V293, P708, DOI 10.1126/science.1059700; Romero S, 2004, CELL, V119, P419, DOI 10.1016/j.cell.2004.09.039; RUBENSTEIN PA, 1990, BIOESSAYS, V12, P309, DOI 10.1002/bies.950120702; Sagot I, 2002, NAT CELL BIOL, V4, P626, DOI 10.1038/ncb834; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SIKORSKI RS, 1989, GENETICS, V122, P19; Simon VR, 1997, CELL MOTIL CYTOSKEL, V37, P199, DOI 10.1002/(SICI)1097-0169(1997)37:3<199::AID-CM2>3.0.CO;2-2; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P3654, DOI 10.1021/bi00258a020; Tang FS, 2003, NATURE, V422, P87, DOI 10.1038/nature01453; TIRION MM, 1995, BIOPHYS J, V68, P5, DOI 10.1016/S0006-3495(95)80156-6; VANDEKERCKHOVE J, 1978, NATURE, V276, P720, DOI 10.1038/276720a0; Vorobiev S, 2003, P NATL ACAD SCI USA, V100, P5760, DOI 10.1073/pnas.0832273100; Wen KK, 2005, J BIOL CHEM, V280, P24168, DOI 10.1074/jbc.M502024200; WOOD, 2002, NATURE, V415, P671; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; Yang HC, 2001, METHOD CELL BIOL, V65, P333, DOI 10.1016/S0091-679X(01)65020-9; Zigmond SH, 2003, CURR BIOL, V13, P1820, DOI 10.1016/j.cub.2003.09.057; Zigmond SH, 2004, CURR OPIN CELL BIOL, V16, P99, DOI 10.1016/j.ceb.2003.10.019	59	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36494	36501		10.1074/jbc.M506970200	http://dx.doi.org/10.1074/jbc.M506970200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16118223	hybrid			2022-12-27	WOS:000232726900083
J	Samudio, I; Konopleva, M; Hail, N; Shi, YX; McQueen, T; Hsu, T; Evans, R; Honda, T; Gribble, GW; Sporn, M; Gilbert, HF; Safe, S; Andreeff, M				Samudio, I; Konopleva, M; Hail, N; Shi, YX; McQueen, T; Hsu, T; Evans, R; Honda, T; Gribble, GW; Sporn, M; Gilbert, HF; Safe, S; Andreeff, M			2-cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) directly targets mitochondrial glutathione to induce apoptosis in pancreatic cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; PERMEABILITY TRANSITION PORE; ACUTE MYELOGENOUS LEUKEMIA; TUMOR-NECROSIS-FACTOR; TRITERPENOID CDDO; 2-CYANO-3,12-DIOXOOLEAN-1,9-DIEN-28-OIC ACID; MEDIATED APOPTOSIS; BIOLOGICAL EVALUATION; ADENOCARCINOMA CELLS; REDOX REGULATION	Surgical resection is the only curative strategy for pancreatic cancer ( PC). Unfortunately, > 80% of pancreatic cancer patients bear inoperable, locally advanced, chemoresistant tumors demonstrating the urgent need for development of novel therapeutic approaches to treat this disease. Here we report that the synthetic triterpenoid 2-cyano-3,12 dioxooleana-1,9dien-28-imidazolide (CDDO-Im) antagonizes PC cell growth by inducing apoptosis at submicromolar concentrations. Notably, we demonstrate for the first time that the cytotoxicity of CDDO-Im is accompanied by the rapid and selective depletion of mitochondrial glutathione that results in accumulation of reactive oxygen species, oxidation of the cellular glutathione pool, loss of mitochondrial membrane potential, and phosphatidylserine externalization. The parent compound CDDO as well as the methyl ester of CDDO also depleted mitochondrial glutathione, demonstrating that this effect is mediated by the triterpenoid nucleus of these agents. Cotreatment with sulfhydryl nucleophiles completely prevented apoptosis and loss of viability induced by CDDO-Im, whereas alkylation of intracellular thiols by diethylmaleate or cotreatment with dithiothreitol decreased the accumulation of a biotinylated derivative of CDDO, TP-301, in PC cells, suggesting that intracellular reduced thiols are functional targets of the electrophilic triterpenoid nucleus of CDDO and its derivatives. In conclusion, our report is the first to identify mitochondrial glutathione as a target of CDDO and its derivatives and demonstrates that depletion of this antioxidant in the mitochondria is an effective strategy to induce cell death in PC cells. These results suggest that CDDO and its derivatives may offer a clinical benefit for the treatment of PC.	Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Sect Mol Hematol & Therapy, Houston, TX 77030 USA; Dartmouth Coll, Dept Chem, Hanover, NH 03755 USA; Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA; Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA	University of Texas System; UTMD Anderson Cancer Center; Dartmouth College; Dartmouth College; Baylor College of Medicine; Texas A&M University System; Texas A&M University College Station	Andreeff, M (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Sect Mol Hematol & Therapy, 1400 Holcombe Blvd,Unit 448, Houston, TX 77030 USA.	mandreef@mdanderson.org	Samudio, Ismael/D-3581-2013	Samudio, Ismael/0000-0001-8676-1035	NCI NIH HHS [CA16672, R01 CA089346, P01 CA55164] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055164, R01CA089346, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbruzzese James L, 2003, Int J Gastrointest Cancer, V33, P1, DOI 10.1385/IJGC:33:1:1; Abbruzzese JL, 2002, SEMIN ONCOL, V29, P2, DOI 10.1053/sonc.2002.37382; Anderson KM, 1998, ANTICANCER RES, V18, P791; Chauhan D, 2004, BLOOD, V103, P3158, DOI 10.1182/blood-2003-08-2873; Chernyak BV, 1997, BIOSCIENCE REP, V17, P293, DOI 10.1023/A:1027384628678; Coffey RNT, 2000, CANCER-AM CANCER SOC, V88, P2092, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2092::AID-CNCR15>3.0.CO;2-9; Colell A, 1998, GASTROENTEROLOGY, V115, P1541, DOI 10.1016/S0016-5085(98)70034-4; Colell A, 2001, HEPATOLOGY, V34, P964, DOI 10.1053/jhep.2001.28510; Coll O, 2003, HEPATOLOGY, V38, P692, DOI 10.1053/jhep.2003.50351; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; DHANBHOORA CM, 1992, ARCH BIOCHEM BIOPHYS, V293, P130, DOI 10.1016/0003-9861(92)90375-7; Dinkova-Kostova AT, 2005, P NATL ACAD SCI USA, V102, P4584, DOI 10.1073/pnas.0500815102; Dragovich PS, 1998, J MED CHEM, V41, P2806, DOI 10.1021/jm980068d; Duxbury MS, 2004, SURGERY, V136, P261, DOI 10.1016/j.surg.2004.04.029; Duxbury MS, 2004, CLIN CANCER RES, V10, P2307, DOI 10.1158/1078-0432.CCR-1183-3; Fernandez-Checa JC, 1998, SEMIN LIVER DIS, V18, P389, DOI 10.1055/s-2007-1007172; Fernandez-Checa JC, 2003, BIOCHEM BIOPH RES CO, V304, P471, DOI 10.1016/S0006-291X(03)00619-3; Fernandez-Checa JC, 1998, BIOFACTORS, V8, P7, DOI 10.1002/biof.5520080102; Filomeni G, 2002, FASEB J, V16, P64, DOI 10.1096/fj.02-0105fje; Hail N, 2004, J BIOL CHEM, V279, P11179, DOI 10.1074/jbc.M312758200; Hancock JT, 2003, ANN NY ACAD SCI, V1010, P446, DOI 10.1196/annals.1299.081; Herzig MCS, 2002, BREAST CANCER RES TR, V71, P133, DOI 10.1023/A:1013855615712; Honda T, 2004, J MED CHEM, V47, P4923, DOI 10.1021/jm049727e; Honda T, 2002, BIOORG MED CHEM LETT, V12, P1027, DOI 10.1016/S0960-894X(02)00105-1; Ikeda T, 2004, MOL CANCER THER, V3, P39, DOI 10.2463/mrms.3.39; Ikeda T, 2003, CANCER RES, V63, P5551; Imai H, 2003, FREE RADICAL BIO MED, V34, P145, DOI 10.1016/S0891-5849(02)01197-8; Inoue S, 2004, LEUKEMIA, V18, P948, DOI 10.1038/sj.leu.2403328; Ito Y, 2001, MOL PHARMACOL, V59, P1094, DOI 10.1124/mol.59.5.1094; Ito Y, 2000, CELL GROWTH DIFFER, V11, P261; Kim KB, 2002, MOL CANCER THER, V1, P177; Konopleva M, 2004, CANCER RES, V64, P7927, DOI 10.1158/0008-5472.CAN-03-2402; Konopleva M, 2002, BLOOD, V99, P326, DOI 10.1182/blood.V99.1.326; Lapillonne H, 2003, CANCER RES, V63, P5926; Latham P, 2001, GUT, V49, P97, DOI 10.1136/gut.49.1.97; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Melichar B, 2004, GYNECOL ONCOL, V93, P149, DOI 10.1016/j.ygyno.2004.01.008; Minns LA, 2004, GASTROENTEROLOGY, V127, P119, DOI 10.1053/j.gastro.2004.03.053; Myers AG, 2003, J AM CHEM SOC, V125, P12080, DOI 10.1021/ja0372006; *NAT CANC I, 2002, SURV EP END RES FAST; Place AE, 2003, CLIN CANCER RES, V9, P2798; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; Rizzardini M, 2003, J NEUROL SCI, V207, P51, DOI 10.1016/S0022-510X(02)00357-X; Saeki K, 2002, BIOCHEM J, V368, P705, DOI 10.1042/BJ20020101; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Suh NJ, 1999, CANCER RES, V59, P336; Suh WS, 2003, LEUKEMIA, V17, P2122, DOI 10.1038/sj.leu.2403112; Wang YP, 2000, MOL ENDOCRINOL, V14, P1550, DOI 10.1210/me.14.10.1550; Woynarowska BA, 2002, BBA-MOL BASIS DIS, V1587, P309, DOI 10.1016/S0925-4439(02)00094-7; Wu GY, 2004, J NUTR, V134, P489, DOI 10.1093/jn/134.3.489; Yao PM, 2001, J BIOL CHEM, V276, P42468, DOI 10.1074/jbc.M101419200; Zou W, 2004, CANCER RES, V64, P7570, DOI 10.1158/0008-5472.CAN-04-1238	52	93	117	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36273	36282		10.1074/jbc.M507518200	http://dx.doi.org/10.1074/jbc.M507518200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16118208	hybrid			2022-12-27	WOS:000232726900060
J	Serban, G; Kouchi, Z; Baki, L; Georgakopoulos, A; Litterst, CM; Shioi, J; Robakis, NK				Serban, G; Kouchi, Z; Baki, L; Georgakopoulos, A; Litterst, CM; Shioi, J; Robakis, NK			Cadherins mediate both the association between PS1 and beta-catenin and the effects of PS1 on beta-catenin stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROXIMAL REGION; ADHERENS JUNCTIONS; CYTOPLASMIC DOMAIN; ADHESION ACTIVITY; PRESENILIN-1; PROTEIN; COMPLEX; MUTATIONS; ARMADILLO; PHOSPHORYLATION	Presenilin1 (PS1), a protein involved in cellular development, forms functional complexes with beta-catenin, a regulator of Wnt signaling and cell-cell adhesion. In addition, both proteins have been shown to play important roles in disease including cancer and Alzheimer disease. Although PS1 and beta-catenin are found in the same complexes, it is not clear whether they bind directly to each other or a third complex component, like cadherin, may mediate their interactions. Here we show that PS1 and beta-catenin form no detectable complexes in cells that express no cadherin. In contrast, these complexes are readily found in E-cadherin containing cells. Furthermore, binding of both PS1 and beta-catenin to E-cadherin is necessary for the formation of PS1/beta-catenin complexes. Importantly, our data show that binding of PS1 to cadherin mediates the effects of PS1 on the phosphorylation, ubiquitination, and destabilization of beta-catenin. Thus, cadherins mediate both the association of PS1 and beta-catenin and the effects of PS1 on the cellular levels of beta-catenin.	NYU, Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA; NYU, Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; New York University; Icahn School of Medicine at Mount Sinai; New York University	Robakis, NK (corresponding author), NYU, Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.	nikos.robakis@mssm.edu	Robakis, Nikolaos/AAA-1838-2021; Serban, Geo/AAO-8819-2020	Serban, Geo/0000-0002-4985-7035; Georgakopoulos, Anastasios/0000-0001-8241-6306	NATIONAL INSTITUTE ON AGING [R01AG008200, R37AG017926, R01AG017926] Funding Source: NIH RePORTER; NIA NIH HHS [AG-17926, R01 AG008200, R37 AG017926, R01 AG017926, AG-08200] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Baki L, 2001, P NATL ACAD SCI USA, V98, P2381, DOI 10.1073/pnas.041603398; COWIN P, 1994, P NATL ACAD SCI USA, V91, P10759, DOI 10.1073/pnas.91.23.10759; Cox RT, 1996, J CELL BIOL, V134, P133, DOI 10.1083/jcb.134.1.133; Fagotto F, 1996, J CELL BIOL, V132, P1105, DOI 10.1083/jcb.132.6.1105; Georgakopoulos A, 1999, MOL CELL, V4, P893, DOI 10.1016/S1097-2765(00)80219-1; Gottardi CJ, 2004, J CELL BIOL, V167, P339, DOI 10.1083/jcb.200402153; Jamora C, 2002, NAT CELL BIOL, V4, pE101, DOI 10.1038/ncb0402-e101; Kang DE, 2002, CELL, V110, P751, DOI 10.1016/S0092-8674(02)00970-4; Killick R, 2001, J BIOL CHEM, V276, P48554, DOI 10.1074/jbc.M108332200; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Lewis JE, 1997, J CELL BIOL, V136, P919, DOI 10.1083/jcb.136.4.919; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Marambaud P, 2003, CELL, V114, P635, DOI 10.1016/j.cell.2003.08.008; Murayama M, 1998, FEBS LETT, V433, P73, DOI 10.1016/S0014-5793(98)00886-2; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Nishimura M, 1999, NAT MED, V5, P164, DOI 10.1038/5526; Ohkubo T, 1999, J BIOL CHEM, V274, P21409, DOI 10.1074/jbc.274.30.21409; Olmeda D, 2003, MOL BIOL CELL, V14, P2844, DOI 10.1091/mbc.E03-01-0865; Onishi M, 1996, EXP HEMATOL, V24, P324; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; Ozawa M, 1998, J CELL BIOL, V142, P1605, DOI 10.1083/jcb.142.6.1605; Polakis P, 2000, GENE DEV, V14, P1837; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; Simcha I, 2001, MOL BIOL CELL, V12, P1177, DOI 10.1091/mbc.12.4.1177; Soriano S, 2001, J CELL BIOL, V152, P785, DOI 10.1083/jcb.152.4.785; Stahl B, 1999, J BIOL CHEM, V274, P9141, DOI 10.1074/jbc.274.14.9141; Xia XF, 2001, P NATL ACAD SCI USA, V98, P10863, DOI 10.1073/pnas.191284198; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208; Zhou JH, 1997, NEUROREPORT, V8, P2085, DOI 10.1097/00001756-199705260-00054	32	30	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36007	36012		10.1074/jbc.M507503200	http://dx.doi.org/10.1074/jbc.M507503200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16126725	Green Published, hybrid			2022-12-27	WOS:000232726900029
J	Theiss, AL; Simmons, JG; Jobin, C; Lund, PK				Theiss, AL; Simmons, JG; Jobin, C; Lund, PK			Tumor necrosis factor (TNF) alpha increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; FACTOR-ALPHA; IGF-I; TISSUE INHIBITOR; GENE-EXPRESSION; MATRIX METALLOPROTEINASES; DIFFERENTIAL EXPRESSION; RESPONSE ELEMENT; TRANSGENIC MICE; CROHNS-DISEASE	Intestinal fibrosis is an incurable complication of Crohn's disease involving increased numbers of collagen-producing myofibroblasts. Tumor necrosis factor (TNF) alpha has defined proinflammatory roles in Crohn's disease but its role in fibrosis is unclear. We tested the hypothesis that TNF alpha increases collagen accumulation and proliferation in intestinal myofibroblasts and has additive effects in combination with insulin-like growth factor (IGF) I. The mechanisms, TNF receptor isoform, and downstream signaling pathways were examined. Intestinal myofibroblasts from wild-type (WT) mice or mice homozygous for disruption of genes encoding TNFR1 ( TNFR1(-/-)), TNFR2 ( TNFR2(-/-)), or both (TNFR1/2(-/-)), were treated with TNF alpha, IGF-I, or both. In WT cells, TNF alpha and IGF- I stimulated type I collagen accumulation and DNA synthesis in an additive manner. IGF- I, but not TNF alpha, stimulated type I collagen gene activation. TNF alpha, but not IGF- I, induced tissue inhibitor of metalloproteinase-1 (TIMP-1) expression and reduced matrix metalloproteinases-2 activity and collagen degradation. TNF alpha also activated ERK1/2. These responses to TNF alpha were absent in TNFR2(-/-) and TNFR1/2(-/-) myofibroblasts, whereas TNFR1(-/-) cells showed similar responses to WT. Inhibition of ERK1/2 diminished TNF alpha-induced DNA synthesis in WT and TNFR1(-/-) cells. Differences in TNF alpha-induced STAT3/DNA binding activity and not NF kappa B and AP-1 transcriptional activation correlated with impaired collagen accumulation/TIMP-1 induction in TNFR2(-/-) cells. Constitutively active STAT3 rescued TIMP-1 expression in TNFR2(-/-) cells. We conclude that TNF alpha and IGF- I may additively contribute to fibrosis during intestinal inflammation. TNFR2 is a primary mediator of fibrogenic actions of TNF alpha acting through ERK1/2 to stimulate proliferation and through STAT3 to stimulate TIMP-1 and inhibit collagen degradation.	Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Gastrointestinal Biol & Dis, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Lund, PK (corresponding author), Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA.	empk@med.unc.edu		Theiss, Arianne/0000-0003-2862-0933	NCI NIH HHS [CA 16086] Funding Source: Medline; NIDDK NIH HHS [R01-DK-40247, P30-DK-34987, R01-DK-47769] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047769, P30DK034987, R01DK040247] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bugno M, 1995, NUCLEIC ACIDS RES, V23, P5041, DOI 10.1093/nar/23.24.5041; Fruchtman S, 2005, AM J PHYSIOL-GASTR L, V289, pG342, DOI 10.1152/ajpgi.00413.2004; Guo DQ, 1998, J IMMUNOL, V160, P2742; Guo GJ, 2001, AM J PHYSIOL-RENAL, V280, pF777, DOI 10.1152/ajprenal.2001.280.5.F777; Haas E, 1999, J BIOL CHEM, V274, P18107, DOI 10.1074/jbc.274.25.18107; Haga S, 2003, J CLIN INVEST, V112, P989, DOI 10.1172/JCI200317970; Helm KA, 2005, NEUROPHARMACOLOGY, V48, P956, DOI 10.1016/j.neuropharm.2005.01.019; Hernandez I, 2000, DNA CELL BIOL, V19, P341, DOI 10.1089/10445490050043317; HernandezMunoz I, 1997, GASTROENTEROLOGY, V113, P625, DOI 10.1053/gast.1997.v113.pm9247485; Holtmann MH, 2002, EUR J IMMUNOL, V32, P3142, DOI 10.1002/1521-4141(200211)32:11<3142::AID-IMMU3142>3.0.CO;2-4; Holtmann MH, 2004, CURR MOL MED, V4, P439, DOI 10.2174/1566524043360636; Houglum K, 1998, AM J PHYSIOL-GASTR L, V274, pG840, DOI 10.1152/ajpgi.1998.274.5.G840; Jijon HB, 2005, EUR J IMMUNOL, V35, P718, DOI 10.1002/eji.200425688; Kimura A, 2004, INT IMMUNOL, V16, P991, DOI 10.1093/intimm/dxh102; Krempen K, 1999, GENE EXPRESSION, V8, P151; Lawrance IC, 2003, GASTROENTEROLOGY, V125, P1750, DOI 10.1053/j.gastro.2003.08.027; Lawrance IC, 2001, INFLAMM BOWEL DIS, V7, P16, DOI 10.1097/00054725-200102000-00003; Lawrance IC, 2001, HUM MOL GENET, V10, P445, DOI 10.1093/hmg/10.5.445; Louis E, 2000, CLIN EXP IMMUNOL, V120, P241, DOI 10.1046/j.1365-2249.2000.01227.x; MATTHES H, 1992, GASTROENTEROLOGY, V102, P431, DOI 10.1016/0016-5085(92)90087-F; MCCRAY PB, 1995, J CLIN INVEST, V95, P2620, DOI 10.1172/JCI117964; McKaig BC, 2003, AM J PATHOL, V162, P1355, DOI 10.1016/S0002-9440(10)63931-4; Miscia S, 2002, CELL GROWTH DIFFER, V13, P13; Mizoguchi E, 2002, GASTROENTEROLOGY, V122, P134, DOI 10.1053/gast.2002.30347; Ohneda K, 1997, GASTROENTEROLOGY, V112, P444, DOI 10.1053/gast.1997.v112.pm9024298; Ortiz LA, 2001, AM J RESP CRIT CARE, V163, P244, DOI 10.1164/ajrccm.163.1.2002123; PETERKOFSKY B, 1995, EXTRACELLULAR MATRIX, P33; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Phan SH, 2002, CHEST, V122, p286S, DOI 10.1378/chest.122.6_suppl.286S; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC183, DOI 10.1152/ajpcell.1999.277.2.C183; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1, DOI 10.1152/ajpcell.1999.277.1.C1; Pucilowska JB, 2000, AM J PHYSIOL-GASTR L, V279, pG1307, DOI 10.1152/ajpgi.2000.279.6.G1307; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Sanlioglu S, 2001, J BIOL CHEM, V276, P30188, DOI 10.1074/jbc.M102061200; Savendahl L, 1997, ENDOCRINOLOGY, V138, P734, DOI 10.1210/en.138.2.734; Simmons JG, 2002, AM J PHYSIOL-GASTR L, V283, pG809, DOI 10.1152/ajpgi.00057.2002; Simmons JG, 1999, AM J PHYSIOL-GASTR L, V276, pG817, DOI 10.1152/ajpgi.1999.276.4.G817; SOLISHERRUZO JA, 1988, J BIOL CHEM, V263, P5841; Taylor PC, 2004, CURR OPIN BIOTECH, V15, P557, DOI 10.1016/j.copbio.2004.09.005; van Tol EAF, 1999, AM J PHYSIOL-GASTR L, V277, pG245, DOI 10.1152/ajpgi.1999.277.1.G245; von Lampe B, 2000, GUT, V47, P63, DOI 10.1136/gut.47.1.63; Wang JW, 1997, J CLIN INVEST, V100, P1425, DOI 10.1172/JCI119663; Williams KL, 2002, AM J PHYSIOL-GASTR L, V283, pG875, DOI 10.1152/ajpgi.00089.2002; Williams KL, 2001, GASTROENTEROLOGY, V120, P925, DOI 10.1053/gast.2001.22470; Wu Q, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-26; Zeeh JM, 1998, J RECEPT SIGNAL TR R, V18, P265, DOI 10.3109/10799899809047747; Zeisberg M, 2004, J MOL MED, V82, P175, DOI 10.1007/s00109-003-0517-9; ZIMMERMANN E, 2004, KIRSNERS INFLAMMATOR, P219; ZIMMERMANN EM, 1993, GASTROENTEROLOGY, V105, P399, DOI 10.1016/0016-5085(93)90713-M; Zimmermann EM, 1997, AM J PHYSIOL-GASTR L, V273, pG875, DOI 10.1152/ajpgi.1997.273.4.G875	52	163	169	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36099	36109		10.1074/jbc.M505291200	http://dx.doi.org/10.1074/jbc.M505291200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16141211	hybrid, Green Published			2022-12-27	WOS:000232726900040
J	Ueda, T; Kato, A; Kuramitsu, S; Terasawa, H; Shimada, I				Ueda, T; Kato, A; Kuramitsu, S; Terasawa, H; Shimada, I			Identification and characterization of a second chromophore of DNA photolyase from Thermus thermophilus HB27	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME-SUBSTRATE COMPLEX; ABSOLUTE ACTION SPECTRUM; ESCHERICHIA-COLI; ANACYSTIS-NIDULANS; CRYSTAL-STRUCTURE; PHOTOREACTIVATING ENZYME; PURIFICATION; MECHANISM; REPAIR; BINDING	Cyclobutane pyrimidine dimer (CPD) photolyases use light to repair CPDs. For efficient light absorption, CPD photolyases use a second chromophore. We purified Thermus thermophilus CPD photolyase with its second chromophore. UV-visible absorption spectra, reverse-phase HPLC, and NMR analyses of the chromophores revealed that the second chromophore of the enzyme is flavin mononucleotide (FMN). To clarify the role of FMN in the CPD repair reaction, the enzyme without FMN (Enz-FMN(-) and that with a stoichiometric amount of FMN ( Enz-FMN(+)) were both successfully obtained. The CPD repair activity of Enz-FMN(+) was higher than that of Enz-FMN(-), and the CPD repair activity ratio of Enz-FMN(+) and Enz-FMN(-) was dependent on the wavelength of light. These results suggest that FMN increases the light absorption efficiency of the enzyme. NMR analyses of Enz-FMN(+) and Enz-FMN(-) revealed that the binding mode of FMN is similar to that of 7,8-didemethyl-8-hydroxy-5-deazariboflavin in Anacystis nidulans CPD photolyase, and thus a direct electron transfer between FMN and CPD is not likely to occur. Based on these results, we concluded that FMN acts as a highly efficient light harvester that gathers light and transfers the energy to FAD.	Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Japan Biol Informat Consortium, Japan Biol Informat Res Ctr, Chuo Ku, Tokyo 1040032, Japan; Osaka Univ, Grad Sch Sci, Osaka 5600043, Japan; Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Koto Ku, Tokyo 1350064, Japan	University of Tokyo; Osaka University; National Institute of Advanced Industrial Science & Technology (AIST)	Shimada, I (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan.	shimada@iw-nmr.f.u-tokyo.ac.jp						BURGESS RR, 1991, METHOD ENZYMOL, V208, P3; Carell T, 2001, CURR OPIN CHEM BIOL, V5, P491, DOI 10.1016/S1367-5931(00)00239-8; EKER APM, 1975, BIOCHIM BIOPHYS ACTA, V378, P54, DOI 10.1016/0005-2787(75)90136-7; EKER APM, 1990, J BIOL CHEM, V265, P8009; Graham DE, 2003, ARCH MICROBIOL, V180, P455, DOI 10.1007/s00203-003-0614-8; HAUSINGER RP, 1986, METHOD ENZYMOL, V122, P199; IWATSUKI N, 1980, BIOCHEMISTRY-US, V19, P1172, DOI 10.1021/bi00547a021; JOHNSON JL, 1988, P NATL ACAD SCI USA, V85, P2046, DOI 10.1073/pnas.85.7.2046; JORNS MS, 1990, BIOCHEMISTRY-US, V29, P552, DOI 10.1021/bi00454a032; Kanai S, 1997, J MOL EVOL, V45, P535, DOI 10.1007/PL00006258; Kato R, 1997, J BACTERIOL, V179, P6499, DOI 10.1128/jb.179.20.6499-6503.1997; KIM ST, 1991, BIOCHEMISTRY-US, V30, P8623, DOI 10.1021/bi00099a019; Kobayashi H, 1998, J BIOCHEM-TOKYO, V123, P182; Komori H, 2001, P NATL ACAD SCI USA, V98, P13560, DOI 10.1073/pnas.241371398; Kort R, 2004, ACTA CRYSTALLOGR D, V60, P1205, DOI 10.1107/S0907444904009321; MALHOTRA K, 1992, J BIOL CHEM, V267, P15406; Mees A, 2004, SCIENCE, V306, P1789, DOI 10.1126/science.1101598; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; PAYNE G, 1990, BIOCHEMISTRY-US, V29, P7715, DOI 10.1021/bi00485a021; RUPERT CS, 1962, J GEN PHYSIOL, V45, P725, DOI 10.1085/jgp.45.4.725; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; SANCAR A, 1984, J MOL BIOL, V172, P223, DOI 10.1016/S0022-2836(84)80040-6; Sancar A, 2003, CHEM REV, V103, P2203, DOI 10.1021/cr0204348; SANCAR GB, 1987, J BIOL CHEM, V262, P492; SMITH CA, 1993, J BIOL CHEM, V268, P11143; SUBRAMANIAN S, 1984, CRC CR REV BIOCH MOL, V16, P169, DOI 10.3109/10409238409102302; Takeda M, 2003, J BIOL CHEM, V278, P43550, DOI 10.1074/jbc.M308199200; Tamada T, 1997, NAT STRUCT BIOL, V4, P887, DOI 10.1038/nsb1197-887; Torizawa T, 2004, J BIOL CHEM, V279, P32950, DOI 10.1074/jbc.M404536200; Torizawa T, 1998, FEBS LETT, V429, P157, DOI 10.1016/S0014-5793(98)00582-1; Ueda T, 2004, J BIOL CHEM, V279, P52574, DOI 10.1074/jbc.M409942200; WALSH C, 1986, ACCOUNTS CHEM RES, V19, P216, DOI 10.1021/ar00127a004; WARD JM, 1991, ANAL CHIM ACTA, V249, P195, DOI 10.1016/0003-2670(91)87022-Y; YAGI T, 1988, BIOCHEMISTRY-US, V27, P2008, DOI 10.1021/bi00406a030; YASUI A, 1994, EMBO J, V13, P6143, DOI 10.1002/j.1460-2075.1994.tb06961.x	36	41	41	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36237	36243		10.1074/jbc.M507972200	http://dx.doi.org/10.1074/jbc.M507972200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16118222	hybrid			2022-12-27	WOS:000232726900056
J	Watt, NT; Taylor, DR; Gillott, A; Thomas, DA; Perera, WSS; Hooper, NM				Watt, NT; Taylor, DR; Gillott, A; Thomas, DA; Perera, WSS; Hooper, NM			Reactive oxygen species-mediated beta-cleavage of the prion protein in the cellular response to oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED-CELLS; BINDING-SITES; AMINO-TERMINUS; SCRAPIE AGENT; IN-VIVO; DISEASE; MICE; PRP; BRAIN; ENDOCYTOSIS	The cellular prion protein (PrPC) is critical for the development of prion diseases. However, the physiological role of PrPC is less clear, although a role in the cellular resistance to oxidative stress has been proposed. PrPC is cleaved at the end of the copper-binding octapeptide repeats through the action of reactive oxygen species (ROS), a process termed beta-cleavage. Here we show that ROS-mediated beta-cleavage of cell surface PrPC occurs within minutes and was inhibited by the hydroxyl radical quencher dimethyl sulfoxide and by an antibody against the octapeptide repeats. A construct of PrP lacking the octapeptide repeats, PrP Delta oct, failed to undergo ROS-mediated beta-cleavage, as did two mutant forms of PrP, PG14 and A116V, associated with human prion diseases. As compared with cells expressing wild type PrP, when challenged with H2O2 and Cu2+, cells expressing PrP Delta oct, PG14, or A116V had reduced viability and glutathione peroxidase activity and increased intracellular free radicals. Thus, lack of ROS-mediated beta-cleavage of PrP correlated with the sensitivity of the cells to oxidative stress. These data indicate that the beta-cleavage of PrPC is an early and critical event in the mechanism by which PrP protects cells against oxidative stress.	Univ Leeds, Leeds Inst Genet Hlth & Therapeut, Sch Biochem & Microbiol, Proteolysis Res Grp, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Hooper, NM (corresponding author), Univ Leeds, Leeds Inst Genet Hlth & Therapeut, Sch Biochem & Microbiol, Proteolysis Res Grp, Leeds LS2 9JT, W Yorkshire, England.	n.m.hooper@leeds.ac.uk		Thomas, Daniel/0000-0002-5177-1900; Hooper, Nigel/0000-0002-5811-3484	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Atarashi R, 2003, J BIOL CHEM, V278, P28944, DOI 10.1074/jbc.M303655200; Brown DR, 2001, TRENDS NEUROSCI, V24, P85, DOI 10.1016/S0166-2236(00)01689-1; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Brown DR, 1997, EXP NEUROL, V146, P104, DOI 10.1006/exnr.1997.6505; Brown DR, 2003, J NEUROCHEM, V87, P377, DOI 10.1046/j.1471-4159.2003.02046.x; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; Burns CS, 2003, BIOCHEMISTRY-US, V42, P6794, DOI 10.1021/bi027138+; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; Chiesa R, 2000, P NATL ACAD SCI USA, V97, P5574, DOI 10.1073/pnas.97.10.5574; Choi SI, 1998, ACTA NEUROPATHOL, V96, P279, DOI 10.1007/s004010050895; GOLDFARB LG, 1991, P NATL ACAD SCI USA, V88, P10926, DOI 10.1073/pnas.88.23.10926; Guentchev M, 2000, NEUROBIOL DIS, V7, P270, DOI 10.1006/nbdi.2000.0290; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Hetz C, 2003, TRENDS MOL MED, V9, P237, DOI 10.1016/S1471-4914(03)00069-8; Hooper NM, 2002, CURR MED CHEM, V9, P1107, DOI 10.2174/0929867023370121; Inouye H, 2000, J MOL BIOL, V300, P1283, DOI 10.1006/jmbi.2000.3926; Jackson GS, 2001, P NATL ACAD SCI USA, V98, P8531, DOI 10.1073/pnas.151038498; Jimenez-Huete A, 1998, AM J PATHOL, V153, P1561, DOI 10.1016/S0002-9440(10)65744-6; KIM K, 1985, J BIOL CHEM, V260, P5394; Krasemann S, 1995, Brain Res Mol Brain Res, V34, P173; Kuwahara C, 1999, NATURE, V400, P225, DOI 10.1038/22241; Lee DW, 1999, FREE RADICAL RES, V30, P499, DOI 10.1080/10715769900300541; Lehmann S, 1996, P NATL ACAD SCI USA, V93, P5610, DOI 10.1073/pnas.93.11.5610; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; Mange A, 2004, BIOL CELL, V96, P125, DOI 10.1016/j.biolcel.2003.11.007; McMahon HEM, 2001, J BIOL CHEM, V276, P2286, DOI 10.1074/jbc.M007243200; Milhavet O, 2002, BRAIN RES REV, V38, P328, DOI 10.1016/S0165-0173(01)00150-3; Miura T, 1999, BIOCHEMISTRY-US, V38, P11560, DOI 10.1021/bi9909389; PAN KM, 1992, PROTEIN SCI, V1, P1343, DOI 10.1002/pro.5560011014; Parkin ET, 2004, J BIOL CHEM, V279, P11170, DOI 10.1074/jbc.M312105200; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Qin KF, 2002, J BIOL CHEM, V277, P1981, DOI 10.1074/jbc.M108744200; Roucou X, 2004, J NEUROSCI RES, V75, P153, DOI 10.1002/jnr.10864; SHYNG SL, 1993, J BIOL CHEM, V268, P15922; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sumudhu W, 2001, CURR BIOL, V11, P519, DOI 10.1016/S0960-9822(01)00147-6; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; Vassallo N, 2003, J NEUROCHEM, V86, P538, DOI 10.1046/j.1471-4159.2003.01882.x; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042; Vincent B, 2001, J BIOL CHEM, V276, P37743; Walmsley AR, 2001, EMBO J, V20, P703, DOI 10.1093/emboj/20.4.703; White AR, 1999, AM J PATHOL, V155, P1723, DOI 10.1016/S0002-9440(10)65487-9; Yadavalli R, 2004, J BIOL CHEM, V279, P21948, DOI 10.1074/jbc.M400793200; Yokoyama T, 2001, J BIOL CHEM, V276, P11265, DOI 10.1074/jbc.M008734200; Zeng FN, 2003, J NEUROCHEM, V84, P480, DOI 10.1046/j.1471-4159.2003.01529.x	47	130	135	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35914	35921		10.1074/jbc.M507327200	http://dx.doi.org/10.1074/jbc.M507327200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16120605	hybrid			2022-12-27	WOS:000232726900018
J	Eriste, E; Norberg, A; Nepomuceno, D; Kuei, C; Kamme, F; Tran, DT; Strupat, K; Jornvall, H; Liu, CL; Lovenberg, TW; Sillard, R				Eriste, E; Norberg, A; Nepomuceno, D; Kuei, C; Kamme, F; Tran, DT; Strupat, K; Jornvall, H; Liu, CL; Lovenberg, TW; Sillard, R			A novel form of neurotensin post-translationally modified by arginylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; PORCINE INTESTINE; NEUROPEPTIDE-Y; ACTIVE PEPTIDE; BRAIN PEPTIDE; NEUROMEDIN-N; RAT-BRAIN; RECEPTOR; SECRETIN; PROTEIN	A novel bioactive form of neurotensin post-translationally modified at a Glu residue was isolated from porcine intestine. Purification of the peptide was guided by detection of intracellular Ca2+ release in SK-N-SH neuroblastoma cells. Using high resolution accurate mass analysis on an ion trap Fourier transform mass spectrometer, the post-translational modification was identified as arginine linked to the gamma-carboxyl of Glu via an isopeptide bond, and we named the newly identified peptide "arginylated neurotensin" (R-NT, N-(neurotensin-C5-4-yl)arginine). Although arginylation is a known modification of N- terminal amino groups in proteins, its presence at a Glu side chain is unique. The finding places neurotensin among the few physiologically active peptides that occur both in post-translationally modified and unmodified forms. Pharmacologically, we characterized R-NT for its ligand activity on three known neurotensin receptors, NTR1, -2, and -3, and found that R-NT has similar pharmacological properties to those of neurotensin, however, with a slightly higher affinity to all three receptors. We expressed the intracellular receptor NTR3 as a soluble protein secreted into the cell culture medium, which allowed characterization of its R-NT and neurotensin binding properties. The creation of soluble NTR3 also provides a potential tool for neutralizing neurotensin action in vivo and in vitro. We have shown that SK-N-SH neuroblastoma cells express NTR1 and NTR3 but not NTR2, suggesting that the Ca2+ mobilization elicited by R-NT is via NTR1.	Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Johnson & Johnson Pharmaceut Res & Dev, San Diego, CA 92121 USA; Thermo Electron Bremen GmbH, D-28197 Bremen, Germany	Karolinska Institutet; Johnson & Johnson; Johnson & Johnson USA	Sillard, R (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.	rannar@ki.se						AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; BARRA HS, 1973, J NEUROCHEM, V20, P97, DOI 10.1111/j.1471-4159.1973.tb12108.x; BENNETT HPJ, 1981, BIOCHEMISTRY-US, V20, P4530, DOI 10.1021/bi00519a004; BISSETTE G, 1976, NATURE, V262, P607, DOI 10.1038/262607a0; Bonetto V, 2001, ARCH BIOCHEM BIOPHYS, V385, P276, DOI 10.1006/abbi.2000.2165; Bonetto V, 1995, P NATL ACAD SCI USA, V92, P11985, DOI 10.1073/pnas.92.26.11985; BONETTO V, 1997, ANAL CHEM, V69, P1314; Botto JM, 1998, BIOCHEM BIOPH RES CO, V243, P585, DOI 10.1006/bbrc.1997.8071; BOUBLIK J, 1989, INT J PEPT PROT RES, V33, P11; CARRAWAY R, 1973, J BIOL CHEM, V248, P6854; CARRAWAY RE, 1991, PEPTIDES, V12, P601, DOI 10.1016/0196-9781(91)90108-2; Chalon P, 1996, FEBS LETT, V386, P91, DOI 10.1016/0014-5793(96)00397-3; Chen ZW, 2001, FEBS LETT, V492, P119, DOI 10.1016/S0014-5793(01)02234-7; Dubuc I, 1999, J NEUROSCI, V19, P503, DOI 10.1523/JNEUROSCI.19-01-00503.1999; Eriste E, 1999, CELL MOL LIFE SCI, V56, P709, DOI 10.1007/s000180050464; FEURLE GE, 1987, GUT, V28, P19, DOI 10.1136/gut.28.Suppl.19; GARVER DL, 1991, AM J PSYCHIAT, V148, P484; Gobom J, 2000, ANAL CHEM, V72, P3320, DOI 10.1021/ac991122g; JORPES JE, 1962, BIOCHEM BIOPH RES CO, V9, P275, DOI 10.1016/0006-291X(62)90073-6; KAJI H, 1963, Biochim Biophys Acta, V76, P474; KITABGI P, 1977, P NATL ACAD SCI USA, V74, P1846, DOI 10.1073/pnas.74.5.1846; KITABGI P, 1976, J BIOL CHEM, V251, P7053; Krause A, 2003, PROTEIN SCI, V12, P143, DOI 10.1110/ps.0213603; Kwon YT, 1999, MOL CELL BIOL, V19, P182; Kwon YT, 2002, SCIENCE, V297, P96, DOI 10.1126/science.1069531; Liu CL, 1997, ENDOCRINOLOGY, V138, P3548, DOI 10.1210/en.138.8.3548; Liu CL, 2003, J BIOL CHEM, V278, P50765, DOI 10.1074/jbc.M308996200; Mazella J, 1998, J BIOL CHEM, V273, P26273, DOI 10.1074/jbc.273.41.26273; MITRA SP, 1990, REGUL PEPTIDES, V28, P11, DOI 10.1016/0167-0115(90)90060-A; MOGARD MH, 1986, REGUL PEPTIDES, V14, P313, DOI 10.1016/0167-0115(86)90173-4; Morris NJ, 1998, J BIOL CHEM, V273, P3582, DOI 10.1074/jbc.273.6.3582; MUTT V, 1968, EUR J BIOCHEM, V6, P156, DOI 10.1111/j.1432-1033.1968.tb00433.x; MUTT V, 1970, EUR J BIOCHEM, V15, P513, DOI 10.1111/j.1432-1033.1970.tb01034.x; MUTT V, 1974, EUR J BIOCHEM, V42, P581, DOI 10.1111/j.1432-1033.1974.tb03373.x; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; SAID SI, 1972, EUR J BIOCHEM, V28, P199, DOI 10.1111/j.1432-1033.1972.tb01903.x; SHAW C, 1990, COMP BIOCHEM PHYS C, V95, P291, DOI 10.1016/0742-8413(90)90120-X; SOFFER RL, 1969, J MOL BIOL, V43, P163, DOI 10.1016/0022-2836(69)90086-2; TANAKA K, 1990, NEURON, V4, P847, DOI 10.1016/0896-6273(90)90137-5; TATEMOTO K, 1980, NATURE, V285, P417, DOI 10.1038/285417a0; TATEMOTO K, 1983, FEBS LETT, V164, P124, DOI 10.1016/0014-5793(83)80033-7; TATEMOTO K, 1982, P NATL ACAD SCI-BIOL, V79, P2514, DOI 10.1073/pnas.79.8.2514; TATEMOTO K, 1982, NATURE, V296, P659, DOI 10.1038/296659a0; TATEMOTO K, 1982, P NATL ACAD SCI-BIOL, V79, P5485, DOI 10.1073/pnas.79.18.5485; TATEMOTO K, 1981, P NATL ACAD SCI-BIOL, V78, P6603, DOI 10.1073/pnas.78.11.6603; Vincent JP, 1999, TRENDS PHARMACOL SCI, V20, P302, DOI 10.1016/S0165-6147(99)01357-7; Vita N, 1998, EUR J PHARMACOL, V360, P265, DOI 10.1016/S0014-2999(98)00678-5; WATKINSON A, 1993, BIOCHEM J, V295, P649, DOI 10.1042/bj2950649; YAMASHITA Y, 1987, PEPTIDES, V8, P639, DOI 10.1016/0196-9781(87)90038-6	49	27	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35089	35097		10.1074/jbc.M502567200	http://dx.doi.org/10.1074/jbc.M502567200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16087676	hybrid			2022-12-27	WOS:000232561200005
J	Furumatsu, T; Tsuda, M; Yoshida, K; Taniguchi, N; Ito, T; Hashimoto, M; Ito, T; Asahara, H				Furumatsu, T; Tsuda, M; Yoshida, K; Taniguchi, N; Ito, T; Hashimoto, M; Ito, T; Asahara, H			Sox9 and p300 cooperatively regulate chromatin-mediated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOME ASSEMBLY PROTEIN-1; RUBINSTEIN-TAYBI SYNDROME; AUTOSOMAL SEX REVERSAL; SRY-RELATED GENE; CHONDROCYTE DIFFERENTIATION; COLLAGEN GENE; IN-VITRO; CAMPOMELIC DYSPLASIA; HISTONE CHAPERONE; EXPRESSION	Chromatin structure is a fundamental component of gene regulation, expression, and cellular differentiation. We have previously reported that the multifunctional coactivator p300 is a member of the Sox9 (Sry-type high mobility group box 9)-related transcriptional apparatus and activates Sox9-dependent transcription during chondrogenesis. However, the mechanism of synergy between Sox9 and p300 in chromatin-mediated transcription has not been elucidated. In the present study we investigated the activity of Sox9 and p300 on chromatinized templates in vitro. Recombinant Sox9 was shown to be associated with several transcriptional cofactors including p300. In vitro transcription assays revealed that p300 potentiated Sox9-dependent transcription on chromatinized DNA and, importantly, was associated with hyperacetylated histones. Consistent with these results, the histone deacetylase inhibitor trichostatin A stimulated the expression of Sox9-regulated cartilage matrix genes and induced histone acetylation around the enhancer region of the collagen alpha 1 (II) gene in chondrocytes. These findings suggest that Sox9 interacts with chromatin and activates transcription via regulation of chromatin modification.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Nagasaki Univ, Sch Med, Dept Biochem, Nagasaki 8528523, Japan; Natl Ctr Child Hlth & Dev, Setagaya Ku, Tokyo 1578535, Japan; Japan Sci & Technol Agcy, Solut Oriented Res Sci & Technol Project, Kawaguchi, Saitama 3320012, Japan	Scripps Research Institute; Nagasaki University; National Center for Child Health & Development - Japan; Japan Science & Technology Agency (JST)	Asahara, H (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd,MEM 161, La Jolla, CA 92037 USA.	asahara@scripps.edu	FURUMATSU, Takayuki/B-2233-2011		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R56AR050631, R01AR050631] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR50631] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802; Akiyama H, 2004, GENE DEV, V18, P1072, DOI 10.1101/gad.1171104; Alsalameh S, 2004, ARTHRITIS RHEUM-US, V50, P1522, DOI 10.1002/art.20269; Asahara H, 2002, MOL CELL BIOL, V22, P2974, DOI 10.1128/MCB.22.9.2974-2983.2002; Asahara H, 2001, MOL CELL BIOL, V21, P7892, DOI 10.1128/MCB.21.23.7892-7900.2001; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Bradney C, 2003, J BIOL CHEM, V278, P2370, DOI 10.1074/jbc.M211464200; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; Chan HM, 2001, J CELL SCI, V114, P2363; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dilworth FJ, 2004, P NATL ACAD SCI USA, V101, P11593, DOI 10.1073/pnas.0404192101; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; Furumatsu T, 2005, J BIOL CHEM, V280, P8343, DOI 10.1074/jbc.M413913200; Furumatsu T, 2002, INT J CANCER, V97, P313, DOI 10.1002/ijc.1607; Haushalter KA, 2003, NAT REV MOL CELL BIO, V4, P613, DOI 10.1038/nrm1177; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Ito T, 2000, GENE DEV, V14, P1899; Ito T, 1999, GENE DEV, V13, P1529, DOI 10.1101/gad.13.12.1529; Ito T, 1996, MOL CELL BIOL, V16, P3112; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Kawakami Y, 2005, P NATL ACAD SCI USA, V102, P2414, DOI 10.1073/pnas.0407510102; Kitagawa H, 2003, CELL, V113, P905, DOI 10.1016/S0092-8674(03)00436-7; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kou I, 2004, J BIOL CHEM, V279, P50942, DOI 10.1074/jbc.M406786200; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Kundu TK, 2000, MOL CELL, V6, P551, DOI 10.1016/S1097-2765(00)00054-X; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Liu CJ, 2004, J BIOL CHEM, V279, P47081, DOI 10.1074/jbc.M405288200; Liu Y, 2000, J BIOL CHEM, V275, P12712, DOI 10.1074/jbc.275.17.12712; Nakagawa T, 2001, J BIOL CHEM, V276, P27384, DOI 10.1074/jbc.M101331200; Narayanan K, 2004, J BIOL CHEM, V279, P44294, DOI 10.1074/jbc.M403511200; Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Sekiya I, 2000, J BIOL CHEM, V275, P10738, DOI 10.1074/jbc.275.15.10738; Song MR, 2004, NAT NEUROSCI, V7, P229, DOI 10.1038/nn1192; Stricker S, 2002, DEV BIOL, V245, P95, DOI 10.1006/dbio.2002.0640; Tan LJ, 2003, J BIOL CHEM, V278, P17688, DOI 10.1074/jbc.M301676200; Tanaka Y, 1997, P NATL ACAD SCI USA, V94, P10215, DOI 10.1073/pnas.94.19.10215; Tsuda M, 2003, J BIOL CHEM, V278, P27224, DOI 10.1074/jbc.M303471200; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhang P, 2003, J BIOL CHEM, V278, P117, DOI 10.1074/jbc.M208049200	48	117	124	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35203	35208		10.1074/jbc.M502409200	http://dx.doi.org/10.1074/jbc.M502409200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16109717	hybrid			2022-12-27	WOS:000232561200017
J	Zhou, AF; Li, J				Zhou, AF; Li, J			Arabidopsis BRS1 is a secreted and active serine carboxypeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE GROWTH-FACTOR; SECONDARY METABOLISM; PROTEIN-KINASE; GENE FAMILY; EXPRESSION; PRECURSOR; BRI1; ACYLTRANSFERASE; POLYPEPTIDE; PHYTOSULFOKINE	The Arabidopsis BRS1 gene encodes a serine carboxypeptidase II-like protein. Its biological role in the brassinosteroid signaling pathway was first established by its capability to specifically suppress a weak brassinosteroid insensitive 1 (bri1) allele, bri1-5, when overexpressed. To gain additional insights into the molecular mechanisms of BRS1 function, the subcellular localization and the biochemical characteristics of BRS1 were determined by using transgenic plants harboring a 35S-BRS1-GFP construct and fusion proteins purified from 35S-BRS1-FLAG transgenic plants. The BRS1-GFP protein was mainly secreted and accumulated in the extracellular space. Immunological data suggest that BRS1 is proteolytically processed by an unknown endoproteinase in planta. Affinity-purified BRS1-FLAG from transgenic plants show strong hydrolytic activity with a broad P1 substrate preference including basic and hydrophobic groups on either side of the scissile bond. The hydrolytic activity of BRS1 can be strongly inhibited by a serine protease inhibitor, phenylmethylsulfonyl fluoride. The pH and temperature optima for the hydrolytic activity of BRS1 are pH 5.5 and 50 C, respectively. These data demonstrate that BRS1 is a secreted and active serine carboxypeptidase, consistent with the hypothesis suggested by our previous genetic evidence that BRS1 may process a protein involved in an early event in the BRI1 signaling pathway.	Univ Oklahoma, Dept Bot & Microbiol, Norman, OK 73019 USA	University of Oklahoma System; University of Oklahoma - Norman	Li, J (corresponding author), Univ Oklahoma, Dept Bot & Microbiol, 770 Van Vleet Oval, Norman, OK 73019 USA.	lij@ou.edu						BECKER D, 1992, PLANT MOL BIOL, V20, P1195, DOI 10.1007/BF00028908; Becraft PW, 2002, DEVELOPMENT, V129, P5217; Berger D, 2000, GENE DEV, V14, P1119; BREDDAM K, 1987, CARLSBERG RES COMMUN, V52, P297, DOI 10.1007/BF02907172; Cercos M, 2003, PLANT MOL BIOL, V51, P165, DOI 10.1023/A:1021142403856; DOAN NP, 1988, J BIOL CHEM, V263, P11106; Dodson G, 1998, TRENDS BIOCHEM SCI, V23, P347, DOI 10.1016/S0968-0004(98)01254-7; Dominguez F, 1999, PLANT PHYSIOL, V119, P81, DOI 10.1104/pp.119.1.81; Fan XM, 2002, J HISTOCHEM CYTOCHEM, V50, P1509, DOI 10.1177/002215540205001111; Fraser CM, 2005, PLANT PHYSIOL, V138, P1136, DOI 10.1104/pp.104.057950; Friedrichsen DM, 2000, PLANT PHYSIOL, V123, P1247, DOI 10.1104/pp.123.4.1247; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Kinoshita T, 2005, NATURE, V433, P167, DOI 10.1038/nature03227; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; Kruger J, 2002, SCIENCE, V296, P744, DOI 10.1126/science.1069288; LATCHINIANSADEK L, 1993, J BIOL CHEM, V268, P534; Lehfeldt C, 2000, PLANT CELL, V12, P1295, DOI 10.1105/tpc.12.8.1295; Li AX, 2000, P NATL ACAD SCI USA, V97, P6902, DOI 10.1073/pnas.110154197; Li J, 2002, CELL, V110, P213, DOI 10.1016/S0092-8674(02)00812-7; Li J, 2001, P NATL ACAD SCI USA, V98, P5916, DOI 10.1073/pnas.091065998; Li JM, 1997, CELL, V90, P929, DOI 10.1016/S0092-8674(00)80357-8; Lid SE, 2002, P NATL ACAD SCI USA, V99, P5460, DOI 10.1073/pnas.042098799; Matsubayashi Y, 2003, J CELL SCI, V116, P3863, DOI 10.1242/jcs.00733; MCGURL B, 1992, SCIENCE, V255, P1570, DOI 10.1126/science.1549783; Nam KH, 2002, CELL, V110, P203, DOI 10.1016/S0092-8674(02)00814-0; PEARCE G, 1991, SCIENCE, V253, P895, DOI 10.1126/science.253.5022.895; PLUMMER TH, 1980, ANAL BIOCHEM, V108, P348, DOI 10.1016/0003-2697(80)90598-9; RAMINGTON SJ, 1993, CURR OPIN BIOTECH, V4, P462; Robatzek S, 2001, PLANT J, V28, P123, DOI 10.1046/j.1365-313X.2001.01131.x; Schaller A, 2004, PLANTA, V220, P183, DOI 10.1007/s00425-004-1407-2; SCHALLER A, 1994, P NATL ACAD SCI USA, V91, P11802, DOI 10.1073/pnas.91.25.11802; Scheer JM, 2002, P NATL ACAD SCI USA, V99, P9585, DOI 10.1073/pnas.132266499; Shirley AM, 2003, J BIOL CHEM, V278, P19870, DOI 10.1074/jbc.M302362200; Shiu SH, 2001, P NATL ACAD SCI USA, V98, P10763, DOI 10.1073/pnas.181141598; Steffens J C, 2000, Plant Cell, V12, P1253; WAJANT H, 1994, PLANT MOL BIOL, V26, P735, DOI 10.1007/BF00013758; Wei SW, 2003, LIFE SCI, V73, P655, DOI 10.1016/S0024-3205(03)00386-2; Yang HP, 1999, P NATL ACAD SCI USA, V96, P13560, DOI 10.1073/pnas.96.23.13560; Yang HP, 2001, PLANT PHYSIOL, V127, P842, DOI 10.1104/pp.010452; Zhou A, 2004, PLANT J, V40, P399, DOI 10.1111/j.1365-313X.2004.02214.x	40	40	46	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35554	35561		10.1074/jbc.M503299200	http://dx.doi.org/10.1074/jbc.M503299200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16123046	hybrid			2022-12-27	WOS:000232561200057
J	Fujiwara, Y; Sardar, V; Tokumura, A; Baker, D; Murakami-Murofushi, K; Parrill, A; Tigyi, G				Fujiwara, Y; Sardar, V; Tokumura, A; Baker, D; Murakami-Murofushi, K; Parrill, A; Tigyi, G			Identification of residues responsible for ligand recognition and regioisomeric selectivity of lysophosphatidic acid receptors expressed in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; MOLECULAR-CLONING; LPA RECEPTORS; EMERGING ROLE; EDG-FAMILY; ACTIVATION; SUBTYPE; ANALOGS; HETERODIMERIZATION; HOMODIMERIZATION	The endothelial differentiation gene family encodes three highly homologous G protein-coupled receptors for lysophosphatidic acid (LPA). Based on baculoviral overexpression studies, differences have been proposed in the structure-activity relationship (SAR) of these receptors. We have compared the SAR of the individual receptors either overexpressed transiently at high or at lower levels following stable transfection in LPA-nonresponsive RH7777 cells. The SAR in transfected RH7777 cells was markedly different from that described in insect cells. The LPA(3) receptor has been proposed to be selectively activated by unsaturated LPA species and shows a strong preference for sn-2 versus the sn-1 acyl-LPA regioisomer. Because of the short half-life of sn-2 LPA due to acyl migration under some conditions, we have synthesized acyl migration-resistant analogs using an acetyl group in place of the free hydroxyl group in order to evaluate LPA receptor SAR. Only LPA(1) and LPA(2) showed regioisomeric preference and only for the 18: 2 fatty acyl-stabilized LPA sn-1 regioisomer. To identify residues involved in ligand recognition of LPA(3), we developed and validated computational models of LPA(3) complexes with the analogs studied. The models revealed that Arg-3.28 and Gln-3.29 conserved within the LPA-selective endothelial differentiation gene receptors and the more variable Lys-7.35 and Arg-5.38 of LPA(3) form critical interactions with the polar head-group of LPA. The models identified Leu-2.60 and Val-7.39 of LPA(3) underlying the regioisomer-selective interaction with the acetyl group of the stabilized regioisomers. Mutation of Leu-2.60 to alanine selectively increased the EC50 of the sn-2 acetyl-LPA regioisomers, whereas alanine replacement of Val-7.39 profoundly affected both regioisomers.	Univ Tennessee, Inst Canc, Hlth Sci Ctr, Memphis, TN 38152 USA; Univ Tennessee, Dept Chem, Memphis, TN 38152 USA; Univ Tennessee, Computat Res Mat Inst, Memphis, TN 38152 USA; Univ Tokushima, Fac Pharmaceut Sci, Tokushima 7708505, Japan; Ochanomizu Univ, Dept Biol, Bunkyo Ku, Tokyo 112, Japan	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Tokushima University; Ochanomizu University	Tigyi, G (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave, Memphis, TN 38163 USA.	gtigyi@physio1.utmem.edu		Parrill, Abby/0000-0003-1658-8497; Baker, Daniel/0000-0003-1482-0416	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061469] Funding Source: NIH RePORTER; NCI NIH HHS [CA92160] Funding Source: Medline; NHLBI NIH HHS [HL61469] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150; Baker DL, 2002, JAMA-J AM MED ASSOC, V287, P3081, DOI 10.1001/jama.287.23.3081; Baker DL, 2001, ANAL BIOCHEM, V292, P287, DOI 10.1006/abio.2001.5063; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; Bandoh K, 2000, FEBS LETT, V478, P159, DOI 10.1016/S0014-5793(00)01827-5; Bulenger S, 2005, TRENDS PHARMACOL SCI, V26, P131, DOI 10.1016/j.tips.2005.01.004; *CHEM COMP GROUP, 2003, MOE; Croset M, 2000, BIOCHEM J, V345, P61, DOI 10.1042/0264-6021:3450061; Fischer DJ, 1998, MOL PHARMACOL, V54, P979, DOI 10.1124/mol.54.6.979; Fischer DJ, 2001, MOL PHARMACOL, V60, P776; Gueguen G, 1999, BIOCHEMISTRY-US, V38, P8440, DOI 10.1021/bi9816756; Halgren TA, 1996, J COMPUT CHEM, V17, P490, DOI 10.1002/(SICI)1096-987X(199604)17:5/6<616::AID-JCC5>3.0.CO;2-X; Hama K, 2002, FEBS LETT, V523, P187, DOI 10.1016/S0014-5793(02)02976-9; Heise CE, 2001, MOL PHARMACOL, V60, P1173, DOI 10.1124/mol.60.6.1173; Holdsworth Gill, 2004, BMC Biochemistry, V5, P1, DOI 10.1186/1471-2091-5-12; Im DS, 2000, MOL PHARMACOL, V57, P753, DOI 10.1124/mol.57.4.753; INAGAKI Y, 2005, IN PRESS BIOCH J; Ishii I, 2000, MOL PHARMACOL, V58, P895, DOI 10.1124/mol.58.5.895; Ishii I, 2004, ANNU REV BIOCHEM, V73, P321, DOI 10.1146/annurev.biochem.73.011303.073731; JALINK K, 1995, BIOCHEM J, V307, P609, DOI 10.1042/bj3070609; JALINK K, 1990, J BIOL CHEM, V265, P12232; KOBAYASHI S, 1993, TETRAHEDRON LETT, V34, P4047, DOI 10.1016/S0040-4039(00)60612-3; Liliom K, 1998, J BIOL CHEM, V273, P13461, DOI 10.1074/jbc.273.22.13461; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Mukai M, 1999, INT J CANCER, V81, P918, DOI 10.1002/(SICI)1097-0215(19990611)81:6<918::AID-IJC13>3.0.CO;2-E; Murakami-Murofushi K, 2002, BBA-MOL CELL BIOL L, V1582, P1, DOI 10.1016/S1388-1981(02)00131-2; Ohta H, 2003, MOL PHARMACOL, V64, P994, DOI 10.1124/mol.64.4.994; Parrill AL, 2000, J BIOL CHEM, V275, P39379, DOI 10.1074/jbc.M007680200; Rother E, 2003, CIRCULATION, V108, P741, DOI 10.1161/01.CIR.0000083715.37658.C4; Sano T, 2002, J BIOL CHEM, V277, P21197, DOI 10.1074/jbc.M201289200; Sardar VM, 2002, BBA-MOL CELL BIOL L, V1582, P309, DOI 10.1016/S1388-1981(02)00185-3; SIMON MF, 1982, BIOCHEM BIOPH RES CO, V108, P1743, DOI 10.1016/S0006-291X(82)80113-7; Tigyi G, 2003, PROG LIPID RES, V42, P498, DOI 10.1016/S0163-7827(03)00035-3; Tokumura A, 2002, BIOCHEM J, V365, P617, DOI 10.1042/BJ20020348; Van Brocklyn JR, 2002, BBA-MOL CELL BIOL L, V1582, P89, DOI 10.1016/S1388-1981(02)00141-5; Wang DA, 2001, J BIOL CHEM, V276, P49213, DOI 10.1074/jbc.M107301200; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; Zhang CX, 2004, J EXP MED, V199, P763, DOI 10.1084/jem.20031619; ZHU BT, 1993, J PHARMACOL TOXICOL, V29, P85, DOI 10.1016/1056-8719(93)90055-J	42	70	78	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					35038	35050		10.1074/jbc.M504351200	http://dx.doi.org/10.1074/jbc.M504351200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16115890	hybrid			2022-12-27	WOS:000232403900077
J	Gomez-Merino, FC; Arana-Ceballos, FA; Trejo-Tellez, LI; Skirycz, A; Brearley, CA; Dormann, P; Mueller-Roeber, B				Gomez-Merino, FC; Arana-Ceballos, FA; Trejo-Tellez, LI; Skirycz, A; Brearley, CA; Dormann, P; Mueller-Roeber, B			Arabidopsis AtDGK7, the smallest member of plant diacylglycerol kinases (DGKs), displays unique biochemical features and saturates at low substrate concentration - The DGK inhibitor R59022 differentially affects AtDGK2 and AtDGK7 activity in vitro and alters plant growth and development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDIC-ACID; PHOSPHOLIPASE-C; PLASMA-MEMBRANE; RICH REGION; PROTEIN; PHOSPHATIDYLINOSITOL; ACCUMULATION; GTPASE; CELLS; TRANSDUCTION	Diacylglycerol kinase (DGK) regulates the level of the second messenger diacylglycerol and produces phosphatidic acid (PA), another signaling molecule. The Arabidopsis thaliana genome encodes seven putative diacylglycerol kinase isozymes (named AtDGK1 to -7), structurally falling into three major clusters. So far, enzymatic activity has not been reported for any plant Cluster II DGK. Here, we demonstrate that a representative of this cluster, AtDGK7, is biochemically active when expressed as a recombinant protein in Escherichia coli. AtDGK7, encoded by gene locus At4g30340, contains 374 amino acids with an apparent molecular mass of 41.2 kDa. AtDGK7 harbors an N-terminal catalytic domain, but in contrast to various characterized DGKs (including AtDGK2), it lacks a cysteine-rich domain at its N terminus, and, importantly, its C-terminal DGK accessory domain is incomplete. Recombinant AtDGK7 expressed in E. coli exhibits Michaelis-Menten type kinetics with 1,2-dioleoyl-sn-glycerol as substrate. AtDGK7 activity was affected by pH, detergents, and the DGK inhibitor R59022. We demonstrate that both AtDGK2 and AtDGK7 phosphorylate diacylglycerol molecular species that are typically found in plants, indicating that both enzymes convert physiologically relevant substrates. AtDGK7 is expressed throughout the Arabidopsis plant, but expression is strongest in flowers and young seedlings. Expression of AtDGK2 is transiently induced by wounding. R59022 at similar to 80 mu M inhibits root elongation and lateral root formation and reduces plant growth, indicating that DGKs play an important role in plant development.	Univ Potsdam, Inst Biochem & Biol, D-14476 Golm, Germany; Coll Postgrad Agr Sci, Montecillo 56230, Mexico; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Max Planck Inst Mol Plant Physiol, Dept Mol Physiol, D-14476 Golm, Germany; Max Planck Inst Mol Plant Physiol, Cooperat Res Grp, D-14476 Golm, Germany	University of Potsdam; Colegio de Postgraduados - Mexico; University of East Anglia; Max Planck Society; Max Planck Society	Mueller-Roeber, B (corresponding author), Univ Potsdam, Inst Biochem & Biol, Karl Liebknecht Str 24-25,Haus 20, D-14476 Golm, Germany.	bmr@rz.uni-potsdam.de	TREJO-TÉLLEZ, LIBIA/B-2635-2015; Gómez-Merino, Fernando Carlos/D-2224-2014; Mueller-Roeber, Bernd/Z-4052-2019; LIBIA, TREJO-TÉLLEZ/AAV-8118-2021; Skirycz, Aleksandra/AAM-7911-2021	Skirycz, Aleksandra/0000-0002-7627-7925; Brearley, Charles/0000-0001-6179-9109				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREARLEY CA, 1992, BIOCHEM J, V283, P255, DOI 10.1042/bj2830255; Czechowski T, 2004, PLANT J, V38, P366, DOI 10.1111/j.1365-313X.2004.02051.x; Deak M, 1999, FEBS LETT, V451, P220, DOI 10.1016/S0014-5793(99)00556-6; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; Farmer PK, 1999, BBA-PROTEIN STRUCT M, V1434, P6, DOI 10.1016/S0167-4838(99)00166-1; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; Gilroy S, 2001, NAT REV MOL CELL BIO, V2, P307, DOI 10.1038/35067109; Gomez-Merino FC, 2003, PROCEEDINGS OF THE XII INTERNATIONAL CONGRESS ON GENES, GENE FAMILIES, AND ISOZYMES, P247; Gomez-Merino FC, 2004, J BIOL CHEM, V279, P8230, DOI 10.1074/jbc.M312187200; HAWKINS PT, 1986, BIOCHEM J, V238, P507, DOI 10.1042/bj2380507; HEIM S, 1987, PLANT SCI, V49, P159, DOI 10.1016/0168-9452(87)90036-7; Houssa B, 1997, J BIOL CHEM, V272, P10422; Igal RA, 2001, J LIPID RES, V42, P88; JEFFERSON RA, 1987, EMBO J, V6, P3901; Jiang Y, 2000, BIOCHEM PHARMACOL, V59, P763, DOI 10.1016/S0006-2952(99)00395-0; Jones MA, 2002, PLANT CELL, V14, P763, DOI 10.1105/tpc.010359; KAMADA Y, 1991, BIOCHIM BIOPHYS ACTA, V1093, P72, DOI 10.1016/0167-4889(91)90140-S; KANOH H, 1981, ARCH BIOCHEM BIOPHYS, V209, P266, DOI 10.1016/0003-9861(81)90280-0; Katagiri T, 1996, PLANT MOL BIOL, V30, P647, DOI 10.1007/BF00049339; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE Y, 1991, P NATL ACAD SCI USA, V88, P2127, DOI 10.1073/pnas.88.6.2127; Li H, 2001, PLANT PHYSIOL, V126, P670, DOI 10.1104/pp.126.2.670; LUNDBERG GA, 1992, BIOCHIM BIOPHYS ACTA, V1123, P177, DOI 10.1016/0005-2760(92)90109-9; MARECHAL E, 1994, J BIOL CHEM, V269, P5788; Martelli AM, 2002, CELL MOL LIFE SCI, V59, P1129, DOI 10.1007/s00018-002-8492-9; Meijer HJG, 2003, ANNU REV PLANT BIOL, V54, P265, DOI 10.1146/annurev.arplant.54.031902.134748; Meyers BC, 2004, PLANT PHYSIOL, V135, P801, DOI 10.1104/pp.104.039495; Miege C, 1999, PLANT PHYSIOL BIOCH, V37, P795, DOI 10.1016/S0981-9428(99)00118-7; Munnik T, 2001, TRENDS PLANT SCI, V6, P227, DOI 10.1016/S1360-1385(01)01918-5; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; QUEST AFG, 1994, J BIOL CHEM, V269, P2953; Ruelland E, 2002, PLANT PHYSIOL, V130, P999, DOI 10.1104/pp.006080; SAMBROOK J, 2000, MOL CLONING LAB MANU; Shirai Y, 2000, J BIOL CHEM, V275, P24760, DOI 10.1074/jbc.M003151200; Snedden WA, 2000, PLANT J, V24, P317, DOI 10.1046/j.1365-313x.2000.00877.x; Testerink C, 2004, PLANT J, V39, P527, DOI 10.1111/j.1365-313X.2004.02152.x; Topham MK, 2002, THROMB HAEMOSTASIS, V88, P912; Toyoda K, 2000, J PHYTOPATHOL, V148, P633, DOI 10.1046/j.1439-0434.2000.00568.x; Undie AS, 1999, BRAIN RES, V816, P286, DOI 10.1016/S0006-8993(98)01076-2; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3; Vernoud V, 2003, PLANT PHYSIOL, V131, P1191, DOI 10.1104/pp.013052; Wang CX, 2000, PLANT CELL, V12, P2237, DOI 10.1105/tpc.12.11.2237; Wang XM, 2004, CURR OPIN PLANT BIOL, V7, P329, DOI 10.1016/j.pbi.2004.03.012; Winge P, 2000, GENETICS, V156, P1959; WISSING JB, 1992, PLANT PHYSIOL, V98, P1148, DOI 10.1104/pp.98.3.1148; Zhang WH, 2004, P NATL ACAD SCI USA, V101, P9508, DOI 10.1073/pnas.0402112101; Zimmermann P, 2004, PLANT PHYSIOL, V136, P2621, DOI 10.1104/pp.104.046367	48	61	68	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34888	34899		10.1074/jbc.M506859200	http://dx.doi.org/10.1074/jbc.M506859200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16081412	hybrid			2022-12-27	WOS:000232403900061
J	Lu, JC; Piazza, TM; Schuler, LA				Lu, JC; Piazza, TM; Schuler, LA			Proteasomes mediate prolactin-induced receptor down-regulation and fragment generation in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; NUCLEAR-LOCALIZATION; SIGNAL-TRANSDUCTION; UBIQUITIN LIGASE; BINDING-PROTEIN; ENDOCYTOSIS; EXPRESSION; INTERNALIZATION; ERYTHROPOIETIN; IDENTIFICATION	Prolactin regulates a variety of physiological processes, including mammary gland growth and differentiation, and recent findings support an important role in breast cancer development and progression. However, little is known about the trafficking of its receptor, a member of the cytokine receptor superfamily. In the present study, we examined the effect of ligand on the endogenous "long" isoform of the prolactin receptor in breast cancer cells. We found that prolactin caused rapid and prolonged down-regulation of this receptor. The prolactin-induced increase in degradation was blocked by inhibitors of both proteasomes and lysosomes. However, the ubiquitin-conjugating system was not required for internalization. Prolactin also resulted in the concomitant appearance of a cell-associated prolactin receptor fragment containing the extracellular domain. This latter process required proteasomal, but not metalloprotease, activity, distinguishing it from ectodomain "shedding" of other membrane receptors, which are secreted as binding proteins. The prolactin receptor fragment was labeled by surface biotinylation and independent of protein synthesis. Together, these data indicated that prolactin binding initiates limited proteasomal cleavage of its receptor, generating a cell-associated fragment containing the extracellular domain. Our findings described a new potential mediator of prolactin action and a novel mechanism whereby proteasomes modulate cellular processes.	Univ Wisconsin, Dept Comparat Biosci, Madison, WI 53706 USA; Univ Wisconsin, Endocrinol Reprod Physiol Program, Madison, WI 53706 USA; Univ Wisconsin, Comparat Biomed Sci Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Schuler, LA (corresponding author), Univ Wisconsin, Dept Comparat Biosci, 2015 Linden Dr, Madison, WI 53706 USA.	schulerl@svm.vetmed.wisc.edu	Lu, Juu-Chin/ABB-3198-2020	Lu, Juu-Chin/0000-0001-8523-6992	NATIONAL CANCER INSTITUTE [R01CA078312] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062783] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA078312, R01 CA78312] Funding Source: Medline; NIDDK NIH HHS [R01 DK62783, R01 DK062783] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilar RC, 2003, CURR OPIN CELL BIOL, V15, P184, DOI 10.1016/S0955-0674(03)00010-3; Althoff K, 2000, EUR J BIOCHEM, V267, P2624, DOI 10.1046/j.1432-1327.2000.01278.x; Baron M, 2002, MOL MEMBR BIOL, V19, P27, DOI 10.1080/09687680110112929; Baumann G, 2002, J ENDOCRINOL, V174, P361, DOI 10.1677/joe.0.1740361; Beckman DL, 1999, BLOOD, V94, P2667, DOI 10.1182/blood.V94.8.2667.420k27_2667_2675; Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/edrv.19.3.0334; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; CAHOREAU C, 1994, FEBS LETT, V350, P230, DOI 10.1016/0014-5793(94)00772-1; Chen L, 2001, EMBO REP, V2, P933, DOI 10.1093/embo-reports/kve203; Clevenger CV, 2003, BREAST CANCER RES, V5, P181, DOI 10.1186/bcr601; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; COHEN H, 1993, ENDOCRINOLOGY, V132, P2601, DOI 10.1210/en.132.6.2601; Cook LB, 2003, MOL ENDOCRINOL, V17, P1777, DOI 10.1210/me.2003-0073; Cowan JW, 2005, J BIOL CHEM, V280, P19331, DOI 10.1074/jbc.M500621200; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; DJIANE J, 1982, MOL CELL ENDOCRINOL, V25, P163, DOI 10.1016/0303-7207(82)90049-1; Edery M, 2001, ENDOCRIN UPDAT, V12, P341; Fang S, 2004, CELL MOL LIFE SCI, V61, P1546, DOI 10.1007/s00018-004-4129-5; Felberbaum-Corti M, 2003, NAT CELL BIOL, V5, P382, DOI 10.1038/ncb0503-382; Fielding CJ, 2003, BBA-BIOMEMBRANES, V1610, P219, DOI 10.1016/S0005-2736(03)00020-8; Freeman ME, 2000, PHYSIOL REV, V80, P1523, DOI 10.1152/physrev.2000.80.4.1523; Friedman AD, 2003, J BIOL CHEM, V278, P26851, DOI 10.1074/jbc.M210039200; GENTY N, 1994, MOL CELL ENDOCRINOL, V99, P221, DOI 10.1016/0303-7207(94)90011-6; Gill S, 2001, J CLIN PATHOL, V54, P956, DOI 10.1136/jcp.54.12.956; Goffin V, 1999, MOL CELL ENDOCRINOL, V151, P79, DOI 10.1016/S0303-7207(99)00023-4; Goffin V, 2002, ANNU REV PHYSIOL, V64, P47, DOI 10.1146/annurev.physiol.64.081501.131049; Gonzallez-Gaitan M, 2003, NAT REV MOL CELL BIO, V4, P213, DOI 10.1038/nrm1053; Gutzman JH, 2004, J STEROID BIOCHEM, V88, P69, DOI 10.1016/j.jsbmb.2003.10.008; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Hu ZZ, 2001, J BIOL CHEM, V276, P41086, DOI 10.1074/jbc.M102109200; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; Kline JB, 1999, J BIOL CHEM, V274, P35461, DOI 10.1074/jbc.274.50.35461; Kline JB, 2001, J BIOL CHEM, V276, P24760, DOI 10.1074/jbc.M011786200; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; KULKA RG, 1988, J BIOL CHEM, V263, P15726; Kumar KGS, 2003, EMBO J, V22, P5480; Li Y, 2004, MOL CELL BIOL, V24, P4038, DOI 10.1128/MCB.24.9.4038-4048.2004; Lu JC, 2002, MOL ENDOCRINOL, V16, P2515, DOI 10.1210/me.2002-0077; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Martinez-Moczygemba M, 2001, J CLIN INVEST, V108, P1797, DOI 10.1172/JCI200113877; Mertani HC, 1998, INT J CANCER, V79, P202; Mullberg J, 2000, EUR CYTOKINE NETW, V11, P27; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; PerrotApplanat M, 1997, MOL ENDOCRINOL, V11, P1020, DOI 10.1210/me.11.8.1020; PerrotApplanat M, 1997, J CELL SCI, V110, P1123; POSTELVINAY MC, 1991, P NATL ACAD SCI USA, V88, P6687, DOI 10.1073/pnas.88.15.6687; Raben DM, 2002, TRENDS ENDOCRIN MET, V13, P93, DOI 10.1016/S1043-2760(02)00573-8; RAO Y, 1993, ENDOCRINOLOGY, V133, P3062, DOI 10.1210/en.133.6.3062; RAO YP, 1995, ARCH BIOCHEM BIOPHYS, V322, P506, DOI 10.1006/abbi.1995.1494; Rape M, 2002, NAT CELL BIOL, V4, pE113, DOI 10.1038/ncb0502-e113; Reynolds C, 1997, ENDOCRINOLOGY, V138, P5555, DOI 10.1210/en.138.12.5555; Rocca A, 2001, MOL BIOL CELL, V12, P1293, DOI 10.1091/mbc.12.5.1293; Saltiel AR, 2003, TRAFFIC, V4, P711, DOI 10.1034/j.1600-0854.2003.00119.x; Schroeder MD, 2002, MOL ENDOCRINOL, V16, P45, DOI 10.1210/me.16.1.45; Schroeder MD, 2001, MOL CELL ENDOCRINOL, V175, P173, DOI 10.1016/S0303-7207(01)00385-9; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Strous GJ, 2002, MOL CELL ENDOCRINOL, V197, P143, DOI 10.1016/S0303-7207(02)00258-7; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Touraine P, 1998, J CLIN ENDOCR METAB, V83, P667, DOI 10.1210/jc.83.2.667; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; Verdier F, 2000, J BIOL CHEM, V275, P18375, DOI 10.1074/jbc.275.24.18375; Vincent V, 1997, J BIOL CHEM, V272, P7062, DOI 10.1074/jbc.272.11.7062; Vonderhaar BK, 2000, CONT ENDOCRINOL, P101; Yu AX, 2001, J BIOL CHEM, V276, P381, DOI 10.1074/jbc.M007991200	69	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33909	33916		10.1074/jbc.M508118200	http://dx.doi.org/10.1074/jbc.M508118200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16103113	hybrid, Green Accepted			2022-12-27	WOS:000232229700027
J	Krebstakies, T; Zimmermann, B; Graber, P; Altendorf, K; Borsch, M; Greie, JC				Krebstakies, T; Zimmermann, B; Graber, P; Altendorf, K; Borsch, M; Greie, JC			Both rotor and stator subunits are necessary for efficient binding of F-1 to F-0 in functionally assembled Escherichia coli ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-MOLECULE FLUORESCENCE; SITE-DIRECTED MUTAGENESIS; GAMMA-SUBUNIT; CROSS-LINKING; B-SUBUNIT; F1F0-ATP SYNTHASE; EPSILON-SUBUNIT; DELTA-SUBUNIT; QUANTITATIVE-DETERMINATION; F0F1-ATP SYNTHASE	In F1F0-ATP synthase, the subunit b(2)delta complex comprises the peripheral stator bound to subunit a in F-0 and to the alpha(3)beta(3) hexamer of F-1. During catalysis, ATP turnover is coupled via an elastic rotary mechanism to proton translocation. Thus, the stator has to withstand the generated rotor torque, which implies tight interactions of the stator and rotor subunits. To quantitatively characterize the contribution of the F-0 subunits to the binding of F-1 within the assembled holoenzyme, the isolated subunit b dimer, ab(2) subcomplex, and fully assembled F-0 complex were specifically labeled with tetramethylrhodamine- 5-maleimide at bCys(64) and functionally reconstituted into liposomes. Proteoliposomes were then titrated with increasing amounts of Cy5-maleimide-labeled F-1 ( at gamma Cys(106)) and analyzed by single-molecule fluorescence resonance energy transfer. The data revealed F-1 dissociation constants of 2.7 nM for the binding of F-0 and 9 - 10 nM for both the ab(2) subcomplex and subunit b dimer. This indicates that both rotor and stator components of F-0 contribute to F-1 binding affinity in the assembled holoenzyme. The subunit c ring plays a crucial role in the binding of F-1 to F-0, whereas subunit a does not contribute significantly.	Univ Stuttgart, Inst Phys, D-70569 Stuttgart, Germany; Univ Osnabruck, Abt Mikrobiol, Fachbereich Biol Chem, D-49069 Osnabruck, Germany; Univ Freiburg, Inst Phys Chem, D-79104 Freiburg, Germany	University of Stuttgart; University Osnabruck; University of Freiburg	Borsch, M (corresponding author), Univ Stuttgart, Inst Phys, Pfaffenwaldring 57, D-70569 Stuttgart, Germany.	m.boersch@physik.uni-stuttgart.de; greie@biologie.uni-osnabrueck.de		Borsch, Michael/0000-0002-0634-2963				AGGELER R, 1992, J BIOL CHEM, V267, P21355; Altendorf K, 2000, J EXP BIOL, V203, P19; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Borsch M, 1998, FEBS LETT, V437, P251, DOI 10.1016/S0014-5793(98)01247-2; Borsch M, 2002, FEBS LETT, V527, P147, DOI 10.1016/S0014-5793(02)03198-8; Bulygin VV, 2004, J BIOL CHEM, V279, P35616, DOI 10.1074/jbc.M405012200; Diez M, 2004, BIOCHEMISTRY-US, V43, P1054, DOI 10.1021/bi0357098; Diez M, 2004, NAT STRUCT MOL BIOL, V11, P135, DOI 10.1038/nsmb718; Dmitriev O, 1999, J BIOL CHEM, V274, P15598, DOI 10.1074/jbc.274.22.15598; Dunn SD, 2000, J BIOENERG BIOMEMBR, V32, P347, DOI 10.1023/A:1005571818730; DUNN SD, 1992, J BIOL CHEM, V267, P7630; Dunn SD, 1998, J BIOL CHEM, V273, P8646, DOI 10.1074/jbc.273.15.8646; Fillingame RH, 2000, BBA-BIOENERGETICS, V1458, P387, DOI 10.1016/S0005-2728(00)00089-X; Fillingame RH, 2002, BBA-BIOMEMBRANES, V1565, P232, DOI 10.1016/S0005-2736(02)00572-2; Fischer S, 2000, J BIOL CHEM, V275, P30157, DOI 10.1074/jbc.275.39.30157; Fischer S, 1999, FEBS LETT, V457, P327, DOI 10.1016/S0014-5793(99)01060-1; FISCHER S, 1994, EUR J BIOCHEM, V225, P167, DOI 10.1111/j.1432-1033.1994.00167.x; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4709, DOI 10.1021/bi00437a030; Greie JC, 2000, J BIOENERG BIOMEMBR, V32, P357, DOI 10.1023/A:1005523902800; Greie JC, 2000, EUR J BIOCHEM, V267, P3040, DOI 10.1046/j.1432-1327.2000.01327.x; Greie JC, 2004, EUR J BIOCHEM, V271, P3036, DOI 10.1111/j.1432-1033.2004.04235.x; Hasler K, 1999, BIOCHEMISTRY-US, V38, P13759, DOI 10.1021/bi991236m; Hermolin J, 1999, J BIOL CHEM, V274, P17011, DOI 10.1074/jbc.274.24.17011; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IWAMOTO A, 1991, J BIOL CHEM, V266, P16350; Junge W, 1999, P NATL ACAD SCI USA, V96, P4735, DOI 10.1073/pnas.96.9.4735; KAUFFER S, 1991, EUR J BIOCHEM, V202, P1307, DOI 10.1111/j.1432-1033.1991.tb16504.x; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; Long JC, 2002, J BIOL CHEM, V277, P27288, DOI 10.1074/jbc.M202118200; McLachlin DT, 2000, BIOCHEMISTRY-US, V39, P3486, DOI 10.1021/bi992586b; McLachlin DT, 2000, J BIOL CHEM, V275, P17571, DOI 10.1074/jbc.M000375200; Meier T, 2005, SCIENCE, V308, P659, DOI 10.1126/science.1111199; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Panke O, 2001, BIOPHYS J, V81, P1220, DOI 10.1016/S0006-3495(01)75780-3; Rodgers AJW, 1997, J BIOL CHEM, V272, P31058, DOI 10.1074/jbc.272.49.31058; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNEIDER E, 1984, P NATL ACAD SCI-BIOL, V81, P7279, DOI 10.1073/pnas.81.23.7279; Stalz WD, 2003, J BIOL CHEM, V278, P27068, DOI 10.1074/jbc.M302027200; Turina P, 2003, EMBO J, V22, P418, DOI 10.1093/emboj/cdg073; WATTS SD, 1995, FEBS LETT, V368, P235, DOI 10.1016/0014-5793(95)00658-V; Watts SD, 1996, J BIOL CHEM, V271, P28341, DOI 10.1074/jbc.271.45.28341; Weber J, 2002, J BIOL CHEM, V277, P18390, DOI 10.1074/jbc.M201047200; Weber J, 2004, J BIOL CHEM, V279, P11253, DOI 10.1074/jbc.M312576200; Weber J, 2003, J BIOL CHEM, V278, P13623, DOI 10.1074/jbc.C300061200; Weber J, 2003, FEBS LETT, V545, P61, DOI 10.1016/S0014-5793(03)00394-6; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P10583, DOI 10.1073/pnas.94.20.10583; Zimmermann B, 2005, EMBO J, V24, P2053, DOI 10.1038/sj.emboj.7600682	51	39	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33338	33345		10.1074/jbc.M506251200	http://dx.doi.org/10.1074/jbc.M506251200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16085645	hybrid			2022-12-27	WOS:000232058100031
J	Pollenz, RS; Dougherty, EJ				Pollenz, RS; Dougherty, EJ			Redefining the role of the endogenous XAP2 and C-terminal hsp70-interacting protein on the endogenous Ah receptors expressed in mouse and rat cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; X-ASSOCIATED PROTEIN-2; NUCLEAR TRANSLOCATOR PROTEIN; SUBCELLULAR-LOCALIZATION; DIOXIN RECEPTOR; CORE COMPLEX; TRANSCRIPTIONAL ACTIVATION; GENE-REGULATION; DEGRADATION; BINDING	Studies using transient expression systems have implicated the XAP2 protein in the control of aryl hydrocarbon receptor (AHR) stability and subcellular location. Thus, studies were performed in cell lines that expressed endogenous rat or mouse Ah(b-1) (C57BL/6) or Ah(b-2) (C3H) AHRs with similar levels of endogenous XAP2. Unliganded rat and mouse Ahb-2 receptor complexes associated with reduced levels of XAP2 and exhibited dynamic nucleocytoplasmic shuttling in comparison with Ah(b-1) receptors. Rat and mouse Ah(b-2) receptors also exhibited a greater magnitude of ligand-induced degradation than Ah(b-1) receptors. Small interfering RNA reduction of endogenous XAP2 by > 80% had minimal impact on the level of Ah(b-2) receptors but resulted in a 25 - 30% reduction of Ah(b-1) receptors. XAP2 reduction resulted in increased susceptibility of the Ah(b-1) receptor to ligand-induced degradation yet produced higher levels of endogenous CYP1A1 induction. Stable expression of the Ah(b-2) receptor in the C57BL/6 background resulted in a protein with reduced association with XAP2, dynamic nucleocytoplasmic shuttling, and increased levels of ligand-induced degradation. Small interfering RNA reduction of endogenous XAP2 in a C-terminal hsp70-interacting protein knockout mouse cell line, exhibited a 25 - 30% reduction in the level of endogenous Ah(b-1) AHR and showed high levels of ligand-induced degradation. Thus, endogenous XAP2 exerts a negative function on a small fraction of the endogenous Ah(b-1) receptor complex but appears to have a minimal impact on endogenous rat or Ah(b-2) receptors. This implies that the analysis of the AHR-mediated signaling via rat and mouse Ah(b-2) receptors may better represent the physiology of this signal transduction pathway.	Univ S Florida, Dept Biol, Tampa, FL 33620 USA	State University System of Florida; University of South Florida	Pollenz, RS (corresponding author), Univ S Florida, Dept Biol, BSF 110,4202 E Fowler Ave, Tampa, FL 33620 USA.	pollenz@chuma1.cas.usf.edu		Dougherty, Edward/0000-0001-7664-9779	NIEHS NIH HHS [ES10991] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010991] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bell DR, 2000, J BIOL CHEM, V275, P36407, DOI 10.1074/jbc.M004236200; Berg P, 2002, J BIOL CHEM, V277, P32310, DOI 10.1074/jbc.M203351200; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CARVER LA, 1994, NUCLEIC ACIDS RES, V22, P3038, DOI 10.1093/nar/22.15.3038; Carver LA, 1997, J BIOL CHEM, V272, P11452; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; Chen HS, 1997, ARCH BIOCHEM BIOPHYS, V348, P190, DOI 10.1006/abbi.1997.0398; Cho YC, 2004, TOXICOL APPL PHARM, V199, P220, DOI 10.1016/j.taap.2003.12.025; Dai Q, 2003, EMBO J, V22, P5446, DOI 10.1093/emboj/cdg529; Davarinos NA, 1999, J BIOL CHEM, V274, P28708, DOI 10.1074/jbc.274.40.28708; Davies TH, 2005, INT J BIOCHEM CELL B, V37, P42, DOI 10.1016/j.biocel.2004.03.013; Dennis A. P., 2004, MOL ENDOCRINOL, V18, P493; DOLWICK KM, 1993, MOL PHARMACOL, V44, P911; GIANNONE JV, 1995, CAN J PHYSIOL PHARM, V73, P7, DOI 10.1139/y95-002; HARPER PA, 1992, MOL PHARMACOL, V42, P603; Hestermann EV, 2003, MOL CELL BIOL, V23, P7920, DOI 10.1128/MCB.23.21.7920-7925.2003; Hollingshead BD, 2004, J BIOL CHEM, V279, P45652, DOI 10.1074/jbc.M407840200; Holmes JL, 1997, MOL PHARMACOL, V52, P202, DOI 10.1124/mol.52.2.202; Kazlauskas A, 2002, J BIOL CHEM, V277, P11795, DOI 10.1074/jbc.M200053200; Kazlauskas A, 2000, J BIOL CHEM, V275, P41317, DOI 10.1074/jbc.M007765200; Kuzhandaivelu N, 1996, NUCLEIC ACIDS RES, V24, P4741, DOI 10.1093/nar/24.23.4741; LaPres JJ, 2000, J BIOL CHEM, V275, P6153, DOI 10.1074/jbc.275.9.6153; Lees MJ, 2003, J BIOL CHEM, V278, P35878, DOI 10.1074/jbc.M302430200; Ma Q, 1997, J BIOL CHEM, V272, P8878; MANCHESTER DK, 1987, CANCER RES, V47, P4861; McDonough H, 2003, CELL STRESS CHAPERON, V8, P303, DOI 10.1379/1466-1268(2003)008<0303:CALBTC>2.0.CO;2; Meyer BK, 2000, CELL STRESS CHAPERON, V5, P243, DOI 10.1379/1466-1268(2000)005<0243:AHARLA>2.0.CO;2; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Meyer BK, 1999, BIOCHEMISTRY-US, V38, P8907, DOI 10.1021/bi982223w; MILLER AG, 1983, J BIOL CHEM, V258, P3523; Petrulis JR, 2000, J BIOL CHEM, V275, P37448, DOI 10.1074/jbc.M006873200; Petrulis JR, 2003, J BIOL CHEM, V278, P2677, DOI 10.1074/jbc.M209331200; Petrulis JR, 2002, CHEM-BIOL INTERACT, V141, P25, DOI 10.1016/S0009-2797(02)00064-9; POLAND A, 1990, MOL PHARMACOL, V38, P306; POLAND A, 1994, MOL PHARMACOL, V46, P915; Pollenz RS, 1998, TOXICOL SCI, V42, P117; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; Pollenz RS, 1996, MOL PHARMACOL, V49, P391; Ramadoss P, 2004, MOL PHARMACOL, V66, P129, DOI 10.1124/mol.66.1.129; Ramadoss P, 2004, BIOCHEMISTRY-US, V43, P700, DOI 10.1021/bi035827v; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Richter CA, 2001, ARCH BIOCHEM BIOPHYS, V389, P207, DOI 10.1006/abbi.2001.2339; Roberts BJ, 1999, J BIOL CHEM, V274, P36351, DOI 10.1074/jbc.274.51.36351; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Song ZJ, 2003, MOL PHARMACOL, V63, P597, DOI 10.1124/mol.63.3.597; Song ZJ, 2002, MOL PHARMACOL, V62, P806, DOI 10.1124/mol.62.4.806; SWANSON HI, 1993, ARCH BIOCHEM BIOPHYS, V302, P167, DOI 10.1006/abbi.1993.1195; Verma S, 2004, MOL CELL BIOL, V24, P8716, DOI 10.1128/MCB.24.19.8716-8726.2004; Wang S, 2004, J BIOL CHEM, V279, P13593, DOI 10.1074/jbc.M312274200; Wentworth JN, 2004, BIOCHEM PHARMACOL, V67, P1363, DOI 10.1016/j.bcp.2003.12.002; Yan F, 2003, MOL ENDOCRINOL, V17, P1315, DOI 10.1210/me.2002-0209	51	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33346	33356		10.1074/jbc.M506619200	http://dx.doi.org/10.1074/jbc.M506619200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16085934	hybrid			2022-12-27	WOS:000232058100032
J	Larance, M; Ramm, G; Stockli, J; van Dam, EM; Winata, S; Wasinger, V; Simpson, F; Graham, M; Junutula, JR; Guilhaus, M; James, DE				Larance, M; Ramm, G; Stockli, J; van Dam, EM; Winata, S; Wasinger, V; Simpson, F; Graham, M; Junutula, JR; Guilhaus, M; James, DE			Characterization of the role of the Rab GTPase-activating protein AS160 in insulin-regulated GLUT4 trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER GLUT4; PLASMA-MEMBRANE; 3T3-L1 ADIPOCYTES; GOLGI NETWORK; CELL-SURFACE; TRANSFERRIN RECEPTORS; SYNAPTIC VESICLES; STORAGE-VESICLES; MAJOR PROTEIN; TRANSLOCATION	Insulin stimulates the translocation of the glucose transporter GLUT4 from intracellular vesicles to the plasma membrane. In the present study we have conducted a comprehensive proteomic analysis of affinity-purified GLUT4 vesicles from 3T3-L1 adipocytes to discover potential regulators of GLUT4 trafficking. In addition to previously identified components of GLUT4 storage vesicles including the insulin-regulated aminopeptidase insulin-regulated aminopeptidase and the vesicle soluble N-ethylmaleimide factor attachment protein (v-SNARE) VAMP2, we have identified three new Rab proteins, Rab10, Rab11, and Rab14, on GLUT4 vesicles. We have also found that the putative Rab GTPase-activating protein AS160 (Akt substrate of 160 kDa) is associated with GLUT4 vesicles in the basal state and dissociates in response to insulin. This association is likely to be mediated by the cytosolic tail of insulin-regulated aminopeptidase, which interacted both in vitro and in vivo with AS160. Consistent with an inhibitory role of AS160 in the basal state, reduced expression of AS160 in adipocytes using short hairpin RNA increased plasma membrane levels of GLUT4 in an insulin-independent manner. These findings support an important role for AS160 in the insulin regulated trafficking of GLUT4.	Garvan Inst Med Res, Diabet & Obes Program, Sydney, NSW 2010, Australia; Univ New S Wales, Bioanalyt Mass Spectrometry Facil, Sydney, NSW 2052, Australia; Univ Queensland, Inst Mol Biol, Brisbane, Qld 4072, Australia; Benitec Inc, Mountain View, CA 94043 USA; Genentech Inc, San Francisco, CA 94080 USA	Garvan Institute of Medical Research; University of New South Wales Sydney; University of Queensland; Roche Holding; Genentech	James, DE (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Diabet & Obes Program, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	d.james@garvan.org.au	Larance, Mark/AAG-8613-2019; Stoeckli, Jacqueline/Z-4443-2019; Wasinger, Valerie/AAC-5004-2021; Stoeckli, Jacqueline/D-7053-2016; Simpson, Fiona/ABE-1276-2020; Junutula, Jagath Reddy/ABD-4753-2020; Simpson, Fiona/J-2721-2012	Stoeckli, Jacqueline/0000-0002-6446-7350; Wasinger, Valerie/0000-0001-5338-0869; Stoeckli, Jacqueline/0000-0002-6446-7350; Simpson, Fiona/0000-0002-0271-781X; Junutula, Jagath Reddy/0000-0002-5942-4428; Simpson, Fiona/0000-0002-0271-781X; Ramm, Georg/0000-0003-3596-2288; James, David/0000-0001-5946-5257; Larance, Mark/0000-0002-8579-2267				Al-Hasani H, 1998, J BIOL CHEM, V273, P17504, DOI 10.1074/jbc.273.28.17504; Antonin W, 2000, J NEUROSCI, V20, P5724, DOI 10.1523/JNEUROSCI.20-15-05724.2000; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; Bock JB, 1997, MOL BIOL CELL, V8, P2461; Bose A, 2004, MOL CELL BIOL, V24, P5447, DOI 10.1128/MCB.24.12.5447-5458.2004; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CHANEY LK, 1983, J BIOL CHEM, V258, P62; CHEN YT, 1993, P NATL ACAD SCI USA, V90, P6508, DOI 10.1073/pnas.90.14.6508; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Cormont M, 1996, ENDOCRINOLOGY, V137, P3408, DOI 10.1210/en.137.8.3408; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; Davey KAB, 2004, J MOL CELL CARDIOL, V37, P264; Fernandez-Chacon R, 2000, J NEUROSCI, V20, P7941; Foran PGP, 1999, J BIOL CHEM, V274, P28087, DOI 10.1074/jbc.274.40.28087; Govers R, 2004, MOL CELL BIOL, V24, P6456, DOI 10.1128/MCB.24.14.6456-6466.2004; Guilherme A, 2000, J BIOL CHEM, V275, P38151, DOI 10.1074/jbc.M003432200; Guo W, 1999, EMBO J, V18, P1071, DOI 10.1093/emboj/18.4.1071; HANPETER D, 1995, MOL MEMBR BIOL, V12, P263, DOI 10.3109/09687689509072426; Hashiramoto M, 2000, MOL CELL BIOL, V20, P416, DOI 10.1128/MCB.20.1.416-427.2000; Huang J, 2001, P NATL ACAD SCI USA, V98, P13084, DOI 10.1073/pnas.241368698; Imamura T, 2003, MOL CELL BIOL, V23, P4892, DOI 10.1128/MCB.23.14.4892-4900.2003; Inoue M, 2003, NATURE, V422, P629, DOI 10.1038/nature01533; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; Junutula JR, 2004, MOL BIOL CELL, V15, P2218, DOI 10.1091/mbc.E03-10-0777; Kalinina EV, 2003, J BIOL CHEM, V278, P9244, DOI 10.1074/jbc.M209379200; Kanda H, 2005, J CLIN INVEST, V115, P291, DOI 10.1172/JCI200522681; Kandror KV, 1996, J BIOL CHEM, V271, P21703, DOI 10.1074/jbc.271.36.21703; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; Karylowski O, 2004, MOL BIOL CELL, V15, P870, DOI 10.1091/mbc.E03-07-0517; Keller SR, 2002, J BIOL CHEM, V277, P17677, DOI 10.1074/jbc.M202037200; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; Kessler A, 2000, DIABETOLOGIA, V43, P1518, DOI 10.1007/s001250051563; Kratchmarova I, 2002, MOL CELL PROTEOMICS, V1, P213, DOI 10.1074/mcp.M200006-MCP200; Kupriyanova TA, 2002, J BIOL CHEM, V277, P9133, DOI 10.1074/jbc.M106999200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE SM, 1993, J BIOL CHEM, V268, P19110; Lee SM, 2004, BIOCHEM BIOPH RES CO, V324, P768, DOI 10.1016/j.bbrc.2004.09.118; Li L, 2001, J BIOL CHEM, V276, P5265, DOI 10.1074/jbc.M003883200; Ligos JM, 1998, BIOCHEM BIOPH RES CO, V249, P380, DOI 10.1006/bbrc.1998.9163; Livingstone C, 1996, BIOCHEM J, V315, P487, DOI 10.1042/bj3150487; Maffucci T, 2003, EMBO J, V22, P4178, DOI 10.1093/emboj/cdg402; Malide D, 2000, J CELL SCI, V113, P4203; Martin S, 2000, J CELL SCI, V113, P3427; MASTICK CC, 1994, J BIOL CHEM, V269, P6089; Mastick CC, 1997, ENDOCRINOLOGY, V138, P2391, DOI 10.1210/en.138.6.2391; Mesa R, 2005, EXP CELL RES, V304, P339, DOI 10.1016/j.yexcr.2004.11.017; Miinea CP, 2005, BIOCHEM J, V391, P87, DOI 10.1042/BJ20050887; Millar CA, 1999, MOL BIOL CELL, V10, P3675, DOI 10.1091/mbc.10.11.3675; Mora S, 2002, DIABETES-METAB RES, V18, P345, DOI 10.1002/dmrr.321; Morel N, 2003, J CELL SCI, V116, P4751, DOI 10.1242/jcs.00791; Morris NJ, 1997, J BIOL CHEM, V272, P9388; Morris NJ, 1998, J BIOL CHEM, V273, P3582, DOI 10.1074/jbc.273.6.3582; Nielsen MS, 2001, EMBO J, V20, P2180, DOI 10.1093/emboj/20.9.2180; Parton RG, 2002, J BIOL CHEM, V277, P46769, DOI 10.1074/jbc.M205683200; Petris MJ, 2002, J BIOL CHEM, V277, P46736, DOI 10.1074/jbc.M208864200; Ralston E, 1996, J CELL SCI, V109, P2967; Ramm G, 2000, MOL BIOL CELL, V11, P4079, DOI 10.1091/mbc.11.12.4079; Randhawa VK, 2000, MOL BIOL CELL, V11, P2403, DOI 10.1091/mbc.11.7.2403; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; Rice RR, 2005, METHOD ENZYMOL, V392, P405, DOI 10.1016/S0076-6879(04)92024-1; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; Sanchez-Pulido L, 2002, TRENDS BIOCHEM SCI, V27, P599, DOI 10.1016/S0968-0004(02)02229-6; Sano H, 2003, J BIOL CHEM, V278, P14599, DOI 10.1074/jbc.C300063200; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; Shewan AM, 2003, MOL BIOL CELL, V14, P973, DOI 10.1091/mbc.E02-06-0315; Simonsen A, 1998, EUR J CELL BIOL, V75, P223, DOI 10.1016/S0171-9335(98)80116-7; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Stockinger W, 2002, EMBO J, V21, P4259, DOI 10.1093/emboj/cdf435; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TANNER LI, 1987, J BIOL CHEM, V262, P8975; Tellam JT, 1997, J BIOL CHEM, V272, P6187, DOI 10.1074/jbc.272.10.6187; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; Trischler M, 1999, J CELL SCI, V112, P4773; van Dam EM, 2005, MOL ENDOCRINOL, V19, P1067, DOI 10.1210/me.2004-0413; Varadi A, 2004, J CELL SCI, V117, P4389, DOI 10.1242/jcs.01299; Waguri S, 2003, MOL BIOL CELL, V14, P142, DOI 10.1091/mbc.E02-06-0338; Wasiak S, 2002, J CELL BIOL, V158, P855, DOI 10.1083/jcb.200205078; Waters SB, 1997, J BIOL CHEM, V272, P23323, DOI 10.1074/jbc.272.37.23323; Zeigerer A, 2002, MOL BIOL CELL, V13, P2421, DOI 10.1091/mbc.E02-02-0071; Zeigerer A, 2004, MOL BIOL CELL, V15, P4406, DOI 10.1091/mbc.e04-04-0333	83	300	309	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37803	37813		10.1074/jbc.M503897200	http://dx.doi.org/10.1074/jbc.M503897200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16154996	hybrid			2022-12-27	WOS:000233044500060
J	Ray, K; Tisdale, J; Dodd, RH; Dauban, P; Ruat, M; Northup, JK				Ray, K; Tisdale, J; Dodd, RH; Dauban, P; Ruat, M; Northup, JK			Calindol, a positive allosteric modulator of the human Ca2+ receptor, activates an extracellular ligand-binding domain-deleted rhodopsin-like seven-transmembrane structure in the absence of Ca2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE-RECEPTOR; CALCIUM-SENSING RECEPTOR; CELL-SURFACE EXPRESSION; PROTEIN-COUPLED RECEPTORS; TRANSMEMBRANE DOMAIN; GABA(B) RECEPTOR; CA2+-SENSING RECEPTOR; CALCIMIMETIC COMPOUND; HEPTAHELICAL DOMAIN; SIGNAL-TRANSDUCTION	The extracellular calcium-sensing human Ca2+ receptor (hCaR),(2) a member of the family-3 G-protein-coupled receptors ( GPCR) possesses a large amino-terminal extracellular ligand-binding domain (ECD) in addition to a seven-transmembrane helical domain (7TMD) characteristic of all GPCRs. Two calcimimetic allosteric modulators, NPS R- 568 and Calindol (( R)- 2-{1-(1-naphthyl) ethylaminomethyl} indole), that bind the 7TMD of the hCaR have been reported to potentiate Ca2+ activation without independently activating the wild type receptor. Because agonists activate rhodopsin-like family-1 GPCRs by binding within the 7TMD, we examined the ability of Calindol, a novel chemically distinct calcimimetic, to activate a Ca2+ receptor construct (T903-Rhoc) in which the ECD and carboxyl-terminal tail have been deleted to produce a rhodopsin-like 7TMD. Here we report that although Calindol has little or no agonist activity in the absence of extracellular Ca2+ for the ECD-containing wild type or carboxyl-terminal deleted receptors, it acts as a strong agonist of the T903-Rhoc. In addition, Ca2+ alone displays little or no agonist activity for the hCaR 7TMD, but potentiates the activation by Calindol. We confirm that the activation of T903-Rhoc by Calindol is truly Ca2+ independent using in vitro reconstitution with purified G(q). These findings demonstrate distinct allosteric linkages between Ca2+ site(s) in the ECD and 7TMD and the 7TMD site( s) for calcimimetics.	NIDCD, Lab Cellular Biol, NIH, Bethesda, MD 20892 USA; CNRS, UPR 9040, Signal Transduct & Dev Neuropharmacol, F-91198 Gif Sur Yvette, France; CNRS, IFR 2118, Inst Neurobiol Alfred Fessard, F-91198 Gif Sur Yvette, France; CNRS, UPR 2301, Inst Chim Subst Nat, F-91198 Gif Sur Yvette, France	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universite Paris Saclay	Ray, K (corresponding author), 5 Res Ct,Rm 2A11, Rockville, MD 20850 USA.	rayk@nidcd.nih.gov	Ruat, Martial/E-5544-2016		Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Binet V, 2004, J BIOL CHEM, V279, P29085, DOI 10.1074/jbc.M400930200; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Chandrashekar J, 2000, CELL, V100, P703, DOI 10.1016/S0092-8674(00)80706-0; FAWZI AB, 1990, BIOCHEMISTRY-US, V29, P3804, DOI 10.1021/bi00467a030; Galvez T, 1999, J BIOL CHEM, V274, P13362, DOI 10.1074/jbc.274.19.13362; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Goudet C, 2004, P NATL ACAD SCI USA, V101, P378, DOI 10.1073/pnas.0304699101; Hammerland LG, 1999, MOL PHARMACOL, V55, P642; Han GM, 1999, J BIOL CHEM, V274, P10008, DOI 10.1074/jbc.274.15.10008; Hartman JL, 1996, J BIOL CHEM, V271, P22591, DOI 10.1074/jbc.271.37.22591; Hauache OM, 2000, ENDOCRINOLOGY, V141, P4156, DOI 10.1210/en.141.11.4156; Jian XY, 1999, J BIOL CHEM, V274, P11573, DOI 10.1074/jbc.274.17.11573; Kessler A, 2004, CHEMBIOCHEM, V5, P1131, DOI 10.1002/cbic.200400049; Kessler A, 2004, BIOORG MED CHEM LETT, V14, P3345, DOI 10.1016/j.bmcl.2004.03.056; Kew JNC, 2004, PHARMACOL THERAPEUT, V104, P233, DOI 10.1016/j.pharmthera.2004.08.010; Krautwurst D, 1998, CELL, V95, P917, DOI 10.1016/S0092-8674(00)81716-X; Kubo Y, 1998, SCIENCE, V279, P1722, DOI 10.1126/science.279.5357.1722; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Miedlich SU, 2004, J BIOL CHEM, V279, P7254, DOI 10.1074/jbc.M307191200; Nemeth EF, 2001, J PHARMACOL EXP THER, V299, P323; Nemeth EF, 1998, P NATL ACAD SCI USA, V95, P4040, DOI 10.1073/pnas.95.7.4040; NEMETH EF, 1999, TRENDS ENDOCRIN MET, V10, P239; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Petrel C, 2004, J BIOL CHEM, V279, P18990, DOI 10.1074/jbc.M400724200; Petrel C, 2003, J BIOL CHEM, V278, P49487, DOI 10.1074/jbc.M308010200; Ray K, 1998, J BIOL CHEM, V273, P34558, DOI 10.1074/jbc.273.51.34558; Ray K, 1997, J BIOL CHEM, V272, P31355, DOI 10.1074/jbc.272.50.31355; Ray K, 2004, ENDOCRINOLOGY, V145, P3892, DOI 10.1210/en.2003-1653; Ray K, 2002, J BIOL CHEM, V277, P18908, DOI 10.1074/jbc.M202113200; RAY K, 2001, INT ARCH BIOSCI, P1027; Schaffhauser H, 2003, MOL PHARMACOL, V64, P798, DOI 10.1124/mol.64.4.798; Wise A, 1999, NEUROPHARMACOLOGY, V38, P1647, DOI 10.1016/S0028-3908(99)00119-7; Zhao XM, 1999, FEBS LETT, V448, P180, DOI 10.1016/S0014-5793(99)00368-3	35	46	46	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37013	37020		10.1074/jbc.M506681200	http://dx.doi.org/10.1074/jbc.M506681200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16135510	hybrid			2022-12-27	WOS:000232901800059
J	D'Eon, TM; Souza, SC; Aronovitz, M; Obin, MS; Fried, SK; Greenberg, AS				D'Eon, TM; Souza, SC; Aronovitz, M; Obin, MS; Fried, SK; Greenberg, AS			Estrogen regulation of adiposity and fuel partitioning - Evidence of genomic and non-genomic regulation of lipogenic and oxidative pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE REPLACEMENT THERAPY; ACTIVATED PROTEIN-KINASE; EARLY POSTMENOPAUSAL WOMEN; CONGENITAL AROMATASE DEFICIENCY; ABDOMINAL FAT DISTRIBUTION; DIET-INDUCED OBESITY; RECEPTOR-ALPHA; BODY-COMPOSITION; ADIPOCYTE LIPOLYSIS; METABOLIC SYNDROME	Menopause is associated with increased adiposity and greater risk of metabolic disease. In the ovariectomized (OVX) rodent model of menopause, increased adiposity is prevented by estrogen (E2) replacement, reflecting both anorexigenic and potentially metabolic actions of E2. To elucidate metabolic and molecular mechanisms by which E2 regulates fat storage and fat mobilization independently of reduced energy intake, C57 BL/6 mice were ovariectomized, randomized to estrogen (OVX-E2) or control pellet implants (OVX-C), and pairfed for 40 days. E2 treatment was associated with reduced adipose mass and adipocyte size and downregulation of lipogenic genes in adipocytes under the control of sterol-regulatory element-binding protein 1c. Adipocytes of OVX-E2 mice contained > 3-fold more perilipin protein than adipocytes of pairfed control ( OVX) mice, and this difference was associated with enhanced ex vivo lipolytic response to catecholamines and with greater levels of serum-free fatty acids following fasting. As in adipose tissue, E2 decreased the expression of lipogenic genes in liver and skeletal muscle. In the latter, E2 appears to promote the partitioning of free fatty acids toward oxidation and away from triglyceride storage by up-regulating the expression of peroxisome proliferation activator receptor-delta and its downstream targets and also by directly and rapidly activating AMP-activated protein kinase. Thus, novel genomic and non-genomic actions of E2 promote leanness in OVX mice independently of reduced energy intake.	Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Tufts New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA; Univ Maryland, Sch Med, Dept Med, Div Gerontol, Baltimore, MD 21201 USA; Baltimore Vet Affairs Med Ctr, Baltimore, MD 21201 USA	Tufts University; United States Department of Agriculture (USDA); Tufts Medical Center; University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baltimore VA Medical Center	Greenberg, AS (corresponding author), Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA.	Andrew.greenberg@tufts.edu		Fried, Susan K./0000-0003-1101-9332				Bajic VB, 2003, NUCLEIC ACIDS RES, V31, P3605, DOI 10.1093/nar/gkg517; Banerjee RR, 2004, SCIENCE, V303, P1195, DOI 10.1126/science.1092341; Bastie CC, 2005, J BIOL CHEM, V280, P14222, DOI 10.1074/jbc.M413625200; Bjornstrom L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486; Campbell SE, 2003, J MOL ENDOCRINOL, V31, P37, DOI 10.1677/jme.0.0310037; Carr MC, 2003, J CLIN ENDOCR METAB, V88, P2404, DOI 10.1210/jc.2003-030242; Cooke PS, 2004, EXP BIOL MED, V229, P1127, DOI 10.1177/153537020422901107; Darimont C, 1997, ENDOCRINOLOGY, V138, P1092, DOI 10.1210/en.138.3.1092; DIGIROLAMO M, 1971, AM J PHYSIOL, V221, P850, DOI 10.1152/ajplegacy.1971.221.3.850; Djouadi F, 1998, J CLIN INVEST, V102, P1083, DOI 10.1172/JCI3949; Dressel U, 2003, MOL ENDOCRINOL, V17, P2477, DOI 10.1210/me.2003-0151; Field FJ, 2002, BIOCHEM J, V368, P855, DOI 10.1042/BJ20020731; Gambacciani M, 2001, MATURITAS, V39, P125, DOI 10.1016/S0378-5122(01)00194-3; Gregoire FM, 2002, AM J PHYSIOL-ENDOC M, V282, pE703, DOI 10.1152/ajpendo.00072.2001; Heine PA, 2000, P NATL ACAD SCI USA, V97, P12729, DOI 10.1073/pnas.97.23.12729; Herrmann BL, 2005, HORM METAB RES, V37, P178, DOI 10.1055/s-2005-861292; Herrmann BL, 2002, J CLIN ENDOCR METAB, V87, P5476, DOI 10.1210/jc.2002-020498; HONNOR RC, 1985, J BIOL CHEM, V260, P5122; Horton JD, 2002, BIOCHEM SOC T, V30, P1091, DOI 10.1042/bst0301091; Jensen L, 2003, J BONE MINER RES, V18, P333, DOI 10.1359/jbmr.2003.18.2.333; Jones MEE, 2000, P NATL ACAD SCI USA, V97, P12735, DOI 10.1073/pnas.97.23.12735; Jones MEE, 2001, J STEROID BIOCHEM, V79, P3, DOI 10.1016/S0960-0760(01)00136-4; Karas RH, 2001, CIRC RES, V89, P534, DOI 10.1161/hh1801.097239; Kelly M, 2004, BIOCHEM BIOPH RES CO, V320, P449, DOI 10.1016/j.bbrc.2004.05.188; Kelly MJ, 2001, TRENDS ENDOCRIN MET, V12, P152, DOI 10.1016/S1043-2760(01)00377-0; Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395; Kliewer SA, 2001, RECENT PROG HORM RES, V56, P239, DOI 10.1210/rp.56.1.239; Krauss S, 2005, NAT REV MOL CELL BIO, V6, P248, DOI 10.1038/nrm1592; KritzSilverstein D, 1996, JAMA-J AM MED ASSOC, V275, P46; LAZZARINI SJ, 1991, AM J PHYSIOL, V260, pR47, DOI 10.1152/ajpregu.1991.260.1.R47; Liang YQ, 2002, INT J OBESITY, V26, P1103, DOI 10.1038/sj.ijo.0802054; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lundholm L, 2004, J MOL ENDOCRINOL, V32, P879, DOI 10.1677/jme.0.0320879; Luquet S, 2003, FASEB J, V17, P2299, DOI 10.1096/fj.03-0269fje; Margolis KL, 2004, DIABETOLOGIA, V47, P1175, DOI 10.1007/s00125-004-1448-x; Meli R, 2004, ENDOCRINOLOGY, V145, P3115, DOI 10.1210/en.2004-0129; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Misso ML, 2003, ENDOCRINOLOGY, V144, P1474, DOI 10.1210/en.2002-221123; Mottagui-Tabar S, 2003, DIABETOLOGIA, V46, P789, DOI 10.1007/s00125-003-1112-x; Muoio DM, 2002, J BIOL CHEM, V277, P26089, DOI 10.1074/jbc.M203997200; PAPPAS TC, 1995, FASEB J, V9, P404, DOI 10.1096/fasebj.9.5.7896011; Park YW, 2003, ARCH INTERN MED, V163, P427, DOI 10.1001/archinte.163.4.427; Perrone G, 1999, GYNECOL OBSTET INVES, V48, P52, DOI 10.1159/000010134; Pold R, 2005, DIABETES, V54, P928, DOI 10.2337/diabetes.54.4.928; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; REUBINOFF BE, 1995, FERTIL STERIL, V64, P963, DOI 10.1016/S0015-0282(16)57910-2; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; RICHARD D, 1986, AM J PHYSIOL, V250, pR245, DOI 10.1152/ajpregu.1986.250.2.R245; Sayegh RA, 1999, MENOPAUSE, V6, P312, DOI 10.1097/00042192-199906040-00007; Schulz E, 2005, CIRCULATION, V111, P3473, DOI 10.1161/CIRCULATIONAHA.105.546812; Seo JB, 2004, J BIOL CHEM, V279, P22108, DOI 10.1074/jbc.M400238200; Shih HH, 1998, MOL CELL BIOL, V18, P4732, DOI 10.1128/MCB.18.8.4732; Shimomura K, 2002, ENDOCR J, V49, P417, DOI 10.1507/endocrj.49.417; Shulman GI, 2004, PHYSIOLOGY, V19, P183, DOI 10.1152/physiol.00007.2004; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; Souza SC, 2002, J BIOL CHEM, V277, P8267, DOI 10.1074/jbc.M108329200; SPACEIIIQQ AJE, 2005, STEROIDS, V70, P361; Sugden MC, 2003, AM J PHYSIOL-ENDOC M, V284, pE855, DOI 10.1152/ajpendo.00526.2002; SULLIVAN TR, 1995, J CLIN INVEST, V96, P2482, DOI 10.1172/JCI118307; Sumino H, 2003, INT J OBESITY, V27, P1044, DOI 10.1038/sj.ijo.0802371; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Tchernof A, 2004, J CLIN ENDOCR METAB, V89, P3425, DOI 10.1210/jc.2003-031561; Tchernof A, 1998, OBES RES, V6, P246, DOI 10.1002/j.1550-8528.1998.tb00344.x; Thomas P, 2005, ENDOCRINOLOGY, V146, P624, DOI 10.1210/en.2004-1064; Tomas E, 2002, P NATL ACAD SCI USA, V99, P16309, DOI 10.1073/pnas.222657499; Toth MJ, 2000, INT J OBESITY, V24, P226, DOI 10.1038/sj.ijo.0801118; WADE GN, 1985, INT J OBESITY, V9, P83; Wang YX, 2003, OBES RES, V11, P930, DOI 10.1038/oby.2003.128; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Zhang HH, 2003, J BIOL CHEM, V278, P51535, DOI 10.1074/jbc.M309591200; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505	71	386	395	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35983	35991		10.1074/jbc.M507339200	http://dx.doi.org/10.1074/jbc.M507339200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16109719	hybrid			2022-12-27	WOS:000232726900026
J	Fulton, D; Church, JE; Ruan, L; Li, CY; Sood, SG; Kemp, BE; Jennings, IG; Venema, RC				Fulton, D; Church, JE; Ruan, L; Li, CY; Sood, SG; Kemp, BE; Jennings, IG; Venema, RC			Src kinase activates endothelial nitric-oxide synthase by phosphorylating Tyr-83	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUID SHEAR-STRESS; AKT-DEPENDENT PHOSPHORYLATION; TYROSINE PHOSPHORYLATION; PROTEIN-KINASE; HYDROGEN-PEROXIDE; GROWTH-FACTOR; C-SRC; CELLS; IDENTIFICATION; DEPHOSPHORYLATION	The endothelial nitric-oxide synthase ( eNOS) is regulated in part by serine/threonine phosphorylation, but eNOS tyrosine phosphorylation is less well understood. In the present study we have examined the tyrosine phosphorylation of eNOS in bovine aortic endothelial cells (BAECs) exposed to oxidant stress. Hydrogen peroxide and pervanadate (PV) treatment stimulates eNOS tyrosine phosphorylation in BAECs. Phosphorylation is blocked by the Src kinase family inhibitor, 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[ 3,4-d] pyrimidine (PP2). Moreover, eNOS and c-Src can be coimmunoprecipitated from BAEC lysates by antibodies directed against either protein. Domain mapping and site-directed mutagenesis studies in COS-7 cells transfected with either eNOS alone and then treated with PV or cotransfected with eNOS and constitutively active v-Src identified Tyr-83 ( bovine sequence) as the major eNOS tyrosine phosphorylation site. Tyr-83 phosphorylation is associated with a 3-fold increase in basal NO release from cotransfected cells. Furthermore, the Y83F eNOS mutation attenuated thapsigargin-stimulated NO production. Taken together, these data indicate that Src-mediated tyrosine phosphorylation of eNOS at Tyr-83 modulates eNOS activity in endothelial cells.	Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pediat, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pharmacol, Augusta, GA 30912 USA; St Vincents Inst, Fitzroy, Vic 3065, Australia; CSIRO Mol & Hlth Technol, Fitzroy, Vic 3065, Australia	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; St. Vincent's Institute of Medical Research; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Fulton, D (corresponding author), Med Coll Georgia, Vasc Biol Ctr, 1459 Laney Walker Blvd, Augusta, GA 30912 USA.	dfulton@mcg.edu; rvenema@mcg.edu	Kemp, Bruce E/L-2633-2014; Kemp, Bruce/G-9602-2019	Kemp, Bruce E/0000-0001-6735-5082; Kemp, Bruce/0000-0001-6735-5082; Jennings, Ian/0000-0002-4781-9465; Church, Jarrod/0000-0001-8266-4043	NHLBI NIH HHS [HL74279, HL72768] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072768, R01HL074279] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Ayajiki K, 1996, CIRC RES, V78, P750, DOI 10.1161/01.RES.78.5.750; Boo YC, 2003, AM J PHYSIOL-CELL PH, V285, pC499, DOI 10.1152/ajpcell.00122.2003; Cai H, 2002, J BIOL CHEM, V277, P48311, DOI 10.1074/jbc.M208884200; Cai H, 2003, MOL PHARMACOL, V63, P325, DOI 10.1124/mol.63.2.325; Corson MA, 1996, CIRC RES, V79, P984, DOI 10.1161/01.RES.79.5.984; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fisslthaler B, 2000, ACTA PHYSIOL SCAND, V168, P81; Fleming I, 1998, CIRC RES, V82, P686, DOI 10.1161/01.RES.82.6.686; Fleming I, 2001, CIRC RES, V88, pE68, DOI 10.1161/hh1101.092677; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Harris MB, 2001, J BIOL CHEM, V276, P16587, DOI 10.1074/jbc.M100229200; Haynes MP, 2003, J BIOL CHEM, V278, P2118, DOI 10.1074/jbc.M210828200; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Jin ZG, 2003, CIRC RES, V93, P354, DOI 10.1161/01.RES.0000089257.94002.96; KEMP BE, 1976, P NATL ACAD SCI USA, V73, P1038, DOI 10.1073/pnas.73.4.1038; Kou RQ, 2002, J BIOL CHEM, V277, P29669, DOI 10.1074/jbc.M204519200; Li HY, 2005, J INORG BIOCHEM, V99, P293, DOI 10.1016/j.jinorgbio.2004.10.016; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200; Michell BJ, 2002, J BIOL CHEM, V277, P42344, DOI 10.1074/jbc.M205144200; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; Papapetropoulos A, 2004, MOL PHARMACOL, V65, P407, DOI 10.1124/mol.65.2.407; Takenouchi Y, 2004, ONCOL REP, V11, P1059; Thomas SR, 2002, J BIOL CHEM, V277, P6017, DOI 10.1074/jbc.M109107200; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; Venema VJ, 1998, BIOCHEM BIOPH RES CO, V246, P70, DOI 10.1006/bbrc.1998.8574	33	84	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35943	35952		10.1074/jbc.M504606200	http://dx.doi.org/10.1074/jbc.M504606200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16123043	hybrid			2022-12-27	WOS:000232726900021
J	Hui, L; Rodrik, V; Pielak, RM; Knirr, S; Zheng, Y; Foster, DA				Hui, L; Rodrik, V; Pielak, RM; Knirr, S; Zheng, Y; Foster, DA			mTOR-dependent suppression of protein phosphatase 2A is critical for phospholipase D survival signals in human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION; PATHWAY; ANTIGEN; KINASE; GROWTH; BAD; PHOSPHORYLATION; COMPLEXES	A critical aspect of tumor progression is the generation of survival signals that overcome default apoptotic programs. Recent studies have revealed that elevated phospholipase D activity generates survival signals in breast and perhaps other human cancers. We report here that the elevated phospholipase D activity in the human breast cancer cell line MDA-MB-231 suppresses the activity of the putative tumor suppressor protein phosphatase 2A in a mammalian target of rapamycin ( mTOR)-dependent manner. Increasing the phospholipase D activity in MCF7 cells also suppressed protein phosphatase 2A activity. Elevated phospholipase D activity suppressed association of protein phosphatase 2A with both ribosomal subunit S6-kinase and eukaryotic initiation factor 4E-binding protein 1. Suppression of protein phosphatase 2A by SV40 small t-antigen has been reported to be critical for the transformation of human cells with SV40 early region genes. Consistent with a critical role for protein phosphatase 2A in phospholipase D survival signals, either SV40 small t-antigen or pharmacological suppression of protein phosphatase 2A restored survival signals lost by the suppression of either phospholipase D or mTOR. Blocking phospholipase D signals also led to reduced phosphorylation of the pro-apoptotic protein BAD at the protein phosphatase 2A dephosphorylation site at Ser-112. The ability of phospholipase D to suppress protein phosphatase 2A identifies a critical target of an emerging phospholipase D/mTOR survival pathway in the transformation of human cells.	CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY)	Foster, DA (corresponding author), CUNY Hunter Coll, Dept Biol Sci, 695 Pk Ave, New York, NY 10021 USA.	foster@genectr.hunter.cuny.edu	Pielak, Rafal/B-2761-2013		NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RR-03037] Funding Source: Medline; NIGMS NIH HHS [GM60654] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046677, R29CA046677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM060654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anthony B, 1996, INT J CANCER, V65, P858, DOI 10.1002/(SICI)1097-0215(19960315)65:6<858::AID-IJC25>3.0.CO;2-Z; Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; BALLOU LM, 1988, J BIOL CHEM, V263, P1188; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chen W, 2003, HISTOL HISTOPATHOL, V18, P541, DOI 10.14670/HH-18.541; Chen YH, 2005, ONCOGENE, V24, P672, DOI 10.1038/sj.onc.1208099; Chen YH, 2003, ONCOGENE, V22, P3937, DOI 10.1038/sj.onc.1206565; Chiang CW, 2003, MOL CELL BIOL, V23, P6350, DOI 10.1128/MCB.23.18.6350-6362.2003; Chiang CW, 2001, BLOOD, V97, P1289, DOI 10.1182/blood.V97.5.1289; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Fang YM, 2003, CURR BIOL, V13, P2037, DOI 10.1016/j.cub.2003.11.021; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; FAVRE B, 1994, J BIOL CHEM, V269, P16311; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Foster DA, 2003, MOL CANCER RES, V1, P789; Foster David A, 2004, Expert Rev Anticancer Ther, V4, P691, DOI 10.1586/14737140.4.4.691; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hui L, 2004, MOL CELL BIOL, V24, P5677, DOI 10.1128/MCB.24.13.5677-5686.2004; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Joseph T, 2001, BIOCHEM BIOPH RES CO, V289, P1019, DOI 10.1006/bbrc.2001.6118; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; Lu ZM, 2000, MOL CELL BIOL, V20, P462, DOI 10.1128/MCB.20.2.462-467.2000; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Polunovsky VA, 2000, J BIOL CHEM, V275, P24776, DOI 10.1074/jbc.M001938200; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Sawyers CL, 2003, CANCER CELL, V4, P343, DOI 10.1016/S1535-6108(03)00275-7; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Shen YJ, 2001, MOL CELL BIOL, V21, P595, DOI 10.1128/MCB.21.2.595-602.2001; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; Van Hoof C, 2004, CANCER CELL, V5, P105, DOI 10.1016/S1535-6108(04)00027-3; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhong MG, 2003, BIOCHEM BIOPH RES CO, V302, P615, DOI 10.1016/S0006-291X(03)00229-8	44	45	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35829	35835		10.1074/jbc.M504192200	http://dx.doi.org/10.1074/jbc.M504192200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16109716	hybrid			2022-12-27	WOS:000232726900009
J	Niiya, F; Xie, XZ; Lee, KS; Inoue, H; Miki, T				Niiya, F; Xie, XZ; Lee, KS; Inoue, H; Miki, T			Inhibition of cyclin-dependent kinase 1 induces cytokinesis without chromosome segregation in an ECT2 and MgcRacGAP-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCHANGE FACTOR; LIGHT-CHAIN; CLEAVAGE FURROW; CITRON KINASE; CELL-DIVISION; MYOSIN-II; RHO; PHOSPHORYLATION; SPINDLE; COMPLEX	Cleavage furrow formation marks the onset of cell division during early anaphase. The small GTPase RhoA and its regulators ECT2 and MgcRacGAP have been implicated in furrow ingression in mammalian cells, but the signaling upstream of these molecules remains unclear. We now show that the inhibition of cyclin-dependent kinase (Cdk) 1 is sufficient to initiate cytokinesis. When mitotically synchronized cells were treated with the Cdk-specific inhibitor BMI-1026, the initiation of cytokinesis was induced precociously before chromosomal separation. Cytokinesis was also induced by the Cdk1-specific inhibitor purvalanol A but not by Cdk2/Cdk5- or Cdk4-specific inhibitors. Consistent with initiation of precocious cytokinesis by Cdk1 inhibition, introduction of anti-Cdk1 monoclonal antibody resulted in cells with aberrant nuclei. Depolymerization of mitotic spindles by nocodazole inhibited BMI-1026-induced precocious cytokinesis. However, in the presence of a low concentration of nocodazole, BMI-1026 induced excessive membrane blebbing, which appeared to be caused by formation of ectopic cleavage furrows. Depletion of ECT2 or MgcRacGAP by RNA interference abolished both of the phenotypes ( precocious furrowing after nocodazole release and excessive blebbing in the presence of nocodazole). RNA interference of RhoA or expression of dominant-negative RhoA efficiently reduced both phenotypes. RhoA was localized at the cleavage furrow or at the necks of blebs. We propose that Cdk1 inactivation is sufficient to activate a signaling pathway leading to cytokinesis, which emanates from mitotic spindles and is regulated by ECT2, MgcRacGAP, and RhoA. Chemical induction of cytokinesis will be a valuable tool to study the initiation mechanism of cytokinesis.	NCI, Mol Tumor Biol Sect, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; NCI, Lab Metab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Miki, T (corresponding author), NCI, Mol Tumor Biol Sect, Cell Biol Lab, NIH, Bldg 37,Rm 2144,37 Convent Dr, Bethesda, MD 20892 USA.	toru@helix.nih.gov			Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Canman JC, 2003, NATURE, V424, P1074, DOI 10.1038/nature01860; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Echard A, 2003, CURR BIOL, V13, P373, DOI 10.1016/S0960-9822(03)00127-1; Glotzer M, 2004, J CELL BIOL, V164, P347, DOI 10.1083/jcb.200310112; Hirose K, 2001, J BIOL CHEM, V276, P5821, DOI 10.1074/jbc.M007252200; Jordan P, 1997, J CELL BIOL, V139, P1805, DOI 10.1083/jcb.139.7.1805; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; Kosako H, 1999, ONCOGENE, V18, P2783, DOI 10.1038/sj.onc.1202633; Lee JS, 2004, EXP CELL RES, V293, P275, DOI 10.1016/j.yexcr.2003.10.015; Liu XF, 2004, MOL CELL BIOL, V24, P6665, DOI 10.1128/mcb.24.15.6665-6675.2004; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Maddox AS, 2003, MOL CELL, V11, P846, DOI 10.1016/S1097-2765(03)00151-5; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; Minoshima Y, 2003, DEV CELL, V4, P549, DOI 10.1016/S1534-5807(03)00089-3; Mishima M, 2004, NATURE, V430, P908, DOI 10.1038/nature02767; O'Connell CB, 1999, J CELL BIOL, V144, P305, DOI 10.1083/jcb.144.2.305; Poperechnaya A, 2000, J CELL BIOL, V151, P697, DOI 10.1083/jcb.151.3.697; Prokopenko SN, 1999, GENE DEV, V13, P2301, DOI 10.1101/gad.13.17.2301; Saito S, 2004, J BIOL CHEM, V279, P7169, DOI 10.1074/jbc.M306725200; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; Seong YS, 2003, CANCER RES, V63, P7384; Somers WG, 2003, DEV CELL, V4, P29, DOI 10.1016/S1534-5807(02)00402-1; Straight AF, 2003, SCIENCE, V299, P1743, DOI 10.1126/science.1081412; Sumara I, 2004, CURR BIOL, V14, P1712, DOI 10.1016/j.cub.2004.09.049; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Van de Putte T, 2001, MECH DEVELOP, V102, P33, DOI 10.1016/S0925-4773(01)00279-9; Wheatley SP, 1997, J CELL BIOL, V138, P385, DOI 10.1083/jcb.138.2.385; Wong K, 2000, CELL MOTIL CYTOSKEL, V45, P121, DOI 10.1002/(SICI)1097-0169(200002)45:2<121::AID-CM4>3.3.CO;2-R; Yamashiro S, 2003, MOL BIOL CELL, V14, P1745, DOI 10.1091/mbc.E02-07-0427	34	70	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36502	36509		10.1074/jbc.M508007200	http://dx.doi.org/10.1074/jbc.M508007200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16118207	hybrid			2022-12-27	WOS:000232726900084
J	Takahashi, Y; Kikuchi, Y				Takahashi, Y; Kikuchi, Y			Yeast PIAS-type Ull1/Siz1 is composed of SUMO ligase and regulatory domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; SACCHAROMYCES-CEREVISIAE; CONJUGATING ENZYME; BUDDING YEAST; PROTEIN SMT3P; DNA-REPAIR; UBIQUITIN; MOTIF; GENE; COMPONENTS	SUMO ( small ubiquitin-like modifier)/Smt3 ( suppressor of mif two) is a member of the ubiquitin-related protein family and is known to conjugate with many proteins. In the sumoylation pathway, SUMO/Smt3 is transferred to substrate lysine residues through the thioester cascade of E1 ( activating enzyme) and E2 ( conjugating enzyme), and E3 ( SUMO ligase) functions as an adaptor between E2 and each substrate. Yeast Ull1 (ubiquitin-like protein ligase 1)/Siz1, a PIAS ( protein inhibitor of activated STAT)type SUMO ligase, modifies both cytoplasmic and nuclear proteins. In this paper, we performed a domain analysis of Ull1/Siz1 by constructing various deletion mutants. A novel conserved N-terminal domain, called PINIT, as well as the RING-like domain (SP-RING) were required for the SUMO ligase activity in the in vitro conjugation system and for interaction with Smt3 in an in vitro binding assay. The most distal N-terminal region, which contains a putative DNA-binding SAF-A/B, Acinus, and PIAS ( SAP) motif, was not required for the ligase activity but was involved in nuclear localization. A strong SUMO-binding motif was identified, which interacted with Smt3 in the two-hybrid system but was not necessary for the ligase activity. The most distal C-terminal domain was important for stable localization at the bud neck region and thereby for the substrate recognition of septins. Furthermore, the C-terminal half conferred protein instability on Ull1/Siz1. Taken together, we conclude that the SP-RING and PINIT of Ull1/Siz1 are core domains of the SUMO ligase, and the other domains are regulatory for protein stability and subcellular localization.	Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Kikuchi, Y (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	kikuchi@biol.s.u-tokyo.ac.jp						Bachant J, 2002, MOL CELL, V9, P1169, DOI 10.1016/S1097-2765(02)00543-9; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; Duval D, 2003, FEBS LETT, V554, P111, DOI 10.1016/S0014-5793(03)01116-5; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; James P, 1996, GENETICS, V144, P1425; JENSEN K, 2004, SUMOYLATION MOL BIOL; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kushnirov VV, 2000, YEAST, V16, P857, DOI 10.1002/1097-0061(20000630)16:9<857::AID-YEA561>3.0.CO;2-B; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Okubo S, 2004, J BIOL CHEM, V279, P31455, DOI 10.1074/jbc.M403561200; Reverter D, 2005, NATURE, V435, P687, DOI 10.1038/nature03588; Sasaki T, 2000, MOL CELL BIOL, V20, P7971, DOI 10.1128/MCB.20.21.7971-7979.2000; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Song J, 2004, P NATL ACAD SCI USA, V101, P14373, DOI 10.1073/pnas.0403498101; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; Takahashi Y, 1999, BIOCHEM BIOPH RES CO, V259, P582, DOI 10.1006/bbrc.1999.0821; Takahashi Y, 2003, J BIOCHEM, V133, P415, DOI 10.1093/jb/mvg054; Takahashi Y, 2001, J BIOL CHEM, V276, P48973, DOI 10.1074/jbc.M109295200; Takahashi Y, 2001, GENE, V275, P223, DOI 10.1016/S0378-1119(01)00662-X; UESONO Y, 1994, GENE, V143, P135; Zhao XL, 2005, P NATL ACAD SCI USA, V102, P4777, DOI 10.1073/pnas.0500537102	37	45	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35822	35828		10.1074/jbc.M506794200	http://dx.doi.org/10.1074/jbc.M506794200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16109721	hybrid			2022-12-27	WOS:000232726900008
J	Tefsen, B; Bos, MP; Beckers, F; Tommassen, J; de Cock, H				Tefsen, B; Bos, MP; Beckers, F; Tommassen, J; de Cock, H			MsbA is not required for phospholipid transport in Neisseria meningitidis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; ESCHERICHIA-COLI K-12; SALMONELLA-TYPHIMURIUM; BACILLUS-SUBTILIS; NULL MUTATIONS; HTRB GENE; LIPOPOLYSACCHARIDE; MUTANT; LIPIDS; TRANSLOCATION	The outer membrane of Gram-negative bacteria contains phospholipids and lipopolysaccharide (LPS) in the inner and outer leaflet, respectively. Little is known about the transport of the phospholipids from their site of synthesis to the outer membrane. The inner membrane protein MsbA of Escherichia coli, which is involved in the transport of LPS across the inner membrane, has been reported to be involved in phospholipid transport as well. Here, we have reported the construction and the characterization of a Neisseria meningitidis msbA mutant. The mutant was viable, and it showed a retarded growth phenotype and contained very low amounts of LPS. However, it produced an outer membrane, demonstrating that phospholipid transport was not affected by the mutation. Notably, higher amounts of phospholipids were produced in the msbA mutant than in its isogenic parental strain, provided that capsular biosynthesis was also disrupted. Although these results confirmed that MsbA functions in LPS transport, they also demonstrated that it is not required for phospholipid transport, at least not in N. meningitidis.	Univ Utrecht, Dept Mol Microbiol, NL-3584 CH Utrecht, Netherlands; Univ Utrecht, Inst Biomembranes, NL-3584 CH Utrecht, Netherlands	Utrecht University; Utrecht University	Tommassen, J (corresponding author), Univ Utrecht, Dept Mol Microbiol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	J.P.M.Tommassen@bio.uu.nl	Tommassen, Jan/I-1690-2016; de Cock, Hans/B-7790-2011; Tefsen, Boris/J-1503-2012	Tommassen, Jan/0000-0001-7633-4945; de Cock, Hans/0000-0002-8420-6764; Tefsen, Boris/0000-0001-6668-217X				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bos MP, 2005, INFECT IMMUN, V73, P6194, DOI 10.1128/IAI.73.9.6194-6197.2005; Bos MP, 2004, P NATL ACAD SCI USA, V101, P9417, DOI 10.1073/pnas.0402340101; Braun M, 2002, MOL MICROBIOL, V45, P1289, DOI 10.1046/j.1365-2958.2002.03091.x; Chami M, 2002, J MOL BIOL, V315, P1075, DOI 10.1006/jmbi.2001.5309; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; Cronan JE, 2003, ANNU REV MICROBIOL, V57, P203, DOI 10.1146/annurev.micro.57.030502.090851; Doerrler WT, 2004, J BIOL CHEM, V279, P45102, DOI 10.1074/jbc.M408106200; Doerrler WT, 2001, J BIOL CHEM, V276, P11461, DOI 10.1074/jbc.C100091200; Gajic O, 2003, J BIOL CHEM, V278, P34291, DOI 10.1074/jbc.M211100200; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; KAROW M, 1993, MOL MICROBIOL, V7, P69, DOI 10.1111/j.1365-2958.1993.tb01098.x; KAROW M, 1992, J BACTERIOL, V174, P7407, DOI 10.1128/jb.174.22.7407-7418.1992; Kloser A, 1998, MOL MICROBIOL, V27, P1003, DOI 10.1046/j.1365-2958.1998.00746.x; Kol MA, 2004, BIOCHEMISTRY-US, V43, P2673, DOI 10.1021/bi036200f; Kol MA, 2003, J BIOL CHEM, V278, P24586, DOI 10.1074/jbc.M301875200; LESSE AJ, 1990, J IMMUNOL METHODS, V126, P109, DOI 10.1016/0022-1759(90)90018-Q; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Rahman MM, 2000, MICROBIOL-UK, V146, P1901, DOI 10.1099/00221287-146-8-1901; Reuter G, 2003, J BIOL CHEM, V278, P35193, DOI 10.1074/jbc.M306226200; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; Seifert HS, 1997, GENE, V188, P215, DOI 10.1016/S0378-1119(96)00810-4; Seigneuret M, 2003, J BIOL CHEM, V278, P30115, DOI 10.1074/jbc.M302443200; Steeghs L, 2001, EMBO J, V20, P6937, DOI 10.1093/emboj/20.24.6937; Steeghs L, 1998, NATURE, V392, P449, DOI 10.1038/33046; Steinfels E, 2004, BIOCHEMISTRY-US, V43, P7491, DOI 10.1021/bi0362018; Tettelin H, 2000, SCIENCE, V287, P1809, DOI 10.1126/science.287.5459.1809; THOM JR, 1988, J BACTERIOL, V170, P5654, DOI 10.1128/jb.170.12.5654-5661.1988; TOMMASSEN J, 1983, EMBO J, V2, P1275, DOI 10.1002/j.1460-2075.1983.tb01581.x; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; VANALPHEN L, 1978, J BACTERIOL, V134, P1089, DOI 10.1128/JB.134.3.1089-1098.1978; VanVeen HW, 1996, P NATL ACAD SCI USA, V93, P10668, DOI 10.1073/pnas.93.20.10668; VOORHOUT WF, 1986, J MICROSC-OXFORD, V141, P303, DOI 10.1111/j.1365-2818.1986.tb02724.x; Voulhoux R, 2003, SCIENCE, V299, P262, DOI 10.1126/science.1078973; Zhou ZM, 2001, J BIOL CHEM, V276, P43111, DOI 10.1074/jbc.M106960200; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	38	45	46	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35961	35966		10.1074/jbc.M509026200	http://dx.doi.org/10.1074/jbc.M509026200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16123038	Green Published, hybrid			2022-12-27	WOS:000232726900023
J	Mitsuzuka, K; Handa, K; Satoh, M; Arai, Y; Hakomori, S				Mitsuzuka, K; Handa, K; Satoh, M; Arai, Y; Hakomori, S			A specific microdomain ("glycosynapse 3") controls phenotypic conversion and reversion of bladder cancer cells through GM3-mediated interaction of alpha 3 beta 1 integrin with CD9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METASTASIS SUPPRESSOR GENE; ALPHA-5-BETA-1 INTEGRIN RECEPTOR; C-GAMMA ACTIVITY; GM3 GANGLIOSIDE; GLUCOSYLCERAMIDE SYNTHASE; INTERFERING RNAS; MAMMALIAN-CELLS; DOWN-REGULATION; TUMOR-CELLS; MOTILITY	Cell motility is highly dependent on the organization and function of microdomains composed of integrin, proteolipid/tetraspanin CD9, and ganglioside (Ono, M., Handa, K., Sonnino, S., Withers, D. A., Nagai, H., and Hakomori, S. (2001) Biochemistry 40, 6414-6421; Kawakami, Y., Kawakami, K., Steelant, W. F. A., Ono, M., Baek, R. C., Handa, K., Withers, D. A., and Hakomori, S. (2002) J. Biol. Chem. 277, 34349-34358), later termed "glycosynapse 3" (Hakomori, S., and Handa, K. (2002) FEBS Lett. 531, 88-92, 2002). Human bladder cancer cell lines KK47 (noninvasive and nonmetastatic) and YTS1 (highly invasive and metastatic), both derived from transitional bladder epithelia, are very similar in terms of integrin composition and levels of tetraspanin CD9. Tetraspanin CD82 is absent in both. The major difference is in the level of ganglioside GM3, which is several times higher in KK47 than in YTS1. We now report that the GM3 level reflects glycosynapse function as follows: (i) a stronger interaction of integrin alpha 3 with CD9 in KK47 than in YTS1; (ii) conversion of benign, low motility KK47 to invasive, high motility cells by depletion of GM3 by P4 (D-threo-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol) treatment or by knockdown of CD9 by the RNA interference method; (iii) reversion of high motility YTS1 to low motility phenotype like that of KK47 by exogenous GM3 addition, whereby the alpha 3-to-CD9 interaction was enhanced; (iv) low GM3 level activated c-Src in YTS1 or in P4-treated KK47, and high GM3 level by exogenous addition caused Csk translocation into glycosynapse, with subsequent inhibition of c-Src activation; (v) inhibition of c-Src by "PP2" in YTS1 greatly reduced cell motility. Thus, GM3 in glycosynapse 3 plays a dual role in defining glycosynapse 3 function. One is by modulating the interaction of alpha 3 with CD9; the other is by activating or inhibiting the c-Src activity, possibly through Csk translocation. High GM3 level decreases tumor cell motility/invasiveness, whereas low GM3 level enhances tumor cell motility/invasiveness. Oncogenic transformation and its reversion can be explained through the difference in glycosynapse organization.	Pacific NW Res Inst, Seattle, WA 98122 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA; Tohoku Univ, Sch Med, Dept Urol, Sendai, Miyagi 9808574, Japan	University of Washington; University of Washington Seattle; Tohoku University	Hakomori, S (corresponding author), Pacific NW Res Inst, 720 Broadway, Seattle, WA 98122 USA.	hakomori@u.washington.edu			NATIONAL CANCER INSTITUTE [R01CA080054] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA80054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Aoki H, 2004, FEBS LETT, V567, P203, DOI 10.1016/j.febslet.2004.04.060; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CARTER BZ, 1991, LAB INVEST, V65, P610; CHERESH DA, 1987, J CELL BIOL, V105, P1163, DOI 10.1083/jcb.105.3.1163; DOHI T, 1988, CANCER RES, V48, P5680; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Dong JT, 1996, CANCER RES, V56, P4387; FOLCH J, 1951, J BIOL CHEM, V191, P807; Frank M, 2000, PROG NEUROBIOL, V60, P531, DOI 10.1016/S0301-0082(99)00039-8; Gu JG, 2002, J BIOL CHEM, V277, P19922, DOI 10.1074/jbc.M200383200; Gu JG, 2004, GLYCOCONJUGATE J, V21, P9, DOI 10.1023/B:GLYC.0000043741.47559.30; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P225, DOI 10.1073/pnas.012540899; Hakomori S, 2004, AN ACAD BRAS CIENC, V76, P553, DOI 10.1590/S0001-37652004000300010; HAKOMORI S, 1968, P NATL ACAD SCI USA, V59, P254, DOI 10.1073/pnas.59.1.254; Hakomori S, 2002, FEBS LETT, V531, P88, DOI 10.1016/S0014-5793(02)03479-8; HAKOMORI SI, 1977, VIROLOGY, V76, P485, DOI 10.1016/0042-6822(77)90231-8; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; HANNUN YA, 1997, SPHINGOLIPID MED SIG; Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609; HISAZUMI H, 1979, JPN J UROL, V70, P485, DOI 10.5980/jpnjurol1928.70.5_485; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Isaji T, 2004, J BIOL CHEM, V279, P19747, DOI 10.1074/jbc.M311627200; Jaffe LF, 2003, ADV CANCER RES, V90, P209, DOI 10.1016/S0065-230X(03)90007-8; KAKIZAKI H, 1986, JPN J UROL, V77, P1790; Kakizaki H., 1990, JPN J UROL, V81, P204; Kawakami Y, 2002, J BIOL CHEM, V277, P34349, DOI 10.1074/jbc.M200771200; Kenny PA, 2003, INT J CANCER, V107, P688, DOI 10.1002/ijc.11491; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; Krummel MF, 2002, CURR OPIN IMMUNOL, V14, P66, DOI 10.1016/S0952-7915(01)00299-0; Lee L, 1999, J BIOL CHEM, V274, P14662, DOI 10.1074/jbc.274.21.14662; Li RX, 2000, J BIOL CHEM, V275, P34213, DOI 10.1074/jbc.M906368199; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Lotem J, 2002, SEMIN CANCER BIOL, V12, P339, DOI 10.1016/S1044-579X(02)00054-8; Mannion BA, 1996, J IMMUNOL, V157, P2039; MASTERS JRW, 1986, CANCER RES, V46, P3630; Mhawech P, 2003, CANCER, V98, P1649, DOI 10.1002/cncr.11698; Miura Y, 2004, P NATL ACAD SCI USA, V101, P16204, DOI 10.1073/pnas.0407297101; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774; NAKAMURA K, 1991, J BIOCHEM-TOKYO, V110, P832, DOI 10.1093/oxfordjournals.jbchem.a123667; OKADA M, 1991, J BIOL CHEM, V266, P24249; Ono M, 1999, CANCER RES, V59, P2335; Ono M, 2001, BIOCHEMISTRY-US, V40, P6414, DOI 10.1021/bi0101998; Ono M, 2000, BIOCHEM BIOPH RES CO, V279, P744, DOI 10.1006/bbrc.2000.4030; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; Satoh M, 2001, INT J ONCOL, V19, P723; SCHLESINGER MJ, 1981, ANNU REV BIOCHEM, V50, P193, DOI 10.1146/annurev.bi.50.070181.001205; Scott WN, 2000, ANAL BIOCHEM, V287, P343, DOI 10.1006/abio.2000.4866; SHAYMAN JA, 1990, J BIOL CHEM, V265, P12135; Shu LM, 2003, J BIOL CHEM, V278, P31419, DOI 10.1074/jbc.M303783200; Shu LM, 2002, J BIOL CHEM, V277, P18447, DOI 10.1074/jbc.M111363200; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Su JS, 2004, INT J UROL, V11, P74, DOI 10.1111/j.1442-2042.2004.00752.x; Sui DX, 2004, BIOCHEM BIOPH RES CO, V319, P768, DOI 10.1016/j.bbrc.2004.04.198; Toledo MS, 2005, J BIOL CHEM, V280, P16227, DOI 10.1074/jbc.M413713200; Toledo MS, 2004, J BIOL CHEM, V279, P34655, DOI 10.1074/jbc.M403857200; Tsuji T, 2002, CLIN EXP METASTAS, V19, P127, DOI 10.1023/A:1014573204062; ZHENG MZ, 1994, J BIOL CHEM, V269, P12325; ZHENG MZ, 1993, J BIOL CHEM, V268, P2217	62	91	95	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35545	35553		10.1074/jbc.M505630200	http://dx.doi.org/10.1074/jbc.M505630200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16103120	hybrid			2022-12-27	WOS:000232561200056
J	Robison, AJ; Bass, MA; Jiao, YX; MacMillan, LB; Carmody, LC; Bartlett, RK; Colbran, RJ				Robison, AJ; Bass, MA; Jiao, YX; MacMillan, LB; Carmody, LC; Bartlett, RK; Colbran, RJ			Multivalent interactions of calcium/calmodulin-dependent protein kinase II with the postsynaptic density proteins NR2B, densin-180, and alpha-actinin-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; D-ASPARTATE RECEPTOR; NMDA RECEPTOR; ALPHA-ACTININ; RAT-BRAIN; SIGNALING COMPLEXES; SYNAPTIC PLASTICITY; HIPPOCAMPAL-NEURONS; DENDRITIC SPINES; CALMODULIN	Dendritic calcium/ calmodulin- dependent protein kinase II ( CaMKII) is dynamically targeted to the synapse. We show that CaMKII alpha is associated with the CaMKII- binding proteins densin-180, the N- methyl- D- aspartate receptor NR2B subunit, and alpha- actinin in postsynaptic density- enriched rat brain fractions. Residues 819 - 894 within the C- terminal domain of alpha- actinin- 2 constitute the minimal CaMKII- binding domain. Similar amounts of Thr(286)-autophosphorylated CaMKII alpha holoenzyme [ P- T-286] CaMKII bind to alpha- actinin- 2 as bind to NR2B ( residues 1260 - 1339) or to densin-180 ( residues 1247 - 1495) in glutathione- agarose cosedimentation assays, even though the CaMKII- binding domains share no amino acid sequence similarity. Like NR2B, alpha- actinin- 2 binds to representative splice variants of each CaMKII gene ( alpha, beta, gamma, and delta), whereas densin- 180 binds selectively to CaMKII alpha. In addition, C- terminal truncated CaMKII alpha monomers can interact with NR2B and alpha- actinin- 2, but not with densin- 180. Soluble alpha- actinin- 2 does not compete for [ P- T-286] CaMKII binding to immobilized densin-180 or NR2B. However, soluble densin- 180, but not soluble NR2B, increases CaMKII binding to immobilized alpha- actinin- 2 by approximate to 10- fold in a PDZ domain- dependent manner. A His(6)- tagged NR2B fragment associates with GST- densin or GST- actinin but only in the presence of [ P- T-286] CaMKII. Similarly, His6- tagged densin- 180 or alpha- actinin fragments associate with GST- NR2B in a[ P-T-286] CaMKII-dependent manner. In addition, GST- NR2B and His(6)- tagged alpha- actinin can bind simultaneously to monomeric CaMKII subunits. In combination, these data support a model in which [ P-T-286] CaMKII alpha can simultaneously interact with multiple dendritic spine proteins, possibly stabilizing the synaptic localization of CaMKII and/ or nucleating a multiprotein synaptic signaling complex.	Vanderbilt Univ, Vanderbilt Kennedy Ctr Res Human Dev, Ctr Mol Neurosci, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	Colbran, RJ (corresponding author), Vanderbilt Univ, Vanderbilt Kennedy Ctr Res Human Dev, Ctr Mol Neurosci, Dept Mol Physiol & Biophys, 702 Light Hall, Nashville, TN 37232 USA.	roger.colbran@vanderbilt.edu	Robison, Alfred J/P-8521-2018; Colbran, Roger/AAU-7708-2021; Jiao, Yuxia/H-3300-2019	Robison, Alfred J/0000-0002-4150-9570; Colbran, Roger/0000-0001-7401-8244; Jiao, Yuxia/0000-0002-8633-7047; Carmody, Leigh/0000-0001-7941-2961	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH063232, F31MH068129] Funding Source: NIH RePORTER; NIDDK NIH HHS [5T32-DK07563] Funding Source: Medline; NIMH NIH HHS [R01 MH063232, F32-MH068129, R01-MH63232, R01 MH063232-05] Funding Source: Medline; NINDS NIH HHS [R01-NS44282] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allison DW, 2000, J NEUROSCI, V20, P4545, DOI 10.1523/JNEUROSCI.20-12-04545.2000; Apperson ML, 1996, J NEUROSCI, V16, P6839; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; Bayer KU, 2001, NATURE, V411, P801, DOI 10.1038/35081080; BRICKEY DA, 1990, BIOCHEM BIOPH RES CO, V173, P578, DOI 10.1016/S0006-291X(05)80074-9; Chen XB, 2005, P NATL ACAD SCI USA, V102, P11551, DOI 10.1073/pnas.0505359102; Colbran RJ, 2004, BIOCHEM J, V378, P1, DOI 10.1042/BJ20031547; Colbran RJ, 2004, CURR OPIN NEUROBIOL, V14, P318, DOI 10.1016/j.conb.2004.05.008; Dhavan R, 2002, J NEUROSCI, V22, P7879; Elgersma Y, 2004, J NEUROSCI, V24, P8410, DOI 10.1523/JNEUROSCI.3622-04.2004; ERONDU NE, 1985, J NEUROSCI, V5, P3270; Fink CC, 2003, NEURON, V39, P283, DOI 10.1016/S0896-6273(03)00428-8; Fong DK, 2002, J NEUROSCI, V22, P2153, DOI 10.1523/JNEUROSCI.22-06-02153.2002; Gardoni F, 1999, FEBS LETT, V456, P394, DOI 10.1016/S0014-5793(99)00985-0; Gardoni F, 1998, J NEUROCHEM, V71, P1733; Griffith LC, 2004, J NEUROSCI, V24, P8391, DOI 10.1523/JNEUROSCI.2888-04.2004; Griffith LC, 2004, J NEUROSCI, V24, P8394, DOI 10.1523/JNEUROSCI.3604-04.2004; HARTWIG JH, 1995, PROTEIN PROFILE, V2, P703; Hata Y, 1996, J NEUROSCI, V16, P2488; Hudmon A, 2002, ANNU REV BIOCHEM, V71, P473, DOI 10.1146/annurev.biochem.71.110601.135410; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Jourdain P, 2003, J NEUROSCI, V23, P10645; Kennedy MB, 2000, SCIENCE, V290, P750, DOI 10.1126/science.290.5492.750; Krupp JJ, 1999, J NEUROSCI, V19, P1165; Leonard AS, 2002, J BIOL CHEM, V277, P48441, DOI 10.1074/jbc.M205164200; Leonard AS, 1999, P NATL ACAD SCI USA, V96, P3239, DOI 10.1073/pnas.96.6.3239; Li WD, 2001, J BIOL CHEM, V276, P21417, DOI 10.1074/jbc.M010744200; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; MCNEILL RB, 1995, J BIOL CHEM, V270, P10043, DOI 10.1074/jbc.270.17.10043; Muller D, 2000, HIPPOCAMPUS, V10, P596, DOI 10.1002/1098-1063(2000)10:5<596::AID-HIPO10>3.3.CO;2-P; Ohtakara K, 2002, GENES CELLS, V7, P1149, DOI 10.1046/j.1365-2443.2002.00589.x; Petersen JD, 2003, J NEUROSCI, V23, P11270; SAHYOUN N, 1985, J BIOL CHEM, V260, P1230; Schulman H, 2004, J NEUROSCI, V24, P8399, DOI 10.1523/JNEUROSCI.3606-04.2004; Sessoms-Sikes S, 2005, MOL CELL NEUROSCI, V29, P139, DOI 10.1016/j.mcn.2005.01.006; Shen K, 1998, NEURON, V21, P593, DOI 10.1016/S0896-6273(00)80569-3; Shen K, 1999, SCIENCE, V284, P162, DOI 10.1126/science.284.5411.162; Shen K, 2000, NAT NEUROSCI, V3, P881, DOI 10.1038/78783; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Sheng M, 2001, J CELL SCI, V114, P1251; Sheng M, 2001, P NATL ACAD SCI USA, V98, P7058, DOI 10.1073/pnas.111146298; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Strack S, 2000, J BIOL CHEM, V275, P25061, DOI 10.1074/jbc.C000319200; Strack S, 2000, J BIOL CHEM, V275, P23798, DOI 10.1074/jbc.M001471200; Strack S, 1998, J BIOL CHEM, V273, P20689, DOI 10.1074/jbc.273.33.20689; Tabuchi K, 2002, J NEUROSCI, V22, P4264, DOI 10.1523/JNEUROSCI.22-11-04264.2002; Thiagarajan TC, 2002, NEURON, V36, P1103, DOI 10.1016/S0896-6273(02)01049-8; TOBIMATSU T, 1989, J BIOL CHEM, V264, P17907; Walikonis RS, 2001, J NEUROSCI, V21, P423, DOI 10.1523/JNEUROSCI.21-02-00423.2001; Wong W, 2004, NAT REV MOL CELL BIO, V5, P959, DOI 10.1038/nrm1527; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; Wyszynski M, 1999, J NEUROSCI, V19, P6528; Wyszynski M, 1998, J NEUROSCI, V18, P1383; Yuste R, 2001, ANNU REV NEUROSCI, V24, P1071, DOI 10.1146/annurev.neuro.24.1.1071; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X	55	100	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35329	35336		10.1074/jbc.M502191200	http://dx.doi.org/10.1074/jbc.M502191200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16120608	hybrid			2022-12-27	WOS:000232561200031
J	Tapodi, A; Debreceni, B; Hanto, K; Bognar, Z; Wittmann, I; Gallyas, F; Varbiro, G; Sumegi, B				Tapodi, A; Debreceni, B; Hanto, K; Bognar, Z; Wittmann, I; Gallyas, F; Varbiro, G; Sumegi, B			Pivotal role of Akt activation in mitochondrial protection and cell survival by poly(ADP-ribose) polymerase-1 inhibition in oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS-INDUCING FACTOR; NF-KAPPA-B; POLY ADP-RIBOSYLATION; AKT/PROTEIN KINASE-B; DNA-BINDING ACTIVITY; PERMEABILITY TRANSITION; NAD(+) DEPLETION; MICE RESISTANT; DEATH; MECHANISM	According to the classical view, the cytoprotective effect of inhibitors of poly( ADP- ribose) polymerase ( PARP) in oxidative stress was based on the prevention of NAD(+) and ATP depletion, thus the attenuation of necrosis. Our previous data on PARP inhibitors in an inflammatory model suggested that PARP- catalyzed ADP- ribosylations may affect signaling pathways, which can play a significant role in cell survival. To clarify the molecular mechanism of cytoprotection, PARP activity was inhibited pharmacologically by suppressing PARP- 1 expression by a small interfering RNA ( siRNA) technique or by transdominantly expressing the N- terminal DNA-binding domain of PARP- 1 ( PARP- DBD) in cultured cells. Cell survival, activation of the phosphatidylinositol 3- kinase ( PI3- kinase)/ Akt system, and the preservation of mitochondrial membrane potential were studied in hydrogen peroxide- treated WRL- 68 cells. Our data showed that suppression of the single- stranded DNA break- induced PARP- 1 activation by pharmacological inhibitor, siRNA, or by the transdominant expression of PARP- DBD protected cells from oxidative stress and induced the phosphorylation and activation of Akt. Furthermore, prevention of Akt activation by inhibiting PI3- kinase counteracted the cytoprotective effect of PARP inhibition. Microscopy data showed that PARP inhibition-induced Akt activation was responsible for protection of mitochondria in oxidative stress because PI3- kinase inhibitors diminished the protective effect of PARP inhibition. Similarly, Src kinase inhibitors, which decrease Akt phosphorylation, also counteracted the protection of mitochondrial membrane potential supporting the pivotal role of Akt in cytoprotection. These data together with the finding that PARP inhibition in the absence of oxidative stress induced the phosphorylation and activation of Akt indicate that PARP inhibition- induced Akt activation is dominantly responsible for the cytoprotection in oxidative stress.	Univ Pecs, Dept Biochem & Med Chem, H-7624 Pecs, Hungary; Univ Pecs, Dept Med 1, Div Cardiol, H-7624 Pecs, Hungary; Univ Pecs, Fac Med, Dept Med 2, H-7624 Pecs, Hungary; Univ Pecs, Fac Med, Hungarian Acad Sci, Res Grp Mitochondrial Funct & Mitochondrial Dis, H-7624 Pecs, Hungary	University of Pecs; University of Pecs; University of Pecs; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Institute of Experimental Medicine; University of Pecs	Sumegi, B (corresponding author), Univ Pecs, Dept Biochem & Med Chem, 12 Szigeti St, H-7624 Pecs, Hungary.	balazs.sumegi@aok.pte.hu	Varbiro, Gabor/AAH-5587-2021; Gallyas, Ferenc/AAY-5343-2020; Gallyas, Ferenc/C-2272-2012	Varbiro, Gabor/0000-0001-5907-3472; Gallyas, Ferenc/0000-0002-1906-4333				Alano CC, 2004, J BIOL CHEM, V279, P18895, DOI 10.1074/jbc.M313329200; Althaus FR, 1999, MOL CELL BIOCHEM, V193, P5, DOI 10.1023/A:1006975002262; AMSTAD PA, 1992, CANCER RES, V52, P3952; Batandier C, 2004, J BIOL CHEM, V279, P17197, DOI 10.1074/jbc.M310329200; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Burkart V, 1999, NAT MED, V5, P314, DOI 10.1038/6535; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; Chang WJ, 2001, J BIOL CHEM, V276, P47664, DOI 10.1074/jbc.M104666200; Chen M, 2004, CARDIOVASC RES, V63, P682, DOI 10.1016/j.cardiores.2004.04.018; Cui QL, 2005, J BIOL CHEM, V280, P8918, DOI 10.1074/jbc.M414267200; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Esposito G, 2002, J BIOL CHEM, V277, P50348, DOI 10.1074/jbc.M207170200; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Halmosi R, 2001, MOL PHARMACOL, V59, P1497, DOI 10.1124/mol.59.6.1497; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; Hong SJ, 2004, TRENDS PHARMACOL SCI, V25, P259, DOI 10.1016/j.tips.2004.03.005; Jagtap P, 2005, NAT REV DRUG DISCOV, V4, P421, DOI 10.1038/nrd1718; Kameoka M, 2000, BIOCHEM J, V346, P641, DOI 10.1042/0264-6021:3460641; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; Kim JW, 2000, J CELL SCI, V113, P955; Komjati K, 2004, INT J MOL MED, V13, P373; Liaudet L, 2002, AM J RESP CRIT CARE, V165, P372, DOI 10.1164/ajrccm.165.3.2106050; Lu S, 2004, APPL BIOCHEM BIOTECH, V118, P133, DOI 10.1385/ABAB:118:1-3:133; Martin D, 2002, J BIOL CHEM, V277, P42943, DOI 10.1074/jbc.M201070200; Masutani M, 1999, P NATL ACAD SCI USA, V96, P2301, DOI 10.1073/pnas.96.5.2301; MCCORD JM, 1987, FASEB J, V46, P2402; MULLER WEG, 1976, MOL CELL BIOCHEM, V12, P147, DOI 10.1007/BF01741713; Murriel CL, 2004, J BIOL CHEM, V279, P47985, DOI 10.1074/jbc.M405071200; Nie J, 1998, FEBS LETT, V424, P27, DOI 10.1016/S0014-5793(98)00131-8; Oei SL, 1997, BIOCHEM BIOPH RES CO, V240, P108, DOI 10.1006/bbrc.1997.7621; OLEINICK NL, 1985, RADIAT RES, V101, P29, DOI 10.2307/3576301; PALFI A, 2005, J PHARM EXP THER JUN; Pieper AA, 1999, P NATL ACAD SCI USA, V96, P3059, DOI 10.1073/pnas.96.6.3059; POWIS G, 1994, CANCER RES, V54, P2419; ROWE GT, 1983, CIRC RES, V53, P584, DOI 10.1161/01.RES.53.5.584; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; SHAH GM, 1995, ANAL BIOCHEM, V227, P1, DOI 10.1006/abio.1995.1245; Soriano FG, 2002, SHOCK, V17, P286, DOI 10.1097/00024382-200204000-00008; Szabo C, 1997, J EXP MED, V186, P1041, DOI 10.1084/jem.186.7.1041; TANIGUCHI T, 1985, BIOCHEM BIOPH RES CO, V127, P526, DOI 10.1016/S0006-291X(85)80191-1; TURNERS JF, 1980, BIOCHEM J, V156, P434; Ullrich O, 2001, NAT CELL BIOL, V3, P1035, DOI 10.1038/ncb1201-1035; Veres B, 2003, BIOCHEM PHARMACOL, V65, P1373, DOI 10.1016/S0006-2952(03)00077-7; Veres B, 2004, J PHARMACOL EXP THER, V310, P247, DOI 10.1124/jpet.104.065151; Virag L, 1998, J IMMUNOL, V161, P3753; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Werner E, 2004, J CELL SCI, V117, P143, DOI 10.1242/jcs.00937; Wesierska-Gadek J, 2001, CELL MOL BIOL LETT, V6, P117; Xia Y, 1996, J BIOL CHEM, V271, P10096, DOI 10.1074/jbc.271.17.10096; Xiao CY, 2005, J PHARMACOL EXP THER, V312, P891, DOI 10.1124/jpet.104.077164; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zingarelli B, 1998, CIRC RES, V83, P85, DOI 10.1161/01.RES.83.1.85	59	144	149	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35767	35775		10.1074/jbc.M507075200	http://dx.doi.org/10.1074/jbc.M507075200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16115861	hybrid			2022-12-27	WOS:000232561200080
J	Urquiza, M; Lopez, R; Patino, H; Rosas, JE; Patarroyo, ME				Urquiza, M; Lopez, R; Patino, H; Rosas, JE; Patarroyo, ME			Identification of three gp350/220 regions involved in Epstein-Barr virus invasion of host cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 MONOCLONAL-ANTIBODY; SYNTHETIC PEPTIDES; RECEPTOR CR-2; B-LYMPHOCYTES; ANTIGENIC DETERMINANTS; ENVELOPE GLYCOPROTEINS; ESCHERICHIA-COLI; EBV/C3D RECEPTOR; VIRAL BINDING; CLASS-II	Epstein-Barr virus (EBV) invasion of B-lymphocytes involves EBV gp350/220 binding to B-lymphocyte CR2. The anti-gp350 monoclonal antibody (mAb)-72A1 Fab inhibits this binding and therefore blocks EBV invasion of target cells. However, gp350/220 regions interacting with mAb 72A1 and involved in EBV invasion of target cells have not yet been identified. This work reports three gp350/220 regions, defined by peptide 11382, 11389, and 11416 sequences, that are involved in EBV binding to B-lymphocytes. Peptides 11382, 11389, and 11416 bound to CR2(+) but not to CR2(-) cells, inhibited EBV invasion of cord blood lymphocytes (CBLs), were recognized by mAb 72A1, and inhibited mAb 72A1 binding to EBV. Peptides 11382 and 11416 binding to peripheral blood lymphocytes (PBLs) induced interleukin-6 protein synthesis in these cells, this phenomenon being inhibited by mAb 72A1. The same behavior has been reported for gp350/220 binding to PBLs. Anti-peptide 11382, 11389, and 11416 antibodies inhibited EBV binding and EBV invasion of PBLs and CBLs. Peptide 11382, 11389, and 11416 sequences presented homology with the C3dg regions coming into contact with CR2 (C3dg and gp350 bound to similar CR2 regions). These peptides could be used in designing strategies against EBV infection.	Fdn Inst Inmunol Colombia, Virol Grp, Bogota, Colombia; Univ Nacl Colombia, Dept Chem, Bogota 030405, Colombia; Univ Nacl Colombia, Fac Med, Bogota 030405, Colombia	Universidad Nacional de Colombia; Universidad Nacional de Colombia	Urquiza, M (corresponding author), Fdn Inst Inmunol Colombia, Virol Grp, Cra 50,26-00, Bogota, Colombia.	mauricio_urquiza@fidic.org.co	; Patarroyo, Manuel-Elkin/S-1422-2017	Urquiza, Mauricio/0000-0001-5478-606X; Patarroyo, Manuel-Elkin/0000-0002-1119-6040				AHEARN JM, 1988, P NATL ACAD SCI USA, V85, P9307, DOI 10.1073/pnas.85.23.9307; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAUMANN H, 1988, J BIOL CHEM, V263, P17390; BEISEL C, 1985, J VIROL, V54, P665, DOI 10.1128/JVI.54.3.665-674.1985; BERTONI G, 1990, INTERVIROLOGY, V31, P290, DOI 10.1159/000150164; Chen PCH, 2002, J PATHOL, V197, P684, DOI 10.1002/path.1141; D'Addario M, 2001, J MOL BIOL, V308, P501, DOI 10.1006/jmbi.2001.4589; DELVES PJ, 1997, ANTIBODY PRODUCTIONS, P64; DUNCAN MR, 1978, J VIROL, V28, P444, DOI 10.1128/JVI.28.2.444-449.1978; Egelhofer M, 2004, J VIROL, V78, P568, DOI 10.1128/JVI.78.2.568-575.2004; EMINI EA, 1989, J MED VIROL, V27, P120, DOI 10.1002/jmv.1890270210; EPSTEIN MA, 1966, J NATL CANCER I, V37, P547; Fraczkiewicz R, 1998, J COMPUT CHEM, V19, P319, DOI 10.1002/(SICI)1096-987X(199802)19:3<319::AID-JCC6>3.0.CO;2-W; FREEMAN CB, 1982, CLIN IMMUNOL IMMUNOP, V25, P103, DOI 10.1016/0090-1229(82)90169-6; Garcia JE, 2002, J HEPATOL, V36, P254, DOI 10.1016/S0168-8278(01)00262-8; Grandi P, 2004, MOL THER, V9, P419, DOI 10.1016/j.ymthe.2003.12.010; Hardy N, 2004, PHARMACOTHERAPY, V24, P198, DOI 10.1592/phco.24.2.198.33141; HEDRICK JA, 1994, J IMMUNOL, V153, P4418; HINUMA YORIO, 1967, J VIROL, V1, P1203; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; Hu CL, 2004, BIOCHEM BIOPH RES CO, V316, P698, DOI 10.1016/j.bbrc.2004.02.106; Keitel T, 1997, CELL, V91, P811, DOI 10.1016/S0092-8674(00)80469-9; Khanna R, 1999, J IMMUNOL, V162, P3063; KLEIN E, 1990, MOL IMMUNOL, V27, P1343, DOI 10.1016/0161-5890(90)90041-W; KOIZUMI S, 1992, VIROLOGY, V188, P859, DOI 10.1016/0042-6822(92)90542-W; Kramer A, 1997, CELL, V91, P799, DOI 10.1016/S0092-8674(00)80468-7; Li QX, 1997, J VIROL, V71, P4657, DOI 10.1128/JVI.71.6.4657-4662.1997; Maruo S, 2001, J GEN VIROL, V82, P2373, DOI 10.1099/0022-1317-82-10-2373; MCKINNEY MM, 1987, J IMMUNOL METHODS, V96, P271, DOI 10.1016/0022-1759(87)90324-3; MOORE MD, 1989, J BIOL CHEM, V264, P20576; NEMEROW GR, 1987, J VIROL, V61, P1416, DOI 10.1128/JVI.61.5.1416-1420.1987; NEMEROW GR, 1989, CELL, V56, P369, DOI 10.1016/0092-8674(89)90240-7; NUEBLING CM, 1992, VIROLOGY, V191, P443; PATEL RA, 1993, VIROLOGY, V195, P121, DOI 10.1006/viro.1993.1352; PITHER RJ, 1992, J VIROL, V66, P1246, DOI 10.1128/JVI.66.2.1246-1251.1992; PITHER RJ, 1992, J GEN VIROL, V73, P1409, DOI 10.1099/0022-1317-73-6-1409; PRIETO I, 1995, EUR J IMMUNOL, V25, P877, DOI 10.1002/eji.1830250403; REISERT PS, 1985, J IMMUNOL, V134, P3776; Roberge CJ, 1996, J IMMUNOL, V156, P4884; Salek-Ardakani S, 2004, J IMMUNOL, V173, P321, DOI 10.4049/jimmunol.173.1.321; Salimi B, 2002, PEDIATR PATHOL MOL M, V21, P433, DOI 10.1080/15227950290097199; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sarrias MR, 2001, J IMMUNOL, V167, P1490, DOI 10.4049/jimmunol.167.3.1490; SERVIS C, 1989, J IMMUNOL, V142, P2207; STOCCO R, 1990, INTERVIROLOGY, V31, P295, DOI 10.1159/000150165; Szakonyi G, 2001, SCIENCE, V292, P1725, DOI 10.1126/science.1059118; TAM JP, 1983, INT J PEPT PROT RES, V21, P57; TANNER J, 1988, J VIROL, V62, P4452, DOI 10.1128/JVI.62.12.4452-4464.1988; TANNER J, 1987, CELL, V50, P203, DOI 10.1016/0092-8674(87)90216-9; TANNER JE, 1994, BLOOD, V84, P3956, DOI 10.1182/blood.V84.11.3956.bloodjournal84113956; Tanner JE, 1996, J VIROL, V70, P570, DOI 10.1128/JVI.70.1.570-575.1996; THORLEYLAWSON DA, 1982, J VIROL, V43, P730, DOI 10.1128/JVI.43.2.730-736.1982; THORLEYLAWSON DA, 1980, P NATL ACAD SCI-BIOL, V77, P5307, DOI 10.1073/pnas.77.9.5307; Urquiza M, 2004, BIOCHEM BIOPH RES CO, V319, P221, DOI 10.1016/j.bbrc.2004.04.177; Vera-Bravo R, 2003, INT J CANCER, V107, P416, DOI 10.1002/ijc.11433; WEILAND GA, 1981, LIFE SCI, V29, P313, DOI 10.1016/0024-3205(81)90324-6; WEIS JJ, 1984, P NATL ACAD SCI-BIOL, V81, P881, DOI 10.1073/pnas.81.3.881; WELLS A, 1981, INT J CANCER, V27, P303, DOI 10.1002/ijc.2910270308; ZHANG PF, 1991, J GEN VIROL, V72, P2747, DOI 10.1099/0022-1317-72-11-2747; ZHANG PF, 1993, J GEN VIROL, V74, P2171, DOI 10.1099/0022-1317-74-10-2171	60	25	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35598	35605		10.1074/jbc.M504544200	http://dx.doi.org/10.1074/jbc.M504544200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16087675	hybrid			2022-12-27	WOS:000232561200062
J	Sasaki, CY; Barberi, TJ; Ghosh, P; Longo, DL				Sasaki, CY; Barberi, TJ; Ghosh, P; Longo, DL			Phosphorylation of RelA/p65 on serine 536 defines an I kappa B alpha-independent NF-kappa B pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; NUCLEAR-FACTOR; P65 SUBUNIT; TRANSCRIPTIONAL ACTIVATION; IKK-BETA; T-CELLS; KINASE; GENE; MECHANISM; PROTEIN	The association of the NF-kappa B p65/p50 dimer with I kappa B alpha plays a pivotal role in regulating its nuclear translocation and gene transcription. In addition, serine phosphorylation at various sites of the p65 subunit has been shown to be important in initiating transcription. Here we demonstrate that the regulation of nuclear translocation of p65 phosphorylated at serine 536 is not dependent on I kappa B alpha. Stimulation of either Jurkat or normal human T cells resulted in the nuclear translocation of phospho-p65 (Ser(536)). In addition, the phospho-p65 (Ser(536)) was not associated with either I kappa B alpha or p50, and the nuclear translocation of phospho-p65 (Ser(536)), but not total p65, was unaffected by the proteosome inhibitor MG-132, which blocks I kappa B protein degradation and prevents p65/p50 dimer nuclear translocation. Accordingly, the co-expression of a dominant negative mutant of I kappa B alpha blocked the transcriptional activity mediated by wild type but not the dominant positive p65 mutant (S536D). Furthermore, the transfection of the S536D form of p65 led to the induction of interleukin-8 transcription following stimulation, whereas the S536A form, which cannot be phosphorylated at this site, did not. Together, the findings suggest that p65 phosphorylated on serine 536 is not associated with or regulated by I kappa B alpha, that it has a distinct set of target genes, and that it may represent a noncanonical NF-kappa B pathway that is independent of I kappa B alpha regulation.	NIA, Immunol Lab, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Sasaki, CY (corresponding author), NIA, Immunol Lab, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	sasakic@grc.nia.nih.gov	Longo, Dan L./F-6022-2011		NATIONAL INSTITUTE ON AGING [Z01AG000426, ZIAAG000426, Z01AG000912, ZICAG000912] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akiyama M, 2003, CANCER RES, V63, P18; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bohuslav J, 2004, J BIOL CHEM, V279, P26115, DOI 10.1074/jbc.M313509200; BUSS H, 2004, J BIOL CHEM; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Duran A, 2003, EMBO J, V22, P3910, DOI 10.1093/emboj/cdg370; Ghosh P, 2002, BLOOD, V99, P4517, DOI 10.1182/blood-2001-11-0062; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; Ghosh P, 1996, J BIOL CHEM, V271, P7700, DOI 10.1074/jbc.271.13.7700; Grisham MB, 1999, METHOD ENZYMOL, V300, P345; Haller D, 2002, J BIOL CHEM, V277, P38168, DOI 10.1074/jbc.M205737200; Harhaj EW, 1999, MOL CELL BIOL, V19, P7088; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hoffmann A, 2003, EMBO J, V22, P5530, DOI 10.1093/emboj/cdg534; Jiang X, 2003, J BIOL CHEM, V278, P919, DOI 10.1074/jbc.M208696200; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; KUNSCH C, 1994, J IMMUNOL, V153, P153; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Leung TH, 2004, CELL, V118, P453, DOI 10.1016/j.cell.2004.08.007; LI CCH, 1994, J BIOL CHEM, V269, P30089; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Marshall HE, 2004, P NATL ACAD SCI USA, V101, P8841, DOI 10.1073/pnas.0403034101; Marshall HE, 2002, J BIOL CHEM, V277, P34223, DOI 10.1074/jbc.M201638200; Mattioli I, 2004, J IMMUNOL, V172, P6336, DOI 10.4049/jimmunol.172.10.6336; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; O'Mahony AM, 2004, J BIOL CHEM, V279, P18137, DOI 10.1074/jbc.M401397200; Okazaki T, 2003, BIOCHEM BIOPH RES CO, V300, P807, DOI 10.1016/S0006-291X(02)02932-7; Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200; Schmittgen TD, 2000, ANAL BIOCHEM, V285, P194, DOI 10.1006/abio.2000.4753; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Tam WF, 2001, MOL CELL BIOL, V21, P4837, DOI 10.1128/MCB.21.14.4837-4846.2001; Tam WF, 2001, J BIOL CHEM, V276, P7701, DOI 10.1074/jbc.C000916200; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Vermeulen L, 2002, BIOCHEM PHARMACOL, V64, P963, DOI 10.1016/S0006-2952(02)01161-9; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Yano S, 2003, J IMMUNOL, V171, P2510, DOI 10.4049/jimmunol.171.5.2510; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	46	270	276	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34538	34547		10.1074/jbc.M504943200	http://dx.doi.org/10.1074/jbc.M504943200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16105840	hybrid			2022-12-27	WOS:000232403900022
J	Thomas, J; Cronan, JE				Thomas, J; Cronan, JE			The enigmatic acyl carrier protein phosphodiesterase of Escherichia coli - Genetic and enzymological characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID BIOSYNTHESIS; PROSTHETIC GROUP; ACP SYNTHASE; PURIFICATION; EXPRESSION; ENZYME; CLONES; TRANSFERASES; DERIVATIVES; SYNTHETASE	The acyl carrier proteins (ACPs) of fatty acid synthesis are functional only when modified by attachment of the prosthetic group, 4'-phosphopantetheine (4'-PP), which is transferred from CoA to the hydroxyl group of a specific serine residue. Almost 40 years ago Vagelos and Larrabee ( Vagelos, P. R., and Larrabee, A. ( 1967) J. Biol. Chem. 242, 1776 - 1781) reported an enzyme from Escherichia coli that removed the prosthetic group. We report that this enzyme, called ACP hydrolyase or ACP phosphodiesterase, is encoded by a gene (yajB) of previously unknown function that we have renamed acpH. A mutant E. coli strain having a total deletion of the acpH gene has been constructed that grows normally, showing that phosphodiesterase activity is not essential for growth, although it is required for turnover of the ACP prosthetic group in vivo. ACP phosphodiesterase (AcpH) has been purified to homogeneity for the first time and is a soluble protein that very readily aggregates upon overexpression in vivo or concentration in vitro. The purified enzyme has been shown to cleave acyl-ACP species with acyl chains of 6 - 16 carbon atoms and is active on some, but not all, non-native ACP species tested. Possible physiological roles for AcpH are discussed.	Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Cronan, JE (corresponding author), Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, 601 S Goodwin Ave, Urbana, IL 61801 USA.	j-cronan@life.uiuc.edu	Cronan, John/V-6626-2019	Thomas, Jacob/0000-0002-7436-8962				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chirgadze NY, 2000, EMBO J, V19, P5281, DOI 10.1093/emboj/19.20.5281; Choi-Rhee E, 2003, J BIOL CHEM, V278, P30806, DOI 10.1074/jbc.M302507200; Clarke L, 1979, Methods Enzymol, V68, P436; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DIGUAN C, 1988, GENE, V67, P21, DOI 10.1016/0378-1119(88)90004-2; FISCHL AS, 1990, J BACTERIOL, V172, P5445, DOI 10.1128/jb.172.9.5445-5449.1990; Flugel RS, 2000, J BIOL CHEM, V275, P959, DOI 10.1074/jbc.275.2.959; Gehring AM, 1997, CHEM BIOL, V4, P17, DOI 10.1016/S1074-5521(97)90233-7; Golovanov AP, 2004, J AM CHEM SOC, V126, P8933, DOI 10.1021/ja049297h; GRANA D, 1988, GENETICS, V120, P319; HOLAK TA, 1988, EUR J BIOCHEM, V175, P9, DOI 10.1111/j.1432-1033.1988.tb14159.x; JACKOWSKI S, 1984, J BACTERIOL, V158, P115, DOI 10.1128/JB.158.1.115-120.1984; JACKOWSKI S, 1981, J BACTERIOL, V148, P926, DOI 10.1128/JB.148.3.926-932.1981; JACKOWSKI S, 1983, J BIOL CHEM, V258, P5186; JACKOWSKI S, 1984, J BIOL CHEM, V259, P1891; Jiang YF, 2005, J BIOL CHEM, V280, P2244, DOI 10.1074/jbc.M408612200; KEATING DH, 1995, J BIOL CHEM, V270, P22229, DOI 10.1074/jbc.270.38.22229; KIM YM, 1990, PROTEINS, V8, P377, DOI 10.1002/prot.340080411; Lambalot RH, 1997, METHOD ENZYMOL, V279, P254; Lambalot RH, 1996, CHEM BIOL, V3, P923, DOI 10.1016/S1074-5521(96)90181-7; Lan R, 2004, INFECT IMMUN, V72, P5080, DOI 10.1128/IAI.72.9.5080-5088.2004; Lu ZJ, 1996, J BIOL CHEM, V271, P5059; McAllister KA, 2000, J BIOL CHEM, V275, P30864, DOI 10.1074/jbc.M004475200; Mofid MR, 2002, J BIOL CHEM, V277, P17023, DOI 10.1074/jbc.M200120200; Nakanishi M, 2001, J BIOL CHEM, V276, P46394, DOI 10.1074/jbc.M104483200; OHLROGGE JB, 1985, J BIOL CHEM, V260, P8032; Parris KD, 2000, STRUCT FOLD DES, V8, P883, DOI 10.1016/S0969-2126(00)00178-7; POLACCO ML, 1981, J BIOL CHEM, V256, P5750; POSTBEITTENMILLER D, 1991, J BIOL CHEM, V266, P1858; POWELL GL, 1969, J BIOL CHEM, V244, P5616; Pupo GM, 2000, P NATL ACAD SCI USA, V97, P10567, DOI 10.1073/pnas.180094797; Quadri LEN, 1998, BIOCHEMISTRY-US, V37, P1585, DOI 10.1021/bi9719861; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAWLINGS M, 1993, THESIS U ILLINOIS UR; ROCK CO, 1979, J BIOL CHEM, V254, P9778; ROCK CO, 1980, ANAL BIOCHEM, V102, P362, DOI 10.1016/0003-2697(80)90168-2; ROCK CO, 1981, J BIOL CHEM, V256, P2669; Rock CO, 2002, BIOCHEM BIOPH RES CO, V292, P1155, DOI 10.1006/bbrc.2001.2022; SHEN ZW, 1992, ANAL BIOCHEM, V204, P34, DOI 10.1016/0003-2697(92)90135-T; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAKIFF HE, 1992, J BACTERIOL, V174, P1544, DOI 10.1128/jb.174.5.1544-1553.1992; Trent MS, 2004, BIOCHEM CELL BIOL, V82, P71, DOI 10.1139/o03-070; VAGELOS PR, 1967, J BIOL CHEM, V242, P1776; VALLARI DS, 1988, J BACTERIOL, V170, P3961, DOI 10.1128/jb.170.9.3961-3966.1988; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; Wada H, 1997, P NATL ACAD SCI USA, V94, P1591, DOI 10.1073/pnas.94.4.1591; Walsh CT, 1997, CURR OPIN CHEM BIOL, V1, P309, DOI 10.1016/S1367-5931(97)80067-1; Waters NC, 2002, MOL BIOCHEM PARASIT, V123, P85, DOI 10.1016/S0166-6851(02)00140-8; WERTMAN KF, 1986, GENE, V49, P253, DOI 10.1016/0378-1119(86)90286-6; Wild J, 2002, GENOME RES, V12, P1434, DOI 10.1101/gr.130502	51	44	50	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34675	34683		10.1074/jbc.M505736200	http://dx.doi.org/10.1074/jbc.M505736200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16107329	hybrid			2022-12-27	WOS:000232403900037
J	Tomura, H; Wang, JQ; Komachi, M; Damirin, A; Mogi, C; Tobo, M; Kon, J; Misawa, N; Sato, K; Okajima, F				Tomura, H; Wang, JQ; Komachi, M; Damirin, A; Mogi, C; Tobo, M; Kon, J; Misawa, N; Sato, K; Okajima, F			Prostaglandin I-2 production and cAMP accumulation in response to acidic extracellular pH through OGR1 in human aortic smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; SPHINGOSINE 1-PHOSPHATE RECEPTORS; SENSITIVE POTASSIUM CHANNELS; K-ATP CHANNELS; INTRACELLULAR ACIDOSIS; LYSOPHOSPHATIDYLCHOLINE; G2A; SPHINGOSYLPHOSPHORYLCHOLINE; IDENTIFICATION; ACTIVATION	Ovarian cancer G-protein-coupled receptor 1 (OGR1) and GPR4 have recently been identified as proton-sensing or extracellular pH-responsive G-protein-coupled receptors stimulating inositol phosphate production and cAMP accumulation, respectively. In the present study, we found that OGR1 and GPR4 mRNAs were expressed in human aortic smooth muscle cells (AoSMCs). Acidic extracellular pH induced inositol phosphate production, a transient increase in intracellular Ca2+ concentration ([Ca2+](i)), and cAMP accumulation in these cells. When small interfering RNAs (siRNAs) targeted for OGR1 and GPR4 were transfected to the cells, the acid-induced inositol phosphate production and [Ca2+](i) increase were markedly inhibited by the OGR1 siRNA but not by the GPR4 siRNA. Unexpectedly, the acid-induced cAMP accumulation was also largely inhibited by OGR1 siRNA but only slightly by GPR4 siRNA. Acidic extracellular pH also stimulated prostaglandin I-2 (PGI(2)) production, which was again inhibited by OGR1 siRNA. The specific inhibitors for extracellular signal-regulated kinase kinase and cyclooxygenase attenuated the acid-induced PGI(2) production and cAMP accumulation without changes in the inositol phosphate production. A specific inhibitor of phospholipase C also inhibited the acid-induced cAMP accumulation. In conclusion, OGR1 is a major receptor involved in the extracellular acid-induced stimulation of PGI(2) production and cAMP accumulation in AoSMCs. The cAMP accumulation may occur through OGR1-mediated stimulation of the phospholipase C/cyclooxygenase/ PGI(2) pathway.	Gunma Univ, Inst Mol & Cellular Regulat, Lab Signal Transduct, Maebashi, Gumma 3718512, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan	Gunma University; Kirin Brewery Company Limited	Tomura, H (corresponding author), Gunma Univ, Inst Mol & Cellular Regulat, Lab Signal Transduct, Maebashi, Gumma 3718512, Japan.	tomurah@showa.gunma-u.ac.jp		Misawa, Norihiko/0000-0003-1373-0769; Sato, Koichi/0000-0001-7694-4014				BATLLE DC, 1993, AM J PHYSIOL, V264, pC932, DOI 10.1152/ajpcell.1993.264.4.C932; Bektas M, 2003, BIOCHEMISTRY-US, V42, P12181, DOI 10.1021/bi035051y; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Bunemann M, 1996, EMBO J, V15, P5527, DOI 10.1002/j.1460-2075.1996.tb00937.x; Damirin A, 2005, MOL PHARMACOL, V67, P1177, DOI 10.1124/mol.104.004317; FITZGERALD GA, 1987, HUM PATHOL, V18, P248, DOI 10.1016/S0046-8177(87)80007-2; Han KH, 2004, J LEUKOCYTE BIOL, V76, P195, DOI 10.1189/jlb.1103563; Hayabuchi Y, 1998, PFLUG ARCH EUR J PHY, V436, P509, DOI 10.1007/s004240050665; Heringdorf DMZ, 2002, BBA-MOL CELL BIOL L, V1582, P178, DOI 10.1016/S1388-1981(02)00154-3; Hyvelin JM, 2004, AM J PHYSIOL-LUNG C, V287, pL673, DOI 10.1152/ajplung.00331.2003; Im DS, 2001, J CELL BIOL, V153, P429, DOI 10.1083/jcb.153.2.429; Ishii S, 2005, J BIOL CHEM, V280, P9083, DOI 10.1074/jbc.M407832200; Ishizaka H, 1999, CIRCULATION, V99, P558, DOI 10.1161/01.CIR.99.4.558; Iwasawa K, 1997, J PHYSIOL-LONDON, V503, P237, DOI 10.1111/j.1469-7793.1997.237bh.x; KIMURA T, 1995, J CARDIOVASC PHARM, V26, P333, DOI 10.1097/00005344-199508000-00021; Klemm DJ, 2001, J BIOL CHEM, V276, P46132, DOI 10.1074/jbc.M104769200; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; KRAMPETZ IK, 1991, AM J PHYSIOL, V260, P516; Kyaw H, 1998, DNA CELL BIOL, V17, P493, DOI 10.1089/dna.1998.17.493; Le LQ, 2001, IMMUNITY, V14, P561, DOI 10.1016/S1074-7613(01)00145-5; Leffler CW, 1999, AM J PHYSIOL-HEART C, V277, pH1878, DOI 10.1152/ajpheart.1999.277.5.H1878; Lin P, 2003, J BIOL CHEM, V278, P14379, DOI 10.1074/jbc.M209101200; Ludwig MG, 2003, NATURE, V425, P93, DOI 10.1038/nature01905; Murakami N, 2004, J BIOL CHEM, V279, P42484, DOI 10.1074/jbc.M406561200; Murata N, 2000, ANAL BIOCHEM, V282, P115, DOI 10.1006/abio.2000.4580; Okajima F, 2002, BBA-MOL CELL BIOL L, V1582, P132, DOI 10.1016/S1388-1981(02)00147-6; Ozkara HA, 2004, BRAIN DEV-JPN, V26, P497, DOI 10.1016/j.braindev.2004.01.005; Radu CG, 2005, P NATL ACAD SCI USA, V102, P1632, DOI 10.1073/pnas.0409415102; Rosenblum WI, 2003, STROKE, V34, P1547, DOI 10.1161/01.STR.0000070425.98202.B5; Sato K, 1999, MOL PHARMACOL, V55, P126, DOI 10.1124/mol.55.1.126; TIAN R, 1995, CIRC RES, V76, P269, DOI 10.1161/01.RES.76.2.269; Tokumura A, 2004, J CELL BIOCHEM, V92, P869, DOI 10.1002/jcb.20147; WALLEY KR, 1990, CIRC RES, V67, P628, DOI 10.1161/01.RES.67.3.628; Wang JQ, 2004, J BIOL CHEM, V279, P45626, DOI 10.1074/jbc.M406966200; Wang XR, 2003, CIRC RES, V92, P1225, DOI 10.1161/01.RES.0000075601.95738.6D; Weber AA, 1998, BASIC RES CARDIOL, V93, P54; Weng ZG, 1998, P NATL ACAD SCI USA, V95, P12334, DOI 10.1073/pnas.95.21.12334; Xu HX, 2001, J BIOL CHEM, V276, P12898, DOI 10.1074/jbc.M009631200; Xu Y, 1996, GENOMICS, V35, P397, DOI 10.1006/geno.1996.0377; Xu Y, 2000, NAT CELL BIOL, V2, P261, DOI 10.1038/35010529; Yamada T, 2004, J BIOL CHEM, V279, P6595, DOI 10.1074/jbc.M308133200; Yan JJ, 2004, NAT MED, V10, P161, DOI 10.1038/nm989; Yang LV, 2005, BLOOD, V105, P1127, DOI 10.1182/blood-2004-05-1916; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200	44	74	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34458	34464		10.1074/jbc.M505287200	http://dx.doi.org/10.1074/jbc.M505287200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16087674	hybrid			2022-12-27	WOS:000232403900012
J	Barker, S; Weinfeld, M; Zheng, J; Li, L; Murray, D				Barker, S; Weinfeld, M; Zheng, J; Li, L; Murray, D			Identification of mammalian proteins cross-linked to DNA by ionizing radiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHINESE-HAMSTER CELLS; DOUBLE-STRAND; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; BIOLOGICAL CONSEQUENCES; THIOREDOXIN PEROXIDASE; HYPOXIC CONDITIONS; HYDROGEN-PEROXIDE; NUCLEAR PROTEINS; HISTONE H3; IN-VITRO	Ionizing radiation (IR) is an important environmental risk factor for various cancers and also a major therapeutic agent for cancer treatment. Exposure of mammalian cells to IR induces several types of damage to DNA, including double- and single-strand breaks, base and sugar damage, as well as DNA-DNA and DNA-protein cross-links (DPCs). Little is known regarding the biological consequences of DPCs. Identifying the proteins that become cross-linked to DNA by IR would be an important first step in this regard. We have therefore undertaken a proteomics study to isolate and identify proteins involved in IR-induced DPCs. DPCs were induced in AA8 Chinese hamster ovary or GM00637 human fibroblast cells using 0 - 4 gray of gamma-rays under either aerated or hypoxic conditions. DPCs were isolated using a recently developed method, and proteins were identified by mass spectrometry. We identified 29 proteins as being cross-linked to DNA by IR under aerated and/or hypoxic conditions. The identified proteins include structural proteins, actin-associated proteins, transcription regulators, RNA-splicing components, stress-response proteins, cell cycle regulatory proteins, and GDP/GTP-binding proteins. The involvement of several proteins ( actin, histone H2B, and others) in DPCs was confirmed by using Western blot analysis. The dose responsiveness of DPC induction was examined by staining one-dimensional SDS-polyacrylamide gels with SYPRO Tangerine followed by analysis using fluorescence imaging. Quantitation of the fluorescence signal indicated no significant difference in total yields of IR-induced DPCs generated under aerated or hypoxic conditions, although differences were observed for several individual protein bands.	Cross Canc Inst, Div Expt Oncol, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Dept Chem W3 39, Edmonton, AB T6G 2G2, Canada	University of Alberta; University of Alberta	Murray, D (corresponding author), Cross Canc Inst, Div Expt Oncol, Dept Oncol, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada.	davem@cancerboard.ab.ca	Li, Liang/D-1822-2011					ABBATE M, 1993, EUR J CELL BIOL, V61, P139; Akhmedov AT, 2000, NUCLEIC ACIDS RES, V28, P3022, DOI 10.1093/nar/28.16.3022; ALEXANDER P, 1960, NATURE, V187, P933, DOI 10.1038/187933b0; AlNabulsi I, 1997, RADIAT RES, V148, P568, DOI 10.2307/3579732; Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Araki M, 2001, J BIOL CHEM, V276, P18665, DOI 10.1074/jbc.M100855200; Barker S, 2005, ANAL BIOCHEM, V344, P204, DOI 10.1016/j.ab.2005.06.039; Barker S, 2005, MUTAT RES-REV MUTAT, V589, P111, DOI 10.1016/j.mrrev.2004.11.003; Batchelor CL, 2004, EXP CELL RES, V296, P208, DOI 10.1016/j.yexcr.2004.02.010; Belyaev IY, 2001, RADIAT RES, V156, P355, DOI 10.1667/0033-7587(2001)156[0355:CICCDR]2.0.CO;2; Berggren MI, 2001, ARCH BIOCHEM BIOPHYS, V392, P103, DOI 10.1006/abbi.2001.2435; Bertrand P, 1999, ONCOGENE, V18, P4515, DOI 10.1038/sj.onc.1203048; Bill CA, 2001, MUTAT RES-DNA REPAIR, V487, P41; BillautMulot O, 1996, GENE, V174, P19, DOI 10.1016/0378-1119(96)00254-5; BOLE DG, 1989, J HISTOCHEM CYTOCHEM, V37, P1817, DOI 10.1177/37.12.2685110; Bouchard WJ, 2003, EXP HEMATOL, V31, P446, DOI 10.1016/S0301-472X(03)00083-3; BoucksonCastaing V, 1996, J CELL SCI, V109, P179; Chai Q, 2003, BIOCHEMISTRY-US, V42, P15045, DOI 10.1021/bi035364t; CHIU SM, 1986, INT J RADIAT ONCOL, V12, P1529, DOI 10.1016/0360-3016(86)90209-9; CHIU SM, 1986, RADIAT RES, V107, P24, DOI 10.2307/3576847; CHIU SM, 1990, INT J RADIAT BIOL, V58, P235, DOI 10.1080/09553009014551591; CHIU SM, 1984, INT J RADIAT BIOL, V46, P681, DOI 10.1080/09553008414551921; Coulombe RA, 1999, TOXICOL APPL PHARM, V154, P198, DOI 10.1006/taap.1998.8552; DIZDAROGLU M, 1989, BIOCHEMISTRY-US, V28, P3625, DOI 10.1021/bi00434a071; Downs JA, 2004, MOL CELL, V16, P979, DOI 10.1016/j.molcel.2004.12.003; ELIA MC, 1992, CANCER RES, V52, P1580; Elphinstone MS, 2003, MOL ECOL NOTES, V3, P317, DOI 10.1046/j.1471-8286.2003.00397.x; Fanta M, 2001, HYBRIDOMA, V20, P237, DOI 10.1089/027245701753179811; FIDLEROVA H, 2005, IN PRESS J CELL BIOC; Ford LP, 2002, ONCOGENE, V21, P580, DOI 10.1038/sj.onc.1205086; FORNACE AJ, 1977, BIOCHIM BIOPHYS ACTA, V477, P343, DOI 10.1016/0005-2787(77)90253-2; FORNACE AJ, 1982, CANCER RES, V42, P145; Friedberg ECW GC, 1995, DNA REPAIR MUTAGENES, P19; GAJEWSKI E, 1988, INT J RADIAT BIOL, V54, P445, DOI 10.1080/09553008814551821; Gruenheid S, 1999, J EXP MED, V189, P831, DOI 10.1084/jem.189.5.831; Hermann Ralph, 2001, Human Antibodies, V10, P83; Hockel M, 2001, SEMIN ONCOL, V28, P36, DOI 10.1016/S0093-7754(01)90211-8; Huang ME, 2003, P NATL ACAD SCI USA, V100, P11529, DOI 10.1073/pnas.2035018100; KOCH CJ, 1984, RADIAT RES, V98, P141, DOI 10.2307/3576058; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; Krynetski EY, 2003, CANCER RES, V63, P100; Kwak IH, 2004, CANCER RES, V64, P572, DOI 10.1158/0008-5472.CAN-03-1856; Laz EV, 2004, MOL CELL PROTEOMICS, V3, P1170, DOI 10.1074/mcp.M400102-MCP200; Lejnine S, 1999, NUCLEIC ACIDS RES, V27, P3676, DOI 10.1093/nar/27.18.3676; Lemos TA, 2003, FEBS LETT, V533, P14, DOI 10.1016/S0014-5793(02)03737-7; Lowell JE, 2004, J CELL SCI, V117, P5937, DOI 10.1242/jcs.01515; Maniatis T., 1982, MOL CLONING; Matsumoto A, 2000, CANCER RES, V60, P3921; Mattagajasingh SN, 1999, MOL CELL BIOCHEM, V199, P149, DOI 10.1023/A:1006910732307; MEE LK, 1981, P NATL ACAD SCI-BIOL, V78, P2194, DOI 10.1073/pnas.78.4.2194; MEYN RE, 1987, RADIAT RES, V109, P419, DOI 10.2307/3577042; MEYN RE, 1986, DNA DAMAGE REPAIR IM, P151; MILLER CA, 1991, CARCINOGENESIS, V12, P269, DOI 10.1093/carcin/12.2.269; Mitsuzawa H, 2005, FEBS LETT, V579, P48, DOI 10.1016/j.febslet.2004.11.045; Murphy GA, 2001, CELL GROWTH DIFFER, V12, P157; Murray D, 1996, INT J RADIAT BIOL, V69, P319, DOI 10.1080/095530096145878; NACKERDIEN Z, 1991, BIOCHEMISTRY-US, V30, P4873, DOI 10.1021/bi00234a006; OCONNOR PM, 1989, J BIOL CHEM, V264, P6391; OLINSKI R, 1992, ARCH BIOCHEM BIOPHYS, V297, P139, DOI 10.1016/0003-9861(92)90651-C; Pouget JP, 2001, EUR J NUCL MED, V28, P541, DOI 10.1007/s002590100484; Przewloka MR, 2003, MOL BIOL CELL, V14, P685, DOI 10.1091/mbc.e01-11-0117; Quievryn G, 2000, CARCINOGENESIS, V21, P1573, DOI 10.1093/carcin/21.8.1573; QUINTILIANI M, 1986, INT J RADIAT BIOL, V50, P573, DOI 10.1080/09553008614550981; RADFORD IR, 1986, INT J RADIAT BIOL, V49, P621; Radyuk SN, 2003, BIOCHEM J, V371, P743, DOI 10.1042/BJ20021522; RAMAKRISHNAN N, 1987, CANCER RES, V47, P2032; Ramirez P, 2000, CARCINOGENESIS, V21, P701, DOI 10.1093/carcin/21.4.701; Ross SJ, 2000, MOL BIOL CELL, V11, P2631, DOI 10.1091/mbc.11.8.2631; Sadacharan SK, 2001, HISTOCHEM CELL BIOL, V116, P507, DOI 10.1007/s00418-001-0344-4; Samuel SK, 1998, CANCER RES, V58, P3004; Tolstonog GV, 2002, DNA CELL BIOL, V21, P213, DOI 10.1089/10445490252925459; Tolstonog GV, 2001, DNA CELL BIOL, V20, P531, DOI 10.1089/104454901317094954; Tsuda M, 2004, J BIOL CHEM, V279, P46843, DOI 10.1074/jbc.M401476200; Vaupel P, 2001, SEMIN ONCOL, V28, P29, DOI 10.1016/S0093-7754(01)90210-6; VERMEULEN W, 1996, HELIX, V1, P22; Voitkun V, 1999, MUTAT RES-FUND MOL M, V424, P97, DOI 10.1016/S0027-5107(99)00011-1; Vorum H, 1999, EXP CELL RES, V248, P473, DOI 10.1006/excr.1999.4431; WOUDSTRA E, 1999, THESIS U GRONINGEN; XUE LY, 1994, INT J RADIAT BIOL, V66, P11, DOI 10.1080/09553009414550901; XUE LY, 1988, RADIAT RES, V116, P89, DOI 10.2307/3577480; You YJ, 2004, AM J PHYSIOL-LUNG C, V286, pL650, DOI 10.1152/ajplung.00170.2003; Zahn RK, 1999, MECH AGEING DEV, V108, P99, DOI 10.1016/S0047-6374(98)00151-1; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5; Zimber A, 2004, CELL SIGNAL, V16, P1085, DOI 10.1016/j.cellsig.2004.03.020; Zinszner H, 1997, ONCOGENE, V14, P451, DOI 10.1038/sj.onc.1200854; Zinszner H, 1997, J CELL SCI, V110, P1741	86	90	95	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33826	33838		10.1074/jbc.M502477200	http://dx.doi.org/10.1074/jbc.M502477200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16093242	hybrid			2022-12-27	WOS:000232229700019
J	Halverson, KM; Panchal, RG; Nguyen, TL; Gussio, R; Little, SF; Misakian, M; Bavari, S; Kasianowicz, JJ				Halverson, KM; Panchal, RG; Nguyen, TL; Gussio, R; Little, SF; Misakian, M; Bavari, S; Kasianowicz, JJ			Anthrax biosensor, protective antigen ion channel asymmetric blockade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYMMETRICAL TETRAALKYLAMMONIUM IONS; PHOSPHOLIPID-BILAYER MEMBRANES; VOLTAGE-DEPENDENT BLOCK; PLANAR LIPID-BILAYERS; LETHAL FACTOR; TOXIN CHANNELS; MONOCLONAL-ANTIBODIES; CRYSTAL-STRUCTURE; MAMMALIAN-CELLS; FACTOR-BINDING	The significant threat posed by biological agents ( e. g. anthrax, tetanus, botulinum, and diphtheria toxins) (Inglesby, T. V., O'Toole, T., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Friedlander, A. M., Gerberding, J., Hauer, J., Hughes, J., McDade, J., Osterholm, M. T., Parker, G., Perl, T. M., Russell, P. K., and Tonat, K. ( 2002) J. Am. Med. Assoc. 287, 2236 - 2252) requires innovative technologies and approaches to understand the mechanisms of toxin action and to develop better therapies. Anthrax toxins are formed from three proteins secreted by fully virulent Bacillus anthracis, protective antigen (PA, 83 kDa), lethal factor (LF, 90 kDa), and edema factor (EF, 89 kDa). Here we present electrophysiological measurements demonstrating that full-length LF and EF convert the current-voltage relationship of the heptameric PA(63) ion channel from slightly nonlinear to highly rectifying and diode-like at pH 6.6. This effect provides a novel method for characterizing functional toxin interactions. The method confirms that a previously well characterized PA(63) monoclonal antibody, which neutralizes anthrax lethal toxin in animals in vivo and in vitro, prevents the binding of LF to the PA(63) pore. The technique can also detect the presence of anthrax lethal toxin complex from plasma of infected animals. The latter two results suggest the potential application of PA(63) nanopore-based biosensors in anthrax therapeutics and diagnostics.	Natl Inst Stand & Technol, Adv Chem Sci Lab, Gaithersburg, MD 20899 USA; Natl Inst Stand & Technol, Elect & Elect Engn Lab, Semicond Engn Div, Gaithersburg, MD 20899 USA; USA, Med Res Inst Infect Dis, Frederick, MD 21702 USA; NCI, Dev Therapeut Program, Target Struct Based Drug Discovery Grp, Sci Applicat Int Corp, Frederick, MD 21702 USA	National Institute of Standards & Technology (NIST) - USA; National Institute of Standards & Technology (NIST) - USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	Kasianowicz, JJ (corresponding author), Natl Inst Stand & Technol, Adv Chem Sci Lab, Bldg 225,Rm B326, Gaithersburg, MD 20899 USA.	john.kasianowicz@nist.gov	Bavari, Sina/L-3642-2019; Panchal, Rekha/None	Bavari, Sina/0000-0001-8424-5635; Panchal, Rekha/0000-0001-8621-9078				Benson EL, 1998, BIOCHEMISTRY-US, V37, P3941, DOI 10.1021/bi972657b; BLAUSTEIN RO, 1990, J GEN PHYSIOL, V96, P921, DOI 10.1085/jgp.96.5.921; BLAUSTEIN RO, 1990, J GEN PHYSIOL, V96, P905, DOI 10.1085/jgp.96.5.905; BLAUSTEIN RO, 1990, J GEN PHYSIOL, V96, P943, DOI 10.1085/jgp.96.5.943; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Chauhan V, 2002, INFECT IMMUN, V70, P4477, DOI 10.1128/IAI.70.8.4477-4484.2002; Cunningham K, 2002, P NATL ACAD SCI USA, V99, P7049, DOI 10.1073/pnas.062160399; Elliott JL, 2000, BIOCHEMISTRY-US, V39, P6706, DOI 10.1021/bi000310u; EZZELL JW, 1992, J GEN MICROBIOL, V138, P543, DOI 10.1099/00221287-138-3-543; FINKELSTEIN A, 1994, TOXICOLOGY, V87, P29, DOI 10.1016/0300-483X(94)90153-8; Inglesby TV, 2002, JAMA-J AM MED ASSOC, V287, P2236, DOI 10.1001/jama.287.17.2236; Kasianowicz JJ, 1996, P NATL ACAD SCI USA, V93, P13770, DOI 10.1073/pnas.93.24.13770; KASIANOWICZ JJ, 1995, BIOPHYS J, V69, P94, DOI 10.1016/S0006-3495(95)79879-4; Kasianowicz JJ, 2001, ANAL CHEM, V73, P2268, DOI 10.1021/ac000958c; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; Leppla S.H., 1991, SOURCEBOOK BACTERIAL, P277; Little SF, 1996, MICROBIOL-SGM, V142, P707, DOI 10.1099/13500872-142-3-707; LITTLE SF, 1988, INFECT IMMUN, V56, P1807, DOI 10.1128/IAI.56.7.1807-1813.1988; Lu Z, 2004, ANNU REV PHYSIOL, V66, P103, DOI 10.1146/annurev.physiol.66.032102.150822; MILNE JC, 1993, MOL MICROBIOL, V10, P647, DOI 10.1111/j.1365-2958.1993.tb00936.x; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; Mourez M, 2002, TRENDS MICROBIOL, V10, P287, DOI 10.1016/S0966-842X(02)02369-7; Nguyen TL, 2004, J BIOMOL STRUCT DYN, V22, P253, DOI 10.1080/07391102.2004.10531226; Panchal RG, 2005, J BIOL CHEM, V280, P10834, DOI 10.1074/jbc.M412210200; Panchal RG, 2004, NAT STRUCT MOL BIOL, V11, P67, DOI 10.1038/nsmb711; Pannifer AD, 2001, NATURE, V414, P229, DOI 10.1038/n35101998; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; QUINN CP, 1991, J BIOL CHEM, V266, P20124; Scobie HM, 2003, P NATL ACAD SCI USA, V100, P5170, DOI 10.1073/pnas.0431098100; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; Singh Y, 1999, INFECT IMMUN, V67, P1853; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Zhang S, 2004, BIOPHYS J, V87, P3842, DOI 10.1529/biophysj.104.050864; ZHAO JM, 1995, J BIOL CHEM, V270, P18626, DOI 10.1074/jbc.270.31.18626	35	69	76	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34056	34062		10.1074/jbc.M507928200	http://dx.doi.org/10.1074/jbc.M507928200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16087661	hybrid			2022-12-27	WOS:000232229700045
J	Buchanan, KT; Ames, JB; Asfaw, SH; Wingard, JN; Olson, CL; Campana, PT; Araujo, APU; Engman, DM				Buchanan, KT; Ames, JB; Asfaw, SH; Wingard, JN; Olson, CL; Campana, PT; Araujo, APU; Engman, DM			A flagellum-specific calcium sensor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTORECEPTOR GUANYLYL CYCLASE; TRYPANOSOMA-CRUZI; BINDING-PROTEINS; CA-2+-BINDING PROTEIN; CA2+-BINDING SITES; RHODOPSIN KINASE; FREEZE-FRACTURE; DNA-BINDING; RECOVERIN; MEMBRANE	The flagellar calcium-binding protein ( FCaBP) of the flagellated protozoan Trypanosoma cruzi associates with the flagellar membrane via its N-terminal myristate and palmitate moieties in a calcium-modulated, conformation-dependent manner. This mechanism of localization is similar to that described for neuronal calcium sensors, which undergo calcium-dependent changes in conformation, which modulate the availability of the acyl groups for membrane interaction and partner association. To test whether FCaBP undergoes a calcium-dependent conformational change and to explore the role of such a change in flagellar targeting, we first introduced point mutations into each of the two EF-hand calcium-binding sites of FCaBP to define their affinities. Analysis of recombinant EF-3 mutant ( E151Q), EF-4 mutant ( E188Q), and double mutant proteins showed EF-3 to be the high affinity site ( K-d similar to 9 mu M) and EF-4 the low affinity site ( K-d similar to 120 mu M). These assignments also correlated with partial ( E188Q), nearly complete ( E151Q), and complete ( E151Q, E188Q) disruption of calcium-induced conformational changes determined by NMR spectrometry. We next expressed the FCaBP E151Q mutant and the double mutant in T. cruzi epimastigotes. These transproteins localized to the flagellum, suggesting the existence of a calcium-dependent interaction of FCaBP that is independent of its intrinsic calcium binding capacity. Several proteins were identified by FCaBP affinity chromatography that interact with FCaBP in a calcium-dependent manner, but with differential dependence on calcium-binding by FCaBP. These findings may have broader implications for the calcium acyl switch mechanism of protein regulation.	Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Dept Microbiol & Immunol, Feinberg Sch Med, Chicago, IL 60611 USA; Inst Fis Sao Carlos, Dept Fis & Informat, Sao Carlos, SP, Brazil; Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA	Northwestern University; Northwestern University; Feinberg School of Medicine; University System of Maryland; University of Maryland Baltimore	Engman, DM (corresponding author), Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA.	d-engman@northwestern.edu	Campana, Patricia T/C-5703-2012; Campana, Patricia/GLS-1060-2022; Araujo, Ana Paula U/I-6664-2012; Engman, David/T-6747-2018	Campana, Patricia T/0000-0002-2337-6372; Campana, Patricia/0000-0002-2337-6372; Araujo, Ana Paula U/0000-0001-5455-084X; Engman, David/0000-0001-5869-9844	NATIONAL EYE INSTITUTE [R01EY012347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046781] Funding Source: NIH RePORTER; NIAID NIH HHS [AI46781] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alekseev AM, 1998, FEBS LETT, V440, P116, DOI 10.1016/S0014-5793(98)01426-4; Ames JB, 2000, BIOCHEMISTRY-US, V39, P12149, DOI 10.1021/bi0012890; Ames JB, 2002, BIOCHEMISTRY-US, V41, P5776, DOI 10.1021/bi012153k; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; BECKINGHAM K, 1991, J BIOL CHEM, V266, P6027; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHEN CK, 1995, J BIOL CHEM, V270, P18066; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; ENGMAN DM, 1989, J BIOL CHEM, V264, P18627; Ermilov AN, 2001, J BIOL CHEM, V276, P48143, DOI 10.1074/jbc.M107539200; Felleisen RSJ, 2001, PARASITOLOGY, V122, P125, DOI 10.1017/S0031182001007168; Godsel LM, 1999, EMBO J, V18, P2057, DOI 10.1093/emboj/18.8.2057; GORODOVIKOVA EN, 1993, FEBS LETT, V335, P277, DOI 10.1016/0014-5793(93)80746-H; KIRCHHOFF LV, 1985, JAMA-J AM MED ASSOC, V254, P3058, DOI 10.1001/jama.254.21.3058; LEE MG, 1990, NUCLEIC ACIDS RES, V18, P4252, DOI 10.1093/nar/18.14.4252; Maldonado RA, 1999, MOL BIOCHEM PARASIT, V101, P61, DOI 10.1016/S0166-6851(99)00055-9; Maldonado RA, 1997, EXP PARASITOL, V86, P200, DOI 10.1006/expr.1997.4159; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; McFerran BW, 1999, J BIOL CHEM, V274, P30258, DOI 10.1074/jbc.274.42.30258; Olshevskaya EV, 1999, J BIOL CHEM, V274, P25583, DOI 10.1074/jbc.274.36.25583; Osawa M, 2005, J BIOL CHEM, V280, P18008, DOI 10.1074/jbc.M500338200; Osawa M, 2001, J BIOL CHEM, V276, P41005, DOI 10.1074/jbc.M105842200; Permyakov SE, 2000, PROTEIN ENG, V13, P783, DOI 10.1093/protein/13.11.783; Pinto APA, 2003, BBA-PROTEINS PROTEOM, V1652, P107, DOI 10.1016/j.bbapap.2003.08.008; Porcel BM, 1996, EXP PARASITOL, V84, P387, DOI 10.1006/expr.1996.0127; Ridgley E, 2000, MOL BIOCHEM PARASIT, V109, P195, DOI 10.1016/S0166-6851(00)00246-2; Rosenbaum JL, 2002, NAT REV MOL CELL BIO, V3, P813, DOI 10.1038/nrm952; Sanada K, 1996, FEBS LETT, V384, P227, DOI 10.1016/0014-5793(96)00318-3; Senin II, 2004, J BIOL CHEM, V279, P48647, DOI 10.1074/jbc.M402516200; Senin II, 2002, J BIOL CHEM, V277, P50365, DOI 10.1074/jbc.M204338200; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SOUTOPADRON T, 1983, J PARASITOL, V69, P129, DOI 10.2307/3281287; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; TETLEY L, 1986, ACTA TROP, V43, P307; TIBBETTS RS, 1995, EXP PARASITOL, V80, P572, DOI 10.1006/expr.1995.1071; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tull D, 2004, MOL BIOL CELL, V15, P4775, DOI 10.1091/mbc.E04-06-0457; WU YM, 1994, BIOCHEM J, V304, P833, DOI 10.1042/bj3040833; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	39	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40104	40111		10.1074/jbc.M505777200	http://dx.doi.org/10.1074/jbc.M505777200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16148003	hybrid			2022-12-27	WOS:000233461300049
J	Tang, ZS; El Far, O; Betz, H; Scheschonka, A				Tang, ZS; El Far, O; Betz, H; Scheschonka, A			Pias1 interaction and sumoylation of metabotropic glutamate receptor 8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE-RECEPTOR; PRESYNAPTIC LOCALIZATION; C-TERMINUS; FILAMIN-A; SUMO; UBIQUITIN; PROTEINS; BINDING; RAT; CALMODULIN	Group III presynaptic metabotropic glutamate receptors (mGluRs) play a central role in regulating presynaptic activity through G-protein effects on ion channels and signal transducing enzymes. Like all Class C G-protein-coupled receptors, mGluR8 has an extended intracellular C-terminal domain (CTD) presumed to allow for modulation of downstream signaling. In a yeast two-hybrid screen of an adult rat brain cDNA library with the CTDs of mGluR8a and 8b (mGluR8-C) as baits, we identified sumo1 and four different components of the sumoylation cascade (ube2a, Pias1, Pias gamma, Piasx beta) as interacting proteins. Binding assays using recombinant GST fusion proteins confirmed that Pias1 interacts not only with mGluR8-C but also with all group III mGluR CTDs. Pias1 binding to mGluR8-C required a region N-terminal to a consensus sumoylation motif and was not affected by arginine substitution of the conserved lysine 882 within this motif. Co-transfection of fluorescently tagged mGluR8a-C, sumo1, and enzymes of the sumoylation cascade into HEK293 cells showed that mGluR8a-C can be sumoylated in vivo. Arginine substitution of lysine 882 within the consensus sumoylation motif, but not other conserved lysines within the CTD, abolished in vivo sumoylation. Our results are consistent with post-translational sumoylation providing a novel mechanism of group III mGluR regulation.	MPI Brain Res, Dept Neurochem, D-60528 Frankfurt, Germany		Betz, H (corresponding author), MPI Brain Res, Dept Neurochem, Deutschordenstr 46, D-60528 Frankfurt, Germany.	neurochemie@mpih-frankfurt.mpg.de; scheschonka@mpih-frankfurt.mpg.de	Far, Oussama El/D-4225-2017; EL FAR, Oussama/P-9915-2019	Far, Oussama El/0000-0002-7473-8345; EL FAR, Oussama/0000-0002-7473-8345				Airas JM, 2001, FEBS LETT, V494, P60, DOI 10.1016/S0014-5793(01)02311-0; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Corti C, 1998, EUR J NEUROSCI, V10, P3629, DOI 10.1046/j.1460-9568.1998.00371.x; Dev KK, 2001, TRENDS PHARMACOL SCI, V22, P355, DOI 10.1016/S0165-6147(00)01684-9; DUVOISIN RM, 1995, J NEUROSCI, V15, P3075; El Far O, 2001, J BIOL CHEM, V276, P30662, DOI 10.1074/jbc.M102573200; El Far O, 2000, EUR J NEUROSCI, V12, P4215, DOI 10.1046/j.1460-9568.2000.01309.x; Enz R, 2003, BIOCHEM J, V372, P183, DOI 10.1042/BJ20021750; Enz R, 2002, FEBS LETT, V514, P184, DOI 10.1016/S0014-5793(02)02361-X; Gerlai R, 2002, NEUROPHARMACOLOGY, V43, P235, DOI 10.1016/S0028-3908(02)00078-3; Giorgino F, 2000, P NATL ACAD SCI USA, V97, P1125, DOI 10.1073/pnas.97.3.1125; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Iacovelli L, 2004, MOL PHARMACOL, V65, P1103, DOI 10.1124/mol.65.5.1103; Ishikawa K, 1999, GENES CELLS, V4, P381, DOI 10.1046/j.1365-2443.1999.00269.x; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; Kammermeier PJ, 2001, BMC NEUROSCI, V2, DOI 10.1186/1471-2202-2-15; Kinoshita A, 1996, NEUROSCI LETT, V207, P61, DOI 10.1016/0304-3940(96)12489-7; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Lalioti VS, 2002, J BIOL CHEM, V277, P19783, DOI 10.1074/jbc.M110294200; Linden AM, 2002, NEUROPHARMACOLOGY, V43, P251, DOI 10.1016/S0028-3908(02)00079-5; Marchese Adriano, 2004, Methods Mol Biol, V259, P299; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Mishra RK, 2004, J BIOL CHEM, V279, P31445, DOI 10.1074/jbc.M402911200; Moriyoshi K, 2004, P NATL ACAD SCI USA, V101, P8614, DOI 10.1073/pnas.0403042101; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; NAKANISHI S, 1994, EXS, V71, P71; Nakanishi S, 1998, BRAIN RES REV, V26, P230, DOI 10.1016/S0165-0173(97)00033-7; O'Connor V, 1999, SCIENCE, V286, P1180, DOI 10.1126/science.286.5442.1180; Okubo S, 2004, J BIOL CHEM, V279, P31455, DOI 10.1074/jbc.M403561200; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Rajan S, 2005, CELL, V121, P37, DOI 10.1016/j.cell.2005.01.019; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Saugstad JA, 1997, MOL PHARMACOL, V51, P119, DOI 10.1124/mol.51.1.119; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Shigemoto R, 1997, J NEUROSCI, V17, P7503, DOI 10.1523/jneurosci.17-19-07503.1997; Song J, 2004, P NATL ACAD SCI USA, V101, P14373, DOI 10.1073/pnas.0403498101; Steffan JS, 2004, SCIENCE, V304, P100, DOI 10.1126/science.1092194; Suzuki T, 1999, J BIOL CHEM, V274, P31131, DOI 10.1074/jbc.274.44.31131; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; Ungureanu D, 2003, BLOOD, V102, P3311, DOI 10.1182/blood-2002-12-3816; Zhao YM, 2004, J BIOL CHEM, V279, P20999, DOI 10.1074/jbc.M401541200	46	57	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38153	38159		10.1074/jbc.M508168200	http://dx.doi.org/10.1074/jbc.M508168200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16144832	hybrid			2022-12-27	WOS:000233239800007
J	Athenstaedt, K; Daum, G				Athenstaedt, K; Daum, G			Tgl4p and Tgl5p, two triacylglycerol lipases of the yeast Saccharomyces cerevisiae are localized to lipid particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOCHEMICAL-CHARACTERIZATION; CELLS; PROTEINS; ESTERS; GENE; STEROIDOGENESIS; IDENTIFICATION; LIPOPROTEINS; METABOLISM; HYDROLASE	Triacylglycerol ( TAG) lipases are required for mobilization of TAG stored in lipid particles. Recently, Tgl3p was identified as a major TAG lipase of the yeast Saccharomyces cerevisiae ( Athenstaedt, K., and Daum, G. ( 2003) J. Biol. Chem. 278, 23317 - 23323). Here, we report the identification of Tgl4p and Tgl5p as additional TAG lipases of the yeast. Both polypeptides, encoded by open reading frames YKR089c/TGL4 and YOR081c/TGL5, share 30 and 26% homology, respectively, to Tgl3p. Cell fractionation experiments and microscopic inspection of strains bearing Tgl4p-GFP and Tgl5p-GFP hybrids demonstrated that both proteins are localized to lipid particles similar to Tgl3p. A 1.7-fold increased amount of TAG enriched in myristic and palmitic acids and the reduced mobilization rate of TAG from tgl4 Delta in the presence of the fatty acid synthesis inhibitor cerulenin demonstrated the lipolytic function of Tgl4p in vivo. In contrast, neither the total amount of TAG nor the TAG mobilization rate after addition of cerulenin was affected in tgl5 Delta cells. However, the enrichment of C26: 0 esterified to TAG of tgl5 Delta, an additional increase of TAG in the tgl4 Delta tgl5 Delta double deletion mutant compared with tgl4 Delta, and the impairment of TAG mobilization in the tgl4 Delta tgl5 Delta strain in the presence of cerulenin suggested that also Tgl5p functions as a TAG lipase in vivo. Most importantly, the purified His(6)-tagged Tgl4p and Tgl5p hybrids exhibited TAG lipase activity demonstrating their function in vitro. In summary, our data obtained by biochemical, molecular, and cell biological analyses unambiguously identified Tgl4p and Tgl5p as novel TAG lipases of yeast lipid particles with certain enzymatic specificities.	Graz Univ Technol, Inst Biochem, A-8010 Graz, Austria	Graz University of Technology	Daum, G (corresponding author), Graz Univ Technol, Inst Biochem, Petersgasse 12-2, A-8010 Graz, Austria.	guenther.daum@tugraz.at		Athenstaedt, Karin/0000-0001-7198-3989				Athenstaedt K, 2003, J BIOL CHEM, V278, P23317, DOI 10.1074/jbc.M302577200; Athenstaedt K, 1999, J BACTERIOL, V181, P6441, DOI 10.1128/JB.181.20.6441-6448.1999; BISGAIER CL, 1985, J STEROID BIOCHEM, V23, P967, DOI 10.1016/0022-4731(85)90054-8; FOLCH J, 1957, J BIOL CHEM, V226, P497; FREEMAN DA, 1982, J BIOL CHEM, V257, P4231; GIETZ RD, 1995, METHODS MOL CELL BIO, V43, P177; GWYNNE JT, 1982, ENDOCR REV, V3, P299, DOI 10.1210/edrv-3-3-299; HAID A, 1983, METHOD ENZYMOL, V96, P192; HUANG AHC, 1992, ANNU REV PLANT PHYS, V43, P177, DOI 10.1146/annurev.pp.43.060192.001141; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; HUXLEY C, 1990, TRENDS GENET, V6, P236, DOI 10.1016/0168-9525(90)90190-H; Jandrositz A, 2005, BBA-MOL CELL BIOL L, V1735, P50, DOI 10.1016/j.bbalip.2005.04.005; Koffel R, 2005, MOL CELL BIOL, V25, P1655, DOI 10.1128/MCB.25.5.1655-1668.2005; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leber R, 1998, MOL BIOL CELL, V9, P375, DOI 10.1091/mbc.9.2.375; LEBER R, 1994, YEAST, V10, P1421, DOI 10.1002/yea.320101105; Lee GC, 2002, BIOCHEM J, V366, P603, DOI 10.1042/BJ20020404; Lehner R, 1999, BIOCHEM J, V338, P761, DOI 10.1042/0264-6021:3380761; LONDOS C, 1995, BIOCHEM SOC T, V23, P611, DOI 10.1042/bst0230611; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORRISON WR, 1964, J LIPID RES, V5, P600; MURPHY DJ, 1990, PROG LIPID RES, V29, P299; Oelkers P, 2002, J BIOL CHEM, V277, P8877, DOI 10.1074/jbc.M111646200; PICKERS P, 2005, FUNGAL GENET BIOL, V42, P264; Schmitt J, 2002, PROTEIN ENG, V15, P595, DOI 10.1093/protein/15.7.595; Schorling S, 2001, MOL BIOL CELL, V12, P3417, DOI 10.1091/mbc.12.11.3417; Sorger D, 2002, J BACTERIOL, V184, P519, DOI 10.1128/JB.184.2.519-524.2002; Spalinger JH, 1998, BBA-LIPID LIPID MET, V1393, P119, DOI 10.1016/S0005-2760(98)00068-X; Sztalryd C, 2003, J CELL BIOL, V161, P1093, DOI 10.1083/jcb.200210169; TAKETANI S, 1978, BIOCHIM BIOPHYS ACTA, V525, P87, DOI 10.1016/0005-2744(78)90202-4; WELLER PF, 1994, J ALLERGY CLIN IMMUN, V94, P1151, DOI 10.1016/0091-6749(94)90325-5; WIGGINS D, 1992, BIOCHEM J, V284, P457, DOI 10.1042/bj2840457; YANG LY, 1995, J LIPID RES, V36, P125; Zhang Q, 2003, J BIOL CHEM, V278, P47145, DOI 10.1074/jbc.M306998200; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602; ZINSER E, 1993, J BACTERIOL, V175, P2853, DOI 10.1128/JB.175.10.2853-2858.1993; Zweytick D, 2000, BBA-REV BIOMEMBRANES, V1469, P101, DOI 10.1016/S0005-2736(00)00294-7	39	152	161	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37301	37309		10.1074/jbc.M507261200	http://dx.doi.org/10.1074/jbc.M507261200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16135509	hybrid			2022-12-27	WOS:000233044500003
J	Cargnin, F; Flora, A; Di Lascio, S; Battaglioli, E; Longhi, R; Clementi, F; Fornasari, D				Cargnin, F; Flora, A; Di Lascio, S; Battaglioli, E; Longhi, R; Clementi, F; Fornasari, D			PHOX2B regulates its own expression by a transcriptional auto-regulatory mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-HYPOVENTILATION-SYNDROME; BONE MORPHOGENETIC PROTEINS; NICOTINIC RECEPTOR SUBUNIT; HOMEOBOX GENE PHOX2B; SYMPATHETIC NEURON DEVELOPMENT; FUNCTIONAL-CHARACTERIZATION; POLYALANINE EXPANSIONS; FRAMESHIFT MUTATIONS; SIGNAL-TRANSDUCTION; AUTONOMIC NEURONS	The specification of neuronal identity is a result of interactions between the following two distinct classes of determinants: extrinsic factors that include secreted or cell membrane-associated signals in the local environment, and intrinsic factors that generally consist of ordered cascades of transcription factors. Little is known about the molecular mechanisms underlying the interplay between these extrinsic and intrinsic factors and the transcriptional processes that establish and maintain a given neuronal phenotype. Phox2b is a vertebrate homeodomain transcription factor and a well established intrinsic factor in developing autonomic ganglia, where its expression is triggered by the bone morphogenic proteins secreted by the dorsal aorta. In this study we characterized its proximal 5'-regulatory region and found that it contained five putative DNA sites that potentially bind homeodomain proteins, including PHOX2B itself. Chromatin immunoprecipitation assays showed that PHOX2B could bind its own promoter in vivo, and electromobility gel shift assays confirmed that four of the five sites could be involved in PHOX2B binding. Functional experiments demonstrated that 65% of the transcriptional activity of the PHOX2B promoter in neuroblastoma cells depends on this auto-regulatory mechanism and that all four sites were required for full self-transactivation. Our data provide a possible molecular explanation for the maintenance of PHOX2B expression in developing ganglia, in which initially its expression is triggered by bone morphogenic proteins, but may become independent of external stimuli when it reaches a certain nuclear concentration and sustains its own transcription.	Univ Milan, Sch Med, Dept Pharmacol, I-20129 Milan, Italy; CNR, Inst Neurosci, I-20129 Milan, Italy; Univ Milan, Ctr Excellence Neurodegenerat Dis, I-20129 Milan, Italy; Univ Milan, Dept Biol & Genet Med Sci, I-20129 Milan, Italy; CNR, Inst Chem & Mol Recognit, I-20129 Milan, Italy	University of Milan; Consiglio Nazionale delle Ricerche (CNR); University of Milan; University of Milan; Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica del Riconoscimento Molecolare (ICRM-CNR)	Fornasari, D (corresponding author), Univ Milan, Sch Med, Dept Pharmacol, Via Vanvitelli 32, I-20129 Milan, Italy.	diego.fornasari@unimi.it	Flora, Adriano/A-9663-2008; battaglioli, elena/H-9350-2017	Battaglioli, Elena/0000-0001-9168-7212; DI LASCIO, SIMONA/0000-0002-5971-1515; Fornasari, Diego/0000-0002-9668-3103				Adachi M, 2002, J BIOL CHEM, V277, P22915, DOI 10.1074/jbc.M201695200; Amiel J, 2003, NAT GENET, V33, P459, DOI 10.1038/ng1130; Bachetti T, 2005, HUM MOL GENET, V14, P1815, DOI 10.1093/hmg/ddi188; Ballas N, 2001, NEURON, V31, P353, DOI 10.1016/S0896-6273(01)00371-3; Battaglioli E, 1998, J NEUROCHEM, V71, P1261; Battaglioli E, 2002, J BIOL CHEM, V277, P41038, DOI 10.1074/jbc.M205691200; Brunet JF, 2002, CURR OPIN GENET DEV, V12, P435, DOI 10.1016/S0959-437X(02)00322-2; Campos-Caro A, 1999, J BIOL CHEM, V274, P4693, DOI 10.1074/jbc.274.8.4693; Chen D, 2004, FRONT BIOSCI-LANDMRK, V9, P349, DOI 10.2741/1090; DESILVESTRIS M, 1995, FEBS LETT, V370, P69, DOI 10.1016/0014-5793(95)00797-D; Dubreuil W, 2002, DEVELOPMENT, V129, P5241; Edlund T, 1999, CELL, V96, P211, DOI 10.1016/S0092-8674(00)80561-9; FIELDS C G, 1991, Peptide Research, V4, P95; Flora A, 2000, J NEUROCHEM, V75, P18, DOI 10.1046/j.1471-4159.2000.0750018.x; Flora A, 2001, J NEUROSCI, V21, P7037, DOI 10.1523/JNEUROSCI.21-18-07037.2001; Gaultier C, 2003, RESP PHYSIOL NEUROBI, V136, P105, DOI 10.1016/S1569-9048(03)00075-2; Goridis C, 2002, NAT REV NEUROSCI, V3, P531, DOI 10.1038/nrn871; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hong SJ, 2004, MOL BRAIN RES, V125, P29, DOI 10.1016/j.molbrainres.2004.02.023; Hong SJ, 2001, J NEUROCHEM, V79, P1225, DOI 10.1046/j.1471-4159.2001.00672.x; Howard MJ, 2005, DEV BIOL, V277, P271, DOI 10.1016/j.ydbio.2004.09.034; KING DS, 1990, INT J PEPT PROT RES, V36, P255; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; Matera I, 2004, J MED GENET, V41, P373, DOI 10.1136/jmg.2003.015412; Pattyn A, 2000, MOL CELL NEUROSCI, V15, P235, DOI 10.1006/mcne.1999.0826; Pattyn A, 1999, NATURE, V399, P366, DOI 10.1038/20700; Rohrer H, 2003, DRUG NEWS PERSPECT, V16, P589, DOI 10.1358/dnp.2003.16.9.829341; Samad OA, 2004, DEVELOPMENT, V131, P4071, DOI 10.1242/dev.01282; Stanke M, 2004, MOL CELL NEUROSCI, V25, P374, DOI 10.1016/j.mcn.2003.10.021; ten Dijke P, 2003, J BONE JOINT SURG AM, V85A, P34; Terzano S, 2000, J BIOL CHEM, V275, P41495, DOI 10.1074/jbc.M006197200	32	34	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37439	37448		10.1074/jbc.M508368200	http://dx.doi.org/10.1074/jbc.M508368200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16144830	hybrid			2022-12-27	WOS:000233044500019
J	Holmes, WF; Braastad, CD; Mitra, P; Hampe, C; Doenecke, D; Albig, W; Stein, JL; van Wijnen, AJ; Stein, GS				Holmes, WF; Braastad, CD; Mitra, P; Hampe, C; Doenecke, D; Albig, W; Stein, JL; van Wijnen, AJ; Stein, GS			Coordinate control and selective expression of the full complement of replication-dependent histone H4 genes in normal and cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS H4TF-1; PROTEIN-DNA INTERACTIONS; FACTOR HINF-D; CYCLE TRANSITION; MESSENGER-RNA; FACTOR IRF-2; G1/S PHASE; S-PHASE; PROMOTER; DIFFERENTIATION	The replication of eukaryotic genomes necessitates the coordination of histone biosynthesis with DNA replication at the onset of S phase. The multiple histone H4 genes encode identical proteins, but their regulatory sequences differ. The contributions of these individual genes to histone H4 mRNA expression have not been described. We have determined, by real-time quantitative PCR and RNase protection, that the human histone H4 genes are not equally expressed and that a subset contributes disproportionately to the total pool of H4 mRNA. Differences in histone H4 gene expression can be attributed to observed unequal activities of the H4 gene promoters, which exhibit variations in gene regulatory elements. The overall expression pattern of the histone H4 gene complement is similar in normal and cancer cells. However, H4 genes that are moderately expressed in normal cells are sporadically silenced in tumor cells with compensation of expression by other H4 gene copies. Chromatin immunoprecipitation analyses and in vitro DNA binding assays indicated that 11 of the 15 histone H4 genes interact with the cell cycle regulatory histone nuclear factor P, which forms a complex with the cyclin E/CDK2-responsive co-regulator p220(NPAT). These 11 H4 genes account for 95% of the histone H4 mRNA pool. We conclude that the cyclin E/CDK2/p220(NPAT)/ histone nuclear factor P signaling pathway is the principal regulator of histone H4 biosynthesis.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01655 USA; Univ Gottingen, Inst Biochem & Mol Cell Biol, D-37073 Gottingen, Germany	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Gottingen	Stein, GS (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, 55 Lake Ave N, Worcester, MA 01655 USA.	gary.stein@umassmed.edu	van Wijnen, Andre J./AAG-3578-2019	van Wijnen, Andre J./0000-0002-4458-0946	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032010] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM032010, GM32010] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albig W, 1997, HUM GENET, V101, P284, DOI 10.1007/s004390050630; Aziz F, 1998, J CELL PHYSIOL, V177, P453, DOI 10.1002/(SICI)1097-4652(199812)177:3<453::AID-JCP8>3.0.CO;2-F; Braastad CD, 2004, GENE, V342, P35, DOI 10.1016/j.gene.2004.07.036; DAILEY L, 1988, GENE DEV, V2, P1700, DOI 10.1101/gad.2.12b.1700; DAILEY L, 1987, MOL CELL BIOL, V7, P4582, DOI 10.1128/MCB.7.12.4582; Dominski Z, 1999, GENE, V239, P1, DOI 10.1016/S0378-1119(99)00367-4; HOLTHUIS J, 1990, SCIENCE, V247, P1454, DOI 10.1126/science.2321007; Hovhannisyan H, 2003, MOL CELL BIOL, V23, P1460, DOI 10.1128/MCB.23.4.1460-1469.2003; Jaskelioff M, 2003, NAT CELL BIOL, V5, P395, DOI 10.1038/ncb0503-395; Koessler H, 2003, DNA CELL BIOL, V22, P233, DOI 10.1089/104454903321908629; LICHTLER AC, 1980, P NATL ACAD SCI-BIOL, V77, P1942, DOI 10.1073/pnas.77.4.1942; LICHTLER AC, 1982, NATURE, V298, P195, DOI 10.1038/298195a0; Liss B, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf088; Miele A, 2005, MOL CELL BIOL, V25, P6140, DOI 10.1128/MCB.25.14.6140-6153.2005; Mitra P, 2003, MOL CELL BIOL, V23, P8110, DOI 10.1128/MCB.23.22.8110-8123.2003; OSLEY MA, 1991, ANNU REV BIOCHEM, V60, P827, DOI 10.1146/annurev.biochem.60.1.827; PAULI U, 1987, SCIENCE, V236, P1308, DOI 10.1126/science.3035717; PLUMB M, 1983, NUCLEIC ACIDS RES, V11, P7927, DOI 10.1093/nar/11.22.7927; RAMSEYEWING A, 1994, P NATL ACAD SCI USA, V91, P4475, DOI 10.1073/pnas.91.10.4475; Stein GS, 1996, CELL BIOL INT, V20, P41, DOI 10.1006/cbir.1996.0007; Stein GS, 1984, HISTONE GENES; van der Meijden CMJ, 1998, BBA-GENE STRUCT EXPR, V1442, P82, DOI 10.1016/S0167-4781(98)00147-X; VANWIJNEN AJ, 1992, MOL CELL BIOL, V12, P3273, DOI 10.1128/MCB.12.7.3273; vanWijnen AJ, 1996, P NATL ACAD SCI USA, V93, P11516, DOI 10.1073/pnas.93.21.11516; VANWIJNEN AJ, 1991, J CELL BIOCHEM, V46, P174, DOI 10.1002/jcb.240460211; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; Vaughan PS, 1998, J BIOL CHEM, V273, P194, DOI 10.1074/jbc.273.1.194	27	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37400	37407		10.1074/jbc.M506995200	http://dx.doi.org/10.1074/jbc.M506995200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16131487	hybrid			2022-12-27	WOS:000233044500014
J	Fay, N; Redeker, V; Savistchenko, J; Dubois, S; Bousset, L; Melki, R				Fay, N; Redeker, V; Savistchenko, J; Dubois, S; Bousset, L; Melki, R			Structure of the prion Ure2p in protein fibrils assembled in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; GLUTATHIONE; FILAMENTS; DOMAIN; CONFORMATION; REGIONS; FORM	The Ure2 protein from the yeast Saccharomyces cerevisiae has prion properties. In vitro and at neutral pH, soluble Ure2p spontaneously forms long, straight, insoluble protein fibrils. Two models have been proposed to account for the assembly of Ure2p into protein fibrils. The "amyloid backbone" model postulates that a segment ranging from 40 to 70 amino acids in the flexible N-terminal domain from different Ure2p molecules forms a parallel superpleated beta-structure running along the fibrils ( Kajava, A. V., Baxa, U., Wickner, R. B., and Steven, A. C. ( 2004) Proc. Natl. Acad. Sci. U. S. A. 101, 7885 - 7890). The second model hypothesizes that assembly of full-length Ure2p is driven by limited conformational rearrangements and non-native inter- and/or intramolecular interactions between Ure2p monomers (Bousset, L., Thomson, N. H., Radford, S. E., and Melki, R. ( 2002) EMBO J. 21, 2903 - 2911). Here, we performed a cysteine scan on residues located in the N- and C-terminal parts of Ure2p to determine whether these domains interact. Amino acid sequences centered around residue 6 in the N- terminal domain of Ure2p and residue 137 in the C-terminal moiety interacted at least transiently via intramolecular interactions. We documented the assembly properties of a Ure2p variant in which a disulfide bond was established between the N- and C-terminal domains and showed that it possesses assembly properties indistinguishable from those of wild-type Ure2p. We probed the structure of Ure2pC6C137 within the fibrils and demonstrate that the polypeptide is in a conformation similar to that of its soluble assembly-competent state. Our results constitute the first structural characterization of the N- terminal domain of Ure2p in both its soluble assembly-competent and fibrillar forms. Our data indicate that the flexibility of the N- terminal domain and conformational changes within this domain are essential for fibril formation and provide new insight into the conformational rearrangements that lead to the assembly of Ure2p into fibrils and the propagation of the [URE3] phenotype in yeast.	CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Redeker, V (corresponding author), CNRS, Lab Enzymol & Biochim Struct, Ave Terrassee, F-91198 Gif Sur Yvette, France.	redeker@lebs.cnrs-gif.fr	Savistchenko, Jimmy/A-6448-2011; Redeker, Virginie/L-8929-2018	Redeker, Virginie/0000-0003-2694-8388; bousset, luc/0000-0002-0433-4337				*APPL BIOS, 1993, US B APPL BIOS, V58; Bai M, 2004, J BIOL CHEM, V279, P50025, DOI 10.1074/jbc.M406612200; Baxa U, 2005, J STRUCT BIOL, V150, P170, DOI 10.1016/j.jsb.2005.02.007; Baxa U, 2003, J BIOL CHEM, V278, P43717, DOI 10.1074/jbc.M306004200; Bousset L, 2001, BIOCHEMISTRY-US, V40, P13564, DOI 10.1021/bi011007b; Bousset L, 2004, BIOCHEMISTRY-US, V43, P5022, DOI 10.1021/bi049828e; Bousset L, 2003, J STRUCT BIOL, V141, P132, DOI 10.1016/S1047-8477(02)00606-8; Bousset L, 2002, EMBO J, V21, P2903, DOI 10.1093/emboj/cdf303; Bousset L, 2001, STRUCTURE, V9, P39, DOI 10.1016/S0969-2126(00)00553-0; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; COURCHESNE WE, 1988, J BACTERIOL, V170, P708, DOI 10.1128/jb.170.2.708-713.1988; Fay N, 2003, J BIOL CHEM, V278, P30199, DOI 10.1074/jbc.M303000200; Fernandez-Bellot E, 2000, EMBO J, V19, P3215, DOI 10.1093/emboj/19.13.3215; Fernandez-Bellot E, 1999, BIOCHEM J, V338, P403, DOI 10.1042/0264-6021:3380403; Jiang Y, 2004, J BIOL CHEM, V279, P3361, DOI 10.1074/jbc.M310494200; Kajava AV, 2004, P NATL ACAD SCI USA, V101, P7885, DOI 10.1073/pnas.0402427101; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LACROUTE F, 1971, J BACTERIOL, V106, P519, DOI 10.1128/JB.106.2.519-522.1971; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maddelein ML, 1999, MOL CELL BIOL, V19, P4516; MASISON DC, 1995, SCIENCE, V270, P93, DOI 10.1126/science.270.5233.93; McParland VJ, 2000, BIOCHEMISTRY-US, V39, P8735, DOI 10.1021/bi000276j; MITCHELL AP, 1984, MOL CELL BIOL, V4, P2758, DOI 10.1128/MCB.4.12.2758; Perrett S, 1999, J MOL BIOL, V290, P331, DOI 10.1006/jmbi.1999.2872; Pierce MM, 2005, BIOCHEMISTRY-US, V44, P321, DOI 10.1021/bi047964d; Thual C, 1999, J BIOL CHEM, V274, P13666, DOI 10.1074/jbc.274.19.13666; Thual C, 2001, BIOCHEMISTRY-US, V40, P1764, DOI 10.1021/bi001916l; Umland TC, 2001, P NATL ACAD SCI USA, V98, P1459, DOI 10.1073/pnas.041607898; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Xu SH, 2001, BIOPHYS J, V81, P446, DOI 10.1016/S0006-3495(01)75712-8	30	25	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37149	37158		10.1074/jbc.M506917200	http://dx.doi.org/10.1074/jbc.M506917200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16131495	hybrid			2022-12-27	WOS:000232901800073
J	Freche, B; Guillaumot, P; Charmetant, J; Pelletier, L; Luquain, C; Christiansen, D; Billaud, M; Manie, SN				Freche, B; Guillaumot, P; Charmetant, J; Pelletier, L; Luquain, C; Christiansen, D; Billaud, M; Manie, SN			Inducible dimerization of RET reveals a specific AKT deregulation in oncogenic signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; LIPID RAFTS; CELL-LINE; C-RET; AUTOPHOSPHORYLATION SITES; NEUROTROPHIC FACTOR; NEURONAL SURVIVAL; ACTIVATION; MEMBRANE; MUTATIONS	Dominant-activating mutations in the RET ( rearranged during transfection) proto-oncogene, a receptor tyrosine kinase, are causally associated with the development of multiple endocrine neoplasia type 2A (MEN2A) syndrome. Such oncogenic RET mutations induce its ligand-independent constitutive activation, but whether it spreads identical signaling to ligand-induced signaling is uncertain. To address this question, we designed a cellular model in which RET can be activated either by its natural ligand, or alternatively, by controlled dimerization of the protein that mimics MEN2A dimerization. We have shown that controlled dimerization leaves proximal RET signaling intact but impacts substantially on the tuning of the distal AKT kinase activation ( delayed and sustained). In marked contrast, distal activation of ERK remained unaffected. We further demonstrated that specific temporal adjustment of ligand-induced AKT activation is dependent upon a lipid-based cholesterol-sensitive environment, and this control step is bypassed by MEN2A RET mutants. Therefore, these studies revealed that MEN2A mutations propagate previously unappreciated subtle differences in signaling pathways and unravel a role for lipid rafts in the temporal regulation of AKT activation.	Fac Med, UMR 5201, Lab Genet Mol Signalisat & Canc, F-69373 Lyon, France; Univ Lyon 1, UMR 754, Lab Retrovirus & Pathol Comparee, F-69366 Lyon, France; Austin Hlth, Austin Res Inst, Heidelberg, Vic 3084, Australia	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Austin Research Institute; Florey Institute of Neuroscience & Mental Health	Manie, SN (corresponding author), Fac Med, UMR 5201, Lab Genet Mol Signalisat & Canc, 8 Ave Rockefeller, F-69373 Lyon, France.	manie@sante.univ-lyon1.fr	Billaud, Marc N/M-6954-2013; Manie, Serge/ABC-8331-2021	manie, serge/0000-0002-9168-1977				Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Caroni P, 2001, EMBO J, V20, P4332, DOI 10.1093/emboj/20.16.4332; Chappuis-Flament S, 1998, ONCOGENE, V17, P2851, DOI 10.1038/sj.onc.1202202; Clackson T, 1998, P NATL ACAD SCI USA, V95, P10437, DOI 10.1073/pnas.95.18.10437; Cosma MP, 1998, MOL CELL BIOL, V18, P3321, DOI 10.1128/MCB.18.6.3321; DI FP, 1987, CELL, V51, P1063; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; Eng C, 1999, J CLIN ONCOL, V17, P380, DOI 10.1200/JCO.1999.17.1.380; Golub T, 2004, CURR OPIN NEUROBIOL, V14, P542, DOI 10.1016/j.conb.2004.08.003; Hansford JR, 2000, J MED GENET, V37, P817, DOI 10.1136/jmg.37.11.817; Heerklotz H, 2002, BIOPHYS J, V83, P2693, DOI 10.1016/S0006-3495(02)75278-8; Heerklotz H, 2003, J MOL BIOL, V329, P793, DOI 10.1016/S0022-2836(03)00504-7; Ichihara M, 2004, CANCER LETT, V204, P197, DOI 10.1016/S0304-3835(03)00456-7; Incoronato M, 2004, CELL SIGNAL, V16, P847, DOI 10.1016/j.cellsig.2004.01.002; JUNG T, 1993, J IMMUNOL METHODS, V159, P197, DOI 10.1016/0022-1759(93)90158-4; Kusumi A, 2004, TRAFFIC, V5, P213, DOI 10.1111/j.1600-0854.2004.0178.x; Kwik J, 2003, P NATL ACAD SCI USA, V100, P13964, DOI 10.1073/pnas.2336102100; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; Leppanen VM, 2004, EMBO J, V23, P1452, DOI 10.1038/sj.emboj.7600174; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Mograbi B, 2001, MOL CELL BIOL, V21, P6719, DOI 10.1128/MCB.21.20.6719-6730.2001; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Nichols B, 2003, J CELL SCI, V116, P4707, DOI 10.1242/jcs.00840; Paratcha G, 2001, NEURON, V29, P171, DOI 10.1016/S0896-6273(01)00188-X; Pasini A, 1997, ONCOGENE, V15, P393, DOI 10.1038/sj.onc.1201199; Poteryaev D, 1999, FEBS LETT, V463, P63, DOI 10.1016/S0014-5793(99)01590-2; Rajendran L, 2005, J CELL SCI, V118, P1099, DOI 10.1242/jcs.01681; Saito K, 2003, IMMUNITY, V19, P669, DOI 10.1016/S1074-7613(03)00297-8; Salvatore D, 2000, J CLIN ENDOCR METAB, V85, P3898, DOI 10.1210/jc.85.10.3898; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; Sharma P, 2004, CELL, V116, P577, DOI 10.1016/S0092-8674(04)00167-9; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Sprong H, 2001, NAT REV MOL CELL BIO, V2, P504, DOI 10.1038/35080071; Tansey MG, 2000, NEURON, V25, P611, DOI 10.1016/S0896-6273(00)81064-8; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; Trupp M, 1998, MOL CELL NEUROSCI, V11, P47, DOI 10.1006/mcne.1998.0667; van Weering DHJ, 1998, J BIOL CHEM, V273, P12077, DOI 10.1074/jbc.273.20.12077; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; Vidalain PO, 2000, EMBO J, V19, P3304, DOI 10.1093/emboj/19.13.3304; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4	46	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36584	36591		10.1074/jbc.M505707200	http://dx.doi.org/10.1074/jbc.M505707200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16123037	hybrid			2022-12-27	WOS:000232901800008
J	Lingwood, D; Harauz, G; Ballantyne, JS				Lingwood, D; Harauz, G; Ballantyne, JS			Regulation of fish gill Na+-K+-ATPase by selective sulfatide-enriched raft partitioning during seawater adaptation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-PUMP; NA/K-ATPASE; OPERCULAR EPITHELIUM; SIGNAL-TRANSDUCTION; ALPHA-SUBUNIT; LIPID RAFTS; MEMBRANE; CELLS; TRANSPORT; RAINBOW	Na+- K+-ATPase is arguably the most important enzyme in the animal cell plasma membrane, but the role of the membrane in its regulation is poorly understood. We investigated the relationship between Na+-K+-ATPase and membrane microdomains or "lipid rafts" enriched in sulfatide ( sulfogalactosylceramide/SGC), a glycosphingolipid implicated as a cofactor for this enzyme, in the basolateral membrane of rainbow trout gill epithelium. Our studies demonstrated that when trout adapt to seawater (33 ppt), Na+- K+-ATPase relocates to these structures. Arylsulfatase-induced desulfation of basolateral membrane SGC prevented this relocation and significantly reduced Na+- K+-ATPase activity in seawater but not freshwater trout. We contend that Na+- K+-ATPase partitions into SGC-enriched rafts to help facilitate the up-regulation of its activity during seawater adaptation. We also suggest that differential partitioning of Na+- K+-ATPase between these novel SGC-enriched regulatory platforms results in two distinct, physiological Na+ transport modes. In addition, we extend the working definition of cholesterol-dependent raft integrity to structural dependence on the sulfate moiety of SGC in this membrane.	Univ Guelph, Dept Integrat Biol, Guelph, ON N1G 2W1, Canada; Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada	University of Guelph; University of Guelph	Lingwood, D (corresponding author), Max Planck Inst Mol Cell Biol & Genet, Pfotenhauerstr 108, D-01307 Dresden, Germany.	lingwood@mpi-cbg.de		Harauz, George/0000-0002-6114-9947				ABRAMSON MB, 1967, BIOCHEMISTRY-US, V6, P295, DOI 10.1021/bi00853a046; Blanco G, 1998, AM J PHYSIOL-RENAL, V275, pF633, DOI 10.1152/ajprenal.1998.275.5.F633; BOGGS JM, 1987, BIOCHIM BIOPHYS ACTA, V906, P353, DOI 10.1016/0304-4157(87)90017-7; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CORNELIUS F, 1991, BIOCHIM BIOPHYS ACTA, V1071, P19, DOI 10.1016/0304-4157(91)90011-K; Dalskov SM, 2005, NEUROCHEM INT, V46, P489, DOI 10.1016/j.neuint.2004.11.010; DeBruin LS, 2005, J NEUROSCI RES, V80, P211, DOI 10.1002/jnr.20452; Evans DH, 2005, PHYSIOL REV, V85, P97, DOI 10.1152/physrev.00050.2003; GIBBS A, 1989, J EXP BIOL, V143, P475; GOLDIN SM, 1974, J BIOL CHEM, V249, P5907; GONZALEZ E, 1983, BIOCHIM BIOPHYS ACTA, V728, P66, DOI 10.1016/0005-2736(83)90437-6; GONZALEZ M, 1979, J MEMBRANE BIOL, V51, P347, DOI 10.1007/BF01869091; Hilgemann D W, 2001, Sci STKE, V2001, pre19, DOI 10.1126/stke.2001.111.re19; HOCHACHKA PW, 1984, BIOCH ADAPTION; Ishibashi T, 2002, J NEUROSCI, V22, P6507; JEDLICKI A, 1985, ARCH BIOCHEM BIOPHYS, V238, P558, DOI 10.1016/0003-9861(85)90200-0; KARLSSON KA, 1992, APMIS, V100, P71; KARLSSON KA, 1982, BIOL MEMBR, V4, P1; KARLSSON KA, 1977, STRUCTURE BIOL MEMBR, P245; Kushi Y, 1996, BBA-LIPID LIPID MET, V1304, P254, DOI 10.1016/S0005-2760(96)00125-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND SC, 1994, AM J PHYSIOL, V266, pC1028, DOI 10.1152/ajpcell.1994.266.4.C1028; Lee TH, 1998, AM J PHYSIOL-REG I, V275, pR926, DOI 10.1152/ajpregu.1998.275.3.R926; Lingwood D, 2004, J MEMBRANE BIOL, V201, P77, DOI 10.1007/s00232-004-0708-3; Liu JA, 2005, KIDNEY INT, V67, P1844, DOI 10.1111/j.1523-1755.2005.00283.x; Marshall WS, 1998, J EXP BIOL, V201, P1959; MARSHALL WS, 1993, P NATL ACAD SCI USA, V90, P5504, DOI 10.1073/pnas.90.12.5504; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; Nutikka A, 2003, GLYCOCONJUGATE J, V20, P33, DOI 10.1023/B:GLYC.0000016740.69726.fb; Ohta K, 1999, BIOCHEM BIOPH RES CO, V258, P616, DOI 10.1006/bbrc.1999.0686; Pelis RM, 2001, AM J PHYSIOL-REG I, V280, pR1844, DOI 10.1152/ajpregu.2001.280.6.R1844; PERRY SF, 1988, AM J PHYSIOL, V254, pR491, DOI 10.1152/ajpregu.1988.254.3.R491; PROVERBIO F, 1991, COMP BIOCHEM PHYS A, V99, P279, DOI 10.1016/0300-9629(91)90002-T; Radeva G, 2004, BIOCHEM J, V380, P219, DOI 10.1042/BJ20031348; Richards JG, 2003, J EXP BIOL, V206, P4475, DOI 10.1242/jeb.00701; Rolfe DFS, 1997, PHYSIOL REV, V77, P731, DOI 10.1152/physrev.1997.77.3.731; Sakamoto T, 2002, J COMP PHYSIOL B, V172, P447, DOI 10.1007/s00360-002-0274-z; Schuck S, 2004, J CELL SCI, V117, P5955, DOI 10.1242/jcs.01596; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Singer TD, 1998, AM J PHYSIOL-CELL PH, V274, pC715, DOI 10.1152/ajpcell.1998.274.3.C715; Suzuki Y, 1999, J BIOL CHEM, V274, P11376, DOI 10.1074/jbc.274.16.11376; Tillman TS, 2003, CELL BIOCHEM BIOPHYS, V38, P161, DOI 10.1385/CBB:38:2:161; Ura K, 1996, ZOOL SCI, V13, P219, DOI 10.2108/zsj.13.219; VENTRELLA V, 1992, COMP BIOCHEM PHYS B, V101, P1, DOI 10.1016/0305-0491(92)90149-L; Ventrella V, 2001, PHYSIOL BIOCHEM ZOOL, V74, P694, DOI 10.1086/322964; Wang HJ, 2004, J BIOL CHEM, V279, P17250, DOI 10.1074/jbc.M313239200; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Xie ZJ, 2003, ANN NY ACAD SCI, V986, P497, DOI 10.1111/j.1749-6632.2003.tb07234.x; Yuan ZK, 2005, MOL BIOL CELL, V16, P4034, DOI 10.1091/mbc.E05-04-0295; ZAMBRANO F, 1981, J MEMBRANE BIOL, V63, P71, DOI 10.1007/BF01969447; ZAMBRANO F, 1987, ARCH BIOCHEM BIOPHYS, V253, P87, DOI 10.1016/0003-9861(87)90640-0	52	36	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36545	36550		10.1074/jbc.M506670200	http://dx.doi.org/10.1074/jbc.M506670200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16096276	hybrid			2022-12-27	WOS:000232901800003
J	Hung, JJ; Wu, CY; Liao, PC; Chang, WC				Hung, JJ; Wu, CY; Liao, PC; Chang, WC			Hsp90 alpha recruited by Sp1 is important for transcription of 12(S)-lipoxygenase in A431 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; O-GLYCOSYLATION; GENE-EXPRESSION; DNA-BINDING; HSP90-BINDING IMMUNOPHILINS; MOLECULAR CHAPERONES; PROMOTER ACTIVATION; ARACHIDONIC-ACID; HSP90; PROTEIN	Sp1 is a basic transcriptional factor that binds to the GC-rich region in the promoter of the target gene. It is involved in transcription of numerous genes by recruiting transcriptional factors to the promoters of target genes. In this study, we found in vivo and in vitro that Hsp90 alpha was recruited to the GC-rich region of the 12(S)-lipoxygenase promoter through interaction with Sp1 in A431 cells by employing DNA affinity immunoprecipitation assay and chromatin immunoprecipitation assay. When Hsp90 alpha was inhibited by geldanamycin ( GA, a specific inhibitor of the Hsp90 family) or by siRNA of Hsp90 alpha ( to block its activity or to knockdown protein levels), respectively, luciferase activity ( driven by the 12( S)-lipoxygenase promoter) and both mRNA and protein levels of 12( S)- lipoxygenase were reduced significantly in cells. In addition, the effect of GA was abolished when the Sp1 binding sites of 12( S)lipoxygenase were mutated in A431 cells. Interestingly, binding of Sp1 to the 12( S)- lipoxygenase promoter was also decreased upon GA treatment in cells. In conclusion, our results indicate that Sp1 interacts with Hsp90 alpha to recruit it to the promoter of 12( S)- lipoxygenase and then to regulate gene transcription by modulating the binding ability of Sp1 to promoters.	Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Occupat Hlth, Tainan 701, Taiwan	National Cheng Kung University; National Cheng Kung University	Chang, WC (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 701, Taiwan.	wcchang@mail.ncku.edu.tw	HUNG, Jan-Jong/G-7872-2011					Alekseev OM, 2005, J BIOL CHEM, V280, P2904, DOI 10.1074/jbc.M410397200; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Bedin M, 2004, INT J CANCER, V109, P643, DOI 10.1002/ijc.20010; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; Boulon S, 2002, MOL CELL BIOL, V22, P7769, DOI 10.1128/MCB.22.22.7769-7779.2002; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Brasse-Lagnel C, 2003, J BIOL CHEM, V278, P52504, DOI 10.1074/jbc.M306752200; Broemer M, 2004, ONCOGENE, V23, P5378, DOI 10.1038/sj.onc.1207705; Chang WC, 2003, PROSTAG OTH LIPID M, V71, P277, DOI 10.1016/S1098-8823(03)00048-0; CHANG WC, 1993, J BIOL CHEM, V268, P18734; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Citri A, 2004, CELL CYCLE, V3, P51; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Dunah AW, 2002, SCIENCE, V296, P2238, DOI 10.1126/science.1072613; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; Eustace BK, 2004, NAT CELL BIOL, V6, P507, DOI 10.1038/ncb1131; FOJAS DB, 2001, EMBO J, V20, P5737; Gale M, 2002, BIOCHEMISTRY-US, V41, P11878, DOI 10.1021/bi020397e; Galigniana MD, 2004, J BIOL CHEM, V279, P22483, DOI 10.1074/jbc.M402223200; Garfinkel Mark D, 2004, Methods Mol Biol, V287, P151; GASC JM, 1990, EXP CELL RES, V186, P362, DOI 10.1016/0014-4827(90)90317-4; Gerges NZ, 2004, J NEUROSCI, V24, P4758, DOI 10.1523/JNEUROSCI.0594-04.2004; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Grammatikakis N, 2002, J BIOL CHEM, V277, P8312, DOI 10.1074/jbc.M109200200; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P3400, DOI 10.1073/pnas.71.9.3400; HAMMARSTROM S, 1975, P NATL ACAD SCI USA, V72, P5130, DOI 10.1073/pnas.72.12.5130; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Hu YZ, 2003, J BIOL CHEM, V278, P17299, DOI 10.1074/jbc.M300788200; Huang YC, 2004, ONCOGENE, V23, P4856, DOI 10.1038/sj.onc.1207621; Hubert DA, 2003, EMBO J, V22, P5679, DOI 10.1093/emboj/cdg547; IWAMOTO I, 1990, NEUROPEPTIDES, V16, P103, DOI 10.1016/0143-4179(90)90119-J; JACKSON S, 1993, ADV SEC MESS PHOSPH, V28, P279; Jez JM, 2003, CHEM BIOL, V10, P361, DOI 10.1016/S1074-5521(03)00075-9; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kamemura K, 2003, PROG NUCLEIC ACID RE, V73, P107, DOI 10.1016/S0079-6603(03)01004-3; Kang HT, 2003, J BIOL CHEM, V278, P51223, DOI 10.1074/jbc.M307332200; Kimmins S, 2000, CELL STRESS CHAPERON, V5, P76, DOI 10.1379/1466-1268(2000)005<0076:MOSRAE>2.0.CO;2; Liang P, 1997, J CELL SCI, V110, P1431; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Liu YW, 1997, BIOCHEM J, V324, P133, DOI 10.1042/bj3240133; Longshaw VM, 2004, J CELL SCI, V117, P701, DOI 10.1242/jcs.00905; Muramatsu T, 1996, J PROTEIN CHEM, V15, P709, DOI 10.1007/BF01887144; Murphy PJM, 2004, J BIOL CHEM, V279, P30195, DOI 10.1074/jbc.M403539200; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Pearl LH, 2000, CURR OPIN STRUC BIOL, V10, P46, DOI 10.1016/S0959-440X(99)00047-0; Piatelli MJ, 2002, J BIOL CHEM, V277, P12144, DOI 10.1074/jbc.M200102200; Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491; Pratt WB, 2004, CELL SIGNAL, V16, P857, DOI 10.1016/j.cellsig.2004.02.004; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; Ryu H, 2003, P NATL ACAD SCI USA, V100, P4281, DOI 10.1073/pnas.0737363100; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; Sinars CR, 2003, P NATL ACAD SCI USA, V100, P868, DOI 10.1073/pnas.0231020100; Sugawara T, 2004, J ENDOCRINOL INVEST, V27, P133, DOI 10.1007/BF03346258; Sumanasekera WK, 2003, BIOCHEMISTRY-US, V42, P10726, DOI 10.1021/bi0347353; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; SZPIRER J, 1991, GENOMICS, V11, P168, DOI 10.1016/0888-7543(91)90114-T; Taatjes DJ, 2002, SCIENCE, V295, P1058, DOI 10.1126/science.1065249; Tago K, 2004, MOL CELL ENDOCRINOL, V213, P131, DOI 10.1016/j.mce.2003.10.057; Tyan YC, 2005, PROTEOMICS, V5, P1062, DOI 10.1002/pmic.200401041; Wang YN, 2003, J BIOL CHEM, V278, P45848, DOI 10.1074/jbc.M302630200; Wu YZ, 2003, ONCOGENE, V22, P8891, DOI 10.1038/sj.onc.1206898; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Young JC, 2004, NAT REV MOL CELL BIO, V5, P781, DOI 10.1038/nrm1492; Zhang YB, 2004, GENE, V325, P43, DOI 10.1016/j.gene.2003.09.039	69	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36283	36292		10.1074/jbc.M504904200	http://dx.doi.org/10.1074/jbc.M504904200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16118214	hybrid			2022-12-27	WOS:000232726900061
J	Kegel, KB; Sapp, E; Yoder, J; Cuiffo, B; Sobin, L; Kim, YJ; Qin, ZH; Hayden, MR; Aronin, N; Scott, DL; Isenberg, F; Goldmann, WH; DiFiglia, M				Kegel, KB; Sapp, E; Yoder, J; Cuiffo, B; Sobin, L; Kim, YJ; Qin, ZH; Hayden, MR; Aronin, N; Scott, DL; Isenberg, F; Goldmann, WH; DiFiglia, M			Huntingtin associates with acidic phospholipids at the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTANT HUNTINGTIN; HOMOLOGY DOMAINS; BINDING-PROTEIN; HEAT REPEATS; SWISS-MODEL; WILD-TYPE; CLATHRIN; HIP1; ENDOCYTOSIS; EXPRESSION	We have identified a domain in the N terminus of huntingtin that binds to membranes. A three-dimensional homology model of the structure of the binding domain predicts helical HEAT repeats, which emanate a positive electrostatic potential, consistent with a charge-based mechanism for membrane association. An amphipathic helix capable of inserting into pure lipid bilayers may serve to anchor huntingtin to the membrane. In cells, N-terminal huntingtin fragments targeted to regions of plasma membrane enriched in phosphatidylinositol 4,5-bisphosphate, receptor bound-transferrin, and endogenous huntingtin. N-terminal huntingtin fragments with an expanded polyglutamine tract aberrantly localized to intracellular regions instead of plasma membrane. Our data support a new model in which huntingtin directly binds membranes through electrostatic interactions with acidic phospholipids.	Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA; Univ British Columbia, Vancouver, BC V5Z 4H4, Canada; Univ Massachusetts, Sch Med, Dept Med & Cell Biol, Worcester, MA 01655 USA; Massachusetts Gen Hosp, Renal Unit, Charlestown, MA 02129 USA; Tech Univ Munich E22, Dept Biophys, D-85747 Garching, Germany; Univ Erlangen Nurnberg, Zent Inst Biomed Tech, D-91052 Erlangen, Germany	Harvard University; Massachusetts General Hospital; University of British Columbia; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Massachusetts General Hospital; Technical University of Munich; University of Erlangen Nuremberg	Kegel, KB (corresponding author), MA Gen Hosp E, Dept Neurol, 114 CNY 16th St,Rm 2125, Charlestown, MA 02129 USA.	kegel@helix.mgh.harvard.edu	Hayden, Michael R/D-8581-2011; Kim, Yun Joong/E-7117-2015; Goldmann, Wolfgang H/H-5572-2013	Hayden, Michael R/0000-0001-5159-1419; Kim, Yun Joong/0000-0002-2956-1552; 	NINDS NIH HHS [NS38194, NS35711, NS16367] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038194, P01NS016367, P50NS016367, R01NS035711] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; BANUELOS S, 1995, J BIOL CHEM, V270, P29910, DOI 10.1074/jbc.270.50.29910; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; Gaidarov I, 1999, J CELL BIOL, V146, P755, DOI 10.1083/jcb.146.4.755; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Harjes P, 2003, TRENDS BIOCHEM SCI, V28, P425, DOI 10.1016/S0968-0004(03)00168-3; Hennig L, 1999, BIOTECHNIQUES, V26, P1170, DOI 10.2144/99266bc02; Huang SH, 2004, MOL CELL BIOL, V24, P9102, DOI 10.1128/MCB.24.20.9102-9123.2004; Hyman J, 2000, J CELL BIOL, V149, P537, DOI 10.1083/jcb.149.3.537; Hyun TS, 2004, J BIOL CHEM, V279, P14294, DOI 10.1074/jbc.M312645200; Kalchman MA, 1997, NAT GENET, V16, P44, DOI 10.1038/ng0597-44; Kegel KB, 2000, J NEUROSCI, V20, P7268, DOI 10.1523/jneurosci.20-19-07268.2000; Kegel KB, 2002, J BIOL CHEM, V277, P7466, DOI 10.1074/jbc.M103946200; Kim M, 1999, J NEUROSCI, V19, P964; Kim YJ, 2001, P NATL ACAD SCI USA, V98, P12784, DOI 10.1073/pnas.221451398; Laux T, 2000, J CELL BIOL, V149, P1455, DOI 10.1083/jcb.149.7.1455; Lemmon MA, 2003, TRAFFIC, V4, P201, DOI 10.1034/j.1600-0854.2004.00071.x; Mao YX, 2001, CELL, V104, P433, DOI 10.1016/S0092-8674(01)00230-6; Mishra SK, 2001, J BIOL CHEM, V276, P46230, DOI 10.1074/jbc.M108177200; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Niggli V, 2001, TRENDS BIOCHEM SCI, V26, P604, DOI 10.1016/S0968-0004(01)01927-2; Okamoto Y, 2002, J BIOL CHEM, V277, P46470, DOI 10.1074/jbc.M207779200; Padron D, 2003, J CELL BIOL, V162, P693, DOI 10.1083/jcb.200302051; Qin ZH, 2003, HUM MOL GENET, V12, P3231, DOI 10.1093/hmg/ddg346; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Seelig A, 2000, J BIOL CHEM, V275, P17954, DOI 10.1074/jbc.M002264200; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; Stevenson JM, 1998, J BIOL CHEM, V273, P22761, DOI 10.1074/jbc.273.35.22761; Szebenyi G, 2003, NEURON, V40, P41, DOI 10.1016/S0896-6273(03)00569-5; TEMPEL M, 1995, BIOPHYS J, V69, P228, DOI 10.1016/S0006-3495(95)79894-0; TEMPEL M, 1994, BIOCHEMISTRY-US, V33, P12565, DOI 10.1021/bi00208a006; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Velier J, 1998, EXP NEUROL, V152, P34, DOI 10.1006/exnr.1998.6832; Waelter S, 2001, HUM MOL GENET, V10, P1807, DOI 10.1093/hmg/10.17.1807; WAINWRIGHT MS, 1995, J NEUROSCI, V15, P676; Wang YQ, 2005, J BIOL CHEM, V280, P284, DOI 10.1074/jbc.M411624200; Wanker EE, 1997, HUM MOL GENET, V6, P487, DOI 10.1093/hmg/6.3.487; Wenk MR, 2004, P NATL ACAD SCI USA, V101, P8262, DOI 10.1073/pnas.0401874101	39	121	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36464	36473		10.1074/jbc.M503672200	http://dx.doi.org/10.1074/jbc.M503672200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16085648	hybrid			2022-12-27	WOS:000232726900080
J	Grinchuk, O; Kozmik, Z; Wu, XF; Tomarev, S				Grinchuk, O; Kozmik, Z; Wu, XF; Tomarev, S			The Optimedin gene is a downstream target of Pax6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRABECULAR MESHWORK CELLS; OLFACTOMEDIN-RELATED PROTEIN; HOMEOBOX-CONTAINING GENE; SEQUENCE TAG ANALYSIS; OPEN-ANGLE GLAUCOMA; DNA-BINDING; ALPHA-LATROTOXIN; SECRETED GLYCOPROTEIN; EXPRESSION PROFILE; COUPLED RECEPTORS	The Optimedin gene, also known as Olfactomedin 3, encodes an olfactomedin domain-containing protein. There are two major splice variants of the Optimedin mRNA, Optimedin A and Optimedin B, transcribed from different promoters. The expression pattern of the Optimedin A variant in the eye and brain overlaps with that for Pax6, which encodes a protein containing the paired and homeobox DNA-binding domains. The Pax6 gene plays a critical role for the development of eyes, central nervous system, and endocrine glands. The proximal promoter of the Optimedin A variant contains a putative Pax6 binding site in position -86/-70. Pax6 binds this site through the paired domain in vitro as judged by electrophoretic mobility shift assay. Mutations in this site eliminate Pax6 binding as well as stimulation of the Optimedin promoter activity by Pax6 in transfection experiments. Pax6 occupies the binding site in the proximal promoter in vivo as demonstrated by the chromatin immunoprecipitation assay. Altogether these results identify the Optimedin gene as a downstream target regulated by Pax6. Although the function of optimedin is still not clear, it is suggested to be involved in cell-cell adhesion and cell attachment to the extracellular matrix. Pax6 regulation of Optimedin in the eye and brain may directly affect multiple developmental processes, including cell migration and axon growth.	NEI, Sect Mol Mech Glaucoma, Mol & Dev Biol Lab, NIH, Bethesda, MD 20892 USA; Acad Sci Czech Republ, Inst Mol Genet, CR-14220 Prague, Czech Republic	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences	Tomarev, S (corresponding author), Bldg 7,Rm 103,7 Mem Dr,MSC 0704, Bethesda, MD 20892 USA.	tomarevs@nei.nih.gov	Kozmik, Zbynek/I-8807-2014; Kozmik, Zbynek/G-3581-2014	Wu, Xiaofang/0000-0002-3782-7701; Kozmik, Zbynek/0000-0002-5850-2105	Intramural NIH HHS Funding Source: Medline; NATIONAL EYE INSTITUTE [Z01EY000311, ZIAEY000311] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adam MF, 1997, HUM MOL GENET, V6, P2091, DOI 10.1093/hmg/6.12.2091; Ahmed F, 2004, INVEST OPHTH VIS SCI, V45, P3081, DOI 10.1167/iovs.04-0302; Azuma N, 2005, HUM MOL GENET, V14, P735, DOI 10.1093/hmg/ddi069; Barembaum M, 2000, NAT CELL BIOL, V2, P219, DOI 10.1038/35008643; Caballero M, 2000, BBA-MOL BASIS DIS, V1502, P447, DOI 10.1016/S0925-4439(00)00068-5; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; Chauhan BK, 2004, NUCLEIC ACIDS RES, V32, P1696, DOI 10.1093/nar/gkh334; Cheung M, 2000, MOL BRAIN RES, V79, P180, DOI 10.1016/S0169-328X(00)00109-1; Cvekl A, 1999, INVEST OPHTH VIS SCI, V40, P1343; Cvekl A, 1996, BIOESSAYS, V18, P621, DOI 10.1002/bies.950180805; DANIELSON PE, 1994, J NEUROSCI RES, V38, P468, DOI 10.1002/jnr.490380413; Davis JA, 1996, J NEUROSCI, V16, P5082; Davletov BA, 1996, J BIOL CHEM, V271, P23239, DOI 10.1074/jbc.271.38.23239; Edelman GM, 1998, BRAIN RES REV, V26, P337, DOI 10.1016/S0165-0173(97)00034-9; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; ESCRIBANO J, 1995, J BIOCHEM-TOKYO, V118, P921, DOI 10.1093/jb/118.5.921; Gan L, 1999, DEV BIOL, V210, P469, DOI 10.1006/dbio.1999.9280; Gobeil S, 2004, INVEST OPHTH VIS SCI, V45, P3560, DOI 10.1167/iovs.04-0300; Gong G, 2004, HUM MOL GENET, V13, pR91, DOI 10.1093/hmg/ddh074; Gonzalez MI, 2002, MOL CELL ENDOCRINOL, V190, P39, DOI 10.1016/S0303-7207(02)00035-7; Graveel CR, 2003, ONCOGENE, V22, P1730, DOI 10.1038/sj.onc.1206309; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; Hatakeyama J, 2004, SEMIN CELL DEV BIOL, V15, P83, DOI 10.1016/j.semcdb.2003.09.005; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; Hillier BJ, 2003, J CELL BIOL, V160, P597, DOI 10.1083/jcb.200210053; Jacobson N, 2001, HUM MOL GENET, V10, P117, DOI 10.1093/hmg/10.2.117; Joe MK, 2003, BIOCHEM BIOPH RES CO, V312, P592, DOI 10.1016/j.bbrc.2003.10.162; Kamachi Y, 2001, GENE DEV, V15, P1272, DOI 10.1101/gad.887101; Kirstein L, 2000, GENES CELLS, V5, P661, DOI 10.1046/j.1365-2443.2000.00355.x; Kondo D, 2000, J AM SOC NEPHROL, V11, P803, DOI 10.1681/ASN.V115803; Koroma BM, 1997, INVEST OPHTH VIS SCI, V38, P108; Kozmik Z, 1997, EMBO J, V16, P6793, DOI 10.1093/emboj/16.22.6793; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Krishnamoorthy RR, 2001, MOL BRAIN RES, V86, P1, DOI 10.1016/S0169-328X(00)00224-2; Kuhlbrodt K, 1998, J BIOL CHEM, V273, P16050, DOI 10.1074/jbc.273.26.16050; Kulkarni NH, 2000, GENET RES, V76, P41, DOI 10.1017/S0016672300004584; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; LI HS, 1994, DEV BIOL, V162, P181, DOI 10.1006/dbio.1994.1077; Liu YH, 2004, HUM MOL GENET, V13, P1193, DOI 10.1093/hmg/ddh128; Matsushita H, 1999, FEBS LETT, V443, P348, DOI 10.1016/S0014-5793(99)00005-8; Meech R, 1999, P NATL ACAD SCI USA, V96, P2420, DOI 10.1073/pnas.96.5.2420; Moreno TA, 2002, MECH DEVELOP, V119, P121, DOI 10.1016/S0925-4773(02)00308-8; Moreno TA, 2001, DEV BIOL, V240, P340, DOI 10.1006/dbio.2001.0472; Mukhopadhyay A, 2004, MOL VIS, V10, P304; Ohto H, 1999, MOL CELL BIOL, V19, P6815; Planque N, 2001, J BIOL CHEM, V276, P29330, DOI 10.1074/jbc.M101812200; Plaza S, 1997, CELL GROWTH DIFFER, V8, P1115; Polansky JR, 1997, OPHTHALMOLOGICA, V211, P126, DOI 10.1159/000310780; Polansky JR, 2000, EYE, V14, P503, DOI 10.1038/eye.2000.137; Rosenbauer F, 2004, BLOOD, V103, P4294, DOI 10.1182/blood-2003-08-2688; Sato M, 2005, P NATL ACAD SCI USA, V102, P5874, DOI 10.1073/pnas.0501972102; Sato S, 2002, HUM MOL GENET, V11, P1045, DOI 10.1093/hmg/11.9.1045; Schedl A, 1996, CELL, V86, P71, DOI 10.1016/S0092-8674(00)80078-1; Schepers GE, 2000, NUCLEIC ACIDS RES, V28, P1473, DOI 10.1093/nar/28.6.1473; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shepard AR, 2001, INVEST OPHTH VIS SCI, V42, P3173; Simpson TI, 2002, BIOESSAYS, V24, P1041, DOI 10.1002/bies.10174; SNYDER DA, 1991, BIOCHEMISTRY-US, V30, P9143, DOI 10.1021/bi00102a004; Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668; STOYKOVA A, 1994, J NEUROSCI, V14, P1395, DOI 10.1523/JNEUROSCI.14-03-01395.1994; Sudhof TC, 2001, ANNU REV NEUROSCI, V24, P933, DOI 10.1146/annurev.neuro.24.1.933; Swiderski RE, 2000, INVEST OPHTH VIS SCI, V41, P3420; Tomarev SI, 1997, P NATL ACAD SCI USA, V94, P2421, DOI 10.1073/pnas.94.6.2421; Tomarev SI, 2003, INVEST OPHTH VIS SCI, V44, P2588, DOI 10.1167/iovs.02-1099; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; Torrado M, 2002, HUM MOL GENET, V11, P1291, DOI 10.1093/hmg/11.11.1291; Tsuda H, 2002, NEURON, V33, P515, DOI 10.1016/S0896-6273(02)00590-1; UWANOGHO D, 1995, MECH DEVELOP, V49, P23, DOI 10.1016/0925-4773(94)00299-3; WALTHER C, 1991, DEVELOPMENT, V113, P1435; Wiebe MS, 2003, J BIOL CHEM, V278, P17901, DOI 10.1074/jbc.M212211200; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; XIANG MQ, 1993, NEURON, V11, P689, DOI 10.1016/0896-6273(93)90079-7; Zeng LC, 2004, FEBS LETT, V571, P74, DOI 10.1016/j.febslet.2004.06.059; Zhang JC, 2002, GENE, V283, P83, DOI 10.1016/S0378-1119(01)00763-6; Zhang WY, 2001, MOL VIS, V7, P1	76	26	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35228	35237		10.1074/jbc.M506195200	http://dx.doi.org/10.1074/jbc.M506195200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16115881	hybrid			2022-12-27	WOS:000232561200020
J	Danielsson, A; Ost, A; Nystrom, FH; Stralfors, P				Danielsson, A; Ost, A; Nystrom, FH; Stralfors, P			Attenuation of insulin-stimulated insulin receptor substrate-1 serine 307 phosphorylation in insulin resistance of type 2 diabetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; AMINO-ACID POLYMORPHISM; GLUCOSE-TRANSPORT; HUMAN ADIPOCYTES; SKELETAL-MUSCLE; OKADAIC ACID; SERINE/THREONINE PHOSPHORYLATION; KINASE-ACTIVITY; IRS-1; ACTIVATION	Insulin resistance is a primary characteristic of type 2 diabetes and likely causally related to the pathogenesis of the disease. It is a result of defects in signal transduction from the cell surface receptor of insulin to target effects. We found that insulin-stimulated phosphorylation of serine 307 ( corresponding to serine 302 in the murine sequence) in the immediate downstream mediator protein of the insulin receptor, insulin receptor substrate-1 (IRS1), is required for efficient insulin signaling and that this phosphorylation is attenuated in adipocytes from patients with type 2 diabetes. Inhibition of serine 307 phosphorylation by rapamycin mimicked type 2 diabetes and reduced the sensitivity of IRS1 tyrosine phosphorylation in response to insulin, while stimulation of the phosphorylation by okadaic acid, in cells from patients with type 2 diabetes, rescued cells from insulin resistance. EC50 for insulin-stimulated phosphorylation of serine 307 was about 0.2 nM with a t(1/2) of about 2 min. The amount of IRS1 was similar in cells from non-diabetic and diabetic subjects. These findings identify a molecular mechanism for insulin resistance in non-selected patients with type 2 diabetes.	Linkoping Univ, Dept Cell Biol, SE-58185 Linkoping, Sweden; Linkoping Univ, Diabet Res Ctr, SE-58185 Linkoping, Sweden	Linkoping University; Linkoping University	Stralfors, P (corresponding author), Linkoping Univ, Dept Cell Biol, SE-58185 Linkoping, Sweden.	peter.stralfors@ibk.liu.se		Stralfors, Peter/0000-0002-1196-1806; Nystrom, Fredrik/0000-0002-1680-1000				Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Almind K, 1996, J CLIN INVEST, V97, P2569, DOI 10.1172/JCI118705; Birnbaum MJ, 2001, J CLIN INVEST, V108, P655, DOI 10.1172/JCI200113714; Carvalho E, 1999, FASEB J, V13, P2173, DOI 10.1096/fasebj.13.15.2173; Cusi K, 2000, J CLIN INVEST, V105, P311, DOI 10.1172/JCI7535; Danielsson A, 2005, FEBS J, V272, P141, DOI 10.1111/j.1432-1033.2004.04396.x; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; Esposito DL, 2003, J CLIN ENDOCR METAB, V88, P1468, DOI 10.1210/jc.2002-020933; Giraud J, 2004, J BIOL CHEM, V279, P3447, DOI 10.1074/jbc.M308631200; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; Greene MW, 2002, BIOCHEMISTRY-US, V41, P7082, DOI 10.1021/bi015992f; Greene MW, 2003, J BIOL CHEM, V278, P8199, DOI 10.1074/jbc.M209153200; Harrington LS, 2005, TRENDS BIOCHEM SCI, V30, P35, DOI 10.1016/j.tibs.2004.11.003; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; Hribal ML, 2000, J CLIN ENDOCR METAB, V85, P2004, DOI 10.1210/jc.85.5.2004; Imai Y, 1997, J CLIN ENDOCR METAB, V82, P4201, DOI 10.1210/jc.82.12.4201; Krook A, 2000, DIABETES, V49, P284, DOI 10.2337/diabetes.49.2.284; Liberman Z, 2005, J BIOL CHEM, V280, P4422, DOI 10.1074/jbc.M410610200; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Paz K, 1997, J BIOL CHEM, V272, P29911, DOI 10.1074/jbc.272.47.29911; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; Rondinone CM, 1999, DIABETOLOGIA, V42, P819, DOI 10.1007/s001250051232; Rondinone CM, 1996, J BIOL CHEM, V271, P18148, DOI 10.1074/jbc.271.30.18148; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; STRALFORS P, 1989, EUR J BIOCHEM, V182, P379, DOI 10.1111/j.1432-1033.1989.tb14842.x; Takano T, 2001, MOL CELL BIOL, V21, P5050, DOI 10.1128/MCB.21.15.5050-5062.2001; Tremblay F, 2005, ENDOCRINOLOGY, V146, P1328, DOI 10.1210/en.2004-0777; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Werner ED, 2004, J BIOL CHEM, V279, P35298, DOI 10.1074/jbc.M405203200; Yoshimura R, 1997, DIABETES, V46, P929, DOI 10.2337/diabetes.46.6.929; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200	36	63	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34389	34392		10.1074/jbc.C500230200	http://dx.doi.org/10.1074/jbc.C500230200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16129690	hybrid			2022-12-27	WOS:000232403900003
J	Zhu, ZY; Ramos, J; Kampa, K; Adimoolam, S; Sirisawad, M; Yu, ZY; Chen, DX; Naumovski, L; Lopez, CD				Zhu, ZY; Ramos, J; Kampa, K; Adimoolam, S; Sirisawad, M; Yu, ZY; Chen, DX; Naumovski, L; Lopez, CD			Control of ASPP2/(53BP2L) protein levels by proteasomal degradation modulates p53 apoptotic function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTHRACYCLINE ANTICANCER AGENTS; MULTIPLE-MYELOMA CELLS; NF-KAPPA-B; INHIBITOR PS-341; DNA-DAMAGE; THERAPEUTIC TARGET; 53BP2; CANCER; INDUCTION; ARREST	The p53 pathway is a central mediator of the apoptotic response. ASPP2/(53BP2L) (apoptosis-stimulating protein of p53 2, also known as 53BP2L) enhances apoptosis through selective stimulation of p53 transactivation of proapoptotic target genes. Although the Rb/E2F pathway regulates ASPP2/(53BP2L) transcription, the complex mechanisms controlling ASPP2/(53BP2L) levels and function remain unknown. We now report that proteasomal degradation modulates ASPP2/(53BP2L) protein levels and apoptotic function. Treatment of cells with proteasomal inhibitors, including the clinically utilized proteasomal inhibitor bortezomib, increases ASPP2/(53BP2L) protein but not RNA levels. Likewise, anthracycline-based chemotherapy, which has multiple mechanisms of action, including proteasomal inhibition, increases ASPP2/(53BP2L) protein but not RNA levels. Proteasomal inhibition or anthracycline treatment increases ASPP2/(53BP2L) protein stability and half-life. Furthermore, the central region of the ASPP2/(53BP2L) protein is ubiquitinated as would be expected for a proteasomal substrate. More importantly, small interfering RNA knockdown of ASPP2/(53BP2L) levels attenuated bortezomib-induced apoptosis, and this effect was greater in wildtype p53 cells. Because elevated levels of ASPP2/(53BP2L) are proapoptotic, these results described an important new molecular mechanism that modulates the p53-ASPP2/(53BP2L) apoptotic pathway.	Pharmacyclics Inc, Sunnyvale, CA 94085 USA; Oregon Hlth & Sci Univ, Dept Med, Div Hematol & Med Oncol, Portland, OR 97239 USA	Pharmacyclics; Oregon Health & Science University	Naumovski, L (corresponding author), Pharmacyclics Inc, Sunnyvale, CA 94085 USA.	lnaumovski@pcyc.com; lopezc@ohsu.edu		Kampa-Schittenhelm, Kerstin/0000-0003-0958-5140	NCI NIH HHS [CA104997, CA076316] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA104997, R01CA076316] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535-6108(04)00120-5; An WG, 2000, LEUKEMIA, V14, P1276, DOI 10.1038/sj.leu.2401812; Ao Y, 2001, ONCOGENE, V20, P2720, DOI 10.1038/sj.onc.1204352; Bergamaschi D, 2004, MOL CELL BIOL, V24, P1341, DOI 10.1128/MCB.24.3.1341-1350.2004; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chen D, 2005, CELL DEATH DIFFER, V12, P358, DOI 10.1038/sj.cdd.4401536; Fogal V, 2005, CELL DEATH DIFFER, V12, P369, DOI 10.1038/sj.cdd.4401562; Fribley A, 2004, MOL CELL BIOL, V24, P9695, DOI 10.1128/MCB.24.22.9695-9704.2004; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Hershko T, 2005, CELL DEATH DIFFER, V12, P377, DOI 10.1038/sj.cdd.4401575; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Iwabuchi K, 1998, J BIOL CHEM, V273, P26061, DOI 10.1074/jbc.273.40.26061; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kiyomiya KI, 2002, INT J ONCOL, V20, P1205; Kiyomiya KI, 2002, INT J ONCOL, V21, P1081; Lin WC, 2001, GENE DEV, V15, P1833; Ling YH, 2003, CLIN CANCER RES, V9, P1145; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Lopez CD, 2000, MOL CELL BIOL, V20, P8018, DOI 10.1128/MCB.20.21.8018-8025.2000; Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099; Mori T, 2000, FEBS LETT, V465, P124, DOI 10.1016/S0014-5793(99)01726-3; Oren M, 2002, BIOCHEM PHARMACOL, V64, P865, DOI 10.1016/S0006-2952(02)01149-8; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Rajkumar SV, 2005, J CLIN ONCOL, V23, P630, DOI 10.1200/JCO.2005.11.030; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Takahashi N, 2004, BIOCHEM BIOPH RES CO, V315, P434, DOI 10.1016/j.bbrc.2004.01.079; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Williams SA, 2003, CANCER RES, V63, P7338; Yang JP, 1999, ONCOGENE, V18, P5177, DOI 10.1038/sj.onc.1202904; Yin D, 2005, ONCOGENE, V24, P344, DOI 10.1038/sj.onc.1208225; YU J, 2003, CANCER BIOL THER, V2, P50	39	27	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34473	34480		10.1074/jbc.M503736200	http://dx.doi.org/10.1074/jbc.M503736200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16091363	hybrid			2022-12-27	WOS:000232403900014
J	Chen, Y; Shertzer, HG; Schneider, SN; Nebert, DW; Dalton, TP				Chen, Y; Shertzer, HG; Schneider, SN; Nebert, DW; Dalton, TP			Glutamate cysteine ligase catalysis - Dependence on ATP and modifier subunit for regulation of tissue glutathione levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; INDUCED OXIDATIVE STRESS; EPITHELIAL L2 CELLS; RAT-KIDNEY; PARKINSONS-DISEASE; MYOCARDIAL-INFARCTION; GENE-EXPRESSION; S-NITROSOTHIOLS; LIGHT SUBUNIT; POLYMORPHISM	Glutamate cysteine ligase (GCL), which synthesizes gamma-glutamyl-cysteine (gamma-GC), is the rate-limiting enzyme in GSH biosynthesis. gamma-GC may be produced by the catalytic subunit GCLC or by the holoenzyme (GCLholo), which comprises GCLC and the modifier subunit GCLM. The Gclm(-/-) knock-out mouse shows tissue levels of GSH that are between 9 and 40% of the Gclm(-/-) wild-type mouse. In the present study, we used recombinant GCLC and GCLM and Gclm(-/-) mice to examine the role of GCLM on gamma-GC synthesis by GCLholo. GCLM decreased the K-m for ATP by similar to 6-fold and, similar to other species, decreased the K-m for glutamate and increased the K-i for feedback inhibition by GSH. Furthermore, GCLM increased by 4.4-fold the K-cat for gamma-GC synthesis; this difference in catalytic efficiency of GCLholo versus GCLC allowed us to derive a mathematical relationship for gamma-GC production and to determine the relative levels of GCLholo and GCLC; in homogenates of brain, liver, and lung, the ratio of GCLC to GCLholo was 7.0, 2.0, and 3.5, respectively. In kidney, however, the relationship between GCLC and GCLholo was complicated. Kidney contains GCLholo, free GCLC, and free GCLM, and free GCLC in kidney cannot interact with GCLM. Taken together, we conclude that, in most tissues, GCLM is limiting, suggesting that an increase in GCLM alone would increase gamma-GC synthesis. On the other hand, our results from kidney suggest that gamma-GC synthesis may be controlled post-translationally.	Univ Cincinnati, Med Ctr, Dept Environm Hlth, Cincinnati, OH 45267 USA; Univ Cincinnati, Med Ctr, Ctr Environm Genet, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Dalton, TP (corresponding author), Univ Cincinnati, Med Ctr, Dept Environm Hlth, Cincinnati, OH 45267 USA.	daltontp@ucmail.uc.edu			NIEHS NIH HHS [R01 ES012463, P30 ES06096, R01 ES10133] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096, R01ES010133, R01ES012463] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arthur JR, 2000, CELL MOL LIFE SCI, V57, P1825; Berman SB, 1999, J NEUROCHEM, V73, P1127, DOI 10.1046/j.1471-4159.1999.0731127.x; Bharath S, 2002, BIOCHEM PHARMACOL, V64, P1037, DOI 10.1016/S0006-2952(02)01174-7; Cai JX, 1997, BIOCHEM J, V326, P167, DOI 10.1042/bj3260167; CAI JX, 1995, MOL PHARMACOL, V48, P212; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Dalton TP, 2000, BIOCHEM BIOPH RES CO, V279, P324, DOI 10.1006/bbrc.2000.3930; Dalton TP, 2004, FREE RADICAL BIO MED, V37, P1511, DOI 10.1016/j.freeradbiomed.2004.06.040; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; Divino JC, 1998, J ENDOCRINOL, V156, P519, DOI 10.1677/joe.0.1560519; Fraser JA, 2002, J BIOL CHEM, V277, P1158, DOI 10.1074/jbc.M106683200; Geerts WJC, 1997, J HISTOCHEM CYTOCHEM, V45, P1217, DOI 10.1177/002215549704500905; GOLDSTEIN L, 1966, AM J PHYSIOL, V210, P661, DOI 10.1152/ajplegacy.1966.210.3.661; Gribble FM, 2000, J BIOL CHEM, V275, P30046, DOI 10.1074/jbc.M001010200; Hogg N, 2002, ANNU REV PHARMACOL, V42, P585, DOI 10.1146/annurev.pharmtox.42.092501.104328; HUANG CS, 1993, J BIOL CHEM, V268, P19675; HUANG CS, 1993, J BIOL CHEM, V268, P20578; Kaplowitz N, 1996, BIOL CHEM H-S, V377, P267; Ko SH, 1997, ANESTHESIOLOGY, V87, P68, DOI 10.1097/00000542-199707000-00010; Koide S, 2003, J AM COLL CARDIOL, V41, P539, DOI 10.1016/S0735-1097(02)02866-8; Kosower N S, 1978, Int Rev Cytol, V54, P109, DOI 10.1016/S0074-7696(08)60166-7; Krzywanski DM, 2004, ARCH BIOCHEM BIOPHYS, V423, P116, DOI 10.1016/j.abb.2003.11.004; Kugiyama K, 2001, AM J PHYSIOL-HEART C, V280, pH264, DOI 10.1152/ajpheart.2001.280.1.H264; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Lipton AJ, 2001, NATURE, V413, P171, DOI 10.1038/35093117; Liu RM, 1996, AM J RESP CELL MOL, V14, P192, DOI 10.1165/ajrcmb.14.2.8630270; Lu SC, 1999, FASEB J, V13, P1169, DOI 10.1096/fasebj.13.10.1169; Marcussen M, 1996, CELL MOTIL CYTOSKEL, V35, P94, DOI 10.1002/(SICI)1097-0169(1996)35:2<94::AID-CM2>3.0.CO;2-I; MEISTER A, 1988, J BIOL CHEM, V263, P17205; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Merad-Boudia M, 1998, BIOCHEM PHARMACOL, V56, P645, DOI 10.1016/S0006-2952(97)00647-3; Moellering D, 1998, ARCH BIOCHEM BIOPHYS, V358, P74, DOI 10.1006/abbi.1998.0854; Nakamura S, 2002, CIRCULATION, V105, P2968, DOI 10.1161/01.CIR.0000019739.66514.1E; Nakamura S, 2003, CIRCULATION, V108, P1425, DOI 10.1161/01.CIR.0000091255.63645.98; Oja SS, 2000, NEUROCHEM INT, V37, P299, DOI 10.1016/S0197-0186(00)00031-0; Pompella A, 2003, BIOCHEM PHARMACOL, V66, P1499, DOI 10.1016/S0006-2952(03)00504-5; Rinaldi R, 2002, DRUG METAB DISPOS, V30, P1053, DOI 10.1124/dmd.30.10.1053; SEELIG GF, 1984, J BIOL CHEM, V259, P9345; SHI MM, 1994, J BIOL CHEM, V269, P26512; Shi ZZ, 2000, P NATL ACAD SCI USA, V97, P5101, DOI 10.1073/pnas.97.10.5101; SMITH JE, 1980, ENZYME, V25, P236, DOI 10.1159/000459258; Sun WM, 1996, BIOCHEM J, V320, P321, DOI 10.1042/bj3200321; Tu ZH, 1998, ARCH BIOCHEM BIOPHYS, V354, P247, DOI 10.1006/abbi.1998.0676; WEBER K, 1969, J BIOL CHEM, V244, P4406; WOODS JS, 1995, BIOCHEM PHARMACOL, V50, P1719, DOI 10.1016/0006-2952(95)02075-6; Yang Y, 2002, J BIOL CHEM, V277, P49446, DOI 10.1074/jbc.M209372200; ZOCCARATO F, 2005, J BIOL CHEM	47	162	166	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33766	33774		10.1074/jbc.M504604200	http://dx.doi.org/10.1074/jbc.M504604200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16081425	hybrid			2022-12-27	WOS:000232229700012
J	Bhattacharyya, S; Lahue, RS				Bhattacharyya, S; Lahue, RS			Srs2 helicase of Saccharomyces cerevisiae selectively unwinds triplet repeat DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRINUCLEOTIDE REPEATS; MISMATCH REPAIR; HAIRPIN STRUCTURES; BLOCKS EXPANSIONS; CAG REPEAT; INSTABILITY; DISEASE; DEFICIENT; SEQUENCE; RAD27	Trinucleotide repeat expansions are the mutational cause of at least 15 genetic diseases. In vitro, single-stranded triplet repeat DNA forms highly stable hairpins, depending on repeat sequence, and a strong correlation exists between hairpin-forming ability and the risk of expansion in vivo. Hairpins are viewed, therefore, as likely mutagenic precursors to expansions. If a helicase unwinds the hairpin, it would be less likely to expand. Previous work indicated that yeast Srs2 DNA helicase selectively blocks expansions in vivo (Bhattacharyya, S., and Lahue, R. S. ( 2004) Mol. Cell. Biol. 24, 7324 7330). For example, srs2 mutants, including an ATPase-defective point mutant, exhibit substantially higher expansion rates than wild type controls. In contrast, mutation of another helicase gene, SGS1, had little effect on expansion rates. These findings prompted the idea that Srs2 might selectively unwind triplet repeat hairpins. In this study, DNA helicase assays were performed with purified Srs2, Sgs1, and Escherichia coli UvrD ( DNA helicase II). Srs2 shows substantially faster unwinding than Sgs1 or UvrD on partial duplex substrates containing (CTG) center dot ( CTG) sequences, provided that Srs2 encounters the triplet repeat DNA immediately on entering the duplex. Srs2 was also faster at unwinding (CAG) center dot ( CAG)and (CCG) center dot(CCG)-containing substrates and an intramolecular ( CTG) center dot( CTG) hairpin. In contrast, all three enzymes unwind about equally well control substrates with either Watson-Crick base pairs or mismatched substrates with non-CNG repeats. Overall, the selective unwinding activity of Srs2 on triplet repeat hairpin DNA helps explain the genetic evidence that Srs2, not the RecQ homolog Sgs1, is a preferred helicase for preventing expansions.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Lahue, RS (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA.	rlahue@unmc.edu		Lahue, Robert/0000-0002-8870-5616	NATIONAL CANCER INSTITUTE [P30CA036727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061961] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09746, P30 CA36727] Funding Source: Medline; NIGMS NIH HHS [R01 GM61961] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1989, NUCLEIC ACIDS RES, V17, P7211, DOI 10.1093/nar/17.18.7211; Arora T, 2003, J BIOL CHEM, V278, P21327, DOI 10.1074/jbc.C300119200; Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; Bhattacharyya S, 2004, MOL CELL BIOL, V24, P7324, DOI 10.1128/MCB.24.17.7324-7330.2004; Brosh RM, 2002, J BIOL CHEM, V277, P23236, DOI 10.1074/jbc.M111446200; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Cleary JD, 2003, CYTOGENET GENOME RES, V100, P25, DOI 10.1159/000072837; Cummings CJ, 2000, HUM MOL GENET, V9, P909, DOI 10.1093/hmg/9.6.909; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; Fry M, 1999, J BIOL CHEM, V274, P12797, DOI 10.1074/jbc.274.18.12797; GACY AM, 1995, CELL, V81, P533; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; JAWORSKI A, 1995, P NATL ACAD SCI USA, V92, P11019, DOI 10.1073/pnas.92.24.11019; Kamath-Loeb AS, 2001, J BIOL CHEM, V276, P16439, DOI 10.1074/jbc.M100253200; Karow JK, 2000, CURR OPIN GENET DEV, V10, P32, DOI 10.1016/S0959-437X(99)00039-8; Klein HL, 2000, NAT GENET, V25, P132, DOI 10.1038/75957; Kovtun IV, 2001, BIOCHEM CELL BIOL, V79, P325, DOI 10.1139/bcb-79-3-325; Kovtun IV, 2001, NAT GENET, V27, P407, DOI 10.1038/86906; Krejci L, 2003, NATURE, V423, P305, DOI 10.1038/nature01577; Krejci L, 2004, J BIOL CHEM, V279, P23193, DOI 10.1074/jbc.M402586200; Liu Y, 2004, MOL CELL BIOL, V24, P4049, DOI 10.1128/MCB.24.9.4049-4064.2004; Manley K, 1999, NAT GENET, V23, P471, DOI 10.1038/70598; MATSON SW, 1986, J BIOL CHEM, V261, P169; Miret JJ, 1998, P NATL ACAD SCI USA, V95, P12438, DOI 10.1073/pnas.95.21.12438; Mitas M, 1997, NUCLEIC ACIDS RES, V25, P2245, DOI 10.1093/nar/25.12.2245; Owen BAL, 2005, NAT STRUCT MOL BIOL, V12, P663, DOI 10.1038/nsmb965; Parenteau J, 1999, MOL CELL BIOL, V19, P4143; Parniewski P, 2000, J MOL BIOL, V299, P865, DOI 10.1006/jmbi.2000.3796; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; Rolfsmeier ML, 2000, MOL CELL, V6, P1501, DOI 10.1016/S1097-2765(00)00146-5; RONG L, 1993, J BIOL CHEM, V268, P1252; Savouret C, 2003, EMBO J, V22, P2264, DOI 10.1093/emboj/cdg202; Schweitzer JK, 1997, HUM MOL GENET, V6, P349, DOI 10.1093/hmg/6.3.349; Schweitzer JK, 1998, HUM MOL GENET, V7, P69, DOI 10.1093/hmg/7.1.69; Sharma S, 2004, MOL BIOL CELL, V15, P734, DOI 10.1091/mbc.E03-08-0567; Spiro C, 2003, MOL CELL BIOL, V23, P6063, DOI 10.1128/MCB.23.17.6063-6074.2003; Spiro C, 1999, MOL CELL, V4, P1079, DOI 10.1016/S1097-2765(00)80236-1; Symington LS, 1998, NUCLEIC ACIDS RES, V26, P5589, DOI 10.1093/nar/26.24.5589; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Usdin K, 2000, CELL MOL LIFE SCI, V57, P914, DOI 10.1007/PL00000734; VALLEN EA, 1995, MOL CELL BIOL, V15, P4291; VANKOMEN S, 2003, J BIOL CHEM; Veaute X, 2005, EMBO J, V24, P180, DOI 10.1038/sj.emboj.7600485; Veaute X, 2003, NATURE, V423, P309, DOI 10.1038/nature01585; Wang WS, 2005, J BIOL CHEM, V280, P5391, DOI 10.1074/jbc.M412359200; Wheeler VC, 2003, HUM MOL GENET, V12, P273, DOI 10.1093/hmg/ddg056; White PJ, 1999, MOL CELL BIOL, V19, P5675	47	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33311	33317		10.1074/jbc.M503325200	http://dx.doi.org/10.1074/jbc.M503325200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16085654	hybrid			2022-12-27	WOS:000232058100027
J	Xu, GH; Sztalryd, C; Lu, XY; Tansey, JT; Gan, JW; Dorward, H; Kimmel, AR; Londos, C				Xu, GH; Sztalryd, C; Lu, XY; Tansey, JT; Gan, JW; Dorward, H; Kimmel, AR; Londos, C			Post-translational regulation of adipose differentiation-related protein by the ubiquitin/proteasome pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; HORMONE-SENSITIVE LIPASE; A-MEDIATED LIPOLYSIS; LIPID DROPLETS; PERILIPIN-A; MESSENGER-RNA; ADIPOCYTE LIPOLYSIS; CELLS; DEGRADATION; EXPRESSION	Adipose differentiation-related protein ( ADRP) is localized to lipid droplets in most mammalian cells. ADRP, proposed to regulate fatty acid mobilization and lipid droplet formation, is linked to lipid accumulation in foam cells of human atherosclerotic lesions. In this report, we show that ADRP protein accumulates in Chinese hamster ovary fibroblastic cells cultured in the presence of oleic acid but is destabilized when fatty acid sources are removed from culture serum. The latter effect was blocked by the proteasome inhibitor MG132, whereas inhibitors of other proteolytic processes were ineffective. Pulse-chase experiments confirmed that ADRP degradation is inhibited by MG132. Conditions that stimulate ADRP degradation also promoted the covalent modification of ADRP by ubiquitin, whereas the addition of oleic acid to culture media, which promotes triacylglycerol deposition, blunted the appearance of ubiquitinated-ADRP. Treatment with MG132 increased the levels of ADRP associated with lipid droplets, as well as throughout the cytosol. Finally, we demonstrate that the disappearance of ADRP protein after the onset of perilipin expression during adipocyte differentiation is due to degradation by proteasomes Thus, proteolytic degradation of ADRP mediated through the ubiquitin/proteasome pathway appears to be a major mode for the post-translational regulation of ADRP.	NIDDK, Cellular & Dev Biol Lab, NIH, Bethesda, MD 20892 USA; Peking Univ, Hlth Sci Ctr, Dept Physiol & Pathophysiol, Beijing 100083, Peoples R China; Minist Educ, Key Lab Mol Cardiovasc Sci, Beijing 100083, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Peking University	Londos, C (corresponding author), NIDDK, Cellular & Dev Biol Lab, NIH, Bldg 50,Rm 3140, Bethesda, MD 20892 USA.	DeanL@intra.niddk.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK015503, Z01DK015505, ZIADK015505] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; Brasaemle DL, 1997, J BIOL CHEM, V272, P9378; Brown DA, 2001, CURR BIOL, V11, pR446, DOI 10.1016/S0960-9822(01)00257-3; Buechler C, 2001, BBA-MOL CELL BIOL L, V1532, P97, DOI 10.1016/S1388-1981(01)00121-4; Ciechanover A, 1998, P NATL ACAD SCI USA, V95, P2727, DOI 10.1073/pnas.95.6.2727; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; Du EZ, 1999, J BIOL CHEM, V274, P1856, DOI 10.1074/jbc.274.3.1856; Faber BCG, 2001, CIRC RES, V89, P547, DOI 10.1161/hh1801.096340; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; FOLCH J, 1957, J BIOL CHEM, V226, P497; Gao J, 1999, J BIOL CHEM, V274, P16825, DOI 10.1074/jbc.274.24.16825; Gao J, 2000, J CELL PHYSIOL, V182, P297; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; Heid HW, 1998, CELL TISSUE RES, V294, P309, DOI 10.1007/s004410051181; Hickenbottom SJ, 2004, STRUCTURE, V12, P1199, DOI 10.1016/j.str.2004.04.021; Imamura M, 2002, AM J PHYSIOL-ENDOC M, V283, pE775, DOI 10.1152/ajpendo.00040.2002; JIANG HP, 1992, CELL GROWTH DIFFER, V3, P21; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Londos C, 1999, SEMIN CELL DEV BIOL, V10, P51, DOI 10.1006/scdb.1998.0275; Londos C, 1999, ANN NY ACAD SCI, V892, P155, DOI 10.1111/j.1749-6632.1999.tb07794.x; Lu XY, 2001, MAMM GENOME, V12, P741, DOI 10.1007/s00335-01-2055-5; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; Mimnaugh EG, 1999, ELECTROPHORESIS, V20, P418, DOI 10.1002/(SICI)1522-2683(19990201)20:2<418::AID-ELPS418>3.0.CO;2-N; Mitchell DM, 1998, P NATL ACAD SCI USA, V95, P14733, DOI 10.1073/pnas.95.25.14733; Miura S, 2002, J BIOL CHEM, V277, P32253, DOI 10.1074/jbc.M204410200; Murphy DJ, 1999, TRENDS BIOCHEM SCI, V24, P109, DOI 10.1016/S0968-0004(98)01349-8; Pariyarath R, 2001, J BIOL CHEM, V276, P541, DOI 10.1074/jbc.M007944200; Schultz CJ, 2002, AM J PHYSIOL-LUNG C, V283, pL288, DOI 10.1152/ajplung.00204.2001; Serrero G, 2000, BBA-MOL CELL BIOL L, V1488, P245, DOI 10.1016/S1388-1981(00)00128-1; SERVETNICK DA, 1995, J BIOL CHEM, V270, P16970, DOI 10.1074/jbc.270.28.16970; Souza SC, 2002, J BIOL CHEM, V277, P8267, DOI 10.1074/jbc.M108329200; Steiner S, 1996, BIOCHEM BIOPH RES CO, V218, P777, DOI 10.1006/bbrc.1996.0138; Sztalryd C, 2003, J CELL BIOL, V161, P1093, DOI 10.1083/jcb.200210169; Taghibiglou C, 2000, J LIPID RES, V41, P499; Tansey JT, 2004, IUBMB LIFE, V56, P379, DOI 10.1080/15216540400009968; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Tansey JT, 2003, J BIOL CHEM, V278, P8401, DOI 10.1074/jbc.M211005200; Wang XK, 1999, FEBS LETT, V462, P145, DOI 10.1016/S0014-5793(99)01521-5; Wenner C, 2001, BIOCHEM BIOPH RES CO, V282, P608, DOI 10.1006/bbrc.2001.4611; White AL, 1999, J LIPID RES, V40, P275; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Wilkinson KD, 1999, J NUTR, V129, P1933, DOI 10.1093/jn/129.11.1933; Wolins NE, 2001, J BIOL CHEM, V276, P5101, DOI 10.1074/jbc.M006775200; Wolins NE, 2003, J BIOL CHEM, V278, P37713, DOI 10.1074/jbc.M304025200; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649; Zweytick D, 2000, BBA-REV BIOMEMBRANES, V1469, P101, DOI 10.1016/S0005-2736(00)00294-7	48	199	211	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42841	42847		10.1074/jbc.M506569200	http://dx.doi.org/10.1074/jbc.M506569200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16115879	hybrid			2022-12-27	WOS:000234200800046
J	Raulo, E; Tumova, S; Pavlov, I; Pekkanen, M; Hienola, A; Klankki, E; Kalkkinen, N; Taira, T; Kilpelainen, I; Rauvala, H				Raulo, E; Tumova, S; Pavlov, I; Pekkanen, M; Hienola, A; Klankki, E; Kalkkinen, N; Taira, T; Kilpelainen, I; Rauvala, H			The two thrombospondin type I repeat domains of the heparin-binding growth-associated molecule bind to heparin/heparan sulfate and regulate neurite extension and plasticity in hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATASE ZETA/RPTP-BETA; LONG-TERM POTENTIATION; HB-GAM; N-SYNDECAN; CELL-SURFACE; BRAIN NEURONS; PROTEIN; OUTGROWTH; LTP; EXPRESSION	HB-GAM (heparin-binding growth-associated molecule, also designated as pleiotrophin) and midkine form a two-member family of extracellular matrix proteins that bind tightly to sulfated carbohydrate structures such as heparan sulfate. These proteins are used by developing neurons as extracellular cues in axonal growth and guidance. HB-GAM was recently reported to enhance differentiation of neural stem cells. Based on the solution structure of HB-GAM, we have recently shown that HB-GAM consists of two beta-sheet domains flanked by flexible lysine-rich N- and C-terminal tails with no apparent structure. These domains are homologous to thrombospondin type I repeats present in numerous extracellular proteins that interact with the cell surface. Our findings showed that the two beta-sheet domains fold independently. We showed that the domains (but not the lysine-rich tails) in HB-GAM are required and sufficient for interaction with hippocampal neurons. The individual domains bind heparan sulfate weakly and fail to produce significant biological effects in neurite outgrowth and long term potentiation assays. The amino acids in the linker region joining the two domains may be replaced with glycines with no effect on protein function. These results suggest a co-operative action of the two beta-sheet domains in the biologically relevant interaction with neuron surface heparan sulfate.	Univ Helsinki, Ctr Neurosci, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Chem, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki	Raulo, E (corresponding author), Univ Helsinki, Ctr Neurosci, Viikinkaari 4,POB 56, FIN-00014 Helsinki, Finland.	erkki.raulo@helsinki.fi; heikki.rauvala@helsinki.fi	Kalkkinen, Nisse EJ/B-3923-2010; Pavlov, Ivan/GVT-5113-2022; Tumova, Sarka/AAD-6353-2019; Pavlov, Ivan/B-5939-2008	Tumova, Sarka/0000-0003-2044-4998; Pavlov, Ivan/0000-0002-9559-4600; Pekkanen-Mattila, Mari/0000-0002-8621-4303; Ahonen-Bishopp, Anni/0000-0002-4215-6228; Raulo, Erkki/0000-0001-9113-3770; Pavlov, Ivan/0000-0003-1266-6988; Rauvala, Heikki/0000-0001-7809-9811				Adams JC, 2000, DEV DYNAM, V218, P280; Anderson WW, 2001, J NEUROSCI METH, V108, P71, DOI 10.1016/S0165-0270(01)00374-0; BREWER GJ, 1989, BRAIN RES, V494, P65, DOI 10.1016/0006-8993(89)90144-3; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CAVANAGH J, PROTEIN NMR SPECTROS, P478; Fath M, 1999, FEBS LETT, V454, P105, DOI 10.1016/S0014-5793(99)00785-1; Hienola A, 2004, MOL CELL NEUROSCI, V26, P75, DOI 10.1016/j.mcn.2004.01.018; Imai S, 1998, J CELL BIOL, V143, P1113, DOI 10.1083/jcb.143.4.1113; Iwasaki W, 1997, EMBO J, V16, P6936, DOI 10.1093/emboj/16.23.6936; Kaksonen M, 2002, MOL CELL NEUROSCI, V21, P158, DOI 10.1006/mcne.2002.1167; Kilpelainen I, 2000, J BIOL CHEM, V275, P13564, DOI 10.1074/jbc.275.18.13564; Kinnunen A, 1998, EUR J NEUROSCI, V10, P635, DOI 10.1046/j.1460-9568.1998.00082.x; Kinnunen T, 1996, J BIOL CHEM, V271, P2243, DOI 10.1074/jbc.271.4.2243; Kinnunen T, 1998, J BIOL CHEM, V273, P10702, DOI 10.1074/jbc.273.17.10702; Kojima T, 1996, J BIOL CHEM, V271, P5914, DOI 10.1074/jbc.271.10.5914; Lauri SE, 1996, NEUROREPORT, V7, P1670, DOI 10.1097/00001756-199607080-00029; Lauri SE, 1999, J NEUROSCI, V19, P1226; Lauri SE, 1998, EUR J NEUROSCI, V10, P188; Lethias C, 2001, J BIOL CHEM, V276, P16432, DOI 10.1074/jbc.M010210200; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; Milev P, 1998, J BIOL CHEM, V273, P21439, DOI 10.1074/jbc.273.34.21439; Milev P, 1998, J BIOL CHEM, V273, P6998, DOI 10.1074/jbc.273.12.6998; Munoz EM, 2004, ARTERIOSCL THROM VAS, V24, P1549, DOI 10.1161/01.ATV.0000137189.22999.3f; Pavlov I, 2002, MOL CELL NEUROSCI, V20, P330, DOI 10.1006/mcne.2002.1104; RAULO E, 1994, J BIOL CHEM, V269, P12999; RAULO E, 1992, J BIOL CHEM, V267, P11408; Rauvala H, 2000, MATRIX BIOL, V19, P377, DOI 10.1016/S0945-053X(00)00084-6; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; RAUVALA H, 1988, J CELL BIOL, V107, P2293, DOI 10.1083/jcb.107.6.2293; RAUVALA H, 1994, DEV BRAIN RES, V79, P157, DOI 10.1016/0165-3806(94)90121-X; SIMMONS DL, 1993, CELLULAR INTERACTION, P93	33	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41576	41583		10.1074/jbc.M506457200	http://dx.doi.org/10.1074/jbc.M506457200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16155004	hybrid			2022-12-27	WOS:000233866900058
J	Bohl, CE; Miller, DD; Chen, JY; Bell, CE; Dalton, JT				Bohl, CE; Miller, DD; Chen, JY; Bell, CE; Dalton, JT			Structural basis for accommodation of nonsteroidal ligands in the androgen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING DOMAIN; PROSTATE-CANCER; WITHDRAWAL SYNDROME; NUCLEAR RECEPTOR; GENE-MUTATIONS; LNCAP CELLS; ANTAGONISM; BICALUTAMIDE; RECOGNITION; ACTIVATION	The mechanism by which the androgen receptor (AR) distinguishes between agonist and antagonist ligands is poorly understood. AR antagonists are currently used to treat prostate cancer. However, mutations commonly develop in patients that convert these compounds to agonists. Recently, our laboratory discovered selective androgen receptor modulators, which structurally resemble the nonsteroidal AR antagonists bicalutamide and hydroxyflutamide but act as agonists for the androgen receptor in a tissue-selective manner. To investigate why subtle structural changes to both the ligand and the receptor (i.e. mutations) result in drastic changes in activity, we studied structure-activity relationships for nonsteroidal AR ligands through crystallography and site-directed mutagenesis, comparing bound conformations of R-bicalutamide, hydroxyflutamide, and two previously reported nonsteroidal androgens, S-1 and R-3. These studies provide the first crystallographic evidence of the mechanism by which nonsteroidal ligands interact with the wild type AR. We have shown that changes induced to the positions of Trp-741, Thr-877, and Met-895 allow for ligand accommodation within the AR binding pocket and that a water-mediated hydrogen bond to the backbone oxygen of Leu-873 and the ketone of hydroxyflutamide is present when bound to the T877A AR variant. Additionally, we demonstrated that R-bicalutamide stimulates transcriptional activation in AR harboring the M895T point mutation. As a whole, these studies provide critical new insight for receptor-based drug design of nonsteroidal AR agonists and antagonists.	Ohio State Univ, Coll Med & Publ Hlth, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Ohio State Univ, Coll Pharm, Div Pharmaceut, Columbus, OH 43210 USA; Univ Tennessee, Coll Pharm, Dept Pharmaceut Sci, Memphis, TN 38163 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Tennessee System; University of Tennessee Health Science Center	Bell, CE (corresponding author), Ohio State Univ, Coll Med & Publ Hlth, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA.	bell.489@osu.edu; dalton.1@osu.edu		Dalton, James T/0000-0002-3915-7326	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065227, R01DK059800] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK059800-06, R01 DK065227, R01 DK59800, R01 DK059800] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balog A, 2004, BIOORG MED CHEM LETT, V14, P6107, DOI 10.1016/j.bmcl.2004.09.049; Bohl CE, 2005, P NATL ACAD SCI USA, V102, P6201, DOI 10.1073/pnas.0500381102; Bohl CE, 2004, J MED CHEM, V47, P3765, DOI 10.1021/jm0499007; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Dalton JT, 1998, BIOCHEM BIOPH RES CO, V244, P1, DOI 10.1006/bbrc.1998.8209; Ellis RJ, 1996, FASEB J, V10, P20, DOI 10.1096/fasebj.10.1.8566542; Gao WQ, 2004, ENDOCRINOLOGY, V145, P5420, DOI 10.1210/en.2004-0627; Gottlieb B, 2004, HUM MUTAT, V23, P527, DOI 10.1002/humu.20044; GRAGEROV A, 1992, P NATL ACAD SCI USA, V89, P10341, DOI 10.1073/pnas.89.21.10341; Hara T, 2003, CANCER RES, V63, P149; He B, 2004, MOL CELL, V16, P425, DOI 10.1016/j.molcel.2004.09.036; Hur E, 2004, PLOS BIOL, V2, P1303, DOI 10.1371/journal.pbio.0020274; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KALLIO PJ, 1994, ENDOCRINOLOGY, V134, P998, DOI 10.1210/en.134.2.998; Kauppi B, 2003, J BIOL CHEM, V278, P22748, DOI 10.1074/jbc.M212711200; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Marhefka CA, 2004, J MED CHEM, V47, P993, DOI 10.1021/jm030336u; Marhefka CA, 2001, J MED CHEM, V44, P1729, DOI 10.1021/jm0005353; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; Matias PM, 2002, J MED CHEM, V45, P1439, DOI 10.1021/jm011072j; Negro-Vilar A, 1999, J CLIN ENDOCR METAB, V84, P3459, DOI 10.1210/jc.84.10.3459; Poujol N, 2000, J BIOL CHEM, V275, P24022, DOI 10.1074/jbc.M001999200; Sack JS, 2001, P NATL ACAD SCI USA, V98, P4904, DOI 10.1073/pnas.081565498; Soderholm AA, 2005, J MED CHEM, V48, P917, DOI 10.1021/jm0495879; Steketee K, 2002, INT J CANCER, V100, P309, DOI 10.1002/ijc.10495; Suzuki H, 1996, PROSTATE, V29, P153, DOI 10.1002/1097-0045(199609)29:3<153::AID-PROS2990290303>3.0.CO;2-5; Tan J, 1997, MOL ENDOCRINOL, V11, P450, DOI 10.1210/me.11.4.450; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; VELDSCHOLTE J, 1992, J STEROID BIOCHEM, V41, P665, DOI 10.1016/0960-0760(92)90401-4; Yin DH, 2003, MOL PHARMACOL, V63, P211, DOI 10.1124/mol.63.1.211	32	160	182	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37747	37754		10.1074/jbc.M507464200	http://dx.doi.org/10.1074/jbc.M507464200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16129672	Green Accepted, hybrid			2022-12-27	WOS:000233044500053
J	Gallagher, MJ; Shen, WZ; Song, LY; Macdonald, RL				Gallagher, MJ; Shen, WZ; Song, LY; Macdonald, RL			Endoplasmic reticulum retention and associated degradation of a GABA(A) receptor epilepsy mutation that inserts an aspartate in the M3 transmembrane segment of the alpha 1 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; CELL-SURFACE EXPRESSION; INTERSUBUNIT CONTACTS; ALPHA-SUBUNITS; IDENTIFICATION; CURRENTS; RESIDUES; POSITION; MEDIATE; NEURONS	A GABA(A) receptor alpha 1 subunit epilepsy mutation (alpha 1(A322D)) introduces a negatively charged aspartate residue into the hydrophobic M3 transmembrane domain of the alpha 1 subunit. We reported previously that heterologous expression of alpha 1(A322D) beta 2 gamma 2 receptors in mammalian cells resulted in reduced total and surface alpha 1 subunit protein. Here we demonstrate the mechanism of this reduction. Total alpha 1(A322D) subunit protein was reduced relative to wild type protein by a similar amount when expressed alone ( 86 +/- 6%) or when coexpressed with beta 2 and gamma 2S subunits (78 +/- 6%), indicating an expression reduction prior to subunit oligomerization. In alpha 1 beta 2 gamma 2S receptors, endoglycosidase H deglycosylated only 26 +/- 5% of alpha 1 subunits, consistent with substantial protein maturation, but in alpha 1(A322D) beta 2 gamma 2S receptors, endoglycosidase H deglycosylated 91 +/- 4% of alpha 1(A322D) subunits, consistent with failure of protein maturation. To determine the cellular localization of wild type and mutant subunits, the alpha 1 subunit was tagged with yellow (alpha 1-YFP) or cyan (alpha 1-CFP) fluorescent protein. Confocal microscopic imaging demonstrated that 36 +/- 4% of alpha 1-YFP beta 2 gamma 2 but only 5 +/- 1% alpha 1(A322D)- YFP beta 2 gamma 2 colocalized with the plasma membrane, whereas the majority of the remaining receptors colocalized with the endoplasmic reticulum (55 +/- 4% alpha 1-YFP beta 2 gamma 2S, 86 +/- 3% alpha 1(A322D)-YFP). Heterozygous expression of alpha 1-CFP beta 2 gamma 2S and alpha 1(A322D)-YFP beta 2 gamma 2S or alpha 1-YFP beta 2 gamma 2S and alpha 1(A322D)CFP beta 2 gamma 2S receptors showed that membrane GABA(A) receptors contained primarily wild type alpha 1 subunits. These data demonstrate that the A322D mutation reduces alpha 1 subunit expression after translation, but before assembly, resulting in endoplasmic reticulum-associated degradation and membrane alpha 1 subunits that are almost exclusively wild type subunits.	Vanderbilt Univ, Dept Neurol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Gallagher, MJ (corresponding author), Vanderbilt Univ, Dept Neurol, 6140 Med Res Bldg 3,465 21st Ave S, Nashville, TN 37232 USA.	Martin.Gallagher@Vanderbilt.edu		Gallagher, Martin/0000-0002-3537-4200	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039479, K08NS044257, R01NS033300] Funding Source: NIH RePORTER; NINDS NIH HHS [K08 NS044257, NS33300, NS39479, K08NS44257-01] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amaral MD, 2004, J MOL NEUROSCI, V23, P41, DOI 10.1385/JMN:23:1-2:041; Baumann SW, 2002, J BIOL CHEM, V277, P46020, DOI 10.1074/jbc.M207663200; Baumann SW, 2001, J BIOL CHEM, V276, P36275, DOI 10.1074/jbc.M105240200; Bianchi MT, 2002, J NEUROSCI, V22, P5321; Bollan K, 2003, J BIOL CHEM, V278, P4747, DOI 10.1074/jbc.M210229200; Bolte S, 2004, J CELL SCI, V117, P943, DOI 10.1242/jcs.00920; BULLER AL, 1994, MOL PHARMACOL, V46, P858; Caputo GA, 2004, BIOCHEMISTRY-US, V43, P8794, DOI 10.1021/bi049696p; Chiara DC, 1997, J BIOL CHEM, V272, P32940, DOI 10.1074/jbc.272.52.32940; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Connor JX, 1998, J BIOL CHEM, V273, P28906, DOI 10.1074/jbc.273.44.28906; Cossette P, 2002, NAT GENET, V31, P184, DOI 10.1038/ng885; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; Dibbens LM, 2004, HUM MOL GENET, V13, P1315, DOI 10.1093/hmg/ddh146; Fisher JL, 2004, NEUROPHARMACOLOGY, V46, P629, DOI 10.1016/j.neuropharm.2003.11.015; Gallagher MJ, 2004, J NEUROSCI, V24, P5570, DOI 10.1523/JNEUROSCI.1301-04.2004; Genton P, 2001, ARCH NEUROL-CHICAGO, V58, P1487, DOI 10.1001/archneur.58.9.1487; Gorrie GH, 1997, J NEUROSCI, V17, P6587; Greenfield LJ, 1997, NEUROPHARMACOLOGY, V36, P63, DOI 10.1016/S0028-3908(96)00150-5; Gregersen N, 2000, J INHERIT METAB DIS, V23, P441, DOI 10.1023/A:1005663728291; Hales TG, 2005, MOL CELL NEUROSCI, V29, P120, DOI 10.1016/j.mcn.2005.01.002; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Hinkle DJ, 2003, BIOTECHNIQUES, V35, P472; Hirsch C, 2004, BBA-MOL CELL RES, V1695, P215, DOI 10.1016/j.bbamcr.2004.10.006; Kang JQ, 2004, J NEUROSCI, V24, P8672, DOI 10.1523/JNEUROSCI.2717-04.2004; Kittler JT, 2000, MOL CELL NEUROSCI, V16, P440, DOI 10.1006/mcne.2000.0882; Klausberger T, 2000, J BIOL CHEM, V275, P8921, DOI 10.1074/jbc.275.12.8921; Klausberger T, 2001, J BIOL CHEM, V276, P16024, DOI 10.1074/jbc.M009508200; Klausberger T, 2001, J NEUROSCI, V21, P9124, DOI 10.1523/JNEUROSCI.21-23-09124.2001; Kralic JE, 2002, J PHARMACOL EXP THER, V302, P1037, DOI 10.1124/jpet.102.036665; Kralic JE, 2002, NEUROPHARMACOLOGY, V43, P685, DOI 10.1016/S0028-3908(02)00174-0; Krampfl K, 2005, EUR J NEUROSCI, V22, P10, DOI 10.1111/j.1460-9568.2005.04168.x; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; Matsuda S, 2004, EUR J NEUROSCI, V19, P1683, DOI 10.1111/j.1460-9568.2004.03307.x; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Sancar F, 2004, J BIOL CHEM, V279, P47034, DOI 10.1074/jbc.M403388200; Taylor PM, 2000, J NEUROSCI, V20, P1297; Taylor PM, 1999, J NEUROSCI, V19, P6360; Tretter V, 1997, J NEUROSCI, V17, P2728; Vicini S, 2001, J NEUROSCI, V21, P3009, DOI 10.1523/JNEUROSCI.21-09-03009.2001	42	53	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37995	38004		10.1074/jbc.M508305200	http://dx.doi.org/10.1074/jbc.M508305200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16123039	hybrid			2022-12-27	WOS:000233044500082
J	Noguchi, T; Takeda, K; Matsuzawa, A; Saegusa, K; Nakano, H; Gohda, J; Inoue, J; Ichijo, H				Noguchi, T; Takeda, K; Matsuzawa, A; Saegusa, K; Nakano, H; Gohda, J; Inoue, J; Ichijo, H			Recruitment of tumor necrosis factor receptor-associated factor family proteins to apoptosis signal-regulating kinase 1 signalosome is essential for oxidative stress-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; IKK ACTIVATION; DEFECTIVE INTERLEUKIN-1; INFLAMMATORY CASPASES; INTERACTING PROTEIN; HUMAN TRAF2; ASK1; COMPLEX; CD40; BETA	Apoptosis signal-regulating kinase 1 (ASK1) plays a pivotal role in oxidative stress-induced cell death. Reactive oxygen species disrupt the interaction of ASK1 with its cellular inhibitor thioredoxin and thereby activates ASK1. However, the precise mechanism by which ASK1 freed from thioredoxin undergoes oligomerization-dependent activation has not been fully elucidated. Here we show that endogenous ASK1 constitutively forms a high molecular mass complex including Trx ( similar to 1,500 - 2,000 kDa), which we designate ASK1 signalosome. Upon H2O2 treatment, the ASK1 signalosome forms a higher molecular mass complex at least in part because of the recruitment of tumor necrosis factor receptor-associated factor 2 (TRAF2) and TRAF6. Consistent with our previous findings that TRAF2 and TRAF6 activate ASK1, H2O2-induced ASK1 activation and cell death were strongly reduced in the cells derived from Traf2-/- and Traf6-/- mice. A novel signaling complex including TRAF2, TRAF6, and ASK1 may thus be the key component in oxidative stress-induced cell death.	Univ Tokyo, Japan Sci & Technol Corp,CREST, Grad Sch Pharmaceut Sci,Lab Cell Signalling, Bunkyo Ku, Tokyo 1130033, Japan; Ctr Excellence Program, Bunkyo Ku, Tokyo 1130033, Japan; Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 1138421, Japan; Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Cellular & Mol Biol,Minato Ku, Tokyo 1088639, Japan	Japan Science & Technology Agency (JST); University of Tokyo; Juntendo University; University of Tokyo	Ichijo, H (corresponding author), Univ Tokyo, Japan Sci & Technol Corp,CREST, Grad Sch Pharmaceut Sci,Lab Cell Signalling, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	ichijo@mol.f.u-tokyo.ac.jp	Matsuzawa, Atsushi/GLU-1387-2022; Noguchi, Takuya/T-6767-2019	Noguchi, Takuya/0000-0001-6187-6645; Takeda, Kohsuke/0000-0002-8359-8399; Matsuzawa, Atsushi/0000-0001-8303-3905; Ichijo, Hidenori/0000-0002-5005-6438; Nakano, Hiroyasu/0000-0003-4843-1427				Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Akiba H, 1998, J BIOL CHEM, V273, P13353, DOI 10.1074/jbc.273.21.13353; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chung JY, 2002, J CELL SCI, V115, P679; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Gohda J, 2004, J IMMUNOL, V173, P2913, DOI 10.4049/jimmunol.173.5.2913; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Habelhah H, 2004, EMBO J, V23, P322, DOI 10.1038/sj.emboj.7600044; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Huang QJ, 2004, NAT IMMUNOL, V5, P98, DOI 10.1038/ni1014; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Lee TH, 2004, J BIOL CHEM, V279, P33185, DOI 10.1074/jbc.M404206200; Lin Y, 2004, J BIOL CHEM, V279, P10822, DOI 10.1074/jbc.M313141200; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Liu YM, 2002, CIRC RES, V90, P1259, DOI 10.1161/01.RES.0000022160.64355.62; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Martinon F, 2004, CELL, V117, P561, DOI 10.1016/j.cell.2004.05.004; Matsukawa J, 2004, J BIOCHEM, V136, P261, DOI 10.1093/jb/mvh134; Matsuzawa A, 2005, NAT IMMUNOL, V6, P587, DOI 10.1038/ni1200; McWhirter SM, 1999, P NATL ACAD SCI USA, V96, P8408, DOI 10.1073/pnas.96.15.8408; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; Nakano H, 1999, P NATL ACAD SCI USA, V96, P9803, DOI 10.1073/pnas.96.17.9803; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Park YC, 1999, NATURE, V398, P533, DOI 10.1038/19110; Pullen SS, 1999, BIOCHEMISTRY-US, V38, P10168, DOI 10.1021/bi9909905; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Shen HM, 2004, MOL CELL BIOL, V24, P5914, DOI 10.1128/MCB.24.13.5914-5922.2004; Shi CS, 2003, J BIOL CHEM, V278, P15429, DOI 10.1074/jbc.M211796200; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Takeda K, 2004, EMBO REP, V5, P161, DOI 10.1038/sj.embor.7400072; Takeda K, 2003, CELL STRUCT FUNCT, V28, P23; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Tschopp J, 2003, NAT REV MOL CELL BIO, V4, P95, DOI 10.1038/nrm1019; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang HF, 2004, J BIOL CHEM, V279, P44955, DOI 10.1074/jbc.M407617200; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	58	170	180	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37033	37040		10.1074/jbc.M506771200	http://dx.doi.org/10.1074/jbc.M506771200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16129676	hybrid			2022-12-27	WOS:000232901800061
J	Luo, XM; Ross, AC				Luo, XM; Ross, AC			Physiological and receptor-selective retinoids modulate interferon gamma signaling by increasing the expression, nuclear localization, and functional activity of interferon regulatory factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; IFN-GAMMA; VITAMIN-A; CROSS-TALK; ACID; IRF-1; ACTIVATION; REQUIRES; INDUCTION; APOPTOSIS	Synergistic actions between all-trans-retinoic acid (atRA) and interferon gamma(IFN gamma) on modulation of cellular functions have been reported both in vitro and in vivo. However, the mechanism of atRA-mediated regulation of IFN gamma signaling is poorly understood. In this study, we have used the human lung epithelial cell line A549 to examine the effect of atRA on IFN gamma-induced expression of IFN regulatory factor-1 (IRF-1), an important transcription factor involved in cell growth and apoptosis, differentiation, and antiviral and antibacterial immune responses. At least 4 h of pretreatment with atRA followed by suboptimal concentrations of IFN gamma induced a faster, higher, and more stable expression of IRF-1 than IFN gamma alone. Actinomycin D completely blocked the induction of IRF-1 by the combination, suggesting regulation at the transcriptional level. Further, we found that activation of signal transducer and activator of transcription-1 was induced more dramatically by atRA and IFN gamma than by IFN gamma alone. Expression of IFN gamma receptor-1 on the cell surface was also increased upon atRA pretreatment. Experiments using receptor-selective retinoids revealed that ligands for retinoic acid receptor-alpha (RAR alpha), including atRA, 9-cis-retinoic acid, and Am580, sequentially increased the levels of IFN gamma receptor-1, activated signal transducer and activator of transcription-1, and IRF-1 and that an RAR alpha antagonist was able to inhibit the effects of atRA and Am580. In addition, atRA pretreatment affected the transcriptional functions of IFN gamma-induced IRF-1, increasing its nuclear localization and DNA binding activity as well as the transcript levels of IRF-1 target genes. These results suggest that atRA, an RAR alpha ligand, regulates IFN gamma-induced IRF-1 by affecting multiple components of the IFN gamma signaling pathway, from the plasma membrane to the nuclear transcription factors.	Penn State Univ, Dept Nutr Sci, University Pk, PA 16802 USA; Penn State Univ, Grad Program Integrat Biosci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Ross, AC (corresponding author), Penn State Univ, Dept Nutr Sci, 126-S Henderson Bldg, University Pk, PA 16802 USA.	acr6@psu.edu	Luo, Xin M/J-6544-2016	Luo, Xin M/0000-0002-2809-5836	NATIONAL CANCER INSTITUTE [R01CA090214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK041479, R01DK041479] Funding Source: NIH RePORTER; NCI NIH HHS [CA 90214, R01 CA090214] Funding Source: Medline; NIDDK NIH HHS [R01 DK041479, R56 DK041479, DK41479] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arany I, 2002, CLIN DIAGN LAB IMMUN, V9, P1102, DOI 10.1128/CDLI.9.5.1102-1106.2002; Austenaa LMI, 2001, J LEUKOCYTE BIOL, V70, P121; Beaton G, 1993, ACC SCN STATE OF THE, V1993; Chelbi-Alix MK, 1999, LEUKEMIA, V13, P1167, DOI 10.1038/sj.leu.2401469; Chen QY, 2002, IMMUNOLOGY, V107, P199, DOI 10.1046/j.1365-2567.2002.01485.x; Clarke N, 2004, EMBO J, V23, P3051, DOI 10.1038/sj.emboj.7600302; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Decicco KL, 2001, IMMUNOLOGY, V104, P341, DOI 10.1046/j.1365-2567.2001.01317.x; DeCicco KL, 2000, J INFECT DIS, V182, pS29, DOI 10.1086/315908; Garattini E, 1998, LEUKEMIA LYMPHOMA, V30, P467, DOI 10.3109/10428199809057559; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; Gianni M, 1997, BLOOD, V89, P1001, DOI 10.1182/blood.V89.3.1001; Hamamoto S, 2003, J LAB CLIN MED, V141, P58, DOI 10.1067/mlc.2003.8; Harada H, 1998, BIOCHIMIE, V80, P641, DOI 10.1016/S0300-9084(99)80017-0; HOWARD AD, 1991, J IMMUNOL, V147, P2964; Iwase S, 1999, FEBS LETT, V450, P263, DOI 10.1016/S0014-5793(99)00515-3; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; Kroger A, 2003, ONCOGENE, V22, P1045, DOI 10.1038/sj.onc.1206260; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; Maruvada P, 2003, J BIOL CHEM, V278, P12425, DOI 10.1074/jbc.M202752200; Matikainen S, 1996, BLOOD, V88, P114; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Nakagawa K, 2000, EUR J BIOCHEM, V267, P1680, DOI 10.1046/j.1432-1327.2000.01163.x; Obora A, 2002, HEPATOLOGY, V36, P1115, DOI 10.1053/jhep.2002.36369; Pelicano L, 1997, ONCOGENE, V15, P2349, DOI 10.1038/sj.onc.1201410; Percario ZA, 1999, CELL GROWTH DIFFER, V10, P263; Pestka Sidney, 1997, Cytokine and Growth Factor Reviews, V8, P189, DOI 10.1016/S1359-6101(97)00009-9; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; Romeo G, 2002, J INTERF CYTOK RES, V22, P39, DOI 10.1089/107999002753452647; Ross AC, 1996, FASEB J, V10, P979, DOI 10.1096/fasebj.10.9.8801180; ROSS DA, 1993, LANCET, V342, P7, DOI 10.1016/0140-6736(93)91879-Q; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Semba RD, 1999, J NUTR, V129, P783, DOI 10.1093/jn/129.4.783; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Sommer A, 1995, B WORLD HEALTH ORGAN, V73, P609; SOMMER A, 1984, AM J CLIN NUTR, V40, P1090, DOI 10.1093/ajcn/40.5.1090; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; vandenBroek MF, 1995, IMMUNOL REV, V148, P5; Villamor E, 2000, J INFECT DIS, V182, pS122, DOI 10.1086/315921; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wu J, 2003, J BIOCHEM MOL BIOL, V36, P354	45	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36228	36236		10.1074/jbc.M505749200	http://dx.doi.org/10.1074/jbc.M505749200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16085646	hybrid, Green Accepted			2022-12-27	WOS:000232726900055
J	Karginov, FV; Caruthers, JM; Hu, YX; McKay, DB; Uhlenbeck, OC				Karginov, FV; Caruthers, JM; Hu, YX; McKay, DB; Uhlenbeck, OC			YxiN is a modular protein combining a DEx(D)/(H) core and a specific RNA-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							23S RIBOSOMAL-RNA; ESCHERICHIA-COLI DBPA; TERMINAL DOMAIN; BOX PROTEINS; HELICASE; RECOGNITION; INITIATION; MECHANISM; PRP16	DEx(D)/(H) proteins, typically described as RNA helicases, participate in rearrangement of RNA- RNA and possibly RNA- protein complexes in the cell. Aside from the conserved DEx(D)/(H) core, members of this protein family often contain N- and C- terminal extensions that are responsible for additional functions. The Bacillus subtilis DEx(D)/ (H)- box protein YxiN and its Escherichia coli ortholog DbpA contain an similar to 80 amino acid C- terminal extension that has been proposed to specifically interact with a region of 23 S ribosomal RNA including hairpin 92. In this study, the DEx(D)/(H)- box core and the C- terminal domain of YxiN were expressed and characterized as separate proteins. The isolated DEx(D)/(H)- box core, YxCat, had weak, nonspecific RNA binding activity and showed RNA- stimulated ATPase activity with a K-m( ATP) that resembled several nonspecific DEx(D)/(H) proteins. The isolated C- terminal domain, YxRBD, bound RNA with the high affinity and specificity seen with full-length YxiN. Thus, YxiN is a modular protein combining the activities of the YxCat and YxRBD domains. Footprinting of YxiN and YxRBD on a 172- nucleotide fragment of 23 S rRNA was used to identify the sites of interaction of the C- terminal and helicase domains with the RNA.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA	Northwestern University; Stanford University	Uhlenbeck, OC (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2153 Sheridan Rd, Evanston, IL 60208 USA.	o-uhlenbeck@northwestern.edu						Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; Bizebard T, 2004, BIOCHEMISTRY-US, V43, P7857, DOI 10.1021/bi049852s; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Caruthers JM, 2002, CURR OPIN STRUC BIOL, V12, P123, DOI 10.1016/S0959-440X(02)00298-1; Charollais J, 2004, NUCLEIC ACIDS RES, V32, P2751, DOI 10.1093/nar/gkh603; Diges CM, 2005, BIOCHEMISTRY-US, V44, P7903, DOI 10.1021/bi050033x; Diges CM, 2001, EMBO J, V20, P5503, DOI 10.1093/emboj/20.19.5503; Fairman ME, 2004, SCIENCE, V304, P730, DOI 10.1126/science.1095596; Iost I, 1999, J BIOL CHEM, V274, P17677, DOI 10.1074/jbc.274.25.17677; Karginov FV, 2004, NUCLEIC ACIDS RES, V32, P3028, DOI 10.1093/nar/gkh640; Kawaoka J, 2004, NAT STRUCT MOL BIOL, V11, P526, DOI 10.1038/nsmb771; Kossen K, 2002, J MOL BIOL, V324, P625, DOI 10.1016/S0022-2836(02)01140-3; Kossen K, 1999, NUCLEIC ACIDS RES, V27, P3811, DOI 10.1093/nar/27.19.3811; Lorsch JR, 1998, BIOCHEMISTRY-US, V37, P2180, DOI 10.1021/bi972430g; NICOL SM, 1995, P NATL ACAD SCI USA, V92, P11681, DOI 10.1073/pnas.92.25.11681; Paolini C, 2000, J GEN VIROL, V81, P1335, DOI 10.1099/0022-1317-81-5-1335; Polach KJ, 2002, BIOCHEMISTRY-US, V41, P3693, DOI 10.1021/bi012062n; Rocak S, 2004, NAT REV MOL CELL BIO, V5, P232, DOI 10.1038/nrm1335; Rogers GW, 1999, J BIOL CHEM, V274, P12236, DOI 10.1074/jbc.274.18.12236; Silverman E, 2003, GENE, V312, P1, DOI 10.1016/S0378-1119(03)00626-7; Studier FW, 2005, PROTEIN EXPRES PURIF, V41, P207, DOI 10.1016/j.pep.2005.01.016; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; Theobald DL, 2003, ANNU REV BIOPH BIOM, V32, P115, DOI 10.1146/annurev.biophys.32.110601.142506; Tsu CA, 1998, BIOCHEMISTRY-US, V37, P16989, DOI 10.1021/bi981837y; Tsu CA, 2001, RNA, V7, P702, DOI 10.1017/S1355838201010135; Wang Y, 1998, RNA, V4, P1216, DOI 10.1017/S1355838298980992; Wang Y, 1998, CURR BIOL, V8, P441, DOI 10.1016/S0960-9822(98)70178-2; Ye JQ, 2004, BBA-BIOENERGETICS, V1659, P1, DOI 10.1016/j.bbabio.2004.06.003	29	57	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35499	35505		10.1074/jbc.M506815200	http://dx.doi.org/10.1074/jbc.M506815200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16118224	hybrid			2022-12-27	WOS:000232561200050
J	Taniguchi, N; Matsuyama, S; Tokuda, H				Taniguchi, N; Matsuyama, S; Tokuda, H			Mechanisms underlying energy-independent transfer of lipoproteins from LolA to LolB, which have similar unclosed beta-barrel structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI LIPOPROTEINS; OUTER-MEMBRANE LIPOPROTEIN; GRAM-NEGATIVE BACTERIA; CYTOPLASMIC MEMBRANE; MOLECULAR CHAPERONE; INNER MEMBRANE; LOCALIZATION; RELEASE; MUTANT; ACCUMULATION	The Lol system, comprising five Lol proteins, transfers lipoproteins from the inner to the outer membrane of Escherichia coli. Periplasmic LolA accepts lipoproteins from LolCDE in the inner membrane and immediately transfers them to LolB, a receptor anchored to the outer membrane. The unclosed beta-barrel structures of LolA and LolB are very similar to each other and form hydrophobic cavities for lipoproteins. The lipoprotein transfer between these similar structures is unidirectional and very efficient, but requires no energy input. To reveal the mechanisms underlying this lipoprotein transfer, Arg and Phe at positions 43 and 47, respectively, of LolA were systematically mutagenized. The two residues were previously found to affect abilities to accept and transfer lipoproteins. Substitution of Phe-47 with polar residues inhibited the ability to accept lipoproteins from the inner membrane. No derivatives caused periplasmic accumulation of lipoproteins. In contrast, many Arg-43 derivatives caused unusual periplasmic accumulation of lipoproteins to various extents. However, all derivatives, except one having Leu instead of Arg, supported the growth of cells. All Arg-43 derivatives retained the ability to accept lipoproteins from the inner membrane, whereas their abilities to transfer associated lipoproteins to LolB were variously reduced. Assessment of the intensity of the hydrophobic interaction between lipoproteins and Arg-43 derivatives revealed that the LolA-lipoprotein interaction should be weak, otherwise lipoprotein transfer to LolB is inhibited, causing accumulation of lipoproteins in the periplasm.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Rikkyo Univ, Dept Life Sci, Toshima Ku, Tokyo 1718501, Japan	University of Tokyo; Rikkyo University	Tokuda, H (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	htokuda@iam.u-tokyo.ac.jp						Brokx SJ, 2004, J BACTERIOL, V186, P3254, DOI 10.1128/JB.186.10.3254-3258.2004; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; Hara T, 2003, J BIOL CHEM, V278, P40408, DOI 10.1074/jbc.M307836200; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; HIROTA Y, 1977, P NATL ACAD SCI USA, V74, P1417, DOI 10.1073/pnas.74.4.1417; HUSSAIN M, 1980, J BIOL CHEM, V255, P3707; Juncker AS, 2003, PROTEIN SCI, V12, P1652, DOI 10.1110/ps.0303703; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUYAMA S, 1993, EMBO J, V12, P265, DOI 10.1002/j.1460-2075.1993.tb05652.x; MATSUYAMA S, 1995, EMBO J, V14, P3365, DOI 10.1002/j.1460-2075.1995.tb07342.x; Matsuyama S, 1997, EMBO J, V16, P6947, DOI 10.1093/emboj/16.23.6947; Miyadai H, 2004, J BIOL CHEM, V279, P39807, DOI 10.1074/jbc.M406390200; Miyamoto A, 2002, FEBS LETT, V528, P193, DOI 10.1016/S0014-5793(02)03305-7; Miyamoto A, 2001, BIOCHEM BIOPH RES CO, V287, P1125, DOI 10.1006/bbrc.2001.5705; Narita S, 2002, J BACTERIOL, V184, P1417, DOI 10.1128/JB.184.5.1417-1422.2002; Osborn M J, 1974, Methods Enzymol, V31, P642; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; SANKARAN K, 1994, J BIOL CHEM, V269, P19701; Seydel A, 1999, MOL MICROBIOL, V34, P810, DOI 10.1046/j.1365-2958.1999.01647.x; Tajima T, 1998, FEBS LETT, V439, P51, DOI 10.1016/S0014-5793(98)01334-9; Takeda K, 2003, EMBO J, V22, P3199, DOI 10.1093/emboj/cdg324; Tanaka K, 2001, J BACTERIOL, V183, P6538, DOI 10.1128/JB.183.22.6538-6542.2001; Terada M, 2001, J BIOL CHEM, V276, P47690, DOI 10.1074/jbc.M109307200; Yakushi T, 2000, NAT CELL BIOL, V2, P212, DOI 10.1038/35008635; YAMAGUCHI K, 1988, CELL, V53, P423, DOI 10.1016/0092-8674(88)90162-6; Yokota N, 1999, J BIOL CHEM, V274, P30995, DOI 10.1074/jbc.274.43.30995	26	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34481	34488		10.1074/jbc.M507388200	http://dx.doi.org/10.1074/jbc.M507388200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16091355	hybrid			2022-12-27	WOS:000232403900015
J	Chen, L; Tian, LJ; MacDonald, SHF; McClafferty, H; Hammond, MSL; Huibant, JM; Ruth, P; Knaus, HG; Shipston, MJ				Chen, L; Tian, LJ; MacDonald, SHF; McClafferty, H; Hammond, MSL; Huibant, JM; Ruth, P; Knaus, HG; Shipston, MJ			Functionally diverse complement of large conductance calcium- and voltage-activated potassium channel (BK) alpha-subunits generated from a single site of splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-ACTIVATED K+ CHANNEL; MOUSE MYOMETRIUM; BETA-SUBUNITS; CA CHANNELS; EXPRESSION; CLONING; VARIANTS; PHOSPHORYLATION; SENSITIVITY; SURFACE	The pore-forming alpha-subunits of large conductance calcium- and voltage-activated potassium (BK) channels are encoded by a single gene that undergoes extensive alternative pre-mRNA splicing. However, the extent to which differential exon usage at a single site of splicing may confer functionally distinct properties on BK channels is largely unknown. Here we demonstrated that alternative splicing at site of splicing C2 in the mouse BK channel C terminus generates five distinct splice variants: ZERO, e20, e21(STREX), e22, and a novel variant Delta e23. Splice variants display distinct patterns of tissue distribution with e21( STREX) expressed at the highest levels in adult endocrine tissues and e22 at embryonic stages of mouse development. Delta e23 is not functionally expressed at the cell surface and acts as a dominant negative of cell surface expression by trapping other BK channel splice variant alpha-subunits in the endoplasmic reticulum and perinuclear compartments. Splice variants display a range of biophysical properties. e21( STREX) and e22 variants display a significant left shift (> 20 mV at 1 mu M[Ca2+](i)) in half-maximal voltage of activation compared with ZERO and e20 as well as considerably slower rates of deactivation. Splice variants are differentially sensitive to phosphorylation by endogenous cAMP-dependent protein kinase; ZERO, e20, and e22 variants are all activated, whereas e21 ( STREX) is the only variant that is inhibited. Thus alternative pre-mRNA splicing from a single site of splicing provides a mechanism to generate a physiologically diverse complement of BK channel alpha-subunits that differ dramatically in their tissue distribution, trafficking, and regulation.	Univ Edinburgh, Ctr Integrat Physiol, Membrane Biol Grp, Edinburgh EH8 9XD, Midlothian, Scotland; Univ Tubingen, D-727076 Tubingen, Germany; Univ Innsbruck, A-6020 Innsbruck, Austria	University of Edinburgh; Eberhard Karls University of Tubingen; University of Innsbruck	Shipston, MJ (corresponding author), Univ Edinburgh, Ctr Integrat Physiol, Membrane Biol Grp, Hugh Robson Bldg, Edinburgh EH8 9XD, Midlothian, Scotland.	mike.shipston@ed.ac.uk	Shipston, Mike/C-7309-2013	Shipston, Mike/0000-0001-7544-582X; Macdonald, Stephen/0000-0001-6306-8035	Wellcome Trust [067683] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; Ahluwalia J, 2004, NATURE, V427, P853, DOI 10.1038/nature02356; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; Behrens R, 2000, FEBS LETT, V474, P99, DOI 10.1016/S0014-5793(00)01584-2; Benkusky NA, 2000, J BIOL CHEM, V275, P27712; Brandle U, 2001, HEARING RES, V161, P23, DOI 10.1016/S0378-5955(01)00323-9; Brenner R, 2000, NATURE, V407, P870, DOI 10.1038/35038011; Brenner R, 2000, J BIOL CHEM, V275, P6453, DOI 10.1074/jbc.275.9.6453; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; Dopico AM, 1999, J PHYSIOL-LONDON, V519, P101, DOI 10.1111/j.1469-7793.1999.0101o.x; DWORETZKY SI, 1994, MOL BRAIN RES, V27, P189, DOI 10.1016/0169-328X(94)90203-8; Eghbali M, 2003, J BIOL CHEM, V278, P45311, DOI 10.1074/jbc.M306564200; Erxleben C, 2002, J BIOL CHEM, V277, P27045, DOI 10.1074/jbc.M203087200; Ha TS, 2000, EUR J BIOCHEM, V267, P910, DOI 10.1046/j.1432-1327.2000.01076.x; Hanaoka K, 1999, J MEMBRANE BIOL, V172, P193, DOI 10.1007/s002329900596; Jiang YX, 2001, NEURON, V29, P593, DOI 10.1016/S0896-6273(01)00236-7; Kukuljan M, 2003, J NEUROPHYSIOL, V90, P3352, DOI 10.1152/jn.00398.2003; Kwon SH, 2004, P NATL ACAD SCI USA, V101, P15237, DOI 10.1073/pnas.0404877101; LAGRUTTA A, 1994, J BIOL CHEM, V269, P20347; Lai GJ, 2002, P NATL ACAD SCI USA, V99, P7722, DOI 10.1073/pnas.112619799; Lhuillier L, 2002, J NEUROPHYSIOL, V88, P954, DOI 10.1152/jn.2002.88.2.954; Liu PQ, 2001, J BIOL CHEM, V276, P11323, DOI 10.1074/jbc.M011172200; Liu XJ, 2002, J NEUROSCI, V22, P1840, DOI 10.1523/JNEUROSCI.22-05-01840.2002; Lovell PV, 2001, J NEUROSCI, V21, P3429, DOI 10.1523/JNEUROSCI.21-10-03429.2001; McCobb DP, 2003, HORM BEHAV, V43, P180, DOI 10.1016/S0018-506X(02)00010-7; MCCOBB DP, 1995, AM J PHYSIOL-HEART C, V38, pH767; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; Meredith AL, 2004, J BIOL CHEM, V279, P36746, DOI 10.1074/jbc.M405621200; Navaratnam DS, 1997, NEURON, V19, P1077, DOI 10.1016/S0896-6273(00)80398-0; PEREZ G, 1994, AM J PHYSIOL, V266, pC1459, DOI 10.1152/ajpcell.1994.266.5.C1459; Piskorowski R, 2002, NATURE, V420, P499, DOI 10.1038/nature01199; Pluger S, 2000, CIRC RES, V87, pE53, DOI 10.1161/01.RES.87.11.e53; Pyott SJ, 2004, J NEUROSCI, V24, P9469, DOI 10.1523/JNEUROSCI.3162-04.2004; Quirk JC, 2001, NEURON, V32, P13, DOI 10.1016/S0896-6273(01)00444-5; ROBITAILLE R, 1992, J NEUROSCI, V12, P297; Rosenblatt KP, 1997, NEURON, V19, P1061, DOI 10.1016/S0896-6273(00)80397-9; Ruttiger L, 2004, P NATL ACAD SCI USA, V101, P12922, DOI 10.1073/pnas.0402660101; Saito M, 1997, J BIOL CHEM, V272, P11710, DOI 10.1074/jbc.272.18.11710; Sausbier M, 2005, CIRCULATION, V112, P60, DOI 10.1161/01.CIR.0000156448.74296.FE; Sausbier M, 2004, P NATL ACAD SCI USA, V101, P9474, DOI 10.1073/pnas.0401702101; Shao LR, 1999, J PHYSIOL-LONDON, V521, P135, DOI 10.1111/j.1469-7793.1999.00135.x; Shipston MJ, 1996, J BIOL CHEM, V271, P9197, DOI 10.1074/jbc.271.16.9197; Shipston MJ, 2001, TRENDS CELL BIOL, V11, P353, DOI 10.1016/S0962-8924(01)02068-2; Shipston MJ, 1999, MOL ENDOCRINOL, V13, P1728, DOI 10.1210/me.13.10.1728; Tian L, 2004, P NATL ACAD SCI USA, V101, P11897, DOI 10.1073/pnas.0402590101; Tian LJ, 2001, J PHYSIOL-LONDON, V537, P57, DOI 10.1111/j.1469-7793.2001.0057k.x; Tian LJ, 2001, J BIOL CHEM, V276, P7717, DOI 10.1074/jbc.C000741200; Toro L, 1998, NEWS PHYSIOL SCI, V13, P112; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; Uebele VN, 2000, J BIOL CHEM, V275, P23211, DOI 10.1074/jbc.M910187199; Van Goor F, 2001, J NEUROSCI, V21, P5902, DOI 10.1523/JNEUROSCI.21-16-05902.2001; Wang ZW, 2001, NEURON, V32, P867, DOI 10.1016/S0896-6273(01)00522-0; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0; Widmer HA, 2003, J PHYSIOL-LONDON, V552, P379, DOI 10.1113/jphysiol.2003.046441; Xie JY, 2001, NATURE, V410, P936, DOI 10.1038/35073593; Xie JY, 1998, SCIENCE, V280, P443, DOI 10.1126/science.280.5362.443; Zarei MM, 2004, P NATL ACAD SCI USA, V101, P10072, DOI 10.1073/pnas.0302919101; Zhou XB, 2001, J BIOL CHEM, V276, P43239, DOI 10.1074/jbc.M104202200	58	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33599	33609		10.1074/jbc.M505383200	http://dx.doi.org/10.1074/jbc.M505383200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16081418	hybrid			2022-12-27	WOS:000232058100061
J	Oria-Hernandez, J; Cabrera, N; Perez-Montfort, R; Ramirez-Silva, L				Oria-Hernandez, J; Cabrera, N; Perez-Montfort, R; Ramirez-Silva, L			Pyruvate kinase revisited - The activating effect of K+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSINE MONOPHOSPHATE DEHYDROGENASE; NUCLEAR MAGNETIC-RESONANCE; RABBIT MUSCLE; ESCHERICHIA-COLI; REGULATORY PROPERTIES; ANGSTROM RESOLUTION; MONOVALENT CATIONS; UNIVALENT CATIONS; DIVALENT-CATIONS; ION-BINDING	For more than 50 years, it has been known that K+ is an essential activator of pyruvate kinase (Kachmar, J. F., and Boyer, P. D. ( 1953) J. Biol. Chem. 200, 669 - 683). However, the role of K+ in the catalysis by pyruvate kinase has not been totally understood. Previous studies without K+ showed that the affinity of ADP-Mg2+ depends on the concentration of phosphoenolpyruvate, although the kinetics of the enzyme at saturating K+ concentrations show independence in the binding of substrates (Reynard, A. M., Hass, L. F., Jacobsen, D. D. & Boyer, P. D. ( 1961) J. Biol. Chem. 236, 2277 - 2283). Here, we explored the kinetics of the enzyme with and without K+. The results show that without K+, the kinetic mechanism of pyruvate kinase changes from random to ordered with phosphoenolpyruvate as first substrate. V-max with K+ was about 400 higher than without K+. In the presence of K+, the affinities for phosphoenolpyruvate, ADP-Mg2+, oxalate, and ADP-Cr2+ were 2 - 6-fold higher than in the absence of K+. This as well as fluorescence data also indicate that K+ is involved in the acquisition of the active conformation of the enzyme, allowing either phosphoenolpyruvate or ADP to bind independently ( random mechanism). In the absence of K+, ADP cannot bind to the enzyme until phosphoenolpyruvate forms a competent active site ( ordered mechanism). We propose that K+ induces the closure of the active site and the arrangement of the residues involved in the binding of the nucleotide.	Univ Nacl Autonoma Mexico, Fac Med, Dept Bioquim, Mexico City 04510, DF, Mexico; Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Bioquim, Mexico City 04510, DF, Mexico	Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico	Ramirez-Silva, L (corresponding author), Univ Nacl Autonoma Mexico, Fac Med, Dept Bioquim, Apartado Postal 70-159, Mexico City 04510, DF, Mexico.	lramirez@bq.unam.mx		Oria-Hernandez, Jesus/0000-0001-7147-1879; Cabrera Gonzalez, Elizabeth Nallely/0000-0001-8766-6996; Perez-Montfort, Ruy/0000-0003-0810-1159				AINSWORTH S, 1973, BIOCHEM J, V131, P223, DOI 10.1042/bj1310223; BUCHER T, 1955, METHOD ENZYMOL, V1, P435, DOI 10.1016/0076-6879(55)01071-9; BUSTO F, 1988, BIOCHEM CELL BIOL, V66, P148, DOI 10.1139/o88-020; Cleland W. W, 1970, ENZYMES, V2, P1; DEPAMPHILIS ML, 1973, BIOCHEMISTRY-US, V12, P3714, DOI 10.1021/bi00743a022; Di Cera E, 2004, CR BIOL, V327, P1065, DOI 10.1016/j.crvi.2004.07.011; GUPTA RK, 1978, J BIOL CHEM, V253, P8878; HEYDE E, 1976, BIOCHIM BIOPHYS ACTA, V429, P645, DOI 10.1016/0005-2744(76)90314-4; HEYDE E, 1976, BIOCHIM BIOPHYS ACTA, V429, P661, DOI 10.1016/0005-2744(76)90315-6; JETTEN MSM, 1994, APPL ENVIRON MICROB, V60, P2501, DOI 10.1128/AEM.60.7.2501-2507.1994; Johnsen U, 2003, J BIOL CHEM, V278, P25417, DOI 10.1074/jbc.M210288200; KACHMAR JF, 1953, J BIOL CHEM, V200, P669; KAYNE FJ, 1971, ARCH BIOCHEM BIOPHYS, V143, P232, DOI 10.1016/0003-9861(71)90204-9; KAYNE FJ, 1965, J AM CHEM SOC, V87, P897, DOI 10.1021/ja01082a035; KAYNE FJ, 1970, J AM CHEM SOC, V92, P220, DOI 10.1021/ja00704a048; KAYNE FJ, 1968, BIOCHEMISTRY-US, V7, P1678, DOI 10.1021/bi00845a009; Kerr KM, 2000, ARCH BIOCHEM BIOPHYS, V375, P131, DOI 10.1006/abbi.1999.1644; Larsen TM, 1998, BIOCHEMISTRY-US, V37, P6247, DOI 10.1021/bi980243s; Larsen TM, 2001, HANDBOOK ON METALLOPROTEINS, P9; Larsen TM, 1997, ARCH BIOCHEM BIOPHYS, V345, P199, DOI 10.1006/abbi.1997.0257; LARSEN TM, 1994, BIOCHEMISTRY-US, V33, P6301, DOI 10.1021/bi00186a033; Laughlin LT, 1997, ARCH BIOCHEM BIOPHYS, V348, P262, DOI 10.1006/abbi.1997.0448; MALCOVATI M, 1982, METHOD ENZYMOL, V90, P170; Markham GD, 1999, BIOCHEMISTRY-US, V38, P4433, DOI 10.1021/bi9829579; MILDVAN AS, 1966, J BIOL CHEM, V241, P1178; MUIRHEAD H, 1986, EMBO J, V5, P475, DOI 10.1002/j.1460-2075.1986.tb04236.x; NOWAK T, 1972, BIOCHEMISTRY-US, V11, P2819, DOI 10.1021/bi00765a014; NOWAK T, 1981, MOL CELL BIOCHEM, V35, P65, DOI 10.1007/BF02354821; PONCE E, 1995, J BACTERIOL, V177, P5719, DOI 10.1128/jb.177.19.5719-5722.1995; Prosise GL, 2002, J BIOL CHEM, V277, P50654, DOI 10.1074/jbc.M208330200; Ramirez-Silva L, 2003, EUR J BIOCHEM, V270, P2377, DOI 10.1046/j.1432-1033.2003.03605.x; Ramirez-Silva L, 2001, EUR J BIOCHEM, V268, P3267, DOI 10.1046/j.1432-1327.2001.02222.x; RAMIREZSILVA L, 1993, BIOCHEMISTRY-US, V32, P5332, DOI 10.1021/bi00071a008; RamirezSilva L, 1997, EUR J BIOCHEM, V250, P583, DOI 10.1111/j.1432-1033.1997.0583a.x; REED GH, 1973, J BIOL CHEM, V248, P6436; REED GH, 1974, BIOCHEMISTRY-US, V13, P3537, DOI 10.1021/bi00714a020; REUBEN J, 1971, J BIOL CHEM, V246, P6227; REYNARD AM, 1961, J BIOL CHEM, V236, P2277; SCHOENMAKERS TJM, 1992, BIOTECHNIQUES, V12, P870; Schramm A, 2000, J BACTERIOL, V182, P2001, DOI 10.1128/JB.182.7.2001-2009.2000; SORGER GJ, 1965, P NATL ACAD SCI USA, V54, P1614, DOI 10.1073/pnas.54.6.1614; Steiner P, 1998, GENE, V220, P31, DOI 10.1016/S0378-1119(98)00418-1; SUELTER CH, 1966, BIOCHEMISTRY-US, V5, P131, DOI 10.1021/bi00865a017; SUELTER CH, 1967, BIOCHEMISTRY-US, V6, P418, DOI 10.1021/bi00854a008; SUELTER CH, 1970, SCIENCE, V168, P789, DOI 10.1126/science.168.3933.789; TONEY MD, 1993, SCIENCE, V261, P756, DOI 10.1126/science.8342040; WILDES RA, 1971, BIOCHIM BIOPHYS ACTA, V229, P850, DOI 10.1016/0005-2795(71)90305-9; WILSON RH, 1967, J BIOL CHEM, V242, P3825	48	38	39	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37924	37929		10.1074/jbc.M508490200	http://dx.doi.org/10.1074/jbc.M508490200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16147999	hybrid			2022-12-27	WOS:000233044500074
J	Silve, C; Petrel, C; Leroy, C; Bruel, H; Mallet, E; Rognan, D; Ruat, M				Silve, C; Petrel, C; Leroy, C; Bruel, H; Mallet, E; Rognan, D; Ruat, M			Delineating a Ca2+ binding pocket within the Venus flytrap module of the human calcium-sensing receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; EXTRACELLULAR CA2+-SENSING RECEPTOR; 7-TRANSMEMBRANE DOMAIN; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; STRUCTURAL BASIS; TASTE RECEPTORS; MUTATIONS; PROTEIN; CATION	The Ca2+-sensing receptor (CaSR) belongs to the class III G-protein-coupled receptors (GPCRs), which include receptors for pheromones, amino acids, sweeteners, and the neurotransmitters glutamate and gamma-aminobutyric acid (GABA). These receptors are characterized by a long extracellular amino-terminal domain called a Venus flytrap module (VFTM) containing the ligand binding pocket. To elucidate the molecular determinants implicated in Ca2+ recognition by the CaSR VFTM, we developed a homology model of the human CaSR VFTM from the x-ray structure of the metabotropic glutamate receptor type 1 (mGluR1), and a phylogenetic analysis of 14 class III GPCR VFTMs. We identified critical amino acids delineating a Ca2+ binding pocket predicted to be adjacent to, but distinct from, a cavity reminiscent of the binding site described for amino acids in mGluRs, GABA-B receptor, and GPRC6a. Most interestingly, these Ca2+-contacting residues are well conserved within class III GPCR VFTMs. Our model was validated by mutational and functional analysis, including the characterization of activating and inactivating mutations affecting a single amino acid, Glu-297, located within the proposed Ca2+ binding pocket of the CaSR and associated with autosomal dominant hypocalcemia and familial hypocalciuric hypercalcemia, respectively, genetic diseases characterized by perturbations in Ca2+ homeostasis. Altogether, these data define a Ca2+ binding pocket within the CaSR VFTM that may be conserved in several other class III GPCRs, thereby providing a molecular basis for extracellular Ca2+ sensing by these receptors.	Inst Neurobiol Alfred Fessard, CNRS, IFR 2118, UPR9040, F-91198 Gif Sur Yvette, France; Univ Paris 07, INSERM, U426, F-75870 Paris, France; IFR02, F-75870 Paris, France; Univ Paris 07, F-75221 Paris, France; Grp Hosp Havre, Serv Med Neonatale, F-76083 Le Havre, France; Hop Charles Nicolle, Dept Pediat, F-76031 Rouen, France; Lab Pharmacochim Commun Cellulaire, CNRS, UMR7081, F-67401 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; CHU de Rouen; Centre National de la Recherche Scientifique (CNRS)	Ruat, M (corresponding author), Inst Neurobiol Alfred Fessard, CNRS, IFR 2118, UPR9040, 1 Ave Terrasse, F-91198 Gif Sur Yvette, France.	ruat@nbcm.cnrs-gif.fr	Ruat, Martial/E-5544-2016; Centeno, Patricia Pacios/O-8368-2016; Rognan, Didier/B-9939-2014					Abe H, 2003, FEBS LETT, V545, P233, DOI 10.1016/S0014-5793(03)00569-6; Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; Bessis AS, 2002, P NATL ACAD SCI USA, V99, P11097, DOI 10.1073/pnas.162138699; Bissantz C, 2003, PROTEINS, V50, P5, DOI 10.1002/prot.10237; Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633; Brauner-Osborne H, 1999, J BIOL CHEM, V274, P18382, DOI 10.1074/jbc.274.26.18382; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Cetani F, 2003, CLIN ENDOCRINOL, V58, P199, DOI 10.1046/j.1365-2265.2003.01696.x; Chang WH, 1998, J BONE MINER RES, V13, P570, DOI 10.1359/jbmr.1998.13.4.570; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; Conigrave AD, 2000, P NATL ACAD SCI USA, V97, P4814, DOI 10.1073/pnas.97.9.4814; Coulombe J, 2004, BIOCHEM BIOPH RES CO, V323, P1184, DOI 10.1016/j.bbrc.2004.08.209; Dyer J, 2005, BIOCHEM SOC T, V33, P302, DOI 10.1042/BST0330302; Galvez T, 2000, MOL PHARMACOL, V57, P419, DOI 10.1124/mol.57.3.419; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; Hendy GN, 2000, HUM MUTAT, V16, P281, DOI 10.1002/1098-1004(200010)16:4<281::AID-HUMU1>3.0.CO;2-A; Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154; Hu JX, 2005, J BIOL CHEM, V280, P5113, DOI 10.1074/jbc.M413403200; Hu JX, 2003, TRENDS ENDOCRIN MET, V14, P282, DOI 10.1016/S1043-2760(03)00104-8; Hu JX, 2002, J BIOL CHEM, V277, P46622, DOI 10.1074/jbc.M207100200; Hu JX, 2002, J BONE MINER RES, V17, P1461, DOI 10.1359/jbmr.2002.17.8.1461; Kuang DH, 2005, J NEUROCHEM, V93, P383, DOI 10.1111/j.1471-4159.2005.03025.x; Kubo Y, 1998, SCIENCE, V279, P1722, DOI 10.1126/science.279.5357.1722; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Li XD, 2002, P NATL ACAD SCI USA, V99, P4692, DOI 10.1073/pnas.072090199; Liu JF, 2004, J BIOL CHEM, V279, P15824, DOI 10.1074/jbc.M313639200; Mombaerts P, 2004, NAT REV NEUROSCI, V5, P263, DOI 10.1038/nrn1365; Nelson G, 2002, NATURE, V416, P199, DOI 10.1038/nature726; Nelson G, 2001, CELL, V106, P381, DOI 10.1016/S0092-8674(01)00451-2; Nemeth EF, 2002, CURR PHARM DESIGN, V8, P2077, DOI 10.2174/1381612023393387; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Pearce SHS, 1995, J CLIN INVEST, V96, P2683, DOI 10.1172/JCI118335; Petrel C, 2004, J BIOL CHEM, V279, P18990, DOI 10.1074/jbc.M400724200; Petrel C, 2003, J BIOL CHEM, V278, P49487, DOI 10.1074/jbc.M308010200; Pi M, 2004, J BONE MINER RES, V19, P862, DOI 10.1359/JBMR.040114; Pi M, 2000, J BIOL CHEM, V275, P3256, DOI 10.1074/jbc.275.5.3256; Pin JP, 2004, BIOL CELL, V96, P335, DOI 10.1016/j.biolcel.2004.03.005; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; Prie D, 2002, NEW ENGL J MED, V347, P983, DOI 10.1056/NEJMoa020028; PUMAIN R, 1987, CAN J PHYSIOL PHARM, V65, P1067, DOI 10.1139/y87-168; PUMAIN R, 1983, SCIENCE, V222, P177, DOI 10.1126/science.6623066; Ray K, 2002, J BIOL CHEM, V277, P18908, DOI 10.1074/jbc.M202113200; Reyes-Cruz G, 2001, J BIOL CHEM, V276, P32145, DOI 10.1074/jbc.M102977200; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; Ruat M, 1996, J BIOL CHEM, V271, P5972, DOI 10.1074/jbc.271.11.5972; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; Wellendorph P, 2005, MOL PHARMACOL, V67, P589, DOI 10.1124/mol.104.007559; Wu SV, 2002, P NATL ACAD SCI USA, V99, P2392, DOI 10.1073/pnas.042617699; Xu H, 2004, P NATL ACAD SCI USA, V101, P14258, DOI 10.1073/pnas.0404384101; Zhang ZX, 2002, J BIOL CHEM, V277, P33727, DOI 10.1074/jbc.M200976200	54	107	127	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37917	37923		10.1074/jbc.M506263200	http://dx.doi.org/10.1074/jbc.M506263200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16147994	hybrid			2022-12-27	WOS:000233044500073
J	Jain, N; Gupta, S; Sudhakar, C; Radha, V; Swarup, G				Jain, N; Gupta, S; Sudhakar, C; Radha, V; Swarup, G			Role of p73 in regulating human caspase-1 gene transcription induced by interferon-gamma and cisplatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE C-ABL; INDUCED APOPTOSIS; SPLICE VARIANTS; CELL-DEATH; P53; EXPRESSION; PATHWAY; IDENTIFICATION; P63; ACTIVATION	Caspase-1, a cysteine protease is primarily involved in proteolytic activation of proinflammatory cytokines such as interleukin-1 beta. It is also involved in some forms of apoptosis. Here we have analyzed the role of p73, a homolog of tumor suppressor p53, in regulating human caspase-1 gene transcription. The caspase-1 promoter was strongly activated by p73 alpha and p73 beta primarily through a p53/p73 responsive site. Overexpression of p73 by transient transfection increased the caspase-1 mRNA level. Treatment of cells with cisplatin ( which increases p73 protein level) resulted in increased caspase-1 promoter activity and its mRNA level. Blocking of p73 function by a dominant negative mutant reduced basal as well as cisplatin-induced caspase-1 promoter activity. Mutation of the p73 responsive site abolished cisplatin-induced activation of the promoter. Interferon-gamma induced caspase-1 promoter activity and this was reduced by p73-directed small hairpin RNA and also by a dominant negative mutant of p73. Abrogation of the p73 responsive site partially inhibited interferon-gamma-induced activation of the caspase-1 promoter. Treatment of HeLa cells with interferon-gamma resulted in an increase in p73 protein as well as its activity. Mutation of the IRF-1 binding site abolished interferon-gamma-induced caspase-1 promoter activity but p73-induced activation was only marginally reduced. IRF-1 cooperated with p73 and cisplatin cooperated with interferon-gamma in the activation of the caspase-1 promoter. Our results show that p73 is a regulator of caspase-1 gene transcription, and is required for optimal activation of the caspase-1 promoter by interferon-gamma.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Swarup, G (corresponding author), Ctr Cellular & Mol Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.	gshyam@ccmb.res.in	Gupta, Sanjeev/AAG-9749-2020; gupta, sanjeev/B-2824-2008	Gupta, Sanjeev/0000-0002-4691-6853; gupta, sanjeev/0000-0002-4691-6853; Swarup, Ghanshyam/0000-0002-8098-0509				CASANO FJ, 1994, GENOMICS, V20, P474, DOI 10.1006/geno.1994.1203; CERRETTI DP, 1994, GENOMICS, V20, P468, DOI 10.1006/geno.1994.1202; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Dai CH, 1999, BLOOD, V93, P3309, DOI 10.1182/blood.V93.10.3309.410k04_3309_3316; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Fontemaggi G, 2001, MOL CELL BIOL, V21, P8461, DOI 10.1128/MCB.21.24.8461-8470.2001; Fu XY, 1999, CELL DEATH DIFFER, V6, P1201, DOI 10.1038/sj.cdd.4400613; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; Gong JG, 1999, NATURE, V399, P806; Gupta S, 2002, FEBS LETT, V532, P61, DOI 10.1016/S0014-5793(02)03628-1; Gupta S, 2001, J BIOL CHEM, V276, P10585, DOI 10.1074/jbc.C100025200; Ikeda H, 2002, CYTOKINE GROWTH F R, V13, P95, DOI 10.1016/S1359-6101(01)00038-7; Innocente SA, 2005, BIOCHEM BIOPH RES CO, V329, P713, DOI 10.1016/j.bbrc.2005.02.028; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Iwase S, 1999, FEBS LETT, V450, P263, DOI 10.1016/S0014-5793(99)00515-3; Kamatkar S, 1996, J BIOL CHEM, V271, P26755, DOI 10.1074/jbc.271.43.26755; King AR, 2003, LAB INVEST, V83, P1497, DOI 10.1097/01.LAB.0000093096.62765.85; Koutsodontis G, 2005, BIOCHEM J, V389, P443, DOI 10.1042/BJ20041980; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; LEVERO M, 2000, J CELL SCI, V113, P1661; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Sadasivam S, 2005, ONCOGENE, V24, P627, DOI 10.1038/sj.onc.1208201; Sato M, 2001, CYTOKINE GROWTH F R, V12, P133, DOI 10.1016/S1359-6101(00)00032-0; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Shinbo J, 2002, BIOCHEM BIOPH RES CO, V295, P501, DOI 10.1016/S0006-291X(02)00707-6; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Strano S, 2001, FEBS LETT, V490, P163, DOI 10.1016/S0014-5793(01)02119-6; Tamura T, 1996, BIOCHEM BIOPH RES CO, V229, P21, DOI 10.1006/bbrc.1996.1752; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Wang J, 2000, J CELL SCI, V113, P753; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zhang WH, 2003, P NATL ACAD SCI USA, V100, P16012, DOI 10.1073/pnas.2534856100; Zhu JH, 1998, CANCER RES, V58, P5061	45	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36664	36673		10.1074/jbc.M413261200	http://dx.doi.org/10.1074/jbc.M413261200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16135520	hybrid			2022-12-27	WOS:000232901800018
J	Lee, JK; Simurdiak, M; Zhao, HM				Lee, JK; Simurdiak, M; Zhao, HM			Reconstitution and characterization of aminopyrrolnitrin oxygenase, a Rieske N-oxygenase that catalyzes unusual arylamine oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; NADH-QUINONE OXIDOREDUCTASE; SITE-DIRECTED MUTAGENESIS; PSEUDOMONAS-ARVILLA C-1; NAPHTHALENE 1,2-DIOXYGENASE; DIOXYGEN ACTIVATION; CYTOCHROME-BC(1) COMPLEX; PARACOCCUS-DENITRIFICANS; PYRROLNITRIN PRODUCTION; SUBSTRATE-SPECIFICITY	Rieske oxygenases catalyze a wide variety of important oxidation reactions. Here we report the characterization of a novel Rieske N-oxygenase, aminopyrrolnitrin oxygenase (PrnD) that catalyzes the unusual oxidation of an arylamine to an arylnitro group. PrnD from Pseudomonas fluorescens Pf5 was functionally expressed in Escherichia coli, and the activity of the purified PrnD was reconstituted, which required in vitro assembly of the Rieske iron-sulfur cluster into the protein and the presence of NADPH, FMN, and an E. coli flavin reductase SsuE. Biochemical and bioinformatics studies indicated that the reconstituted PrnD contains a Rieske iron-sulfur cluster and a mononuclear iron center that are formed by residues Cys(69), Cys(88), His(71), His(91), Asp(323), His(186), and His(191), respectively. The enzyme showed a limited range of substrate specificity and catalyzed the conversion of aminopyrrolnitrin into pyrrolnitrin with K-m = 191 mu M and k(cat) = 6.8 min(-1). Isotope labeling experiments with O-18(2) and (H2O)-O-18 suggested that the oxygen atoms in the pyrrolnitrin product are derived exclusively from molecular oxygen. In addition, it was found that the oxygenation of the arylamine substrates catalyzed by PrnD occurs at the enzyme active site and does not involve free radical chain reactions. By analogy to known examples of arylamine oxidation, a catalytic mechanism for the bioconversion of amino pyrrolnitrin into pyrrolnitrin was proposed. Our results should facilitate further mechanistic and crystallographic studies of this arylamine oxygenase and may provide a new enzymatic route for the synthesis of aromatic nitro compounds from their corresponding aromatic amines.	Univ Illinois, Inst Genom Biol, Ctr Biophys & Computat Biol, Dept Chem & Biomol Engn, Urbana, IL 61801 USA; Univ Illinois, Inst Genom Biol, Ctr Biophys & Computat Biol, Dept Chem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Zhao, HM (corresponding author), Univ Illinois, Inst Genom Biol, Ctr Biophys & Computat Biol, Dept Chem & Biomol Engn, 600 S Mathews Ave, Urbana, IL 61801 USA.	zhao5@uiuc.edu						ARIMA K, 1965, J ANTIBIOT, V18, P201; BALDWIN JE, 1993, TETRAHEDRON, V49, P7499, DOI 10.1016/S0040-4020(01)87226-4; Bassan A, 2004, J BIOL INORG CHEM, V9, P439, DOI 10.1007/s00775-004-0537-0; BATIE CJ, 1987, J BIOL CHEM, V262, P1510; Bertini I, 1996, COORDIN CHEM REV, V151, P145, DOI 10.1016/S0010-8545(96)90203-9; BURKHEAD KD, 1994, APPL ENVIRON MICROB, V60, P2031, DOI 10.1128/AEM.60.6.2031-2039.1994; CAMMACK R, 1984, CHARGE FIELD EFFECTS, P41; CEDERBAUM AI, 1978, BIOCHEMISTRY-US, V17, P3058, DOI 10.1021/bi00608a018; CHENG H, 1995, ARCH BIOCHEM BIOPHYS, V316, P619, DOI 10.1006/abbi.1995.1082; CHENG H, 1994, BIOCHEMISTRY-US, V33, P3155, DOI 10.1021/bi00177a003; Costas M, 2004, CHEM REV, V104, P939, DOI 10.1021/cr020628n; CRUTCHER SE, 1979, BIOCHEM J, V177, P393, DOI 10.1042/bj1770393; DAVIDSON E, 1992, BIOCHEMISTRY-US, V31, P3342, DOI 10.1021/bi00128a006; De Montellano P, 2005, CYTOCHROME P 450 STR; DOERGE DR, 1991, CHEM RES TOXICOL, V4, P556, DOI 10.1021/tx00023a011; FEE JA, 1984, J BIOL CHEM, V259, P124; FEE JA, 1986, BIOCHIM BIOPHYS ACTA, V853, P153, DOI 10.1016/0304-4173(86)90009-1; FOX BG, 1990, BIOCHEMISTRY-US, V29, P6419, DOI 10.1021/bi00479a013; GEARY PJ, 1990, METHOD ENZYMOL, V188, P52; Gong XM, 2003, ANAL BIOCHEM, V321, P259, DOI 10.1016/S0003-2697(03)00456-1; GRAHAM LA, 1991, J BIOL CHEM, V266, P22485; Hammer PE, 1997, APPL ENVIRON MICROB, V63, P2147, DOI 10.1128/AEM.63.6.2147-2154.1997; He J, 2004, J AM CHEM SOC, V126, P3694, DOI 10.1021/ja039328t; Holton B, 1996, BIOCHEMISTRY-US, V35, P15485, DOI 10.1021/bi961367c; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; JESPERS ABK, 1995, PESTIC SCI, V44, P167, DOI 10.1002/ps.2780440210; Kauppi B, 1998, STRUCTURE, V6, P571, DOI 10.1016/S0969-2126(98)00059-8; Keller S, 2000, ANGEW CHEM INT EDIT, V39, P2300, DOI 10.1002/1521-3773(20000703)39:13<2300::AID-ANIE2300>3.0.CO;2-I; KERSCHER L, 1976, EUR J BIOCHEM, V71, P101, DOI 10.1111/j.1432-1033.1976.tb11094.x; KIM IC, 1992, J BIOL CHEM, V267, P22108; Kim YW, 2003, APPL ENVIRON MICROB, V69, P4866, DOI 10.1128/AEM.69.8.4866-4874.2003; King RR, 1998, PHYTOCHEMISTRY, V49, P1265, DOI 10.1016/S0031-9422(98)00137-X; Kirner S, 1996, MICROBIOL-UK, V142, P2129, DOI 10.1099/13500872-142-8-2129; Kirner S, 1998, J BACTERIOL, V180, P1939, DOI 10.1128/JB.180.7.1939-1943.1998; KIRNER S, 1994, ANGEW CHEM INT EDIT, V33, P352, DOI 10.1002/anie.199403521; KUILA D, 1986, J BIOL CHEM, V261, P2768; LAMBERT B, 1987, APPL ENVIRON MICROB, V53, P1866, DOI 10.1128/AEM.53.8.1866-1871.1987; LAMBOWITZ AM, 1972, J BACTERIOL, V112, P1020, DOI 10.1128/JB.112.2.1020-1022.1972; LANCINI GC, 1966, BIOCHIM BIOPHYS ACTA, V130, P37, DOI 10.1016/0304-4165(66)90006-7; Lessner DJ, 2002, APPL ENVIRON MICROB, V68, P634, DOI 10.1128/AEM.68.2.634-641.2002; LUBBEN M, 1994, EUR J BIOCHEM, V224, P151, DOI 10.1111/j.1432-1033.1994.tb20006.x; MALKIN R, 1975, BIOCHEM BIOPH RES CO, V63, P1157, DOI 10.1016/0006-291X(75)90690-7; MALKIN R, 1973, IRON SULFUR PROTEINS, P1; MASON JR, 1992, ANNU REV MICROBIOL, V46, P277, DOI 10.1146/annurev.mi.46.100192.001425; McKay DB, 2003, J BACTERIOL, V185, P2944, DOI 10.1128/JB.185.9.2944-2951.2003; Meunier B, 2004, CHEM REV, V104, P3947, DOI 10.1021/cr020443g; MORRIS MP, 1954, SCIENCE, V119, P322, DOI 10.1126/science.119.3088.322; MURRAY RW, 1986, TETRAHEDRON LETT, V27, P2335, DOI 10.1016/S0040-4039(00)84522-0; NISHIDA M, 1965, J ANTIBIOT, V18, P211; Parales JV, 1998, J BACTERIOL, V180, P1194, DOI 10.1128/JB.180.5.1194-1199.1998; PFENDER WF, 1993, PHYTOPATHOLOGY, V83, P1223, DOI 10.1094/Phyto-83-1223; Que L, 1996, CHEM REV, V96, P2607, DOI 10.1021/cr960039f; Resnick SM, 1996, J IND MICROBIOL BIOT, V17, P438, DOI 10.1007/BF01574775; Riedel A, 1995, J BIOL CHEM, V270, P30869, DOI 10.1074/jbc.270.52.30869; RIESKE JS, 1964, J BIOL CHEM, V239, P3017; SALCHER O, 1978, TETRAHEDRON LETT, P3097; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; van Pee KH, 2000, NAT PROD REP, V17, P157, DOI 10.1039/a902138h; VANPEE KH, 1980, ANGEW CHEM INT EDIT, V19, P828, DOI 10.1002/anie.198008281; Wallar BJ, 1996, CHEM REV, V96, P2625, DOI 10.1021/cr9500489; Winkler R, 2005, ANGEW CHEM INT EDIT, V44, P4083, DOI 10.1002/anie.200500365; Wolfe MD, 2001, J BIOL CHEM, V276, P1945, DOI 10.1074/jbc.M007795200; YAMAGUCHI M, 1980, J BIOL CHEM, V255, P5058; YAMAGUCHI M, 1982, J BIOL CHEM, V257, P2497; Yano T, 1996, J BIOL CHEM, V271, P5907, DOI 10.1074/jbc.271.10.5907; Yano T, 1999, J BIOL CHEM, V274, P28598, DOI 10.1074/jbc.274.40.28598	67	63	65	4	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36719	36728		10.1074/jbc.M505334200	http://dx.doi.org/10.1074/jbc.M505334200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16150698	hybrid			2022-12-27	WOS:000232901800025
J	Ammosova, T; Jerebtsova, M; Beullens, M; Lesage, B; Jackson, A; Kashanchi, F; Southerland, W; Gordeuk, VR; Bollen, M; Nekhai, S				Ammosova, T; Jerebtsova, M; Beullens, M; Lesage, B; Jackson, A; Kashanchi, F; Southerland, W; Gordeuk, VR; Bollen, M; Nekhai, S			Nuclear targeting of protein phosphatase-1 by HIV-1 Tat protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RNA-POLYMERASE-II; C-TERMINAL DOMAIN; P-TEFB; TRANSCRIPTIONAL ACTIVITY; GAMMA(1)34.5 PROTEIN; STRUCTURAL BASIS; KINASE; ELONGATION; SUBUNIT	Transcription of human immunodeficiency virus (HIV)-1 genes is activated by HIV-1 Tat protein, which induces phosphorylation of the C-terminal domain of RNA polymerase-II by CDK9/cyclin T1. We previously showed that Tat-induced HIV-1 transcription is regulated by protein phosphatase-1 (PP1). In the present study we demonstrate that Tat interacts with PP1 and that disruption of this interaction prevents induction of HIV-1 transcription. We show that PP1 interacts with Tat in part through the binding of Val(36) and Phe(38) of Tat to PP1 and that Tat is involved in the nuclear and subnuclear targeting of PP1. The PP1 binding mutant Tat-V36A/ F38A displayed a decreased affinity for PP1 and was a poor activator of HIV-1 transcription. Surprisingly, Tat-Q35R mutant that had a higher affinity for PP1 was also a poor activator of HIV-1 transcription, because strong PP1 binding competed out binding of Tat to CDK9/ cyclin T1. Our results suggest that Tat might function as a nuclear regulator of PP1 and that interaction of Tat with PP1 is critical for activation of HIV-1 transcription by Tat.	Howard Univ, Ctr Sickle Cell Dis, Washington, DC 20059 USA; Howard Univ, Dept Biochem & Mol Biol, Washington, DC 20059 USA; Childrens Natl Med Ctr, CRI Ctr 3, Washington, DC 20010 USA; Catholic Univ Louvain, Div Biochem, B-3000 Louvain, Belgium; George Washington Univ, Dept Biochem & Mol Biol, Washington, DC 20037 USA	Howard University; Howard University; Children's National Health System; Universite Catholique Louvain; George Washington University	Nekhai, S (corresponding author), 2121 Georgia Ave NW, Washington, DC 20059 USA.	snekhai@howard.edu	Ammosova, Tatiana/J-7564-2018; , nekhai/AAW-3105-2021; Ammosova, Tatiana/HIA-0704-2022; Gordeuk, Victor/AAG-6577-2019; , nekhai/AFO-2652-2022	Ammosova, Tatiana/0000-0001-8777-1032; 	NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003048] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [UH1HL003679] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043894, R21AI056973, R29AI044357] Funding Source: NIH RePORTER; NCRR NIH HHS [5G12RR03048] Funding Source: Medline; NHLBI NIH HHS [UH1 HL03679] Funding Source: Medline; NIAID NIH HHS [AI43894, AI44357, R21 AI056973, R21 AI056973-02, AI056973-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ammosova T, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-47; Ammosova T, 2003, J BIOL CHEM, V278, P32189, DOI 10.1074/jbc.M300521200; Beullens M, 1998, METH MOL B, V93, P145; Beullens M, 2000, BIOCHEM J, V352, P651, DOI 10.1042/0264-6021:3520651; Bharucha DC, 2002, VIROLOGY, V296, P6, DOI 10.1006/viro.2002.1438; Bollen M, 2002, TRENDS CELL BIOL, V12, P138, DOI 10.1016/S0962-8924(01)02247-4; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Ceulemans H, 2002, J BIOL CHEM, V277, P47331, DOI 10.1074/jbc.M206838200; Chen RC, 2004, J BIOL CHEM, V279, P4153, DOI 10.1074/jbc.M310044200; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; DEGUZMAN A, 1988, METHOD ENZYMOL, V159, P356; Deng LW, 2002, J BIOL CHEM, V277, P33922, DOI 10.1074/jbc.M111349200; Deng LW, 2000, VIROLOGY, V277, P278, DOI 10.1006/viro.2000.0593; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Faulkner NE, 2003, J VIROL, V77, P2276, DOI 10.1128/JVI.77.3.2276-2281.2003; Greene WC, 2002, NAT MED, V8, P673, DOI 10.1038/nm0702-673; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; He B, 1998, J BIOL CHEM, V273, P20737, DOI 10.1074/jbc.273.33.20737; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; JEANG KT, 1992, J BIOL CHEM, V267, P17891; JEANG KT, 1993, J BIOL CHEM, V268, P24940; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Kim YK, 2002, MOL CELL BIOL, V22, P4622, DOI 10.1128/MCB.22.13.4622-4637.2002; Lesage B, 2004, J BIOL CHEM, V279, P55978, DOI 10.1074/jbc.M411911200; Marshall NF, 2000, J BIOL CHEM, V275, P32430, DOI 10.1074/jbc.M005898200; Marshall NF, 1998, J BIOL CHEM, V273, P31726, DOI 10.1074/jbc.273.48.31726; Nekhai S, 1997, J VIROL, V71, P7436, DOI 10.1128/JVI.71.10.7436-7441.1997; Nekhai S, 2002, BIOCHEM J, V364, P649, DOI 10.1042/BJ20011191; Ott M, 1999, CURR BIOL, V9, P1489, DOI 10.1016/S0960-9822(00)80120-7; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Raha T, 2005, PLOS BIOL, V3, P221, DOI 10.1371/journal.pbio.0030044; Ruediger R, 1997, VIROLOGY, V238, P432, DOI 10.1006/viro.1997.8873; Stauber RH, 1998, VIROLOGY, V252, P126, DOI 10.1006/viro.1998.9400; Terrak M, 2004, NATURE, V429, P780, DOI 10.1038/nature02582; Trinkle-Mulcahy L, 2001, J CELL SCI, V114, P4219; Verhoef K, 1998, AIDS RES HUM RETROV, V14, P1553, DOI 10.1089/aid.1998.14.1553; Verhoef K, 1999, J VIROL, V73, P2781, DOI 10.1128/JVI.73.4.2781-2789.1999; Wakula P, 2003, J BIOL CHEM, V278, P18817, DOI 10.1074/jbc.M300175200; Washington K, 2002, J BIOL CHEM, V277, P40442, DOI 10.1074/jbc.M205687200; Yang XZ, 1997, P NATL ACAD SCI USA, V94, P12331, DOI 10.1073/pnas.94.23.12331; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	43	46	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36364	36371		10.1074/jbc.M503673200	http://dx.doi.org/10.1074/jbc.M503673200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16131488	hybrid			2022-12-27	WOS:000232726900070
J	Jethanandani, P; Kramer, RH				Jethanandani, P; Kramer, RH			alpha 7 integrin expression is negatively regulated by delta EF1 during skeletal myogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE DIFFERENTIATION; BINDING-PROTEINS; REPRESSOR; MYOD; ACTIVATION; CELLS; ZEB; MECHANISMS; JUNCTION; FOS	alpha 7 integrin levels increase dramatically as myoblasts differentiate to myotubes. A negative regulatory element with putative sites for delta EF1 is present in the alpha 7 proximal promoter region. To define the role of delta EF1 in regulating alpha 7 integrin expression, we overexpressed delta EF1 in C2C12 myoblasts. This resulted in a major downregulation of alpha 7 protein expression. Promoter assays revealed that C2C12 myoblasts transfected with delta EF1 showed a decrease in activity of the 2.8-kb alpha 7 promoter fragment, indicating regulation of alpha 7 integrin at the transcriptional level. We have identified two E-box-like sites for delta EF1 in the negative regulatory region. Mutation of these sites enhanced alpha 7 promoter activity, indicating that these sites function in repression. MYOD, an activator of alpha 7 integrin transcription, can compete with delta EF1 for binding at these sites in gel shift assay. By using chromatin immunoprecipitation, we demonstrated a reciprocal binding of delta EF1 and MYOD to this regulatory element depending on the stage of differentiation: delta EF1 is preferentially bound in myoblasts to this region, whereas MYOD is bound in myotubes. The N-terminal region of delta EF1 is necessary for alpha 7 repression, and this region also binds the co-activator p300/CBP. Importantly, we found that the p300/CBP co-activator can overcome repression by delta EF1, suggesting that delta EF1 can titrate limiting amounts of this co-activator. These findings suggest that delta EF1 has a role in suppressing integrin expression in myoblasts by displacing MYOD and competing for p300/CBP co-activator.	Univ Calif San Francisco, Dept Cell & Tissue Biol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Kramer, RH (corresponding author), Univ Calif San Francisco, Dept Cell & Tissue Biol, Box 0640,C-640,521 Parnassus Ave, San Francisco, CA 94143 USA.	Randall.Kramer@ucsf.edu			NIDCR NIH HHS [DE015404] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE015404] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Belkin AM, 1996, J CELL BIOL, V132, P211, DOI 10.1083/jcb.132.1.211; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOA ZZ, 1993, J CELL SCI, V106, P579; Burkin DJ, 1999, CELL TISSUE RES, V296, P183, DOI 10.1007/s004410051279; Chen CMA, 1996, CELL, V86, P731, DOI 10.1016/S0092-8674(00)80148-8; Hayashi YK, 1998, NAT GENET, V19, P94, DOI 10.1038/ng0598-94; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; Lemercier C, 1998, EMBO J, V17, P1412, DOI 10.1093/emboj/17.5.1412; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; Martin PT, 1996, DEV BIOL, V174, P125, DOI 10.1006/dbio.1996.0057; McKinsey TA, 2002, CURR OPIN CELL BIOL, V14, P763, DOI 10.1016/S0955-0674(02)00389-7; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; Miosge N, 1999, LAB INVEST, V79, P1591; Pegoraro E, 2002, AM J PATHOL, V160, P2135, DOI 10.1016/S0002-9440(10)61162-5; Postigo AA, 1999, MOL CELL BIOL, V19, P7961; Postigo AA, 2003, EMBO J, V22, P2453, DOI 10.1093/emboj/cdg226; Postigo AA, 1997, EMBO J, V16, P3935, DOI 10.1093/emboj/16.13.3935; Rajabi HN, 2005, J BIOL CHEM, V280, P361, DOI 10.1074/jbc.M408633200; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sekido R, 1997, GENES CELLS, V2, P771, DOI 10.1046/j.1365-2443.1997.1570355.x; SEKIDO R, 1994, MOL CELL BIOL, V14, P5692, DOI 10.1128/MCB.14.9.5692; VanderFlier A, 1997, DEV DYNAM, V210, P472, DOI 10.1002/(SICI)1097-0177(199712)210:4<472::AID-AJA10>3.0.CO;2-9; VANDROMME M, 1994, J CELL SCI, V107, P613; Xiao JQ, 2003, J BIOL CHEM, V278, P49780, DOI 10.1074/jbc.M308542200; Yao CC, 1997, J CELL SCI, V110, P1477; Zhao P, 2004, DEV DYNAM, V229, P380, DOI 10.1002/dvdy.10457; Ziober BL, 1996, J BIOL CHEM, V271, P22915, DOI 10.1074/jbc.271.37.22915	28	20	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36037	36046		10.1074/jbc.M508698200	http://dx.doi.org/10.1074/jbc.M508698200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16129691	hybrid			2022-12-27	WOS:000232726900033
J	Shao, BH; Fu, XY; McDonald, TO; Green, PS; Uchida, K; O'Brien, KD; Oram, JF; Heinecke, JW				Shao, BH; Fu, XY; McDonald, TO; Green, PS; Uchida, K; O'Brien, KD; Oram, JF; Heinecke, JW			Acrolein impairs ATP binding cassette transporter A1-dependent cholesterol export from cells through site-specific modification of apolipoprotein A-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; HUMAN ATHEROSCLEROTIC LESIONS; CELLULAR CHOLESTEROL; LIPID-PEROXIDATION; ALPHA,BETA-UNSATURATED ALDEHYDES; HDL APOLIPOPROTEINS; OXIDATIVE DAMAGE; LYSINE RESIDUES; MYELOPEROXIDASE; EFFLUX	Acrolein is a highly reactive alpha,beta-unsaturated aldehyde, but the factors that control its reactions with nucleophilic groups on proteins remain poorly understood. Lipid peroxidation and threonine oxidation by myeloperoxidase are potential sources of acrolein during inflammation. Because both pathways are implicated in atherogenesis and high density lipoprotein (HDL) is anti-atherogenic, we investigated the possibility that acrolein might target the major protein of HDL, apolipoprotein A-I (apoA-I), for modification. Tandem mass spectrometric analysis demonstrated that lysine 226, located near the center of helix 10 in apoA-I, was the major site modified by acrolein. Importantly, this region plays a critical role in the cellular interactions and ability of apoA-I to transport lipid. Indeed, we found that conversion of Lys-226 to N-epsilon-(3-methylpyridinium) lysine by acrolein associated quantitatively with decreased cholesterol efflux from cells via the ATP-binding cassette transporter A1 pathway. In the crystal structure of truncated apoA-I, Glu-234 lies adjacent to Lys-226, suggesting that negatively charged residues might direct the modification of specific lysine residues in proteins. Finally, immunohistochemical studies with a monoclonal antibody revealed co-localization of apoA-I with acrolein adducts in human atherosclerotic lesions. Our observations suggest that acrolein might interfere with normal reverse cholesterol transport by HDL by modifying specific sites in apoA-I. Thus, acrolein might contribute to atherogenesis by impairing cholesterol removal from the artery wall.	Univ Washington, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA 98195 USA; Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan	University of Washington; University of Washington Seattle; Nagoya University	Heinecke, JW (corresponding author), Univ Washington, Div Metab Endocrinol & Nutr, Dept Med, Box 356426, Seattle, WA 98195 USA.	heinecke@u.washington.edu	O'Brien, Kevin/CAH-4638-2022; O'Brien, Kevin Douglas/HDO-1461-2022	O'Brien, Kevin/0000-0002-2293-9196; O'Brien, Kevin Douglas/0000-0002-2293-9196; Uchida, Koji/0000-0003-3894-5299; Shao, Baohai/0000-0001-8832-2845	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075340, R01HL039934, R01HL075381, P01HL030086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK017047, P30DK035816] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007033] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021191] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL075340, P01HL030086, HL39934, HL075381] Funding Source: Medline; NIA NIH HHS [AG021191] Funding Source: Medline; NIDDK NIH HHS [DK02456, P30DK017047, P30DK35816] Funding Source: Medline; NIEHS NIH HHS [P30ES07033] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Anderson MM, 1999, J CLIN INVEST, V104, P103, DOI 10.1172/JCI3042; Anderson MM, 1997, J CLIN INVEST, V99, P424, DOI 10.1172/JCI119176; Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1; Bergt C, 2004, P NATL ACAD SCI USA, V101, P13032, DOI 10.1073/pnas.0405292101; Bergt C, 2004, J BIOL CHEM, V279, P7856, DOI 10.1074/jbc.M309046200; Bergt C, 2003, ARTERIOSCL THROM VAS, V23, P1488, DOI 10.1161/01.ATV.0000090570.99836.9C; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; BOWRY VW, 1992, P NATL ACAD SCI USA, V89, P10316, DOI 10.1073/pnas.89.21.10316; BROUILLETTE CG, 1995, BBA-LIPID LIPID MET, V1256, P103, DOI 10.1016/0005-2760(95)00018-8; Chroni A, 2003, J BIOL CHEM, V278, P6719, DOI 10.1074/jbc.M205232200; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; Davidson WS, 2005, CURR OPIN LIPIDOL, V16, P295, DOI 10.1097/01.mol.0000169349.38321.ad; Drapeau G R, 1977, Methods Enzymol, V47, P189; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Francis GA, 2000, BBA-MOL CELL BIOL L, V1483, P217, DOI 10.1016/S1388-1981(99)00181-X; Frank PG, 2000, J LIPID RES, V41, P853; Fu XY, 2001, J BIOL CHEM, V276, P41279, DOI 10.1074/jbc.M106958200; Furuhata A, 2003, J BIOL CHEM, V278, P48658, DOI 10.1074/jbc.M309401200; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; HEINECKE JW, 1986, J CLIN INVEST, V77, P757, DOI 10.1172/JCI112371; Heinecke JW, 1997, CURR OPIN LIPIDOL, V8, P268, DOI 10.1097/00041433-199710000-00005; Heinecke JW, 1999, J LAB CLIN MED, V133, P321, DOI 10.1016/S0022-2143(99)90061-6; Heinecke JW, 1998, ATHEROSCLEROSIS, V141, P1, DOI 10.1016/S0021-9150(98)00173-7; HOBERMAN HD, 1988, J BIOCHEM TOXICOL, V3, P105, DOI 10.1002/jbt.2570030205; Lewis GF, 2005, CIRC RES, V96, P1221, DOI 10.1161/01.RES.0000170946.56981.5c; MCCALL M, 1995, ARTERIOSCL THROM VAS, V15, P1599, DOI 10.1161/01.ATV.15.10.1599; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; Mohamad N., 2004, J LIPID RES, V45, P993, DOI [10.1194/jlr.R400001-JLR200, DOI 10.1194/JLR.R400001-JLR200]; Natarajan P, 2004, J BIOL CHEM, V279, P24044, DOI 10.1074/jbc.M400561200; O'Brien KD, 1998, CIRCULATION, V98, P519, DOI 10.1161/01.CIR.98.6.519; Oram JF, 2003, ARTERIOSCL THROM VAS, V23, P720, DOI 10.1161/01.ATV.0000054662.44688.9A; Panagotopulos SE, 2002, J BIOL CHEM, V277, P39477, DOI 10.1074/jbc.M207005200; Pennathur S, 2004, J BIOL CHEM, V279, P42977, DOI 10.1074/jbc.M406762200; Richter T, 2005, NEUROBIOL AGING, V26, P465, DOI 10.1016/j.neurobiolaging.2004.04.009; Sakata K, 2003, BIOCHEM BIOPH RES CO, V305, P143, DOI 10.1016/S0006-291X(03)00716-2; SAVENKOVA MI, 1994, J BIOL CHEM, V269, P20394; Segrest JP, 1999, J BIOL CHEM, V274, P31755, DOI 10.1074/jbc.274.45.31755; SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303; Shao BH, 2005, ANN NY ACAD SCI, V1043, P396, DOI 10.1196/annals.1333.046; Shao BH, 2005, J BIOL CHEM, V280, P5983, DOI 10.1074/jbc.M411484200; Sorci-Thomas MG, 2002, TRENDS CARDIOVAS MED, V12, P121, DOI 10.1016/S1050-1738(01)00163-3; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; Tang CR, 2004, J BIOL CHEM, V279, P7622, DOI 10.1074/jbc.M312571200; TU CK, 1989, J BIOL CHEM, V264, P12389; Uchida K, 1998, J BIOL CHEM, V273, P16058, DOI 10.1074/jbc.273.26.16058; Uchida K, 1998, P NATL ACAD SCI USA, V95, P4882, DOI 10.1073/pnas.95.9.4882; Uchida K, 1999, TRENDS CARDIOVAS MED, V9, P109, DOI 10.1016/S1050-1738(99)00016-X; Vaughan AM, 2003, J LIPID RES, V44, P1373, DOI 10.1194/jlr.M300078-JLR200; Wang N, 2003, ARTERIOSCL THROM VAS, V23, P1178, DOI 10.1161/01.ATV.0000075912.83860.26; WITZ G, 1989, FREE RADICAL BIO MED, V7, P333, DOI 10.1016/0891-5849(89)90137-8; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; Zheng LM, 2004, J CLIN INVEST, V114, P529, DOI 10.1172/JCI200421109	55	97	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36386	36396		10.1074/jbc.M508169200	http://dx.doi.org/10.1074/jbc.M508169200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16126721	hybrid			2022-12-27	WOS:000232726900073
J	Yang, JS; Zhang, L; Erbel, PJA; Gardner, KH; Ding, K; Garcia, JA; Bruick, RK				Yang, JS; Zhang, L; Erbel, PJA; Gardner, KH; Ding, K; Garcia, JA; Bruick, RK			Functions of the Per/ARNT/Sim domains of the hypoxia-inducible factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAS DOMAIN; STRUCTURAL BASIS; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; FACTOR 1-ALPHA; TARGET GENE; DNA-BINDING; HIF-ALPHA; FACTOR-I; OXYGEN	The heterodimeric transcription factor hypoxia-inducible factor (HIF) plays an important role in the progression of a number of processes in which O-2 availability is compromised and, as such, has become an increasingly attractive therapeutic target. Although tremendous progress has been made in recent years in unraveling the mechanisms underlying O-2-dependent regulation of HIF through its O-2-dependent degradation domain and C-terminal transactivation domain, our understanding of the contributions of other structural elements, particularly the Per/ARNT/Sim (PAS)-A and PAS-B domains, to the activity of HIF is incomplete. Using insights derived from the recently determined solution structures of the HIF PAS-B domains as a starting point, we have explored the function(s) of the HIF-2 alpha PAS domains via mutational analysis. In contrast to recent models, our data reveal that both PAS domains of the HIF-alpha subunit are necessary for heterodimer formation but are not required to mediate other HIF functions in which PAS domains have been implicated. Because disruption of individual PAS domains compromise HIF function independent of the mechanism of HIF induction, these data demonstrate the potential utility of targeting these domains for therapeutic applications.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Bruick, RK (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Richard.Bruick@UTSouthwestern.edu	Gardner, Kevin/K-5493-2019; Gardner, Kevin H./K-7802-2012	Gardner, Kevin H./0000-0002-8671-2556; , Kan/0000-0003-3485-8200; Garcia, Joseph/0000-0002-5621-7538	NCI NIH HHS [CA95471, CA90601] Funding Source: Medline; NCRR NIH HHS [C06 RR-15437] Funding Source: Medline; NHLBI NIH HHS [K08 HL067154] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA095471, R01CA090601] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR015437] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL067154] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amezcua CA, 2002, STRUCTURE, V10, P1349, DOI 10.1016/S0969-2126(02)00857-2; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Bruick RK, 2003, GENE DEV, V17, P2614, DOI 10.1101/gad.1145503; CARD PB, 2005, IN PRESS J MOL BIOL; Chapman-Smith A, 2004, J BIOL CHEM, V279, P5353, DOI 10.1074/jbc.M310041200; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Erbel PJA, 2003, P NATL ACAD SCI USA, V100, P15504, DOI 10.1073/pnas.2533374100; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Giaccia A, 2003, NAT REV DRUG DISCOV, V2, P803, DOI 10.1038/nrd1199; Gorlach A, 2000, BBA-GENE STRUCT EXPR, V1493, P125, DOI 10.1016/S0167-4781(00)00172-X; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Isaacs JS, 2004, J BIOL CHEM, V279, P16128, DOI 10.1074/jbc.M313342200; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENOMICS, V52, P159, DOI 10.1006/geno.1998.5416; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Katschinski DM, 2004, CELL PHYSIOL BIOCHEM, V14, P351, DOI 10.1159/000080345; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Minet E, 1999, FEBS LETT, V460, P251, DOI 10.1016/S0014-5793(99)01359-9; Minet E, 1999, BIOCHEM BIOPH RES CO, V261, P534, DOI 10.1006/bbrc.1999.0995; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Sanchez-Puig N, 2005, MOL CELL, V17, P11, DOI 10.1016/j.molcel.2004.11.019; Semenza GL, 2000, GENE DEV, V14, P1983; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Takahashi R, 2004, BIOCHEM BIOPH RES CO, V317, P84, DOI 10.1016/j.bbrc.2004.03.010; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WANG GL, 1996, METH MOL G, V8, P298; Warnecke C, 2004, FASEB J, V18, P1462, DOI 10.1096/fj.04-1640fje; Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360; Zelzer E, 1997, GENE DEV, V11, P2079, DOI 10.1101/gad.11.16.2079	51	61	64	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36047	36054		10.1074/jbc.M501755200	http://dx.doi.org/10.1074/jbc.M501755200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16129688	hybrid			2022-12-27	WOS:000232726900034
J	Zhu, GZ; Fujii, K; Liu, Y; Codrea, V; Herrero, J; Shaw, S				Zhu, GZ; Fujii, K; Liu, Y; Codrea, V; Herrero, J; Shaw, S			A single pair of acidic residues in the kinase major groove mediates strong substrate preference for P-2 or P-5 arginine in the AGC, CAMK, and STE kinase families	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SPECIFICITY DETERMINANTS; PHOSPHORYLATION SITE; RECOGNITION SEQUENCE; PEPTIDE SPECIFICITY; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; BASIC RESIDUES; MOTIFS; IDENTIFICATION	Most basophilic serine/threonine kinases preferentially phosphorylate substrates with Arg at P - 3 but vary greatly in additional strong preference for Arg at P - 2 or P - 5. The structural basis for P - 2 or P - 5 preference is known for two AGC kinases ( family of protein kinases A, G, and C) in which it is mediated by a single pair of acidic residues ( PEN + 1 and YEM + 1). We sought a general understanding of P - 2 and P - 5Arg preference. The strength of Arg preference at each position was assessed in 15 kinases using a new degenerate peptide library approach. Strong P - 2 or P - 5 Arg preference occurred not only in AGC kinases ( 7 of 8 studied) but also in calmodulin-dependent protein kinase (CAMK, 1 of 3) and Ste20 (STE) kinases ( 2 of 4). Analysis of sequence conservation demonstrated almost perfect correlation between ( a) strong P - 2 or P - 5 Arg preference and (b) acidic residues at both PEN + 1 and YEM + 1. Mutation of two kinases (PKC-theta and p21-activated kinase 1 (PAK1)) confirmed critical roles of both PEN + 1 and YEM + 1 residues in determining strong R-2 Arg preference. PAK kinases were unique in having exceptionally strong Arg preference at P - 2 but lacking strong Arg preference at P - 3. Preference for Arg at P - 2 was so critical to PAK recognition that PAK1 activity was virtually eliminated by mutating the PEN + 1 or YEM + 1 residues. The fact that this specific pair of acidic residues has been repeatedly and exclusively used by evolution for conferring strong Arg preference at two different substrate positions in three different kinase families implies it is uniquely well suited to mediate sufficiently good substrate binding without unduly restricting product release.	NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; AxCell Biosci, Newtown, PA 18940 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Shaw, S (corresponding author), NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA.	sshaw@nih.gov			NATIONAL CANCER INSTITUTE [Z01BC010272, ZIABC009257, ZIABC010272, Z01BC009257] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Batkin M, 2000, BIOCHEMISTRY-US, V39, P5366, DOI 10.1021/bi000153z; BENNER GE, 1995, J BIOL CHEM, V270, P21121, DOI 10.1074/jbc.270.36.21121; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Brinkworth RI, 2003, P NATL ACAD SCI USA, V100, P74, DOI 10.1073/pnas.0134224100; Burch LR, 2004, J MOL BIOL, V337, P115, DOI 10.1016/j.jmb.2003.10.081; Cheek S, 2002, J MOL BIOL, V320, P855, DOI 10.1016/S0022-2836(02)00538-7; DALE S, 1995, FEBS LETT, V361, P191, DOI 10.1016/0014-5793(95)00172-6; Ebneth A, 1999, CELL MOTIL CYTOSKEL, V44, P209, DOI 10.1002/(SICI)1097-0169(199911)44:3<209::AID-CM6>3.0.CO;2-4; FRIEDMANN M, 1992, ARCH BIOCHEM BIOPHYS, V298, P594, DOI 10.1016/0003-9861(92)90454-5; Fujii K, 2004, P NATL ACAD SCI USA, V101, P13744, DOI 10.1073/pnas.0401881101; GIBBS CS, 1991, BIOCHEMISTRY-US, V30, P5329, DOI 10.1021/bi00236a001; He XG, 2003, AM J PATHOL, V163, P243, DOI 10.1016/S0002-9440(10)63647-4; HOUSE C, 1987, J BIOL CHEM, V262, P772; HUANG CYF, 1995, J BIOL CHEM, V270, P7183, DOI 10.1074/jbc.270.13.7183; Hutchins JRA, 2000, FEBS LETT, V466, P91, DOI 10.1016/S0014-5793(99)01763-9; Hutti JE, 2004, NAT METHODS, V1, P27, DOI 10.1038/NMETH708; KEMP BE, 1975, P NATL ACAD SCI USA, V72, P3448, DOI 10.1073/pnas.72.9.3448; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KEMP BE, 1977, J BIOL CHEM, V252, P4888; Kreegipuu A, 1998, FEBS LETT, V430, P45, DOI 10.1016/S0014-5793(98)00503-1; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; Madhavan R, 1999, BBA-PROTEIN STRUCT M, V1434, P260, DOI 10.1016/S0167-4838(99)00193-4; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Nolen B, 2003, BIOCHEMISTRY-US, V42, P9575, DOI 10.1021/bi0344331; O'Neill T, 2002, J BIOL CHEM, V277, P16102, DOI 10.1074/jbc.M111705200; OBRIAN CA, 1984, BIOCHEM BIOPH RES CO, V124, P296, DOI 10.1016/0006-291X(84)90951-3; Palaty CK, 1997, BIOCHEM CELL BIOL, V75, P153, DOI 10.1139/bcb-75-2-153; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; Qian ZJ, 2001, J BIOL CHEM, V276, P22439, DOI 10.1074/jbc.M009323200; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; Tuazon PT, 1997, BIOCHEMISTRY-US, V36, P16059, DOI 10.1021/bi9717845; TURNER RS, 1985, J BIOL CHEM, V260, P1503; Velentza AV, 2001, J BIOL CHEM, V276, P38956, DOI 10.1074/jbc.M104273200; White RR, 1998, J BIOL CHEM, V273, P3166, DOI 10.1074/jbc.273.6.3166; Xu ZB, 2004, J BIOL CHEM, V279, P50401, DOI 10.1074/jbc.M409216200; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9; Zhu GZ, 2005, CELL CYCLE, V4, P52, DOI 10.4161/cc.4.1.1353	46	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36372	36379		10.1074/jbc.M505031200	http://dx.doi.org/10.1074/jbc.M505031200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16131491	hybrid			2022-12-27	WOS:000232726900071
J	Al-Khouri, AM; Ma, YL; Togo, SH; Williams, S; Mustelin, T				Al-Khouri, AM; Ma, YL; Togo, SH; Williams, S; Mustelin, T			Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; CELL-SURVIVAL; GENE; STABILITY; BINDING; IDENTIFICATION; SITES; AKT	The phosphatase and tensin homologue (PTEN) tumor suppressor is a phosphatidylinositol D3-phosphatase that counteracts the effects of phosphatidylinositol 3-kinase and negatively regulates cell growth and survival. PTEN is itself regulated by phosphorylation on multiple serine and threonine residues in its C terminus. Previous work has implicated casein kinase 2 (CK2) as the kinase responsible for this phosphorylation. Here we showed that CK2 does not phosphorylate all sites in PTEN and that glycogen synthase kinase 3 beta (GSK3 beta) also participates in PTEN phosphorylation. Although CK2 mainly phosphorylated PTEN at Ser-370 and Ser-385, GSK3 beta phosphorylated Ser-362 and Thr-366. More importantly, prior phosphorylation of PTEN at Ser-370 by CK2 strongly increased its phosphorylation at Thr-366 by GSK3 beta, suggesting that the two may synergize. Using RNA interference, we showed that GSK3 phosphorylates PTEN in intact cells. Finally, PTEN phosphorylation was affected by insulin-like growth factor in intact cells. We concluded that multiple kinases, including CK2 and GSK3 beta, participate in PTEN phosphorylation and that GSK3 beta may provide feedback regulation of PTEN.	Burnham Inst, Inflammatory & Infect Dis Ctr, Program Inflammat, La Jolla, CA 92037 USA; Burnham Inst, Program Signal Transduct, Ctr Canc, La Jolla, CA 92037 USA; Burnham Inst, Prote Facil, Ctr Canc, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute; Sanford Burnham Prebys Medical Discovery Institute; Sanford Burnham Prebys Medical Discovery Institute	Mustelin, T (corresponding author), Burnham Inst, Inflammatory & Infect Dis Ctr, Program Inflammat, N Torrey Pines Rd, La Jolla, CA 92037 USA.	tmustelin@burnham-inst.org		Mustelin, Tomas/0000-0001-5912-8840	NATIONAL CANCER INSTITUTE [R01CA096949] Funding Source: NIH RePORTER; NCI NIH HHS [CA96949] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alonso A, 2003, NAT IMMUNOL, V4, P44, DOI 10.1038/ni856; Bijur GN, 2001, J BIOL CHEM, V276, P37436, DOI 10.1074/jbc.M105725200; Birle D, 2002, J IMMUNOL, V169, P286, DOI 10.4049/jimmunol.169.1.286; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Gronbaek K, 1998, BLOOD, V91, P4388; Huynh H, 2004, NAT CELL BIOL, V6, P831, DOI 10.1038/ncb1164; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; LUO K, 1990, ONCOGENE, V5, P921; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Miller SJ, 2002, FEBS LETT, V528, P145, DOI 10.1016/S0014-5793(02)03274-X; Okumura K, 2005, P NATL ACAD SCI USA, V102, P2703, DOI 10.1073/pnas.0409370102; Sakai A, 1998, BLOOD, V92, P3410, DOI 10.1182/blood.V92.9.3410.421a06_3410_3415; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; SPEAKS SL, 1992, GENE CHROMOSOME CANC, V5, P239, DOI 10.1002/gcc.2870050311; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; TAKEUCHI S, 1995, CANCER RES, V55, P5377; Teng DHF, 1997, CANCER RES, V57, P5221; Tolkacheva T, 2001, CANCER RES, V61, P4985; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Valiente M, 2005, J BIOL CHEM, V280, P28936, DOI 10.1074/jbc.M504761200; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; Wang XD, 2000, J IMMUNOL, V164, P1934, DOI 10.4049/jimmunol.164.4.1934	29	184	198	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35195	35202		10.1074/jbc.M503045200	http://dx.doi.org/10.1074/jbc.M503045200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16107342	hybrid			2022-12-27	WOS:000232561200016
J	Rahmani, M; Davis, EM; Bauer, C; Dent, P; Grant, S				Rahmani, M; Davis, EM; Bauer, C; Dent, P; Grant, S			Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; INITIATION-FACTOR 4E; MULTIPLE-MYELOMA CELLS; BCL-2 FAMILY; HEMATOPOIETIC-CELLS; TRANSCRIPTION FACTOR; RAF/MEK/ERK PATHWAY; MEDIATED APOPTOSIS; IMATINIB MESYLATE; SIGNALING PATHWAY	BAY 43-9006 is a kinase inhibitor that induces apoptosis in a variety of tumor cells. Here we report that treatment with BAY 43-9006 results in marked cytochrome c and AIF release into the cytosol, caspase-9, -8, -7, and -3 activation, and apoptosis in human leukemia cells (U937, Jurkat, and K562). Pronounced apoptosis was also observed in blasts from patients with acute myeloid leukemia. These events were accompanied by ERK1/2 inactivation and caspase-independent down-regulation of Mcl-1. Inducible expression of a constitutively active MEK1 construct did not prevent Mcl-1 down-regulation, suggesting that this event is not related to MEK/ERK pathway inactivation. Furthermore, BAY 43-9006 did not induce major changes in Mcl-1 mRNA levels monitored by real-time PCR or Mcl-1 promoter activity demonstrated by luciferase reporter assays, but it did enhance Mcl-1 down-regulation in actinomycin D-treated cells. Inhibition of protein synthesis by cycloheximide or proteasome function with MG132 and pulse-chase studies with [S-35]methionine demonstrated that BAY 43-9006 did not diminish Mcl-1 protein stability, nor did it enhance Mcl-1 ubiquitination, but instead markedly attenuated Mcl-1 translation in association with the rapid and potent dephosphorylation of the eIF4E translation initiation factor. Finally, ectopic expression of Mcl-1 in leukemic cells markedly inhibited BAY 43-9006-mediated cytochrome c cytosolic release, caspase-9, -7, and -3 activation, as well as cell death, indicating that Mcl-1 operates upstream of cytochrome c release and caspase activation. Together, these findings demonstrate that BAY 43-9006 mediates cell death in human leukemia cells, at least in part, through down-regulation of Mcl-1 via inhibition of translation.	Virginia Commonwealth Univ, Div Hematol Oncol, Sch Med, Dept Med, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Sch Med, Dept Biochem, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Sch Med, Dept Pharmacol, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Grant, S (corresponding author), Virginia Commonwealth Univ, Div Hematol Oncol, Sch Med, Dept Med, MCV Stn Box 230, Richmond, VA 23298 USA.	stgrant@hsc.vcu.edu		Rahmani, Mohamed/0000-0002-3992-8039	NCI NIH HHS [CA-100866, CA-63753, CA-88906, CA-93738] Funding Source: Medline; NIDDK NIH HHS [DK52825] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063753, R01CA093738, R01CA088906, R01CA100866] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052825] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmad T, 2004, CLIN CANCER RES, V10, p6388S, DOI 10.1158/1078-0432.CCR-040028; Aichberger KJ, 2005, BLOOD, V105, P3303, DOI 10.1182/blood-2004-02-0749; Alvi AJ, 2005, BLOOD, V105, P4484, DOI 10.1182/blood-2004-07-2713; Blalock WL, 2000, ONCOGENE, V19, P526, DOI 10.1038/sj.onc.1203337; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200; Cohen J, 2003, J NATL CANCER I, V95, P625, DOI 10.1093/jnci/95.8.625; Croxton R, 2002, ONCOGENE, V21, P1359, DOI 10.1038/sj.onc.1205157; Croxton R, 2002, ONCOGENE, V21, P1563, DOI 10.1038/sj.onc.1205232; Dai Y, 2004, J BIOL CHEM, V279, P34227, DOI 10.1074/jbc.M402290200; Dai Y, 2003, ONCOGENE, V22, P7108, DOI 10.1038/sj.onc.1206863; Dai Y, 2001, CANCER RES, V61, P5106; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Derouet M, 2004, J BIOL CHEM, V279, P26915, DOI 10.1074/jbc.M313875200; Gojo I, 2002, CLIN CANCER RES, V8, P3527; Graff JR, 2003, CLIN EXP METASTAS, V20, P265, DOI 10.1023/A:1022943419011; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Han J, 2004, J BIOL CHEM, V279, P22020, DOI 10.1074/jbc.M313234200; Hirasawa K, 2003, J VIROL, V77, P5649, DOI 10.1128/JVI.77.10.5649-5656.2003; Hoyle PE, 2000, LEUKEMIA, V14, P642, DOI 10.1038/sj.leu.2401720; Huang HM, 2000, BLOOD, V96, P1764, DOI 10.1182/blood.V96.5.1764.h8001764_1764_1771; Iglesias-Serret D, 2003, ARCH BIOCHEM BIOPHYS, V417, P141, DOI 10.1016/S0003-9861(03)00345-X; Kang CD, 2000, LEUKEMIA RES, V24, P527, DOI 10.1016/S0145-2126(00)00010-2; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; Knauf U, 2001, MOL CELL BIOL, V21, P5500, DOI 10.1128/MCB.21.16.5500-5511.2001; Kramer BW, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-24; Le Gouill S, 2004, BLOOD, V104, P2886, DOI 10.1182/blood-2004-05-1760; Leu CM, 2000, ONCOGENE, V19, P1665, DOI 10.1038/sj.onc.1203452; Martin KA, 2002, ADV CANCER RES, V86, P1, DOI 10.1016/S0065-230X(02)86001-8; Moulding DA, 2000, BLOOD, V96, P1756, DOI 10.1182/blood.V96.5.1756.h8001756_1756_1763; Moulding DA, 2001, J LEUKOCYTE BIOL, V70, P783; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; OKUDA K, 1994, EXP HEMATOL, V22, P1111; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Opferman JT, 2005, SCIENCE, V307, P1101, DOI 10.1126/science.1106114; Orlowski RZ, 2002, J BIOL CHEM, V277, P27864, DOI 10.1074/jbc.M201519200; Othumpangat S, 2005, J BIOL CHEM, V280, P25162, DOI 10.1074/jbc.M414303200; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Poruchynsky MS, 2001, BIOCHEM PHARMACOL, V62, P1469, DOI 10.1016/S0006-2952(01)00804-8; Proud CG, 2005, CELL DEATH DIFFER, V12, P541, DOI 10.1038/sj.cdd.4401588; Rahmani M, 2005, MOL PHARMACOL, V67, P1166, DOI 10.1124/mol.104.007831; Rahmani M, 2003, ONCOGENE, V22, P6231, DOI 10.1038/sj.onc.1206646; Rahmani M, 2002, EXP CELL RES, V277, P31, DOI 10.1006/excr.2002.5548; Rahmani M, 2005, CANCER RES, V65, P2422, DOI 10.1158/0008-5472.CAN-04-2440; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Selzer E, 2002, MOL MED, V8, P877, DOI 10.1007/BF03402094; Sharma A, 2005, CANCER RES, V65, P2412, DOI 10.1158/0008-5472.CAN-04-2423; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; Sridhar SS, 2005, MOL CANCER THER, V4, P677, DOI 10.1158/1535-7163.MCT-04-0297; Strumberg D, 2005, ONKOLOGIE, V28, P101, DOI 10.1159/000083373; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; Wang JM, 2003, MOL CELL BIOL, V23, P1896, DOI 10.1128/MCB.23.6.1896-1909.2003; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Weng CJ, 2005, J BIOL CHEM, V280, P10491, DOI 10.1074/jbc.M412819200; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Wu JH, 2004, CANCER RES, V64, P6461, DOI 10.1158/0008-5472.CAN-04-0866; Xu Z, 2000, MOL CELL BIOL, V20, P5285, DOI 10.1128/MCB.20.14.5285-5299.2000; Yu CR, 2002, CANCER RES, V62, P188; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630; Zhou P, 1998, BLOOD, V92, P3226, DOI 10.1182/blood.V92.9.3226.421k49_3226_3239	70	256	265	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35217	35227		10.1074/jbc.M506551200	http://dx.doi.org/10.1074/jbc.M506551200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16109713	hybrid			2022-12-27	WOS:000232561200019
J	Fan, B; Wu, TD; Li, W; Kirchhofer, D				Fan, B; Wu, TD; Li, W; Kirchhofer, D			Identification of hepatocyte growth factor activator inhibitor-1B as a potential physiological inhibitor of prostasin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE INHIBITOR; CELLULAR-LOCALIZATION; FACTOR/SCATTER FACTOR; KUNITZ DOMAINS; OVARIAN-CANCER; TYPE-1 HAI-1; EXPRESSION; MATRIPTASE; CELLS; PURIFICATION	Prostasin is a trypsin-like serine protease that is glycosylphosphatidyl-inositol-anchored to the epithelial cell surface, from where it can be released in a soluble form. We undertook a co-expression search using the Genesis Enterprise System Database from Gene Logic to identify prostasin inhibitors, on the assumption that prostasin and its natural inhibitors may have a similar gene expression pattern. We found the expression profile of prostasin in normal human tissues to correlate highly with hepatocyte growth factor activator inhibitor-1B (HAI-1B) and its splice variant HAI-1. Soluble HAI-1B (sHAI-1B), comprising the entire extracellular domain, formed a 1: 1 complex with purified prostasin in protein binding assays and inhibited prostasin enzymatic activity with an IC50 of 66 +/- 15 nM. Two sHAI-1B mutants with inactivated N- and C-terminal Kunitz domains ( KD1 and KD2) were used to show that the interaction of sHAI-1B with prostasin is mediated by KD1. In agreement, KD1 (Thr(246)- Val(303)) alone potently inhibited prostasin activity (IC50 = 4.7 +/- 0.5 nM). Furthermore, prostasin was isolated with two major HAI-1/1B fragments (40 and 58 kDa) from OVCAR3 cell medium, demonstrating that prostasin center dot HAI- 1/ 1B complexes are formed naturally. Moreover, when prostasin and HAI- 1B were coexpressed in Chinese hamster ovary cells, complexes of prostasin with HAI- 1B were detected on the cell membrane as well as in the culture medium, suggesting that preformed complexes were shed from the cell surface. The identification of HAI- 1B as a potential physiological regulator of prostasin function, as described herein, may further the investigation of the role of prostasin in normal physiology and cancer.	Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; Genentech Inc, Dept Bioinformat, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Kirchhofer, D (corresponding author), Genentech Inc, Dept Prot Engn, 1 DNA Way, San Francisco, CA 94080 USA.	dak@gene.com						Benaud C, 2002, J BIOL CHEM, V277, P10539, DOI 10.1074/jbc.M109064200; Bouton MC, 2003, ARTERIOSCL THROM VAS, V23, P142, DOI 10.1161/01.ATV.0000047867.98019.2D; Chen LM, 2001, J BIOL CHEM, V276, P21434, DOI 10.1074/jbc.M011423200; Chen LM, 2001, PROSTATE, V48, P93, DOI 10.1002/pros.1085; Chen LM, 2004, PROSTATE, V59, P1, DOI 10.1002/pros.10346; Chen LM, 2002, INT J CANCER, V97, P323, DOI 10.1002/ijc.1601; Denda K, 2002, J BIOL CHEM, V277, P14053, DOI 10.1074/jbc.M112263200; DENNIS MS, 1995, J BIOL CHEM, V270, P25411, DOI 10.1074/jbc.270.43.25411; Donaldson SH, 2002, J BIOL CHEM, V277, P8338, DOI 10.1074/jbc.M105044200; Graeber TG, 2001, NAT GENET, V29, P295, DOI 10.1038/ng755; Herter S, 2005, BIOCHEM J, V390, P125, DOI 10.1042/BJ20041955; Itoh H, 2000, AM J PHYSIOL-GASTR L, V278, pG635, DOI 10.1152/ajpgi.2000.278.4.G635; Kataoka H, 2000, CANCER RES, V60, P6148; Kataoka H, 2000, J BIOL CHEM, V275, P40453, DOI 10.1074/jbc.M006412200; Kataoka H, 1998, CANCER LETT, V128, P219, DOI 10.1016/S0304-3835(98)00067-6; Kataoka H, 1999, J HISTOCHEM CYTOCHEM, V47, P673, DOI 10.1177/002215549904700509; Kawaguchi T, 1997, J BIOL CHEM, V272, P27558, DOI 10.1074/jbc.272.44.27558; Kirchhofer D, 2005, FEBS LETT, V579, P1945, DOI 10.1016/j.febslet.2005.01.085; Kirchhofer D, 2003, J BIOL CHEM, V278, P36341, DOI 10.1074/jbc.M304643200; Klezovitch O, 2004, CANCER CELL, V6, P185, DOI 10.1016/j.ccr.2004.07.008; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; Lin CY, 1997, J BIOL CHEM, V272, P9147; Liu GY, 2003, NUCLEIC ACIDS RES, V31, P82, DOI 10.1093/nar/gkg121; Marlor CW, 1997, J BIOL CHEM, V272, P12202, DOI 10.1074/jbc.272.18.12202; Miyazawa K, 1996, J BIOL CHEM, V271, P3615; Mok SC, 2001, J NATL CANCER I, V93, P1458, DOI 10.1093/jnci/93.19.1458; Muthukumar T, 2003, TRANSPLANTATION, V75, P1565, DOI 10.1097/01.TP.0000058230.91518.2F; Oberst MD, 2002, CLIN CANCER RES, V8, P1101; Parr C, 2001, INT J ONCOL, V19, P857; Phillips T, 2004, J IMMUNOL, V173, P3801, DOI 10.4049/jimmunol.173.6.3801; Shia S, 2005, J MOL BIOL, V346, P1335, DOI 10.1016/j.jmb.2004.12.048; Shimomura T, 1999, J BIOCHEM-TOKYO, V126, P821, DOI 10.1093/oxfordjournals.jbchem.a022522; Shimomura T, 1997, J BIOL CHEM, V272, P6370, DOI 10.1074/jbc.272.10.6370; Shipway A, 2004, BIOCHEM BIOPH RES CO, V324, P953, DOI 10.1016/j.bbrc.2004.09.123; Takahashi S, 2003, PROSTATE, V54, P187, DOI 10.1002/pros.10178; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Tanaka H, 2005, MOL CELL BIOL, V25, P5687, DOI 10.1128/MCB.25.13.5687-5698.2005; Tong ZY, 2004, AM J PHYSIOL-LUNG C, V287, pL928, DOI 10.1152/ajplung.00160.2004; TYAGI SC, 1995, J MOL CELL CARDIOL, V27, P2177, DOI 10.1016/S0022-2828(95)91443-9; YU JX, 1995, J BIOL CHEM, V270, P13483, DOI 10.1074/jbc.270.22.13483; YU JX, 1994, J BIOL CHEM, V269, P18843	43	70	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34513	34520		10.1074/jbc.M502119200	http://dx.doi.org/10.1074/jbc.M502119200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16103126	hybrid			2022-12-27	WOS:000232403900019
J	Kim, KS; Sim, S; Ko, JH; Lee, Y				Kim, KS; Sim, S; Ko, JH; Lee, Y			Processing of M1 RNA at the 3 ' end protects its primary transcript from degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO ANALYSIS; ESCHERICHIA-COLI; MESSENGER-RNA; RIBONUCLEASE-P; CATALYTIC SUBUNIT; GENE; MATURATION; POLYADENYLATION; INITIATION; COMPONENT	M1 RNA, the catalytic subunit of Escherichia coli RNase P, is an essential ribozyme that processes the 5' leader sequence of precursor tRNAs. It is generated by the removal of 36 nucleotides from the 3' end of the primary rnpB transcript (pM1 RNA), but the biological significance of this reaction in bacterial metabolism remains obscure. In this study, we constructed and analyzed bacterial strains carrying mutations in the rne-dependent site of their rnpB genes, showing that the 3' processing of M1 RNA is essential for cell viability. Furthermore, we demonstrate that pM1 RNA can undergo not only 3' processing but also poly(A)-dependent degradation. Therefore, our results suggest that the 3' processing of M1 RNA provides a functional mechanism for the protection of its primary transcript against degradation.	Korea Adv Inst Sci & Technol, Dept Chem, Taejon 305701, South Korea; Korea Adv Inst Sci & Technol, Ctr Mol Design & Synth, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST)	Lee, Y (corresponding author), Korea Adv Inst Sci & Technol, Dept Chem, Taejon 305701, South Korea.	Younghoon.Lee@kaist.ac.kr	Lee, Younghoon/C-1991-2011; Kim, Kwang-sun/AAB-6478-2020	Lee, Younghoon/0000-0002-3841-719X; Kim, Kwang-sun/0000-0003-3703-5461				Bensing BA, 1996, P NATL ACAD SCI USA, V93, P7794, DOI 10.1073/pnas.93.15.7794; Bernstein JA, 2002, P NATL ACAD SCI USA, V99, P9697, DOI 10.1073/pnas.112318199; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BOURGAIZE DB, 1987, NATURE, V325, P281, DOI 10.1038/325281a0; CAO GJ, 1992, P NATL ACAD SCI USA, V89, P10380, DOI 10.1073/pnas.89.21.10380; Coburn GA, 1999, PROG NUCLEIC ACID RE, V62, P55; EHRETSMANN CP, 1992, GENE DEV, V6, P149, DOI 10.1101/gad.6.1.149; Frank DN, 1998, ANNU REV BIOCHEM, V67, P153, DOI 10.1146/annurev.biochem.67.1.153; GHORA BK, 1978, CELL, V15, P1055, DOI 10.1016/0092-8674(78)90289-1; GUERRIERTAKADA C, 1984, SCIENCE, V223, P285, DOI 10.1126/science.6199841; GUERRIERTAKADA C, 1986, CELL, V45, P177, DOI 10.1016/0092-8674(86)90381-8; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; JAIN SK, 1982, J MOL BIOL, V162, P515, DOI 10.1016/0022-2836(82)90386-2; Kim KS, 2004, NUCLEIC ACIDS RES, V32, P6057, DOI 10.1093/nar/gkh939; Kim S, 1996, J BIOL CHEM, V271, P19330, DOI 10.1074/jbc.271.32.19330; Kim S, 1999, NUCLEIC ACIDS RES, V27, P895, DOI 10.1093/nar/27.3.895; KOMINE Y, 1994, P NATL ACAD SCI USA, V73, P1912; Kurz JC, 2000, CURR OPIN CHEM BIOL, V4, P553, DOI 10.1016/S1367-5931(00)00131-9; Kushner SR, 2002, J BACTERIOL, V184, P4658, DOI 10.1128/JB.184.17.4658-4665.2002; Lee K, 2002, MOL MICROBIOL, V43, P1445, DOI 10.1046/j.1365-2958.2002.02848.x; LEE Y, 1989, J BIOL CHEM, V264, P5098; Li Y, 2003, P NATL ACAD SCI USA, V100, P13213, DOI 10.1073/pnas.2235589100; Li ZW, 1998, P NATL ACAD SCI USA, V95, P2856, DOI 10.1073/pnas.95.6.2856; Li ZW, 2002, EMBO J, V21, P1132, DOI 10.1093/emboj/21.5.1132; Li ZW, 2002, RNA, V8, P97, DOI 10.1017/S1355838202014929; Li ZW, 1998, P NATL ACAD SCI USA, V95, P12158, DOI 10.1073/pnas.95.21.12158; Lin-Chao S, 1999, P NATL ACAD SCI USA, V96, P12406, DOI 10.1073/pnas.96.22.12406; LUNDBERG U, 1995, RNA, V1, P327; Mohanty BK, 2004, MOL MICROBIOL, V54, P905, DOI 10.1111/j.1365-2958.2004.04337.x; Ow MC, 2002, GENE DEV, V16, P1102, DOI 10.1101/gad.983502; Park JW, 1996, J BIOCHEM MOL BIOL, V29, P221; REED RE, 1982, CELL, V30, P627, DOI 10.1016/0092-8674(82)90259-8; ROBERTSON HD, 1972, J BIOL CHEM, V247, P5243; SAKAMOTO H, 1983, P NATL ACAD SCI-BIOL, V80, P6187, DOI 10.1073/pnas.80.20.6187; SAKANO H, 1974, NUCLEIC ACIDS RES, V1, P355, DOI 10.1093/nar/1.3.355; Sarkar N, 1997, ANNU REV BIOCHEM, V66, P173, DOI 10.1146/annurev.biochem.66.1.173; Silhavy T.J., 1984, EXPT GENE FUSIONS, P303; Sim S, 2002, FEBS LETT, V529, P225, DOI 10.1016/S0014-5793(02)03345-8; Sim S, 2001, FEBS LETT, V505, P291, DOI 10.1016/S0014-5793(01)02822-8; SINGER M, 1989, MICROBIOL REV, V53, P1; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597	42	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34667	34674		10.1074/jbc.M505005200	http://dx.doi.org/10.1074/jbc.M505005200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16105832	hybrid			2022-12-27	WOS:000232403900036
J	Zabel, BA; Allen, SJ; Kulig, P; Allen, JA; Cichy, J; Handel, TM; Butcher, EC				Zabel, BA; Allen, SJ; Kulig, P; Allen, JA; Cichy, J; Handel, TM; Butcher, EC			Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMACYTOID DENDRITIC CELLS; PLASMINOGEN-ACTIVATOR; HUMAN BLOOD; RECEPTOR; CHEMOKINE; CHEMOATTRACTANT; COMPLEMENT; CHEMOTAXIS; INHIBITOR; CLEAVAGE	Proteases function at every level in host defense, from regulating vascular hemostasis and inflammation to mobilizing the "rapid responder" leukocytes of the immune system by regulating the activities of various chemoattractants. Recent studies implicate proteolysis in the activation of a ubiquitous plasma chemoattractant, chemerin, a ligand for the G-protein-coupled receptor CMKLR1 present on plasmacytoid dendritic cells and macrophages. To define the pathophysiologic triggers of chemerin activity, we evaluated the ability of serum- and inflammation-associated proteases to cleave chemerin and stimulate CMKLR1-mediated chemotaxis. We showed that serine proteases factor XIIa and plasmin of the coagulation and fibrinolytic cascades, elastase and cathepsin G released from activated neutrophil granules and mast cell tryptase are all potent activators of chemerin. Activation results from cleavage of the labile carboxyl terminus of the chemoattractant at any of several different sites. Activation of chemerin by the serine protease cascades that trigger rapid defenses in the body may direct CMKLR1-positive plasmacytoid dendritic cell and tissue macrophage recruitment to sterile sites of tissue damage, as well as trafficking to sites of infectious and allergic inflammation.	Stanford Univ, Sch Med, Dept Pathol, Lab Immunol & Vasc Biol, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Ctr Mol Biol & Med, Palo Alto, CA 94304 USA; Univ Calif Berkeley, Berkeley, CA 94720 USA; Jagiellonian Univ, Fac Biotechnol, PL-30387 Krakow, Poland	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; University of California System; University of California Berkeley; Jagiellonian University	Zabel, BA (corresponding author), Stanford Univ, Dept Pathol 5234, Med Ctr, Stanford, CA 94305 USA.	bazabel@alum.mit.edu		Cichy, Joanna/0000-0002-0552-8344	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL067674, P01HL067674] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI059635, R01AI059635, R37AI047822, R01AI037113, R01AI037832, R21AI047822, R01AI047822] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037734, R01GM037734] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-67674] Funding Source: Medline; NIAID NIH HHS [AI-37832, AI-59635, AI37113-09, AI-47822] Funding Source: Medline; NIDDK NIH HHS [DK56339] Funding Source: Medline; NIGMS NIH HHS [GM-37734] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bajzar L, 2004, CRIT CARE MED, V32, pS320, DOI 10.1097/01.CCM.0000126361.00450.B1; Bangert K, 2000, THROMB HAEMOSTASIS, V84, P299, DOI 10.1055/s-0037-1614011; Busmann A, 2004, J CHROMATOGR B, V811, P217, DOI 10.1016/j.jchromb.2004.09.006; CAR BD, 1991, BIOCHEM J, V275, P581, DOI 10.1042/bj2750581; Colonna M, 2004, NAT IMMUNOL, V5, P1219, DOI 10.1038/ni1141; de la Rosa G, 2003, J LEUKOCYTE BIOL, V73, P639, DOI 10.1189/jlb.1002516; DRAKE TA, 1989, AM J PATHOL, V134, P1087; Dybendal T, 2003, ACTA ANAESTH SCAND, V47, P1211, DOI 10.1046/j.1399-6576.2003.00237.x; EKDAHL KN, 1990, J IMMUNOL, V144, P4269; ELLIS V, 1993, J BIOL CHEM, V268, P4806; FALK W, 1980, INFECT IMMUN, V29, P953; FERNANDEZ HN, 1978, J IMMUNOL, V120, P109; FRANK MM, 1991, IMMUNOL TODAY, V12, P322, DOI 10.1016/0167-5699(91)90009-I; Gilliet M, 2002, J EXP MED, V195, P695, DOI 10.1084/jem.20011603; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Gudmundsson GH, 1996, EUR J BIOCHEM, V238, P325, DOI 10.1111/j.1432-1033.1996.0325z.x; Guimaraes AHC, 2004, THROMB HAEMOSTASIS, V91, P473, DOI 10.1160/TH03-06-0377; Hartmann K, 1997, BLOOD, V89, P2863, DOI 10.1182/blood.V89.8.2863; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; JANDL JH, 1996, BLOOD TXB HEMATOLOGY, P1213; Joost P, 2002, GENOME BIOL, V3; Kardos J, 2001, J IMMUNOL, V167, P5202, DOI 10.4049/jimmunol.167.9.5202; Kawamura T, 2002, MICROBIOL IMMUNOL, V46, P225, DOI 10.1111/j.1348-0421.2002.tb02690.x; Matthews KW, 2004, MOL IMMUNOL, V40, P785, DOI 10.1016/j.molimm.2003.10.002; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; Meder W, 2003, FEBS LETT, V555, P495, DOI 10.1016/S0014-5793(03)01312-7; Myles T, 2003, J BIOL CHEM, V278, P51059, DOI 10.1074/jbc.M306977200; NAGASAWA S, 1977, P NATL ACAD SCI USA, V74, P2998, DOI 10.1073/pnas.74.7.2998; Oravecz T, 1997, J EXP MED, V186, P1865, DOI 10.1084/jem.186.11.1865; Penna G, 2001, J IMMUNOL, V167, P1862, DOI 10.4049/jimmunol.167.4.1862; Proost P, 1998, FEBS LETT, V432, P73, DOI 10.1016/S0014-5793(98)00830-8; Samson M, 1998, EUR J IMMUNOL, V28, P1689, DOI 10.1002/(SICI)1521-4141(199805)28:05<1689::AID-IMMU1689>3.0.CO;2-I; SchulzKnappe P, 1996, J EXP MED, V183, P295, DOI 10.1084/jem.183.1.295; Sim RB, 2004, BIOCHEM SOC T, V32, P21, DOI 10.1042/BST0320021; Stoy N, 2001, PATHOBIOLOGY, V69, P179, DOI 10.1159/000055944; Syrovets T, 1997, BLOOD, V89, P4574, DOI 10.1182/blood.V89.12.4574; Tani Kenji, 2001, Journal of Medical Investigation, V48, P133; Taylor FR, 1999, BIOCHEMISTRY-US, V38, P2849, DOI 10.1021/bi982140f; Vakili J, 2001, J IMMUNOL, V167, P3406, DOI 10.4049/jimmunol.167.6.3406; Wittamer V, 2004, J BIOL CHEM, V279, P9956, DOI 10.1074/jbc.M313016200; Wittamer V, 2003, J EXP MED, V198, P977, DOI 10.1084/jem.20030382; Yang D, 2000, J EXP MED, V192, P1069, DOI 10.1084/jem.192.7.1069; YEE JA, 1993, J CELL PHYSIOL, V157, P528, DOI 10.1002/jcp.1041570312; Zabel BA, 2005, J IMMUNOL, V174, P244, DOI 10.4049/jimmunol.174.1.244	44	283	301	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34661	34666		10.1074/jbc.M504868200	http://dx.doi.org/10.1074/jbc.M504868200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16096270	hybrid			2022-12-27	WOS:000232403900035
J	Horng, YC; Leary, SC; Cobine, PA; Young, FBJ; George, GN; Shoubridge, EA; Winge, DR				Horng, YC; Leary, SC; Cobine, PA; Young, FBJ; George, GN; Shoubridge, EA; Winge, DR			Human Sco1 and Sco2 function as copper-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; SACCHAROMYCES-CEREVISIAE; CU(I)-BINDING PROTEIN; CRYSTAL-STRUCTURE; YEAST; DEFICIENCY; MUTATIONS; METALLOCHAPERONE; CHAPERONE; COX17	The function of human Sco1 and Sco2 is shown to be dependent on copper ion binding. Expression of soluble domains of human Sco1 and Sco2 either in bacteria or the yeast cytoplasm resulted in the recovery of copper-containing proteins. The metallation of human Sco1, but not Sco2, when expressed in the yeast cytoplasm is dependent on the co-expression of human Cox17. Two conserved cysteines and a histidyl residue, known to be important for both copper binding and in vivo function in yeast Sco1, are also critical for in vivo function of human Sco1 and Sco2. Human and yeast Sco proteins can bind either a single Cu(I) or Cu(II) ion. The Cu( II) site yields S-Cu(II) charge transfer transitions that are not bleached by weak reductants or chelators. The Cu( I) site exhibits trigonal geometry, whereas the Cu( II) site resembles a type II Cu( II) site with a higher coordination number. To identify additional potential ligands for the Cu( II) site, a series of mutant proteins with substitutions in conserved residues in the vicinity of the Cu( I) site were examined. Mutation of several conserved carboxylates did not alter either in vivo function or the presence of the Cu( II) chromophore. In contrast, replacement of Asp(238) in human or yeast Sco1 abrogated the Cu( II) visible transitions and in yeast Sco1 attenuated Cu( II), but not Cu( I), binding. Both the mutant yeast and human proteins were nonfunctional, suggesting the importance of this aspartate for normal function. Taken together, these data suggest that both Cu( I) and Cu( II) binding are critical for normal Sco function.	McGill Univ, Dept Human Genet, Montreal, PQ H3A 2B4, Canada; Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada; Univ Saskatchewan, Saskatoon, SK S7N 5E2, Canada	McGill University; Utah System of Higher Education; University of Utah; McGill University; University of Saskatchewan	Winge, DR (corresponding author), McGill Univ, Dept Human Genet, 3801 Univ St,Rm 660, Montreal, PQ H3A 2B4, Canada.	eric@ericpc.mni.mcgill.ca; dennis.winge@hsc.utah.edu	Cobine, Paul/AAH-6619-2020; Winge, Dennis/G-3611-2010; Leary, Scot/B-3036-2012; Horng, Yih-Chern/I-6682-2018; George, Graham N/E-3290-2013; Cobine, Paul A/G-3107-2011	Cobine, Paul/0000-0001-6012-0985; Horng, Yih-Chern/0000-0001-9558-3189; Cobine, Paul A/0000-0001-6012-0985; George, Graham/0000-0002-0420-7493; Young, Fiona/0000-0002-3534-6875	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES003817, R01ES003817] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 03817] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arnesano F, 2001, J BIOL CHEM, V276, P41365, DOI 10.1074/jbc.M104807200; Arnesano F, 2001, BIOCHEMISTRY-US, V40, P1528, DOI 10.1021/bi0014711; Balatri E, 2003, STRUCTURE, V11, P1431, DOI 10.1016/j.str.2003.10.004; Basumallick L, 2005, J AM CHEM SOC, V127, P3531, DOI 10.1021/ja044412+; Beers J, 2002, J BIOL CHEM, V277, P22185, DOI 10.1074/jbc.M202545200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; Capaldi RA, 1995, METHOD ENZYMOL, V260, P117, DOI 10.1016/0076-6879(95)60134-1; Carr HS, 2003, ACCOUNTS CHEM RES, V36, P309, DOI 10.1021/ar0200807; Carr HS, 2002, J BIOL CHEM, V277, P31237, DOI 10.1074/jbc.M204854200; Carroll MC, 2004, P NATL ACAD SCI USA, V101, P5964, DOI 10.1073/pnas.0308298101; Dickinson EK, 2000, J BIOL CHEM, V275, P26780; Foltopoulou PF, 2004, MOL GENET METAB, V81, P225, DOI 10.1016/j.ymgme.2003.11.006; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Heaton DN, 2001, BIOCHEMISTRY-US, V40, P743, DOI 10.1021/bi002315x; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; Horng YC, 2004, J BIOL CHEM, V279, P35334, DOI 10.1074/jbc.M404747200; Jaksch M, 2000, HUM MOL GENET, V9, P795, DOI 10.1093/hmg/9.5.795; Jaksch M, 2001, HUM MOL GENET, V10, P3025, DOI 10.1093/hmg/10.26.3025; Jaksch M, 2001, NEUROLOGY, V57, P1440, DOI 10.1212/WNL.57.8.1440; KLEMENT P, 1995, ANAL BIOCHEM, V231, P218, DOI 10.1006/abio.1995.1523; Leary SC, 2004, HUM MOL GENET, V13, P1839, DOI 10.1093/hmg/ddh197; Lieberman RL, 2001, BIOCHEMISTRY-US, V40, P5674, DOI 10.1021/bi0102611; Lode A, 2000, FEBS LETT, V485, P19, DOI 10.1016/S0014-5793(00)02176-1; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; Maxfield AB, 2004, J BIOL CHEM, V279, P5072, DOI 10.1074/jbc.M311772200; Nittis T, 2001, J BIOL CHEM, V276, P42520, DOI 10.1074/jbc.M107077200; Papadopoulou LC, 1999, NAT GENET, V23, P333; Paret C, 1999, FEBS LETT, V447, P65, DOI 10.1016/S0014-5793(99)00266-5; Poyton RO, 1995, METHOD ENZYMOL, V260, P97, DOI 10.1016/0076-6879(95)60133-3; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rentzsch A, 1999, CURR GENET, V35, P103, DOI 10.1007/s002940050438; SALVIATI L, 2002, BIOCHEM J, V15, P321; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; Valnot I, 2000, AM J HUM GENET, V67, P1104; Wernimont AK, 2004, J BIOL CHEM, V279, P12269, DOI 10.1074/jbc.M311213200; Williams JC, 2005, J BIOL CHEM, V280, P15202, DOI 10.1074/jbc.M410705200; Xiao ZG, 2004, J AM CHEM SOC, V126, P3081, DOI 10.1021/ja0390350; Ye QL, 2005, BIOCHEMISTRY-US, V44, P2934, DOI 10.1021/bi0480537	40	132	133	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34113	34122		10.1074/jbc.M506801200	http://dx.doi.org/10.1074/jbc.M506801200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16091356	hybrid			2022-12-27	WOS:000232229700052
J	Zhang, Y; Takami, K; Lo, MS; Huang, GM; Yu, Q; Roswit, WT; Holtzman, MJ				Zhang, Y; Takami, K; Lo, MS; Huang, GM; Yu, Q; Roswit, WT; Holtzman, MJ			Modification of the stat1 SH2 domain broadly improves interferon efficacy in proportion to p300/CREB-binding protein coactivator recruitment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNATE IMMUNITY; DNA-BINDING; SIGNAL TRANSDUCER; VIRAL DISEASE; ACTIVATION; ALPHA; GAMMA; TRANSCRIPTION; EXPRESSION; MECHANISMS	A normal level of interferon (IFN) responsiveness via the Stat1 transcription factor is critical to the host, since decreased Stat1 signaling causes immune compromise and increased signaling is associated with inflammatory and neoplastic disease. Here we report how this balance may be influenced by novel alterations in the efficiency of Stat1 signaling. To enable disulfide-dependent and spontaneous formation of active Stat1 homodimer ( as was done previously for Stat3), we engineered Stat1-CC with double-cysteine substitutions in the Src homology 2 (SH2)-homodimerization domain ( at Ala-656 and Asn-658). In this case, however, mutant and wild-type Stat1 exhibited no difference in spontaneous dimerization. Moreover, Stat1-CCstill required ligand-dependent Tyr-701 phosphorylation for function and exhibited hyperresponsiveness to IFN-beta ( that depends on Stat1/Stat2 heterodimerization) as well as IFN-gamma (that depends on Stat1/Stat1 homodimerization). Hyperresponsivenss of Stat1-CC was accompanied by increased capacities for Tyr-701 phosphorylation and DNA binding, but these features were also found in a similarly substituted serine mutant (Stat1-SS) that showed no hyperresponsiveness to IFN-gamma. This finding raised the possibility that SH2 domain mutations also influence downstream transcriptional efficiency. Indeed, each of these mutations also enhanced recruitment of the normally rate-limiting p300/CREB-binding Protein (CBP) coactivator to the transcriptional complex in proportion to the level of IFN-driven transactivation and gene expression. Additional modifications indicated that the mutant residues in the SH2 domain appeared to cooperate with Ser-727 in the C-terminal domain to regulate p300/ CBP interaction with Stat1. The profile of IFN responsiveness translated into the same progressive increase in the level of viral clearance from Stat1- to Stat1- SS-to Stat1- CC-expressing cells. Thus, SH2 domain determinants may be modified to direct better Stat1 phosphorylation, DNA binding, and coactivator recruitment to fully improve IFN efficacy.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Holtzman, MJ (corresponding author), Washington Univ, Sch Med, Dept Med, Campus Box 8052,660 S Euclid Ave, St Louis, MO 63110 USA.	holtzman@im.wustl.edu						Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Chen XM, 2003, PROTEIN SCI, V12, P361, DOI 10.1110/ps.0218903; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Dupuis S, 2003, NAT GENET, V33, P388, DOI 10.1038/ng1097; Dupuis S, 2001, SCIENCE, V293, P300, DOI 10.1126/science.1061154; Durbin JE, 2000, J IMMUNOL, V164, P4220, DOI 10.4049/jimmunol.164.8.4220; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Frank DA, 1997, J CLIN INVEST, V100, P3140, DOI 10.1172/JCI119869; Guo FH, 2000, J IMMUNOL, V164, P5970, DOI 10.4049/jimmunol.164.11.5970; Haga S, 2003, J CLIN INVEST, V112, P989, DOI 10.1172/JCI200317970; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Inoue H, 2004, NAT MED, V10, P168, DOI 10.1038/nm980; Jayaraman S, 1999, J IMMUNOL, V162, P1717; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li XX, 1996, J BIOL CHEM, V271, P5790, DOI 10.1074/jbc.271.10.5790; Liu B, 2004, NAT IMMUNOL, V5, P891, DOI 10.1038/ni1104; Lo MS, 2005, J VIROL, V79, P9315, DOI 10.1128/JVI.79.14.9315-9319.2005; Look DC, 1998, IMMUNITY, V9, P871, DOI 10.1016/S1074-7613(00)80652-4; Megidish T, 2002, J BIOL CHEM, V277, P8255, DOI 10.1074/jbc.C200001200; Meyer T, 2003, GENE DEV, V17, P1992, DOI 10.1101/gad.268003; Mowen K, 2000, MOL CELL BIOL, V20, P7273, DOI 10.1128/MCB.20.19.7273-7281.2000; Ota N, 2004, NAT IMMUNOL, V5, P208, DOI 10.1038/ni1032; Park C, 2000, IMMUNITY, V13, P795, DOI 10.1016/S1074-7613(00)00077-7; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Pilz A, 2003, EMBO REP, V4, P368, DOI 10.1038/sj.embor.embor802; Sakamoto S, 2004, J BIOL CHEM, V279, P3245, DOI 10.1074/jbc.M309631200; Sampath D, 1999, J CLIN INVEST, V103, P1353, DOI 10.1172/JCI6130; Sano S, 2005, NAT MED, V11, P43, DOI 10.1038/nm1162; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; Shimoda K, 2000, IMMUNITY, V13, P561, DOI 10.1016/S1074-7613(00)00055-8; Sironi JJ, 2004, J BIOL CHEM, V279, P4066, DOI 10.1074/jbc.M307774200; Ting LM, 1999, J IMMUNOL, V163, P3898; Varinou L, 2003, IMMUNITY, V19, P793, DOI 10.1016/S1074-7613(03)00322-4; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; Walter MJ, 1997, J BIOL CHEM, V272, P28582, DOI 10.1074/jbc.272.45.28582; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Yang E, 2002, J BIOL CHEM, V277, P13455, DOI 10.1074/jbc.M112038200; Yasukawa H, 2003, J CLIN INVEST, V111, P469, DOI 10.1172/JCI200316491; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhong MH, 2005, P NATL ACAD SCI USA, V102, P3966, DOI 10.1073/pnas.0501063102; Zong C, 1996, EMBO J, V15, P4515, DOI 10.1002/j.1460-2075.1996.tb00829.x	50	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34306	34315		10.1074/jbc.M503263200	http://dx.doi.org/10.1074/jbc.M503263200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16107341	hybrid			2022-12-27	WOS:000232229700073
J	Ijiri, K; Zerbini, LF; Peng, HB; Correa, RG; Lu, BF; Walsh, N; Zhao, YN; Taniguchi, N; Huang, XL; Otu, H; Wang, H; Wang, JF; Komiya, S; Ducy, P; Rahman, MU; Flavell, RA; Gravallese, EM; Oettgen, P; Libermann, TA; Goldring, MB				Ijiri, K; Zerbini, LF; Peng, HB; Correa, RG; Lu, BF; Walsh, N; Zhao, YN; Taniguchi, N; Huang, XL; Otu, H; Wang, H; Wang, JF; Komiya, S; Ducy, P; Rahman, MU; Flavell, RA; Gravallese, EM; Oettgen, P; Libermann, TA; Goldring, MB			A novel role for GADD45 beta as a mediator of MMP-13 gene expression during chondrocyte terminal differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; GROWTH-FACTOR-BETA; NF-KAPPA-B; X COLLAGEN GENE; TRANSCRIPTION FACTOR; IN-VIVO; HYPERTROPHIC CHONDROCYTES; ENDOCHONDRAL OSSIFICATION; SKELETAL MORPHOGENESIS; CBFA1-DEFICIENT MICE	The growth arrest and DNA damage-inducible 45 beta(GADD45 beta) gene product has been implicated in the stress response, cell cycle arrest, and apoptosis. Here we demonstrated the unexpected expression of GADD45 beta in the embryonic growth plate and uncovered its novel role as an essential mediator of matrix metalloproteinase-13 (MMP-13) expression during terminal chondrocyte differentiation. We identified GADD45 beta as a prominent early response gene induced by bone morphogenetic protein-2 (BMP-2) through a Smad1/Runx2-dependent pathway. Because this pathway is involved in skeletal development, we examined mouse embryonic growth plates, and we observed expression of Gadd45 beta mRNA coincident with Runx2 protein in pre-hypertrophic chondrocytes, whereas GADD45 beta protein was localized prominently in the nucleus in late stage hypertrophic chondrocytes where Mmp-13 mRNA was expressed. In Gadd45 beta(-/-) mouse embryos, defective mineralization and decreased bone growth accompanied deficient Mmp-13 and Col10a1 gene expression in the hypertrophic zone. Transduction of small interfering RNA-GADD45 beta in epiphyseal chondrocytes in vitro blocked terminal differentiation and the associated expression of Mmp-13 and Col10a1 mRNA in vitro. Finally, GADD45 beta stimulated MMP-13 promoter activity in chondrocytes through the JNK-mediated phosphorylation of JunD, partnered with Fra2, in synergy with Runx2. These observations indicated that GADD45 beta plays an essential role during chondrocyte terminal differentiation.	Harvard Univ, Sch Med, Inst Med, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, New England Baptist Bone & Joint Inst, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Genom Ctr, Boston, MA 02115 USA; Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA; Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA 15261 USA; Kagoshima Univ, Grad Sch Med & Dent, Dept Neuromusculoskeletal Disorders, Kagoshima 8908520, Japan; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; New England Baptist Hospital; Harvard University; Beth Israel Deaconess Medical Center; Salk Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Kagoshima University; Baylor College of Medicine; Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Yale University	Goldring, MB (corresponding author), Harvard Univ, Sch Med, Inst Med, HIM 246,4 Blackfan Circle, Boston, MA 02115 USA.	mgoldrin@bidmc.harvard.edu	Oettgen, Peter/AAF-5026-2021; Correa, Ricardo G/G-7613-2012; Wang, Hong/H-6298-2012; Zerbini, Luiz/B-7720-2015; Zhao, Yani/A-1968-2013; Libermann, Towia/F-9866-2010	Correa, Ricardo G/0000-0001-6940-7034; Zerbini, Luiz/0000-0003-0736-9508; Libermann, Towia/0000-0002-4006-8179; Otu, Hasan/0000-0002-9253-8152	NIAID NIH HHS [R01 AI049527, R01-AI49527] Funding Source: Medline; NIAMS NIH HHS [R01-AR45378] Funding Source: Medline; NIA NIH HHS [R01 AG022021, R01-AG22021] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049527] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045378] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG022021] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABDOLLAHI A, 1991, ONCOGENE, V6, P165; Afzal F, 2005, J CELL PHYSIOL, V204, P63, DOI 10.1002/jcp.20258; Aigner T, 2001, ARTHRITIS RHEUM-US, V44, P2777, DOI 10.1002/1529-0131(200112)44:12<2777::AID-ART465>3.0.CO;2-H; Amanullah A, 2003, NATURE, V424, P741, DOI 10.1038/424741b; Balliet AG, 2003, DNA CELL BIOL, V22, P457, DOI 10.1089/104454903322247334; BALLOCK RT, 1994, J CELL BIOL, V126, P1311, DOI 10.1083/jcb.126.5.1311; Ballock RT, 2003, J BONE JOINT SURG AM, V85A, P715, DOI 10.2106/00004623-200304000-00021; Colnot C, 2005, J CELL BIOCHEM, V95, P688, DOI 10.1002/jcb.20449; Colnot C, 2004, DEV BIOL, V269, P55, DOI 10.1016/j.ydbio.2004.01.011; Colnot CI, 2001, MECH DEVELOP, V100, P245, DOI 10.1016/S0925-4773(00)00532-3; D'Alonzo RC, 2002, J BIOL CHEM, V277, P816, DOI 10.1074/jbc.M107082200; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Enomoto H, 2000, J BIOL CHEM, V275, P8695, DOI 10.1074/jbc.275.12.8695; Enomoto-Iwamoto M, 1998, J CELL BIOL, V140, P409, DOI 10.1083/jcb.140.2.409; Ferguson CM, 1998, ANN NY ACAD SCI, V857, P33, DOI 10.1111/j.1749-6632.1998.tb10105.x; Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; GOLDRING MB, 1994, J CLIN INVEST, V94, P2307, DOI 10.1172/JCI117595; GOLDRING MB, 2004, KELLEYS TXB RHEUMATO, P203; Gress CJ, 2000, J CELL BIOL, V149, P983, DOI 10.1083/jcb.149.4.983; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; Hess J, 2003, J CELL SCI, V116, P4587, DOI 10.1242/jcs.00772; Hess J, 2001, J BIOL CHEM, V276, P20029, DOI 10.1074/jbc.M010601200; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Inada M, 2004, P NATL ACAD SCI USA, V101, P17192, DOI 10.1073/pnas.0407788101; Inada M, 1999, DEV DYNAM, V214, P279, DOI 10.1002/(SICI)1097-0177(199904)214:4<279::AID-AJA1>3.0.CO;2-W; Jacenko O, 2001, AM J PATHOL, V159, P2257, DOI 10.1016/S0002-9440(10)63076-3; Jimenez MJG, 1999, MOL CELL BIOL, V19, P4431; Jin RG, 2002, DNA CELL BIOL, V21, P491, DOI 10.1089/104454902320219059; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Johansson N, 1997, DEV DYNAM, V208, P387, DOI 10.1002/(SICI)1097-0177(199703)208:3<387::AID-AJA9>3.0.CO;2-E; Karreth F, 2004, DEVELOPMENT, V131, P5717, DOI 10.1242/dev.01414; Kartsogiannis V, 1997, BONE, V21, P385, DOI 10.1016/S8756-3282(97)00180-4; Kim IS, 1999, MECH DEVELOP, V80, P159, DOI 10.1016/S0925-4773(98)00210-X; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lai CF, 2002, J BIOL CHEM, V277, P15514, DOI 10.1074/jbc.M200794200; Leboy PS, 2001, J BONE JOINT SURG AM, V83A, pS15; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; Locklin RM, 2001, J BONE MINER RES, V16, P2192, DOI 10.1359/jbmr.2001.16.12.2192; Lu BF, 2004, NAT IMMUNOL, V5, P38, DOI 10.1038/ni1020; Lu BF, 2001, IMMUNITY, V14, P583, DOI 10.1016/S1074-7613(01)00141-8; MacLean HE, 2003, DEV BIOL, V262, P51, DOI 10.1016/S0012-1606(03)00324-5; Maeda Y, 2004, J CELL BIOCHEM, V93, P337, DOI 10.1002/jcb.20154; Maes C, 2002, MECH DEVELOP, V111, P61, DOI 10.1016/S0925-4773(01)00601-3; Mei W, 2005, BIOCHEM BIOPH RES CO, V328, P651, DOI 10.1016/j.bbrc.2004.11.067; Mengshol JA, 2001, NUCLEIC ACIDS RES, V29, P4361, DOI 10.1093/nar/29.21.4361; Mita H, 2002, MOL CELL BIOL, V22, P4544, DOI 10.1128/MCB.22.13.4544-4555.2002; Nakamura K, 1999, EXP CELL RES, V250, P351, DOI 10.1006/excr.1999.4535; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Ortega N, 2004, TRENDS CELL BIOL, V14, P86, DOI 10.1016/j.tcb.2003.12.003; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Papa S, 2004, NAT CELL BIOL, V6, P146, DOI 10.1038/ncb1093; Pfeifer A, 2001, ANNU REV GENOM HUM G, V2, P177, DOI 10.1146/annurev.genom.2.1.177; Porte D, 1999, ONCOGENE, V18, P667, DOI 10.1038/sj.onc.1202333; Provot S, 2005, BIOCHEM BIOPH RES CO, V328, P658, DOI 10.1016/j.bbrc.2004.11.068; Qiao B, 2005, J BIOL CHEM, V280, P17562, DOI 10.1074/jbc.M500646200; Qiu WH, 2003, AM J PATHOL, V162, P1961, DOI 10.1016/S0002-9440(10)64329-5; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; Seghatoleslami MR, 2003, J CELL BIOCHEM, V88, P1129, DOI 10.1002/jcb.10458; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; Shukunami C, 1998, EXP CELL RES, V241, P1, DOI 10.1006/excr.1998.4045; Sironen RK, 2002, BBA-MOL CELL RES, V1591, P45, DOI 10.1016/S0167-4889(02)00247-1; Spentzos D, 2004, J CLIN ONCOL, V22, P4700, DOI 10.1200/JCO.2004.04.070; Stickens D, 2004, DEVELOPMENT, V131, P5883, DOI 10.1242/dev.01461; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Tan LJ, 2003, J BIOL CHEM, V278, P17688, DOI 10.1074/jbc.M301676200; Thirunavukkarasu K, 2000, BIOTECHNIQUES, V28, P506, DOI 10.2144/00283st09; Tiscornia G, 2003, P NATL ACAD SCI USA, V100, P1844, DOI 10.1073/pnas.0437912100; Ungefroren H, 2005, J BIOL CHEM, V280, P2644, DOI 10.1074/jbc.M411925200; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Vairapandi M, 2002, J CELL PHYSIOL, V192, P327, DOI 10.1002/jcp.10140; Valcourt U, 2002, J BIOL CHEM, V277, P33545, DOI 10.1074/jbc.M202086200; Volk SW, 1998, J BONE MINER RES, V13, P1521, DOI 10.1359/jbmr.1998.13.10.1521; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wu CW, 2002, J BONE MINER RES, V17, P639, DOI 10.1359/jbmr.2002.17.4.639; Xu L, 2005, J BIOL CHEM, V280, P548, DOI 10.1074/jbc.M411036200; Xu SC, 2001, DNA CELL BIOL, V20, P359, DOI 10.1089/10445490152122479; Yazgan O, 2002, J BIOL CHEM, V277, P29710, DOI 10.1074/jbc.M204552200; Yoo JY, 2003, J BIOL CHEM, V278, P43001, DOI 10.1074/jbc.M307869200; Yoon BS, 2004, J CELL BIOCHEM, V93, P93, DOI 10.1002/jcb.20211; Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499; Zerbini LF, 2004, P NATL ACAD SCI USA, V101, P13618, DOI 10.1073/pnas.0402069101; Zerbini LF, 2003, CANCER RES, V63, P2206; Zheng QP, 2003, J CELL BIOL, V162, P833, DOI 10.1083/jcb.200211089	90	80	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38544	38555		10.1074/jbc.M504202200	http://dx.doi.org/10.1074/jbc.M504202200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16144844	Green Accepted, Green Published, hybrid			2022-12-27	WOS:000233239800053
J	Gingras, AR; Ziegler, WH; Frank, R; Barsukov, IL; Roberts, GCK; Critchley, DR; Emsley, J				Gingras, AR; Ziegler, WH; Frank, R; Barsukov, IL; Roberts, GCK; Critchley, DR; Emsley, J			Mapping and consensus sequence identification for multiple vinculin binding sites within the Talin rod	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN-BINDING; INTRAMOLECULAR ASSOCIATION; STRUCTURAL BASIS; I/LWEQ MODULE; DOMAIN; PROTEINS; ACTIVATION; CONTAINS; MOTIFS; LOCALIZATION	The interaction between the cytoskeletal proteins talin and vinculin plays a key role in integrin-mediated cell adhesion and migration. Three vinculin binding sites (VBS1-3) have previously been identified in the talin rod using a yeast two-hybrid assay. To extend these studies, we spot-synthesized a series of peptides spanning all the alpha-helical regions predicted for the talin rod and identified eight additional VBSs, two of which overlap key functional regions of the rod, including the integrin binding site and C-terminal actin binding site. The talin VBS alpha-helices bind to a hydrophobic cleft in the N-terminal vinculin Vd1 domain. We have defined the specificity of this interaction by spot-synthesizing a series of 25-mer talin VBS1 peptides containing substitutions with all the commonly occurring amino acids. The consensus for recognition is LXXAAXXVAXXVXXLIXXA with distinct classes of hydrophobic side chains at positions 1, 4, 5, 8, 9, 12, 15, and 16 required for vinculin binding. Positions 1, 8, 12, 15, and 16 require an aliphatic residue and will not tolerate alanine, whereas positions 4, 5, and 9 are less restrictive. These preferences are common to all 11 VBS sequences with a minor variation occurring in one case. A crystal structure of this variant VBS peptide in complex with the vinculin Vd1 domain reveals a subtly different mode of vinculin binding.	Univ Nottingham, Sch Pharm, Ctr Biomol Sci, Nottingham NG7 2RD, England; Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ Leipzig, Fac Med, Interdisciplinary Ctr Clin Res IZKF Leipzig, D-04103 Leipzig, Germany; German Res Ctr Biotechnol, Dept Biol Chem, D-38124 Braunschweig, Germany	University of Nottingham; University of Leicester; Leipzig University; Helmholtz Association; Helmholtz-Center for Infection Research	Emsley, J (corresponding author), Univ Nottingham, Sch Pharm, Ctr Biomol Sci, Nottingham NG7 2RD, England.	jonas.emsley@nottingham.ac.uk	Gingras, Alexandre R/E-1867-2011; emsley, jonas/A-8509-2016	Gingras, Alexandre R/0000-0002-5373-0176; emsley, jonas/0000-0002-8949-8030; Roberts, Gordon/0000-0001-6200-1373; Ziegler, Wolfgang H./0000-0003-4529-1916	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; Arold ST, 2002, STRUCTURE, V10, P319, DOI 10.1016/S0969-2126(02)00717-7; Bakolitsa C, 2004, NATURE, V430, P583, DOI 10.1038/nature02610; Barsukov IL, 2003, J BIOL CHEM, V278, P31202, DOI 10.1074/jbc.M303850200; Bass MD, 1999, BIOCHEM J, V341, P257, DOI 10.1042/0264-6021:3410257; Borowsky ML, 1998, J CELL BIOL, V143, P429, DOI 10.1083/jcb.143.2.429; Brindle NPJ, 1996, BIOCHEM J, V318, P753, DOI 10.1042/bj3180753; Brown NH, 2002, DEV CELL, V3, P569, DOI 10.1016/S1534-5807(02)00290-3; Calderwood DA, 2004, J BIOL CHEM, V279, P28889, DOI 10.1074/jbc.M402161200; Campbell ID, 2004, TRENDS BIOCHEM SCI, V29, P429, DOI 10.1016/j.tibs.2004.06.005; Chandrasekar I, 2005, J CELL SCI, V118, P1461, DOI 10.1242/jcs.01734; Cram EJ, 2004, TRENDS CELL BIOL, V14, P55, DOI 10.1016/j.tcb.2003.12.009; Cram EJ, 2003, J CELL SCI, V116, P3871, DOI 10.1242/jcs.00705; Critchley DR, 2004, BIOCHEM SOC T, V32, P831, DOI 10.1042/BST0320831; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; Fillingham I, 2005, STRUCTURE, V13, P65, DOI 10.1016/j.str.2004.11.006; Frank R, 1996, Methods Mol Biol, V66, P149; Galbraith CG, 2002, J CELL BIOL, V159, P695, DOI 10.1083/jcb.200204153; GILMORE AP, 1992, J CELL SCI, V103, P719; GILMORE AP, 1993, J CELL BIOL, V122, P337, DOI 10.1083/jcb.122.2.337; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hemmings L, 1996, J CELL SCI, V109, P2715; Huttelmaier S, 1997, EUR J BIOCHEM, V247, P1136, DOI 10.1111/j.1432-1033.1997.01136.x; Huttelmaier S, 1998, CURR BIOL, V8, P479, DOI 10.1016/S0960-9822(98)70199-X; Izard T, 2004, NATURE, V427, P171, DOI 10.1038/nature02281; JASPER CL, 2004, AM CHEM SOC, V126, P13679; Jiang GY, 2003, NATURE, V424, P334, DOI 10.1038/nature01805; Jockusch BM, 1996, TRENDS CELL BIOL, V6, P311, DOI 10.1016/0962-8924(96)10022-2; Johnson RP, 1998, BIOCHEMISTRY-US, V37, P10211, DOI 10.1021/bi9727242; Johnson RP, 2000, J BIOL CHEM, V275, P95, DOI 10.1074/jbc.275.1.95; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Kleiger G, 2002, J MOL BIOL, V323, P69, DOI 10.1016/S0022-2836(02)00885-9; Kleiger G, 2002, BIOCHEMISTRY-US, V41, P5990, DOI 10.1021/bi0200763; KROEMKER M, 1994, FEBS LETT, V355, P259, DOI 10.1016/0014-5793(94)01216-4; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; McCann RO, 1999, BIOCHEM BIOPH RES CO, V266, P135, DOI 10.1006/bbrc.1999.1776; McCann RO, 1997, P NATL ACAD SCI USA, V94, P5679, DOI 10.1073/pnas.94.11.5679; MCLACHLAN AD, 1994, J MOL BIOL, V235, P1278, DOI 10.1006/jmbi.1994.1081; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Monkley SJ, 2000, DEV DYNAM, V219, P560, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1079>3.0.CO;2-Y; Nayal A, 2004, CURR OPIN CELL BIOL, V16, P94, DOI 10.1016/j.ceb.2003.11.007; Papagrigoriou E, 2004, EMBO J, V23, P2942, DOI 10.1038/sj.emboj.7600285; Priddle H, 1998, J CELL BIOL, V142, P1121, DOI 10.1083/jcb.142.4.1121; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tremuth L, 2004, J BIOL CHEM, V279, P22258, DOI 10.1074/jbc.M400947200; Winkler J, 1996, J STRUCT BIOL, V116, P270, DOI 10.1006/jsbi.1996.0042; WOOD CK, 1994, J CELL SCI, V107, P709; Xing BD, 2001, J BIOL CHEM, V276, P44373, DOI 10.1074/jbc.M108587200	52	137	140	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37217	37224		10.1074/jbc.M508060200	http://dx.doi.org/10.1074/jbc.M508060200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16135522	hybrid			2022-12-27	WOS:000232901800080
J	Guichard, C; Pedruzzi, E; Dewas, C; Fay, M; Pouzet, C; Bens, M; Vandewalle, A; Ogier-Denis, E; Gougerot-Pocidalo, MA; Elbim, C				Guichard, C; Pedruzzi, E; Dewas, C; Fay, M; Pouzet, C; Bens, M; Vandewalle, A; Ogier-Denis, E; Gougerot-Pocidalo, MA; Elbim, C			Interleukin-8-induced priming of neutrophil oxidative burst requires sequential recruitment of NADPH oxidase components into lipid rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; TUMOR-NECROSIS-FACTOR; ACTIVATED PROTEIN-KINASE; SUPEROXIDE ANION PRODUCTION; RESPIRATORY BURST; INTRAMOLECULAR INTERACTION; PARTIAL PHOSPHORYLATION; HUMAN-GRANULOCYTES; PHOSPHATIDIC-ACID; SUBUNIT P47(PHOX)	The superoxide-producing phagocyte NADPH oxidase consists of a membrane-bound flavocytochrome b(558), the cytosol factors p47(phox), p67(phox), p40(phox), and the small GTPase Rac2, which translocate to the membrane to assemble the active complex following neutrophil activation. Interleukin-8 (IL-8) does not activate NADPH oxidase, but potentiates the oxidative burst induced by stimuli such as formyl-methionyl-leucyl-phenylalanine ( fMLP) via a priming mechanism. The effect of IL-8 on the components of NADPH oxidase during the priming process has never been investigated in human neutrophils. Here we showed that within 3 min, IL-8 treatment enhanced the Btk- and ERK1/2-dependent phosphorylation of p47(phox), as well as the recruitment of flavocytochrome b558, p47(phox), and Rac2 into cholesterol-enriched detergent-resistant microdomains ( or lipid rafts). Conversely, IL-8 treatment lasting 15 min failed to recruit flavocytochrome b(558), p47(phox), or Rac2, but did enhance the Btk- and p38 MAPK-dependent phosphorylation and the translocation of p67(phox) into detergent-resistant microdomains. Moreover, methyl-beta-cyclodextrin, which disrupts lipid rafts, inhibited IL-8-induced priming in response to fMLP. Our findings indicate that IL-8-induced priming of the oxidative burst in response to fMLP involves a sequential assembly of the NADPH oxidase components in the lipid rafts of neutrophils.	Univ Paris 07, INSERM, U683, F-75870 Paris, France; Univ Paris 07, INSERM, U478, F-75870 Paris, France; Univ Paris 07, IFR02, F-75870 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Guichard, C (corresponding author), Univ Paris 07, INSERM, U683, BP 416, F-75870 Paris, France.	guichard@bichat.inserm.fr	Ogier-Denis, Eric/E-5030-2016; pedruzzi, eric/B-6050-2017	Ogier-Denis, Eric/0000-0002-0057-7593				Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; AMAR M, 1990, J IMMUNOL, V144, P4749; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Babior BM, 2004, CURR OPIN IMMUNOL, V16, P42, DOI 10.1016/j.coi.2003.12.001; BERKOW RL, 1988, J LEUKOCYTE BIOL, V44, P345, DOI 10.1002/jlb.44.5.345; Bokoch GM, 2002, BLOOD, V100, P2692, DOI 10.1182/blood-2002-04-1149; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Brown GE, 2004, J BIOL CHEM, V279, P27059, DOI 10.1074/jbc.M314258200; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; Chen QD, 2003, J IMMUNOL, V170, P5302, DOI 10.4049/jimmunol.170.10.5302; Dang PMC, 1999, J BIOL CHEM, V274, P20704, DOI 10.1074/jbc.274.29.20704; Dang PMC, 2003, BIOCHEMISTRY-US, V42, P4520, DOI 10.1021/bi0205754; Dang PMC, 2001, P NATL ACAD SCI USA, V98, P3001, DOI 10.1073/pnas.061029698; DANIELS RH, 1992, IMMUNOLOGY, V75, P157; DeLeo FR, 1998, J CLIN INVEST, V101, P455, DOI 10.1172/JCI949; Dewas C, 2000, J IMMUNOL, V165, P5238, DOI 10.4049/jimmunol.165.9.5238; Dewas C, 2003, J IMMUNOL, V171, P4392, DOI 10.4049/jimmunol.171.8.4392; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ElBenna J, 1997, J BIOL CHEM, V272, P17204, DOI 10.1074/jbc.272.27.17204; Forbes LV, 1999, FEBS LETT, V449, P225, DOI 10.1016/S0014-5793(99)00444-5; Gilbert C, 2003, J IMMUNOL, V170, P5235, DOI 10.4049/jimmunol.170.10.5235; HALLETT MB, 1995, IMMUNOL TODAY, V16, P264, DOI 10.1016/0167-5699(95)80178-2; Karathanassis D, 2002, EMBO J, V21, P5057, DOI 10.1093/emboj/cdf519; Katsumata O, 2001, J IMMUNOL, V167, P5814, DOI 10.4049/jimmunol.167.10.5814; KITAGAWA S, 1987, BIOCHEM BIOPH RES CO, V144, P1143, DOI 10.1016/0006-291X(87)91430-6; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; Lian JP, 1999, J IMMUNOL, V163, P4527; MCCOLL SR, 1990, J IMMUNOL, V145, P3047; METZNER B, 1995, J INVEST DERMATOL, V104, P789, DOI 10.1111/1523-1747.ep12606993; Nauseef WM, 2004, HISTOCHEM CELL BIOL, V122, P277, DOI 10.1007/s00418-004-0679-8; Nisimoto Y, 1999, J BIOL CHEM, V274, P22999, DOI 10.1074/jbc.274.33.22999; OKAMURA N, 1988, J BIOL CHEM, V263, P6777; Park HS, 2001, BIOCHEM J, V358, P783, DOI 10.1042/0264-6021:3580783; PARK JW, 1992, J BIOL CHEM, V267, P19901; PARK JW, 1994, BIOCHEMISTRY-US, V33, P2907, DOI 10.1021/bi00176a021; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; Rietveld A, 1998, BBA-REV BIOMEMBRANES, V1376, P467, DOI 10.1016/S0304-4157(98)00019-7; ROTROSEN D, 1990, J BIOL CHEM, V265, P8745; Shao DM, 2003, FEBS LETT, V550, P101, DOI 10.1016/S0014-5793(03)00845-7; Stahelin RV, 2003, J BIOL CHEM, V278, P14469, DOI 10.1074/jbc.M212579200; Tuluc F, 2003, INT IMMUNOPHARMACOL, V3, P1775, DOI 10.1016/j.intimp.2003.08.002; van Bruggen R, 2004, J BIOL CHEM, V279, P9097, DOI 10.1074/jbc.M309284200; VANLINT J, 1993, MOL CELL BIOCHEM, V128, P171, DOI 10.1007/BF01076768; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; Vilhardt F, 2004, EMBO J, V23, P739, DOI 10.1038/sj.emboj.7600066; Waite KA, 1997, J BIOL CHEM, V272, P15569, DOI 10.1074/jbc.272.24.15569; Ward RA, 2000, J BIOL CHEM, V275, P36713, DOI 10.1074/jbc.M003017200; WEISBART RH, 1985, NATURE, V314, P361, DOI 10.1038/314361a0; WOODMAN RC, 1991, J CLIN INVEST, V87, P1345, DOI 10.1172/JCI115138; WOZNIAK A, 1993, IMMUNOLOGY, V79, P608; YUO A, 1991, BLOOD, V78, P2708; YUO A, 1990, BIOCHEM BIOPH RES CO, V171, P491, DOI 10.1016/0006-291X(90)91420-W; YUO A, 1989, J IMMUNOL, V142, P1678	53	93	97	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37021	37032		10.1074/jbc.M506594200	http://dx.doi.org/10.1074/jbc.M506594200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16115878	hybrid			2022-12-27	WOS:000232901800060
J	Zhang, L; Balcerzak, M; Radisson, J; Thouverey, C; Pikula, S; Azzar, G; Buchet, R				Zhang, L; Balcerzak, M; Radisson, J; Thouverey, C; Pikula, S; Azzar, G; Buchet, R			Phosphodiesterase activity of alkaline phosphatase in ATP-initiated Ca2+ and phosphate deposition in isolated chicken matrix vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL MEMBRANE GLYCOPROTEIN-1; NUCLEOTIDE PYROPHOSPHATASE; INORGANIC PYROPHOSPHATE; EPIPHYSEAL CARTILAGE; ENRICHED FRACTIONS; NUCLEATIONAL CORE; MINERALIZATION; CALCIFICATION; RELEASE; PROTEIN	Inorganic pyrophosphate is a potent inhibitor of bone mineralization by preventing the seeding of calcium-phosphate complexes. Plasma cell membrane glycoprotein-1 and tissue nonspecific alkaline phosphatase were reported to be antagonistic regulators of mineralization toward inorganic pyrophosphate formation (by plasma cell membrane glycoprotein-1) and degradation (by tissue nonspecific alkaline phosphatase) under physiological conditions. In addition, they possess broad overlapping enzymatic functions. Therefore, we examined the roles of tissue nonspecific alkaline phosphatase within matrix vesicles isolated from femurs of 17-day-old chick embryos, under conditions where these both antagonistic and overlapping functions could be evidenced. Addition of 25 mu M ATP significantly increased duration of mineralization process mediated by matrix vesicles, while supplementation of mineralization medium with levamisole, an alkaline phosphatase inhibitor, reduces the ATP-induced retardation of mineral formation. Phosphodiesterase activity of tissue nonspecific alkaline phosphatase for bis-p-nitrophenyl phosphate was confirmed, the rate of this phosphodiesterase activity is in the same range as that of phosphomonoesterase activity for p-nitrophenyl phosphate under physiological pH. In addition, tissue nonspecific alkaline phosphatase at pH 7.4 can hydrolyze ADPR. On the basis of these observations, it can be concluded that tissue nonspecific alkaline phosphatase, acting as a phosphomonoesterase, could hydrolyze free phosphate esters such as pyrophosphate and ATP, while as phosphodiesterase could contribute, together with plasma cell membrane glycoprotein-1, in the production of pyrophosphate from ATP.	Univ Lyon 1, CNRS, UMR 5013, UFR Chim Biochim, F-69622 Villeurbanne, France; Polish Acad Sci, M Nencki Inst Expt Biol, Warsaw, Poland	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences	Zhang, L (corresponding author), Univ Lyon 1, CNRS, UMR 5013, UFR Chim Biochim, 43 Blvd 11 Novembre 1918, F-69622 Villeurbanne, France.	le_zhang@hotmail.com	Rene, Buchet/I-9781-2019	Rene, Buchet/0000-0002-7966-3856; Thouverey, Cyril/0000-0002-2741-1825; Pikula, Slawomir/0000-0003-4640-3094				ABNEY ER, 1976, BIOCHEM J, V159, P293, DOI 10.1042/bj1590293; Ali S.Y., 1992, BONE BIOL SKELETAL D, P19; ANDERSON HC, 1995, CLIN ORTHOP RELAT R, P266; Angrand M, 1997, EUR J BIOCHEM, V250, P168, DOI 10.1111/j.1432-1033.1997.t01-1-00168.x; BELLI SI, 1994, BIOCHEM J, V304, P75, DOI 10.1042/bj3040075; BELLI SI, 1995, EUR J BIOCHEM, V228, P669, DOI 10.1111/j.1432-1033.1995.tb20308.x; Boskey AL, 1996, CONNECT TISSUE RES, V35, P357, DOI 10.3109/03008209609029212; Bowler WB, 1998, BONE, V22, P195, DOI 10.1016/S8756-3282(97)00280-9; BOWLER WB, 1998, J BONE MINER RES, V13, P524; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRECEVIC L, 1972, CALC TISS RES, V10, P82, DOI 10.1007/BF02012538; BRENNER S, 1959, BIOCHIM BIOPHYS ACTA, V34, P103, DOI 10.1016/0006-3002(59)90237-9; Buckley KA, 2003, FASEB J, V17, P1401, DOI 10.1096/fj.02-0940com; Camolezi FL, 2002, INT J BIOCHEM CELL B, V34, P1091, DOI 10.1016/S1357-2725(02)00029-8; Clair T, 1997, J BIOL CHEM, V272, P996, DOI 10.1074/jbc.272.2.996; CYBORON GW, 1981, J BIOL CHEM, V256, P7262; Derfus B, 1998, CALCIFIED TISSUE INT, V63, P258, DOI 10.1007/s002239900523; Derfus BA, 1996, CONNECT TISSUE RES, V35, P337, DOI 10.3109/03008209609029209; EVANS WH, 1973, BIOCHEM J, V135, P819, DOI 10.1042/bj1350819; Galperin MY, 1998, PROTEIN SCI, V7, P1829, DOI 10.1002/pro.5560070819; Garimella Rama, 2004, Biol Proced Online, V6, P263, DOI 10.1251/bpo97; Genetos DC, 2005, J BONE MINER RES, V20, P41, DOI 10.1359/jbmr.041009; Gijsbers R, 2001, J BIOL CHEM, V276, P1361, DOI 10.1074/jbc.M007552200; Goding JW, 2000, J LEUKOCYTE BIOL, V67, P285, DOI 10.1002/jlb.67.3.285; Goding JW, 1998, IMMUNOL REV, V161, P11, DOI 10.1111/j.1600-065X.1998.tb01568.x; Graff RD, 2000, ARTHRITIS RHEUM-US, V43, P1571, DOI 10.1002/1529-0131(200007)43:7<1571::AID-ANR22>3.3.CO;2-C; Harmey D, 2004, AM J PATHOL, V164, P1199, DOI 10.1016/S0002-9440(10)63208-7; Harris PD, 1997, PARASITOL RES, V83, P533, DOI 10.1007/s004360050294; HATORI M, 1995, J CELL PHYSIOL, V165, P468, DOI 10.1002/jcp.1041650304; HEPPEL LA, 1962, J BIOL CHEM, V237, P841; Hessle L, 2002, P NATL ACAD SCI USA, V99, P9445, DOI 10.1073/pnas.142063399; HOWELL DS, 1968, J CLIN INVEST, V47, P1121, DOI 10.1172/JCI105801; Hsu HHT, 1996, J BIOL CHEM, V271, P26383, DOI 10.1074/jbc.271.42.26383; HSU HHT, 1994, INT J BIOCHEM, V26, P1351, DOI 10.1016/0020-711X(94)90177-5; HSU HHT, 1983, J BIOL CHEM, V258, P3463; HSU HHT, 1995, INT J BIOCHEM CELL B, V27, P1349, DOI 10.1016/1357-2725(95)00103-V; HULL WE, 1976, BIOCHEMISTRY-US, V15, P1547, DOI 10.1021/bi00652a028; HUNG CT, 1997, AM J PHYSIOL, V272, P1611; Johnson K, 1999, ARTHRITIS RHEUM-US, V42, P1986, DOI 10.1002/1529-0131(199909)42:9<1986::AID-ANR26>3.0.CO;2-O; Johnson K, 2003, J BONE MINER RES, V18, P994, DOI 10.1359/jbmr.2003.18.6.994; Johnson KA, 2000, AM J PHYSIOL-REG I, V279, pR1365, DOI 10.1152/ajpregu.2000.279.4.R1365; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; Kirsch T, 2000, J BIOL CHEM, V275, P35577, DOI 10.1074/jbc.M005648200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LLOYD DK, 1999, CALCIFIED TISSUE INT, V64, P58; MAJESKA RJ, 1975, BIOCHIM BIOPHYS ACTA, V391, P51, DOI 10.1016/0005-2744(75)90151-5; MEYER JL, 1984, ARCH BIOCHEM BIOPHYS, V231, P1, DOI 10.1016/0003-9861(84)90356-4; MONTESSUIT C, 1991, J BIOL CHEM, V266, P17791; Mornet E, 2001, J BIOL CHEM, V276, P31171, DOI 10.1074/jbc.M102788200; MOSS DW, 1967, BIOCHEM J, V102, P53, DOI 10.1042/bj1020053; MOSS DW, 1969, BIOCHIM BIOPHYS ACTA, V191, P476, DOI 10.1016/0005-2744(69)90269-1; MURPHY J, 1962, ANAL CHIM ACTA, V26, P31; O'Brien PJ, 2001, BIOCHEMISTRY-US, V40, P5691, DOI 10.1021/bi0028892; REGISTER TC, 1986, J BIOL CHEM, V261, P9354; REGISTER TC, 1985, BONE, V6, P307, DOI 10.1016/8756-3282(85)90320-5; REGISTER TC, 1984, J BIOL CHEM, V259, P3511; REZENDE AA, 1994, BIOCHEM J, V301, P517, DOI 10.1042/bj3010517; Solan JL, 1996, J BONE MINER RES, V11, P183; Stefan C, 1996, EUR J BIOCHEM, V241, P338, DOI 10.1111/j.1432-1033.1996.00338.x; Strater N, 1996, ANGEW CHEM INT EDIT, V35, P2024, DOI 10.1002/anie.199620241; VAANANEN HK, 1979, CALCIFIED TISSUE INT, V28, P65, DOI 10.1007/BF02441219; VANBELLE H, 1972, BIOCHIM BIOPHYS ACTA, V289, P158, DOI 10.1016/0005-2744(72)90118-0; Wilcox DE, 1996, CHEM REV, V96, P2435, DOI 10.1021/cr950043b; Wu LNY, 2002, J BIOL CHEM, V277, P5126, DOI 10.1074/jbc.M107899200; WU LNY, 1993, J BIOL CHEM, V268, P25084; Wu LNY, 1997, J BIOL CHEM, V272, P4404, DOI 10.1074/jbc.272.7.4404; Zhang L, 2004, BIOPHYS J, V86, P3873, DOI 10.1529/biophysj.103.034116	67	44	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37289	37296		10.1074/jbc.M504260200	http://dx.doi.org/10.1074/jbc.M504260200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16147995	hybrid			2022-12-27	WOS:000232901800087
J	Interthal, H; Chen, HJ; Champoux, JJ				Interthal, H; Chen, HJ; Champoux, JJ			Human Tdp1 cleaves a broad spectrum of substrates, including phosphoamide linkages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSYL-DNA PHOSPHODIESTERASE; PHOSPHOLIPASE-D SUPERFAMILY; HUMAN TOPOISOMERASE-I; COVALENT COMPLEXES; CRYSTAL-STRUCTURE; HUMAN-CELLS; SPINOCEREBELLAR ATAXIA; CATALYTIC MECHANISM; DRUG CAMPTOTHECIN; D FAMILY	Human tyrosyl-DNA phosphodiesterase (Tdp1) hydrolyzes the phosphodiester bond between a DNA 3' end and a tyrosyl moiety. In eukaryotic cells, this type of linkage is found in stalled topoisomerase I-DNA covalent complexes, and Tdp1 has been implicated in the repair of such complexes in vivo. We confirm here that the Tdp1 catalytic cycle involves a covalent reaction intermediate in which a histidine residue is connected to a DNA 3'-phosphate through a phosphoamide linkage. Most surprisingly, this linkage can be hydrolyzed by Tdp1, and unlike a topoisomerase I-DNA complex, which requires modification to be an efficient substrate for Tdp1, the native form of Tdp1 can be removed from the DNA. The spinocerebellar ataxia with axonal neuropathy neurodegenerative disease is caused by the H493R mutant form of Tdp1, which shows reduced enzymatic activity and accumulates the Tdp1-DNA covalent intermediate. The ability of wild type Tdp1 to remove the stalled mutant protein from the DNA likely explains the recessive nature of spinocerebellar ataxia with axonal neuropathy. In addition to its activity on phosphotyrosine and phosphohistidine substrates, Tdp1 also possesses a limited DNA and RNA 3'-exonuclease activity in which a single nucleoside is removed from the 3'-hydroxyl end of the substrate. Furthermore, Tdp1 also removes a 3' abasic site and an artificial 3'-biotin adduct from the DNA. In combination with earlier data showing that Tdp1 can use 3'-phosphoglycolate as a substrate, these data suggest that Tdp1 may function to remove a variety of 3' adducts from DNA during DNA repair.	Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Champoux, JJ (corresponding author), Univ Washington, Sch Med, Dept Microbiol, Box 357242, Seattle, WA 98195 USA.	champoux@u.washington.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049156] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM049156, GM49156] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BADICELLA JP, 1997, P NATL ACAD SCI USA, V94, P8010; Barnes DE, 2004, ANNU REV GENET, V38, P445, DOI 10.1146/annurev.genet.38.072902.092448; Barthelmes HU, 2004, J BIOL CHEM, V279, P55618, DOI 10.1074/jbc.M405042200; BURGIN AB, 1995, NUCLEIC ACIDS RES, V23, P2973, DOI 10.1093/nar/23.15.2973; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Chou KM, 2002, NATURE, V415, P655, DOI 10.1038/415655a; Davies DR, 2004, J MED CHEM, V47, P829, DOI 10.1021/jm030487x; Davies DR, 2003, CHEM BIOL, V10, P139, DOI 10.1016/S1074-5521(03)00021-8; Davies DR, 2002, J MOL BIOL, V324, P917, DOI 10.1016/S0022-2836(02)01154-3; Davies DR, 2002, STRUCTURE, V10, P237, DOI 10.1016/S0969-2126(02)00707-4; Debethune L, 2002, NUCLEIC ACIDS RES, V30, P1198, DOI 10.1093/nar/30.5.1198; Desai SD, 2003, MOL CELL BIOL, V23, P2341, DOI 10.1128/MCB.23.7.2341-2350.2003; Desai SD, 1997, J BIOL CHEM, V272, P24159, DOI 10.1074/jbc.272.39.24159; El-Khamisy SF, 2005, NATURE, V434, P108, DOI 10.1038/nature03314; Exton JH, 2002, REV PHYSIOL BIOCH P, V144, P1, DOI 10.1007/BFb0116585; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; Gottlin EB, 1998, P NATL ACAD SCI USA, V95, P9202, DOI 10.1073/pnas.95.16.9202; HSIANG YH, 1988, CANCER RES, V48, P1722; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; Ikeda S, 1998, J BIOL CHEM, V273, P21585, DOI 10.1074/jbc.273.34.21585; Inamdar KV, 2002, J BIOL CHEM, V277, P27162, DOI 10.1074/jbc.M204688200; Interthal H, 2005, EMBO J, V24, P2224, DOI 10.1038/sj.emboj.7600694; Interthal H, 2001, P NATL ACAD SCI USA, V98, P12009, DOI 10.1073/pnas.211429198; Jiricny J, 2002, NATURE, V415, P593, DOI 10.1038/415593a; Klumpp S, 2002, EUR J BIOCHEM, V269, P1067, DOI 10.1046/j.1432-1033.2002.02755.x; Koonin EV, 1996, TRENDS BIOCHEM SCI, V21, P242, DOI 10.1016/0968-0004(96)30024-8; Leppard JB, 2005, CHROMOSOMA, V114, P75, DOI 10.1007/s00412-005-0345-5; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Liu CY, 2004, DNA REPAIR, V3, P593, DOI 10.1016/j.dnarep.2004.03.030; Morris AJ, 1996, TRENDS PHARMACOL SCI, V17, P182, DOI 10.1016/0165-6147(96)10016-X; Nitiss JL, 1998, BBA-GENE STRUCT EXPR, V1400, P63, DOI 10.1016/S0167-4781(98)00128-6; Nivens MC, 2004, CANCER CHEMOTH PHARM, V53, P107, DOI 10.1007/s00280-003-0717-6; Oh MK, 2003, BBA-PROTEINS PROTEOM, V1649, P146, DOI 10.1016/S1570-9639(03)00166-3; Plo I, 2003, DNA REPAIR, V2, P1087, DOI 10.1016/S1568-7864(03)00116-2; Ponting CP, 1996, PROTEIN SCI, V5, P914; Poon HF, 2004, CLIN GERIATR MED, V20, P329, DOI 10.1016/j.cger.2004.02.005; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; Pouliot JJ, 2001, GENES CELLS, V6, P677, DOI 10.1046/j.1365-2443.2001.00452.x; Pourquier P, 2001, ADV CANCER RES, V80, P189, DOI 10.1016/S0065-230X(01)80016-6; Povirk LF, 1996, MUTAT RES-FUND MOL M, V355, P71, DOI 10.1016/0027-5107(96)00023-1; Raymond AC, 2004, J MOL BIOL, V338, P895, DOI 10.1016/j.jmb.2004.03.013; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Rideout MC, 2004, NUCLEIC ACIDS RES, V32, P4657, DOI 10.1093/nar/gkh796; Rudolph AE, 1999, J BIOL CHEM, V274, P11824, DOI 10.1074/jbc.274.17.11824; Sapranauskas R, 2000, J BIOL CHEM, V275, P30878, DOI 10.1074/jbc.M003350200; Schultz SJ, 2004, J MOL BIOL, V344, P635, DOI 10.1016/j.jmb.2004.09.081; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stuckey JA, 1999, NAT STRUCT BIOL, V6, P278; Takashima H, 2002, NAT GENET, V32, P267, DOI 10.1038/ng987; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wiederhold L, 2004, MOL CELL, V15, P209, DOI 10.1016/j.molcel.2004.06.003; Yang SW, 1996, P NATL ACAD SCI USA, V93, P11534, DOI 10.1073/pnas.93.21.11534; Zhao Y, 1997, PROTEIN SCI, V6, P2655; Zhou T, 2005, NUCLEIC ACIDS RES, V33, P289, DOI 10.1093/nar/gki170	55	168	173	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36518	36528		10.1074/jbc.M508898200	http://dx.doi.org/10.1074/jbc.M508898200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16141202	hybrid, Green Accepted			2022-12-27	WOS:000232726900086
J	Markova, M; Peneff, C; Hewlins, MJE; Schirmer, T; John, RA				Markova, M; Peneff, C; Hewlins, MJE; Schirmer, T; John, RA			Determinants of substrate specificity in omega-aminotransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ORNITHINE	Ornithine aminotransferase and 4-aminobutyrate aminotransferase are related pyridoxal phosphate-dependent enzymes having different substrate specificities. The atomic structures of these enzymes have shown (i) that active site differences are limited to the steric positions occupied by two tyrosine residues in ornithine aminotransferase and (ii) that, uniquely among related, structurally characterized aminotransferases, the conserved arginine that binds the alpha-carboxylate of alpha-amino acids interacts tightly with a glutamate residue. To determine the contribution of these residues to the specificities of the enzymes, we analyzed site-directed mutants of ornithine aminotransferase by rapid reaction kinetics, x-ray crystallography, and C-13 NMR spectroscopy. Mutation of one tyrosine (Tyr-85) to isoleucine, as found in aminobutyrate aminotransferase, decreased the rate of the reaction of the enzyme with ornithine 1000-fold and increased that with 4-aminobutyrate 16-fold, indicating that Tyr-85 is amajor determinant of specificity toward ornithine. Unexpectedly, the limiting rate of the second half of the reaction, conversion of ketoglutarate to glutamate, was greatly increased, although the kinetics of the reverse reaction were unaffected. A mutant in which the glutamate (Glu-235) that interacts with the conserved arginine was replaced by alanine retained its regiospecificity for the delta-amino group of ornithine, but the glutamate reaction was enhanced 650-fold, whereas only a 5-fold enhancement of the ketoglutarate reaction rate resulted. A model is proposed in which conversion of the enzyme to its pyridoxamine phosphate form disrupts the internal glutamate-arginine interaction, thus enabling ketoglutarate but not glutamate to be a good substrate.	Cardiff Univ, Sch Biosci, Cardiff CF23 6QU, Wales; Cardiff Univ, Sch Chem, Cardiff CF23 6QU, Wales; Univ Basel, Biozentrum, Abt Strukturbiol, CH-4056 Basel, Switzerland	Cardiff University; Cardiff University; University of Basel	John, RA (corresponding author), Cardiff Univ, Sch Biosci, Museum Ave,POB 911, Cardiff CF10 3US, S Glam, Wales.	JohnRA@cf.ac.uk						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANKS BEC, 1966, PYRIDOXAL CATALYSIS, P191; DUNATHAN HC, 1966, P NATL ACAD SCI USA, V55, P712, DOI 10.1073/pnas.55.4.712; FORD GC, 1980, P NATL ACAD SCI-BIOL, V77, P2559, DOI 10.1073/pnas.77.5.2559; JOHN RA, 1976, BIOCHEM J, V155, P645, DOI 10.1042/bj1550645; JOHN RA, 1985, TRANSAMINASES, P413; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIU W, 1994, BIOCHEMISTRY-US, V43, P10896; Liu WS, 2005, BIOCHEMISTRY-US, V44, P2982, DOI 10.1021/bi048657a; MEHTA PK, 1993, EUR J BIOCHEM, V214, P549, DOI 10.1111/j.1432-1033.1993.tb17953.x; Mehta PK, 2000, ADV ENZYMOL RAMB, V74, P129; PERAINO C, 1969, J BIOL CHEM, V255, P10284; PHILIPPSEN A, 1998, DINO VISUALIZATION S; Shen BW, 1998, J MOL BIOL, V277, P81, DOI 10.1006/jmbi.1997.1583; SILVERMAN RB, 1981, BIOCHEMISTRY-US, V20, P1197, DOI 10.1021/bi00508a022; Storici P, 1999, J MOL BIOL, V285, P297, DOI 10.1006/jmbi.1998.2289; Storici P, 1999, BIOCHEMISTRY-US, V38, P8628, DOI 10.1021/bi990478j; WILLIAMS JA, 1982, BIOCHEM J, V201, P221, DOI 10.1042/bj2010221	20	39	41	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36409	36416		10.1074/jbc.M506977200	http://dx.doi.org/10.1074/jbc.M506977200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16096275	hybrid, Green Published			2022-12-27	WOS:000232726900075
J	Merino, E; Montserrat, V; Paradela, A; de Castro, JAL				Merino, E; Montserrat, V; Paradela, A; de Castro, JAL			Two HLA-B14 subtypes (B*1402 and b*1403) differentially associated with ankylosing spondylitis differ substantially in peptide specificity but have limited peptide and T-cell epitope sharing with HLA-B27	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I MOLECULES; ANTIGEN; MHC; HLA; BINDING; POLYMORPHISM; REPERTOIRE; DIVERSITY; RESIDUES; SPONDYLOARTHROPATHIES	The peptide specificity of HLA-B*1403, an allotype associated with ankylosing spondylitis (Lopez-Larrea, C., Mijiyawa, M., Gonzalez, S., Fernandez-Morera, J. L., Blanco-Gelaz, M. A., Martinez- Borra, J., and Lopez-Vazquez, A. ( 2002) Arthritis Rheum. 46, 2968 - 2971) was compared with those of the non-associated B*1402 and the prototypic disease-associated B*2705 allotypes. Although differing by a single residue (L156R), B*1402 and B*1403 shared only 32 - 35% of their peptide repertoires. Subtype-related differences observed in multiple peptide positions, including P3 and P7, were largely explained by a direct effect of the L156R change on peptide specificity. The HLA-B14 subtypes sharedonly similar to 3% of their peptide repertoires with B*2705. This was due to distinct residue usage at most positions, as revealed by statistical comparison of B*1402, B*1403, and B*2705-bound nonamers. Nevertheless, shared ligands between B*2705 and B*1403 were formally identified, although ligands common to B*2705 and B* 1403, but absent from B* 1402, were not found. Alloreactive T-cells were used as a tool to analyze epitope sharing among B* 1402, B* 1403, and B*2705. The percentage of cross-reactive T-cell clones closely paralleled peptide overlap, suggesting that shared ligands tend to maintain their antigenic features when bound to the different allotypes. Our results indicate that B* 1403 and B* 2705 can present common peptides. However, both the disparity of their peptide repertoires and the lack of binding features shared by these two allotypes, but not B* 1402, argue against, although do not exclude, a mechanism of spondyloarthritis mediated by specific ligands of B* 2705 and B* 1403.	Univ Autonoma Madrid, Fac Ciencias, E-28049 Madrid, Spain	Autonomous University of Madrid	de Castro, JAL (corresponding author), Consejo Super Invest Cient, Ctr Biol Mol Severo Ochoa, Madrid 28049, Spain.	aldecastro@cbm.uam.es	Paradela, Alberto/H-2113-2015	Paradela, Alberto/0000-0001-6837-7056				BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; BREWERTON DA, 1973, LANCET, V1, P904; BRODSKY FM, 1979, EUR J IMMUNOL, V9, P536, DOI 10.1002/eji.1830090709; CALVO V, 1990, J IMMUNOL, V144, P4038; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; Colbert RA, 2004, CURR MOL MED, V4, P21, DOI 10.2174/1566524043479293; CRIVELLATO E, 1987, ACTA DERM-VENEREOL, V67, P249; Daniel S, 1997, J IMMUNOL, V159, P2350; Daniel S, 1998, J IMMUNOL, V161, P617; de Castro JAL, 2004, TISSUE ANTIGENS, V63, P424, DOI 10.1111/j.0001-2815.2004.00220.x; DIBRINO M, 1994, J BIOL CHEM, V269, P32426; Ellis JM, 2000, TISSUE ANTIGENS, V56, P291, DOI 10.1034/j.1399-0039.2000.560401.x; EVAVOLD BD, 1995, IMMUNITY, V2, P655, DOI 10.1016/1074-7613(95)90010-1; FALK K, 1995, IMMUNOGENETICS, V41, P162, DOI 10.1007/BF00182332; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GAUCHATFEISS D, 1994, TISSUE ANTIGENS, V44, P261, DOI 10.1111/j.1399-0039.1994.tb02392.x; HEATH WR, 1991, P NATL ACAD SCI USA, V88, P5101, DOI 10.1073/pnas.88.12.5101; Hulsmeyer M, 2005, J MOL BIOL, V346, P1367, DOI 10.1016/j.jmb.2004.12.047; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; Khan MA, 2002, ANN INTERN MED, V136, P896, DOI 10.7326/0003-4819-136-12-200206180-00011; Lankat-Buttgereit B, 2002, PHYSIOL REV, V82, P187, DOI 10.1152/physrev.00025.2001; LOPEZ D, 1994, J IMMUNOL, V152, P5557; Lopez-Larrea C, 2002, ARTHRITIS RHEUM-US, V46, P2968, DOI 10.1002/art.10584; Macdonald WA, 2003, J EXP MED, V198, P679, DOI 10.1084/jem.20030066; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; Marina A, 1999, J MASS SPECTROM, V34, P17, DOI 10.1002/(SICI)1096-9888(199901)34:1<17::AID-JMS746>3.3.CO;2-Y; Neisig A, 1996, J IMMUNOL, V156, P3196; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; Paradela A, 2000, J IMMUNOL, V164, P329, DOI 10.4049/jimmunol.164.1.329; Paradela A, 1998, J IMMUNOL, V161, P5481; Pohlmann T, 2004, J BIOL CHEM, V279, P28197, DOI 10.1074/jbc.C400128200; Ramos M, 2002, J BIOL CHEM, V277, P28749, DOI 10.1074/jbc.M204155200; Ramos M, 2002, TISSUE ANTIGENS, V60, P191, DOI 10.1034/j.1399-0039.2002.600301.x; ROTZSCHKE O, 1991, J EXP MED, V174, P1059, DOI 10.1084/jem.174.5.1059; SCHLOSSTEIN L, 1973, NEW ENGL J MED, V288, P704, DOI 10.1056/NEJM197304052881403; Serwold T, 2002, NATURE, V419, P480, DOI 10.1038/nature01074; Sesma L, 2002, J BIOL CHEM, V277, P16744, DOI 10.1074/jbc.M200371200; SHERMAN LA, 1988, IMMUNOL REV, V101, P115, DOI 10.1111/j.1600-065X.1988.tb00734.x; Sobao Y, 1999, ARTHRITIS RHEUM, V42, P175, DOI 10.1002/1529-0131(199901)42:1<175::AID-ANR21>3.0.CO;2-7; STORKUS WJ, 1987, J IMMUNOL, V138, P1657; Tynan FE, 2005, J BIOL CHEM, V280, P23900, DOI 10.1074/jbc.M503060200; Urvater JA, 2001, J IMMUNOL, V166, P3334, DOI 10.4049/jimmunol.166.5.3334; VANENDERT PM, 1995, J EXP MED, V182, P1883, DOI 10.1084/jem.182.6.1883; Wang W, 1998, J IMMUNOL, V160, P1091; Yague J, 1998, TISSUE ANTIGENS, V52, P416, DOI 10.1111/j.1399-0039.1998.tb03067.x; YAMAGUCHI A, 1995, ARTHRITIS RHEUM-US, V38, P1672, DOI 10.1002/art.1780381120; York IA, 2002, NAT IMMUNOL, V3, P1177, DOI 10.1038/ni860; ZEMMOUR J, 1992, J IMMUNOL, V148, P1941	50	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35868	35880		10.1074/jbc.M505641200	http://dx.doi.org/10.1074/jbc.M505641200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16115862	hybrid			2022-12-27	WOS:000232726900013
J	Wigneshweraraj, SR; Burrows, PC; Severinov, K; Buck, M				Wigneshweraraj, SR; Burrows, PC; Severinov, K; Buck, M			Stable DNA opening within open promoter complexes is mediated by the RNA polymerase beta '-jaw domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TRANSCRIPTIONAL ACTIVATION; TERMINAL SEQUENCES; STRUCTURAL BASIS; SIGMA(54); SUBUNIT; PROTEIN; BINDING; HOLOENZYME; INITIATION	DNA opening for transcription-competent open promoter complex (OC) formation by the bacterial RNA polymerase ( RNAP) relies upon a complex network of interactions between the structurally conserved and flexible modules of the catalytic beta and beta'-subunits, RNAP-associated sigma-subunit, and the DNA. Here, we show that one such module, the beta'-jaw, functions to stabilize the OC. In OCs formed by the major sigma(70)-RNAP, the stabilizing role of the beta'-jaw is not restricted to any particular melted DNA segment. In contrast, in OCs formed by the major variant sigma(54)-RNAP, the beta'-jaw and a conserved sigma(54) regulatory domain co-operate to stabilize the melted DNA segment immediately upstream of the transcription start site. Clearly, regulated communication between the mobile modules of the RNAP and the functional domain(s) of the sigma subunit is required for stable DNA opening.	Rutgers State Univ, Waksman Inst, Piscataway, NJ 08854 USA; Univ London Imperial Coll Sci Technol & Med, Fac Life Sci, Div Biol, London SW7 2AZ, England; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Russian Acad Sci, Inst Mol Genet, Moscow 123182, Russia	Rutgers State University New Brunswick; Imperial College London; Rutgers State University New Brunswick; Russian Academy of Sciences	Severinov, K (corresponding author), Rutgers State Univ, Waksman Inst, POB 759, Piscataway, NJ 08854 USA.	severik@waksman.rutgers.edu; m.buck@imperial.ac.uk	Severinov, Konstantin/C-8545-2016	Wigneshweraraj, Sivaramesh/0000-0002-1418-4029	NIGMS NIH HHS [R01 GM64530] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064530] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bordes P, 2004, MOL MICROBIOL, V54, P489, DOI 10.1111/j.1365-2958.2004.04280.x; Buck M, 2000, J BACTERIOL, V182, P4129, DOI 10.1128/JB.182.15.4129-4136.2000; Burrows PC, 2004, EMBO J, V23, P4253, DOI 10.1038/sj.emboj.7600406; Burrows PC, 2003, J BIOL CHEM, V278, P29728, DOI 10.1074/jbc.M303596200; Bushnell DA, 2004, SCIENCE, V303, P983, DOI 10.1126/science.1090838; CANNON W, 1995, NUCLEIC ACIDS RES, V23, P351, DOI 10.1093/nar/23.3.351; Cannon W, 1999, GENE DEV, V13, P357, DOI 10.1101/gad.13.3.357; Cannon W, 2001, J BIOL CHEM, V276, P386, DOI 10.1074/jbc.M007779200; Cannon WV, 2000, NAT STRUCT BIOL, V7, P594; Casaz P, 1999, J MOL BIOL, V292, P229, DOI 10.1006/jmbi.1999.3076; Chaney M, 2001, GENE DEV, V15, P2282, DOI 10.1101/gad.205501; Ederth J, 2002, J BIOL CHEM, V277, P37456, DOI 10.1074/jbc.M207038200; Helmann JD, 1999, BIOCHEMISTRY-US, V38, P5959, DOI 10.1021/bi990206g; Kashlev M, 1996, METHOD ENZYMOL, V274, P326; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; MAYER AN, 1995, GENE, V153, P1, DOI 10.1016/0378-1119(94)00752-E; Mekler V, 2002, CELL, V108, P599, DOI 10.1016/S0092-8674(02)00667-0; MORRIS L, 1994, J BIOL CHEM, V269, P11563; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; Nechaev S, 1999, J MOL BIOL, V289, P815, DOI 10.1006/jmbi.1999.2782; Nechaev S, 2000, J BIOL CHEM, V275, P25516, DOI 10.1074/jbc.M002511200; Rappas M, 2005, SCIENCE, V307, P1972, DOI 10.1126/science.1105932; Sclavi B, 2005, P NATL ACAD SCI USA, V102, P4706, DOI 10.1073/pnas.0408218102; Tsujikawa L, 2002, P NATL ACAD SCI USA, V99, P3493, DOI 10.1073/pnas.062487299; Van Wynsberghe A, 2004, BIOCHEMISTRY-US, V43, P13083, DOI 10.1021/bi049738+; WEDEL A, 1995, GENE DEV, V9, P2042, DOI 10.1101/gad.9.16.2042; Wigneshweraraj SR, 2000, EMBO J, V19, P3038, DOI 10.1093/emboj/19.12.3038; Wigneshweraraj SR, 2004, EMBO J, V23, P4264, DOI 10.1038/sj.emboj.7600407; Wigneshweraraj SR, 2003, METHOD ENZYMOL, V370, P646; Wigneshweraraj SR, 2003, J BIOL CHEM, V278, P3455, DOI 10.1074/jbc.M209442200; Wigneshweraraj SR, 2002, J MOL BIOL, V319, P1067, DOI 10.1016/S0022-2836(02)00330-3; Wigneshweraraj SR, 2001, J MOL BIOL, V306, P681, DOI 10.1006/jmbi.2000.4393; Zenkin N, 2004, P NATL ACAD SCI USA, V101, P4396, DOI 10.1073/pnas.0400886101; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9; Zhang X, 2002, MOL MICROBIOL, V45, P895, DOI 10.1046/j.1365-2958.2002.03065.x	35	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36176	36184		10.1074/jbc.M506416200	http://dx.doi.org/10.1074/jbc.M506416200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16123036	hybrid			2022-12-27	WOS:000232726900049
J	Anborgh, PH; Godin, C; Pampillo, M; Dhami, GK; Dale, LB; Cregan, SP; Truant, R; Ferguson, SSG				Anborgh, PH; Godin, C; Pampillo, M; Dhami, GK; Dale, LB; Cregan, SP; Truant, R; Ferguson, SSG			Inhibition of metabotropic glutamate receptor signaling by the huntingtin-binding protein optineurin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOLOGY DOMAIN; DISEASE; DEGENERATION; ACTIVATION; LESIONS; MODEL; ONSET	Huntington disease is caused by a polyglutamine expansion in the huntingtin protein (Htt) and is associated with excitotoxic death of striatal neurons. Group I metabotropic glutamate receptors (mGluRs) that are coupled to inositol 1,4,5-triphosphate formation and the release of intracellular Ca2+ stores play an important role in regulating neuronal function. We show here that mGluRs interact with the Htt-binding protein optineurin that is also linked to normal pressure open angled glaucoma and, when expressed in HEK 293 cells, optineurin functions to antagonize agonist-stimulated mGluR1a signaling. We find that Htt is co-precipitated with mGluR1a and that mutant Htt functions to facilitate optineurin-mediated attenuation of mGluR1a signaling. In striatal cell lines derived from Htt(Q111/Q111) mutant knock-in mice mGluR5-stimulated inositol phosphate formation is also severely impaired when compared with striatal cells derived from Htt(Q7/Q7) knock-in mice. In addition, we show that a missense single nucleotide polymorphism optineurin H486R variant previously identified to be associated with glaucoma is selectively impaired in mutant Htt binding. Although optineurin H486R retains the capacity to bind to mGluR1a, optineurin H486R-dependent attenuation of mGluR1a signaling is not enhanced by the expression of mutant Htt. Because G protein-coupled receptor kinase 2 (GRK2) protein expression is relatively low in striatal tissue, we propose that optineurin may substitute for GRK2 in the striatum to mediate mGluR desensitization. Taken together, these studies identify a novel mechanism for mGluR desensitization and an additional biochemical link between altered glutamate receptor signaling and Huntington disease.	John P Robarts Res Inst, Cell Biol Res Grp, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5K8, Canada; McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); McMaster University	Ferguson, SSG (corresponding author), John P Robarts Res Inst, Cell Biol Res Grp, 100 Perth Dr,POB 5015, London, ON N6A 5K8, Canada.	ferguson@robarts.ca	Cregan, Sean/M-3205-2013					Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; Arning L, 2005, NEUROGENETICS, V6, P25, DOI 10.1007/s10048-004-0198-8; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Battaglia G, 2002, J NEUROSCI, V22, P2135, DOI 10.1523/JNEUROSCI.22-06-02135.2002; Battaglia G, 2004, J NEUROSCI, V24, P828, DOI 10.1523/JNEUROSCI.3831-03.2004; BEAL MF, 1991, J NEUROSCI, V11, P1649; Bhattacharya M, 2004, J NEUROSCI, V24, P8752, DOI 10.1523/JNEUROSCI.3155-04.2004; Bordi F, 1999, PROG NEUROBIOL, V59, P55, DOI 10.1016/S0301-0082(98)00095-1; BRUNO V, 2001, EUR J NEUROSCI, V13, P69; Calabresi P, 1999, EXP NEUROL, V158, P97, DOI 10.1006/exnr.1999.7092; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Dale LB, 2004, J BIOL CHEM, V279, P13110, DOI 10.1074/jbc.M313333200; Dale LB, 2000, J BIOL CHEM, V275, P38213, DOI 10.1074/jbc.M006075200; Dhami GK, 2004, J BIOL CHEM, V279, P16614, DOI 10.1074/jbc.M314090200; Dhami GK, 2002, J BIOL CHEM, V277, P25266, DOI 10.1074/jbc.M203593200; DIFIGLIA M, 1990, TRENDS NEUROSCI, V13, P286, DOI 10.1016/0166-2236(90)90111-M; Dyka FM, 2004, J NEUROCHEM, V90, P190, DOI 10.1111/j.1471-4159.2004.02474.x; Faber PW, 1998, HUM MOL GENET, V7, P1463, DOI 10.1093/hmg/7.9.1463; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferguson Stephen S. G., 2003, V237, P121; Harjes P, 2003, TRENDS BIOCHEM SCI, V28, P425, DOI 10.1016/S0968-0004(03)00168-3; Hattula K, 2000, CURR BIOL, V10, P1603, DOI 10.1016/S0960-9822(00)00864-2; Helmlinger D, 2002, HUM MOL GENET, V11, P3351, DOI 10.1093/hmg/11.26.3351; Jackson GR, 1998, NEURON, V21, P633, DOI 10.1016/S0896-6273(00)80573-5; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Li SH, 2004, TRENDS GENET, V20, P146, DOI 10.1016/j.tig.2004.01.008; Li YG, 1998, MOL CELL BIOL, V18, P1601, DOI 10.1128/MCB.18.3.1601; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Melki R, 2003, J MED GENET, V40, P842, DOI 10.1136/jmg.40.11.842; Moreland RJ, 2000, NUCLEIC ACIDS RES, V28, P1986, DOI 10.1093/nar/28.9.1986; Nicoletti F, 1999, NEUROPHARMACOLOGY, V38, P1477, DOI 10.1016/S0028-3908(99)00102-1; Nicoletti F, 1996, TRENDS NEUROSCI, V19, P267, DOI 10.1016/S0166-2236(96)20019-0; PAULUS W, 1993, ANN NEUROL, V34, P574, DOI 10.1002/ana.410340411; Rezaie T, 2002, SCIENCE, V295, P1077, DOI 10.1126/science.1066901; Schlefer J, 2004, BRAIN RES, V1019, P246, DOI 10.1016/j.brainres.2004.06.005; STOREY E, 1992, ANN NEUROL, V32, P526, DOI 10.1002/ana.410320408; Tang TS, 2005, P NATL ACAD SCI USA, V102, P2602, DOI 10.1073/pnas.0409402102; Tang TS, 2003, NEURON, V39, P227, DOI 10.1016/S0896-6273(03)00366-0; Trettel F, 2000, HUM MOL GENET, V9, P2799, DOI 10.1093/hmg/9.19.2799; Willoughby CE, 2004, INVEST OPHTH VIS SCI, V45, P3122, DOI 10.1167/iovs.04-0107; Young AB, 2003, J CLIN INVEST, V111, P299, DOI 10.1172/JCI200317742; Zeron MM, 2002, NEURON, V33, P849, DOI 10.1016/S0896-6273(02)00615-3	42	116	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34840	34848		10.1074/jbc.M504508200	http://dx.doi.org/10.1074/jbc.M504508200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16091361	hybrid			2022-12-27	WOS:000232403900056
J	Castillo-Flores, A; Weinberger, A; Robinson, M; Gerst, JE				Castillo-Flores, A; Weinberger, A; Robinson, M; Gerst, JE			Mso1 is a novel component of the yeast exocytic SNARE complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE EXOCYTOSIS; MEMBRANE-FUSION; SACCHAROMYCES-CEREVISIAE; SEC1/MUNC18 PROTEINS; VESICULAR TRANSPORT; SYNTAXIN HOMOLOG; MUNC13 ISOFORM; C-ELEGANS; SECRETION; GOLGI	The yeast exocytic SNARE complex consists of one molecule each of the Sso1/ 2 target SNAREs, Snc1/2 vesicular SNAREs, and the Sec9 target SNARE, which form a fusion complex that is conserved in evolution. Another protein, Sec1, binds to the SNARE complex to facilitate assembly. We show that Mso1, a Sec1-interacting protein, also binds to the SNARE complex and plays a role in mediating Sec1 functions. Like Sec1, Mso1 bound to SNAREs in cells containing SNARE complexes (i.e. wild-type, sec1-1, and sec18-1 cells), but not in cells in which complex formation is inhibited (i.e. sec4-8 cells). Nevertheless, Mso1 remained associated with Sec1 even in sec4-8 cells, indicating that they act as a pair. Mso1 localized primarily to the plasma membrane of the bud when SNARE complex formation was not impaired but was mostly in the cytoplasm when assembly was prevented. Genetic studies suggest that Mso1 enhances Sec1 function while attenuating Sec4 GTPase function. This dual action may impart temporal regulation between Sec4 turnoff and Sec1-mediated SNARE assembly. Notably, a small region at the C terminus of Mso1 is conserved in the mammalian Munc13/Mint proteins and is necessary for proper membrane localization. Overexpression of Mso1 lacking this domain (Mso1-(1-193)) inhibited the growth of cells bearing an attenuated Sec4 GTPase. These results suggest that Mso1 is a component of the exocytic SNARE complex and a possible ortholog of the Munc13/Mint proteins.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Gerst, JE (corresponding author), Weizmann Inst Sci, Dept Mol Genet, Belfer Bldg, IL-76100 Rehovot, Israel.	jeffrey.gerst@weizmann.ac.il						Aalto MK, 1997, P NATL ACAD SCI USA, V94, P7331, DOI 10.1073/pnas.94.14.7331; AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; Augustin I, 2001, J NEUROSCI, V21, P10, DOI 10.1523/JNEUROSCI.21-01-00010.2001; Augustin I, 1999, NATURE, V400, P457, DOI 10.1038/22768; Betz A, 1997, J BIOL CHEM, V272, P2520; Biederer T, 2000, J BIOL CHEM, V275, P39803, DOI 10.1074/jbc.C000656200; BOWSER R, 1992, J CELL BIOL, V118, P1041, DOI 10.1083/jcb.118.5.1041; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; Bryant NJ, 2001, EMBO J, V20, P3380, DOI 10.1093/emboj/20.13.3380; Carr CM, 1999, J CELL BIOL, V146, P333, DOI 10.1083/jcb.146.2.333; COUVE A, 1994, J BIOL CHEM, V269, P23391; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; Fasshauer D, 2003, BBA-MOL CELL RES, V1641, P87, DOI 10.1016/S0167-4889(03)00090-9; Feldmann J, 2003, CELL, V115, P461, DOI 10.1016/S0092-8674(03)00855-9; Fix M, 2004, P NATL ACAD SCI USA, V101, P7311, DOI 10.1073/pnas.0401779101; Gao XD, 2003, J CELL BIOL, V162, P635, DOI 10.1083/jcb.200302038; Gerst JE, 2003, BBA-MOL CELL RES, V1641, P99, DOI 10.1016/S0167-4889(03)00096-X; GERST JE, 1992, P NATL ACAD SCI USA, V89, P4338, DOI 10.1073/pnas.89.10.4338; Grote E, 2000, J CELL BIOL, V151, P439, DOI 10.1083/jcb.151.2.439; Gurunathan S, 2000, MOL BIOL CELL, V11, P3629, DOI 10.1091/mbc.11.10.3629; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; Ho A, 2003, P NATL ACAD SCI USA, V100, P1409, DOI 10.1073/pnas.252774899; Holthuis JCM, 1998, EMBO J, V17, P113, DOI 10.1093/emboj/17.1.113; Hu C, 2003, SCIENCE, V300, P1745, DOI 10.1126/science.1084909; Jahn R, 2000, NEURON, V27, P201, DOI 10.1016/S0896-6273(00)00029-5; Jahn R, 2002, CURR OPIN CELL BIOL, V14, P488, DOI 10.1016/S0955-0674(02)00356-3; Jantti J, 2002, J CELL SCI, V115, P409; Katz L, 2000, MOL BIOL CELL, V11, P3849, DOI 10.1091/mbc.11.11.3849; Kauppi M, 2004, TOP CURR GENET, V10, P115; KNOP M, 2005, IN PRESS MOL BIOL CE; Koch H, 2000, BIOCHEM J, V349, P247, DOI 10.1042/0264-6021:3490247; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Marash M, 2001, EMBO J, V20, P411, DOI 10.1093/emboj/20.3.411; Neeft M, 2005, MOL BIOL CELL, V16, P731, DOI 10.1091/mbc.E04-10-0923; Novick P, 2002, TRENDS CELL BIOL, V12, P247, DOI 10.1016/S0962-8924(02)02293-6; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Ossig R, 2000, EMBO J, V19, P6000, DOI 10.1093/emboj/19.22.6000; Peng RW, 2002, J CELL BIOL, V157, P645, DOI 10.1083/jcb.200202006; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; Richmond JE, 2002, CURR OPIN NEUROBIOL, V12, P499, DOI 10.1016/S0959-4388(02)00360-4; Richmond JE, 2001, NATURE, V412, P338, DOI 10.1038/35085583; Richmond JE, 1999, NAT NEUROSCI, V2, P791, DOI 10.1038/12160; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Rose MD., 1990, METHODS YEAST GENETI; Rossi G, 1997, J BIOL CHEM, V272, P16610, DOI 10.1074/jbc.272.26.16610; Rossner S, 2004, J BIOL CHEM, V279, P27841, DOI 10.1074/jbc.C400122200; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SALMINEN A, 1989, J CELL BIOL, V109, P1023, DOI 10.1083/jcb.109.3.1023; Sassa T, 1999, J NEUROSCI, V19, P4772; Scott BL, 2004, J CELL BIOL, V167, P75, DOI 10.1083/jcb.200405018; Sheu L, 2003, J BIOL CHEM, V278, P27556, DOI 10.1074/jbc.M303203200; Shirakawa R, 2004, J BIOL CHEM, V279, P10730, DOI 10.1074/jbc.M309426200; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; Sollner TH, 2003, MOL MEMBR BIOL, V20, P209, DOI 10.1080/0968768031000104953; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; Ungar D, 2003, ANNU REV CELL DEV BI, V19, P493, DOI 10.1146/annurev.cellbio.19.110701.155609; Varoqueaux F, 2002, P NATL ACAD SCI USA, V99, P9037, DOI 10.1073/pnas.122623799; WalchSolimena C, 1997, J CELL BIOL, V137, P1495, DOI 10.1083/jcb.137.7.1495; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Yamaguchi T, 2002, DEV CELL, V2, P295, DOI 10.1016/S1534-5807(02)00125-9	62	12	12	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34033	34041		10.1074/jbc.M507142200	http://dx.doi.org/10.1074/jbc.M507142200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16087665	hybrid			2022-12-27	WOS:000232229700042
J	Rezaie, AR; Manithody, C; Yang, LK				Rezaie, AR; Manithody, C; Yang, LK			Identification of factor Xa residues critical for interaction with protein Z-dependent protease inhibitor - Both active site and exosite interactions are required for inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCES HEPARIN CATALYSIS; ANTITHROMBIN-FACTOR XA; COAGULATION FACTOR-XA; FACTOR VA BINDING; BLOOD-COAGULATION; PROTHROMBINASE COMPLEX; BASIC RESIDUES; CONFORMATIONAL-CHANGE; MOLECULAR-BASIS; AUTOLYSIS LOOP	Protein Z-dependent protease inhibitor (ZPI) is a plasma serpin, which can rapidly inactivate factor Xa (fXa) in the presence of protein Z (PZ), negatively charged phospholipids, and Ca2+ . To investigate the mechanism by which ZPI inactivates fXa, we expressed the serpin in mammalian cells and characterized its reactivity with both wild-type and selected mutants of fXa that 1) contained substitutions in the autolysis loop and the heparin binding exosite, 2) lacked the first EGF-like domain (fXa-des-EGF-1), or 3) contained the Gla domain of protein C (fXa/PC-Gla). Inhibition studies in both the presence and absence of PZ revealed that Arg-143, Lys-147, and Arg-154 of the autolysis loop and Lys-96, Lys-169, and Lys-236 of the heparin binding exosite are required for recognition of ZPI, with Arg-143 being essential for the interaction. Similar studies with fXa-des-EGF-1 and fXa/PC-Gla suggested that protein-protein interaction with either the Gla or the EGF-1 domain may not play a dominant role in the PZ-dependent recognition of fXa by the serpin on phospholipid vesicles. Further studies showed that an inactive Ser-195 to Ala mutant of fXa effectively competes with wild-type fXa for binding to the non-serpin inhibitors tissue factor pathway inhibitor and recombinant tick anticoagulant peptide, but does not compete for binding to ZPI. This suggests that the catalytic residue of fXa is required for interaction with ZPI.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Rezaie, AR (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	rezaiear@slu.edu			NHLBI NIH HHS [R01 HL068571, R01 HL062565, HL 68571, HL 62565] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068571, R01HL062565] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Belzar KJ, 2002, J BIOL CHEM, V277, P8551, DOI 10.1074/jbc.M110807200; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; Chen L, 2004, PROTEIN SCI, V13, P431, DOI 10.1110/ps.03406904; DAMUS PS, 1973, NATURE, V246, P355, DOI 10.1038/246355a0; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; FURIE B, 1982, J BIOL CHEM, V257, P3875; GETTINS PGW, 1993, BIOCHEMISTRY-US, V32, P8385, DOI 10.1021/bi00084a001; Han X, 1999, BIOCHEMISTRY-US, V38, P11073, DOI 10.1021/bi990641a; Han X, 2000, BLOOD, V96, P3049; Han X, 1998, P NATL ACAD SCI USA, V95, P9250, DOI 10.1073/pnas.95.16.9250; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; Kittur FS, 2004, J BIOL CHEM, V279, P24189, DOI 10.1074/jbc.M402302200; Manithody C, 2002, BIOCHEMISTRY-US, V41, P6780, DOI 10.1021/bi0255367; NESHEIM ME, 1981, J BIOL CHEM, V256, P6537; OLSON ST, 1995, J BIOL CHEM, V270, P30007; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1992, THROMBIN STRUCTURE F, P159; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; Rezaie AR, 1998, J BIOL CHEM, V273, P16824, DOI 10.1074/jbc.273.27.16824; Rezaie AR, 2000, BIOCHEMISTRY-US, V39, P12083, DOI 10.1021/bi0011126; Rezaie AR, 2000, J BIOL CHEM, V275, P3320, DOI 10.1074/jbc.275.5.3320; Rezaie AR, 2004, J BIOL CHEM, V279, P48262, DOI 10.1074/jbc.M409964200; Rezaie AR, 2004, BIOCHEMISTRY-US, V43, P3368, DOI 10.1021/bi036177y; Rezaie AR, 2004, BIOCHEMISTRY-US, V43, P2898, DOI 10.1021/bi036145a; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; Rezaie AR, 2001, BBA-GEN SUBJECTS, V1528, P167, DOI 10.1016/S0304-4165(01)00189-1; Rudolph AE, 2001, J BIOL CHEM, V276, P5123, DOI 10.1074/jbc.M006961200; SEJIMA H, 1990, BIOCHEM BIOPH RES CO, V171, P661, DOI 10.1016/0006-291X(90)91197-Z; SMIRNOV MD, 1994, J BIOL CHEM, V269, P816; STENFLO J, 1991, BLOOD, V78, P1637; Yang LK, 2004, BLOOD, V104, P1753, DOI 10.1182/blood-2004-03-1092; Yang LK, 2002, BIOCHEMISTRY-US, V41, P6149, DOI 10.1021/bi015899r; Yin ZF, 2000, P NATL ACAD SCI USA, V97, P6734, DOI 10.1073/pnas.120081897	39	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32722	32728		10.1074/jbc.M505517200	http://dx.doi.org/10.1074/jbc.M505517200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16079143	Green Accepted, hybrid			2022-12-27	WOS:000231920300022
J	Kumar, S; Roychowdhury, A; Ember, B; Wang, Q; Guan, RJ; Mariuzza, RA; Boons, GJ				Kumar, S; Roychowdhury, A; Ember, B; Wang, Q; Guan, RJ; Mariuzza, RA; Boons, GJ			Selective recognition of synthetic lysine and meso-diaminopimelic acid-type peptidoglycan fragments by human peptidoglycan recognition proteins I alpha and S	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTORS; GRAM-POSITIVE BACTERIA; L-ALANINE AMIDASE; INNATE IMMUNITY; DROSOPHILA; BINDING; NOD1; INFLAMMATION; TECHNOLOGY; ACTIVATION	The interactions of a range of synthetic peptidoglycan derivatives with PGRP-I alpha and PGRP-S have been studied in real-time using surface plasmon resonance. A dissociation constant of K-D = 62 mu M was obtained for the interaction of peptidoglycan recognition protein (PGRP)-I alpha with the lysine-containing muramyl pentapeptide ( compound 6). The normalized data for the lysine-containing muramyl tetra- ( compound 5) and pentapeptide ( compound 6) showed that these compounds have similar affinities, whereas a much lower affinity for muramyl tripeptide ( compound 3) was measured. Similar affinities were obtained when the lysine moiety of the muramyl peptides was replaced by meso-diaminopimelic acid (DAP). Furthermore, the compounds that contained only a stem peptide ( pentapeptide, compound 1) and (DAP-PP, compound 2) as well as muramyldipeptide ( compound 3) exhibited no binding indicating that the muramyltripeptide ( compound 4) is the smallest peptidoglycan fragment that can be recognized by PGRP-I alpha. Surprisingly, PGRP-S derived significantly higher affinities for the DAP-containing fragments to similar lysine-containing derivatives, and the following dissociation constants were measured: muramylpentapeptide-DAP, K-D = 104 nM; muramyltetrapeptide-DAP, 92.4 nM; and muramyltripeptide-DAP, 326 nM. The binding profiles were rationalized by using a recently reported x-ray crystal structure of PGRP-I alpha with the lysine-containing muramyltripeptide (4).	Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, WM Keck Lab Struct Biol, Rockville, MD 20850 USA	University System of Georgia; University of Georgia; University System of Maryland; University of Maryland Baltimore	Mariuzza, RA (corresponding author), Univ Georgia, Complex Carbohydrate Res Ctr, 315 Riverbend Rd, Athens, GA 30602 USA.	mariuzza@carb.nist.gov; gjboons@ccrc.uga.edu	Boons, Geert-Jan P H/J-3211-2016	Boons, Geert-Jan P H/0000-0003-3111-5954	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047990, R01AI065612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065248] Funding Source: NIH RePORTER; NIAID NIH HHS [AI47990, AI065612] Funding Source: Medline; NIGMS NIH HHS [GM065248] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beutler B, 2003, J LEUKOCYTE BIOL, V74, P479, DOI 10.1189/jlb.0203082; Beutler B, 2004, MOL IMMUNOL, V40, P845, DOI 10.1016/j.molimm.2003.10.005; Cannon MJ, 2004, ANAL BIOCHEM, V330, P98, DOI 10.1016/j.ab.2004.02.027; Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; Chamaillard M, 2003, CELL MICROBIOL, V5, P581, DOI 10.1046/j.1462-5822.2003.00304.x; Check W, 2004, ASM NEWS, V70, P317; CHENG XD, 1994, P NATL ACAD SCI USA, V91, P4034, DOI 10.1073/pnas.91.9.4034; Choe KM, 2002, SCIENCE, V296, P359, DOI 10.1126/science.1070216; Chowdhury AR, 2005, TETRAHEDRON LETT, V46, P1675, DOI 10.1016/j.tetlet.2005.01.062; Chowdhury AR, 2002, TETRAHEDRON LETT, V43, P7805; Dziarski R, 2003, BLOOD, V102, P689, DOI 10.1182/blood-2002-12-3853; Dziarski R, 2004, MOL IMMUNOL, V40, P877, DOI 10.1016/j.molimm.2003.10.011; Gelius E, 2003, BIOCHEM BIOPH RES CO, V306, P988, DOI 10.1016/S0006-291X(03)01096-9; Girardin SE, 2003, J BIOL CHEM, V278, P41702, DOI 10.1074/jbc.M307198200; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; Guan RJ, 2004, P NATL ACAD SCI USA, V101, P17168, DOI 10.1073/pnas.0407856101; Guan RJ, 2004, J BIOL CHEM, V279, P31873, DOI 10.1074/jbc.M404920200; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Kaneko T, 2004, IMMUNITY, V20, P637, DOI 10.1016/S1074-7613(04)00104-9; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Leulier F, 2003, NAT IMMUNOL, V4, P478, DOI 10.1038/ni922; Lien E., 2002, CRIT CARE MED, V30, P1; Liu C, 2001, J BIOL CHEM, V276, P34686, DOI 10.1074/jbc.M105566200; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Mellroth P, 2003, J BIOL CHEM, V278, P7059, DOI 10.1074/jbc.M208900200; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; O'Neill LAJ, 2004, TRENDS IMMUNOL, V25, P687, DOI 10.1016/j.it.2004.10.005; O'Neill LAJ, 2004, SCIENCE, V303, P1481, DOI 10.1126/science.1096113; Pasare C, 2003, CURR OPIN IMMUNOL, V15, P677, DOI 10.1016/j.coi.2003.09.002; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; Sarkar SN, 2004, NAT STRUCT MOL BIOL, V11, P1060, DOI 10.1038/nsmb847; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; Schmitz F, 2004, EUR J IMMUNOL, V34, P2863, DOI 10.1002/eji.200425228; SIEBER P, 1987, TETRAHEDRON LETT, V28, P2107, DOI 10.1016/S0040-4039(00)96055-6; Travassos LH, 2004, EMBO REP, V5, P1000, DOI 10.1038/sj.embor.7400248; Tsan MF, 2004, J LEUKOCYTE BIOL, V76, P514, DOI 10.1189/jlb.0304127; Tydell CC, 2002, J BIOL CHEM, V277, P19658, DOI 10.1074/jbc.M200659200; Van Amersfoort ES, 2003, CLIN MICROBIOL REV, V16, P379, DOI 10.1128/CMR.16.3.379-414.2003; Wang ZM, 2003, J BIOL CHEM, V278, P49044, DOI 10.1074/jbc.M307758200; Werner T, 2003, J BIOL CHEM, V278, P26319, DOI 10.1074/jbc.C300184200; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772	45	45	46	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37005	37012		10.1074/jbc.M506385200	http://dx.doi.org/10.1074/jbc.M506385200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16129677	hybrid			2022-12-27	WOS:000232901800058
J	Coblitz, B; Shikano, S; Wu, M; Gabelli, SB; Cockrell, LM; Spieker, M; Hanyu, Y; Fu, H; Amzel, LM; Li, M				Coblitz, B; Shikano, S; Wu, M; Gabelli, SB; Cockrell, LM; Spieker, M; Hanyu, Y; Fu, H; Amzel, LM; Li, M			C-terminal recognition by 14-3-3 proteins for surface expression of membrane receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							14-3-3 PROTEINS; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; RAF-1 KINASE; POTASSIUM CHANNELS; CYTOPLASMIC DOMAIN; BINDING; PHOSPHORYLATION; TRAFFICKING; TRANSPORT	Diverse functions of 14-3-3proteins are directly coupled to their ability to interact with targeted peptide substrates. RSX(pS/pT) XP and RX Phi X(pS/pT) XP are two canonical consensus binding motifs for 14-3-3 proteins representing the two common binding modes, modes I and II, between 14-3-3 and internal peptides. Using a genetic selection, we have screened a random peptide library and identified a group of C-terminal motifs, termed SWTY, capable of overriding an endoplasmic reticulum localization signal and redirecting membrane proteins to cell surface. Here we report that the C-terminal SWTY motif, although different from mode I and II consensus, binds tightly to 14-3-3 proteins with a dissociation constant (K-D) of 0.17 mu M, comparable with that of internal canonical binding peptides. We show that all residues but proline in -SWTX-COOH are compatible for the interaction and surface expression. Because SWTY-like sequences have been found in native proteins, these results support a broad significance of 14-3-3 interaction with protein C termini. The C-terminal binding consensus, mode III, represents an expansion of the repertoire of 14-3-3-targeted sequences.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, High Throughput Biol Ctr, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA; Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Natl Inst Adv Ind Sci & Technol, Inst Biol Resources & Funct, Tsukuba, Ibaraki 3058566, Japan	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Emory University; National Institute of Advanced Industrial Science & Technology (AIST)	Shikano, S (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, BRB311,733 N Broadway, Baltimore, MD 21205 USA.	minli@jhmi.edu	Gabelli, Sandra B/A-3705-2008; Wu, Meng/F-3958-2010; Hanyu, Yoshiro/M-2573-2018	Gabelli, Sandra B/0000-0003-1205-5204; Hanyu, Yoshiro/0000-0002-3718-1920; Wu, Meng/0000-0003-2222-0736; Amzel, L. Mario/0000-0002-0129-9572	NIGMS NIH HHS [GM53165, GM70959, GM60033] Funding Source: Medline; NINDS NIH HHS [NS33324] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060033, R29GM053165, R01GM053165, R01GM070959] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033324, R55NS033324] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aitken A, 2002, BIOCHEM SOC T, V30, P351, DOI 10.1042/bst0300351; Andrews RK, 1998, BIOCHEMISTRY-US, V37, P638, DOI 10.1021/bi970893g; Dougherty MK, 2004, J CELL SCI, V117, P1875, DOI 10.1242/jcs.01171; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Du XP, 1996, J BIOL CHEM, V271, P7362, DOI 10.1074/jbc.271.13.7362; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Fuglsang AT, 2003, J BIOL CHEM, V278, P42266, DOI 10.1074/jbc.M306707200; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Ganguly S, 2005, P NATL ACAD SCI USA, V102, P1222, DOI 10.1073/pnas.0406871102; GELPERIN D, 1995, P NATL ACAD SCI USA, V92, P11539, DOI 10.1073/pnas.92.25.11539; Harris BZ, 2001, BIOCHEMISTRY-US, V40, P5921, DOI 10.1021/bi010142l; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Ma D, 2002, CURR OPIN NEUROBIOL, V12, P287, DOI 10.1016/S0959-4388(02)00319-7; Moore BE, 1967, PHYSL BIOCH ASPECTS, P343; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; O'Kelly I, 2002, CELL, V111, P577, DOI 10.1016/S0092-8674(02)01040-1; Rajan S, 2002, J PHYSIOL-LONDON, V545, P13, DOI 10.1113/jphysiol.2002.027052; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Roberts RL, 1997, CELL, V89, P1055, DOI 10.1016/S0092-8674(00)80293-7; Shikano S, 2003, P NATL ACAD SCI USA, V100, P5783, DOI 10.1073/pnas.1031748100; SHIKANO S, 2005, NAT CELL BIOL; VANHEUSDEN GPH, 1995, EUR J BIOCHEM, V229, P45; Wang BC, 1999, BIOCHEMISTRY-US, V38, P12499, DOI 10.1021/bi991353h; Wang HN, 1998, J BIOL CHEM, V273, P16297, DOI 10.1074/jbc.273.26.16297; Wurtele M, 2003, EMBO J, V22, P987, DOI 10.1093/emboj/cdg104; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yip-Schneider MT, 2000, BIOCHEM J, V351, P151, DOI 10.1042/0264-6021:3510151; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717	32	71	73	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36263	36272		10.1074/jbc.M507559200	http://dx.doi.org/10.1074/jbc.M507559200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16123035	hybrid			2022-12-27	WOS:000232726900059
J	Geddie, ML; O'Loughlin, TL; Woods, KK; Matsumura, I				Geddie, ML; O'Loughlin, TL; Woods, KK; Matsumura, I			Rational design of p53, an intrinsically unstructured protein, for the fabrication of novel molecular sensors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDASE; HIV-1 PROTEASE; LETHAL FACTOR; BINDING-SITE; DNA; COMPLEMENTATION; SPECIFICITY; COMPLEXES; PURIFICATION; RECOGNITION	The dominant paradigm of protein engineering is structure based site-directed mutagenesis. This rational approach is generally more effective for the engineering of local properties, such as substrate specificity, than global ones such as allostery. Previous workers have modified normally unregulated reporter enzymes, including beta-galactosidase, alkaline phosphatase, and beta-lactamase, so that the engineered versions are activated (up to 4-fold) by monoclonal antibodies. A reporter that could easily be "reprogrammed" for the facile detection of novel effectors (binding or modifying activities) would be useful in high throughput screens for directed evolution or drug discovery. Here we describe a straightforward and general solution to this potentially difficult design problem. The transcription factor p53 is normally regulated by a variety of post-translational modifications. The insertion of peptides into intrinsically unstructured domains of p53 generated variants that were activated up to 100-fold by novel effectors (proteases or antibodies). An engineered p53 was incorporated into an existing high throughput screen for the detection of human immunodeficiency virus protease, an arbitrarily chosen novel effector. These results suggest that the molecular recognition properties of intrinsically unstructured proteins are relatively easy to engineer and that the absence of crystal structures should not deter the rational engineering of this class of proteins.	Emory Univ, Sch Med, Ctr Fundamental & Appl Mol Evolut, Rollins Res Ctr,Dept Biochem, Atlanta, GA 30322 USA	Emory University	Matsumura, I (corresponding author), Emory Univ, Sch Med, Ctr Fundamental & Appl Mol Evolut, Rollins Res Ctr,Dept Biochem, Rm 4119,1510 Clifton Rd, Atlanta, GA 30322 USA.	imatsum@emory.edu	Matsumura, Ichiro/E-1985-2011		NIAID NIH HHS [R21 AI054602-02, 1 R21AI054602-01, R21 AI054602] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI054602] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahn J, 2001, NAT STRUCT BIOL, V8, P730, DOI 10.1038/nsb0901-730; Baker K, 2002, P NATL ACAD SCI USA, V99, P16537, DOI 10.1073/pnas.262420099; BAUM EZ, 1990, P NATL ACAD SCI USA, V87, P10023, DOI 10.1073/pnas.87.24.10023; Bell S, 2002, J MOL BIOL, V322, P917, DOI 10.1016/S0022-2836(02)00848-3; BERG JM, 2002, BIOCHEMISTRY-US, P266; Brannigan JA, 2002, NAT REV MOL CELL BIO, V3, P964, DOI 10.1038/nrm975; BRENNAN CA, 1995, P NATL ACAD SCI USA, V92, P5783, DOI 10.1073/pnas.92.13.5783; Drees BL, 1999, CURR OPIN CHEM BIOL, V3, P64, DOI 10.1016/S1367-5931(99)80012-X; Dueber JE, 2003, SCIENCE, V301, P1904, DOI 10.1126/science.1085945; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Feliu JX, 1998, FEBS LETT, V434, P23, DOI 10.1016/S0014-5793(98)00943-0; Feliu JX, 2002, BBA-PROTEIN STRUCT M, V1596, P212, DOI 10.1016/S0167-4838(02)00226-1; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Geddie ML, 2004, J BIOL CHEM, V279, P26462, DOI 10.1074/jbc.M401447200; HALL AR, 1995, ONCOGENE, V10, P561; Hansen S, 1996, J BIOL CHEM, V271, P3917; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Lee H, 2000, J BIOL CHEM, V275, P29426, DOI 10.1074/jbc.M003107200; Legendre D, 1999, NAT BIOTECHNOL, V17, P67, DOI 10.1038/5243; LI CJ, 1995, P NATL ACAD SCI USA, V92, P5461, DOI 10.1073/pnas.92.12.5461; Liu SH, 2005, NAT BIOTECHNOL, V23, P725, DOI 10.1038/nbt1091; Louis JM, 1999, J BIOL CHEM, V274, P23437, DOI 10.1074/jbc.274.33.23437; MATAYOSHI ED, 1990, SCIENCE, V247, P954, DOI 10.1126/science.2106161; Matsumura I, 1999, PROTEIN SCI, V8, P731; Michnick SW, 2003, CURR OPIN BIOTECH, V14, P610, DOI 10.1016/j.copbio.2003.10.014; Park S, 2000, PROTEIN EXPRES PURIF, V18, P293, DOI 10.1006/prep.2000.1208; Prabu-Jeyabalan M, 2002, STRUCTURE, V10, P369, DOI 10.1016/S0969-2126(02)00720-7; SINGH H, 1989, BIOTECHNIQUES, V7, P252; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Tompa P, 2003, BIOESSAYS, V25, P847, DOI 10.1002/bies.10324; Tompa P, 2005, FEBS LETT, V579, P3346, DOI 10.1016/j.febslet.2005.03.072; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Turk BE, 2004, NAT STRUCT MOL BIOL, V11, P60, DOI 10.1038/nsmb708; Vickrey JF, 2003, PROTEIN EXPRES PURIF, V28, P165, DOI 10.1016/S1046-5928(02)00650-2; Villaverde A, 2003, FEBS LETT, V554, P169, DOI 10.1016/S0014-5793(03)01160-8; Violin JD, 2003, J CELL BIOL, V161, P899, DOI 10.1083/jcb.200302125; Vocero-Akbani AM, 1999, NAT MED, V5, P29, DOI 10.1038/4710; Vucetic S, 2005, BIOINFORMATICS, V21, P137, DOI 10.1093/bioinformatics/bth476; Weinberg RL, 2004, J MOL BIOL, V341, P1145, DOI 10.1016/j.jmb.2004.06.071; Zhang WW, 2000, J BIOTECHNOL, V84, P79, DOI 10.1016/S0168-1656(00)00330-8	46	8	9	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35641	35646		10.1074/jbc.M508149200	http://dx.doi.org/10.1074/jbc.M508149200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16118206	Green Accepted, hybrid			2022-12-27	WOS:000232561200067
J	Tarran, R; Button, B; Picher, M; Paradiso, AM; Ribeiro, CM; Lazarowski, ER; Zhang, LQ; Collins, PL; Pickles, RJ; Fredberg, JJ; Boucher, RC				Tarran, R; Button, B; Picher, M; Paradiso, AM; Ribeiro, CM; Lazarowski, ER; Zhang, LQ; Collins, PL; Pickles, RJ; Fredberg, JJ; Boucher, RC			Normal and cystic fibrosis airway surface liquid homeostasis - The effects of phasic shear stress and viral infections	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY SYNCYTIAL VIRUS; TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMAN BRONCHIAL EPITHELIA; ION-TRANSPORT; MUCOCILIARY CLEARANCE; MUCUS CLEARANCE; LUNG-DISEASE; WILD-TYPE; PERICILIARY LIQUID; CHLORIDE SECRETION	Mammalian airways normally regulate the volume of a thin liquid layer, the periciliary liquid ( PCL), to facilitate the mucus clearance component of lung defense. Studies under standard ( static) culture conditions revealed that normal airway epithelia possess an adenosine-regulated pathway that blends Na+ absorption and Cl- secretion to optimize PCL volume. In cystic fibrosis ( CF), the absence of CF transmembrane conductance regulator results in a failure of adenosine regulation of PCL volume, which is predicted to initiate mucus stasis and infection. However, under conditions that mimic the phasic motion of the lung in vivo, ATP release into PCL was increased, CF ion transport was rebalanced, and PCL volume was restored to levels adequate for lung defense. This ATP signaling system was vulnerable, however, to insults that trigger CF bacterial infections, such as viral ( respiratory syncitial virus) infections, which up- regulated extracellular ATPase activity and abolished motion- dependent ATP regulation of CF PCL height. These studies demonstrate ( i) how the normal coordination of opposing ion transport pathways to maintain PCL volume is disrupted in CF, ( ii) the hitherto unknown role of phasic motion in regulating key aspects of normal and CF innate airways defense, and ( iii) that maneuvers directed at increasing motion- induced nucleotide release may be therapeutic in CF patients.	Univ N Carolina, Cyct Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA; NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Harvard T.H. Chan School of Public Health	Tarran, R (corresponding author), Univ N Carolina, Cyct Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA.	robert_tarran@med.unc.edu	Ribeiro, Carla Maria P/A-6955-2009; Zhang, Liqun/A-6861-2011; Fredberg, Jeffrey/M-9877-2019		NHLBI NIH HHS [HL60280, HL34322, R01 HL076303-01A2, R01 HL076303, P01 HL034322, R01 HL074158, P50 HL060280, HL074158] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074158, P50HL060280, R01HL076303, P01HL034322] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABMAN SH, 1988, J PEDIATR-US, V113, P826, DOI 10.1016/S0022-3476(88)80008-8; ALSUWAIDAN S, 1994, THORAX, V49, P1249, DOI 10.1136/thx.49.12.1249; Armstrong D, 1998, PEDIATR PULM, V26, P371, DOI 10.1002/(SICI)1099-0496(199812)26:6<371::AID-PPUL1>3.3.CO;2-E; BASSER PJ, 1989, J BIOMECH ENG-T ASME, V111, P288, DOI 10.1115/1.3168381; BENNETT WD, 1990, J APPL PHYSIOL, V69, P1670, DOI 10.1152/jappl.1990.69.5.1670; Boucher RC, 1999, J PHYSIOL-LONDON, V516, P631, DOI 10.1111/j.1469-7793.1999.0631u.x; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P271, DOI 10.1164/ajrccm.150.1.8025763; BRADLEY J, 2002, COCHRANE DATABASE SY; Burnstock G, 2002, CLIN MED, V2, P45, DOI 10.7861/clinmedicine.2-1-45; Caldwell RA, 2002, J GEN PHYSIOL, V119, P3, DOI 10.1085/jgp.119.1.3; Carpenter LR, 2002, BMC INFECT DIS, V2, DOI 10.1186/1471-2334-2-5; Clancy JP, 1999, AM J PHYSIOL-CELL PH, V276, pC361, DOI 10.1152/ajpcell.1999.276.2.C361; Davis IC, 2004, AM J PHYSIOL-LUNG C, V286, pL112, DOI 10.1152/ajplung.00218.2003; Devor DC, 2000, AM J PHYSIOL-CELL PH, V279, pC461, DOI 10.1152/ajpcell.2000.279.2.C461; Devor DC, 1999, AM J PHYSIOL-CELL PH, V276, pC827, DOI 10.1152/ajpcell.1999.276.4.C827; Dietl P, 2001, NEWS PHYSIOL SCI, V16, P239; Gibson RL, 2003, AM J RESP CRIT CARE, V168, P918, DOI 10.1164/rccm.200304-505SO; Gondor M, 1999, PEDIATR PULM, V28, P255, DOI 10.1002/(SICI)1099-0496(199910)28:4<255::AID-PPUL4>3.3.CO;2-B; Guggino WB, 2001, NAT MED, V7, P888, DOI 10.1038/90914; Guyot A, 2002, J PHYSIOL-LONDON, V545, P199, DOI 10.1113/jphysiol.2002.030148; Hebestreit A, 2001, AM J RESP CRIT CARE, V164, P443, DOI 10.1164/ajrccm.164.3.2007168; Hiatt PW, 1999, PEDIATRICS, V103, P619, DOI 10.1542/peds.103.3.619; Huang PB, 2001, P NATL ACAD SCI USA, V98, P14120, DOI 10.1073/pnas.241318498; Ji HL, 2000, J BIOL CHEM, V275, P27947; Joo NS, 2002, J BIOL CHEM, V277, P50710, DOI 10.1074/jbc.M208826200; KILBURN KH, 1968, AM REV RESPIR DIS, V98, P449; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; Knowles MR, 1997, J CLIN INVEST, V100, P2588, DOI 10.1172/JCI119802; Kunzelmann K, 2000, PFLUG ARCH EUR J PHY, V440, P193, DOI 10.1007/s004240000255; Lazarowski ER, 2004, J BIOL CHEM, V279, P36855, DOI 10.1074/jbc.M405367200; Lazarowski ER, 2000, J BIOL CHEM, V275, P31061, DOI 10.1074/jbc.M003255200; LAZAROWSKI ER, 1992, BRIT J PHARMACOL, V106, P774, DOI 10.1111/j.1476-5381.1992.tb14412.x; Lechner J F, 1985, J TISSUE CULT METHOD, V9, P43; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; Mastronarde JG, 1998, J INFECT DIS, V177, P1275, DOI 10.1086/515279; Matsui H, 1998, J CLIN INVEST, V102, P1125, DOI 10.1172/JCI2687; Matsui H, 2000, J CLIN INVEST, V105, P1419, DOI 10.1172/JCI4546; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; McShane D, 2004, EUR RESPIR J, V24, P95, DOI 10.1183/09031936.04.00097503; MILICEMI.J, 1966, J APPL PHYSIOL, V21, P749, DOI 10.1152/jappl.1966.21.3.749; Paradiso AM, 2001, J GEN PHYSIOL, V117, P53, DOI 10.1085/jgp.117.1.53; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; Picher M, 2000, AM J RESP CELL MOL, V23, P255, DOI 10.1165/ajrcmb.23.2.4088; Picher M, 2003, J BIOL CHEM, V278, P11256, DOI 10.1074/jbc.M208071200; PUCHELLE E, 1995, RESPIRATION, V62, P2; REGNIS JA, 1994, AM J RESP CRIT CARE, V150, P66, DOI 10.1164/ajrccm.150.1.8025774; REISMAN JJ, 1988, J PEDIATR-US, V113, P632, DOI 10.1016/S0022-3476(88)80370-6; Robinson M, 2002, PEDIATR PULM, V33, P293, DOI 10.1002/ppul.10079; SANTIS G, 1991, CLIN RADIOL, V44, P20, DOI 10.1016/S0009-9260(05)80220-X; Schneiderman-Walker J, 2000, J PEDIATR-US, V136, P304, DOI 10.1067/mpd.2000.103408; Song YL, 2001, J GEN PHYSIOL, V117, P573, DOI 10.1085/jgp.117.6.573; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Tarran R, 2001, J GEN PHYSIOL, V118, P223, DOI 10.1085/jgp.118.2.223; Tarran R, 2001, MOL CELL, V8, P149, DOI 10.1016/S1097-2765(01)00286-6; Tarran Robert, 2002, Methods Mol Med, V70, P479; Thiagarajah JR, 2004, FASEB J, V18, P875, DOI 10.1096/fj.03-1248fje; Thomas WE, 2002, CELL, V109, P913, DOI 10.1016/S0092-8674(02)00796-1; Verkman AS, 2001, AM J PHYSIOL-LUNG C, V281, pL306, DOI 10.1152/ajplung.2001.281.2.L306; Wine JJ, 1999, J CLIN INVEST, V103, P309, DOI 10.1172/JCI6222; Zhang LQ, 2002, J VIROL, V76, P5654, DOI 10.1128/JVI.76.11.5654-5666.2002; Zsembery A, 2004, J BIOL CHEM, V279, P10720, DOI 10.1074/jbc.M313391200	61	273	281	0	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35751	35759		10.1074/jbc.M505832200	http://dx.doi.org/10.1074/jbc.M505832200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16087672	Green Accepted, hybrid			2022-12-27	WOS:000232561200078
J	Zhang, XH; Li, PF; Bao, JY; Nicosia, SV; Wang, HG; Enkemann, SA; Bai, WL				Zhang, XH; Li, PF; Bao, JY; Nicosia, SV; Wang, HG; Enkemann, SA; Bai, WL			Suppression of death receptor-mediated apoptosis by 1,25-dihydroxyvitamin D-3 revealed by microarray analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARIAN-CANCER CELLS; VITAMIN-D-RECEPTOR; SQUAMOUS CARCINOMA-CELLS; GENE-EXPRESSION; PROSTATE-CANCER; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; ANALOG EB1089; LYSOPHOSPHATIDIC ACID; HUMAN KERATINOCYTES; GROWTH-INHIBITION	Recent studies suggest that growth inhibition by 1,25- dihydroxyvitamin D-3 represents an innovative approach to ovarian cancer therapy. To understand the molecular mechanism of 1,25- dihydroxyvitamin D-3 action, we profiled the hormone- induced changes in the transcriptome of ovarian cancer cells using microarray technology. More than 200 genes were identified to be regulated by 1,25-dihydroxyvitamin D-3. Reverse transcription- PCR analyses confirmed the regulation of a group of apoptosis- related genes, including the up- regulation of the decoy receptor that inhibits tumor necrosis factor- related apoptosis- inducing ligand ( TRAIL) action, TRAIL receptor 4, and the down- regulation of Fas, the receptor that mediates the action of Fas ligand. The regulation was further confirmed at the protein level. Consistent with the regulation of the death receptors, pretreatment with 1,25- dihydroxyvitamin D-3 decreased apoptosis induced by TRAIL and Fas ligand. Because persistent 1,25- dihydroxyvitamin D-3 treatment has been shown to induce apoptosis in ovarian cancer, the hormone appears to exert a dual effect on the death of ovarian cancer cells. Knockdown of TRAIL receptor 4 by RNA interference or ectopic expression of Fas relieved the suppressive effect of 1,25- dihydroxyvitamin D-3, showing that molecular manipulation of death receptors is a viable approach to overcome the protective effect of 1,25- dihydroxyvitamin D-3 on the apoptosis of ovarian cancer. These strategies may allow ovarian cancer patients to benefit from therapy with both 1,25- dihydroxyvitamin D-3 and ligands for death receptors, such as TRAIL, shown to selectively induce apoptosis in cancer but not normal cells.	Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; H Lee Moffitt Canc Ctr, Program Mol Oncol, Tampa, FL 33612 USA; H Lee Moffitt Canc Ctr, Program Drug Discovery, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute	Bai, WL (corresponding author), Univ S Florida, Coll Med, Dept Pathol, 12901 Bruce B Downs Blvd,MDC 11, Tampa, FL 33612 USA.	wbai@hsc.usf.edu	Wang, Hong-Gang/A-3018-2015; Bai, Wenlong/A-8977-2013	Wang, Hong-Gang/0000-0003-0551-0571; Bai, Wenlong/0000-0002-9536-0556	NATIONAL CANCER INSTITUTE [R01CA093666, R01CA111334] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA111334-01A1, R01 CA093666, 1R01 CA111334, R01 CA093666-02, R01 CA111334] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akutsu N, 2001, MOL ENDOCRINOL, V15, P1127, DOI 10.1210/me.15.7.1127; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; Barila D, 2003, MOL CELL BIOL, V23, P2790, DOI 10.1128/MCB.23.8.2790-2799.2003; Baudet C, 1996, J NEUROSCI RES, V46, P540, DOI 10.1002/(SICI)1097-4547(19961201)46:5<540::AID-JNR3>3.0.CO;2-J; Behrens P, 2003, APOPTOSIS, V8, P39, DOI 10.1023/A:1021644918117; Belcredito S, 2001, BRAIN RES REV, V37, P335, DOI 10.1016/S0165-0173(01)00138-2; Boyle BJ, 2001, J UROLOGY, V165, P1319, DOI 10.1016/S0022-5347(01)69892-6; Cippitelli M, 2002, J IMMUNOL, V168, P1154, DOI 10.4049/jimmunol.168.3.1154; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; De Haes P, 2003, J CELL BIOCHEM, V89, P663, DOI 10.1002/jcb.10540; Devesa SS, 1999, NIH PUBLICATION; Diker-Cohen T, 2003, ANN NY ACAD SCI, V1010, P350, DOI 10.1196/annals.1299.064; Duque G, 2004, BONE, V35, P57, DOI 10.1016/j.bone.2004.03.005; Fang XJ, 2000, ANN NY ACAD SCI, V905, P188; Gianfrancesco F, 1999, CYTOGENET CELL GENET, V84, P164, DOI 10.1159/000015247; Gurlek A, 2002, ENDOCR REV, V23, P763, DOI 10.1210/er.2001-0044; Guzey M, 2002, MOL CANCER THER, V1, P667; Hansen CM, 2001, J STEROID BIOCHEM, V77, P1, DOI 10.1016/S0960-0760(01)00033-4; Harbig J, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni027; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; HAVRILESKY LJ, 1995, CANCER RES, V55, P944; Hedlund TE, 1996, ENDOCRINOLOGY, V137, P1554, DOI 10.1210/en.137.5.1554; Jiang F, 2004, J BIOL CHEM, V279, P53213, DOI 10.1074/jbc.M410395200; Jiang F, 2003, J BIOL CHEM, V278, P48030, DOI 10.1074/jbc.M308430200; Johansen C, 2003, J INVEST DERMATOL, V120, P561, DOI 10.1046/j.1523-1747.2003.12095.x; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Krishnan AV, 2004, PROSTATE, V59, P243, DOI 10.1002/pros.20006; Lankat-Buttgereit B, 2004, MOL CELL ENDOCRINOL, V214, P149, DOI 10.1016/j.mce.2003.10.058; Li PF, 2004, J BIOL CHEM, V279, P25260, DOI 10.1074/jbc.M311052200; Lin R, 2002, MOL ENDOCRINOL, V16, P1243, DOI 10.1210/me.16.6.1243; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Loukinova E, 2000, ONCOGENE, V19, P3477, DOI 10.1038/sj.onc.1203687; Maurer U, 2001, J BIOL CHEM, V276, P3727, DOI 10.1074/jbc.M005292200; Miettinen S, 2004, INT J CANCER, V108, P367, DOI 10.1002/ijc.11520; MUIR CS, 1987, IARC SCI PUBLICATION, V88; O'Donovan N, 1999, CYTOGENET CELL GENET, V84, P39, DOI 10.1159/000015209; ONATE SA, 1995, SCIENCE, V270, P1354; Palmer HG, 2003, CANCER RES, V63, P7799; Rachez C, 2000, GENE, V246, P9, DOI 10.1016/S0378-1119(00)00052-4; ROSS TK, 1994, VITAM HORM, V49, P281; Shen ZZ, 2001, GYNECOL ONCOL, V83, P25, DOI 10.1006/gyno.2001.6357; So J, 2004, GYNECOL ONCOL, V95, P314, DOI 10.1016/j.ygyno.2004.08.001; Stewart LV, 2004, EXP BIOL MED, V229, P277, DOI 10.1177/153537020422900401; Suzuki T, 2000, INT J CANCER, V88, P992, DOI 10.1002/1097-0215(20001215)88:6<992::AID-IJC24>3.0.CO;2-9; Swami S, 2003, BREAST CANCER RES TR, V80, P49, DOI 10.1023/A:1024487118457; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang SH, 1999, ENDOCRINOLOGY, V140, P1649, DOI 10.1210/en.140.4.1649; WEBB AR, 1988, J CLIN ENDOCR METAB, V67, P373, DOI 10.1210/jcem-67-2-373; Weitsman GE, 2003, ANN NY ACAD SCI, V1010, P437, DOI 10.1196/annals.1299.079; Wood RJ, 2004, PHYSIOL GENOMICS, V17, P122, DOI 10.1152/physiolgenomics.00002.2003; Zhang XH, 2005, CLIN CANCER RES, V11, P323; Zou AH, 1997, J BIOL CHEM, V272, P19027, DOI 10.1074/jbc.272.30.19027	53	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35458	35468		10.1074/jbc.M506648200	http://dx.doi.org/10.1074/jbc.M506648200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16093247	Green Accepted, hybrid			2022-12-27	WOS:000232561200046
J	Tam, YYC; Fagarasanu, A; Fagarasanu, M; Rachubinski, RA				Tam, YYC; Fagarasanu, A; Fagarasanu, M; Rachubinski, RA			Pex3p initiates the formation of a preperoxisomal compartment from a subdomain of the endoplasmic reticulum in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXISOMAL MEMBRANE-PROTEINS; YARROWIA-LIPOLYTICA; HANSENULA-POLYMORPHA; FLUORESCENT PROTEIN; BIOGENESIS; YEAST; PEX19; DELETION; PATHWAYS; STRAINS	Peroxisomes are dynamic organelles that often proliferate in response to compounds that they metabolize. Peroxisomes can proliferate by two apparent mechanisms, division of preexisting peroxisomes and de novo synthesis of peroxisomes. Evidence for de novo peroxisome synthesis comes from studies of cells lacking the peroxisomal integral membrane peroxin Pex3p. These cells lack peroxisomes, but peroxisomes can assemble upon reintroduction of Pex3p. The source of these peroxisomes has been the subject of debate. Here, we show that the amino-terminal 46 amino acids of Pex3p of Saccharomyces cerevisiae target to a subdomain of the endoplasmic reticulum and initiate the formation of a preperoxisomal compartment for de novo peroxisome synthesis. In vivo video microscopy showed that this preperoxisomal compartment can import both peroxisomal matrix and membrane proteins leading to the formation of bona fide peroxisomes through the continued activity of full-length Pex3p. Peroxisome formation from the preperoxisomal compartment depends on the activity of the genes PEX14 and PEX19, which are required for the targeting of peroxisomal matrix and membrane proteins, respectively. Our findings support a direct role for the endoplasmic reticulum in de novo peroxisome formation.	Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada	University of Alberta	Rachubinski, RA (corresponding author), Univ Alberta, Dept Cell Biol, Med Sci Bldg 5-14, Edmonton, AB T6G 2H7, Canada.	rick.rachubinski@ualberta.ca						Adames NR, 2001, J CELL BIOL, V153, P159, DOI 10.1083/jcb.153.1.159; AITCHISON JD, 1992, YEAST, V8, P721, DOI 10.1002/yea.320080905; Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; Baerends RJS, 1996, J BIOL CHEM, V271, P8887, DOI 10.1074/jbc.271.15.8887; Bascom RA, 2003, MOL BIOL CELL, V14, P939, DOI 10.1091/mbc.E02-10-0633; Bevis BJ, 2002, NAT CELL BIOL, V4, P750, DOI 10.1038/ncb852; Brachmann CB, 1998, YEAST, V14, P115; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Dilworth DJ, 2001, J CELL BIOL, V153, P1465, DOI 10.1083/jcb.153.7.1465; Eckert JH, 2003, REV PHYSIOL BIOCH P, V147, P75, DOI 10.1007/s10254-003-0007-z; Eitzen GA, 1996, J BIOL CHEM, V271, P20300, DOI 10.1074/jbc.271.34.20300; Eitzen GA, 1997, J CELL BIOL, V137, P1265, DOI 10.1083/jcb.137.6.1265; Fang Y, 2004, J CELL BIOL, V164, P863, DOI 10.1083/jcb.200311131; Geuze HJ, 2003, MOL BIOL CELL, V14, P2900, DOI 10.1091/mbc.E02-11-0734; Ghaedi K, 2000, MOL BIOL CELL, V11, P2085, DOI 10.1091/mbc.11.6.2085; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Gotte K, 1998, MOL CELL BIOL, V18, P616; Hammond AT, 2000, TRAFFIC, V1, P935, DOI 10.1034/j.1600-0854.2000.011203.x; Hettema EH, 2000, EMBO J, V19, P223, DOI 10.1093/emboj/19.2.223; HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; Lisenbee CS, 2003, PLANT PHYSIOL, V132, P870, DOI 10.1104/pp.103.019976; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116; Sacksteder KA, 2000, J CELL BIOL, V148, P931, DOI 10.1083/jcb.148.5.931; Salomons FA, 1997, FEBS LETT, V411, P133, DOI 10.1016/S0014-5793(97)00679-0; Scholz O, 2000, EUR J BIOCHEM, V267, P1565, DOI 10.1046/j.1432-1327.2000.01170.x; SIKORSKI RS, 1989, GENETICS, V122, P19; Smith JJ, 2002, J CELL BIOL, V158, P259, DOI 10.1083/jcb.200204059; South ST, 2000, J CELL BIOL, V149, P1345, DOI 10.1083/jcb.149.7.1345; South ST, 1999, J CELL BIOL, V144, P255, DOI 10.1083/jcb.144.2.255; South ST, 2001, P NATL ACAD SCI USA, V98, P12027, DOI 10.1073/pnas.221289498; Tabak HF, 1999, TRENDS CELL BIOL, V9, P447, DOI 10.1016/S0962-8924(99)01650-5; Tam YYC, 2002, MOL BIOL CELL, V13, P2681, DOI 10.1091/mbc.E02-02-0117; Titorenko VI, 2000, J CELL BIOL, V148, P29, DOI 10.1083/jcb.148.1.29; Titorenko VI, 1997, MOL CELL BIOL, V17, P5210, DOI 10.1128/MCB.17.9.5210; Titorenko VI, 2001, NAT REV MOL CELL BIO, V2, P357, DOI 10.1038/35073063; Voorn-Brouwer T, 2001, J CELL SCI, V114, P2199	38	132	134	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34933	34939		10.1074/jbc.M506208200	http://dx.doi.org/10.1074/jbc.M506208200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16087670	hybrid			2022-12-27	WOS:000232403900066
J	Tiesong, SS; Joseph, J; Hillard, CJ; Kalyanaraman, B				Tiesong, SS; Joseph, J; Hillard, CJ; Kalyanaraman, B			Death-associated protein kinase as a sensor of mitochondrial membrane potential - Role of lysosome in mitochondrial toxin-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUNTINGTONS-DISEASE; PARKINSONS-DISEASE; DAP-KINASE; TRANSPORT; APOPTOSIS; CHAIN; IRON; NEURODEGENERATION; ANTIOXIDANT; OXIDATION	We have investigated here the mechanism of dephosphorylation and activation of death-associated protein kinase ( DAPK) and the role of lysosome in neuroblastoma cells (SH-SY5Y) treated with mitochondrial toxins, such as MPP+ and rotenone. Mitochondrial respiratory chain inhibitors and uncouplers decreased mitochondrial membrane potential leading to DAPK dephosphorylation and activation. The class III phosphoinositide 3-kinase inhibitors attenuated DAPK dephosphorylation induced by mitochondrial toxins. Complex I inhibition by mitochondrial toxins ( e. g. MPP+) resulted in mitochondrial swelling and lysosome reduction. Inhibition of class III phosphoinositide 3-kinase attenuated MPP+-induced lysosome reduction and cell death. The role of DAPK as a sensor of mitochondrial membrane potential in mitochondrial diseases was addressed.	Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Free Rad Res Ctr, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin	Kalyanaraman, B (corresponding author), Med Coll Wisconsin, Dept Biophys, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	balarama@mcw.edu	Hillard, Cecilia J/O-6693-2018		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039958] Funding Source: NIH RePORTER; NINDS NIH HHS [NS39958, R01 NS039958] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Bizat N, 2003, J NEUROSCI, V23, P5020; Brookes PS, 2002, FREE RADICAL BIO MED, V33, P755, DOI 10.1016/S0891-5849(02)00901-2; BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; Cohen I, 2002, TRENDS CELL BIOL, V12, P293, DOI 10.1016/S0962-8924(02)02299-7; Connor KM, 2005, J BIOL CHEM, V280, P16916, DOI 10.1074/jbc.M410690200; Dan Z, 2005, FASEB J, V19, P845, DOI 10.1096/fj.04-2809fje; Davis RE, 1997, P NATL ACAD SCI USA, V94, P4526, DOI 10.1073/pnas.94.9.4526; De Vos KJ, 2003, MOL BIOL CELL, V14, P3636, DOI 10.1091/mbc.E02-10-0638; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Desai BN, 2002, P NATL ACAD SCI USA, V99, P4319, DOI 10.1073/pnas.261702698; Dhanasekaran A, 2004, J BIOL CHEM, V279, P37575, DOI 10.1074/jbc.M404003200; Di Paolo G, 2004, NATURE, V431, P415, DOI 10.1038/nature02896; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Gu M, 1996, ANN NEUROL, V39, P385, DOI 10.1002/ana.410390317; Gunter TE, 2004, FEBS LETT, V567, P96, DOI 10.1016/j.febslet.2004.03.071; Habermann A, 2001, J CELL SCI, V114, P229; Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094; Kalivendi SV, 2003, BIOCHEM J, V371, P151, DOI 10.1042/BJ20021525; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; Lenaz G, 2002, ANN NY ACAD SCI, V959, P199, DOI 10.1111/j.1749-6632.2002.tb02094.x; Li QY, 2001, J NEUROCHEM, V78, P746, DOI 10.1046/j.1471-4159.2001.00457.x; LIPSKY NG, 1981, J BIOL CHEM, V256, P8652; Lockwood AH, 2000, CURR OPIN NEUROL, V13, P687, DOI 10.1097/00019052-200012000-00013; Mazzio E, 2003, BRAIN RES, V962, P48, DOI 10.1016/S0006-8993(02)03695-8; Miller KE, 2004, J CELL SCI, V117, P2791, DOI 10.1242/jcs.01130; Muller FL, 2004, J BIOL CHEM, V279, P49064, DOI 10.1074/jbc.M407715200; Nakai M, 2003, EXP NEUROL, V179, P103, DOI 10.1006/exnr.2002.8056; NICKLAS WJ, 1992, ANN NY ACAD SCI, V648, P28, DOI 10.1111/j.1749-6632.1992.tb24521.x; Paraskeva E, 1996, FEBS LETT, V389, P40, DOI 10.1016/0014-5793(96)00574-1; PARKER WD, 1994, NEUROLOGY, V44, P1090, DOI 10.1212/WNL.44.6.1090; SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Shohat G, 2002, BBA-PROTEINS PROTEOM, V1600, P45, DOI 10.1016/S1570-9639(02)00443-0; Smith RAJ, 1999, EUR J BIOCHEM, V263, P709, DOI 10.1046/j.1432-1327.1999.00543.x; Storch A, 2000, BRAIN RES, V855, P67, DOI 10.1016/S0006-8993(99)02272-6; Stumvoll M, 2005, LANCET, V365, P1333, DOI 10.1016/S0140-6736(05)61032-X; Tanaka Y, 1998, CELL, V93, P1147, DOI 10.1016/S0092-8674(00)81459-2; van Gurp M, 2003, BIOCHEM BIOPH RES CO, V304, P487, DOI 10.1016/S0006-291X(03)00621-1; Verma M, 2003, NAT REV CANCER, V3, P789, DOI 10.1038/nrc1192; Wiedemann FR, 2002, J NEUROCHEM, V80, P616, DOI 10.1046/j.0022-3042.2001.00731.x; Wright AF, 2004, NAT GENET, V36, P1153, DOI 10.1038/ng1448; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Xue L, 2001, CURR BIOL, V11, P361, DOI 10.1016/S0960-9822(01)00100-2; Yamamoto M, 1999, J NEUROSCI RES, V58, P674, DOI 10.1002/(SICI)1097-4547(19991201)58:5<674::AID-JNR8>3.0.CO;2-3	45	34	39	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34644	34653		10.1074/jbc.M506466200	http://dx.doi.org/10.1074/jbc.M506466200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16085644	hybrid			2022-12-27	WOS:000232403900033
J	Galkin, A; Lu, XF; Dunaway-Mariano, D; Herzberg, O				Galkin, A; Lu, XF; Dunaway-Mariano, D; Herzberg, O			Crystal structures representing the Michaelis complex and the thiouronium reaction intermediate of Pseudomonas aeruginosa arginine deiminase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIMETHYLARGININE DIMETHYLAMINOHYDROLASE; ENZYME; AMIDINOTRANSFERASE; BIOSYNTHESIS; HYDROLYSIS; CATALYSIS; MECHANISM; SOFTWARE	L-Arginine deiminase (ADI) catalyzes the irreversible hydrolysis of L-arginine to citrulline and ammonia. In a previous report of the structure of apoADI from Pseudomonas aeruginosa, the four residues that form the catalytic motif were identified as Cys(406), His(278), Asp(280), and Asp(166). The function of Cys(406) in nucleophilic catalysis has been demonstrated by transient kinetic studies. In this study, the structure of the C406A mutant in complex with L-arginine is reported to provide a snapshot of the enzyme center dot substrate complex. Through the comparison of the structures of apoenzyme and substrate-bound enzyme, a substrate-induced conformational transition, which might play an important role in activity regulation, was discovered. Furthermore, the position of the guanidinium group of the bound substrate relative to the side chains of His(278), Asp(280), and Asp(166) indicated that these residues mediate multiple proton transfers. His(278) and Asp(280), which are positioned to activate the water nucleophile in the hydrolysis of the S-alkylthiouronium intermediate, were replaced with alanine to stabilize the intermediate for structure determination. The structures determined for the H278A and D280A mutants co-crystallized with L-arginine provide a snapshot of the S-alkylthiouronium adduct formed by attack of Cys406 on the guanidinium carbon of L-arginine followed by the elimination of ammonia. Asp280 and Asp166 engage in ionic interactions with the guanidinium group in the C406A ADI center dot L-arginine structure and might orient the reaction center and participate in proton transfer. Structure determination of D166A revealed the apoD166A ADI. The collection of structures is interpreted in the context of recent biochemical data to propose a model for ADI substrate recognition and catalysis.	Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA	University of New Mexico	Herzberg, O (corresponding author), Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, 9600 Gudelsky Dr, Rockville, MD 20850 USA.	osnat@carb.nist.gov		Herzberg, Osnat/0000-0003-2823-7627	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI059733] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028688, P01GM057890] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI59733] Funding Source: Medline; NIGMS NIH HHS [P01 GM57890, R01 GM28688] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arita K, 2004, NAT STRUCT MOL BIOL, V11, P777, DOI 10.1038/nsmb799; Beloussow K, 2002, CANCER LETT, V183, P155, DOI 10.1016/S0304-3835(01)00793-5; Bhattacharyya R, 2003, J PROTEOME RES, V2, P255, DOI 10.1021/pr025584d; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Das K, 2004, STRUCTURE, V12, P657, DOI 10.1016/j.str.2004.02.017; DeLano WL, 2002, PYMOL USERS MANUAL; Fritsche E, 1998, BIOCHEMISTRY-US, V37, P17664, DOI 10.1021/bi981949p; Galkin A, 2004, J BIOL CHEM, V279, P14001, DOI 10.1074/jbc.M313410200; Humm A, 1997, EMBO J, V16, P3373, DOI 10.1093/emboj/16.12.3373; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P941, DOI 10.1107/S0907444999001031; Knodler LA, 1998, J BIOL CHEM, V273, P4470, DOI 10.1074/jbc.273.8.4470; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leiper JM, 1999, BIOCHEM J, V343, P209, DOI 10.1042/0264-6021:3430209; Lu XF, 2004, J AM CHEM SOC, V126, P5374, DOI 10.1021/ja049543p; Murray-Rust J, 2001, NAT STRUCT BIOL, V8, P679, DOI 10.1038/90387; Nakayama-Hamada M, 2005, BIOCHEM BIOPH RES CO, V327, P192, DOI 10.1016/j.bbrc.2004.11.152; Stone EA, 2005, BIOCHEMISTRY-US, V44, P7069, DOI 10.1021/bi047407r; WEICKMANN JL, 1977, J BIOL CHEM, V252, P2615; Wheatley Denys N., 2002, Pathology and Oncology Research, V8, P18; Zuniga M, 2002, MOL PHYLOGENET EVOL, V25, P429, DOI 10.1016/S1055-7903(02)00277-4	20	63	65	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34080	34087		10.1074/jbc.M505471200	http://dx.doi.org/10.1074/jbc.M505471200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16091358	hybrid			2022-12-27	WOS:000232229700048
J	Kruse, O; Rupprecht, J; Bader, KP; Thomas-Hall, S; Schenk, PM; Finazzi, G; Hankamer, B				Kruse, O; Rupprecht, J; Bader, KP; Thomas-Hall, S; Schenk, PM; Finazzi, G; Hankamer, B			Improved photobiological H-2 production in engineered green algal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLAMYDOMONAS-REINHARDTII; NUCLEAR TRANSFORMATION; STATE TRANSITIONS; OXYGEN EVOLUTION; CLIMATE-CHANGE; LIGHT; FLUORESCENCE; HYDROGENASE; GENE; IRON	Oxygenic photosynthetic organisms use solar energy to split water (H2O) into protons (H+), electrons (e(-)), and oxygen. A select group of photosynthetic microorganisms, including the green alga Chlamydomonas reinhardtii, has evolved the additional ability to redirect the derived H+ and e(-) to drive hydrogen (H-2) production via the chloroplast hydrogenases HydA1 and A2 (H(2)ase). This process occurs under anaerobic conditions and provides a biological basis for solar-driven H-2 production. However, its relatively poor yield is a major limitation for the economic viability of this process. To improve H-2 production in Chlamydomonas, we have developed a new approach to increase H+ and e(-) supply to the hydrogenases. In a first step, mutants blocked in the state 1 transition were selected. These mutants are inhibited in cyclic e(-) transfer around photosystem I, eliminating possible competition for e(-) with H(2)ase. Selected strains were further screened for increased H-2 production rates, leading to the isolation of Stm6. This strain has a modified respiratory metabolism, providing it with two additional important properties as follows: large starch reserves ( i.e. enhanced substrate availability), and a low dissolved O-2 concentration (40% of the wild type (WT)), resulting in reduced inhibition of H2ase activation. The H-2 production rates of Stm6 were 5 - 13 times that of the control WT strain over a range of conditions ( light intensity, culture time, +/- uncoupler). Typically, similar to 540 ml of H-2 liter(-1) culture ( up to 98% pure) were produced over a 10-14-day period at a maximal rate of 4 ml h(-1) ( efficiency = similar to 5 times the WT). Stm6 therefore represents an important step toward the development of future solar-powered H-2 production systems.	Univ Bielefeld, Dept Biol 8, D-33501 Bielefeld, Germany; Inst Biol Physicochim, CNRS, UPR 1261, F-75005 Paris, France; Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia; Univ Queensland, Fac Biol & Chem Sci, St Lucia, Qld 4072, Australia	University of Bielefeld; Centre National de la Recherche Scientifique (CNRS); University of Queensland; University of Queensland	Kruse, O (corresponding author), Univ Bielefeld, Dept Biol 8, D-33501 Bielefeld, Germany.	olaf.kruse@uni-bielefeld.de	Kruse, Olaf/O-1127-2015; Hankamer, Ben D/C-9688-2015; Schenk, Peer/B-7879-2016	Hankamer, Ben D/0000-0001-9284-4929; Schenk, Peer/0000-0003-4878-3799; Kruse, Olaf/0000-0001-9874-382X; Thomas-Hall, Skye/0000-0002-4208-5992				ABRAHAM S, 2002, NATL HYDROGEN ENERGY; ADAMS MWW, 1990, BIOCHIM BIOPHYS ACTA, V1020, P115, DOI 10.1016/0005-2728(90)90044-5; ALLEN JF, 1981, NATURE, V291, P25, DOI 10.1038/291025a0; Antal TK, 2003, BBA-BIOENERGETICS, V1607, P153, DOI 10.1016/j.bbabio.2003.09.008; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; BENDALL DS, 1982, BIOCHIM BIOPHYS ACTA, V683, P119, DOI 10.1016/0304-4173(82)90008-8; BENNOUN P, 1970, BIOCHIM BIOPHYS ACTA, V216, P357, DOI 10.1016/0005-2728(70)90227-6; BONAVENTURA C, 1969, BIOCHIM BIOPHYS ACTA, V189, P366, DOI 10.1016/0005-2728(69)90168-6; BULTE L, 1990, BIOCHIM BIOPHYS ACTA, V1020, P72, DOI 10.1016/0005-2728(90)90095-L; BUTLER WL, 1978, ANNU REV PLANT PHYS, V29, P345, DOI 10.1146/annurev.pp.29.060178.002021; Cournac L, 2004, J BACTERIOL, V186, P1737, DOI 10.1128/JB.186.6.1737-1746.2003; DEBUCHY R, 1989, EMBO J, V8, P2803, DOI 10.1002/j.1460-2075.1989.tb08426.x; DEFFEYES KS, 2001, HUBBERTS PEAK IMPEND, P5; Depege N, 2003, SCIENCE, V299, P1572, DOI 10.1126/science.1081397; Engels A, 1997, BBA-PROTEIN STRUCT M, V1340, P33, DOI 10.1016/S0167-4838(97)00025-3; Finazzi G, 2003, EMBO J, V22, P807, DOI 10.1093/emboj/cdg081; Finazzi G, 2002, EMBO REP, V3, P280, DOI 10.1093/embo-reports/kvf047; Florin L, 2001, J BIOL CHEM, V276, P6125, DOI 10.1074/jbc.M008470200; Forestier M, 2003, EUR J BIOCHEM, V270, P2750, DOI 10.1046/j.1432-1033.2003.03656; FRANK K, 1995, PHOTOCHEM PHOTOBIOL, V61, P2, DOI 10.1111/j.1751-1097.1995.tb09237.x; Ghirardi ML, 2000, TRENDS BIOTECHNOL, V18, P506, DOI 10.1016/S0167-7799(00)01511-0; Gumpel Nicola J., 1994, Trends in Cell Biology, V4, P299, DOI 10.1016/0962-8924(94)90222-4; HANKAMER B, 2005, Patent No. 2005003024; HAPPE T, 1993, EUR J BIOCHEM, V214, P475, DOI 10.1111/j.1432-1033.1993.tb17944.x; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HELDT HW, 1973, BIOCHIM BIOPHYS ACTA, V314, P224, DOI 10.1016/0005-2728(73)90137-0; KINDLE KL, 1989, J CELL BIOL, V109, P2589, DOI 10.1083/jcb.109.6.2589; Kosourov S, 2003, PLANT CELL PHYSIOL, V44, P146, DOI 10.1093/pcp/pcg020; Kruse O, 1999, PHOTOSYNTH RES, V61, P43, DOI 10.1023/A:1006229308606; Lyon EJ, 2004, EUR J BIOCHEM, V271, P195, DOI 10.1046/j.1432-1033.2003.03920.x; Melis A, 2001, PLANT PHYSIOL, V127, P740, DOI 10.1104/pp.127.3.740; Melis A, 2000, PLANT PHYSIOL, V122, P127, DOI 10.1104/pp.122.1.127; MELIS A, 1999, P 1999 US DOE HYDR P, P1; MURATA N, 1969, BIOCHIM BIOPHYS ACTA, V172, P242, DOI 10.1016/0005-2728(69)90067-X; O'Neill BC, 2002, SCIENCE, V296, P1971, DOI 10.1126/science.1071238; Peters JW, 1999, CURR OPIN STRUC BIOL, V9, P670, DOI 10.1016/S0959-440X(99)00028-7; Peters JW, 1998, SCIENCE, V282, P1853, DOI 10.1126/science.282.5395.1853; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; Posewitz MC, 2004, PLANT CELL, V16, P2151, DOI 10.1105/tpc.104.021972; PURTON S, 1995, EUR J PHYCOL, V30, P141, DOI 10.1080/09670269500650901; RIFKIN J, 2002, HYDROGEN EC, P64; Schonfeld C, 2004, J BIOL CHEM, V279, P50366, DOI 10.1074/jbc.M408477200; Thomas CD, 2004, NATURE, V427, P145, DOI 10.1038/nature02121; Wollman FA, 2001, EMBO J, V20, P3623, DOI 10.1093/emboj/20.14.3623; Zhang LP, 2002, PLANTA, V214, P552, DOI 10.1007/s004250100660	45	247	261	4	66	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34170	34177		10.1074/jbc.M503840200	http://dx.doi.org/10.1074/jbc.M503840200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16100118	hybrid			2022-12-27	WOS:000232229700058
J	Vaughn, JP; Creacy, SD; Routh, ED; Joyner-Butt, C; Jenkins, GS; Pauli, S; Nagamine, Y; Akman, SA				Vaughn, JP; Creacy, SD; Routh, ED; Joyner-Butt, C; Jenkins, GS; Pauli, S; Nagamine, Y; Akman, SA			The DEXH protein product of the DHX36 gene is the major source of tetramolecular quadruplex G4-DNA resolving activity in HeLa cell lysates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA HELICASE-A; SMALL-MOLECULE; PROMOTER REGION; DNA-BINDING; IDENTIFICATION; TRANSCRIPTION; NUCLEOLIN; AFFINITY; ROLES	G4-DNA is a highly stable alternative DNA structure that can form spontaneously in guanine-rich regions of single-stranded DNA under physiological conditions. Since a number of biological processes create such single-stranded regions, G4-DNA occurrence must be regulated. To date, resolution of tetramolecular G4-DNA into single strands (G4-resolvase activity) has been observed only in recombinant RecQ DNA helicases. We previously reported that human cell lysates possess tetramolecular G4-DNA resolving activity (Harrington, C., Lan, Y., and Akman, S. (1997) J. Biol Chem. 272, 24631-24636). Here we report the first complete purification of a major non-RecQ, NTP-dependent G4-DNA resolving enzyme from human cell lysates. This enzyme is identified as the DEXH helicase product of gene DHX36 (also known as RHAU). G4-DNA resolving activity was captured from HeLa cell lysates on G4-DNA affinity beads and further purified by gel filtration chromatography. The DHX36 gene product was identified by mass spectrometric sequencing of a tryptic digest from the protein band on SDS-PAGE associated with activity. DHX36 was cloned within a His(6)-tagging vector, expressed, and purified from Escherichia coli. Inhibition and substrate resolution assays showed that recombinant DHX36 protein displayed robust, highly specific G4-DNA resolving activity. Immunodepletion of HeLa lysates by a monoclonal antibody to the DHX36 product removed ca. 77% of the enzyme from lysates and reduced G4-DNA resolving activity to 46.0 +/- 0.4% of control, demonstrating that DHX36 protein is responsible for the majority of tetramolecular G4-DNA resolvase activity.	Wake Forest Med Ctr, Dept Canc Biol, Winston Salem, NC 27157 USA; Wake Forest Med Ctr, Ctr Comprehens Canc, Winston Salem, NC 27157 USA; Novartis Res Fdn, Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University School of Medicine; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University School of Medicine; Friedrich Miescher Institute for Biomedical Research; Novartis	Akman, SA (corresponding author), Wake Forest Med Ctr, Dept Canc Biol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	sakman@wfubmc.edu		Routh, Eric/0000-0002-7371-1802	NATIONAL CANCER INSTITUTE [P30CA012197] Funding Source: NIH RePORTER; NCI NIH HHS [2-P30 CA12197] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Aratani S, 2001, MOL CELL BIOL, V21, P4460, DOI 10.1128/MCB.21.14.4460-4469.2001; Arthanari H, 2001, CHEM BIOL, V8, P221, DOI 10.1016/S1074-5521(01)00007-2; Chang CC, 2004, ANAL CHEM, V76, P4490, DOI 10.1021/ac049510s; Cheung I, 2002, NAT GENET, V31, P405, DOI [10.1038/ng928, 10.1038/417405a]; Dempsey LA, 1999, J BIOL CHEM, V274, P1066, DOI 10.1074/jbc.274.2.1066; Ding H, 2004, CELL, V117, P873, DOI 10.1016/j.cell.2004.05.026; Duquette ML, 2004, GENE DEV, V18, P1618, DOI 10.1101/gad.1200804; FRANTZ JD, 1995, J BIOL CHEM, V270, P9413, DOI 10.1074/jbc.270.16.9413; Fry M, 1999, J BIOL CHEM, V274, P12797, DOI 10.1074/jbc.274.18.12797; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; Fu JJ, 2002, ACTA BIOCH BIOPH SIN, V34, P655; Gowan SM, 2002, MOL PHARMACOL, V61, P1154, DOI 10.1124/mol.61.5.1154; Grand CL, 2004, P NATL ACAD SCI USA, V101, P6140, DOI 10.1073/pnas.0400460101; Hanakahi LA, 1999, J BIOL CHEM, V274, P15908, DOI 10.1074/jbc.274.22.15908; Harrigan JA, 2003, J BIOL CHEM, V278, P22686, DOI 10.1074/jbc.M213103200; Harrington C, 1997, J BIOL CHEM, V272, P24631, DOI 10.1074/jbc.272.39.24631; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Lew A, 2000, P NATL ACAD SCI USA, V97, P12508, DOI 10.1073/pnas.97.23.12508; LIU ZP, 1994, CELL, V77, P1083, DOI 10.1016/0092-8674(94)90447-2; Mergny JL, 1998, NAT MED, V4, P1366, DOI 10.1038/3949; Myohanen S, 2001, J BIOL CHEM, V276, P1634, DOI 10.1074/jbc.M004481200; Patel SD, 2004, BIOCHEMISTRY-US, V43, P13452, DOI 10.1021/bi048892t; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Rezler EM, 2003, CLIN CANCER RES, V9, p6124S; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; Siddiqui-Jain A, 2002, P NATL ACAD SCI USA, V99, P11593, DOI 10.1073/pnas.182256799; Simonsson T, 1998, NUCLEIC ACIDS RES, V26, P1167, DOI 10.1093/nar/26.5.1167; Sun DY, 2003, CLIN CANCER RES, V9, p6122S; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; Sun H, 2001, P NATL ACAD SCI USA, V98, P12444, DOI 10.1073/pnas.231479198; Tran H, 2004, MOL CELL, V13, P101, DOI 10.1016/S1097-2765(03)00481-7	33	127	132	3	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38117	38120		10.1074/jbc.C500348200	http://dx.doi.org/10.1074/jbc.C500348200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16150737	hybrid			2022-12-27	WOS:000233239800002
J	Chen, SJ; Beaton, D; Nguyen, N; Senekeo-Effenberger, K; Brace-Sinnokrak, E; Argikar, U; Remmel, RP; Trottier, J; Barbier, O; Ritter, JK; Tukey, RH				Chen, SJ; Beaton, D; Nguyen, N; Senekeo-Effenberger, K; Brace-Sinnokrak, E; Argikar, U; Remmel, RP; Trottier, J; Barbier, O; Ritter, JK; Tukey, RH			Tissue-specific, inducible, and hormonal control of the human UDP-glucuronosyltransferase-1 (UGT1) locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN UDP-GLUCURONOSYLTRANSFERASES; PREGNANE-X-RECEPTOR; HUMAN BILIRUBIN; HUMAN LIVER; AH RECEPTOR; TRANSCRIPTIONAL REGULATION; GENE-EXPRESSION; COMPLEX LOCUS; 1A LOCUS; GLUCURONIDATION	The human UDP-glucuronosyltransferase1(UGT1) locus spans nearly 200 kb on chromosome 2 and encodes nine UGT1A proteins that play a prominent role in drug and xenobiotic metabolism. Transgenic UGT1 (Tg-UGT1) mice have been created, and it has been demonstrated that tissue-specific and xenobiotic receptor control of the UGT1A genes is influenced through circulating humoral factors. In Tg-UGT1 mice, the UGT1A proteins are differentially expressed in the liver and gastrointestinal tract. Gene expression profiles confirmed that all of the UGT1A genes can be targeted for regulation by the pregnane X receptor activator pregnenolone-16 alpha-carbonitrile (PCN) or the Ah receptor ligand 2,3,7,8-tetrachlorodibenzop- dioxin ( TCDD). In addition, the selective induction of glucuronidation activity toward lamotrigine, ethinyl estradiol, chenodeoxycholic acid, and lithocholic acid by either PCN or TCDD in small intestine from Tg-UGT1 mice corresponded to expression of the locus in this tissue. Induction of UGT1A1 by PCN and TCDD is believed to be highly dependent upon glucocorticoids, because submicromolar concentrations of dexamethasone actively promote PCN and TCDD induction of UGT1A1 in Tg-UGT1 primary hepatocytes. The role of hormonal control of the UGT1 locus was further verified in pregnant and nursing Tg-UGT1 mice. Inmaternal 14-daypost-conception Tg-UGT1mice, liver UGT1A1, UGT1A4, and UGT1A6 were induced, with the levels returning to near normal by birth. However, maternal liver UGT1A4 and UGT1A6 were dramatically elevated and maintained after birth, indicating that these proteins may play a critical role in maternal metabolism during lactation. With expression of the UGT1 locus confirmed in a variety of mouse tissues, these results suggested that the Tg-UGT1 mice will be a useful model to examine the regulatory and functional properties of human glucuronidation.	Univ Calif San Diego, Dept Pharmacol, Lab Environm Toxicol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Laval, Fac Pharm, Quebec City, PQ G1K 7P4, Canada; Univ Laval, Ctr Hosp Univ Laval Res Ctr, Mol Endocrinol & Oncol Res Ctr, Quebec City, PQ G1K 7P4, Canada; Univ Minnesota, Coll Pharm, Dept Med Chem, Minneapolis, MN 55455 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Laval University; Laval University; University of Minnesota System; University of Minnesota Twin Cities; Virginia Commonwealth University	Tukey, RH (corresponding author), Univ Calif San Diego, Dept Pharmacol, Lab Environm Toxicol, Leichtag Biomed Res Bldg, La Jolla, CA 92093 USA.	rtukey@ucsd.edu	Remmel, Rory/N-2453-2015	Barbier, Olivier/0000-0002-3067-1134; Argikar, Upendra/0000-0002-0939-0813; Chen, Shujuan/0000-0002-1068-195X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007762, P42ES010337, R29ES007762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049135] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS016308] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES10337, ES07762] Funding Source: Medline; NIGMS NIH HHS [GM49135] Funding Source: Medline; NINDS NIH HHS [P50-NS16308] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barbier O, 2003, J BIOL CHEM, V278, P13975, DOI 10.1074/jbc.M300749200; Bock KW, 1998, ADV ENZYME REGUL, V38, P207, DOI 10.1016/S0065-2571(97)00013-7; Court MH, 2000, PHARMACOGENETICS, V10, P355, DOI 10.1097/00008571-200006000-00009; Dutton G.F., 1980, GLUCURONIDATION DRUG; EBNER T, 1993, MOL PHARMACOL, V43, P649; Gall WE, 1999, J STEROID BIOCHEM, V70, P101, DOI 10.1016/S0960-0760(99)00088-6; Gardner-Stephen D, 2004, DRUG METAB DISPOS, V32, P340, DOI 10.1124/dmd.32.3.340; Gentile S, 2005, ARCH WOMEN MENT HLTH, V8, P57, DOI 10.1007/s00737-005-0070-3; Gong QH, 2001, PHARMACOGENETICS, V11, P357, DOI 10.1097/00008571-200106000-00011; Granvil CP, 2003, DRUG METAB DISPOS, V31, P548, DOI 10.1124/dmd.31.5.548; Green MD, 1998, DRUG METAB DISPOS, V26, P860; GREEN MD, 1995, DRUG METAB DISPOS, V23, P299; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Harden Cynthia L., 2002, Epilepsy Curr, V2, P183, DOI 10.1046/j.1535-7597.2002.00068.x; Inoue H, 2005, DRUG METAB DISPOS, V33, P55, DOI 10.1124/dmd.104.001537; Ishihara T, 2001, J GASTROEN HEPATOL, V16, P678, DOI 10.1046/j.1440-1746.2001.02495.x; King CD, 1999, ARCH BIOCHEM BIOPHYS, V365, P156, DOI 10.1006/abbi.1999.1155; King CD, 2000, CURR DRUG METAB, V1, P143, DOI 10.2174/1389200003339171; Krasowski MD, 2005, MOL ENDOCRINOL, V19, P1720, DOI 10.1210/me.2004-0427; Krishnaswamy S, 2005, J PHARMACOL EXP THER, V313, P1340, DOI 10.1124/jpet.104.081968; Lepine J, 2004, J CLIN ENDOCR METAB, V89, P5222, DOI 10.1210/jc.2004-0331; LUQUITA MG, 1994, BIOCHEM PHARMACOL, V47, P1179, DOI 10.1016/0006-2952(94)90390-5; Luquita MG, 2001, J PHARMACOL EXP THER, V298, P49; Mackenzie PI, 2000, CLIN CHEM LAB MED, V38, P889, DOI 10.1515/CCLM.2000.129; MACKENZIE PI, 1995, REV BIOCHEM TOXICOL, V11, P29; MINERS JO, 1986, BRIT J CLIN PHARMACO, V22, P359, DOI 10.1111/j.1365-2125.1986.tb02901.x; Munzel PA, 2003, BIOCHEM PHARMACOL, V66, P841, DOI 10.1016/S0006-2952(03)00389-7; Munzel PA, 1999, DRUG METAB DISPOS, V27, P569; Munzel PA, 1998, ARCH BIOCHEM BIOPHYS, V350, P72, DOI 10.1006/abbi.1997.0485; Neville MC, 2002, J MAMMARY GLAND BIOL, V7, P49, DOI 10.1023/A:1015770423167; REMMEL RP, 1991, DRUG METAB DISPOS, V19, P630; Ritter JK, 1999, HEPATOLOGY, V30, P476, DOI 10.1002/hep.510300205; RITTER JK, 1992, J BIOL CHEM, V267, P3257; RITTER JK, 1991, J BIOL CHEM, V266, P1043; Strassburg CP, 1997, MOL PHARMACOL, V52, P212, DOI 10.1124/mol.52.2.212; Strassburg CP, 1998, MOL PHARMACOL, V54, P647; Strassburg CP, 1997, CANCER RES, V57, P2979; Strassburg CP, 1999, BIOCHEM J, V338, P489, DOI 10.1042/0264-6021:3380489; Strassburg CP, 1999, GASTROENTEROLOGY, V116, P149, DOI 10.1016/S0016-5085(99)70239-8; Strassburg CP, 1998, J BIOL CHEM, V273, P8719, DOI 10.1074/jbc.273.15.8719; Sugatani J, 2001, HEPATOLOGY, V33, P1232, DOI 10.1053/jhep.2001.24172; Sugatani J, 2005, MOL PHARMACOL, V67, P845, DOI 10.1124/mol.104.007161; Tran TA, 2002, NEUROLOGY, V59, P251, DOI 10.1212/WNL.59.2.251; Tukey RH, 2001, MOL PHARMACOL, V59, P405, DOI 10.1124/mol.59.3.405; Tukey RH, 2000, ANNU REV PHARMACOL, V40, P581, DOI 10.1146/annurev.pharmtox.40.1.581; Tukey RH, 2002, MOL PHARMACOL, V62, P446, DOI 10.1124/mol.62.3.446; Xie W, 2003, P NATL ACAD SCI USA, V100, P4150, DOI 10.1073/pnas.0438010100; Yueh MF, 2003, J BIOL CHEM, V278, P15001, DOI 10.1074/jbc.M300645200; Zheng Z, 2002, DRUG METAB DISPOS, V30, P397, DOI 10.1124/dmd.30.4.397; Zheng Z, 2001, JNCI-J NATL CANCER I, V93, P1411, DOI 10.1093/jnci/93.18.1411	50	97	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37547	37557		10.1074/jbc.M506683200	http://dx.doi.org/10.1074/jbc.M506683200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16155002	hybrid			2022-12-27	WOS:000233044500031
J	Madureira, PA; Matos, P; Soeiro, I; Dixon, LK; Simas, JP; Eric, WF				Madureira, PA; Matos, P; Soeiro, I; Dixon, LK; Simas, JP; Eric, WF			Murine gamma-herpesvirus 68 latency protein M2 binds to Vav signaling proteins and inhibits B-cell receptor-induced cell cycle arrest and apoptosis in WEHI-231 B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; ANTIGEN RECEPTOR; GAMMA; D2; HUMAN-HERPESVIRUS-8; EXPRESSION; GENE; GAMMAHERPESVIRUS-68; IDENTIFICATION; PROLIFERATION	The MHV-68 latent protein, M2, does not have homology to any known viral or cellular proteins, and its function is unclear. To define the role played by M2 during MHV-68 latency as well as the molecular mechanism involved, we used M2 as bait to screen a yeast two-hybrid mouse B-cell cDNA library. Vav1 was identified as an M2-interacting protein in two independent screenings. Subsequent yeast two-hybrid interaction studies showed that M2 also binds to Vav2, but not Vav3, and that three "PXXP" motifs located at the C terminus of M2 are important for this interaction. The interactions between M2 and Vav proteins were also confirmed in vivo in 293T and WEHI-231 B-cells by co-immunoprecipitation assays. Rac1/ GST-PAK "pull-down" experiments and Western blot analysis using a phospho-Vav antibody demonstrated that expression of M2 in WEHI-231 cells enhances Vav activity. We further showed in WEHI-231 cells that M2 expression promotes proliferation and survival and is associated with enhanced cyclin D2 and repressed p27(Kip1), p130, and Bim expression. Taken together, these experiments suggest that M2 might have an important role in disseminating the latent virus during the establishment and maintenance of latency by modulating B-cell receptor-mediated signaling events through Vav to promote B-cell activation, proliferation, and survival.	Hammersmith Hosp, Imperial Coll London, Dept Canc Med, Canc Res UK Labs, London W12 0NN, England; Inst Gulbenkian Ciencias, P-2780156 Oeiras, Portugal; Univ Lisbon, Fac Med, Inst Microbiol, P-1699 Lisbon, Portugal; Inst Nacl Saude Dr Ricardo Jorge, Ctr Genet Humana, P-1649016 Lisbon, Portugal; Inst Food Res, Inst Anim Hlth, Woking GU24 0NF, Surrey, England	Cancer Research UK; Imperial College London; Instituto Gulbenkian de Ciencia; Universidade de Lisboa; Instituto Nacional de Saude Dr. Ricardo Jorge; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; Quadram Institute	Madureira, PA (corresponding author), Hammersmith Hosp, Imperial Coll London, Dept Canc Med, Canc Res UK Labs, MRC Cyclotron Bldg,Du Cane Rd, London W12 0NN, England.	p.madureira@imperial.ac.uk; jpsimas@igc.gulbenkian.pt	Madureira, Patricia/F-4656-2012; Simas, J Pedro/M-5157-2013; Lam, Eric W-F/AAW-8566-2020; Madureira, Patricia A/C-9666-2013; Matos, Paulo/F-5245-2012; Dixon, Linda K/B-9063-2019; Matos, Paulo/P-3012-2019	Madureira, Patricia/0000-0002-4856-3908; Simas, J Pedro/0000-0001-6982-9253; Lam, Eric W-F/0000-0003-1274-3576; Madureira, Patricia A/0000-0002-4856-3908; Matos, Paulo/0000-0002-9379-9696; Matos, Paulo/0000-0002-9379-9696; Dixon, Linda/0000-0003-3845-3016	Biotechnology and Biological Sciences Research Council [BBS/E/I/00001003, BBS/E/I/00001040] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Addlagatta A, 2005, BIOCHEMISTRY-US, V44, P7166, DOI 10.1021/bi0501176; ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Banerji L, 2001, ONCOGENE, V20, P7352, DOI 10.1038/sj.onc.1204951; Caldwell RG, 1998, IMMUNITY, V9, P405, DOI 10.1016/S1074-7613(00)80623-8; Child ES, 2001, ONCOGENE, V20, P3311, DOI 10.1038/sj.onc.1204447; Choi JK, 2000, J VIROL, V74, P436, DOI 10.1128/JVI.74.1.436-446.2000; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Doody GM, 2000, EMBO J, V19, P6173, DOI 10.1093/emboj/19.22.6173; Dourmishev LA, 2003, MICROBIOL MOL BIOL R, V67, P175, DOI 10.1128/MMBR.67.2.175-212.2003; Eliopoulos AG, 1998, CURR BIOL, V8, pR196, DOI 10.1016/S0960-9822(98)70123-X; Esteban M, 2003, J GEN VIROL, V84, P1463, DOI 10.1099/vir.0.19014-0; Field N, 2003, J CELL SCI, V116, P3721, DOI 10.1242/jcs.00691; Flano E, 2003, J IMMUNOL, V170, P3828, DOI 10.4049/jimmunol.170.7.3828; Flano E, 2002, J EXP MED, V196, P1363, DOI 10.1084/jem.20020890; Fruehling S, 1998, J VIROL, V72, P7796, DOI 10.1128/JVI.72.10.7796-7806.1998; Glassford J, 2001, J BIOL CHEM, V276, P41040, DOI 10.1074/jbc.M105305200; GoddenKent D, 1997, J VIROL, V71, P4193, DOI 10.1128/JVI.71.6.4193-4198.1997; Hammerschmidt W, 2004, TRENDS MOL MED, V10, P331, DOI 10.1016/j.molmed.2004.05.006; Harada Hisashi, 2003, Rev Clin Exp Hematol, V7, P117; Jacoby MA, 2002, J VIROL, V76, P1790, DOI 10.1128/JVI.76.4.1790-1801.2002; Jia CYH, 2005, MOL CELL PROTEOMICS, V4, P1155, DOI 10.1074/mcp.M500108-MCP200; Klein E, 1999, IMMUNOL LETT, V68, P147, DOI 10.1016/S0165-2478(99)00044-9; Lam EWF, 1999, EUR J IMMUNOL, V29, P3380, DOI 10.1002/(SICI)1521-4141(199910)29:10<3380::AID-IMMU3380>3.0.CO;2-C; Lam EWF, 2000, J BIOL CHEM, V275, P3479, DOI 10.1074/jbc.275.5.3479; Li MT, 1997, J VIROL, V71, P1984, DOI 10.1128/JVI.71.3.1984-1991.1997; Longnecker R, 2000, EXP CELL RES, V257, P332, DOI 10.1006/excr.2000.4900; Lutz RJ, 2000, BIOCHEM SOC T, V28, P51, DOI 10.1042/bst0280051; Marques S, 2003, J VIROL, V77, P7308, DOI 10.1128/JVI.77.13.7308-7318.2003; Muralidhar S, 2000, J CLIN VIROL, V16, P203, DOI 10.1016/S1386-6532(99)00081-5; Nash AA, 2001, PHILOS T R SOC B, V356, P569, DOI 10.1098/rstb.2000.0779; Persons DA, 1998, BLOOD CELL MOL DIS, V24, P167, DOI 10.1006/bcmd.1998.0184; Pokrovskaja K, 2001, J GEN VIROL, V82, P345, DOI 10.1099/0022-1317-82-2-345; Rivas C, 2001, J VIROL, V75, P429, DOI 10.1128/JVI.75.1.429-438.2001; Scholle F, 2000, J VIROL, V74, P10681, DOI 10.1128/JVI.74.22.10681-10689.2000; Sharp TV, 2002, J VIROL, V76, P802, DOI 10.1128/JVI.76.2.802-816.2002; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Solvason N, 2000, INT IMMUNOL, V12, P631, DOI 10.1093/intimm/12.5.631; Stevenson PG, 2000, P NATL ACAD SCI USA, V97, P8455, DOI 10.1073/pnas.150240097; Swart R, 2000, J VIROL, V74, P10838, DOI 10.1128/JVI.74.22.10838-10845.2000; Tedford K, 2001, NAT IMMUNOL, V2, P548, DOI 10.1038/88756; Turner M, 2002, ADV EXP MED BIOL, V512, P29; Verma SC, 2003, FEMS MICROBIOL LETT, V222, P155, DOI 10.1016/S0378-1097(03)00261-1; Vigorito E, 2004, J IMMUNOL, V173, P3209, DOI 10.4049/jimmunol.173.5.3209; VIGORITO E, 2005, BLOOD; Willer DO, 2003, J VIROL, V77, P8310, DOI 10.1128/JVI.77.15.8310-8321.2003; Young LS, 2000, J CLIN PATHOL-MOL PA, V53, P238; Zimber-Strobl U, 2001, SEMIN CANCER BIOL, V11, P423, DOI 10.1006/scbi.2001.0409	48	20	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37310	37318		10.1074/jbc.M507478200	http://dx.doi.org/10.1074/jbc.M507478200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16150693	hybrid			2022-12-27	WOS:000233044500004
J	Abbasi, S; Su, B; Kellems, RE; Yang, JH; Xia, Y				Abbasi, S; Su, B; Kellems, RE; Yang, JH; Xia, Y			The essential role of MEKK3 signaling in angiotensin II-induced calcineurin/nuclear factor of activated T-cells activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC HYPERTROPHIC RESPONSE; SYNDROME CRITICAL REGION; GENE-EXPRESSION; INHIBITION; PROTEIN; PHOSPHATASE; PATHWAYS; FAMILY; NFAT; DEPHOSPHORYLATION	Calcineurin is a serine/threonine protein phosphatase that plays a critical role in many physiologic processes, such as T-cell activation, apoptosis, skeletal myocyte differentiation, and cardiac hypertrophy. We determined that active MEKK3 was capable of activating calcineurin/nuclear factor of activated T-cells ( NFAT) signaling in cardiac myocytes and reprogramming cardiac gene expression. In contrast, small interference RNA directed against MEKK3 and a dominant negative form of MEKK3 caused the reduction of NFAT activation in response to angiotensin II in cardiac myocytes. Genetic studies showed that MEKK3-deficient mouse embryo fibroblasts failed to activate calcineurin/NFAT in response to angiotensin II, a potent NFAT activator. Conversely, restoring MEKK3 to the MEKK3-deficient cells restored angiotensin II-mediated calcineurin/NFAT activation. We determined that angiotensin II induced MEKK3 phosphorylation. Thus, MEKK3 functions downstream of the AT1 receptor and is essential for calcineurin/ NFAT activation. Finally, we determined that MEKK3-mediated activation of calcineurin/ NFAT signaling was associated with the phosphorylation of modulatory calcineurin-interacting protein 1 at Ser(108) and Ser(112). Taken together, our studies reveal a previously unrecognized novel essential regulatory role of MEKK3 signaling in calcineurin/ NFAT activation.	Univ Texas, Hlth Sci Ctr, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Texas Childrens Hosp, Baylor Coll Med, Ctr Canc, Dept Pediat, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77054 USA	University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Xia, Y (corresponding author), Univ Texas, Hlth Sci Ctr, Sch Med, Dept Biochem & Mol Biol, 6431 Fannin St, Houston, TX 77030 USA.	Yang.Xia@uth.tmc.edu						Bueno OF, 2002, CARDIOVASC RES, V53, P806, DOI 10.1016/S0008-6363(01)00493-X; Bueno OF, 2002, P NATL ACAD SCI USA, V99, P4586, DOI 10.1073/pnas.072647999; Bushdid PB, 2003, CIRC RES, V92, P1305, DOI 10.1161/01.RES.0000077045.84609.9F; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Cheng JK, 2005, J BIOL CHEM, V280, P13477, DOI 10.1074/jbc.M414258200; Chien KR, 2002, CELL, V110, P153, DOI 10.1016/S0092-8674(02)00834-6; Chien KR, 1999, CELL, V98, P555, DOI 10.1016/S0092-8674(00)80043-4; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; FUENTES JJ, 1995, HUM MOL GENET, V4, P1935, DOI 10.1093/hmg/4.10.1935; Gorlach J, 2000, EMBO J, V19, P3618, DOI 10.1093/emboj/19.14.3618; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; Hilioti Z, 2004, GENE DEV, V18, P35, DOI 10.1101/gad.1159204; Hilioti Z, 2003, BIOCHEM BIOPH RES CO, V311, P1089, DOI 10.1016/S0006-291X(03)01515-8; Hill JA, 2002, J BIOL CHEM, V277, P10251, DOI 10.1074/jbc.M110722200; Huang QJ, 2004, NAT IMMUNOL, V5, P98, DOI 10.1038/ni1014; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kingsbury TJ, 2000, GENE DEV, V14, P1595; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; Leinwand LA, 2001, P NATL ACAD SCI USA, V98, P2947, DOI 10.1073/pnas.051033698; Lin X, 1999, J BIOL CHEM, V274, P36125, DOI 10.1074/jbc.274.51.36125; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; Liu SF, 1997, EMBO J, V16, P143, DOI 10.1093/emboj/16.1.143; Malleret G, 2001, CELL, V104, P675, DOI 10.1016/S0092-8674(01)00264-1; MARUTA H, 1991, J BIOL CHEM, V266, P11661; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Molkentin JD, 2004, CARDIOVASC RES, V63, P467, DOI 10.1016/j.cardiores.2004.01.021; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Olson EN, 1999, CIRC RES, V84, P623, DOI 10.1161/01.RES.84.6.623; Olson EN, 2000, CELL, V101, P689, DOI 10.1016/S0092-8674(00)80880-6; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; Rothermel BA, 2001, P NATL ACAD SCI USA, V98, P3328, DOI 10.1073/pnas.041614798; Rothermel BA, 2003, TRENDS CARDIOVAS MED, V13, P15, DOI 10.1016/S1050-1738(02)00188-3; Ryeom S, 2003, NAT IMMUNOL, V4, P874, DOI 10.1038/ni966; Sun L, 1998, IMMUNITY, V8, P703, DOI 10.1016/S1074-7613(00)80575-0; Thway TM, 2004, CIRCULATION, V110, P1612, DOI 10.1161/01.CIR.0000142855.68398.3A; Vega RB, 2003, P NATL ACAD SCI USA, V100, P669, DOI 10.1073/pnas.0237225100; Vega RB, 2002, J BIOL CHEM, V277, P30401, DOI 10.1074/jbc.M200123200; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963; Xia Y, 2003, J BIOL CHEM, V278, P13143, DOI 10.1074/jbc.M208500200; Xia Y, 2000, J BIOL CHEM, V275, P1855, DOI 10.1074/jbc.275.3.1855; Xu BE, 2004, J BIOL CHEM, V279, P7826, DOI 10.1074/jbc.M313465200; Yang J, 2000, CIRC RES, V87, pE61, DOI 10.1161/01.RES.87.12.e61; Yang JH, 2000, NAT GENET, V24, P309, DOI 10.1038/73550; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769	48	46	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36737	36746		10.1074/jbc.M506493200	http://dx.doi.org/10.1074/jbc.M506493200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16126726	hybrid			2022-12-27	WOS:000232901800027
J	Al-Abed, Y; Dabideen, D; Aljabari, B; Valster, A; Messmer, D; Ochani, M; Tanovic, M; Ochani, K; Bacher, M; Nicoletti, F; Metz, C; Pavlov, VA; Miller, EJ; Tracey, KJ				Al-Abed, Y; Dabideen, D; Aljabari, B; Valster, A; Messmer, D; Ochani, M; Tanovic, M; Ochani, K; Bacher, M; Nicoletti, F; Metz, C; Pavlov, VA; Miller, EJ; Tracey, KJ			ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENYLPYRUVATE TAUTOMERASE; CRYSTAL-STRUCTURE; RAT-LIVER; EXPRESSION; DISCOVERY; CYTOKINE; MEDIATOR	MIF is a proinflammatory cytokine that has been implicated in the pathogenesis of sepsis, arthritis, and other inflammatory diseases. Antibodies against MIF are effective in experimental models of inflammation, and there is interest in strategies to inhibit its deleterious cytokine activities. Here we identify a mechanism of inhibiting MIF pro-inflammatory activities by targeting MIF tautomerase activity. We designed small molecules to inhibit this tautomerase activity; a lead molecule, "ISO-1 (( S, R)3-( 4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester)," significantly inhibits the cytokine activity in vitro. Moreover, ISO-1 inhibits tumor necrosis factor release from macrophages isolated from LPS-treated wild type mice but has no effect on cytokine release from MIF-deficient macrophages. The therapeutic importance of the MIF inhibition by ISO-1 is demonstrated by the significant protection from sepsis, induced by cecal ligation and puncture in a clinically relevant time frame. These results identify ISO-1 as the first small molecule inhibitor of MIF proinflammatory activities with therapeutic implications and indicate the potential of the MIF active site as a novel target for therapeutic interventions in human sepsis.	N Shore Long Isl Jewish Inst Med Res, Med Chem Lab, Manhasset, NY 11030 USA; New York Sch Med, New York, NY 10016 USA; N Shore Long Isl Jewish Inst Med Res, Ctr Oncol & Cell Biol, Manhasset, NY 11030 USA; N Shore Long Isl Jewish Inst Med Res, Expt Immunol Lab, Manhasset, NY 11030 USA; N Shore Long Isl Jewish Inst Med Res, Lab Biomed Sci, Manhasset, NY 11030 USA; Univ Bonn, Dept Neurol, D-53105 Bonn, Germany; Univ Catania, Dept Biomed Sci, I-95021 Catania, Italy; N Shore Univ Hosp, N Shore Long Isl Jewish Inst Med Res, Med Biochem Lab, Manhasset, NY 11030 USA; N Shore Univ Hosp, N Shore Long Isl Jewish Inst Med Res, Dept Surg, Manhasset, NY 11030 USA	Northwell Health; Northwell Health; Northwell Health; Northwell Health; University of Bonn; University of Catania; Northwell Health; North Shore University Hospital; Northwell Health; North Shore University Hospital	Al-Abed, Y (corresponding author), N Shore Long Isl Jewish Inst Med Res, Med Chem Lab, 350 Community Dr, Manhasset, NY 11030 USA.	yalabed@nshs.edu	Nicoletti, Ferdinando/M-4428-2016	Nicoletti, Ferdinando/0000-0002-4570-8462; Tracey, Kevin J/0000-0003-1884-6314; Christine, Metz/0000-0002-1013-1691; Pavlov, Valentin/0000-0002-1994-2853	NIGMS NIH HHS [R01 GM062508] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062508] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341; Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200; Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262; Cvetkovic I, 2005, ENDOCRINOLOGY, V146, P2942, DOI 10.1210/en.2004-1393; Dios A, 2002, J MED CHEM, V45, P2410, DOI 10.1021/jm010534q; Lan HY, 2000, KIDNEY INT, V57, P499, DOI 10.1046/j.1523-1755.2000.00869.x; Lubetsky JB, 1999, BIOCHEMISTRY-US, V38, P7346, DOI 10.1021/bi990306m; Lubetsky JB, 2002, J BIOL CHEM, V277, P24976, DOI 10.1074/jbc.M203220200; Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599; Murakami H, 2002, CLIN EXP IMMUNOL, V128, P504, DOI 10.1046/j.1365-2249.2002.01838.x; Onodera S, 2000, J BIOL CHEM, V275, P444, DOI 10.1074/jbc.275.1.444; Riedemann NC, 2003, NAT MED, V9, P517, DOI 10.1038/nm0503-517; Roger T, 2001, NATURE, V414, P920, DOI 10.1038/414920a; Rosengren E, 1996, MOL MED, V2, P143, DOI 10.1007/BF03402210; Rosengren E, 1997, FEBS LETT, V417, P85, DOI 10.1016/S0014-5793(97)01261-1; Rosengren E, 1997, MELANOMA RES, V7, P517, DOI 10.1097/00008390-199712000-00012; Senter PD, 2002, P NATL ACAD SCI USA, V99, P144, DOI 10.1073/pnas.011569399; Sugimoto H, 1995, J STRUCT BIOL, V115, P331, DOI 10.1006/jsbi.1995.1057; Sun HW, 1996, P NATL ACAD SCI USA, V93, P5191, DOI 10.1073/pnas.93.11.5191; Suzuki M, 1996, NAT STRUCT BIOL, V3, P259, DOI 10.1038/nsb0396-259; Swope M, 1998, EMBO J, V17, P3534, DOI 10.1093/emboj/17.13.3534; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Xue CB, 1997, J MED CHEM, V40, P2064, DOI 10.1021/jm960799i; Zang XX, 2002, J BIOL CHEM, V277, P44261, DOI 10.1074/jbc.M204655200	25	238	257	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36541	36544		10.1074/jbc.C500243200	http://dx.doi.org/10.1074/jbc.C500243200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16115897	hybrid			2022-12-27	WOS:000232901800002
J	Chang, TC; Huang, CJ; Tam, K; Chen, SF; Tan, KT; Tsai, MS; Lin, TN; Shyue, SK				Chang, TC; Huang, CJ; Tam, K; Chen, SF; Tan, KT; Tsai, MS; Lin, TN; Shyue, SK			Stabilization of hypoxia-inducible factor-1 alpha by prostacyclin under prolonged hypoxia via reducing reactive oxygen species level in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL RESPIRATORY-CHAIN; HUMAN ERYTHROPOIETIN GENE; PROSTAGLANDIN E-2; FACTOR 1-ALPHA; NADPH OXIDASE; HIF-ALPHA; ACTIVATION; EXPRESSION; PATHWAY; CYCLOOXYGENASE-2	Hypoxia-inducible factor-1 (HIF-1) takes part in the transcriptional activation of hypoxia-responsive genes. HIF-1 alpha, a subunit of HIF-1, is rapidly degraded under normoxic conditions by the ubiquitin-proteosome system. Hypoxia up-regulates HIF-1 alpha by inhibiting its degradation, thereby allowing it to accumulate to high levels with 3 - 6 h of hypoxia treatment and decreasing thereafter. In vascular tissues, prostacyclin ( prostaglandin I-2 (PGI(2))) is a potent vasodilator and inhibitor of platelet aggregation and is known as a vasoprotective molecule. However, the role of PGI(2) in HIF-1 activation has not been studied. In the present study, we investigated the effect of PGI(2) on HIF-1 regulation in human umbilical vein endothelial cells under prolonged hypoxia ( 12 h). Augmentation of PGI2 via adenovirus-mediated gene transfer of both cyclooxygenase-1 and PGI(2) synthase activated HIF-1 by stabilizing HIF-1 alpha in cells under prolonged hypoxia or the hypoxia-normoxia transition but not under normoxia. Exogenous H2O2 abolished PGI(2)- and catalase-induced HIF-1 alpha up-regulation, which suggests that degradation of HIF-1 alpha under prolonged hypoxia is through a reactive oxygen species-dependent pathway. Moreover, PGI(2) attenuated NADPH oxidase activity by suppressing Rac1 and p47(phox) expression under hypoxia. These data demonstrate a novel function of PGI(2) in down-regulating reactive oxygen species production by attenuating NADPH oxidase activity, which stabilizes HIF-1 alpha in human umbilical vein endothelial cells exposed to prolonged hypoxia.	Natl Def Med Ctr, Grad Inst Life Sci, Taipei 114, Taiwan; Acad Sinica, Inst Biomed Sci, Div Cardiovasc, Taipei 115, Taiwan; Cathay Gen Hosp, Dept Obstet & Gynecol, Prenatal Diag Ctr, Taipei 106, Taiwan	National Defense Medical Center; Academia Sinica - Taiwan; Cathay General Hospital	Shyue, SK (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Acad Rd,Sec 2, Taipei 11529, Taiwan.	skshyue@ibms.sinica.edu.tw	Shyue, Song-Kun/Q-2583-2018; Lin, Teng-nan/Q-4566-2018	Shyue, Song-Kun/0000-0002-1057-8696; Lin, Teng-nan/0000-0002-4009-0798				Archer SL, 1999, P NATL ACAD SCI USA, V96, P7944, DOI 10.1073/pnas.96.14.7944; Blouin CC, 2004, BLOOD, V103, P1124, DOI 10.1182/blood-2003-07-2427; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; FANDREY J, 1994, BIOCHEM J, V303, P507, DOI 10.1042/bj3030507; FitzGerald GA, 2004, NEW ENGL J MED, V351, P1709, DOI 10.1056/NEJMp048288; Frigola J, 2005, ONCOGENE; Fukuda R, 2003, CANCER RES, V63, P2330; Gerald D, 2004, CELL, V118, P781, DOI 10.1016/j.cell.2004.08.025; GLEADLE JM, 1995, EUR J BIOCHEM, V234, P92, DOI 10.1111/j.1432-1033.1995.092_c.x; GOLDWASSER E, 1995, J BIOL CHEM, V270, P2628, DOI 10.1074/jbc.270.6.2628; Golpon HA, 2004, FASEB J, V18, P1716, DOI 10.1096/fj.04-1853fje; Goyal P, 2004, FREE RADICAL BIO MED, V36, P1279, DOI 10.1016/j.freeradbiomed.2004.02.071; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kiriyama M, 1997, BRIT J PHARMACOL, V122, P217, DOI 10.1038/sj.bjp.0701367; Kluckow M, 1999, ARCH DIS CHILD-FETAL, V80, pF34, DOI 10.1136/fn.80.1.F34; Kolsut Piotr, 2003, Kardiol Pol, V59, P373; Kumar P, 2004, J BIOL CHEM, V279, P43352, DOI 10.1074/jbc.M405777200; Lin H, 2002, CIRCULATION, V105, P1962, DOI 10.1161/01.CIR.0000015365.49180.05; Lin SJ, 2004, J MOL CELL CARDIOL, V36, P129, DOI 10.1016/j.yjmcc.2003.10.011; Liou JY, 2001, J BIOL CHEM, V276, P34975, DOI 10.1074/jbc.M105946200; Liu XH, 2002, J BIOL CHEM, V277, P50081, DOI 10.1074/jbc.M201095200; Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958; MATSUMOTO M, 1992, ANESTH ANALG, V75, P773; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; Mukherjee D, 2001, JAMA-J AM MED ASSOC, V286, P954, DOI 10.1001/jama.286.8.954; Muzaffar S, 2004, BRIT J PHARMACOL, V141, P488, DOI 10.1038/sj.bjp.0705626; OKUYAMA M, 1995, LIFE SCI, V57, P1051, DOI 10.1016/0024-3205(95)02050-S; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; Shyue SK, 2001, CIRCULATION, V103, P2090; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; Srinivas V, 2001, J BIOL CHEM, V276, P21995, DOI 10.1074/jbc.C100177200; Uchida T, 2004, J BIOL CHEM, V279, P14871, DOI 10.1074/jbc.M400461200; UMEKI S, 1994, INT J BIOCHEM, V26, P1003, DOI 10.1016/0020-711X(94)90071-X; Vaux EC, 2001, BLOOD, V98, P296, DOI 10.1182/blood.V98.2.296; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WU KK, 1995, AGENT ACTION SUPPL, V45, P11	42	42	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36567	36574		10.1074/jbc.M504280200	http://dx.doi.org/10.1074/jbc.M504280200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16115891	hybrid			2022-12-27	WOS:000232901800006
J	Van de Walle, GR; Vanhoorelbeke, K; Majer, Z; Illyes, E; Baert, J; Pareyn, I; Deckmyn, H				Van de Walle, GR; Vanhoorelbeke, K; Majer, Z; Illyes, E; Baert, J; Pareyn, I; Deckmyn, H			Two functional active conformations of the integrin alpha 2 beta 1, depending on activation condition and cell type	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA(L)BETA(2) HYBRID DOMAIN; VON-WILLEBRAND-FACTOR; LIGAND-BINDING SITES; HAMSTER OVARY CELLS; MONOCLONAL-ANTIBODY; COLLAGEN RECEPTOR; I-DOMAIN; CYTOPLASMIC DOMAINS; STRUCTURAL BASIS; GLYCOPROTEIN-VI	For several integrins, the existence of multiple conformational states has been studied intensively. For the integrin alpha 2 beta 1, a major collagen receptor on platelets and other cell types, however, no such experimental data were available thus far. Recently, our group has developed a monoclonal antibody IAC-1 sensitive to the molecular conformation of alpha 2 beta 1 because it only binds to the activated state of alpha 2 beta 1 on platelets, induced upon inside-out signaling. By investigating IAC-1 binding in combination with collagen binding after inside-out stimulation and outside manipulation, we demonstrated the existence of three different conformations of alpha 2 beta 1 on platelets and Chinese hamster ovary cells as follows: (i) a nonactivated, resting state with no collagen nor IAC-1 binding; (ii) an intermediate state, induced by outside manipulation, with collagen but no IAC-1 binding; and (iii) a fully activated state, induced after inside-out stimulation, with both collagen and IAC-1 binding. Moreover, these different conformational states of alpha 2 beta 1 are dependent on the cell type where alpha 2 beta 1 is expressed, as IAC-1 binding to peripheral blood mononuclear cells and Jurkat cells could also be induced by outside manipulation, in contrast to platelets and alpha 2 beta 1-expressing Chinese hamster ovary cells. Finally, we revealed a functional relevance for these different conformational states because the conformation of alpha 2 beta 1, induced after outside manipulation, resulted in significantly more cell spreading on coated collagen compared with nonactivated or inside-out stimulated cells.	Katholieke Univ Leuven, Interdisciplinary Res Ctr, Lab Thrombosis Res, B-8500 Kortrijk, Belgium; Katholieke Univ Leuven, Interdisciplinary Res Ctr, Histol Lab, B-8500 Kortrijk, Belgium; Eotvos Lorand Univ, Dept Organ Chem, H-1518 Budapest, Hungary	KU Leuven; KU Leuven; Eotvos Lorand University	Deckmyn, H (corresponding author), Katholieke Univ Leuven, Interdisciplinary Res Ctr, Lab Thrombosis Res, Campus Kortrijk,E Sabbelaan 53, B-8500 Kortrijk, Belgium.	Hans.deckmyn@kulak.ac.be	Majer, Zsuzsa/B-3910-2016; Deckmyn, Hans/L-9434-2015; Deckmyn, Hans/N-8932-2019	Deckmyn, Hans/0000-0003-3952-5501; Deckmyn, Hans/0000-0003-3952-5501; Vanhoorelbeke, Karen/0000-0003-2288-8277; Van de Walle, Gerlinde/0000-0002-2064-8029				Adair BD, 2002, P NATL ACAD SCI USA, V99, P14059, DOI 10.1073/pnas.212498199; ALTIERI DC, 1988, J IMMUNOL, V141, P2656; Chigaev A, 2001, J BIOL CHEM, V276, P48670, DOI 10.1074/jbc.M103194200; Chung J, 1999, BLOOD, V94, P642, DOI 10.1182/blood.V94.2.642.414k35_642_648; Depraetere H, 1997, THROMB HAEMOSTASIS, V77, P981; Drbal K, 2001, BLOOD, V98, P1561, DOI 10.1182/blood.V98.5.1561; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; Gao AG, 1996, J CELL BIOL, V135, P533, DOI 10.1083/jcb.135.2.533; Gendron S, 2003, J BIOL CHEM, V278, P48633, DOI 10.1074/jbc.M305169200; GOLDMAN R, 1992, EUR J IMMUNOL, V22, P1109, DOI 10.1002/eji.1830220502; Gullberg DE, 2002, PROG HISTOCHEM CYTO, V37, P9; HEMLER ME, 1990, CELL DIFFER DEV, V32, P229, DOI 10.1016/0922-3371(90)90035-U; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; Henderson RB, 2001, J EXP MED, V194, P219, DOI 10.1084/jem.194.2.219; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; JandrotPerrus M, 1997, J BIOL CHEM, V272, P27035, DOI 10.1074/jbc.272.43.27035; Jin M, 2004, STRUCTURE, V12, P2137, DOI 10.1016/j.str.2004.10.005; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; Kanse SM, 2004, ARTERIOSCL THROM VAS, V24, P2251, DOI 10.1161/01.ATV.0000146529.68729.8b; KAWAGUCHI S, 1993, J BIOL CHEM, V268, P16279; Lecut C, 2004, ARTERIOSCL THROM VAS, V24, P1727, DOI 10.1161/01.ATV.0000137974.85068.93; Luo BH, 2004, PLOS BIOL, V2, P776, DOI 10.1371/journal.pbio.0020153; Mekrache M, 2002, BRIT J HAEMATOL, V119, P1024, DOI 10.1046/j.1365-2141.2002.03960.x; Mekrache M, 2002, BRIT J HAEMATOL, V116, P636, DOI 10.1046/j.0007-1048.2001.03332.x; Mould AP, 2004, CURR OPIN CELL BIOL, V16, P544, DOI 10.1016/j.ceb.2004.07.003; Mould AP, 1998, BIOCHEM J, V331, P821, DOI 10.1042/bj3310821; Ni HY, 1998, J BIOL CHEM, V273, P7981, DOI 10.1074/jbc.273.14.7981; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PARDI R, 1995, J IMMUNOL, V155, P1252; Perrault C, 1998, CELL ADHES COMMUN, V6, P335, DOI 10.3109/15419069809010792; Reinhold MI, 1997, J EXP MED, V185, P1, DOI 10.1084/jem.185.1.1; Ruoslahti E, 1997, CURR OPIN CELL BIOL, V9, P605, DOI 10.1016/S0955-0674(97)80112-3; Salas A, 2004, IMMUNITY, V20, P393, DOI 10.1016/S1074-7613(04)00082-2; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SANTORO SA, 1995, THROMB HAEMOSTASIS, V74, P813; Schoolmeester A, 2004, BLOOD, V104, P390, DOI 10.1182/blood-2003-12-4224; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; Springer TA, 2002, CURR OPIN STRUC BIOL, V12, P802, DOI 10.1016/S0959-440X(02)00384-6; STEWART JM, 1976, J MACROMOL SCI CHEM, VA 10, P259, DOI 10.1080/00222337608068099; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2003, EMBO J, V22, P4607, DOI 10.1093/emboj/cdg445; Tan SM, 2001, J BIOL CHEM, V276, P36370, DOI 10.1074/jbc.M102392200; Tang RH, 2005, J BIOL CHEM, V280, P29208, DOI 10.1074/jbc.M503239200; Ticchioni M, 1998, FASEB J, V12, pA577; Tng E, 2004, J BIOL CHEM, V279, P54334, DOI 10.1074/jbc.M407818200; Waclavicek M, 1997, J IMMUNOL, V159, P5345; Wang XQ, 1998, MOL BIOL CELL, V9, P865, DOI 10.1091/mbc.9.4.865; Wang ZY, 2003, BLOOD, V102, P1307, DOI 10.1182/blood-2002-09-2753; Woods ML, 2000, EUR J IMMUNOL, V30, P38, DOI 10.1002/1521-4141(200001)30:1<38::AID-IMMU38>3.3.CO;2-2; Xiao T, 2004, NATURE, V432, P59, DOI 10.1038/nature02976; Xiong JP, 2003, BLOOD, V102, P1155, DOI 10.1182/blood-2003-01-0334; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040	55	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36873	36882		10.1074/jbc.M508148200	http://dx.doi.org/10.1074/jbc.M508148200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16103112	Green Published, hybrid			2022-12-27	WOS:000232901800043
J	Chen, GC; Nomura, M; Morinaga, H; Matsubara, E; Okabe, T; Goto, K; Yanase, T; Zheng, H; Lu, J; Nawata, H				Chen, GC; Nomura, M; Morinaga, H; Matsubara, E; Okabe, T; Goto, K; Yanase, T; Zheng, H; Lu, J; Nawata, H			Modulation of androgen receptor transactivation by FoxH1 - A newly identified androgen receptor corepressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER CELL-LINE; ELEMENT-BINDING PROTEIN; PROSTATE-CANCER; ACTIVIN RECEPTOR; CROSS-TALK; TGF-BETA; TRANSCRIPTIONAL ACTIVITY; MEDIATED TRANSCRIPTION; SIGNAL TRANSDUCER; NUCLEAR RECEPTOR	Androgen signaling plays key roles in the development and progression of prostate cancer, and numerous ongoing studies focus on the regulation of androgen receptor (AR) transactivity to develop novel therapies for the treatment of androgen-independent prostate cancer. FoxH1, amember of the Forkhead-box ( FOX) gene family of transcription factors, takes part in mediating transforming growth factor-beta/activin signaling through its interaction with the Smad2 center dot Smad4 complex. Using a series of experiments, we found that FoxH1 repressed both ligand-dependent and - independent transactivation of the AR on androgen-induced promoters. This action of FoxH1 was independent of its transactivation capacity and activin A but relieved by Smad2 center dot Smad4. In addition, the repression of the AR by FoxH1 did not require deacetylase activity. A protein-protein interaction was identified between the AR and FoxH1 independently of dihydrotestosterone. Furthermore, a confocal microscopic analysis of LNCaP cells revealed that the interaction between the AR and FoxH1 occurred in the nucleus and that FoxH1 specifically blocked the foci formation of dihydrotestosterone-activated AR, which has been shown to be correlated with the AR transactivation potential. Taken together, our results indicate that FoxH1 functions as a new corepressor of the AR. Our observations not only strengthen the role of FoxH1 in AR-mediated transactivation but also suggest that therapeutic interventions based on AR-coregulator interactions could be designed to block both androgen-dependent and - independent growth of prostate cancer.	Kyushu Univ, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, Higashi Ku, Fukuoka 8128582, Japan; Second Mil Med Univ, Dept Pathophysiol, Shanghai 200433, Peoples R China; Second Mil Med Univ, Lab Ctr Pharmacol, Shanghai 200433, Peoples R China	Kyushu University; Naval Medical University; Naval Medical University	Nomura, M (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, Higashi Ku, Maidashi 3-1-1, Fukuoka 8128582, Japan.	nomura@med.kyushu-u.ac.jp	Eri, MATSUBARA/AAJ-8405-2021; chen, guangchun/F-3910-2011	Eri, MATSUBARA/0000-0003-2385-0078; 				Abe Y, 2004, GROWTH FACTORS, V22, P105, DOI 10.1080/08977190410001704688; Adachi M, 2000, NEW ENGL J MED, V343, P856, DOI 10.1056/NEJM200009213431205; Baker JC, 1997, CURR OPIN GENET DEV, V7, P467, DOI 10.1016/S0959-437X(97)80072-X; Belandia B, 2005, MOL CELL BIOL, V25, P1425, DOI 10.1128/MCB.25.4.1425-1436.2005; Berrevoets CA, 2004, BIOCHEM J, V379, P731, DOI 10.1042/BJ20031456; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Brinkmann AO, 1999, J STEROID BIOCHEM, V69, P307, DOI 10.1016/S0960-0760(99)00049-7; Carey JL, 2004, MOL ENDOCRINOL, V18, P696, DOI 10.1210/me.2003-0360; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen TS, 2000, CANCER RES, V60, P2132; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen YG, 2002, EXP BIOL MED, V227, P75, DOI 10.1177/153537020222700201; Culig Z, 2003, UROLOGY, V62, P21, DOI 10.1016/S0090-4295(03)00698-8; Dalkin AC, 1996, ENDOCRINOLOGY, V137, P5230, DOI 10.1210/en.137.12.5230; Dehm SM, 2005, EXPERT REV ANTICANC, V5, P63, DOI 10.1586/14737140.5.1.63; Dotzlaw H, 2003, MOL CELL ENDOCRINOL, V213, P79, DOI 10.1016/j.mce.2003.10.036; Dotzlaw H, 2002, MOL ENDOCRINOL, V16, P661, DOI 10.1210/me.16.4.661; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Fronsdal K, 1998, J BIOL CHEM, V273, P31853, DOI 10.1074/jbc.273.48.31853; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Fujii Y, 2004, AM J PHYSIOL-ENDOC M, V286, pE927, DOI 10.1152/ajpendo.00443.2003; Haendler B, 2002, BIOMED PHARMACOTHER, V56, P78, DOI 10.1016/S0753-3322(01)00159-7; Hayes SA, 2001, CANCER RES, V61, P2112; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Hobisch A, 1998, CANCER RES, V58, P4640; Hsiao PW, 1999, J BIOL CHEM, V274, P22373, DOI 10.1074/jbc.274.32.22373; Hsiao PW, 1999, J BIOL CHEM, V274, P20229, DOI 10.1074/jbc.274.29.20229; Huang H, 2002, CRIT REV EUKAR GENE, V12, P193, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i3.30; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jeong BC, 2004, MOL ENDOCRINOL, V18, P13, DOI 10.1210/me.2003-0065; Jia L, 2004, CANCER RES, V64, P2619, DOI 10.1158/0008-5472.CAN-03-3486; Kawate H, 2005, MOL CELL ENDOCRINOL, V230, P77, DOI 10.1016/j.mce.2004.10.009; Kim J, 2005, J MOL ENDOCRINOL, V34, P107, DOI 10.1677/jme.1.01701; Kokontis J, 1991, Receptor, V1, P271; Lau KM, 2000, CANCER RES, V60, P3175; Lee ECY, 2004, J CELL BIOCHEM, V91, P662, DOI 10.1002/jcb.20040; Lee HJ, 2003, CELL MOL LIFE SCI, V60, P1613, DOI 10.1007/s00018-003-2309-3; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Liu B, 1999, MOL CELL BIOL, V19, P424; Lou W, 2000, PROSTATE, V42, P239, DOI 10.1002/(SICI)1097-0045(20000215)42:3<239::AID-PROS10>3.0.CO;2-G; Matsuda T, 2001, BIOCHEM BIOPH RES CO, V283, P179, DOI 10.1006/bbrc.2001.4758; McEwan IJ, 2004, ENDOCR-RELAT CANCER, V11, P281, DOI 10.1677/erc.0.0110281; McPherson SJ, 1999, ENDOCRINOLOGY, V140, P5303, DOI 10.1210/en.140.11.5303; McPherson SJ, 1997, J ENDOCRINOL, V154, P535, DOI 10.1677/joe.0.1540535; Mellor SL, 2000, J CLIN ENDOCR METAB, V85, P4851, DOI 10.1210/jc.85.12.4851; Mukasa C, 2003, ENDOCRINOLOGY, V144, P1603, DOI 10.1210/en.2002-220978; NAKAO R, 1992, J CLIN ENDOCR METAB, V74, P1152, DOI 10.1210/jc.74.5.1152; Navarro D, 2002, J STEROID BIOCHEM, V81, P191, DOI 10.1016/S0960-0760(02)00064-X; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ordentlich P, 2001, CURR TOP MICROBIOL, V254, P101; Petre CE, 2002, J BIOL CHEM, V277, P2207, DOI 10.1074/jbc.M106399200; Privalsky ML, 2001, CURR TOP MICROBIOL, V254, P117; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; Saitoh M, 2002, MOL ENDOCRINOL, V16, P694, DOI 10.1210/me.16.4.694; Santos AF, 2004, STEROIDS, V69, P79, DOI 10.1016/j.steroids.2003.10.005; Sato N, 1997, J BIOL CHEM, V272, P17485, DOI 10.1074/jbc.272.28.17485; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Sharma M, 2001, MOL ENDOCRINOL, V15, P1918, DOI 10.1210/me.15.11.1918; Slagsvold T, 2000, MOL ENDOCRINOL, V14, P1603, DOI 10.1210/me.14.10.1603; Taplin ME, 2004, J CELL BIOCHEM, V91, P483, DOI 10.1002/jcb.10653; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Thomas TZ, 1998, PROSTATE, V34, P34, DOI 10.1002/(SICI)1097-0045(19980101)34:1<34::AID-PROS5>3.0.CO;2-K; Tomura A, 2001, J BIOL CHEM, V276, P28395, DOI 10.1074/jbc.M101755200; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; Ueda T, 2002, J BIOL CHEM, V277, P7076, DOI 10.1074/jbc.M108255200; van Schaik RHN, 2000, BRIT J CANCER, V82, P112; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; Wang L, 2005, PROSTATE, V63, P117, DOI 10.1002/pros.20170; Wang QF, 1996, ENDOCRINOLOGY, V137, P5476, DOI 10.1210/en.137.12.5476; Warnmark A, 2003, MOL ENDOCRINOL, V17, P1901, DOI 10.1210/me.2002-0384; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; YING SY, 1989, J STEROID BIOCHEM, V33, P705; Ying SY, 1997, P SOC EXP BIOL MED, V214, P114; Yu X, 2001, MOL CELL BIOL, V21, P4614, DOI 10.1128/MCB.21.14.4614-4625.2001; Zhang Z, 1997, BIOCHEM BIOPH RES CO, V234, P362, DOI 10.1006/bbrc.1997.6649; Zhao Y, 2002, J BIOL CHEM, V277, P30031, DOI 10.1074/jbc.M203811200; Zhou J, 2001, CANCER METAST REV, V20, P351, DOI 10.1023/A:1015504015302; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	79	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36355	36363		10.1074/jbc.M506147200	http://dx.doi.org/10.1074/jbc.M506147200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16120611	hybrid			2022-12-27	WOS:000232726900069
J	Cuomo, ME; Knebel, A; Platt, G; Morrice, N; Cohen, P; Mittnacht, S				Cuomo, ME; Knebel, A; Platt, G; Morrice, N; Cohen, P; Mittnacht, S			Regulation of microfilament organization by Kaposi sarcoma-associated herpes virus-cyclin center dot CDK6 phosphorylation of caldesmon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CALDESMON; CASEIN KINASE-II; CYCLIN-DEPENDENT KINASES; HUMAN ENDOTHELIAL-CELLS; ACTIN-BINDING; NONMUSCLE CALDESMON; CALMODULIN-BINDING; TRANSFORMED-CELLS; DNA-SEQUENCES; RETINOBLASTOMA PROTEIN	Kaposi sarcoma-associated herpes virus ( KSHV) encodes a D-like cyclin ( K-cyclin) that is thought to contribute to the viral oncogenicity. K-cyclin activates cellular cyclin-dependent kinases (CDK) 4 and 6, generating enzymes with a substrate selectivity deviant from CDK4 and CDK6 activated by D-type cyclins, suggesting different biochemical and biological functions. Here we report the identification of the actin- and calmodulin-binding protein caldesmon (CALD1) as a novel K-cyclin center dot CDK substrate, which is not phosphorylated by D center dot CDK. CALD1 plays a central role in the regulation of microfilament organization, consequently controlling cell shape, adhesion, cytokinesis and motility. K-cyclin center dot CDK6 specifically phosphorylates four Ser/Thr sites in the human CALD1 carboxyl terminus, abolishing CALD1 binding to its effector protein, actin, and its regulator protein, calmodulin. CALD1 is hyperphosphorylated in cells following K-cyclin expression and in KSHV-transformed lymphoma cells. Moreover, expression of exogenous K-cyclin results in microfilament loss and changes in cell morphology; both effects are reliant on CDK catalysis and can be reversed by the expression of a phosphorylation defective CALD1. Together, these data strongly suggest that K-cyclin expression modulates the activity of caldesmon and through this the microfilament functions in cells. These results establish a novel link between KSHV infection and the regulation of the actin cytoskeleton.	Inst Canc Res, Chester Beatty Labs, Canc Res UK Ctr Cell & Mol Biol, London SW3 6JB, England; Univ Dundee, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland; Kinasource, Lab 4 21, Dundee DD1 5EH, Scotland	Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Dundee	Mittnacht, S (corresponding author), Inst Canc Res, Chester Beatty Labs, Canc Res UK Ctr Cell & Mol Biol, 237 Fulham Rd, London SW3 6JB, England.	sibylle@icr.ac.uk		Knebel, Axel/0000-0002-9197-6054				ADAM LP, 1993, FEBS LETT, V322, P56, DOI 10.1016/0014-5793(93)81110-L; Arvanitakis L, 1996, BLOOD, V88, P2648, DOI 10.1182/blood.V88.7.2648.bloodjournal8872648; Bartegi A, 1998, EUR J BIOCHEM, V254, P571, DOI 10.1046/j.1432-1327.1998.2540571.x; Berwick DC, 2004, TRENDS BIOCHEM SCI, V29, P227, DOI 10.1016/j.tibs.2004.03.004; Boshoff C, 1998, BLOOD, V91, P1671, DOI 10.1182/blood.V91.5.1671.1671_1671_1679; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; Cole AR, 2004, J BIOL CHEM, V279, P50176, DOI 10.1074/jbc.C400412200; D'Angelo G, 1999, J BIOL CHEM, V274, P30115, DOI 10.1074/jbc.274.42.30115; Donnellan R, 1998, J CLIN PATHOL-MOL PA, V51, P1; Ellis M, 1999, EMBO J, V18, P644, DOI 10.1093/emboj/18.3.644; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; Foster DB, 2000, J BIOL CHEM, V275, P1959, DOI 10.1074/jbc.275.3.1959; Foster DB, 2004, J BIOL CHEM, V279, P53387, DOI 10.1074/jbc.M410109200; Franz CM, 2002, DEV CELL, V2, P153, DOI 10.1016/S1534-5807(02)00120-X; Fraser IDC, 1997, BIOCHEMISTRY-US, V36, P5483, DOI 10.1021/bi962969z; Gao SJ, 2003, J VIROL, V77, P9738, DOI 10.1128/JVI.77.18.9738-9749.2003; GoddenKent D, 1997, J VIROL, V71, P4193, DOI 10.1128/JVI.71.6.4193-4198.1997; Hedges JC, 2000, AM J PHYSIOL-CELL PH, V278, pC718, DOI 10.1152/ajpcell.2000.278.4.C718; Helfman DM, 1999, MOL BIOL CELL, V10, P3097, DOI 10.1091/mbc.10.10.3097; HOSOYA N, 1993, J CELL BIOL, V121, P1075, DOI 10.1083/jcb.121.5.1075; Huang RJ, 2003, BIOCHEMISTRY-US, V42, P2513, DOI 10.1021/bi0268605; Huber PAJ, 1997, INT J BIOCHEM CELL B, V29, P1047, DOI 10.1016/S1357-2725(97)00004-6; Huber PAJ, 1998, BIOCHEMISTRY-US, V37, P2314, DOI 10.1021/bi971727b; IKEBE M, 1990, J BIOL CHEM, V265, P17607; ISHIKAWA R, 1989, J BIOL CHEM, V264, P16764; Ishikawa R, 1998, J BIOL CHEM, V273, P26991, DOI 10.1074/jbc.273.41.26991; Knebel A, 2001, EMBO J, V20, P4360, DOI 10.1093/emboj/20.16.4360; Laman H, 2001, EXP CELL RES, V271, P230, DOI 10.1006/excr.2001.5360; Laman H, 2001, MOL CELL BIOL, V21, P624, DOI 10.1128/MCB.21.2.624-635.2001; Li Y, 2004, J CELL SCI, V117, P3593, DOI 10.1242/jcs.01216; Li Y, 2003, CELL MOL LIFE SCI, V60, P198, DOI 10.1007/s000180300014; Li YH, 2000, J BIOL CHEM, V275, P10989, DOI 10.1074/jbc.275.15.10989; MAK AS, 1991, J BIOL CHEM, V266, P19971; MAK AS, 1991, J BIOL CHEM, V266, P6678; Manes T, 2003, J CELL BIOL, V161, P817, DOI 10.1083/jcb.200212172; Mann DJ, 1999, EMBO J, V18, P654, DOI 10.1093/emboj/18.3.654; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; MARSTON SB, 1994, J BIOL CHEM, V269, P8134; Matsumura F, 1993, CURR OPIN CELL BIOL, V5, P70, DOI 10.1016/S0955-0674(05)80010-9; McManus MJ, 1997, P NATL ACAD SCI USA, V94, P11351, DOI 10.1073/pnas.94.21.11351; McNeill H, 2004, BIOCHEM J, V384, P391, DOI 10.1042/BJ20041498; MEZGUELDI M, 1994, J BIOL CHEM, V269, P12824; Mirzapoiazova T, 2005, J CELL PHYSIOL, V203, P520, DOI 10.1002/jcp.20244; Mittnacht S, 2000, REV MED VIROL, V10, P175, DOI 10.1002/(SICI)1099-1654(200005/06)10:3<175::AID-RMV283>3.0.CO;2-F; Mody N, 2003, BIOCHEM J, V372, P567, DOI 10.1042/BJ20030193; Murray JT, 2004, BIOCHEM J, V384, P489, DOI 10.1042/BJ20041058; Murray JT, 2004, BIOCHEM J, V384, P477, DOI 10.1042/BJ20041057; NOVY RE, 1991, J BIOL CHEM, V266, P16917; Ojala PM, 2000, NAT CELL BIOL, V2, P819, DOI 10.1038/35041064; OWADA MK, 1984, P NATL ACAD SCI-BIOL, V81, P3133, DOI 10.1073/pnas.81.10.3133; Patchell VB, 2002, BBA-PROTEIN STRUCT M, V1596, P121, DOI 10.1016/S0167-4838(02)00210-8; Platt GM, 2000, VIROLOGY, V272, P257, DOI 10.1006/viro.2000.0343; Rao JY, 2004, CURR CANCER DRUG TAR, V4, P345, DOI 10.2174/1568009043332998; Rousseau S, 2002, EMBO J, V21, P6505, DOI 10.1093/emboj/cdf639; Sahai E, 2005, CURR OPIN GENET DEV, V15, P87, DOI 10.1016/j.gde.2004.12.002; Sarid R, 1999, J VIROL, V73, P1438, DOI 10.1128/JVI.73.2.1438-1446.1999; Smith GA, 2002, ANNU REV CELL DEV BI, V18, P135, DOI 10.1146/annurev.cellbio.18.012502.105920; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Sugaya M, 2005, BLOOD, V105, P2356, DOI 10.1182/blood-2004-08-3364; SUTHERLAND C, 1994, J MUSCLE RES CELL M, V15, P440, DOI 10.1007/BF00122118; TANAKA J, 1993, J CELL SCI, V104, P595; TANAKA T, 1990, EUR J BIOCHEM, V188, P495, DOI 10.1111/j.1432-1033.1990.tb15427.x; Van Dross R, 2005, JNCI-J NATL CANCER I, V97, P656, DOI 10.1093/jnci/dji113; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Verschuren EW, 2004, CANCER RES, V64, P581, DOI 10.1158/0008-5472.CAN-03-1863; Verschuren EW, 2002, CANCER CELL, V2, P229, DOI 10.1016/S1535-6108(02)00123-X; VOROTNIKOV AV, 1993, FEBS LETT, V334, P18, DOI 10.1016/0014-5793(93)81671-L; VOROTNIKOV AV, 1994, J MUSCLE RES CELL M, V15, P37, DOI 10.1007/BF00123831; WANG CLA, 1991, J BIOL CHEM, V266, P9166; Wang Z, 2000, BIOCHEMISTRY-US, V39, P11114, DOI 10.1021/bi0006767; WARREN KS, 1994, J CELL BIOL, V125, P359, DOI 10.1083/jcb.125.2.359; Warren KS, 1996, CELL MOTIL CYTOSKEL, V34, P215, DOI 10.1002/(SICI)1097-0169(1996)34:3<215::AID-CM5>3.0.CO;2-8; Yamakita Y, 2003, J BIOL CHEM, V278, P17937, DOI 10.1074/jbc.M208739200; YAMAKITA Y, 1992, J BIOL CHEM, V267, P12022; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; YAMASHIRO S, 1990, NATURE, V344, P675, DOI 10.1038/344675a0; YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0; Yamashiro S, 2001, MOL BIOL CELL, V12, P239, DOI 10.1091/mbc.12.1.239; YAMASHIRO S, 1995, J BIOL CHEM, V270, P4023, DOI 10.1074/jbc.270.8.4023; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zheng PP, 2004, AM J PATHOL, V164, P2217, DOI 10.1016/S0002-9440(10)63778-9	83	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35844	35858		10.1074/jbc.M503877200	http://dx.doi.org/10.1074/jbc.M503877200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16115893	hybrid			2022-12-27	WOS:000232726900011
J	Kudo, M; Bao, M; D'Souza, A; Ying, F; Pan, HQ; Roe, BA; Canfield, WM				Kudo, M; Bao, M; D'Souza, A; Ying, F; Pan, HQ; Roe, BA; Canfield, WM			The alpha- and beta-subunits of the human UDP-N-acetylglucosamine : lysosomal enzyme phosphotransferase are encoded by a single cDNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDO-HURLER POLYDYSTROPHY; I-CELL DISEASE; RAPID INTERNALIZATION; N-ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE; SEQUENCE; GENE; ACETYLGLUCOSAMINYLPHOSPHOTRANSFERASE; PURIFICATION; SEROGROUP; DOMAIN	Lysosomal enzymes are targeted to the lysosome through binding to mannose 6-phosphate receptors because their glycans are modified with mannose 6-phosphate. This modification is catalyzed by UDP-N-acetylglucosamine: lysosomal enzyme N-acetylglucosamine-1- phosphotransferase (GlcNAc- phosphotransferase). Bovine GlcNAc- phosphotransferase was isolated using monoclonal antibody affinity chromatography, and an alpha(2)beta(2)gamma(2)-subunit structure was proposed. Although cDNA encoding the gamma-subunit has been described, cDNAs for the alpha- and beta-subunits have not. Using partial amino acid sequences from the bovine alpha-and beta-subunits, we have isolated a human cDNA that encodes both the alpha-and beta-subunits. Both subunits contain a single predicted membrane-spanning domain. The alpha- and beta-subunits appear to be generated by a proteolytic cleavage at the Lys(928)-Asp(929) bond. Transfection of 293T cells with the alpha/beta-subunits-precursor cDNA with or without the gamma-subunit cDNA results in a 3.6- or 17-fold increase in GlcNAc- phosphotransferase activity in cell lysates, suggesting that the precursor cDNA contains the catalytic domain. The sequence lacks significant similarity with any described vertebrate enzyme except for two Notch-like repeats in the alpha-subunit. However, a 112-amino acid sequence is highly similar to a group of bacterial capsular polymerases (46% identity). A BAC clone containing the gene that spanned 85.3 kb and was composed of 21 exons was sequenced and localized to chromosome 12q23. We now report the cloning of both the cDNA and genomic DNA of the precursor of GlcNAc- phosphotransferase. The completion of cloning all three subunits of GlcNAc- phosphotransferase allows expression of recombinant enzyme and dissection of lysosomal targeting disorders.	Genzyme Corp, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, WK Warren Med Res Inst, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK 73104 USA; Berlex Biosci, Syst Biol, Richmond, CA 94804 USA; Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA; Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA; N Carolina State Univ, Ctr Integrated Fungal Res, Raleigh, NC 27606 USA	Sanofi-Aventis; Genzyme Corporation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma - Norman; University of North Carolina; North Carolina State University	Canfield, WM (corresponding author), Genzyme Corp, 800 Res Pkwy,Suite 200, Oklahoma City, OK 73104 USA.	William.Canfield@genzyme.com			NHGRI NIH HHS [5 U54 HG02152] Funding Source: Medline; NICHD NIH HHS [HD31920] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD031920] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG002152] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ASHTON FE, 1983, J CLIN MICROBIOL, V17, P722, DOI 10.1128/JCM.17.5.722-727.1983; Bao M, 1996, J BIOL CHEM, V271, P31437, DOI 10.1074/jbc.271.49.31437; Bao M, 1996, J BIOL CHEM, V271, P31446, DOI 10.1074/jbc.271.49.31446; Bodenteich A, 1993, AUTOMATED DNA SEQUEN, P42; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHISSOE SL, 1995, GENOMICS, V27, P67, DOI 10.1006/geno.1995.1008; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; GRABOWSKI GA, 1995, ANN INTERN MED, V122, P33, DOI 10.7326/0003-4819-122-1-199501010-00005; HASILIK A, 1981, BIOCHEM BIOPH RES CO, V98, P761, DOI 10.1016/0006-291X(81)91177-3; JADOT M, 1992, J BIOL CHEM, V267, P11069; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MUELLER OT, 1987, CYTOGENET CELL GENET, V46, P664; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; PAN HQ, 1994, GENET ANAL-BIOMOL E, V11, P181; Raas-Rothschild A, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.015222; Raas-Rothschild A, 2000, J CLIN INVEST, V105, P673, DOI 10.1172/JCI5826; Raben N, 2003, MOL GENET METAB, V80, P159, DOI 10.1016/j.ymgme.2003.08.022; REITMAN ML, 1981, J CLIN INVEST, V67, P1574, DOI 10.1172/JCI110189; REITMAN ML, 1981, J BIOL CHEM, V256, P4275; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; REITMAN ML, 1984, METHOD ENZYMOL, V107, P163; Steet RA, 2005, AM J MED GENET A, V132A, P369, DOI 10.1002/ajmg.a.30498; Swartley JS, 1998, J BACTERIOL, V180, P1533, DOI 10.1128/JB.180.6.1533-1539.1998; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tzeng YL, 2003, INFECT IMMUN, V71, P6712, DOI 10.1128/IAI.71.12.6712-6720.2003; VARKI A, 1981, J BIOL CHEM, V256, P9937; VARKI A, 1982, AM J HUM GENET, V34, P717; VARKI AP, 1981, P NATL ACAD SCI-BIOL, V78, P7773, DOI 10.1073/pnas.78.12.7773; WAHEED A, 1982, BIOCHEM BIOPH RES CO, V105, P1052, DOI 10.1016/0006-291X(82)91076-2; WAHEED A, 1982, J BIOL CHEM, V257, P2322; WAHEED A, 1981, J BIOL CHEM, V256, P5717	43	92	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36141	36149		10.1074/jbc.m509008200	http://dx.doi.org/10.1074/jbc.m509008200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16120602	hybrid			2022-12-27	WOS:000232726900045
J	Wang, YT; Oram, JF				Wang, YT; Oram, JF			Unsaturated fatty acids phosphorylate and destabilize ABCA1 through a phospholipase D2 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CASSETTE TRANSPORTER 1; APOLIPOPROTEIN-A-I; PROTEIN-KINASE-C; CHOLESTEROL EFFLUX; TANGIER-DISEASE; MESSENGER-RNA; GENE; RECEPTOR; DEGRADATION	Abnormal high density lipoprotein (HDL) metabolism among patients with diabetes and insulin resistance may contribute to their increased risk of atherosclerosis. ATP-binding cassette transporter ABCA1 mediates the transport of cholesterol and phospholipids from cells to HDL apolipoproteins and thus modulates HDL levels and atherogenesis. Unsaturated fatty acids, which are elevated in diabetes, impair the ABCA1 pathway in cultured cells by destabilizing ABCA1 protein. Here we examined the cellular pathway that mediates the ABCA1 destabilizing effects of fatty acids. The long-chain acyl-CoA synthetase inhibitor triacsin C completely reversed fatty acid-induced ABCA1 destabilization, indicating that fatty acids need to be activated to their CoA derivatives to enhance ABCA1 degradation. Unsaturated but not saturated fatty acids stimulated phospholipase D(PLD) activity, the PLD inhibitor 1-butanol prevented the unsaturated fatty acid-induced reduction in ABCA1 levels, and the PLD2 activator mastoparan markedly reduced ABCA1 protein levels, implicating a role for PLD2 in the ABCA1 destabilizing effects of fatty acids. Unsaturated fatty acids and mastoparan increased phosphorylation of ABCA1 serines. PLD2 small interfering RNA abolished the ability of unsaturated fatty acids to inhibit lipid transport activity, to reduce protein levels, and to increase serine phosphorylation of ABCA1. The diacylglycerol analog oleoylacetylglycerol also reduced ABCA1 protein levels and increased its serine phosphorylation, suggesting that PLD2-generated diacylglycerols promote the destabilizing phosphorylation of ABCA1. These data provide evidence that intracellular unsaturated acyl-CoA derivatives destabilize ABCA1 by activating a PLD2 signaling pathway.	Univ Washington, Dept Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Oram, JF (corresponding author), Univ Washington, Dept Med, Seattle, WA 98195 USA.	joram@u.washington.edu			NHLBI NIH HHS [HL55362, HL18645] Funding Source: Medline; NIDDK NIH HHS [DK02456] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055362, P01HL018645] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aiello RJ, 2003, ARTERIOSCL THROM VAS, V23, P972, DOI 10.1161/01.ATV.0000054661.21499.FB; Ali H, 1996, J PHARMACOL EXP THER, V276, P837; ANGEL A, 1974, J LIPID RES, V15, P491; Askari B, 2002, J BIOL CHEM, V277, P36338, DOI 10.1074/jbc.M205112200; ASSMANN G, 1995, METABOLIC MOL BASES, P2053; Basso F, 2003, J LIPID RES, V44, P296, DOI 10.1194/jlr.M200414-JLR200; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Cavelier LB, 2001, J BIOL CHEM, V276, P18046, DOI 10.1074/jbc.M100565200; Chahdi A, 2003, J BIOL CHEM, V278, P12039, DOI 10.1074/jbc.M212084200; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Costet P, 2000, J BIOL CHEM, V275, P28240; Garver WS, 1997, ARTERIOSCL THROM VAS, V17, P2698, DOI 10.1161/01.ATV.17.11.2698; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Joyce C, 2003, ARTERIOSCL THROM VAS, V23, P965, DOI 10.1161/01.ATV.0000055194.85073.FF; Kim JH, 1999, FEBS LETT, V454, P42, DOI 10.1016/S0014-5793(99)00745-0; Kodaki T, 1997, J BIOL CHEM, V272, P11408; Kotter K, 1999, BRAIN RES, V830, P138, DOI 10.1016/S0006-8993(99)01416-X; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Liscovitch M, 1999, BBA-MOL CELL BIOL L, V1439, P245, DOI 10.1016/S1388-1981(99)00098-0; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; Martinez LO, 2003, J BIOL CHEM, V278, P37368, DOI 10.1074/jbc.M307161200; MENDEZ AJ, 1994, J CLIN INVEST, V94, P1698, DOI 10.1172/JCI117515; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 2003, ARTERIOSCL THROM VAS, V23, P720, DOI 10.1161/01.ATV.0000054662.44688.9A; Repa JJ, 1999, CURR OPIN BIOTECH, V10, P557, DOI 10.1016/S0958-1669(99)00031-2; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Sarri E, 2003, BIOCHEM J, V369, P319, DOI 10.1042/BJ20021347; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; See RH, 2002, J BIOL CHEM, V277, P41835, DOI 10.1074/jbc.M204923200; SERFATYLACROSNIERE C, 1994, ATHEROSCLEROSIS, V107, P85, DOI 10.1016/0021-9150(94)90144-9; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; Vaughan AM, 2003, J LIPID RES, V44, P1373, DOI 10.1194/jlr.M300078-JLR200; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Wang N, 2003, ARTERIOSCL THROM VAS, V23, P1178, DOI 10.1161/01.ATV.0000075912.83860.26; Wang Y, 2004, J LIPID RES, V45, P972, DOI 10.1194/jlr.M400011-JLR200; Wang YT, 2002, J BIOL CHEM, V277, P5692, DOI 10.1074/jbc.M109977200; Wellington CL, 2002, LAB INVEST, V82, P273, DOI 10.1038/labinvest.3780421; Yamauchi Y, 2003, J BIOL CHEM, V278, P47890, DOI 10.1074/jbc.M306258200	43	82	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35896	35903		10.1074/jbc.M506210200	http://dx.doi.org/10.1074/jbc.M506210200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16118212	Green Submitted, hybrid			2022-12-27	WOS:000232726900016
J	Hsu, IW; Hsu, M; Li, C; Chuang, TW; Lin, RI; Tarn, WY				Hsu, IW; Hsu, M; Li, C; Chuang, TW; Lin, RI; Tarn, WY			Phosphorylation of Y14 modulates its interaction with proteins involved in mRNA metabolism and influences its methylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXON JUNCTION COMPLEX; NONSENSE-MEDIATED DECAY; ARGININE METHYLATION; MAMMALIAN-CELLS; EXPORT; TRANSLATION; BINDS; ASSOCIATION; EXPRESSION; CYTOPLASM	The multicomponent exon junction complex (EJC) is deposited on the spliced mRNA during pre-mRNA splicing and is implicated in several post-splicing events, including mRNA export, nonsense-mediated mRNA decay (NMD), and translation control. This report is the first to identify potential post-translational modifications of the EJC core component Y14. We demonstrate that Y14 is phosphorylated at its repeated arginine/serine (RS) dipeptides, likely by SR protein-specific kinases. Phosphorylation of Y14 abolished its interaction with EJC components as well as factors that function downstream of the EJC. A non-phosphorylatable Y14 mutant was equivalent to the wild-type protein with respect to its association with spliced mRNA and its ability in NMD activation, but the mutant sequestered EJC and NMD factors on ribosome-containing mRNA ribonucleoproteins (mRNPs). We therefore hypothesize that phosphorylation of Y14 occurs upon completion of mRNA surveillance, leading to dissociation of Y14 from ribosome-containing mRNPs. Moreover, we found that Y14 is possibly methylated at multiple arginine residues in the carboxyl-terminal domain and that methylation of Y14 was antagonized by phosphorylation of RS dipeptides. This study reveals antagonistic post-translational modifications of Y14 that may be involved in the remodeling of Y14-containing mRNPs.	Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; Natl Yang Ming Univ, Inst Anat & Cell Biol, Taipei 11221, Taiwan	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University	Hsu, IW (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Acad Rd,Sect 2, Taipei 11529, Taiwan.	wtarn@ibms.sinica.edu.tw	Tarn, Woan-Yuh/N-8464-2018					Bedford MT, 2005, MOL CELL, V18, P263, DOI 10.1016/j.molcel.2005.04.003; Bono F, 2004, EMBO REP, V5, P304, DOI 10.1038/sj.embor.7400091; Chan CC, 2004, RNA, V10, P200, DOI 10.1261/rna.5230104; Degot S, 2004, J BIOL CHEM, V279, P33702, DOI 10.1074/jbc.M402754200; Dimaano C, 2004, MOL CELL BIOL, V24, P3069, DOI 10.1128/MCB.24.8.3069-3076.2004; Dostie J, 2002, CURR BIOL, V12, P1060, DOI 10.1016/S0960-9822(02)00902-8; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Fribourg S, 2003, NAT STRUCT BIOL, V10, P433, DOI 10.1038/nsb926; Gatfield D, 2002, J CELL BIOL, V159, P579, DOI 10.1083/jcb.200207128; Gehring NH, 2003, MOL CELL, V11, P939, DOI 10.1016/S1097-2765(03)00142-4; Gilbert W, 2004, MOL CELL, V13, P201, DOI 10.1016/S1097-2765(04)00030-9; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Green DM, 2002, J BIOL CHEM, V277, P7752, DOI 10.1074/jbc.M110053200; Huang YQ, 2005, MOL CELL, V17, P613, DOI 10.1016/j.molcel.2005.02.020; Huang YQ, 2004, P NATL ACAD SCI USA, V101, P9666, DOI 10.1073/pnas.0403533101; Huang YQ, 2003, MOL CELL, V11, P837, DOI 10.1016/S1097-2765(03)00089-3; Kataoka N, 2001, EMBO J, V20, P6424, DOI 10.1093/emboj/20.22.6424; Kim VN, 2001, SCIENCE, V293, P1832, DOI 10.1126/science.1062829; Kim VN, 2001, EMBO J, V20, P2062, DOI 10.1093/emboj/20.8.2062; Lai MC, 2004, J BIOL CHEM, V279, P31745, DOI 10.1074/jbc.C400173200; Lai MC, 2003, BIOCHEM J, V371, P937, DOI 10.1042/BJ20021827; Lau CK, 2003, CURR BIOL, V13, P933, DOI 10.1016/S0960-9822(03)00328-2; Le Hir H, 2003, TRENDS BIOCHEM SCI, V28, P215, DOI 10.1016/S0968-0004(03)00052-5; Le Hir H, 2001, EMBO J, V20, P4987, DOI 10.1093/emboj/20.17.4987; Lejeune F, 2002, EMBO J, V21, P3536, DOI 10.1093/emboj/cdf345; Li C, 2003, MOL CELL BIOL, V23, P7363, DOI 10.1128/MCB.23.20.7363-7376.2003; Lu SH, 2003, RNA, V9, P618, DOI 10.1261/rna.5260303; Lukong KE, 2004, NAT STRUCT MOL BIOL, V11, P914, DOI 10.1038/nsmb1004-914; Lykke-Andersen J, 2000, CELL, V103, P1121, DOI 10.1016/S0092-8674(00)00214-2; Maquat LE, 2004, NAT REV MOL CELL BIO, V5, P89, DOI 10.1038/nrm1310; Mingot JM, 2001, EMBO J, V20, P3685, DOI 10.1093/emboj/20.14.3685; Nott A, 2004, GENE DEV, V18, P210, DOI 10.1101/gad.1163204; Palacios IM, 2004, NATURE, V427, P753, DOI 10.1038/nature02351; Pawlak MR, 2002, J CELL BIOCHEM, V87, P394, DOI 10.1002/jcb.10307; Shibuya T, 2004, NAT STRUCT MOL BIOL, V11, P346, DOI 10.1038/nsmb750; Tam JP, 1997, METHOD ENZYMOL, V289, P612; Wiegand HL, 2003, P NATL ACAD SCI USA, V100, P11327, DOI 10.1073/pnas.1934877100; Xu C, 2004, MOL CELL BIOL, V24, P10742, DOI 10.1128/MCB.24.24.10742-10756.2004; Yu MC, 2004, GENE DEV, V18, P2024, DOI 10.1101/gad.1223204	39	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34507	34512		10.1074/jbc.M507658200	http://dx.doi.org/10.1074/jbc.M507658200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16100109	hybrid			2022-12-27	WOS:000232403900018
J	Abraham, R; Schafer, J; Rothe, M; Bange, J; Knyazev, P; Ullrich, A				Abraham, R; Schafer, J; Rothe, M; Bange, J; Knyazev, P; Ullrich, A			Identification of MMP-15 as an anti-apoptotic factor in cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-TYPE 1; CASPASE RECRUITMENT DOMAIN; PROTEIN-KINASE; TISSUE INHIBITOR; MATRIX METALLOPROTEINASES; FAS LIGAND; PROMOTES ACTIVATION; RNA INTERFERENCE; GENE-EXPRESSION; DECOY RECEPTOR	We have performed an in vitro selection for an anti-apoptotic phenotype that resembles the selection process that pre-malignant cells undergo in the initial phase of carcinogenesis in vivo. Using the cervical carcinoma cell line HeLa S3 as a model system, the selection procedure yielded cell clones that displayed increased resistance to apoptosis induced by Fas, tumor necrosis factor-related apoptosis-inducing ligand, and serum starvation. Gene expression profiling using gene family focused cDNA arrays revealed numerous genes that are differentially expressed in HeLa S3 and the resistant subclones and therefore are potentially involved in the definition of sensitivity to apoptotic stimuli. From the genes identified in this functional genomics approach we validated the anti-apoptotic activity of the membrane-anchored matrix metalloproteinase 15 (MMP-15) by means of small interfering RNA-mediated knockdown and ectopic expression in parental HeLa S3 cells and, to confirm a more general significance of our findings, in other cancer cell lines. The in vivo relevance of these findings is supported by the overexpression of MMP-15 in human lung adenocarcinoma compared with normal lung. Because MMP-15 is known to promote invasion, our results suggest that this protease connects metastasis and apoptosis resistance by an unknown regulatory mechanism. Our findings therefore strongly suggest that cancer characteristics such as metastatic potential, which are thought to evolve late in cancer progression, could be manifested early on by selection for an anti-apoptotic phenotype.	Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany; U3 Pharma AG, D-82152 Martinsried, Germany; Venetian Inst Mol Med, I-35129 Padua, Italy; Univ Munich, Dept Stat, D-80539 Munich, Germany	Max Planck Society; Veneto Institute Molecular Medicine; University of Munich	Abraham, R (corresponding author), Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany.	reimar.abraham@unipd.it						Ahonen M, 2003, ONCOGENE, V22, P2121, DOI 10.1038/sj.onc.1206292; ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brott BK, 1998, P NATL ACAD SCI USA, V95, P963, DOI 10.1073/pnas.95.3.963; Cheng M, 1996, J BIOL CHEM, V271, P8951, DOI 10.1074/jbc.271.15.8951; Chiarugi P, 2002, J BIOL CHEM, V277, P37331, DOI 10.1074/jbc.M205203200; Chiarugi P, 1997, BIOCHEM BIOPH RES CO, V238, P676, DOI 10.1006/bbrc.1997.7355; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Dumont N, 2003, CANCER CELL, V3, P531, DOI 10.1016/S1535-6108(03)00135-1; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ellenrieder V, 2000, INT J CANCER, V85, P14, DOI 10.1002/(SICI)1097-0215(20000101)85:1<14::AID-IJC3>3.3.CO;2-F; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Galic S, 2003, MOL CELL BIOL, V23, P2096, DOI 10.1128/MCB.23.6.2096-2108.2003; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; GUAN K, 1992, P NATL ACAD SCI USA, V89, P12175, DOI 10.1073/pnas.89.24.12175; Gupta S, 2002, FEBS LETT, V532, P61, DOI 10.1016/S0014-5793(02)03628-1; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Huber Wolfgang, 2002, Bioinformatics, V18 Suppl 1, pS96; HUDZIAK RM, 1990, CELL GROWTH DIFFER, V1, P129; Husain A, 1998, CANCER RES, V58, P1120; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Julien C, 2003, J BIOL CHEM, V278, P42615, DOI 10.1074/jbc.M302724200; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kayagaki N, 1999, J IMMUNOL, V162, P2639; Kayagaki N, 1999, J IMMUNOL, V163, P1906; Khursigara G, 2001, J NEUROSCI, V21, P5854, DOI 10.1523/JNEUROSCI.21-16-05854.2001; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Klingler-Hoffmann M, 2001, J BIOL CHEM, V276, P46313, DOI 10.1074/jbc.M106571200; Kramer OH, 2001, TRENDS ENDOCRIN MET, V12, P294, DOI 10.1016/S1043-2760(01)00438-6; Kurschat P, 1999, J BIOL CHEM, V274, P21056, DOI 10.1074/jbc.274.30.21056; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; Lim MS, 1999, ANN NY ACAD SCI, V878, P522, DOI 10.1111/j.1749-6632.1999.tb07715.x; Liu XW, 2003, J BIOL CHEM, V278, P40364, DOI 10.1074/jbc.M302999200; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; Maeda T, 1999, J EXP MED, V189, P1063, DOI 10.1084/jem.189.7.1063; Mansouri A, 2003, J BIOL CHEM, V278, P19245, DOI 10.1074/jbc.M208134200; Mariani SM, 1998, EUR J IMMUNOL, V28, P973, DOI 10.1002/(SICI)1521-4141(199803)28:03<973::AID-IMMU973>3.0.CO;2-T; MARIANI SM, 1995, EUR J IMMUNOL, V25, P2303, DOI 10.1002/eji.1830250828; Meneghini MD, 1999, NATURE, V399, P793, DOI 10.1038/21666; Miyamori H, 2001, J BIOL CHEM, V276, P28204, DOI 10.1074/jbc.M103083200; Morrison CJ, 2001, J BIOL CHEM, V276, P47402, DOI 10.1074/jbc.M108643200; Muda M, 1999, J BIOL CHEM, V274, P23991, DOI 10.1074/jbc.274.34.23991; Nakada M, 1999, AM J PATHOL, V154, P417, DOI 10.1016/S0002-9440(10)65288-1; Nakamura H, 1999, CANCER RES, V59, P467; Nayler O, 1998, J BIOL CHEM, V273, P34341, DOI 10.1074/jbc.273.51.34341; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nishihara H, 2004, J BIOL CHEM, V279, P26176, DOI 10.1074/jbc.M313346200; Ojala PM, 2000, NAT CELL BIOL, V2, P819, DOI 10.1038/35041064; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Ruckdeschel K, 2002, J IMMUNOL, V168, P4601, DOI 10.4049/jimmunol.168.9.4601; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sanchez-Perez I, 2000, ONCOGENE, V19, P5142, DOI 10.1038/sj.onc.1203887; Sanjo H, 1998, J BIOL CHEM, V273, P29066, DOI 10.1074/jbc.273.44.29066; Sato H, 1997, GENOMICS, V39, P412, DOI 10.1006/geno.1996.4496; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Shao NS, 1996, ONCOGENE, V13, P1; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shin HJ, 2003, CANCER CELL, V4, P483, DOI 10.1016/S1535-6108(03)00302-7; Shin MS, 2001, CANCER RES, V61, P4942; Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Strand S, 2004, ONCOGENE, V23, P3732, DOI 10.1038/sj.onc.1207387; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Tiganis T, 1999, J BIOL CHEM, V274, P27768, DOI 10.1074/jbc.274.39.27768; Ueno H, 1997, CANCER RES, V57, P2055; Valente P, 1998, INT J CANCER, V75, P246, DOI 10.1002/(SICI)1097-0215(19980119)75:2<246::AID-IJC13>3.0.CO;2-B; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wang YL, 2004, CANCER BIOL THER, V3, P305, DOI 10.4161/cbt.3.3.697; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Yasuda J, 2003, BIOCHEM BIOPH RES CO, V308, P227, DOI 10.1016/S0006-291X(03)01343-3	97	58	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34123	34132		10.1074/jbc.M508155200	http://dx.doi.org/10.1074/jbc.M508155200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16093241	hybrid			2022-12-27	WOS:000232229700053
J	Ficklin, MB; Zhao, SL; Feng, GP				Ficklin, MB; Zhao, SL; Feng, GP			Ubiquilin-1 regulates nicotine-induced up-regulation of neuronal nicotinic acetylcholine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE LACKING; RAT-BRAIN; CHOLINERGIC RECEPTOR; CHRONIC EXPOSURE; BINDING-SITES; IN-VIVO; ALPHA 3; PROTEIN; SUBUNIT; TRAFFICKING	Chronic exposure to nicotine, as in tobacco smoking, up-regulates nicotinic acetylcholine receptor surface expression in neurons. This up-regulation has been proposed to play a role in nicotine addiction and withdrawal. The regulatory mechanisms behind nicotine-induced up-regulation of surface nicotinic acetylcholine receptors remain to be determined. It has recently been suggested that nicotine stimulation acts through increased assembly and maturation of receptor subunits into functional pentameric receptors. Studies of muscle nicotinic acetylcholine receptors suggest that the availability of unassembled subunits in the endoplasmic reticulum can be regulated by the ubiquitin-proteosome pathway, resulting in altered surface expression. Here, we describe a role for ubiquilin-1, a ubiquitin-like protein with the capacity to interact with both the proteosome and ubiquitin ligases, in regulating nicotine-induced up-regulation of neuronal nicotinic acetylcholine receptors. Ubiquilin-1 interacts with unassembled alpha 3 and alpha 4 subunits when coexpressed in heterologous cells and interacts with endogenous nicotinic acetylcholine receptors in neurons. Coexpression of ubiquilin-1 and neuronal nicotinic acetylcholine receptors in heterologous cells dramatically reduces the expression of the receptors on the cell surface. In cultured superior cervical ganglion neurons, expression of ubiquilin-1 abolishes nicotine-induced up-regulation of nicotinic acetylcholine receptors but has no effect on the basal level of surface receptors. Coimmunostaining shows that the interaction of ubiquilin-1 with the alpha 3 subunit draws the receptor subunit and proteosome into a complex. These data suggest that ubiquilin-1 limits the availability of unassembled nicotinic acetylcholine receptor subunits in neurons by drawing them to the proteosome, thus regulating nicotine-induced up-regulation.	Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	Duke University; Duke University	Feng, GP (corresponding author), Duke Univ, Med Ctr, Dept Neurobiol, Box 3209,Res Dr, Durham, NC 27710 USA.	feng@neuro.duke.edu	Feng, Guoping/Y-2827-2019		NINDS NIH HHS [NS042609] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042609] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albuquerque EX, 1997, J PHARMACOL EXP THER, V280, P1117; Arroyo-Jimenez MD, 1999, J NEUROSCI, V19, P6475; Bedford FK, 2001, NAT NEUROSCI, V4, P908, DOI 10.1038/nn0901-908; Ben-Ami HC, 2005, J BIOL CHEM, V280, P28053, DOI 10.1074/jbc.M504369200; BENCHERIF M, 1995, J PHARMACOL EXP THER, V275, P987; BENWELL MEM, 1988, J NEUROCHEM, V50, P1243, DOI 10.1111/j.1471-4159.1988.tb10600.x; Bertram L, 2005, NEW ENGL J MED, V352, P884, DOI 10.1056/NEJMoa042765; Bredt DS, 2003, NEURON, V40, P361, DOI 10.1016/S0896-6273(03)00640-8; Buisson B, 2001, J NEUROSCI, V21, P1819, DOI 10.1523/JNEUROSCI.21-06-01819.2001; Castillo M, 2005, J BIOL CHEM, V280, P27062, DOI 10.1074/jbc.M503746200; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; Christianson JC, 2004, EMBO J, V23, P4156, DOI 10.1038/sj.emboj.7600436; Dani JA, 1996, NEURON, V16, P905, DOI 10.1016/S0896-6273(00)80112-9; Darsow T, 2005, J BIOL CHEM, V280, P18311, DOI 10.1074/jbc.M501157200; Del Signore A, 2002, NEUROBIOL DIS, V10, P54, DOI 10.1006/nbdi.2002.0495; Doi H, 2004, FEBS LETT, V571, P171, DOI 10.1016/j.febslet.2004.06.077; Feng GP, 1998, J NEUROSCI, V18, P4166; FENG GP, 1995, GENETICS, V139, P1679; Feng PH, 2004, MOL CELL BIOL, V24, P3938, DOI 10.1128/MCB.24.9.3938-3948.2004; Fenster CP, 1999, J NEUROSCI, V19, P4804; FLORES CM, 1992, MOL PHARMACOL, V41, P31; Gopalakrishnan M, 1997, MOL PHARMACOL, V52, P524, DOI 10.1124/mol.52.3.524; Gotti C, 2004, PROG NEUROBIOL, V74, P363, DOI 10.1016/j.pneurobio.2004.09.006; Halevi S, 2003, J BIOL CHEM, V278, P34411, DOI 10.1074/jbc.M300170200; Halevi S, 2002, EMBO J, V21, P1012, DOI 10.1093/emboj/21.5.1012; Jeanclos EM, 2001, J BIOL CHEM, V276, P28281, DOI 10.1074/jbc.M011549200; Kaye FJ, 2000, FEBS LETT, V467, P348, DOI 10.1016/S0014-5793(00)01135-2; Keller SH, 1996, J BIOL CHEM, V271, P22871, DOI 10.1074/jbc.271.37.22871; Kleijnen MF, 2000, MOL CELL, V6, P409, DOI 10.1016/S1097-2765(00)00040-X; Kleijnen MF, 2003, MOL BIOL CELL, V14, P3868, DOI 10.1091/mbc.E02-11-0766; Lassle M, 1997, J BIOL CHEM, V272, P1876, DOI 10.1074/jbc.272.3.1876; Lindstrom J, 1996, Ion Channels, V4, P377; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Mah AL, 2000, J CELL BIOL, V151, P847, DOI 10.1083/jcb.151.4.847; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; MANDELZYS A, 1994, J NEUROSCI, V14, P2357; MARKS MJ, 1985, J PHARMACOL EXP THER, V235, P619; MARKS MJ, 1992, J NEUROSCI, V12, P2765; Marubio LM, 1999, NATURE, V398, P805, DOI 10.1038/19756; Massey LK, 2004, J ALZHEIMERS DIS, V6, P79; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; MULLE C, 1991, J NEUROSCI, V11, P2588; Nashmi R, 2003, J NEUROSCI, V23, P11554; Pakkanen JS, 2005, EUR J NEUROSCI, V21, P2681, DOI 10.1111/j.1460-9568.2005.04105.x; Parker MJ, 2004, J NEUROSCI, V24, P378, DOI 10.1523/JNEUROSCI.3865-03.2004; Peng X, 1997, MOL PHARMACOL, V51, P776, DOI 10.1124/mol.51.5.776; PENG X, 1994, MOL PHARMACOL, V46, P523; Perry DC, 1999, J PHARMACOL EXP THER, V289, P1545; PICCIOTTO MR, 1995, NATURE, V374, P65, DOI 10.1038/374065a0; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Role LW, 1996, NEURON, V16, P1077, DOI 10.1016/S0896-6273(00)80134-8; RUST G, 1994, EUR J NEUROSCI, V6, P478, DOI 10.1111/j.1460-9568.1994.tb00290.x; Sallette J, 2004, J BIOL CHEM, V279, P18767, DOI 10.1074/jbc.M308260200; Sallette J, 2005, NEURON, V46, P595, DOI 10.1016/j.neuron.2005.03.029; SCHWARTZ RD, 1983, SCIENCE, V220, P214, DOI 10.1126/science.6828889; SCHWARTZ RD, 1985, J NEUROCHEM, V45, P427, DOI 10.1111/j.1471-4159.1985.tb04005.x; Vallejo YF, 2005, J NEUROSCI, V25, P5563, DOI 10.1523/JNEUROSCI.5240-04.2005; VOJTEK AB, 1993, J CELL SCI, V105, P777; Wang F, 1996, J BIOL CHEM, V271, P17656, DOI 10.1074/jbc.271.30.17656; Wang F, 1998, J BIOL CHEM, V273, P28721, DOI 10.1074/jbc.273.44.28721; Wang JM, 2002, NAT NEUROSCI, V5, P963, DOI 10.1038/nn918; Whiteaker P, 1998, MOL PHARMACOL, V53, P950; Williams BM, 1998, NAT NEUROSCI, V1, P557, DOI 10.1038/2792; WONNACOTT S, 1990, TRENDS PHARMACOL SCI, V11, P216, DOI 10.1016/0165-6147(90)90242-Z; Xu W, 1999, P NATL ACAD SCI USA, V96, P5746, DOI 10.1073/pnas.96.10.5746; Xu W, 1999, J NEUROSCI, V19, P9298; Yeh JJ, 2001, J NEUROCHEM, V77, P336, DOI 10.1046/j.1471-4159.2001.00259.x; ZOLI M, 1995, J NEUROSCI, V15, P1912, DOI 10.1523/JNEUROSCI.15-03-01912.1995	68	48	49	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34088	34095		10.1074/jbc.M506781200	http://dx.doi.org/10.1074/jbc.M506781200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16091357	hybrid			2022-12-27	WOS:000232229700049
J	Lahiri, S; Futerman, AH				Lahiri, S; Futerman, AH			LASS5 is a bona fide dihydroceramide synthase that selectively utilizes palmitoyl-CoA as acyl donor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONGEVITY ASSURANCE GENE-1; CERAMIDE SYNTHASE; SPHINGOLIPID SYNTHESIS; FAMILY-MEMBERS; LAG1; DOMAINS; GROWTH; LAC1P	We demonstrated recently (Riebeling, C., Allegood, J. C., Wang, E., Merrill, A. H. Jr., and Futerman, A. H. ( 2003) J. Biol. Chem. 278, 43452 - 43459) that upon over-expression in human embryonic kidney cells, longevity assurance gene homolog 5 (LASS5, previously named TRH4) elevates the synthesis of ( dihydro) ceramides selectively enriched in palmitic acid. To determine whether LASS5 is a bona fide dihydroceramide synthase or, alternatively, whether it modifies an endogenous dihydroceramide synthase, we over-expressed LASS5 with a hemagglutinin ( HA) tag at the C terminus, solubilized it using digitonin, and purified it by immunoprecipitation. Solubilized LASS5-HA displays the same fatty acid selectivity as the membrane-bound enzyme. After elution from agarose beads, only one band could be detected by SDS-PAGE, and its identity was confirmed to be LASS5 by mass spectrometry. Dihydroceramide synthase activity of the eluted LASS5-HA protein was totally dependent on exogenously added phospholipids. Moreover, eluted LASS5-HA was highly selective toward palmitoyl-CoA as acyl donor and was inhibited by the ( dihydro) ceramide synthase inhibitor, fumonisin B1. This study identifies LASS5 as a genuine dihydroceramide synthase and demonstrates that mammalian dihydroceramide synthases do not require additional subunits for their activity.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Futerman, AH (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	tony.futerman@weizmann.ac.il		Futerman, Anthony/0000-0003-0013-0115				Bodennec J, 2002, FASEB J, V16, P1814, DOI 10.1096/fj.02-0149fje; Futerman AH, 2004, EMBO REP, V5, P777, DOI 10.1038/sj.embor.7400208; Futerman AH, 2005, TRENDS CELL BIOL, V15, P312, DOI 10.1016/j.tcb.2005.04.006; Guillas I, 2001, EMBO J, V20, P2655, DOI 10.1093/emboj/20.11.2655; Gulbins E, 2003, ONCOGENE, V22, P7070, DOI 10.1038/sj.onc.1207146; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; Kok JW, 1997, J BIOL CHEM, V272, P21128, DOI 10.1074/jbc.272.34.21128; Koybasi S, 2004, J BIOL CHEM, V279, P44311, DOI 10.1074/jbc.M406920200; Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200; Merrill AH, 1996, TRENDS CELL BIOL, V6, P218, DOI 10.1016/0962-8924(96)10021-0; Mizutani Y, 2005, BIOCHEM J, V390, P263, DOI 10.1042/BJ20050291; Riebeling C, 2003, J BIOL CHEM, V278, P43452, DOI 10.1074/jbc.M307104200; Schorling S, 2001, MOL BIOL CELL, V12, P3417, DOI 10.1091/mbc.12.11.3417; Vallee B, 2005, EMBO J, V24, P730, DOI 10.1038/sj.emboj.7600562; Venkataraman K, 2002, FEBS LETT, V528, P3, DOI 10.1016/S0014-5793(02)03248-9; Venkataraman K, 2002, J BIOL CHEM, V277, P35642, DOI 10.1074/jbc.M205211200; Winter E, 2002, TRENDS BIOCHEM SCI, V27, P381, DOI 10.1016/S0968-0004(02)02154-0; Xu ZW, 2005, J LIPID RES, V46, P1229, DOI 10.1194/jlr.M500001-JLR200	19	92	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33735	33738		10.1074/jbc.M506485200	http://dx.doi.org/10.1074/jbc.M506485200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16100120	hybrid			2022-12-27	WOS:000232229700008
J	Wu, ZLL; Lech, M				Wu, ZLL; Lech, M			Characterizing the non-reducing end structure of heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDURONATE 2-SULFATE RESIDUES; FIBROBLAST-GROWTH; BINDING-SITES; PROTEOGLYCANS; GLUCOSAMINE; INVOLVEMENT; LOCATION	The reducing end of heparan sulfate has been known for a long time, but information on the non-reducing end has been lacking. Recent studies indicate that the non-reducing end of heparan sulfate might be the place where fibroblast growth factor signaling complex forms. The non-reducing end also changes with heparanase digestion and, thus, might serve as amarker for tumor pathology. Using high performance liquid chromatography-coupled mass spectrometry, we have identified and characterized the non-reducing end of bovine kidney heparan sulfate. We find that the non-reducing end region is highly sulfated and starts with a glucuronic acid ( GlcA) residue. The likely sequence of the non-reducing end hexasaccharides is GlcA-GlcNS6S-UA +/- 2S- GlcNS +/- 6S- Ido2SGlcNS +/- 6S ( where GlcNS is N-sulfate-D-glucosamine, S is sulfate, UA is uronic acid, and Ido is iduronic acid). Our data suggests that the non-reducing end of bovine kidney heparan sulfate is not trimmed by heparanase and is capable of supporting fibroblast growth factor signaling complex formation.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Wu, ZLL (corresponding author), MIT, Dept Biol, 31 Ames St,Bldg 68-247, Cambridge, MA 02139 USA.	zwu@mit.edu		Wu, Zhengliang/0000-0002-0700-0906	NHLBI NIH HHS [P01 HL66105, R501 HL59479] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL066105, R01HL059479] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bame KJ, 2001, GLYCOBIOLOGY, V11, p91R, DOI 10.1093/glycob/11.6.91R; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; Goldshmidt O, 2002, EXP CELL RES, V281, P50, DOI 10.1006/excr.2002.5651; KNECHT J, 1967, J BIOL CHEM, V242, P4652; Kreuger J, 2005, BIOCHEM J, V389, P145, DOI 10.1042/BJ20042129; Kuberan B, 2002, J AM CHEM SOC, V124, P8707, DOI 10.1021/ja0178867; Lander AD, 1998, MATRIX BIOL, V17, P465, DOI 10.1016/S0945-053X(98)90093-2; Lin XH, 2004, DEVELOPMENT, V131, P6009, DOI 10.1242/dev.01522; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LINKER A, 1984, CARBOHYD RES, V127, P75, DOI 10.1016/0008-6215(84)85107-1; Liu J, 2002, J BIOL CHEM, V277, P33456, DOI 10.1074/jbc.M202034200; LYON M, 1987, BIOCHEM J, V242, P493, DOI 10.1042/bj2420493; LYON M, 1994, J BIOL CHEM, V269, P11208; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; Merry CLR, 1999, J BIOL CHEM, V274, P18455, DOI 10.1074/jbc.274.26.18455; PARTHASARATHY N, 1984, J BIOL CHEM, V259, P2749; Perrimon N, 2004, DEVELOPMENT, V131, P2509, DOI 10.1242/dev.01225; Pikas DS, 1998, J BIOL CHEM, V273, P18770, DOI 10.1074/jbc.273.30.18770; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Sanderson RD, 2004, MATRIX BIOL, V23, P341, DOI 10.1016/j.matbio.2004.08.004; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Stringer SE, 2003, GLYCOBIOLOGY, V13, P97, DOI 10.1093/glycob/cwg006; Thanawiroon C, 2004, J BIOL CHEM, V279, P2608, DOI 10.1074/jbc.M304772200; Turnbull J E, 2001, Methods Mol Biol, V171, P129; TURNBULL JE, 1991, BIOCHEM J, V277, P297, DOI 10.1042/bj2770297; Turnbull JE, 1999, P NATL ACAD SCI USA, V96, P2698, DOI 10.1073/pnas.96.6.2698; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; Venkataraman G, 1999, SCIENCE, V286, P537, DOI 10.1126/science.286.5439.537; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; Westling C, 2002, J BIOL CHEM, V277, P49247, DOI 10.1074/jbc.M209139200; Wu ZLL, 2004, J BIOL CHEM, V279, P1861, DOI 10.1074/jbc.M311398200; Wu ZLL, 2003, J BIOL CHEM, V278, P17121, DOI 10.1074/jbc.M212590200; Xu D, 2005, BIOCHEM J, V385, P451, DOI 10.1042/BJ20040908; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Zetser A, 2004, J CELL SCI, V117, P2249, DOI 10.1242/jcs.01068; Zhang LJ, 2001, J BIOL CHEM, V276, P42311, DOI 10.1074/jbc.M101441200; Zhang Z, 2001, J BIOL CHEM, V276, P41921, DOI 10.1074/jbc.M106608200	38	26	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33749	33755		10.1074/jbc.M505677200	http://dx.doi.org/10.1074/jbc.M505677200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16079142	hybrid			2022-12-27	WOS:000232229700010
J	Hirano, K; Miki, Y; Hirai, Y; Sato, R; Itoh, T; Hayashi, A; Yamanaka, M; Eda, S; Beppu, M				Hirano, K; Miki, Y; Hirai, Y; Sato, R; Itoh, T; Hayashi, A; Yamanaka, M; Eda, S; Beppu, M			A multifunctional shuttling protein nucleolin is a macrophage receptor for apoptotic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLLACTOSAMINYL SACCHARIDE CHAINS; DENSITY-LIPOPROTEIN RECEPTOR; SURFACE-EXPRESSED NUCLEOLIN; 3 AUTOANTIBODY BINDING; OXIDIZED ERYTHROCYTES; ENDOTHELIAL-CELLS; TARGET-CELLS; SUGAR CHAINS; THP-1 CELLS; RECOGNITION	Early apoptotic Jurkat T cells undergo capping of CD43, and its polylactosaminyl saccharide chains serve as ligands for phagocytosis by macrophages. This suggests the presence of a polylactosaminoglycan-binding receptor on macrophages. Here we show that this receptor is nucleolin, a multifunctional shuttling protein present in nucleus, cytoplasm, and on the surface of some types of cells. Nucleolin was detected at the surface of macrophages, and anti-nucleolin antibody inhibited the binding of the early apoptotic cells to macrophages. Nucleolin-transfected HEK293 cells expressed nucleolin on the cell surface and bound the early apoptotic cells but not phosphatidylserine-exposing late apoptotic cells. This binding was inhibited by anti-nucleolin antibody, by polylactosamine-containing oligosaccharides, and by anti-CD43 antibody. Deletion of the antibody binding region of nucleolin resulted in loss of the apoptotic cell-binding ability. Moreover, truncated recombinant nucleolin in solution containing this region blocked the apoptotic cell binding to macrophages, and the blocking effect was cancelled by the oligosaccharides. These results indicate that nucleolin is a macrophage receptor for apoptotic cells.	Tokyo Univ Pharm & Life Sci, Sch Pharm, Hachioji, Tokyo 1920392, Japan	Tokyo University of Pharmacy & Life Sciences	Beppu, M (corresponding author), Tokyo Univ Pharm & Life Sci, Sch Pharm, 1432-1 Horinouchi, Hachioji, Tokyo 1920392, Japan.	beppum@ps.toyaku.ac.jp						Ando K, 1997, ARCH BIOCHEM BIOPHYS, V339, P250, DOI 10.1006/abbi.1996.9831; Balasubramanian K, 1997, J BIOL CHEM, V272, P31113, DOI 10.1074/jbc.272.49.31113; BEPPU M, 1994, ARCH BIOCHEM BIOPHYS, V312, P189, DOI 10.1006/abbi.1994.1298; Beppu M, 2001, BIOL PHARM BULL, V24, P19, DOI 10.1248/bpb.24.19; Beppu M, 2000, ARCH BIOCHEM BIOPHYS, V384, P368, DOI 10.1006/abbi.2000.2122; Beppu M, 1996, BIOL PHARM BULL, V19, P188; Beppu M, 1996, CELL MOL BIOL, V42, P1007; Bose S, 2004, J VIROL, V78, P8146, DOI 10.1128/JVI.78.15.8146-8158.2004; CHEN CM, 1991, J BIOL CHEM, V266, P7754; Christian S, 2003, J CELL BIOL, V163, P871, DOI 10.1083/jcb.200304132; DEVERDUGO UR, 1995, J VIROL, V69, P6751, DOI 10.1128/JVI.69.11.6751-6757.1995; Devitt A, 1998, NATURE, V392, P505, DOI 10.1038/33169; DINI L, 1992, FEBS LETT, V296, P174, DOI 10.1016/0014-5793(92)80373-O; DUVALL E, 1985, IMMUNOLOGY, V56, P351; Eda S, 2004, J BIOL CHEM, V279, P5967, DOI 10.1074/jbc.M310805200; Eda S, 2001, ARCH BIOCHEM BIOPHYS, V385, P186, DOI 10.1006/abbi.2000.2142; Eda S, 1997, BIOL PHARM BULL, V20, P127, DOI 10.1248/bpb.20.127; Fadok VA, 2001, J CLIN INVEST, V108, P957, DOI 10.1172/JCI14122; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Fadok VA, 1998, CELL DEATH DIFFER, V5, P551, DOI 10.1038/sj.cdd.4400404; Falasca L, 1996, EXP CELL RES, V224, P152, DOI 10.1006/excr.1996.0123; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; Garcia-Garcia E, 2002, J LEUKOCYTE BIOL, V72, P107; Ginisty H, 1999, J CELL SCI, V112, P761; HALL SE, 1994, J IMMUNOL, V153, P3218; Hanakahi LA, 1997, P NATL ACAD SCI USA, V94, P3605, DOI 10.1073/pnas.94.8.3605; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Harms G, 2001, BIOCHEM J, V360, P531, DOI 10.1042/0264-6021:3600531; Hovanessian AG, 2000, EXP CELL RES, V261, P312, DOI 10.1006/excr.2000.5071; JORDAN G, 1987, NATURE, V329, P489, DOI 10.1038/329489a0; KIBBEY MC, 1995, J NEUROSCI RES, V42, P314, DOI 10.1002/jnr.490420305; Legrand D, 2004, EUR J BIOCHEM, V271, P303, DOI 10.1046/j.1432-1033.2003.03929.x; Maderna P, 2003, BBA-MOL BASIS DIS, V1639, P141, DOI 10.1016/j.bbadis.2003.09.004; MATSUMOTO A, 1982, J BIOCHEM-TOKYO, V91, P143, DOI 10.1093/oxfordjournals.jbchem.a133671; MEHES G, 1995, CELL PROLIFERAT, V28, P329, DOI 10.1111/j.1365-2184.1995.tb00074.x; Mevorach D, 1998, J EXP MED, V188, P2313, DOI 10.1084/jem.188.12.2313; MORRIS RG, 1984, AM J PATHOL, V115, P426; MURAKAMI T, 1991, J BIOCHEM-TOKYO, V110, P146, DOI 10.1093/oxfordjournals.jbchem.a123533; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Nisole S, 2002, J BIOL CHEM, V277, P20877, DOI 10.1074/jbc.M110024200; Nisole S, 2002, EXP CELL RES, V276, P155, DOI 10.1006/excr.2002.5522; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Oka K, 1998, P NATL ACAD SCI USA, V95, P9535, DOI 10.1073/pnas.95.16.9535; Ostberg JR, 1998, IMMUNOL TODAY, V19, P546, DOI 10.1016/S0167-5699(98)01343-7; PEARSON AM, 1993, J BIOL CHEM, V268, P3546; Ren Y, 1998, CELL DEATH DIFFER, V5, P563, DOI 10.1038/sj.cdd.4400407; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Said EA, 2002, J BIOL CHEM, V277, P37492, DOI 10.1074/jbc.M201194200; SAMBRANO GR, 1995, P NATL ACAD SCI USA, V92, P1396, DOI 10.1073/pnas.92.5.1396; SAPP M, 1989, EUR J BIOCHEM, V179, P541, DOI 10.1111/j.1432-1033.1989.tb14581.x; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; Schwende H, 1996, J LEUKOCYTE BIOL, V59, P555, DOI 10.1002/jlb.59.4.555; SEMENKOVICH CF, 1990, BIOCHEMISTRY-US, V29, P9708, DOI 10.1021/bi00493a028; Sinclair JF, 2002, J BIOL CHEM, V277, P2876, DOI 10.1074/jbc.M110230200; Somersan S, 2001, J CELL BIOL, V155, P501, DOI 10.1083/jcb.200110066; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; Vandivier RW, 2002, J IMMUNOL, V169, P3978, DOI 10.4049/jimmunol.169.7.3978; Williamson P, 2002, BBA-MOL CELL BIOL L, V1585, P53, DOI 10.1016/S1388-1981(02)00324-4; Yamanaka M, 2005, BIOCHEM BIOPH RES CO, V328, P273, DOI 10.1016/j.bbrc.2004.12.171	61	56	58	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39284	39293		10.1074/jbc.M505275200	http://dx.doi.org/10.1074/jbc.M505275200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16135517	hybrid			2022-12-27	WOS:000233362200047
J	Lagor, WR; de Groh, ED; Ness, GC				Lagor, WR; de Groh, ED; Ness, GC			Diabetes alters the occupancy of the hepatic 3-hydroxy-3-methylglutaryl-CoA reductase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; STEROL-REGULATORY-ELEMENT; HMG-COA REDUCTASE; IN-VIVO; DIETARY-CHOLESTEROL; GENE-EXPRESSION; BINDING PROTEIN; HORMONAL-REGULATION; IDENTIFICATION; TRANSCRIPTION	Hepatic 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) protein and mRNA are substantially decreased in diabetic animals and rapidly restored by the administration of insulin. To begin to examine the underlying molecular mechanisms, measurements of transcription by nuclear run-on assays and an investigation of occupancy of the promoter were performed. The rate of transcription was substantially reduced in the diabetic rats and fully restored within 2 h after insulin treatment. In vivo footprinting revealed several areas of protein binding as shown by dimethyl sulfate protection or enhancement. The cAMP-response element was heavily protected in all conditions, including diabetes, feeding of dietary cholesterol, or statin treatment. Striking enhancements in footprints from diabetic animals were visible at - 142 and at - 161 ( in the sterol-response element). Protections at a newly identified NF-Y site at - 70/-71 were observed in normal animals and not in diabetics. This NF-Y site was found to be required for efficient HMGR transcription in luciferase assays. CREB-1 was able to bind the HMGR cAMP-response element in vitro and the promoter in vivo. This evidence supports an essential role for cAMP-response element-binding protein in transcription of hepatic HMGR and identifies at least two sites where in vivo occupancy is regulated by insulin.	Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	State University System of Florida; University of South Florida	Ness, GC (corresponding author), Univ S Florida, Coll Med, Dept Biochem & Mol Biol, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.	gness@hsc.usf.edu		Lagor, William/0000-0002-1703-5125				Armitage J, 2004, CURR OPIN LIPIDOL, V15, P439, DOI 10.1097/01.mol.0000137219.31407.16; Bennett MK, 2004, J BIOL CHEM, V279, P37360, DOI 10.1074/jbc.M404693200; BIFULCO M, 1995, J BIOL CHEM, V270, P15231, DOI 10.1074/jbc.270.25.15231; Bossard P, 1997, METHODS, V11, P180, DOI 10.1006/meth.1996.0404; Chambers CM, 1997, BIOCHEM BIOPH RES CO, V232, P278, DOI 10.1006/bbrc.1997.6288; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; Kersten S, 2001, EMBO REP, V2, P282, DOI 10.1093/embo-reports/kve071; KRIWACKI RW, 1992, P NATL ACAD SCI USA, V89, P9759, DOI 10.1073/pnas.89.20.9759; Latasa MJ, 2003, MOL CELL BIOL, V23, P5896, DOI 10.1128/MCB.23.16.5896-5907.2003; LLOYD DB, 1995, J BIOL CHEM, V270, P25812, DOI 10.1074/jbc.270.43.25812; Lopez D, 1997, ARCH BIOCHEM BIOPHYS, V343, P118, DOI 10.1006/abbi.1997.0162; MANO H, 1994, J BIOL CHEM, V269, P1591; Miettinen TA, 2004, DIABETES CARE, V27, P53, DOI 10.2337/diacare.27.1.53; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Ness GC, 2004, EXP BIOL MED, V229, P407, DOI 10.1177/153537020422900508; Ness GC, 2004, EXP BIOL MED, V229, P412, DOI 10.1177/153537020422900509; NESS GC, 1994, ARCH BIOCHEM BIOPHYS, V309, P193, DOI 10.1006/abbi.1994.1102; Ness GC, 2000, P SOC EXP BIOL MED, V224, P8, DOI 10.1046/j.1525-1373.2000.22359.x; Ngo TT, 2002, J BIOL CHEM, V277, P33901, DOI 10.1074/jbc.M202135200; Osborne AR, 2004, BIOCHEM BIOPH RES CO, V318, P814, DOI 10.1016/j.bbrc.2004.04.105; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; OSBORNE TF, 1985, CELL, V42, P203, DOI 10.1016/S0092-8674(85)80116-1; OSBORNE TF, 1987, P NATL ACAD SCI USA, V84, P3614, DOI 10.1073/pnas.84.11.3614; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; SINGER II, 1984, P NATL ACAD SCI-BIOL, V81, P5556, DOI 10.1073/pnas.81.17.5556; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang CK, 2005, BIOCHEM J, V386, P161, DOI 10.1042/BJ20041514	30	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36601	36608		10.1074/jbc.M504346200	http://dx.doi.org/10.1074/jbc.M504346200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16127173	hybrid			2022-12-27	WOS:000232901800010
J	Matsui, T; Nakajima, A; Fujii, H; Matera, KM; Migita, CT; Yoshida, T; Ikeda-Saito, M				Matsui, T; Nakajima, A; Fujii, H; Matera, KM; Migita, CT; Yoshida, T; Ikeda-Saito, M			O-2- and H2O2-dependent verdoheme degradation by heme oxygenase - Reaction mechanisms and potential physiological roles of the dual pathway degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERROUS-NO FORMS; CARBON-MONOXIDE; CRYSTAL-STRUCTURE; CORYNEBACTERIUM-DIPHTHERIAE; CATALYTIC IMPLICATIONS; BILIVERDIN REDUCTASE; ACTIVATION; COMPLEX; DIOXYGEN; SYSTEM	Heme oxygenase (HO) catalyzes the catabolism of heme to biliverdin, CO, and a free iron through three successive oxygenation steps. The third oxygenation, oxidative degradation of verdoheme to biliverdin, has been the least understood step despite its importance in regulating HO activity. We have examined in detail the degradation of a synthetic verdoheme IX alpha complexed with rat HO-1. Our findings include: 1) HO degrades verdoheme through a dual pathway using either O-2 or H2O2; 2) the verdoheme reactivity with O-2 is the lowest among the three O-2 reactions in the HO catalysis, and the newly found H2O2 pathway is similar to 40-fold faster than the O-2-dependent verdoheme degradation; 3) both reactions are initiated by the binding of O-2 or H2O2 to allow the first direct observation of degradation intermediates of verdoheme; and 4) Asp(140) in HO-1 is critical for the verdoheme degradation regardless of the oxygen source. On the basis of these findings, we propose that the HO enzyme activates O-2 and H2O2 on the verdoheme iron with the aid of a nearby water molecule linked with Asp140. These mechanisms are similar to the well established mechanism of the first oxygenation, meso-hydroxylation of heme, and thus, HO can utilize a common architecture to promote the first and third oxygenation steps of the heme catabolism. In addition, our results infer the possible involvement of the H2O2-dependent verdoheme degradation in vivo, and potential roles of the dual pathway reaction of HO against oxidative stress are proposed.	Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan; Natl Inst Nat Sci, Inst Mol Sci, Okazaki, Aichi 4448787, Japan; Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Okazaki, Aichi 4448787, Japan; Baldwin Wallace Coll, Dept Chem, Berea, OH 44017 USA; Yamaguchi Univ, Fac Agr, Dept Biol Chem, Yamaguchi 7538515, Japan; Yamagata Univ, Sch Med, Dept Biochem, Yamagata 9909585, Japan	Tohoku University; National Institutes of Natural Sciences (NINS) - Japan; Institute for Molecular Science (IMS); National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); Baldwin Wallace University; Yamaguchi University; Yamagata University	Matsui, T (corresponding author), Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan.	matsui@tagen.tohoku.ac.jp; mis2@tagen.tohoku.ac.jp	Ikeda-Saito, Masao/K-2703-2015; Ikeda-Saito, Masao/A-5992-2008; Matsui, Toshitaka/B-1570-2008	Matsui, Toshitaka/0000-0003-3865-8468				Antunes F, 2000, FEBS LETT, V475, P121, DOI 10.1016/S0014-5793(00)01638-0; Baranano DE, 2002, P NATL ACAD SCI USA, V99, P16093, DOI 10.1073/pnas.252626999; BEALE SI, 1993, CHEM REV, V93, P785, DOI 10.1021/cr00018a008; Boehning D, 2004, J BIOL CHEM, V279, P30927, DOI 10.1074/jbc.C400222200; Boehning D, 2003, NEURON, V40, P129, DOI 10.1016/S0896-6273(03)00596-8; Braun RD, 2001, AM J PHYSIOL-HEART C, V280, pH2533, DOI 10.1152/ajpheart.2001.280.6.H2533; Davis SJ, 1999, P NATL ACAD SCI USA, V96, P6541, DOI 10.1073/pnas.96.11.6541; Davydov R, 2004, J AM CHEM SOC, V126, P15960, DOI 10.1021/ja044646t; Davydov R, 2002, J AM CHEM SOC, V124, P1798, DOI 10.1021/ja0122391; De Montellano PRO, 1998, ACCOUNTS CHEM RES, V31, P543; DOCHERTY JC, 1984, J BIOL CHEM, V259, P3066; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Erecinska M, 2001, RESP PHYSIOL, V128, P263, DOI 10.1016/S0034-5687(01)00306-1; Fujii H, 2001, J AM CHEM SOC, V123, P6475, DOI 10.1021/ja010490a; Genco CA, 2001, MOL MICROBIOL, V39, P1, DOI 10.1046/j.1365-2958.2001.02231.x; HIROTA T, 1983, TETRAHEDRON LETT, V24, P995, DOI 10.1016/S0040-4039(00)81585-3; ISHIKAWA K, 1995, J BIOL CHEM, V270, P6345, DOI 10.1074/jbc.270.11.6345; Jiang JJ, 1996, J APPL PHYSIOL, V80, P552, DOI 10.1152/jappl.1996.80.2.552; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; Koerner R, 1998, J AM CHEM SOC, V120, P9246, DOI 10.1021/ja980558v; Kumar D, 2005, J AM CHEM SOC, V127, P8204, DOI 10.1021/ja0446956; Lad L, 2004, J INORG BIOCHEM, V98, P1686, DOI 10.1016/j.jinorgbio.2004.07.004; Lad L, 2003, J MOL BIOL, V330, P527, DOI 10.1016/S0022-2836(03)00578-3; Lightning LK, 2001, J BIOL CHEM, V276, P10612, DOI 10.1074/jbc.M010349200; Liu Y, 2000, J BIOL CHEM, V275, P5297, DOI 10.1074/jbc.275.8.5297; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Matera KM, 1996, J BIOL CHEM, V271, P6618, DOI 10.1074/jbc.271.12.6618; Matera KM, 1997, BIOCHEMISTRY-US, V36, P4909, DOI 10.1021/bi962321m; Matsui T, 2005, J BIOL CHEM, V280, P2981, DOI 10.1074/jbc.M410263200; Migita CT, 1998, J BIOL CHEM, V273, P945, DOI 10.1074/jbc.273.2.945; Nguyen KT, 2004, J AM CHEM SOC, V126, P6210, DOI 10.1021/ja049222d; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; RAMETTE RW, 1965, J AM CHEM SOC, V87, P5001, DOI 10.1021/ja00950a005; SAITO S, 1982, P NATL ACAD SCI-BIOL, V79, P1393, DOI 10.1073/pnas.79.5.1393; SAITO S, 1986, J CHEM SOC PERK T 1, P1, DOI 10.1039/p19860000001; Sakamoto H, 2002, EUR J BIOCHEM, V269, P5231, DOI 10.1046/j.1432-1033.2002.03230.x; Sakamoto H, 2000, J INORG BIOCHEM, V82, P113, DOI 10.1016/S0162-0134(00)00149-5; SCHACTER BA, 1972, J BIOL CHEM, V247, P3601; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; Suematsu M, 2000, HEPATOLOGY, V31, P3, DOI 10.1002/hep.510310102; Sugishima M, 2000, FEBS LETT, V471, P61, DOI 10.1016/S0014-5793(00)01353-3; Sun D, 2000, ACTA CRYSTALLOGR D, V56, P1180, DOI 10.1107/S0907444900008520; Takahashi S, 1997, BIOCHEMISTRY-US, V36, P1402, DOI 10.1021/bi962361q; TAKAHASHI S, 1994, J BIOL CHEM, V269, P1010; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; Unno M, 2004, J BIOL CHEM, V279, P21055, DOI 10.1074/jbc.M400491200; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Wandersman C, 2000, CURR OPIN MICROBIOL, V3, P215, DOI 10.1016/S1369-5274(00)00078-3; WILKS A, 1993, J BIOL CHEM, V268, P22357; Williams SEJ, 2004, SCIENCE, V306, P2093, DOI 10.1126/science.1105010; YOSHIDA T, 1978, J BIOL CHEM, V253, P4230; Zhang XH, 2003, BIOCHEMISTRY-US, V42, P7418, DOI 10.1021/bi027173g	52	52	53	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36833	36840		10.1074/jbc.M503529200	http://dx.doi.org/10.1074/jbc.M503529200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16115896	hybrid, Green Submitted			2022-12-27	WOS:000232901800038
J	Tomidokoro, Y; Lashley, T; Rostagno, A; Neubert, TA; Bojsen-Moller, M; Braendgaard, H; Plant, G; Holton, J; Frangione, B; Revesz, T; Ghiso, J				Tomidokoro, Y; Lashley, T; Rostagno, A; Neubert, TA; Bojsen-Moller, M; Braendgaard, H; Plant, G; Holton, J; Frangione, B; Revesz, T; Ghiso, J			Familial Danish dementia - Co-existence of Danish and Alzheimer amyloid subunits (ADan and A beta) in the absence of compact plaques	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY CEREBRAL-HEMORRHAGE; ANGIOPATHY BRITISH TYPE; PYROGLUTAMYL-PEPTIDES; PRESENILE-DEMENTIA; GLUTAMINYL CYCLASE; MASS-SPECTROMETRY; SPASTIC PARALYSIS; APOLIPOPROTEIN-E; TRANSGENIC MICE; DOWNS-SYNDROME	Familial Danish dementia is an early onset autosomal dominant neurodegenerative disorder linked to a genetic defect in the BRI2 gene and clinically characterized by dementia and ataxia. Cerebral amyloid and preamyloid deposits of two unrelated molecules ( Danish amyloid (ADan) and beta-amyloid(A beta)), the absence of compact plaques, and neurofibrillary degeneration indistinguishable from that observed in Alzheimer disease ( AD) are the main neuropathological features of the disease. Biochemical analysis of extracted amyloid and preamyloid species indicates that as the solubility of the deposits decreases, the heterogeneity and complexity of the extracted peptides exponentially increase. Nonfibrillar deposits were mainly composed of intact A Dan-(1-34) and its N-terminally modified ( pyroglutamate) counterpart together with A beta- ( 1 - 42) and A beta-( 4 - 42) in similar to 1: 1 mixture. The post-translational modification, glutamate to pyroglutamate, was not present in soluble circulating ADan. In the amyloid fractions, ADan was heavily oligomerized and highly heterogeneous at the N and C terminus, and, when intact, its N terminus was post-translationally modified ( pyroglutamate), whereas A beta was mainly A beta- ( 4 - 42). In all cases, the presence of A beta-(X-40) was negligible, a surprising finding in view of the prevalence of A beta 40 in vascular deposits observed in sporadic and familial AD, Down syndrome, and normal aging. Whether the presence of the two amyloid subunits is imperative for the disease phenotype or just reflects a conformational mimicry remains to be elucidated; nonetheless, a specific interaction between ADan oligomers and A beta molecules was demonstrated in vitro by ligand blot analysis using synthetic peptides. The absence of compact plaques in the presence of extensive neurofibrillar degeneration strongly suggests that compact plaques, fundamental lesions for the diagnosis of AD, are not essential for the mechanism of dementia.	NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Dept Psychiat, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10016 USA; Inst Neurol, Dept Neuropathol, London WC1N 3BG, England; Inst Neurol, Brain Bank, London WC1N 3BG, England; Aarhus Univ Hosp, Dept Neuropathol, DK-8000 Aarhus, Denmark; Aarhus Univ Hosp, Dept Neurol, DK-8000 Aarhus, Denmark; UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England	New York University; New York University; New York University; New York University; University of London; University College London; University of London; King's College London; University College London; Aarhus University; Aarhus University; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Ghiso, J (corresponding author), NYU, Sch Med, Dept Pathol, 550 1st Ave,TH-432, New York, NY 10016 USA.	ghisoj01@popmail.med.nyu.edu	Holton, Janice L/F-6831-2011; Revesz, Tamas/A-8732-2010; Rostagno, Agueda/A-5801-2008; Lashley, Tammaryn/D-2583-2009	Holton, Janice L/0000-0002-3882-5249; Revesz, Tamas/0000-0003-2501-0259; Rostagno, Agueda/0000-0002-6817-2074; Lashley, Tammaryn/0000-0001-7389-0348	NCRR NIH HHS [S10RR14662] Funding Source: Medline; NIA NIH HHS [AG05891, AG08721] Funding Source: Medline; NINDS NIH HHS [NS38777] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR014662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038777] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG008721, R37AG005891, R01AG005891] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BATEMAN A, 1990, J BIOL CHEM, V265, P22130; Bek T, 2000, BRIT J OPHTHALMOL, V84, P1298, DOI 10.1136/bjo.84.11.1298; BUSBY WH, 1987, J BIOL CHEM, V262, P8532; Butterfield DA, 2002, FREE RADICAL RES, V36, P1307, DOI 10.1080/1071576021000049890; Castano EM, 1996, J BIOL CHEM, V271, P32185, DOI 10.1074/jbc.271.50.32185; COHEN AS, 1964, J CELL BIOL, V21, P481, DOI 10.1083/jcb.21.3.481; Duewell HS, 1998, J PROTEIN CHEM, V17, P337, DOI 10.1023/A:1022555232364; FISCHER WH, 1987, P NATL ACAD SCI USA, V84, P3628, DOI 10.1073/pnas.84.11.3628; Fryer JD, 2003, J NEUROSCI, V23, P7889; Garden RW, 1999, J NEUROCHEM, V72, P676, DOI 10.1046/j.1471-4159.1999.0720676.x; GHISO J, 1995, J NEUROL SCI, V129, P74, DOI 10.1016/0022-510X(94)00274-R; Ghiso J, 2002, ADV DRUG DELIVER REV, V54, P1539, DOI 10.1016/S0169-409X(02)00149-7; Ghiso JA, 2001, J BIOL CHEM, V276, P43909, DOI 10.1074/jbc.M105956200; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOWING E, 1994, J BIOL CHEM, V269, P10987; Grabowski TJ, 2001, ANN NEUROL, V49, P697, DOI 10.1002/ana.1009; Haass C, 2001, NAT NEUROSCI, V4, P859, DOI 10.1038/nn0901-859; Herzig MC, 2004, NAT NEUROSCI, V7, P954, DOI 10.1038/nn1302; Hiraiwa M, 1999, CELL MOL LIFE SCI, V56, P894, DOI 10.1007/s000180050482; HIXSON JE, 1990, J LIPID RES, V31, P545; Holton JL, 2002, J NEUROPATH EXP NEUR, V61, P254, DOI 10.1093/jnen/61.3.254; Holton JL, 2001, AM J PATHOL, V158, P515, DOI 10.1016/S0002-9440(10)63993-4; HOWELL S, 1995, PEPTIDES, V16, P647, DOI 10.1016/0196-9781(95)00021-B; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; Iwatsubo T, 1996, AM J PATHOL, V149, P1823; Kim SH, 1999, NAT NEUROSCI, V2, P984, DOI 10.1038/14783; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Kuo YM, 2001, J BIOL CHEM, V276, P12991, DOI 10.1074/jbc.M007859200; Lalowski M, 1996, J BIOL CHEM, V271, P33623, DOI 10.1074/jbc.271.52.33623; Lansbury PT, 1999, P NATL ACAD SCI USA, V96, P3342, DOI 10.1073/pnas.96.7.3342; Lia LJ, 2004, J BIOL CHEM, V279, P37061, DOI 10.1074/jbc.M403672200; MATSUBARA E, 1995, J BIOL CHEM, V270, P7563, DOI 10.1074/jbc.270.13.7563; McGowan E, 2005, NEURON, V47, P191, DOI 10.1016/j.neuron.2005.06.030; Mead S, 2000, BRAIN, V123, P975, DOI 10.1093/brain/123.5.975; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; Morelli L, 2003, J BIOL CHEM, V278, P23221, DOI 10.1074/jbc.M300276200; MORI H, 1992, J BIOL CHEM, V267, P17082; NOVOKHATNY VV, 1994, J MOL BIOL, V238, P833, DOI 10.1006/jmbi.1994.1337; PIKE CJ, 1995, J BIOL CHEM, V270, P23895, DOI 10.1074/jbc.270.41.23895; Pittois K, 1998, GENE, V217, P141, DOI 10.1016/S0378-1119(98)00354-0; PLANT GT, 1990, BRAIN, V113, P721, DOI 10.1093/brain/113.3.721; PRELLI F, 1988, J NEUROCHEM, V51, P648, DOI 10.1111/j.1471-4159.1988.tb01087.x; Revesz T, 1999, ACTA NEUROPATHOL, V97, P170, DOI 10.1007/s004010050970; Rostagno A, 2005, CELL MOL LIFE SCI, V62, P1814, DOI 10.1007/s00018-005-5092-5; Saido TC, 1996, NEUROSCI LETT, V215, P173, DOI 10.1016/0304-3940(96)12970-0; Small D H, 1998, Amyloid, V5, P301, DOI 10.3109/13506129809007304; STROMGREN E, 1970, ACTA NEUROL SCAND, V46, P261; STROMGREN E, 1981, HDB CLIN NEUROLOGY, V42, P150; Sykes PA, 1999, FEBS LETT, V455, P159, DOI 10.1016/S0014-5793(99)00872-8; Tekirian TL, 1998, J NEUROPATH EXP NEUR, V57, P76, DOI 10.1097/00005072-199801000-00009; van den Burg HA, 2003, J BIOL CHEM, V278, P27340, DOI 10.1074/jbc.M212196200; Van Dorpe J, 2000, AM J PATHOL, V157, P1283, DOI 10.1016/S0002-9440(10)64644-5; Vidal R, 2000, P NATL ACAD SCI USA, V97, P4920, DOI 10.1073/pnas.080076097; Vidal R, 1999, NATURE, V399, P776; Wallis TP, 2001, PROTEIN SCI, V10, P2251, DOI 10.1110/ps.15401; Wisniewski T, 1996, BIOCHEM J, V313, P575, DOI 10.1042/bj3130575; WOODS AS, 1995, ANAL CHEM, V67, P4462, DOI 10.1021/ac00120a005; Worster-Drought C, 1940, BRAIN, V63, P237, DOI 10.1093/brain/63.3.237; Worster-Drought C, 1933, J NEUROL PSYCHOPATHO, V14, P27; YAMASHIRO D, 1976, BIOCHIM BIOPHYS ACTA, V451, P124, DOI 10.1016/0304-4165(76)90264-6	62	51	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36883	36894		10.1074/jbc.M504038200	http://dx.doi.org/10.1074/jbc.M504038200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16091362	hybrid			2022-12-27	WOS:000232901800044
J	Hou, ZJ; Stapels, SE; Haska, CL; Matherly, LH				Hou, ZJ; Stapels, SE; Haska, CL; Matherly, LH			Localization of a substrate binding domain of the human reduced folate carrier to transmembrane domain 11 by radioaffinity labeling and cysteine-substituted accessibility methods	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCANNING MUTAGENESIS; MEMBRANE TOPOLOGY; METHOTREXATE SENSITIVITY; CELLULAR PHARMACOLOGY; TRANSPORT-DEFICIENT; LACTOSE PERMEASE; FUNCTIONAL-ROLE; FOLIC-ACID; CELLS; IDENTIFICATION	The human reduced folate carrier (hRFC) mediates the membrane transport of reduced folates and classical anti-folates into mammalian cells. RFC is characterized by 12 transmembrane domains (TMDs), internally oriented N and C termini, and a large central linker connecting TMDs 1 - 6 and 7 - 12. By co-expression and N-hydroxysuccinimide methotrexate (Mtx) radioaffinity labeling of hRFC TMD 1 - 6 and TMD 7 - 12 half-molecules, combined with endoproteinase GluC digestion, a substrate binding domain was previously localized to within TMDs 8 - 12 (Witt, T. L., Stapels, S. E., and Matherly, L. H. ( 2004) J. Biol. Chem. 279, 46755 - 46763). In this report, this region was further refined to TMDs 11 - 12 by digestion with 2-nitro-5-thiocyanatobenzoic acid. A transport-competent cysteine-less hRFC was used as a template to prepare single cysteine-replacement mutant constructs in which each residue from Glu-394 to Asp-420 of TMD11 and Tyr-435 to His-457 of TMD 12 was replaced individually by a cysteine. The mutant constructs were transfected into hRFC-null HeLa cells. Most of the 50 single cysteine-substituted constructs were expressed at high levels on Western blots. With the exception of G401C hRFC, all mutants were active for Mtx transport. Treatment with sodium (2-sulfonatoethyl) methanethiosulfonate ( MTSES) had no effect on hRFC activity for all of the cysteine mutants within TMD 12 and for the majority of the cysteine mutants within TMD 11. However, MTSES inhibited Mtx uptake by the T404C, A407C, T408C, T412C, F416C, I417C, V418C, and S419C mutants by 25 - 65%. Losses of activity by MTSES treatment for T404C, A407C, T412C, and I417C hRFCs were appreciably reversed in the presence of excess leucovorin, a hRFC substrate. Our results strongly suggest that residues within TMD11 are likely critical structural and/or functional components of the putative hRFC transmembrane channel for anionic folate and anti-folate substrates.	Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Dev Therapeut Program, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Canc Biol Program, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University; Wayne State University	Matherly, LH (corresponding author), Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Dev Therapeut Program, 110 E Warren Ave, Detroit, MI 48201 USA.	matherly@kci.wayne.edu			NCI NIH HHS [CA53535] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Abramson J, 2004, CURR OPIN STRUC BIOL, V14, P413, DOI 10.1016/j.sbi.2004.07.005; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Bailey LB, 2003, J NUTR, V133, p1961S, DOI 10.1093/jn/133.6.1961S; BRIGLE KE, 1995, J BIOL CHEM, V270, P22974, DOI 10.1074/jbc.270.39.22974; Cao W, 2004, BIOCHEM J, V378, P201, DOI 10.1042/BJ20031288; Cao W, 2003, BIOCHEM J, V374, P27, DOI 10.1042/BJ20030301; DIXON KH, 1994, J BIOL CHEM, V269, P17; Ferguson PL, 1999, J BIOL CHEM, V274, P16269, DOI 10.1074/jbc.274.23.16269; Flintoff WF, 2003, J BIOL CHEM, V278, P40867, DOI 10.1074/jbc.M302102200; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; FRY DW, 1982, J BIOL CHEM, V257, P1890; GOLDMAN ID, 1985, PHARMACOL THERAPEUT, V28, P77, DOI 10.1016/0163-7258(85)90083-X; Goldman ID, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.37461; HENDERSON GB, 1984, J BIOL CHEM, V259, P4558; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Karlin A, 1998, METHOD ENZYMOL, V293, P123; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu XY, 2001, BIOCHEM J, V358, P511, DOI 10.1042/0264-6021:3580511; Liu XY, 2002, BBA-BIOMEMBRANES, V1564, P333, DOI 10.1016/S0005-2736(02)00467-4; Loo TW, 1999, BBA-BIOMEMBRANES, V1461, P315, DOI 10.1016/S0005-2736(99)00165-0; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lucock M, 2000, MOL GENET METAB, V71, P121, DOI 10.1006/mgme.2000.3027; MATHERLY LH, 1991, CANCER RES, V51, P3420; Matherly LH, 2003, VITAM HORM, V66, P403, DOI 10.1016/S0083-6729(03)01012-4; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOSCOW JA, 1995, CANCER RES, V55, P3790; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; PRASAD PD, 1995, BIOCHEM BIOPH RES CO, V206, P681, DOI 10.1006/bbrc.1995.1096; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sadlish H, 2002, J BIOL CHEM, V277, P42105, DOI 10.1074/jbc.M206459200; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sharina IG, 2001, MOL PHARMACOL, V59, P1022, DOI 10.1124/mol.59.5.1022; Stokstad ELR, 1990, FOLIC ACID METABOLIS, P1; Tse A, 1998, J BIOL CHEM, V273, P25953, DOI 10.1074/jbc.273.40.25953; Vardy E, 2004, PROTEIN SCI, V13, P1832, DOI 10.1110/ps.04657704; Whetstine JR, 2002, BIOCHEM J, V367, P629, DOI 10.1042/BJ20020512; WILLIAMS FMR, 1994, J BIOL CHEM, V269, P5810; WILLIAMS FMR, 1995, J BIOL CHEM, V270, P2987, DOI 10.1074/jbc.270.7.2987; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1; Witt TL, 2004, J BIOL CHEM, V279, P46755, DOI 10.1074/jbc.M408696200; Witt TL, 2002, BBA-BIOMEMBRANES, V1567, P56, DOI 10.1016/S0005-2736(02)00583-7; Wong SC, 1999, J BIOL CHEM, V274, P10388, DOI 10.1074/jbc.274.15.10388; WONG SC, 1995, J BIOL CHEM, V270, P17468, DOI 10.1074/jbc.270.29.17468; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; Zhao R, 2000, CLIN CANCER RES, V6, P3304; Zhao R, 1998, J BIOL CHEM, V273, P19065, DOI 10.1074/jbc.273.30.19065; ZHAO R, 1999, MOL PHARM, V56, P1832; Zhao RB, 1999, BIOCHEM PHARMACOL, V58, P1615, DOI 10.1016/S0006-2952(99)00257-9; Zhao RB, 2004, CLIN CANCER RES, V10, P8735, DOI 10.1158/1078-0432.CCR-04-0932; Zhao RB, 1998, J BIOL CHEM, V273, P7873, DOI 10.1074/jbc.273.14.7873	53	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36206	36213		10.1074/jbc.M507295200	http://dx.doi.org/10.1074/jbc.M507295200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16115875	hybrid			2022-12-27	WOS:000232726900052
J	Netea, MG; Ferwerda, G; de Jong, DJ; Werts, C; Boneca, IG; Jehanno, M; Van der Meer, JWM; Mengin-Lecreulx, D; Sansonetti, PJ; Philpott, DJ; Dharancy, S; Girardin, SE				Netea, MG; Ferwerda, G; de Jong, DJ; Werts, C; Boneca, IG; Jehanno, M; Van der Meer, JWM; Mengin-Lecreulx, D; Sansonetti, PJ; Philpott, DJ; Dharancy, S; Girardin, SE			The frameshift mutation in Nod2 results in unresponsiveness not only to Nod2-but also Nod1-activating peptidoglycan agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; REQUIREMENTS ALLOWING DETECTION; INFLAMMATORY-BOWEL-DISEASE; CROHNS-DISEASE; MURAMYL DIPEPTIDE; INNATE IMMUNITY; BACTERIAL PEPTIDOGLYCAN; RECOGNITION PROTEINS; ESCHERICHIA-COLI; HOST RECOGNITION	NOD2/CARD15 is the first characterized susceptibility gene in Crohn disease. The Nod2 1007fs (Nod2fs) frameshift mutation is the most prevalent in Crohn disease patients. Muramyl dipeptide from bacterial peptidoglycan is the minimal motif detected by Nod2 but not by Nod2fs. Here we investigated the response of human peripheral blood mononuclear cells (PBMCs) from Crohn disease patients not only to muramyl dipeptide but also to several other muramyl peptides. Most unexpectedly, we observed that patients homozygous for the Nod2fs mutation were totally unresponsive to MurNAc-L-Ala-D-Glu-meso-diaminopimelic acid (DAP) (M-Tri(DAP)), the specific agonist of Nod1, and to Gram-negative bacterial peptidoglycan. In contrast, PBMCs from a patient homozygous for the Nod2 R702W mutation, also associated with Crohn disease, displayed normal response to Gram-negative bacterial peptidoglycan. In addition, the blockage of the Nod1/M-Tri(DAP) pathway could be partially overcome by co-stimulation with the Toll-like receptors agonists lipoteichoic acid or lipopolysaccharide. Investigation into the mechanism of this finding revealed that Nod2fs did not act as a dominant-negative molecule for the Nod1/M-Tri(DAP) pathway, implying that the blockage is dependent upon the expression or activity of other factors. We demonstrated that PBMCs from Nod2fs patients express high levels of the peptidoglycan recognition protein S, a secreted protein known to interact with muramyl peptides. We proposed that through a scavenger function, peptidoglycan recognition protein S may dampen M-Tri(DAP)-dependent responses in Nod2fs patients. Together, our results identified a cross-talk between the Nod1 and Nod2 pathways and suggested that down-regulation of Nod1/M-Tri(DAP) pathway may be associated with Crohn disease.	Inst Pasteur, Grp Inserm Avenir Peptidoglycan & Innate Immun, F-75724 Paris, France; Radboud Univ Nijmegen Med Ctr, Dept Gastroenterol, NL-6500 HB Nijmegen, Netherlands; Radboud Univ Nijmegen Med Ctr, Univ Nijmegen, Ctr Infect Dis, NL-6500 HB Nijmegen, Netherlands; Radboud Univ Nijmegen Med Ctr, Dept Internal Med, NL-6500 HB Nijmegen, Netherlands; Univ Paris 11, CNRS, UMR 8619, Inst Biochim & Biophys Mol & Cellulaire, F-91400 Orsay, France; CHRU, Hop Swynghedauw, INSERM, EPI 114, F-59000 Lille, France; Inst Pasteur, Unite Pathogenie Bacterienne Muqueuses, F-75724 Paris, France; Inst Pasteur, Unite Pathogenie Microbienne Mol, INSERM, U389, F-75724 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Girardin, SE (corresponding author), Inst Pasteur, 28 Rue Dr Roux, F-75724 Paris, France.	girardin@pasteur.fr	van der Meer, Jos W.M./C-8521-2013; de Jong, D.J./L-4417-2015; WERTS, Catherine/AAD-5447-2020; Boneca, Ivo G/H-1677-2014; Netea, Mihai/N-5155-2014; Ferwerda, J.G./L-4305-2015	van der Meer, Jos W.M./0000-0001-5120-3690; WERTS, Catherine/0000-0003-3079-5476; Boneca, Ivo G/0000-0001-8122-509X; MENGIN-LECREULX, Dominique/0000-0003-3205-0275				Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; Bonen DK, 2003, GASTROENTEROLOGY, V124, P140, DOI 10.1053/gast.2003.50019; Chamaillard M, 2003, P NATL ACAD SCI USA, V100, P3455, DOI 10.1073/pnas.0530276100; Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; Chin AI, 2002, NATURE, V416, P190, DOI 10.1038/416190a; FLOURET B, 1981, ANAL BIOCHEM, V114, P59, DOI 10.1016/0003-2697(81)90451-6; Fritz JH, 2005, EUR J IMMUNOL, V35, P2459, DOI 10.1002/eji.200526286; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Girardin SE, 2003, J BIOL CHEM, V278, P41702, DOI 10.1074/jbc.M307198200; Girardin SE, 2004, EUR J IMMUNOL, V34, P1777, DOI 10.1002/eji.200425095; Girardin SE, 2001, EMBO REP, V2, P736, DOI 10.1093/embo-reports/kve155; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Girardin SE, 2003, TRENDS IMMUNOL, V24, P652, DOI 10.1016/j.it.2003.10.007; Hisamatsu T, 2003, GASTROENTEROLOGY, V124, P993, DOI 10.1053/gast.2003.50153; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Inohara N, 2005, ANNU REV BIOCHEM, V74, P355, DOI 10.1146/annurev.biochem.74.082803.133347; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Kobayashi KS, 2005, SCIENCE, V307, P731, DOI 10.1126/science.1104911; Li J, 2004, HUM MOL GENET, V13, P1715, DOI 10.1093/hmg/ddh182; Liu C, 2000, J BIOL CHEM, V275, P24490, DOI 10.1074/jbc.M001239200; Liu C, 2001, J BIOL CHEM, V276, P34686, DOI 10.1074/jbc.M105566200; Maeda S, 2005, SCIENCE, V307, P734, DOI 10.1126/science.1103685; McGovern DPB, 2005, HUM MOL GENET, V14, P1245, DOI 10.1093/hmg/ddi135; Mellroth P, 2005, P NATL ACAD SCI USA, V102, P6455, DOI 10.1073/pnas.0407559102; Mengin-Lecreulx D, 1999, J BACTERIOL, V181, P5909, DOI 10.1128/JB.181.19.5909-5914.1999; MENGINLECREULX D, 1985, J BACTERIOL, V163, P208, DOI 10.1128/JB.163.1.208-212.1985; Netea MG, 2004, EUR J IMMUNOL, V34, P2052, DOI 10.1002/eji.200425229; Netea MG, 2005, J IMMUNOL, V174, P6518, DOI 10.4049/jimmunol.174.10.6518; Ogura Y, 2003, GUT, V52, P1591, DOI 10.1136/gut.52.11.1591; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Philpott DJ, 2001, CURR OPIN IMMUNOL, V13, P410; Rogler G, 2004, CURR OPIN GASTROEN, V20, P311, DOI 10.1097/00001574-200407000-00003; Stenbak CR, 2004, J IMMUNOL, V173, P7339, DOI 10.4049/jimmunol.173.12.7339; Traub S, 2004, J BIOL CHEM, V279, P8694, DOI 10.1074/jbc.M310556200; Travassos LH, 2004, EMBO REP, V5, P1000, DOI 10.1038/sj.embor.7400248; van Heel DA, 2005, EUR J IMMUNOL, V35, P2471, DOI 10.1002/eji.200526296; Vavricka SR, 2004, GASTROENTEROLOGY, V127, P1401, DOI 10.1053/j.gastro.2004.07.024; Watanabe T, 2004, NAT IMMUNOL, V5, P800, DOI 10.1038/ni1092; Wehkamp J, 2004, GUT, V53, P1658, DOI 10.1136/gut.2003.032805	44	66	68	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35859	35867		10.1074/jbc.M504924200	http://dx.doi.org/10.1074/jbc.M504924200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16115863	Green Published, hybrid			2022-12-27	WOS:000232726900012
J	Pulukuri, SM; Gondi, CS; Lakka, SS; Jutla, A; Estes, N; Gujrati, M; Rao, JS				Pulukuri, SM; Gondi, CS; Lakka, SS; Jutla, A; Estes, N; Gujrati, M; Rao, JS			RETRACTED: RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo (Retracted article. See vol. 295, pg. 13136, 2020)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							GROWTH-FACTOR-RECEPTOR; TUMOR-GROWTH; ANTISENSE OLIGONUCLEOTIDES; GENE-EXPRESSION; DOWN-REGULATION; UPA PROMOTER; CATHEPSIN-B; INVASIVENESS; MIGRATION; APOPTOSIS	The invasive ability of tumor cells plays a key role in prostate cancer metastasis and is a major cause of treatment failure. Urokinase plasminogen activator- (uPA) and its receptor ( uPAR)-mediated signaling have been implicated in tumor cell invasion, survival, and metastasis in a variety of cancers. This study was undertaken to investigate the biological roles of uPA and uPAR in prostate cancer cell invasion and survival, and the potential of uPA and uPAR as targets for prostate cancer therapy. uPA and uPAR expression correlates with the metastatic potential of prostate cancer cells. Thus, therapies designed to inhibit uPA and uPAR expression would be beneficial. LNCaP, DU145, and PC3 are prostate cancer cell lines with low, moderate, and high metastatic potential, respectively, as demonstrated by their capacity to invade the extracellular matrix. In this study we utilized small hairpin RNAs (shRNAs), also referred to as small interfering RNAs, to target human uPA and uPAR. These small interfering RNA constructs significantly inhibited uPA and uPAR expression at both the mRNA and protein levels in the highly metastatic prostate cancer cell line PC3. Our data demonstrated that uPA-uPAR knockdown in PC3 cells resulted in a dramatic reduction of tumor cell invasion as indicated by a Matrigel invasion assay. Furthermore, simultaneous silencing of the genes for uPA and uPAR using a single plasmid construct expressing shRNAs for both uPA and uPAR significantly reduced cell viability and ultimately resulted in the induction of apoptotic cell death. RNA interference for uPA and uPAR also abrogated uPA-uPAR signaling to downstream target molecules such as ERK1/2 and Stat 3. In addition, our results demonstrated that intratumoral injection with the plasmid construct expressing shRNAs for uPA and uPAR almost completely inhibited established tumor growth and survival in an orthotopic mouse prostate cancer model. These findings uncovered evidence of a complex signaling network operating downstream of uPA-uPAR that actively advances tumor cell invasion, proliferation, and survival of prostate cancer cells. Thus, RNA interference-directed targeting of uPA and uPAR is a convenient and novel tool for studying the biological role of the uPA-uPAR system and raises the potential of its application for prostate cancer therapy.	Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Program Canc Biol, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Surg, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Pathol, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Program Canc Biol, Box 1649, Peoria, IL 61656 USA.	jsrao@uic.edu		Gondi, Christopher/0000-0002-3036-9920	NCI NIH HHS [R01 CA085216, CA92393, R01 CA092393, R01 CA075557, CA75557, CA116708, CA95058, CA85216, R01 CA116708, R01 CA095058] Funding Source: Medline; NINDS NIH HHS [R01 NS047699, NS47699] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085216, R01CA092393, R01CA075557, R01CA116708, R01CA095058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047699] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Ahmed N, 2003, BRIT J CANCER, V89, P374, DOI 10.1038/sj.bjc.6601098; Arens N, 2005, INT J ONCOL, V26, P113; Behren A, 2005, EXP CELL RES, V303, P321, DOI 10.1016/j.yexcr.2004.10.004; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Boyd DD, 2003, AM J PATHOL, V162, P619, DOI 10.1016/S0002-9440(10)63855-2; Campbell TN, 2005, CURR ISSUES MOL BIOL, V7, P1; Carlin SM, 2005, FASEB J, V19, P195, DOI 10.1096/fj.04-1644com; Chandrasekar N, 2003, ONCOGENE, V22, P392, DOI 10.1038/sj.onc.1206164; D'Alessio S, 2004, INT J CANCER, V110, P125, DOI 10.1002/ijc.20077; DAHIYA R, 1994, INT J CANCER, V59, P126, DOI 10.1002/ijc.2910590122; Desrosiers RR, 2005, INT J CANCER, V114, P702, DOI 10.1002/ijc.20807; Dumler I, 1998, J BIOL CHEM, V273, P315, DOI 10.1074/jbc.273.1.315; Fabbrini MS, 1997, FASEB J, V11, P1169, DOI 10.1096/fasebj.11.13.9367352; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Gondi CS, 2004, ONCOGENE, V23, P8486, DOI 10.1038/sj.onc.1207879; Gondi CS, 2003, ONCOGENE, V22, P5967, DOI 10.1038/sj.onc.1206535; Hegeman Robert B, 2004, Clin Prostate Cancer, V3, P150, DOI 10.3816/CGC.2004.n.025; Hendry L, 2004, EUR J BIOCHEM, V271, P4613, DOI 10.1111/j.1432-1033.2004.04424.x; HOOSEIN NM, 1991, CANCER COMMUN, V3, P255, DOI 10.3727/095535491820873146; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Jiang M, 2004, OLIGONUCLEOTIDES, V14, P239, DOI 10.1089/oli.2004.14.239; Jo MJ, 2005, J BIOL CHEM, V280, P17449, DOI 10.1074/jbc.M413141200; Joossens J, 2004, J MED CHEM, V47, P2411, DOI 10.1021/jm0499209; KEER HN, 1991, PROSTATE, V18, P201, DOI 10.1002/pros.2990180303; Kim SJ, 2004, CANCER RES, V64, P4201, DOI 10.1158/0008-5472.CAN-03-3763; Kim SJ, 2003, CLIN CANCER RES, V9, P5161; Kiyan J, 2005, EMBO J, V24, P1787, DOI 10.1038/sj.emboj.7600669; Lakka SS, 2004, ONCOGENE, V23, P4681, DOI 10.1038/sj.onc.1207616; Laniado ME, 1997, AM J PATHOL, V150, P1213; Legrand C, 2001, EXP CELL RES, V264, P326, DOI 10.1006/excr.2000.5125; Ma Z, 2001, J CELL SCI, V114, P3387; Mamoune A, 2004, EXP CELL RES, V299, P91, DOI 10.1016/j.yexcr.2004.05.008; Margheri F, 2005, GENE THER, V12, P702, DOI 10.1038/sj.gt.3302456; Miyagishi M, 2003, ANTISENSE NUCLEIC A, V13, P1, DOI 10.1089/108729003764097296; Mora LB, 2002, CANCER RES, V62, P6659; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; Nguyen DHD, 2000, J BIOL CHEM, V275, P19382, DOI 10.1074/jbc.M909575199; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Nishimura K, 2003, INT J ANDROL, V26, P175, DOI 10.1046/j.1365-2605.2003.00413.x; Pakneshan P, 2004, J BIOL CHEM, V279, P31735, DOI 10.1074/jbc.M401669200; Pakneshan P, 2003, FASEB J, V17, P1081, DOI 10.1096/fj.02-0973com; Patel P, 2004, PROSTATE CANCER P D, V7, pS14, DOI 10.1038/sj.pcan.4500743; Pinthus JH, 2004, J CLIN INVEST, V114, P1774, DOI 10.1172/JCI200422284; Rabbani SA, 2002, CANCER RES, V62, P2390; Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121; Resnati M, 2002, P NATL ACAD SCI USA, V99, P1359, DOI 10.1073/pnas.022652999; Rye PD, 2004, TUMOR BIOL, V25, P329, DOI 10.1159/000081403; Salvi A, 2004, MOL CANCER THER, V3, P671; Sato S, 2002, FEBS LETT, V528, P212, DOI 10.1016/S0014-5793(02)03311-2; Schuh T, 2003, BIOL CHEM, V384, P311, DOI 10.1515/BC.2003.035; Schweinitz A, 2004, J BIOL CHEM, V279, P33613, DOI 10.1074/jbc.M314151200; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; Singh S, 2004, CLIN CANCER RES, V10, P8743, DOI 10.1158/1078-0432.CCR-04-0266; Sontheimer EJ, 2005, NAT REV MOL CELL BIO, V6, P127, DOI 10.1038/nrm1568; Stewart Delisha A, 2004, Reprod Biol Endocrinol, V2, P2, DOI 10.1186/1477-7827-2-2; Tarui T, 2003, J BIOL CHEM, V278, P29863, DOI 10.1074/jbc.M304694200; Usher PA, 2005, INT J CANCER, V113, P870, DOI 10.1002/ijc.20665; Woessmann Willi, 2003, Rev Clin Exp Hematol, V7, P270; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zhang XP, 2004, CANCER RES, V64, P7086, DOI 10.1158/0008-5472.CAN-04-1498; Zhang Y, 2004, CLIN CANCER RES, V10, P3667, DOI 10.1158/1078-0432.CCR-03-0740; Zhang Z, 2003, P NATL ACAD SCI USA, V100, P11636, DOI 10.1073/pnas.1934692100	63	239	258	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36529	36540		10.1074/jbc.M503111200	http://dx.doi.org/10.1074/jbc.M503111200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16127174	Green Accepted, hybrid			2022-12-27	WOS:000232726900087
J	Bhaskar, K; Yen, SH; Lee, G				Bhaskar, K; Yen, SH; Lee, G			Disease-related modifications in tau affect the interaction between Fyn and tau	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; ALZHEIMERS-DISEASE; SH3 DOMAINS; NEURODEGENERATIVE TAUOPATHIES; MICROTUBULE-BINDING; TYROSINE KINASE; PROLINE-RICH; IN-VITRO; PROTEIN; PHOSPHORYLATION	Microtubule-associated protein tau is the major component of the neurofibrillary tangles of Alzheimer disease (AD) and is genetically linked to frontotemporal dementias (FTDP-17). We have recently shown that tau interacts with the SH3 domain of Fyn, an Src family non-receptor tyrosine kinase, and is tyrosine-phosphorylated by Fyn on Tyr-18. Also, tyrosine-phosphorylated tau is present in the neuropathology of AD. To determine whether alterations in the tau-Fyn interaction might correlate with disease-related factors in AD and FTDP-17, we have performed real-time surface plasmon resonance studies on a panel of 21 tau constructs with Fyn SH3. We report that the interaction between Fyn SH3 and 3R-tau was 20-fold higher than that with 4R-tau. In addition, the affinity between 4R-tau and Fyn SH3 was increased 25-45-fold by phosphorylation-mimicking mutations or by FTDP-17 mutations. In vitro kinase reactions show that tau, with lower affinity SH3 interactions, exhibited a lower level of Tyr-18 phosphorylation under our reaction conditions. Lastly, we have demonstrated that tau is phosphorylated on Tyr-18 in the tau P301L mouse model for tauopathy (JNPL3). In summary, our results suggest that disease-related phosphorylation and missense mutations of tau increase association of tau with Fyn. Because these effects are mediated through the 4R component of the tau population, these results also have implications for the FTDP-17 diseases caused by increased expression of 4R-tau. Our data support a role for the Fyn-tau interaction in neurodegeneration.	Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Mayo Clin Jacksonville, Dept Neurosci, Jacksonville, FL 32224 USA	University of Iowa; Mayo Clinic	Lee, G (corresponding author), Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Internal Med, 500 Newton Rd,MRC 17, Iowa City, IA 52242 USA.	gloria-lee@uiowa.edu	Lee, Gloria/F-5965-2011; Bhaskar, Kiran/AAF-2755-2020	Lee, Gloria/0000-0002-8633-1534	NATIONAL INSTITUTE ON AGING [R01AG017753] Funding Source: NIH RePORTER; NIA NIH HHS [AG17753] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abraha A, 2000, J CELL SCI, V113, P3737; Alonso AD, 2004, J BIOL CHEM, V279, P34873, DOI 10.1074/jbc.M405131200; Augustinack JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/s004010100423; Barghorn S, 2004, BIOCHEMISTRY-US, V43, P1694, DOI 10.1021/bi0357006; Berry RW, 2003, BIOCHEMISTRY-US, V42, P8325, DOI 10.1021/bi027348m; Brandt R, 2005, BBA-MOL BASIS DIS, V1739, P331, DOI 10.1016/j.bbadis.2004.06.018; BRANDT R, 1993, J BIOL CHEM, V268, P3414; Chin J, 2004, J NEUROSCI, V24, P4692, DOI 10.1523/JNEUROSCI.0277-04.2004; D'Souza I, 2005, BBA-MOL BASIS DIS, V1739, P104, DOI 10.1016/j.bbadis.2004.08.009; Dalgarno DC, 1997, BIOPOLYMERS, V43, P383; DeTure M, 2000, BRAIN RES, V853, P5, DOI 10.1016/S0006-8993(99)02124-1; Gamblin TC, 2003, BIOCHEMISTRY-US, V42, P2252, DOI 10.1021/bi0272510; Goedert M, 2005, BBA-MOL BASIS DIS, V1739, P240, DOI 10.1016/j.bbadis.2004.08.007; Goode BL, 1997, MOL BIOL CELL, V8, P353, DOI 10.1091/mbc.8.2.353; Goode BL, 2000, J BIOL CHEM, V275, P38182, DOI 10.1074/jbc.M007489200; GUSTKE N, 1992, FEBS LETT, V307, P199, DOI 10.1016/0014-5793(92)80767-B; Haase C, 2004, J NEUROCHEM, V88, P1509, DOI 10.1046/j.1471-4159.2003.02287.x; Hasegawa M, 1998, FEBS LETT, V437, P207, DOI 10.1016/S0014-5793(98)01217-4; Ho GJ, 2005, NEUROBIOL AGING, V26, P625, DOI 10.1016/j.neurobiolaging.2004.06.016; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 2000, ANN NY ACAD SCI, V920, P63; Iqbal K, 2005, BBA-MOL BASIS DIS, V1739, P198, DOI 10.1016/j.bbadis.2004.09.008; Jicha GA, 1997, J NEUROCHEM, V69, P2087; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kuret J, 2005, BBA-MOL BASIS DIS, V1739, P167, DOI 10.1016/j.bbadis.2004.06.016; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lee G, 1998, J CELL SCI, V111, P3167; Lee G, 2004, J NEUROSCI, V24, P2304, DOI 10.1523/JNEUROSCI.4162-03.2004; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Lesort M, 1999, J NEUROCHEM, V72, P576, DOI 10.1046/j.1471-4159.1999.0720576.x; Levy SF, 2005, J BIOL CHEM, V280, P13520, DOI 10.1074/jbc.M413490200; Lewis J, 2000, NAT GENET, V25, P402, DOI 10.1038/78078; Mayer BJ, 2001, J CELL SCI, V114, P1253; Sasaki Y, 2002, NEURON, V35, P907, DOI 10.1016/S0896-6273(02)00857-7; Sengupta A, 1998, ARCH BIOCHEM BIOPHYS, V357, P299, DOI 10.1006/abbi.1998.0813; Sergeant N, 2005, BBA-MOL BASIS DIS, V1739, P179, DOI 10.1016/j.bbadis.2004.06.020; SHIRAZI SK, 1993, NEUROREPORT, V4, P435, DOI 10.1097/00001756-199304000-00024; Singh TJ, 1997, MOL CELL BIOCHEM, V168, P141, DOI 10.1023/A:1006807105059; Stoothoff WH, 2005, BBA-MOL BASIS DIS, V1739, P280, DOI 10.1016/j.bbadis.2004.06.017; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; Williams R, 2002, MATER WORLD, V10, P20; Zamora-Leon SP, 2001, J BIOL CHEM, V276, P39950, DOI 10.1074/jbc.M107807200; Zhao ZS, 2000, MOL CELL BIOL, V20, P3906, DOI 10.1128/MCB.20.11.3906-3917.2000	43	174	182	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35119	35125		10.1074/jbc.M505895200	http://dx.doi.org/10.1074/jbc.M505895200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16115884	hybrid			2022-12-27	WOS:000232561200008
J	Kang, SG; Dimitrova, MN; Ortega, JQ; Ginsburg, A; Maurizi, MR				Kang, SG; Dimitrova, MN; Ortega, JQ; Ginsburg, A; Maurizi, MR			Human mitochondrial ClpP is a stable heptamer that assembles into a tetradecamer in the presence of ClpX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASES; ESCHERICHIA-COLI; MOLECULAR CHAPERONE; REGULATORY SUBUNITS; DEGRADATION MACHINE; PROTEIN-BINDING; BACTERIAL CLPX; AMINO-ACID; PROTEOLYSIS; SPECIFICITY	The functional form of ClpP, the proteolytic component of ATP-dependent Clp proteases, is a hollow- cored particle composed of two heptameric rings joined face- to- face forming an aqueous chamber containing the proteolytic active sites. We have found that isolated human mitochondrial ClpP ( hClpP) is stable as a heptamer and remains a monodisperse species ( s(20,w) 7.0 S; M-app 169, 200) at concentrations >= 3 mg/ ml. Heptameric hClpP has no proteolytic activity and very low peptidase activity. In the presence of ATP, hClpX interacts with hClpP forming a complex, which by equilibrium sedimentation measurements has a M-app of 1 x 10(6). Electron microscopy confirmed that the complex consisted of a double ring of hClpP with an hClpX ring axially aligned on each end. The hClpXP complex has protease activity and greatly increased peptidase activity, indicating that interaction with hClpX affects the conformation of the hClpP catalytic active site. A mutant of hClpP, in which a cysteine residue was introduced into the handle region at the interface between the two rings formed stable tetradecamers under oxidizing conditions but spontaneously dissociated into two heptamers upon reduction. Thus, hClpP rings interact transiently but very weakly in solution, and hClpX must exert an allosteric effect on hClpP to promote a conformation that stabilizes the tetradecamer. These data suggest that hClpX can regulate the appearance of hClpP peptidase activity in mitochondria and might affect the nature of the degradation products released during ATP- dependent proteolytic cycles.	NCI, Cell Biol Lab, Bethesda, MD 20892 USA; NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA; NIAMS, Struct Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Maurizi, MR (corresponding author), NCI, Cell Biol Lab, Bldg 37 Rm 2128,37 Convent Dr, Bethesda, MD 20892 USA.	mmaurizi@helix.nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000310] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adam Z, 2002, TRENDS PLANT SCI, V7, P451, DOI 10.1016/S1360-1385(02)02326-9; Becker G, 1999, P NATL ACAD SCI USA, V96, P6439, DOI 10.1073/pnas.96.11.6439; Bross P, 1995, FEBS LETT, V377, P249, DOI 10.1016/0014-5793(95)01353-9; Corydon TJ, 2000, MAMM GENOME, V11, P899, DOI 10.1007/s003350010173; Flynn JM, 2003, MOL CELL, V11, P671, DOI 10.1016/S1097-2765(03)00060-1; Gottesman S, 2003, ANNU REV CELL DEV BI, V19, P565, DOI 10.1146/annurev.cellbio.19.110701.153228; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Gribun A, 2005, J BIOL CHEM, V280, P16185, DOI 10.1074/jbc.M414124200; Grimaud R, 1998, J BIOL CHEM, V273, P12476, DOI 10.1074/jbc.273.20.12476; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; Halperin T, 2001, PLANT MOL BIOL, V45, P461, DOI 10.1023/A:1010677220323; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hoskins JR, 2000, P NATL ACAD SCI USA, V97, P8892, DOI 10.1073/pnas.97.16.8892; Kang SG, 2004, J STRUCT BIOL, V148, P338, DOI 10.1016/j.jsb.2004.07.004; Kang SG, 2002, J BIOL CHEM, V277, P21095, DOI 10.1074/jbc.M201642200; Kenniston JA, 2003, CELL, V114, P511, DOI 10.1016/S0092-8674(03)00612-3; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Kim DY, 2003, J BIOL CHEM, V278, P50664, DOI 10.1074/jbc.M305882200; Levchenko I, 2000, SCIENCE, V289, P2354, DOI 10.1126/science.289.5488.2354; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; Levchenko I, 1997, CELL, V91, P939, DOI 10.1016/S0092-8674(00)80485-7; Lupas A, 1997, TRENDS BIOCHEM SCI, V22, P399, DOI 10.1016/S0968-0004(97)01117-1; Maurizi MR, 1998, BIOCHEMISTRY-US, V37, P7778, DOI 10.1021/bi973093e; Maurizi MR, 2004, STRUCTURE, V12, P175, DOI 10.1016/j.str.2004.01.021; Neuwald AF, 1999, GENOME RES, V9, P27; Nosworthy NJ, 1998, BIOCHEMISTRY-US, V37, P6718, DOI 10.1021/bi980126x; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Ortega J, 2002, EMBO J, V21, P4938, DOI 10.1093/emboj/cdf483; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; Santagata S, 1999, J BIOL CHEM, V274, P16311, DOI 10.1074/jbc.274.23.16311; SCHACHMAN HK, 1959, ULTRACENTRIFUGATION, P116; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schweder T, 1996, J BACTERIOL, V178, P470, DOI 10.1128/jb.178.2.470-476.1996; SHAPIRO BM, 1968, BIOCHEMISTRY-US, V7, P2153, DOI 10.1021/bi00846a018; Singh SK, 2000, P NATL ACAD SCI USA, V97, P8898, DOI 10.1073/pnas.97.16.8898; Singh SK, 2001, J BIOL CHEM, V276, P29420, DOI 10.1074/jbc.M103489200; Stafford WF, 1997, CURR OPIN BIOTECH, V8, P14, DOI 10.1016/S0958-1669(97)80152-8; THOMPSON MW, 1994, J BIOL CHEM, V269, P18201; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Whitby FG, 2000, NATURE, V408, P115, DOI 10.1038/35040607; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; ZAMYATNIN AA, 1984, ANNU REV BIOPHYS BIO, V13, P145, DOI 10.1146/annurev.bb.13.060184.001045; Zhou YN, 2001, GENE DEV, V15, P627, DOI 10.1101/gad.864401; Zolkiewski M, 1997, BIOCHEMISTRY-US, V36, P7876, DOI 10.1021/bi962947c	45	86	94	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35424	35432		10.1074/jbc.M507240200	http://dx.doi.org/10.1074/jbc.M507240200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16115876	hybrid			2022-12-27	WOS:000232561200042
J	Wei, X; Ni, S; Correll, PH				Wei, X; Ni, S; Correll, PH			Uncoupling ligand-dependent and -independent mechanisms for mitogen-activated protein kinase activation by the murine ron receptor tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE-STIMULATING PROTEIN; CELL-TRANSFORMATION; STRUCTURAL BASIS; TRUNCATED FORM; IFN-GAMMA; GROWTH; GRB2; MET; BINDING; PATHWAYS	Receptor tyrosine kinases (RTKs) activate downstream signaling through cognate growth factor receptor-induced dimerization and autophosphorylation. Overexpression of RTKs can lead to constitutive activation due to increased dimerization in the absence of ligand, and downstream signals are presumed to be the same as the ligand-induced signals. We have shown that the murine Ron (mRon) receptor tyrosine kinase exhibits constitutive activation of the MAP kinase pathway that is independent of the two docking site tyrosines, whereas activation of this pathway in response to ligand (macrophage-stimulating protein) is abolished in the absence of these tyrosines. Furthermore, we identified three tyrosines (Tyr-1175, Tyr-1265, and Tyr-1294) within the kinase domain that play critical but overlapping roles in controlling constitutive Erk activation by mRon. Phenylalanine mutations at these three tyrosines results in a receptor that fails to constitutively activate the Erk pathway but retains the ability to induce Erk phosphorylation in response to ligand stimulation. The ability of mRon to activate the MAP kinase pathway is dependent on c-Src activity, and we have shown that c-Src co-immunoprecipitates with mRon. c-Src fails to interact with mRon when the three tyrosines required for MAP kinase activation are mutated, whereas the presence of any one of these tyrosines alone restores Erk phosphorylation and recruitment of c-Src. Thus, the ligand-dependent and -independent activity of mRon can be uncoupled through the alteration of selective sets of tyrosines.	Penn State Univ, Grad Program Biochem & Mol Biol, University Pk, PA 16802 USA; Penn State Univ, Integrat Biosci Grad Program, University Pk, PA 16802 USA; Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Correll, PH (corresponding author), Penn State Univ, Grad Program Biochem & Mol Biol, 115 Henning Bldg, University Pk, PA 16802 USA.	phc7@psu.edu	wei, xin/C-1395-2011		NHLBI NIH HHS [R01-HL66471] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066471] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arevalo JC, 2000, MOL CELL BIOL, V20, P5908, DOI 10.1128/MCB.20.16.5908-5916.2000; Bezerra JA, 1998, J CLIN INVEST, V101, P1175, DOI 10.1172/JCI1744; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Carlomagno F, 1997, CANCER RES, V57, P391; Chan EL, 2005, ONCOGENE, V24, P479, DOI 10.1038/sj.onc.1208231; Correll Pamela H., 1997, Genes and Function, V1, P69; Cross NCP, 2002, LEUKEMIA, V16, P1207, DOI 10.1038/sj.leu.2402556; Encinas M, 2004, J BIOL CHEM, V279, P18262, DOI 10.1074/jbc.M400505200; Finkelstein LD, 2002, ONCOGENE, V21, P3562, DOI 10.1038/sj.onc.1205442; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; Griffith J, 2004, MOL CELL, V13, P169, DOI 10.1016/S1097-2765(03)00505-7; Hirota S, 2001, J PATHOL, V193, P505, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH818>3.0.CO;2-E; Hong L, 2004, MOL CELL BIOL, V24, P1401, DOI 10.1128/MCB.24.3.1401-1410.2004; Ischenko I, 2003, ONCOGENE, V22, P6311, DOI 10.1038/sj.onc.1206742; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Kiyoi H, 2002, ONCOGENE, V21, P2555, DOI 10.1038/sj.onc.1205332; Lewitzky M, 2001, ONCOGENE, V20, P1052, DOI 10.1038/sj.onc.1204202; Liu QP, 1999, J IMMUNOL, V163, P6606; Maina F, 2001, MOL CELL, V7, P1293, DOI 10.1016/S1097-2765(01)00261-1; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; Morrison AC, 2004, J IMMUNOL, V172, P1825, DOI 10.4049/jimmunol.172.3.1825; Morrison AC, 2002, J IMMUNOL, V168, P853, DOI 10.4049/jimmunol.168.2.853; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; NIEMANN C, 1996, NATURE, V384, P173; Nishigaki K, 2001, J VIROL, V75, P7893, DOI 10.1128/JVI.75.17.7893-7903.2001; Park CY, 1999, J BIOL CHEM, V274, P7583, DOI 10.1074/jbc.274.11.7583; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Peace BE, 2005, CANCER RES, V65, P1285, DOI 10.1158/0008-5472.CAN-03-3580; Persons DA, 1999, NAT GENET, V23, P159, DOI 10.1038/13787; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rosario M, 2003, TRENDS CELL BIOL, V13, P328, DOI 10.1016/S0962-8924(03)00104-1; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; Santoro MM, 2000, ONCOGENE, V19, P5208, DOI 10.1038/sj.onc.1203819; Santoro MM, 2003, DEV CELL, V5, P257, DOI 10.1016/S1534-5807(03)00201-6; Sasaki A, 2003, NAT CELL BIOL, V5, P427, DOI 10.1038/ncb978; Saucier C, 2002, ONCOGENE, V21, P1800, DOI 10.1038/sj.onc.1205261; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Schiering N, 2003, P NATL ACAD SCI USA, V100, P12654, DOI 10.1073/pnas.1734128100; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; van den Akker E, 2004, BLOOD, V103, P4457, DOI 10.1182/blood-2003-08-2713; Wybenga-Groot LE, 2001, CELL, V106, P745, DOI 10.1016/S0092-8674(01)00496-2; Zhou YQ, 2003, ONCOGENE, V22, P186, DOI 10.1038/sj.onc.1206075	45	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35098	35107		10.1074/jbc.M505737200	http://dx.doi.org/10.1074/jbc.M505737200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16103119	hybrid			2022-12-27	WOS:000232561200006
J	Yoo, D; Fang, L; Mason, A; Kim, BY; Welling, PA				Yoo, D; Fang, L; Mason, A; Kim, BY; Welling, PA			A phosphorylation-dependent export structure in ROMK (Kir 1.1) channel overrides an endoplasmic reticulum localization signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; CORTICAL COLLECTING TUBULE; CONDUCTANCE K+ CHANNEL; THICK ASCENDING LIMB; POTASSIUM CHANNEL; SURFACE EXPRESSION; CELL-SURFACE; MEMBRANE-PROTEINS; BARTTERS-SYNDROME; RETENTION SIGNAL	The cell surface density of functional Kir1.1 (ROMK, KCNJ1) channels in the renal collecting duct is precisely regulated to maintain potassium balance. Here, we explore the mechanism by which phosphorylation of Kir1.1a serine 44 controls plasmalemma expression. Studies in Xenopus oocytes, expressing wild-type, phosphorylation mimic (S44D), or phosphorylation null (S44A) Kir1.1a, revealed that phosphorylation of serine 44 is required to stimulate traffic of newly synthesized channels to the plasma membrane through a brefeldin A-sensitive pathway. ROMK channels were found to acquire mature glycosylation in a serine 44 phosphorylation-dependent manner, consistent with a phosphorylation- dependent trafficking step within the endoplasmic reticulum/Golgi. Serine 44 neighbors a string of three "RXR" motifs, reminiscent of basic trafficking signals involved in directing early transport steps within the secretory pathway. Replacement of the arginine residues with alanine (R35A, R37A, R39A, R41A, or all Arg to Ala) did not restore cell surface expression of the phospho-null S44A channel, making it unlikely that phosphorylation abrogates a nearby RXR-type endoplasmic reticulum (ER) localization signal. Instead, analysis of the compound S44D phospho-mimic mutants revealed that the neighboring arginine residues are also necessary for cell surface expression, identifying a structure that determines export in the biosynthetic pathway. Suppressor mutations in a putative dibasic ER retention signal, located within the cytoplasmic C terminus (K370A, R371A), restored cell surface expression of the phospho-null S44A channel to levels exhibited by the phospho-mimic S44D channel. Taken together, these studies indicate that phosphorylation of Ser(44) drives an export step within the secretory pathway to override an independent endoplasmic reticulum localization signal.	Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Welling, PA (corresponding author), Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA.	pwelling@umeryland.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054231, R01DK063049] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK63049, DK54231] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson HA, 1999, J IMMUNOL, V163, P5435; CASSOLA AC, 1993, AM J PHYSIOL, V264, pF502, DOI 10.1152/ajprenal.1993.264.3.F502; Ecelbarger CA, 2001, J AM SOC NEPHROL, V12, P10, DOI 10.1681/ASN.V12110; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; Flagg TP, 1999, J GEN PHYSIOL, V114, P685, DOI 10.1085/jgp.114.5.685; Giebisch G, 1998, AM J PHYSIOL-RENAL, V274, pF817, DOI 10.1152/ajprenal.1998.274.5.F817; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Huang DY, 2004, J AM SOC NEPHROL, V15, P885, DOI 10.1097/01.ASN.0000120368.59693.A8; Jessus C, 1998, BIOL CELL, V90, P573, DOI 10.1016/S0248-4900(99)80015-X; Kahle KT, 2003, NAT GENET, V35, P372, DOI 10.1038/ng1271; Kamsteeg EJ, 2001, BIOCHEM BIOPH RES CO, V282, P683, DOI 10.1006/bbrc.2001.4629; Keller SH, 2001, J BIOL CHEM, V276, P18384, DOI 10.1074/jbc.M100691200; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Kuwana T, 1998, P NATL ACAD SCI USA, V95, P1056, DOI 10.1073/pnas.95.3.1056; Lin DH, 2002, AM J PHYSIOL-RENAL, V283, pF671, DOI 10.1152/ajprenal.00160.2002; Lin DH, 2005, P NATL ACAD SCI USA, V102, P4306, DOI 10.1073/pnas.0409767102; Lin DH, 2002, J BIOL CHEM, V277, P44278, DOI 10.1074/jbc.M203702200; Lorenz JN, 2002, J BIOL CHEM, V277, P37871, DOI 10.1074/jbc.M205627200; Lu M, 2002, J BIOL CHEM, V277, P37881, DOI 10.1074/jbc.M206644200; Ma D, 2002, CURR OPIN NEUROBIOL, V12, P287, DOI 10.1016/S0959-4388(02)00319-7; MacGregor GG, 1998, AM J PHYSIOL-RENAL, V275, pF415, DOI 10.1152/ajprenal.1998.275.3.F415; Moral Z, 2001, J BIOL CHEM, V276, P7156, DOI 10.1074/jbc.M008671200; O'Connell AD, 2005, P NATL ACAD SCI USA, V102, P9954, DOI 10.1073/pnas.0504332102; O'Kelly I, 2002, CELL, V111, P577, DOI 10.1016/S0092-8674(02)01040-1; PALMER LG, 1994, J GEN PHYSIOL, V104, P693, DOI 10.1085/jgp.104.4.693; Palmer LG, 1999, AM J PHYSIOL-RENAL, V277, pF821, DOI 10.1152/ajprenal.1999.277.6.F821; Palmer LG, 2000, KIDNEY INT, V57, P1324, DOI 10.1046/j.1523-1755.2000.00970.x; Rajan S, 2002, J PHYSIOL-LONDON, V545, P13, DOI 10.1113/jphysiol.2002.027052; SCHWALBE RA, 1995, J BIOL CHEM, V270, P15336, DOI 10.1074/jbc.270.25.15336; Schwappach B, 2000, NEURON, V26, P155, DOI 10.1016/S0896-6273(00)81146-0; Scott DB, 2003, NEUROPHARMACOLOGY, V45, P755, DOI 10.1016/S0028-3908(03)00250-8; Scott DB, 2001, J NEUROSCI, V21, P3063, DOI 10.1523/JNEUROSCI.21-09-03063.2001; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Sterling H, 2002, J BIOL CHEM, V277, P4317, DOI 10.1074/jbc.M109739200; Stockklausner C, 2003, J BIOL CHEM, V278, P17000, DOI 10.1074/jbc.M212243200; Stockklausner C, 2001, FEBS LETT, V493, P129, DOI 10.1016/S0014-5793(01)02286-4; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; Tinker A, 1996, CELL, V87, P857, DOI 10.1016/S0092-8674(00)81993-5; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; WANG WH, 1990, AM J PHYSIOL, V259, pF494, DOI 10.1152/ajprenal.1990.259.3.F494; Wei Y, 2001, AM J PHYSIOL-RENAL, V281, pF206, DOI 10.1152/ajprenal.2001.281.2.F206; Welling PA, 1997, AM J PHYSIOL-RENAL, V273, pF825, DOI 10.1152/ajprenal.1997.273.5.F825; Wilson FH, 2001, SCIENCE, V293, P1107, DOI 10.1126/science.1062844; Xu ZC, 1996, J BIOL CHEM, V271, P9313, DOI 10.1074/jbc.271.16.9313; Yoo D, 2003, J BIOL CHEM, V278, P23066, DOI 10.1074/jbc.M212301200; Yoo D, 2004, J BIOL CHEM, V279, P6863, DOI 10.1074/jbc.M311599200; Yuan HB, 2003, CURR BIOL, V13, P638, DOI 10.1016/S0960-9822(03)00208-2; Yun CC, 2002, J AM SOC NEPHROL, V13, P2823, DOI 10.1097/01.ASN.0000035085.54451.81; Zeng WZ, 2002, AM J PHYSIOL-RENAL, V283, pF630, DOI 10.1152/ajprenal.00378.2001; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zerangue N, 2001, P NATL ACAD SCI USA, V98, P2431, DOI 10.1073/pnas.051630198	53	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35281	35289		10.1074/jbc.M504836200	http://dx.doi.org/10.1074/jbc.M504836200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16118216	hybrid			2022-12-27	WOS:000232561200026
J	Liu, AMF; Wong, YH				Liu, AMF; Wong, YH			Activation of nuclear factor kappa B by somatostatin type 2 receptor in pancreatic acinar AR42J cells involves G alpha(14) and multiple signaling components - A mechanism requiring protein kinase C, calmodulin-dependent kinase II, ERK, AND c-Src	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-BETA-GAMMA; TUMOR-NECROSIS-FACTOR; N-TERMINAL KINASE; COUPLED RECEPTOR; TYROSINE PHOSPHORYLATION; OPIOID RECEPTOR; PHOSPHOLIPASE-C; ALPHA; EXPRESSION; PATHWAY	Medications targeting the somatostatin type 2 receptor (SSTR2) have been employed for pancreatic inflammations and cancers, possibly via the regulation of the transcription factor nuclear factor kappa B (NF kappa B). Here we demonstrate that in tumoral pancreatic acinar AR42J cells, activation of SSTR2 leads to stimulation of the inhibitor kappa B kinase (IKK)/ NF kappa B signaling cascade via pertussis toxin-insensitive G proteins in a time- and dose-dependent manner. The inability of G(q/11) and G(12/13) proteins to activate IKK/NF kappa B by SSTR2 in transfected human embryonic kidney 293 cells and the lack of G alpha(16) in AR42J cells suggested a possible role of G alpha(14) in mediating SSTR2-induced responses. This regulatory role of G alpha(14) was further confirmed by the activation of IKK and NF kappa B in human embryonic kidney 293 cells expressing SSTR2 and G alpha(14) upon induction. The stimulatory effect of G beta(1)gamma(2) and the abrogation by overexpressing transducin confirmed the participation of G beta gamma in SSTR2-mediated IKK/NF kappa B activation. By the application of specific inhibitors and dominant negative mutants, phospholipase C beta, protein kinase C, and calmodulin-dependent kinase II were shown to be involved in SSTR2-induced responses. Inhibition of c-Src and numerous intermediates, including Ras, Raf-1 kinase, MEK1/2, along with the extracellular signal-regulated kinase cascade attenuated somatostatin-mediated IKK/NF kappa B activation. Although c-Jun N-terminal kinase and p38 mitogen-activated protein kinase ( MAPK) were also stimulated by SSTR2, suppression of these two MAPKs was ineffective in altering the somatostatin-mediated responses. Similar results were also obtained using AR42J cells. These data suggest that activation of the IKK/NF kappa B signaling cascade by SSTR2 requires a complicated network consisting of G alpha(14) and multiple intermediates.	Hong Kong Univ Sci & Technol, Mol Neurosci Ctr, Dept Biochem, Kowloon, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Biotechnol Res Inst, Kowloon, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology	Wong, YH (corresponding author), Hong Kong Univ Sci & Technol, Mol Neurosci Ctr, Dept Biochem, Clear Water Bay, Kowloon, Hong Kong, Peoples R China.	boyung@ust.hk		Wong, Yung Hou/0000-0002-0123-7697				Adayev T, 2003, BBA-MOL CELL RES, V1640, P85, DOI 10.1016/S0167-4889(03)00023-5; Castrillo A, 2001, J EXP MED, V194, P1231, DOI 10.1084/jem.194.9.1231; Chan ASL, 2000, J PHARMACOL EXP THER, V295, P1094; Chandrasekar B, 2004, J BIOL CHEM, V279, P3188, DOI 10.1074/jbc.M311660200; Chen BC, 2001, BRIT J PHARMACOL, V134, P1055, DOI 10.1038/sj.bjp.0704334; Elberg G, 2002, MOL ENDOCRINOL, V16, P2502, DOI 10.1210/me.2002-0207; Gao H, 2004, MOL CELL, V14, P303, DOI 10.1016/S1097-2765(04)00216-3; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ho MKC, 2001, BRIT J PHARMACOL, V132, P1431, DOI 10.1038/sj.bjp.0703933; Huang WC, 2003, J IMMUNOL, V170, P4767, DOI 10.4049/jimmunol.170.9.4767; Huang WC, 2003, J BIOL CHEM, V278, P9944, DOI 10.1074/jbc.M208521200; Hughes K, 2001, J BIOL CHEM, V276, P36008, DOI 10.1074/jbc.M106125200; Illario M, 2003, J BIOL CHEM, V278, P45101, DOI 10.1074/jbc.M305355200; ITO A, 1995, FEBS LETT, V368, P183, DOI 10.1016/0014-5793(95)00643-N; Khoshnan A, 2000, J IMMUNOL, V165, P6933, DOI 10.4049/jimmunol.165.12.6933; Kitagawa M, 1998, PANCREAS, V16, P427, DOI 10.1097/00006676-199804000-00035; Kraus S, 2003, J BIOL CHEM, V278, P32618, DOI 10.1074/jbc.M303886200; Liu AMF, 2005, NEUROSIGNALS, V14, P136, DOI 10.1159/000086296; Liu AMF, 2004, J BIOL CHEM, V279, P53196, DOI 10.1074/jbc.M410196200; Lo RKH, 2004, MOL PHARMACOL, V65, P1427, DOI 10.1124/mol.65.6.1427; Lo RKH, 2003, J BIOL CHEM, V278, P52154, DOI 10.1074/jbc.M307299200; Lowes VL, 2002, NEUROSIGNALS, V11, P5, DOI 10.1159/000057317; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Mody SM, 2000, MOL PHARMACOL, V57, P13; Paran Daphna, 2003, Curr Opin Investig Drugs, V4, P578; Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; REUBI JC, 1994, CANCER RES, V54, P3455; Rosenberg L, 2003, EXPERT OPIN BIOL TH, V3, P319, DOI 10.1517/14712598.3.2.319; Shepard LW, 2001, J BIOL CHEM, V276, P45979, DOI 10.1074/jbc.M104783200; TAYLOR JE, 1995, BIOCHEM BIOPH RES CO, V214, P81, DOI 10.1006/bbrc.1995.2259; Trushin SA, 2003, MOL CELL BIOL, V23, P7068, DOI 10.1128/MCB.23.19.7068-7081.2003; Tuyt LML, 1999, J IMMUNOL, V162, P4893; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Wang Y, 2003, J AM SOC NEPHROL, V14, P28, DOI 10.1097/01.ASN.0000043180.18456.47; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; Xie P, 2000, J BIOL CHEM, V275, P24907, DOI 10.1074/jbc.M001051200; Yang M, 2003, MOL PHARMACOL, V64, P447, DOI 10.1124/mol.64.2.447; Yang M, 2001, J IMMUNOL, V166, P6885, DOI 10.4049/jimmunol.166.11.6885; Yule DI, 1999, AM J PHYSIOL-GASTR L, V276, pG271, DOI 10.1152/ajpgi.1999.276.1.G271; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355; ZIGMAN JM, 1994, ENDOCRINOLOGY, V135, P31, DOI 10.1210/en.135.1.31	45	41	44	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34617	34625		10.1074/jbc.M504264200	http://dx.doi.org/10.1074/jbc.M504264200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16115892	hybrid			2022-12-27	WOS:000232403900030
J	Song, YT; Masison, DC				Song, YT; Masison, DC			Independent regulation of Hsp70 and Hsp90 chaperones by Hsp70/Hsp90-organizing protein Sti1 (Hop1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; STEROID-RECEPTOR ACTION; HEAT-SHOCK PROTEINS; PROGESTERONE-RECEPTOR; SIGNAL-TRANSDUCTION; IN-VIVO; BINDING; PROPAGATION; STRESS; PRION	Hsp70 and Hsp90 protein chaperones cooperate in a protein-folding pathway required by many "client" proteins. The co-chaperone Sti1p coordinates functions of Hsp70 and Hsp90 in this pathway. Sti1p has three tetratricopeptide repeat (TPR) domains. TPR1 binds Hsp70, TPR2a binds Hsp90, and the ligand for TPR2b is unknown. Although Sti1p is thought to be dedicated to the client folding pathway, we earlier showed that Sti1p regulated Hsp70, independently of Hsp90, in a way that impairs yeast [PSI+] prion propagation. Using this prion system to monitor Sti1p regulation of Hsp70 and an Hsp90-inhibiting compound to monitor Hsp90 regulation, we identified Sti1p mutations that separately affect Hsp70 and Hsp90. TPR1 mutations impaired Sti1p regulation of Hsp70, but deletion of TPR2a and TPR2b did not. Conversely, TPR2a and TPR2b mutations impaired Sti1p regulation of Hsp90, but deletion of TPR1 did not. All Sti1p mutations variously impaired the client folding pathway, which requires both Hsp70 and Hsp90. Thus, Sti1p regulated Hsp70 and Hsp90 separately, Hsp90 is implicated as a TPR2b ligand, and mutations separately affecting regulation of either chaperone impair a pathway that is dependent upon both. We further demonstrate that client folding depended upon bridging of Hsp70 and Hsp90 by Sti1p and find conservation of the independent regulation of Hsp70 and Hsp90 by human Hop1.	NIDDK, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Masison, DC (corresponding author), NIDDK, Lab Biochem & Genet, NIH, Bldg 8,Rm 407,8 Ctr Dr, Bethesda, MD 20892 USA.	masisond@helix.nih.gov			NIDDK NIH HHS [Z01 DK024946-08] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK024946, Z01DK024946] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbas-Terki T, 2001, MOL CELL BIOL, V21, P7569, DOI 10.1128/MCB.21.22.7569-7575.2001; Carrigan PE, 2005, J BIOL CHEM, V280, P8906, DOI 10.1074/jbc.M414245200; Carrigan PE, 2004, J BIOL CHEM, V279, P16185, DOI 10.1074/jbc.M314130200; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Chen SY, 1998, J BIOL CHEM, V273, P35194, DOI 10.1074/jbc.273.52.35194; COX BS, 1965, HEREDITY, V20, P505, DOI 10.1038/hdy.1965.65; Duina AA, 1996, SCIENCE, V274, P1713, DOI 10.1126/science.274.5293.1713; Harger JW, 2003, RNA, V9, P1019, DOI 10.1261/rna.5930803; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Hernandez MP, 2002, J BIOL CHEM, V277, P38294, DOI 10.1074/jbc.M206566200; Hernandez MP, 2002, J BIOL CHEM, V277, P11873, DOI 10.1074/jbc.M111445200; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; Jones G, 2004, MOL CELL BIOL, V24, P3928, DOI 10.1128/MCB.24.9.3928-3937.2004; Jones GW, 2003, GENETICS, V163, P495; Jung G, 2000, GENETICS, V156, P559; Lassle M, 1997, J BIOL CHEM, V272, P1876, DOI 10.1074/jbc.272.3.1876; Lee J, 2004, BIOTECHNIQUES, V36, P398, DOI 10.2144/04363BM04; Louvion JF, 1996, P NATL ACAD SCI USA, V93, P13937, DOI 10.1073/pnas.93.24.13937; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; Odunuga OO, 2003, J BIOL CHEM, V278, P6896, DOI 10.1074/jbc.M206867200; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; Pratt WB, 2004, ESSAYS BIOCHEM, V40, P41, DOI 10.1042/bse0400041; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Richter K, 2003, J BIOL CHEM, V278, P10328, DOI 10.1074/jbc.M213094200; Riggs DL, 2003, EMBO J, V22, P1158, DOI 10.1093/emboj/cdg108; SCHATZ PJ, 1988, GENETICS, V120, P681; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; SHERMAN F, 1994, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; Song YT, 2002, FEBS LETT, V512, P213, DOI 10.1016/S0014-5793(02)02258-5; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; Wegele H, 2003, J BIOL CHEM, V278, P25970, DOI 10.1074/jbc.M301548200; Wickner RB, 2000, J STRUCT BIOL, V130, P310, DOI 10.1006/jsbi.2000.4250; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	38	83	83	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34178	34185		10.1074/jbc.M505420200	http://dx.doi.org/10.1074/jbc.M505420200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16100115	hybrid, Green Accepted			2022-12-27	WOS:000232229700059
J	Ruehl, M; Erben, U; Schuppan, D; Wagner, C; Zeller, A; Freise, C; Al-Hasani, H; Loesekann, M; Notter, M; Wittig, BM; Zeitz, M; Dieterich, W; Somasundaram, R				Ruehl, M; Erben, U; Schuppan, D; Wagner, C; Zeller, A; Freise, C; Al-Hasani, H; Loesekann, M; Notter, M; Wittig, BM; Zeitz, M; Dieterich, W; Somasundaram, R			The elongated first fibronectin type III domain of collagen XIV is an inducer of quiescence and differentiation in fibroblasts and preadipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; BINDING-PROPERTIES; CELL-ADHESION; GROWTH; VI; EXPRESSION; UNDULIN; PROLIFERATION; LOCALIZATION; KINASE	Collagen XIV (CXIV) is a fibril-associated collagen that is mainly expressed in well differentiated tissues and in late embryonic development. Because CXIV is almost absent in proliferating and/or dedifferentiated tissues, a functional role in maintaining cell differentiation is suspected. We demonstrate antiproliferative, quiescence- and differentiation-inducing effects of human CXIV and its recombinant fragments on mesenchymal cells. In primary human fibroblasts, in mouse 3T3 fibroblasts and in 3T3-L1 preadipocytes, CXIV reduced de novo DNA synthesis by 75%, whereas cell numbers and viability remained unaltered. Cells showed no signs of apoptosis, and maximal proliferation was restored when serum was supplemented, thus indicating that CXIV induced reversible cellular quiescence. Exposure of fibroblasts to CXIV in vitro led to cellular bundles and clusters. CXIV also triggered trans-differentiation of 3T3-L1 preadipocytes into adipocytes, as could be shown by lipid accumulation and by expression of the glucose transporter Glut4. These effects were also observed with the amino-terminal recombinant fragment Gln(29)-Pro(154) that harbors the first fibronectin type III domain and a 39-amino-acid extension, whereas no activity was found for all other recombinant CXIV fragments. Based on these finding the development of small molecular analogs that modulate fibroblast cell growth and differentiation, e. g. in wound healing and fibrosis, seems feasible.	Dept Gastroenterol, D-12200 Berlin, Germany; Dept Hematol, D-12200 Berlin, Germany; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA; German Inst Human Nutr, D-14558 Nuthetal, Germany; Univ Erlangen Nurnberg, Dept Med 1, D-91054 Erlangen, Germany	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE); University of Erlangen Nuremberg	Somasundaram, R (corresponding author), Dept Gastroenterol, Charite Campus,Hindenburgdamm 30, D-12200 Berlin, Germany.	rajan.somasundaram@charite.de	Freise, Christian/P-4285-2019; Freise, Christian/H-9892-2012	Freise, Christian/0000-0003-2602-226X; Somasundaram, Rajan/0000-0003-3461-3326				Atkinson JC, 1996, EXP CELL RES, V228, P283, DOI 10.1006/excr.1996.0328; AUBERTFOUCHER E, 1992, J BIOL CHEM, V267, P15759; Bauer M, 1997, BBA-GENE STRUCT EXPR, V1354, P183, DOI 10.1016/S0167-4781(97)00131-0; BECKER J, 1987, VIRCHOWS ARCH A, V412, P161, DOI 10.1007/BF00716189; Berthod F, 1997, J INVEST DERMATOL, V108, P737, DOI 10.1111/1523-1747.ep12292122; BROWN JC, 1994, MATRIX BIOL, V14, P287, DOI 10.1016/0945-053X(94)90194-5; BROWN JC, 1993, J CELL BIOL, V120, P557, DOI 10.1083/jcb.120.2.557; Ehnis T, 1997, J BIOL CHEM, V272, P20414, DOI 10.1074/jbc.272.33.20414; Ehnis T, 1996, EXP CELL RES, V229, P388, DOI 10.1006/excr.1996.0384; Ehnis T, 1998, EXP CELL RES, V239, P477, DOI 10.1006/excr.1997.3895; Gaca MDA, 2003, MATRIX BIOL, V22, P229, DOI 10.1016/S0945-053X(03)00017-9; Gagnon A, 2001, ENDOCRINOLOGY, V142, P205, DOI 10.1210/en.142.1.205; Gerecke DR, 2004, MATRIX BIOL, V22, P593, DOI 10.1016/j.matbio.2003.11.004; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Imhof M, 2001, J BIOL CHEM, V276, P9141, DOI 10.1074/jbc.M009148200; JUST M, 1991, J BIOL CHEM, V266, P17326; Klein G, 1998, MATRIX BIOL, V16, P307, DOI 10.1016/S0945-053X(98)90002-6; KNITTEL T, 1992, EXP CELL RES, V203, P312, DOI 10.1016/0014-4827(92)90004-R; Marhaba R, 2004, J MOL HISTOL, V35, P211; Nakagawa H, 1999, BIOCHEM BIOPH RES CO, V256, P642, DOI 10.1006/bbrc.1999.0393; Ntambi JM, 2000, J NUTR, V130, p3122S, DOI 10.1093/jn/130.12.3122S; RICARDBLUM S, 2000, UNCONVENTIONAL COLLA, P93; Ruhl M, 1999, EXP CELL RES, V250, P548, DOI 10.1006/excr.1999.4540; Ruhl M, 1999, J BIOL CHEM, V274, P34361, DOI 10.1074/jbc.274.48.34361; SCHUPPAN D, 1990, J BIOL CHEM, V265, P8823; Schuppan D, 1998, GASTROENTEROLOGY, V114, P139, DOI 10.1016/S0016-5085(98)70642-0; Schuppan D, 2001, SEMIN LIVER DIS, V21, P351, DOI 10.1055/s-2001-17556; SCHUPPAN D, 2002, J GASTROENTEROL H S3, V17, P300; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Sohara N, 2002, J HEPATOL, V37, P214, DOI 10.1016/S0168-8278(02)00103-4; Somasundaram R, 1996, J BIOL CHEM, V271, P26884, DOI 10.1074/jbc.271.43.26884; WALCHLI C, 1994, J CELL SCI, V107, P669; WALCHLI C, 1993, EUR J BIOCHEM, V212, P483, DOI 10.1111/j.1432-1033.1993.tb17685.x; Young BB, 2000, DEV DYNAM, V217, P430, DOI 10.1002/(SICI)1097-0177(200004)217:4<430::AID-DVDY10>3.0.CO;2-5; Young BB, 2002, J CELL BIOCHEM, V87, P208, DOI 10.1002/jcb.10290	35	25	26	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38537	38543		10.1074/jbc.M502210200	http://dx.doi.org/10.1074/jbc.M502210200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16129687	hybrid			2022-12-27	WOS:000233239800052
J	Vos, WL; Koehorst, RBM; Spruijt, RB; Hemminga, MA				Vos, WL; Koehorst, RBM; Spruijt, RB; Hemminga, MA			Membrane-bound conformation of M13 major coat protein - A structure validation through fret-derived constraints	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE M13; ENERGY-TRANSFER; LIPID-BILAYERS; SPECTROSCOPY; TRYPTOPHAN; DOMAIN; MODEL; MODULATION; SIMULATION; MICELLES	M13 major coat protein, a 50-amino-acid-long protein, was incorporated into DOPC/DOPG (80/20 molar ratio) unilamellar vesicles. Over 60% of all amino acid residues was replaced with cysteine residues, and the single cysteine mutants were labeled with the fluorescent label I-AEDANS. The coat protein has a single tryptophan residue that is used as a donor in fluorescence ( or Forster) resonance energy transfer ( FRET) experiments, using AEDANS-labeled cysteines as acceptors. Based on FRET-derived constraints, a straight alpha-helix is proposed as the membrane-bound conformation of the coat protein. Different models were tested to represent the molecular conformations of the donor and acceptor moieties. The best model was used to make a quantitative comparison of the FRET data to the structures of M13 coat protein and related coat proteins in the Protein Data Bank. This shows that the membrane-bound conformation of the coat protein is similar to the structure of the coat protein in the bacteriophage that was obtained from x-ray diffraction. Coat protein embedded in stacked, oriented bilayers and in micelles turns out to be strongly affected by the environmental stress of these membrane-mimicking environments. Our findings emphasize the need to study membrane proteins in a suitable environment, such as in fully hydrated unilamellar vesicles. Although larger proteins than M13 major coat protein may be able to handle environmental stress in a different way, any membrane protein with water exposed parts in the C or N termini and hydrophilic loop regions should be treated with care.	Univ Wageningen & Res Ctr, Biophys Lab, NL-6703 HA Wageningen, Netherlands	Wageningen University & Research	Hemminga, MA (corresponding author), Univ Wageningen & Res Ctr, Biophys Lab, Dreijenlaan 3, NL-6703 HA Wageningen, Netherlands.	marcus.hemminga@wur.nl						Anderluh G, 2003, J BIOL CHEM, V278, P21860, DOI 10.1074/jbc.M300411200; BAUDETNESSLER S, 1993, BIOCHEMISTRY-US, V32, P8457, DOI 10.1021/bi00084a010; Chou JJ, 2002, J AM CHEM SOC, V124, P2450, DOI 10.1021/ja017875d; CORNELL WD, 1995, J AM CHEM SOC, V117, P5197; CREIGHTON TE, 1983, PROTEINS; DATEMA KP, 1987, BIOCHEMISTRY-US, V26, P6145, DOI 10.1021/bi00393a030; EATON DF, 1988, PURE APPL CHEM, V60, P1107, DOI 10.1351/pac198860071107; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Eisenhawer M, 2001, BIOCHEMISTRY-US, V40, P12321, DOI 10.1021/bi0107694; Fernandes F, 2003, BIOPHYS J, V85, P2430, DOI 10.1016/S0006-3495(03)74666-9; Fisher CA, 1999, J LIPID RES, V40, P93; FUNG BKK, 1978, BIOCHEMISTRY-US, V17, P5241, DOI 10.1021/bi00617a025; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HEMMINGA MA, 1992, PROG LIPID RES, V31, P301, DOI 10.1016/0163-7827(92)90011-7; HEMMINGA MA, 1993, NEW COMPREHENSIVE BI, P191; HUDSON EN, 1973, BIOCHEMISTRY-US, V12, P4154, DOI 10.1021/bi00745a019; JOHNSON ID, 1989, BIOCHEMISTRY-US, V28, P6392, DOI 10.1021/bi00441a035; Koehorst RBM, 2004, BIOPHYS J, V87, P1445, DOI 10.1529/biophysj.104.043208; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lakowicz J.R, 1999, PRINCIPLES FLUORESCE, P368; Lakshmikanth GS, 2001, NAT STRUCT BIOL, V8, P799, DOI 10.1038/nsb0901-799; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Lovell SC, 2000, PROTEINS, V40, P389, DOI 10.1002/1097-0134(20000815)40:3<389::AID-PROT50>3.0.CO;2-2; Marassi FM, 2003, PROTEIN SCI, V12, P403, DOI 10.1110/ps.0211503; Marassi FM, 1997, P NATL ACAD SCI USA, V94, P8551, DOI 10.1073/pnas.94.16.8551; MARVIN DA, 1994, J MOL BIOL, V235, P260, DOI 10.1016/S0022-2836(05)80032-4; Marvin DA, 1998, CURR OPIN STRUC BIOL, V8, P150, DOI 10.1016/S0959-440X(98)80032-8; Meijer AB, 2001, BIOCHEMISTRY-US, V40, P8815, DOI 10.1021/bi002956s; Nazarov PV, 2004, J CHEM INF COMP SCI, V44, P568, DOI 10.1021/ci034149g; Papavoine CHM, 1998, J MOL BIOL, V282, P401, DOI 10.1006/jmbi.1998.1860; Salamon Z, 2000, BIOPHYS J, V78, P1400, DOI 10.1016/S0006-3495(00)76693-8; SHON KJ, 1991, SCIENCE, V252, P1303, DOI 10.1126/science.1925542; Spruijt RB, 2004, BIOCHEMISTRY-US, V43, P13972, DOI 10.1021/bi048437x; SPRUIJT RB, 1989, BIOCHEMISTRY-US, V28, P9158, DOI 10.1021/bi00449a030; Spruijt RB, 2000, BBA-BIOMEMBRANES, V1509, P311, DOI 10.1016/S0005-2736(00)00314-X; Stopar D, 2003, BBA-BIOMEMBRANES, V1611, P5, DOI 10.1016/S0005-2736(03)00047-6; Strancar J, 2005, J CHEM INF MODEL, V45, P394, DOI 10.1021/ci049748h; Torres J, 2003, TRENDS BIOCHEM SCI, V28, P137, DOI 10.1016/S0968-0004(03)00026-4; Tristram-Nagle S, 2004, CHEM PHYS LIPIDS, V127, P3, DOI 10.1016/j.chemphyslip.2003.09.002; WALL L, 1996, PROGRAMMING PERL	40	18	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38522	38527		10.1074/jbc.M505875200	http://dx.doi.org/10.1074/jbc.M505875200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16150733	hybrid			2022-12-27	WOS:000233239800050
J	Abdulaev, NG; Ngo, T; Zhang, C; Dinh, A; Brabazon, DM; Ridge, KD; Marino, JP				Abdulaev, NG; Ngo, T; Zhang, C; Dinh, A; Brabazon, DM; Ridge, KD; Marino, JP			Heterotrimeric G-protein alpha-subunit adopts a "preactivated" conformation when associated with beta gamma-subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; LIGHT-ACTIVATED RHODOPSIN; PHOTORECEPTOR G-PROTEIN; X-RAY CRYSTALLOGRAPHY; EF-TS COMPLEX; CRYSTAL-STRUCTURE; STRUCTURAL DETERMINANTS; ANGSTROM RESOLUTION; CATALYTIC DOMAINS; ESCHERICHIA-COLI	Activation of a heterotrimeric G-protein by an agonist-stimulated G-protein-coupled receptor requires the propagation of structural signals from the receptor binding interface to the guanine nucleotide binding pocket of the G-protein. To probe the molecular basis of this signaling process, we are applying high resolution NMR to track structural changes in an isotope-labeled, full-length G-protein alpha-subunit (G(alpha)) chimera (ChiT) associated with G-protein beta gamma-subunit (G(beta gamma)) and activated receptor (R*) interactions. Here, we show that ChiT can be functionally reconstituted with G(beta gamma) as assessed by aluminum fluoride-dependent changes in intrinsic tryptophan fluorescence and light-activated rhodopsin-catalyzed guanine nucleotide exchange. We further show that N-15-ChiT can be titrated with G(beta gamma) to form stable heterotrimers at NMR concentrations. To assess structural changes in ChiT upon heterotrimer formation, HSQC spectra of the N-15-ChiT-reconstituted heterotrimer have been acquired and compared with spectra obtained for GDP/Mg2+-bound N-15-ChiT in the presence and absence of aluminum fluoride and guanosine 5'-3-O-(thio) triphosphate (GTP gamma S)/ Mg2+-bound N-15-ChiT. As anticipated, G(beta gamma) association with N-15-ChiT results in (HN)-H-1, N-15 chemical shift changes relative to the GDP/ Mg2+-bound state. Strikingly, however, most 1HN, 15N chemical shift changes associated with heterotrimer formation are the same as those observed upon formation of the GDP center dot AlF4-/Mg2+- and GTP gamma S/Mg2+-bound states. Based on these comparative analyses, assembly of the heterotrimer appears to induce structural changes in the switch II and carboxyl-terminal regions of G(alpha) ("preactivation") that may facilitate the interaction with R* and subsequent GDP/GTP exchange.	Univ Texas, Hlth Sci Ctr, Dept Biochem & Mol Biol, Ctr Membrane Biol, Houston, TX 77030 USA; Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Natl Inst Stand & Technol, Rockville, MD 20850 USA; Loyola Coll, Dept Chem, Baltimore, MD 21210 USA	University of Texas System; University of Texas Health Science Center Houston; University System of Maryland; University of Maryland Baltimore; National Institute of Standards & Technology (NIST) - USA; Loyola University Maryland	Ridge, KD (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem & Mol Biol, Ctr Membrane Biol, Houston, TX 77030 USA.	Kevin.D.Ridge@uth.tmc.edu; john.marino@nist.gov			NCRR NIH HHS [RR015744] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR015744] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Abdulaev NG, 2005, J BIOMOL NMR, V32, P31, DOI 10.1007/s10858-005-3340-5; Abdulaev NG, 2000, J BIOL CHEM, V275, P39354, DOI 10.1074/jbc.M005642200; ANTONNY B, 1992, J BIOL CHEM, V267, P6710; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Brabazon DM, 2003, BIOCHEMISTRY-US, V42, P302, DOI 10.1021/bi0268899; Cabrera-Vera TM, 2003, ENDOCR REV, V24, P765, DOI 10.1210/er.2000-0026; Cherfils J, 2003, TRENDS BIOCHEM SCI, V28, P13, DOI 10.1016/S0968-0004(02)00006-3; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; Grishina G, 1998, J BIOL CHEM, V273, P15053, DOI 10.1074/jbc.273.24.15053; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Herrmann R, 2004, J BIOL CHEM, V279, P24283, DOI 10.1074/jbc.M311166200; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P3396; Hubbell WL, 2003, ADV PROTEIN CHEM, V63, P243; Iiri T, 1998, NATURE, V394, P35, DOI 10.1038/27831; Jawad Z, 2002, STRUCTURE, V10, P447, DOI 10.1016/S0969-2126(02)00750-5; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; Kisselev OG, 2003, STRUCTURE, V11, P367, DOI 10.1016/S0969-2126(03)00045-5; Kisselev OG, 1998, P NATL ACAD SCI USA, V95, P4270, DOI 10.1073/pnas.95.8.4270; Koenig BW, 2000, J BIOMOL NMR, V16, P121, DOI 10.1023/A:1008378523816; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; Medkova M, 2002, BIOCHEMISTRY-US, V41, P9962, DOI 10.1021/bi0255726; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; Natochin M, 1998, J BIOL CHEM, V273, P21808, DOI 10.1074/jbc.273.34.21808; Natochin M, 1999, J BIOL CHEM, V274, P7865, DOI 10.1074/jbc.274.12.7865; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PHILLIPS WJ, 1988, J BIOL CHEM, V263, P15498; Preininger AM, 2003, BIOCHEMISTRY-US, V42, P7931, DOI 10.1021/bi0345438; PREININGER AM, 2004, SCI STKE, pRE3; RAO ST, 1973, J MOL BIOL, V76, P241, DOI 10.1016/0022-2836(73)90388-4; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P3261, DOI 10.1021/bi00010a016; Ridge KD, 2003, TRENDS BIOCHEM SCI, V28, P479, DOI 10.1016/S0968-0004(03)00172-5; Ruan B, 2004, BIOCHEMISTRY-US, V43, P14539, DOI 10.1021/bi048177j; SKIBA NP, 1995, J BIOL CHEM, V270, P13210, DOI 10.1074/jbc.270.22.13210; Skiba NP, 2000, METHOD ENZYMOL, V315, P502; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wang Y, 1997, NAT STRUCT BIOL, V4, P650, DOI 10.1038/nsb0897-650; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; YANG ZH, 1992, J BIOL CHEM, V267, P23197	63	23	25	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					38071	38080		10.1074/jbc.M505259200	http://dx.doi.org/10.1074/jbc.M505259200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16129667	hybrid			2022-12-27	WOS:000233044500090
J	Guo, ZY; Lin, S; Heinen, JA; Chang, CCY; Chang, TY				Guo, ZY; Lin, S; Heinen, JA; Chang, CCY; Chang, TY			The active site His-460 of human acyl-coenzyme A : cholesterol acyltransferase 1 resides in a hitherto undisclosed transmembrane domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; MEMBRANE TOPOLOGY; ACAT-1; EXPRESSION; MUTANT; COA; LOCALIZATION; PROTEIN	Human acyl-coenzyme A: cholesterol acyltransferase 1 (hACAT1) esterifies cholesterol at the endoplasmic reticulum ( ER). We had previously reported that hACAT1 contains seven transmembrane domains (TMD) (Lin, S., Cheng, D., Liu, M. S., Chen, J., and Chang, T. Y. ( 1999) J. Biol. Chem. 274, 23276 - 23285) and nine cysteines. The Cys near the N-terminal is located at the cytoplasm; the two cysteines near the C-terminal form a disulfide bond and are located in the ER lumen. The other six free cysteines are located in buried region(s) of the enzyme (Guo, Z.- Y., Chang, C. C. Y., Lu, X., Chen, J., Li, B.- L., and Chang, T.- Y. ( 2005) Biochemistry 44, 6537 6548). In the current study, we show that the conserved His-460 is a key active site residue for hACAT1. We next performed Cys-scanning mutagenesis within the region of amino acids 354 - 493, expressed these mutants in Chinese hamster ovary cells lacking ACAT1, and prepared microsomes from transfected cells. The microsomes are either left intact or permeabilized with detergent. The accessibility of the engineered cysteines of microsomal hACAT1 to various maleimide derivatives, including mPEG(5000)-maleimide ( large, hydrophilic, and membrane-impermeant), N-ethylmaleimide, 4-acetamido-4'-maleimidylstilbene-2,2'-disulfonic acid ( small, hydrophilic, and ER membrane-permeant), and N-phenylmaleimide ( small, hydrophobic, and ER membrane-permeant), were monitored by Western blot analysis. The results led us to construct a revised, nine-TMD model, with the active site His460 located within a hitherto undisclosed transmembrane domain, between Arg-443 and Tyr-462.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Chang, TY (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, 7200 Vail,Room 304, Hanover, NH 03755 USA.	Ta.Yuan.Chang@dartmouth.edu		Chang, Ta-Yuan/0000-0002-3249-0468	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060306] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60306] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CADIGAN KM, 1988, J BIOL CHEM, V263, P274; Chang CCY, 2000, J BIOL CHEM, V275, P28083; CHANG CCY, 1995, J BIOL CHEM, V270, P29532; CHANG CCY, 1986, BIOCHEMISTRY-US, V25, P1693, DOI 10.1021/bi00355a038; Chang CCY, 1998, J BIOL CHEM, V273, P35132, DOI 10.1074/jbc.273.52.35132; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; CHANG TY, 1981, ANAL BIOCHEM, V116, P298, DOI 10.1016/0003-2697(81)90360-2; Chang TY, 2001, J LIPID RES, V42, P1933; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; Chang TY, 2001, CURR OPIN LIPIDOL, V12, P289, DOI 10.1097/00041433-200106000-00008; Feramisco JD, 2004, J BIOL CHEM, V279, P8487, DOI 10.1074/jbc.M312623200; GALL SL, 2004, MOL BIOL CELL, V15, P447; GOGL G, 2004, ANN NY ACAD SCI, V1033, P17; Guo ZY, 2005, BIOCHEMISTRY-US, V44, P6537, DOI 10.1021/bi047409b; Hofmann K, 2000, TRENDS BIOCHEM SCI, V25, P111, DOI 10.1016/S0968-0004(99)01539-X; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Jonas A, 2000, BBA-MOL CELL BIOL L, V1529, P245, DOI 10.1016/S1388-1981(00)00153-0; Joyce CW, 2000, MOL BIOL CELL, V11, P3675, DOI 10.1091/mbc.11.11.3675; Katzen F, 2003, P NATL ACAD SCI USA, V100, P10471, DOI 10.1073/pnas.1334136100; Kosolapov A, 2003, J BIOL CHEM, V278, P4305, DOI 10.1074/jbc.M209422200; Lee KA, 2003, J BIOL CHEM, V278, P44593, DOI 10.1074/jbc.M308312200; Lin S, 1999, J BIOL CHEM, V274, P23276, DOI 10.1074/jbc.274.33.23276; Lin S, 2003, MOL BIOL CELL, V14, P2447, DOI 10.1091/mbc.E02-11-0725; LIU J, 2005, IN PRESS BIOCH J, V390; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Lu JL, 2001, BIOCHEMISTRY-US, V40, P13288, DOI 10.1021/bi0107647; LU X, 2002, 3 AHA NAT C ATH THRO; Lu XH, 2002, J BIOL CHEM, V277, P711, DOI 10.1074/jbc.M109427200; Miyazaki A, 1998, ARTERIOSCL THROM VAS, V18, P1568, DOI 10.1161/01.ATV.18.10.1568; Rudel LL, 2001, CURR OPIN LIPIDOL, V12, P121, DOI 10.1097/00041433-200104000-00005; Sakashita N, 2000, AM J PATHOL, V156, P227, DOI 10.1016/S0002-9440(10)64723-2; Spady DK, 2000, J BIOL CHEM, V275, P27005; Yang L, 2004, J BIOL CHEM, V279, P46253, DOI 10.1074/jbc.M408155200; Yu CJ, 2002, BIOCHEMISTRY-US, V41, P3762, DOI 10.1021/bi0120188; Yu CJ, 1999, J BIOL CHEM, V274, P36139, DOI 10.1074/jbc.274.51.36139; Zhang Y, 2003, J BIOL CHEM, V278, P11642, DOI 10.1074/jbc.M211559200	37	66	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37814	37826		10.1074/jbc.M508384200	http://dx.doi.org/10.1074/jbc.M508384200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16154994	hybrid			2022-12-27	WOS:000233044500061
J	Landsman, T; Waxman, DJ				Landsman, T; Waxman, DJ			Role of the cytokine-induced SH2 domain-containing protein CIS in growth hormone receptor internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER GENE-EXPRESSION; LIGAND-INDUCED INTERNALIZATION; UBIQUITIN-PROTEASOME PATHWAY; CLATHRIN-COATED PITS; SOCS-BOX MOTIF; GH RECEPTOR; C-CBL; SEXUAL-DIMORPHISM; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCER	The cytokine-inducible SH2 domain-containing protein CIS inhibits signaling from the growth hormone (GH) receptor (GHR) to STAT5b by a proteasome-dependent mechanism. Here, we used the GH-responsive rat liver cell line CWSV-1 to investigate the role of CIS and the proteasome in GH-induced GHR internalization. Cell-surface GHR localization and internalization were monitored in GH-stimulated cells by confocal immunofluorescence microscopy using an antibody directed against the GHR extracellular domain. In GH naive cells, GHR was detected in small, randomly distributed granules on the cell surface and in the cytoplasm, with accumulation in the perinuclear area. GH treatment induced a rapid ( within 5 min) internalization of GH center dot GHR complexes, which coincided with the onset of GHR tyrosine phosphorylation and the appearance in the cytosol of distinct granular structures containing internalized GH. GHR signaling to STAT5b continued for similar to 30 - 40 min, however, indicating that GHR signaling and deactivation of the GH center dot GHR complex both proceed from an intracellular compartment. The internalization of GH and GHR was inhibited by CIS-R107K, a dominant-negative SH2 domain mutant of CIS, and by the proteasome inhibitors MG132 and epoxomicin, which prolong GHR signaling to STAT5b. GH pulse-chase studies established that the internalized GH center dot GHR complexes did not recycle back to the cell surface in significant amounts under these conditions. Given the established specificity of CIS-R107K for blocking the GHR signaling inhibitory actions of CIS, but not those of other SOCS/CIS family members, these findings implicate CIS and the proteasome in the control of GHR internalization following receptor activation and suggest that CIS-dependent receptor internalization is a prerequisite for efficient termination of GHR signaling.	Boston Univ, Dept Biol, Div Cell & Mol Biol, Boston, MA 02215 USA	Boston University	Waxman, DJ (corresponding author), Boston Univ, Dept Biol, Div Cell & Mol Biol, 5 Cummington St, Boston, MA 02215 USA.	djw@bu.edu		Waxman, David/0000-0001-7982-9206	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033765] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33765, R01 DK033765] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Ahluwalia A, 2004, MOL ENDOCRINOL, V18, P747, DOI 10.1210/me.2003-0138; Aman MJ, 1999, J BIOL CHEM, V274, P30266, DOI 10.1074/jbc.274.42.30266; Blesofsky WA, 2001, ONCOGENE, V20, P7326, DOI 10.1038/sj.onc.1204919; Choi HK, 2000, ENDOCRINOLOGY, V141, P3245, DOI 10.1210/en.141.9.3245; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; de Melker AA, 2004, J BIOL CHEM, V279, P55465, DOI 10.1074/jbc.M409765200; Du L, 2003, ENDOCRINOLOGY, V144, P868, DOI 10.1210/en.2002-220830; Frank SJ, 2002, ENDOCRINOLOGY, V143, P2, DOI 10.1210/en.143.1.2; FRICK GP, 1994, ENDOCRINOLOGY, V134, P307, DOI 10.1210/en.134.1.307; Gebert CA, 1999, MOL ENDOCRINOL, V13, P213, DOI 10.1210/me.13.2.213; Gebert CA, 1999, MOL ENDOCRINOL, V13, P38, DOI 10.1210/me.13.1.38; Gebert CA, 1997, MOL ENDOCRINOL, V11, P400, DOI 10.1210/me.11.4.400; Goh ELK, 2002, ENDOCRINOLOGY, V143, P3590, DOI 10.1210/en.2002-220374; Gonzalez L, 2002, ENDOCRINOLOGY, V143, P386, DOI 10.1210/en.143.2.386; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Govers R, 1997, EMBO J, V16, P4851, DOI 10.1093/emboj/16.16.4851; Greenhalgh CJ, 2004, GROWTH HORM IGF RES, V14, P200, DOI 10.1016/j.ghir.2003.12.011; Haan S, 2003, J BIOL CHEM, V278, P31972, DOI 10.1074/jbc.M303170200; Hanada T, 2001, J BIOL CHEM, V276, P40746, DOI 10.1074/jbc.M106139200; Hansen JA, 1999, MOL ENDOCRINOL, V13, P1832, DOI 10.1210/me.13.11.1832; Herrington J, 2000, ONCOGENE, V19, P2585, DOI 10.1038/sj.onc.1203526; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Ilangumaran S, 2003, IMMUNOL REV, V192, P196, DOI 10.1034/j.1600-065X.2003.00020.x; JANSSON JO, 1985, ENDOCR REV, V6, P128, DOI 10.1210/edrv-6-2-128; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kario E, 2005, J BIOL CHEM, V280, P7038, DOI 10.1074/jbc.M408575200; KEMPE KC, 1995, BIOCHEM PHARMACOL, V49, P1091, DOI 10.1016/0006-2952(95)98506-5; Kuhn ER, 2002, COMP BIOCHEM PHYS B, V132, P299, DOI 10.1016/S1096-4959(02)00037-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lobie PE, 1999, EXP CELL RES, V246, P47, DOI 10.1006/excr.1998.4288; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; Miquet JG, 2004, ENDOCRINOLOGY, V145, P2824, DOI 10.1210/en.2003-1498; Moulin S, 2003, CELL SIGNAL, V15, P47, DOI 10.1016/S0898-6568(02)00054-2; Moutoussamy S, 1998, J BIOL CHEM, V273, P15906, DOI 10.1074/jbc.273.26.15906; Nicholson SE, 2005, P NATL ACAD SCI USA, V102, P2328, DOI 10.1073/pnas.0409675102; Nicola NA, 2000, EXP HEMATOL, V28, P1105, DOI 10.1016/S0301-472X(00)00525-7; Park SH, 1999, J BIOL CHEM, V274, P7421, DOI 10.1074/jbc.274.11.7421; Park SH, 2001, MOL ENDOCRINOL, V15, P2157, DOI 10.1210/me.15.12.2157; Piwien-Pilipuk G, 2002, J PEDIATR ENDOCR MET, V15, P771; Ram PA, 1999, J BIOL CHEM, V274, P35553, DOI 10.1074/jbc.274.50.35553; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; Ram PK, 2000, J BIOL CHEM, V275, P39487, DOI 10.1074/jbc.M004755200; Sachse M, 2002, MOL BIOL CELL, V13, P1313, DOI 10.1091/mbc.01-10-0525; Sachse M, 2001, J CELL SCI, V114, P3943; SILVA CM, 1993, ENDOCRINOLOGY, V133, P2307, DOI 10.1210/en.133.5.2307; Smit LS, 1996, MOL ENDOCRINOL, V10, P519, DOI 10.1210/me.10.5.519; Strous GJ, 2002, MOL CELL ENDOCRINOL, V197, P143, DOI 10.1016/S0303-7207(02)00258-7; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; Takagi K, 2001, BIOL PHARM BULL, V24, P744, DOI 10.1248/bpb.24.744; Tannenbaum GS, 2001, ENDOCRINOLOGY, V142, P4599, DOI 10.1210/en.142.11.4599; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tollet-Egnell P, 1999, ENDOCRINOLOGY, V140, P3693, DOI 10.1210/en.140.8.3693; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; van Kerkhof P, 2002, ENDOCRINOLOGY, V143, P1243, DOI 10.1210/en.143.4.1243; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; Wakioka T, 1999, LEUKEMIA, V13, P760, DOI 10.1038/sj.leu.2401397; Wan Y, 2004, J BIOL CHEM, V279, P44775, DOI 10.1074/jbc.M406092200; Wan Y, 2003, MOL ENDOCRINOL, V17, P2240, DOI 10.1210/me.2003-0162; Wang L, 2002, ONCOGENE, V21, P5346, DOI 10.1038/sj.onc.1205670; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; Yang N, 2004, J BIOL CHEM, V279, P20898, DOI 10.1074/jbc.M400625200; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; Zhang Y, 2000, ENDOCRINOLOGY, V141, P4342, DOI 10.1210/en.141.12.4342; Zhu T, 2001, CELL SIGNAL, V13, P599, DOI 10.1016/S0898-6568(01)00186-3; Zhu T, 1998, J BIOL CHEM, V273, P33864, DOI 10.1074/jbc.273.50.33864	71	54	57	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37471	37480		10.1074/jbc.M504125200	http://dx.doi.org/10.1074/jbc.M504125200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16154995	hybrid			2022-12-27	WOS:000233044500023
J	Liu, F; Grundke-Iqbal, I; Iqbal, K; Oda, Y; Tomizawa, K; Gong, CX				Liu, F; Grundke-Iqbal, I; Iqbal, K; Oda, Y; Tomizawa, K; Gong, CX			Truncation and activation of calcineurin A by calpain I in Alzheimer disease brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABNORMALLY PHOSPHORYLATED-TAU; PAIRED HELICAL FILAMENTS; PROTEIN PHOSPHATASE-2B CALCINEURIN; AUTOINHIBITORY DOMAIN; CLEAVAGE; P25; P35; DEPHOSPHORYLATION; NEUROTOXICITY; DEGRADATION	A disturbance of calcium homeostasis is believed to play an important role in the neurodegeneration of the brains of Alzheimer disease ( AD) patients, but the molecular pathways by which it contributes to the disease are not well understood. Here we studied the activation of two major Ca2+-regulated brain proteins, calpain and calcineurin, in AD brain. We found that calpain I is activated, which in turn cleaves and activates calcineurin in AD brain. Mass spectrometric analysis indicated that the cleavage of calcineurin by calpain I is at lysine 501, a position C-terminal to the autoinhibitory domain, which produces a 57-kDa truncated form. The 57-kDa calcineurin maintains its Ca2+/calmodulin dependence of the phosphatase activity, but the phosphatase activity is remarkably activated upon truncation. The cleavage and activation of calcineurin correlate to the number of neurofibrillary tangles in human brains. These findings suggest that the overactivation of calpain I and calcineurin may mediate the role of calcium homeostatic disturbance in the neurodegeneration of AD.	New York State Inst Basic Res Dev Disabil, Dept Neurochem, Staten Isl, NY 10314 USA; Eisai & Co Ltd, Lab Seeds Finding Technol, Tsukuba, Ibaraki 3002635, Japan; Okayama Univ, Grad Sch Med & Dent, Dept Physiol, Okayama 7008585, Japan	Institute for Basic Research in Developmental Disabilities; Eisai Co Ltd; Okayama University	Liu, F (corresponding author), New York State Inst Basic Res Dev Disabil, Dept Neurochem, 1050 Forest Hill Rd, Staten Isl, NY 10314 USA.	feiliu63@hotmail.com; cxgong@ultinet.net	Tomizawa, Kazuhito/F-2405-2015	Tomizawa, Kazuhito/0000-0002-5663-2627	NATIONAL INSTITUTE ON AGING [R01AG019158] Funding Source: NIH RePORTER; NIA NIH HHS [AG19158] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; Bahl R, 2001, MOL BRAIN RES, V90, P101, DOI 10.1016/S0169-328X(01)00089-4; Blomgren K, 1999, J BIOL CHEM, V274, P14046, DOI 10.1074/jbc.274.20.14046; BRAAK H, 1995, NEUROBIOL AGING, V16, P271, DOI 10.1016/0197-4580(95)00021-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Gong CX, 1996, BRAIN RES, V741, P95, DOI 10.1016/S0006-8993(96)00904-3; Gong CX, 2005, J NEURAL TRANSM, V112, P813, DOI 10.1007/s00702-004-0221-0; GONG CX, 1994, J NEUROCHEM, V62, P803; GONG CX, 1993, J NEUROCHEM, V61, P921, DOI 10.1111/j.1471-4159.1993.tb03603.x; GRUNDKEIQBAL I, 1988, MOL BRAIN RES, V4, P43, DOI 10.1016/0169-328X(88)90017-4; Grynspan F, 1997, BRAIN RES, V763, P145, DOI 10.1016/S0006-8993(97)00384-3; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; Khachaturian Z S, 1989, Aging (Milano), V1, P17; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Kusakawa G, 2000, J BIOL CHEM, V275, P17166, DOI 10.1074/jbc.M907757199; Ladner CJ, 1996, J NEUROPATH EXP NEUR, V55, P924, DOI 10.1097/00005072-199608000-00008; LaFerla FM, 2002, NAT REV NEUROSCI, V3, P862, DOI 10.1038/nrn960; Lakshmikuttyamma A, 2004, NEUROCHEM RES, V29, P1913, DOI 10.1023/B:NERE.0000042218.27842.79; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Lian QY, 2001, EXP NEUROL, V167, P158, DOI 10.1006/exnr.2000.7534; LITERSKY JM, 1992, J BIOL CHEM, V267, P1563; Liu F, 2005, J BIOL CHEM, V280, P1790, DOI 10.1074/jbc.M410775200; Liu F, 2002, FEBS LETT, V530, P209, DOI 10.1016/S0014-5793(02)03487-7; LIU F, 2005, IN PRESS EUR J NEURO; Mattson MP, 2003, CELL CALCIUM, V34, P385, DOI 10.1016/S0143-4160(03)00128-3; MATTSON MP, 1992, NEUROBIOL AGING, V13, P617, DOI 10.1016/0197-4580(92)90068-9; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Nath R, 2000, BIOCHEM BIOPH RES CO, V274, P16, DOI 10.1006/bbrc.2000.3070; Nixon RA, 2003, AGEING RES REV, V2, P407, DOI 10.1016/S1568-1637(03)00029-1; Pei JJ, 1998, J NEURAL TRANSM, V105, P69, DOI 10.1007/s007020050039; PERRINO BA, 1995, J BIOL CHEM, V270, P340, DOI 10.1074/jbc.270.1.340; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; Stanciu M, 2002, J BIOL CHEM, V277, P4010, DOI 10.1074/jbc.M104479200; Tompa P, 2004, J BIOL CHEM, V279, P20775, DOI 10.1074/jbc.M313873200; Veeranna, 2004, AM J PATHOL, V165, P795, DOI 10.1016/S0002-9440(10)63342-1; WANG JZ, 1995, J BIOL CHEM, V270, P4854, DOI 10.1074/jbc.270.9.4854; WANG KKW, 1989, BIOCHEM CELL BIOL, V67, P703, DOI 10.1139/o89-105; Wu HY, 2004, J BIOL CHEM, V279, P4929, DOI 10.1074/jbc.M309767200; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YANG LS, 1995, EUR J BIOCHEM, V233, P9, DOI 10.1111/j.1432-1033.1995.009_1.x	44	62	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37755	37762		10.1074/jbc.M507475200	http://dx.doi.org/10.1074/jbc.M507475200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16150694	hybrid			2022-12-27	WOS:000233044500054
J	Liu, ZP; Li, HB; Derouet, M; Filmus, J; LaCasse, EC; Korneluk, RG; Kerbel, RS; Rosen, KV				Liu, ZP; Li, HB; Derouet, M; Filmus, J; LaCasse, EC; Korneluk, RG; Kerbel, RS; Rosen, KV			ras oncogene triggers up-regulation of cIAP2 and XIAP in intestinal epithelial cells - Epidermal growth factor receptor-dependent and -independent mechanisms of ras-induced transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROSTATE-CANCER; BCL-2 PROTEIN FAMILY; HUMAN LUNG-CANCER; INDUCED APOPTOSIS; DOWN-REGULATION; CYTOCHROME-C; FACTOR-ALPHA; MITOCHONDRIAL PROTEIN; BCL-X(L) EXPRESSION; HUMAN KERATINOCYTES	Detachment of normal epithelial cells from the extracellular matrix (ECM) triggers apoptosis, a phenomenon called anoikis. Conversely, carcinomas ( cancers of epithelial origin) represent three-dimensional disorganized multicellular masses in which cells are deprived of adhesion to the ECM but remain viable. Resistance of cancer cells to anoikis is thought to be critical for tumor progression. However, the knowledge about molecular mechanisms of this type of resistance remains limited. Herein we report that ras oncogene, an established inhibitor of anoikis, triggers a significant upregulation of anti-apoptotic proteins cIAP2 and XIAP in intestinal epithelial cells. We also observed that the effect of ras on cIAP2 requires ras-induced autocrine production of transforming growth factor alpha (TGF-alpha), a ligand for epidermal growth factor receptor, whereas ras-triggered up-regulation of XIAP is TGF-alpha-independent. Moreover, overexpression of either cIAP2 or XIAP in nonmalignant intestinal epithelial cell was found to block anoikis. In addition, an established IAP antagonist Smac or Smac-derived cell-permeable peptide suppressed ras-induced anoikis resistance and subsequent anchorage-independent growth of ras-transformed cells. We conclude that ras-induced overexpression of cIAP2 and XIAP significantly contributes to the ability of ras-transformed intestinal epithelial cells to survive in the absence of adhesion to the ECM and grow in a three-dimensional manner.	Dalhousie Univ, Atlantic Res Ctr, Dept Pediat, CRC, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Atlantic Res Ctr, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Mol & Cellular Biol, Toronto, ON M4N 3M5, Canada; Childrens Hosp Eastern Ontario, Res Inst, Aegera Oncol Inc, Ottawa, ON K1H 8L1, Canada; Childrens Hosp Eastern Ontario, Res Inst, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada	Dalhousie University; Dalhousie University; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa	Rosen, KV (corresponding author), Dalhousie Univ, Atlantic Res Ctr, Dept Pediat, CRC, Rm C-302,5849 Univ Ave, Halifax, NS B3H 4H7, Canada.	Kirill.Rosen@Dal.Ca		Rosen, Kirill/0000-0002-4317-9907				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Arnt CR, 2002, J BIOL CHEM, V277, P44236, DOI 10.1074/jbc.M207578200; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Berezovskaya O, 2005, CANCER RES, V65, P2378, DOI 10.1158/0008-5472.CAN-04-2649; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; Ciardiello F, 2000, CLIN CANCER RES, V6, P2053; Coll ML, 2002, ONCOGENE, V21, P2908, DOI 10.1038/sj.onc.1205388; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Farahani R, 1997, GENOMICS, V42, P514, DOI 10.1006/geno.1997.4742; Ferreira CG, 2001, CLIN CANCER RES, V7, P2468; FILMUS J, 1993, ONCOGENE, V8, P1017; FILMUS J, 1994, ONCOGENE, V9, P3627; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Gangarosa LM, 1997, J BIOL CHEM, V272, P18926, DOI 10.1074/jbc.272.30.18926; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Gottfried Y, 2004, EMBO J, V23, P1627, DOI 10.1038/sj.emboj.7600155; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HARPER ME, 1993, PROSTATE, V23, P9, DOI 10.1002/pros.2990230103; Hofmann HS, 2002, J CANCER RES CLIN, V128, P554, DOI 10.1007/s00432-002-0364-z; Holcik M, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-5; Hu YP, 2003, CLIN CANCER RES, V9, P2826; Jan YW, 2004, CELL, V116, P751, DOI 10.1016/S0092-8674(04)00204-1; Jost M, 2001, MOL BIOL CELL, V12, P1519, DOI 10.1091/mbc.12.5.1519; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; Krajewska M, 2003, CLIN CANCER RES, V9, P4914; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327; Li L, 2004, SCIENCE, V305, P1471, DOI 10.1126/science.1098231; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin LJ, 2003, WORLD J GASTROENTERO, V9, P974; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Mitsiades N, 2002, BLOOD, V99, P2162, DOI 10.1182/blood.V99.6.2162; Miyazaki T, 2004, J BIOL CHEM, V279, P44667, DOI 10.1074/jbc.M408101200; Olson AL, 2001, AMBUL PEDIATR, V1, P91, DOI 10.1367/1539-4409(2001)001<0091:PCPRAP>2.0.CO;2; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Park CM, 2005, BIOORG MED CHEM LETT, V15, P771, DOI 10.1016/j.bmcl.2004.11.010; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; RAK J, 1995, J CELL BIOL, V131, P1587, DOI 10.1083/jcb.131.6.1587; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; REYNOLDS NJ, 1993, BIOCHEM J, V294, P535, DOI 10.1042/bj2940535; Rodeck U, 1997, P NATL ACAD SCI USA, V94, P5067, DOI 10.1073/pnas.94.10.5067; RODENHUIS S, 1988, CANCER RES, V48, P5738; Rosen K, 1998, CURR BIOL, V8, P1331, DOI 10.1016/S0960-9822(07)00564-7; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Rosen K, 2002, J BIOL CHEM, V277, P46123, DOI 10.1074/jbc.M207883200; Rosen K, 2001, J BIOL CHEM, V276, P37273, DOI 10.1074/jbc.M106424200; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Rytomaa M, 2000, ONCOGENE, V19, P4461, DOI 10.1038/sj.onc.1203805; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schimmer AD, 2004, CANCER CELL, V5, P25, DOI 10.1016/S1535-6108(03)00332-5; Shi Y, 2001, J UROLOGY, V166, P1514, DOI 10.1016/S0022-5347(05)65822-3; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Signoretti S, 2000, JNCI-J NATL CANCER I, V92, P1918, DOI 10.1093/jnci/92.23.1918; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Wang ZX, 1998, MOL CELL BIOL, V18, P590, DOI 10.1128/MCB.18.1.590	73	45	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37383	37392		10.1074/jbc.M503724200	http://dx.doi.org/10.1074/jbc.M503724200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16115895	hybrid			2022-12-27	WOS:000233044500012
J	Wang, J; Devgan, V; Corrado, M; Prabhu, NS; El-Deiry, WS; Riccardi, C; Pandolfi, PP; Missero, C; Dotto, GP				Wang, J; Devgan, V; Corrado, M; Prabhu, NS; El-Deiry, WS; Riccardi, C; Pandolfi, PP; Missero, C; Dotto, GP			Glucocorticoid-induced tumor necrosis factor receptor is a p21(Cip1/WAF1) transcriptional target conferring resistance of keratinocytes to UV light-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DEATH RECEPTORS; P21(WAF1/CIP1); INDUCTION; GITR; ACTIVATION; LIGAND; GROWTH; TNF; DIFFERENTIATION	Glucocorticoid-induced tumor necrosis factor receptor ( GITR) is a member of the tumor necrosis factor receptor superfamily, is expressed in T lymphocytes, and exerts an anti-apoptotic function in these cells. We reported that GITR is also highly expressed in the skin, specifically in keratinocytes, and that it is under negative transcriptional control of p21(Cip1/WAF1), independently from the cell cycle. Although GITR expression is higher in p21-deficient keratinocytes and skin, it is down-modulated with differentiation and in response to UVB. The combined analysis of keratinocytes with increased GITR expression versus normal keratinocytes and skin of mice with a disruption of the GITR gene indicates that this protein protects keratinocytes from UVB-induced apoptosis both in vitro and in vivo.	Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland; Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Telethon Inst Genet & Med, I-80131 Naples, Italy; Univ Penn, Sch Med, Abramson Comprehens Canc Ctr, Philadelphia, PA 19104 USA; Univ Perugia, Sch Med, Pharmacol Sect, Dept Clin & Expt Med, I-06100 Perugia, Italy; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Canc Biol & Genet Program, New York, NY 10021 USA; Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland	University of Lausanne; Harvard University; Massachusetts General Hospital; Harvard University; Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); University of Pennsylvania; Pennsylvania Medicine; University of Perugia; Memorial Sloan Kettering Cancer Center; University of Lausanne	Dotto, GP (corresponding author), Univ Lausanne, Dept Biochem, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.	gdotto@partners.org	Riccardi, Carlo/N-4610-2014	Riccardi, Carlo/0000-0001-9257-3997; El-Deiry, Wafik/0000-0002-9577-8266; Missero, Caterina/0000-0003-0905-5123	NATIONAL CANCER INSTITUTE [R01CA073796, P01CA016038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039190] Funding Source: NIH RePORTER; NCI NIH HHS [CA73796, CA16038] Funding Source: Medline; NIAMS NIH HHS [AR39190] Funding Source: Medline; Telethon [TGM06S01, TGM03P14] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Telethon(Fondazione Telethon)		Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Basile JR, 2003, MOL CANCER RES, V1, P262; Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Delavaine L, 1999, ONCOGENE, V18, P5381, DOI 10.1038/sj.onc.1202923; Devgan V, 2005, GENE DEV, V19, P1485, DOI 10.1101/gad.341405; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; Fritah A, 2005, MOL CELL BIOL, V25, P2419, DOI 10.1128/MCB.25.6.2419-2430.2005; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gaur U, 2003, BIOCHEM PHARMACOL, V66, P1403, DOI 10.1016/S0006-2952(03)00490-8; Harvey KJ, 2000, J CELL BIOL, V148, P59, DOI 10.1083/jcb.148.1.59; Headon DJ, 1999, NAT GENET, V22, P370, DOI 10.1038/11943; Hehlgans T, 2005, IMMUNOLOGY, V115, P1, DOI 10.1111/j.1365-2567.2005.02143.x; Ji HB, 2004, J IMMUNOL, V172, P5823, DOI 10.4049/jimmunol.172.10.5823; Kim JD, 2003, GENES IMMUN, V4, P564, DOI 10.1038/sj.gene.6364026; Kitaura H, 2000, J BIOL CHEM, V275, P10477, DOI 10.1074/jbc.275.14.10477; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Murphy M, 2002, J CLIN PATHOL, V55, P829, DOI 10.1136/jcp.55.11.829; Nocentini G, 1997, P NATL ACAD SCI USA, V94, P6216, DOI 10.1073/pnas.94.12.6216; Nocentini G, 2005, EUR J IMMUNOL, V35, P1016, DOI 10.1002/eji.200425818; Nocentini G, 2000, DNA CELL BIOL, V19, P205, DOI 10.1089/104454900314474; Poole JC, 2004, CELL CYCLE, V3, P931; Reagan-Shaw S, 2004, ONCOGENE, V23, P5151, DOI 10.1038/sj.onc.1207666; Ronchetti S, 2002, BLOOD, V100, P350, DOI 10.1182/blood-2001-12-0276; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Snowden AW, 2000, MOL CELL BIOL, V20, P2676, DOI 10.1128/MCB.20.8.2676-2686.2000; Spinicelli S, 2002, CELL DEATH DIFFER, V9, P1382, DOI 10.1038/sj.cdd.4401140; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Tone M, 2003, P NATL ACAD SCI USA, V100, P15059, DOI 10.1073/pnas.2334901100; Tsao YP, 1999, J VIROL, V73, P4983, DOI 10.1128/JVI.73.6.4983-4990.1999; Wehrli P, 2000, J INVEST DERMATOL, V115, P141, DOI 10.1046/j.1523-1747.2000.00037.x; Xu SQ, 2000, BIOCHEM BIOPH RES CO, V269, P179, DOI 10.1006/bbrc.2000.2247	35	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37725	37731		10.1074/jbc.M507976200	http://dx.doi.org/10.1074/jbc.M507976200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16155000	hybrid			2022-12-27	WOS:000233044500050
J	Wingard, JN; Chan, J; Bosanac, I; Haeseleer, F; Palczewski, K; Ikura, M; Ames, JB				Wingard, JN; Chan, J; Bosanac, I; Haeseleer, F; Palczewski, K; Ikura, M; Ames, JB			Structural analysis of Mg2+ and Ca2+ binding to CaBP1, a neuron-specific regulator of calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-ION BINDING; CRYSTAL-STRUCTURE; TROPONIN-C; 3-DIMENSIONAL STRUCTURE; CA2+-BINDING PROTEIN-1; THERMAL-STABILITY; MAGNESIUM-BINDING; LIGAND-BINDING; CALMODULIN; CALDENDRIN	CaBP1 (calcium-binding protein 1) is a 19.4-kDa protein of the EF-hand superfamily that modulates the activity of Ca2+ channels in the brain and retina. Here we present data from NMR, microcalorimetry, and other biophysical studies that characterize Ca2+ binding, Mg2+ binding, and structural properties of recombinant CaBP1 purified from Escherichia coli. Mg2+ binds constitutively to CaBP1 at EF-1 with an apparent dissociation constant (K-d) of 300 mu M. Mg2+ binding to CaBP1 is enthalpic ( Delta H = - 3.725 kcal/mol) and promotes NMR spectral changes, indicative of a concerted Mg2+-induced conformational change. Ca2+ binding to CaBP1 induces NMR spectral changes assigned to residues in EF-3 and EF-4, indicating localized Ca2+-induced conformational changes at these sites. Ca2+ binds cooperatively to CaBP1 at EF-3 and EF-4 with an apparent K-d of 2.5 mu M and a Hill coefficient of 1.3. Ca2+ binds to EF-1 with low affinity (K-d > 100 mu M), and no Ca2+ binding was detected at EF-2. In the absence of Mg2+ and Ca2+, CaBP1 forms a flexible molten globule-like structure. Mg2+ and Ca2+ induce distinct conformational changes resulting in protein dimerization and markedly increased folding stability. The unfolding temperatures are 53, 74, and 76 degrees C for apo-, Mg2+-bound, and Ca2+-bound CaBP1, respectively. Together, our results suggest that CaBP1 switches between structurally distinct Mg2+-bound and Ca2+-bound states in response to Ca2+ signaling. Both conformational states may serve to modulate the activity of Ca2+ channel targets.	Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Ontario Canc Inst, Div Signaling Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA	University System of Maryland; University of Maryland Baltimore; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Ames, JB (corresponding author), Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA.	james@carb.nist.gov		Ikura, Mitsuhiko/0000-0002-9524-1303	NATIONAL EYE INSTITUTE [R01EY008061, R29EY008061, R01EY012347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045909] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY008061, EY08061, EY012347, R01 EY012347] Funding Source: Medline; NINDS NIH HHS [NS045909, R01 NS045909] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTIERI AS, 1995, J AM CHEM SOC, V117, P7566, DOI 10.1021/ja00133a039; Ames JB, 2000, BIOCHEMISTRY-US, V39, P12149, DOI 10.1021/bi0012890; Ames JB, 2002, BIOCHEMISTRY-US, V41, P5776, DOI 10.1021/bi012153k; Ames JB, 1999, J BIOL CHEM, V274, P19329, DOI 10.1074/jbc.274.27.19329; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; Biekofsky RR, 2002, BIOCHEMISTRY-US, V41, P6850, DOI 10.1021/bi012187s; Bosanac I, 2005, MOL CELL, V17, P193, DOI 10.1016/j.molcel.2004.11.047; Bourne Y, 2001, J BIOL CHEM, V276, P11949, DOI 10.1074/jbc.M009373200; BROCARD JB, 1993, NEURON, V11, P751, DOI 10.1016/0896-6273(93)90084-5; Burgoyne RD, 2001, BIOCHEM J, V353, P1; Chakrabarti MC, 1999, NUCLEIC ACIDS RES, V27, P4801, DOI 10.1093/nar/27.24.4801; Clore GM, 1997, NAT STRUCT BIOL, V4, P849; COX JA, 1994, J BIOL CHEM, V269, P32807; DASILVA ACR, 1995, J BIOL CHEM, V270, P6773, DOI 10.1074/jbc.270.12.6773; EIGEN M, 1963, ADV ENZYMOL REL S BI, V25, P1; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GAO ZH, 1993, J BIOL CHEM, V268, P20096; Gilli R, 1998, BIOCHEMISTRY-US, V37, P5450, DOI 10.1021/bi972083a; Gombos Z, 2003, BIOCHEMISTRY-US, V42, P5531, DOI 10.1021/bi034047j; Haeseleer F, 2004, NAT NEUROSCI, V7, P1079, DOI 10.1038/nn1320; Haeseleer F, 2000, J BIOL CHEM, V275, P1247, DOI 10.1074/jbc.275.2.1247; Haeseleer F, 2002, BIOCHEM BIOPH RES CO, V290, P615, DOI 10.1006/bbrc.2001.6228; Haynes LP, 2004, J BIOL CHEM, V279, P547, DOI 10.1074/jbc.M309617200; Hendricks KB, 1999, NAT CELL BIOL, V1, P234, DOI 10.1038/12058; Henzl MT, 2003, ANAL BIOCHEM, V319, P216, DOI 10.1016/S0003-2697(03)00288-4; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; Kasri NN, 2004, EMBO J, V23, P312, DOI 10.1038/sj.emboj.7600037; Kinoshita-Kawada M, 2005, PFLUG ARCH EUR J PHY, V450, P345, DOI 10.1007/s00424-005-1419-1; Laube G, 2002, MOL CELL NEUROSCI, V19, P459, DOI 10.1006/mcne.2001.1078; Lee A, 2002, NAT NEUROSCI, V5, P210, DOI 10.1038/nn805; LINSE S, 1991, J BIOL CHEM, V266, P8050; Masino L, 2000, PROTEIN SCI, V9, P1519, DOI 10.1110/ps.9.8.1519; MCCUBBIN WD, 1980, CAN J BIOCHEM CELL B, V58, P683, DOI 10.1139/o80-096; Menger N, 1999, CELL TISSUE RES, V298, P21, DOI 10.1007/s004419900060; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; Osawa M, 2005, J BIOL CHEM, V280, P18008, DOI 10.1074/jbc.M500338200; Palczewski K, 2000, BIOESSAYS, V22, P337, DOI 10.1002/(SICI)1521-1878(200004)22:4<337::AID-BIES4>3.0.CO;2-Z; Papish AL, 2002, BIOPHYS J, V83, P1455, DOI 10.1016/S0006-3495(02)73916-7; PAULUS H, 1969, ANAL BIOCHEM, V32, P91, DOI 10.1016/0003-2697(69)90107-9; Peshenko IV, 2004, J BIOL CHEM, V279, P16903, DOI 10.1074/jbc.C400065200; Qi XF, 2001, EUR J BIOCHEM, V268, P4653, DOI 10.1046/j.1432-1327.2001.02388.x; RASHIN AA, 1985, J PHYS CHEM-US, V89, P5588, DOI 10.1021/j100272a006; SCHWARZ FP, 1993, J BIOL CHEM, V268, P7668; Seidenbecher CI, 2002, ADV EXP MED BIOL, V514, P451; Seidenbecher CI, 1998, J BIOL CHEM, V273, P21324, DOI 10.1074/jbc.273.33.21324; SNYDER EE, 1990, BIOCHEMISTRY-US, V29, P3937, DOI 10.1021/bi00468a021; StevensTruss R, 1997, BIOCHEMISTRY-US, V36, P12337, DOI 10.1021/bi970973k; STRYNADKA NCJ, 1988, PROTEINS, V3, P1, DOI 10.1002/prot.340030102; SUSSMAN F, 1989, P NATL ACAD SCI USA, V86, P7880, DOI 10.1073/pnas.86.20.7880; TSALKOVA TN, 1985, J MOL BIOL, V181, P533, DOI 10.1016/0022-2836(85)90425-5; Vijay-Kumar S, 1999, NAT STRUCT BIOL, V6, P80; VIJAYKUMAR S, 1992, J MOL BIOL, V224, P413, DOI 10.1016/0022-2836(92)91004-9; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; WNUK W, 1979, J BIOL CHEM, V254, P5284; Yamniuk AP, 2004, BIOCHEMISTRY-US, V43, P2558, DOI 10.1021/bi035432b; Yang C, 2001, J BIOMOL STRUCT DYN, V19, P247, DOI 10.1080/07391102.2001.10506736; Yang J, 2002, P NATL ACAD SCI USA, V99, P7711, DOI 10.1073/pnas.102006299; Zhou H, 2005, J BIOL CHEM, V280, P29612, DOI 10.1074/jbc.M504167200; Zhou H, 2004, J NEUROSCI, V24, P4698, DOI 10.1523/JNEUROSCI.5523-03.2004; Zhou W, 2004, NEURON, V41, P573, DOI 10.1016/S0896-6273(04)00045-5; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	63	68	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37461	37470		10.1074/jbc.M508541200	http://dx.doi.org/10.1074/jbc.M508541200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16147998	Green Accepted, hybrid			2022-12-27	WOS:000233044500022
J	Essmann, F; Pohlmann, S; Gillissen, B; Daniel, PT; Schulze-Osthoff, K; Janicke, RU				Essmann, F; Pohlmann, S; Gillissen, B; Daniel, PT; Schulze-Osthoff, K; Janicke, RU			Irradiation-induced translocation of p53 to mitochondria in the absence of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION-INDEPENDENT DEATH; CYTOCHROME-C RELEASE; STRESS-INDUCED P53; P53-DEPENDENT APOPTOSIS; IONIZING-RADIATION; DNA-DAMAGE; CELL-DEATH; IN-VIVO; ACTIVATION; BAX	The tumor suppressor protein p53 promotes apoptosis in response to death stimuli by transactivation of target genes and by transcription-independent mechanisms. Recently, it was shown that during apoptosis p53 can specifically translocate to mitochondria, where it physically interacts with and inactivates prosurvival Bcl-2 proteins. In the present study, we therefore investigated the role of mitochondrial translocation of p53 for the stress response of tumor cells. In various cell lines, DNA damage induced by either ionizing irradiation or topoisomerase inhibitors triggered a robust translocation of a fraction of p53 to mitochondria to a similar extent. Nevertheless, the cells succumbed to apoptosis only in response to topoisomerase inhibitors, but remained resistant to apoptosis induced by ionizing radiation. Irradiated cells became senescent, although irradiation triggered a functional p53 response and induced expression of p21, Bax, and Puma. Interestingly, even the targeted expression of p53 to mitochondria was insufficient to launch apoptosis, whereas overexpression of wild-type p53 induced Bax activation and apoptotic alterations. Together, these results suggest that, in contrast to previous reports, mitochondrial translocation of p53 does not per se lead to cell death and that this might constitute a mechanism that contributes to the resistance of tumor cells to ionizing radiation-induced apoptosis.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany; Humboldt Univ, Charite, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany	Heinrich Heine University Dusseldorf; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Janicke, RU (corresponding author), Univ Str 1, D-40225 Dusseldorf, Germany.	janicke@uniduesseldorf.de	Schulze-Osthoff, Klaus/N-9025-2013; Essmann, Frank/ABG-7409-2020	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Essmann, Frank/0000-0003-4369-8456; Gillissen, Bernhard/0000-0002-1815-2091				Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Chipuk JE, 2003, J CLIN IMMUNOL, V23, P355, DOI 10.1023/A:1025365432325; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Erster S, 2005, BIOCHEM BIOPH RES CO, V331, P843, DOI 10.1016/j.bbrc.2005.03.187; Erster S, 2004, MOL CELL BIOL, V24, P6728, DOI 10.1128/MCB.24.15.6728-6741.2004; Essmann F, 2004, CANCER RES, V64, P7065, DOI 10.1158/0008-5472.CAN-04-1082; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Haupt Ygal, 1997, Leukemia (Basingstoke), V11, P337; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 2001, ONCOGENE, V20, P5043, DOI 10.1038/sj.onc.1204659; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MIYASHITA T, 1995, J BIOL CHEM, V270, P26049, DOI 10.1074/jbc.270.44.26049; Moll UM, 2001, FEBS LETT, V493, P65, DOI 10.1016/S0014-5793(01)02284-0; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nemajerova A, 2005, CELL DEATH DIFFER, V12, P197, DOI 10.1038/sj.cdd.4401526; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nister M, 2005, ONCOGENE, V24, P3563, DOI 10.1038/sj.onc.1208354; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Sax JK, 2003, CELL DEATH DIFFER, V10, P413, DOI 10.1038/sj.cdd.4401227; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; von Haefen C, 2004, ONCOGENE, V23, P8320, DOI 10.1038/sj.onc.1207971; Vousden KH, 2005, CELL, V120, P7, DOI 10.1016/j.cell.2004.12.027; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yee KS, 2005, CARCINOGENESIS, V26, P1317, DOI 10.1093/carcin/bgi122	41	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37169	37177		10.1074/jbc.M502052200	http://dx.doi.org/10.1074/jbc.M502052200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16148012	hybrid			2022-12-27	WOS:000232901800075
J	Francis, J; Chakrabarti, SK; Garmey, JC; Mirmira, RG				Francis, J; Chakrabarti, SK; Garmey, JC; Mirmira, RG			Pdx-1 links histone H3-Lys-4 methylation to RNA polymerase II elongation during activation of insulin transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CELL DIFFERENTIATION; GENE-TRANSCRIPTION; ACETYLTRANSFERASE COMPLEXES; METHYLTRANSFERASE; PHOSPHORYLATION; NKX6.1; HOMEODOMAIN; MECHANISM; PROMOTER; BINDING	Expression of the insulin gene is nearly exclusive to the beta cells of the pancreatic islets. Although the sequence-specific transcription factors that regulate insulin expression have been well studied, the interrelationship between these factors, chromatin structure, and transcriptional elongation by RNA polymerase II (pol II) has remained undefined. In this regard, recent studies have begun to establish a role for the methylation of histone H3 in the initiation or elongation of transcription by pol II. To determine a role for the transcriptional activator Pdx-1 in the maintenance of chromatin structure and pol II recruitment at the insulin gene, we performed small interfering RNA-mediated knockdown of Pdx-1 in beta TC3 cells and subsequently studied histone modifications and pol II recruitment by chromatin immunoprecipitation. We demonstrated here that the 50% fall in insulin transcription following knockdown of Pdx-1 is accompanied by a 60% fall in dimethylated histone H3-Lys-4 at the insulin promoter. H3-Lys-4 methylation at the insulin promoter may bemediated, at least partially, by the methyltransferase Set9. Immunohistochemical analysis revealed that Set9 is expressed in an islet-enriched pattern in the pancreas, similar to the pattern of Pdx-1 expression. The recruitment of Set9 to the insulin gene appears to be a consequence of its direct interaction with Pdx-1, and small interfering RNA-mediated knockdown of Set9 attenuates insulin transcription. Pdx-1 knockdown was also associated with an overall shift in the recruitment of pol II isoforms to the insulin gene, from an elongation isoform (Ser( P)-2) to an initiation isoform ( Ser( P)-5). Our findings therefore suggest a model whereby Pdx-1 plays a novel role in linking H3-Lys-4 dimethylation and pol II elongation to insulin transcription.	Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Internal Med, Charlottesville, VA 22908 USA; Univ Virginia, Ctr Diabet, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Mirmira, RG (corresponding author), Univ Virginia Hlth Syst, 450 Ray C Hunt Dr,Box 801407, Charlottesville, VA 22908 USA.	mirmira@virginia.edu	Mirmira, Raghavendra G/AAD-7592-2020	Mirmira, Raghavendra G/0000-0002-5013-6075	NIDDK NIH HHS [R01 DK60581, R01 DK060581] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060581] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chakrabarti SK, 2003, TRENDS ENDOCRIN MET, V14, P78, DOI 10.1016/S1043-2760(02)00039-5; Chakrabarti SK, 2003, J BIOL CHEM, V278, P23617, DOI 10.1074/jbc.M303423200; Chakrabarti SK, 2002, J BIOL CHEM, V277, P13286, DOI 10.1074/jbc.M111857200; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EFRAT S, 1991, J BIOL CHEM, V266, P11141; Gerber M, 2003, J BIOL CHEM, V278, P26303, DOI 10.1074/jbc.R300014200; Habener JF, 2005, ENDOCRINOLOGY, V146, P1025, DOI 10.1210/en.2004-1576; Hampsey M, 2003, CELL, V113, P429, DOI 10.1016/S0092-8674(03)00360-X; Iype T, 2004, MOL ENDOCRINOL, V18, P1363, DOI 10.1210/me.2004-0006; Iype T, 2005, J BIOL CHEM, V280, P16798, DOI 10.1074/jbc.M414381200; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Kizer KO, 2005, MOL CELL BIOL, V25, P3305, DOI 10.1128/MCB.25.8.3305-3316.2005; Kouskouti A, 2004, MOL CELL, V14, P175, DOI 10.1016/S1097-2765(04)00182-0; Melloul D, 2004, ANN NY ACAD SCI, V1014, P28, DOI 10.1196/annals.1294.003; Mirmira RG, 2000, J BIOL CHEM, V275, P14743, DOI 10.1074/jbc.275.19.14743; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Offield MF, 1996, DEVELOPMENT, V122, P983; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; Ohneda K, 2000, SEMIN CELL DEV BIOL, V11, P227, DOI 10.1006/scdb.2000.0171; Okada Y, 2005, CELL, V121, P167, DOI 10.1016/j.cell.2005.02.020; Palancade B, 2003, EUR J BIOCHEM, V270, P3859, DOI 10.1046/j.1432-1033.2003.03794.x; Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242; Schisler JC, 2005, P NATL ACAD SCI USA, V102, P7297, DOI 10.1073/pnas.0502168102; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; Schwartz BE, 2005, GENE DEV, V19, P804, DOI 10.1101/gad.1259805; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Steger DJ, 1998, P NATL ACAD SCI USA, V95, P12924, DOI 10.1073/pnas.95.22.12924; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1; Weston RJ, 2004, J ESSENT OIL RES, V16, P453, DOI 10.1080/10412905.2004.9698770; Xiao B, 2003, NATURE, V421, P652, DOI 10.1038/nature01378; Xiao TJ, 2003, GENE DEV, V17, P654, DOI 10.1101/gad.1055503; YANG Z, 2003, PANCREAS, V26, P99; Yoshida T, 2003, CIRC RES, V92, P856, DOI 10.1161/01.RES.0000068405.49081.09	37	77	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36244	36253		10.1074/jbc.M505741200	http://dx.doi.org/10.1074/jbc.M505741200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16141209	hybrid, Green Accepted			2022-12-27	WOS:000232726900057
J	Ravia, JJ; Stephen, RM; Ghishan, FK; Collins, JF				Ravia, JJ; Stephen, RM; Ghishan, FK; Collins, JF			Menkes copper ATPase (Atp7a) is a novel metal-responsive gene in rat duodenum, and immunoreactive protein is present on brush-border and basolateral membrane domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIMICROBIAL PEPTIDE HEPCIDIN; NA+-H+ EXCHANGE; PHOSPHATE-TRANSPORT; IRON-DEFICIENCY; MICROVILLUS MEMBRANE; PLASMA-MEMBRANES; EXPRESSION; VESICLES; LIVER; CERULOPLASMIN	We previously noted strong induction of genes related to intestinal copper homeostasis ( Menkes Copper ATPase (Atp7a) and metallothionein) in the duodenal epithelium of iron-deficient rats across several stages of postnatal development ( Collins, J. F., Franck, C. A., Kowdley, K. V., and Ghishan, F. K. ( 2005) Am. J. Physiol., 288, G964 - G971). We now report significant copper loading in the livers and intestines of iron-deficient rats. These findings are consistent with the hypothesis that there is increased intestinal copper transport during iron deficiency. We additionally found that hepatic Atp7b gene expression does not change with iron deficiency, suggesting that liver copper excretion is not altered. We have developed polyclonal antibodies against rat ATP7A, and we demonstrate the specificity of the immunogenic reaction. We show that the ATP7A protein is present on apical domains of duodenal enterocytes in control rats and on brush-border and basolateral membrane domains in iron-deprived rats. This localization is surprising, as previous in vitro studies have suggested that ATP7A traffics between the trans-Golgi network and the basolateral membrane. We further demonstrate that ATP7A protein levels are dramatically increased in brush-border and basolateral membrane vesicles isolated from iron-deficient rats. Other experiments show that iron refeeding partially corrects the hematological abnormalities seen in iron-deficient rats but that it does not ameliorate ATP7A protein induction, suggesting that Atp7a does not respond to intracellular iron levels. We conclude that ATP7A is involved in copper loading observed during iron deficiency and that increased intestinal copper transport is of physiological relevance, as copper plays important roles in overall body iron homeostasis.	Univ Arizona, Hlth Sci Ctr, Steele Childrens Res Ctr, Dept Pediat, Tucson, AZ 85724 USA; Univ Arizona, Hlth Sci Ctr, Steele Childrens Res Ctr, Dept Nutr Sci, Tucson, AZ 85724 USA	University of Arizona; University of Arizona Health Sciences; University of Arizona; University of Arizona Health Sciences	Collins, JF (corresponding author), SUNY Buffalo, Dept Exercise & Nutr Sci, 15 Farber Hall, Buffalo, NY 14214 USA.	jfc8@buffalo.edu			NIDDK NIH HHS [R21 DK068349, 5 R21 DK068349] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK068349] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200; ACRA S, 1993, AM J PHYSIOL, V264, pG45, DOI 10.1152/ajpgi.1993.264.1.G45; ACRA S, 1991, GASTROENTEROLOGY, V101, P430, DOI 10.1016/0016-5085(91)90022-D; Arredondo M, 2003, AM J PHYSIOL-CELL PH, V284, pC1525, DOI 10.1152/ajpcell.00480.2002; Baltussen R, 2004, J NUTR, V134, P2678, DOI 10.1093/jn/134.10.2678; BARNARD JA, 1985, J CLIN INVEST, V75, P869, DOI 10.1172/JCI111785; BJORKMAN DJ, 1990, BIOCHEM BIOPH RES CO, V170, P433, DOI 10.1016/0006-291X(90)92110-L; BOROWITZ SM, 1985, PEDIATR RES, V19, P1308, DOI 10.1203/00006450-198512000-00021; BULL PC, 1994, TRENDS GENET, V10, P246, DOI 10.1016/0168-9525(94)90172-4; CHERUKURI S, 2005, 1 C INT BIOIR SOC PR, P35; Collins JF, 1998, BBA-BIOMEMBRANES, V1369, P247, DOI 10.1016/S0005-2736(97)00226-5; COLLINS JF, 1995, AM J PHYSIOL-GASTR L, V268, pG917, DOI 10.1152/ajpgi.1995.268.6.G917; Collins JF, 2005, AM J PHYSIOL-GASTR L, V288, pG964, DOI 10.1152/ajpgi.00489.2004; Collins JF, 1997, AM J PHYSIOL-CELL PH, V273, pC1937, DOI 10.1152/ajpcell.1997.273.6.C1937; DAHER M, 1992, P SOC EXP BIOL MED, V201, P254; Dameron CT, 1998, AM J CLIN NUTR, V67, p1091S, DOI 10.1093/ajcn/67.5.1091S; Dudeja PK, 2003, DIGEST DIS SCI, V48, P109, DOI 10.1023/A:1021794600864; FAELLI A, 1983, ARCH INT PHYSIOL BIO, V91, P423, DOI 10.3109/13813458309067990; Fox PL, 2003, BIOMETALS, V16, P9, DOI 10.1023/A:1020799512190; Frazer DM, 2002, GASTROENTEROLOGY, V123, P835, DOI 10.1053/gast.2002.35353; GHISHAN FK, 1985, DIABETES, V34, P723, DOI 10.2337/diabetes.34.8.723; GHISHAN FK, 1985, AM J PHYSIOL, V248, pG87, DOI 10.1152/ajpgi.1985.248.1.G87; GHISHAN FK, 1987, BIOCHEM J, V243, P641, DOI 10.1042/bj2430641; GHISHAN FK, 1989, BIOCHIM BIOPHYS ACTA, V979, P77, DOI 10.1016/0005-2736(89)90525-7; Greenough M, 2004, AM J PHYSIOL-CELL PH, V287, pC1463, DOI 10.1152/ajpcell.00179.2004; Griffiths WJH, 1999, MOL MED TODAY, V5, P431, DOI 10.1016/S1357-4310(99)01541-5; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Harris ED, 2000, ANNU REV NUTR, V20, P291, DOI 10.1146/annurev.nutr.20.1.291; Harris ZL, 1998, AM J CLIN NUTR, V67, p972S, DOI 10.1093/ajcn/67.5.972S; Harris ZL, 1999, P NATL ACAD SCI USA, V96, P10812, DOI 10.1073/pnas.96.19.10812; HAUSER H, 1980, BIOCHIM BIOPHYS ACTA, V602, P567, DOI 10.1016/0005-2736(80)90335-1; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Kelly EJ, 1996, NAT GENET, V13, P219, DOI 10.1038/ng0696-219; KIKUCHI K, 1988, GASTROENTEROLOGY, V95, P388, DOI 10.1016/0016-5085(88)90495-7; KIKUCHI K, 1987, GASTROENTEROLOGY, V93, P106, DOI 10.1016/0016-5085(87)90321-0; Knopfel M, 2005, BIOCHEM BIOPH RES CO, V330, P645, DOI 10.1016/j.bbrc.2005.03.023; Ludwiczek S, 2004, J MOL MED, V82, P373, DOI 10.1007/s00109-004-0542-3; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; McKie AT, 2001, SCIENCE, V291, P1755, DOI 10.1126/science.1057206; Mercer JFB, 2003, BIOMETALS, V16, P175, DOI 10.1023/A:1020719016675; MOE AJ, 1985, J NUTR, V115, P1173, DOI 10.1093/jn/115.9.1173; Muckenthaler M, 2003, NAT GENET, V34, P102, DOI 10.1038/ng1152; Mukhopadhyay CK, 1998, SCIENCE, V279, P714, DOI 10.1126/science.279.5351.714; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Nicolas G, 2002, P NATL ACAD SCI USA, V99, P4596, DOI 10.1073/pnas.072632499; Nicolas G, 2002, J CLIN INVEST, V110, P1037, DOI 10.1172/JCI200215686; Nicolas G, 2001, P NATL ACAD SCI USA, V98, P8780, DOI 10.1073/pnas.151179498; Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200; Pase L, 2004, BIOCHEM J, V378, P1031, DOI 10.1042/BJ20031181; Petris MJ, 2002, J BIOL CHEM, V277, P46736, DOI 10.1074/jbc.M208864200; Pigeon C, 2001, J BIOL CHEM, V276, P7811, DOI 10.1074/jbc.M008923200; Roetto A, 2003, NAT GENET, V33, P21, DOI 10.1038/ng1053; SAID HM, 1987, AM J PHYSIOL, V252, pG229, DOI 10.1152/ajpgi.1987.252.2.G229; STIEGER B, 1983, EUR J BIOCHEM, V135, P95; Tapiero H, 2001, BIOMED PHARMACOTHER, V55, P324, DOI 10.1016/S0753-3322(01)00067-1; Trinder D, 2000, GUT, V46, P270, DOI 10.1136/gut.46.2.270; Tyagi S, 2000, DIGEST DIS SCI, V45, P2282, DOI 10.1023/A:1005670404456; Vulpe CD, 1999, NAT GENET, V21, P195, DOI 10.1038/5979; VULPE CD, 1995, ANNU REV NUTR, V15, P293, DOI 10.1146/annurev.nu.15.070195.001453; Weinstein DA, 2002, BLOOD, V100, P3776, DOI 10.1182/blood-2002-04-1260; WILLIAMS LM, 1989, TOXICOLOGY, V55, P307, DOI 10.1016/0300-483X(89)90020-6; Wollenberg P, 1990, Biol Met, V3, P1, DOI 10.1007/BF01141169; Xu H, 2003, AM J PHYSIOL-GASTR L, V285, pG1317, DOI 10.1152/ajpgi.00172.2003; Xu H, 2001, AM J PHYSIOL-CELL PH, V280, pC628, DOI 10.1152/ajpcell.2001.280.3.C628; Yeh KY, 2000, AM J PHYSIOL-GASTR L, V279, pG1070, DOI 10.1152/ajpgi.2000.279.5.G1070; Young SP, 1997, FEBS LETT, V411, P93, DOI 10.1016/S0014-5793(97)00478-X; Zhou B, 1997, P NATL ACAD SCI USA, V94, P7481, DOI 10.1073/pnas.94.14.7481; Zoller H, 2001, GASTROENTEROLOGY, V120, P1412, DOI 10.1053/gast.2001.24033	68	68	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36221	36227		10.1074/jbc.M506727200	http://dx.doi.org/10.1074/jbc.M506727200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16081413	Green Accepted, hybrid			2022-12-27	WOS:000232726900054
J	Bera, AK; Akabas, MH				Bera, AK; Akabas, MH			Spontaneous thermal motion of the GABA(A) receptor M2 channel-lining segments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC-ACID; NICOTINIC ACETYLCHOLINE-RECEPTOR; CYSTEINE-SUBSTITUTION; PROTEIN MOBILITY; GENERAL-METHOD; ALPHA-HELIX; SUBUNIT; PACKING; BINDING; SITE	The gamma- aminobutyric acid type A ( GABA(A)) receptor channel opening involves translational and rotational motions of the five channel- lining, M2 transmembrane segments. The M2 segment's extracellular half is loosely packed and undergoes significant thermal motion. To characterize the extent of the M2 segment's motion, we used disulfide trapping experiments between pairs of engineered cysteines. In alpha(1)beta(1)gamma(2S) receptors the single gamma subunit is flanked by an alpha and beta subunit. The gamma(2)M2 - 14' position is located in the alpha-gamma subunit interface. gamma(2) 13' faces the channel lumen. We expressed either the gamma(2)14' or the gamma(2)13' cysteine substitution mutants with alpha(1) cysteine substitution mutants between 12' and 16' and wild- type beta(1). Disulfide bonds formed spontaneously between gamma(2)14'C and both alpha(1)15'C and alpha(1)16'C and also between gamma(2)13'C and alpha(1)13'C. Oxidation by copper phenanthroline induced disulfide bond formation between gamma(2)14'C and alpha(1)13' C. Disulfide bond formation rates with gamma(2)14'C were similar in the presence and absence of GABA, although the rate with alpha(1)13' C was slower than with the other two positions. In a homology model based on the acetylcholine receptor structure, alpha M2 would need to rotate in opposite directions by similar to 80 degrees to bring alpha(1)13' and alpha(1)15' into close proximity with gamma(2)14'. Alternatively, translational motion of alpha M2 would reduce the extent of rotational motion necessary to bring these two alpha subunit residues into close proximity with the gamma(2)14' position. These experiments demonstrate that in the closed state the M2 segments undergo continuous spontaneous motion in the region near the extracellular end of the channel gate. Opening the gate may involve similar but concerted motions of the M2 segments.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Akabas, MH (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	makabas@aecom.yu.edu		Bera, Amal Kanti/0000-0003-0362-5578; Akabas, Myles/0000-0001-8781-7846	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM061925] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030808] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61925] Funding Source: Medline; NINDS NIH HHS [NS30808] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Baumann SW, 2001, J BIOL CHEM, V276, P36275, DOI 10.1074/jbc.M105240200; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; CAREAGA CL, 1992, J MOL BIOL, V226, P1219, DOI 10.1016/0022-2836(92)91063-U; Cha A, 1999, NATURE, V402, P809, DOI 10.1038/45552; Chakrapani S, 2005, P NATL ACAD SCI USA, V102, P87, DOI 10.1073/pnas.0406777102; Chang YC, 1996, J NEUROSCI, V16, P5415; Cromer BA, 2002, TRENDS BIOCHEM SCI, V27, P280, DOI 10.1016/S0968-0004(02)02092-3; Dahan DS, 2004, P NATL ACAD SCI USA, V101, P10195, DOI 10.1073/pnas.0301885101; Goren EN, 2004, J BIOL CHEM, V279, P11198, DOI 10.1074/jbc.M314050200; Halle B, 2002, P NATL ACAD SCI USA, V99, P1274, DOI 10.1073/pnas.032522499; Hastrup H, 2001, P NATL ACAD SCI USA, V98, P10055, DOI 10.1073/pnas.181344298; Horenstein J, 2005, J BIOL CHEM, V280, P1573, DOI 10.1074/jbc.M410881200; Horenstein J, 2001, NAT NEUROSCI, V4, P477, DOI 10.1038/87425; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Johnson JP, 2001, NATURE, V412, P917, DOI 10.1038/35091089; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Kihira Y, 2004, BIOCHEMISTRY-US, V43, P15204, DOI 10.1021/bi0494222; KOBASHI K, 1968, BIOCHIM BIOPHYS ACTA, V158, P239, DOI 10.1016/0304-4165(68)90136-0; Lester HA, 2004, TRENDS NEUROSCI, V27, P329, DOI 10.1016/j.tins.2004.04.002; MILLER C, 1989, NEURON, V2, P1195, DOI 10.1016/0896-6273(89)90304-8; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Olsen RW, 2004, BIOCHEM PHARMACOL, V68, P1675, DOI 10.1016/j.bcp.2004.07.026; Panicker S, 2004, J BIOL CHEM, V279, P28149, DOI 10.1074/jbc.M403545200; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; Reeves DC, 2002, MOL MEMBR BIOL, V19, P11, DOI 10.1080/09687680110110048; REGAN L, 1994, PROTEIN SCI, V3, P2419, DOI 10.1002/pro.5560031225; SOWDHAMINI R, 1989, PROTEIN ENG, V3, P95, DOI 10.1093/protein/3.2.95; Teissere JA, 2001, J NEUROSCI, V21, P4977, DOI 10.1523/JNEUROSCI.21-14-04977.2001; Tretter V, 1997, J NEUROSCI, V17, P2728; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031; Wu JH, 1996, P NATL ACAD SCI USA, V93, P14498, DOI 10.1073/pnas.93.25.14498; Xiao WZ, 2000, J MOL BIOL, V304, P715, DOI 10.1006/jmbi.2000.4255; XU M, 1993, J BIOL CHEM, V268, P21505; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; YU HB, 1995, BIOCHEMISTRY-US, V34, P14963, DOI 10.1021/bi00046a002	37	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35506	35512		10.1074/jbc.M504645200	http://dx.doi.org/10.1074/jbc.M504645200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16091360	hybrid			2022-12-27	WOS:000232561200051
J	Kwon, H; Ogle, L; Benitez, B; Bohuslav, J; Montano, M; Felsher, DW; Greene, WC				Kwon, H; Ogle, L; Benitez, B; Bohuslav, J; Montano, M; Felsher, DW; Greene, WC			Lethal cutaneous disease in transgenic mice conditionally expressing type I human T cell leukemia virus tax	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INTERLEUKIN-10 GENE-EXPRESSION; RECEPTOR BETA-GENE; HTLV-I; INFECTIVE DERMATITIS; RAT FIBROBLASTS; SKIN-DISEASE; PROVIRAL DNA; GAMMA-GENE; LYMPHOMA	Type I human T cell leukemia virus ( HTLV- I) is etiologically linked with adult T cell leukemia, an aggressive and usually fatal expansion of activated CD4(+) T lymphocytes that frequently traffic to skin. T cell transformation induced by HTLV- I involves the action of the 40- kDa viral Tax transactivator protein. Tax both stimulates the HTLV- I long terminal repeat and deregulates the expression of select cellular genes by altering the activity of specific host transcription factors, including cyclic AMP- responsive element-binding protein ( CREB)/ activating transcription factor, NF-kappa B/ Rel, and serum response factor. To study initiating events involved in HTLV- I Tax- induced T cell transformation, we generated " Tet- off" transgenic mice conditionally expressing in a lymphocyte- restricted manner ( E mu SR alpha promoter- enhancer) either wild- type Tax or mutant forms of Tax that selectively compromise the NF-kappa B ( M22) or CREB/ activating transcription factor ( M47) activation pathways. Wild- type Tax and M47 Tax- expressing mice, but not M22- Tax expressing mice, developed progressive alopecia, hyperkeratosis, and skin lesions containing profuse activated CD4 T cell infiltrates with evidence of deregulated inflammatory cytokine production. In addition, these animals displayed systemic lymphadenopathy and splenomegaly. These findings suggest that Tax- mediated activation of NF-kappa B plays a key role in the development of this aggressive skin disease that shares several features in common with the skin disease occurring during the preleukemic stage in HTLV-I-infected patients. Of note, this skin disease completely resolved when Tax transgene expression was suppressed by administration of doxycycline, emphasizing the key role played by this viral oncoprotein in the observed pathology.	Gladstone Inst Virol & Immunol, San Francisco, CA 94158 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Stanford Univ, Dept Med, Div Oncol, Stanford, CA 94305 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University	Greene, WC (corresponding author), Gladstone Inst Virol & Immunol, 1650 Owens St, San Francisco, CA 94158 USA.	wgreene@gladstone.ucsf.edu			NCI NIH HHS [R01CA89001] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089001] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; Azran Inbal, 2004, Retrovirology, V1, P20; Baker M, 2000, EMBO J, V19, P4644, DOI 10.1093/emboj/19.17.4644; Barton D, 2000, EUR J IMMUNOL, V30, P2323, DOI 10.1002/1521-4141(2000)30:8<2323::AID-IMMU2323>3.0.CO;2-H; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BLANK A, 1995, LANCET, V346, P710, DOI 10.1016/S0140-6736(95)92326-8; Boland CR, 1999, P NATL ACAD SCI USA, V96, P14675, DOI 10.1073/pnas.96.26.14675; Bouvier G, 1996, P NATL ACAD SCI USA, V93, P7877, DOI 10.1073/pnas.93.15.7877; BROWN DA, 1991, EUR J IMMUNOL, V21, P1879, DOI 10.1002/eji.1830210815; BUNKER CB, 1990, LANCET, V335, P426, DOI 10.1016/0140-6736(90)90274-9; Carroll JM, 1997, J INVEST DERMATOL, V108, P412, DOI 10.1111/1523-1747.ep12289702; CHENG J, 1992, GENE DEV, V6, P1444, DOI 10.1101/gad.6.8.1444; Coscoy L, 1998, VIROLOGY, V248, P332, DOI 10.1006/viro.1998.9298; Daniel D, 2003, J EXP MED, V197, P1017, DOI 10.1084/jem.20021047; DOSAKA N, 1991, J INVEST DERMATOL, V96, P196, DOI 10.1111/1523-1747.ep12461033; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; FURUKAWA Y, 1994, CANCER RES, V54, P6533; FURUTA Y, 1989, J VIROL, V63, P3185, DOI 10.1128/JVI.63.7.3185-3189.1989; Gartner F, 1999, IMMUNITY, V10, P537, DOI 10.1016/S1074-7613(00)80053-9; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Germain M, 2000, INT J DERMATOL, V39, P815, DOI 10.1046/j.1365-4362.2000.00937.x; GESSAIN A, 1990, J AM ACAD DERMATOL, V23, P994, DOI 10.1016/0190-9622(90)70321-8; GESSAIN A, 1985, LANCET, V2, P407; Goncalves DU, 2003, AM J TROP MED HYG, V68, P562, DOI 10.4269/ajtmh.2003.68.562; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; GROVES RW, 1995, P NATL ACAD SCI USA, V92, P11874, DOI 10.1073/pnas.92.25.11874; Hall AP, 1998, J PATHOL, V186, P209; HALL WW, 1994, J EXP MED, V180, P1581, DOI 10.1084/jem.180.5.1581; HANCHARD B, 1991, LANCET, V338, P1593, DOI 10.1016/0140-6736(91)92413-V; Hasegawa H, 2000, BLOOD, V95, P30; Higaki Y, 2003, DERMATOLOGY, V206, P157, DOI 10.1159/000068460; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; Ishida Y, 1989, Int Immunol, V1, P113, DOI 10.1093/intimm/1.2.113; Kato N, 2001, BRIT J DERMATOL, V144, P1244, DOI 10.1046/j.1365-2133.2001.04242.x; KIM SJ, 1991, MOL CELL BIOL, V11, P5222, DOI 10.1128/MCB.11.10.5222; Kindt TJ, 2000, MICROBES INFECT, V2, P1139, DOI 10.1016/S1286-4579(00)01268-5; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; Klement JF, 1996, MOL CELL BIOL, V16, P2341; Kohler S, 1997, J CUTAN PATHOL, V24, P292, DOI 10.1111/j.1600-0560.1997.tb00794.x; La Grenade L, 1998, ARCH DERMATOL, V134, P439, DOI 10.1001/archderm.134.4.439; LAGRENADE L, 1990, LANCET, V336, P1345; LaGrenade L, 1996, AM J MED GENET, V61, P37, DOI 10.1002/(SICI)1096-8628(19960102)61:1<37::AID-AJMG7>3.0.CO;2-U; Lenzi MER, 2003, CLIN INFECT DIS, V36, P507, DOI 10.1086/367572; Mahe A, 1999, LANCET, V354, P1386, DOI 10.1016/S0140-6736(05)76239-5; Mori N, 1998, LEUKEMIA LYMPHOMA, V29, P239, DOI 10.3109/10428199809068561; Mori N, 1996, BLOOD, V88, P1035; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; PAGLIUCA A, 1990, LANCET, V335, P733, DOI 10.1016/0140-6736(90)90854-X; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; RICH BE, 1993, J EXP MED, V177, P305, DOI 10.1084/jem.177.2.305; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; Rosin O, 1998, J BIOL CHEM, V273, P6698, DOI 10.1074/jbc.273.12.6698; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x; Simpson RM, 1996, J INFECT DIS, V173, P722, DOI 10.1093/infdis/173.3.722; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Steele KE, 2001, VET PATHOL, V38, P203, DOI 10.1354/vp.38-2-203; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; TAJIMA K, 1988, INT J CANCER, V41, P505; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TANAKA T, 1989, J AM ACAD DERMATOL, V21, P218, DOI 10.1016/S0190-9622(89)70164-X; TENDLER CL, 1991, J CELL BIOCHEM, V46, P302, DOI 10.1002/jcb.240460405; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; UEHIRA M, 1993, INT IMMUNOL, V5, P1619, DOI 10.1093/intimm/5.12.1619; WANO Y, 1987, J CLIN INVEST, V80, P911, DOI 10.1172/JCI113152; Williams IR, 1997, J IMMUNOL, V159, P3044; Yajima A, 2001, DERMATOLOGY, V203, P53, DOI 10.1159/000051704; YAMADA M, 1989, INT J DERMATOL, V28, P107, DOI 10.1111/j.1365-4362.1989.tb01329.x; Yamada Y, 1996, LEUKEMIA LYMPHOMA, V21, P443, DOI 10.3109/10428199609093442; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yoshie O, 2002, BLOOD, V99, P1505, DOI 10.1182/blood.V99.5.1505	75	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35713	35722		10.1074/jbc.M504848200	http://dx.doi.org/10.1074/jbc.M504848200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16105841	hybrid			2022-12-27	WOS:000232561200074
J	Lee, MH; Kim, YJ; Yoon, WJ; Kim, JI; Kim, BG; Hwang, YS; Wozney, JM; Chi, XZ; Bae, SC; Choi, KY; Cho, JY; Choi, JY; Ryoo, HM				Lee, MH; Kim, YJ; Yoon, WJ; Kim, JI; Kim, BG; Hwang, YS; Wozney, JM; Chi, XZ; Bae, SC; Choi, KY; Cho, JY; Choi, JY; Ryoo, HM			Dlx5 specifically regulates Runx2 type II expression by binding to homeodomain-response elements in the Runx2 distal promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; CRANIAL SUTURE MORPHOGENESIS; OSTEOCALCIN GENE-EXPRESSION; GROWTH-FACTOR BETA-1; OSTEOBLAST DIFFERENTIATION; MSX2; TRANSCRIPTION; CBFA1; ISOFORMS; PATTERNS	Two major isoforms of the Runx2 gene are expressed by alternative promoter usage: Runx2 type I (Runx2-I) is derived from the proximal promoter (P2), and Runx2 type II (Runx2-II) is produced by the distal promoter (P1). Our previous results indicate that Dlx5 mediates BMP-2-induced Runx2 expression and osteoblast differentiation (Lee, M.-H., Kim, Y-J., Kim, H-J., Park, H-D., Kang, A-R., Kyung, H.-M., Sung, J-H., Wozney, J. M., Kim, H-J., and Ryoo, H-M. (2003) J. Biol. Chem. 278, 34387-34394). However, little is known of the molecular mechanisms by which Dlx5 up-regulates Runx2 expression in BMP-2 signaling. Here, Runx2-II expression was found to be specifically stimulated by BMP-2 treatment or by Dlx5 overexpression. In addition, BMP-2, Dlx5, and Runx2-II were found to be expressed in osteogenic fronts and parietal bones of the developing cranial vault and Runx2-I and Msx2 in the sutural mesenchyme. Furthermore, Runx2 P1 promoter activity was strongly stimulated by Dlx5 overexpression, whereas Runx2 P2 promoter activity was not. Runx2 P1 promoter deletion analysis indicated that the Dlx5-specific response is due to sequences between -756 and -342 bp of the P1 promoter, where three Dlx5-response elements are located. Dlx5 responsiveness to these elements was confirmed by gel mobility shift assay and site-directed mutagenesis. Moreover, Msx2 specifically suppressed the Runx2 P1 promoter, and the responsible region overlaps with that recognized by Dlx5. In summary, Dlx5 specifically transactivates the Runx2 P1 promoter, and its action on the P1 promoter is antagonized by Msx2.	Kyungpook Natl Univ, Sch Dent, Dept Biochem, Taegu 700422, South Korea; Kyungpook Natl Univ, Skeletal Dis Genome Res Ctr, Taegu 700422, South Korea; Kyungpook Natl Univ, Sch Med, Dept Anat, Taegu 700422, South Korea; Kyungpook Natl Univ, Sch Med, Dept Biochem, Taegu 700422, South Korea; Wyeth Pharmaceut, Cambridge, MA 02140 USA; Chungbuk Natl Univ, Sch Med, Dept Biochem, Cheongju 361763, South Korea	Kyungpook National University; Kyungpook National University; Kyungpook National University; Kyungpook National University; Pfizer; Chungbuk National University	Ryoo, HM (corresponding author), Seoul Natl Univ, Coll Dent, Dept Cell & Dev Biol, 28 Yeongeon Dong, Seoul 110749, South Korea.	hmryoo@snu.ac.kr	Ryoo, Hyun-Mo/D-5839-2012	Ryoo, Hyun-Mo/0000-0001-6769-8341; Lee, Mi-Hye/0000-0002-5484-3383				Banerjee C, 2001, ENDOCRINOLOGY, V142, P4026, DOI 10.1210/en.142.9.4026; Bangsow C, 2001, GENE, V279, P221, DOI 10.1016/S0378-1119(01)00760-0; Barnes GL, 2003, CANCER RES, V63, P2631; Benson MD, 2000, J BIOL CHEM, V275, P13907, DOI 10.1074/jbc.275.18.13907; Bidder M, 1998, J BONE MINER RES, V13, P609, DOI 10.1359/jbmr.1998.13.4.609; Cheng SL, 2003, J BIOL CHEM, V278, P45969, DOI 10.1074/jbc.M306972200; Choi KY, 2005, DEV DYNAM, V233, P115, DOI 10.1002/dvdy.20323; Choi KY, 2002, EXP MOL MED, V34, P426, DOI 10.1038/emm.2002.60; Dodig M, 1996, J BIOL CHEM, V271, P16422, DOI 10.1074/jbc.271.27.16422; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Geoffroy V, 1998, MAMM GENOME, V9, P54, DOI 10.1007/s003359900679; Ghozi MC, 1996, P NATL ACAD SCI USA, V93, P1935, DOI 10.1073/pnas.93.5.1935; Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660; Hassan MQ, 2004, MOL CELL BIOL, V24, P9248, DOI 10.1128/MCB.24.20.9248-9261.2004; HOFFMANN HM, 1994, P NATL ACAD SCI USA, V91, P12887, DOI 10.1073/pnas.91.26.12887; Ichida F, 2004, J BIOL CHEM, V279, P34015, DOI 10.1074/jbc.M403621200; JABS EW, 1993, CELL, V75, P443, DOI 10.1016/0092-8674(93)90379-5; Kim HJ, 2003, J BIOL CHEM, V278, P319, DOI 10.1074/jbc.M203750200; Kim HJ, 1998, DEVELOPMENT, V125, P1241; Kim YJ, 2004, J BIOL CHEM, V279, P50773, DOI 10.1074/jbc.M404145200; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097-4644(19990401)73:1<114::AID-JCB13>3.3.CO;2-D; Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058; Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200; Lengner CJ, 2002, MECH DEVELOP, V114, P167, DOI 10.1016/S0925-4773(02)00050-3; Ma L, 1996, HUM MOL GENET, V5, P1915, DOI 10.1093/hmg/5.12.1915; Miyama K, 1999, DEV BIOL, V208, P123, DOI 10.1006/dbio.1998.9197; Newberry EP, 1998, BIOCHEMISTRY-US, V37, P16360, DOI 10.1021/bi981878u; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Park MH, 2001, J BONE MINER RES, V16, P885, DOI 10.1359/jbmr.2001.16.5.885; Ryoo HM, 1997, MOL ENDOCRINOL, V11, P1681, DOI 10.1210/me.11.11.1681; Shen J, 2003, MOL ENDOCRINOL, V17, P743, DOI 10.1210/me.2002-0122; Shen JL, 2002, J BIOL CHEM, V277, P20284, DOI 10.1074/jbc.M112440200; Shirakabe K, 2001, GENES CELLS, V6, P851, DOI 10.1046/j.1365-2443.2001.00466.x; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Tadic T, 2002, J BONE MINER RES, V17, P1008, DOI 10.1359/jbmr.2002.17.6.1008; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P1484, DOI 10.1210/me.8.11.1484; Ueta C, 2001, J CELL BIOL, V153, P87, DOI 10.1083/jcb.153.1.87; Xiao ZS, 2001, J CELL BIOCHEM, V82, P647, DOI 10.1002/jcb.1192; Xiao ZS, 2005, DEV BIOL, V283, P345, DOI 10.1016/j.ydbio.2005.04.028; Xiao ZS, 2004, J BIOL CHEM, V279, P20307, DOI 10.1074/jbc.M401109200; Zhang HL, 1997, MOL CELL BIOL, V17, P2920, DOI 10.1128/MCB.17.5.2920	45	160	168	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35579	35587		10.1074/jbc.M502267200	http://dx.doi.org/10.1074/jbc.M502267200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16115867	hybrid, Green Published			2022-12-27	WOS:000232561200060
J	Meng, Q; Wang, YF; Liu, XQ				Meng, Q; Wang, YF; Liu, XQ			An intron-encoded protein assists RNA splicing of multiple similar introns of different bacterial genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-II INTRONS; ELEMENTS; DATABASE; PLANT; ORFS	Four group II introns were found in an unusually intron-rich dnaN gene (encoding the beta subunit of DNA polymerase III) of the cyanobacterium Trichodesmium erythraeum, and they have strong similarities to two introns of the RIR gene (encoding ribonucleotide reductase) of the same organism. Of these six introns, only the RIR-3 intron encodes a maturase protein and showed efficient RNA splicing when expressed in Escherichia coli cells. The other five introns do not encode a maturase protein and did not show RNA splicing in E. coli. But these maturase-less introns showed efficient RNA splicing when the RIR-3 intron-encoded maturase protein was co-expressed from a freestanding gene in the same cell. These findings demonstrated that an intron-encoded protein could function as a general maturase for multiple introns of different genes. Major implications may include an intron-mediated co-regulation of the different genes and a resemblance of the evolutionary origin of spliceosomal introns.	Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada	Dalhousie University	Liu, XQ (corresponding author), Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada.	pxqliu@dal.ca						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bonen L, 2001, TRENDS GENET, V17, P322, DOI 10.1016/S0168-9525(01)02324-1; CAVALIERSMITH T, 1991, TRENDS GENET, V7, P145, DOI 10.1016/0168-9525(91)90102-V; Dai LX, 2003, RNA, V9, P14, DOI 10.1261/rna.2126203; Dai LX, 2003, NUCLEIC ACIDS RES, V31, P424, DOI 10.1093/nar/gkg049; Edgell DR, 2000, J BACTERIOL, V182, P5281, DOI 10.1128/JB.182.19.5281-5289.2000; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Huang HR, 2003, MOL CELL BIOL, V23, P8809, DOI 10.1128/MCB.23.23.8809-8819.2003; Lambowitz AM, 2004, ANNU REV GENET, V38, P1, DOI 10.1146/annurev.genet.38.072902.091600; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; LAMBOWITZ AM, 1999, RNA WORLD; Liu XQ, 2003, J BIOL CHEM, V278, P46826, DOI 10.1074/jbc.M309575200; Matsuura M, 2001, EMBO J, V20, P7259, DOI 10.1093/emboj/20.24.7259; MICHEL F, 1995, ANNU REV BIOCHEM, V64, P435, DOI 10.1146/annurev.bi.64.070195.002251; Mohr G, 2003, NUCLEIC ACIDS RES, V31, P647, DOI 10.1093/nar/gkg153; Toro N, 2003, ENVIRON MICROBIOL, V5, P143, DOI 10.1046/j.1462-2920.2003.00398.x; Vogel J, 1999, NUCLEIC ACIDS RES, V27, P3866, DOI 10.1093/nar/27.19.3866; WOLFE KH, 1992, P NATL ACAD SCI USA, V89, P10648, DOI 10.1073/pnas.89.22.10648; Zimmerly S, 2001, NUCLEIC ACIDS RES, V29, P1238, DOI 10.1093/nar/29.5.1238; ZUKER M, 2003, NUCLEIC ACIDS RES, V31, P1	20	25	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35085	35088		10.1074/jbc.C500328200	http://dx.doi.org/10.1074/jbc.C500328200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16150738	hybrid			2022-12-27	WOS:000232561200004
J	Niederhoff, K; Meindl-Beinker, NM; Kerssen, D; Perband, U; Schafer, A; Schliebs, W; Kunau, WH				Niederhoff, K; Meindl-Beinker, NM; Kerssen, D; Perband, U; Schafer, A; Schliebs, W; Kunau, WH			Yeast Pex14p possesses two functionally distinct Pex5p and one Pex7p binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXISOMAL TARGETING SIGNAL; SACCHAROMYCES-CEREVISIAE; HANSENULA-POLYMORPHA; MEMBRANE-PROTEIN; DIHYDROXYACETONE SYNTHASE; ESCHERICHIA-COLI; IMPORT; RECEPTOR; BIOGENESIS; GENE	Current evidence favors a cycling receptor model for the import of peroxisomal matrix proteins. The yeast Pex14 protein together with Pex13p and Pex17p form the docking subcomplex at the peroxisomal membrane and interact in this cycle with both soluble import receptors Pex5p and Pex7p. In a first step of a structure-function analysis of Saccharomyces cerevisiae Pex14p, we mapped its binding sites with both receptors. Using the yeast two-hybrid system and pull-down assays, we showed that Pex5p directly interacts with two separate regions of ScPex14p, amino acid residues 1-58 and 235-308. The latter binding site at the C terminus of ScPex14p overlaps with a binding site of Pex7p at amino acid residues 235-325. The functional assessment of these two binding sites of ScPex14p with the peroxisomal targeting signal receptors indicates that they have distinct roles. Deletion of the N-terminal 58 amino acids caused a partial defect of matrix protein import in pex14 Delta cells expressing the Pex14-(59-341)-p fragment; however, it did not lead to a pex phenotype. In contrast, truncation of the C-terminal 106 amino acids of ScPex14p completely blocked this process. On the basis of these and other published data, we propose that the C terminus of Pex14p contains the actual docking site and discuss the possibility that the N terminus could be involved in a Pex5p-Pex14p association inside the peroxisomal membrane.	Ruhr Univ Bochum, Fak Med, Abt Syst Biochem, Inst Physiol Chem, D-44780 Bochum, Germany	Ruhr University Bochum	Kunau, WH (corresponding author), Ruhr Univ Bochum, Fak Med, Abt Syst Biochem, Inst Physiol Chem, D-44780 Bochum, Germany.	wolf-h.kunau@ruhr-uni-bochum.de		Schliebs, Wolfgang/0000-0003-2762-3403				Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; Ausubel FM, 1992, CURRENT PROTOCOLS MO; Baudhuin P, 1974, Methods Enzymol, V31, P356; BERGMEYER HU, 1974, METHODEN ENZYMATISCH, V1, P479; BIGL M, 1994, BIOL CHEM H-S, V375, P153, DOI 10.1515/bchm3.1994.375.3.153; Blobel F, 1996, EUR J BIOCHEM, V240, P468, DOI 10.1111/j.1432-1033.1996.0468h.x; Brocard C, 1997, EMBO J, V16, P5491, DOI 10.1093/emboj/16.18.5491; Brown LA, 2003, J CELL MOL MED, V7, P388, DOI 10.1111/j.1582-4934.2003.tb00241.x; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Dammai V, 2001, CELL, V105, P187, DOI 10.1016/S0092-8674(01)00310-5; DOUMA AC, 1985, ARCH MICROBIOL, V143, P237, DOI 10.1007/BF00411242; Eckert JH, 2003, REV PHYSIOL BIOCH P, V147, P75, DOI 10.1007/s10254-003-0007-z; ERDMANN R, 1994, YEAST, V10, P935, DOI 10.1002/yea.320100708; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Girzalsky W, 1999, J CELL BIOL, V144, P1151, DOI 10.1083/jcb.144.6.1151; Gouveia AM, 2003, J BIOL CHEM, V278, P226, DOI 10.1074/jbc.M209498200; Gouveia AMM, 2000, J BIOL CHEM, V275, P32444, DOI 10.1074/jbc.M004366200; Graham J M, 1993, Methods Mol Biol, V19, P29; Johnson MA, 2001, YEAST, V18, P621, DOI 10.1002/yea.711; Klein ATJ, 2002, J BIOL CHEM, V277, P25011, DOI 10.1074/jbc.M203254200; Komori M, 1997, EMBO J, V16, P44, DOI 10.1093/emboj/16.1.44; Kunau WH, 2001, CURR BIOL, V11, pR659, DOI 10.1016/S0960-9822(01)00386-4; Lloyd MD, 1996, ANAL BIOCHEM, V241, P139, DOI 10.1006/abio.1996.0389; Nair DM, 2004, J CELL BIOL, V167, P599, DOI 10.1083/jcb.200407119; Oliveira MEM, 2002, BBA-BIOMEMBRANES, V1567, P13, DOI 10.1016/S0005-2736(02)00635-1; Rehling P, 1996, EMBO J, V15, P2901, DOI 10.1002/j.1460-2075.1996.tb00653.x; Salomons FA, 2000, J BIOL CHEM, V275, P12603, DOI 10.1074/jbc.275.17.12603; Schafer A, 2004, MOL CELL BIOL, V24, P8895, DOI 10.1128/MCB.24.20.8895-8906.2004; Schliebs W, 1999, J BIOL CHEM, V274, P5666, DOI 10.1074/jbc.274.9.5666; Shimizu N, 1999, J BIOL CHEM, V274, P12593, DOI 10.1074/jbc.274.18.12593; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Will GK, 1999, MOL CELL BIOL, V19, P2265	35	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35571	35578		10.1074/jbc.M502460200	http://dx.doi.org/10.1074/jbc.M502460200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16107331	hybrid			2022-12-27	WOS:000232561200059
J	Tomomura, M; Furuichi, T				Tomomura, M; Furuichi, T			Apoptosis-associated tyrosine kinase (AATYK) has differential Ca2+-dependent phosphorylation states in response to survival and apoptotic conditions in cerebellar granule cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TROPHIC-FACTOR DEPRIVATION; NERVE GROWTH-FACTOR; C-JUN; NEURONAL APOPTOSIS; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; PKC-DELTA; PROTEIN; LITHIUM; DEATH	In dissociated cultures of cerebellar granule cells, extracellular high potassium (HK) and low potassium (LK) concentrations control cell survival and apoptosis, respectively. Apoptosis-associated tyrosine kinase (AATYK) is up-regulated during the LK-induced apoptosis. Overexpression of wild-type AATYK, but not its kinase-deficient mutant, stimulates apoptosis in LK. In this study, we analyzed the relationship between the phosphorylation states of AATYK and the survival of granule cells. AATYK was hypophosphorylated in HK, whereas it was hyperphosphorylated in apoptotic LK. HK-dependent hypophosphorylation of AATYK was controlled by L-type voltage-dependent calcium channel-mediated Ca2+ influx followed by Ca2+-dependent protein phosphatase activity. However, LK-induced hyperphosphorylation of AATYK at multiple sites was blocked by kainate, lithium, and protein kinase C-delta inhibitor. AATYK phosphorylation was concurrent with c-Jun phosphorylation. In addition, mutations of AATYK on either the kinase domain or Ser-480, Ser-558, and Ser-566 residues suppressed the LK-induced hyperphosphorylation and apoptosis, suggesting the involvement of self-kinase activity and these Ser residues in this process. Our data therefore indicate that the phosphorylation states of AATYK are closely related to the HK-induced survival and LK-induced apoptosis of cerebellar granule cells.	RIKEN, Brain Sci Inst, Lab Mol Neurogenesis, Wako, Saitama 3510198, Japan	RIKEN	Tomomura, M (corresponding author), RIKEN, Brain Sci Inst, Lab Mol Neurogenesis, Wako, Saitama 3510198, Japan.	mtomomura@brain.riken.go.jp	Furuichi, Teiichi/B-5086-2014	Furuichi, Teiichi/0000-0002-9676-1888				Basu A, 2003, J CELL MOL MED, V7, P341, DOI 10.1111/j.1582-4934.2003.tb00237.x; Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Chiang LW, 2001, P NATL ACAD SCI USA, V98, P2814, DOI 10.1073/pnas.051630598; Ciani E, 1997, DEV BRAIN RES, V99, P112, DOI 10.1016/S0165-3806(96)00187-3; Coffey ET, 2002, J NEUROSCI, V22, P4335, DOI 10.1523/JNEUROSCI.22-11-04335.2002; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; D'MELLO SR, 1994, EXP CELL RES, V211, P332, DOI 10.1006/excr.1994.1095; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; GALLI C, 1995, J NEUROSCI, V15, P1172; GALLO V, 1987, J NEUROSCI, V7, P2203; Gaozza E, 1997, ONCOGENE, V15, P3127, DOI 10.1038/sj.onc.1201575; Grignon S, 1996, EUR J PHARMACOL, V315, P111, DOI 10.1016/S0014-2999(96)00591-2; Gutcher I, 2003, CELL MOL LIFE SCI, V60, P1061, DOI 10.1007/s00018-003-2281-y; HACK N, 1993, NEUROSCIENCE, V57, P9, DOI 10.1016/0306-4522(93)90108-R; HALLCHER LM, 1980, J BIOL CHEM, V255, P896; Ham J, 2000, BIOCHEM PHARMACOL, V60, P1015, DOI 10.1016/S0006-2952(00)00372-5; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Jin N, 2005, NEUROPHARMACOLOGY, V48, P576, DOI 10.1016/j.neuropharm.2004.11.010; Kawa S, 2004, GENES CELLS, V9, P219, DOI 10.1111/j.1356-9597.2004.00714.x; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; Koponen S, 2000, J CEREBR BLOOD F MET, V20, P93, DOI 10.1097/00004647-200001000-00013; Kurschner C, 1999, J NEUROSCI, V19, P7770; LASHER RS, 1972, BRAIN RES, V41, P482, DOI 10.1016/0006-8993(72)90521-5; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Linseman DA, 2003, J NEUROCHEM, V85, P1488, DOI 10.1046/j.1471-4159.2003.09799.x; Miettinen S, 1996, J NEUROSCI, V16, P6236; Miller TM, 1996, J NEUROSCI, V16, P7487; Mora A, 2001, J NEUROCHEM, V78, P199, DOI 10.1046/j.1471-4159.2001.00410.x; NAHORSKI SR, 1991, TRENDS PHARMACOL SCI, V12, P297, DOI 10.1016/0165-6147(91)90581-C; Nijhawan D, 2000, ANNU REV NEUROSCI, V23, P73, DOI 10.1146/annurev.neuro.23.1.73; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Tomomura M, 2003, MOL BRAIN RES, V112, P103, DOI 10.1016/S0169-328X(03)00054-8; Tomomura M, 2001, ONCOGENE, V20, P1022, DOI 10.1038/sj.onc.1204210; Villalba M, 1998, NEUROREPORT, V9, P2381, DOI 10.1097/00001756-199807130-00042; Wang H, 2002, J BIOL CHEM, V277, P49605, DOI 10.1074/jbc.M209335200; Watson A, 1998, J NEUROSCI, V18, P751; WOOD KA, 1993, NEURON, V11, P621, DOI 10.1016/0896-6273(93)90074-2; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zhao LZ, 2003, ACTA PHARMACOL SIN, V24, P539	46	19	19	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35157	35163		10.1074/jbc.M500353200	http://dx.doi.org/10.1074/jbc.M500353200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16100393	hybrid			2022-12-27	WOS:000232561200012
J	Azzouz, TN; Pillai, RS; Dapp, C; Chari, A; Meister, G; Kambach, C; Fischer, U; Schumperli, D				Azzouz, TN; Pillai, RS; Dapp, C; Chari, A; Meister, G; Kambach, C; Fischer, U; Schumperli, D			Toward an assembly line for U7 snRNPs - Interactions of U7-specific Lsm proteins with PRMT5 and SMN complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL MUSCULAR-ATROPHY; ARGININE METHYLTRANSFERASE PRMT5; TUDOR DOMAIN; SYMMETRIC DIMETHYLARGININE; CRYSTAL-STRUCTURE; BINDING-SITE; 20S COMPLEX; X-RAY; RNA; METHYLATION	The survival of motor neurons (SMN) complex mediates the assembly of small nuclear ribonucleoproteins (snRNPs) involved in splicing and histone RNA processing. A crucial step in this process is the binding of Sm proteins onto the SMN protein. For Sm B/B', D1, and D3, efficient binding to SMN depends on symmetrical dimethyl arginine (sDMA) modifications of their RG-rich tails. This methylation is achieved by another entity, the PRMT5 complex. Its pICln subunit binds Sm proteins whereas the PRMT5 subunit catalyzes the methylation reaction. Here, we provide evidence that Lsm10 and Lsm11, which replace the Sm proteins D1 and D2 in the histone RNA processing U7 snRNPs, associate with pICln in vitro and in vivo without receiving sDMA modifications. This implies that the PRMT5 complex is involved in an early stage of U7 snRNP assembly and hence may have a second snRNP assembly function unrelated to sDMA modification. We also show that the binding of Lsm10 and Lsm11 to SMN is independent of any methylation activity. Furthermore, we present evidence for two separate binding sites in SMN for Sm/Lsm proteins. One recognizes Sm domains and the second one, the sDMA-modified RG-tails, which are present only in a subset of these proteins.	Univ Bern, Inst Cell Biol, CH-3012 Bern, Switzerland; Univ Wurzburg, Bioctr, Inst Biochem, D-97074 Wurzburg, Germany; Paul Scherrer Inst, CH-5232 Villigen, Switzerland	University of Bern; University of Wurzburg; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Schumperli, D (corresponding author), Univ Bern, Inst Cell Biol, Baltzerstr 4, CH-3012 Bern, Switzerland.	daniel.schuemperli@izb.unibe.ch	Fischer, Utz/A-4090-2016; Fischer, Utz/AAT-8422-2020; Chari, Ashwin/ABC-5304-2020	Fischer, Utz/0000-0002-1465-6591; Fischer, Utz/0000-0002-1465-6591; Chari, Ashwin/0000-0001-6220-9828; Schumperli, Daniel/0000-0002-9644-134X				Amente S, 2005, FEBS LETT, V579, P683, DOI 10.1016/j.febslet.2004.12.045; Azzouz TN, 2005, NUCLEIC ACIDS RES, V33, P2106, DOI 10.1093/nar/gki516; BALDWIN GS, 1991, BIOCHEM J, V123, P69; Brahms H, 2000, J BIOL CHEM, V275, P17122, DOI 10.1074/jbc.M000300200; Brahms H, 2001, RNA, V7, P1531, DOI 10.1017/S135583820101442X; Branscombe TL, 2001, J BIOL CHEM, V276, P32971, DOI 10.1074/jbc.M105412200; Buhler D, 1999, HUM MOL GENET, V8, P2351, DOI 10.1093/hmg/8.13.2351; Collins BM, 2001, J MOL BIOL, V309, P915, DOI 10.1006/jmbi.2001.4693; Fabbrizio E, 2002, EMBO REP, V3, P641, DOI 10.1093/embo-reports/kvf136; Friesen MJ, 2000, J BIOL CHEM, V275, P26370, DOI 10.1074/jbc.M003299200; Friesen WJ, 2001, MOL CELL BIOL, V21, P8289, DOI 10.1128/MCB.21.24.8289-8300.2001; Friesen WJ, 2001, MOL CELL, V7, P1111, DOI 10.1016/S1097-2765(01)00244-1; GRIMM C, 1993, EMBO J, V12, P1229, DOI 10.1002/j.1460-2075.1993.tb05764.x; Grimmler M, 2005, EMBO REP, V6, P70, DOI 10.1038/sj.embor.7400301; Kambach C, 1999, CURR OPIN STRUC BIOL, V9, P222, DOI 10.1016/S0959-440X(99)80032-3; Kambach C, 1999, CELL, V96, P375, DOI 10.1016/S0092-8674(00)80550-4; Kwak YT, 2003, MOL CELL, V11, P1055, DOI 10.1016/S1097-2765(03)00101-1; Lee JH, 2005, J BIOL CHEM, V280, P3656, DOI 10.1074/jbc.M405295200; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; Meister G, 2000, HUM MOL GENET, V9, P1977, DOI 10.1093/hmg/9.13.1977; Meister G, 2001, CURR BIOL, V11, P1990, DOI 10.1016/S0960-9822(01)00592-9; Meister G, 2002, EMBO J, V21, P5853, DOI 10.1093/emboj/cdf585; Meister G, 2002, TRENDS CELL BIOL, V12, P472, DOI 10.1016/S0962-8924(02)02371-1; Miranda TB, 2004, J BIOL CHEM, V279, P22902, DOI 10.1074/jbc.M312904200; Moore M., 1993, RNA WORLD, P303; Muller B, 1997, SEMIN CELL DEV BIOL, V8, P567, DOI 10.1006/scdb.1997.0182; Mura C, 2001, P NATL ACAD SCI USA, V98, P5532, DOI 10.1073/pnas.091102298; Pal S, 2004, MOL CELL BIOL, V24, P9630, DOI 10.1128/MCB.24.21.9630-9645.2004; Pal S, 2003, MOL CELL BIOL, V23, P7475, DOI 10.1128/MCB.23.21.7475-7487.2003; Paushkin S, 2002, CURR OPIN CELL BIOL, V14, P305, DOI 10.1016/S0955-0674(02)00332-0; Pellizzoni L, 1999, P NATL ACAD SCI USA, V96, P11167, DOI 10.1073/pnas.96.20.11167; Pillai RS, 2003, GENE DEV, V17, P2321, DOI 10.1101/gad.274403; Pillai RS, 2001, EMBO J, V20, P5470, DOI 10.1093/emboj/20.19.5470; Raker VA, 1996, EMBO J, V15, P2256, DOI 10.1002/j.1460-2075.1996.tb00579.x; Richard S, 2005, BIOCHEM J, V388, P379, DOI 10.1042/BJ20040373; Selenko P, 2001, NAT STRUCT BIOL, V8, P27; Sprangers R, 2003, J MOL BIOL, V327, P507, DOI 10.1016/S0022-2836(03)00148-7; STEFANOVIC B, 1995, NUCLEIC ACIDS RES, V23, P3141, DOI 10.1093/nar/23.16.3141; Toro I, 2001, EMBO J, V20, P2293, DOI 10.1093/emboj/20.9.2293; Will CL, 2001, CURR OPIN CELL BIOL, V13, P290, DOI 10.1016/S0955-0674(00)00211-8; WILL CL, 1994, RNA PROCESSING PRACT, V1, P141	41	32	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34435	34440		10.1074/jbc.M505077200	http://dx.doi.org/10.1074/jbc.M505077200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16087681	Green Published, hybrid			2022-12-27	WOS:000232403900009
J	Barth, S; Hury, A; Liang, XH; Michaeli, S				Barth, S; Hury, A; Liang, XH; Michaeli, S			Elucidating the role of H/ACA-like RNAs in trans-splicing and rRNA processing via RNA interference silencing of the Trypanosoma brucei CBF5 pseudouridine synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEOLAR RNAS; LEADER-ASSOCIATED RNA; SMALL NUCLEAR-RNA; 5' SPLICE-SITE; SACCHAROMYCES-CEREVISIAE; U2 SNRNA; LEPTOMONAS-COLLOSOMA; U3 SNORNA; SEQUENCE CONSERVATION; MODIFIED NUCLEOTIDES	Most pseudouridinylation in eukaryotic rRNA and small nuclear RNAs is guided by H/ACA small nucleolar RNAs. In this study, the Trypanosoma brucei pseudouridine synthase, Cbf5p, a snoRNP protein, was identified and silenced by RNAi. Depletion of this protein destabilized all small nucleolar RNAs of the H/ACA-like family. Following silencing, defects in rRNA processing, such as accumulation of precursors and inhibition of cleavages to generate the mature rRNA, were observed. snR30, an H/ACA RNA involved in rRNA maturation, was identified based on prototypical conserved domains characteristic of this RNA in other eukaryotes. The silencing of CBF5 also eliminated the spliced leader-associated (SLA1) RNA that directs pseudouridylation on the spliced leader RNA (SL RNA), which is the substrate for the trans-splicing reaction. Surprisingly, the depletion of Cbf5p not only eliminated the pseudouridine on the SL RNA but also abolished capping at the fourth cap-4 nucleotide. As a result of defects in the SL RNA and decreased modification on the U small nuclear RNA, trans-splicing was inhibited at the first step of the reaction, providing evidence for the essential role of H/ACA RNAs and the modifications they guide on trans-splicing.	Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel	Bar Ilan University	Michaeli, S (corresponding author), Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel.	michaes@mail.biu.ac.il	Michaeli, Shulamit/AAC-8255-2022					Atzorn V, 2004, MOL CELL BIOL, V24, P1769, DOI 10.1128/MCB.24.4.1769-1778.2004; Bachellerie JP, 2002, BIOCHIMIE, V84, P775, DOI 10.1016/S0300-9084(02)01402-5; Bakin AV, 1998, METH MOL B, V77, P297; BALLY M, 1988, NUCLEIC ACIDS RES, V16, P5291, DOI 10.1093/nar/16.12.5291; Behm-Ansmant I, 2003, RNA, V9, P1371, DOI 10.1261/rna.5520403; Bell M, 1999, NUCLEIC ACIDS RES, V27, P3986, DOI 10.1093/nar/27.20.3986; CAMPBELL DA, 1987, J MOL BIOL, V196, P113, DOI 10.1016/0022-2836(87)90514-6; Donmez G, 2004, RNA, V10, P1925, DOI 10.1261/rna.7186504; Dunbar DA, 2000, J BIOL CHEM, V275, P14767, DOI 10.1074/jbc.M001180200; Dungan JM, 1996, EMBO J, V15, P4016, DOI 10.1002/j.1460-2075.1996.tb00775.x; Filipowicz W, 2002, CURR OPIN CELL BIOL, V14, P319, DOI 10.1016/S0955-0674(02)00334-4; Ganot P, 1997, CELL, V89, P799, DOI 10.1016/S0092-8674(00)80263-9; Gu J, 1996, RNA, V2, P909; Hartshorne T, 1999, NUCLEIC ACIDS RES, V27, P3300, DOI 10.1093/nar/27.16.3300; Hartshorne T, 1998, NUCLEIC ACIDS RES, V26, P2541, DOI 10.1093/nar/26.11.2541; HARTSHORNE T, 1993, MOL CELL BIOL, V13, P144, DOI 10.1128/MCB.13.1.144; Hartshorne T, 2001, J MOL BIOL, V313, P733, DOI 10.1006/jmbi.2001.5078; JIANG WD, 1993, MOL CELL BIOL, V13, P4884, DOI 10.1128/MCB.13.8.4884; Kiss T, 2002, CELL, V109, P145, DOI 10.1016/S0092-8674(02)00718-3; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; Lafontaine DLJ, 1998, GENE DEV, V12, P527, DOI 10.1101/gad.12.4.527; Liang XH, 2005, RNA, V11, P619, DOI 10.1261/rna.7174805; Liang XH, 2004, J BIOL CHEM, V279, P5100, DOI 10.1074/jbc.M308264200; Liang XH, 2002, RNA, V8, P237, DOI 10.1017/S1355838202018290; Lin YR, 2003, GENETICS, V165, P543; Liu Q, 2004, J BIOL CHEM, V279, P18210, DOI 10.1074/jbc.M400678200; Ma XJ, 2003, EMBO J, V22, P1889, DOI 10.1093/emboj/cdg191; Mandelboim M, 2003, J BIOL CHEM, V278, P51469, DOI 10.1074/jbc.M308997200; Mandelboim M, 2002, J BIOL CHEM, V277, P35210, DOI 10.1074/jbc.M201910200; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; MORRISSEY JP, 1993, MOL CELL BIOL, V13, P2469, DOI 10.1128/MCB.13.4.2469; Newby MI, 2001, RNA, V7, P833, DOI 10.1017/S1355838201002308; Ni JW, 1997, CELL, V89, P565, DOI 10.1016/S0092-8674(00)80238-X; PALFI Z, 1994, J BIOL CHEM, V269, P30620; Phillips B, 1998, MOL GEN GENET, V260, P20, DOI 10.1007/s004380050866; Roberts TG, 1998, MOL CELL BIOL, V18, P4409, DOI 10.1128/MCB.18.8.4409; Ruggero D, 2003, SCIENCE, V299, P259, DOI 10.1126/science.1079447; Russell AG, 2004, RNA, V10, P1034, DOI 10.1261/rna.7300804; Schnaufer A, 2003, MOL CELL, V12, P307, DOI 10.1016/S1097-2765(03)00286-7; Sturm NR, 1998, J BIOL CHEM, V273, P18689, DOI 10.1074/jbc.273.30.18689; TOLLERVEY D, 1987, EMBO J, V6, P4169, DOI 10.1002/j.1460-2075.1987.tb02763.x; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; UDEM SA, 1972, J MOL BIOL, V65, P227, DOI 10.1016/0022-2836(72)90279-3; Uliel S, 2004, INT J PARASITOL, V34, P445, DOI 10.1016/j.ijpara.2003.10.014; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; Wang ZF, 2001, EMBO J, V20, P4674, DOI 10.1093/emboj/20.17.4674; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; WATKINS KP, 1994, CELL, V76, P171, DOI 10.1016/0092-8674(94)90181-3; Watkins NJ, 1998, RNA, V4, P1549, DOI 10.1017/S1355838298980761; WHITE TC, 1986, NUCLEIC ACIDS RES, V14, P9471, DOI 10.1093/nar/14.23.9471; Xu YX, 1997, P NATL ACAD SCI USA, V94, P8473, DOI 10.1073/pnas.94.16.8473; Xu YX, 2000, J BIOL CHEM, V275, P27883; Yu YT, 1998, EMBO J, V17, P5783, DOI 10.1093/emboj/17.19.5783	53	39	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34558	34568		10.1074/jbc.M503465200	http://dx.doi.org/10.1074/jbc.M503465200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16107339	hybrid			2022-12-27	WOS:000232403900024
J	Osanai, T; Sato, S; Tabata, S; Tanaka, K				Osanai, T; Sato, S; Tabata, S; Tanaka, K			Identification of PamA as a PII-binding membrane protein important in nitrogen-related and sugar-catabolic gene expression in Synechocystis sp PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PROTEIN; PHOSPHOPROTEIN P-II; CYANOBACTERIUM SYNECHOCOCCUS; SIGMA-FACTOR; NTCA; PCC-7942; PRODUCT; ASSIMILATION; DEGRADATION; ACTIVATION	The PII signaling protein plays a pivotal role in the coordination of carbon and nitrogen metabolism in a wide variety of bacteria, Archaea, and plant chloroplasts. By using a yeast two-hybrid screening system, we identified a transmembrane protein, designated PamA ( encoded by sll0985), as a PII-binding protein in Synechocystis sp. PCC 6803. The interaction between PII and PamA was confirmed in vitro, and the interaction was inhibited in the presence of ATP and 2-oxoglutarate, whereas the interaction was not influenced by the phosphorylation status of PII. Northern blot analyses revealed that the transcripts of a set of nitrogen-related genes, including nblA, nrtABCD, and ureG, were decreased in a pamA deletion mutant. The mRNA and protein levels of a group 2 sigma factor SigE were also reduced by the pamA mutation, and transcripts for sugar catabolic genes, such as gap1, zwf, and gnd that are under the control of SigE, were consequently decreased in the pamA mutant. In addition, the pamA mutant was found to be unable to grow in glucose-containing media. These results indicate that PamA has a role in the transcript control of genes for nitrogen and sugar metabolism in Synechocystis sp. PCC 6803.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Kazusa DNA Res Inst, Chiba 2920818, Japan	University of Tokyo; Kazusa DNA Research Institute	Tanaka, K (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	kntanaka@iam.u-tokyo.ac.jp	Sato, Shusei/A-3616-2015; Tanaka, Kan/E-3724-2015	Sato, Shusei/0000-0002-0293-5366; Tanaka, Kan/0000-0001-7560-7884				Aichi M, 2001, J BACTERIOL, V183, P5840, DOI 10.1128/JB.183.20.5840-5847.2001; Aldehni MF, 2003, J BACTERIOL, V185, P2582, DOI 10.1128/JB.185.8.2582-2591.2003; Arcondeguy T, 2001, MICROBIOL MOL BIOL R, V65, P80, DOI 10.1128/MMBR.65.1.80-105.2001; Burillo S, 2004, J BACTERIOL, V186, P3346, DOI 10.1128/JB.186.11.3346-3354.2004; COLLIER JL, 1994, EMBO J, V13, P1039, DOI 10.1002/j.1460-2075.1994.tb06352.x; Forchhammer K, 2004, FEMS MICROBIOL REV, V28, P319, DOI 10.1016/j.femsre.2003.11.001; Forchhammer K, 1997, EUR J BIOCHEM, V244, P869, DOI 10.1111/j.1432-1033.1997.00869.x; FORCHHAMMER K, 1995, J BACTERIOL, V177, P2033, DOI 10.1128/jb.177.8.2033-2040.1995; FORCHHAMMER K, 1994, J BACTERIOL, V176, P84, DOI 10.1128/JB.176.1.84-91.1994; Heinrich A, 2004, MOL MICROBIOL, V52, P1303, DOI 10.1111/j.1365-2958.2004.04058.x; Herrero A, 2001, J BACTERIOL, V183, P411, DOI 10.1128/JB.183.2.411-425.2001; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Hisbergues M, 1999, FEBS LETT, V463, P216, DOI 10.1016/S0014-5793(99)01624-5; Irmler A, 2001, P NATL ACAD SCI USA, V98, P12978, DOI 10.1073/pnas.231254998; Irmler A, 1997, MOL MICROBIOL, V26, P81, DOI 10.1046/j.1365-2958.1997.5521918.x; Kanamaru K, 2001, PLANT CELL PHYSIOL, V42, P1034, DOI 10.1093/pcp/pce155; Koksharova O, 1998, PLANT MOL BIOL, V36, P183, DOI 10.1023/A:1005925732743; Lee HM, 1998, FEBS LETT, V427, P291, DOI 10.1016/S0014-5793(98)00451-7; Los DA, 1997, MOL MICROBIOL, V25, P1167, DOI 10.1046/j.1365-2958.1997.5641912.x; Magasanik B, 2000, TRENDS MICROBIOL, V8, P447, DOI 10.1016/S0966-842X(00)01849-7; Muro-Pastor AM, 2001, J BACTERIOL, V183, P1090, DOI 10.1128/JB.183.3.1090-1095.2001; Muro-Pastor MI, 2001, J BIOL CHEM, V276, P38320; Ninfa AJ, 2000, TRENDS MICROBIOL, V8, P172, DOI 10.1016/S0966-842X(00)01709-1; OMATA T, 1989, P NATL ACAD SCI USA, V86, P6612, DOI 10.1073/pnas.86.17.6612; Osanai T, 2005, J BIOL CHEM, V280, P30653, DOI 10.1074/jbc.M505043200; Palinska KA, 2000, MICROBIOL-SGM, V146, P3099, DOI 10.1099/00221287-146-12-3099; Paz-Yepes J, 2003, FEBS LETT, V543, P42, DOI 10.1016/S0014-5793(03)00384-3; Pivetti CD, 2003, MICROBIOL MOL BIOL R, V67, P66, DOI 10.1128/MMBR.67.1.66-85.2003; REECE KS, 1995, GENE, V165, P141, DOI 10.1016/0378-1119(95)00529-F; Richaud C, 2001, J BACTERIOL, V183, P2989, DOI 10.1128/JB.183.10.2989-2994.2001; RIPPKA R, 1988, METHOD ENZYMOL, V167, P3; SHESTOPALOV VI, 1994, GENETIKA+, V30, P452; STANIER RY, 1977, ANNU REV MICROBIOL, V31, P225, DOI 10.1146/annurev.mi.31.100177.001301; TANAKA K, 1993, P NATL ACAD SCI USA, V90, P3511, DOI 10.1073/pnas.90.8.3511; Tanigawa R, 2002, P NATL ACAD SCI USA, V99, P4251, DOI 10.1073/pnas.072587199; Vazquez-Bermudez MF, 2002, FEBS LETT, V512, P71, DOI 10.1016/S0014-5793(02)02219-6; VEGAPALAS MA, 1992, MOL MICROBIOL, V6, P1853, DOI 10.1111/j.1365-2958.1992.tb01357.x; VEGAPALAS MA, 1990, J BACTERIOL, V172, P643, DOI 10.1128/jb.172.2.643-647.1990; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; Zinchenko VV, 1999, RUSS J GENET+, V35, P228	40	46	47	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34684	34690		10.1074/jbc.M507489200	http://dx.doi.org/10.1074/jbc.M507489200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16109709	hybrid			2022-12-27	WOS:000232403900038
J	Yang, CH; Szeliga, J; Jordan, J; Faske, S; Sever-Chroneos, Z; Dorsett, B; Christian, RE; Settlage, RE; Shabanowitz, J; Hunt, DF; Whitsett, JA; Chroneos, ZC				Yang, CH; Szeliga, J; Jordan, J; Faske, S; Sever-Chroneos, Z; Dorsett, B; Christian, RE; Settlage, RE; Shabanowitz, J; Hunt, DF; Whitsett, JA; Chroneos, ZC			Identification of the surfactant protein A receptor 210 as the unconventional myosin 18A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACTANT PROTEIN-A; RAT ALVEOLAR MACROPHAGES; NITRIC-OXIDE PRODUCTION; PDZ-CONTAINING MYOSIN; DEFICIENT MICE; MYCOBACTERIUM-TUBERCULOSIS; LYMPHOCYTE-PROLIFERATION; SUBCELLULAR-LOCALIZATION; MARROW TRANSPLANTATION; LUNG SURFACTANT	Mass spectrometric characterization of the surfactant protein A (SP-A) receptor 210 (SP-R210) led to the identification of myosin (Myo) XVIIIA and nonmuscle myosin IIA. Antibodies generated against the unique C-terminal tail of MyoXVIIIA revealed that MyoXVIIIA, MyoIIA, and SP-R210 have overlapping tissue distribution, all being highly expressed in myeloid cells, bone marrow, spleen, lymph nodes, and lung. Western blot analysis of COS-1 cells stably transfected with either MyoXVIIIA or MyoIIA indicated that SP-R210 antibodies recognize MyoXVIIIA. Furthermore, MyoXVIIIA but not MyoIIA localized to the surface of COS-1 cells, and most importantly, expression of MyoXVIIIA in COS-1 cells conferred SP-A binding. Western analysis of recombinant MyoXVIIIA domains expressed in bacteria mapped the epitopes of previously derived SP-R210 antibodies to the neck region of MyoXVIIIA. Antibodies raised against the neck domain of MyoXVIIIA blocked the binding of SP-A to macrophages. Together, these findings indicate that MyoXVIIIA constitutes a novel receptor for SP-A.	Univ Texas Hlth Ctr, Ctr Biomed Res, Tyler, TX 75708 USA; Cincinnati Childrens Hosp Med Ctr, Sect Neonatol Perinatal & Pulm Biol, Cincinnati, OH 45229 USA; Univ Virginia, Dept Chem, Charlottesville, VA 22904 USA; Univ Virginia, Dept Chem, Charlottesville, VA 22904 USA; Univ Virginia, Dept Pathol, Charlottesville, VA 22904 USA	Cincinnati Children's Hospital Medical Center; University of Virginia; University of Virginia; University of Virginia	Chroneos, ZC (corresponding author), Univ Texas Hlth Ctr, Ctr Biomed Res, 11937 US Highway 271, Tyler, TX 75708 USA.	zissis.chroneos@uthct.edu	Hunt, Donald F/I-6936-2012	Hunt, Donald F/0000-0003-2815-6368; , Zissis/0000-0002-9841-7917	NHLBI NIH HHS [HL56387, P50 HL056387, R01 HL068127, HL068127] Funding Source: Medline; NIGMS NIH HHS [R01 GM037537, GM37537] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068127, P01HL056387, P50HL056387] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037537] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alcorn JF, 2004, AM J PHYSIOL-LUNG C, V286, pL129, DOI 10.1152/ajplung.00427.2002; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; Beharka AA, 2002, J IMMUNOL, V169, P3565, DOI 10.4049/jimmunol.169.7.3565; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; Borron P, 2000, AM J PHYSIOL-LUNG C, V278, pL840, DOI 10.1152/ajplung.2000.278.4.L840; Borron P, 1996, AM J RESP CELL MOL, V15, P115, DOI 10.1165/ajrcmb.15.1.8679215; Borron P, 1998, AM J PHYSIOL-LUNG C, V275, pL679, DOI 10.1152/ajplung.1998.275.4.L679; Borron PJ, 2002, J IMMUNOL, V169, P5844, DOI 10.4049/jimmunol.169.10.5844; Brinker KG, 2003, AM J PHYSIOL-LUNG C, V284, pL232, DOI 10.1152/ajplung.00187.2002; Brown SD, 1998, BIOCHEM BIOPH RES CO, V248, P879, DOI 10.1006/bbrc.1998.9061; Chabot S, 2003, J IMMUNOL, V171, P995, DOI 10.4049/jimmunol.171.2.995; Chroneos ZC, 1996, J BIOL CHEM, V271, P16375, DOI 10.1074/jbc.271.27.16375; Cox D, 2002, NAT CELL BIOL, V4, P469, DOI 10.1038/ncb805; Cross M, 2004, BIOCHEM J, V380, P243, DOI 10.1042/BJ20031978; Di Cunto F, 1998, J BIOL CHEM, V273, P29706, DOI 10.1074/jbc.273.45.29706; Furmanek A, 2000, ACTA BIOCHIM POL, V47, P781, DOI 10.18388/abp.2000_3996; Furusawa T, 2000, BIOCHEM BIOPH RES CO, V270, P67, DOI 10.1006/bbrc.2000.2377; Gardai SJ, 2003, CELL, V115, P13, DOI 10.1016/S0092-8674(03)00758-X; GAYNOR CD, 1995, J IMMUNOL, V155, P5343; Ghosh S, 2004, BLOOD, V103, P2369, DOI 10.1182/blood-2003-09-3050; Golomb E, 2004, J BIOL CHEM, V279, P2800, DOI 10.1074/jbc.M309981200; Guillot L, 2002, J IMMUNOL, V168, P5989, DOI 10.4049/jimmunol.168.12.5989; HAAGSMAN HP, 1990, BIOCHEMISTRY-US, V29, P8894, DOI 10.1021/bi00490a003; Haddad IY, 2003, AM J PHYSIOL-LUNG C, V285, pL602, DOI 10.1152/ajplung.00088.2003; Hawgood S, 2002, AM J PHYSIOL-LUNG C, V283, pL1002, DOI 10.1152/ajplung.00118.2002; Hey PJ, 1998, GENE, V216, P103, DOI 10.1016/S0378-1119(98)00311-4; Hickman-Davis JM, 2004, AM J RESP CELL MOL, V30, P319, DOI 10.1165/rcmb.2003-0246OC; Hickman-Davis JM, 2001, AM J PHYSIOL-LUNG C, V281, pL517, DOI 10.1152/ajplung.2001.281.3.L517; Hohlfeld JM, 2002, PATHOBIOLOGY, V70, P287, DOI 10.1159/000070744; Ikemoto M, 2000, P NATL ACAD SCI USA, V97, P6538, DOI 10.1073/pnas.100114397; Isogawa Y, 2005, BIOCHEMISTRY-US, V44, P6190, DOI 10.1021/bi0475931; JENSEN ON, 1999, 2 D PROTEOME ANAL PR, V112, P487; Kato M, 2005, J BIOCHEM, V137, P157, DOI 10.1093/jb/mvi015; Kim KY, 2005, J BIOL CHEM, V280, P22769, DOI 10.1074/jbc.M503488200; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; Kramer BW, 2001, AM J RESP CRIT CARE, V163, P158, DOI 10.1164/ajrccm.163.1.2005084; Kuronuma K, 2004, J BIOL CHEM, V279, P21421, DOI 10.1074/jbc.M312490200; LeVine AM, 2002, AM J PHYSIOL-LUNG C, V282, pL563, DOI 10.1152/ajplung.00280.2001; LeVine AM, 1999, AM J RESP CELL MOL, V20, P279, DOI 10.1165/ajrcmb.20.2.3303; LeVine AM, 1998, AM J RESP CELL MOL, V19, P700, DOI 10.1165/ajrcmb.19.4.3254; LeVine AM, 2000, J IMMUNOL, V165, P3934, DOI 10.4049/jimmunol.165.7.3934; Li G, 2002, AM J RESP CELL MOL, V26, P277, DOI 10.1165/ajrcmb.26.3.4584; Linke MJ, 2001, J INFECT DIS, V183, P943, DOI 10.1086/319252; Lopez JP, 2003, J LEUKOCYTE BIOL, V74, P523, DOI 10.1189/jlb.0103027; Madan T, 1997, INFECT IMMUN, V65, P3171, DOI 10.1128/IAI.65.8.3171-3179.1997; McCormack FX, 2002, J CLIN INVEST, V109, P707, DOI 10.1172/JCI200215293; MICHELIS D, 1994, AM J RESP CELL MOL, V11, P692, DOI 10.1165/ajrcmb.11.6.7946398; Mor-Vaknin N, 2003, NAT CELL BIOL, V5, P59, DOI 10.1038/ncb898; Mori K, 2005, BIOCHEM BIOPH RES CO, V326, P491, DOI 10.1016/j.bbrc.2004.11.058; Mori K, 2003, J BIOCHEM, V133, P405, DOI 10.1093/jb/mvg053; Murakami S, 2002, J BIOL CHEM, V277, P6830, DOI 10.1074/jbc.M106671200; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Oberley RE, 2004, AM J PHYSIOL-LUNG C, V287, pL296, DOI 10.1152/ajplung.00440.2003; OLDEN K, 1976, CELL, V8, P383, DOI 10.1016/0092-8674(76)90150-1; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; Pasula R, 1999, J CLIN INVEST, V103, P483, DOI 10.1172/JCI2991; Puntervoll P, 2003, NUCLEIC ACIDS RES, V31, P3625, DOI 10.1093/nar/gkg545; Rey M, 2002, J IMMUNOL, V169, P5410, DOI 10.4049/jimmunol.169.10.5410; Rezniczek GA, 2003, HUM MOL GENET, V12, P3181, DOI 10.1093/hmg/ddg345; Sanchez JC, 1999, METH MOL B, V112, P221; Sano H, 2000, J BIOL CHEM, V275, P22442, DOI 10.1074/jbc.M001107200; Sato M, 2003, J IMMUNOL, V171, P417, DOI 10.4049/jimmunol.171.1.417; Schagat TL, 2003, AM J PHYSIOL-LUNG C, V284, pL140, DOI 10.1152/ajplung.00125.2002; Schagat TL, 2001, J IMMUNOL, V166, P2727, DOI 10.4049/jimmunol.166.4.2727; Shabanowitz J, 2000, MASS SPECTROMETRY IN BIOLOGY & MEDICINE, P163; Shibata Y, 2001, IMMUNITY, V15, P557, DOI 10.1016/S1074-7613(01)00218-7; Song MC, 2000, INFECT IMMUN, V68, P6611, DOI 10.1128/IAI.68.12.6611-6617.2000; Stamme C, 2000, AM J RESP CELL MOL, V23, P772, DOI 10.1165/ajrcmb.23.6.4083; Swanson JA, 1999, J CELL SCI, V112, P307; SZELIGA J, 2003, IN PRESS ANAL BIOCH; TINO MJ, 1996, AM J PHYSIOL, V270, P677; Togo T, 2004, MOL BIOL CELL, V15, P688, DOI 10.1091/mbc.E03-06-0430; van de Wetering JK, 2004, EUR J BIOCHEM, V271, P1229, DOI 10.1111/j.1432-1033.2004.04040.x; Vandivier RW, 2002, J IMMUNOL, V169, P3978, DOI 10.4049/jimmunol.169.7.3978; VANIWAARDEN F, 1990, AM J RESP CELL MOL, V2, P91, DOI 10.1165/ajrcmb/2.1.91; Wang JY, 1998, AM J RESP CRIT CARE, V158, P510, DOI 10.1164/ajrccm.158.2.9709111; Weikert LF, 2000, AM J PHYSIOL-LUNG C, V279, pL216, DOI 10.1152/ajplung.2000.279.2.L216; Weikert LF, 1997, AM J PHYSIOL-LUNG C, V272, pL989, DOI 10.1152/ajplung.1997.272.5.L989; Wilkins MR, 1997, J THEOR BIOL, V186, P7, DOI 10.1006/jtbi.1996.0346; WRIGHT JR, 1993, AM J PHYSIOL, V264, pL338, DOI 10.1152/ajplung.1993.264.4.L338; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266; Xu B, 2004, MOL CELL BIOL, V24, P9198, DOI 10.1128/MCB.24.20.9198-9206.2004; Xu XXS, 2001, DEV BIOL, V232, P255, DOI 10.1006/dbio.2000.0132; Yang SX, 2002, AM J RESP CELL MOL, V27, P297, DOI 10.1165/rcmb.2002-0035OC; YATES JR, 1995, ANAL CHEM, V67, P3202, DOI 10.1021/ac00114a016; Zhu Q, 1997, BIOCHEM BIOPH RES CO, V232, P354, DOI 10.1006/bbrc.1997.6195; [No title captured]	88	44	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34447	34457		10.1074/jbc.M505229200	http://dx.doi.org/10.1074/jbc.M505229200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16087679	Green Accepted, hybrid			2022-12-27	WOS:000232403900011
J	Ma, YM; Pannicke, U; Lu, HH; Niewolik, D; Schwarz, K; Lieber, MR				Ma, YM; Pannicke, U; Lu, HH; Niewolik, D; Schwarz, K; Lieber, MR			The DNA-dependent protein kinase catalytic subunit phosphorylation sites in human artemis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V(D)J RECOMBINATION; RAG PROTEINS; REPAIR; AUTOPHOSPHORYLATION; COMPLEX; IDENTIFICATION; DEFICIENCY; PATHWAY; DOMAIN; DAMAGE	Artemis protein has irreplaceable functions in V( D) J recombination and nonhomologous end joining (NHEJ) as a hairpin and 5' and 3' overhang endonuclease. The kinase activity of the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is necessary in activating Artemis as an endonuclease. Here we report that three basal phosphorylation sites and 11 DNA-PKcs phosphorylation sites within the mammalian Artemis are all located in the C-terminal domain. All but one of these phosphorylation sites deviate from the SQ or TQ motif of DNA-PKcs that was predicted previously from in vitro phosphorylation studies. Phosphatase- treated mammalian Artemis and Artemis that is mutated at the three basal phosphorylation sites still retain DNA- PKcs-dependent endonucleolytic activities, indicating that basal phosphorylation is not required for the activation. In vivo studies of Artemis lacking the C-terminal domain have been reported to be sufficient to complement V( D) J recombination in Artemis null cells. Therefore, the C-terminal domain may have a negative regulatory effect on the Artemis endonucleolytic activities, and phosphorylation by DNA- PKcs in the C-terminal domain may relieve this inhibition.	Univ Ulm, Dept Transfus Med, Inst Clin Transfus Med & Immunogenet, D-89081 Ulm, Germany; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Pathol, Los Angeles, CA 90089 USA; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biol Sci, Los Angeles, CA 90089 USA; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Mol Microbiol & Immunol, Los Angeles, CA 90089 USA	Ulm University; University of Southern California; University of Southern California; University of Southern California; University of Southern California	Schwarz, K (corresponding author), Univ Ulm, Dept Transfus Med, Inst Clin Transfus Med & Immunogenet, D-89081 Ulm, Germany.	klaus.schwarz@medizin.uni-ulm.de; lieber@usc.edu	Pannicke, Ulrich/D-7348-2014	Lieber, Michael/0000-0003-3700-6345; Lieber, Michael/0000-0001-8809-0909				Anderson CW, 1996, CURR TOP MICROBIOL, V217, P91; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; Callebaut I, 2002, NUCLEIC ACIDS RES, V30, P3592, DOI 10.1093/nar/gkf470; Chan DW, 1999, BIOCHEMISTRY-US, V38, P1819, DOI 10.1021/bi982584b; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; Chen L, 2005, CANCER SCI, V96, P134, DOI 10.1111/j.1349-7006.2005.00019.x; de Villartay JP, 2002, CURR OPIN ALLERGY CL, V2, P473, DOI 10.1097/00130832-200212000-00001; Ding Q, 2003, MOL CELL BIOL, V23, P5836, DOI 10.1128/MCB.23.16.5836-5848.2003; Douglas P, 2002, BIOCHEM J, V368, P243, DOI 10.1042/BJ20020973; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; Jung D, 2004, CELL, V116, P299, DOI 10.1016/S0092-8674(04)00039-X; KULESZA P, 1999, THESIS WASHINGTON U; Lee KJ, 2004, DNA REPAIR, V3, P267, DOI 10.1016/j.dnarep.2003.11.005; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Lieber MR, 2004, DNA REPAIR, V3, P817, DOI 10.1016/j.dnarep.2004.03.015; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Meek K, 2004, IMMUNOL REV, V200, P132, DOI 10.1111/j.0105-2896.2004.00162.x; Merkle D, 2002, BIOCHEMISTRY-US, V41, P12706, DOI 10.1021/bi0263558; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Pannicke U, 2004, EMBO J, V23, P1987, DOI 10.1038/sj.emboj.7600206; Poinsignon C, 2004, EUR J IMMUNOL, V34, P3146, DOI 10.1002/eji.200425455; Poinsignon C, 2004, J EXP MED, V199, P315, DOI 10.1084/jem.20031142; Reddy YVR, 2004, J BIOL CHEM, V279, P39408, DOI 10.1074/jbc.M406432200; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Rooney S, 2004, IMMUNOL REV, V200, P115, DOI 10.1111/j.0105-2896.2004.00165.x; Rooney S, 2003, J EXP MED, V197, P553, DOI 10.1084/jem.20021891; Rooney S, 2002, MOL CELL, V10, P1379, DOI 10.1016/S1097-2765(02)00755-4; Schwarz K, 2003, BIOESSAYS, V25, P1061, DOI 10.1002/bies.10344; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Wang JH, 2005, DNA REPAIR, V4, P556, DOI 10.1016/j.dnarep.2005.02.001; Yu YP, 2003, DNA REPAIR, V2, P1239, DOI 10.1016/S1568-7864(03)00143-5; Zhang XS, 2004, MOL CELL BIOL, V24, P9207, DOI 10.1128/MCB.24.20.9207-9220.2004	33	103	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33839	33846		10.1074/jbc.M507113200	http://dx.doi.org/10.1074/jbc.M507113200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16093244	hybrid			2022-12-27	WOS:000232229700020
J	Ren, Y; Liu, WH; Jiang, HB; Jiang, Q; Feng, J				Ren, Y; Liu, WH; Jiang, HB; Jiang, Q; Feng, J			Selective vulnerability of dopaminergic neurons to microtubule depolymerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSONS-DISEASE; TUBULIN POLYMERIZATION; ROTENONE INHIBITION; SUBSTANTIA-NIGRA; IN-VITRO; CELLS; MECHANISM; PROTEINS; MODELS; SYSTEM	Parkinson disease (PD) is characterized by the specific degeneration of dopaminergic (DA) neurons in substantia nigra and has been linked to a variety of environmental and genetic factors. Rotenone, an environmental PD toxin, exhibited much greater toxicity to DA neurons in midbrain neuronal cultures than to non-DA neurons. The effect was significantly decreased by the microtubule-stabilizing drug taxol and mimicked by microtubule-depolymerizing agents such as colchicine or nocodazole. Microtubule depolymerization disrupted vesicular transport along microtubules and caused the accumulation of dopamine vesicles in the soma. This led to increased oxidative stress due to oxidation of cytosolic dopamine leaked from vesicles. Inhibition of dopamine metabolism significantly reduced rotenone toxicity. Thus, our results suggest that microtubule depolymerization induced by PD toxins such as rotenone plays a key role in the selective death of dopaminergic neurons.	SUNY Buffalo, Dept Physiol & Biophys, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Feng, J (corresponding author), SUNY Buffalo, Dept Physiol & Biophys, 124 Sherman Hall, Buffalo, NY 14214 USA.	jianfeng@buffalo.edu		Liu, Wenhua/0000-0003-0903-8497	NINDS NIH HHS [NS41722] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041722] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barrientos A, 1999, J BIOL CHEM, V274, P16188, DOI 10.1074/jbc.274.23.16188; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; BORISY GG, 1972, ANAL BIOCHEM, V50, P373, DOI 10.1016/0003-2697(72)90046-2; BRINKLEY BR, 1974, EXP CELL RES, V85, P41, DOI 10.1016/0014-4827(74)90210-9; Cappelletti G, 1999, J NEUROSCI RES, V56, P28, DOI 10.1002/(SICI)1097-4547(19990401)56:1<28::AID-JNR4>3.0.CO;2-2; Cappelletti G, 2001, CELL BIOL INT, V25, P981, DOI 10.1006/cbir.2001.0772; CHANCE B, 1963, J BIOL CHEM, V238, P418; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Di Monte DA, 2003, LANCET NEUROL, V2, P531, DOI 10.1016/S1474-4422(03)00501-5; Eisenhofer G, 2004, ANN NY ACAD SCI, V1018, P224, DOI 10.1196/annals.1296.027; Feng J, 2000, P NATL ACAD SCI USA, V97, P9287, DOI 10.1073/pnas.97.16.9287; FLOOR E, 1995, J NEUROCHEM, V64, P689; Goldstein LSB, 2003, NEURON, V40, P415, DOI 10.1016/S0896-6273(03)00630-5; Hastings TG, 1996, P NATL ACAD SCI USA, V93, P1956, DOI 10.1073/pnas.93.5.1956; HIMES RH, 1976, P NATL ACAD SCI USA, V73, P4397, DOI 10.1073/pnas.73.12.4397; Jiang HB, 2004, HUM MOL GENET, V13, P1745, DOI 10.1093/hmg/ddh180; JOSHI HC, 1989, J CELL BIOL, V109, P663, DOI 10.1083/jcb.109.2.663; Langston JW, 2002, NEUROTOXICOLOGY, V23, P443, DOI 10.1016/S0161-813X(02)00098-0; Liu YJ, 1997, ANNU REV NEUROSCI, V20, P125; MARSHALL LE, 1978, BIOCHIM BIOPHYS ACTA, V543, P590, DOI 10.1016/0304-4165(78)90315-X; Miller GW, 1999, TRENDS PHARMACOL SCI, V20, P424, DOI 10.1016/S0165-6147(99)01379-6; Ren Y, 2003, J NEUROSCI, V23, P3316; Seo BB, 2002, MOL THER, V6, P336, DOI 10.1006/mthe.2002.0674; Sherer TB, 2003, J NEUROSCI, V23, P10756, DOI 10.1523/jneurosci.23-34-10756.2003; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; SOFIC E, 1991, J NEUROCHEM, V56, P978, DOI 10.1111/j.1471-4159.1991.tb02017.x; Thiruchelvam M, 2000, J NEUROSCI, V20, P9207; TSE C, 1980, J NEUROCHEM, V35, P767, DOI 10.1111/j.1471-4159.1980.tb07072.x; Zecca L, 2003, TRENDS NEUROSCI, V26, P578, DOI 10.1016/j.tins.2003.08.009; Zhao JH, 2003, J CELL SCI, V116, P4011, DOI 10.1242/jcs.00700	31	145	149	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34105	34112		10.1074/jbc.M503483200	http://dx.doi.org/10.1074/jbc.M503483200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16091364	hybrid			2022-12-27	WOS:000232229700051
J	Fujita, K; Oura, F; Nagamine, N; Katayama, T; Hiratake, J; Sakata, K; Kumagai, H; Yamamoto, K				Fujita, K; Oura, F; Nagamine, N; Katayama, T; Hiratake, J; Sakata, K; Kumagai, H; Yamamoto, K			Identification and molecular cloning of a novel glycoside hydrolase family of core 1 type O-glycan-specific endo-alpha-N-acetylgalactosaminidase from Bifidobacterium longum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-D-GALACTOSAMINIDASE; DIPLOCOCCUS-PNEUMONIAE; PARTIAL-PURIFICATION; TRANSGLYCOSYLATION ACTIVITY; MUCIN DEGRADATION; CULTURE-MEDIUM; OLIGOSACCHARIDES; GLYCOSYLATION; PHOSPHORYLASE; ANTIGENS	We found endo-alpha-N-acetylgalactosaminidase in most bifidobacterial strains, which are predominant bacteria in the human colon. This enzyme catalyzes the liberation of galactosyl beta 1,3-N-acetyl-D-galactosamine (Gal beta 1,3GalNAc) alpha-linked to serine or threonine residues from mucin-type glycoproteins. The gene (engBF) encoding the enzyme has been cloned from Bifidobacterium longum JCM 1217. The protein consisted of 1,966 amino acid residues, and the central domain ( 590 - 1381 amino acid residues) exhibited 31 - 53% identity to hypothetical proteins of several bacteria including Clostridium perfringens and Streptococcus pneumoniae. The recombinant protein expressed in Escherichia coli liberated Gal beta 1,3GalNAc disaccharide from Gal beta 1,3GalNAc alpha 1pNP and asialofetuin, but did not release GalNAc, Gal beta 1,3(GlcNAc beta 1,6) GalNAc, GlcNAc beta 1,3GalNAc, and Gal beta 1,3GlcNAc from each p-nitrophenyl (pNP) substrate, and also did not release sialo-oligosaccharides from fetuin, indicating its strict substrate specificity for the Core 1-type structure. The stereochemical course of hydrolysis was determined by H-1 NMR and was found to be retention. Site-directed mutagenesis of a total of 22 conserved Asp and Glu residues suggested that Asp-682 and Asp-789 are critical residues for the catalytic activity of the enzyme. The enzyme also exhibited transglycosylation activity toward various mono- and disaccharides and 1-alkanols, demonstrating its potential to synthesize neoglycoconjugates. This is the first report for the isolation of a gene encoding endo-alpha-N-acetylgalactosaminidase from any organisms and for the establishment of a new glycoside hydrolase family (GH family 101).	Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068502, Japan; Ishikawa Prefectural Univ, Res Inst Bioresources & Biotechnol, Nonoichi, Ishikawa 9218836, Japan; Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol Program, Kawaguchi, Saitama 3320012, Japan	Kyoto University; Ishikawa Prefecture University; Kyoto University; Japan Science & Technology Agency (JST)	Fujita, K (corresponding author), Kagoshima Univ, Fac Agr, Dept Biochem Sci & Technol, Korimoto 1-21-24, Kagoshima 8900065, Japan.	kfujita@lif.kyoto.u.ac.jp		Fujita, Kiyotaka/0000-0002-3780-3750; Katayama, Takane/0000-0003-4009-7874				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ashida H, 2000, ARCH BIOCHEM BIOPHYS, V373, P394, DOI 10.1006/abbi.1999.1565; Ashida H, 2001, CARBOHYD RES, V330, P487, DOI 10.1016/S0008-6215(01)00008-8; BAILEY RW, 1960, J CHROMATOGR, V4, P206, DOI 10.1016/S0021-9673(01)98394-3; BERNET MF, 1993, APPL ENVIRON MICROB, V59, P4121, DOI 10.1128/AEM.59.12.4121-4128.1993; BHAVANANDAN VP, 1976, BIOCHEM BIOPH RES CO, V70, P738, DOI 10.1016/0006-291X(76)90654-9; Brooks MM, 1997, GLYCOCONJUGATE J, V14, P183, DOI 10.1023/A:1018585604073; CARTRON JP, 1979, NATURE, V282, P621, DOI 10.1038/282621a0; Derensy-Dron D, 1999, BIOTECHNOL APPL BIOC, V29, P3; ENDO Y, 1976, J BIOCHEM-TOKYO, V80, P1; FAN JQ, 1988, AGR BIOL CHEM TOKYO, V52, P1715; Femia AP, 2002, CARCINOGENESIS, V23, P1953, DOI 10.1093/carcin/23.11.1953; GIBSON GR, 1994, J APPL BACTERIOL, V77, P412, DOI 10.1111/j.1365-2672.1994.tb03443.x; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; GROSS V, 1989, FEBS LETT, V247, P323, DOI 10.1016/0014-5793(89)81361-4; Hooper LV, 2001, SCIENCE, V292, P1115, DOI 10.1126/science.1058709; HOSKINS LC, 1985, J CLIN INVEST, V75, P944, DOI 10.1172/JCI111795; HUANG CC, 1972, J BIOL CHEM, V247, P6737; IshiiKarakasa I, 1997, EUR J BIOCHEM, V247, P709, DOI 10.1111/j.1432-1033.1997.00709.x; ISHIIKARAKASA I, 1992, BIOCHEM J, V288, P475, DOI 10.1042/bj2880475; Katayama T, 2004, J BACTERIOL, V186, P4885, DOI 10.1128/JB.186.15.4885-4893.2004; Kitaoka M, 2005, APPL ENVIRON MICROB, V71, P3158, DOI 10.1128/AEM.71.6.3158-3162.2005; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON G, 1988, J BIOL CHEM, V263, P10790; MATSUURA H, 1988, J BIOL CHEM, V263, P3314; NAIM HY, 1992, J BIOL CHEM, V267, P25494; Novak J, 2001, J CLIN IMMUNOL, V21, P310, DOI 10.1023/A:1012284402054; Ouwehand A., 2002, European Journal of Nutrition, V41; Sambrook J., 1983, MOL CLONING LAB MANU; Schell MA, 2002, P NATL ACAD SCI USA, V99, P14422, DOI 10.1073/pnas.212527599; Sediva A, 1999, NEPHROL DIAL TRANSPL, V14, P2885, DOI 10.1093/ndt/14.12.2885; SIMON GL, 1986, DIG DIS SCI S, V31, P147; SPRINGER GF, 1995, CANCER DETECT PREV, V19, P173; SPRINGER GF, 1984, SCIENCE, V224, P1198, DOI 10.1126/science.6729450; UMEMOTO J, 1977, J BIOL CHEM, V252, P8609; Varki A., 1999, ESSENTIALS GLYCOBIOL	36	120	127	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37415	37422		10.1074/jbc.M506874200	http://dx.doi.org/10.1074/jbc.M506874200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16141207	hybrid			2022-12-27	WOS:000233044500016
J	Iguchi, H; Ikeda, Y; Okamura, M; Tanaka, T; Urashima, Y; Ohguchi, H; Takayasu, S; Kojima, N; Iwasaki, S; Ohashi, R; Jiang, SY; Hasegawa, G; Ioca, RX; Magoori, K; Sumi, K; Maejima, T; Uchida, A; Naito, M; Osborne, TF; Yanagisawa, M; Yamamoto, TT; Kodama, T; Sakai, J				Iguchi, H; Ikeda, Y; Okamura, M; Tanaka, T; Urashima, Y; Ohguchi, H; Takayasu, S; Kojima, N; Iwasaki, S; Ohashi, R; Jiang, SY; Hasegawa, G; Ioca, RX; Magoori, K; Sumi, K; Maejima, T; Uchida, A; Naito, M; Osborne, TF; Yanagisawa, M; Yamamoto, TT; Kodama, T; Sakai, J			SOX6 attenuates glucose-stimulated insulin secretion by repressing PDX1 transcriptional actvity and is down-regulated in hyperinsulinemic obese mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEINS; GENE-TRANSCRIPTION; IDENTIFICATION; EXPRESSION; ACTIVATION; CELLS; METABOLISM; REQUIRES; CLEAVAGE; SREBPS	In obesity-related insulin resistance, pancreatic islets compensate for insulin resistance by increasing secretory capacity. Here, we report the identification of sex-determining region Y-box 6 (SOX6), a member of the high mobility group box superfamily of transcription factors, as a co-repressor for pancreatic-duodenal homeobox factor-1 (PDX1). SOX6 mRNA levels were profoundly reduced by both a long term high fat feeding protocol in normal mice and in genetically obese ob/ob mice on a normal chow diet. Interestingly, we show that SOX6 is expressed in adult pancreatic insulin-producing beta-cells and that overexpression of SOX6 decreased glucose-stimulated insulin secretion, which was accompanied by decreased ATP/ADP ratio, Ca2+ mobilization, proinsulin content, and insulin gene expression. In a complementary fashion, depletion of SOX6 by small interfering RNAs augmented glucose-stimulated insulin secretion in insulinoma mouse MIN6 and rat INS-1E cells. These effects can be explained by our mechanistic studies that show SOX6 acts to suppress PDX1 stimulation of the insulin II promoter through a direct protein/protein interaction. Furthermore, SOX6 retroviral expression decreased acetylation of histones H3 and H4 in chromatin from the promoter for the insulin II gene, suggesting that SOX6 may decrease PDX1 stimulation through changes in chromatin structure at specific promoters. These results suggest that perturbations in transcriptional regulation that are coordinated through SOX6 and PDX1 in beta-cells may contribute to the beta-cell adaptation in obesity-related insulin resistance.	Univ Tokyo, Adv Sci & Technol Res Ctr, Lab Syst Biol & Med, Tokyo 1538904, Japan; Japan Sci & Technol Agcy, Yanagisawa Orphan Receptor Project, Tokyo 1350064, Japan; Niigata Univ, Grad Sch Med & Dent Sci, Dept Cellular Funct, Div Cellular & Mol Pathol, Niigata 9518510, Japan; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92717 USA; Univ Texas, SW Med Ctr Dallas, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr Dallas, Dept Mol Genet, Dallas, TX 75390 USA; Tohoku Univ, Inst Dev Aging & Canc, Ctr Adv Genome Res, Sendai, Miyagi 9818555, Japan	University of Tokyo; Japan Science & Technology Agency (JST); Niigata University; University of California System; University of California Irvine; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Tohoku University	Sakai, J (corresponding author), Univ Tokyo, Adv Sci & Technol Res Ctr, Lab Syst Biol & Med, Tokyo 1538904, Japan.	jmsakai-tky@umin.ac.jp	Ohashi, Riuko/AAH-1415-2019	Ohashi, Riuko/0000-0001-5820-7870; Sakai, Juro/0000-0003-4043-1035				ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Brissova M, 2002, J BIOL CHEM, V277, P11225, DOI 10.1074/jbc.M111272200; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Detimary P, 1996, J BIOL CHEM, V271, P20559, DOI 10.1074/jbc.271.34.20559; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; Dutta S, 2001, P NATL ACAD SCI USA, V98, P1065, DOI 10.1073/pnas.031561298; Fujino T, 2003, P NATL ACAD SCI USA, V100, P229, DOI 10.1073/pnas.0133792100; Gauthier BR, 2004, J BIOL CHEM, V279, P31121, DOI 10.1074/jbc.M405030200; Hani EH, 1999, J CLIN INVEST, V104, pR41, DOI 10.1172/JCI7469; Hui HX, 2002, EUR J ENDOCRINOL, V146, P129, DOI 10.1530/eje.0.1460129; HWUNG YP, 1990, MOL CELL BIOL, V10, P1784, DOI 10.1128/MCB.10.4.1784; Ikeda Y, 2005, BIOCHEM BIOPH RES CO, V333, P778, DOI 10.1016/j.bbrc.2005.06.005; Ikeda Y, 2001, J BIOL CHEM, V276, P34259, DOI 10.1074/jbc.M103848200; Iype T, 2005, J BIOL CHEM, V280, P16798, DOI 10.1074/jbc.M414381200; Janjic D, 1999, BIOCHEM PHARMACOL, V57, P639, DOI 10.1016/S0006-2952(98)00346-3; Johnson JD, 2003, J CLIN INVEST, V111, P1147, DOI 10.1172/JCI200316537; Kasimiotis H, 2000, DIABETES, V49, P555, DOI 10.2337/diabetes.49.4.555; Kitamura T, 1998, INT J HEMATOL, V67, P351; Kulkarni RN, 2004, J CLIN INVEST, V114, P828, DOI 10.1172/JCI200421845; Laybutt DR, 2003, J BIOL CHEM, V278, P2997, DOI 10.1074/jbc.M210581200; Le Lay J, 2004, J BIOL CHEM, V279, P22228, DOI 10.1074/jbc.M312673200; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; LIBERMANN TA, 1993, MOL CELL BIOL, V13, P5957, DOI 10.1128/MCB.13.10.5957; Liu YQ, 2002, J BIOL CHEM, V277, P39163, DOI 10.1074/jbc.M207157200; Macfarlane WM, 1999, J CLIN INVEST, V104, pR33, DOI 10.1172/JCI7449; Merglen A, 2004, ENDOCRINOLOGY, V145, P667, DOI 10.1210/en.2003-1099; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Moede T, 1999, FEBS LETT, V461, P229, DOI 10.1016/S0014-5793(99)01446-5; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Mosley AL, 2004, J BIOL CHEM, V279, P54241, DOI 10.1074/jbc.M410379200; Mosley AL, 2003, J BIOL CHEM, V278, P19660, DOI 10.1074/jbc.M212375200; Mosley AL, 2004, MOL ENDOCRINOL, V18, P2279, DOI 10.1210/me.2003-0463; OKAMOTO H, 1981, MOL CELL BIOCHEM, V37, P43, DOI 10.1007/BF02355886; Okita K, 1999, BIOCHEM BIOPH RES CO, V263, P566, DOI 10.1006/bbrc.1999.1412; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; Peshavaria M, 2000, MOL ENDOCRINOL, V14, P1907, DOI 10.1210/me.14.12.1907; Petersen HV, 1998, FEBS LETT, V431, P362, DOI 10.1016/S0014-5793(98)00776-5; Qiu Y, 2002, MOL CELL BIOL, V22, P412, DOI 10.1128/MCB.22.2.412-420.2002; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Rhodes CJ, 2005, SCIENCE, V307, P380, DOI 10.1126/science.1104345; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; Sakai J, 1998, J BIOL CHEM, V273, P5785, DOI 10.1074/jbc.273.10.5785; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; Schepers GE, 2002, DEV CELL, V3, P167, DOI 10.1016/S1534-5807(02)00223-X; Smits P, 2001, DEV CELL, V1, P277, DOI 10.1016/S1534-5807(01)00003-X; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; Tanaka T, 2003, P NATL ACAD SCI USA, V100, P15924, DOI 10.1073/pnas.0306981100; Vaulont S, 2000, J BIOL CHEM, V275, P31555, DOI 10.1074/jbc.R000016200; WHELAN J, 1989, MOL CELL BIOL, V9, P3253, DOI 10.1128/MCB.9.8.3253; Wilson M, 2002, CURR OPIN GENET DEV, V12, P441, DOI 10.1016/S0959-437X(02)00323-4; Wollheim CB, 2000, DIABETOLOGIA, V43, P265, DOI 10.1007/s001250050044; Yamamoto J, 2004, J BIOL CHEM, V279, P16954, DOI 10.1074/jbc.M312079200	53	66	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37669	37680		10.1074/jbc.M505392200	http://dx.doi.org/10.1074/jbc.M505392200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16148004	hybrid			2022-12-27	WOS:000233044500044
J	Li, ZY; Agellon, LB; Vance, DE				Li, ZY; Agellon, LB; Vance, DE			Phosphatidylcholine homeostasis and liver failure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE; RAT HEPATOCYTES; ESSENTIAL NUTRIENT; CDP-CHOLINE; BIOSYNTHESIS; N-METHYLTRANSFERASE-2; PURIFICATION; METHYLATION; DISRUPTION; EXPRESSION	In mammals, the only endogenous pathway for choline biosynthesis is the methylation of phosphatidylethanolamine to phosphatidylcholine ( PC) by phosphatidylethanolamine N-methyltransferase ( PEMT) coupled to PC degradation. Complete choline deprivation in mice by feeding Pemt(-/-) mice a choline-deficient ( CD) diet decreases hepatic PC by 50% and is lethal within 5 days. PC secretion into bile is mediated by a PC-specific flippase, multiple drug-resistant protein 2 (MDR2). Here, we report that mice that lack both PEMT and MDR2 and are fed a CD diet survive for > 90 days. Unexpectedly, the amount of PC also decreases by 50% in the livers of Mdr2(-/-)/ Pemt(-/-) mice. The Mdr2(-/-)/ Pemt(-/-) mice adapt to the severe choline deprivation via choline recycling by induction of phospholipase A(2), choline kinase, and CTP: phosphocholine cytidylyltransferase activities and by a strikingly decreased expression of choline oxidase. The ability of Mdr2(-/-)/ Pemt(-/-) mice to survive complete choline deprivation suggests that acute lethality in CD-Pemt(-/-) mice results from rapid depletion of hepatic PC via biliary secretion.	Univ Alberta, Dept Biochem, Heritage Med Res Ctr 328, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Li, ZY (corresponding author), Univ Alberta, Dept Biochem, Heritage Med Res Ctr 328, Edmonton, AB T6G 2S2, Canada.	dennis.vance@ualberta.ca		Li, Zhaoyu/0000-0002-1136-2758				Abdelmalek MF, 2001, AM J GASTROENTEROL, V96, P2711; Adibhatla R, 2005, NEUROCHEM RES, V30, P15, DOI 10.1007/s11064-004-9681-8; BEST CH, 1954, ANN NY ACAD SCI, V57, P646, DOI 10.1111/j.1749-6632.1954.tb36441.x; Best CH, 1932, J PHYSIOL-LONDON, V75, P405, DOI 10.1113/jphysiol.1932.sp002899; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Blusztajn JK, 1998, SCIENCE, V281, P794, DOI 10.1126/science.281.5378.794; Borgstrom B., 1976, LIPID ABSORPTION BIO, P65; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cui Z, 1996, J BIOL CHEM, V271, P2839, DOI 10.1074/jbc.271.5.2839; Cui Z, 1997, BBA-LIPID LIPID MET, V1346, P10, DOI 10.1016/S0005-2760(97)00012-X; DATKO AH, 1988, PLANT PHYSIOL, V88, P854, DOI 10.1104/pp.88.3.854; DeLong CJ, 1999, J BIOL CHEM, V274, P29683, DOI 10.1074/jbc.274.42.29683; Farber SA, 2001, SCIENCE, V292, P1385, DOI 10.1126/science.1060418; Fioravanti M, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000269.pub3; HISE MK, 1983, ANAL BIOCHEM, V135, P78, DOI 10.1016/0003-2697(83)90733-9; KLAUNIG JE, 1981, IN VITRO CELL DEV B, V17, P913; KO KWS, 1986, J BIOL CHEM, V261, P7846; Krug E L, 1981, Methods Enzymol, V72, P347; Kuipers F, 1997, Subcell Biochem, V28, P295; MCCLUER RH, 1986, ADV CHROMATOGR, V25, P309; PELECH SL, 1981, J BIOL CHEM, V256, P8283; Reo NV, 2002, BBA-MOL CELL BIOL L, V1580, P171, DOI 10.1016/S1388-1981(01)00202-5; ROBINS SJ, 1975, AM J PHYSIOL, V229, P598, DOI 10.1152/ajplegacy.1975.229.3.598; SCHNEIDER WJ, 1978, EUR J BIOCHEM, V85, P181, DOI 10.1111/j.1432-1033.1978.tb12226.x; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; SUNDLER R, 1975, J BIOL CHEM, V250, P3359; Vance D.E., 2002, BIOCH LIPIDS LIPOPRO, P205; Vance DE, 1997, BBA-LIPID LIPID MET, V1348, P142, DOI 10.1016/S0005-2760(97)00108-2; Voelker DR, 2003, J LIPID RES, V44, P441, DOI 10.1194/jlr.R200020-JLR200; WAITE M, 1990, ADV EXP MED BIOL, V279, P1; Walkey CJ, 1998, J BIOL CHEM, V273, P27043, DOI 10.1074/jbc.273.42.27043; Walkey CJ, 1997, P NATL ACAD SCI USA, V94, P12880, DOI 10.1073/pnas.94.24.12880; WEINHOLD PA, 1974, BIOCHEMISTRY-US, V13, P5135, DOI 10.1021/bi00722a013; YAO ZM, 1988, J BIOL CHEM, V263, P2998; Zeisel SH, 2000, NUTRITION, V16, P669, DOI 10.1016/S0899-9007(00)00349-X; ZEISEL SH, 1994, ANNU REV NUTR, V14, P269, DOI 10.1146/annurev.nu.14.070194.001413; ZEISEL SH, 1991, FASEB J, V5, P2093, DOI 10.1096/fasebj.5.7.2010061	37	106	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37798	37802		10.1074/jbc.M508575200	http://dx.doi.org/10.1074/jbc.M508575200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16144842	hybrid			2022-12-27	WOS:000233044500059
J	Marjanovic, JA; Li, ZY; Stojanovic, A; Du, XP				Marjanovic, JA; Li, ZY; Stojanovic, A; Du, XP			Stimulatory roles of nitric-oxide synthase 3 and guanylyl cyclase in platelet activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CYCLIC-GMP; GUANOSINE 3',5'-MONOPHOSPHATE; INTEGRIN ALPHA(IIB)BETA(3); SODIUM-NITROPRUSSIDE; ENDOTHELIAL-CELLS; L-ARGININE; AGGREGATION; INHIBITION; MICE	Nitric oxide ( NO) stimulates soluble guanylyl cyclase and, thus, enhances cyclic guanosine monophosphate ( cGMP) levels. It is a currently prevailing concept that NO inhibits platelet activation. This concept, however, does not fully explain why platelet agonists stimulate NO production. Here we show that a major platelet NO synthase ( NOS) isoform, NOS3, plays a stimulatory role in platelet secretion and aggregation induced by low doses of platelet agonists. Furthermore, we show that NOS3 promotes thrombosis in vivo. The stimulatory role of NOS is mediated by soluble guanylyl cyclase and results from a cGMP-dependent stimulation of platelet granule secretion. These findings delineate a novel signaling pathway in which agonists sequentially activate NOS3, elevate cGMP, and induce platelet secretion and aggregation. Our data also suggest that NO plays a biphasic role in platelet activation, a stimulatory role at low NO concentrations and an inhibitory role at high NO concentrations.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Du, XP (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave,Rm E403, Chicago, IL 60612 USA.	xdu@uic.edu			NHLBI NIH HHS [R01 HL068819, HL68819, R01 HL062350, HL62350] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068819, R01HL062350] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTONIADES HN, 1979, P NATL ACAD SCI USA, V76, P1809, DOI 10.1073/pnas.76.4.1809; Azula FJ, 1996, MOL PHARMACOL, V50, P367; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Chen JH, 2004, BLOOD, V104, P1703, DOI 10.1182/blood-2003-10-3428; Day SM, 2004, THROMB HAEMOSTASIS, V92, P486, DOI 10.1055/s-0037-1613739; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Du X, 1997, THROMB HAEMOSTASIS, V78, P96; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; Feil R, 2003, CIRC RES, V93, P907, DOI 10.1161/01.RES.0000100390.68771.CC; Freedman JE, 1997, J CLIN INVEST, V100, P350, DOI 10.1172/JCI119540; FUSTER V, 1999, LANCET S2, V353, P5; HAWRYLOWICZ CM, 1989, J IMMUNOL, V143, P4015; IGNARRO LJ, 1993, THROMB HAEMOSTASIS, V70, P148; Jang EK, 2002, BRIT J HAEMATOL, V117, P664, DOI 10.1046/j.1365-2141.2002.03479.x; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; Li ZY, 2001, J BIOL CHEM, V276, P42226, DOI 10.1074/jbc.M106129200; Li ZY, 2004, J BIOL CHEM, V279, P42469, DOI 10.1074/jbc.M401532200; Li ZY, 2003, J BIOL CHEM, V278, P30725, DOI 10.1074/jbc.M301838200; Li ZY, 2003, BLOOD, V101, P4423, DOI 10.1182/blood-2002-10-3210; Li ZY, 2003, CELL, V112, P77, DOI 10.1016/S0092-8674(02)01254-0; MALINSKI T, 1993, BIOCHEM BIOPH RES CO, V194, P960, DOI 10.1006/bbrc.1993.1914; Marshall SJ, 2004, BLOOD, V103, P2601, DOI 10.1182/blood-2003-09-3319; Massberg S, 1999, J EXP MED, V189, P1255, DOI 10.1084/jem.189.8.1255; Matsushita K, 2003, CELL, V115, P139, DOI 10.1016/S0092-8674(03)00803-1; MAURICE DH, 1990, MOL PHARMACOL, V37, P671; McDonald LJ, 1996, P SOC EXP BIOL MED, V211, P1; MELLION BT, 1981, BLOOD, V57, P946; MELLION BT, 1983, MOL PHARMACOL, V23, P653; Ozaki M, 2002, J CLIN INVEST, V110, P331, DOI 10.1172/JCI200215215; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P5193, DOI 10.1073/pnas.87.13.5193; Randriamboavonjy V, 2004, J EXP MED, V199, P347, DOI 10.1084/jem.20030694; Reed GL, 2000, BLOOD, V96, P3334; Ruggeri ZM, 2002, NAT MED, V8, P1227, DOI 10.1038/nm1102-1227; SASE K, 1995, LIFE SCI, V57, P2049, DOI 10.1016/0024-3205(95)02191-K; SAXON A, 1976, BLOOD, V47, P957; Schlossmann J, 2003, ANN MED, V35, P21, DOI 10.1080/07853890310004093; Schrammel A, 1996, MOL PHARMACOL, V50, P1; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; Shi WB, 2002, CIRCULATION, V105, P2078, DOI 10.1161/01.CIR.0000015853.59427.32; SOMERVILLE B, 1975, CLIN CHIM ACTA, V65, P399, DOI 10.1016/0009-8981(75)90267-3; Woulfe D, 2004, J CLIN INVEST, V113, P441, DOI 10.1172/JCI200420267; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; Yan BX, 2000, J BIOL CHEM, V275, P39964, DOI 10.1074/jbc.M007041200; Zhang J, 1996, J BIOL CHEM, V271, P6265, DOI 10.1074/jbc.271.11.6265	47	64	69	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37430	37438		10.1074/jbc.M506518200	http://dx.doi.org/10.1074/jbc.M506518200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16144836	hybrid			2022-12-27	WOS:000233044500018
J	Mishra, S; Mishra, JP; Gee, K; McManus, DC; LaCasse, EC; Kumar, A				Mishra, S; Mishra, JP; Gee, K; McManus, DC; LaCasse, EC; Kumar, A			Distinct role of calmodulin and calmodulin-dependent protein kinase-II in lipopolysaccharide and tumor necrosis factor-alpha-mediated suppression of apoptosis and antiapoptotic c-IAP2 gene expression in human monocytic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; COLON-CANCER CELLS; N-TERMINAL KINASE; CELLULAR INHIBITOR; HUMAN NEUTROPHILS; BACTERIAL LIPOPOLYSACCHARIDE; INTRACELLULAR CALCIUM; SIGNAL-TRANSDUCTION; CYTOCHROME-C; ACTIVATION	Exposure of phagocytic cells to bacterial endotoxin ( lipopolysaccharide; LPS) or inflammatory cytokines confers antiapoptotic survival signals; however, in the absence of the appropriate stimulus, monocytes are programmed to undergo apoptosis. Macrophage survival may thus influence inflammatory and immune responses and susceptibility to microbial pathogens. Herein, we demonstrate that LPS and the proinflammatory cytokine, tumor necrosis factor-alpha(TNF-alpha), enhance monocytic cell survival through the induction of the antiapoptotic c-IAP2 gene in a human promonocytic THP-1 cell line. We also investigated the role of upstream signaling molecules including the mitogen-activated protein kinases, phosphatidylinositol 3-kinase, and the calcium signaling pathways in the regulation of c-IAP2 expression and eventual survival of monocytic cells. Our results suggest that LPS and TNF-alpha-induced c-IAP2 expression was regulated by calmodulin (CaM) through the activation of calmodulin-dependent protein kinase-II ( CaMKII). In addition, CaM and CaMKII regulated c-IAP2 expression in LPS- and TNF-alpha-stimulated cells through NF-kappa B activation. Moreover, the CaM/ CaMKII pathway also regulated LPS- and TNF-alpha-mediated inhibition of apoptosis in these cells. Taken together, these results suggest that LPS- and TNF-alpha-induced c-IAP2 expression and its associated antiapoptotic survival signals in THP-1 cells are regulated selectively by CaM/ CaMKII through NF-kappa B activation.	Univ Ottawa, Childrens Hosp Eastern Ontario, Res Inst, Div Virol,Infect Dis & Vaccine Res Ctr, Ottawa, ON K1H 8L1, Canada; Univ Ottawa, Dept Pathol & Lab Med, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada; Aegera Therapeut Inc, Ottawa, ON K1H 8L1, Canada	University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; University of Ottawa	Kumar, A (corresponding author), Univ Ottawa, Childrens Hosp Eastern Ontario, Res Inst, Div Virol,Infect Dis & Vaccine Res Ctr, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.	akumar@uottawa.ca	Gee, Katrina/H-3093-2016	Gee, Katrina/0000-0002-7535-2882				Amrani Y, 2000, Respir Res, V1, P49, DOI 10.1186/rr12; Antonsson A, 2003, MOL CELL BIOL, V23, P1418, DOI 10.1128/MCB.23.4.1418-1427.2003; Aramburu J, 2000, CURR TOP CELL REGUL, V36, P237; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Bultynck G, 2003, BIOCHEM BIOPH RES CO, V311, P1181, DOI 10.1016/j.bbrc.2003.08.084; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Colbran RJ, 2004, CURR OPIN NEUROBIOL, V14, P318, DOI 10.1016/j.conb.2004.05.008; Cui XF, 2000, BBA-GEN SUBJECTS, V1524, P178, DOI 10.1016/S0304-4165(00)00155-0; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Feske S, 2000, J IMMUNOL, V165, P297, DOI 10.4049/jimmunol.165.1.297; Flad HD, 1999, PATHOBIOLOGY, V67, P291, DOI 10.1159/000028082; Gee K, 2003, J BIOL CHEM, V278, P37275, DOI 10.1074/jbc.M302309200; Han H, 2005, J EXP MED, V202, P353, DOI 10.1084/jem.20050778; Hasegawa T, 2003, BLOOD, V101, P1164, DOI 10.1182/blood-2002-05-1505; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Holcik M, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-5; Hong SY, 2000, J BIOL CHEM, V275, P18022, DOI 10.1074/jbc.M001202200; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu P, 2004, J BIOL CHEM, V279, P49420, DOI 10.1074/jbc.M407700200; Hu XJ, 2005, J BIOL CHEM, V280, P9498, DOI 10.1074/jbc.M410455200; Hughes K, 2001, J BIOL CHEM, V276, P36008, DOI 10.1074/jbc.M106125200; Hughes K, 1998, FEBS LETT, V441, P132, DOI 10.1016/S0014-5793(98)01537-3; Imoto I, 2002, CANCER RES, V62, P4860; Imoto I, 2001, CANCER RES, V61, P6629; Kasri NN, 2004, EMBO J, V23, P312, DOI 10.1038/sj.emboj.7600037; Kim KM, 2000, EXP MOL MED, V32, P246, DOI 10.1038/emm.2000.41; Kim Y, 2004, BIOCHEM BIOPH RES CO, V314, P695, DOI 10.1016/j.bbrc.2003.12.153; LETARI O, 1991, J IMMUNOL, V147, P980; Lilienbaum A, 2003, MOL CELL BIOL, V23, P2680, DOI 10.1128/MCB.23.8.2680-2698.2003; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Lo CJ, 1996, ARCH SURG-CHICAGO, V131, P44; Ma W, 2004, J IMMUNOL, V172, P318, DOI 10.4049/jimmunol.172.1.318; Ma W, 2001, J BIOL CHEM, V276, P13664, DOI 10.1074/jbc.M011157200; MANGAN DF, 1991, J IMMUNOL, V147, P3408; Manna SK, 1999, J IMMUNOL, V162, P1510; MCLEISH KR, 1989, INFLAMMATION, V13, P681, DOI 10.1007/BF00914312; Meffert MK, 2003, NAT NEUROSCI, V6, P1072, DOI 10.1038/nn1110; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; Mishra JP, 2005, J BIOL CHEM, V280, P26825, DOI 10.1074/jbc.M500244200; NGHIEM P, 1993, J BIOL CHEM, V268, P5471; Nishihara H, 2003, P NATL ACAD SCI USA, V100, P8921, DOI 10.1073/pnas.1533221100; Nishihara H, 2004, J BIOL CHEM, V279, P26176, DOI 10.1074/jbc.M313346200; Peppiatt CM, 2003, CELL CALCIUM, V34, P97, DOI 10.1016/S0143-4160(03)00026-5; PORTOLES MT, 1991, BIOCHIM BIOPHYS ACTA, V1092, P1; PRPIC V, 1987, J IMMUNOL, V139, P526; QU JM, 1991, BIOCHEM SOC T, V19, pS95, DOI 10.1042/bst019095s; RajcanSeparovic E, 1996, GENOMICS, V37, P404, DOI 10.1006/geno.1996.0579; RICHTER J, 1990, P NATL ACAD SCI USA, V87, P9472, DOI 10.1073/pnas.87.23.9472; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sanna MG, 1998, P NATL ACAD SCI USA, V95, P6015, DOI 10.1073/pnas.95.11.6015; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SCHUMANN MA, 1993, J BIOL CHEM, V268, P2134; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Stull JT, 2001, J BIOL CHEM, V276, P2311, DOI 10.1074/jbc.R000030200; Sutterwala FS, 1997, J EXP MED, V185, P1977, DOI 10.1084/jem.185.11.1977; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang QD, 2003, J BIOL CHEM, V278, P51091, DOI 10.1074/jbc.M306541200; Waterhouse NJ, 2001, J CELL BIOL, V153, P319, DOI 10.1083/jcb.153.2.319; Webster JC, 2002, ENDOCRINOLOGY, V143, P3866, DOI 10.1210/en.2002-220188; Wilkinson MF, 1996, FASEB J, V10, P785, DOI 10.1096/fasebj.10.7.8635696; Young SS, 1999, MAMM GENOME, V10, P44; Yu CR, 2003, CANCER RES, V63, P1822; Zou TT, 2004, AM J PHYSIOL-CELL PH, V286, pC1009, DOI 10.1152/ajpcell.00480.2003	74	26	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37536	37546		10.1074/jbc.M504971200	http://dx.doi.org/10.1074/jbc.M504971200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16154993	hybrid			2022-12-27	WOS:000233044500030
J	Burgess, BR; Schuck, P; Garboczi, DN				Burgess, BR; Schuck, P; Garboczi, DN			Dissection of merozoite surface protein 3, a representative of a family of Plasmodium falciparum surface proteins, reveals an oligomeric and highly elongated molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE PREDICTION; SIZE-DISTRIBUTION ANALYSIS; ANALYTICAL ULTRACENTRIFUGATION; CIRCULAR-DICHROISM; SEDIMENTATION; MALARIA; ANTIGEN; DOMAIN; MACROMOLECULES; CONSERVATION	Vaccination with the merozoite surface protein 3 (MSP3) of Plasmodium falciparum protects against infection in primates and is under development as a vaccine against malaria in humans. MSP3 is secreted and associates with the parasite membrane but lacks a predicted transmembrane domain or a glycosylphosphatidylinositol anchor. Its role in the invasion of red blood cells is unclear. To study MSP3, we produced recombinant full-length protein and found by size exclusion chromatography that the apparent size of MSP3 was much larger than predicted from its sequence. To investigate this, we used several biophysical techniques to characterize the full-length molecule and four smaller polypeptides. The MSP3 polypeptides contain a large amount of alpha-helix and random coil secondary structure as measured by circular dichroism spectroscopy. The full-length MSP3 forms highly elongated dimers and tetramers as revealed by chemical cross-linking and analytical ultracentrifugation. The dimer is formed through a leucine zipper-like domain located between residues 306 and 362 at the C terminus. Two dimers interact through their C termini to form a tetramer with an apparent association constant of 3 mu M. Sedimentation velocity experiments determined that the MSP3 molecules are highly extended in solution (some with f/f(0)>2). These data, in light of the recent discoveries of three other Plasmodium proteins containing very similar C-terminal sequences, suggest that the members of this newly identified family may adopt highly extended and oligomeric novel structures capable of interacting with a red blood cell at relatively long distances.	NIAID, Struct Biol Sect, Immunogenet Lab, NIH, Rockville, MD 20852 USA; NIH, Div Bioengn & Phys Sci, Off Director, Off Res Serv,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA	Garboczi, DN (corresponding author), NIAID, Struct Biol Sect, Immunogenet Lab, NIH, Twinbrook 2,12441 Parklawn Dr, Rockville, MD 20852 USA.	dgarboczi@niaid.nih.gov	Schuck, Peter/AAA-6888-2020	Schuck, Peter/0000-0002-8859-6966	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000881] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [Z01OD010485] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		BALBO A, 2005, IN PRESS PROTEIN PRO; BANNISTER LH, 1986, CELL TISSUE RES, V245, P281, DOI 10.1007/BF00213933; Carvalho LJM, 2004, SCAND J IMMUNOL, V59, P363, DOI 10.1111/j.0300-9475.2004.01409.x; Chen J, 1995, P NATL ACAD SCI USA, V92, P12205, DOI 10.1073/pnas.92.26.12205; Dam J, 2005, BIOPHYS J, V89, P619, DOI 10.1529/biophysj.105.059568; Frishman D, 1997, PROTEINS, V27, P329, DOI 10.1002/(SICI)1097-0134(199703)27:3<329::AID-PROT1>3.0.CO;2-8; Galinski MR, 1999, MOL BIOCHEM PARASIT, V101, P131, DOI 10.1016/S0166-6851(99)00063-8; Galinski MR, 1996, PARASITOL TODAY, V12, P20, DOI 10.1016/0169-4758(96)80641-7; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; GILBERT GA, 1959, PROC R SOC LON SER-A, V250, P377, DOI 10.1098/rspa.1959.0070; Hisaeda H, 2002, J INFECT DIS, V185, P657, DOI 10.1086/339187; HUDSON DE, 1983, J IMMUNOL, V130, P2886; Kimura T, 2002, J AM CHEM SOC, V124, P11596, DOI 10.1021/ja026639f; King RD, 1997, COMPUT APPL BIOSCI, V13, P473; KUNTZ ID, 1971, J AM CHEM SOC, V93, P514, DOI 10.1021/ja00731a036; Lebowitz J, 2002, PROTEIN SCI, V11, P2067, DOI 10.1110/ps.0207702; McColl DJ, 1997, MOL BIOCHEM PARASIT, V90, P21, DOI 10.1016/S0166-6851(97)00130-8; MCCOLL DJ, 1994, MOL BIOCHEM PARASIT, V68, P53, DOI 10.1016/0166-6851(94)00149-9; Mills KE, 2002, MOL MICROBIOL, V43, P1401, DOI 10.1046/j.1365-2958.2002.02834.x; MULHERN TD, 1995, BIOCHEMISTRY-US, V34, P3479, DOI 10.1021/bi00011a001; OEUVRAY C, 1994, BLOOD, V84, P1594; Okenu DMN, 2000, MOL BIOCHEM PARASIT, V109, P185, DOI 10.1016/S0166-6851(00)00245-0; Pearce JA, 2005, MOL BIOCHEM PARASIT, V139, P141, DOI 10.1016/j.molbiopara.2004.09.012; Pearce JA, 2004, EXP PARASITOL, V108, P186, DOI 10.1016/j.exppara.2004.07.017; Pearce JA, 2004, INFECT IMMUN, V72, P2321, DOI 10.1128/IAI.72.4.2321-2328.2004; Perkins SJ, 2001, BIOPHYS CHEM, V93, P129, DOI 10.1016/S0301-4622(01)00216-2; Schuck P, 1999, BIOPHYS J, V76, P2288, DOI 10.1016/S0006-3495(99)77384-4; Schuck P, 2002, BIOPHYS J, V82, P1096, DOI 10.1016/S0006-3495(02)75469-6; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SCHUCK P, 2000, CURRENT PROTOCOLS IM; Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342; SODEOKA M, 1993, BIOORG MED CHEM LETT, V3, P1089, DOI 10.1016/S0960-894X(00)80293-0; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Svedberg T, 1940, THE ULTRACENTRIFUGE; Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2; Trucco C, 2001, MOL BIOCHEM PARASIT, V112, P91, DOI 10.1016/S0166-6851(00)00350-9; VANHOLDE KE, 2005, PRINCIPLES PHYS BIOC, P223; Vistica J, 2004, ANAL BIOCHEM, V326, P234, DOI 10.1016/j.ab.2003.12.014; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Yikilmaz E, 2005, BIOCHEMISTRY-US, V44, P8470, DOI 10.1021/bi0500325	40	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37236	37245		10.1074/jbc.M506753200	http://dx.doi.org/10.1074/jbc.M506753200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16135515	hybrid			2022-12-27	WOS:000232901800082
J	Kim, YK; Lee, JY; Cho, HS; Lee, SS; Ha, HJ; Kim, S; Choi, D; Pai, HS				Kim, YK; Lee, JY; Cho, HS; Lee, SS; Ha, HJ; Kim, S; Choi, D; Pai, HS			Inactivation of organellar glutamyl- and seryl-tRNA synthetases leads to developmental arrest of chloroplasts and mitochondria in higher plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; PLASTID RIBOSOMAL-PROTEIN; NUCLEAR GENE-EXPRESSION; ARABIDOPSIS-THALIANA; PHASEOLUS-VULGARIS; GENOME; TOBACCO; MAIZE; DNA; VIRUS	Aminoacyl-tRNA synthetases (ARSs) are key enzymes involved in protein translation, and both cytosolic and organellar forms are present in the genomes of eukaryotes. In this study, we investigated cellular effects of depletion of organellar forms of ARS using virus-induced gene silencing (VIGS) in Nicotiana benthamiana. VIGS of NbERS and NbSRS, which encode organellar GluRS and SerRS, respectively, resulted in a severe leaf-yellowing phenotype. The NbERS and NbSRS genes were ubiquitously expressed in plant tissues, and induced in response to light. Green fluorescent protein (GFP) fusion proteins of the full-length glutamyl-tRNA synthetase (ERS) and seryl-tRNA synthetase (SRS) of Arabidopsis and GFP fusions to the N-terminal extension of these proteins were all dual-targeted to chloroplasts and mitochondria. At the cell level, depletion of NbERS and NbSRS resulted in dramatically reduced numbers of chloroplasts with reduced sizes and chlorophyll content. The numbers and/or physiology of mitochondria were also severely affected. The abnormal chloroplasts lacked most of the thylakoid membranes and appeared to be degenerating, whereas some of them showed doublet morphology, indicating defective chloroplast division. Pulse-field gel electrophoresis analyses demonstrated that chloroplast DNA in subgenomic sizes is the predominant form in the abnormal chloroplasts. Interestingly, despite severe abnormalities in chloroplasts and mitochondria, expression of many nuclear genes encoding chloroplast- or mitochondria-targeted proteins, and chlorophyll biosynthesis genes remained unchanged in the ERS and SRS VIGS lines. This is the first report to analyze the effect of ARS disruption on organelle development in plants.	Korea Res Inst Biosci & Biotechnol, Lab Plant Genom, Taejon 305333, South Korea; Myongji Univ, Div Biosci & Bioinformat, Yongin 449728, Kyonggi Do, South Korea; Chungbuk Univ, Dept Biochem, Cheongju, Chungcheongbuk, South Korea; Seoul Natl Univ, Natl Creat Res Initiat Ctr ARS Network, Seoul 151742, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Myongji University; Chungbuk National University; Seoul National University (SNU)	Choi, D (corresponding author), Korea Res Inst Biosci & Biotechnol, Lab Plant Genom, Taejon 305333, South Korea.	doil@kribb.re.kr; hspai@mju.ac.kr	Choi, Doil/F-5002-2011; Kim, Sunghoon/AAE-8314-2020					Ahlert D, 2003, P NATL ACAD SCI USA, V100, P15730, DOI 10.1073/pnas.2533668100; Ahn JW, 2004, PLANT J, V38, P969, DOI 10.1111/j.1365-313X.2004.02102.x; Akashi K, 1998, FEBS LETT, V431, P39, DOI 10.1016/S0014-5793(98)00717-0; Austin MJ, 2002, SCIENCE, V295, P2077, DOI 10.1126/science.1067747; Azevedo C, 2002, SCIENCE, V295, P2073, DOI 10.1126/science.1067554; Browning KS, 1996, PLANT MOL BIOL, V32, P107, DOI 10.1007/BF00039380; Burch-Smith TM, 2004, PLANT J, V39, P734, DOI 10.1111/j.1365-313X.2004.02158.x; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; Chen XJ, 1999, TRENDS CELL BIOL, V9, P222, DOI 10.1016/S0962-8924(99)01554-8; Cho HS, 2004, PLANT CELL, V16, P2665, DOI 10.1105/tpc.104.024281; Duchene AM, 2001, BIOCHEM BIOPH RES CO, V285, P1213, DOI 10.1006/bbrc.2001.5303; Duchene AM, 2001, J BIOL CHEM, V276, P15275, DOI 10.1074/jbc.M011525200; Garesse R, 2001, GENE, V263, P1, DOI 10.1016/S0378-1119(00)00582-5; Ge S J, 1998, Cell Res, V8, P119; Glover KE, 2001, J BIOL CHEM, V276, P639, DOI 10.1074/jbc.M007708200; GUILLEMAUT P, 1975, BIOCHIM BIOPHYS ACTA, V378, P64, DOI 10.1016/0005-2787(75)90137-9; Hanaoka M, 2005, EMBO REP, V6, P545, DOI 10.1038/sj.embor.7400411; Handa H, 2003, NUCLEIC ACIDS RES, V31, P5907, DOI 10.1093/nar/gkg795; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; Ibba M, 2001, EMBO REP, V2, P382; Kubo T, 2000, NUCLEIC ACIDS RES, V28, P2571, DOI 10.1093/nar/28.13.2571; Kumar R, 1996, MOL GEN GENET, V252, P404, DOI 10.1007/BF02173005; KUROIWA T, 1981, PLANT CELL PHYSIOL, V22, P381; Larkin RM, 2003, SCIENCE, V299, P902, DOI 10.1126/science.1079978; Lee SW, 2004, J CELL SCI, V117, P3725, DOI 10.1242/jcs.01342; Lee YJ, 2001, PLANT CELL, V13, P2175, DOI 10.1105/tpc.13.10.2175; Lilly JW, 2001, PLANT CELL, V13, P245, DOI 10.1105/tpc.13.2.245; Liu Y, 2002, PLANT CELL, V14, P1483, DOI 10.1105/tpc.002493; Lopez-Juez E, 1998, PLANT PHYSIOL, V118, P803, DOI 10.1104/pp.118.3.803; Ma ZR, 2004, PLANT J, V37, P92, DOI 10.1046/j.1365-313X.2003.01942.x; Magnard JL, 2004, PLANT PHYSIOL, V134, P649, DOI 10.1104/pp.103.030767; MARECHALDROUARD L, 1993, ANNU REV PLANT PHYS, V44, P13, DOI 10.1146/annurev.pp.44.060193.000305; Menand B, 1998, P NATL ACAD SCI USA, V95, P11014, DOI 10.1073/pnas.95.18.11014; Mireau H, 1996, PLANT CELL, V8, P1027, DOI 10.1105/tpc.8.6.1027; Miyata S, 1998, CURR GENET, V34, P216, DOI 10.1007/s002940050389; Notsu Y, 2002, MOL GENET GENOMICS, V268, P434, DOI 10.1007/s00438-002-0767-1; OELMULLER R, 1989, PHOTOCHEM PHOTOBIOL, V49, P229, DOI 10.1111/j.1751-1097.1989.tb04101.x; Oldenburg DJ, 2004, J MOL BIOL, V344, P1311, DOI 10.1016/j.jmb.2004.10.001; Osteryoung KW, 2003, SCIENCE, V302, P1698, DOI 10.1126/science.1082192; Osteryoung KW, 2001, ANNU REV PLANT PHYS, V52, P315, DOI 10.1146/annurev.arplant.52.1.315; Oubrahim H, 2001, P NATL ACAD SCI USA, V98, P9505, DOI 10.1073/pnas.181319898; Peeters N, 2001, BBA-MOL CELL RES, V1541, P54, DOI 10.1016/S0167-4889(01)00146-X; Peeters NM, 2000, J MOL EVOL, V50, P413, DOI 10.1007/s002390010044; Pfannschmidt T, 2003, TRENDS PLANT SCI, V8, P33, DOI 10.1016/S1360-1385(02)00005-5; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Ratcliff F, 2001, PLANT J, V25, P237, DOI 10.1046/j.0960-7412.2000.00942.x; Rokov-Plavec J, 2002, ARCH BIOCHEM BIOPHYS, V397, P40, DOI 10.1006/abbi.2001.2600; Rowan BA, 2004, CURR GENET, V46, P176, DOI 10.1007/s00294-004-0515-7; Sato N, 2001, TRENDS PLANT SCI, V6, P151, DOI 10.1016/S1360-1385(01)01888-X; Small I, 1999, J HERED, V90, P333, DOI 10.1093/jhered/90.3.333; Souciet G, 1999, EUR J BIOCHEM, V266, P848, DOI 10.1046/j.1432-1327.1999.00922.x; STEINMETZ A, 1986, METHOD ENZYMOL, V118, P212; Strand A, 2003, NATURE, V421, P79, DOI 10.1038/nature01204; Sugiyama Y, 2005, MOL GENET GENOMICS, V272, P603, DOI 10.1007/s00438-004-1075-8; SUSEK RE, 1993, CELL, V74, P787, DOI 10.1016/0092-8674(93)90459-4; TAYLOR WC, 1989, ANNU REV PLANT PHYS, V40, P211, DOI 10.1146/annurev.pp.40.060189.001235; Unseld M, 1997, NAT GENET, V15, P57, DOI 10.1038/ng0197-57; Uwer U, 1998, PLANT CELL, V10, P1277, DOI 10.1105/tpc.10.8.1277; Zhang H, 2001, ANAL BIOCHEM, V298, P170, DOI 10.1006/abio.2001.5348; Zhang JZ, 1997, P NATL ACAD SCI USA, V94, P7349, DOI 10.1073/pnas.94.14.7349	60	29	42	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37098	37106		10.1074/jbc.M504805200	http://dx.doi.org/10.1074/jbc.M504805200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16107332	hybrid			2022-12-27	WOS:000232901800068
J	Miranda, JJL; Maillett, DH; Soman, J; Olson, JS				Miranda, JJL; Maillett, DH; Soman, J; Olson, JS			Thermoglobin, oxygen-avid hemoglobin in a bacterial hyperthermophile	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE DIOXYGENASE; LIGAND-BINDING PROPERTIES; SPERM-WHALE MYOGLOBIN; ASCARIS HEMOGLOBIN; ESCHERICHIA-COLI; VITREOSCILLA HEMOGLOBIN; ALCALIGENES-EUTROPHUS; ANGSTROM RESOLUTION; BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE	The hemoglobin family of proteins, ubiquitous in all domains of life, evolved from an ancestral protein of primordial function to extant hemoglobins that perform a myriad of functions with diverged biochemical properties. Study of homologs in bacterial hyperthermophiles may shed light on both mechanisms of adaptation to extreme conditions and the nature of the ancestral protein. A hemoglobin was identified in Aquifex aeolicus, cloned, recombinantly expressed, purified, and characterized. This hemoglobin is monomeric, resistant to thermal and chemical denaturation, pentacoordinate in the ferrous deoxygenated state, and oxygen-avid. The oxygen equilibrium dissociation constant is approximately 1 nM at room temperature, due in part to a hydrogen bond between the bound ligand and a tyrosine residue in the distal pocket. These biochemical properties of A. aeolicus thermoglobin, AaTgb, may have been shared by the ancestral hemoglobin, thus suggesting possible primordial functions and providing a starting point for consequent evolution of the hemoglobin family.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; Rice Univ, Keck Ctr Computat Biol, Houston, TX 77005 USA	Harvard University; Rice University; Rice University	Miranda, JJL (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 250 Longwood Ave, Boston, MA 02115 USA.	jjmirand@fas.harvard.edu		Olson, John/0000-0002-0760-5403	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035649] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47020] Funding Source: Medline; NIGMS NIH HHS [GM 35649] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHENBACHRICHTER L, 1987, SYST APPL MICROBIOL, V9, P34, DOI 10.1016/S0723-2020(87)80053-X; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ArredondoPeter R, 1997, PLANT PHYSIOL, V115, P1259, DOI 10.1104/pp.115.3.1259; Ascoli F, 1981, Methods Enzymol, V76, P72; BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; Bolognesi M, 1999, J MOL BIOL, V291, P637, DOI 10.1006/jmbi.1999.2975; Brown JR, 2001, NAT GENET, V28, P281, DOI 10.1038/90129; BURGGRAF S, 1992, SYST APPL MICROBIOL, V15, P352, DOI 10.1016/S0723-2020(11)80207-9; Burmester T, 2002, MOL BIOL EVOL, V19, P416, DOI 10.1093/oxfordjournals.molbev.a004096; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; DEBAERE I, 1994, P NATL ACAD SCI USA, V91, P1594, DOI 10.1073/pnas.91.4.1594; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; Draghi F, 2002, J BIOL CHEM, V277, P7509, DOI 10.1074/jbc.M109206200; Duff SMG, 1997, J BIOL CHEM, V272, P16746, DOI 10.1074/jbc.272.27.16746; Ermler U, 1995, EMBO J, V14, P6067, DOI 10.1002/j.1460-2075.1995.tb00297.x; Farres J, 2005, BIOCHEMISTRY-US, V44, P4125, DOI 10.1021/bi047389d; Freitas TAK, 2005, J INORG BIOCHEM, V99, P23, DOI 10.1016/j.jinorgbio.2004.10.024; Freitas TAK, 2004, P NATL ACAD SCI USA, V101, P6675, DOI 10.1073/pnas.0308657101; Gardner AM, 2000, J BIOL CHEM, V275, P12581, DOI 10.1074/jbc.275.17.12581; Gardner PR, 2005, J INORG BIOCHEM, V99, P247, DOI 10.1016/j.jinorgbio.2004.10.003; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; Giangiacomo L, 2001, BIOCHEMISTRY-US, V40, P9311, DOI 10.1021/bi0101143; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; Hardison RC, 1996, P NATL ACAD SCI USA, V93, P5675, DOI 10.1073/pnas.93.12.5675; HARDMAN KD, 1966, J BIOL CHEM, V241, P432; Hou SB, 2000, NATURE, V403, P540, DOI 10.1038/35000570; Ilari A, 2002, J BIOL CHEM, V277, P23725, DOI 10.1074/jbc.M202228200; IWAASA H, 1989, J MOL BIOL, V208, P355, DOI 10.1016/0022-2836(89)90395-1; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; KLOEK AP, 1994, J BIOL CHEM, V269, P2377; Kundu S, 2003, TRENDS PLANT SCI, V8, P387, DOI 10.1016/S1360-1385(03)00163-8; Lecomte JTJ, 2005, CURR OPIN STRUC BIOL, V15, P290, DOI 10.1016/j.sbi.2005.05.008; Liong EC, 2001, J BIOL CHEM, V276, P9093, DOI 10.1074/jbc.M008593200; LIU CY, 1974, J BIOL CHEM, V249, P4261; Moens L, 1996, MOL BIOL EVOL, V13, P324, DOI 10.1093/oxfordjournals.molbev.a025592; Nisbet EG, 2001, NATURE, V409, P1083, DOI 10.1038/35059210; Ochman H, 2000, NATURE, V405, P299, DOI 10.1038/35012500; Ollesch G, 1999, EUR J BIOCHEM, V262, P396, DOI 10.1046/j.1432-1327.1999.00381.x; Olson J S, 1981, Methods Enzymol, V76, P631; Olson JS, 2003, METH MOLEC MED, V82, P65; Panne D, 2004, EMBO J, V23, P4384, DOI 10.1038/sj.emboj.7600453; Park KW, 2002, J BIOL CHEM, V277, P33334, DOI 10.1074/jbc.M203820200; Pesce A, 2000, EMBO J, V19, P2424, DOI 10.1093/emboj/19.11.2424; Pesce A, 2004, J BIOL CHEM, V279, P33662, DOI 10.1074/jbc.M403597200; Pesce A, 2002, STRUCTURE, V10, P725, DOI 10.1016/S0969-2126(02)00763-3; Phillips GN, 1999, J PHYS CHEM B, V103, P8817, DOI 10.1021/jp9918205; PITULLE C, 1994, INT J SYST BACTERIOL, V44, P620, DOI 10.1099/00207713-44-4-620; POTTS M, 1992, SCIENCE, V256, P1690, DOI 10.1126/science.256.5064.1690; RAMSAY G, 1995, BIOPHYS J, V69, P701, DOI 10.1016/S0006-3495(95)79945-3; Riggs AF, 1998, J EXP BIOL, V201, P1073; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; Scott EE, 2000, J BIOL CHEM, V275, P27129; Smith L., 2003, THESIS RICE U HOUSTO; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; Tarricone C, 1997, STRUCTURE, V5, P497, DOI 10.1016/S0969-2126(97)00206-2; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Trent JT, 2002, J BIOL CHEM, V277, P19538, DOI 10.1074/jbc.M201934200; VANASSENDELFT OW, 1975, ANAL BIOCHEM, V69, P43, DOI 10.1016/0003-2697(75)90563-1; VASUDEVAN SG, 1991, MOL GEN GENET, V226, P49, DOI 10.1007/BF00273586; Vinogradov SN, 2005, P NATL ACAD SCI USA, V102, P11385, DOI 10.1073/pnas.0502103102; WAKABAYASHI S, 1986, NATURE, V322, P481, DOI 10.1038/322481a0; Weber RE, 2001, PHYSIOL REV, V81, P569, DOI 10.1152/physrev.2001.81.2.569; Wittenberg JB, 2002, J BIOL CHEM, V277, P871, DOI 10.1074/jbc.R100058200; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; Wu GH, 2003, ADV MICROB PHYSIOL, V47, P255, DOI 10.1016/S0065-2911(03)47005-7; YANG J, 1995, P NATL ACAD SCI USA, V92, P4224, DOI 10.1073/pnas.92.10.4224; Zhang W, 2005, BIOPHYS J, V88, P2801, DOI 10.1529/biophysj.104.047936; Zhang W, 2003, STRUCTURE, V11, P1097, DOI 10.1016/S0969-2126(03)00169-2	68	17	17	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36754	36761		10.1074/jbc.M505918200	http://dx.doi.org/10.1074/jbc.M505918200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16135523	hybrid			2022-12-27	WOS:000232901800029
J	Okamoto, K; Isohashi, F				Okamoto, K; Isohashi, F			Macromolecular translocation inhibitor II (Zn2+-binding protein, parathymosin) interacts with the glucocorticoid receptor and enhances transcription in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTHYMOSIN-ALPHA BINDS; NUCLEAR ANTIGEN 3C; HISTONE H1; RAT-LIVER; MESSENGER-RNA; C-MYC; PURIFICATION; CHROMATIN; LOCALIZATION; COACTIVATOR	Macromolecular translocation inhibitor II (MTI-II), which was first identified as an in vitro inhibitor of binding between the highly purified glucocorticoid receptor (GR) and isolated nuclei, is an 11.5-kDa Zn2+-binding protein that is also known as ZnBP or parathymosin. MTI-II is a small nuclear acidic protein that is highly conserved in rats, cows, and humans and widely distributed in mammalian tissues, yet its physiological function is unknown. To elucidate its in vivo function in relation to GR, we transiently transfected mammalian cells with an expression plasmid encoding MTI-II. Unexpectedly, we found that the expression of MTI-II enhances the transcriptional activity of GR. The magnitude of the transcriptional enhancement induced by MTI-II is comparable with that induced by the steroid receptor coactivator SRC-1. In contrast, MTI-II had little effect on the transcriptional activity of estrogen receptor. Immunoprecipitation analysis showed that in the presence of glucocorticoid hormone, GR coprecipitates with MTI-II, and, vice versa, MTI-II coprecipitates with GR. The expression of various deletion mutants of MTI-II revealed that the central acidic domain is essential for the enhancement of GR-dependent transcription. Microscopic analysis of MTI-II fused to green fluorescent protein and GR fused to red fluorescent protein in living HeLa cells showed that MTI-II colocalizes with GR in discrete subnuclear domains in a hormone-dependent manner. Coexpression of MTI-II with the coactivator SRC-1 or p300 further enhances GR-dependent transcription. Immunoprecipitation analysis showed that in the presence of glucocorticoid hormone, p300 and CREB-binding protein are coprecipitated with MTI-II. Furthermore, the knockdown of endogenous MTI-II by RNAi reduces the transcriptional activity of GR in cells. Moreover, expression of MTI-II enhances the glucocorticoid-dependent transcription of the endogenous glucocorticoid-inducible enzyme in cells. Taken together, these results indicate that MTI-II enhances GR-dependent transcription via a direct interaction with GR in vivo. Thus, MTI-II is a new member of the GR-coactivator complex.	St Marianna Univ, Sch Med, Dept Biochem, Miyamae Ku, Kanagawa 2168511, Japan	Saint Marianna University	Okamoto, K (corresponding author), St Marianna Univ, Sch Med, Dept Biochem, Miyamae Ku, Sugao 2-16-1, Kanagawa 2168511, Japan.	k2oka@marianna-u.ac.jp						Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; BRAND IA, 1986, J BIOL CHEM, V261, P5892; BRAND IA, 1991, EUR J CELL BIOL, V54, P157; BRAND IA, 1991, J BIOL CHEM, V266, P20984; Castro JM, 1996, BIOCHEM BIOPH RES CO, V224, P140, DOI 10.1006/bbrc.1996.0997; CLINTON M, 1989, ARCH BIOCHEM BIOPHYS, V269, P256, DOI 10.1016/0003-9861(89)90107-0; CLINTON M, 1989, BIOCHEM BIOPH RES CO, V158, P855, DOI 10.1016/0006-291X(89)92801-5; CLINTON M, 1991, P NATL ACAD SCI USA, V88, P6608, DOI 10.1073/pnas.88.15.6608; Cotter MA, 2000, MOL CELL BIOL, V20, P5722, DOI 10.1128/MCB.20.15.5722-5735.2000; DiazJullien C, 1996, BBA-PROTEIN STRUCT M, V1296, P219, DOI 10.1016/0167-4838(96)00072-6; Dion V, 2003, J BIOL CHEM, V278, P11495, DOI 10.1074/jbc.M211938200; EARNSHAW WC, 1987, J CELL BIOL, V105, P1479, DOI 10.1083/jcb.105.4.1479; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; Gomez-Marquez J, 1998, BIOCHEM J, V333, P1; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; Hall DB, 2002, J BIOL CHEM, V277, P46043, DOI 10.1074/jbc.M208911200; HARITOS AA, 1985, P NATL ACAD SCI USA, V82, P1050, DOI 10.1073/pnas.82.4.1050; HARITOS AA, 1984, P NATL ACAD SCI-BIOL, V81, P1008, DOI 10.1073/pnas.81.4.1008; HARITOS AA, 1985, P NATL ACAD SCI USA, V82, P343, DOI 10.1073/pnas.82.2.343; Hyodo M, 2001, J CHROMATOGR B, V765, P89, DOI 10.1016/S0378-4347(01)00408-X; ISOHASHI F, 1984, J STEROID BIOCHEM, V20, P1117; Karetsou Z, 1998, NUCLEIC ACIDS RES, V26, P3111, DOI 10.1093/nar/26.13.3111; Karetsou Z, 2002, EMBO REP, V3, P361, DOI 10.1093/embo-reports/kvf071; Knight JS, 2003, J VIROL, V77, P4261, DOI 10.1128/JVI.77.7.4261-4272.2003; KOMIYAMA T, 1986, P NATL ACAD SCI USA, V83, P1242, DOI 10.1073/pnas.83.5.1242; Kondili K, 1996, EUR J BIOCHEM, V242, P67, DOI 10.1111/j.1432-1033.1996.0067r.x; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; Martic G, 2005, J BIOL CHEM, V280, P16143, DOI 10.1074/jbc.M410175200; Martini PGV, 2000, MOL CELL BIOL, V20, P6224, DOI 10.1128/MCB.20.17.6224-6232.2000; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Molenda HA, 2003, BIOL REPROD, V69, P1449, DOI 10.1095/biolreprod.103.019364; OKAMOTO K, 1983, ENDOCRINOLOGY, V112, P336, DOI 10.1210/endo-112-1-336; Okamoto K, 2003, J CHROMATOGR B, V790, P349, DOI 10.1016/S1570-0232(03)00166-1; Okamoto K, 1996, J BIOCHEM, V119, P920; OKAMOTO K, 1982, BIOCHEM BIOPH RES CO, V108, P1655, DOI 10.1016/S0006-291X(82)80100-9; Okamoto K, 2000, EUR J BIOCHEM, V267, P155, DOI 10.1046/j.1432-1327.2000.00987.x; Orre RS, 2001, J BIOL CHEM, V276, P1794, DOI 10.1074/jbc.M008560200; PANNEERSELVAM C, 1987, IMMUNOL METHODS, V104, P131; PAPAMARCAKI T, 1994, FEBS LETT, V345, P71, DOI 10.1016/0014-5793(94)00439-0; Pineiro A, 2000, PEPTIDES, V21, P1433, DOI 10.1016/S0196-9781(00)00288-6; Rodriguez P, 1998, BIOCHEM J, V331, P753, DOI 10.1042/bj3310753; Subramanian C, 2002, J VIROL, V76, P4699, DOI 10.1128/JVI.76.10.4699-4708.2002; Trompeter HI, 1996, J BIOL CHEM, V271, P1187, DOI 10.1074/jbc.271.2.1187; TROMPETER HI, 1989, FEBS LETT, V253, P63, DOI 10.1016/0014-5793(89)80930-5; Trompeter HI, 1999, J CELL SCI, V112, P4113; VARELI K, 1995, FEBS LETT, V371, P337, DOI 10.1016/0014-5793(95)00938-6; Vareli K, 2000, EXP CELL RES, V257, P152, DOI 10.1006/excr.2000.4857; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; WATTS JD, 1990, EUR J BIOCHEM, V192, P643, DOI 10.1111/j.1432-1033.1990.tb19271.x; Xu JM, 2003, MOL ENDOCRINOL, V17, P1681, DOI 10.1210/me.2003-0116	52	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36986	36993		10.1074/jbc.M506056200	http://dx.doi.org/10.1074/jbc.M506056200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16150697	hybrid			2022-12-27	WOS:000232901800056
J	Rimessi, A; Coletto, L; Pinton, P; Rizzuto, R; Brini, M; Carafoli, E				Rimessi, A; Coletto, L; Pinton, P; Rizzuto, R; Brini, M; Carafoli, E			Inhibitory interaction of the 14-3-3 epsilon protein with isoform 4 of the plasma membrane Ca2+-ATPase pump	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ ATPASE; CALCIUM-PUMP; 4B; PURIFICATION; CALMODULIN; EXPRESSION; PEPTIDE; BINDS; 2B	The isoform-specific interaction of plasma membrane Ca2+-ATPase (PMCA) pumps with partner proteins has been explored using a yeast two-hybrid technique. The 90 N-terminal residues of two pump isoforms (PMCA2 and PMCA4), which have a low degree of sequence homology, have been used as baits. Screening of 5x10(6) clones of a human brain cDNA library yielded similar to 100 LEU2- and galactoside-positive clones for both pumps. A clone obtained with the PMCA4 bait specified the epsilon-isoform of the 14-3-3 protein, whereas no 14-3-3 epsilon clone was obtained with the PMCA2 bait. The 14-3-3 epsilon protein immunoprecipitated with PMCA4 (not with PMCA2) when expressed in HeLa cells. Overexpression of 14-3-3 epsilon in HeLa cells together with targeted aequorins showed that the ability of the cells to export Ca2+ was impaired; stimulation with histamine, an inositol 1,4,5-trisphosphate-producing agonist, generated higher cytosolic [Ca2+] transients, higher post-transient plateaus of the cytosolic [Ca2+], and higher Ca2+ levels in the endoplasmic reticulum lumen and in the subplasmalemmal domain. Thus, the interaction with 14-3-3 epsilon inhibited PMCA4. Silencing of the 14-3-3 epsilon gene by RNA interference significantly reduced the expression of 14-3-3 epsilon, substantially decreasing the height of the histamine-induced cytosolic [Ca2+] transient and of the post-transient cytosolic [Ca2+] plateau.	Univ Ferrara, Dept Expt & Diagnost Med, Interdisciplinary Ctr Study Inflammat, I-44100 Ferrara, Italy; Venetian Inst Mol Med, I-35129 Padua, Italy; Univ Padua, Dept Biochem, I-35121 Padua, Italy	University of Ferrara; Veneto Institute Molecular Medicine; University of Padua	Rizzuto, R (corresponding author), Univ Ferrara, Dept Expt & Diagnost Med, Interdisciplinary Ctr Study Inflammat, Via Borsari 46, I-44100 Ferrara, Italy.	rzr@unife.it; ernesto.carafoli@unipd.it	Carafoli, Ernesto/K-5192-2016; Brini, Marisa/K-5189-2016; Rimessi, Alessandro/K-5420-2016; Pinton, Paolo/J-8025-2012; rimessi, alessandro/O-3335-2019; Rizzuto, Rosario/B-6312-2008	Carafoli, Ernesto/0000-0002-7826-0094; Rimessi, Alessandro/0000-0001-7091-5765; Pinton, Paolo/0000-0001-7108-6508; rimessi, alessandro/0000-0001-7091-5765; Rizzuto, Rosario/0000-0001-7044-5097; Brini, Marisa/0000-0001-5141-0243	Telethon [1285, GGP04169] Funding Source: Medline	Telethon(Fondazione Telethon)		Armesilla AL, 2004, J BIOL CHEM, V279, P31318, DOI 10.1074/jbc.M307557200; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; Brini M, 2003, J BIOL CHEM, V278, P24500, DOI 10.1074/jbc.M300784200; Buch MH, 2005, J BIOL CHEM, V280, P29479, DOI 10.1074/jbc.M501326200; Cardoso C, 2003, AM J HUM GENET, V72, P918, DOI 10.1086/374320; CARRINGTON WA, 1995, SCIENCE, V268, P1483, DOI 10.1126/science.7770772; Chicka MC, 2003, J BIOL CHEM, V278, P18464, DOI 10.1074/jbc.M301482200; Chiesa A, 2001, BIOCHEM J, V355, P1, DOI 10.1042/0264-6021:3550001; DeMarco SJ, 2002, J BIOL CHEM, V277, P10506, DOI 10.1074/jbc.M111616200; DeMarco SJ, 2001, J BIOL CHEM, V276, P21594, DOI 10.1074/jbc.M101448200; Elwess NL, 1997, J BIOL CHEM, V272, P17981, DOI 10.1074/jbc.272.29.17981; Guerini D, 2003, J BIOL CHEM, V278, P38141, DOI 10.1074/jbc.M302400200; HILFIKER H, 1994, J BIOL CHEM, V269, P26178; JAMES PH, 1989, BIOCHEMISTRY-US, V28, P4253, DOI 10.1021/bi00436a020; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; Mackintosh C, 2004, BIOCHEM J, V381, P329, DOI 10.1042/BJ20031332; Marsault R, 1997, EMBO J, V16, P1575, DOI 10.1093/emboj/16.7.1575; Masters SC, 1999, BIOCHEMISTRY-US, V38, P5216, DOI 10.1021/bi982492m; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; RIZZUTO R, 1995, CURR BIOL, V5, P635, DOI 10.1016/S0960-9822(95)00128-X; Rubio MP, 2004, BIOCHEM J, V379, P395, DOI 10.1042/bj20031797; Schuh K, 2003, J BIOL CHEM, V278, P9778, DOI 10.1074/jbc.M212507200; Schuh K, 2001, J CELL BIOL, V155, P201, DOI 10.1083/jcb.200104131; Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21; Wang BC, 1999, BIOCHEMISTRY-US, V38, P12499, DOI 10.1021/bi991353h; WANG KKW, 1991, J BIOL CHEM, V266, P9078	27	60	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37195	37203		10.1074/jbc.M504921200	http://dx.doi.org/10.1074/jbc.M504921200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16126729	hybrid			2022-12-27	WOS:000232901800078
J	Das, A; Hazra, TK; Boldogh, I; Mitra, S; Bhakat, KK				Das, A; Hazra, TK; Boldogh, I; Mitra, S; Bhakat, KK			Induction of the human oxidized base-specific DNA glycosylase NEIL1 by reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI ENDONUCLEASE-III; OXIDATIVELY DAMAGED DNA; EXCISION-REPAIR; MAMMALIAN-CELLS; APURINIC/APYRIMIDINIC ENDONUCLEASE; TRANSCRIPTIONAL REGULATION; NTH1 GENE; STRESS; PROTEIN; LESIONS	NEIL1, a mammalian DNA glycosylase and ortholog of Escherichia coli Nei/Fpg, is involved in the repair of oxidatively damaged bases in mammalian cells. Exposure of HCT116 human colon carcinoma cells to reactive oxygen species, generated by glucose oxidase (GO), enhanced the levels of NEIL1 mRNA and polypeptide by 2-4-fold by 6 h after GO treatment. A similar oxidative stress-induced increase in human NEIL1 (hNEIL1) promoter-dependent luciferase expression in HCT116 cells indicates that reactive oxygen species activates NEIL1 transcription. The transcriptional start site of hNEIL1 was mapped, and the upstream promoter sequence was characterized via luciferase reporter assay. Two identical CRE/AP-1-binding sites were identified in the promoter that binds transcription factors c-Jun and CREB/ATF2. This binding was significantly enhanced in extracts of cells treated with GO. Furthermore, a simultaneous increase in the level of phosphorylated c-Jun suggests its involvement in up-regulating the NEIL1 promoter. Oxidative stress-induced activation of NEIL1 appears to be involved in the feedback regulation of cellular repair activity needed to handle an increase in the level of oxidative base damage.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Mitra, S (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, 6-136 Med Res Bldg,Rte 1079, Galveston, TX 77555 USA.	samitra@utmb.edu	Classen, Scott/AAY-8176-2020; Bhakat, Kishor/C-8072-2012		NCI NIH HHS [P01 CA92584, R01 CA81063] Funding Source: Medline; NIA NIH HHS [P01 AG021830] Funding Source: Medline; NIEHS NIH HHS [P30 ES006676, ES06676] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA092584, R01CA081063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG021830] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Bandaru V, 2002, DNA REPAIR, V1, P517, DOI 10.1016/S1568-7864(02)00036-8; Boldogh I, 1998, CANCER RES, V58, P3950; BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; Chen KH, 1998, NUCLEIC ACIDS RES, V26, P2001, DOI 10.1093/nar/26.8.2001; Dou H, 2003, J BIOL CHEM, V278, P49679, DOI 10.1074/jbc.M308658200; Elder RH, 2002, J BIOL CHEM, V277, P50487, DOI 10.1074/jbc.M208153200; FRITZ G, 1991, MOL CELL BIOL, V11, P4660, DOI 10.1128/MCB.11.9.4660; GOTZ ME, 1994, PHARMACOL THERAPEUT, V63, P37, DOI 10.1016/0163-7258(94)90055-8; Grombacher T, 1996, CARCINOGENESIS, V17, P2329, DOI 10.1093/carcin/17.11.2329; Grosch S, 1999, BIOCHEM BIOPH RES CO, V261, P859, DOI 10.1006/bbrc.1999.1125; Grosch S, 1998, CANCER RES, V58, P4410; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Hailer MK, 2005, DNA REPAIR, V4, P41, DOI 10.1016/j.dnarep.2004.07.006; Hazra TK, 2003, CARCINOGENESIS, V24, P155, DOI 10.1093/carcin/24.2.155; Hazra TK, 2002, J BIOL CHEM, V277, P30417, DOI 10.1074/jbc.C200355200; Hazra TK, 2002, P NATL ACAD SCI USA, V99, P3523, DOI 10.1073/pnas.062053799; He F, 2003, BIOL CHEM, V384, P19, DOI 10.1515/BC.2003.003; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Ikeda S, 1998, J BIOL CHEM, V273, P21585, DOI 10.1074/jbc.273.34.21585; Jiang DY, 1997, J BACTERIOL, V179, P3773, DOI 10.1128/jb.179.11.3773-3782.1997; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Katafuchi A, 2004, J BIOL CHEM, V279, P14464, DOI 10.1074/jbc.M400393200; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; KOW YW, 1987, BIOCHEMISTRY-US, V26, P8200, DOI 10.1021/bi00399a027; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; Lee MR, 2004, J BIOL CHEM, V279, P9857, DOI 10.1074/jbc.M311132200; Lovell MA, 2000, BRAIN RES, V855, P116, DOI 10.1016/S0006-8993(99)02335-5; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; Morland I, 2002, NUCLEIC ACIDS RES, V30, P4926, DOI 10.1093/nar/gkf618; NADA S, 1993, J BIOL CHEM, V268, P7660; Ramana CV, 1998, P NATL ACAD SCI USA, V95, P5061, DOI 10.1073/pnas.95.9.5061; Ribardo DA, 2002, MICROB PATHOGENESIS, V32, P149, DOI 10.1006/mpat.2001.0490; Rosenquist TA, 2003, DNA REPAIR, V2, P581, DOI 10.1016/S1568-7864(03)00025-9; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; Takao M, 2002, J BIOL CHEM, V277, P42205, DOI 10.1074/jbc.M206884200; Takao M, 2002, EMBO J, V21, P3486, DOI 10.1093/emboj/cdf350; Zahringer H, 1997, FEBS LETT, V412, P615, DOI 10.1016/S0014-5793(97)00868-5; Zharkov DO, 1997, J BIOL CHEM, V272, P5335, DOI 10.1074/jbc.272.8.5335	40	60	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35272	35280		10.1074/jbc.M505526200	http://dx.doi.org/10.1074/jbc.M505526200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16118226	hybrid			2022-12-27	WOS:000232561200025
J	An, S; Musier-Forsyth, K				An, S; Musier-Forsyth, K			Cys-tRNA(Pro) editing by Haemophilus influenzae YbaK via a novel synthetase center dot YbaK center dot tRNA ternary complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOACYL-TRANSFER-RNA; ELONGATION-FACTOR-TU; ESCHERICHIA-COLI; PROTEIN-SYNTHESIS; CROSS-LINKING; INSERTION DOMAIN; IN-VITRO; BINDING; RECOGNITION; ISOLEUCINE	Aminoacyl-tRNA synthetases are multidomain enzymes that often possess two activities to ensure translational accuracy. A synthetic active site catalyzes tRNA aminoacylation, while an editing active site hydrolyzes mischarged tRNAs. Prolyl-tRNA synthetases (ProRS) have been shown to misacylate Cys onto tRNA(Pro), but lack a Cys-specific editing function. The synthetase-like Haemophilus influenzae YbaK protein was recently shown to hydrolyze misacylated Cys-tRNA(Pro) in trans. However, the mechanism of specific substrate selection by this single domain hydrolase is unknown. Here, we demonstrate that YbaK alone appears to lack specific tRNA recognition capabilities. Moreover, YbaK cannot compete for aminoacyl-tRNAs in the presence of elongation factor Tu, suggesting that YbaK acts before release of the aminoacyl-tRNA from the synthetase. In support of this idea, cross-linking studies reveal the formation of binary ( ProRS center dot YbaK) and ternary ( ProRS center dot YbaK center dot tRNA) complexes. The binding constants for the interaction between ProRS and YbaK are 550 nM and 45 nM in the absence and presence of tRNA(Pro), respectively. These results suggest that the specificity of trans-editing by YbaK is ensured through formation of a novel ProRS center dot YbaK center dot tRNA complex.	Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Musier-Forsyth, K (corresponding author), Univ Minnesota, Dept Chem, 207 Pleasant St SE, Minneapolis, MN 55455 USA.	musier@chem.umn.edu	An, Songon/A-6714-2009	An, Songon/0000-0003-2189-7374	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049928, R29GM049928, R55GM049928] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49928] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahel I, 2003, P NATL ACAD SCI USA, V100, P15422, DOI 10.1073/pnas.2136934100; Ahel I, 2002, J BIOL CHEM, V277, P34743, DOI 10.1074/jbc.M206928200; Ambrogelly A, 2002, J BIOL CHEM, V277, P34749, DOI 10.1074/jbc.M206929200; Amini F, 2003, CHEM BIOL, V10, P1115, DOI 10.1016/j.chembiol.2003.11.001; ARAI KI, 1972, J BIOL CHEM, V247, P7029; BALDWIN AN, 1966, J BIOL CHEM, V241, P839; Beebe K, 2004, P NATL ACAD SCI USA, V101, P5958, DOI 10.1073/pnas.0401530101; Beebe K, 2003, EMBO J, V22, P668, DOI 10.1093/emboj/cdg065; Beuning PJ, 2000, P NATL ACAD SCI USA, V97, P8916, DOI 10.1073/pnas.97.16.8916; Beuning PJ, 2001, J BIOL CHEM, V276, P30779, DOI 10.1074/jbc.M104761200; Beuning PJ, 1997, J AM CHEM SOC, V119, P8397, DOI 10.1021/ja971020c; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campanacci V, 2004, J MOL BIOL, V337, P273, DOI 10.1016/j.jmb.2004.01.027; Chen JF, 2000, BIOCHEMISTRY-US, V39, P6726, DOI 10.1021/bi000108r; Christian T, 2000, J MOL BIOL, V303, P503, DOI 10.1006/jmbi.2000.4169; DELARUE M, 1993, BIOESSAYS, V15, P675, DOI 10.1002/bies.950151007; Dock-Bregeon AC, 2000, CELL, V103, P877, DOI 10.1016/S0092-8674(00)00191-4; ELDRED EW, 1972, J BIOL CHEM, V247, P2961; ENGLISCH S, 1986, NUCLEIC ACIDS RES, V14, P7529, DOI 10.1093/nar/14.19.7529; Fancy DA, 1999, P NATL ACAD SCI USA, V96, P6020, DOI 10.1073/pnas.96.11.6020; Fersht AR, 1998, SCIENCE, V280, P541, DOI 10.1126/science.280.5363.541; FERSHT AR, 1975, BIOCHEMISTRY-US, V14, P1, DOI 10.1021/bi00672a001; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P2627, DOI 10.1021/bi00579a030; GANOZA MC, 1995, J BIOL CHEM, V270, P26377, DOI 10.1074/jbc.270.44.26377; Geslain R, 2004, TRENDS GENET, V20, P604, DOI 10.1016/j.tig.2004.09.012; Gruic-Sovulj I, 2005, J BIOL CHEM, V280, P23978, DOI 10.1074/jbc.M414260200; Heacock D, 1996, BIOORG CHEM, V24, P273, DOI 10.1006/bioo.1996.0025; Hendrickson TL, 2003, MOL B INT U, P34; HOPFIELD JJ, 1976, P NATL ACAD SCI USA, V73, P1164, DOI 10.1073/pnas.73.4.1164; HOU YM, 1993, P NATL ACAD SCI USA, V90, P6776, DOI 10.1073/pnas.90.14.6776; JAKUBOWSKI H, 1994, NUCLEIC ACIDS RES, V22, P1155, DOI 10.1093/nar/22.7.1155; JASIN M, 1983, NATURE, V306, P441, DOI 10.1038/306441a0; Korencic D, 2004, P NATL ACAD SCI USA, V101, P10260, DOI 10.1073/pnas.0403926101; Kurbanyan K, 2003, BIOCHEMISTRY-US, V42, P10269, DOI 10.1021/bi020713p; LaRiviere FJ, 2001, SCIENCE, V294, P165, DOI 10.1126/science.1064242; Lin L, 1996, NATURE, V384, P33, DOI 10.1038/384033b0; Lipman RSA, 2002, J MOL BIOL, V315, P943, DOI 10.1006/jmbi.2001.5297; Lipman RSA, 2002, J MOL BIOL, V316, P421, DOI 10.1006/jmbi.2001.5373; LIU HJ, 1995, NUCLEIC ACIDS RES, V23, P165, DOI 10.1093/nar/23.1.165; LIU HJ, 1994, BIOCHEMISTRY-US, V33, P12708, DOI 10.1021/bi00208a023; Lundblad JR, 1996, MOL ENDOCRINOL, V10, P607, DOI 10.1210/me.10.6.607; MCCLAIN WH, 1994, NUCLEIC ACIDS RES, V22, P522, DOI 10.1093/nar/22.3.522; MULLER B, 1991, BIOCHEMISTRY-US, V30, P3709, DOI 10.1021/bi00229a017; Mursinna RS, 2001, BIOCHEMISTRY-US, V40, P5376, DOI 10.1021/bi002915w; MUSIERFORSYTH K, 1991, P NATL ACAD SCI USA, V88, P209, DOI 10.1073/pnas.88.1.209; NAZARENKO IA, 1995, BIOCHEMISTRY-US, V34, P2545, DOI 10.1021/bi00008a019; NEGRUTSKII BS, 1991, P NATL ACAD SCI USA, V88, P4991, DOI 10.1073/pnas.88.11.4991; PARMEGGIANI A, 1981, MOL CELL BIOCHEM, V35, P129, DOI 10.1007/BF02357085; Petrushenko ZM, 2002, EUR J BIOCHEM, V269, P4811, DOI 10.1046/j.1432-1033.2002.03178.x; Pleiss JA, 2001, J MOL BIOL, V308, P895, DOI 10.1006/jmbi.2001.4612; Reid SL, 2001, BIOCHEMISTRY-US, V40, P2484, DOI 10.1021/bi001956p; Roy H, 2004, EMBO J, V23, P4639, DOI 10.1038/sj.emboj.7600474; Ruan BF, 2005, J BIOL CHEM, V280, P25887, DOI 10.1074/jbc.M502174200; Sankaranarayanan R, 2000, NAT STRUCT BIOL, V7, P461; Schimmel P, 2000, TRENDS BIOCHEM SCI, V25, P207, DOI 10.1016/S0968-0004(00)01553-X; SCHIMMEL P, 1995, CELL, V81, P983, DOI 10.1016/S0092-8674(05)80002-9; SCHMIDT E, 1995, BIOCHEMISTRY-US, V34, P11204, DOI 10.1021/bi00035a028; STARZYK RM, 1987, SCIENCE, V237, P1614, DOI 10.1126/science.3306924; STEINBERG S, 1993, NUCLEIC ACIDS RES, V21, P3011, DOI 10.1093/nar/21.13.3011; TSUI WC, 1981, NUCLEIC ACIDS RES, V9, P4627, DOI 10.1093/nar/9.18.4627; Wong FC, 2003, J BIOL CHEM, V278, P52857, DOI 10.1074/jbc.M309627200; Wong FC, 2002, BIOCHEMISTRY-US, V41, P7108, DOI 10.1021/bi012178j; Zhang H, 2000, PROTEINS, V40, P86, DOI 10.1002/(SICI)1097-0134(20000701)40:1<86::AID-PROT100>3.0.CO;2-Y; Zuurmond AM, 2000, J MOL BIOL, V304, P995, DOI 10.1006/jmbi.2000.4260	64	60	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34465	34472		10.1074/jbc.M507550200	http://dx.doi.org/10.1074/jbc.M507550200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16087664	hybrid			2022-12-27	WOS:000232403900013
J	Randak, CO; Welsh, MJ				Randak, CO; Welsh, MJ			Adenylate kinase activity in ABC transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							TRANSMEMBRANE CONDUCTANCE REGULATOR; NUCLEOTIDE-BINDING DOMAIN; ATP-BINDING; INSULIN-SECRETION; CATALYTIC CYCLE; CFTR; MECHANISM; SITE; 2ND; ADP		Univ Iowa, Roy J & Lucille A Carver Coll Med, Howard Hughes Med Inst, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Roy J & Lucille A Carver Coll Med, Howard Hughes Med Inst, Dept Physiol & Biophys, Iowa City, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa	Welsh, MJ (corresponding author), Univ Iowa, Roy J & Lucille A Carver Coll Med, Howard Hughes Med Inst, Dept Internal Med, 500 EMRB, Iowa City, IA 52242 USA.	michael-welsh@uiowa.edu		Randak, Christoph/0000-0003-3264-4137; Welsh, Michael/0000-0002-1646-6206	NHLBI NIH HHS [HL29851-21, HL1234-05] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029851, R37HL029851] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERTY RA, 1992, BIOCHEMISTRY-US, V31, P10610, DOI 10.1021/bi00158a025; Aleksandrov L, 2002, J BIOL CHEM, V277, P15419, DOI 10.1074/jbc.M111713200; AMES GF, 1992, ADV ENZYMOL RAMB, V65, P1; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; Babenko AP, 1998, ANNU REV PHYSIOL, V60, P667, DOI 10.1146/annurev.physiol.60.1.667; Balakrishnan L, 2004, J BIOL CHEM, V279, P11273, DOI 10.1074/jbc.M308494200; Basso C, 2003, J GEN PHYSIOL, V122, P333, DOI 10.1085/jgp.200308798; Berger AL, 2005, P NATL ACAD SCI USA, V102, P455, DOI 10.1073/pnas.0408575102; Berger AL, 2002, J BIOL CHEM, V277, P2125, DOI 10.1074/jbc.M109539200; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; Boyer P.D, 1973, ENZYMES, P279; BOZZI A, 1994, BIOCHEM MOL BIOL INT, V32, P95; BYEON IJL, 1995, BIOCHEMISTRY-US, V34, P3172, DOI 10.1021/bi00010a006; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; Csanady L, 2000, J GEN PHYSIOL, V116, P477, DOI 10.1085/jgp.116.3.477; Davidson AL, 2004, ANNU REV BIOCHEM, V73, P241, DOI 10.1146/annurev.biochem.73.011303.073626; DAVIDSON AL, 1990, J BIOL CHEM, V265, P4254; Dzeja PP, 1998, FASEB J, V12, P523, DOI 10.1096/fasebj.12.7.523; FELDHAUS P, 1975, EUR J BIOCHEM, V57, P197, DOI 10.1111/j.1432-1033.1975.tb02291.x; Gadsby D. C., 1999, PHYSIOL REV, V79, pS77; Gottesman MM, 2001, J BIOENERG BIOMEMBR, V33, P453, DOI 10.1023/A:1012866803188; Hallows KR, 2000, J CLIN INVEST, V105, P1711, DOI 10.1172/JCI9622; Hanrahan JW, 2003, ABC PROTEINS BACTERI, P589; Hardie DG, 2003, ENDOCRINOLOGY, V144, P5179, DOI 10.1210/en.2003-0982; Higgins CF, 2004, NAT STRUCT MOL BIOL, V11, P918, DOI 10.1038/nsmb836; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; Higgins CF, 2001, RES MICROBIOL, V152, P205, DOI 10.1016/S0923-2508(01)01193-7; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Huopio H, 2002, AM J PHYSIOL-ENDOC M, V283, pE207, DOI 10.1152/ajpendo.00047.2002; Janas E, 2003, J BIOL CHEM, V278, P26862, DOI 10.1074/jbc.M301227200; LIENHARD GE, 1973, J BIOL CHEM, V248, P1121; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; MALAISSE WJ, 1987, BIOCHIM BIOPHYS ACTA, V927, P190, DOI 10.1016/0167-4889(87)90134-0; Matsuo M., 2003, ABC PROTEINS BACTERI, P551; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; OKAJIMA T, 1993, J BIOCHEM-TOKYO, V114, P627, DOI 10.1093/oxfordjournals.jbchem.a124228; Olson LK, 1996, J BIOL CHEM, V271, P16544, DOI 10.1074/jbc.271.28.16544; Omote H, 2002, J BIOL CHEM, V277, P45688, DOI 10.1074/jbc.M206479200; Pucar D, 2002, AM J PHYSIOL-HEART C, V283, pH776, DOI 10.1152/ajpheart.00116.2002; Randak C, 1997, FEBS LETT, V410, P180, DOI 10.1016/S0014-5793(97)00574-7; Randak C, 2003, CELL, V115, P837, DOI 10.1016/S0092-8674(03)00983-8; RANDAK C, 1995, FEBS LETT, V363, P189, DOI 10.1016/0014-5793(95)00314-Y; Randak CO, 2005, P NATL ACAD SCI USA, V102, P2216, DOI 10.1073/pnas.0409787102; Ren H, 2005, P NATL ACAD SCI USA, V102, P303, DOI 10.1073/pnas.0407459102; SCHULTZ BD, 1995, J GEN PHYSIOL, V105, P329, DOI 10.1085/jgp.105.3.329; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; Sheppard DN, 1999, PHYSIOL REV, V79, P23; Smith CA, 1996, BIOPHYS J, V70, P1590, DOI 10.1016/S0006-3495(96)79745-X; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Szellas T, 2003, FEBS LETT, V535, P141, DOI 10.1016/S0014-5793(02)03892-9; VONRHEIN C, 1995, STRUCTURE, V3, P483, DOI 10.1016/S0969-2126(01)00181-2; Vonrhein C, 1998, J MOL BIOL, V282, P167, DOI 10.1006/jmbi.1998.2003; Weinreich F, 1999, J GEN PHYSIOL, V114, P55, DOI 10.1085/jgp.114.1.55; Yan HG, 1999, ADV ENZYMOL RAMB, V73, P103, DOI 10.1002/9780470123195.ch4; ZELEZNIKAR RJ, 1995, J BIOL CHEM, V270, P7311, DOI 10.1074/jbc.270.13.7311	56	17	17	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34385	34388		10.1074/jbc.R500009200	http://dx.doi.org/10.1074/jbc.R500009200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16100108	hybrid			2022-12-27	WOS:000232403900002
J	Rajashankar, KR; Bryk, R; Kniewel, R; Buglino, JA; Nathan, CF; Lima, CD				Rajashankar, KR; Bryk, R; Kniewel, R; Buglino, JA; Nathan, CF; Lima, CD			Crystal structure and functional analysis of lipoamide dehydrogenase from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROLIPOAMIDE DEHYDROGENASE; AZOTOBACTER-VINELANDII; PYRUVATE-DEHYDROGENASE; ANTIOXIDANT DEFENSE; SUBSTRATE-BINDING; CATALYTIC DOMAIN; REDUCTASE; DISULFIDE; ENZYMES; SEQUENCE	We report the 2.4 angstrom crystal structure for lipoamide dehydrogenase encoded by lpdC from Mycobacterium tuberculosis. Based on the Lpd structure and sequence alignment between bacterial and eukaryotic Lpd sequences, we generated single point mutations in Lpd and assayed the resulting proteins for their ability to catalyze lipoamide reduction/ oxidation alone and in complex with other proteins that participate in pyruvate dehydrogenase and peroxidase activities. The results suggest that amino acid residues conserved in mycobacterial species but not conserved in eukaryotic Lpd family members modulate either or both activities and include Arg-93, His-98, Lys-103, and His-386. In addition, Arg-93 and His- 386 are involved in forming both "open" and "closed" active site conformations, suggesting that these residues play a role in dynamically regulating Lpd function. Taken together, these data suggest protein surfaces that should be considered while developing strategies for inhibiting this enzyme.	Cloan Kettering Inst, Struct Biol Program, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Lima, CD (corresponding author), Cloan Kettering Inst, Struct Biol Program, New York, NY 10021 USA.	limac@mskcc.org		Kniewel, Ryan/0000-0003-3462-6450; Lima, Christopher/0000-0002-9163-6092	NHLBI NIH HHS [HL072718] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072718] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Argyrou A, 2004, PROG NUCLEIC ACID RE, V78, P89, DOI 10.1016/S0079-6603(04)78003-4; Argyrou A, 2004, J BIOL CHEM, V279, P52694, DOI 10.1074/jbc.M410704200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENEN J, 1992, EUR J BIOCHEM, V207, P487, DOI 10.1111/j.1432-1033.1992.tb17075.x; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; Brautigam CA, 2005, J MOL BIOL, V350, P543, DOI 10.1016/j.jmb.2005.05.014; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bryk R, 2000, NATURE, V407, P211, DOI 10.1038/35025109; Bryk R, 2002, SCIENCE, V295, P1073, DOI 10.1126/science.1067798; Chang CF, 2002, J BIOL CHEM, V277, P15865, DOI 10.1074/jbc.M110952200; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; DELANO WL, 2002, PYMOL USERS MANUAL D; Gouet P, 2003, NUCLEIC ACIDS RES, V31, P3320, DOI 10.1093/nar/gkg556; Guimaraes BG, 2005, J BIOL CHEM, V280, P25735, DOI 10.1074/jbc.M503076200; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HOPKINS N, 1995, BIOCHEMISTRY-US, V34, P11757, DOI 10.1021/bi00037a013; Igamberdiev AU, 2004, FEBS LETT, V568, P146, DOI 10.1016/j.febslet.2004.05.024; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; Kato M, 2005, EMBO J, V24, P1763, DOI 10.1038/sj.emboj.7600663; Knapp JE, 1998, J MOL BIOL, V280, P655, DOI 10.1006/jmbi.1998.1924; Knapp JE, 2000, PROTEIN SCI, V9, P37; Koshkin A, 2004, ARCH BIOCHEM BIOPHYS, V427, P41, DOI 10.1016/j.abb.2004.04.017; MATTEVI A, 1993, BIOCHEMISTRY-US, V32, P3887, DOI 10.1021/bi00066a007; MATTEVI A, 1992, PROTEINS, V13, P336, DOI 10.1002/prot.340130406; MATTEVI A, 1993, J MOL BIOL, V230, P1183, DOI 10.1006/jmbi.1993.1235; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; Nunn CM, 2002, J BIOL CHEM, V277, P20033, DOI 10.1074/jbc.M200864200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Tian J, 2005, MOL MICROBIOL, V57, P859, DOI 10.1111/j.1365-2958.2005.04741.x; Zhang YH, 1996, PROTEIN SCI, V5, P52	35	26	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33977	33983		10.1074/jbc.M507466200	http://dx.doi.org/10.1074/jbc.M507466200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16093239	hybrid			2022-12-27	WOS:000232229700035
J	Zvonic, S; Baugh, JE; Arbour-Reily, P; Mynatt, RL; Stephens, JM				Zvonic, S; Baugh, JE; Arbour-Reily, P; Mynatt, RL; Stephens, JM			Cross-talk among gp130 cytokines in adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; SIGNAL TRANSDUCER GP130; CILIARY NEUROTROPHIC FACTOR; ONCOSTATIN-M RECEPTOR; MOLECULAR-CLONING; INTERLEUKIN-6 RECEPTOR; REGULATED EXPRESSION; 3T3-L1 ADIPOCYTES; HEXAMERIC COMPLEX; IL-11 RECEPTOR	The interleukin-6 (IL-6) family of cytokines is a family of structurally and functionally related proteins, including IL-6, IL-11, leukemia inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor ( CNTF), and cardiotrophin-1 (CT-1). These proteins are also known as gp130 cytokines because they all share gp130 as a common transducer protein within their functional receptor complexes. Several of these cytokines ( LIF, OSM, CNTF, and CT-1) also utilize the LIF receptor (LIFR) as a component of their receptor complex. We have shown that all of these cytokines are capable of activating both the JAK/STAT and p42/44 mitogen-activated protein kinase signaling pathways in 3T3-L1 adipocytes. By performing a variety of preincubation studies and examining the ability of these cytokines to activate STATs, ERKs, and induce transcription of SOCS-3 mRNA, we have also examined the ability of gp130 cytokines to modulate the action of their family members. Our results indicate that a subset of gp130 cytokines, in particular CT-1, LIF, and OSM, has the ability to impair subsequent signaling activity initiated by gp130 cytokines. However, IL-6 and CNTF do not exhibit this cross-talk ability. Moreover, our results indicate that the cross-talk among gp130 cytokines is mediated by the ability of these cytokines to induce ligand-dependent degradation of the LIFR, in a proteasome-independent manner, which coincides with decreased levels of LIFR at the plasma membrane. In summary, our results demonstrate that an inhibitory cross-talk among specific gp130 cytokines in 3T3-L1 adipocytes occurs as a result of specific degradation of LIFR via a lysosome-mediated pathway.	Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA; Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA	Louisiana State University System; Louisiana State University; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Stephens, JM (corresponding author), Louisiana State Univ, Dept Biol Sci, 202 Life Sci Bldg, Baton Rouge, LA 70803 USA.	jsteph1@lsu.edu	Mynatt, Randall L/N-1980-2017; Stephens, Jacqueline M/R-5217-2018	Mynatt, Randall L/0000-0003-4399-0019; 				AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Aubert J, 1999, J BIOL CHEM, V274, P24965, DOI 10.1074/jbc.274.35.24965; Balhoff JP, 1998, BIOCHEM BIOPH RES CO, V247, P894, DOI 10.1006/bbrc.1998.8890; Baumann H, 1996, J IMMUNOL, V157, P284; Blanchard F, 2001, J BIOL CHEM, V276, P47038, DOI 10.1074/jbc.M107971200; Blanchard F, 2000, J BIOL CHEM, V275, P28793, DOI 10.1074/jbc.M003986200; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DESERIO A, 1995, J MOL BIOL, V254, P795, DOI 10.1006/jmbi.1995.0655; Dinerstein-Cali H, 2000, MOL CELL ENDOCRINOL, V166, P89, DOI 10.1016/S0303-7207(00)00277-X; GEARING DP, 1993, ADV IMMUNOL, V53, P31, DOI 10.1016/S0065-2776(08)60497-6; GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GIMBLE JM, 1994, J CELL BIOCHEM, V54, P122, DOI 10.1002/jcb.240540113; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1992, TRENDS BIOCHEM SCI, V17, P72, DOI 10.1016/0968-0004(92)90505-4; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HIRANO T, 1992, CHEM IMMUNOL, V51, P153; Hirano T, 1998, Int Rev Immunol, V16, P249; HIRANO T, 1994, STEM CELLS, V12, P262, DOI 10.1002/stem.5530120303; Hirota H, 1996, J EXP MED, V183, P2627, DOI 10.1084/jem.183.6.2627; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Ip NY, 1996, ANNU REV NEUROSCI, V19, P491; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; Kamimura D, 2004, REV PHYSIOL BIOCH P, V149, P1, DOI 10.1007/s10254-003-0012-2; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; LIU JW, 1992, J BIOL CHEM, V267, P16763; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Mackiewicz A, 1995, ANN NY ACAD SCI, V762, P361; Mahboubi K, 2003, J BIOL CHEM, V278, P25014, DOI 10.1074/jbc.M211867200; METCALF D, 1991, INT J CELL CLONING, V9, P95, DOI 10.1002/stem.5530090201; Metcalf D, 2003, STEM CELLS, V21, P5, DOI 10.1634/stemcells.21-1-5; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; MURAKAMIMORI K, 1995, J CLIN INVEST, V96, P1319, DOI 10.1172/JCI118167; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; Path G, 2001, J CLIN ENDOCR METAB, V86, P2281, DOI 10.1210/jc.86.5.2281; PATTERSON PH, 1993, CELL, V72, P123, DOI 10.1016/S0092-8674(05)80032-7; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; PAUL WE, 1989, CELL, V57, P521, DOI 10.1016/0092-8674(89)90121-9; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; Pennica Diane, 1996, Cytokine and Growth Factor Reviews, V7, P81, DOI 10.1016/1359-6101(96)00007-X; SAITO M, 1992, J IMMUNOL, V148, P4066; SATOH T, 1992, J BIOL CHEM, V267, P24149; SAVINO R, 1994, EMBO J, V13, P1357, DOI 10.1002/j.1460-2075.1994.tb06389.x; SEHGAL PB, 1988, J EXP MED, V167, P1951, DOI 10.1084/jem.167.6.1951; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; Stephens JM, 1998, J BIOL CHEM, V273, P31408, DOI 10.1074/jbc.273.47.31408; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; Taga T, 1996, J NEUROCHEM, V67, P1; THOMA B, 1994, J BIOL CHEM, V269, P6215; WARD LD, 1994, J BIOL CHEM, V269, P23286; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wollert KC, 1996, J BIOL CHEM, V271, P9535, DOI 10.1074/jbc.271.16.9535; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; YANG YC, 1993, STEM CELLS, V11, P474, DOI 10.1002/stem.5530110617; YIN TG, 1993, J IMMUNOL, V151, P2555; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zvonic S, 2004, J BIOL CHEM, V279, P47572, DOI 10.1074/jbc.M403998200; Zvonic S, 2003, J BIOL CHEM, V278, P2228, DOI 10.1074/jbc.M205871200	71	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33856	33863		10.1074/jbc.M508020200	http://dx.doi.org/10.1074/jbc.M508020200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16096272	Green Published, hybrid			2022-12-27	WOS:000232229700022
J	Sauter, K; Grampp, T; Fritschy, JM; Kaupmann, K; Bettler, B; Mohler, H; Benke, D				Sauter, K; Grampp, T; Fritschy, JM; Kaupmann, K; Bettler, B; Mohler, H; Benke, D			Subtype-selective interaction with the transcription factor CCAAT/enhancer-binding protein (C/EBP) homologous protein (CHOP) regulates cell surface expression of GABA(B) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; ENDOPLASMIC-RETICULUM; GADD153; TRAFFICKING; APOPTOSIS; ISCHEMIA; DEATH	The metabotropic gamma-aminobutyric acid, type B (GABA(B)) receptors mediate the slow component of GABAergic transmission in the brain. Functional GABA(B) receptors are heterodimers of the two subunits GABA(B1) and GABA(B2), of which GABA(B1) exists in two main isoforms, GABA(B1a) and GABA(B1b). The significance of the structural heterogeneity of GABAB receptors, the mechanism leading to their differential targeting in neurons as well as the regulation of cell surface numbers of GABAB receptors, is poorly understood. To gain insights into these processes, we searched for proteins interacting with the C-terminal domain of GABA(B2). Here, we showed that the transcription factor CCAAT/enhancer-binding protein (C/EBP) homologous protein ( CHOP) directly interacts with GABA(B) receptors in a subtype-selective manner to regulate cell surface expression of GABA(B1a)/GABA(B2) receptors upon co-expression in HEK293 cells. The interaction of CHOP with GABA(B1a)/ GABA(B2) receptors resulted in their intracellular accumulation and in a reduced number of cell surface receptors. This regulation required the interaction of CHOP via two distinct domains with the heterodimeric receptor; its C-terminal leucine zipper associates with the leucine zipper present in the C-terminal domain of GABA(B2), and its N-terminal domain associates with an as yet unidentified site on GABA(B1a). In conclusion, the data indicated a subtype-selective regulation of cell surface receptors by interaction with the transcription factor CHOP.	Univ Zurich, Inst Pharmacol & Toxicol, CH-8057 Zurich, Switzerland; ETH, Fed Inst Technol, Dept Chem & Appl Biosci, CH-8093 Zurich, Switzerland; Novartis Pharma AG, Novartis Inst Biomed Res, Neurosci Res, CH-4002 Basel, Switzerland; Univ Basel, Pharmazentrum, Dept Clin Biol Sci, Inst Physiol, CH-4056 Basel, Switzerland	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; Novartis; University of Basel	Benke, D (corresponding author), Univ Zurich, Inst Pharmacol & Toxicol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	benke@pharma.unizh.ch	bettler, bernhard/AAO-8018-2020	Bettler, Bernhard/0000-0003-0842-8207; Fritschy, Jean-Marc/0000-0002-8552-3702; Kaupmann, Klemens/0000-0001-8903-2508				Benke D, 1999, J BIOL CHEM, V274, P27323, DOI 10.1074/jbc.274.38.27323; Benke D, 2002, J RECEPT SIGNAL TR R, V22, P253, DOI 10.1081/RRS-120014600; Bettler B, 2004, PHYSIOL REV, V84, P835, DOI 10.1152/physrev.00036.2003; Blein S, 2004, J BIOL CHEM, V279, P48292, DOI 10.1074/jbc.M406540200; Bowery NG, 2002, PHARMACOL REV, V54, P247, DOI 10.1124/pr.54.2.247; Calver AR, 2002, NEUROSIGNALS, V11, P299, DOI 10.1159/000068257; Couve A, 2004, J BIOL CHEM, V279, P13934, DOI 10.1074/jbc.M311737200; Couve A, 2004, BIOCHEM PHARMACOL, V68, P1527, DOI 10.1016/j.bcp.2004.06.036; Couve A, 1998, J BIOL CHEM, V273, P26361, DOI 10.1074/jbc.273.41.26361; Couve A, 2001, MOL CELL NEUROSCI, V17, P317, DOI 10.1006/mcne.2000.0938; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Milhavet O, 2002, J NEUROCHEM, V83, P673, DOI 10.1046/j.1471-4159.2002.01165.x; Nehring RB, 2000, J BIOL CHEM, V275, P35185, DOI 10.1074/jbc.M002727200; Oyadomari S, 2002, APOPTOSIS, V7, P335, DOI 10.1023/A:1016175429877; Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550; Oyadomari S, 2001, P NATL ACAD SCI USA, V98, P10845, DOI 10.1073/pnas.191207498; Pagano A, 2001, J NEUROSCI, V21, P1189; Paschen W, 1998, MOL BRAIN RES, V60, P115, DOI 10.1016/S0169-328X(98)00180-6; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; Steiger JL, 2004, J NEUROSCI, V24, P6115, DOI 10.1523/JNEUROSCI.1200-04.2004; Stokes AH, 2002, NEUROTOXICOLOGY, V23, P675, DOI 10.1016/S0161-813X(02)00093-1; Tajiri S, 2004, CELL DEATH DIFFER, V11, P403, DOI 10.1038/sj.cdd.4401365; Vernon E, 2001, MOL CELL NEUROSCI, V17, P637, DOI 10.1006/mcne.2000.0960; White JH, 2000, P NATL ACAD SCI USA, V97, P13967, DOI 10.1073/pnas.240452197; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	27	26	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33566	33572		10.1074/jbc.M503482200	http://dx.doi.org/10.1074/jbc.M503482200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16081421	hybrid			2022-12-27	WOS:000232058100057
J	Peric-Concha, N; Borovicka, B; Long, PF; Hranueli, D; Waterman, PG; Hunter, IS				Peric-Concha, N; Borovicka, B; Long, PF; Hranueli, D; Waterman, PG; Hunter, IS			Ablation of the otcC gene encoding a post-polyketide hydroxylase from the oxytetracyline biosynthetic pathway in Streptomyces rimosus results in novel polyketides with altered chain length	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL CARRIER PROTEIN; AROMATIC POLYKETIDE; ENGINEERED BIOSYNTHESIS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; COELICOLOR A3(2); RATIONAL DESIGN; SYNTHASE; CLONING; TETRACYCLINES	Oxytetracycline (OTC) is a 19-carbon polyketide antibiotic made by Streptomyces rimosus. The otcC gene encodes an anhydrotetracycline oxygenase that catalyzes a hydroxylation of the anthracycline structure at position C-6 after biosynthesis of the polyketide backbone is completed. A recombinant strain of S. rimosus that was disrupted in the genomic copy of otcC synthesized a novel C-17 polyketide. This result indicates that the absence of the otcC gene product significantly influences the ability of the OTC "minimal" polyketide synthase to make a polyketide product of the correct chain length. A mutant copy of otcC was made by site-directed mutagenesis of three essential glycine codons located within the putative NADPH-binding domain. The mutant gene was expressed in Escherichia coli, and biochemical analysis confirmed that the gene product was catalytically inactive. When the mutant gene replaced the ablated gene in the chromosome of S. rimosus, the ability to make a 19-carbon backbone was restored, indicating that OtcC is an essential partner in the quaternary structure of the synthase complex.	Univ Strathclyde, Royal Coll, Dept Biosci, Glasgow G1 1QW, Lanark, Scotland; PLIVA Res & Dev Ltd, Biotechnol, Zagreb 10000, Croatia; Univ London, Sch Pharm, London WC1N 1AX, England	University of Strathclyde; Teva Pharmaceutical Industries; Pliva; University of London; University College London; University of London School of Pharmacy	Hunter, IS (corresponding author), Univ Strathclyde, Royal Coll, Dept Biosci, Glasgow G1 1QW, Lanark, Scotland.	i.s.hunter@strath.ac.uk		Hunter, Iain/0000-0003-2571-6016	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARDEN TC, 1994, J MED CHEM, V37, P3205, DOI 10.1021/jm00046a003; BEHAL V, 1979, BIOTECHNOL LETT, V1, P177, DOI 10.1007/BF01388144; BINNIE C, 1989, J BACTERIOL, V171, P887, DOI 10.1128/jb.171.2.887-895.1989; Bisang C, 1999, NATURE, V401, P502, DOI 10.1038/46829; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER MJ, 1989, MOL GEN GENET, V215, P231, DOI 10.1007/BF00339722; BUTLER MJ, 1990, DEV IND MICROBIOL, V31, P41; Castaldo G, 2005, FOOD TECHNOL BIOTECH, V43, P109; CHOPRA I, 1992, J ANTIMICROB CHEMOTH, V29, P245, DOI 10.1093/jac/29.3.245; Crump MP, 1997, BIOCHEMISTRY-US, V36, P6000, DOI 10.1021/bi970006+; DAIRI T, 1995, BIOSCI BIOTECH BIOCH, V59, P1099, DOI 10.1271/bbb.59.1099; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; Dreier J, 2000, BIOCHEMISTRY-US, V39, P2088, DOI 10.1021/bi992121l; Findlow SC, 2003, BIOCHEMISTRY-US, V42, P8423, DOI 10.1021/bi0342259; Fu H, 1994, Chem Biol, V1, P205, DOI 10.1016/1074-5521(94)90012-4; GIBSON T, 1984, THESIS U CAMBRIDGE U; GRAVIUS B, 1993, APPL ENVIRON MICROB, V59, P2220, DOI 10.1128/AEM.59.7.2220-2228.1993; Hadfield AT, 2004, STRUCTURE, V12, P1865, DOI 10.1016/j.str.2004.08.002; Hitchman TS, 1998, CHEM BIOL, V5, P35, DOI 10.1016/S1074-5521(98)90085-0; HRANUELI D, 1979, J GEN MICROBIOL, V114, P295, DOI 10.1099/00221287-114-2-295; Hranueli D, 1999, FOOD TECHNOL BIOTECH, V37, P117; Hunter I. S., 1997, BIOTECHNOLOGY ANTIBI, P659; Keatinge-Clay A, 2004, NAT STRUCT MOL BIOL, V11, P888, DOI 10.1038/nsmb808; Khosla C, 1999, ANNU REV BIOCHEM, V68, P219, DOI 10.1146/annurev.biochem.68.1.219; Kieser T., 2000, PRACTICAL STREPTOMYC, V4362; Kramer PJ, 1997, J AM CHEM SOC, V119, P635, DOI 10.1021/ja962888q; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li Q, 2003, BIOCHEMISTRY-US, V42, P4648, DOI 10.1021/bi0274120; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; MCDANIEL R, 1994, P NATL ACAD SCI USA, V91, P11542, DOI 10.1073/pnas.91.24.11542; MCDANIEL R, 1995, NATURE, V375, P549, DOI 10.1038/375549a0; McDowall KJ, 1999, J BACTERIOL, V181, P3025, DOI 10.1128/JB.181.10.3025-3032.1999; MCDOWALL KJ, 1991, FEMS SYMP, V55, P105; Moore BS, 2002, NAT PROD REP, V19, P70, DOI 10.1039/b003939j; Nicholson TP, 2003, CHEM COMMUN, P686, DOI 10.1039/b300847a; NOVOTNA J, 1989, FEMS MICROBIOL LETT, V59, P241; PALMER BR, 1994, GENE, V143, P1, DOI 10.1016/0378-1119(94)90597-5; Pan H, 2002, STRUCTURE, V10, P1559, DOI 10.1016/S0969-2126(02)00889-4; Pandza K, 1997, MICROBIOL-UK, V143, P1493, DOI 10.1099/00221287-143-5-1493; PARK W, 1994, BIOTECHNIQUES, V17, P657; Petkovic H, 1999, J BIOL CHEM, V274, P32829; PIGAC J, 1995, APPL ENVIRON MICROB, V61, P352, DOI 10.1128/AEM.61.1.352-356.1995; REVILL WP, 1995, J BACTERIOL, V177, P3946, DOI 10.1128/jb.177.14.3946-3952.1995; Ryan MJ, 1996, United States patent, Patent No. 5589385; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shen YM, 1999, P NATL ACAD SCI USA, V96, P3622, DOI 10.1073/pnas.96.7.3622; SKEGGS PA, 1987, J GEN MICROBIOL, V133, P915; Tang Y, 2004, PLOS BIOL, V2, P227, DOI 10.1371/journal.pbio.0020031; Tang Y, 2004, BIOCHEMISTRY-US, V43, P9546, DOI 10.1021/bi049157k; THOMAS R, 1983, J CHEM SOC CHEM COMM, P128, DOI 10.1039/c39830000128; THOMAS R, 1983, J CHEM SOC CHEM COMM, V7, P443; VASLIGAJ M, 1981, APPL ENVIRON MICROB, V41, P986; WARD JM, 1986, MOL GEN GENET, V203, P468, DOI 10.1007/BF00422072; Yu TW, 1998, J AM CHEM SOC, V120, P7749, DOI 10.1021/ja9803658; Zawada RJX, 1997, J BIOL CHEM, V272, P16184, DOI 10.1074/jbc.272.26.16184	55	34	37	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37455	37460		10.1074/jbc.M503191200	http://dx.doi.org/10.1074/jbc.M503191200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16148009	hybrid			2022-12-27	WOS:000233044500021
J	Pochynyuk, O; Staruschenko, A; Tong, QS; Medina, J; Stockand, JD				Pochynyuk, O; Staruschenko, A; Tong, QS; Medina, J; Stockand, JD			Identification of a functional phosphatidylinositol 3,4,5-trisphosphate binding site in the epithelial Na+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE 3-OH KINASE; K-ATP CHANNELS; SODIUM-CHANNEL; PIP2 REGULATION; KIR CHANNELS; ACTIVATION; ALDOSTERONE; TRANSPORT; ENAC; INHIBITION	Membrane phospholipids, such as phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5) P-3), are signaling molecules that can directly modulate the activity of ion channels, including the epithelial Na+ channel (ENaC). Whereas PI(3,4,5) P-3 directly activates ENaC, its binding site within the channel has not been identified. We identify here a region of gamma-mENaC just following the second trans-membrane domain ( residues 569 - 583) important to PI( 3,4,5) P3 binding and regulation. Deletion of this track decreases activity of ENaC heterologously expressed in Chinese hamster ovary cells. K-Ras and its first effector phosphoinositide 3-OH kinase (PI3-K), as well as RhoA and its effector phosphatidylinositol 4-phosphate 5-kinase increase ENaC activity. Whereas the former, via generation of PI( 3,4,5) P-3, increases ENaC open probability, the latter increases activity by increasing membrane levels of the channel. Deletion of the region just distal to the second trans-membrane domain disrupted regulation by K-Ras and PI3-K but not RhoA and phosphatidylinositol 4-phosphate 5-kinase. Moreover, PI( 3,4,5) P-3 binds ENaC with deletion of the region following the second transmembrane domain disrupting this interaction and disrupting direct activation of the channel by PI( 3,4,5) P-3. Mutation analysis revealed the importance of conserved positive and negative charged residues as well as bulky amino acids within this region to modulation of ENaC by PI3-K. The current results identify the region just distal to the second trans-membrane domain within gamma-mENaC as being part of a functional PI( 3,4,5) P-3 binding site that directly impacts ENaC activity. Phospholipid binding to this site is probably mediated by the positively charged amino acids within this track, with negatively charged and bulky residues also influencing specificity of interactions.	Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Stockand, JD (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Physiol 7756, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	stockand@uthscsa.edu		Staruschenko, Alexander/0000-0002-5190-8356; Stockand, James/0000-0002-3817-4319	NIDDK NIH HHS [R01-DK59594] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059594] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bhargava A, 2001, ENDOCRINOLOGY, V142, P1587, DOI 10.1210/en.142.4.1587; Bian JS, 2004, AM J PHYSIOL-HEART C, V287, pH2154, DOI 10.1152/ajpheart.00120.2004; Blazer-Yost BL, 1999, AM J PHYSIOL-CELL PH, V277, pC531, DOI 10.1152/ajpcell.1999.277.3.C531; Blazer-Yost BL, 2004, AM J PHYSIOL-CELL PH, V287, pC1569, DOI 10.1152/ajpcell.00226.2004; Blazer-Yost BL, 2003, AM J PHYSIOL-CELL PH, V284, pC1645, DOI 10.1152/ajpcell.00372.2002; Blazer-Yost BL, 1998, AM J PHYSIOL-CELL PH, V274, pC1373, DOI 10.1152/ajpcell.1998.274.5.C1373; Booth RE, 2003, J BIOL CHEM, V278, P41367, DOI 10.1074/jbc.M305400200; Booth RE, 2003, AM J PHYSIOL-RENAL, V284, pF938, DOI 10.1152/ajprenal.00373.2002; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Casamayor A, 2003, MOL CELL BIOL, V23, P2762, DOI 10.1128/MCB.23.8.2762-2777.2003; Cukras CA, 2002, J GEN PHYSIOL, V119, P581, DOI 10.1085/jgp.20028562; Cukras CA, 2002, J GEN PHYSIOL, V120, P437, DOI 10.1085/jgp.20028621; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Donaldson MR, 2003, NEUROLOGY, V60, P1811, DOI 10.1212/01.WNL.0000072261.14060.47; Dong K, 2002, J BIOL CHEM, V277, P49366, DOI 10.1074/jbc.M208679200; Du XO, 2004, J BIOL CHEM, V279, P37271, DOI 10.1074/jbc.M403413200; Faletti CJ, 2002, AM J PHYSIOL-CELL PH, V282, pC494, DOI 10.1152/ajpcell.00408.2001; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Gupta S, 2003, J BIOL CHEM, V278, P43541, DOI 10.1074/jbc.M308960200; Hendron E, 2002, J BIOL CHEM, V277, P34480, DOI 10.1074/jbc.M204615200; HILGEMANN DW, 2001, SCI STKE; Hiromura M, 2004, J BIOL CHEM, V279, P53407, DOI 10.1074/jbc.M403775200; Hummler E, 1999, AM J PHYSIOL-GASTR L, V276, pG567, DOI 10.1152/ajpgi.1999.276.3.G567; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kunzelmann K, 2005, FASEB J, V19, P969, DOI 10.1096/fj.04-2469fje; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; Lopes CMB, 2005, J PHYSIOL-LONDON, V564, P117, DOI 10.1113/jphysiol.2004.081935; Lopes CMB, 2002, NEURON, V34, P933, DOI 10.1016/S0896-6273(02)00725-0; Ma HP, 2002, J BIOL CHEM, V277, P7641, DOI 10.1074/jbc.C100737200; Mall M, 2004, NAT MED, V10, P487, DOI 10.1038/nm1028; Paunescu TG, 2000, AM J PHYSIOL-CELL PH, V279, pC236, DOI 10.1152/ajpcell.2000.279.1.C236; Plaster NM, 2001, CELL, V105, P511, DOI 10.1016/S0092-8674(01)00342-7; Prescott ED, 2003, SCIENCE, V300, P1284, DOI 10.1126/science.1083646; Record RD, 1998, AM J PHYSIOL-ENDOC M, V274, pE611, DOI 10.1152/ajpendo.1998.274.4.E611; Rohacs T, 2003, P NATL ACAD SCI USA, V100, P745, DOI 10.1073/pnas.0236364100; Schulte U, 1999, P NATL ACAD SCI USA, V96, P15298, DOI 10.1073/pnas.96.26.15298; Shyng SL, 2000, J GEN PHYSIOL, V116, P599, DOI 10.1085/jgp.116.5.599; Snyder PM, 2002, ENDOCR REV, V23, P258, DOI 10.1210/er.23.2.258; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; Soom M, 2001, FEBS LETT, V490, P49, DOI 10.1016/S0014-5793(01)02136-6; Spehr M, 2002, NEURON, V33, P731, DOI 10.1016/S0896-6273(02)00610-4; Staruschenko A, 2005, BIOPHYS J, V88, P3966, DOI 10.1529/biophysj.104.056804; Staruschenko A, 2005, BBA-BIOMEMBRANES, V1669, P108, DOI 10.1016/j.bbamem.2005.01.005; Staruschenko A, 2004, J BIOL CHEM, V279, P49989, DOI 10.1074/jbc.M409812200; Staruschenko A, 2004, J BIOL CHEM, V279, P37771, DOI 10.1074/jbc.M402176200; Stockand JD, 1999, J BIOL CHEM, V274, P35449, DOI 10.1074/jbc.274.50.35449; Suh BC, 2002, NEURON, V35, P507, DOI 10.1016/S0896-6273(02)00790-0; Tong QS, 2004, J BIOL CHEM, V279, P22654, DOI 10.1074/jbc.M401004200; Tong QS, 2005, AM J PHYSIOL-RENAL, V288, pF150, DOI 10.1152/ajprenal.00261.2004; Tong QS, 2004, AM J PHYSIOL-RENAL, V286, pF1232, DOI 10.1152/ajprenal.00345.2003; Xiao J, 2003, NAT NEUROSCI, V6, P811, DOI 10.1038/nn1090; Yue G, 2002, J BIOL CHEM, V277, P11965, DOI 10.1074/jbc.M108951200; Zhainazarov AB, 2004, J MEMBRANE BIOL, V201, P51, DOI 10.1007/s00232-004-0707-4; Zhang HL, 1999, NAT CELL BIOL, V1, P183, DOI 10.1038/11103	55	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37565	37571		10.1074/jbc.M509071200	http://dx.doi.org/10.1074/jbc.M509071200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16154997	hybrid			2022-12-27	WOS:000233044500033
J	Swiatecka-Urban, A; Andrea, B; Moreau-Marquis, S; Renuka, J; Coutermarsh, B; Barnaby, R; Karlson, KH; Flotte, TR; Fukuda, M; Langford, GM; Stranton, BA				Swiatecka-Urban, A; Andrea, B; Moreau-Marquis, S; Renuka, J; Coutermarsh, B; Barnaby, R; Karlson, KH; Flotte, TR; Fukuda, M; Langford, GM; Stranton, BA			The short apical membrane half-life of rescued Delta F508-cystic fibrosis transmembrane conductance regulator (CFTR) results from accelerated endocytosis of Delta F508-CFTR in polarized human airway epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							GOLGI NETWORK LOCALIZATION; PLASMA-MEMBRANE; CYTOPLASMIC DOMAIN; CHLORIDE CHANNELS; ENDOPLASMIC-RETICULUM; NUCLEOTIDE-BINDING; PROTEIN EXPRESSION; HOMOZYGOUS TWINS; CL-SECRETION; MYOSIN VB	The most common mutation in the cystic fibrosis transmembrane conductance regulator ( CFTR) gene in individuals with cystic fibrosis, Delta F508, causes retention of Delta F508-CFTR in the endoplasmic reticulum and leads to the absence of CFTR Cl- channels in the apical plasma membrane. Rescue of Delta F508-CFTR by reduced temperature or chemical means reveals that the Delta F508 mutation reduces the half-life of Delta F508-CFTR in the apical plasma membrane. Because Delta F508-CFTR retains some Cl- channel activity, increased expression of \Delta F508-CFTR in the apical membrane could serve as a potential therapeutic approach for cystic fibrosis. However, little is known about the mechanisms responsible for the short apical membrane half-life of Delta F508-CFTR in polarized human airway epithelial cells. Accordingly, the goal of this study was to determine the cellular defects in the trafficking of rescued Delta F508-CFTR that lead to the decreased apical membrane half-life of Delta F508-CFTR in polarized human airway epithelial cells. We report that in polarized human airway epithelial cells (CFBE41o-) the Delta F508 mutation increased endocytosis of CFTR from the apical membrane without causing a global endocytic defect or affecting the endocytic recycling of CFTR in the Rab11a-specific apical recycling compartment.	Dartmouth Coll Sch Med, Dept Physiol, Hanover, NH 03755 USA; Univ Florida, Coll Med, Dept Pediat, Gainesville, FL 32610 USA; RIKEN, Inst Phys & Chem Res, Fukuda Initiat Res Unit, Wako, Saitama 3510198, Japan; Dartmouth Coll, Dept Biol Sci, Hanover, NH 03755 USA	Dartmouth College; State University System of Florida; University of Florida; RIKEN; Dartmouth College	Swiatecka-Urban, A (corresponding author), Dartmouth Coll Sch Med, Dept Physiol, Hanover, NH 03755 USA.	Agnieszka.Swiatecka-Urban@Dartmouth.edu	SWIATECKA-URBAN, AGNIESZKA/H-6494-2015; Fukuda, MItsunori/I-1511-2015; Swiatecka-Urban, Agnieszka/AAP-6041-2020	SWIATECKA-URBAN, AGNIESZKA/0000-0002-6575-0334; Fukuda, MItsunori/0000-0002-8620-5853; Langford, George/0000-0001-9737-2182	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018787] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045881, R01DK034533] Funding Source: NIH RePORTER; NCRR NIH HHS [P20-RR018787] Funding Source: Medline; NIDDK NIH HHS [R01-DK34533, R01-DK45881] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AlvarezDominguez C, 1996, J BIOL CHEM, V271, P13834, DOI 10.1074/jbc.271.23.13834; Bebok Z, 1998, AM J PHYSIOL-CELL PH, V275, pC599, DOI 10.1152/ajpcell.1998.275.2.C599; Bilan F, 2004, J CELL SCI, V117, P1923, DOI 10.1242/jcs.01070; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; BRADBURY NA, 1994, J BIOL CHEM, V269, P8296; Brezillon S, 1997, HUM PATHOL, V28, P944, DOI 10.1016/S0046-8177(97)90010-1; Bronsveld I, 2001, J CLIN INVEST, V108, P1705; Bronsveld I, 2000, GASTROENTEROLOGY, V119, P32, DOI 10.1053/gast.2000.8524; Brown CR, 1996, CELL STRESS CHAPERON, V1, P117, DOI 10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2; Brown PS, 2000, TRAFFIC, V1, P124, DOI 10.1034/j.1600-0854.2000.010205.x; Bruscia E, 2002, GENE THER, V9, P683, DOI 10.1038/sj.gt.3301741; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Calhoun BC, 1998, AM J PHYSIOL-CELL PH, V275, pC163, DOI 10.1152/ajpcell.1998.275.1.C163; Carvalho-Oliveira I, 2004, J HISTOCHEM CYTOCHEM, V52, P193, DOI 10.1177/002215540405200207; Casanova JE, 1999, MOL BIOL CELL, V10, P47, DOI 10.1091/mbc.10.1.47; Castillon N, 2002, LAB INVEST, V82, P989, DOI 10.1097/01.LAB.0000022221.88025.43; Chen J, 2005, J BIOL CHEM, V280, P29912, DOI 10.1074/jbc.M504516200; Cheng J, 2004, J BIOL CHEM, V279, P1892, DOI 10.1074/jbc.M308640200; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Cormet-Boyaka E, 2002, P NATL ACAD SCI USA, V99, P12477, DOI 10.1073/pnas.192203899; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; Dale LB, 2004, J BIOL CHEM, V279, P13110, DOI 10.1074/jbc.M313333200; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Desrosiers RR, 1998, BIOCHEM CELL BIOL, V76, P63, DOI 10.1139/bcb-76-1-63; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; Duman JG, 1999, AM J PHYSIOL-CELL PH, V277, pC361, DOI 10.1152/ajpcell.1999.277.3.C361; DUNN KW, 1994, J BIOL CHEM, V269, P5336; EGAN ME, 1995, AM J PHYSIOL-CELL PH, V268, pC243, DOI 10.1152/ajpcell.1995.268.1.C243; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; Freedman SD, 2001, GASTROENTEROLOGY, V121, P950, DOI 10.1053/gast.2001.27992; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FULLER CM, 1992, AM J PHYSIOL, V263, pC267, DOI 10.1152/ajpcell.1992.263.2.C267; Gentzsch M, 2004, MOL BIOL CELL, V15, P2684, DOI 10.1091/mbc.E04-03-0176; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Goldenring JR, 1996, AM J PHYSIOL-GASTR L, V270, pG515, DOI 10.1152/ajpgi.1996.270.3.G515; Hales CM, 2001, J BIOL CHEM, V276, P39067, DOI 10.1074/jbc.M104831200; Haws CM, 1996, AM J PHYSIOL-CELL PH, V270, pC1544, DOI 10.1152/ajpcell.1996.270.5.C1544; Heda GD, 2000, BIOCHEM BIOPH RES CO, V271, P659, DOI 10.1006/bbrc.2000.2684; Hentchel-Franks K, 2004, AM J RESP CELL MOL, V31, P140, DOI 10.1165/rcmb.2004-0012OC; Howard M, 1995, AM J PHYSIOL-CELL PH, V269, pC1565, DOI 10.1152/ajpcell.1995.269.6.C1565; HOWARD M, 2002, AM J PHYSIOL-CELL PH, V279, P375; Hu W, 2001, BIOCHEM J, V354, P561, DOI 10.1042/0264-6021:3540561; Jiang CW, 1998, AM J PHYSIOL-CELL PH, V275, pC171, DOI 10.1152/ajpcell.1998.275.1.C171; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; Kalin N, 1999, J CLIN INVEST, V103, P1379, DOI 10.1172/JCI5731; Kim H, 1997, AM J PHYSIOL-CELL PH, V273, pC687, DOI 10.1152/ajpcell.1997.273.2.C687; Komatani H, 2001, CANCER RES, V61, P2827; Kuroda TS, 2002, J BIOL CHEM, V277, P9212, DOI 10.1074/jbc.M112414200; Lapierre LA, 2001, MOL BIOL CELL, V12, P1843, DOI 10.1091/mbc.12.6.1843; Lavialle F, 2000, BBA-BIOMEMBRANES, V1464, P83, DOI 10.1016/S0005-2736(99)00251-5; Lehrich RW, 1998, J CLIN INVEST, V101, P737, DOI 10.1172/JCI803; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; Lewis HA, 2005, J BIOL CHEM, V280, P1346, DOI 10.1074/jbc.M410968200; Loffing J, 1998, AM J PHYSIOL-CELL PH, V275, pC913, DOI 10.1152/ajpcell.1998.275.4.C913; Lu H, 2004, AM J PHYSIOL-RENAL, V286, pF233, DOI 10.1152/ajprenal.00179.2003; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; Lukacs GL, 1997, BIOCHEM J, V328, P353; LUKACS GL, 1993, J BIOL CHEM, V268, P21592; Maliepaard M, 2001, CANCER RES, V61, P3458; MELLMAN I, 1993, J CELL SCI, P1; Moore RH, 2004, J CELL SCI, V117, P3107, DOI 10.1242/jcs.01168; Moyer BD, 1998, J BIOL CHEM, V273, P21759, DOI 10.1074/jbc.273.34.21759; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Musch A, 1996, J CELL BIOL, V133, P543, DOI 10.1083/jcb.133.3.543; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; Ohno H, 1998, J BIOL CHEM, V273, P25915, DOI 10.1074/jbc.273.40.25915; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; Peters KW, 1999, AM J PHYSIOL-CELL PH, V277, pC174, DOI 10.1152/ajpcell.1999.277.1.C174; Picciano JA, 2003, AM J PHYSIOL-CELL PH, V285, pC1009, DOI 10.1152/ajpcell.00140.2003; Poschet JF, 2002, J BIOL CHEM, V277, P13959, DOI 10.1074/jbc.M105441200; Prince LS, 1999, J BIOL CHEM, V274, P3602, DOI 10.1074/jbc.274.6.3602; Ren MD, 1998, P NATL ACAD SCI USA, V95, P6187, DOI 10.1073/pnas.95.11.6187; RIORDAN JR, 1989, SCIENCE, V245, P1066; Roberts RL, 2000, J LEUKOCYTE BIOL, V68, P627; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Rubenstein RC, 1997, J CLIN INVEST, V100, P2457, DOI 10.1172/JCI119788; SANTOS GF, 1994, BBA-BIOMEMBRANES, V1195, P96, DOI 10.1016/0005-2736(94)90014-0; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; Schnatwinkel C, 2004, PLOS BIOL, V2, P1363, DOI 10.1371/journal.pbio.0020261; Segev N, 2001, SCI STKE, pre11, DOI DOI 10.1126/STKE.2001.100.RE11; Sharma M, 2004, J CELL BIOL, V164, P923, DOI 10.1083/jcb.200312018; Sharma M, 2001, J BIOL CHEM, V276, P8942, DOI 10.1074/jbc.M009172200; Spilmont C, 1996, BIOCHEM BIOPH RES CO, V227, P182, DOI 10.1006/bbrc.1996.1486; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Swiatecka-Urban A, 2004, J BIOL CHEM, V279, P38025, DOI 10.1074/jbc.M403141200; Swiatecka-Urban A, 2002, J BIOL CHEM, V277, P40099, DOI 10.1074/jbc.M206964200; Tsigelny I, 2005, CELL BIOCHEM BIOPHYS, V42, P41, DOI 10.1385/CBB:42:1:041; Tuma PL, 2002, MOL BIOL CELL, V13, P3400, DOI 10.1091/mbc.02-04-0054; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; van der Deen M, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-59; Virella-Lowell I, 2004, MOL THER, V10, P562, DOI 10.1016/j.ymthe.2004.06.215; Volpicelli LA, 2002, J NEUROSCI, V22, P9776, DOI 10.1523/jneurosci.22-22-09776.2002; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; Wang XY, 2000, J BIOL CHEM, V275, P29138, DOI 10.1074/jbc.M004410200; Weixel KM, 2001, J BIOL CHEM, V276, P46251, DOI 10.1074/jbc.M104545200; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247	103	154	159	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36762	36772		10.1074/jbc.M508944200	http://dx.doi.org/10.1074/jbc.M508944200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16131493	hybrid			2022-12-27	WOS:000232901800030
J	Valeva, A; Walev, I; Kemmer, H; Weis, S; Siegel, I; Boukhallouk, F; Wassenaar, TM; Chavakis, T; Bhakdi, S				Valeva, A; Walev, I; Kemmer, H; Weis, S; Siegel, I; Boukhallouk, F; Wassenaar, TM; Chavakis, T; Bhakdi, S			Binding of Escherichia coli hemolysin and activation of the target cells is not receptor-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHILS; ALPHA-HEMOLYSIN; RESPIRATORY BURST; RTX TOXINS; MEMBRANES; ACYLATION; INTEGRIN; ERYTHROCYTES; ASSOCIATION; INSERTION	Production of a single cysteine substitution mutant, S177C, allowed Escherichia coli hemolysin ( HlyA) to be radioactively labeled with tritiated N-ethylmaleimide without affecting biological activity. It thus became possible to study the binding characteristics of HlyA as well as of toxin mutants in which one or both acylation sites were deleted. All toxins bound to erythrocytes and granulocytes in a nonsaturable manner. Only wild-type toxin and the lytic monoacylated mutant stimulated production of superoxide anions in granulocytes. An oxidative burst coincided with elevation of intracellular Ca2+, which was likely because of passive influx of Ca2+ through the toxin pores. Competition experiments showed that binding to the cells was receptor-independent, and preloading of cells with a nonlytic HlyA mutant did not abrogate the respiratory burst provoked by a subsequent application of wild-type HlyA. In contrast to a previous report, expression or activation of the beta(2) integrin lymphocyte function-associated antigen-1 did not affect binding of HlyA. We conclude that HlyA binds nonspecifically to target cells and a receptor is involved neither in causing hemolysis nor in triggering cellular reactions.	Univ Mainz, Inst Med Microbiol & Hyg, D-55101 Mainz, Germany; Mol Microbiol & Genom Consultants, D-55576 Zotzenheim, Germany; NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA	Johannes Gutenberg University of Mainz; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Valeva, A (corresponding author), Univ Mainz, Inst Med Microbiol & Hyg, Hochhaus Augustuspl, D-55101 Mainz, Germany.	avaleva@uni-mainz.de	Chavakis, Triantafyllos/ABE-8845-2020	Wassenaar, Trudy/0000-0002-7024-1139	Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bakas L, 1996, BIOPHYS J, V71, P1869, DOI 10.1016/S0006-3495(96)79386-4; Basar T, 2001, J BIOL CHEM, V276, P348, DOI 10.1074/jbc.M006463200; Bauer ME, 1996, INFECT IMMUN, V64, P4665, DOI 10.1128/IAI.64.11.4665-4672.1996; BENZ R, 1989, INFECT IMMUN, V57, P887, DOI 10.1128/IAI.57.3.887-895.1989; BHAKDI S, 1989, J EXP MED, V169, P737, DOI 10.1084/jem.169.3.737; BHAKDI S, 1989, INFECT IMMUN, V57, P3512, DOI 10.1128/IAI.57.11.3512-3519.1989; BHAKDI S, 1991, INFECT IMMUN, V59, P2955, DOI 10.1128/IAI.59.9.2955-2962.1991; Cortajarena AL, 2001, J BIOL CHEM, V276, P12513, DOI 10.1074/jbc.M006792200; Dahlgren C, 1999, J IMMUNOL METHODS, V232, P3, DOI 10.1016/S0022-1759(99)00146-5; EBERSPACHER B, 1989, INFECT IMMUN, V57, P983; GARNOTEL R, 1995, J BIOL CHEM, V270, P27495, DOI 10.1074/jbc.270.46.27495; GRIMMINGER F, 1991, J CLIN INVEST, V88, P1531, DOI 10.1172/JCI115463; GRIMMINGER F, 1991, J BIOL CHEM, V266, P14262; Herlax V, 2003, CHEM PHYS LIPIDS, V122, P185, DOI 10.1016/S0009-3084(02)00191-3; Hyland C, 2001, J BACTERIOL, V183, P5364, DOI 10.1128/JB.183.18.5364-5370.2001; Jeyaseelan S, 2001, INFECT IMMUN, V69, P6131, DOI 10.1128/IAI.69.10.6131-6139.2001; Krauss K, 1999, J BIOL CHEM, V274, P36921, DOI 10.1074/jbc.274.52.36921; Lally ET, 1997, J BIOL CHEM, V272, P30463, DOI 10.1074/jbc.272.48.30463; MENESTRINA G, 1987, BIOCHIM BIOPHYS ACTA, V905, P109, DOI 10.1016/0005-2736(87)90014-9; Schindel C, 2001, EUR J BIOCHEM, V268, P800, DOI 10.1046/j.1432-1327.2001.01937.x; Soloaga A, 1996, EUR J BIOCHEM, V238, P418, DOI 10.1111/j.1432-1033.1996.0418z.x; STANLEY P, 1994, SCIENCE, V266, P1992, DOI 10.1126/science.7801126; Stanley P, 1998, MICROBIOL MOL BIOL R, V62, P309, DOI 10.1128/MMBR.62.2.309-333.1998; Stephens P, 1995, CELL ADHES COMMUN, V3, P375, DOI 10.3109/15419069509081292; Valeva A, 2004, J BIOL CHEM, V279, P25143, DOI 10.1074/jbc.M313913200; VANEPPS DE, 1989, J IMMUNOL, V143, P3207; Welch RA, 2001, CURR TOP MICROBIOL, V257, P85; Weller U, 1996, EUR J BIOCHEM, V236, P34, DOI 10.1111/j.1432-1033.1996.00034.x	28	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36657	36663		10.1074/jbc.M507690200	http://dx.doi.org/10.1074/jbc.M507690200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16131494	hybrid			2022-12-27	WOS:000232901800017
J	Huang, LY; Hwang, J; Sharma, SD; Hargittai, MRS; Chen, YF; Arnold, JJ; Raney, KD; Cameron, CE				Huang, LY; Hwang, J; Sharma, SD; Hargittai, MRS; Chen, YF; Arnold, JJ; Raney, KD; Cameron, CE			Hepatitis C virus nonstructural protein 5A (NS5A) is an RNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME ENTRY SITE; NONTRANSLATED REGION; SECONDARY STRUCTURE; NS3 PROTEASE; CELL-LINES; LA PROTEIN; CDNA-CLONE; REPLICATION; POLYMERASE; DOMAIN	Hepatitis C virus (HCV) nonstructural protein 5A (NS5A) has been shown to antagonize numerous cellular pathways, including the antiviral interferon-alpha response. However, the capacity of this protein to interact with the viral polymerase suggests a more direct role for NS5A in genome replication. In this study, we employed two bacterially expressed, soluble derivatives of NS5A to probe for novel functions of this protein. We find that NS5A has the capacity to bind to the 3'-ends of HCV plus and minus strand RNAs. The high affinity binding site for NS5A in the 3'-end of plus strand RNA maps to the polypyrimidine tract, an element known to be essential for genome replication and infectivity. NS5A has a preference for single-stranded RNA containing stretches of uridine or guanosine. Values for the equilibrium dissociation constants for high affinity binding sites were in the 10 nM range. Two-dimensional gel electrophoresis followed by Western blotting revealed the presence of unphosphorylated NS5A in Huh-7 cells stably expressing the subgenomic replicon. Moreover, RNA immunoprecipitation and NS5A pull-down experiments showed the capacity of replicon-derived NS5A to bind to synthetic RNA and the HCV genome, respectively. Deletion of all of the casein kinase II phosphorylation sites in NS5A supported stable replication of a subgenomic replicon in Huh-7. However, this derivative could not be labeled with inorganic phosphate, suggesting that extensive phosphorylation of NS5A is not required for the replication functions of NS5A. The discovery that NS5A is an RNA-binding protein defines a new functional target for development of agents to treat HCV infection and a new structural class of RNA-binding proteins.	Penn State Univ, Dept Biochem & Mol Biol, Althouse Lab 201, University Pk, PA 16802 USA; Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Arkansas System; University of Arkansas Medical Sciences	Cameron, CE (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, Althouse Lab 201, University Pk, PA 16802 USA.	cec9@psu.edu	SHARMA, Suresh/C-4431-2008; Hwang, Jungwook/P-1614-2015; SHARMA, Suresh D./AAD-7723-2022	SHARMA, Suresh/0000-0002-8633-4145; Hwang, Jungwook/0000-0002-2290-1649; SHARMA, Suresh D./0000-0002-8633-4145	NIAID NIH HHS [AI66919] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ali N, 1997, P NATL ACAD SCI USA, V94, P2249, DOI 10.1073/pnas.94.6.2249; Allers J, 2001, J MOL BIOL, V311, P75, DOI 10.1006/jmbi.2001.4857; [Anonymous], 2002, NIH Consens State Sci Statements, V19, P1; Asabe SI, 1997, J VIROL, V71, P790, DOI 10.1128/JVI.71.1.790-796.1997; Blight KJ, 2002, J VIROL, V76, P13001, DOI 10.1128/JVI.76.24.13001-13014.2002; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Brass V, 2002, J BIOL CHEM, V277, P8130, DOI 10.1074/jbc.M111289200; Canadillas JMP, 2003, EMBO J, V22, P2821, DOI 10.1093/emboj/cdg259; Chadalavada DM, 2000, J MOL BIOL, V301, P349, DOI 10.1006/jmbi.2000.3953; Chen L, 2003, NEUROSCIENCE, V120, P1005, DOI 10.1016/S0306-4522(03)00406-8; Collier AJ, 2002, NAT STRUCT BIOL, V9, P375, DOI 10.1038/nsb785; De Gaudenzi JG, 2003, J BIOL CHEM, V278, P18884, DOI 10.1074/jbc.M301756200; Dimitrova M, 2003, J VIROL, V77, P5401, DOI 10.1128/JVI.77.9.5401-5414.2003; Egger D, 2002, J VIROL, V76, P5974, DOI 10.1128/JVI.76.12.5974-5984.2002; Forch P, 2000, MOL CELL, V6, P1089, DOI 10.1016/S1097-2765(00)00107-6; Friebe P, 2002, J VIROL, V76, P5326, DOI 10.1128/JVI.76.11.5326-5338.2002; Friebe P, 2001, J VIROL, V75, P12047, DOI 10.1128/JVI.75.24.12047-12057.2001; Gallinari P, 1999, BIOCHEMISTRY-US, V38, P5620, DOI 10.1021/bi982892+; Gong GZ, 2001, P NATL ACAD SCI USA, V98, P9599, DOI 10.1073/pnas.171311298; GUERON M, 1987, NATURE, V328, P89, DOI 10.1038/328089a0; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; Herold J, 2001, MOL CELL, V7, P581, DOI 10.1016/S1097-2765(01)00205-2; Huang LY, 2004, PROTEIN EXPRES PURIF, V37, P144, DOI 10.1016/j.pep.2004.05.005; Ito T, 1998, J VIROL, V72, P8789, DOI 10.1128/JVI.72.11.8789-8796.1998; Ito T, 1997, J VIROL, V71, P8698, DOI 10.1128/JVI.71.11.8698-8706.1997; Kieft JS, 2002, NAT STRUCT BIOL, V9, P370, DOI 10.1038/nsb781; Koch JO, 1999, J VIROL, V73, P7138; Kolykhalov AA, 1997, SCIENCE, V277, P570, DOI 10.1126/science.277.5325.570; Kolykhalov AA, 1996, J VIROL, V70, P3363, DOI 10.1128/JVI.70.6.3363-3371.1996; Konan KV, 2003, J VIROL, V77, P7843, DOI 10.1128/JVI.77.14.7843-7855.2003; LEROY JL, 1985, J BIOMOL STRUCT DYN, V2, P915, DOI 10.1080/07391102.1985.10507609; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Lytle JR, 2002, RNA, V8, P1045, DOI 10.1017/S1355838202029965; Neddermann P, 1999, J VIROL, V73, P9984, DOI 10.1128/JVI.73.12.9984-9991.1999; Ohndorf UM, 2001, J BIOL CHEM, V276, P27188, DOI 10.1074/jbc.M102891200; Pang PS, 2002, EMBO J, V21, P1168, DOI 10.1093/emboj/21.5.1168; Pathak HB, 2002, J BIOL CHEM, V277, P31551, DOI 10.1074/jbc.M204408200; Piccininni S, 2002, J BIOL CHEM, V277, P45670, DOI 10.1074/jbc.M204124200; Pietschmann T, 2001, J VIROL, V75, P1252, DOI 10.1128/JVI.75.3.1252-1264.2001; Reyes GR, 2002, J BIOMED SCI, V9, P187, DOI 10.1007/BF02256065; Schuster C, 2002, J VIROL, V76, P8058, DOI 10.1128/JVI.76.16.8058-8068.2002; Shimakami T, 2004, J VIROL, V78, P2738, DOI 10.1128/JVI.78.6.2738-2748.2004; Shirota Y, 2002, J BIOL CHEM, V277, P11149, DOI 10.1074/jbc.M111392200; Spangberg K, 1999, J HUMAN VIROL, V2, P296; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; Tallet-Lopez B, 2003, NUCLEIC ACIDS RES, V31, P734, DOI 10.1093/nar/gkg139; Tan SL, 2001, VIROLOGY, V284, P1, DOI 10.1006/viro.2001.0885; TANJI Y, 1995, J VIROL, V69, P3980, DOI 10.1128/JVI.69.7.3980-3986.1995; Tellinghuisen TL, 2005, NATURE, V435, P374, DOI 10.1038/nature03580; Tellinghuisen TL, 2004, J BIOL CHEM, V279, P48576, DOI 10.1074/jbc.M407787200; Tellinghuisen TL, 2002, CURR OPIN MICROBIOL, V5, P419, DOI 10.1016/S1369-5274(02)00341-7; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; Yanagi M, 1998, VIROLOGY, V244, P161, DOI 10.1006/viro.1998.9092; Yanagi M, 1997, P NATL ACAD SCI USA, V94, P8738, DOI 10.1073/pnas.94.16.8738; Yanagi M, 1999, P NATL ACAD SCI USA, V96, P2291, DOI 10.1073/pnas.96.5.2291; Yi MK, 2003, J VIROL, V77, P3557, DOI 10.1128/JVI.77.6.3557-3568.2003; You SY, 2004, J VIROL, V78, P1352, DOI 10.1128/JVI.78.3.1352-1366.2004	57	191	202	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36417	36428		10.1074/jbc.M508175200	http://dx.doi.org/10.1074/jbc.M508175200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16126720	Green Published, hybrid			2022-12-27	WOS:000232726900076
J	Mikami, F; Gu, H; Jono, H; Andalibi, A; Kai, H; Li, JD				Mikami, F; Gu, H; Jono, H; Andalibi, A; Kai, H; Li, JD			Epidermal growth factor receptor acts as a negative regulator for bacterium nontypeable Haemophilus influenzae-induced toll-like receptor 2 expression via an Src-dependent p38 mitogen-activated protein kinase signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TOLL-LIKE RECEPTORS; MUC5AC MUCIN TRANSCRIPTION; EPITHELIAL-CELLS; HUMAN CYTOMEGALOVIRUS; STAPHYLOCOCCUS-AUREUS; FAMILY KINASES; PAF RECEPTOR; MAP KINASE; INDUCTION	Epidermal growth factor receptor ( EGFR) has been shown to play important roles in regulating diverse biological processes, including cell growth, differentiation, apoptosis, adhesion, and migration. Its role in regulating human Toll-like receptors (TLRs), key host defense receptors that recognize invading bacterial pathogens, however, remains unknown. Here we show for the first time that EGFR acts as a negative regulator for TLR2 induction by the bacterium nontypeable Haemophilus influenzae (NTHi) in vitro and in vivo. The negative regulation of TLR2 induction by EGFR is mediated via an Src-MKK3/6-p38 alpha/beta MAP kinase-dependent mechanism. Moreover, direct activation of EGFR signaling by the bacterium NTHi-derived EGF-like factor appears to be responsible for triggering the downstream Src-MKK3/6-p38 MAPK signaling, which in turn leads to the negative regulation of TLR2 induction. Finally, exogenous EGF increases NTHi invasion of host epithelial cells, thereby demonstrating the biological significance of TLR2 regulation by EGFR signaling. The evidence we provided in the present study may suggest a novel strategy utilized by bacteria to attenuate host defensive and immune response by negatively regulating the expression of host defense receptor TLR2. These studies may bring new insight for fully understanding the important role of EGFR signaling in regulating host defense and immune response by tightly controlling TLR2 induction during bacterial infections.	Univ So Calif, House Ear Inst, Gonda Dept Cell & Mol Biol, Los Angeles, CA 90057 USA; Univ So Calif, Dept Otolaryngol, Los Angeles, CA 90057 USA; Kumamoto Univ, Dept Mol Med, Kumamoto 8620973, Japan	House Research Institute; University of Southern California; University of Southern California; Kumamoto University	Li, JD (corresponding author), Univ So Calif, House Ear Inst, Gonda Dept Cell & Mol Biol, 2100 W 3rd St, Los Angeles, CA 90057 USA.	jdli@hei.org		Li, Jian-Dong/0000-0002-5593-050X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070293] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC005843, R01DC004562] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL070293] Funding Source: Medline; NIDCD NIH HHS [DC005843, DC004562] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Boyer L, 2004, NAT REV MICROBIOL, V2, P779, DOI 10.1038/nrmicro1005; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; Chen R, 2004, BIOCHEM BIOPH RES CO, V324, P1087, DOI 10.1016/j.bbrc.2004.09.157; Compton T, 2004, TRENDS CELL BIOL, V14, P5, DOI 10.1016/j.tcb.2003.10.009; Frey MR, 2004, J BIOL CHEM, V279, P44513, DOI 10.1074/jbc.M406253200; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Imasato A, 2002, J BIOL CHEM, V277, P47444, DOI 10.1074/jbc.M208140200; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jono H, 2003, J BIOL CHEM, V278, P27811, DOI 10.1074/jbc.M301773200; Jono H, 2002, J BIOL CHEM, V277, P45547, DOI 10.1074/jbc.M206883200; Jono H, 2004, J BIOL CHEM, V279, P36171, DOI 10.1074/jbc.M406638200; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Keates S, 2001, J BIOL CHEM, V276, P48127, DOI 10.1074/jbc.M107630200; KELLY SJ, 2003, AM J PHYSIOL, V284, pC339; Kopp E, 2003, CURR OPIN IMMUNOL, V15, P396, DOI 10.1016/S0952-7915(03)00080-3; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; Li JD, 2003, J PHARMACOL SCI, V91, P1, DOI 10.1254/jphs.91.1; Li JD, 1998, P NATL ACAD SCI USA, V95, P5718, DOI 10.1073/pnas.95.10.5718; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X; Miller WE, 1999, TRENDS MICROBIOL, V7, P453, DOI 10.1016/S0966-842X(99)01605-4; Monick MM, 2005, J BIOL CHEM, V280, P2147, DOI 10.1074/jbc.M408745200; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Orth K, 2000, SCIENCE, V290, P1594, DOI 10.1126/science.290.5496.1594; Ouwens DM, 2002, EMBO J, V21, P3782, DOI 10.1093/emboj/cdf361; Shuto T, 2002, J BIOL CHEM, V277, P17263, DOI 10.1074/jbc.M112190200; Shuto T, 2001, P NATL ACAD SCI USA, V98, P8774, DOI 10.1073/pnas.151236098; Swords WE, 2000, MOL MICROBIOL, V37, P13, DOI 10.1046/j.1365-2958.2000.01952.x; Swords WE, 2001, CELL MICROBIOL, V3, P525, DOI 10.1046/j.1462-5822.2001.00132.x; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Thoma-Uszynski S, 2001, SCIENCE, V291, P1544, DOI 10.1126/science.291.5508.1544; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tschumperlin DJ, 2004, NATURE, V429, P83, DOI 10.1038/nature02543; Visintin A, 2001, J IMMUNOL, V166, P249, DOI 10.4049/jimmunol.166.1.249; Wang BN, 2002, J BIOL CHEM, V277, P949, DOI 10.1074/jbc.M107484200; Wang X, 2005, NAT MED, V11, P515, DOI 10.1038/nm1236; Wang X, 2003, NATURE, V424, P456, DOI 10.1038/nature01818; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351	42	50	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36185	36194		10.1074/jbc.M503941200	http://dx.doi.org/10.1074/jbc.M503941200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16115866	hybrid			2022-12-27	WOS:000232726900050
J	Xu, HY; Yang, Q; Shen, MH; Huang, XM; Dembski, M; Gimeno, R; Tartaglia, LA; Kapeller, R; Wu, ZD				Xu, HY; Yang, Q; Shen, MH; Huang, XM; Dembski, M; Gimeno, R; Tartaglia, LA; Kapeller, R; Wu, ZD			Dual specificity MAPK phosphatase 3 activates PEPCK gene transcription and increases gluconeogenesis in rat hepatoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYKINASE GTP GENE; PROTEIN-KINASE; INSULIN-RESISTANCE; EXPRESSION; ADIPOCYTES; PATHWAY; TARGETS; CLONING; MKP-3	Insulin is a key hormone that controls glucose homeostasis. In liver, insulin suppresses gluconeogenesis by inhibiting the transcriptions of phosphoenolpyruvate carboxylase ( PEPCK) and glucose-6-phosphatase (G6Pase) genes. In insulin resistance and type II diabetes there is an elevation of hepatic gluconeogenesis, which contributes to hyperglycemia. To search for novel genes that negatively regulate insulin signaling in controlling metabolic pathways, we screened a cDNA library derived from the white adipose tissue of ob/ob mice using a reporter system comprised of the PEPCK promoter placed upstream of the alkaline phosphatase gene. The mitogen-activated dual specificity protein kinase phosphatase 3 (MKP-3) was identified as a candidate gene that antagonized insulin suppression on PEPCK gene transcription from this screen. In this study, we showed that MKP-3 was expressed in insulin-responsive tissues and that its expression was markedly elevated in the livers of insulin-resistant obese mice. In addition, MKP-3 can activate PEPCK promoter in synergy with dexamethasone in hepatoma cells. Furthermore, ectopic expression of MKP-3 in hepatoma cells by adenoviral infection increased the expression of PEPCK and G6Pase genes and led to elevated glucose production. Taken together, our data strongly suggests that MKP-3 plays a role in regulating gluconeogenic gene expression and hepatic gluconeogenesis. Therefore, dysregulation of MKP-3 expression and/or function in liver may contribute to the pathogenesis of insulin resistance and type II diabetes.	Millennium Pharmaceut Inc, Cambridge, MA 02139 USA	Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Wu, ZD (corresponding author), Novartis Inst Biomed Res Inc, 100 Technol Sq, Cambridge, MA 02139 USA.	zhidan.wu@pharma.novartis.com		Wu, Zhidan/0000-0001-7289-9420	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK080746] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK080746] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barf T, 2004, MINI-REV MED CHEM, V4, P897, DOI 10.2174/1389557043403459; Barthel A, 2003, AM J PHYSIOL-ENDOC M, V285, pE685, DOI 10.1152/ajpendo.00253.2003; Bazuine M, 2004, MOL ENDOCRINOL, V18, P1697, DOI 10.1210/me.2003-0213; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Dickinson RJ, 2002, MECH DEVELOP, V113, P193, DOI 10.1016/S0925-4773(02)00024-2; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; Hanson R W, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P203; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Jascur T, 1997, J BIOL CHEM, V272, P14483, DOI 10.1074/jbc.272.22.14483; Klock A, 2002, MECH DEVELOP, V116, P243, DOI 10.1016/S0925-4773(02)00153-3; KRAUSFRIEDMANN N, 1984, PHYSIOL REV, V64, P170, DOI 10.1152/physrev.1984.64.1.170; Moller DE, 2001, NATURE, V414, P821, DOI 10.1038/414821a; Muda M, 1996, J BIOL CHEM, V271, P4319; O'Brien RM, 2001, BIOCHEM SOC T, V29, P552, DOI 10.1042/BST0290552; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; OBRIEN RM, 1990, DIABETES CARE, V13, P327, DOI 10.2337/diacare.13.3.327; Olswang Y, 2003, J BIOL CHEM, V278, P12929, DOI 10.1074/jbc.M300263200; Sakaue H, 2004, J BIOL CHEM, V279, P39951, DOI 10.1074/jbc.M407353200; Sutherland C, 1996, PHILOS T ROY SOC B, V351, P191, DOI 10.1098/rstb.1996.0016; Sutherland C, 1998, J BIOL CHEM, V273, P3198, DOI 10.1074/jbc.273.6.3198; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Waltner-Law M, 2003, J BIOL CHEM, V278, P10427, DOI 10.1074/jbc.M211846200; Xu HY, 2003, J BIOL CHEM, V278, P30187, DOI 10.1074/jbc.M302010200	26	34	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36013	36018		10.1074/jbc.M508027200	http://dx.doi.org/10.1074/jbc.M508027200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16126724	hybrid			2022-12-27	WOS:000232726900030
J	Holm, MM; Naur, P; Vestergaard, B; Geballe, MT; Gajhede, M; Kastrup, JS; Traynelis, SF; Egebjerg, J				Holm, MM; Naur, P; Vestergaard, B; Geballe, MT; Gajhede, M; Kastrup, JS; Traynelis, SF; Egebjerg, J			A binding site tyrosine shapes desensitization kinetics and agonist potency at GluR2 - A mutagenic, kinetic, and crystallographic study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMATE-RECEPTOR DESENSITIZATION; AMPA RECEPTORS; CRYSTAL-STRUCTURES; KAINATE RECEPTORS; STRUCTURAL BASIS; NMDA RECEPTOR; ION CHANNELS; ACTIVATION; CORE; MECHANISMS	Binding of an agonist to the 2- amino- 3-( 3- hydroxy- 5- methyl- 4-isoxazolyl)- propionic acid ( AMPA) receptor family of the glutamate receptors ( GluRs) results in rapid activation of an ion channel. Continuous application results in a non- desensitizing response for agonists like kainate, whereas most other agonists, such as the endogenous agonist ( S)- glutamate, induce desensitization. We demonstrate that a highly conserved tyrosine, forming a wedge between the agonist and the N- terminal part of the bi- lobed ligand- binding site, plays a key role in the receptor kinetics as well as agonist potency and selectivity. The AMPA receptor GluR2, with mutations in Tyr450, were expressed in Xenopus laevis oocytes and characterized in a two- electrode voltage clamp setup. The mutation GluR2( Y450A) renders the receptor highly kainate selective, and rapid application of kainate to outside- out patches induced strongly desensitizing currents. When Tyr- 450 was substituted with the larger tryptophan, the ( S)- glutamate desensitization is attenuated with a 10- fold increase in steady- state/ peak currents ( 19% compared with 1.9% at the wild type). Furthermore, the tryptophan mutant was introduced into the GluR2- S1S2J ligand binding core construct and co- crystallized with kainate, and the 2.1- angstrom x- ray structure revealed a slightly more closed ligand binding core as compared with the wild- type complex. Through genetic manipulations combined with structural and electrophysiological analysis, we report that mutations in position 450 invert the potency of two central agonists while concurrently strongly shaping the agonist efficacy and the desensitization kinetics of the AMPA receptor GluR2.	Univ Aarhus, Inst Physiol & Biophys, Dept Mol Biol, DK-8000 Aarhus, Denmark; Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Danish Univ Pharmaceut Sci, Dept Med Chem, DK-2100 Copenhagen, Denmark; Emory Univ, Dept Chem, Atlanta, GA 30322 USA	Aarhus University; Emory University; University of Copenhagen; Emory University	Holm, MM (corresponding author), Univ Aarhus, Inst Physiol & Biophys, Dept Mol Biol, Bldg 16,, DK-8000 Aarhus, Denmark.	mmh@fi.au.dk		Kastrup, Jette Sandholm/0000-0003-2654-1510; Holm, Mai/0000-0001-7347-8724; Vestergaard, Bente/0000-0001-8011-6414; Gajhede, Michael/0000-0001-9864-2287				Anson LC, 1998, J NEUROSCI, V18, P581; Armstrong N, 2003, P NATL ACAD SCI USA, V100, P5736, DOI 10.1073/pnas.1037393100; Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Ayalon G, 2001, NEURON, V31, P103, DOI 10.1016/S0896-6273(01)00333-6; Bowie D, 2002, J PHYSIOL-LONDON, V539, P725, DOI 10.1113/jphysiol.2001.013407; Bowie D, 2002, J NEUROSCI, V22, P3392; Brauner-Osborne H, 2000, J MED CHEM, V43, P2609, DOI 10.1021/jm000007r; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen GQ, 1999, NATURE, V402, P817, DOI 10.1038/45568; Chen GQ, 1997, P NATL ACAD SCI USA, V94, P13431, DOI 10.1073/pnas.94.25.13431; Dingledine R, 1999, PHARMACOL REV, V51, P7; Furukawa H, 2003, EMBO J, V22, P2873, DOI 10.1093/emboj/cdg303; Gouaux E, 2004, J PHYSIOL-LONDON, V554, P249, DOI 10.1113/jphysiol.2003.054320; Hogner A, 2003, J MED CHEM, V46, P214, DOI 10.1021/jm020989v; Hogner A, 2002, J MOL BIOL, V322, P93, DOI 10.1016/S0022-2836(02)00650-2; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Holm MM, 2005, P NATL ACAD SCI USA, V102, P12053, DOI 10.1073/pnas.0505522102; Jin RS, 2003, NAT NEUROSCI, V6, P803, DOI 10.1038/nn1091; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Koike M, 2000, J NEUROSCI, V20, P2166; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURYATOV A, 1994, NEURON, V12, P1291, DOI 10.1016/0896-6273(94)90445-6; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Madden DR, 2004, BIOCHEMISTRY-US, V43, P15838, DOI 10.1021/bi048447y; Mansour M, 2001, NEURON, V32, P841, DOI 10.1016/S0896-6273(01)00520-7; Mayer ML, 2004, ANNU REV PHYSIOL, V66, P161, DOI 10.1146/annurev.physiol.66.050802.084104; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Nielsen MM, 2003, MOL PHARMACOL, V63, P19, DOI 10.1124/mol.63.1.19; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pentikainen OT, 2003, BIOCHEM PHARMACOL, V66, P2413, DOI 10.1016/j.bcp.2003.08.013; Robert A, 2001, J NEUROSCI, V21, P5574, DOI 10.1523/JNEUROSCI.21-15-05574.2001; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; Stern-Bach Y, 1998, NEURON, V21, P907, DOI 10.1016/S0896-6273(00)80605-4; Sun Y, 2002, NATURE, V417, P245, DOI 10.1038/417245a	37	22	23	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35469	35476		10.1074/jbc.M507800200	http://dx.doi.org/10.1074/jbc.M507800200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16103115	hybrid			2022-12-27	WOS:000232561200047
J	Verma, SK; Mani, P; Sharma, NR; Krishnan, A; Kumar, VV; Reddy, BS; Chaudhuri, A; Roy, RP; Sarkar, DP				Verma, SK; Mani, P; Sharma, NR; Krishnan, A; Kumar, VV; Reddy, BS; Chaudhuri, A; Roy, RP; Sarkar, DP			Histidylated lipid-modified Sendai viral envelopes mediate enhanced membrane fusion and potentiate targeted gene delivery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS ENVELOPES; F-PROTEIN; HEMAGGLUTININ-NEURAMINIDASE; CATIONIC LIPIDS; HEPG2 CELLS; LIVER-CELLS; THERAPY; NANOPARTICLES; HEPATOCYTES; ACTIVATION	Recent studies have demonstrated that covalent grafting of a single histidine residue into a twin- chain aliphatic hydrocarbon compound enhances its endosome- disrupting properties and thereby generates an excellent DNA transfection system. Significant increase in gene delivery efficiencies has thus been obtained by using endosome- disrupting multiple histidine functionalities in the molecular architecture of various cationic polymers. To take advantage of this unique feature, we have incorporated L- histidine ( N, N-di-n- hexadecylamine) ethylamide ( L-H) in the membrane of hepatocyte-specific Sendai virosomes containing only the fusion protein ( F- virosomes ( Process for Producing a Targeted Gene ( Sarkar, D. P., Ramani, K., Bora, R. S., Kumar, M., and Tyagi, S. K. ( November 4, 1997) U. S. Patent 5,683,866))). Such L-H- modified virosomal envelopes were four times more ( p< 0.001) active in terms of fusion with its target cell membrane. On the other hand, the presence of L-H in reconstituted influenza and vesicular stomatitis virus envelopes failed to enhance spike glycoprotein- induced membrane fusion with host cell membrane. Circular dichroism and limited proteolysis experiments with F- virosomes indicated that the presence of L-H leads to conformational changes in the F protein. The molecular mechanism associated with the increased membrane fusion induced by L-H has been addressed in the light of fusion- competent conformational change in F protein. Such enhancement of fusion resulted in a highly efficient gene delivery system specific for liver cells in culture and in whole animals.	Univ Delhi, Dept Biochem, New Delhi 110021, India; Indian Inst Chem Technol, Div Lipid Sci & Technol, Hyderabad 500007, Andhra Pradesh, India; Natl Inst Immunol, New Delhi 110067, India	University of Delhi; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Technology (IICT); Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Sarkar, DP (corresponding author), Univ Delhi, Dept Biochem, S Campus,Benito Juarez Rd, New Delhi 110021, India.	dpsarkar59@rediffmail.com	krishnan, anuja/AAS-3567-2021; Verma, Santosh/AAQ-8952-2020	Verma, Santosh/0000-0001-6058-6494; Sarkar, Debi P/0000-0002-8886-8415; , Anuja/0000-0001-6538-2044				BAGAI S, 1993, J VIROL, V67, P3312, DOI 10.1128/JVI.67.6.3312-3318.1993; BAGAI S, 1993, BIOCHIM BIOPHYS ACTA, V1152, P15, DOI 10.1016/0005-2736(93)90226-P; BAGAI S, 1994, J BIOL CHEM, V269, P1966; BAGAI S, 1993, FEBS LETT, V326, P183, DOI 10.1016/0014-5793(93)81787-Z; Branca MA, 2005, NAT BIOTECHNOL, V23, P519, DOI 10.1038/nbt0505-519; Cavazzana-Calvo M, 2004, NATURE, V427, P779, DOI 10.1038/427779a; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Dandekar DH, 2005, ANAL BIOCHEM, V342, P341, DOI 10.1016/j.ab.2005.02.006; Fasbender A, 1997, J BIOL CHEM, V272, P6479, DOI 10.1074/jbc.272.10.6479; Fontana A, 2004, ACTA BIOCHIM POL, V51, P299; HSU MC, 1981, J BIOL CHEM, V256, P3557; Jana SS, 2002, FEBS LETT, V515, P184, DOI 10.1016/S0014-5793(02)02467-5; Kichler A, 2003, P NATL ACAD SCI USA, V100, P1564, DOI 10.1073/pnas.0337677100; Koshiba T, 2004, SCIENCE, V305, P858, DOI 10.1126/science.1099793; KREN BT, 2003, GENE THER MOL BIOL, V7, P229; Kumar M, 1997, J VIROL, V71, P6398, DOI 10.1128/JVI.71.9.6398-6406.1997; Kumar VV, 2003, GENE THER, V10, P1206, DOI 10.1038/sj.gt.3301979; Lamb R.A., 2001, FIELDS VIROLOGY; Ludwig K, 2003, EMBO J, V22, P3761, DOI 10.1093/emboj/cdg385; Luo D, 2004, TRENDS BIOTECHNOL, V22, P101, DOI 10.1016/j.tibtech.2004.01.002; Niidome T, 2002, GENE THER, V9, P1647, DOI 10.1038/sj.gt.3301923; Nijhara R, 2001, J VIROL, V75, P10348, DOI 10.1128/JVI.75.21.10348-10358.2001; Okada Y., 1988, TRANSPORT-VILNIUS, P297, DOI [10.1016/S0070-2161(08)60138-0, DOI 10.1016/S0070-2161(08)60138-0]; PATERNOSTRE MT, 1989, FEBS LETT, V243, P251, DOI 10.1016/0014-5793(89)80139-5; Ramani K, 1997, FEBS LETT, V404, P164, DOI 10.1016/S0014-5793(97)00120-8; Ramanj K, 1998, P NATL ACAD SCI USA, V95, P11886, DOI 10.1073/pnas.95.20.11886; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SARKAR DI, 1997, Patent No. 5683866; SCHEID A, 1977, VIROLOGY, V80, P54, DOI 10.1016/0042-6822(77)90380-4; Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632; Tsuboniwa N, 2001, HUM GENE THER, V12, P469, DOI 10.1089/104303401300042366; Yamada T, 2003, NAT BIOTECHNOL, V21, P885, DOI 10.1038/nbt843; Zhao X, 2000, P NATL ACAD SCI USA, V97, P14172, DOI 10.1073/pnas.260499197	33	19	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35399	35409		10.1074/jbc.M506615200	http://dx.doi.org/10.1074/jbc.M506615200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16085643	hybrid			2022-12-27	WOS:000232561200039
J	Bickel, T; Lehle, L; Schwarz, M; Aebi, M; Jakob, CA				Bickel, T; Lehle, L; Schwarz, M; Aebi, M; Jakob, CA			Biosynthesis of lipid-linked oligosaccharides in Saccharomyces cerevisiae - Alg13p AND Alg14p form a complex required for the formation of GlcNAc(2)-PP-dolichol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; STREPTOCOCCUS-PNEUMONIAE SEROTYPE-14; YEAST MUTANTS DEFICIENT; OLIGOSACCHARYLTRANSFERASE COMPLEX; ENDOPLASMIC-RETICULUM; N-ACETYLGLUCOSAMINE; GLYCOSYLATION PATHWAY; SUBSTRATE-SPECIFICITY; GLUCOSYLATION STEPS; FUNCTIONAL-ANALYSIS	N-Glycosylation in the endoplasmic reticulum is an essential protein modification and highly conserved in evolution from yeast to man. Here we identify and characterize two essential yeast proteins having homology to bacterial glycosyltransferases, designated Alg13p and Alg14p, as being required for the formation of Glc-NAc2-PP-dolichol ( Dol), the second step in the biosynthesis of the unique lipid-linked core oligosaccharide. Down-regulation of each gene led to a defect in protein N-glycosylation and an accumulation of GlcNAc(1)-PP-Dol in vivo as revealed by metabolic labeling with [H-3] glucosamine. Microsomal membranes from cells repressed for ALG13 or ALG14, as well as detergent-solubilized extracts thereof, were unable to catalyze the transfer of N-acetylglucosamine from UDP-GlcNAc to [C-14] GlcNAc(1)-PP-Dol, but did not impair the formation of GlcNAc(1)-PP-Dol or GlcNAc-GPI. Immunoprecipitating Alg13p from solubilized extracts resulted in the formation of Glc-NAc2-PP-Dol but required Alg14p for activity, because an Alg13p immunoprecipitate obtained from cells in which ALG14 was downregulated lacked this activity. In Western blot analysis it was demonstrated that Alg13p, for which no well defined transmembrane segment has been predicted, localizes both to the membrane and cytosol; the latter form, however, is enzymatically inactive. In contrast, Alg14p is exclusively membrane-bound. Repression of the ALG14 gene causes a depletion of Alg13p from the membrane. By affinity chromatography on IgG-Sepharose using Alg14-ZZ as bait, we demonstrate that Alg13-myc co-fractionates with Alg14-ZZ. The data suggest that Alg13p associates with Alg14p to a complex forming the active transferase catalyzing the biosynthesis of GlcNAc(2)-PP-Dol.	Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, D-93053 Regensburg, Germany; Swiss Fed Inst Technol, Inst Mikrobiol, CH-8093 Zurich, Switzerland	University of Regensburg; Swiss Federal Institutes of Technology Domain; ETH Zurich	Lehle, L (corresponding author), Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, Univ Str 31, D-93053 Regensburg, Germany.	ludwig.lehle@biologie.uni-regensburg.de						ABEIJON C, 1992, TRENDS BIOCHEM SCI, V17, P32, DOI 10.1016/0968-0004(92)90424-8; BECK PJ, 1990, SOMAT CELL MOLEC GEN, V16, P539, DOI 10.1007/BF01233094; Belli G, 1998, YEAST, V14, P1127, DOI 10.1002/(SICI)1097-0061(19980915)14:12<1127::AID-YEA300>3.0.CO;2-#; Burda P, 1999, BBA-GEN SUBJECTS, V1426, P239, DOI 10.1016/S0304-4165(98)00127-5; Burda P, 1998, GLYCOBIOLOGY, V8, P455, DOI 10.1093/glycob/8.5.455; Burda P, 1999, GLYCOBIOLOGY, V9, P617, DOI 10.1093/glycob/9.6.617; Chantret I, 2005, J BIOL CHEM, V280, P9236, DOI 10.1074/jbc.M413941200; CHAPMAN A, 1980, J BIOL CHEM, V255, P4441; DSOUZA C, 1992, ANAL BIOCHEM, V203, P211, DOI 10.1016/0003-2697(92)90305-Q; FOLCH J, 1957, J BIOL CHEM, V226, P497; Ha S, 2000, PROTEIN SCI, V9, P1045, DOI 10.1110/ps.9.6.1045; Hall CW, 1997, J CELL BIOCHEM, V67, P201, DOI 10.1002/(SICI)1097-4644(19971101)67:2<201::AID-JCB5>3.3.CO;2-Q; HANOVER JA, 1981, ARCH BIOCHEM BIOPHYS, V211, P1, DOI 10.1016/0003-9861(81)90423-9; HEIFETZ A, 1977, J BIOL CHEM, V252, P3057; Helenius J, 2002, NATURE, V415, P447, DOI 10.1038/415447a; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HUFFAKER TC, 1982, J BIOL CHEM, V257, P3203; HUFFAKER TC, 1983, P NATL ACAD SCI-BIOL, V80, P7466, DOI 10.1073/pnas.80.24.7466; KEAN EL, 1983, BIOCHIM BIOPHYS ACTA, V750, P268, DOI 10.1016/0005-2760(83)90028-0; KEAN EL, 1991, J BIOL CHEM, V266, P942; Knauer R, 1999, BBA-GEN SUBJECTS, V1426, P259, DOI 10.1016/S0304-4165(98)00128-7; KNAUER R, 1994, FEBS LETT, V344, P83, DOI 10.1016/0014-5793(94)00356-4; Knauer R, 1999, J BIOL CHEM, V274, P17249, DOI 10.1074/jbc.274.24.17249; Kolkman MAB, 1997, MOL MICROBIOL, V26, P197, DOI 10.1046/j.1365-2958.1997.5791940.x; Kolkman MAB, 1997, J BIOL CHEM, V272, P19502, DOI 10.1074/jbc.272.31.19502; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEHLE L, 1976, FEBS LETT, V71, P167, DOI 10.1016/0014-5793(76)80922-2; Lehle L., 1995, GLYCOPROTEINS A, V29a, P475; MCLACHLAN KR, 1994, J LIPID RES, V35, P1861; MCLACHLAN KR, 1992, GLYCOBIOLOGY, V2, P313, DOI 10.1093/glycob/2.4.313; MENGINLECREULX D, 1991, J BACTERIOL, V173, P4625, DOI 10.1128/jb.173.15.4625-4636.1991; PALAMARCZYK G, 1980, EUR J BIOCHEM, V105, P517, DOI 10.1111/j.1432-1033.1980.tb04527.x; REARICK JI, 1981, J BIOL CHEM, V256, P3762; RUNGE KW, 1984, J BIOL CHEM, V259, P412; RUNGE KW, 1986, J BIOL CHEM, V261, P5582; SHAILUBHAI K, 1988, J BIOL CHEM, V263, P15964; SHARMA CB, 1990, BIOCHEMISTRY-US, V29, P8901, DOI 10.1021/bi00490a004; SHARMA CB, 1982, EUR J BIOCHEM, V126, P319; Sharma CB, 2001, BIOL CHEM, V382, P321, DOI 10.1515/BC.2001.039; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; Videira P, 2001, BIOCHEM J, V358, P457, DOI 10.1042/0264-6021:3580457; ZENG Y, 1991, ANAL BIOCHEM, V193, P266, DOI 10.1016/0003-2697(91)90020-T; Zhang Z, 1998, NUCLEIC ACIDS RES, V26, P3986, DOI 10.1093/nar/26.17.3986; ZHU XY, 1992, J BIOL CHEM, V267, P8895	44	49	52	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34500	34506		10.1074/jbc.M506358200	http://dx.doi.org/10.1074/jbc.M506358200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16100113	hybrid			2022-12-27	WOS:000232403900017
J	Openshaw, AEA; Race, PR; Monzo, HJ; Vazquez-Boland, JA; Banfield, MJ				Openshaw, AEA; Race, PR; Monzo, HJ; Vazquez-Boland, JA; Banfield, MJ			Crystal structure of SmcL, a bacterial neutral sphingomyelinase C from Listeria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CEREUS SPHINGOMYELINASE; PHOSPHOLIPASE-C; NUCLEOTIDE-SEQUENCE; CATALYTIC RESIDUES; COMPLEX; GENE; EXPRESSION; ALIGNMENT; ENZYMES; TOXINS	Sphingomyelinases C are enzymes that catalyze the hydrolysis of sphingomyelin in biological membranes to ceramide and phosphorylcholine. Various pathogenic bacteria produce secreted neutral sphingomyelinases C that act as membrane-damaging virulence factors. Mammalian neutral sphingomyelinases C, which display sequence homology to the bacterial enzymes, are involved in sphingolipid metabolism and signaling. This article describes the first structure to be determined for a member of the neutral sphingomyelinase C family, SmcL, from the intracellular bacterial pathogen Listeria ivanovii. The structure has been refined to 1.9-angstrom resolution with phases derived by single isomorphous replacement with anomalous scattering techniques from a single iridium derivative. SmcL adopts a DNase I-like fold, and is the first member of this protein superfamily to have its structure determined that acts as a phospholipase. The structure reveals several unique features that adapt the protein to its phospholipid substrate. These include large hydrophobic beta-hairpin and hydrophobic loops surrounding the active site that may bind and penetrate the lipid bilayer to position sphingomyelin in a catalytically competent position. The structure also provides insight into the proposed general base/acid catalytic mechanism, in which His-325 and His-185 play key roles.	Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Bristol, Bacterial Mol Pathogenesis Grp, Fac Med & Vet Sci, Bristol BS40 5DU, Avon, England; Univ Leon, E-24071 Leon, Spain	Newcastle University - UK; University of Bristol; Universidad de Leon	Banfield, MJ (corresponding author), Newcastle Univ, Inst Cell & Mol Biosci, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	M.J.Banfield@ncl.ac.uk	Banfield, Mark/C-7453-2013	Banfield, Mark/0000-0001-8921-3835				Andrieu-Abadie N, 2002, BBA-MOL CELL BIOL L, V1585, P126, DOI 10.1016/S1388-1981(02)00332-3; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Cho WH, 2005, ANNU REV BIOPH BIOM, V34, P119, DOI 10.1146/annurev.biophys.33.110502.133337; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; DeLano W.L, PYMOL MOL GRAPHICS S; DUAN RD, 1995, BBA-LIPID LIPID MET, V1259, P49, DOI 10.1016/0005-2760(95)00137-2; Dziewanowska K, 1996, ARCH BIOCHEM BIOPHYS, V335, P102, DOI 10.1006/abbi.1996.0486; Futerman AH, 2004, EMBO REP, V5, P777, DOI 10.1038/sj.embor.7400208; GEOFFROY C, 1991, INFECT IMMUN, V59, P2382, DOI 10.1128/IAI.59.7.2382-2388.1991; Goni FM, 2002, FEBS LETT, V531, P38, DOI 10.1016/S0014-5793(02)03482-8; Gonzalez-Zorn B, 1999, MOL MICROBIOL, V33, P510, DOI 10.1046/j.1365-2958.1999.01486.x; Hakogi T, 2002, J ORG CHEM, V67, P4839, DOI 10.1021/jo025529o; Hanada K, 2002, J EXP MED, V195, P23, DOI 10.1084/jem.20010724; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Heinz DW, 1996, BIOCHEMISTRY-US, V35, P9496, DOI 10.1021/bi9606105; HEINZ DW, 1995, EMBO J, V14, P3855, DOI 10.1002/j.1460-2075.1995.tb00057.x; Hofmann K, 2000, P NATL ACAD SCI USA, V97, P5895, DOI 10.1073/pnas.97.11.5895; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Jones SJ, 1996, J MOL BIOL, V264, P1154, DOI 10.1006/jmbi.1996.0703; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB; Luberto C, 2002, J BIOL CHEM, V277, P41128, DOI 10.1074/jbc.M206747200; Mahfoud R, 2002, J BIOL CHEM, V277, P11292, DOI 10.1074/jbc.M111679200; Matsuo Y, 1996, PROTEIN SCI, V5, P2459, DOI 10.1002/pro.5560051208; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; Murakami MT, 2005, J BIOL CHEM, V280, P13658, DOI 10.1074/jbc.M412437200; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nesic D, 2004, NATURE, V429, P429, DOI 10.1038/nature02532; Obama T, 2003, BIOL PHARM BULL, V26, P920; Obama T, 2003, J BIOCHEM, V133, P279, DOI 10.1093/jb/mvg038; Page R, 2003, ACTA CRYSTALLOGR D, V59, P1028, DOI 10.1107/S0907444903007790; Parker MW, 2005, PROG BIOPHYS MOL BIO, V88, P91, DOI 10.1016/j.pbiomolbio.2004.01.009; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; PROJAN SJ, 1989, NUCLEIC ACIDS RES, V17, P3305, DOI 10.1093/nar/17.8.3305; Rodrigues-Lima F, 2000, J BIOL CHEM, V275, P28316; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; SEGERS RPAM, 1990, INFECT IMMUN, V58, P2177, DOI 10.1128/IAI.58.7.2177-2185.1990; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; TITBALL RW, 1993, FEMS MICROBIOL LETT, V110, P45, DOI 10.1016/0378-1097(93)90240-3; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; Tsujishita Y, 2001, CELL, V105, P379, DOI 10.1016/S0092-8674(01)00326-9; Vargas-Villarreal Javier, 2003, Med Sci Monit, V9, pBR225; Weichenrieder O, 2004, STRUCTURE, V12, P975, DOI 10.1016/j.str.2004.04.011; Weichsel A, 2005, P NATL ACAD SCI USA, V102, P594, DOI 10.1073/pnas.0406549102; WESTON SA, 1992, J MOL BIOL, V226, P1237, DOI 10.1016/0022-2836(92)91064-V; YAMADA A, 1988, EUR J BIOCHEM, V175, P213, DOI 10.1111/j.1432-1033.1988.tb14186.x; Yu BZ, 2002, BBA-MOL CELL BIOL L, V1583, P122, DOI 10.1016/S1388-1981(02)00192-0	51	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					35011	35017		10.1074/jbc.M506800200	http://dx.doi.org/10.1074/jbc.M506800200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16093240	hybrid			2022-12-27	WOS:000232403900074
J	Stray, JE; Crisona, NJ; Belotserkovskii, BP; Lindsley, JE; Cozzarelli, NR				Stray, JE; Crisona, NJ; Belotserkovskii, BP; Lindsley, JE; Cozzarelli, NR			The Saccharomyces cerevisiae Smc2/4 condensin compacts DNA into (plus) chiral structures without net supercoiling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOTIC CHROMOSOME ARCHITECTURE; STRAND BREAK REPAIR; 13S CONDENSIN; COMPLEX; PROTEINS; COHESIN; ATP; SUBUNITS; MUKB; PHOSPHORYLATION	Smc2/4 forms the core of the Saccharomyces cerevisiae condensin, which promotes metaphase chromosome compaction. To understand how condensin manipulates DNA, we used two in vitro assays to study the role of SMC ( structural maintenance of chromosome) proteins and ATP in reconfiguring the path of DNA. The first assay evaluated the topology of knots formed in the presence of topoisomerase II. Unexpectedly, both wild-type Smc2/4 and an ATPase mutant promoted (+) chiral knotting of nicked plasmids, revealing that ATP hydrolysis and the non-SMC condensins are not required to compact DNA chirally. The second assay measured Smc2/4-dependent changes in linking number (Lk). Smc2/4 did not induce (+) supercoiling, but instead induced broadening of topoisomer distributions in a cooperative manner without altering Lk(0). To explain chiral knotting in substrates devoid of chiral supercoiling, we propose that Smc2/4 directs chiral DNA compaction by constraining the duplex to retrace its own path. In this highly cooperative process, both (+) and (-) loops are sequestered ( about one per kb), leaving net writhe and twist unchanged while broadening Lk. We have developed a quantitative theory to account for these results. Additionally, we have shown at higher molar stoichiometries that Smc2/4 prevents relaxation by topoisomerase I and nick closure by DNA ligase, indicating that Smc2/4 can saturate DNA. By electron microscopy of Smc2/4-DNA complexes, we observed primarily two protein-laden bound species: long flexible filaments and uniform rings or "doughnuts." Close packing of Smc2/4 on DNA explains the substrate protection we observed. Our results support the hypothesis that SMC proteins bind multiple DNA duplexes.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Utah, Dept Biochem, Salt Lake City, UT 84132 USA	University of California System; University of California Berkeley; Utah System of Higher Education; University of Utah	Cozzarelli, NR (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 16 Barker Hall, Berkeley, CA 94720 USA.	ncozzare@berkeley.edu		Belotserkovskii, Boris/0000-0002-1570-9923	NIGMS NIH HHS [GM31657, GM31655, GM072366-01, GM51194, 5T32GM07464-24] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007464, R01GM031655, F32GM072366, R01GM051194, R37GM031657, R01GM031657] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson DE, 2002, J CELL BIOL, V156, P419, DOI 10.1083/jcb.200111002; BAUER WR, 1980, SCI AM, V243, P118; Bazett-Jones DP, 2002, MOL CELL, V9, P1183, DOI 10.1016/S1097-2765(02)00546-4; Chuang PT, 1996, SCIENCE, V274, P1736, DOI 10.1126/science.274.5293.1736; Cobbe N, 2000, J STRUCT BIOL, V129, P123, DOI 10.1006/jsbi.2000.4255; Cozzarelli N. R., 1990, DNA TOPOLOGY ITS BIO, P139; CRISONA NJ, 1994, J MOL BIOL, V243, P437, DOI 10.1006/jmbi.1994.1671; Dazey I. D., 1997, KNOTS 96, P267; DYNAN WS, 1981, J BIOL CHEM, V256, P5860; Fennell-Fezzie R, 2005, EMBO J, V24, P1921, DOI 10.1038/sj.emboj.7600680; Freeman L, 2000, J CELL BIOL, V149, P811, DOI 10.1083/jcb.149.4.811; Gassmann R, 2004, EXP CELL RES, V296, P35, DOI 10.1016/j.yexcr.2004.03.006; Haering CH, 2003, BIOESSAYS, V25, P1178, DOI 10.1002/bies.10361; Haering CH, 2002, MOL CELL, V9, P773, DOI 10.1016/S1097-2765(02)00515-4; Hagstrom KA, 2003, NAT REV GENET, V4, P520, DOI 10.1038/nrg1110; Hagstrom KA, 2002, GENE DEV, V16, P729, DOI 10.1101/gad.968302; Harvey SH, 2002, GENOME BIOL, V3; Hazbun TR, 2003, MOL CELL, V12, P1353, DOI 10.1016/S1097-2765(03)00476-3; Hirano M, 2004, EMBO J, V23, P2664, DOI 10.1038/sj.emboj.7600264; Hirano M, 2002, EMBO J, V21, P5733, DOI 10.1093/emboj/cdf575; Hirano M, 2001, EMBO J, V20, P3238, DOI 10.1093/emboj/20.12.3238; Hirano M, 1998, EMBO J, V17, P7139, DOI 10.1093/emboj/17.23.7139; Hirano T, 2005, CURR BIOL, V15, pR265, DOI 10.1016/j.cub.2005.03.037; Hirano T, 2002, GENE DEV, V16, P399, DOI 10.1101/gad.955102; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Hopfner KP, 2000, J BACTERIOL, V182, P6036, DOI 10.1128/JB.182.21.6036-6041.2000; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hopfner KP, 2001, CELL, V105, P473, DOI 10.1016/S0092-8674(01)00335-X; Jessberger R, 1996, EMBO J, V15, P4061, DOI 10.1002/j.1460-2075.1996.tb00779.x; Kagansky A, 2004, J BIOL CHEM, V279, P3382, DOI 10.1074/jbc.M306078200; Kimura K, 1999, CELL, V98, P239, DOI 10.1016/S0092-8674(00)81018-1; Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3; Kimura K, 2001, J BIOL CHEM, V276, P5417, DOI 10.1074/jbc.C000873200; Kimura K, 1998, SCIENCE, V282, P487, DOI 10.1126/science.282.5388.487; Kimura K, 2000, P NATL ACAD SCI USA, V97, P11972, DOI 10.1073/pnas.220326097; KLENIN KV, 1989, J BIOMOL STRUCT DYN, V6, P707, DOI 10.1080/07391102.1989.10507731; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; Koshland DE, 2000, CURR OPIN CELL BIOL, V12, P297, DOI 10.1016/S0955-0674(00)00092-2; Lavoie BD, 2004, GENE DEV, V18, P76, DOI 10.1101/gad.1150404; Lavoie BD, 2000, MOL BIOL CELL, V11, P1293, DOI 10.1091/mbc.11.4.1293; LEVINGER L, 1980, P NATL ACAD SCI-BIOL, V77, P3244, DOI 10.1073/pnas.77.6.3244; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Losada A, 2001, BIOESSAYS, V23, P924, DOI 10.1002/bies.1133; Losada A, 2001, CURR BIOL, V11, P268, DOI 10.1016/S0960-9822(01)00066-5; LOSADA A, 1954, GENE DEV, V19, P1269; Mascarenhas J, 2002, EMBO J, V21, P3108, DOI 10.1093/emboj/cdf314; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; NIKI H, 1991, EMBO J, V10, P183, DOI 10.1002/j.1460-2075.1991.tb07935.x; Ono T, 2003, CELL, V115, P109, DOI 10.1016/S0092-8674(03)00724-4; Rybenkov VV, 1997, SCIENCE, V277, P690, DOI 10.1126/science.277.5326.690; Sakai A, 2003, EMBO J, V22, P2764, DOI 10.1093/emboj/cdg247; Schleiffer A, 2003, MOL CELL, V11, P571, DOI 10.1016/S1097-2765(03)00108-4; Stray JE, 2003, J BIOL CHEM, V278, P26238, DOI 10.1074/jbc.M302699200; Strunnikov AV, 1999, EUR J BIOCHEM, V263, P6, DOI 10.1046/j.1432-1327.1999.00509.x; Sutani T, 1997, NATURE, V388, P798, DOI 10.1038/42062; Sutani T, 1999, GENE DEV, V13, P2271, DOI 10.1101/gad.13.17.2271; Uhlmann F, 2004, EXP CELL RES, V296, P80, DOI 10.1016/j.yexcr.2004.03.005; Volkov A, 2003, MOL CELL BIOL, V23, P5638, DOI 10.1128/MCB.23.16.5638-5650.2003; Vologodskii AV., 1992, TOPOLOGY PHYS CIRCUL; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WASSERMAN SA, 1991, J BIOL CHEM, V266, P20567; Yamanaka K, 1996, MOL GEN GENET, V250, P241; Yamazoe M, 1999, EMBO J, V18, P5873, DOI 10.1093/emboj/18.21.5873; Yoshimura SH, 2002, CURR BIOL, V12, P508, DOI 10.1016/S0960-9822(02)00719-4; Zhao XL, 2005, P NATL ACAD SCI USA, V102, P4777, DOI 10.1073/pnas.0500537102	67	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34723	34734		10.1074/jbc.M506589200	http://dx.doi.org/10.1074/jbc.M506589200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16100111	hybrid			2022-12-27	WOS:000232403900043
J	Fitter, S; James, R				Fitter, S; James, R			Deconvolution of a complex target using DNA aptamers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO SELECTION; NUCLEIC-ACID APTAMERS; AFFINITY RNA LIGANDS; SYSTEMATIC EVOLUTION; COMBINATORIAL SELECTION; PROTEIN MICROARRAYS; BINDING; CELLS; TRANSCRIPTOME; RECEPTORS	In vitro selection of single-stranded nucleic acid aptamers from large random sequence libraries is now a straightforward process particularly when screening with a single target molecule. These libraries contain considerable shape diversity as evident by the successful isolation of aptamers that bind with high affinity and specificity to chemically diverse targets. We propose that aptamer libraries contain sufficient shape diversity to allow deconvolution of a complex mixture of targets. Using unfractionated human plasma as our experimental model, we aim to develop methods to obtain aptamers against as many proteins as possible. To begin, it is critical that we understand how aptamer populations change with increasing rounds of in vitro selection when using complex mixtures. Our results show that sequence representation in the selected population changes dramatically with increasing rounds of selection. Certain aptamer families were apparent after only three selection rounds. Two additional cycles saw a decline in the relative abundance of these families and the emergence of yet another family that accounted for more than 60% of sequences in the pool. To overcome this population convergence, an aptamer-based target depletion method was developed, and the library screen was repeated. The previous dominant family effectively disappeared from the selected populations but was replaced by other aptamer families. Insights gained from these initial experiments are now being applied in the creation of second generation plasma protein screens and also to the analysis of other complex biological targets.	Flinders Med Ctr, Dept Gastroenterol & Hepatol, Adelaide, SA 5042, Australia	Flinders Medical Centre	James, R (corresponding author), Flinders Med Ctr, Dept Gastroenterol & Hepatol, Bedford Pk, SA 5042, Australia.	rob.james@flinders.edu.au		Fitter, Stephen/0000-0003-1663-6807				Anderson NL, 2002, MOL CELL PROTEOMICS, V1, P845, DOI 10.1074/mcp.R200007-MCP200; Baliga NS, 2002, P NATL ACAD SCI USA, V99, P14913, DOI 10.1073/pnas.192558999; Batey RT, 1999, ANGEW CHEM INT EDIT, V38, P2327; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Blank M, 2001, J BIOL CHEM, V276, P16464, DOI 10.1074/jbc.M100347200; Brandenberger R, 2004, NAT BIOTECHNOL, V22, P707, DOI 10.1038/nbt971; Califano A, 2000, BIOINFORMATICS, V16, P341, DOI 10.1093/bioinformatics/16.4.341; Carothers JM, 2004, J AM CHEM SOC, V126, P5130, DOI 10.1021/ja031504a; Charlton J, 1997, CHEM BIOL, V4, P809, DOI 10.1016/S1074-5521(97)90114-9; Clark SL, 2002, ELECTROPHORESIS, V23, P1335, DOI 10.1002/1522-2683(200205)23:9<1335::AID-ELPS1335>3.0.CO;2-E; Conrad RC, 1996, METHOD ENZYMOL, V267, P336; Daniels DA, 2003, P NATL ACAD SCI USA, V100, P15416, DOI 10.1073/pnas.2136683100; Davidson EH, 2002, SCIENCE, V295, P1669, DOI 10.1126/science.1069883; de Wildt RMT, 2000, NAT BIOTECHNOL, V18, P989, DOI 10.1038/79494; Farokhzad OC, 2004, CANCER RES, V64, P7668, DOI 10.1158/0008-5472.CAN-04-2550; Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800; Hicke BJ, 2001, J BIOL CHEM, V276, P48644, DOI 10.1074/jbc.M104651200; Homann M, 1999, NUCLEIC ACIDS RES, V27, P2006, DOI 10.1093/nar/27.9.2006; Hoogenboom HR, 1999, EUR J BIOCHEM, V260, P774, DOI 10.1046/j.1432-1327.1999.00214.x; IRVINE D, 1991, J MOL BIOL, V222, P739, DOI 10.1016/0022-2836(91)90509-5; Kampa D, 2004, GENOME RES, V14, P331, DOI 10.1101/gr.2094104; Kodadek T, 2001, CHEM BIOL, V8, P105, DOI 10.1016/S1074-5521(00)90067-X; Lin BY, 2005, CANCER RES, V65, P3081, DOI 10.1158/0008-5472.CAN-04-3218; Liotta LA, 2003, CANCER CELL, V3, P317, DOI 10.1016/S1535-6108(03)00086-2; Lorger M, 2003, EUKARYOT CELL, V2, P84, DOI 10.1128/EC.2.1.84-94.2003; MANDECKI W, 1995, J THEOR BIOL, V176, P523, DOI 10.1006/jtbi.1995.0218; Masayesva BG, 2004, P NATL ACAD SCI USA, V101, P8715, DOI 10.1073/pnas.0400027101; Messmer BT, 2000, J MOL BIOL, V296, P821, DOI 10.1006/jmbi.1999.3487; Morris KN, 1998, P NATL ACAD SCI USA, V95, P2902, DOI 10.1073/pnas.95.6.2902; Mutuberria R, 1999, J IMMUNOL METHODS, V231, P65, DOI 10.1016/S0022-1759(99)00141-6; Nimjee SM, 2005, ANNU REV MED, V56, P555, DOI 10.1146/annurev.med.56.062904.144915; Noronha EJ, 1998, J IMMUNOL, V161, P2968; Osborne SE, 1997, CHEM REV, V97, P349, DOI 10.1021/cr960009c; PAN WH, 1995, P NATL ACAD SCI USA, V92, P11509, DOI 10.1073/pnas.92.25.11509; Pieper R, 2003, PROTEOMICS, V3, P422, DOI 10.1002/pmic.200390057; Rimmele M, 2003, CHEMBIOCHEM, V4, P963, DOI 10.1002/cbic.200300648; RINGQUIST S, 1995, BIOCHEMISTRY-US, V34, P3640, DOI 10.1021/bi00011a019; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shi H, 2002, RNA, V8, P1461, DOI 10.1017/S1355838202029941; Soukup JK, 2004, CURR OPIN STRUC BIOL, V14, P344, DOI 10.1016/j.sbi.2004.04.007; Sperger JM, 2003, P NATL ACAD SCI USA, V100, P13350, DOI 10.1073/pnas.2235735100; Thomas M, 1997, J BIOL CHEM, V272, P27980, DOI 10.1074/jbc.272.44.27980; Tian HC, 2002, MOL CELL PROTEOMICS, V1, P99, DOI 10.1074/mcp.T100002-MCP200; Tirumalai RS, 2003, MOL CELL PROTEOMICS, V2, P1096, DOI 10.1074/mcp.M300031-MCP200; Ulrich H, 2002, J BIOL CHEM, V277, P20756, DOI 10.1074/jbc.M111859200; Vant-Hull B, 1998, J MOL BIOL, V278, P579, DOI 10.1006/jmbi.1998.1727; Wang J, 2000, RNA, V6, P571, DOI 10.1017/S1355838200992215; Wilson DS, 1999, ANNU REV BIOCHEM, V68, P611, DOI 10.1146/annurev.biochem.68.1.611; Wlotzka B, 2002, P NATL ACAD SCI USA, V99, P8898, DOI 10.1073/pnas.132067399	49	26	30	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34193	34201		10.1074/jbc.M504772200	http://dx.doi.org/10.1074/jbc.M504772200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16081419	hybrid			2022-12-27	WOS:000232229700061
J	Heeb, MJ; Cabral, KM; Ruan, LJ				Heeb, MJ; Cabral, KM; Ruan, LJ			Down-regulation of factor IXa in the factor Xase complex by protein Z-dependent protease inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; Z PLASMA-LEVELS; ISCHEMIC-STROKE; Z-DEFICIENCY; ANTIPHOSPHOLIPID ANTIBODIES; Z GENE; RISK; THROMBOSIS; FREQUENCY; COMMON	Protein Z-dependent protease inhibitor (ZPI) is a serpin inhibitor of coagulation factor ( F) Xa dependent on protein Z, Ca2+, and phospholipids. In new studies, ZPI inhibited FIXa in the FXase complex. Since this observation could merely represent inhibition of the FXa product whose activity was measured, inhibition of FIXa was investigated five ways. 1) FXase incubation mixtures with/without ZPI/ protein Z were diluted in EDTA; FXa activity was measured after reversal of its inhibition. 2) FXase incubation mixtures were immunoblotted for FXa product. 3) FX activation peptide region was H-3-labeled; release of H-3 was used to measure FXase activity. 4) Activity was monitored in a FIXa-based clotting assay. 5) FIXa amidolytic activity was measured. In all cases, FIXa was inhibited by subphysiologic levels of ZPI. Unlike inhibition of FXa, inhibition of FIXa did not strictly require protein Z. Low concentrations of FVIIIa increased the efficiency of ZPI inhibition of FIXa; FVIIIa in molar excess was not protective of FIXa unless FIXa/FVIIIa interacted prior to ZPI exposure. Unusual time courses were observed for inhibition of both FIXa in the FXase complex and FXa in the prothrombinase complex. Activity loss stabilized in <100 s at a level dependent on ZPI concentration, suggesting equilibrium interactions rather than typical covalent serpin-protease interactions. Surface plasmon resonance binding experiments revealed binding and dissociation of ZPI/ FIXa with K-d(app) of 9-12 nM, similar to the concentration of ZPI needed for 50% inhibition. ZPI may be an unusual physiologic regulator of both the intrinsic FXase and the prothrombinase complexes.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Heeb, MJ (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, MEM 180,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	heeb@scripps.edu						Al-Shanqeeti A, 2005, THROMB HAEMOSTASIS, V93, P411, DOI 10.1160/TH04-11-0715; Ayoub N, 2004, STROKE, V35, P1329, DOI 10.1161/01.STR.0000127534.54538.15; BROZE GJ, 1984, J CLIN INVEST, V73, P933, DOI 10.1172/JCI111317; Broze GJ, 2001, LANCET, V357, P900, DOI 10.1016/S0140-6736(00)04229-X; Forastiero RR, 2003, J THROMB HAEMOST, V1, P1764, DOI 10.1046/j.1538-7836.2003.00303.x; Gris JC, 2002, BLOOD, V99, P2606, DOI 10.1182/blood.V99.7.2606; Han X, 1999, BIOCHEMISTRY-US, V38, P11073, DOI 10.1021/bi990641a; Han X, 2000, BLOOD, V96, P3049; Han X, 1998, P NATL ACAD SCI USA, V95, P9250, DOI 10.1073/pnas.95.16.9250; Heeb MJ, 2002, BLOOD CELL MOL DIS, V29, P139, DOI 10.1006/bcmd.2002.0549; HEEB MJ, 1993, J BIOL CHEM, V268, P2872; HOGG PJ, 1991, J BIOL CHEM, V266, P10953; Kemkes-Matthes B, 2001, SEMIN THROMB HEMOST, V27, P551, DOI 10.1055/s-2001-17966; Kobelt K, 2001, BRIT J HAEMATOL, V114, P169, DOI 10.1046/j.1365-2141.2001.02913.x; Konstantinides S, 2001, CIRCULATION, V103, P576, DOI 10.1161/01.CIR.103.4.576; LAMPHEAR BJ, 1992, J BIOL CHEM, V267, P3725; Lichy C, 2004, STROKE, V35, P40, DOI 10.1161/01.STR.0000106909.75418.E4; Lopaciuk S, 2002, THROMB HAEMOSTASIS, V88, P536; McColl MD, 2003, BRIT J HAEMATOL, V120, P913, DOI 10.1046/j.1365-2141.2003.04151_5.x; McQuillan AM, 2003, STROKE, V34, P2415, DOI 10.1161/01.STR.0000092124.52084.4B; Mikolajczyk SD, 1999, INT J CANCER, V81, P438, DOI 10.1002/(SICI)1097-0215(19990505)81:3<438::AID-IJC18>3.3.CO;2-L; MILETICH JP, 1987, BLOOD, V69, P1580; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; New L, 1996, BIOCHEM BIOPH RES CO, V223, P404, DOI 10.1006/bbrc.1996.0906; Santacroce R, 2004, J THROMB HAEMOST, V2, P1197, DOI 10.1111/j.1538-7836.2004.00808.x; Tabatabai A, 2001, THROMB HAEMOSTASIS, V85, P655, DOI 10.1055/s-0037-1615649; TANS G, 1991, BLOOD, V77, P2641; Vasse M, 2001, LANCET, V357, P933, DOI 10.1016/S0140-6736(00)04218-5; WATER N, 2004, BRIT J HAEMATOL, V127, P190; Yin ZF, 2000, P NATL ACAD SCI USA, V97, P6734, DOI 10.1073/pnas.120081897; ZUR M, 1980, J BIOL CHEM, V255, P5703	31	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33819	33825		10.1074/jbc.M506502200	http://dx.doi.org/10.1074/jbc.M506502200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16093243	hybrid			2022-12-27	WOS:000232229700018
J	Kepert, JF; Mazurkiewicz, J; Heuvelman, GL; Toth, KF; Rippe, K				Kepert, JF; Mazurkiewicz, J; Heuvelman, GL; Toth, KF; Rippe, K			NAP1 modulates binding of linker histone H1 to chromatin and induces an extended chromatin fiber conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOME ASSEMBLY PROTEIN-1; SCANNING FORCE MICROSCOPY; TRANSCRIPTION FACTOR-BINDING; RNA-POLYMERASE; ANALYTICAL ULTRACENTRIFUGATION; GENE-EXPRESSION; H2A-H2B DIMERS; NONRANDOM BEHAVIOR; PAF1 COMPLEX; IN-VITRO	NAP1 ( nucleosome assembly protein 1) is a histone chaperone that has been described to bind predominantly to the histone H2A center dot H2B dimer in the cell during shuttling of histones into the nucleus, nucleosome assembly/ remodeling, and transcription. Here it was examined how NAP1 interacts with chromatin fibers isolated from HeLa cells. NAP1 induced a reversible change toward an extended fiber conformation as demonstrated by sedimentation velocity ultracentrifugation experiments. This transition was due to the removal of the linker histone H1. The H2A center dot H2B dimer remained stably bound to the native fiber fragments and to fibers devoid of linker histone H1. This was in contrast to mononucleosome substrates, which displayed a NAP1-induced removal of a single H2A center dot H2B dimer from the core particle. The effect of NAP1 on the chromatin fiber structure was examined by scanning/ atomic force microscopy. A quantitative image analysis of similar to 36,000 nucleosomes revealed an increase of the average internucleosomal distance from 22.3 +/- 0.4 to 27.6 +/- 0.6 nm, whereas the overall fiber structure was preserved. This change reflects the disintegration of the chromatosome due to binding of H1 to NAP1 as chromatin fibers stripped from H1 showed an average nucleosome distance of 27.4 +/- 0.8 nm. The findings suggest a possible role of NAP1 in chromatin remodeling processes involved in transcription and replication by modulating the local linker histone content.	Heidelberg Univ, Kirchhoff Inst Phys, Mol Biophys Grp, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Rippe, K (corresponding author), Heidelberg Univ, Kirchhoff Inst Phys, Mol Biophys Grp, Neuenheimer Feld 227, D-69120 Heidelberg, Germany.	Karsten.Rippe@kip.uni-heidelberg.de	Rippe, Karsten/A-3562-2012	Rippe, Karsten/0000-0001-9951-9395				Adams CR, 1999, CURR OPIN GENET DEV, V9, P185, DOI 10.1016/S0959-437X(99)80028-8; AUSIO J, 1984, J MOL BIOL, V177, P373, DOI 10.1016/0022-2836(84)90291-2; Ausio J, 2000, BIOPHYS CHEM, V86, P141, DOI 10.1016/S0301-4622(00)00144-7; Bash R, 2003, BIOCHEMISTRY-US, V42, P4681, DOI 10.1021/bi026887o; Bash RC, 2001, J BIOL CHEM, V276, P48362, DOI 10.1074/jbc.M104916200; Bednar J, 1998, P NATL ACAD SCI USA, V95, P14173, DOI 10.1073/pnas.95.24.14173; BELLARD M, 1980, NUCLEIC ACIDS RES, V8, P2737, DOI 10.1093/nar/8.12.2737; BELMONT AS, 1994, J CELL BIOL, V127, P287, DOI 10.1083/jcb.127.2.287; Belotserkovskaya R, 2004, BBA-GENE STRUCT EXPR, V1677, P87, DOI 10.1016/j.bbaexp.2003.09.017; Belotserkovskaya R, 2003, SCIENCE, V301, P1090, DOI 10.1126/science.1085703; Bruno M, 2003, MOL CELL, V12, P1599, DOI 10.1016/S1097-2765(03)00499-4; Carruthers LM, 1998, BIOCHEMISTRY-US, V37, P14776, DOI 10.1021/bi981684e; Carruthers LM, 2000, J BIOL CHEM, V275, P37285, DOI 10.1074/jbc.M006801200; Carruthers LM, 2000, METHOD ENZYMOL, V321, P66; CHEN H, 1994, EMBO J, V13, P380, DOI 10.1002/j.1460-2075.1994.tb06272.x; Crane-Robinson C, 1999, BIOESSAYS, V21, P367, DOI 10.1002/(SICI)1521-1878(199905)21:5<367::AID-BIES2>3.0.CO;2-4; d'Erme M, 2001, BIOCHEMISTRY-US, V40, P10947, DOI 10.1021/bi002742a; Dillon N, 2004, BIOL CELL, V96, P631, DOI 10.1016/j.biolcel.2004.06.003; Dorigo B, 2003, J MOL BIOL, V327, P85, DOI 10.1016/S0022-2836(03)00025-1; Fan JY, 2002, NAT STRUCT BIOL, V9, P172, DOI 10.1038/nsb767; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; GARCIARAMIREZ M, 1992, J BIOL CHEM, V267, P19587; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; GIANNASCA PJ, 1993, J CELL SCI, V105, P551; Gilbert N, 2004, CELL, V118, P555, DOI 10.1016/j.cell.2004.08.011; Grummt I, 2003, NAT REV MOL CELL BIO, V4, P641, DOI 10.1038/nrm1171; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P9129, DOI 10.1021/bi00449a026; Hansen JC, 1999, METH MOL B, V119, P127; Hartzog GA, 2002, BBA-GENE STRUCT EXPR, V1577, P276, DOI 10.1016/S0167-4781(02)00458-X; Haushalter KA, 2003, NAT REV MOL CELL BIO, V4, P613, DOI 10.1038/nrm1177; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; Ito T, 2000, GENE DEV, V14, P1899; Karymov MA, 2001, FASEB J, V15, P2631, DOI 10.1096/fj.01-0345com; KELLOGG DR, 1995, J CELL BIOL, V130, P675, DOI 10.1083/jcb.130.3.675; Kepert JF, 2003, BIOPHYS J, V85, P4012, DOI 10.1016/S0006-3495(03)74815-2; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lee KM, 1997, P NATL ACAD SCI USA, V94, P8959, DOI 10.1073/pnas.94.17.8959; LEUBA SH, 1994, P NATL ACAD SCI USA, V91, P11621, DOI 10.1073/pnas.91.24.11621; Leuba SH, 1998, BIOPHYS J, V74, P2823, DOI 10.1016/S0006-3495(98)77989-5; Levchenko V, 2005, BIOCHEMISTRY-US, V44, P5357, DOI 10.1021/bi047786o; Levchenko V, 2004, BIOCHEMISTRY-US, V43, P2359, DOI 10.1021/bi035737q; Loyola A, 2004, BBA-GENE STRUCT EXPR, V1677, P3, DOI 10.1016/j.bbaexp.2003.09.012; Martic G, 2005, J BIOL CHEM, V280, P16143, DOI 10.1074/jbc.M410175200; McBryant SJ, 2003, J BIOL CHEM, V278, P44574, DOI 10.1074/jbc.M305636200; McKittrick E, 2004, P NATL ACAD SCI USA, V101, P1525, DOI 10.1073/pnas.0308092100; McQuibban GA, 1998, J BIOL CHEM, V273, P6582, DOI 10.1074/jbc.273.11.6582; Misteli T, 2001, SCIENCE, V291, P843, DOI 10.1126/science.291.5505.843; Mizuguchi G, 2004, SCIENCE, V303, P343, DOI 10.1126/science.1090701; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; Neben K, 2004, ONCOGENE, V23, P2379, DOI 10.1038/sj.onc.1207401; Ohkuni K, 2003, BIOCHEM BIOPH RES CO, V306, P5, DOI 10.1016/S0006-291X(03)00907-0; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; Park YJ, 2005, J BIOL CHEM, V280, P1817, DOI 10.1074/jbc.M411347200; Peng HF, 1997, BIOCHEMISTRY-US, V36, P12371, DOI 10.1021/bi971046g; Philo JS, 2000, ANAL BIOCHEM, V279, P151, DOI 10.1006/abio.2000.4480; Rabbani A, 1999, J BIOL CHEM, V274, P18401, DOI 10.1074/jbc.274.26.18401; Ramos I, 2005, BIOCHEMISTRY-US, V44, P8274, DOI 10.1021/bi050386w; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Rivetti C, 1996, J MOL BIOL, V264, P919, DOI 10.1006/jmbi.1996.0687; Rivetti C, 2001, ULTRAMICROSCOPY, V87, P55, DOI 10.1016/S0304-3991(00)00064-4; Schuck P, 2003, ANAL BIOCHEM, V320, P104, DOI 10.1016/S0003-2697(03)00289-6; SCHWARZ PM, 1994, J BIOL CHEM, V269, P16284; SEDAT J, 1977, COLD SPRING HARB SYM, V42, P331, DOI 10.1101/SQB.1978.042.01.035; Shintomi K, 2005, P NATL ACAD SCI USA, V102, P8210, DOI 10.1073/pnas.0500822102; Sims RJ, 2004, CURR OPIN CELL BIOL, V16, P263, DOI 10.1016/j.ceb.2004.04.004; Squazzo SL, 2002, EMBO J, V21, P1764, DOI 10.1093/emboj/21.7.1764; Studitsky VM, 1997, SCIENCE, V278, P1960, DOI 10.1126/science.278.5345.1960; Studitsky VM, 2004, TRENDS BIOCHEM SCI, V29, P127, DOI 10.1016/j.tibs.2004.01.003; Toth KF, 2005, J BIOL CHEM, V280, P15690, DOI 10.1074/jbc.M413329200; Tumbar T, 1999, J CELL BIOL, V145, P1341, DOI 10.1083/jcb.145.7.1341; Tyler JK, 2002, EUR J BIOCHEM, V269, P2268, DOI 10.1046/j.1432-1033.2002.02890.x; van Holde KE., 1989, SPRINGER SERIES MOL; Vermaak D, 2003, CURR OPIN CELL BIOL, V15, P266, DOI 10.1016/S0955-0674(03)00043-7; WALTER PP, 1995, MOL CELL BIOL, V15, P6178; Wang HD, 2002, BIOPHYS J, V83, P3619, DOI 10.1016/S0006-3495(02)75362-9; Wang XY, 2001, J BIOL CHEM, V276, P12764, DOI 10.1074/jbc.M100501200; WEINTRAUB H, 1976, SCIENCE, V193, P848, DOI 10.1126/science.948749; WU C, 1979, CELL, V16, P807, DOI 10.1016/0092-8674(79)90096-5; Yodh JG, 2002, BIOCHEMISTRY-US, V41, P3565, DOI 10.1021/bi011612e; Yodh JG, 1999, BIOCHEMISTRY-US, V38, P15756, DOI 10.1021/bi991034q; Zlatanova J, 2000, FASEB J, V14, P1697, DOI 10.1096/fj.99-0869rev; Zlatanova J, 1996, PROG NUCLEIC ACID RE, V52, P217, DOI 10.1016/S0079-6603(08)60968-X; Zlatanova J, 1998, BIOPHYS J, V74, P2554, DOI 10.1016/S0006-3495(98)77963-9; ZLATANOVA J, 1990, TRENDS BIOCHEM SCI, V15, P273, DOI 10.1016/0968-0004(90)90053-E	90	61	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34063	34072		10.1074/jbc.M507322200	http://dx.doi.org/10.1074/jbc.M507322200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16105835	Green Accepted, hybrid, Green Published			2022-12-27	WOS:000232229700046
J	Kim, HP; Kim, BG; Letterio, J; Leonard, WJ				Kim, HP; Kim, BG; Letterio, J; Leonard, WJ			Smad-dependent cooperative regulation of interleukin 2 receptor alpha chain gene expression by T cell receptor and transforming growth factor-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; IL-2 RECEPTOR; TARGETED DISRUPTION; MOLECULAR-CLONING; PROMOTER REGION; POTENTIAL ROLE; LYMPHOCYTES-T; ACTIVATION; MICE; GROWTH-FACTOR-BETA-1	The interleukin 2 receptor alpha chain (IL-2R alpha) is a component of high affinity IL-2 receptors and thus critically regulates T cell growth and other lymphoid functions. Five positive regulatory regions together control lineage-restricted and activation-dependent IL-2R alpha induction in response to antigen and IL-2. We now show that TGF-beta cooperates with T cell receptor (TCR) signaling to increase IL-2R alpha gene expression. Moreover, we identify a sixth positive regulatory region that regulates IL-2R alpha expression in cells treated with anti-CD3 + anti-CD28 as well as TGF-beta and show that this region contains binding sites for Smad3, AP-1, and cAMP-responsive element-binding protein/ ATF proteins. The importance of Smad complexes is indicated by impaired IL-2R alpha induction by TGF-beta in CD4(+) T cells from both Smad3(-/-) and Smad4(-/-) mice. Thus, we have identified a novel positive regulatory region in the IL-2R alpha gene that mediates TGF-beta-dependent induction of the gene. These findings have implications related to IL-2R alpha expression on activated T cells and regulatory T cells.	NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA; NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Leonard, WJ (corresponding author), NHLBI, Lab Mol Immunol, NIH, Bldg 10,Rm 7N252, Bethesda, MD 20892 USA.	wjl@helix.nih.gov	Leonard, Warren/AAA-1397-2022	Kim, Hyoung-Pyo/0000-0003-1441-8822	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000711] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000711] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL005402, Z01HL005402] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BROWN PH, 1994, ONCOGENE, V9, P791; Cerwenka A, 1996, J IMMUNOL, V156, P459; CERWENKA A, 1994, J IMMUNOL, V153, P4367; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; Datto MB, 1999, MOL CELL BIOL, V19, P2495; DEJONG R, 1994, INT IMMUNOL, V6, P631, DOI 10.1093/intimm/6.4.631; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dubchak I, 2000, GENOME RES, V10, P1304, DOI 10.1101/gr.142200; Gorelik L, 2000, IMMUNITY, V12, P171, DOI 10.1016/S1074-7613(00)80170-3; Gorelik L, 2002, NAT REV IMMUNOL, V2, P46, DOI 10.1038/nri704; Gray JD, 1998, J IMMUNOL, V160, P2248; GRAY JD, 1994, J EXP MED, V180, P1937, DOI 10.1084/jem.180.5.1937; Guo LY, 2004, IMMUNITY, V20, P193, DOI 10.1016/S1074-7613(04)00025-1; JOHN S, 1995, MOL CELL BIOL, V15, P1786; John S, 1996, EMBO J, V15, P5627, DOI 10.1002/j.1460-2075.1996.tb00947.x; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; Kim HP, 2002, EMBO J, V21, P3051, DOI 10.1093/emboj/cdf321; Kim HP, 2001, IMMUNITY, V15, P159, DOI 10.1016/S1074-7613(01)00167-4; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Lecine P, 1996, MOL CELL BIOL, V16, P6829; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; Leonard WJ, 2001, NAT REV IMMUNOL, V1, P200, DOI 10.1038/35105066; LEONARD WJ, 1985, P NATL ACAD SCI USA, V82, P6281, DOI 10.1073/pnas.82.18.6281; LEONARD WJ, 1985, SCIENCE, V230, P633, DOI 10.1126/science.2996141; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LEONARD WJ, 1982, NATURE, V300, P267, DOI 10.1038/300267a0; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LIN BB, 1990, MOL CELL BIOL, V10, P850, DOI 10.1128/MCB.10.2.850; Lin Jian-Xin, 1997, Cytokine and Growth Factor Reviews, V8, P313; LIN JX, 2003, SIGNAL TRANSDUCERS A, P435; Liu H, 2002, MOL CELL BIOL, V22, P6471, DOI 10.1128/MCB.22.18.6471-6479.2002; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Lucas PJ, 2000, J EXP MED, V191, P1187, DOI 10.1084/jem.191.7.1187; Malek TR, 2002, IMMUNITY, V17, P167, DOI 10.1016/S1074-7613(02)00367-9; Mayor C, 2000, BIOINFORMATICS, V16, P1046, DOI 10.1093/bioinformatics/16.11.1046; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; PROETZEL G, 1995, NAT GENET, V11, P409, DOI 10.1038/ng1295-409; Rao SH, 2001, J IMMUNOL, V167, P4494, DOI 10.4049/jimmunol.167.8.4494; Reeves R, 2000, MOL CELL BIOL, V20, P4666, DOI 10.1128/MCB.20.13.4666-4679.2000; ROMAN D, 1990, New Biologist, V2, P642; Sanford LP, 1997, DEVELOPMENT, V124, P2659; SCHLUESENER H, 1990, J NEUROIMMUNOL, V28, P271, DOI 10.1016/0165-5728(90)90020-N; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SIEBENLIST U, 1986, MOL CELL BIOL, V6, P3042, DOI 10.1128/MCB.6.9.3042; SOLDAINI E, 1995, J BIOL CHEM, V270, P10733, DOI 10.1074/jbc.270.18.10733; SOMPAYRAC LM, 1981, P NATL ACAD SCI-BIOL, V78, P7575, DOI 10.1073/pnas.78.12.7575; SPERISEN P, 1995, J BIOL CHEM, V270, P10743, DOI 10.1074/jbc.270.18.10743; STOECK M, 1989, J IMMUNOL, V143, P3258; TOLEDANO MB, 1990, P NATL ACAD SCI USA, V87, P1830, DOI 10.1073/pnas.87.5.1830; VanParijs L, 1997, J IMMUNOL, V158, P3738; Yamagiwa S, 2001, J IMMUNOL, V166, P7282, DOI 10.4049/jimmunol.166.12.7282; Yang X, 2002, GENESIS, V32, P80, DOI 10.1002/gene.10029; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Yeh JH, 2001, MOL CELL BIOL, V21, P4515, DOI 10.1128/MCB.21.14.4515-4527.2001; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; ZHANG XH, 1995, J EXP MED, V182, P699, DOI 10.1084/jem.182.3.699; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	66	33	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34042	34047		10.1074/jbc.M505833200	http://dx.doi.org/10.1074/jbc.M505833200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16087671	hybrid			2022-12-27	WOS:000232229700043
J	Chernyavsky, AI; Arredondo, J; Karlsson, E; Wessler, I; Grando, SA				Chernyavsky, AI; Arredondo, J; Karlsson, E; Wessler, I; Grando, SA			The Ras/Raf-1/MEK1/ERK signaling pathway coupled to integrin expression mediates cholinergic regulation of keratinocyte directional migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; PULMONARY NEUROENDOCRINE CELLS; NERVE GROWTH CONES; ELECTRIC-FIELDS; MUSCARINIC RECEPTORS; CALCIUM INFLUX; KINASE PATHWAY; MUSCLE-CELLS; RAT; ACTIVATION	The physiologic mechanisms that determine directionality of lateral migration are a subject of intense research. Galvanotropism in a direct current ( DC) electric field represents a natural model of cell re-orientation toward the direction of future migration. Keratinocyte migration is regulated through both the nicotinic and muscarinic classes of acetylcholine (ACh) receptors. We sought to identify the signaling pathway mediating the cholinergic regulation of chemotaxis and galvanotropism. The pharmacologic and molecular modifiers of the Ras/Raf-1/MEK1/ERK signaling pathway altered both chemotaxis toward choline and galvanotropism toward the cathode in a similar way, indicating that the same signaling steps were involved. The galvanotropism was abrogated due to inhibition of ACh production by hemicholinium-3 and restored by exogenously added carbachol. The concentration gradients of ACh and choline toward the cathode in a DC field were established by high-performance liquid chromatographic measurements. This suggested that keratinocyte galvanotaxis is, in effect, chemotaxis toward the concentration gradient of ACh, which it creates in a DC field due to its highly positive charge. A time-course immunofluorescence study of the membrane redistribution of ACh receptors in keratinocytes exposed to a DC field revealed rapid relocation to and clustering at the leading edge of alpha 7 nicotinic and M-1 muscarinic receptors. Their inactivation with selective antagonists or small interfering RNAs inhibited galvanotropism, which could be prevented by transfecting the cells with constitutively active MEK1. The end-point effect of the cooperative signaling downstream from alpha 7 and M-1 through the MEK1/ERK was an up-regulated expression of alpha(2) and alpha(3) integrins, as judged from the results of real-time PCR and quantitative immunoblotting. Thus, alpha 7 works together with M-1 to orient a keratinocyte toward direction of its future migration. Both alpha 7 and M-1 apparently engage the Ras/Raf/MEK/ERK pathway to up-regulate expression of the "sedentary" integrins required for stabilization of the lamellipodium at the keratinocyte leading edge.	Univ Calif Davis, Sch Med, Dept Dermatol, Davis, CA 95616 USA; Karolinska Inst, Sect Expt Geriatr, NEUROTEC, S-14186 Huddinge, Sweden; Johannes Gutenberg Univ Mainz, Univ Hosp, Inst Pathol, D-55101 Mainz, Germany	University of California System; University of California Davis; Karolinska Institutet; Johannes Gutenberg University of Mainz; University Hospital Mainz	Grando, SA (corresponding author), Univ Calif Davis, Dept Dermatol, UC Davis Med Ctr, 4860 Y St,3400, Sacramento, CA 95817 USA.	sagrando@ucdavis.edu			NIDCR NIH HHS [DE14173] Funding Source: Medline; NIGMS NIH HHS [GM62136] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE014173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062136] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alkondon M, 1997, EUR J NEUROSCI, V9, P2734, DOI 10.1111/j.1460-9568.1997.tb01702.x; Arredondo J, 2005, AM J PATHOL, V166, P597, DOI 10.1016/S0002-9440(10)62281-X; BARKER AT, 1982, AM J PHYSIOL, V242, pR358, DOI 10.1152/ajpregu.1982.242.3.R358; BLOCH RJ, 1988, AM J PHYSIOL, V254, pC345, DOI 10.1152/ajpcell.1988.254.3.C345; Buchli R, 1999, J CELL BIOCHEM, V74, P264, DOI 10.1002/(SICI)1097-4644(19990801)74:2<264::AID-JCB11>3.0.CO;2-Z; BURR H. S., 1940, YALE JOUR BIOL AND MED, V12, P483; CAULFIELD MP, 1993, PHARMACOL THERAPEUT, V58, P319, DOI 10.1016/0163-7258(93)90027-B; Chernyavsky AI, 2004, J CELL SCI, V117, P5665, DOI 10.1242/jcs.01492; Chernyavsky AI, 2004, J CELL BIOL, V166, P261, DOI 10.1083/jcb.200401034; Dajas-Bailador FA, 2002, J NEUROCHEM, V80, P520, DOI 10.1046/j.0022-3042.2001.00725.x; DIPALMA JR, 1994, BASIC PHARM MED; Elwary SMA, 2004, J INVEST DERMATOL, V123, P1206, DOI 10.1111/j.0022-202X.2004.23493.x; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; ERICKSON CA, 1984, J CELL BIOL, V98, P296, DOI 10.1083/jcb.98.1.296; Genersch E, 2000, J CELL SCI, V113, P4319; GRANDO SA, 1993, J INVEST DERMATOL, V101, P804, DOI 10.1111/1523-1747.ep12371699; Grando SA, 1996, J INVEST DERMATOL, V107, P412, DOI 10.1111/1523-1747.ep12363399; GRANDO SA, 1993, J INVEST DERMATOL, V101, P32, DOI 10.1111/1523-1747.ep12358588; GRANDO SA, 1997, CURR OPIN DERMATOL, V4, P262; GUYENET P, 1973, MOL PHARMACOL, V9, P630; HARA M, 1993, P NATL ACAD SCI USA, V90, P2281, DOI 10.1073/pnas.90.6.2281; Jaffe L F, 1984, Clin Dermatol, V2, P34, DOI 10.1016/0738-081X(84)90025-7; Jull BA, 2001, J CANCER RES CLIN, V127, P707; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Karlsson E, 2000, BIOCHIMIE, V82, P793, DOI 10.1016/S0300-9084(00)01176-7; Kostouros GD, 1996, EUR J ORAL SCI, V104, P570, DOI 10.1111/j.1600-0722.1996.tb00143.x; Kuffler DP, 1996, MOL CHEM NEUROPATHOL, V28, P199, DOI 10.1007/BF02815223; Lackey K, 2000, BIOORG MED CHEM LETT, V10, P223, DOI 10.1016/S0960-894X(99)00668-X; Li S, 2004, J PHARMACOL SCI, V94, P334, DOI 10.1254/jphs.94.334; Liang CC, 2001, J BIOL CHEM, V276, P21146, DOI 10.1074/jbc.M010669200; LUTHER PW, 1985, J CELL BIOL, V100, P235, DOI 10.1083/jcb.100.1.235; Morris SJ, 1996, J PHYSIOL-LONDON, V496, P531, DOI 10.1113/jphysiol.1996.sp021704; Ndoye A, 1998, J INVEST DERMATOL, V111, P410, DOI 10.1046/j.1523-1747.1998.00299.x; Nguyen VT, 2000, AM J PATHOL, V157, P1377, DOI 10.1016/S0002-9440(10)64651-2; Nguyen VT, 2000, J DENT RES, V79, P939; Nguyen VT, 2001, J CELL SCI, V114, P1189; Nishimura KY, 1996, J CELL SCI, V109, P199; NOWAK D, 1990, EXP PATHOL-JENA, V39, P37; Nuccitelli R, 2003, CURR TOP DEV BIOL, V58, P1, DOI 10.1016/S0070-2153(03)58001-2; Papke RL, 1996, NEUROSCI LETT, V213, P201; PENG HB, 1993, J CELL BIOL, V120, P197, DOI 10.1083/jcb.120.1.197; POO MM, 1981, ANNU REV BIOPHYS BIO, V10, P245, DOI 10.1146/annurev.bb.10.060181.001333; QIAN NX, 1995, LIFE SCI, V56, P945, DOI 10.1016/0024-3205(95)00032-2; Quik M, 1996, J NEUROCHEM, V67, P145; Reinheimer T, 1996, AM J PHYSIOL-LUNG C, V270, pL722, DOI 10.1152/ajplung.1996.270.5.L722; Schuller HM, 2003, ANAT REC PART A, V270A, P51, DOI 10.1002/ar.a.10019; SLIWA L, 1995, ARCH ANDROLOGY, V35, P105, DOI 10.3109/01485019508987860; STOLLBERG J, 1990, J CELL BIOL, V111, P2029, DOI 10.1083/jcb.111.5.2029; TESSIERLAVIGNE M, 1994, CURR OPIN GENET DEV, V4, P596, DOI 10.1016/0959-437X(94)90078-H; TOTTI N, 1984, SCIENCE, V223, P169, DOI 10.1126/science.6318317; Trollinger DR, 2002, J CELL PHYSIOL, V193, P1, DOI 10.1002/jcp.10144; VANDERMEERS A, 1995, TOXICON, V33, P1171, DOI 10.1016/0041-0101(95)00057-S; VELDSEMACURRIE RD, 1984, BRAIN RES, V324, P305, DOI 10.1016/0006-8993(84)90041-6; Vindis C, 2003, J CELL BIOL, V162, P661, DOI 10.1083/jcb.200302073; VODOVNIK L, 1992, MED BIOL ENG COMPUT, V30, P257, DOI 10.1007/BF02446963; Wang ET, 2003, INVEST OPHTH VIS SCI, V44, P244, DOI 10.1167/iovs.02-0456; WEISS DS, 1990, ARCH DERMATOL, V126, P222, DOI 10.1001/archderm.126.2.222; WILSON WS, 1986, EXP EYE RES, V43, P235, DOI 10.1016/S0014-4835(86)80091-4; Wityak J, 2004, BIOORG MED CHEM LETT, V14, P1483, DOI 10.1016/j.bmcl.2004.01.012; Yassin L, 2001, MOL CELL NEUROSCI, V17, P589, DOI 10.1006/mcne.2000.0944; YOUNG SH, 1983, NATURE, V304, P161, DOI 10.1038/304161a0; Zheng JQ, 1996, PERSPECT DEV NEUROBI, V4, P205; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0; Zia SH, 2000, J PHARMACOL EXP THER, V293, P973	64	70	72	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39220	39228		10.1074/jbc.M504407200	http://dx.doi.org/10.1074/jbc.M504407200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16150734	hybrid			2022-12-27	WOS:000233362200038
J	de Bouteiller, O; Merck, E; Hasan, UA; Hubac, S; Benguigui, B; Trinchieri, G; Bates, EEM; Caux, C				de Bouteiller, O; Merck, E; Hasan, UA; Hubac, S; Benguigui, B; Trinchieri, G; Bates, EEM; Caux, C			Recognition of double-stranded RNA by human Toll-like receptor 3 and downstream receptor signaling requires multimerization and an acidic pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HUMAN DENDRITIC CELLS; FC-RECEPTOR; CPG-DNA; SUBCELLULAR-LOCALIZATION; ENDOPLASMIC-RETICULUM; ESSENTIAL COMPONENTS; IMMUNE-RESPONSES; APOPTOTIC CELLS; ACTIVATION	Studies involving Toll-like receptor 3 (TLR3)-deficient mice suggest that this receptor binds double-stranded RNA. In the present study, we analyzed ligand/receptor interactions and receptor-proximal events leading to TLR3 activation. The mutagenesis approach showed that certain cysteine residues and glycosylation in TLR3 amino-terminal leucine-rich repeats were necessary for ligand-induced signaling. Furthermore, inactive mutants had a dominant negative effect, suggesting that the signaling module is a multimer. We constructed a chimeric molecule fusing the amino-terminal ectodomain of TLR3 to the transmembrane and carboxyl terminal domains of CD32a containing an immunoreceptor tyrosine-based motif. Expression of TLR3-CD32 in HEK293T cells and the myeloid cell line U937 resulted in surface localization of the receptor, whereas the nonrecombinant molecule was intracellularly localized. The synthetic double-stranded RNAs poly(I-C) and poly(A-U) induced calcium mobilization in a TLR3-CD32 stably transfected U937 clone but not in control cells transfected with other constructs. An anti-TLR3 antibody also induced Ca2+ flux but only when cross-linked by a secondary anti-immunoglobulin antibody, confirming that multimerization by the ligand is a requirement for signaling. The inhibitors of lysosome maturation, bafilomycin and chloroquine, inhibited the poly(I-C)-induced biological response in immune cells, showing that TLR3 interacted with its ligand in acidic subcellular compartments. Furthermore, TLR3-CD32 activation with poly(I-C) was only observed within a narrow pH window (pH 5.7-6.7), whereas anti-TLR3-mediated Ca2+ flux was pH-insensitive. The importance of an acidic pH for TLR3-ligand interaction becomes critical when using oligomeric poly(I-C) (15-40-mers). These observations demonstrate that engagement of TLR3 by poly(I-C) at an acidic pH, probably in early phagolysosomes or endosomes, induces receptor aggregation leading to signaling.	Schering Plough Res Inst, Lab Immunol Res, F-69571 Dardilly, France	Merck & Company	Caux, C (corresponding author), INSERM, U590, Ctr Leon Berard, 28 Rue Laennec, F-69373 Lyon, France.	CAUXC@lyon.fnclcc.fr	Caux, Christophe/G-2851-2013; hasan, uzma A/G-3247-2013; Trinchieri, Giorgio/F-9369-2015	Caux, Christophe/0000-0003-2438-833X; Trinchieri, Giorgio/0000-0001-5892-7464; Hasan, Uzma/0000-0002-1770-5539				Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Aksoy E, 2005, J BIOL CHEM, V280, P277, DOI 10.1074/jbc.M411223200; Akula SM, 2003, J VIROL, V77, P7978, DOI 10.1128/JVI.77.14.7978-7990.2003; Albert ML, 2004, NAT REV IMMUNOL, V4, P223, DOI 10.1038/nri11308; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Beg AA, 2002, TRENDS IMMUNOL, V23, P509, DOI 10.1016/S1471-4906(02)02317-7; Bell JK, 2005, P NATL ACAD SCI USA, V102, P10976, DOI 10.1073/pnas.0505077102; Choe J, 2005, SCIENCE, V309, P581, DOI 10.1126/science.1115253; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Edelmann KH, 2004, VIROLOGY, V322, P231, DOI 10.1016/j.virol.2004.01.033; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Funami K, 2004, INT IMMUNOL, V16, P1143, DOI 10.1093/intimm/dxh115; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; Garoff H, 2004, VIRUS RES, V106, P103, DOI 10.1016/j.virusres.2004.08.008; Guillot L, 2004, J BIOL CHEM, V279, P2712, DOI 10.1074/jbc.M305790200; Hasan U, 2005, J IMMUNOL, V174, P2942, DOI 10.4049/jimmunol.174.5.2942; Hasan UA, 2004, BIOCHEM BIOPH RES CO, V321, P124, DOI 10.1016/j.bbrc.2004.06.134; Hasan UA, 2005, J BIOL CHEM, V280, P20620, DOI 10.1074/jbc.M500877200; Heil F, 2003, EUR J IMMUNOL, V33, P2987, DOI 10.1002/eji.200324238; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Hoebe K, 2004, J ENDOTOXIN RES, V10, P130, DOI 10.1179/096805104225004031; Kaisho T, 2003, CURR MOL MED, V3, P373, DOI 10.2174/1566524033479726; Kariko K, 2004, J BIOL CHEM, V279, P12542, DOI 10.1074/jbc.M310175200; Kariko K, 2004, J IMMUNOL, V172, P6545, DOI 10.4049/jimmunol.172.11.6545; Kariko K, 2004, J CEREBR BLOOD F MET, V24, P1288, DOI 10.1097/01.WCB.0000145666.68576.71; Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Lee HK, 2004, J BIOL CHEM, V279, P10564, DOI 10.1074/jbc.M311564200; Lee J, 2003, P NATL ACAD SCI USA, V100, P6646, DOI 10.1073/pnas.0631696100; Leifer CA, 2004, J IMMUNOL, V173, P1179, DOI 10.4049/jimmunol.173.2.1179; Matsumoto M, 2001, Uirusu, V51, P209; Matsumoto M, 2002, BIOCHEM BIOPH RES CO, V293, P1364, DOI 10.1016/S0006-291X(02)00380-7; Matsumoto M, 2003, J IMMUNOL, V171, P3154, DOI 10.4049/jimmunol.171.6.3154; Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Mukhopadhyay S, 2004, IMMUNOLOGY, V112, P521, DOI 10.1111/j.1365-2567.2004.01941.x; Nishiya T, 2004, J BIOL CHEM, V279, P19008, DOI 10.1074/jbc.M311618200; O'Neill LAJ, 2003, TRENDS IMMUNOL, V24, P287, DOI 10.1016/S1471-4906(03)00115-7; ODIN JA, 1991, SCIENCE, V254, P1785, DOI 10.1126/science.1837175; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Pelchen-Matthews A, 2003, J CELL BIOL, V162, P443, DOI 10.1083/jcb.200304008; Rutz M, 2004, EUR J IMMUNOL, V34, P2541, DOI 10.1002/eji.200425218; Salio M, 2000, EUR J IMMUNOL, V30, P705, DOI 10.1002/1521-4141(200002)30:2<705::AID-IMMU705>3.0.CO;2-P; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Salonen A, 2003, J VIROL, V77, P1691, DOI 10.1128/JVI.77.3.1691-1702.2003; Sandor F, 2003, J CELL BIOL, V162, P1099, DOI 10.1083/jcb.200304093; Sarkar SN, 2004, NAT STRUCT MOL BIOL, V11, P1060, DOI 10.1038/nsmb847; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; Schulz O, 2005, NATURE, V433, P887, DOI 10.1038/nature03326; SHEN L, 1994, J IMMUNOL, V153, P5849; Sherer NM, 2003, TRAFFIC, V4, P785, DOI 10.1034/j.1600-0854.2003.00135.x; Shi XH, 2004, J VIROL, V78, P5414, DOI 10.1128/JVI.78.10.5414-5422.2004; Sugimoto N, 2001, BIOCHEMISTRY-US, V40, P9396, DOI 10.1021/bi010666l; Tabeta K, 2004, P NATL ACAD SCI USA, V101, P3516, DOI 10.1073/pnas.0400525101; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; VANDENHERIKOUDIJK IE, 1995, BLOOD, V86, P3302, DOI 10.1182/blood.V86.9.3302.bloodjournal8693302; Wang T, 2004, NAT MED, V10, P1366, DOI 10.1038/nm1140; Weber ANR, 2003, NAT IMMUNOL, V4, P794, DOI 10.1038/ni955; Weber SM, 2002, J IMMUNOL, V168, P5303, DOI 10.4049/jimmunol.168.10.5303; Wu CCN, 2004, J BIOL CHEM, V279, P33071, DOI 10.1074/jbc.M311662200; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986; Zhang GL, 2002, J BIOL CHEM, V277, P7059, DOI 10.1074/jbc.M109537200	68	204	217	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38133	38145		10.1074/jbc.M507163200	http://dx.doi.org/10.1074/jbc.M507163200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16144834	hybrid			2022-12-27	WOS:000233239800005
J	Lubarski, I; Pihakaski-Maunsbach, K; Karlish, SJD; Maunsbach, AB; Garty, H				Lubarski, I; Pihakaski-Maunsbach, K; Karlish, SJD; Maunsbach, AB; Garty, H			Interaction with the Na, K-ATPase and tissue distribution of FXYD5 (related to ion channel)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLEMMAN-LIKE PROTEIN; NA,K-ATPASE GAMMA-SUBUNIT; IMMUNOCYTOCHEMICAL LOCALIZATION; FUNCTIONAL INTERACTION; XENOPUS OOCYTES; E-CADHERIN; EXPRESSION; DYSADHERIN; CHIF; FAMILY	FXYD5 ( related to ion channel, dysadherin) is a member of the FXYD family of single span type I membrane proteins. Five members of this group have been shown to interact with the Na, K-ATPase and to modulate its properties. However, FXYD5 is structurally different from other family members and has been suggested to play a role in regulating E-cadherin and promoting metastasis ( Ino, Y., Gotoh, M., Sakamoto, M., Tsukagoshi, K., and Hirohashi, S. ( 2002) Proc. Natl. Acad. Sci. U. S. A. 99, 365 - 370). The goal of this study was to determine whether FXYD5 can modulate the Na, KA-TPase activity, establish its cellular and tissue distribution, and characterize its biochemical properties. Anti-FXYD5 antibodies detected a 24-kDa polypeptide that was preferentially expressed in kidney, intestine, spleen, and lung. In kidney, FXYD5 resides in the basolateral membrane of the connecting tubule, the collecting tubule, and the intercalated cells of the collecting duct. However, there is also labeling of the apical membrane in long thin limb of Henle's loop. FXYD5 was effectively immunoprecipitated by antibodies to the alpha subunit of Na, K-ATPase and the anti-FXYD5 antibody immunoprecipitates alpha. Co-expressing FXYD5 with the alpha 1 and beta 1 subunits of the Na, K-ATPase in Xenopus oocytes elicited a more than 2-fold increase in pump activity, measured either as ouabain-blockable outward current or as ouabain-sensitive Rb-86(+) uptake. Thus, as found with other FXYD proteins, FXYD5 interacts with the Na, K-ATPase and modulates its properties.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Aarhus Univ, Water & Salt Res Ctr, DK-8000 Aarhus, Denmark	Weizmann Institute of Science; Aarhus University	Garty, H (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	h.garty@weizmann.ac.il						Ahlers BA, 2005, J BIOL CHEM, V280, P19875, DOI 10.1074/jbc.M414703200; Aoki S, 2003, BRIT J CANCER, V88, P726, DOI 10.1038/sj.bjc.6600778; ATTALI B, 1995, P NATL ACAD SCI USA, V92, P6092, DOI 10.1073/pnas.92.13.6092; Beguin P, 2002, EMBO J, V21, P3264, DOI 10.1093/emboj/cdf330; Beguin P, 2001, EMBO J, V20, P3993, DOI 10.1093/emboj/20.15.3993; Cornelius F, 2003, NEWS PHYSIOL SCI, V18, P119, DOI 10.1152/nips.01434.2003; Crambert G, 2002, P NATL ACAD SCI USA, V99, P11476, DOI 10.1073/pnas.182267299; Crambert G, 2005, MOL BIOL CELL, V16, P2363, DOI 10.1091/mbc.E04-10-0878; CRAMBERT G, 2003, SCI STKE, pRE1; Feschenko MS, 2003, J NEUROSCI, V23, P2161; Fu XY, 1997, MOL CELL BIOL, V17, P1503, DOI 10.1128/MCB.17.3.1503; Fuller W, 2004, FASEB J, V18, P197, DOI 10.1096/fj.03-0213fje; Garty H, 2003, ANN NY ACAD SCI, V986, P395, DOI 10.1111/j.1749-6632.2003.tb07220.x; Garty H, 2002, AM J PHYSIOL-RENAL, V283, pF607, DOI 10.1152/ajprenal.00112.2002; GARTY H, 2005, IN PRESS ANN REV PHY; Ino Y, 2002, P NATL ACAD SCI USA, V99, P365, DOI 10.1073/pnas.012425299; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; JAUNIN P, 1992, J BIOL CHEM, V267, P577; Jia LG, 2005, AM J PHYSIOL-HEART C, V288, pH1982, DOI 10.1152/ajpheart.00142.2004; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Lindzen M, 2003, J BIOL CHEM, V278, P18738, DOI 10.1074/jbc.M213253200; LUBARSKI L, 2005, J GEN PHYSIOL, V126, P51; Mahmmoud YA, 2000, J BIOL CHEM, V275, P35969, DOI 10.1074/jbc.M005168200; Mahmmoud YA, 2003, J BIOL CHEM, V278, P37427, DOI 10.1074/jbc.M305126200; Minor NT, 1998, P NATL ACAD SCI USA, V95, P6521, DOI 10.1073/pnas.95.11.6521; Moorman JR, 1998, ADV EXP MED BIOL, V442, P219; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Omasa T, 2001, BBA-GENE STRUCT EXPR, V1517, P307, DOI 10.1016/S0167-4781(00)00251-7; Pihakaski-Maunsbach K, 2003, ANN NY ACAD SCI, V986, P401, DOI 10.1111/j.1749-6632.2003.tb07221.x; Pu HX, 2001, J BIOL CHEM, V276, P20370, DOI 10.1074/jbc.M010836200; Sato H, 2003, J CLIN ENDOCR METAB, V88, P4407, DOI 10.1210/jc.2002-021757; Shi HK, 2001, AM J PHYSIOL-RENAL, V280, pF505, DOI 10.1152/ajprenal.2001.280.3.F505; Shimamura T, 2003, J CLIN ONCOL, V21, P659, DOI 10.1200/JCO.2003.06.179; Silverman BD, 2005, CARDIOVASC RES, V65, P93, DOI 10.1016/j.cardiores.2004.09.005; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; Therien AG, 1999, J BIOL CHEM, V274, P12252, DOI 10.1074/jbc.274.18.12252; Tsuiji H, 2003, GLYCOBIOLOGY, V13, P521, DOI 10.1093/glycob/cwg065; Wetzel RK, 2004, J BIOL CHEM, V279, P41750, DOI 10.1074/jbc.M405622200; Wetzel RK, 2001, AM J PHYSIOL-RENAL, V281, pF531, DOI 10.1152/ajprenal.2001.281.3.F531	40	84	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37717	37724		10.1074/jbc.M506397200	http://dx.doi.org/10.1074/jbc.M506397200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16148001	hybrid			2022-12-27	WOS:000233044500049
J	Meyer, S; van Liempt, E; Imberty, A; van Kooyk, Y; Geyer, H; Geyer, R; van Die, I				Meyer, S; van Liempt, E; Imberty, A; van Kooyk, Y; Geyer, H; Geyer, R; van Die, I			DC-SIGN mediates binding of dendritic cells to authentic pseudo-Lewis(Y) glycolipids of Schistosoma mansoni cercariae, the first parasite-specific ligand of DC-SIGN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTORS; C-TYPE LECTINS; LEWIS-X; CARBOHYDRATE EPITOPES; STRUCTURAL BASIS; EGG ANTIGENS; GLYCOSPHINGOLIPIDS; OLIGOSACCHARIDES; IDENTIFICATION; EXPRESSION	During schistosomiasis, parasite-derived glycoconjugates play a key role in manipulation of the host immune response, associated with persistence of the parasite. Among the candidate host receptors that are triggered by glycoconjugates are C-type lectins (CLRs) on dendritic cells (DCs), which in concerted action with Toll-like receptors determine the balance in DCs between induction of immunity versus tolerance. Here we report that the CLR DC-SIGN mediates adhesion of DCs to authentic glycolipids derived from Schistosoma mansoni cercariae and their excretory/secretory products. Structural characterization of the glycolipids, in combination with solid phase and cellular binding studies revealed that DC-SIGN binds to the carbohydrate moieties of both glycosphingolipid species with Gal beta 1-4(Fuc alpha 1-3) GlcNAc (Lewis(X)) and Fuc alpha 1-3Gal beta 1-4( Fuc alpha 1-3) GlcNAc (pseudo-Lewis(Y)) determinants. Importantly, these data indicate that surveying DCs in the skin may encounter schistosome-derived glycolipids immediately after infection. Recent analysis of crystals of the carbohydrate binding domain of DC-SIGN bound to LewisX provided insight into the ability of DC-SIGN to bind fucosylated ligands. Using molecular modeling we showed that the observed binding of the schistosome-specific pseudo-Lewis(Y) to DC-SIGN is not directly compatible with the model described. To fit pseudo-Lewis(Y) into the model, the orientation of the side chain of Phe(313) in the secondary binding site of DC-SIGN was slightly changed, which results in a perfect stacking of Phe313 with the hydrophobic side of the galactose-linked fucose of pseudo-Lewis(Y). We propose that pathogens such as S. mansoni may use the observed flexibility in the secondary binding site of DC-SIGN to target DCs, which may contribute to immune escape.	Univ Giessen, Fac Med, Inst Biochem, D-35392 Giessen, Germany; Vrije Univ Amsterdam Med Ctr, Dept Mol Cell Biol & Immunol, NL-1081 BT Amsterdam, Netherlands; Univ Grenoble 1, CNRS, Ctr Rech Macromol Vegetales, F-38041 Grenoble, France	Justus Liebig University Giessen; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	van Die, I (corresponding author), Vrije Univ Amsterdam Med Ctr, Dept Mol Cell Biol & Immunol, Postbus 7057, NL-1007 MB Amsterdam, Netherlands.	im.vandie@vumc.nl	Imberty, Anne/P-6451-2018	Imberty, Anne/0000-0001-6825-9527				Appelmelk BJ, 2003, J IMMUNOL, V170, P1635, DOI 10.4049/jimmunol.170.4.1635; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804; Cummings RD, 1999, BBA-MOL BASIS DIS, V1455, P363, DOI 10.1016/S0925-4439(99)00063-0; DOMON B, 1988, BIOCHEMISTRY-US, V27, P1534, DOI 10.1021/bi00405a021; DYATLOVITSKAYA EV, 1987, BIOCHIM BIOPHYS ACTA, V907, P125, DOI 10.1016/0304-419X(87)90002-3; Ebner S, 2004, INT IMMUNOL, V16, P877, DOI 10.1093/intimm/dxh088; Feinberg H, 2005, J BIOL CHEM, V280, P1327, DOI 10.1074/jbc.M409925200; Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371; Figdor CG, 2002, NAT REV IMMUNOL, V2, P77, DOI 10.1038/nri723; Geijtenbeek TBH, 2004, ANNU REV IMMUNOL, V22, P33, DOI 10.1146/annurev.immunol.22.012703.104558; Geijtenbeek TBH, 2002, J BIOL CHEM, V277, P11314, DOI 10.1074/jbc.M111532200; Geijtenbeek TBH, 2003, J EXP MED, V197, P7, DOI 10.1084/jem.20021229; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Guo Y, 2004, NAT STRUCT MOL BIOL, V11, P591, DOI 10.1038/nsmb784; Hertz CJ, 2001, J IMMUNOL, V166, P2444, DOI 10.4049/jimmunol.166.4.2444; Hokke CH, 2001, GLYCOCONJUGATE J, V18, P573, DOI 10.1023/A:1020634602161; IMBERTY A, 1995, GLYCOCONJUGATE J, V12, P331, DOI 10.1007/BF00731336; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; Khoo KH, 1997, GLYCOBIOLOGY, V7, P653, DOI 10.1093/glycob/7.5.653; KHOO KH, 1995, J BIOL CHEM, V270, P17114, DOI 10.1074/jbc.270.29.17114; Lee HK, 2002, J IMMUNOL, V168, P4012, DOI 10.4049/jimmunol.168.8.4012; Lochnit G, 1998, J BIOL CHEM, V273, P466, DOI 10.1074/jbc.273.1.466; MAKAARU CK, 1992, J BIOL CHEM, V267, P2251; Michelsen KS, 2001, J BIOL CHEM, V276, P25680, DOI 10.1074/jbc.M011615200; NYAME K, 1989, J BIOL CHEM, V264, P3235; Okano M, 2001, J IMMUNOL, V167, P442, DOI 10.4049/jimmunol.167.1.442; Okano M, 1999, J IMMUNOL, V163, P6712; Pearce EJ, 2002, NAT REV IMMUNOL, V2, P499, DOI 10.1038/nri843; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SLUITERS JF, 1980, Z PARASITENKD, V63, P13, DOI 10.1007/BF00927722; Soilleux EJ, 2002, J LEUKOCYTE BIOL, V71, P445; Sorme P, 2005, J AM CHEM SOC, V127, P1737, DOI 10.1021/ja043475p; SRIVATSAN J, 1992, J BIOL CHEM, V267, P20196; STOLL MS, 1988, BIOCHEM J, V256, P661, DOI 10.1042/bj2560661; van der Kleij D, 2002, J BIOL CHEM, V277, P48122, DOI 10.1074/jbc.M206941200; van Die I, 2003, GLYCOBIOLOGY, V13, P471, DOI 10.1093/glycob/cwg052; van Kooyk Y, 2004, CURR OPIN IMMUNOL, V16, P488, DOI 10.1016/j.coi.2004.05.010; van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182; Van Liempt E, 2004, J BIOL CHEM, V279, P33161, DOI 10.1074/jbc.M404988200; van Remoortere A, 2000, GLYCOBIOLOGY, V10, P601, DOI 10.1093/glycob/10.6.601; VANDAM GJ, 1994, EUR J BIOCHEM, V225, P467, DOI 10.1111/j.1432-1033.1994.00467.x; Velupillai P, 2000, HUM IMMUNOL, V61, P225, DOI 10.1016/S0198-8859(99)00136-6; VELUPILLAI P, 1994, P NATL ACAD SCI USA, V91, P18, DOI 10.1073/pnas.91.1.18; Visintin A, 2001, J IMMUNOL, V166, P249, DOI 10.4049/jimmunol.166.1.249; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; WEISS JB, 1986, J IMMUNOL, V136, P4275; Wuhrer M, 2002, EUR J BIOCHEM, V269, P481, DOI 10.1046/j.0014-2956.2001.02673.x; Wuhrer M, 2000, GLYCOBIOLOGY, V10, P89, DOI 10.1093/glycob/10.1.89; Wuhrer M, 1999, MOL BIOCHEM PARASIT, V103, P155, DOI 10.1016/S0166-6851(99)00123-1; Wuhrer M, 2000, BBA-GEN SUBJECTS, V1524, P155, DOI 10.1016/S0304-4165(00)00152-5; ZIEGLERHEITBROCK HWL, 1992, J IMMUNOL, V148, P1753	54	78	81	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37349	37359		10.1074/jbc.M507100200	http://dx.doi.org/10.1074/jbc.M507100200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16155001	hybrid, Green Published			2022-12-27	WOS:000233044500008
J	Miller, PS; Da Silva, HMA; Smart, TG				Miller, PS; Da Silva, HMA; Smart, TG			Molecular basis for zinc potentiation at strychnine-sensitive glycine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT 5-HT3 RECEPTOR; SIGNATURE DISULFIDE LOOP; SPINAL-CORD NEURONS; CHLORIDE CHANNEL; STRUCTURAL BASIS; MODULATION; SUBUNIT; INHIBITION; BINDING; ZN2+	The divalent cation Zn2+ is a potent potentiator at the strychnine-sensitive glycine receptor (GlyR). This occurs at nanomolar concentrations, which are the predicted endogenous levels of extracellular neuronal Zn2+. Using structural modeling and functional mutagenesis, we have identified the molecular basis for the elusive Zn2+ potentiation site on GlyRs and account for the differential sensitivity of GlyR alpha(1) and GlyR alpha(2) to Zn2+ potentiation. In addition, juxtaposed to this Zn2+ site, which is located externally on the N-terminal domain of the alpha subunit, another residue was identified in the nearby Cys loop, a region that is critical for receptor gating in all Cys loop ligand-gated ion channels. This residue acted as a key control element in the allosteric transduction pathway for Zn2+ potentiation, enabling either potentiation or overt inhibition of receptor activation depending upon the moiety resident at this location. Overall, we propose that Zn2+ binds to a site on the extracellular outer face of the GlyR alpha subunit and exerts its positive allosteric effect via an interaction with the Cys loop to increase the efficacy of glycine receptor gating.	UCL, Dept Pharmacol, London WC1E 6BT, England	University of London; University College London	Smart, TG (corresponding author), UCL, Dept Pharmacol, Gower St, London WC1E 6BT, England.	t.smart@ucl.ac.uk		Miller, Paul/0000-0002-6512-9441	Medical Research Council [G9722520] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G9722520] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; Auld DS, 2001, BIOMETALS, V14, P271, DOI 10.1023/A:1012976615056; Birinyi A, 2001, J COMP NEUROL, V433, P208, DOI 10.1002/cne.1136; BLOOMENTHAL AB, 1994, MOL PHARMACOL, V46, P1156; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Brown CE, 2002, J NEUROSCI, V22, P2617, DOI 10.1523/JNEUROSCI.22-07-02617.2002; CELENTANO JJ, 1988, BRAIN RES, V455, P377, DOI 10.1016/0006-8993(88)90098-4; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; FREDERICKSON CJ, 1990, PROG BRAIN RES, V83, P71; Frederickson CJ, 2000, J NUTR, V130, p1471S, DOI 10.1093/jn/130.5.1471S; Frederickson CJ, 2001, BIOMETALS, V14, P353, DOI 10.1023/A:1012934207456; GILL CH, 1995, BRIT J PHARMACOL, V114, P1211, DOI 10.1111/j.1476-5381.1995.tb13335.x; HARRISON NL, 1993, MOL PHARMACOL, V44, P628; Harvey RJ, 1999, J PHYSIOL-LONDON, V520, P53, DOI 10.1111/j.1469-7793.1999.00053.x; Hosie AM, 2003, NAT NEUROSCI, V6, P362, DOI 10.1038/nn1030; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; Hubbard PC, 2000, EUR J PHARMACOL, V394, P189, DOI 10.1016/S0014-2999(00)00143-6; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Kash TL, 2003, NATURE, V421, P272, DOI 10.1038/nature01280; Laube B, 2000, J PHYSIOL-LONDON, V522, P215, DOI 10.1111/j.1469-7793.2000.t01-1-00215.x; Laube B, 2002, TRENDS PHARMACOL SCI, V23, P519, DOI 10.1016/S0165-6147(02)02138-7; Lester HA, 2004, TRENDS NEUROSCI, V27, P329, DOI 10.1016/j.tins.2004.04.002; Lynch JW, 1998, J NEUROCHEM, V71, P2159; Lynch JW, 2004, PHYSIOL REV, V84, P1051, DOI 10.1152/physrev.00042.2003; Miller PS, 2005, J PHYSIOL-LONDON, V566, P657, DOI 10.1113/jphysiol.2005.088575; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Morris KDW, 2004, MOL PHARMACOL, V66, P56, DOI 10.1124/mol.66.1.56; Nevin ST, 2003, J BIOL CHEM, V278, P28985, DOI 10.1074/jbc.M300097200; Paoletti P, 1997, J NEUROSCI, V17, P5711; PFEIFFER F, 1982, J BIOL CHEM, V257, P9389; PRIBILLA I, 1992, EMBO J, V11, P4305, DOI 10.1002/j.1460-2075.1992.tb05529.x; RUIZ A, 2003, J NEUROPHYSIOL; Schofield CM, 2004, BIOCHEMISTRY-US, V43, P10058, DOI 10.1021/bi036159g; Schofield CM, 2003, J BIOL CHEM, V278, P34079, DOI 10.1074/jbc.M302416200; SMART TG, 1994, PROG NEUROBIOL, V42, P393, DOI 10.1016/0301-0082(94)90082-5; Suwa H, 2001, J NEUROPHYSIOL, V85, P912, DOI 10.1152/jn.2001.85.2.912; Wilkins ME, 2002, J NEUROSCI, V22, P5328; Wu FS, 1997, BRAIN RES, V750, P318, DOI 10.1016/S0006-8993(97)00053-X; XIE XM, 1991, NATURE, V349, P521, DOI 10.1038/349521a0; YARON A, 1993, CRIT REV BIOCHEM MOL, V28, P31, DOI 10.3109/10409239309082572	40	71	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37877	37884		10.1074/jbc.M508303200	http://dx.doi.org/10.1074/jbc.M508303200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16144831	hybrid			2022-12-27	WOS:000233044500068
J	Jin, WJ; Fuki, IV; Seidah, NG; Benjannet, S; Glick, JM; Rader, DJ				Jin, WJ; Fuki, IV; Seidah, NG; Benjannet, S; Glick, JM; Rader, DJ			Proprotein covertases are responsible for proteolysis and inactivation of endothelial lipase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DERIVED LIPASE; GENE-EXPRESSION; PROHORMONE CONVERTASES; TRIGLYCERIDE LIPASE; PRECURSOR PROTEINS; HDL METABOLISM; IN-VITRO; FURIN; FAMILY; ACTIVATION	Plasma lipoprotein metabolism is tightly regulated by several members of the triglyceride lipase family, including endothelial lipase (EL) and lipoprotein lipase (LPL). Our previous work suggested that EL is proteolytically processed. In this report, we have used a combination of epitope tagging, mutagenesis, and N-terminal sequencing to determine the precise location of the cleavage site within EL. The cleavage occurs immediately after the sequence RNKR, a known recognition sequence for the proprotein convertase ( PC) family. We demonstrate that some PCs, but not all, can proteolytically cleave EL at this site and thereby directly regulate EL enzymatic activity through modulating EL cleavage. Furthermore, specific knockdown of individual PCs proves that PCs are the proteases that cleave EL in human endothelial cells. Interestingly, a homologous site in LPL is also cleaved by PCs. This action is unusual for PCs, which are traditionally known as activators of pro-proteins, and highlights a potential role of PCs in lipid metabolism through their proteolytic processing of lipases.	Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Clin Res Inst Montreal, Labs Biochem Neuroendocrinol, Montreal, PQ H2W 1R7, Canada	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Jin, WJ (corresponding author), BRB 2-3,Rm 646,421 Curie Blvd, Philadelphia, PA 19104 USA.	weijun@mail.med.upenn.edu	Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342	NHLBI NIH HHS [HL55323] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL055323, R01HL055323] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abifadel M, 2003, NAT GENET, V34, P154, DOI 10.1038/ng1161; Azumi H, 2003, CARDIOVASC RES, V58, P647, DOI 10.1016/S0008-6363(03)00287-6; Bazan JF, 1996, NATURE, V380, P21, DOI 10.1038/380021a0; BEAUBIEN G, 1995, CELL TISSUE RES, V279, P539; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Broedl UC, 2004, CIRC RES, V94, P1554, DOI 10.1161/01.RES.0000130657.00222.39; BURKHARDT JK, 1989, J CELL SCI, V92, P643; Bush G, 2001, DEV BIOL, V229, P494, DOI 10.1006/dbio.2000.9992; Campan M, 1996, BIOCHEMISTRY-US, V35, P3797, DOI 10.1021/bi952552d; Cheng M, 1997, INT J CANCER, V71, P966, DOI 10.1002/(SICI)1097-0215(19970611)71:6<966::AID-IJC10>3.3.CO;2-A; Choi SY, 2002, J LIPID RES, V43, P1763, DOI 10.1194/jlr.R200011-JLR200; Cohen J, 2005, NAT GENET, V37, P328, DOI 10.1038/ng0305-328c; ENERBACK S, 1993, BIOCHIM BIOPHYS ACTA, V1169, P107, DOI 10.1016/0005-2760(93)90196-G; Fuki IV, 2003, J BIOL CHEM, V278, P34331, DOI 10.1074/jbc.M302181200; GARTEN W, 1989, VIROLOGY, V172, P25, DOI 10.1016/0042-6822(89)90103-7; Gauster M, 2005, J LIPID RES, V46, P1517, DOI 10.1194/jlr.M500054-JLR200; Hirata K, 2000, BIOCHEM BIOPH RES CO, V272, P90, DOI 10.1006/bbrc.2000.2747; Horton JD, 2002, COLD SPRING HARB SYM, V67, P491, DOI 10.1101/sqb.2002.67.491; Ishida T, 2004, J BIOL CHEM, V279, P45085, DOI 10.1074/jbc.M406360200; Ishida T, 2003, J CLIN INVEST, V111, P347, DOI [10.1172/JCI200316306, 10.1172/JCI16306]; Jaye M, 2004, CURR OPIN LIPIDOL, V15, P183, DOI 10.1097/00041433-200404000-00011; Jaye M, 1999, NAT GENET, V21, P424, DOI 10.1038/7766; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; Jin WJ, 2003, CIRC RES, V92, P644, DOI 10.1161/01.RES.0000064502.47539.6D; Jin WJ, 2003, J CLIN INVEST, V111, P357, DOI [10.1172/JCI16146, 10.1172/JCI200316146]; Kageyama T, 2002, CELL MOL LIFE SCI, V59, P288, DOI 10.1007/s00018-002-8423-9; Kalus I, 2003, J BIOL CHEM, V278, P10381, DOI 10.1074/jbc.M208351200; KERN PA, 1988, J CLIN INVEST, V81, P398, DOI 10.1172/JCI113332; Ko KWS, 1998, J BIOL CHEM, V273, P27779, DOI 10.1074/jbc.273.43.27779; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; Ma K, 2003, P NATL ACAD SCI USA, V100, P2748, DOI 10.1073/pnas.0438039100; Maugeais C, 2003, CIRCULATION, V108, P2121, DOI 10.1161/01.CIR.0000092889.24713.DC; Mayer G, 2003, J CELL SCI, V116, P1763, DOI 10.1242/jcs.00394; McCoy MG, 2002, J LIPID RES, V43, P921; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nour N, 2003, J BIOL CHEM, V278, P2886, DOI 10.1074/jbc.M208009200; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; Rader DJ, 2000, CURR OPIN LIPIDOL, V11, P141, DOI 10.1097/00041433-200004000-00006; REDMAN CM, 1975, J CELL BIOL, V66, P42, DOI 10.1083/jcb.66.1.42; Salvesen GS, 2004, ONCOGENE, V23, P2774, DOI 10.1038/sj.onc.1207522; Seidah NG, 2002, ESSAYS BIOCHEM, V38, P79, DOI 10.1042/bse0380079; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Seidah NG, 2003, P NATL ACAD SCI USA, V100, P928, DOI 10.1073/pnas.0335507100; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; Tikhonov I, 2004, FEBS LETT, V565, P89, DOI 10.1016/j.febslet.2004.03.079; Tsuji A, 2003, BBA-PROTEINS PROTEOM, V1645, P95, DOI 10.1016/S1570-9639(02)00532-0; Willnow TE, 1996, BIOCHEM J, V313, P71, DOI 10.1042/bj3130071; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; Wong H, 2002, J LIPID RES, V43, P993, DOI 10.1194/jlr.R200007-JLR200; Zhong M, 1999, J BIOL CHEM, V274, P33913, DOI 10.1074/jbc.274.48.33913	51	82	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36551	36559		10.1074/jbc.M502264200	http://dx.doi.org/10.1074/jbc.M502264200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16109723	hybrid			2022-12-27	WOS:000232901800004
J	Balabanian, K; Lagane, B; Infantino, S; Chow, KYC; Harriague, J; Moepps, B; Arenzana-Seisdedos, F; Thelen, M; Bachelerie, F				Balabanian, K; Lagane, B; Infantino, S; Chow, KYC; Harriague, J; Moepps, B; Arenzana-Seisdedos, F; Thelen, M; Bachelerie, F			The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; IMMUNODEFICIENCY-VIRUS CORECEPTOR; VIP RECEPTOR; BONE-MARROW; FACTOR-I; CXCR4; SDF-1; EXPRESSION; CLONING; GENE	Combined phylogenetic and chromosomal location studies suggest that the orphan receptor RDC1 is related to CXC chemokine receptors. RDC1 provides a co- receptor function for a restricted number of human immunodeficiency virus ( HIV) isolates, in particular for the CXCR4- using HIV- 2 ROD strain. Here we show that CXCL12, the only known natural ligand for CXCR4, binds to and signals through RDC1. We demonstrate that RDC1 is expressed in T lymphocytes and that CXCL12- promoted chemotaxis is inhibited by an anti- RDC1 monoclonal antibody. Concomitant blockade of RDC1 and CXCR4 produced additive inhibitory effects in CXCL12-induced T cell migration. Furthermore, we provide evidence that interaction of CXCL12 with RDC1 is specific, saturable, and of high affinity ( apparent K-D = 0.4 nM). In CXCR4- negative cells expressing RDC1, CXCL12 promotes internalization of the receptor and chemotactic signals through RDC1. Collectively, our data indicate that RDC1, which we propose to rename as CXCR7, is a receptor for CXCL12.	Inst Pasteur, Unite Immunol Virale, F-75015 Paris, France; Inst Biomed Res, CH-6500 Bellinzona, Switzerland; Univ Ulm, Dept Pharmacol & Toxicol, D-89081 Ulm, Germany	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universita della Svizzera Italiana; Ulm University	Bachelerie, F (corresponding author), Inst Pasteur, Unite Immunol Virale, 28 Rue Dr Roux, F-75015 Paris, France.	fbachele@pasteur.fr	Lagane, Bernard/AAA-2205-2019; Balabanian, Karl/I-2990-2016; BACHELERIE, FRANCOISE/F-8823-2013; Balabanian, Karl/S-6250-2019; Lagane, Bernard/K-8446-2016; Arenzana-Seisdedos, Fernando/E-5835-2016	Lagane, Bernard/0000-0002-3459-7867; Balabanian, Karl/0000-0002-0534-3198; BACHELERIE, FRANCOISE/0000-0002-0399-3277; Balabanian, Karl/0000-0002-0534-3198; Harriague, Julie/0000-0001-6824-9169				AHUJA SK, 1992, NAT GENET, V2, P31, DOI 10.1038/ng0992-31; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Balabanian K, 2005, BLOOD, V105, P2449, DOI 10.1182/blood-2004-06-2289; Balabanian K, 2004, J IMMUNOL, V173, P7150, DOI 10.4049/jimmunol.173.12.7150; Brelot A, 2000, J BIOL CHEM, V275, P23736, DOI 10.1074/jbc.M000776200; Brelot A, 1999, J VIROL, V73, P2576, DOI 10.1128/JVI.73.4.2576-2586.1999; Brelot A, 1997, J VIROL, V71, P4744, DOI 10.1128/JVI.71.6.4744-4751.1997; Buckley CD, 2000, J IMMUNOL, V165, P3423, DOI 10.4049/jimmunol.165.6.3423; Campbell DJ, 2003, IMMUNOL REV, V195, P58, DOI 10.1034/j.1600-065X.2003.00067.x; COOK JS, 1992, FEBS LETT, V300, P149, DOI 10.1016/0014-5793(92)80184-I; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Epstein RJ, 2004, NAT REV CANCER, V4, P901, DOI 10.1038/nrc1473; EVA C, 1993, DNA CELL BIOL, V12, P393, DOI 10.1089/dna.1993.12.393; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; Haribabu B, 1997, J BIOL CHEM, V272, P28726, DOI 10.1074/jbc.272.45.28726; Heesen M, 1998, IMMUNOGENETICS, V47, P364, DOI 10.1007/s002510050371; Joost P, 2002, GENOME BIOL, V3; Lagane B, 2005, MOL PHARMACOL, V67, P1966, DOI 10.1124/mol.104.009779; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; LIBERT F, 1990, NUCLEIC ACIDS RES, V18, P1917, DOI 10.1093/nar/18.7.1917; LIBERT F, 1991, GENOMICS, V11, P225, DOI 10.1016/0888-7543(91)90125-X; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; Loetscher P, 2001, J LEUKOCYTE BIOL, V69, P881; Lukacs NW, 2002, AM J PATHOL, V160, P1353, DOI 10.1016/S0002-9440(10)62562-X; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Madden SL, 2004, AM J PATHOL, V165, P601, DOI 10.1016/S0002-9440(10)63324-X; Martin C, 2003, IMMUNITY, V19, P583, DOI 10.1016/S1074-7613(03)00263-2; MOEPPS B, 2005, IN PRESS MOL IMMUNOL; Moser B, 2004, TRENDS IMMUNOL, V25, P75, DOI 10.1016/j.it.2003.12.005; Murphy PM, 2000, PHARMACOL REV, V52, P145; NAGATA S, 1992, TRENDS PHARMACOL SCI, V13, P102; Nelson PJ, 2001, IMMUNITY, V14, P377, DOI 10.1016/S1074-7613(01)00118-2; Okada T, 2002, J EXP MED, V196, P65, DOI 10.1084/jem.20020201; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813; Raggo C, 2005, CANCER RES, V65, P5084, DOI 10.1158/0008-5472.CAN-04-2822; Shimizu N, 2000, J VIROL, V74, P619, DOI 10.1128/JVI.74.2.619-626.2000; Shimizu N, 2000, GENE, V259, P199, DOI 10.1016/S0378-1119(00)00432-7; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; SREEDHARAN SP, 1991, P NATL ACAD SCI USA, V88, P4986, DOI 10.1073/pnas.88.11.4986; Thelen M, 2001, NAT IMMUNOL, V2, P129, DOI 10.1038/84224; Valenzuela-Fernandez A, 2002, J BIOL CHEM, V277, P15677, DOI 10.1074/jbc.M111388200; Venkatesan S, 2001, J BIOL CHEM, V276, P40133, DOI 10.1074/jbc.M105722200; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	48	808	881	0	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35760	35766		10.1074/jbc.M508234200	http://dx.doi.org/10.1074/jbc.M508234200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16107333	hybrid			2022-12-27	WOS:000232561200079
J	Folgueira, C; Quijada, L; Soto, M; Abanades, DR; Alonso, C; Requena, JM				Folgueira, C; Quijada, L; Soto, M; Abanades, DR; Alonso, C; Requena, JM			The translational efficiencies of the two Leishmania infantum HSP70 mRNAs, differing in their 3 '-untranslated regions, are affected by shifts in the temperature of growth through different mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; MAJOR FRIEDLIN CHROMOSOME-1; 3 UNTRANSLATED REGION; POSTTRANSCRIPTIONAL REGULATION; DEVELOPMENTAL REGULATION; GENOMIC ORGANIZATION; TRYPANOSOMA-BRUCEI; EXPRESSION; GENES; TRANSCRIPTION	Exposure of Leishmania promastigotes to the temperature of their mammalian hosts induces a typical heat-shock response. In Leishmania infantum, HSP70 is encoded by two types of genes that differ in their 3'-untranslated regions (3'-UTRs). Previously, we have shown that specific transcripts for each gene are present in promastigotes growing at normal temperature (26 degrees C), but only transcripts with 3'-UTR-type I (3'-UTRI) accumulate in a temperature-dependent manner. Here, we have investigated the translational efficiencies of both types of HSP70 transcripts at the different temperatures that the parasite encounters in the insect (26 degrees C, normal temperature) or in the mammalian host (heat-shock temperatures). Interestingly, 3'-UTRI-bearing transcripts (HSP70-I) were found associated with ribosomes in promastigotes at normal and heat-shock temperatures, whereas the HSP70-II transcripts appear to be preferentially translated at heat-shock temperatures but not at 26 C. We have analyzed the function of these UTRs in the translational control by use of plasmid constructs in which the CAT reporter gene was flanked by UTRs of the HSP70 genes. Unexpectedly, it was found that CAT transcripts with 3'-UTRII bind to ribosomes at 26 C, and, indeed, the CAT protein is synthesized. A valid conclusion of these experiments was that both types of 3'-UTRs are essential for translation of HSP70 mRNAs at heat shock temperatures, although the 3'-UTRII is more efficient during severe heat shock (39 degrees C). In addition, these results suggest that sequence region other than the 3'-UTR of HSP70-II gene is involved in the translational silent state of HSP70-II transcripts at 26 degrees C. Finally, a null mutant has been created by targeted disruption of both HSP70-II alleles. Remarkably, the Delta HSP70 mutant synthesizes HSP70 at a lower rate than the wild-type parasites. Overall, our data suggest that the biological function of the HSP70-II gene is to top up HSP70 levels under conditions of stress.	Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Requena, JM (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.	jmrequena@cbm.uam.es	Álvarez, Manuel Soto/Q-5234-2018; Requena, Jose M/I-2022-2019	Álvarez, Manuel Soto/0000-0001-6825-841X; Requena, Jose M/0000-0001-7550-0198				AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; Angel SO, 1996, ACTA TROP, V62, P45, DOI 10.1016/S0001-706X(96)00020-4; Arava Y, 2005, NUCLEIC ACIDS RES, V33, P2421, DOI 10.1093/nar/gki331; Boucher N, 2002, J BIOL CHEM, V277, P19511, DOI 10.1074/jbc.M200500200; BRANDAU S, 1995, BIOCHEM J, V310, P225, DOI 10.1042/bj3100225; Campbell DA, 2003, MICROBES INFECT, V5, P1231, DOI 10.1016/j.micinf.2003.09.005; Clayton C, 1998, MOL BIOCHEM PARASIT, V97, P221, DOI 10.1016/S0166-6851(98)00115-7; Clayton CE, 2002, EMBO J, V21, P1881, DOI 10.1093/emboj/21.8.1881; Clos J, 1999, AM ZOOL, V39, P848; De Bor VV, 2004, CURR OPIN CELL BIOL, V16, P300, DOI 10.1016/j.ceb.2004.03.008; Desjeux P, 2004, COMP IMMUNOL MICROB, V27, P305, DOI 10.1016/j.cimid.2004.03.004; Feder ME, 1999, ANNU REV PHYSIOL, V61, P243, DOI 10.1146/annurev.physiol.61.1.243; Furger A, 1997, MOL CELL BIOL, V17, P4372, DOI 10.1128/MCB.17.8.4372; GENSKE JE, 1991, MOL CELL BIOL, V11, P240, DOI 10.1128/MCB.11.1.240; Gong WJ, 2004, GENETICS, V168, P1467, DOI 10.1534/genetics.104.030874; Hotz HR, 1997, NUCLEIC ACIDS RES, V25, P3017, DOI 10.1093/nar/25.15.3017; Ivens AC, 2005, SCIENCE, V309, P436, DOI 10.1126/science.1112680; Kloc M, 2002, CELL, V108, P533, DOI 10.1016/S0092-8674(02)00651-7; Larreta R, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-3; LEBOWITZ JH, 1991, GENE, V103, P119, DOI 10.1016/0378-1119(91)90402-W; Mahmood R, 1999, MOL CELL BIOL, V19, P6174; Martinez-Calvillo S, 2003, MOL CELL, V11, P1291, DOI 10.1016/S1097-2765(03)00143-6; Martinez-Calvillo S, 2004, EUKARYOT CELL, V3, P506, DOI 10.1128/EC.3.2.506-517.2004; McKoy G, 1997, MOL BIOCHEM PARASIT, V90, P169, DOI 10.1016/S0166-6851(97)00172-2; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; Myler PJ, 1999, P NATL ACAD SCI USA, V96, P2902, DOI 10.1073/pnas.96.6.2902; Myung KS, 2002, J BIOL CHEM, V277, P16489, DOI 10.1074/jbc.M200174200; Quijada L, 2003, MOL BIOCHEM PARASIT, V130, P139, DOI 10.1016/S0166-6851(03)00159-2; Quijada L, 1997, J BIOL CHEM, V272, P4493, DOI 10.1074/jbc.272.7.4493; Quijada L, 2000, MOL BIOCHEM PARASIT, V110, P79, DOI 10.1016/S0166-6851(00)00258-9; Requena JM, 1997, MEM I OSWALDO CRUZ, V92, P853, DOI 10.1590/S0074-02761997000600022; Rico AI, 1999, MOL IMMUNOL, V36, P1131, DOI 10.1016/S0161-5890(99)00136-4; Robinson KA, 2003, MOL BIOCHEM PARASIT, V128, P217, DOI 10.1016/S0166-6851(03)00079-3; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schurch N, 1997, MOL BIOCHEM PARASIT, V89, P109, DOI 10.1016/S0166-6851(97)00107-2; SOARES CMA, 1989, FEBS LETT, V250, P497, DOI 10.1016/0014-5793(89)80784-7; SOTO M, 1993, J BIOL CHEM, V268, P21835; SOTO M, 1993, MOL BIOCHEM PARASIT, V61, P265, DOI 10.1016/0166-6851(93)90072-6; Soto M, 2004, BIOCHEM J, V379, P617, DOI 10.1042/BJ20031522; Soto M, 2003, PARASITOLOGY, V127, P95, DOI 10.1017/S0031182003003445; Stiles JK, 1999, ANN TROP MED PARASIT, V93, P781, DOI 10.1080/00034989957781; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; Weston D, 1999, MOL BIOCHEM PARASIT, V102, P53, DOI 10.1016/S0166-6851(99)00079-1; Worthey EA, 2003, NUCLEIC ACIDS RES, V31, P4201, DOI 10.1093/nar/gkg469; Yao CQ, 2003, MOL BIOCHEM PARASIT, V132, P1, DOI 10.1016/S0166-6851(03)00211-1; ZILBERSTEIN D, 1994, ANNU REV MICROBIOL, V48, P449, DOI 10.1146/annurev.mi.48.100194.002313; Zilka A, 2001, J BIOL CHEM, V276, P47922, DOI 10.1074/jbc.M108271200	47	46	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35172	35183		10.1074/jbc.M505559200	http://dx.doi.org/10.1074/jbc.M505559200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16105831	hybrid			2022-12-27	WOS:000232561200014
J	Xue, X; Piao, JH; Nakajima, A; Sakon-Komazawa, S; Kojima, Y; Mori, K; Yagita, H; Okumura, K; Harding, H; Nakano, H				Xue, X; Piao, JH; Nakajima, A; Sakon-Komazawa, S; Kojima, Y; Mori, K; Yagita, H; Okumura, K; Harding, H; Nakano, H			Tumor necrosis factor alpha (TNF alpha) induces the unfolded protein response (UPR) in a reactive oxygen species (ROS)-dependent fashion, and the UPR counteracts ROS accumulation by TNF alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETICULUM STRESS-RESPONSE; NF-KAPPA-B; ENDOPLASMIC-RETICULUM; ER STRESS; TRANSLATIONAL CONTROL; MESSENGER-RNA; ATF6; ACTIVATION; KINASE; INITIATION	Accumulation of unfolded proteins in the endoplasmic reticulum ( ER) causes ER overload, resulting in ER stress. To cope with ER stress, mammalian cells trigger a specific response known as the unfolded protein response (UPR). Although recent studies have indicated cross-talk between ER stress and oxidative stress, the mechanistic link is not fully understood. By using murine fibrosarcoma ;L929 cells, in which tumor necrosis factor (TNF) alpha induces accumulation of reactive oxygen species (ROS) and cell death, we show that TNF alpha induces the UPR in a ROS-dependent fashion. In contrast to TNF alpha, oxidative stresses by H2O2 or arsenite only induce eukaroytic initiation factor 2 alpha phosphorylation, but not activation of PERK- or IRE1-dependent pathways, indicating the specificity of downstream signaling induced by various oxidative stresses. Conversely, the UPR induced by tunicamycin substantially suppresses TNF alpha-induced ROS accumulation and cell death by inhibiting reduction of cellular glutathione levels. Collectively, some, but not all, oxidative stresses induce the UPR, and pre-emptive UPR counteracts TNF alpha-induced ROS accumulation.	Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 1138421, Japan; Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan; NYU, Sch Med, Skirball Inst, Dept Pharmacol, New York, NY 10016 USA	Juntendo University; Kyoto University; New York University	Nakano, H (corresponding author), Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	hnakano@med.juntendo.ac.jp	Mori, Kazutoshi/K-6106-2015; Longo, Kenneth A/A-5631-2010	Nakano, Hiroyasu/0000-0003-4843-1427; Harding, Heather P/0000-0002-7359-7974				Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Liu CY, 2000, J BIOL CHEM, V275, P24881, DOI 10.1074/jbc.M004454200; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Nakano H, 2004, TRENDS IMMUNOL, V25, P402, DOI 10.1016/j.it.2004.05.007; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; PIA JH, 2004, GENE THER MOL BIOL, V8, P163; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Sasazuki T, 2004, MOL IMMUNOL, V41, P547, DOI 10.1016/j.molimm.2004.03.030; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Shen XH, 2001, CELL, V107, P893, DOI 10.1016/S0092-8674(01)00612-2; Shindo M, 1998, BIOCHEM BIOPH RES CO, V244, P285, DOI 10.1006/bbrc.1998.8250; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Wang Y, 2000, J BIOL CHEM, V275, P27013; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741	31	315	332	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33917	33925		10.1074/jbc.M505818200	http://dx.doi.org/10.1074/jbc.M505818200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16107336	hybrid			2022-12-27	WOS:000232229700028
J	Westin, MAK; Hunt, MC; Alexson, SEH				Westin, MAK; Hunt, MC; Alexson, SEH			The identification of a succinyl-CoA thioesterase suggests a novel pathway for succinate production in peroxisomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN DICARBOXYLIC-ACIDS; ACTIVATED-RECEPTOR-ALPHA; CLOFIBRATE-TREATED RATS; LONG-CHAIN; BETA-OXIDATION; LIPID-METABOLISM; MOLECULAR-CLONING; OMEGA-OXIDATION; FATTY-ACIDS; MALONYL-COA	Dicarboxylic acids are formed by omega-oxidation of fatty acids in the endoplasmic reticulum and degraded as the CoA ester via beta-oxidation in peroxisomes. Both synthesis and degradation of dicarboxylic acids occur mainly in kidney and liver, and the chain-shortened dicarboxylic acids are excreted in the urine as the free acids, implying that acyl-CoA thioesterases (ACOTs), which hydrolyze CoA esters to the free acid and CoASH, are needed for the release of the free acids. Recent studies show that peroxisomes contain several acyl-CoA thioesterases with different functions. We have now expressed a peroxisomal acyl-CoA thioesterase with a previously unknown function, ACOT4, which we show is active on dicarboxylyl-CoA esters. We also expressed ACOT8, another peroxisomal acyl-CoA thioesterase that was previously shown to hydrolyze a large variety of CoA esters. Acot4 and Acot8 are both strongly expressed in kidney and liver and are also target genes for the peroxisome proliferator-activated receptor alpha. Enzyme activity measurements with expressed ACOT4 and ACOT8 show that both enzymes hydrolyze CoA esters of dicarboxylic acids with high activity but with strikingly different specificities. Whereas ACOT4 mainly hydrolyzes succinyl-CoA, ACOT8 preferentially hydrolyzes longer dicarboxylyl-CoA esters (glutaryl-CoA, adipyl-CoA, suberyl-CoA, sebacyl-CoA, and dodecanedioyl-CoA). The identification of a highly specific succinyl-CoA thioesterase in peroxisomes strongly suggests that peroxisomal beta-oxidation of dicarboxylic acids leads to formation of succinate, at least under certain conditions, and that ACOT4 and ACOT8 are responsible for the termination of beta-oxidation of dicarboxylic acids of medium-chain length with the concomitant release of the corresponding free acids.	Karolinska Univ Hos Huddinge, Dept Lab Med, Div Clin Chem, SE-14186 Stockholm, Sweden		Alexson, SEH (corresponding author), Karolinska Univ Hos Huddinge, Dept Lab Med, Div Clin Chem, C1-74, SE-14186 Stockholm, Sweden.	stefan.alexson@ki.se		Hunt, Mary/0000-0001-6415-2992; Watter, Maria/0000-0001-9047-5517				ALEXSON SEH, 1989, BIOCHEM J, V262, P41, DOI 10.1042/bj2620041; BERGE RK, 1984, EUR J BIOCHEM, V141, P637, DOI 10.1111/j.1432-1033.1984.tb08239.x; BERGSETH S, 1988, BIOCHIM BIOPHYS ACTA, V961, P103, DOI 10.1016/0005-2760(88)90135-X; Bian F, 2005, J BIOL CHEM, V280, P9265, DOI 10.1074/jbc.M412850200; BJORKHEM I, 1984, BIOCHIM BIOPHYS ACTA, V795, P15, DOI 10.1016/0005-2760(84)90099-7; BJORKHEM I, 1976, J BIOL CHEM, V251, P5259; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CERDAN S, 1988, J BIOL CHEM, V263, P11664; CHASE JFA, 1967, BIOCHEM J, P510; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; Ferdinandusse S, 2004, J LIPID RES, V45, P1104, DOI 10.1194/jlr.M300512-JLR200; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GREGERSEN N, 1982, SCAND J CLIN LAB INV, V42, P15; HORIE S, 1989, LIFE SCI, V44, P1141, DOI 10.1016/0024-3205(89)90342-1; Hunt MC, 2005, J LIPID RES, V46, P2029, DOI 10.1194/jlr.E500003-JLR200; Hunt MC, 2002, PROG LIPID RES, V41, P99, DOI 10.1016/S0163-7827(01)00017-0; Hunt MC, 2002, J BIOL CHEM, V277, P1128, DOI 10.1074/jbc.M106458200; Hunt MC, 1999, J BIOL CHEM, V274, P34317, DOI 10.1074/jbc.274.48.34317; Hunt MC, 2000, J LIPID RES, V41, P814; Jones JM, 1999, J BIOL CHEM, V274, P9216, DOI 10.1074/jbc.274.14.9216; Kasumov T, 2005, BIOCHEM J, V389, P397, DOI 10.1042/BJ20050144; KOLVRAA S, 1986, BIOCHIM BIOPHYS ACTA, V876, P515, DOI 10.1016/0005-2760(86)90039-1; Korman SH, 2000, J INHERIT METAB DIS, V23, P425, DOI 10.1023/A:1005624523611; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LEIGHTON F, 1989, J BIOL CHEM, V264, P10347; Lindquist PJG, 1998, EUR J BIOCHEM, V251, P631, DOI 10.1046/j.1432-1327.1998.2510631.x; Liu LX, 1997, J BIOL CHEM, V272, P13779, DOI 10.1074/jbc.272.21.13779; Magnes C, 2005, ANAL CHEM, V77, P2889, DOI 10.1021/ac048314i; MORTENSEN PB, 1986, BIOCHIM BIOPHYS ACTA, V878, P14, DOI 10.1016/0005-2760(86)90338-3; MORTENSEN PB, 1982, BIOCHIM BIOPHYS ACTA, V713, P393, DOI 10.1016/0005-2760(82)90258-2; MORTENSEN PB, 1982, BIOCHIM BIOPHYS ACTA, V710, P477, DOI 10.1016/0005-2760(82)90132-1; MORTENSEN PB, 1980, CLIN CHIM ACTA, V103, P33, DOI 10.1016/0009-8981(80)90227-2; MORTENSEN PB, 1980, BIOCHIM BIOPHYS ACTA, V620, P177, DOI 10.1016/0005-2760(80)90199-X; Ofman R, 2002, BIOCHEM BIOPH RES CO, V290, P629, DOI 10.1006/bbrc.2001.6245; Okita RT, 2001, CURR DRUG METAB, V2, P265; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; Reszko AE, 2004, J BIOL CHEM, V279, P19574, DOI 10.1074/jbc.M400162200; ROCCHICCIOLI F, 1986, PEDIATR RES, V20, P62, DOI 10.1203/00006450-198601000-00018; Sacksteder KA, 1999, J BIOL CHEM, V274, P24461, DOI 10.1074/jbc.274.35.24461; Sanders RJ, 2005, J LIPID RES, V46, P1001, DOI 10.1194/jlr.M400510-JLR200; Singh I, 1997, MOL CELL BIOCHEM, V167, P1, DOI 10.1023/A:1006883229684; Suga Tetsuya, 2003, Drug Metab Pharmacokinet, V18, P155, DOI 10.2133/dmpk.18.155; SVENSSON LT, 1995, J BIOL CHEM, V270, P12177, DOI 10.1074/jbc.270.20.12177; SVENSSON LT, 1995, EUR J BIOCHEM, V230, P813; Svensson LT, 1998, BIOCHEM J, V329, P601, DOI 10.1042/bj3290601; VAMECQ J, 1985, BIOCHEM J, V230, P683, DOI 10.1042/bj2300683; VAMECQ J, 1985, EUR J BIOCHEM, V146, P663, DOI 10.1111/j.1432-1033.1985.tb08702.x; VAMECQ J, 1989, AM J PHYSIOL, V256, pG680, DOI 10.1152/ajpgi.1989.256.4.G680; VAMECQ J, 1989, J BIOCHEM-TOKYO, V106, P216, DOI 10.1093/oxfordjournals.jbchem.a122835; Verkade PE, 1934, BIOCHEM J, V28, P31, DOI 10.1042/bj0280031; WADA F, 1977, BIOCHIM BIOPHYS ACTA, V487, P261, DOI 10.1016/0005-2760(77)90002-9; Wanders RJA, 2004, MOL GENET METAB, V83, P16, DOI 10.1016/j.ymgme.2004.08.016; Wanders RJA, 2004, AM J MED GENET A, V126A, P355, DOI 10.1002/ajmg.a.20661; Watanabe W, 1997, BIOCHEM BIOPH RES CO, V238, P234, DOI 10.1006/bbrc.1997.7217; Westin MAK, 2004, J BIOL CHEM, V279, P21841, DOI 10.1074/jbc.M313863200; WILCKE M, 1994, EUR J BIOCHEM, V222, P803, DOI 10.1111/j.1432-1033.1994.tb18927.x; YAMADA J, 1994, ARCH BIOCHEM BIOPHYS, V308, P118, DOI 10.1006/abbi.1994.1017; Yamada J, 1998, BIOCHEM BIOPH RES CO, V248, P608, DOI 10.1006/bbrc.1998.9048	58	63	125	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38125	38132		10.1074/jbc.M508479200	http://dx.doi.org/10.1074/jbc.M508479200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16141203	hybrid			2022-12-27	WOS:000233239800004
J	Kang, SH; Li, HM; Rao, AJ; Hogan, PG				Kang, SH; Li, HM; Rao, AJ; Hogan, PG			Inhibition of the calcineurin-NFAT interaction by small organic molecules reflects binding at an allosteric site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUINOHEMOPROTEIN AMINE DEHYDROGENASE; TYROSINE-PHOSPHATASE 1B; S-TRANSFERASE P1-1; CYCLOSPORINE-A; T-CELLS; TRANSCRIPTION FACTORS; NUCLEAR FACTOR; LYMPHOCYTE-ACTIVATION; SELECTIVE-INHIBITION; SULFUR NUCLEOPHILES	Transcriptional signaling from the Ca2+-calmodulin-activated phosphatase calcineurin to its substrate NFAT ( nuclear factor of activated T cells, also termed NFATc) is critically dependent on a protein-protein docking interaction between calcineurin and the PXIXIT motif in NFAT. Several inhibitors of NFAT-calcineurin association (INCA compounds) prevent binding of NFAT or the peptide ligand PVIVIT to calcineurin. Here we show that the binding site on calcineurin for INCA1, INCA2, and INCA6 is centered on cysteine 266 of calcineurin A alpha and does not coincide with the core PXIXIT-binding site. Although ample evidence indicates that INCA1 and INCA2 react covalently with cysteine 266, covalent derivatization alone is not sufficient for maximal inhibition of the calcineurin-PVIVIT interaction, because the maleimide INCA12 reacts with the same site and produces only very modest inhibition. Thus, inhibition arises through an allosteric change affecting the PXIXIT docking site, which may be assisted by covalent binding but depends on other specific features of the ligand. The spatial arrangement of the binding sites for PVIVIT and INCA makes it probable that the change in conformation involves the beta 11-beta 12 loop of calcineurin. The finding that an allosteric site controls NFAT binding opens new alternatives for inhibition of calcineurin-NFAT signaling.	CBR Inst Biomed Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard University; Harvard Medical School	Hogan, PG (corresponding author), CBR Inst Biomed Res, 200 Longwood Ave, Boston, MA 02115 USA.	hogan@cbr.med.harvard.edu		Kang, Sunghyun/0000-0003-1542-9750	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040127, R21AI059940] Funding Source: NIH RePORTER; NIAID NIH HHS [R21 AI059940, R01 AI40127] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aramburu J, 1998, MOL CELL, V1, P627, DOI 10.1016/S1097-2765(00)80063-5; Aramburu J, 2000, CURR TOP CELL REGUL, V36, P237; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Batiuk TD, 1997, J CLIN INVEST, V100, P1894, DOI 10.1172/JCI119719; BATIUK TD, 1995, J CLIN INVEST, V96, P1254, DOI 10.1172/JCI118159; Boatman RJ, 2000, CHEM RES TOXICOL, V13, P853, DOI 10.1021/tx000037x; Bueno OF, 2002, P NATL ACAD SCI USA, V99, P9398, DOI 10.1073/pnas.152665399; Chang MS, 2001, BIOCHEMISTRY-US, V40, P4811, DOI 10.1021/bi002513o; Chen G, 2003, J AM CHEM SOC, V125, P8130, DOI 10.1021/ja034287m; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Chen WQ, 1999, BIOCHEMISTRY-US, V38, P8159, DOI 10.1021/bi990125k; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Datta S, 2001, P NATL ACAD SCI USA, V98, P14268, DOI 10.1073/pnas.241429098; DUMONT FJ, 1992, J EXP MED, V176, P751, DOI 10.1084/jem.176.3.751; Erlanson DA, 2004, ANNU REV BIOPH BIOM, V33, P199, DOI 10.1146/annurev.biophys.33.110502.140409; FRUMAN DA, 1995, MOL CELL BIOL, V15, P3857; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; Fruman David A., 1996, Methods (Orlando), V9, P146, DOI 10.1006/meth.1996.0020; Fujii H, 2002, EUR J NEUROSCI, V16, P1777, DOI 10.1046/j.1460-9568.2002.02235.x; Furuke K, 1999, J IMMUNOL, V162, P1988; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; HANZLIK RP, 1994, CHEM RES TOXICOL, V7, P177, DOI 10.1021/tx00038a010; HOFFMANN KJ, 1985, MOL PHARMACOL, V27, P566; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Li HM, 2004, J MOL BIOL, V342, P1659, DOI 10.1016/j.jmb.2004.07.068; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Liu J, 2001, J IMMUNOL, V167, P2677, DOI 10.4049/jimmunol.167.5.2677; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Macian F, 2000, EMBO J, V19, P4783, DOI 10.1093/emboj/19.17.4783; Namgaladze D, 2002, J BIOL CHEM, V277, P5962, DOI 10.1074/jbc.M111268200; NARDONE J, 1994, P NATL ACAD SCI USA, V91, P4417, DOI 10.1073/pnas.91.10.4417; Noguchi H, 2004, NAT MED, V10, P305, DOI 10.1038/nm994; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Peterson BR, 1996, P NATL ACAD SCI USA, V93, P13671, DOI 10.1073/pnas.93.24.13671; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Reiter TA, 2002, J BIOL INORG CHEM, V7, P823, DOI 10.1007/s00775-002-0367-x; Roehrl MHA, 2004, P NATL ACAD SCI USA, V101, P7554, DOI 10.1073/pnas.0401835101; Rusnak F, 2000, TRENDS BIOCHEM SCI, V25, P527, DOI 10.1016/S0968-0004(00)01659-5; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; Salmeen A, 2003, NATURE, V423, P769, DOI 10.1038/nature01680; Satoh A, 2002, J BIOL CHEM, V277, P2830, DOI 10.1074/jbc.M109090200; SERAFINI AT, 1995, IMMUNITY, V3, P239, DOI 10.1016/1074-7613(95)90093-4; Serfling E, 2000, BBA-MOL CELL RES, V1498, P1, DOI 10.1016/S0167-4889(00)00082-3; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; SLAUGHTER DE, 1993, ANAL BIOCHEM, V208, P288, DOI 10.1006/abio.1993.1048; Sommer D, 2002, ARCH BIOCHEM BIOPHYS, V404, P271, DOI 10.1016/S0003-9861(02)00242-4; TSUBOI A, 1994, MOL BIOL CELL, V5, P119, DOI 10.1091/mbc.5.1.119; van Zanden JJ, 2003, CHEM-BIOL INTERACT, V145, P139, DOI 10.1016/S0009-2797(02)00250-8; Venkatesh N, 2004, P NATL ACAD SCI USA, V101, P8969, DOI 10.1073/pnas.0402803101; Wang QP, 2004, BIOCHEMISTRY-US, V43, P4294, DOI 10.1021/bi035986e; Wang XT, 1996, NATURE, V383, P434, DOI 10.1038/383434a0; Way JC, 2000, CURR OPIN CHEM BIOL, V4, P40, DOI 10.1016/S1367-5931(99)00049-6; Wesselborg S, 1996, J BIOL CHEM, V271, P1274, DOI 10.1074/jbc.271.3.1274; Zheng J, 1997, CHEM RES TOXICOL, V10, P1008, DOI 10.1021/tx970061j	59	40	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37698	37706		10.1074/jbc.M502247200	http://dx.doi.org/10.1074/jbc.M502247200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16148011	hybrid			2022-12-27	WOS:000233044500047
J	Kim, DJ; Kim, KH; Lee, HH; Lee, SJ; Ha, JY; Yoon, HJ; Suh, SW				Kim, DJ; Kim, KH; Lee, HH; Lee, SJ; Ha, JY; Yoon, HJ; Suh, SW			Crystal structure of lipoate-protein ligase A bound with the activated intermediate - Insights into interaction with lipoyl domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; POSTTRANSLATIONAL MODIFICATION; MULTIFUNCTIONAL ENZYMES; SWINGING ARMS; ACID; CLONING; LIPOYLTRANSFERASE; ALIGNMENT; BINDING; SYSTEM	Lipoic acid is the covalently attached cofactor of several multicomponent enzyme complexes that catalyze key metabolic reactions. Attachment of lipoic acid to the lipoyl-dependent enzymes is catalyzed by lipoate-protein ligases (LPLs). In Escherichia coli, two distinct enzymes lipoate-protein ligase A (LplA) and lipB-encoded lipoyltransferase ( LipB) catalyze independent pathways for lipoylation of the target proteins. The reaction catalyzed by LplA occurs in two steps. First, LplA activates exogenously supplied lipoic acid at the expense of ATP to lipoyl-AMP. Next, it transfers the enzyme-bound lipoyl-AMP to the epsilon-amino group of a specific lysine residue of the lipoyl domain to give an amide linkage. To gain insight into the mechanism of action by LplA, we have determined the crystal structure of Thermoplasma acidophilum LplA in three forms: (i) the apo form; (ii) the ATP complex; and (iii) the lipoyl-AMP complex. The overall fold of LplA bears some resemblance to that of the biotinyl protein ligase module of the E. coli biotin holoenzyme synthetase/ bio repressor (BirA). Lipoyl-AMP is bound deeply in the bifurcated pocket of LplA and adopts a U-shaped conformation. Only the phosphate group and part of the ribose sugar of lipoyl-AMP are accessible from the bulk solvent through a tunnel-like passage, whereas the rest of the activated intermediate is completely buried inside the active site pocket. This first view of the activated intermediate bound to LplA allowed us to propose a model of the complexes between Ta LplA and lipoyl domains, thus shedding light on the target protein/lysine residue specificity of LplA.	Seoul Natl Univ, Coll Nat Sci, Dept Chem, Seoul 151742, South Korea	Seoul National University (SNU)	Suh, SW (corresponding author), Seoul Natl Univ, Coll Nat Sci, Dept Chem, Seoul 151742, South Korea.	sewonsuh@snu.ac.kr	Kim, Do Jin/I-7675-2014; Suh, Won/H-8306-2013; Lee, Sang Jae/AAX-7611-2021	Suh, Won/0000-0002-1768-4635; Lee, Sang Jae/0000-0002-5366-2900				Athappilly FK, 1995, STRUCTURE, V3, P1407, DOI 10.1016/S0969-2126(01)00277-5; Berg A, 1997, EUR J BIOCHEM, V244, P352, DOI 10.1111/j.1432-1033.1997.00352.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Fujiwara K, 1999, EUR J BIOCHEM, V260, P761, DOI 10.1046/j.1432-1327.1999.00204.x; Fujiwara K, 1997, J BIOL CHEM, V272, P31974, DOI 10.1074/jbc.272.51.31974; Fujiwara K, 2005, J BIOL CHEM, V280, P33645, DOI 10.1074/jbc.M505010200; Fujiwara K, 2001, J BIOL CHEM, V276, P28819, DOI 10.1074/jbc.M101748200; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jordan SW, 1997, METHOD ENZYMOL, V279, P176; Jordan SW, 2003, J BACTERIOL, V185, P1582, DOI 10.1128/JB.185.5.1582-1589.2003; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MORRIS TW, 1995, J BACTERIOL, V177, P1; Nakai T, 2003, ACTA CRYSTALLOGR D, V59, P1610, DOI 10.1107/S0907444903014975; Nicholas KB, 1997, EMBNEW NEWS, V4, P14; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; Reche P, 1999, EMBO J, V18, P2673, DOI 10.1093/emboj/18.10.2673; Reche PA, 2000, PROTEIN SCI, V9, P1922, DOI 10.1110/ps.9.10.1922; Reddy DV, 1998, PROTEIN SCI, V7, P2156, DOI 10.1002/pro.5560071013; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; WILSON KP, 1992, P NATL ACAD SCI USA, V89, P9257, DOI 10.1073/pnas.89.19.9257; Zhao X, 2003, CHEM BIOL, V10, P1293, DOI 10.1016/j.chembiol.2003.11.016	28	40	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					38081	38089		10.1074/jbc.M507284200	http://dx.doi.org/10.1074/jbc.M507284200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16141198	hybrid			2022-12-27	WOS:000233044500091
J	Orr, WC; Radyuk, SN; Prabhudesai, L; Toroser, D; Benes, JJ; Luchak, JM; Mockett, RJ; Rebrin, I; Hubbard, JG; Sohal, RS				Orr, WC; Radyuk, SN; Prabhudesai, L; Toroser, D; Benes, JJ; Luchak, JM; Mockett, RJ; Rebrin, I; Hubbard, JG; Sohal, RS			Overexpression of glutamate-cysteine ligase extends life span in Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; GLUTATHIONE SYNTHESIS; OXIDATIVE STRESS; REDOX STATE; MODEL; CELL; RAT; DISULFIDES; EXPRESSION; SUBUNIT	The hypothesis that overexpression of glutamate-cysteine ligase (GCL), which catalyzes the rate-limiting reaction in de novo glutathione biosynthesis, could extend life span was tested in the fruit fly, Drosophila melanogaster. The GAL4-UAS binary transgenic system was used to generate flies overexpressing either the catalytic (GCLc) or modulatory (GCLm) subunit of this enzyme, in a global or neuronally targeted pattern. The GCL protein content of the central nervous system was elevated dramatically in the presence of either global or neuronal drivers. GCL activity was increased in the whole body or in heads, respectively, of GCLc transgenic flies containing global or neuronal drivers. The glutathione content of fly homogenates was increased by overexpression of GCLc or GCLm, particularly in flies overexpressing either subunit globally, or in the heads of GCLc flies possessing neuronal drivers. Neuronal overexpression of GCLc in a long-lived background extended mean and maximum life spans up to 50%, without affecting the rate of oxygen consumption by the flies. In contrast, global overexpression of GCLm extended the mean life span only up to 24%. These results demonstrate that enhancement of the glutathione biosynthetic capability, particularly in neuronal tissues, can extend the life span of flies, and thus support the oxidative stress hypothesis of aging.	So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA; Univ So Calif, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90089 USA	Southern Methodist University; University of Southern California	Orr, WC (corresponding author), So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA.	borr@smu.edu	Toroser, Dikran/AAT-9352-2021	Radyuk, Svetlana/0000-0002-3467-5255	NATIONAL INSTITUTE ON AGING [R01AG015122] Funding Source: NIH RePORTER; NIA NIH HHS [R01-AG15122] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bharath S, 2002, BIOCHEM PHARMACOL, V64, P1037, DOI 10.1016/S0006-2952(02)01174-7; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Fraser JA, 2002, J BIOL CHEM, V277, P1158, DOI 10.1074/jbc.M106683200; Griffith OW, 1999, FREE RADICAL BIO MED, V27, P922, DOI 10.1016/S0891-5849(99)00176-8; HERMAN MM, 1971, ACTA NEUROPATHOL, V19, P167, DOI 10.1007/BF00684595; HUANG CS, 1993, J BIOL CHEM, V268, P20578; Klichko VI, 1999, NEUROBIOL AGING, V20, P537, DOI 10.1016/S0197-4580(99)00090-1; MARTENSSON J, 1991, P NATL ACAD SCI USA, V88, P9360, DOI 10.1073/pnas.88.20.9360; MEISTER A, 1995, METHOD ENZYMOL, V251, P3, DOI 10.1016/0076-6879(95)51106-7; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Mockett RJ, 2002, METHOD ENZYMOL, V349, P213, DOI 10.1016/S0076-6879(02)49336-6; MOORE WR, 1989, P NATL ACAD SCI USA, V86, P1461, DOI 10.1073/pnas.86.5.1461; Pan ZH, 1996, INT J DEV NEUROSCI, V14, P559; Parkes TL, 1998, NAT GENET, V19, P171, DOI 10.1038/534; Radyuk SN, 2000, ARCH INSECT BIOCHEM, V45, P79, DOI 10.1002/1520-6327(200010)45:2&lt;79::AID-ARCH4&gt;3.0.CO;2-Y; Rebrin I, 2004, BIOCHEM J, V382, P131, DOI 10.1042/BJ20040506; ROBERTSON HM, 1988, GENETICS, V118, P461; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Schuster Christoph M., 1993, Experientia Supplementum (Basel), V63, P234; SHI MM, 1994, J BIOL CHEM, V269, P26512; Sies H, 1999, FREE RADICAL BIO MED, V27, P916, DOI 10.1016/S0891-5849(99)00177-X; Sohal RS, 2002, FREE RADICAL BIO MED, V33, P575, DOI 10.1016/S0891-5849(02)00886-9; TOMLINSON A, 1988, CELL, V55, P771, DOI 10.1016/0092-8674(88)90133-X; Toroser D, 2005, BIOCHEM BIOPH RES CO, V326, P586, DOI 10.1016/j.bbrc.2004.11.066; WINTERBOURN CC, 1993, FREE RADICAL BIO MED, V14, P85, DOI 10.1016/0891-5849(93)90512-S; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	26	105	111	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37331	37338		10.1074/jbc.M508272200	http://dx.doi.org/10.1074/jbc.M508272200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16148000	hybrid			2022-12-27	WOS:000233044500006
J	Wei, H; Ruthenburg, AJ; Bechis, SK; Verdine, GL				Wei, H; Ruthenburg, AJ; Bechis, SK; Verdine, GL			Nucleotide-dependent domain movement in the ATPase domain of a human type IIA DNA topoisomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND-PASSAGE REACTION; STEADY-STATE ANALYSIS; CRYSTAL-STRUCTURE; OPERATED CLAMP; DOUBLE HELIX; GYRASE-B; ALPHA; MECHANISM; TRANSPORT; YEAST	Type IIA DNA topoisomerases play multiple essential roles in the management of higher-order DNA structure, including modulation of topological state, chromosome segregation, and chromatin condensation. These diverse physiologic functions are all accomplished through a common molecular mechanism, wherein the protein catalyzes transient cleavage of a DNA duplex ( the G-segment) to yield a double-stranded gap through which another duplex ( the T-segment) is passed. The overall process is orchestrated by the opening and closing of molecular "gates" in the topoisomerase structure, which is regulated by ATP binding, hydrolysis, and release of ADP and inorganic phosphate. Here we present two crystal structures of the ATPase domain of human DNA topoisomerase II alpha in different nucleotide-bound states. Comparison of these structures revealed rigid-body movement of the structural modules within the ATPase domain, suggestive of the motions of a molecular gate.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Dana Farber Canc Inst, Program Canc Chem Biol, Boston, MA 02115 USA	Harvard University; Harvard University; Harvard University; Dana-Farber Cancer Institute	Verdine, GL (corresponding author), Harvard Univ, Dept Chem & Biol Chem, 12 Oxford St,Rm 194, Cambridge, MA 02138 USA.	Gregory_verdine@harvard.edu	Ruthenburg, Alexander/F-3992-2015; Ruthenburg, Alexander/C-3941-2008	Ruthenburg, Alexander/0000-0003-2709-4564; 	NCRR NIH HHS [RR-15301] Funding Source: Medline; NIGMS NIH HHS [GM044853, R01 GM044853] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR015301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044853] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baird CL, 1999, P NATL ACAD SCI USA, V96, P13685, DOI 10.1073/pnas.96.24.13685; Baird CL, 2001, J BIOL CHEM, V276, P27893, DOI 10.1074/jbc.M102544200; Bellon S, 2004, ANTIMICROB AGENTS CH, V48, P1856, DOI 10.1128/AAC.48.5.1856-1864.2004; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Bjergbaek L, 2000, J BIOL CHEM, V275, P13041, DOI 10.1074/jbc.275.17.13041; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cabral JHM, 1997, NATURE, V388, P903, DOI 10.1038/42294; Campbell S, 2002, J MOL BIOL, V320, P171, DOI 10.1016/S0022-2836(02)00461-8; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Classen S, 2003, P NATL ACAD SCI USA, V100, P10629, DOI 10.1073/pnas.1832879100; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; CORBETT AH, 1992, J BIOL CHEM, V267, P683; Corbett KD, 2005, STRUCTURE, V13, P873, DOI 10.1016/j.str.2005.03.013; Corbett KD, 2004, ANNU REV BIOPH BIOM, V33, P95, DOI 10.1146/annurev.biophys.33.110502.140357; Corbett KD, 2003, EMBO J, V22, P151, DOI 10.1093/emboj/cdg008; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; Fass D, 1999, NAT STRUCT BIOL, V6, P322; Gardiner LP, 1998, BIOCHEMISTRY-US, V37, P16997, DOI 10.1021/bi9818321; Hammonds TR, 1997, J BIOL CHEM, V272, P32696, DOI 10.1074/jbc.272.51.32696; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7299, DOI 10.1021/bi9729108; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7292, DOI 10.1021/bi9729099; Hu T, 2002, J BIOL CHEM, V277, P5944, DOI 10.1074/jbc.M111394200; Hu T, 1998, J BIOL CHEM, V273, P9586, DOI 10.1074/jbc.273.16.9586; JACKSON AP, 1993, P NATL ACAD SCI USA, V90, P11232, DOI 10.1073/pnas.90.23.11232; Lamour V, 2002, ACTA CRYSTALLOGR D, V58, P1376, DOI 10.1107/S0907444902010429; Lindsley JE, 1996, P NATL ACAD SCI USA, V93, P2975, DOI 10.1073/pnas.93.7.2975; LINDSLEY JE, 1993, NATURE, V361, P749, DOI 10.1038/361749a0; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; Maxwell A, 1996, NAT STRUCT BIOL, V3, P109, DOI 10.1038/nsb0296-109; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Oestergaard VH, 2004, J BIOL CHEM, V279, P28093, DOI 10.1074/jbc.M402120200; Oestergaard VH, 2004, J BIOL CHEM, V279, P1684, DOI 10.1074/jbc.M309624200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Roca J, 1996, P NATL ACAD SCI USA, V93, P4057, DOI 10.1073/pnas.93.9.4057; Roca J, 2004, J BIOL CHEM, V279, P25783, DOI 10.1074/jbc.M402555200; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; Skouboe C, 2003, J BIOL CHEM, V278, P5768, DOI 10.1074/jbc.M210332200; Smith CV, 1998, BIOCHEMISTRY-US, V37, P9658, DOI 10.1021/bi9801309; Tingey AP, 1996, NUCLEIC ACIDS RES, V24, P4868, DOI 10.1093/nar/24.24.4868; Topcu Z, 2001, J CLIN PHARM THER, V26, P405, DOI 10.1046/j.1365-2710.2001.00368.x; Walker JV, 2004, J BIOL CHEM, V279, P25947, DOI 10.1074/jbc.M312314200; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; WASSERMAN RA, 1993, CANCER RES, V53, P3591; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0	46	178	182	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37041	37047		10.1074/jbc.M506520200	http://dx.doi.org/10.1074/jbc.M506520200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16100112	Green Published, hybrid			2022-12-27	WOS:000232901800062
J	Elward, K; Griffiths, M; Mizuno, M; Harris, CL; Neal, JW; Morgan, BP; Gasque, P				Elward, K; Griffiths, M; Mizuno, M; Harris, CL; Neal, JW; Morgan, BP; Gasque, P			CD46 plays a key role in tailoring innate immune recognition of apoptotic and necrotic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING LECTIN; COFACTOR PROTEIN MCP; COMPLEMENT ACTIVATION; ENDOTHELIAL-CELLS; CLASSICAL PATHWAY; MEMBRANE-PROTEIN; DOWN-REGULATION; MYELOID CELLS; C1Q; CLEARANCE	Complement is the canonical innate immune system involved in host defense and tissue repair with the clearance of cell debris. In contrast to the robust armory mounted against microbial nonself-pathogens, complement is selectively activated on altered self (i.e. apoptotic and necrotic cells) to instruct the safe demise by poorly characterized mechanisms. Our data shed new light on the role of complement C1q in sensing nucleic acids (NA) rapidly exposed on apoptotic Jurkat T cell membranes and in driving C3 opsonization but without the lytic membrane attack complex. DNA/RNase-treated apoptotic cells failed to activate complement. We found that several other apoptotic cell models, including senescent keratinocytes, ionophore-treated sperm cells, and CMK-derived platelets, stained for cleaved caspase 3 were rapidly losing the key complement regulator CD46. CD46 from nuclear and membrane stores was found to cluster into blebs and shed into microparticles together with NA, phosphatidylserine, C1q, and factor H. Classical and alternative pathways of complement were involved in the recognition of H2O2-treated necrotic cells. Membrane attack complex was detected on necrotic cells possibly as a result of CD46 and CD59 shedding into soluble forms. Our data highlight a novel and universal paradigm whereby the complement innate immune system is using two synergistic strategies with the recognition of altered self-NA and missing self-CD46 signals to instruct and tailor the efficient removal of apoptotic and necrotic cells in immunoprivileged sites.	Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Brain Inflammat & Immun Grp, Cardiff CF14 4XN, Wales; Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Complement Biol Grp, Cardiff CF14 4XN, Wales; Cardiff Univ, Sch Med, Dept Pathol, Neuropathol Lab, Cardiff CF14 4XN, Wales	Cardiff University; Cardiff University; Cardiff University	Gasque, P (corresponding author), Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Brain Inflammat & Immun Grp, Heath Pk Campus, Cardiff CF14 4XN, Wales.	gasque@cardiff.ac.uk		Morgan, Paul/0000-0003-4075-7676	Multiple Sclerosis Society [714] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Multiple Sclerosis Society(National Multiple Sclerosis Society); Wellcome Trust(Wellcome TrustEuropean Commission)		Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Anderson HA, 2003, NAT IMMUNOL, V4, P87, DOI 10.1038/ni871; Arama E, 2003, DEV CELL, V4, P687, DOI 10.1016/S1534-5807(03)00120-5; Arur S, 2003, DEV CELL, V4, P587, DOI 10.1016/S1534-5807(03)00090-X; Barclay AN, 2002, TRENDS IMMUNOL, V23, P285, DOI 10.1016/S1471-4906(02)02223-8; Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56; Caragine TA, 2002, BLOOD, V100, P3304, DOI 10.1182/blood.V100.9.3304; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; Ciurana CLF, 2004, EUR J IMMUNOL, V34, P2609, DOI 10.1002/eji.200425045; Clarke MCH, 2003, J CELL BIOL, V160, P577, DOI 10.1083/jcb.200210111; Crocker PR, 2001, TRENDS IMMUNOL, V22, P337, DOI 10.1016/S1471-4906(01)01930-5; Eda S, 2004, J BIOL CHEM, V279, P5967, DOI 10.1074/jbc.M310805200; Elward K, 2003, MOL IMMUNOL, V40, P85, DOI 10.1016/S0161-5890(03)00109-3; Fishelson Z, 2001, MOL IMMUNOL, V38, P207, DOI 10.1016/S0161-5890(01)00055-4; Franc NC, 1999, CURR OPIN IMMUNOL, V11, P47, DOI 10.1016/S0952-7915(99)80009-0; GASQUE P, 1995, J IMMUNOL, V154, P4726; Gasque P, 1998, J IMMUNOL, V160, P3543; Gasque P, 2004, MOL IMMUNOL, V41, P1089, DOI 10.1016/j.molimm.2004.06.011; Gasque P, 2000, IMMUNOPHARMACOLOGY, V49, P171, DOI 10.1016/S0162-3109(00)80302-1; Ghiran I, 2000, J EXP MED, V192, P1797, DOI 10.1084/jem.192.12.1797; Gorczynski R, 2004, J IMMUNOL, V172, P7744, DOI 10.4049/jimmunol.172.12.7744; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Gregory CD, 2004, IMMUNOLOGY, V113, P1, DOI 10.1111/j.1365-2567.2004.01959.x; Gregory CD, 2000, CURR OPIN IMMUNOL, V12, P27, DOI 10.1016/S0952-7915(99)00047-3; Hara T, 1997, IMMUNOBIOLOGY, V196, P491, DOI 10.1016/S0171-2985(97)80066-6; Hart SP, 2004, CLIN EXP IMMUNOL, V135, P181, DOI 10.1111/j.1365-2249.2003.02330.x; Hoek RM, 2000, SCIENCE, V290, P1768, DOI 10.1126/science.290.5497.1768; Hoffmann PR, 2001, J CELL BIOL, V155, P649, DOI 10.1083/jcb.200108080; JIANG HX, 1992, J BIOL CHEM, V267, P25597; Jones J, 1995, IMMUNOLOGY, V86, P651; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KAUL M, 1995, J IMMUNOL, V155, P5795; Kim SJ, 2002, J EXP MED, V196, P655, DOI 10.1084/jem.20020542; Kishore U, 2004, TRENDS IMMUNOL, V25, P551, DOI 10.1016/j.it.2004.08.006; Kishore U, 2003, J IMMUNOL, V171, P812, DOI 10.4049/jimmunol.171.2.812; Kishore U, 2002, IMMUNOBIOLOGY, V205, P355, DOI 10.1078/0171-2985-00138; Korb LC, 1997, J IMMUNOL, V158, P4525; Kovacs GG, 2004, NEUROBIOL DIS, V15, P21, DOI 10.1016/j.nbd.2003.09.010; Lauber K, 2003, CELL, V113, P717, DOI 10.1016/S0092-8674(03)00422-7; Lozahic S, 2000, EUR J IMMUNOL, V30, P900, DOI 10.1002/1521-4141(200003)30:3<900::AID-IMMU900>3.0.CO;2-X; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Mevorach D, 1998, J EXP MED, V188, P2313, DOI 10.1084/jem.188.12.2313; Mevorach D, 1998, J EXP MED, V188, P387, DOI 10.1084/jem.188.2.387; Morgan BP, 1999, CRIT REV IMMUNOL, V19, P173; Morgan BP, 1997, CLIN EXP IMMUNOL, V107, P1, DOI 10.1046/j.1365-2249.1997.d01-890.x; Nauta AJ, 2002, EUR J IMMUNOL, V32, P1726, DOI 10.1002/1521-4141(200206)32:6<1726::AID-IMMU1726>3.0.CO;2-R; Navratil JS, 2001, J IMMUNOL, V166, P3231, DOI 10.4049/jimmunol.166.5.3231; NICHOLSONWELLER A, 1992, CURR TOP MICROBIOL, V178, P7; Nusbaum P, 2005, J BIOL CHEM, V280, P5843, DOI 10.1074/jbc.M413405200; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; Palaniyar N, 2004, J BIOL CHEM, V279, P32728, DOI 10.1074/jbc.M403763200; PEITSCH MC, 1988, BIOCHEM J, V249, P495, DOI 10.1042/bj2490495; Quartier P, 2005, EUR J IMMUNOL, V35, P252, DOI 10.1002/eji.200425497; Richards A, 2003, P NATL ACAD SCI USA, V100, P12966, DOI 10.1073/pnas.2135497100; Riley RC, 2002, MOL REPROD DEV, V62, P534, DOI 10.1002/mrd.10144; Riley-Vargas RC, 2004, TRENDS IMMUNOL, V25, P496, DOI 10.1016/j.it.2004.07.004; Roos A, 2004, EUR J IMMUNOL, V34, P921, DOI 10.1002/eji.200424904; Sohn JH, 2003, NAT MED, V9, P206, DOI 10.1038/nm814; Taylor PR, 2000, J EXP MED, V192, P359, DOI 10.1084/jem.192.3.359; Tenner AJ, 1999, CURR OPIN IMMUNOL, V11, P34, DOI 10.1016/S0952-7915(99)80007-7; Trouw LA, 2004, J CLIN INVEST, V114, P679, DOI 10.1172/JCI200421075; TSUJI S, 1994, J BIOCHEM-TOKYO, V116, P794, DOI 10.1093/oxfordjournals.jbchem.a124598; Valazquez P, 1997, NAT MED, V3, P77, DOI 10.1038/nm0197-77; Verbovetski I, 2002, J EXP MED, V196, P1553, DOI 10.1084/jem.20020263; Wang GX, 2000, J IMMUNOL, V164, P1839, DOI 10.4049/jimmunol.164.4.1839; Wright GJ, 2000, IMMUNITY, V13, P233, DOI 10.1016/S1074-7613(00)00023-6; Xu CG, 2000, SCIENCE, V287, P498, DOI 10.1126/science.287.5452.498	68	115	121	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36342	36354		10.1074/jbc.M506579200	http://dx.doi.org/10.1074/jbc.M506579200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16087667	hybrid			2022-12-27	WOS:000232726900068
J	Germann, M; Gallo, C; Donahue, T; Shirzadi, R; Stukey, J; Lang, S; Ruckenstuhl, C; Oliaro-Bosso, S; McDonough, V; Turnowsky, F; Balliano, G; Nickels, JT				Germann, M; Gallo, C; Donahue, T; Shirzadi, R; Stukey, J; Lang, S; Ruckenstuhl, C; Oliaro-Bosso, S; McDonough, V; Turnowsky, F; Balliano, G; Nickels, JT			Characterizing sterol defect suppressors uncovers a novel transcriptional signaling pathway regulating zymosterol biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SQUALENE EPOXIDASE GENE; SACCHAROMYCES-CEREVISIAE; TERBINAFINE RESISTANCE; MOLECULAR-CLONING; CELL-SURFACE; YEAST; CHOLESTEROL; EXPRESSION; REDUCTASE; ERGOSTEROL	erg26-1(ts) cells harbor defects in the 4 alpha-carboxysterol-C3 dehydrogenase activity necessary for conversion of 4,4-dimethylzymosterol to zymosterol. Mutant cells accumulate toxic 4-carboxysterols and are inviable at high temperature. A genetic screen aimed at cloning recessive mutations remediating the temperature sensitive growth defect has resulted in the isolation of four complementation groups, ets1-4 (erg26-1(ts) temperature sensitive suppressor). We describe the characterization of ets1-1 and ets2-1. Gas chromatography/ mass spectrometry analyses demonstrate that erg26-1(ts) ets1-1 and erg26-1(ts) ets2-1 cells do not accumulate 4-carboxysterols, rather these cells have increased levels of squalene and squalene epoxide, respectively. ets1-1 and ets2-1 cells accumulate these same sterol intermediates. Chromosomal integration of ERG1 and ERG7 at their loci in erg26-1(ts) ets1-1 and erg26-1(ts) ets2-1 mutants, respectively, results in the loss of accumulation of squalene and squalene epoxide, re- accumulation of 4-carboxysterols and cell inviability at high temperature. Enzymatic assays demonstrate that mutants harboring the ets1-1 allele have decreased squalene epoxidase activity, while those containing the ets2-1 allele show weakened oxidosqualene cyclase activity. Thus, ETS1 and ETS2 are allelic to ERG1 and ERG7, respectively. We have mapped mutations within the erg1-1/ ets1-1 (G247D) and erg7-1/ets2-1 (D530N, V615E) alleles that suppress the inviability of erg26-1(ts) at high temperature, and cause accumulation of sterol intermediates and decreased enzymatic activities. Finally using erg1-1 and erg7-1 mutant strains, we demonstrate that the expression of the ERG25/26/27 genes required for zymosterol biosynthesis are coordinately transcriptionally regulated, along with ERG1 and ERG7, in response to blocks in sterol biosynthesis. Transcriptional regulation requires the transcription factors, Upc2p and Ecm22p.	Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19102 USA; Hope Coll, Dept Biol, Holland, MI 49422 USA; Karl Franzens Univ Graz, Inst Mol Biol Biochem & Microbiol, A-8010 Graz, Austria; Univ Turin, Fac Farm, Dipartimento Sci & Tecnol Farmaco, I-10125 Turin, Italy	Drexel University; Hope College; University of Graz; University of Turin	Germann, M (corresponding author), Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19102 USA.			Gallo-Ebert, Christina/0000-0003-0985-3547; Ruckenstuhl, Christoph/0000-0002-4338-4679	NHLBI NIH HHS [HL67401] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067401] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ArthingtonSkaggs BA, 1996, FEBS LETT, V392, P161, DOI 10.1016/0014-5793(96)00807-1; Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; BAKER CH, 1995, BIOCHEM BIOPH RES CO, V213, P154, DOI 10.1006/bbrc.1995.2110; BALLIANO G, 1988, BIOCHIM BIOPHYS ACTA, V959, P9, DOI 10.1016/0005-2760(88)90144-0; Bard M, 1996, P NATL ACAD SCI USA, V93, P186, DOI 10.1073/pnas.93.1.186; Baudry K, 2001, J BIOL CHEM, V276, P12702, DOI 10.1074/jbc.M100274200; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; CHAMBAZ EM, 1969, ANAL BIOCHEM, V30, P7, DOI 10.1016/0003-2697(69)90368-6; Coleman RA, 2004, PROG LIPID RES, V43, P134, DOI 10.1016/S0163-7827(03)00051-1; Daum G, 1998, YEAST, V14, P1471, DOI 10.1002/(SICI)1097-0061(199812)14:16<1471::AID-YEA353>3.0.CO;2-Y; DimsterDenk D, 1996, MOL CELL BIOL, V16, P3981; Farese RV, 1998, TRENDS GENET, V14, P115, DOI 10.1016/S0168-9525(97)01377-2; FAUST JR, 1988, BIOL CHOLESTEROL, P20; FIELD RB, 1979, LIPIDS, V14, P741, DOI 10.1007/BF02533900; Gachotte D, 1999, P NATL ACAD SCI USA, V96, P12655, DOI 10.1073/pnas.96.22.12655; Gachotte D, 1998, P NATL ACAD SCI USA, V95, P13794, DOI 10.1073/pnas.95.23.13794; Gachotte D, 2001, J LIPID RES, V42, P150; Grishin AV, 1998, GENETICS, V149, P879; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Hinson DD, 1997, J LIPID RES, V38, P2216; Hongay C, 2002, EMBO J, V21, P4114, DOI 10.1093/emboj/cdf415; Incardona JP, 2000, CURR OPIN CELL BIOL, V12, P193, DOI 10.1016/S0955-0674(99)00076-9; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JINGAMI H, 1987, J CELL BIOL, V104, P1693, DOI 10.1083/jcb.104.6.1693; Kastaniotis AJ, 2000, MOL CELL BIOL, V20, P7088, DOI 10.1128/MCB.20.19.7088-7098.2000; Kennedy MA, 1999, BBA-GENE STRUCT EXPR, V1445, P110, DOI 10.1016/S0167-4781(99)00035-4; Klobucnikova V, 2003, BIOCHEM BIOPH RES CO, V309, P666, DOI 10.1016/j.bbrc.2003.08.051; Konig A, 2000, AM J MED GENET, V90, P339; Kuge O, 2003, J BIOCHEM, V133, P397, DOI 10.1093/jb/mvg052; Laden BP, 2000, ARCH BIOCHEM BIOPHYS, V374, P381, DOI 10.1006/abbi.1999.1629; Lange Y, 1997, J BIOL CHEM, V272, P13103, DOI 10.1074/jbc.272.20.13103; Leber R, 1998, MOL BIOL CELL, V9, P375, DOI 10.1091/mbc.9.2.375; Leber R, 2003, ANTIMICROB AGENTS CH, V47, P3890, DOI 10.1128/AAC.47.12.3890-3900.2003; Leber R, 2001, EUR J BIOCHEM, V268, P914, DOI 10.1046/j.1432-1327.2001.01940.x; Lechner M, 1999, J CHROMATOGR A, V857, P231, DOI 10.1016/S0021-9673(99)00751-7; Lees N., 1997, BIOCH FUNCTION STERO, P85; LEES ND, 1995, LIPIDS, V30, P221, DOI 10.1007/BF02537824; Li LT, 1996, J BIOL CHEM, V271, P16927, DOI 10.1074/jbc.271.28.16927; LISCUM L, 1992, J LIPID RES, V33, P1239; Liu XY, 1999, NAT GENET, V22, P182, DOI 10.1038/9700; Marijanovic Z, 2003, MOL ENDOCRINOL, V17, P1715, DOI 10.1210/me.2002-0436; MBAYA B, 1989, LIPIDS, V24, P1020, DOI 10.1007/BF02544072; Mo C, 2003, BBA-MOL CELL BIOL L, V1633, P68, DOI 10.1016/S1388-1981(03)00088-X; Mo C, 2002, P NATL ACAD SCI USA, V99, P9739, DOI 10.1073/pnas.112202799; Mullner H, 2004, BBA-BIOMEMBRANES, V1663, P9, DOI 10.1016/S0005-2736(04)00079-3; Munn AL, 1999, MOL BIOL CELL, V10, P3943, DOI 10.1091/mbc.10.11.3943; Nagai M, 2002, BIOCHEM BIOPH RES CO, V295, P74, DOI 10.1016/S0006-291X(02)00623-X; Nagai M, 1997, GENOMICS, V44, P141, DOI 10.1006/geno.1997.4825; NES W D, 1989, Steroids, V53, P533, DOI 10.1016/0039-128X(89)90030-5; NICKELS JT, 1994, J BIOL CHEM, V269, P11018; Oshiro J, 2000, J BIOL CHEM, V275, P40887, DOI 10.1074/jbc.M008144200; PARKS LW, 1995, LIPIDS, V30, P227, DOI 10.1007/BF02537825; PATTERSON GW, 1971, ANAL CHEM, V43, P1165, DOI 10.1021/ac60304a015; Phillips KM, 1999, J CHROMATOGR B, V732, P17, DOI 10.1016/S0378-4347(99)00257-1; POPJAK G, 1969, METHOD ENZYMOL, V15, P393; Ravid T, 2000, J BIOL CHEM, V275, P35840, DOI 10.1074/jbc.M004793200; Rodriguez C, 2003, CARDIOVASC RES, V58, P178, DOI 10.1016/S0008-6363(02)00856-8; RODRIGUEZ RJ, 1983, ARCH BIOCHEM BIOPHYS, V225, P861, DOI 10.1016/0003-9861(83)90099-1; Sato R, 1995, CELL STRUCT FUNCT, V20, P421, DOI 10.1247/csf.20.421; SIKORSKI RS, 1989, GENETICS, V122, P19; SLOTTE JP, 1989, BIOCHIM BIOPHYS ACTA, V985, P90, DOI 10.1016/0005-2736(89)90108-9; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; Storey MK, 1998, BIOCHEM J, V336, P247, DOI 10.1042/bj3360247; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; SUNG CK, 1995, BIOL PHARM BULL, V18, P1459; Swain E, 2002, J BIOL CHEM, V277, P36152, DOI 10.1074/jbc.M206624200; Thoma R, 2004, NATURE, V432, P118, DOI 10.1038/nature02993; Tinkelenberg AH, 2000, J BIOL CHEM, V275, P40667, DOI 10.1074/jbc.C000710200; Umebayashi K, 2003, J CELL BIOL, V161, P1117, DOI 10.1083/jcb.200303088; Vik A, 2001, MOL CELL BIOL, V21, P6395, DOI 10.1128/MCB.21.19.6395-6405.2001; WELIHINDA AA, 1994, BBA-BIOMEMBRANES, V1193, P107, DOI 10.1016/0005-2736(94)90339-5; Worgall TS, 2002, J BIOL CHEM, V277, P3878, DOI 10.1074/jbc.M102393200; Wu WI, 2000, METHOD ENZYMOL, V312, P373; XU SH, 1988, J CHROMATOGR, V452, P377, DOI 10.1016/S0021-9673(01)81462-X; Zweytick D, 2000, FEBS LETT, V470, P83, DOI 10.1016/S0014-5793(00)01290-4	77	25	26	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35904	35913		10.1074/jbc.M504978200	http://dx.doi.org/10.1074/jbc.M504978200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16120615	hybrid			2022-12-27	WOS:000232726900017
J	Kray, AE; Carter, RS; Pennington, KN; Gomez, RJ; Sanders, LW; Llanes, JM; Khan, WN; Ballard, DW; Wadzinski, BE				Kray, AE; Carter, RS; Pennington, KN; Gomez, RJ; Sanders, LW; Llanes, JM; Khan, WN; Ballard, DW; Wadzinski, BE			Positive regulation of I kappa B kinase signaling by protein serine/threonine phosphatase 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS TYROSINE KINASE; OKADAIC ACID; IKK COMPLEX; AFFINITY-CHROMATOGRAPHY; CELL-GROWTH; HIGH-TITER; ACTIVATION; ALPHA; PHOSPHORYLATION; BETA	Transcription factor NF-kappa B plays a key regulatory role in the cellular response to pro-inflammatory cytokines such as tumor necrosis factor-alpha(TNF). In the absence of TNF, NF-kappa B is sequestered in the cytoplasm by inhibitory I kappa B proteins. Phosphorylation of I kappa B by the beta-catalytic subunit of IKK, a multicomponent I kappa B kinase, targets the inhibitor for proteolytic destruction and facilitates nuclear translocation of NF-kappa B. This pathway is initiated by TNF-dependent phosphorylation of T loop serines in IKK beta, which greatly stimulates I kappa B kinase activity. Prior in vitro mixing experiments indicate that protein serine/threonine phosphatase 2A (PP2A) can dephosphorylate these T loop serines and inactivate IKK, suggesting a negative regulatory role for PP2A in IKK signaling. Here we provided several in vivo lines of evidence indicating that PP2A plays a positive rather than a negative role in the regulation of IKK. First, TNF-induced degradation of I kappa B is attenuated in cells treated with okadaic acid or fostriecin, two potent inhibitors of PP2A. Second, PP2A forms stable complexes with IKK in untransfected mammalian cells. This interaction is critically dependent on amino acid residues 121 - 179 of the IKK gamma regulatory subunit. Third, deletion of the PP2A-binding site in IKK gamma attenuates T loop phosphorylation and catalytic activation of IKK beta in cells treated with TNF. Taken together, these data provide strong evidence that the formation of IKK center dot PP2A complexes is required for the proper induction of I kappa B kinase activity in vivo.	Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Microbiol & Immunol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Wadzinski, BE (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, 424 RRB, Nashville, TN 37232 USA.	brian.wadzinski@vanderbilt.edu			NATIONAL CANCER INSTITUTE [R01CA082556, P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050213, R01AI052379] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051366, R56GM051366, T32GM007628, R01GM062265] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485, CA082556] Funding Source: Medline; NIAID NIH HHS [AI052379, AI50213] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline; NIGMS NIH HHS [GM51366, GM62265, 2-T32-GM07628] Funding Source: Medline; NIMH NIH HHS [MH19732] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Agou F, 2004, J BIOL CHEM, V279, P27861, DOI 10.1074/jbc.M314278200; Bauman AL, 2000, J NEUROSCI, V20, P7571; Campos M, 1996, J BIOL CHEM, V271, P28478, DOI 10.1074/jbc.271.45.28478; Carter RS, 2003, J BIOL CHEM, V278, P48903, DOI 10.1074/jbc.M310686200; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Colbran RJ, 1997, J NEUROCHEM, V69, P920; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Fan GH, 2001, J BIOL CHEM, V276, P16960, DOI 10.1074/jbc.M009292200; Fernandez PC, 1999, BIOCHEM BIOPH RES CO, V263, P63, DOI 10.1006/bbrc.1999.1312; Fu DX, 2003, J BIOL CHEM, V278, P1487, DOI 10.1074/jbc.M210631200; Fujita M, 2004, ORAL ONCOL, V40, P199, DOI 10.1016/S1368-8375(03)00152-0; Garcia A, 2000, MICROBES INFECT, V2, P401, DOI 10.1016/S1286-4579(00)00327-0; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; HAYSTEAD CMM, 1993, EUR J BIOCHEM, V214, P459, DOI 10.1111/j.1432-1033.1993.tb17942.x; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kabashima T, 2003, P NATL ACAD SCI USA, V100, P5107, DOI 10.1073/pnas.0730817100; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Krueger KM, 1997, J BIOL CHEM, V272, P5; Kupfer R, 2002, J IMMUNOL METHODS, V266, P155, DOI 10.1016/S0022-1759(02)00146-1; Lewy DS, 2002, CURR MED CHEM, V9, P2005, DOI 10.2174/0929867023368809; Mahboubi K, 1997, J PHARMACOL EXP THER, V282, P452; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Miskolci V, 2003, ARCH BIOCHEM BIOPHYS, V417, P44, DOI 10.1016/S0003-9861(03)00336-9; MOORHEAD G, 1994, FEBS LETT, V356, P46, DOI 10.1016/0014-5793(94)01232-6; Morimoto H, 2004, J BIOCHEM, V136, P433, DOI 10.1093/jb/mvh144; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Petro JB, 2000, J EXP MED, V191, P1745, DOI 10.1084/jem.191.10.1745; Petro JB, 2001, J BIOL CHEM, V276, P1715, DOI 10.1074/jbc.M009137200; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Price NE, 1999, MOL BRAIN RES, V73, P68, DOI 10.1016/S0169-328X(99)00237-5; Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudolph D, 2000, GENE DEV, V14, P854; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; Strack S, 1997, MOL BRAIN RES, V49, P15, DOI 10.1016/S0169-328X(97)00117-4; Strack S, 1998, J COMP NEUROL, V392, P515; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUN SC, 1995, J BIOL CHEM, V270, P18347, DOI 10.1074/jbc.270.31.18347; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Tegethoff S, 2003, MOL CELL BIOL, V23, P2029, DOI 10.1128/MCB.23.6.2029-2041.2003; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamamoto Y, 2001, J BIOL CHEM, V276, P36327, DOI 10.1074/jbc.M104090200; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang JM, 2001, J BIOL CHEM, V276, P47828, DOI 10.1074/jbc.M106103200; Ye JJ, 2000, J BIOL CHEM, V275, P9882, DOI 10.1074/jbc.275.13.9882; YEE JK, 1994, METHOD CELL BIOL, V43, P99; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zolnierowicz S, 2000, BIOCHEM PHARMACOL, V60, P1225, DOI 10.1016/S0006-2952(00)00424-X	59	66	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35974	35982		10.1074/jbc.M506093200	http://dx.doi.org/10.1074/jbc.M506093200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16126728	hybrid			2022-12-27	WOS:000232726900025
J	van der Westhuyzen, DR; Cai, L; de Beer, MC; de Beer, FC				van der Westhuyzen, DR; Cai, L; de Beer, MC; de Beer, FC			Serum amyloid A promotes cholesterol efflux mediated by scavenger receptor B-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; ACUTE-PHASE PROTEIN; CELLULAR CHOLESTEROL; MACROPHAGE CHOLESTEROL; MESSENGER-RNA; EXPRESSION; BINDING; IDENTIFICATION; METABOLISM; ISOFORM	Serum amyloid A (SAA) is an acute phase protein whose expression is markedly up-regulated during inflammation and infection. The physiological function of SAA is unclear. In this study, we reported that SAA promotes cellular cholesterol efflux mediated by scavenger receptor B-I (SR-BI). In Chinese hamster ovary cells, SAA promoted cellular cholesterol efflux in an SR-BI-dependent manner, whereas apoA-I did not. Similarly, SAA, but not apoA-I, promoted cholesterol efflux from HepG2 cells in an SR-BI-dependent manner as shown by using the SR-BI inhibitor BLT-1. When SAA was overexpressed in HepG2 cells using adenovirus-mediated gene transfer, the endogenously expressed SAA promoted SR-BI-dependent efflux. To assess the effect of SAA on SR-BI-mediated efflux to high density lipoprotein (HDL), we compared normal HDL, acute phase HDL(AP-HDL, prepared from mice injected with lipopolysaccharide), and AdSAA-HDL ( HDL prepared from mice overexpressing SAA). Both AP-HDL and AdSAA-HDL promoted 2-fold greater cholesterol efflux than normal HDL. Lipid-free SAA was shown to also stimulate ABCA1-dependent cholesterol efflux in fibroblasts, in line with an earlier report (Stonik, J. A., Remaley, A. T., Demosky, S. J., Neufeld, E. B., Bocharov, A., and Brewer, H. B. ( 2004) Biochem. Biophys. Res. Commun. 321, 936 - 941). When added to cells together, SAA and HDL exerted a synergistic effect in promoting ABCA1-dependent efflux, suggesting that SAA may remodel HDL in a manner that releases apoA-I or other efficient ABCA1 ligands from HDL. SAA also facilitated efflux by a process that was independent of SR-BI and ABCA1. We conclude that the acute phase protein SAA plays an important role in HDL cholesterol metabolism by promoting cellular cholesterol efflux through a number of different efflux pathways.	Univ Kentucky, Grad Ctr Nutr Sci, Dept Internal Med, Lexington, KY 40536 USA; Univ Kentucky, Grad Ctr Nutr Sci, Dept Physiol, Lexington, KY 40536 USA; Dept Vet Affairs Med Ctr, Lexington, KY 40511 USA	University of Kentucky; University of Kentucky; US Department of Veterans Affairs; Veterans Health Administration (VHA); Lexington VA Medical Center	van der Westhuyzen, DR (corresponding author), Univ Kentucky, Grad Ctr Nutr Sci, Dept Internal Med, Wethington Hlth Sci Bldg 541,900 S Limestone St, Lexington, KY 40536 USA.	dvwest1@uky.edu	Eckhardt, Erik/G-1567-2010		NHLBI NIH HHS [HL-65730, HL-63763] Funding Source: Medline; NIA NIH HHS [AG-17237] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065730, R01HL063763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017237] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BANKA CL, 1995, J LIPID RES, V36, P1058; Baranova IN, 2005, J BIOL CHEM, V280, P8031, DOI 10.1074/jbc.M405009200; Cai L, 2005, J BIOL CHEM, V280, P2954, DOI 10.1074/jbc.M411555200; Chinetti G, 2000, CIRCULATION, V101, P2411, DOI 10.1161/01.CIR.101.20.2411; CLIFTON PM, 1985, J LIPID RES, V26, P1389; COETZEE GA, 1986, J BIOL CHEM, V261, P9644; Connelly MA, 2004, CURR OPIN LIPIDOL, V15, P287, DOI 10.1097/00041433-200406000-00008; DEBEER MC, 1993, J BIOL CHEM, V268, P20606; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Gu XJ, 2000, J BIOL CHEM, V275, P29993, DOI 10.1074/jbc.275.39.29993; Hayat S, 1997, BIOCHEM SOC T, V25, pS348, DOI 10.1042/bst025348s; Hirano K, 1999, CIRC RES, V85, P108; Hosoai H, 1999, J LIPID RES, V40, P648; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Kellner-Weibel G, 2000, BIOCHEMISTRY-US, V39, P221, DOI 10.1021/bi991666c; Kisilevsky R, 2003, J LIPID RES, V44, P2257, DOI 10.1194/jlr.M300133-JLR200; Kisilevsky R, 2002, PEDIATR PATHOL MOL M, V21, P291, DOI 10.1080/02770930290056523; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; LIANG JS, 1995, J LIPID RES, V36, P37; LY H, 1995, J LIPID RES, V36, P1254; MEEK RL, 1994, P NATL ACAD SCI USA, V91, P3186, DOI 10.1073/pnas.91.8.3186; MORROW JF, 1981, P NATL ACAD SCI-BIOL, V78, P4718, DOI 10.1073/pnas.78.8.4718; Nieland TJF, 2002, P NATL ACAD SCI USA, V99, P15422, DOI 10.1073/pnas.222421399; Rigotti A, 2003, ENDOCR REV, V24, P357, DOI 10.1210/er.2001-0037; Rothblat GH, 1999, J LIPID RES, V40, P781; SAMMALKORPI K, 1988, METABOLISM, V37, P859, DOI 10.1016/0026-0495(88)90120-5; Stonik JA, 2004, BIOCHEM BIOPH RES CO, V321, P936, DOI 10.1016/j.bbrc.2004.07.052; STRACHAN AF, 1988, BIOCHEM J, V250, P203, DOI 10.1042/bj2500203; Su SB, 1999, J EXP MED, V189, P395, DOI 10.1084/jem.189.2.395; Tam SP, 2002, J LIPID RES, V43, P1410, DOI 10.1194/jlr.M100388-JLR200; Tsukamoto K, 1997, J LIPID RES, V38, P1869; TURNELL W, 1986, MOL BIOL MED, V3, P387; Uhlar CM, 1999, EUR J BIOCHEM, V265, P501, DOI 10.1046/j.1432-1327.1999.00657.x; Urieli-Shoval S, 2000, CURR OPIN HEMATOL, V7, P64, DOI 10.1097/00062752-200001000-00012; Wang LM, 2004, BIOCHEM BIOPH RES CO, V317, P157, DOI 10.1016/j.bbrc.2004.03.027; Webb NR, 1997, J LIPID RES, V38, P1583; Webb NR, 1998, J BIOL CHEM, V273, P15241, DOI 10.1074/jbc.273.24.15241; Yancey PG, 2000, J BIOL CHEM, V275, P36596, DOI 10.1074/jbc.M006924200	38	110	113	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35890	35895		10.1074/jbc.M505685200	http://dx.doi.org/10.1074/jbc.M505685200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16120612	hybrid			2022-12-27	WOS:000232726900015
J	Van Kanegan, MJ; Adams, DG; Wadzinski, BE; Strack, S				Van Kanegan, MJ; Adams, DG; Wadzinski, BE; Strack, S			Distinct protein phosphatase 2A heterotrimers modulate growth factor signaling to extracellular signal-regulated kinases and Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; PHOSPHORYLATION STATUS; CORE ENZYME; B56 SUBUNIT; B-SUBUNITS; ACTIVATION; PP2A; BINDING; CELLS; DEPHOSPHORYLATION	A key regulator of many kinase cascades, heterotrimeric protein serine/threonine phosphatase 2A (PP2A), is composed of catalytic ( C), scaffold ( A), and variable regulatory subunits (B, B', B '' gene families). In neuronal PC12 cells, PP2A acts predominantly as a gatekeeper of extracellular signal-regulated kinase (ERK) activity, as shown by inducible RNA interference of the A alpha scaffolding subunit and PP2A inhibition by okadaic acid. Although okadaic acid potentiates Akt/protein kinase B and ERK phosphorylation in response to epidermal, basic fibroblast, or nerve growth factor, silencing of A alpha paradoxically has the opposite effect. Epidermal growth factor receptor Tyr phosphorylation was unchanged following A alpha knockdown, suggesting that chronic Akt and ERK hyperphosphorylation leads to compensatory down-regulation of signaling molecules upstream of Ras and blunted growth factor responses. Inducible exchange of wild-type A alpha with a mutant with selective B' subunit binding deficiency implicated PP2A/B' heterotrimers as Akt modulators. Conversely, silencing of the B-family regulatory subunits B alpha and B delta led to hyperactivation of ERK stimulated by constitutively active MEK1. In vitro dephosphorylation assays further support a role for B alpha and B delta in targeting the PP2A heterotrimer to dephosphorylate and inactivate ERKs. Thus, receptor tyrosine kinase signaling cascades leading to Akt and ERK activation are modulated by PP2A holoenzymes with distinct regulatory properties.	Univ Iowa, Carver Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	University of Iowa; Vanderbilt University	Strack, S (corresponding author), Univ Iowa, Carver Coll Med, Dept Pharmacol, 2-432 BSB,51 Newton Rd, Iowa City, IA 52242 USA.	stefan-strack@uiowa.edu		Strack, Stefan/0000-0002-6175-7280	NIDDK NIH HHS [5T32DK07563] Funding Source: Medline; NIGMS NIH HHS [GM62265, GM51366] Funding Source: Medline; NINDS NIH HHS [NS43254] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM051366, R01GM062265, R01GM051366] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043254] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Bennin DA, 2002, J BIOL CHEM, V277, P27449, DOI 10.1074/jbc.M111693200; Berry M, 2000, EMBO J, V19, P2946, DOI 10.1093/emboj/19.12.2946; Borgatti P, 2003, J CELL PHYSIOL, V196, P79, DOI 10.1002/jcp.10279; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Ceulemans H, 2004, PHYSIOL REV, V84, P1, DOI 10.1152/physrev.00013.2003; CHANDLER LP, 1985, J BIOL CHEM, V260, P3360; Dagda RK, 2005, J BIOL CHEM, V280, P27375, DOI 10.1074/jbc.M503693200; Dagda RK, 2003, J BIOL CHEM, V278, P24976, DOI 10.1074/jbc.M302832200; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; El-Shemerly MYM, 1997, J BIOL CHEM, V272, P30599, DOI 10.1074/jbc.272.49.30599; Fan GH, 2001, J BIOL CHEM, V276, P16960, DOI 10.1074/jbc.M009292200; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; Firulli BA, 2003, MOL CELL, V12, P1225, DOI 10.1016/S1097-2765(03)00425-8; Fukunaga K, 2000, J NEUROCHEM, V74, P807, DOI 10.1046/j.1471-4159.2000.740807.x; Gual P, 2001, ONCOGENE, V20, P156, DOI 10.1038/sj.onc.1204047; Hartley D, 2002, J CELL BIOCHEM, V85, P304, DOI 10.1002/jcb.10135; Hashigasako A, 2004, J BIOL CHEM, V279, P26445, DOI 10.1074/jbc.M314254200; Hatakeyama M, 2004, ONCOGENE, V23, P5023, DOI 10.1038/sj.onc.1207664; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; Honkanen RE, 2002, CURR MED CHEM, V9, P2055, DOI 10.2174/0929867023368836; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Hupfeld CJ, 2005, J BIOL CHEM, V280, P1016, DOI 10.1074/jbc.M403674200; Ito A, 2000, EMBO J, V19, P562, DOI 10.1093/emboj/19.4.562; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Janssens V, 2003, J BIOL CHEM, V278, P10697, DOI 10.1074/jbc.M211717200; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kao GT, 2004, DEVELOPMENT, V131, P755, DOI 10.1242/dev.00987; Keyse SM, 1999, FREE RADICAL RES, V31, P341, DOI 10.1080/10715769900300911; Kubicek M, 2002, J BIOL CHEM, V277, P7913, DOI 10.1074/jbc.M108733200; Li XH, 2002, EUR J BIOCHEM, V269, P546, DOI 10.1046/j.0014-2956.2001.02680.x; Li XH, 2002, MOL CELL BIOL, V22, P3674, DOI 10.1128/MCB.22.11.3674-3684.2002; Liu W, 2003, CELL DEATH DIFFER, V10, P772, DOI 10.1038/sj.cdd.4401238; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Moreno CS, 2000, J BIOL CHEM, V275, P5257, DOI 10.1074/jbc.275.8.5257; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Ory S, 2003, CURR BIOL, V13, P1356, DOI 10.1016/S0960-9822(03)00535-9; Ratcliffe MJ, 2000, J BIOL CHEM, V275, P35680, DOI 10.1074/jbc.C000639200; Resjo S, 2002, CELL SIGNAL, V14, P231, DOI 10.1016/S0898-6568(01)00238-8; Ruediger R, 1999, J VIROL, V73, P839, DOI 10.1128/JVI.73.1.839-842.1999; Ruvolo PP, 2002, J BIOL CHEM, V277, P22847, DOI 10.1074/jbc.M201830200; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Sieburth DS, 1999, GENE DEV, V13, P2562, DOI 10.1101/gad.13.19.2562; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; Spurney RF, 2001, J PHARMACOL EXP THER, V296, P592; Strack S, 2004, J BIOL CHEM, V279, P47732, DOI 10.1074/jbc.M408015200; Strack S, 2002, J BIOL CHEM, V277, P20750, DOI 10.1074/jbc.M202992200; Strack S, 2002, J BIOL CHEM, V277, P41525, DOI 10.1074/jbc.M203767200; Usui H, 1998, FEBS LETT, V430, P312, DOI 10.1016/S0014-5793(98)00684-X; Wassarman DA, 1996, GENE DEV, V10, P272, DOI 10.1101/gad.10.3.272; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; Westermarck J, 2001, MOL CELL BIOL, V21, P2373, DOI 10.1128/MCB.21.7.2373-2383.2001; Xu Z, 2000, MOL CELL BIOL, V20, P5285, DOI 10.1128/MCB.20.14.5285-5299.2000; Yamamoto H, 2001, J BIOL CHEM, V276, P26875, DOI 10.1074/jbc.M100443200; Yang J, 2003, DEVELOPMENT, V130, P5569, DOI 10.1242/dev.00762; Yu LG, 2004, J BIOL CHEM, V279, P41377, DOI 10.1074/jbc.M400017200; Zhou B, 2002, J BIOL CHEM, V277, P31818, DOI 10.1074/jbc.M203969200; Zhou B, 2002, J BIOL CHEM, V277, P13889, DOI 10.1074/jbc.M200377200	61	113	114	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36029	36036		10.1074/jbc.M506986200	http://dx.doi.org/10.1074/jbc.M506986200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16129692	hybrid			2022-12-27	WOS:000232726900032
J	Chuang, LC; Yew, PR				Chuang, LC; Yew, PR			Proliferating cell nuclear antigen recruits cyclin-dependent kinase inhibitor Xic1 to DNA and couples its proteolysis to DNA polymerase switching	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							XENOPUS EGG EXTRACTS; REPLICATION LICENSING SYSTEM; ORIGIN RECOGNITION COMPLEX; S-PHASE; CDK INHIBITOR; PROTEIN-KINASE; IN-VITRO; PCNA; DEGRADATION; INITIATION	The Xenopus cyclin- dependent kinase ( CDK) inhibitor, p27(Xic1) ( Xic1), binds to CDK2- cyclins and proliferating cell nuclear antigen ( PCNA), inhibits DNA synthesis in Xenopus extracts, and is targeted for ubiquitin- mediated proteolysis. Previous studies suggest that Xic1 ubiquitination and degradation are coupled to the initiation of DNA replication, but the precise timing and molecular mechanism of Xic1 proteolysis has not been determined. Here we demonstrate that Xic1 proteolysis is temporally restricted to late replication initiation following the requirements for DNA polymerase alpha- primase, replication factor C, and PCNA. Our studies also indicate that Xic1 degradation is absolutely dependent upon the binding of Xic1 to PCNA in both Xenopus egg and gastrulation stage extracts. Additionally, extracts depleted of PCNA do not support Xic1 proteolysis. Importantly, while the addition of recombinant wild- type PCNA alone restores Xic1 degradation, the addition of a PCNA mutant defective for trimer formation does not restore Xic1 proteolysis in PCNA- depleted extracts, suggesting Xic1 proteolysis requires both PCNA binding to Xic1 and the ability of PCNA to be loaded onto primed DNA by replication factor C. Taken together, our studies suggest that Xic1 is targeted for ubiquitination and degradation during DNA polymerase switching through its interaction with PCNA at a site of initiation.	Univ Texas, Hlth Sci Ctr, Dept Mol Med, Inst Biotechnol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio	Yew, PR (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Mol Med, Inst Biotechnol, San Antonio, TX 78245 USA.	yew@uthscsa.edu			NIGMS NIH HHS [1R01-GM066226] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066226] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Blow JJ, 2000, NATURE, V404, P560, DOI 10.1038/35007187; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; Bogan JA, 2000, J CELL PHYSIOL, V184, P139, DOI 10.1002/1097-4652(200008)184:2<139::AID-JCP1>3.0.CO;2-8; BUNZ F, 1993, P NATL ACAD SCI USA, V90, P11014, DOI 10.1073/pnas.90.23.11014; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; Cayrol C, 1998, ONCOGENE, V17, P2437, DOI 10.1038/sj.onc.1202189; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chen XY, 2004, MOL CELL, V16, P839, DOI 10.1016/j.molcel.2004.11.011; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Chuang LC, 2005, J BIOL CHEM, V280, P35290, DOI 10.1074/jbc.M506430200; Chuang LC, 2001, J BIOL CHEM, V276, P1610, DOI 10.1074/jbc.M008896200; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Coverley D, 2000, J CELL SCI, V113, P1929; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; Coverley D, 2002, NAT CELL BIOL, V4, P523, DOI 10.1038/ncb813; Daniels M, 2004, GENE, V342, P41, DOI 10.1016/j.gene.2004.07.038; DePamphilis ML, 2000, J STRUCT BIOL, V129, P186, DOI 10.1006/jsbi.2000.4219; Diffley JFX, 1998, CURR BIOL, V8, pR771, DOI 10.1016/S0960-9822(07)00483-6; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Fotedar A, 1996, J BIOL CHEM, V271, P31627, DOI 10.1074/jbc.271.49.31627; FUJITA M, 1999, FRONT BIOSCI, V4, P816; Furstenthal L, 2001, NAT CELL BIOL, V3, P715, DOI 10.1038/35087026; Furstenthal L, 2001, J CELL BIOL, V152, P1267, DOI 10.1083/jcb.152.6.1267; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Guo ZJ, 2000, MOL BIOL CELL, V11, P1535, DOI 10.1091/mbc.11.5.1535; Hardcastle Z, 2000, DEVELOPMENT, V127, P1303; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HOWE JA, 1995, GENE DEV, V9, P1164, DOI 10.1101/gad.9.10.1164; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; Ishimi Y, 2000, J BIOL CHEM, V275, P16235, DOI 10.1074/jbc.M909040199; JACKSON AL, 1993, MOL CELL BIOL, V13, P2899, DOI 10.1128/MCB.13.5.2899; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295; JONSSON ZO, 1995, EMBO J, V14, P5745, DOI 10.1002/j.1460-2075.1995.tb00261.x; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Koundrioukoff S, 2000, J BIOL CHEM, V275, P22882, DOI 10.1074/jbc.M001850200; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; Leatherwood J, 1998, CURR OPIN CELL BIOL, V10, P742, DOI 10.1016/S0955-0674(98)80117-8; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lei M, 2001, J CELL SCI, V114, P1447; Loor G, 1997, NUCLEIC ACIDS RES, V25, P5041, DOI 10.1093/nar/25.24.5041; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Maniatis T., 1982, MOL CLONING; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Mattock H, 2001, EXP CELL RES, V265, P242, DOI 10.1006/excr.2001.5181; Michael WM, 2000, SCIENCE, V289, P2133, DOI 10.1126/science.289.5487.2133; Mihaylov IS, 2002, MOL CELL BIOL, V22, P1868, DOI 10.1128/MCB.22.6.1868-1880.2002; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Newlon CS, 1997, CELL, V91, P717, DOI 10.1016/S0092-8674(00)80459-6; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Ohnuma S, 1999, CELL, V99, P499, DOI 10.1016/S0092-8674(00)81538-X; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; Roberts JM, 1999, CELL, V98, P129, DOI 10.1016/S0092-8674(00)81007-7; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Romanowski P, 1996, P NATL ACAD SCI USA, V93, P10189, DOI 10.1073/pnas.93.19.10189; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Sambrook J., 1989, MOL CLONING, pA1; Sclafani R A, 1998, Trends Genet, V14, P441, DOI 10.1016/S0168-9525(98)01610-2; Sexl V, 1999, ONCOGENE, V18, P573, DOI 10.1038/sj.onc.1202362; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; Shou WY, 1996, MOL BIOL CELL, V7, P457, DOI 10.1091/mbc.7.3.457; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; SU JY, 1995, P NATL ACAD SCI USA, V92, P10187, DOI 10.1073/pnas.92.22.10187; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Swanson C, 2000, P NATL ACAD SCI USA, V97, P7796, DOI 10.1073/pnas.97.14.7796; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; TANAKA S, 1982, J BIOL CHEM, V257, P8386; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vernon AE, 2003, DEVELOPMENT, V130, P71, DOI 10.1242/dev.00180; Vernon AE, 2003, DEVELOPMENT, V130, P85, DOI 10.1242/dev.00193; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0; Walter JC, 2000, J BIOL CHEM, V275, P39773, DOI 10.1074/jbc.M008107200; Watanabe H, 1998, P NATL ACAD SCI USA, V95, P1392, DOI 10.1073/pnas.95.4.1392; Wohlschlegel JA, 2002, MOL CELL, V9, P233, DOI 10.1016/S1097-2765(02)00456-2; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yam CH, 1999, MOL CELL BIOL, V19, P635; Yew PR, 1997, SCIENCE, V277, P1672, DOI 10.1126/science.277.5332.1672; Yew PR, 2001, J CELL PHYSIOL, V187, P1, DOI 10.1002/1097-4652(2001)9999:9999<1::AID-JCP1049>3.0.CO;2-O; You ZS, 2002, GENE DEV, V16, P1182, DOI 10.1101/gad.985302; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zheleva DI, 2000, BIOCHEMISTRY-US, V39, P7388, DOI 10.1021/bi992498r	116	26	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35299	35309		10.1074/jbc.M506429200	http://dx.doi.org/10.1074/jbc.M506429200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16118211	hybrid			2022-12-27	WOS:000232561200028
J	de Keyzer, J; van der Sluis, EO; Spelbrink, REJ; Nijstad, N; de Kruijff, B; Nouwen, N; van der Does, C; Driessen, AJM				de Keyzer, J; van der Sluis, EO; Spelbrink, REJ; Nijstad, N; de Kruijff, B; Nouwen, N; van der Does, C; Driessen, AJM			Covalently dimerized SecA is functional in protein translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI MEMBRANE-VESICLES; ESCHERICHIA-COLI; SIGNAL SEQUENCE; PREPROTEIN TRANSLOCASE; ESSENTIAL COMPONENT; TERMINAL REGION; ATPASE SECA; BINDING; SECYEG; DISSOCIATION	The ATPase SecA provides the driving force for the transport of secretory proteins across the cytoplasmic membrane of Escherichia coli. SecA exists as a dimer in solution, but the exact oligomeric state of SecA during membrane binding and preprotein translocation is a topic of debate. To study the requirements of oligomeric changes in SecA during protein translocation, a non-dissociable SecA dimer was formed by oxidation of the carboxyl-terminal cysteines. The cross-linked SecA dimer interacts with the SecYEG complex with a similar stoichiometry as non-cross-linked SecA. Cross-linking reversibly disrupts the SecB binding site on SecA. However, in the absence of SecB, the activity of the disulfide-bonded SecA dimer is indistinguishable from wild-type SecA. Moreover, SecYEG binding stabilizes a cold sodium dodecylsulfate-resistant dimeric state of SecA. The results demonstrate that dissociation of the SecA dimer is not an essential feature of the protein translocation reaction.	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Mol Microbiol, NL-9751 NN Haren, Netherlands; Univ Groningen, Mat & Sci Ctr Plus, NL-9751 NN Haren, Netherlands; Univ Utrecht, Dept Biochem & Membranes, Inst Biomembranes, NL-3584 CH Utrecht, Netherlands; Univ Utrecht, Bijvoet Ctr Biomol Res, NL-3584 CH Utrecht, Netherlands; Goethe Univ Frankfurt, Biozentrum Frankfurt, Inst Biochem, D-60439 Frankfurt, Germany	University of Groningen; University of Groningen; Utrecht University; Utrecht University; Goethe University Frankfurt	Driessen, AJM (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Mol Microbiol, Kerklaan 30, NL-9751 NN Haren, Netherlands.	a.j.m.driessen@rug.nl	Driessen, Arnold J.M./D-1876-2012	Driessen, Arnold J.M./0000-0001-9258-9104				AKITA M, 1991, BIOCHEM BIOPH RES CO, V174, P211, DOI 10.1016/0006-291X(91)90507-4; Benach J, 2003, J BIOL CHEM, V278, P3628, DOI 10.1074/jbc.M205992200; BREUKINK E, 1995, J BIOL CHEM, V270, P7902, DOI 10.1074/jbc.270.14.7902; Bu ZM, 2003, J MOL BIOL, V332, P23, DOI 10.1016/S0022-2836(03)00840-4; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; de Keyzer J, 2003, J BIOL CHEM, V278, P29581, DOI 10.1074/jbc.M303490200; de Keyzer J, 2002, J BIOL CHEM, V277, P46059, DOI 10.1074/jbc.M208449200; de Keyzer J, 2002, FEBS LETT, V510, P17, DOI 10.1016/S0014-5793(01)03213-6; DRIESSEN AJM, 1993, BIOCHEMISTRY-US, V32, P13190, DOI 10.1021/bi00211a030; Duong F, 2003, EMBO J, V22, P4375, DOI 10.1093/emboj/cdg418; Fekkes P, 1999, BIOCHEMISTRY-US, V38, P5111, DOI 10.1021/bi982818r; Fekkes P, 1998, MOL MICROBIOL, V29, P1179, DOI 10.1046/j.1365-2958.1998.00997.x; Fekkes P, 1997, EMBO J, V16, P6105, DOI 10.1093/emboj/16.20.6105; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; Hunt JF, 2002, SCIENCE, V297, P2018, DOI 10.1126/science.1074424; Jilaveanu LB, 2005, P NATL ACAD SCI USA, V102, P7511, DOI 10.1073/pnas.0502774102; Karamanou S, 2005, FEBS LETT, V579, P1267, DOI 10.1016/j.febslet.2005.01.025; Kaufmann A, 1999, BIOCHEMISTRY-US, V38, P9115, DOI 10.1021/bi990539d; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MATSUYAMA S, 1990, J BIOL CHEM, V265, P8760; Or E, 2005, J BIOL CHEM, V280, P9097, DOI 10.1074/jbc.M413947200; Or E, 2002, EMBO J, V21, P4470, DOI 10.1093/emboj/cdf471; Osborne AR, 2004, P NATL ACAD SCI USA, V101, P10937, DOI 10.1073/pnas.0401742101; RAJAPANDI T, 1994, BIOCHEM BIOPH RES CO, V200, P1477, DOI 10.1006/bbrc.1994.1617; Randall LL, 2005, J MOL BIOL, V348, P479, DOI 10.1016/j.jmb.2005.02.036; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; Spelbrink REJ, 2005, J BIOL CHEM, V280, P28742, DOI 10.1074/jbc.M501617200; Tziatzios C, 2004, J MOL BIOL, V340, P513, DOI 10.1016/j.jmb.2004.04.076; van der Does C, 2003, METHOD ENZYMOL, V372, P86; van der Wolk JPW, 1998, EMBO J, V17, P3631, DOI 10.1093/emboj/17.13.3631; Veenendaal AKJ, 2004, BBA-MOL CELL RES, V1694, P81, DOI 10.1016/j.bbamcr.2004.02.009; Woodbury RL, 2002, PROTEIN SCI, V11, P875, DOI 10.1110/ps.4090102; Zhou JH, 2003, NAT STRUCT BIOL, V10, P942, DOI 10.1038/nsb980	33	71	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35255	35260		10.1074/jbc.M506157200	http://dx.doi.org/10.1074/jbc.M506157200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16115882	hybrid, Green Published			2022-12-27	WOS:000232561200023
J	Pirok, EW; Domowicz, MS; Henry, J; Wang, YL; Santore, M; Mueller, MM; Schwartz, NB				Pirok, EW; Domowicz, MS; Henry, J; Wang, YL; Santore, M; Mueller, MM; Schwartz, NB			APBP-1, a DNA/RNA-binding protein, interacts with the chick aggrecan regulatory region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2(I) COLLAGEN GENE; TRANSCRIPTION FACTOR; TRANSLATIONAL REGULATION; RNA; RICH; PROTEOGLYCAN; CHONDROCYTES; RECOGNITION; EXPRESSION; PROMOTER	Expression of the extracellular proteoglycan aggrecan is both cell-specific and developmentally regulated. Previous studies identified six functionally defined cis elements in the aggrecan promoter region which were shown to repress aggrecan gene expression (1). Using competition electrophoretic mobility shift assays (EMSAs) we have now identified in nuclear extracts a functional repressor cis element, (T/C)TCCCCT(A/C)RRC, which occurs at multiple locations within the chick aggrecan regulatory region. We purified the factor that binds to this cis element and established that it, APBP-1 (aggrecan promoter-binding protein-1), is a 19-kDa protein that has significant homology to CIRP (cold inducible RNA-binding protein). Recombinantly expressed APBP-1 mimics the native cis element-trans factor interaction in EMSAs. In situ hybridization demonstrates that aggrecan and APBP-1 RNA expression are restricted to complementary tissues in the developing limb, and Northern blot analysis of chick limb bud mRNA shows that APBP-1 mRNA expression is inversely correlated with aggrecan mRNA expression. Functional analyses by transient transfections and Northern blot analyses suggest APBP-1 has the capacity to repress aggrecan expression, indicating that this factor may be important regulator of aggrecan gene expression.	Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	Schwartz, NB (corresponding author), Univ Chicago, Dept Pediat, 5841 S Maryland Ave,MC 5058, Chicago, IL 60637 USA.	n-schwartz@uchicago.edu	Domowicz, Miriam/AFL-7930-2022; Domowicz, Miriam/AAG-7886-2022	Domowicz, Miriam/0000-0001-7860-4427; Domowicz, Miriam/0000-0001-7860-4427	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD017332, P01HD009402] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-07237] Funding Source: Medline; NICHD NIH HHS [HD-09402, HD-17332, HD-007009] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aoki K, 2002, NUCLEIC ACIDS RES, V30, P5182, DOI 10.1093/nar/gkf638; Auboeuf D, 2004, MOL CELL BIOL, V24, P442, DOI 10.1128/MCB.24.1.442-453.2004; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CLEMENS KR, 1993, SCIENCE, V260, P530, DOI 10.1126/science.8475383; Day JM, 2004, J BIOL CHEM, V279, P12511, DOI 10.1074/jbc.M400242200; Deyrup AT, 1998, J BIOL CHEM, V273, P9450, DOI 10.1074/jbc.273.16.9450; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; Ghayor C, 2001, J BIOL CHEM, V276, P36881, DOI 10.1074/jbc.M105083200; Grove EA, 1998, DEVELOPMENT, V125, P2315; Ihn H, 1996, J BIOL CHEM, V271, P26717, DOI 10.1074/jbc.271.43.26717; Ihn H, 1997, J BIOL CHEM, V272, P24666, DOI 10.1074/jbc.272.39.24666; Maruyama K, 1999, NUCLEIC ACIDS RES, V27, P2029, DOI 10.1093/nar/27.9.2029; Mayfield S, 1996, CHEM BIOL, V3, P415, DOI 10.1016/S1074-5521(96)90088-5; MCBRYANT SJ, 1995, J MOL BIOL, V248, P44, DOI 10.1006/jmbi.1995.0201; Murray D, 2000, J BIOL CHEM, V275, P3610, DOI 10.1074/jbc.275.5.3610; Nishiyama H, 1997, GENE, V204, P115, DOI 10.1016/S0378-1119(97)00530-1; Nishiyama H, 1997, J CELL BIOL, V137, P899, DOI 10.1083/jcb.137.4.899; Pirok EW, 1997, J BIOL CHEM, V272, P11566, DOI 10.1074/jbc.272.17.11566; Pirok EW, 2001, J BIOL CHEM, V276, P16894, DOI 10.1074/jbc.M009944200; Saito T, 2000, COMP BIOCHEM PHYS B, V125, P237, DOI 10.1016/S0305-0491(99)00174-1; SCHWARTZ NB, 1993, PROG CLIN BIOL RES, V383, P505; Tanaka KJ, 2000, DEV GENES EVOL, V210, P464, DOI 10.1007/s004270000080; Xue JH, 1999, FREE RADICAL BIO MED, V27, P1238, DOI 10.1016/S0891-5849(99)00158-6	24	3	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35606	35616		10.1074/jbc.M505380200	http://dx.doi.org/10.1074/jbc.M505380200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16100116	hybrid			2022-12-27	WOS:000232561200063
J	Cape, JL; Strahan, JR; Lenaeus, MJ; Yuknis, BA; Le, TT; Shepherd, JN; Bowman, MK; Kramer, DM				Cape, JL; Strahan, JR; Lenaeus, MJ; Yuknis, BA; Le, TT; Shepherd, JN; Bowman, MK; Kramer, DM			The respiratory substrate rhodoquinol induces Q-cycle bypass reactions in the yeast cytochrome bc(1) complex - Mechanistic and physiological implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSPORT CHAIN; IRON-SULFUR PROTEIN; ANAEROBICALLY FUNCTIONING EUKARYOTES; FUMARATE REDUCTASE-ACTIVITY; THERMOPHILIC BACTERIUM PS3; LUMBRICOIDES VAR SUIS; Q(O) SITE; UBIQUINOL OXIDATION; RHODOBACTER-SPHAEROIDES; RHODOSPIRILLUM-RUBRUM	The mitochondrial cytochrome bc(1) complex catalyzes the transfer of electrons from ubiquinol to cyt c while generating a proton motive force for ATP synthesis via the "Q-cycle" mechanism. Under certain conditions electron flow through the Q-cycle is blocked at the level of a reactive intermediate in the quinol oxidase site of the enzyme, resulting in "bypass reactions," some of which lead to superoxide production. Using analogs of the respiratory substrates ubiquinol-3 and rhodoquinol-3, we show that the relative rates of Q-cycle bypass reactions in the Saccharomyces cerevisiae cyt bc1 complex are highly dependent by a factor of up to 100-fold on the properties of the substrate quinol. Our results suggest that the rate of Q-cycle bypass reactions is dependent on the steady state concentration of reactive intermediates produced at the quinol oxidase site of the enzyme. We conclude that normal operation of the Q-cycle requires a fairly narrow window of redox potentials with respect to the quinol substrate to allow normal turnover of the complex while preventing potentially damaging bypass reactions.	Gonzaga Univ, Dept Chem, Spokane, WA 99258 USA; Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA; Battelle NW Lab, Struct Biol & Microimaging, Richland, WA 99352 USA	Gonzaga University; Washington State University; United States Department of Energy (DOE); Pacific Northwest National Laboratory	Shepherd, JN (corresponding author), Gonzaga Univ, Dept Chem, 502 E Boone Ave, Spokane, WA 99258 USA.	shepherd@gonzaga.edu	Bowman, Michael/F-4265-2011; Kramer, David/B-9588-2016	Bowman, Michael/0000-0003-3464-9409; Kramer, David/0000-0003-2181-6888	NIGMS NIH HHS [GM61904] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061904] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN PC, 1973, EXP PARASITOL, V34, P211, DOI 10.1016/0014-4894(73)90080-5; BAUSCHER M, 1992, J PHYS CHEM-US, V96, P11101, DOI 10.1021/j100205a087; BEACH DH, 1980, MOL BIOCHEM PARASIT, V1, P269, DOI 10.1016/0166-6851(80)90060-2; BEROZA P, 1995, BIOPHYS J, V68, P2233, DOI 10.1016/S0006-3495(95)80406-6; Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; Brasseur G, 2004, J BIOL CHEM, V279, P24203, DOI 10.1074/jbc.M311576200; Brasseur G, 2002, BBA-BIOENERGETICS, V1555, P37, DOI 10.1016/S0005-2728(02)00251-7; Brasseur G, 2001, BBA-BIOENERGETICS, V1506, P89, DOI 10.1016/S0005-2728(01)00186-4; Cape JL, 2005, J AM CHEM SOC, V127, P4208, DOI 10.1021/ja043955g; Covian R, 2004, J BIOL CHEM, V279, P15040, DOI 10.1074/jbc.M400193200; Crofts AR, 2004, BBA-BIOENERGETICS, V1655, P77, DOI 10.1016/j.bbabio.2003.10.012; Crofts AR, 2004, ANNU REV PHYSIOL, V66, P689, DOI 10.1146/annurev.physiol.66.032102.150251; Crofts AR, 2003, J BIOL CHEM, V278, P36191, DOI 10.1074/jbc.M305461200; Crofts AR, 2002, BBA-BIOENERGETICS, V1555, P48, DOI 10.1016/S0005-2728(02)00253-0; CROFTS AR, 1989, PHOTOSYNTH RES, V22, P69, DOI 10.1007/BF00114768; Crofts AR, 2000, BBA-BIOENERGETICS, V1459, P456, DOI 10.1016/S0005-2728(00)00184-5; ERABI T, 1975, J BIOCHEM-TOKYO, V78, P795, DOI 10.1093/oxfordjournals.jbchem.a130968; FIORAVANTI CF, 1988, MOL BIOCHEM PARASIT, V28, P129, DOI 10.1016/0166-6851(88)90060-6; Fisher N, 2001, EUR J BIOCHEM, V268, P1155, DOI 10.1046/j.1432-1327.2001.02010.x; FORQUER I, 2005, PHOTOSYNTHESIS FUNDA, V1, P430; GIBSON F, 1973, Biochemical Society Transactions, V1, P317; GIMENEZGALLEGO G, 1982, EUR J BIOCHEM, V121, P343, DOI 10.1111/j.1432-1033.1982.tb05792.x; GLERUM DM, 1995, J BIOL CHEM, V270, P15585, DOI 10.1074/jbc.270.26.15585; Gong X, 2005, J BIOL CHEM, V280, P9251, DOI 10.1074/jbc.M409994200; GU LQ, 1990, BIOCHIM BIOPHYS ACTA, V1015, P482, DOI 10.1016/0005-2728(90)90082-F; GU LQ, 1989, J BIOL CHEM, V264, P4506; Gutierrez-Cirlos EB, 2002, J BIOL CHEM, V277, P1195, DOI 10.1074/jbc.M109097200; HENDLER RW, 1985, J BIOENERG BIOMEMBR, V17, P51, DOI 10.1007/BF00744988; Hoffmeister M, 2004, J BIOL CHEM, V279, P22422, DOI 10.1074/jbc.M400913200; Hong SJ, 1999, J BIOL CHEM, V274, P33931, DOI 10.1074/jbc.274.48.33931; KANTILAL PB, 1973, J CHEM SOC F1, P814; KITA K, 1988, BIOCHIM BIOPHYS ACTA, V935, P130, DOI 10.1016/0005-2728(88)90210-1; Knox PP, 2004, BIOCHEMISTRY-MOSCOW+, V69, P890, DOI 10.1023/B:BIRY.0000040221.43531.00; Kolling DRJ, 2003, J BIOL CHEM, V278, P39747, DOI 10.1074/jbc.M305913200; Kramer D, 2004, METHOD ENZYMOL, V382, P21; Kramer DM, 1997, BIOCHEMISTRY-US, V36, P4203, DOI 10.1021/bi962241i; Kramer DM, 2005, PHOTOSYNTHESIS FUNDA, P424; KUTOH E, 1988, J BIOL CHEM, V263, P9020; Link TA, 1997, FEBS LETT, V412, P257, DOI 10.1016/S0014-5793(97)00772-2; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; Lundbaek JA, 2003, BIOPHYS J, V84, P2080, DOI 10.1016/S0006-3495(03)75015-2; Marbois B, 2005, J BIOL CHEM, V280, P20231, DOI 10.1074/jbc.M501315200; Miyadera H, 2003, EUR J BIOCHEM, V270, P1863, DOI 10.1046/j.1432-1033.2003.03553.x; MOORE HW, 1965, J AM CHEM SOC, V87, P1409, DOI 10.1021/ja01084a065; MOORE HW, 1966, J AM CHEM SOC, V88, P567, DOI 10.1021/ja00955a032; Muller F, 2002, BIOCHEMISTRY-US, V41, P7866, DOI 10.1021/bi025581e; Muller F, 2000, J AM AGING ASSOC, V23, P227, DOI 10.1007/s11357-000-0022-9; Muller FL, 2003, BIOCHEMISTRY-US, V42, P6493, DOI 10.1021/bi0342160; NAGARAJAN S, 1987, J ORG CHEM, V52, P5044, DOI 10.1021/jo00231a044; NARUTA Y, 1980, J ORG CHEM, V45, P4097, DOI 10.1021/jo01309a006; OHNISHI T, 1980, J BIOL CHEM, V255, P3278; OKAYAMA S, 1968, J BIOL CHEM, V243, P2995; OLSON RE, 1983, VITAM HORM, V40, P1, DOI 10.1016/S0083-6729(08)60431-8; Osyczka A, 2005, TRENDS BIOCHEM SCI, V30, P176, DOI 10.1016/j.tibs.2005.02.001; Osyczka A, 2004, NATURE, V427, P607, DOI 10.1038/nature02242; OZAWA H, 1969, EXPERIENTIA, V25, P484, DOI 10.1007/BF01900769; Palsdottir H, 2003, J BIOL CHEM, V278, P31303, DOI 10.1074/jbc.M302195200; Poon WW, 1999, J BIOL CHEM, V274, P21665, DOI 10.1074/jbc.274.31.21665; Roginsky VA, 1999, J CHEM SOC PERK T 2, P871, DOI 10.1039/a807650b; Sakamoto K, 2002, J PESTIC SCI, V27, P147; SATO M, 1969, J BIOCHEM-TOKYO, V65, P861, DOI 10.1093/oxfordjournals.jbchem.a129090; Shim YB, 1997, J ELECTROANAL CHEM, V425, P201, DOI 10.1016/S0022-0728(96)04956-X; Shinkarev VP, 2001, BIOCHEMISTRY-US, V40, P12584, DOI 10.1021/bi011334j; Snyder CH, 1999, J BIOL CHEM, V274, P31209, DOI 10.1074/jbc.274.44.31209; Snyder CH, 2000, J BIOL CHEM, V275, P13535, DOI 10.1074/jbc.275.18.13535; SONE N, 1987, J BIOL CHEM, V262, P15386; Sun H, 2003, ARCH BIOCHEM BIOPHYS, V419, P198, DOI 10.1016/j.abb.2003.08.028; TAKAHASHI E, 1992, BIOCHEMISTRY-US, V31, P855, DOI 10.1021/bi00118a031; Takamiya S, 1999, ARCH BIOCHEM BIOPHYS, V371, P284, DOI 10.1006/abbi.1999.1465; Tielens AGM, 1998, BBA-BIOENERGETICS, V1365, P71, DOI 10.1016/S0005-2728(98)00045-0; TRUMPOWER BL, 1981, J BIOENERG BIOMEMBR, V13, P1, DOI 10.1007/BF00744743; Trumpower BL, 2002, BBA-BIOENERGETICS, V1555, P166, DOI 10.1016/S0005-2728(02)00273-6; van Hellemond JJ, 2003, PHILOS T ROY SOC B, V358, P205, DOI 10.1098/rstb.2002.1182; VanHellemond JJ, 1995, J BIOL CHEM, V270, P31065, DOI 10.1074/jbc.270.52.31065; VanHellemond JJ, 1996, MOL BIOCHEM PARASIT, V82, P217, DOI 10.1016/0166-6851(96)02738-7; VAULTIER M, 1983, TETRAHEDRON LETT, V24, P763, DOI 10.1016/S0040-4039(00)81520-8; Wang TY, 2000, BIOPHYS J, V79, P1478, DOI 10.1016/S0006-3495(00)76399-5; Yamashita T, 2004, BBA-BIOENERGETICS, V1608, P97, DOI 10.1016/j.bbabio.2003.10.006; Zhang L, 2002, BBA-BIOENERGETICS, V1556, P226, DOI 10.1016/S0005-2728(02)00368-7; Zhang L, 1998, J BIOL CHEM, V273, P33972, DOI 10.1074/jbc.273.51.33972	80	22	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34654	34660		10.1074/jbc.M507616200	http://dx.doi.org/10.1074/jbc.M507616200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16087663	hybrid			2022-12-27	WOS:000232403900034
J	Nordahl, EA; Rydengard, V; Morgelin, M; Schmidtchen, A				Nordahl, EA; Rydengard, V; Morgelin, M; Schmidtchen, A			Domain 5 of high molecular weight kininogen is antibacterial	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIMICROBIAL PEPTIDE LL-37; VASCULAR-PERMEABILITY ENHANCEMENT; INHIBITS ANGIOGENESIS; NEUTROPHIL ELASTASE; CYSTEINE PROTEINASE; ENDOTHELIAL-CELLS; INNATE IMMUNITY; LIGHT-CHAIN; ACTIVATION; BINDING	Antimicrobial peptides are important effectors of the innate immune system. These peptides belong to a multifunctional group of molecules that apart from their antibacterial activities also interact with mammalian cells and glycosaminoglycans and control chemotaxis, apoptosis, and angiogenesis. Here we demonstrate a novel antimicrobial activity of the heparin-binding and cell-binding domain 5 of high molecular weight kininogen. Antimicrobial epitopes of domain 5 were characterized by analysis of overlapping peptides. A peptide, HKH20 (His(479) - His(498)), efficiently killed the Gram-negative bacteria Escherichia coli and Pseudomonas aeruginosa and the Gram-positive Enterococcus faecalis. Fluorescence microscopy and electron microscopy demonstrated that HKH20 binds to and induces breaks in bacterial membranes. Furthermore, no discernible hemolysis or membrane-permeabilizing effects on eukaryotic cells were noted. Proteolytic degradation of high molecular weight kininogen by neutrophil-derived proteases as well as the metalloproteinase elastase from P. aeruginosa yielded fragments comprising HKH20 epitopes, indicating that kininogen-derived antibacterial peptides are released during proteolysis.	Lund Univ, Biomed Ctr, Dept Clin Sci, Sect Dermatol & Venereol, SE-22184 Lund, Sweden; Lund Univ, Biomed Ctr, Dept Clin Sci, Sect Clin & Expt Infect Med, SE-22184 Lund, Sweden	Lund University; Lund University	Nordahl, EA (corresponding author), Biomed Ctr B14, Dept Clin Sci, Tornavagen 10, SE-22184 Lund, Sweden.	emma.nordahl@med.lu.se	Schmidtchen, Artur/F-9507-2015					Agerberth B, 2000, BLOOD, V96, P3086, DOI 10.1182/blood.V96.9.3086.h8003086_3086_3093; Andersson E, 2004, EUR J BIOCHEM, V271, P1219, DOI 10.1111/j.1432-1033.2004.04035.x; Blondelle SE, 2000, BIOPOLYMERS, V55, P74, DOI 10.1002/1097-0282(2000)55:1&lt;74::AID-BIP70&gt;3.0.CO;2-S; Brogden KA, 2005, NAT IMMUNOL, V6, P558, DOI 10.1038/ni1209; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Ciornei CD, 2003, ACTA ANAESTH SCAND, V47, P213, DOI 10.1034/j.1399-6576.2003.00045.x; Cole AM, 2001, J IMMUNOL, V167, P623, DOI 10.4049/jimmunol.167.2.623; Colman RW, 1997, J CLIN INVEST, V100, P1481, DOI 10.1172/JCI119669; Colman RW, 1997, BLOOD, V90, P3819, DOI 10.1182/blood.V90.10.3819; Colman RW, 2000, BLOOD, V95, P543, DOI 10.1182/blood.V95.2.543; de Kreij A, 2000, J BIOL CHEM, V275, P31115, DOI 10.1074/jbc.M003889200; DELACADENA RA, 1992, PROTEIN SCI, V1, P151; Elsbach P, 2003, J CLIN INVEST, V111, P1643, DOI 10.1172/JCI200318761; Ganz T, 2001, Semin Respir Infect, V16, P4; Goumon Y, 1998, J BIOL CHEM, V273, P29847, DOI 10.1074/jbc.273.45.29847; HABAZETTL J, 1992, NATURE, V359, P855, DOI 10.1038/359855a0; HASAN AAK, 1995, J BIOL CHEM, V270, P19256, DOI 10.1074/jbc.270.33.19256; Herwald H, 1996, J EXP MED, V184, P665, DOI 10.1084/jem.184.2.665; Herwald H, 1996, J BIOL CHEM, V271, P13040, DOI 10.1074/jbc.271.22.13040; Herwald H, 2001, EUR J BIOCHEM, V268, P396, DOI 10.1046/j.1432-1327.2001.01888.x; Imamura T, 2004, BIOL CHEM, V385, P989, DOI 10.1515/BC.2004.129; IMAMURA T, 1994, J CLIN INVEST, V94, P361, DOI 10.1172/JCI117330; Imamura T, 1996, LAB INVEST, V74, P861; Imamura T, 2002, BIOCHEM BIOPH RES CO, V294, P423, DOI 10.1016/S0006-291X(02)00490-4; Jacobson MP, 2004, PROTEINS, V55, P351, DOI 10.1002/prot.10613; Kaplan AP, 2002, J ALLERGY CLIN IMMUN, V109, P195, DOI 10.1067/mai.2002.121316; Koczulla R, 2003, J CLIN INVEST, V111, P1665, DOI 10.1172/JCI200317545; Kowalska K, 2002, LIFE SCI, V71, P747, DOI 10.1016/S0024-3205(02)01740-X; Kozik A, 1998, J BIOL CHEM, V273, P33224, DOI 10.1074/jbc.273.50.33224; LEHRER RI, 1991, J IMMUNOL METHODS, V137, P167, DOI 10.1016/0022-1759(91)90021-7; Li J, 2000, NAT MED, V6, P49, DOI 10.1038/71527; MOR A, 1994, BIOCHEMISTRY-US, V33, P6642, DOI 10.1021/bi00187a034; Murakami M, 2004, J IMMUNOL, V172, P3070, DOI 10.4049/jimmunol.172.5.3070; Nordahl EA, 2004, P NATL ACAD SCI USA, V101, P16879, DOI 10.1073/pnas.0406678101; OHKUBO I, 1984, BIOCHEMISTRY-US, V23, P5691, DOI 10.1021/bi00319a005; Okumura K, 2004, CANCER LETT, V212, P185, DOI 10.1016/j.canlet.2004.04.006; Oren Z, 1999, BIOCHEM J, V341, P501, DOI 10.1042/0264-6021:3410501; Park PW, 2001, NATURE, V411, P98, DOI 10.1038/35075100; Pixley RA, 2003, J THROMB HAEMOST, V1, P1791, DOI 10.1046/j.1538-7836.2003.00291.x; Rozalski A, 1997, MICROBIOL MOL BIOL R, V61, P65; SCHMAIER AH, 1983, J CLIN INVEST, V71, P1477, DOI 10.1172/JCI110901; Schmidtchen A, 2002, MOL MICROBIOL, V46, P157, DOI 10.1046/j.1365-2958.2002.03146.x; Shimizu M, 1998, ANTIMICROB AGENTS CH, V42, P2745, DOI 10.1128/AAC.42.10.2745; Sieprawska-Lupa M, 2004, ANTIMICROB AGENTS CH, V48, P4673, DOI 10.1128/AAC.48.12.4673-4679.2004; STEINER H, 1981, NATURE, V292, P246, DOI 10.1038/292246a0; TERRITO MC, 1989, J CLIN INVEST, V84, P2017, DOI 10.1172/JCI114394; Tossi A, 2000, BIOPOLYMERS, V55, P4; Vouldoukis I, 1996, FEBS LETT, V380, P237, DOI 10.1016/0014-5793(96)00050-6; WACHTFOGEL YT, 1994, J BIOL CHEM, V269, P19307; Yang D, 2000, J EXP MED, V192, P1069, DOI 10.1084/jem.192.7.1069; Yoo YC, 1997, BIOCHEM BIOPH RES CO, V237, P624, DOI 10.1006/bbrc.1997.7199; Zanetti M, 2004, J LEUKOCYTE BIOL, V75, P39, DOI 10.1189/jlb.0403147; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449; ZEYA HI, 1963, SCIENCE, V142, P1085, DOI 10.1126/science.142.3595.1085; Zhang JC, 2000, FASEB J, V14, P2589, DOI 10.1096/fj.99-1025com	55	88	99	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34832	34839		10.1074/jbc.M507249200	http://dx.doi.org/10.1074/jbc.M507249200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16091369	Green Submitted, hybrid			2022-12-27	WOS:000232403900055
J	Zhang, XH; Shirahatti, NV; Mahadevan, D; Wright, SH				Zhang, XH; Shirahatti, NV; Mahadevan, D; Wright, SH			A conserved glutamate residue in transmembrane helix 10 influences substrate specificity of rabbit OCT2 (SLC22A2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGANIC CATION TRANSPORTERS; FUNCTIONAL EXPRESSION; ANION TRANSPORTER; AMINO-ACIDS; 3-DIMENSIONAL STRUCTURE; GLUCOSE-TRANSPORTER; RENAL SECRETION; BINDING; CLONING; MECHANISM	OCT1 and OCT2 are involved in renal secretion of cationic drugs. Although they have similar selectivity for some substrates ( e. g. tetraethylammonium ( TEA)), they have distinct selectivities for others ( e. g. cimetidine). We postulated that "homolog-specific residues," i.e. the 24 residues that are conserved in OCT1 orthologs as one amino acid and in OCT2 as a different one, influence homolog-specific selectivity and examined the influence on substrate binding of three of these conserved residues that are found in the C-terminal half of the rabbit orthologs of OCT1/2. The N353L and R403I substitutions ( OCT2 to OCT1) did not significantly change the properties of OCT2. However, the E447Q replacement shifted substrate selectivity toward an OCT1-like phenotype. Substitution of glutamate with cationic amino acids (E447K and E447R) abolished transport activity, and the E447L mutant displayed markedly reduced transport of TEA and cimetidine while retaining transport of 1-methyl-4-phenylpyridinium. In a novel homology model of the three-dimensional structure of OCT2, Glu(447) was found in a putative docking region within a hydrophilic cleft of the protein. In addition, six residues identified in separate studies as exerting significant effects on OCT binding were also found within the putative cleft region. There was a significant correlation (r(2) = 0.82) between the IC50 values for inhibition of TEA transport by 14 different compounds and their calculated K-D values for binding to the model of rabbit OCT2. The results suggest that homology modeling offers an opportunity to direct future site-directed studies of OCT/substrate interaction.	Univ Arizona, Coll Med, Dept Physiol, Tucson, AZ 85724 USA; Univ Arizona, Dept Med, Tucson, AZ 85724 USA	University of Arizona; University of Arizona	Wright, SH (corresponding author), Univ Arizona, Coll Med, Dept Physiol, Tucson, AZ 85724 USA.	shwright@u.arziona.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058251, R56DK058251] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07249] Funding Source: Medline; NIDDK NIH HHS [DK58251] Funding Source: Medline; NIEHS NIH HHS [ES06694] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Arndt P, 2001, AM J PHYSIOL-RENAL, V281, pF454, DOI 10.1152/ajprenal.2001.281.3.F454; Bednarczyk D, 2000, PFLUG ARCH EUR J PHY, V440, P184, DOI 10.1007/s004240051038; DANTZLER WH, 1997, COMPREHENSIVE TOXICO, V7, P61; Eraly SA, 2004, PHYSIOL GENOMICS, V18, P12, DOI 10.1152/physiolgenomics.00014.2004; Feng B, 2002, BIOCHEMISTRY-US, V41, P8941, DOI 10.1021/bi0200615; Feng B, 2001, BIOCHEMISTRY-US, V40, P5511, DOI 10.1021/bi002841o; Gorboulev V, 1999, MOL PHARMACOL, V56, P1254, DOI 10.1124/mol.56.6.1254; Gorboulev V, 2005, MOL PHARMACOL, V67, P1612, DOI 10.1124/mol.104.008821; Gorboulev V, 1997, DNA CELL BIOL, V16, P871, DOI 10.1089/dna.1997.16.871; Green RM, 1999, HEPATOLOGY, V29, P1556, DOI 10.1002/hep.510290530; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; Hayer-Zillgen M, 2002, BRIT J PHARMACOL, V136, P829, DOI 10.1038/sj.bjp.0704785; Hirai T, 2002, NAT STRUCT BIOL, V9, P597, DOI 10.1038/nsb821; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Jonker JW, 2004, J PHARMACOL EXP THER, V308, P2, DOI 10.1124/jpet.103.053298; Jonker JW, 2003, MOL CELL BIOL, V23, P7902, DOI 10.1128/MCB.23.21.7902-7908.2003; Kaewmokul S, 2003, AM J PHYSIOL-RENAL, V285, pF1149, DOI 10.1152/ajprenal.00112.2003; Karbach U, 2000, AM J PHYSIOL-RENAL, V279, pF679, DOI 10.1152/ajprenal.2000.279.4.F679; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leabman MK, 2002, PHARMACOGENETICS, V12, P395, DOI 10.1097/00008571-200207000-00007; Mooslehner KA, 1999, MAMM GENOME, V10, P218, DOI 10.1007/s003359900976; Motohashi H, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134866; Mueckler M, 2004, J BIOL CHEM, V279, P46876, DOI 10.1074/jbc.M408632200; Okuda M, 1996, BIOCHEM BIOPH RES CO, V224, P500, DOI 10.1006/bbrc.1996.1056; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Pontius J, 1996, J MOL BIOL, V264, P121, DOI 10.1006/jmbi.1996.0628; Popp C, 2005, MOL PHARMACOL, V67, P1600, DOI 10.1124/mol.104.008839; POWELL MJD, 1977, MATH PROGRAM, V12, P241, DOI 10.1007/BF01593790; PRITCHARD JB, 1993, PHYSIOL REV, V73, P765, DOI 10.1152/physrev.1993.73.4.765; Robbins MJ, 1999, J NEUROCHEM, V72, P2539, DOI 10.1046/j.1471-4159.1999.0722539.x; Roch-Ramel F., 1992, HDB PHYSL 8, P2189; Salas-Burgos A, 2004, BIOPHYS J, V87, P2990, DOI 10.1529/biophysj.104.047886; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Suhre WM, 2005, MOL PHARMACOL, V67, P1067, DOI 10.1124/mol.104.004713; Tanaka K, 2004, J BIOL CHEM, V279, P14961, DOI 10.1074/jbc.M400197200; Terashita S, 1998, BBA-BIOMEMBRANES, V1369, P1, DOI 10.1016/S0005-2736(97)00207-1; Towbin H, 1992, Biotechnology, V24, P145; Vardy E, 2004, PROTEIN SCI, V13, P1832, DOI 10.1110/ps.04657704; Volk C, 2003, MOL PHARMACOL, V64, P1037, DOI 10.1124/mol.64.5.1037; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wolff NA, 2001, J AM SOC NEPHROL, V12, P2012, DOI 10.1681/ASN.V12102012; Wright SH, 2004, AM J PHYSIOL-RENAL, V287, pF442, DOI 10.1152/ajprenal.00115.2004; Wright SH, 2004, PHYSIOL REV, V84, P987, DOI 10.1152/physrev.00040.2003; Xing L, 2004, J COMPUT AID MOL DES, V18, P333, DOI 10.1023/B:JCAM.0000047812.39758.ab; Zhang C, 2005, J MED CHEM, V48, P2325, DOI 10.1021/jm049314d; Zhang L, 1997, MOL PHARMACOL, V51, P913, DOI 10.1124/mol.51.6.913; Zhang XH, 2002, AM J PHYSIOL-RENAL, V283, pF124, DOI 10.1152/ajprenal.00367.2001	49	58	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34813	34822		10.1074/jbc.M506342200	http://dx.doi.org/10.1074/jbc.M506342200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16087669	hybrid			2022-12-27	WOS:000232403900053
J	Huang, CH; Lai, WL; Lee, MH; Chen, CJ; Vasella, A; Tsai, YC; Liaw, SH				Huang, CH; Lai, WL; Lee, MH; Chen, CJ; Vasella, A; Tsai, YC; Liaw, SH			Crystal structure of glucooligosaccharide oxidase from Acremonium strictum - A novel flavinylation of 6-S-cysteinyl, 8 alpha-N1-histidyl FAD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEHYDROGENASE; ENZYME; RESOLUTION; PROTEIN; MONONUCLEOTIDE; MECHANISM; CRYSTALLOGRAPHY; COMPLEXES; CATALYSIS; DOMAIN	Glucooligosaccharide oxidase from Acremonium strictum has been screened for potential applications in oligosaccharide acid production and alternative carbohydrate detection, because it catalyzes the oxidation of glucose, maltose, lactose, cellobiose and cello- and maltooligosaccharides. We report the crystal structures of the enzyme and of its complex with an inhibitor, 5-amino-5-deoxycellobiono-1,5- lactam at 1.55- and 1.98-angstrom resolution, respectively. Unexpectedly, the protein structure demonstrates the first known double attachment flavinylation, 6-S-cysteinyl, 8 alpha-N1-histidyl FAD. The FAD cofactor is cross-linked to the enzyme via the C-6 atom and the 8 alpha-methyl group of the isoalloxazine ring with Cys(130) and His(70), respectively. This sugar oxidase possesses an open carbohydrate-binding groove, allowing the accommodation of higher oligosaccharides. The complex structure suggests that this enzyme may prefer a beta-D-glucosyl residue at the reducing end with the conserved Tyr(429) acting as a general base to abstract the OH1 proton in concert with the H-1 hydride transfer to the flavin N-5. Finally, a detailed comparison illustrates the structural conservation as well as the divergence between this protein and its related flavoenzymes.	Natl Yang Ming Univ, Inst Biochem, Taipei 11221, Taiwan; Natl Yang Ming Univ, Struct Biol Program, Taipei 11221, Taiwan; Natl Yang Ming Univ, Fac Life Sci, Taipei 11221, Taiwan; Natl Synchrotron Radiat Res Ctr, Div Res, Biol Grp, Hsinchu 30076, Taiwan; ETH Honggerberg, Organ Chem Lab, CH-8093 Zurich, Switzerland; Vet Gen Hosp, Dept Med Res & Educ, Taipei 11217, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Synchrotron Radiation Research Center; Swiss Federal Institutes of Technology Domain; ETH Zurich	Tsai, YC (corresponding author), Natl Yang Ming Univ, Inst Biochem, Taipei 11221, Taiwan.	tasiyc@edu.tw; shliaw@ym.edu.tw	Chen, Chun-Jung/A-6880-2011	Chen, Chun-Jung/0000-0002-5157-4288				Aravind L, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-r30; Benson TE, 1997, BIOCHEMISTRY-US, V36, P806, DOI 10.1021/bi962221g; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carter CJ, 2004, PLANT PHYSIOL, V134, P460, DOI 10.1104/pp.103.027482; Cunane LM, 2005, BIOCHEMISTRY-US, V44, P2963, DOI 10.1021/bi048020r; Custers JHHV, 2004, PLANT J, V39, P147, DOI 10.1111/j.1365-313X.2004.02117.x; Dietmann S, 2001, NUCLEIC ACIDS RES, V29, P55, DOI 10.1093/nar/29.1.55; Dobbek H, 2002, P NATL ACAD SCI USA, V99, P15971, DOI 10.1073/pnas.212640899; Dym O, 2001, PROTEIN SCI, V10, P1712, DOI 10.1110/ps.12801; Dym O, 2000, P NATL ACAD SCI USA, V97, P9413, DOI 10.1073/pnas.97.17.9413; Enroth C, 2000, P NATL ACAD SCI USA, V97, P10723, DOI 10.1073/pnas.97.20.10723; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Firbank SJ, 2001, P NATL ACAD SCI USA, V98, P12932, DOI 10.1073/pnas.231463798; Fitzpatrick PF, 2004, BIOORG CHEM, V32, P125, DOI 10.1016/j.bioorg.2003.02.001; Fraaije MW, 2000, TRENDS BIOCHEM SCI, V25, P126, DOI 10.1016/S0968-0004(99)01533-9; Fraaije MW, 2000, J BIOL CHEM, V275, P38654, DOI 10.1074/jbc.M004753200; Fujieda N, 2004, BIOCHEMISTRY-US, V43, P10800, DOI 10.1021/bi049061q; Groen BW, 1997, EUR J BIOCHEM, V244, P858, DOI 10.1111/j.1432-1033.1997.00858.x; Hallberg BM, 2004, J MOL BIOL, V341, P781, DOI 10.1016/j.jmb.2004.06.033; Hallberg BM, 2003, J BIOL CHEM, V278, P7160, DOI 10.1074/jbc.M210961200; Lario PI, 2003, J MOL BIOL, V326, P1635, DOI 10.1016/S0022-2836(03)00054-8; LEE MH, 2005, IN PRESS APPL ENV MI; LIN SF, 1991, BIOCHIM BIOPHYS ACTA, V1118, P41, DOI 10.1016/0167-4838(91)90439-7; Malito E, 2004, J MOL BIOL, V341, P1237, DOI 10.1016/j.jmb.2004.06.083; MATHEWS FS, 1991, BIOCHEMISTRY-US, V30, P2338; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mewies M, 1998, PROTEIN SCI, V7, P7, DOI 10.1002/pro.5560070102; Mewies M, 1997, BIOCHEMISTRY-US, V36, P7162, DOI 10.1021/bi970621d; MEYER AS, 1995, TRENDS FOOD SCI TECH, V6, P300, DOI 10.1016/S0924-2244(00)89140-2; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; SCHOMBURG I, 2004, NUCLEIC ACIDS RES, V32, P431; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wang JW, 2004, ACTA CRYSTALLOGR D, V60, P1244, DOI 10.1107/S0907444904010674; Wohlfahrt G, 1999, ACTA CRYSTALLOGR D, V55, P969, DOI 10.1107/S0907444999003431; [No title captured]	38	77	81	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38831	38838		10.1074/jbc.M506078200	http://dx.doi.org/10.1074/jbc.M506078200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16154992	hybrid			2022-12-27	WOS:000233239800085
J	Mainardi, JL; Fourgeaud, M; Hugonnet, JE; Dubost, L; Brouard, JP; Ouazzani, J; Rice, LB; Gutmann, L; Arthur, M				Mainardi, JL; Fourgeaud, M; Hugonnet, JE; Dubost, L; Brouard, JP; Ouazzani, J; Rice, LB; Gutmann, L; Arthur, M			A novel peptidoglycan cross-linking enzyme for a beta-lactam-resistant transpeptidation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENICILLIN-BINDING-PROTEINS; GRAM-POSITIVE BACTERIA; ENTEROCOCCUS-FAECIUM; ESCHERICHIA-COLI; STAPHYLOCOCCUS-AUREUS; MECHANISMS; EXPRESSION; VANCOMYCIN; GROWTH	The beta-lactam antibiotics remain the most commonly used to treat severe infections. Because of structural similarity between the beta-lactam ring and the D-alanyl(4)-D-alanine(5) extremity of bacterial cell wall precursors, the drugs act as suicide substrates of the DD-transpeptidases that catalyze the last cross-linking step of cell wall assembly. Here, we show that this mechanism of action can be defeated by a novel type of transpeptidase identified for the first time by reverse genetics in a beta-lactam-resistant mutant of Enterococcus faecium. The enzyme, Ldt(fm), catalyzes in vitro the cross-linking of peptidoglycan subunits in a beta-lactam-insensitive LD-transpeptidation reaction. The specificity of Ldt(fm) for the L-lysyl(3)-D-alanine(4) peptide bond of tetrapeptide donors accounts for resistance because the substrate does not mimic beta-lactams in contrast to D-alanyl(4)-D-alanine(5) in the pentapeptide donors required for DD-transpeptidation. Ldt(fm) homologues are encountered sporadically among taxonomically distant bacteria, indicating that LD-transpeptidase-mediated resistance may emerge in various pathogens.	Univ Paris Descartes, Fac Med, INSERM, U655,Lab Rech Mol Antibiot, F-75270 Paris, France; Ctr Rech Biomed Cordeliers, F-75270 Paris, France; Univ Paris Descartes, Fac Med, Hop Europeen Georges Pompidou, AP HP, F-75908 Paris, France; Museum Natl Hist Nat, Dept Rech Dev & Divers Mol, Plateforme Spectrometrie Masse & Prote Museum, USM0502,CNRS,UMR8041, F-75005 Paris, France; CNRS, Inst Chim Subst Nat, Appl Microbiol Lab, F-91190 Gif Sur Yvette, France; Louis Stokes Cleveland Vet Affairs Med Ctr, Med & Res Serv, Cleveland, OH 44106 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	Mainardi, JL (corresponding author), Univ Paris Descartes, Fac Med, INSERM, U655,Lab Rech Mol Antibiot, 15 Rue Ecole Med, F-75270 Paris, France.	jlmainar@bhdc.jussieu.fr	HUGONNET, Jean-Emmanuel/H-3581-2014; MAINARDI, Jean-Luc/E-2714-2014; Arthur, Michel/G-3680-2013; HUGONNET, Jean-Emmanuel/ABC-7914-2021	HUGONNET, Jean-Emmanuel/0000-0003-4150-0944; MAINARDI, Jean-Luc/0000-0002-4159-0129; Arthur, Michel/0000-0003-1007-636X; HUGONNET, Jean-Emmanuel/0000-0003-4150-0944; Ouazzani, Jamal/0000-0003-4483-6638	NIAID NIH HHS [R01 AI45626] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045626] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMREIN KE, 1995, P NATL ACAD SCI USA, V92, P1048, DOI 10.1073/pnas.92.4.1048; Anderson JW, 2003, BIOCHEM J, V373, P949, DOI 10.1042/BJ20030217; Arbeloa A, 2004, J BIOL CHEM, V279, P41546, DOI 10.1074/jbc.M407149200; BillotKlein D, 1997, J BACTERIOL, V179, P4684, DOI 10.1128/jb.179.15.4684-4688.1997; BILLOTKLEIN D, 1992, ANTIMICROB AGENTS CH, V36, P1487, DOI 10.1128/AAC.36.7.1487; Chastanet A, 2003, MOL MICROBIOL, V47, P1061, DOI 10.1046/j.1365-2958.2003.03355.x; COYETTE J, 1974, EUR J BIOCHEM, V44, P459, DOI 10.1111/j.1432-1033.1974.tb03504.x; FONTANA R, 1983, J BACTERIOL, V155, P1343, DOI 10.1128/JB.155.3.1343-1350.1983; Goffin C, 1998, MICROBIOL MOL BIOL R, V62, P1079, DOI 10.1128/MMBR.62.4.1079-1093.1998; Grohs P, 2000, J BACTERIOL, V182, P6228, DOI 10.1128/JB.182.21.6228-6232.2000; Jacoby GA, 2005, NEW ENGL J MED, V352, P380, DOI 10.1056/NEJMra041359; KELLY JA, 1982, SCIENCE, V218, P479, DOI 10.1126/science.7123246; KLARE I, 1992, ANTIMICROB AGENTS CH, V36, P783, DOI 10.1128/AAC.36.4.783; Mainard JL, 2002, J BIOL CHEM, V277, P35801, DOI 10.1074/jbc.M204319200; Mainardi JL, 2000, J BIOL CHEM, V275, P16490, DOI 10.1074/jbc.M909877199; Mengin-Lecreulx D, 1999, J BACTERIOL, V181, P5909, DOI 10.1128/JB.181.19.5909-5914.1999; Messer M, 1997, COMP BIOCHEM PHYS B, V118, P403, DOI 10.1016/S0305-0491(97)00162-4; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; PISABARRO AG, 1985, J BACTERIOL, V161, P238, DOI 10.1128/JB.161.1.238-242.1985; Rice LB, 2004, ANTIMICROB AGENTS CH, V48, P3028, DOI 10.1128/AAC.48.8.3028-3032.2004; SPRATT BG, 1975, P NATL ACAD SCI USA, V72, P2999, DOI 10.1073/pnas.72.8.2999; STRYNADKA NCJ, 1994, NATURE, V368, P657, DOI 10.1038/368657a0; Templin MF, 1999, EMBO J, V18, P4108, DOI 10.1093/emboj/18.15.4108; Walsh C, 2000, NATURE, V406, P775, DOI 10.1038/35021219; WILLIAMSON R, 1985, J GEN MICROBIOL, V131, P1933	25	153	156	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38146	38152		10.1074/jbc.M507384200	http://dx.doi.org/10.1074/jbc.M507384200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16144833	hybrid			2022-12-27	WOS:000233239800006
J	Bertsche, U; Breukink, E; Kast, T; Vollmer, W				Bertsche, U; Breukink, E; Kast, T; Vollmer, W			In vitro murein (peptidoglycan) synthesis by dimers of the bifunctional transglycosylase-transpeptidase PBP1B from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENICILLIN-BINDING PROTEINS; CELL-WALL PEPTIDOGLYCAN; LIPID-II; 1B; GLYCOSYLTRANSFERASE; BIOSYNTHESIS; PURIFICATION; INHIBITORS; COMPONENT; MEMBRANE	PBP1B is a major bifunctional murein ( peptidoglycan) synthase catalyzing transglycosylation and transpeptidation reactions in Escherichia coli. PBP1B has been shown to form dimers in vivo. The K-D value for PBP1B dimerization was determined by surface plasmon resonance. The effect of the dimerization of PBP1B on its activities was studied with a newly developed in vitro murein synthesis assay with radioactively labeled lipid II precursor as substrate. Under conditions at which PBP1B dimerizes, the enzyme synthesized murein with long glycan strands (> 25 disaccharide units) and with almost 50% of the peptides being part of cross-links. PBP1B was also capable of synthesizing trimeric muropeptide structures. Tri-, tetra-, and pentapeptide compounds could serve as acceptors in the PBP1B-catalyzed transpeptidation reaction.	Univ Tubingen, D-72076 Tubingen, Germany; Univ Utrecht, Biomembrane Inst, Ctr Biomembranes & Lipid Enzymol, Dept Membrane Biochem, NL-3584 CH Utrecht, Netherlands; Max Planck Inst Entwicklungsbiol, Abt Biochem, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Utrecht University; Max Planck Society	Vollmer, W (corresponding author), Univ Tubingen, Morgenstelle 28, D-72076 Tubingen, Germany.	waldemar.vollmer@uni-tuebingen.de	Breukink, Eefjan/I-3039-2016	Breukink, Eefjan/0000-0002-7311-0660				Barrett DS, 2004, BIOCHEMISTRY-US, V43, P12375, DOI 10.1021/bi049142m; Breukink E, 2003, J BIOL CHEM, V278, P19898, DOI 10.1074/jbc.M301463200; Chalut C, 1999, J BACTERIOL, V181, P2970, DOI 10.1128/JB.181.9.2970-2972.1999; Chandrakala B, 2004, ANTIMICROB AGENTS CH, V48, P30, DOI 10.1128/AAC.48.1.30-40.2004; Charpentier X, 2002, J BACTERIOL, V184, P3749, DOI 10.1128/JB.184.13.3749-3752.2002; DARGIS M, 1994, ANTIMICROB AGENTS CH, V38, P973, DOI 10.1128/AAC.38.5.973; DiBerardino M, 1996, FEBS LETT, V392, P184, DOI 10.1016/0014-5793(96)00809-5; GLAUNER B, 1988, ANAL BIOCHEM, V172, P451, DOI 10.1016/0003-2697(88)90468-X; GLAUNER B, 1988, J BIOL CHEM, V263, P10088; Goffin C, 1998, MICROBIOL MOL BIOL R, V62, P1079, DOI 10.1128/MMBR.62.4.1079-1093.1998; Holtje JV, 1998, MICROBIOL MOL BIOL R, V62, P181; Holtje JV, 1996, MICROB DRUG RESIST, V2, P99, DOI 10.1089/mdr.1996.2.99; HUBER G, 1968, BIOCHEM BIOPH RES CO, V30, P7, DOI 10.1016/0006-291X(68)90704-3; ISHINO F, 1980, BIOCHEM BIOPH RES CO, V97, P287, DOI 10.1016/S0006-291X(80)80166-5; KATO J, 1984, MOL GEN GENET, V196, P449, DOI 10.1007/BF00436192; KOHLRAUSCH U, 1991, FEMS MICROBIOL LETT, V78, P253; Laan EVDD, 2003, J BACTERIOL, V185, P3773, DOI 10.1128/JB.185.3773.3779.2003; MATSUHASHI M, 1990, RES MICROBIOL, V141, P89, DOI 10.1016/0923-2508(90)90101-U; Meisel U, 2003, J BACTERIOL, V185, P5342, DOI 10.1128/JB.185.18.5342-5348.2003; NAKAGAWA J, 1984, J BIOL CHEM, V259, P3937; NAKAGAWA J, 1982, BIOCHEM BIOPH RES CO, V105, P1546, DOI 10.1016/0006-291X(82)90964-0; ROJO F, 1984, EUR J BIOCHEM, V144, P571, DOI 10.1111/j.1432-1033.1984.tb08503.x; Schiffer G, 1999, J BIOL CHEM, V274, P32031, DOI 10.1074/jbc.274.45.32031; Schwartz B, 2001, J AM CHEM SOC, V123, P11638, DOI 10.1021/ja0166848; SUZUKI H, 1978, P NATL ACAD SCI USA, V75, P664, DOI 10.1073/pnas.75.2.664; Terrak M, 1999, MOL MICROBIOL, V34, P350, DOI 10.1046/j.1365-2958.1999.01612.x; VANHEIJENOORT Y, 1992, J BACTERIOL, V174, P3549, DOI 10.1128/JB.174.11.3549-3557.1992; VANHEIJENOORT Y, 1978, FEBS LETT, V89, P141, DOI 10.1016/0014-5793(78)80540-7; Vollmer W, 1999, J BIOL CHEM, V274, P6726, DOI 10.1074/jbc.274.10.6726; Vollmer W, 2000, ANTIMICROB AGENTS CH, V44, P1181, DOI 10.1128/AAC.44.5.1181-1185.2000; Vollmer W, 2001, CURR OPIN MICROBIOL, V4, P625, DOI 10.1016/S1369-5274(01)00261-2; WEIDEL W, 1964, ADV ENZYMOL REL S BI, V26, P193; ZIJDERVELD CAL, 1995, J BACTERIOL, V177, P1860, DOI 10.1128/jb.177.7.1860-1863.1995; ZIJDERVELD CAL, 1991, J BACTERIOL, V173, P5740, DOI 10.1128/jb.173.18.5740-5746.1991	34	114	117	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					38096	38101		10.1074/jbc.M508646200	http://dx.doi.org/10.1074/jbc.M508646200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16154998	Green Published, hybrid			2022-12-27	WOS:000233044500093
J	Riedel, CG; Mazza, M; Maier, P; Korner, R; Knop, M				Riedel, CG; Mazza, M; Maier, P; Korner, R; Knop, M			Differential requirement for phospholipase D/Spo14 and its novel interactor Sma1 for regulation of exocytotic vesicle fusion in yeast meiosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINDLE POLE BODY; SACCHAROMYCES-CEREVISIAE; MEMBRANE FORMATION; PROSPORE MEMBRANE; SPORULATION; PROTEIN; GENES; D1; LOCALIZATION; EXPRESSION	During sporulation and meiosis of budding yeast a developmental program determines the formation of the new plasma membranes of the spores. This process of prospore membrane (PSM) formation leads to the formation of meiotic daughter cells, the spores, within the lumen of the mother cell. It is initiated at the spindle pole bodies during meiosis II. Spore formation, but not meiotic cell cycle progression, requires the function of phospholipase D (PLD/Spo14). Here we show that PLD/Spo14 forms a complex with Sma1, ameiotically expressed protein essential for spore formation. Detailed analysis revealed that both proteins are required for early steps of prospore membrane assembly but with distinct defects in the respective mutants. In the Delta spo14 mutant the initiation of PSM formation is blocked and aggregated vesicles of homogenous size are detected at the spindle pole bodies. In contrast, initiation of PSM formation does occur in the Delta sma1 mutant, but the enlargement of the membrane is impaired. During PSM growth both Spo14 and Sma1 localize to the membrane, and localization of Spo14 is independent of Sma1. Biochemical analysis revealed that Sma1 is not necessary for PLD activity per se and that PLD present in a complex with Sma1 is highly active. Together, our results suggest that yeast PLD is involved in two distinct but essential steps during the regulated vesicle fusion necessary for the assembly of the membranous encapsulations of the spores.	European Mol Biol Lab, Cell Biol & Biophys Unit, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Knop, M (corresponding author), European Mol Biol Lab, Cell Biol & Biophys Unit, D-69117 Heidelberg, Germany.	knop@embl.de	Mazza, Massimiliano/AAA-4420-2021; Körner, Roman/G-8565-2011	Mazza, Massimiliano/0000-0001-9053-5743; Körner, Roman/0000-0001-9285-9290; Riedel, Christian/0000-0002-3689-8022				ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; Bajgier BK, 2001, MOL BIOL CELL, V12, P1611, DOI 10.1091/mbc.12.6.1611; BROWN HA, 1995, J BIOL CHEM, V270, P14935, DOI 10.1074/jbc.270.25.14935; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DAVIDOW LS, 1980, GENETICS, V94, P581; Davis L, 2001, GENETICS, V157, P1179; Du GW, 2003, J CELL BIOL, V162, P305, DOI 10.1083/jcb.200302033; Exton JH, 2002, REV PHYSIOL BIOCH P, V144, P1, DOI 10.1007/BFb0116585; Exton JH, 2002, FEBS LETT, V531, P58, DOI 10.1016/S0014-5793(02)03405-1; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Guthrie C., 1991, METHOD ENZYMOL, V194, P429; Huijbregts RPH, 2000, TRAFFIC, V1, P195, DOI 10.1034/j.1600-0854.2000.010301.x; Janke C, 2004, YEAST, V21, P947, DOI 10.1002/yea.1142; Jantti J, 2002, J CELL SCI, V115, P409; Knop M, 2000, EMBO J, V19, P3657, DOI 10.1093/emboj/19.14.3657; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; KNOP M, 2005, MOL BIOL CELL   0719; Ktistakis NT, 2003, BIOCHEM SOC T, V31, P94, DOI 10.1042/bst0310094; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Lynn R R, 1970, J Cell Biol, V44, P688, DOI 10.1083/jcb.44.3.688; MOENS PB, 1971, J CELL BIOL, V50, P344, DOI 10.1083/jcb.50.2.344; Moreno-Borchart AC, 2001, EMBO J, V20, P6946, DOI 10.1093/emboj/20.24.6946; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Nakanishi H, 2004, MOL BIOL CELL, V15, P1802, DOI 10.1091/mbc.e03-11-0798; Neiman AM, 1998, J CELL BIOL, V140, P29, DOI 10.1083/jcb.140.1.29; Nelson WJ, 2003, NATURE, V422, P766, DOI 10.1038/nature01602; OKAMOTO S, 1982, J GEN MICROBIOL, V128, P1309; Outeiro TF, 2003, SCIENCE, V302, P1772, DOI 10.1126/science.1090439; Powner DJ, 2002, FEBS LETT, V531, P62, DOI 10.1016/S0014-5793(02)03410-5; Rabitsch KP, 2001, CURR BIOL, V11, P1001, DOI 10.1016/S0960-9822(01)00274-3; Rudge SA, 1998, J CELL BIOL, V140, P81, DOI 10.1083/jcb.140.1.81; Rudge SA, 1998, MOL BIOL CELL, V9, P2025, DOI 10.1091/mbc.9.8.2025; Rudge SA, 2002, GENETICS, V160, P1353; Sciorra VA, 2002, J CELL BIOL, V159, P1039, DOI 10.1083/jcb.200205056; Sciorra VA, 1999, EMBO J, V18, P5911, DOI 10.1093/emboj/18.21.5911; Vitale N, 2001, EMBO J, V20, P2424, DOI 10.1093/emboj/20.10.2424; Xie ZG, 1998, P NATL ACAD SCI USA, V95, P12346, DOI 10.1073/pnas.95.21.12346; Zouwail S, 2005, BIOCHEM J, V389, P207, DOI 10.1042/BJ20050085	39	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37846	37852		10.1074/jbc.M504244200	http://dx.doi.org/10.1074/jbc.M504244200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16148007	hybrid			2022-12-27	WOS:000233044500065
J	Sander, P; Hamann, H; Drogemuller, C; Kashkevich, K; Schiebel, K; Leeb, T				Sander, P; Hamann, H; Drogemuller, C; Kashkevich, K; Schiebel, K; Leeb, T			Bovine prion protein gene (PRNP) promoter polymorphisms modulate PRNP expression and may be responsible for differences in bovine spongiform encephalopathy susceptibility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SP1; NATURAL SCRAPIE; DENDRITIC CELLS; FINGER PROTEIN; PRP GENE; SHEEP; MICE; VARIANTS; SPLEEN; TISSUE	The susceptibility of humans to the variant Creutzfeldt-Jakob disease is greatly influenced by polymorphisms within the human prion protein gene (PRNP). Similar genetic differences exist in sheep, in which PRNP polymorphisms modify the susceptibility to scrapie. However, the known coding polymorphisms within the bovine PRNP gene have little or no effect on bovine spongiform encephalopathy (BSE) susceptibility in cattle. We have recently found a tentative association between PRNP promoter polymorphisms and BSE susceptibility in German cattle ( Sander, P., Hamann, H., Pfeiffer, I., Wemheuer, W., Brenig, B., Groschup, M., Ziegler, U., Distl, O., and Leeb, T. ( 2004) Neurogenetics 5, 19 - 25). A plausible hypothesis explaining this observation could be that the bovine PRNP promoter polymorphisms cause changes in PRNP expression that might be responsible for differences in BSE incubation time and/or BSE susceptibility. To test this hypothesis, we performed a functional promoter analysis of the different bovine PRNP promoter alleles by reporter gene assays in vitro and by measuring PRNP mRNA levels in calves with different PRNP genotypes in vivo. Two variable sites, a 23-bp insertion/deletion (indel) polymorphism containing a RP58-binding site and a 12-bp indel polymorphism containing an SP1-binding site, were investigated. Band shift assays indicated differences in transcription factor binding to the different alleles at the two polymorphisms. Reporter gene assays demonstrated an interaction between the two postulated transcription factors and lower expression levels of the ins/ins allele compared with the del/del allele. The in vivo data revealed substantial individual variation of PRNP expression in different tissues. In intestinal lymph nodes, expression levels differed between the different PRNP genotypes.	Univ Vet Med, Inst Genet & Anim Breeding, D-30559 Hannover, Germany; Univ Erlangen Nurnberg, Inst Biochem, D-91054 Erlangen, Germany	University of Veterinary Medicine Hannover, Foundation; University of Erlangen Nuremberg	Leeb, T (corresponding author), Inst Genet, Bremgartenstr 109A, CH-3001 Bern, Switzerland.	Tosso.Leeb@itz.unibe.ch	Leeb, Tosso/G-3187-2014	Leeb, Tosso/0000-0003-0553-4880; Nicken, Petra/0000-0002-8535-1453; Drogemuller, Cord/0000-0001-9773-522X				ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; Aoki K, 1998, J BIOL CHEM, V273, P26698, DOI 10.1074/jbc.273.41.26698; Becker KG, 1997, INT J DEV NEUROSCI, V15, P891, DOI 10.1016/S0736-5748(97)00034-8; BELT PBGM, 1995, J GEN VIROL, V76, P509, DOI 10.1099/0022-1317-76-3-509; Blattler T, 1997, NATURE, V389, P69, DOI 10.1038/37981; Bossers A, 1996, J GEN VIROL, V77, P2669, DOI 10.1099/0022-1317-77-10-2669; Bossers A, 2000, J VIROL, V74, P1407, DOI 10.1128/JVI.74.3.1407-1414.2000; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CROSBY SD, 1992, P NATL ACAD SCI USA, V89, P4739, DOI 10.1073/pnas.89.10.4739; Daude N, 2004, VIRAL IMMUNOL, V17, P334, DOI 10.1089/vim.2004.17.334; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eddy RG, 1995, VET REC, V137, P648; GOLDMANN W, 1990, P NATL ACAD SCI USA, V87, P2476, DOI 10.1073/pnas.87.7.2476; Hecker KH, 1996, BIOTECHNIQUES, V20, P478; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; Huang FP, 2002, J GEN VIROL, V83, P267, DOI 10.1099/0022-1317-83-1-267; HUNTER N, 1992, VET REC, V130, P389, DOI 10.1136/vr.130.18.389; Inoue S, 1997, J VET MED SCI, V59, P175, DOI 10.1292/jvms.59.175; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; LAPLANCHE JL, 1993, GENOMICS, V15, P30, DOI 10.1006/geno.1993.1006; Lee DK, 2002, J BIOL CHEM, V277, P26761, DOI 10.1074/jbc.M202078200; Mabbott NA, 2003, J VIROL, V77, P6845, DOI 10.1128/JVI.77.12.6845-6854.2003; Maignien T, 1999, J GEN VIROL, V80, P3035, DOI 10.1099/0022-1317-80-11-3035; Montrasio F, 2000, SCIENCE, V288, P1257, DOI 10.1126/science.288.5469.1257; Paltrinieri S, 2004, J HISTOCHEM CYTOCHEM, V52, P1639, DOI 10.1369/jhc.4A6441.2004; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Sander P, 2004, NEUROGENETICS, V5, P19, DOI 10.1007/s10048-003-0171-y; SAS Institute Inc, 2003, SAS VERS 9 1; Sun Y, 2001, CELL, V104, P365, DOI 10.1016/S0092-8674(01)00224-0; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	32	104	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37408	37414		10.1074/jbc.M506361200	http://dx.doi.org/10.1074/jbc.M506361200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16141216	hybrid			2022-12-27	WOS:000233044500015
J	van den Akker, E; Ano, S; Shih, HM; Wang, LC; Pironin, M; Palvimo, JJ; Kotaja, N; Kirsh, O; Dejean, A; Ghysdael, J				van den Akker, E; Ano, S; Shih, HM; Wang, LC; Pironin, M; Palvimo, JJ; Kotaja, N; Kirsh, O; Dejean, A; Ghysdael, J			FLI-1 functionally interacts with PIASx alpha, a member of the PIAS E3 SUMO ligase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION PROPERTIES; GENE-TARGETED MICE; ANDROGEN RECEPTOR; DNA-BINDING; FLI-1-TRANSFORMED ERYTHROBLASTS; TRANSGENIC MICE; PROTEINS; NUCLEAR; REPRESSION; EXPRESSION	FLI-1 is a transcription factor of the ETS family that is involved in several developmental processes and that becomes oncogenic when overexpressed or mutated. As the functional regulators of FLI-1 are largely unknown, we performed a yeast two-hybrid screen with FLI-1 and identified the SUMO E3 ligase PIASx alpha/ARIP3 as a novel in vitro and in vivo binding partner of FLI-1. This interaction involved the ETS domain of FLI-1 and required the integrity of the SAP domain of PIASx alpha/ARIP3. SUMO-1 and Ubc9, the ubiquitin carrier protein component in the sumoylation pathway, were also identified as interactors of FLI-1. Both PIASx alpha/ARIP3 and the closely related PIASx beta isoform specifically enhanced sumoylation of FLI-1 at Lys(67), located in its N-terminal activation domain. PIASx alpha/ARIP3 relocalized the normally nuclear but diffusely distributed FLI-1 protein to PIASx alpha nuclear bodies and repressed FLI-1 transcriptional activation as assessed using different ETS-binding site-dependent promoters and different cell systems. PIASx alpha repressive activity was independent of sumoylation and did not result from inhibition of FLI-1 DNA-binding activity. Analysis of the properties of a series of ARIP3 mutants showed that the repressive properties of PIASx alpha/ARIP3 require its physical interaction with FLI-1, identifying PIASx alpha as a novel corepressor of FLI-1.	Inst Curie, Ctr Univ, CNRS, UMR 146, F-91405 Orsay, France; Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; Univ Kuopio, Dept Biochem Med, FIN-70211 Kuopio, Finland; Univ Helsinki, Biomedicum Helsinki, Inst Biomed, FIN-00014 Helsinki, Finland; Inst Pasteur, INSERM, U579, F-75015 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Academia Sinica - Taiwan; University of Eastern Finland; University of Helsinki; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Ghysdael, J (corresponding author), Inst Curie, Ctr Univ, CNRS, UMR 146, Bat 110, F-91405 Orsay, France.	Jacques.Ghysdael@curie.u-psud.fr	Shih, Hsiu-Ming/S-7023-2018; GHYSDAEL, Jacques/F-3377-2013; Dejean, Anne/L-5145-2018	Kotaja, Noora/0000-0003-1503-9170; Kirsh, Olivier/0000-0001-6200-5681; Palvimo, Jorma/0000-0003-2373-0578				Ano S, 2004, J BIOL CHEM, V279, P2993, DOI 10.1074/jbc.M303816200; Arora T, 2003, J BIOL CHEM, V278, P21327, DOI 10.1074/jbc.C300119200; Arvand A, 2001, CANCER RES, V61, P5311; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Chun TH, 2003, CIRC RES, V92, P1201, DOI 10.1161/01.RES.0000076893.70898.36; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Czuwara-Ladykowska J, 2001, J BIOL CHEM, V276, P20839, DOI 10.1074/jbc.M010133200; Darby TG, 1997, ONCOGENE, V15, P3067, DOI 10.1038/sj.onc.1201503; de Boer E, 2003, P NATL ACAD SCI USA, V100, P7480, DOI 10.1073/pnas.1332608100; Eisbacher M, 2003, MOL CELL BIOL, V23, P3427, DOI 10.1128/MCB.23.10.3427-3441.2003; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Gross M, 2004, ONCOGENE, V23, P3059, DOI 10.1038/sj.onc.1207443; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hahn SL, 1997, ONCOGENE, V15, P1489, DOI 10.1038/sj.onc.1201301; Hart A, 2000, IMMUNITY, V13, P167, DOI 10.1016/S1074-7613(00)00017-0; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kawada H, 2001, INT J HEMATOL, V73, P463, DOI 10.1007/BF02994008; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Kotaja N, 2002, J BIOL CHEM, V277, P17781, DOI 10.1074/jbc.M106354200; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Lebigot I, 2003, BLOOD, V102, P4555, DOI 10.1182/blood-2003-06-2077; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; Lesault I, 2002, EMBO J, V21, P694, DOI 10.1093/emboj/21.4.694; Liu B, 2004, NAT IMMUNOL, V5, P891, DOI 10.1038/ni1104; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu B, 2001, P NATL ACAD SCI USA, V98, P3203, DOI 10.1073/pnas.051489598; Masuya M, 2005, BLOOD, V105, P95, DOI 10.1182/blood-2003-12-4345; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Nishida T, 2002, J BIOL CHEM, V277, P41311, DOI 10.1074/jbc.M206741200; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; RABAULT B, 1994, J BIOL CHEM, V269, P28143; Roth W, 2004, J IMMUNOL, V173, P6189, DOI 10.4049/jimmunol.173.10.6189; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Santti H, 2005, J MOL ENDOCRINOL, V34, P645, DOI 10.1677/jme.1.01666; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Spyropoulos DD, 2000, MOL CELL BIOL, V20, P5643, DOI 10.1128/MCB.20.15.5643-5652.2000; Starck J, 2003, MOL CELL BIOL, V23, P1390, DOI 10.1128/MCB.23.4.1390-1402.2003; Starck J, 1999, EXP HEMATOL, V27, P630, DOI 10.1016/S0301-472X(99)00006-5; Stein GS, 1998, J CELL BIOCHEM, P220; Tamir A, 1999, MOL CELL BIOL, V19, P4452; Tan JA, 2002, J BIOL CHEM, V277, P16993, DOI 10.1074/jbc.M109217200; Truong AHL, 2000, ONCOGENE, V19, P6482, DOI 10.1038/sj.onc.1204042; Ungureanu D, 2003, BLOOD, V102, P3311, DOI 10.1182/blood-2002-12-3816; van den Akker E, 2004, BLOOD, V103, P4457, DOI 10.1182/blood-2003-08-2713; van Dijk TB, 2000, BLOOD, V96, P3406; Wong KA, 2004, MOL CELL BIOL, V24, P5577, DOI 10.1128/MCB.24.12.5577-5586.2004	48	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					38035	38046		10.1074/jbc.M502938200	http://dx.doi.org/10.1074/jbc.M502938200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16148010	Green Published, hybrid			2022-12-27	WOS:000233044500087
J	Cusson-Hermance, N; Khurana, S; Lee, TH; Fitzgerald, KA; Kelliher, MA				Cusson-Hermance, N; Khurana, S; Lee, TH; Fitzgerald, KA; Kelliher, MA			Rip1 mediates the Trif-dependent Toll-like receptor 3- and 4-induced NF-kappa B activation but does not contribute to interferon regulatory factor 3 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING ADAPTER; CUTTING EDGE; TRANSCRIPTION FACTORS; TNF RECEPTOR-1; MAP KINASE; A20; PATHWAY; RECRUITMENT; IKK; UBIQUITINATION	Rip1 is required for I kappa B kinase activation in response to tumor necrosis factor alpha (TNF-alpha) and has been implicated in the Toll-like receptor 3 (TLR3) response to double-stranded RNA. Cytokine production is impaired when rip1-/- cells are treated with TNF-alpha, poly(I-C), or lipopolysaccharide, implicating Rip1 in the Trif-dependent TLR3 and TLR4 pathways. To examine the role of Rip1 in the Trif-dependent TLR4 pathway, we generated rip1(-/-) MyD88(-/-) cells. Lipopolysaccharide failed to stimulate NF-kappa B activation in rip1-/- MyD88-/- cells, revealing that Rip1 is also required for the Trif-dependent TLR4-induced NF-kappa B pathway. In addition to activating NF-kappa B, TLR3/4 pathways also stimulate interferon regulatory factor 3 activation. However, we find that Rip1 expression stimulates NF-kappa B but not interferon regulatory factor 3 activity. In the TNF-alpha pathway, Rip1 interacts with the E3 ubiquitin ligase Traf2 and is modified by polyubiquitin chains. Upon TLR3 activation, Rip1 is also modified by polyubiquitin chains and is recruited to TLR3 along with Traf6 and the ubiquitin-activated kinase Tak1. These studies suggest that Rip1 uses a similar, ubiquitin-dependent mechanism to activate I kappa B kinase-beta in response to TNF-alpha and TLR3 ligands.	Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Kelliher, MA (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, Lazare Res Bldg,364 Plantat St, Worcester, MA 01605 USA.	michelle.kelliher@umassmed.edu	Fitzgerald, Katherine/ABE-6317-2020	Fitzgerald, Kate/0000-0003-3175-609X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061298] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM061298, GM061298] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		Balachandran S, 2004, NATURE, V432, P401, DOI 10.1038/nature03124; Boone DL, 2004, NAT IMMUNOL, V5, P1052, DOI 10.1038/ni1110; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Gohda J, 2004, J IMMUNOL, V173, P2913, DOI 10.4049/jimmunol.173.5.2913; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Janssens S, 2003, MOL CELL, V11, P293, DOI 10.1016/S1097-2765(03)00053-4; Jiang ZF, 2003, J BIOL CHEM, V278, P16713, DOI 10.1074/jbc.M300562200; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Lee TH, 2004, J BIOL CHEM, V279, P33185, DOI 10.1074/jbc.M404206200; Lee TH, 2003, MOL CELL BIOL, V23, P8377, DOI 10.1128/MCB.23.22.8377-8385.2003; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Li K, 2005, J BIOL CHEM, V280, P16739, DOI 10.1074/jbc.M414139200; Meylan E, 2004, NAT IMMUNOL, V5, P503, DOI 10.1038/ni1061; Saitoh T, 2005, J IMMUNOL, V174, P1507, DOI 10.4049/jimmunol.174.3.1507; Sato S, 2003, J IMMUNOL, V171, P4304, DOI 10.4049/jimmunol.171.8.4304; Silverman N, 2000, GENE DEV, V14, P2461, DOI 10.1101/gad.817800; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Wang YY, 2004, FEBS LETT, V576, P86, DOI 10.1016/j.febslet.2004.08.071; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	30	245	254	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36560	36566		10.1074/jbc.M506831200	http://dx.doi.org/10.1074/jbc.M506831200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16115877	hybrid			2022-12-27	WOS:000232901800005
J	Dalmas, O; Orelle, C; Foucher, AE; Geourjon, C; Crouzy, S; Di Pietro, A; Jault, JM				Dalmas, O; Orelle, C; Foucher, AE; Geourjon, C; Crouzy, S; Di Pietro, A; Jault, JM			The Q-loop disengages from the first intracellular loop during the catalytic cycle of the multidrug ABC transporter BmrA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-BINDING CASSETTE; RECONSTITUTED P-GLYCOPROTEIN; TERTIARY STRUCTURE CHANGES; NUCLEOTIDE-BINDING; CONFORMATIONAL-CHANGES; ESCHERICHIA-COLI; TRANSMEMBRANE DOMAINS; SUBUNIT INTERACTIONS; BACILLUS-SUBTILIS; CROSS-LINKING	The ATP-binding cassette is the most abundant family of transporters including many medically relevant members and gathers both importers and exporters involved in the transport of a wide variety of substrates. Although three high resolution three-dimensional structures have been obtained for a prototypic exporter, MsbA, two have been subjected to much criticism. Here, conformational changes of BmrA, amultidrug bacterial transporter structurally related to MsbA, have been studied. A three-dimensional model of BmrA, based on the "open" conformation of Escherichia coli MsbA, was probed by simultaneously introducing two cysteine residues, one in the first intracellular loop of the transmembrane domain and the other in the Q-loop of the nucleotide- binding domain (NBD). Intramolecular disulfide bonds could be created in the absence of any effectors, which prevented both drug transport and ATPase activity. Interestingly, addition of ATP/Mg plus vanadate strongly prevented this bond formation in a cysteine double mutant, whereas ATP/Mg alone was sufficient when the ATPase-inactive E504Q mutation was also introduced, in agreement with additional BmrA models where the ATP-binding sites are positioned at the NBD/NBD interface. Furthermore, cross-linking between the two cysteine residues could still be achieved in the presence of ATP/Mg plus vanadate when homobifunctional cross-linkers separated by more than 13 angstrom were added. Altogether, these results give support to the existence, in the resting state, of amonomeric conformation of BmrA similar to that found within the open MsbA dimer and show that a large motion is required between intracellular loop 1 and the nucleotide- binding domain for the proper functioning of a multidrug ATP-binding cassette transporter.	Commiss Energie Atom, UJF, CNRS,Unite Mixte Rech 5090, DRDC,Lab Biophys Mol & Cellulaire, F-38054 Grenoble, France; Inst Biol & Chim Prot, CNRS, Unite Mixte Rech 5086, UCBL 1, F-69367 Lyon, France; Inst Biol & Chim Prot, CNRS, Unite Mixte Rech 5086, IFR 128, F-69367 Lyon, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS)	Jault, JM (corresponding author), Commiss Energie Atom, UJF, CNRS,Unite Mixte Rech 5090, DRDC,Lab Biophys Mol & Cellulaire, 17 Rue Martyrs,Batiment K, F-38054 Grenoble, France.	jean-michel.jault@cea.fr	Orelle, Cédric/AAI-1495-2020; jault, jean-michel/G-2086-2012	Orelle, Cédric/0000-0003-3418-3290; jault, jean-michel/0000-0003-1743-2777				Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buchaklian AH, 2004, BIOCHEMISTRY-US, V43, P8600, DOI 10.1021/bi0497751; Campbell JD, 2004, BIOPHYS J, V87, P3703, DOI 10.1529/biophysj.104.046870; Campbell JD, 2003, BIOCHEMISTRY-US, V42, P3666, DOI 10.1021/bi027337t; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; Combet C, 2002, BIOINFORMATICS, V18, P213, DOI 10.1093/bioinformatics/18.1.213; CURRIER SJ, 1992, J BIOL CHEM, V267, P25153; Dalmas O, 2005, BIOCHEMISTRY-US, V44, P4312, DOI 10.1021/bi0482809; Fetsch EE, 2002, P NATL ACAD SCI USA, V99, P9685, DOI 10.1073/pnas.152204499; GEOURJON C, 1995, J MOL GRAPHICS, V13, P209, DOI 10.1016/0263-7855(95)00035-5; Geourjon C, 2001, TRENDS BIOCHEM SCI, V26, P539, DOI 10.1016/S0968-0004(01)01907-7; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; Haimeur A, 2004, CURR DRUG METAB, V5, P21, DOI 10.2174/1389200043489199; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Higgins CF, 2004, NAT STRUCT MOL BIOL, V11, P918, DOI 10.1038/nsmb836; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hunke S, 2000, J BIOL CHEM, V275, P15526, DOI 10.1074/jbc.275.20.15526; Janas E, 2003, J BIOL CHEM, V278, P26862, DOI 10.1074/jbc.M301227200; Jones PM, 2004, CELL MOL LIFE SCI, V61, P682, DOI 10.1007/s00018-003-3336-9; Jones PM, 2002, P NATL ACAD SCI USA, V99, P12639, DOI 10.1073/pnas.152439599; Julien M, 2000, BIOCHEMISTRY-US, V39, P4559, DOI 10.1021/bi992744z; Kaur P, 2005, BIOCHEMISTRY-US, V44, P2661, DOI 10.1021/bi048959c; Kwan T, 1998, BIOCHEMISTRY-US, V37, P3337, DOI 10.1021/bi972680x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Locher KP, 2004, CURR OPIN STRUC BIOL, V14, P426, DOI 10.1016/j.sbi.2004.06.005; Loo TW, 2002, J BIOL CHEM, V277, P41303, DOI 10.1074/jbc.C200484200; Loo TW, 2001, J BIOL CHEM, V276, P36877, DOI 10.1074/jbc.C100467200; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; Mourez M, 1997, EMBO J, V16, P3066, DOI 10.1093/emboj/16.11.3066; Muneyuki E, 2000, BBA-BIOENERGETICS, V1458, P467, DOI 10.1016/S0005-2728(00)00095-5; Orelle C, 2003, J BIOL CHEM, V278, P47002, DOI 10.1074/jbc.M308268200; Payen LF, 2003, J BIOL CHEM, V278, P38537, DOI 10.1074/jbc.M305786200; Qu Q, 2001, BIOCHEMISTRY-US, V40, P1413, DOI 10.1021/bi002035h; Reuter G, 2003, J BIOL CHEM, V278, P35193, DOI 10.1074/jbc.M306226200; Reyes CL, 2005, SCIENCE, V308, P1028, DOI 10.1126/science.1107733; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Shilling RA, 2003, INT J ANTIMICROB AG, V22, P200, DOI 10.1016/S0924-8579(03)00212-7; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Sonveaux N, 1996, J BIOL CHEM, V271, P24617, DOI 10.1074/jbc.271.40.24617; Sonveaux N, 1999, J BIOL CHEM, V274, P17649, DOI 10.1074/jbc.274.25.17649; Steinfels E, 2004, BIOCHEMISTRY-US, V43, P7491, DOI 10.1021/bi0362018; Steinfels E, 2002, BBA-BIOMEMBRANES, V1565, P1, DOI 10.1016/S0005-2736(02)00515-1; Stenham DR, 2003, FASEB J, V17, P2287, DOI 10.1096/fj.03-0107fje; Tombline G, 2004, J BIOL CHEM, V279, P31212, DOI 10.1074/jbc.M404689200; Van Bambeke F, 2000, BIOCHEM PHARMACOL, V60, P457, DOI 10.1016/S0006-2952(00)00291-4; Verdon G, 2003, J MOL BIOL, V330, P343, DOI 10.1016/S0022-2836(03)00575-8; Wang GC, 1997, BIOCHEM J, V328, P897, DOI 10.1042/bj3280897; Yuan YR, 2001, J BIOL CHEM, V276, P32313, DOI 10.1074/jbc.M100758200	57	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36857	36864		10.1074/jbc.M503266200	http://dx.doi.org/10.1074/jbc.M503266200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16107340	hybrid, Green Published			2022-12-27	WOS:000232901800041
J	Hurne, AM; O'Brien, JJ; Wingrove, D; Cherednichenko, G; Allen, PD; Beam, KG; Pessah, IN				Hurne, AM; O'Brien, JJ; Wingrove, D; Cherednichenko, G; Allen, PD; Beam, KG; Pessah, IN			Ryanodine receptor type 1 (RyR1) mutations C4958S and C4961S reveal excitation-coupled calcium entry (ECCE) is independent of sarcoplasmic reticulum store depletion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II-III-LOOP; OPERATED CA2+ ENTRY; INOSITOL TRISPHOSPHATE RECEPTOR; GREEN FLUORESCENT PROTEIN; SKELETAL-MUSCLE; DIHYDROPYRIDINE-RECEPTOR; ENDOPLASMIC-RETICULUM; RELEASE CHANNEL; HYPERREACTIVE SULFHYDRYLS; REDOX SENSOR	Bi-directional signaling between ryanodine receptor type 1 (RyR1) and dihydropyridine receptor ( DHPR) in skeletal muscle serves as a prominent example of conformational coupling. Evidence for a physiological mechanism that upon depolarization of myotubes tightly couples three calcium channels, DHPR, RyR1, and a Ca2+ entry channel with SOCC-like properties, has recently been presented ( Cherednichenko, G., Hurne, A. M., Fessenden, J. D., Lee, E. H., Allen, P. D., Beam, K. G., and Pessah, I. N. ( 2004) Proc. Natl. Acad. Sci. U. S. A. 101, 15793 - 15798). This form of conformational coupling, termed excitation-coupled calcium entry (ECCE) is triggered by the alpha(1s)-DHPR voltage sensor and is highly dependent on RyR1 conformation. In this report, we substitute RyR1 cysteines 4958 or 4961 within the TXCFICG motif, common to all ER/SR Ca2+ channels, with serine. When expressed in skeletal myotubes, C4958S- and C4961S-RyR1 properly target and restore L-type current via the DHPR. However, these mutants do not respond to RyR activators and do not support skeletal type EC coupling. Nonetheless, depolarization of cells expressing C4958S- or C4961S-RyR1 triggers calcium entry via ECCE that resembles that for wild-type RyR1, except for substantially slowed inactivation and deactivation kinetics. ECCE in these cells is completely independent of store depletion, displays a cation selectivity of Ca2+> Sr2+ similar to Ba2+, and is fully inhibited by SKF-96365 or 2-APB. Mutation of other non-CXXC motif cysteines within the RyR1 transmembrane assembly (C3635S, C4876S, and C4882S) did not replicate the phenotype observed with C4958S- and C4961S-RyR1. This study demonstrates the essential role of Cys(4958) and Cys(4961) within an invariant CXXC motif for stabilizing conformations of RyR1 that influence both its function as a release channel and its interaction with ECCE channels.	Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA; Univ Calif Davis, Ctr Childrens Environm Hlth & Dis Prevent, Davis, CA 95616 USA; Colorado State Univ, Dept Biomed Sci, Ft Collins, CO 80523 USA; Brigham & Womens Hosp, Dept Anesthesia Perioperat & Pain Med, Boston, MA 02115 USA	University of California System; University of California Davis; University of California System; University of California Davis; Colorado State University; Harvard University; Brigham & Women's Hospital	Pessah, IN (corresponding author), Univ Calif Davis, Dept VM Mol Biosci, Davis, CA 95616 USA.	inpessah@ucdavis.edu	Pessah, Isaac N/K-7985-2017	Pessah, Isaac N/0000-0002-8149-588X	NIAMS NIH HHS [2R01 AR43140, 2P0 AR17605] Funding Source: Medline; NIEHS NIH HHS [1P0ES11269] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011269] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aghdasi B, 1997, J BIOL CHEM, V272, P3739, DOI 10.1074/jbc.272.6.3739; AIREY JA, 1990, J BIOL CHEM, V265, P14187; Anelli T, 2002, EMBO J, V21, P835, DOI 10.1093/emboj/21.4.835; Avila G, 2000, J GEN PHYSIOL, V115, P467, DOI 10.1085/jgp.115.4.467; Avila G, 2001, J BIOL CHEM, V276, P17732, DOI 10.1074/jbc.M009685200; Bakowski D, 2003, J PHYSIOL-LONDON, V553, P387, DOI 10.1113/jphysiol.2003.055335; Barritt GJ, 1999, BIOCHEM J, V337, P153, DOI 10.1042/0264-6021:3370153; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Beurg M, 1999, BIOPHYS J, V77, P2953, DOI 10.1016/S0006-3495(99)77128-6; Bezzerides VJ, 2004, NAT CELL BIOL, V6, P709, DOI 10.1038/ncb1150; Chavis P, 1998, EUR J NEUROSCI, V10, P2322, DOI 10.1046/j.1460-9568.1998.00243.x; Chavis P, 1996, NATURE, V382, P719, DOI 10.1038/382719a0; Cherednichenko G, 2004, P NATL ACAD SCI USA, V101, P15793, DOI 10.1073/pnas.0403485101; CLEMENTI E, 1992, J BIOL CHEM, V267, P2164; Dirksen RT, 1999, J GEN PHYSIOL, V114, P393, DOI 10.1085/jgp.114.3.393; Diver JM, 2001, CELL CALCIUM, V30, P323, DOI 10.1054/ceca.2001.0239; Dulhunty A, 2000, ANTIOXID REDOX SIGN, V2, P27, DOI 10.1089/ars.2000.2.1-27; Elliott AC, 2001, CELL CALCIUM, V30, P73, DOI 10.1054/ceca.2001.0215; Feng W, 2000, J BIOL CHEM, V275, P35902, DOI 10.1074/jbc.C000523200; Fessenden JD, 2001, P NATL ACAD SCI USA, V98, P2865, DOI 10.1073/pnas.041608898; Fleig A, 1996, J PHYSIOL-LONDON, V496, P339, DOI 10.1113/jphysiol.1996.sp021689; Fomenko DE, 2003, BIOCHEMISTRY-US, V42, P11214, DOI 10.1021/bi034459s; Fomenko DE, 2002, PROTEIN SCI, V11, P2285, DOI 10.1110/ps.0218302; Grabner M, 1998, P NATL ACAD SCI USA, V95, P1903, DOI 10.1073/pnas.95.4.1903; Grabner M, 1999, J BIOL CHEM, V274, P21913, DOI 10.1074/jbc.274.31.21913; Hamilton SL, 2000, ANTIOXID REDOX SIGN, V2, P41, DOI 10.1089/ars.2000.2.1-41; Holmgren Arne, 2000, Biofactors, V11, P63; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov KI, 2000, MOL CELL, V6, P421, DOI 10.1016/S1097-2765(00)00041-1; Kurebayashi N, 2001, J PHYSIOL-LONDON, V533, P185, DOI 10.1111/j.1469-7793.2001.0185b.x; Launikonis BS, 2003, P NATL ACAD SCI USA, V100, P2941, DOI 10.1073/pnas.0536227100; LIU GH, 1994, J BIOL CHEM, V269, P33028; LIU GH, 1994, MOL PHARMACOL, V45, P189; Lorenzon NM, 2001, ARCH BIOCHEM BIOPHYS, V388, P13, DOI 10.1006/abbi.2000.2263; Ma JJ, 2003, CELL CALCIUM, V33, P375, DOI 10.1016/S0143-4160(03)00050-2; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; Moore RA, 1998, J CELL BIOL, V140, P843, DOI 10.1083/jcb.140.4.843; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; Nakai J, 1998, J BIOL CHEM, V273, P24983, DOI 10.1074/jbc.273.39.24983; O'Brien JJ, 2002, BIOPHYS J, V82, P2428, DOI 10.1016/S0006-3495(02)75586-0; Paolini C, 2004, P NATL ACAD SCI USA, V101, P12748, DOI 10.1073/pnas.0404836101; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Parekh AB, 2003, J PHYSIOL-LONDON, V547, P333, DOI 10.1113/jphysiol.2002.034140; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Perez CF, 2003, J BIOL CHEM, V278, P39644, DOI 10.1074/jbc.M305160200; Perez CF, 2003, BIOPHYS J, V84, P2655, DOI 10.1016/S0006-3495(03)75071-1; Perez GJ, 1999, J GEN PHYSIOL, V113, P229, DOI 10.1085/jgp.113.2.229; Pessah IN, 2002, FRONT BIOSCI-LANDMRK, V7, pA72, DOI 10.2741/pessah; Protasi F, 1998, J CELL BIOL, V140, P831, DOI 10.1083/jcb.140.4.831; Protasi F, 2002, BIOPHYS J, V83, P3230, DOI 10.1016/S0006-3495(02)75325-3; Putney JW, 2004, TRENDS CELL BIOL, V14, P282, DOI 10.1016/j.tcb.2004.04.002; Putney JW, 2001, J CELL SCI, V114, P2223; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; RINK TJ, 1990, FEBS LETT, V268, P381, DOI 10.1016/0014-5793(90)81290-5; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; Smani T, 2004, NAT CELL BIOL, V6, P113, DOI 10.1038/ncb1089; Sun JH, 2001, J BIOL CHEM, V276, P15625, DOI 10.1074/jbc.M100083200; Takekura H, 2004, MOL BIOL CELL, V15, P5408, DOI 10.1091/mbc.E04-05-0414; Taylor CW, 2002, CELL, V111, P767, DOI 10.1016/S0092-8674(02)01197-2; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Uehara A, 2002, CELL CALCIUM, V31, P89, DOI 10.1054/ceca.2001.0257; Voss AA, 2004, J BIOL CHEM, V279, P34514, DOI 10.1074/jbc.M404290200; Wang Y, 2000, AM J PHYSIOL-CELL PH, V278, pC619, DOI 10.1152/ajpcell.2000.278.3.C619; Wilkens CM, 2001, P NATL ACAD SCI USA, V98, P5892, DOI 10.1073/pnas.101618098; Xia RH, 2000, J BIOL CHEM, V275, P36556, DOI 10.1074/jbc.M007613200; ZIMANYI I, 1992, MOL PHARMACOL, V42, P1049	71	44	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36994	37004		10.1074/jbc.M506441200	http://dx.doi.org/10.1074/jbc.M506441200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16120606	hybrid			2022-12-27	WOS:000232901800057
J	Jones, HM; Hamilton, KL; Devor, DC				Jones, HM; Hamilton, KL; Devor, DC			Role of an S4-S5 linker lysine in the trafficking of the Ca2+-activated K+ channels IK1 and SK3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNEL; LONG QT SYNDROME; INTERMEDIATE-CONDUCTANCE; ENDOPLASMIC-RETICULUM; CHLORIDE SECRETION; ARACHIDONIC-ACID; T84 CELLS; K(IR)1.1 CHANNELS; CYSTIC-FIBROSIS; GATING DOMAIN	We have investigated the role of the S4-S5 linker in the trafficking of the intermediate (human (h) IK1) and small (rat SK3) conductance K+ channels using a combination of patch-clamp, protein biochemical, and immunofluorescence-based techniques. We demonstrate that a lysine residue (Lys(197)) located on the intracellular loop between the S4 and S5 domains is necessary for the correct trafficking of hIK1 to the plasma membrane. Mutation of this residue to either alanine or methionine precluded trafficking of the channel to the membrane, whereas the charge-conserving arginine mutation had no effect on channel localization or function. Immunofluorescence localization demonstrated that the K197A mutation resulted in a channel that was primarily retained in the endoplasmic reticulum, and this could not be rescued by incubation at 27 degrees C. Furthermore, immunoblot analysis revealed that the K197A mutation was overexpressed compared with wild-type hIK1 and that this was due to a greatly diminished rate of channel degradation. Co-immunoprecipitation studies demonstrated that the K197A mutation did not preclude multimer formation. Indeed, the K197A mutation dramatically suppressed expression of wild-type hIK1 at the cell surface. Finally, mutation of this conserved lysine in rat SK3 similarly resulted in a channel that failed to correctly traffic to the plasma membrane. These results are the first to demonstrate a critical role for the S4-S5 linker in the trafficking and/or function of IK and SK channels.	Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; Univ Otago, Dept Physiol, Dunedin, New Zealand	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Otago	Devor, DC (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, S312 BST,3500 Terrace St, Pittsburgh, PA 15261 USA.	dd2@pitt.edu			NIDDK NIH HHS [DK54941, T32-DK061296] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK061296, R01DK054941] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adeagbo ASO, 1999, EUR J PHARMACOL, V379, P151, DOI 10.1016/S0014-2999(99)00489-6; Alvarez C, 2001, J BIOL CHEM, V276, P2693, DOI 10.1074/jbc.M007957200; Begenisich T, 2004, J BIOL CHEM, V279, P47681, DOI 10.1074/jbc.M409627200; Caprini M, 2005, J BIOL CHEM, V280, P18253, DOI 10.1074/jbc.M413389200; Chiavegatto S, 2001, P NATL ACAD SCI USA, V98, P1277, DOI 10.1073/pnas.031487198; Clay JR, 2002, J NEUROSCI RES, V67, P745, DOI 10.1002/jnr.10182; Decher N, 2004, J BIOL CHEM, V279, P13859, DOI 10.1074/jbc.M313704200; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Devor DC, 1998, AM J PHYSIOL-CELL PH, V274, pC149, DOI 10.1152/ajpcell.1998.274.1.C149; Devor DC, 1998, AM J PHYSIOL-CELL PH, V274, pC138, DOI 10.1152/ajpcell.1998.274.1.C138; DEVOR DC, 1993, AM J PHYSIOL, V265, pC1271, DOI 10.1152/ajpcell.1993.265.5.C1271; Devor DC, 1997, AM J PHYSIOL-CELL PH, V273, pC531, DOI 10.1152/ajpcell.1997.273.2.C531; DHARMSATHAPHORN K, 1986, J CLIN INVEST, V77, P348, DOI 10.1172/JCI112311; Ficker E, 2003, CIRC RES, V92, pE87, DOI 10.1161/01.RES.0000079028.31393.15; Franqueza L, 1999, J BIOL CHEM, V274, P21063, DOI 10.1074/jbc.274.30.21063; Frenkel Z, 2004, MOL BIOL CELL, V15, P2133, DOI 10.1091/mbc.E03-12-0899; Hamilton KL, 2003, J BIOL CHEM, V278, P16690, DOI 10.1074/jbc.M212959200; Hanley PJ, 2004, P NATL ACAD SCI USA, V101, P9479, DOI 10.1073/pnas.0400733101; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hoffman JF, 2003, P NATL ACAD SCI USA, V100, P7366, DOI 10.1073/pnas.1232342100; Holmgren M, 1996, J GEN PHYSIOL, V108, P195, DOI 10.1085/jgp.108.3.195; HOPPNER CA, 2004, BIOPHYS J S, V86, pA288; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; Ishii TM, 1997, J BIOL CHEM, V272, P23195, DOI 10.1074/jbc.272.37.23195; Joiner WJ, 2001, J BIOL CHEM, V276, P37980; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; Jones HM, 2005, BIOPHYS J, V88, p469A; Jones HM, 2004, J BIOL CHEM, V279, P15531, DOI 10.1074/jbc.M400069200; Khanna R, 1999, J BIOL CHEM, V274, P14838, DOI 10.1074/jbc.274.21.14838; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; Kohler R, 2000, CIRC RES, V87, P496; Kohler R, 2003, CIRCULATION, V108, P1119, DOI 10.1161/01.CIR.0000086464.04719.DD; Koster JC, 1998, BIOPHYS J, V74, P1821, DOI 10.1016/S0006-3495(98)77892-0; KRIJNSELOCKER J, 1995, MOL BIOL CELL, V6, P1315, DOI 10.1091/mbc.6.10.1315; Kubota T, 2000, J CARDIOVASC ELECTR, V11, P1048, DOI 10.1111/j.1540-8167.2000.tb00178.x; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Long SB, 2005, SCIENCE, V309, P903, DOI 10.1126/science.1116270; Lu Z, 2002, J GEN PHYSIOL, V120, P663, DOI 10.1085/jgp.20028696; Mauler F, 2004, EUR J NEUROSCI, V20, P1761, DOI 10.1111/j.1460-9568.2004.03615.x; Nathan DF, 1997, P NATL ACAD SCI USA, V94, P12949, DOI 10.1073/pnas.94.24.12949; Odunuga OO, 2003, J BIOL CHEM, V278, P6896, DOI 10.1074/jbc.M206867200; Ouadid-Ahidouch H, 2001, RECEPTOR CHANNEL, V7, P345; Pedersen KA, 2000, PFLUG ARCH EUR J PHY, V440, P153, DOI 10.1007/s004240051033; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; Reich EP, 2005, EUR J IMMUNOL, V35, P1027, DOI 10.1002/eji.200425954; Rufo PA, 1997, J CLIN INVEST, V100, P3111, DOI 10.1172/JCI119866; Sanguinetti MC, 1999, J PHYSIOL-LONDON, V514, P667, DOI 10.1111/j.1469-7793.1999.667ad.x; Schnaider T, 1999, LIFE SCI, V65, P2417, DOI 10.1016/S0024-3205(99)00508-1; Schulte U, 2001, J PHYSIOL-LONDON, V534, P49, DOI 10.1111/j.1469-7793.2001.t01-1-00049.x; Schulte U, 1999, P NATL ACAD SCI USA, V96, P15298, DOI 10.1073/pnas.96.26.15298; Schumacher MA, 2004, STRUCTURE, V12, P849, DOI 10.1016/S0969-2126(04)00112-1; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; Singh S, 2001, J PHARMACOL EXP THER, V296, P600; SLESINGER PA, 1993, NEURON, V11, P739, DOI 10.1016/0896-6273(93)90083-4; Stockklausner C, 2003, J BIOL CHEM, V278, P17000, DOI 10.1074/jbc.M212243200; Syme CA, 2003, J BIOL CHEM, V278, P8476, DOI 10.1074/jbc.M210072200; Szkotak AJ, 2004, BRIT J PHARMACOL, V142, P531, DOI 10.1038/sj.bjp.0705846; Tristani-Firouzi M, 2002, J BIOL CHEM, V277, P18994, DOI 10.1074/jbc.M200410200; Ueda K, 2004, J BIOL CHEM, V279, P27194, DOI 10.1074/jbc.M311953200; Wible BA, 1998, J BIOL CHEM, V273, P11745, DOI 10.1074/jbc.273.19.11745; Wulff H, 2001, J BIOL CHEM, V276, P32040, DOI 10.1074/jbc.M105231200; Zhou ZF, 1999, J BIOL CHEM, V274, P31123, DOI 10.1074/jbc.274.44.31123	63	20	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37257	37265		10.1074/jbc.M508601200	http://dx.doi.org/10.1074/jbc.M508601200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16135513	hybrid			2022-12-27	WOS:000232901800084
J	Meruvu, S; Walther, M; Ivanov, I; Hammarstrom, S; Furstenberger, G; Krieg, P; Reddanna, P; Kuhn, H				Meruvu, S; Walther, M; Ivanov, I; Hammarstrom, S; Furstenberger, G; Krieg, P; Reddanna, P; Kuhn, H			Sequence determinants for the reaction specificity of murine (12R)-lipoxygenase - Targeted substrate modification and site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITIONAL SPECIFICITY; SOYBEAN LIPOXYGENASE-1; ARACHIDONIC-ACID; ACTIVE-SITE; MOLECULAR-CLONING; 12-LIPOXYGENASE; 15-LIPOXYGENASE; LEUKOTRIENES; ALIGNMENT; EPIDERMIS	Mammalian lipoxygenases (LOXs) are categorized with respect to their positional specificity of arachidonic acid oxygenation. Site-directed mutagenesis identified sequence determinants for the positional specificity of these enzymes, and a critical amino acid for the stereoselectivity was recently discovered. To search for sequence determinants of murine (12R)-LOX, we carried out multiple amino acid sequence alignments and found that Phe(390), Gly(441), Ala(455), and Val(631) align with previously identified positional determinants of S-LOX isoforms. Multiple site-directed mutagenesis studies on Phe(390) and Ala(455) did not induce specific alterations in the reaction specificity, but yielded enzyme species with reduced specific activities and stereo random product patterns. Mutation of Gly(441) to Ala, which caused drastic alterations in the reaction specificity of other LOX isoforms, failed to induce major alterations in the positional specificity of mouse (12R)-LOX, but markedly modified the enantioselectivity of the enzyme. When Val(631), which aligns with the positional determinant Ile(593) of rabbit 15-LOX, was mutated to a less space-filling residue ( Ala or Gly), we obtained an enzyme species with augmented catalytic activity and specifically altered reaction characteristics ( major formation of chiral (11R)hydroxyeicosatetraenoic acid methyl ester). The importance of Val(631) for the stereo control of murine (12R)-LOX was confirmed with other substrates such as methyl linoleate and 20-hydroxyeicosatetraenoic acid methyl ester. These data identify Val(631) as the major sequence determinant for the specificity of murine ( 12R)LOX. Furthermore, we conclude that substrate fatty acids may adopt different catalytically productive arrangements at the active site of murine ( 12R)-LOX and that each of these arrangements may lead to the formation of chiral oxygenation products.	Univ Med Berlin Charite, Inst Biochem, D-10117 Berlin, Germany; Linkoping Univ, Div Cell Biol, SE-58185 Linkoping, Sweden; Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany; Univ Hyderabad, Sch Life Sci, Hyderabad 500046, Andhra Pradesh, India	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Linkoping University; Helmholtz Association; German Cancer Research Center (DKFZ); University of Hyderabad	Kuhn, H (corresponding author), Univ Med Berlin Charite, Inst Biochem, Monbijoustr 2, D-10117 Berlin, Germany.	hartmut.kuehn@charite.de	Ivanov, Igor V./I-5606-2016	Ivanov, Igor V./0000-0003-0543-2067				Boeglin WE, 1998, P NATL ACAD SCI USA, V95, P6744, DOI 10.1073/pnas.95.12.6744; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; Brash AR, 1996, J BIOL CHEM, V271, P20949, DOI 10.1074/jbc.271.34.20949; Browner MF, 1998, NAT STRUCT BIOL, V5, P179, DOI 10.1038/nsb0398-179; Cathcart MK, 2000, FREE RADICAL BIO MED, V28, P1726, DOI 10.1016/S0891-5849(00)00230-6; Coffa G, 2004, P NATL ACAD SCI USA, V101, P15579, DOI 10.1073/pnas.0406727101; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GARDNER HW, 1989, BIOCHIM BIOPHYS ACTA, V1001, P274, DOI 10.1016/0005-2760(89)90111-2; Gillmor SA, 1997, NAT STRUCT BIOL, V4, P1003, DOI 10.1038/nsb1297-1003; HAMMARSTROM S, 1975, P NATL ACAD SCI USA, V72, P5130, DOI 10.1073/pnas.72.12.5130; Ivanov I, 2001, BIOCHEMISTRY-US, V40, P10223, DOI 10.1021/bi010700w; Jisaka M, 2000, J BIOL CHEM, V275, P1287, DOI 10.1074/jbc.275.2.1287; Klein RF, 2004, SCIENCE, V303, P229, DOI 10.1126/science.1090985; Krieg P, 1999, FEBS LETT, V446, P142, DOI 10.1016/S0014-5793(99)00196-9; KUHN H, 1990, J BIOL CHEM, V265, P16300; Kuhn H, 2000, PROSTAG OTH LIPID M, V62, P255, DOI 10.1016/S0090-6980(00)00084-8; Pidgeon GP, 2002, CANCER RES, V62, P2721; Prigge ST, 1998, NAT STRUCT BIOL, V5, P178, DOI 10.1038/nsb0398-178; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Schwarz K, 1998, BIOCHEMISTRY-US, V37, P15327, DOI 10.1021/bi9816204; Serhan CN, 2003, CHEM IMMUNOL, V83, P115; Siebert M, 2001, BIOCHEM J, V355, P97, DOI 10.1042/0264-6021:3550097; SLOANE DL, 1991, NATURE, V354, P149, DOI 10.1038/354149a0; SUZUKI H, 1994, BBA-LIPID LIPID MET, V1210, P308, DOI 10.1016/0005-2760(94)90234-8; Thuresson ED, 2000, J BIOL CHEM, V275, P8501, DOI 10.1074/jbc.275.12.8501; van Leyen K, 1998, NATURE, V395, P392, DOI 10.1038/26500; VANOS CPA, 1981, BIOCHIM BIOPHYS ACTA, V663, P177, DOI 10.1016/0005-2760(81)90204-6; WALTHER M, 2001, CHEM BIOL, V115, P1; WATANABE T, 1993, BIOCHEM BIOPH RES CO, V192, P1023, DOI 10.1006/bbrc.1993.1519	29	34	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36633	36641		10.1074/jbc.M508260200	http://dx.doi.org/10.1074/jbc.M508260200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16129665	hybrid			2022-12-27	WOS:000232901800014
J	Xia, M; Hou, MJ; Zhu, HL; Ma, J; Tang, ZH; Wang, Q; Li, Y; Chi, DS; Yu, XP; Zhao, T; Han, PH; Xia, XD; Ling, WH				Xia, M; Hou, MJ; Zhu, HL; Ma, J; Tang, ZH; Wang, Q; Li, Y; Chi, DS; Yu, XP; Zhao, T; Han, PH; Xia, XD; Ling, WH			Anthocyanins induce cholesterol efflux from mouse peritoneal macrophages - The role of the peroxisome proliferator-activated receptor gamma-liver X receptor alpha-ABCA1 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; PPAR-GAMMA; CELLULAR CHOLESTEROL; ABCA1; CELLS; ATHEROSCLEROSIS; EXPRESSION; DIFFERENTIATION; METABOLISM; MECHANISMS	It is widely accepted that stimulation of reverse cholesterol transport, the efflux of excess cholesterol from peripheral tissues and transferring it to the liver for biliary excretion, is becoming an important component in reducing excess cholesterol deposition in atherosclerotic plaques. The ATP-binding cassette transporter has been identified as a key regulator of macrophage cholesterol efflux and apoAI-mediated reverse cholesterol transport. In vivo studies have documented anthocyanins, a large group of naturally phenolic compounds rich in plants, possess substantial capacities in improving plasma cholesterol levels. In this study, we investigated the potential role of anthocyanins in modulating cholesterol efflux from mouse peritoneal macrophages and macrophage-derived foam cells and the possible molecular mechanism linking ABCA1 to cholesterol efflux. Incubation of the mouse peritoneal macrophages and macrophage-derived foam cells with cyanidin-3-O-beta-glucoside and peonidin-3-O-beta-glucoside led to dose-dependent ( 1 - 100 mu M) induction in cholesterol efflux and ABCA1 mRNA expression, and this effect could be blocked by the ABCA1 inhibitor 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid, disodium salt, and a general inhibitor of gene transcription actinomycin D. Treatment of the macrophages with anthocyanins also activated peroxisome proliferator-activated receptor gamma, liver X receptor alpha mRNA expression, and their mediated gene expression. Addition of geranylgeranyl pyrophosphate ammonium salt or GW9662 markedly inhibited the anthocyanin-induced increase of ABCA1 gene expression and apoAI-mediated cholesterol efflux. These data demonstrated that anthocyanin induces cholesterol efflux from mouse peritoneal macrophages and macrophage-derived foam cells and that stimulation of cholesterol efflux by anthocyanin is mediated, at least in part, by peroxisome proliferator-activated receptor gamma-liver X receptor alpha-ABCA1 signaling pathway activation.	Sun Yat Sen Univ, Sch Publ Hlth, Dept Nutr, Guangzhou 510080, Guangdong, Peoples R China	Sun Yat Sen University	Ling, WH (corresponding author), Sun Yat Sen Univ, Sch Publ Hlth, Dept Nutr, No Campus,Zhongshan Rd 2, Guangzhou 510080, Guangdong, Peoples R China.	whling@gzsums.edu.cn						Acquaviva R, 2003, CELL BIOL TOXICOL, V19, P243, DOI 10.1023/B:CBTO.0000003974.27349.4e; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chinetti G, 2003, CIRC RES, V92, P212, DOI 10.1161/01.RES.0000053386.46813.E9; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; Costet P, 2000, J BIOL CHEM, V275, P28240; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; FALK E, 1992, CIRCULATION, V86, P30; Favari E, 2004, ARTERIOSCL THROM VAS, V24, P2345, DOI 10.1161/01.ATV.0000148706.15947.8a; Field FJ, 2004, J LIPID RES, V45, P905, DOI 10.1194/jlr.M300473-JLR200; HARBORNE JB, 1988, FLAVONOIDS ADV RES 1, P1, DOI DOI 10.1007/978-1-4899-2913-6_1; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Kritharides L, 1998, ARTERIOSCL THROM VAS, V18, P1589, DOI 10.1161/01.ATV.18.10.1589; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Le Goff W, 2004, ARTERIOSCL THROM VAS, V24, P2155, DOI 10.1161/01.ATV.0000144811.94581.52; Le Lay S, 2003, J LIPID RES, V44, P1499, DOI 10.1194/jlr.M200466-JLR200; Liuzzo G, 2001, Rays, V26, P221; Lougheed M, 1999, ARTERIOSCL THROM VAS, V19, P1881, DOI 10.1161/01.ATV.19.8.1881; LOWRY OH, 1951, J BIOL CHEM, V193, P275; Marx N, 1999, ARTERIOSCL THROM VAS, V19, P546, DOI 10.1161/01.ATV.19.3.546; Marx N, 1998, AM J PATHOL, V153, P17, DOI 10.1016/S0002-9440(10)65540-X; Moller P, 2004, MUTAT RES-FUND MOL M, V551, P119, DOI 10.1016/j.mrfmmm.2004.02.020; Oram JF, 2000, CURR OPIN LIPIDOL, V11, P253, DOI 10.1097/00041433-200006000-00005; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; OTTNAD E, 1995, P NATL ACAD SCI USA, V92, P1391, DOI 10.1073/pnas.92.5.1391; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Ruan XZ, 2003, J AM SOC NEPHROL, V14, P593, DOI 10.1097/01.ASN.0000050414.52908.DA; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Strohm C, 2002, CARDIOVASC RES, V55, P602, DOI 10.1016/S0008-6363(02)00453-4; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Wang YT, 2002, J BIOL CHEM, V277, P5692, DOI 10.1074/jbc.M109977200; Williams CA, 2004, NAT PROD REP, V21, P539, DOI 10.1039/b311404j; Witting SR, 2003, J BIOL CHEM, V278, P40121, DOI 10.1074/jbc.M305193200; Xia M, 2003, J NUTR, V133, P744, DOI 10.1093/jn/133.3.744; Zaman AG, 2000, ATHEROSCLEROSIS, V149, P251, DOI 10.1016/S0021-9150(99)00479-7; Zhang YY, 2002, MOL GENET METAB, V77, P150, DOI 10.1016/S1096-7192(02)00111-7	40	117	135	0	34	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36792	36801		10.1074/jbc.M505047200	http://dx.doi.org/10.1074/jbc.M505047200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16107338	hybrid			2022-12-27	WOS:000232901800033
J	Liu, Y; Soto, I; Tong, Q; Chin, A; Buhring, HJ; Wu, T; Zen, K; Parkos, CA				Liu, Y; Soto, I; Tong, Q; Chin, A; Buhring, HJ; Wu, T; Zen, K; Parkos, CA			SIRP beta 1 is expressed as a disulfide-linked homodimer in leukocytes and positively regulates neutrophil transepithelial migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER-CELLS; INTEGRIN-ASSOCIATED PROTEIN; T-CELL; MYELOID CELLS; SIRP-ALPHA; NEGATIVE REGULATION; ADHESION MOLECULE; ACTIVATION MOTIF; DENDRITIC CELLS; CUTTING EDGE	Signal regulatory proteins (SIRPs) comprise a family of cell surface signaling receptors differentially expressed in leukocytes and the central nervous system. Although the extracellular domains of SIRPs are highly similar, classical motifs in the cytoplasmic or transmembrane domains distinguish them as either activating (beta) or inhibitory (alpha) isoforms. We reported previously that human neutrophils ( polymorphonuclear leukocytes (PMN)) express multiple SIRP isoforms and that SIRP alpha binding to its ligand CD47 regulates PMN transmigration. Here we further characterized the expression of PMN SIRPs, and we reported that the major SIRP alpha and SIRP beta isoforms expressed in PMN include Bit/PTPNS-1 and SIRP beta 1, respectively. Furthermore, although SIRP alpha (Bit/PTPNS-1) is expressed as a monomer, we showed that SIRP beta 1 is expressed on the cell surface as a disulfide-linked homodimer with bond formation mediated by Cys-320 in the membrane-proximal Ig loop. Subcellular fractionation studies revealed a major pool of SIRP beta 1 within the plasma membrane fractions of PMN. In contrast, the majority of SIRP alpha(Bit/PTPNS-1) is present in fractions enriched in secondary granules and is translocated to the cell surface after chemoattractant (formylmethionylleucylphenylalanine) stimulation. Functional studies revealed that antibody-mediated ligation of SIRP beta 1 enhanced formylmethionylleucylphenylalanine-driven PMN transepithelial migration. Co-immunoprecipitation experiments to identify associated adaptor proteins revealed a 10-12-kDa protein associated with SIRP beta 1 that was tyrosine-phosphorylated after PMN stimulation and is not DAP10/12 or Fc receptor gamma chain. These results provide new insights into the structure and function of SIRPs in leukocytes and their potential role(s) in fine-tuning responses to inflammatory stimuli.	Georgia State Univ, Dept Biol, Atlanta, GA 30302 USA; Emory Univ, Dept Pathol & Lab Med, Epithelial Pathobiol Res Unit, Atlanta, GA 30322 USA; Univ Tubingen, Dept Internal Med 2, Div Hematol Immunol & Oncol, Tubingen, Germany	University System of Georgia; Georgia State University; Emory University; Eberhard Karls University of Tubingen	Liu, Y (corresponding author), Georgia State Univ, Dept Biol, POB 4010, Atlanta, GA 30303 USA.	yliu@gsu.edu; cparkos@emory.edu	Parkos, Charles a/B-3896-2009	Mauldin, Ileana/0000-0002-9318-8342	NIDDK NIH HHS [DK61379, DK62894, DK72564, DK064399] Funding Source: Medline; PHS HHS [DL72124] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK062894, R01DK072564, R01DK061379, R24DK064399] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams S, 1998, J IMMUNOL, V161, P1853; Brooke G, 2004, J IMMUNOL, V173, P2562, DOI 10.4049/jimmunol.173.4.2562; Chen TT, 2004, CANCER RES, V64, P117, DOI 10.1158/0008-5472.CAN-3455-2; Chiesa S, 2005, MOL IMMUNOL, V42, P477, DOI 10.1016/j.molimm.2004.07.030; de Vries HE, 2002, J IMMUNOL, V168, P5832, DOI 10.4049/jimmunol.168.11.5832; Dietrich J, 2000, J IMMUNOL, V164, P9, DOI 10.4049/jimmunol.164.1.9; Florian S, 2005, J LEUKOCYTE BIOL, V77, P984, DOI 10.1189/jlb.0604349; Han X, 2000, J BIOL CHEM, V275, P37984, DOI 10.1074/jbc.M002334200; Hope JC, 2001, J LEUKOCYTE BIOL, V69, P271; Jiang PH, 1999, J BIOL CHEM, V274, P559, DOI 10.1074/jbc.274.2.559; Kapoor GS, 2004, CANCER RES, V64, P6444, DOI 10.1158/0008-5472.CAN-04-0256; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; LANIER LL, 1991, J IMMUNOL, V146, P1571; Lanier LL, 2003, CURR OPIN IMMUNOL, V15, P308, DOI 10.1016/S0952-7915(03)00039-6; Lanier LL, 2001, NAT IMMUNOL, V2, P23, DOI 10.1038/83130; Lanier LL, 1998, IMMUNITY, V8, P693, DOI 10.1016/S1074-7613(00)80574-9; Lanier LL, 1998, NATURE, V391, P703, DOI 10.1038/35642; Latour S, 2001, J IMMUNOL, V167, P2547, DOI 10.4049/jimmunol.167.5.2547; Litman GW, 2001, IMMUNOL REV, V181, P250, DOI 10.1034/j.1600-065X.2001.1810121.x; Liu Y, 2004, J IMMUNOL, V172, P2578, DOI 10.4049/jimmunol.172.4.2578; Liu Y, 2002, J BIOL CHEM, V277, P10028, DOI 10.1074/jbc.M109720200; Liu Y, 2000, J CELL SCI, V113, P2363; Liu Y, 2001, J BIOL CHEM, V276, P40156, DOI 10.1074/jbc.M104138200; Mi ZP, 2000, J COMP NEUROL, V416, P335; Nakajima H, 1999, J IMMUNOL, V162, P5; Ohnishi H, 1996, J BIOL CHEM, V271, P25569, DOI 10.1074/jbc.271.41.25569; Olcese L, 1997, J IMMUNOL, V158, P5083; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; Parkos CA, 1996, J CELL BIOL, V132, P437, DOI 10.1083/jcb.132.3.437; Piccio L, 2005, BLOOD, V105, P2421, DOI 10.1182/blood-2004-07-2823; REINHOLD MI, 1995, J CELL SCI, V108, P3419; Saginario C, 1998, MOL CELL BIOL, V18, P6213, DOI 10.1128/MCB.18.11.6213; Seiffert M, 1999, BLOOD, V94, P3633, DOI 10.1182/blood.V94.11.3633.423k01_3633_3643; Seiffert M, 2001, BLOOD, V97, P2741, DOI 10.1182/blood.V97.9.2741; Taniguchi H, 2004, BIOCHEM BIOPH RES CO, V319, P178, DOI 10.1016/j.bbrc.2004.04.173; Tomasello E, 2000, EUR J IMMUNOL, V30, P2147, DOI 10.1002/1521-4141(2000)30:8<2147::AID-IMMU2147>3.0.CO;2-1; Veillette A, 1998, J BIOL CHEM, V273, P22719, DOI 10.1074/jbc.273.35.22719; Vernon-Wilson EF, 2000, EUR J IMMUNOL, V30, P2130; Voehringer D, 2004, J BIOL CHEM, V279, P54117, DOI 10.1074/jbc.M406997200; Wu J, 2000, J EXP MED, V192, P1059, DOI 10.1084/jem.192.7.1059; Yan HX, 2004, HEPATOLOGY, V40, P618, DOI 10.1002/hep.20360	41	38	39	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36132	36140		10.1074/jbc.M506419200	http://dx.doi.org/10.1074/jbc.M506419200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16081415	hybrid			2022-12-27	WOS:000232726900044
J	Mare, L; Iatta, R; Montagna, MT; Luberto, C; Del Poeta, M				Mare, L; Iatta, R; Montagna, MT; Luberto, C; Del Poeta, M			APP1 transcription is regulated by inositolphosphorylceramide synthase 1-diacylglycerol pathway and is controlled by ATF2 transcription factor in Cryptococcus neoformans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SACCHAROMYCES-CEREVISIAE; SPHINGOLIPID METABOLISM; GENE; YEAST; DIACYLGLYCEROL; PKC1; CERAMIDE; HOMOLOG; ENCODES	Inositol-phosphorylceramide synthase 1 (Ipc1) is a fungal-specific enzyme that regulates the level of two bioactive molecules, phytoceramide and diacylglycerol (DAG). In previous studies, we demonstrated that Ipc1 regulates the expression of the antiphagocytic protein 1 (App1), a novel fungal factor involved in pathogenicity of Cryptococcus neoformans. Here, we investigated the molecular mechanism by which Ipc1 regulates App1. To this end, the APP1 promoter was fused to the firefly luciferase gene in the C. neoformans GAL7: IPC1 strain, in which the Ipc1 expression can be modulated, and found that the luciferase activity was indeed regulated when Ipc1 was modulated. Next, using the luciferase reporter assay in both C. neoformans wild-type and GAL7: IPC1 strains, we investigated the role of DAG and sphingolipids in the activation of the APP1 promoter and found that treatment with 1,2-dioctanoylglycerol does increase APP1 transcription, whereas treatment with phytosphingosine or ceramides does not. Two putative consensus sequences were found in the APP1 promoter for ATF and AP-2 transcription factors. Mutagenesis analysis of these sequences revealed that they play a key role in the regulation of APP1 transcription: ATF is an activator, whereas AP-2 in a negative regulator. Finally, we identified a putative Atf2 transcription factor, which is required for APP1 transcription and under the control of Ipc1-DAG pathway. These studies provide novel regulatory mechanisms of the sphingolipid pathway involved in the regulation of gene transcription of C. neoformans.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA; Univ Bari, Dept Internal & Publ Med, I-70124 Bari, Italy	Medical University of South Carolina; Medical University of South Carolina; Universita degli Studi di Bari Aldo Moro	Del Poeta, M (corresponding author), 173 Ashley Ave,BSB 503, Charleston, SC 29425 USA.	delpoeta@musc.edu		Iatta, Roberta/0000-0003-2386-8542; Montagna, Maria Teresa/0000-0002-2958-5458	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056168] Funding Source: NIH RePORTER; NCRR NIH HHS [RR17677] Funding Source: Medline; NIAID NIH HHS [AI56168] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANTONSSON B, 1994, J BIOL CHEM, V269, P16821; BELL R, 1992, ADV EXP MED BIOL, V318, P275; CASADEVALL A, 1998, CRYPTOCOCCUS NEOFORM, P381; Cerbon J, 2005, BIOCHEM J, V388, P169, DOI 10.1042/BJ20040475; Chung N, 2000, METHOD ENZYMOL, V311, P319; Costa M, 1996, EUR J BIOCHEM, V237, P532, DOI 10.1111/j.1432-1033.1996.00532.x; DHAWALE SS, 1993, NUCLEIC ACIDS RES, V21, P5537, DOI 10.1093/nar/21.24.5537; Dickson RC, 1999, BBA-MOL CELL BIOL L, V1438, P305, DOI 10.1016/S1388-1981(99)00068-2; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Heidler SA, 2000, BBA-MOL BASIS DIS, V1500, P147, DOI 10.1016/S0925-4439(99)00097-6; Heung LJ, 2005, J BIOL CHEM, V280, P28547, DOI 10.1074/jbc.M503404200; Heung LJ, 2004, J BIOL CHEM, V279, P21144, DOI 10.1074/jbc.M312995200; Hirayoshi K, 1999, METHOD ENZYMOL, V304, P351; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Jiang K, 1998, BIOCHEM BIOPH RES CO, V246, P192, DOI 10.1006/bbrc.1998.8591; Kawasaki H, 1998, GENE DEV, V12, P233, DOI 10.1101/gad.12.2.233; Kuroda M, 1999, MOL GEN GENET, V261, P290, DOI 10.1007/s004380050969; Loftus BJ, 2005, SCIENCE, V307, P1321, DOI 10.1126/science.1103773; Luberto C, 1999, LIPIDS, V34, pS5, DOI 10.1007/BF02562221; Luberto C, 2003, J CLIN INVEST, V112, P1080, DOI 10.1172/JCI200318309; Luberto C, 2001, GENE DEV, V15, P201, DOI 10.1101/gad.856001; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Paravicini G, 1996, YEAST, V12, P741, DOI 10.1002/(SICI)1097-0061(19960630)12:8<741::AID-YEA967>3.0.CO;2-G; Persengiev SP, 2003, APOPTOSIS, V8, P225, DOI 10.1023/A:1023633704132; PINTO WJ, 1992, J BACTERIOL, V174, P2565, DOI 10.1128/jb.174.8.2565-2574.1992; Spychala J, 1999, J BIOL CHEM, V274, P22705, DOI 10.1074/jbc.274.32.22705; Steinmuller L, 2003, BIOL CHEM, V384, P667, DOI 10.1515/BC.2003.074; Takeda T, 1995, EMBO J, V14, P6193, DOI 10.1002/j.1460-2075.1995.tb00310.x; TOFFALETTI DL, 1993, J BACTERIOL, V175, P1405, DOI 10.1128/JB.175.5.1405-1411.1993; WATANABE M, 1994, J BIOL CHEM, V269, P16829; Welsh N, 1996, J BIOL CHEM, V271, P8307, DOI 10.1074/jbc.271.14.8307; Wilkinson MG, 1996, GENE DEV, V10, P2289, DOI 10.1101/gad.10.18.2289	32	25	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36055	36064		10.1074/jbc.M507285200	http://dx.doi.org/10.1074/jbc.M507285200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16129666	hybrid			2022-12-27	WOS:000232726900035
J	de Mestre, AM; Rao, S; Hornby, JR; Soe-Htwe, T; Khachigian, LM; Hulett, MD				de Mestre, AM; Rao, S; Hornby, JR; Soe-Htwe, T; Khachigian, LM; Hulett, MD			Early growth response gene 1 (EGR1) regulates heparanase gene transcription in tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROSTATE-CANCER; A-CHAIN PROMOTER; MAMMALIAN HEPARANASE; ENDOTHELIAL-CELLS; BREAST-CANCER; IN-VITRO; SULFATE PROTEOGLYCANS; EXPRESSION; METASTASIS; ACTIVATION	Heparanase is an endoglycosidase that degrades heparan sulfate chains of heparan sulfate proteoglycans, a key component of extracellular matrix and basement membranes. Studies using heparanase inhibitors and gene silencing have provided evidence to support an important role for heparanase in tumor metastasis and angiogenesis. The expression of heparanase is normally very tightly controlled, however, it is commonly deregulated in tumor cells, which express elevated heparanase activity that correlates with high levels of heparanase mRNA. We recently identified the transcription factor early growth response gene 1, EGR1, as a key regulator of inducible heparanase transcription in T cells. In this study using chromatin immunoprecipitation, we demonstrate for the first time that EGR1 binds to the heparanase gene promoter in vivo. The important question of the role of EGR1 in regulating heparanase transcription in tumor cells was then assessed. Studies were carried out in four epithelial tumor lines of different tissue origin. Functional dissection of the heparanase promoter identified a 280-bp region that was critical for transcription of the heparanase gene. Transactivation studies using an EGR1 expression vector co-transfected with a reporter construct containing the 280-bp region showed EGR1-activated heparanase promoter activity in a dose-dependent manner in prostate or breast adenocarcinoma and colon carcinoma cell lines. In contrast, overexpression of EGR1 resulted in a dose-dependent repression of promoter activity in melanoma cells. Using site-directed mutagenesis the 280-bp region was found to contain two functional EGR1 sites and electrophoretic mobility shift assays showed binding of EGR1 to both of these sites upon activation of tumor cells. Furthermore, the heparanase promoter region containing the EGR1 sites was also inducible in tumor cells and induction corresponded to HPSE expression levels. These studies show that EGR1 regulates heparanase transcription in tumor cells and importantly, can have a repressive or activating role depending on the tumor type.	Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Genet, Canc & Vasc Biol Grp, Acton, ACT 2601, Australia; Univ New S Wales, Ctr Vasc Res, Sydney, NSW 2052, Australia	Australian National University; John Curtin School of Medical Research; University of New South Wales Sydney	Hulett, MD (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Genet, Canc & Vasc Biol Grp, Acton, ACT 2601, Australia.	mark.hulett@anu.edu.au	Hulett, Mark D/C-4160-2012; Rao, Sudha/AAW-5192-2020; Khachigian, Levon/AAZ-7458-2020; de Mestre, Amanda/H-7455-2018	Rao, Sudha/0000-0001-9547-947X; Khachigian, Levon/0000-0003-3446-0323; Hulett, Mark/0000-0003-2072-5968; de Mestre, Amanda/0000-0002-9422-2370				Abboud-Jarrous G, 2005, J BIOL CHEM, V280, P13568, DOI 10.1074/jbc.M413370200; Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; Aucoin R, 2004, J CELL BIOCHEM, V93, P215, DOI 10.1002/jcb.20231; Baron V, 2003, ANN NY ACAD SCI, V1002, P197, DOI 10.1196/annals.1281.024; Bernard D, 2001, J INVEST DERMATOL, V117, P1266, DOI 10.1046/j.1523-1747.2001.15401.x; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Castellanos MD, 2002, EUR J IMMUNOL, V32, P3108; Chen GP, 2004, BIOCHEMISTRY-US, V43, P4971, DOI 10.1021/bi0356552; Chen XX, 2005, MOL CELL BIOL, V25, P3209, DOI 10.1128/MCB.25.8.3209-3219.2005; Day FL, 1999, J BIOL CHEM, V274, P23726, DOI 10.1074/jbc.274.34.23726; de Mestre AM, 2003, J BIOL CHEM, V278, P50377, DOI 10.1074/jbc.M310154200; Dempsey LA, 2000, GLYCOBIOLOGY, V10, P467, DOI 10.1093/glycob/10.5.467; Dong J, 2000, GENE, V253, P171, DOI 10.1016/S0378-1119(00)00251-1; Edovitsky E, 2004, JNCI-J NATL CANCER I, V96, P1219, DOI 10.1093/jnci/djh230; Eid MA, 1998, CANCER RES, V58, P2461; Elkin M, 2003, CANCER RES, V63, P8821; Fahmy RG, 2003, NAT MED, V9, P1026, DOI 10.1038/nm905; Fairbanks MB, 1999, J BIOL CHEM, V274, P29587, DOI 10.1074/jbc.274.42.29587; Friedmann Y, 2000, AM J PATHOL, V157, P1167, DOI 10.1016/S0002-9440(10)64632-9; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GODDER K, 1991, J CELL PHYSIOL, V148, P274, DOI 10.1002/jcp.1041480213; Gohji K, 2001, J UROLOGY, V166, P1286, DOI 10.1016/S0022-5347(05)65754-0; Goshen R, 1996, MOL HUM REPROD, V2, P679, DOI 10.1093/molehr/2.9.679; HAN J, 2004, CARDIOVASC PATHOL, V13, P85; Huang RP, 1997, INT J CANCER, V72, P102, DOI 10.1002/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L; Hulett MD, 2000, BIOCHEMISTRY-US, V39, P15659, DOI 10.1021/bi002080p; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Ihrcke NS, 1998, J CELL PHYSIOL, V175, P255, DOI 10.1002/(SICI)1097-4652(199806)175:3<255::AID-JCP3>3.0.CO;2-N; Jiang P, 2002, J BIOL CHEM, V277, P8989, DOI 10.1074/jbc.M105682200; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1998, J MOL MED-JMM, V76, P613, DOI 10.1007/s001090050258; Khachigian LM, 1997, ARTERIOSCL THROM VAS, V17, P2280, DOI 10.1161/01.ATV.17.10.2280; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kobayashi D, 2002, ANTICANCER RES, V22, P3963; Koliopanos A, 2001, CANCER RES, V61, P4655; Levkovitz Y, 2002, J NEUROSCI, V22, P3845, DOI 10.1523/JNEUROSCI.22-10-03845.2002; Levy-Adam F, 2003, BIOCHEM BIOPH RES CO, V308, P885, DOI 10.1016/S0006-291X(03)01478-5; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Lowe HC, 2001, CIRC RES, V89, P670, DOI 10.1161/hh2001.097867; Lu WC, 2003, ONCOGENE, V22, P919, DOI 10.1038/sj.onc.1206201; Maxhimer JB, 2002, SURGERY, V132, P326, DOI 10.1067/msy.2002.125719; McKenzie E, 2003, BIOCHEM J, V373, P423, DOI 10.1042/BJ20030318; Mitchell A, 2004, NUCLEIC ACIDS RES, V32, P3065, DOI 10.1093/nar/gkh626; Murry BP, 2005, INT J ONCOL, V26, P345; Nadav L, 2002, J CELL SCI, V115, P2179; Ogishima T, 2005, CLIN CANCER RES, V11, P1028; Parish CR, 1999, CANCER RES, V59, P3433; Parish CR, 2001, BIOCHIM BIOPHYS ACTA, V1471, P99, DOI DOI 10.1016/S0304-419X(01)00017-8; Pratt MAC, 2003, MOL CELL BIOL, V23, P6887, DOI 10.1128/MCB.23.19.6887-6900.2003; RATNER S, 1992, INVAS METAST, V12, P82; Robinson L, 1997, P NATL ACAD SCI USA, V94, P7170, DOI 10.1073/pnas.94.14.7170; Sasaki M, 2001, MEDIAT INFLAMM, V10, P259, DOI 10.1080/09629350120093731; Sato T, 2004, J SURG ONCOL, V87, P174, DOI 10.1002/jso.20097; Shteper PJ, 2003, ONCOGENE, V22, P7737, DOI 10.1038/sj.onc.1207056; Simizu S, 2003, CANCER LETT, V193, P83, DOI 10.1016/S0304-3835(02)00719-X; Toyoshima M, 1999, J BIOL CHEM, V274, P24153, DOI 10.1074/jbc.274.34.24153; Uno F, 2001, CANCER RES, V61, P7855; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; VLODAVSKY I, 1994, INVAS METAST, V14, P290; Vlodavsky I, 2000, ISRAEL MED ASSOC J, V2, P37; VLODAVSKY I, 1992, INVAS METAST, V12, P112; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Walch ET, 1999, CLIN EXP METASTAS, V17, P307, DOI 10.1023/A:1006652605568; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; Zetser A, 2004, J CELL SCI, V117, P2249, DOI 10.1242/jcs.01068; Zhang R, 2003, APPL PHYS LETT, V83, P204, DOI 10.1063/1.1592624	67	70	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35136	35147		10.1074/jbc.M503414200	http://dx.doi.org/10.1074/jbc.M503414200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16093249	Green Published, hybrid			2022-12-27	WOS:000232561200010
J	Liu, YN; Motyka, SA; Englund, PT				Liu, YN; Motyka, SA; Englund, PT			Effects of RNA interference of Trypanosoma brucei structure-specific endonuclease-I on kinetoplast DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRITHIDIA-FASCICULATA; CELL-CYCLE; TOPOISOMERASE-II; POLYMERASE-BETA; 2 SITES; MINICIRCLES; LOCALIZATION; NETWORKS; ORGANIZATION; SEGREGATION	Kinetoplast DNA, the mitochondrial DNA of trypanosomatid protozoa, is a network containing several thousand topologically interlocked DNA minicircles. Kinetoplast DNA synthesis involves release of minicircles from the network, replication of the free minicircles, and reattachment of the progeny back onto the network. One enzyme involved in this process is structure- specific endonuclease- I. This enzyme, originally purified from Crithidia fasciculata, has been proposed to remove minicircle replication primers ( Engel, M. L., and Ray, D. S. ( 1998) Nucleic Acids Res. 26, 4773 - 4778). We have studied the structure- specific endonuclease-I homolog from Trypanosoma brucei, showing it to be localized in the antipodal sites flanking the kinetoplast DNA disk, as previously shown in C. fasciculata. RNA interference of structure- specific endonuclease- I caused persistence of a single ribonucleotide at the 5 ' end of both the leading strand and at least the first Okazaki fragment in network minicircles, demonstrating that this enzyme in fact functions in primer removal. Probably because of the persistence of primers, RNA interference also impeded the reattachment of newly replicated free minicircles to the network and caused a delay in kinetoplast DNA segregation. These effects ultimately led to shrinkage and loss of the kinetoplast DNA network and cessation of growth of the cell.	Johns Hopkins Med Sch, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine	Englund, PT (corresponding author), Johns Hopkins Med Sch, Dept Biol Chem, Baltimore, MD 21205 USA.	penglund@jhmi.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058613] Funding Source: NIH RePORTER; NIAID NIH HHS [AI058613] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abu-Elneel K, 2001, J CELL BIOL, V153, P725, DOI 10.1083/jcb.153.4.725; BIRKENMEYER L, 1987, J BIOL CHEM, V262, P2384; COSGROVE WB, 1970, J PROTOZOOL, V17, P172, DOI 10.1111/j.1550-7408.1970.tb02350.x; DOWNEY N, 2002, EUKARYOT CELL, V4, P765; Drew ME, 2001, J CELL BIOL, V153, P735, DOI 10.1083/jcb.153.4.735; Engel ML, 2001, NUCLEIC ACIDS RES, V29, P725, DOI 10.1093/nar/29.3.725; Engel ML, 1998, NUCLEIC ACIDS RES, V26, P4733, DOI 10.1093/nar/26.20.4733; Engel ML, 1999, P NATL ACAD SCI USA, V96, P8455, DOI 10.1073/pnas.96.15.8455; ENGLUND PT, 1979, J BIOL CHEM, V254, P4895; FERGUSON M, 1992, CELL, V70, P621, DOI 10.1016/0092-8674(92)90431-B; FERGUSON ML, 1994, J CELL BIOL, V126, P631, DOI 10.1083/jcb.126.3.631; Guilbride DL, 1998, J CELL SCI, V111, P675; Hesslein DGT, 1997, MOL BIOCHEM PARASIT, V86, P121, DOI 10.1016/S0166-6851(97)90014-1; Hines JC, 2001, MOL BIOCHEM PARASIT, V115, P63, DOI 10.1016/S0166-6851(01)00272-9; HOEIJMAKERS JHJ, 1980, PLASMID, V4, P97, DOI 10.1016/0147-619X(80)90086-4; Hong M, 2003, PROTIST, V154, P265, DOI 10.1078/143446103322166554; Johnson CE, 1998, J CELL BIOL, V143, P911, DOI 10.1083/jcb.143.4.911; Kao HI, 2003, CRIT REV BIOCHEM MOL, V38, P433, DOI 10.1080/10409230390259382; Klingbeil MM, 2002, MOL CELL, V10, P175, DOI 10.1016/S1097-2765(02)00571-3; Klingbeil MM, 2001, PROTIST, V152, P255, DOI 10.1078/1434-4610-00066; Kobil JH, 2000, BIOCHEM BIOPH RES CO, V270, P336, DOI 10.1006/bbrc.2000.2397; Li CJ, 1997, J BIOL CHEM, V272, P20787, DOI 10.1074/jbc.272.33.20787; Liu BY, 2005, TRENDS PARASITOL, V21, P363, DOI 10.1016/j.pt.2005.06.008; Liu Y, 2004, ANNU REV BIOCHEM, V73, P589, DOI 10.1146/annurev.biochem.73.012803.092453; Lukes J, 2002, EUKARYOT CELL, V1, P495, DOI 10.1128/EC.1.4.495-502.2002; Madison-Antenucci S, 2002, CELL, V108, P435, DOI 10.1016/S0092-8674(02)00653-0; Marchetti MA, 2000, J CELL SCI, V113, P899; MELENDY T, 1988, CELL, V55, P1083, DOI 10.1016/0092-8674(88)90252-8; NTAMBI JM, 1986, J BIOL CHEM, V261, P1890; Ogbadoyi EO, 2003, MOL BIOL CELL, V14, P1769, DOI 10.1091/mbc.E02-08-0525; PEREZMORGA DL, 1993, CELL, V74, P703, DOI 10.1016/0092-8674(93)90517-T; ROBINSON DR, 1991, NATURE, V352, P731, DOI 10.1038/352731a0; ROBINSON DR, 1994, J CELL BIOL, V126, P641, DOI 10.1083/jcb.126.3.641; RYAN KA, 1989, J BIOL CHEM, V264, P823; RYAN KA, 1989, MOL CELL BIOL, V9, P3212, DOI 10.1128/MCB.9.8.3212; Shen SY, 2001, MOL BIOCHEM PARASIT, V113, P171, DOI 10.1016/S0166-6851(00)00383-2; SHERWIN T, 1987, J CELL BIOL, V104, P439, DOI 10.1083/jcb.104.3.439; Shlomai J, 2004, CURR MOL MED, V4, P623, DOI 10.2174/1566524043360096; SIMPSON AM, 1976, J PROTOZOOL, V23, P583, DOI 10.1111/j.1550-7408.1976.tb03846.x; Simpson L, 2003, RNA, V9, P265, DOI 10.1261/rna.2178403; Sinha KM, 2004, P NATL ACAD SCI USA, V101, P4361, DOI 10.1073/pnas.0305705101; TORRI AF, 1995, J BIOL CHEM, V270, P3495, DOI 10.1074/jbc.270.8.3495; Wang ZF, 2002, EMBO J, V21, P4998, DOI 10.1093/emboj/cdf482; Wang ZF, 2001, EMBO J, V20, P4674, DOI 10.1093/emboj/20.17.4674; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; WOODWARD R, 1990, J CELL SCI, V95, P49; Yang MY, 2002, CELL, V111, P495, DOI 10.1016/S0092-8674(02)01075-9	47	19	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35513	35520		10.1074/jbc.M507296200	http://dx.doi.org/10.1074/jbc.M507296200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16096280	hybrid			2022-12-27	WOS:000232561200052
J	Lay, D; Grosshans, BL; Heid, H; Gorgas, K; Just, WW				Lay, D; Grosshans, BL; Heid, H; Gorgas, K; Just, WW			Binding and functions of ADP-ribosylation factor on mammalian and yeast peroxisomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DILYSINE RETRIEVAL MOTIFS; ENDOPLASMIC-RETICULUM; PHOSPHOLIPASE-D; COATED VESICLES; SACCHAROMYCES-CEREVISIAE/; NUCLEOTIDE-EXCHANGE; GOLGI MEMBRANES; RAT-LIVER; ARF; COATOMER	We have analyzed in vitro the binding characteristics of members of the ADP-ribosylation factor (ARF) family of proteins to a highly purified rat liver peroxisome preparation void of Golgi membranes and studied in vivo a role these proteins play in the proliferation of yeast peroxisomes. Although both ARF1 and ARF6 were found on peroxisomes, coatomer recruitment only depended on ARF1-GTP. Recruitment of ARF1 and coatomer to peroxisomes was significantly affected both by pretreating the animals with peroxisome proliferators and by ATP and a cytosolic fraction designated the intermediate pool fraction depleted of ARF and coatomer. In the presence of ATP, the concentrations of ARF1 and coatomer on peroxisomes were reduced, whereas intermediate pool fraction led to a concentration-dependent decrease in ARF and increase in coatomer. Brefeldin A, a fungal toxin that is known to reduce ARF1 binding to Golgi membranes, did not affect ARF1 binding to peroxisomes. In Saccharomyces cerevisiae, both ScARF1 and ScARF3, the yeast orthologs of mammalian ARF1 and ARF6, were implicated in the control of peroxisome proliferation. ScARF1 regulated this process in a positive manner, and ScARF3 regulated it in a negative manner.	Heidelberg Univ, Zentrum Biochem, D-69120 Heidelberg, Germany; Yale Univ, Dept Cell Biol, New Haven, CT 06520 USA; Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany; Heidelberg Univ, Inst Anat & Zellbiol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Yale University; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Just, WW (corresponding author), Heidelberg Univ, Zentrum Biochem, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	wilhelm.just@urz.uni-heidelberg.de						AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; Anton M, 2000, CELL BIOCHEM BIOPHYS, V32, P27, DOI 10.1385/CBB:32:1-3:27; Asp L, 2000, J BIOL CHEM, V275, P26285, DOI 10.1074/jbc.M003520200; Brugger B, 2000, J CELL BIOL, V151, P507, DOI 10.1083/jcb.151.3.507; Donaldson JG, 2000, P NATL ACAD SCI USA, V97, P3792, DOI 10.1073/pnas.97.8.3792; Donaldson JG, 2000, CURR OPIN CELL BIOL, V12, P475, DOI 10.1016/S0955-0674(00)00119-8; Exton JH, 2002, FEBS LETT, V531, P58, DOI 10.1016/S0014-5793(02)03405-1; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Funato K, 2001, J CELL BIOL, V155, P949, DOI 10.1083/jcb.200105033; Geuze HJ, 2003, MOL BIOL CELL, V14, P2900, DOI 10.1091/mbc.E02-11-0734; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; Gommel DU, 2001, EMBO J, V20, P6751, DOI 10.1093/emboj/20.23.6751; Harter C, 1996, P NATL ACAD SCI USA, V93, P1902, DOI 10.1073/pnas.93.5.1902; Harter C, 1998, P NATL ACAD SCI USA, V95, P11649, DOI 10.1073/pnas.95.20.11649; HARTL FU, 1985, ARCH BIOCHEM BIOPHYS, V237, P124, DOI 10.1016/0003-9861(85)90261-9; Heid HW, 1998, CELL TISSUE RES, V294, P309, DOI 10.1007/s004410051181; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; Hoepfner D, 2005, CELL, V122, P85, DOI 10.1016/j.cell.2005.04.025; Hoepfner D, 2001, J CELL BIOL, V155, P979, DOI 10.1083/jcb.200107028; Hosaka M, 1996, J BIOCHEM-TOKYO, V120, P813; Huber CN, 1999, EMBO J, V18, P5476, DOI 10.1093/emboj/18.20.5476; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; JUST WW, 1989, HEPATOLOGY, V9, P570, DOI 10.1002/hep.1840090411; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Koch A, 2003, J BIOL CHEM, V278, P8597, DOI 10.1074/jbc.M211761200; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; LEE FJS, 1994, J BIOL CHEM, V269, P20931; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Li XL, 2003, J BIOL CHEM, V278, P17012, DOI 10.1074/jbc.M212031200; Li XL, 2002, MOL CELL BIOL, V22, P4358, DOI 10.1128/MCB.22.12.4358-4365.2002; Li XL, 2002, J CELL BIOL, V156, P643, DOI 10.1083/jcb.200112028; Li YW, 2004, FASEB J, V18, P1834, DOI 10.1096/fj.04-2273com; Marelli M, 2004, J CELL BIOL, V167, P1099, DOI 10.1083/jcb.200404119; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Nakamura N, 2004, BIOCHEM BIOPH RES CO, V322, P957, DOI 10.1016/j.bbrc.2004.08.010; Passreiter M, 1998, J CELL BIOL, V141, P373, DOI 10.1083/jcb.141.2.373; Powner DJ, 2002, FEBS LETT, V531, P62, DOI 10.1016/S0014-5793(02)03410-5; Purdue PE, 2001, ANNU REV CELL DEV BI, V17, P701, DOI 10.1146/annurev.cellbio.17.1.701; Randazzo PA, 1997, J BIOL CHEM, V272, P7688; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; Roth MG, 1999, CELL, V97, P149, DOI 10.1016/S0092-8674(00)80723-0; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Rottensteiner H, 2003, MOL BIOL CELL, V14, P4316, DOI 10.1091/mbc.E03-03-0153; Sacksteder KA, 2000, ANNU REV GENET, V34, P623, DOI 10.1146/annurev.genet.34.1.623; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schrader M, 1998, J BIOL CHEM, V273, P29607, DOI 10.1074/jbc.273.45.29607; Seidel RD, 2004, BIOCHEMISTRY-US, V43, P15393, DOI 10.1021/bi0490385; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Short B, 2003, CURR BIOL, V13, pR311, DOI 10.1016/S0960-9822(03)00234-3; SMIDSROD O, 1990, TRENDS BIOTECHNOL, V8, P71, DOI 10.1016/0167-7799(90)90139-O; Smith KD, 1999, NEUROCHEM RES, V24, P521, DOI 10.1023/A:1022535930009; Spang A, 2002, CURR OPIN CELL BIOL, V14, P423, DOI 10.1016/S0955-0674(02)00346-0; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tam YYC, 2003, MOL BIOL CELL, V14, P4089, DOI 10.1091/mbc.E03-03-0150; Tanaka A, 2003, BIOCHEM BIOPH RES CO, V300, P819, DOI 10.1016/S0006-291X(02)02936-4; Titorenko VI, 1998, TRENDS BIOCHEM SCI, V23, P231, DOI 10.1016/S0968-0004(98)01226-2; Titorenko VI, 2000, CELL BIOCHEM BIOPHYS, V32, P21, DOI 10.1385/CBB:32:1-3:21; Trotter PJ, 2001, ANNU REV NUTR, V21, P97, DOI 10.1146/annurev.nutr.21.1.97; Yu S, 2002, MOL BIOL CELL, V13, P2559, DOI 10.1091/mbc.E02-04-0189; Yu ST, 2003, CURR MOL MED, V3, P561, DOI 10.2174/1566524033479537; Zhao LY, 1999, J BIOL CHEM, V274, P14198, DOI 10.1074/jbc.274.20.14198; Zhao LY, 1997, P NATL ACAD SCI USA, V94, P4418, DOI 10.1073/pnas.94.9.4418	69	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34489	34499		10.1074/jbc.M503497200	http://dx.doi.org/10.1074/jbc.M503497200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16100119	hybrid			2022-12-27	WOS:000232403900016
J	Cordle, A; Koenigsknecht-Talboo, J; Wilkinson, B; Limpert, A; Landreth, G				Cordle, A; Koenigsknecht-Talboo, J; Wilkinson, B; Limpert, A; Landreth, G			Mechanisms of statin-mediated inhibition of small G-protein function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COA REDUCTASE INHIBITOR; TRANSGENIC MOUSE MODEL; CENTRAL-NERVOUS-SYSTEM; NITRIC-OXIDE SYNTHASE; AMYLOID-BETA-PEPTIDE; ALZHEIMERS-DISEASE; ALPHA-SECRETASE; SIMVASTATIN; CHOLESTEROL; EXPRESSION	3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have been reported to reduce the risk of Alzheimer disease. We have shown previously that statins inhibit a beta-amyloid (A beta)mediated inflammatory response through mechanisms independent of cholesterol reduction. Specifically, statins exert anti-inflammatory actions through their ability to prevent the isoprenylation of members of the Rho family of small G-proteins, resulting in the functional inactivation of these G-proteins. We report that statin treatment of microglia results in perturbation of the cytoskeleton and morphological changes due to alteration in Rho family function. Statins also block A beta-stimulated phagocytosis through inhibition of Rac action. Paradoxically, the statin-mediated inactivation of G-protein function was associated with increased GTP loading of Rac and RhoA, and this effect was observed in myeloid lineage cells and other cell types. Statin treatment disrupted the interaction of Rac with its negative regulator the Rho guanine nucleotide dissociation inhibitor ( RhoGDI), an interaction that is dependent on protein isoprenylation. We propose that lack of negative regulation accounts for the increased GTP loading. Isoprenylation of Rac is also required for efficient interaction with the plasma membrane, and we report that statin treatment dramatically reduces the capacity of Rac to interact with membranes. These results suggest amechanism by which statins inhibit the actions of Rho GTPases and attenuate A beta-stimulated inflammation.	Case Western Reserve Univ, Sch Med, Dept Neurosci, Cleveland, OH 44106 USA	Case Western Reserve University	Landreth, G (corresponding author), Case Western Reserve Univ, Sch Med, Dept Neurosci, Cleveland, OH 44106 USA.	gel2@cwru.edu			NIA NIH HHS [AG20202, AG16740] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG016740, R01AG020202] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bi XN, 2004, J BIOL CHEM, V279, P48238, DOI 10.1074/jbc.M405442200; Blanco-Colio LM, 2002, ATHEROSCLEROSIS, V161, P17, DOI 10.1016/S0021-9150(01)00613-X; Bodovitz S, 1996, J BIOL CHEM, V271, P4436; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURDICK D, 1992, J BIOL CHEM, V267, P546; Burns M, 2002, ANN NY ACAD SCI, V977, P367, DOI 10.1111/j.1749-6632.2002.tb04839.x; Buxbaum JD, 2002, FRONT BIOSCI, V7, pA50, DOI 10.2741/buxbaum; Caballero J, 2004, J CLIN PHARM THER, V29, P209, DOI 10.1111/j.1365-2710.2004.00560.x; Cole SL, 2005, J BIOL CHEM, V280, P18755, DOI 10.1074/jbc.M413895200; Combs CK, 2001, J NEUROSCI, V21, P1179; Cordle A, 2005, J NEUROSCI, V25, P299, DOI 10.1523/JNEUROSCI.2544-04.2005; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; del Real G, 2004, J EXP MED, V200, P541, DOI 10.1084/jem.20040061; Di-Poi N, 2001, BIOCHEMISTRY-US, V40, P10014, DOI 10.1021/bi010289c; Engel ME, 1998, J BIOL CHEM, V273, P9921, DOI 10.1074/jbc.273.16.9921; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; Gorzalczany Y, 2000, J BIOL CHEM, V275, P40073, DOI 10.1074/jbc.M006013200; Hernandez-Perera O, 2000, CIRC RES, V87, P616, DOI 10.1161/01.RES.87.7.616; Ishibashi T, 2002, BBA-MOL CELL RES, V1590, P123, DOI 10.1016/S0167-4889(02)00201-X; Ito T, 2002, CARDIOVASC DRUG THER, V16, P121, DOI 10.1023/A:1015701415588; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Klegeris A, 2004, J NEUROIMMUNOL, V152, P73, DOI 10.1016/j.jneuroim.2004.04.001; Koenigsknecht J, 2004, J NEUROSCI, V24, P9838, DOI 10.1523/JNEUROSCI.2557-04.2004; Kunieda Y, 2003, THROMB RES, V110, P227, DOI 10.1016/S0049-3848(03)00346-3; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Laufs U, 1998, J BIOL CHEM, V273, P24266, DOI 10.1074/jbc.273.37.24266; Laufs U, 2002, CARDIOVASC RES, V53, P911, DOI 10.1016/S0008-6363(01)00540-5; LEONARD S, 1990, J BIOL CHEM, V265, P5157; Lian LY, 2000, STRUCT FOLD DES, V8, P47, DOI 10.1016/S0969-2126(00)00080-0; Liao JK, 2005, ANNU REV PHARMACOL, V45, P89, DOI 10.1146/annurev.pharmtox.45.120403.095748; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Matos P, 2003, J BIOL CHEM, V278, P50442, DOI 10.1074/jbc.M308215200; Miida Takashi, 2004, J Atheroscler Thromb, V11, P253; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Nath N, 2004, J IMMUNOL, V172, P1273, DOI 10.4049/jimmunol.172.2.1273; Parvathy S, 2004, J NEUROCHEM, V90, P1005, DOI 10.1111/j.1471-4159.2004.02521.x; Patel NS, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-9; Patel TR, 2004, J SURG RES, V116, P116, DOI 10.1016/j.jss.2003.07.006; Pedrini S, 2005, PLOS MED, V2, P69, DOI 10.1371/journal.pmed.0020018; Petanceska SS, 2002, J MOL NEUROSCI, V19, P155, DOI 10.1007/s12031-002-0026-2; Refolo LM, 2001, NEUROBIOL DIS, V8, P890, DOI 10.1006/nbdi.2001.0422; Rockwood K, 2002, ARCH NEUROL-CHICAGO, V59, P223, DOI 10.1001/archneur.59.2.223; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Simons M, 2002, ANN NEUROL, V52, P346, DOI 10.1002/ana.10292; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Sjogren M, 2003, DEMENT GERIATR COGN, V16, P25, DOI 10.1159/000069989; Sparks DL, 2005, ARCH NEUROL-CHICAGO, V62, P753, DOI 10.1001/archneur.62.5.753; Stamatakis K, 2002, J BIOL CHEM, V277, P49389, DOI 10.1074/jbc.M204049200; Stuve O, 2003, CURR OPIN NEUROL, V16, P393, DOI 10.1097/01.wco.0000073942.19076.d1; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; TERZI E, 1994, BIOCHEMISTRY-US, V33, P7434, DOI 10.1021/bi00189a051; Tobert JA, 2003, NAT REV DRUG DISCOV, V2, P517, DOI 10.1038/nrd1112; VAN AL, 1997, GENE DEV, V11, P2295; Vecchione C, 2002, CIRC RES, V91, P173, DOI 10.1161/01.RES.0000028004.76218.B8; Wahrle S, 2002, NEUROBIOL DIS, V9, P11, DOI 10.1006/nbdi.2001.0470; Wilcock DM, 2004, J NEUROSCI, V24, P6144, DOI 10.1523/JNEUROSCI.1090-04.2004; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; Yates SL, 2000, J NEUROCHEM, V74, P1017, DOI 10.1046/j.1471-4159.2000.0741017.x; Yoshida Masayuki, 2003, J Atheroscler Thromb, V10, P140; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zhao XX, 2002, J BIOL CHEM, V277, P25385, DOI 10.1074/jbc.M203630200	65	189	200	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34202	34209		10.1074/jbc.M505268200	http://dx.doi.org/10.1074/jbc.M505268200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16085653	hybrid			2022-12-27	WOS:000232229700062
J	Chung, SK; Brown, JM; Provo, JN; Hopkins, R; McIntosh, MK				Chung, SK; Brown, JM; Provo, JN; Hopkins, R; McIntosh, MK			Conjugated linoleic acid promotes human adipocyte insulin resistance through NF kappa B-dependent cytokine production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ACTIVATED-RECEPTOR-GAMMA; PROTEIN-KINASE-C; FACTOR-ALPHA; SIGNAL-TRANSDUCTION; ADIPOSE-TISSUES; TNF-ALPHA; IKK-BETA; EXPRESSION; INTERLEUKIN-6	We previously demonstrated that trans-10,cis-12 conjugated linoleic acid (CLA) reduced the triglyceride content of human adipocytes by activating mitogen-activated protein kinase kinase/extracellular signal-related kinase (MEK/ERK) signaling via interleukins (IL) 6 and 8. However, the upstream mechanism is unknown. Here we show that CLA increased (>= 6 h) the secretion of IL-6 and IL-8 in cultures containing both differentiated adipocytes and stromal vascular (SV) cells, non-differentiated SV cells, and adipose tissue explants. CLA isomer-specific induction of IL-6 and tumor necrosis factor-alpha was associated with the activation of nuclear factor kappa B (NF kappa B) as evidenced by 1) phosphorylation of I kappa B alpha, I kappa B alpha kinase, and NF kappa B p65, 2) I kappa B alpha degradation, and 3) nuclear translocation of NF kappa B. Pretreatment with selective NF kappa B inhibitors and the MEK/ ERK inhibitor U0126 blocked CLA-mediated IL-6 gene expression. Trans-10, cis-12 CLA suppression of insulin-stimulated glucose uptake at 24 h was associated with decreased total and plasma membrane glucose transporter 4 proteins. Inhibition of NF kappa B activation or depletion of NF kappa B by RNA interference using small interfering NF kappa B p65 attenuated CLA suppression of glucose transporter 4 and peroxisome proliferator-activated receptor gamma proteins and glucose uptake. Collectively, these data demonstrate for the first time that trans-10, cis-12 CLA promotes NF kappa B activation and subsequent induction of IL-6, which are at least in part responsible for trans-10, cis-12 CLA-mediated suppression of peroxisome proliferator-activated receptor gamma target gene expression and insulin sensitivity in mature human adipocytes.	Univ N Carolina, Dept Nutr, Greensboro, NC 27402 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol & Comparat Med, Winston Salem, NC 27157 USA	University of North Carolina; University of North Carolina Greensboro; Wake Forest University; Wake Forest Baptist Medical Center	McIntosh, MK (corresponding author), Univ N Carolina, Dept Nutr, 318 Stone Bldg, Greensboro, NC 27402 USA.	mkmcinto@uncg.edu		Chung, Soonkyu/0000-0001-6279-7017	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R00HL096166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063070] Funding Source: NIH RePORTER; NHLBI NIH HHS [R00 HL096166] Funding Source: Medline; NIDDK NIH HHS [R01DK-63070, R01 DK063070] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Akira S, 1997, INT J BIOCHEM CELL B, V29, P1401, DOI 10.1016/S1357-2725(97)00063-0; Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086; Brown JM, 2004, J BIOL CHEM, V279, P26735, DOI 10.1074/jbc.M401766200; Brown JM, 2003, J LIPID RES, V44, P1287, DOI 10.1194/jlr.M300001-JLR200; Bruun JM, 2003, AM J PHYSIOL-ENDOC M, V285, pE527, DOI 10.1152/ajpendo.00110.2003; Bruun JM, 2004, AM J PHYSIOL-ENDOC M, V286, pE8, DOI 10.1152/ajpendo.00269.2003; Cai DS, 2005, NAT MED, V11, P183, DOI 10.1038/nm1166; Camp HS, 1997, J BIOL CHEM, V272, P10811; Carvalho E, 2004, J BIOL CHEM, V279, P21598, DOI 10.1074/jbc.M312269200; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chung SY, 2005, J LIPID RES, V46, P885, DOI 10.1194/jlr.M400476-JLR200; Clement L, 2002, J LIPID RES, V43, P1400, DOI 10.1194/jlr.M20008-JLR200; deMora JF, 1997, MOL CELL BIOL, V17, P6068, DOI 10.1128/MCB.17.10.6068; Dixit V, 2002, CELL, V111, P615, DOI 10.1016/S0092-8674(02)01166-2; Fain JN, 2004, INT J OBESITY, V28, P616, DOI 10.1038/sj.ijo.0802594; Fain JN, 2004, ENDOCRINOLOGY, V145, P2273, DOI 10.1210/en.2003-1336; FRIED SK, 1993, J CLIN INVEST, V92, P2191, DOI 10.1172/JCI116821; Gao ZG, 2004, MOL ENDOCRINOL, V18, P2024, DOI 10.1210/me.2003-0383; Gerhardt CC, 2001, MOL CELL ENDOCRINOL, V175, P81, DOI 10.1016/S0303-7207(01)00394-X; Harkins JM, 2004, J NUTR, V134, P2673, DOI 10.1093/jn/134.10.2673; House RL, 2005, OBES REV, V6, P247, DOI 10.1111/j.1467-789X.2005.00198.x; Houseknecht KL, 1998, BIOCHEM BIOPH RES CO, V244, P678, DOI 10.1006/bbrc.1998.8303; HU E, 1996, SCIENCE, V274, P31771; Itani SI, 2002, DIABETES, V51, P2005, DOI 10.2337/diabetes.51.7.2005; Jiang BB, 2001, ARTERIOSCL THROM VAS, V21, P1915, DOI 10.1161/hq1201.099424; Jove M, 2005, ENDOCRINOLOGY, V146, P3087, DOI 10.1210/en.2004-1560; Lagathu C, 2003, BIOCHEM BIOPH RES CO, V311, P372, DOI 10.1016/j.bbrc.2003.10.013; Lappas M, 2005, ENDOCRINOLOGY, V146, P1491, DOI 10.1210/en.2004-0809; Larsen TM, 2003, J LIPID RES, V44, P2234, DOI 10.1194/jlr.R300011-JLR200; Lau DCW, 2005, AM J PHYSIOL-HEART C, V288, pH2031, DOI 10.1152/ajpheart.01058.2004; Li X, 2002, J BIOL CHEM, V277, P45129, DOI 10.1074/jbc.M205165200; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Nie M, 2005, J BIOL CHEM, V280, P2550, DOI 10.1074/jbc.M410616200; Park Y, 1999, LIPIDS, V34, P235, DOI 10.1007/s11745-999-0358-8; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Riserus U, 2004, AM J CLIN NUTR, V79, p1146S; Riserus U, 2004, DIABETOLOGIA, V47, P1016, DOI 10.1007/s00125-004-1421-8; Rotter V, 2003, J BIOL CHEM, V278, P45777, DOI 10.1074/jbc.M301977200; Ruan H, 2003, J BIOL CHEM, V278, P28181, DOI 10.1074/jbc.M303141200; Ruan H, 2002, DIABETES, V51, P3176, DOI 10.2337/diabetes.51.11.3176; Shoelson SE, 2003, INT J OBESITY, V27, pS49, DOI 10.1038/sj.ijo.0802501; Sinha S, 2004, J BIOL CHEM, V279, P41294, DOI 10.1074/jbc.M406514200; Sopasakis VR, 2004, OBES RES, V12, P454, DOI 10.1038/oby.2004.51; Suzawa M, 2003, NAT CELL BIOL, V5, P224, DOI 10.1038/ncb942; Tsuboyama-Kasaoka N, 2003, J NUTR, V133, P1793, DOI 10.1093/jn/133.6.1793; Vanden Berghe W, 2000, BIOCHEM PHARMACOL, V60, P1185, DOI 10.1016/S0006-2952(00)00412-3; Weigert C, 2004, J BIOL CHEM, V279, P23942, DOI 10.1074/jbc.M312692200; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wellen KE, 2003, J CLIN INVEST, V112, P1785, DOI 10.1172/JCI20514; Xu HY, 2002, DIABETES, V51, P1876, DOI 10.2337/diabetes.51.6.1876; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620	54	128	136	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38445	38456		10.1074/jbc.M508159200	http://dx.doi.org/10.1074/jbc.M508159200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16155293	Green Accepted, hybrid			2022-12-27	WOS:000233239800041
J	Eckerdt, F; Yuan, JP; Saxena, K; Martin, B; Kappel, S; Lindenau, C; Kramer, A; Naumann, S; Daum, S; Fischer, G; Dikic, I; Kaufmann, M; Strebhardt, K				Eckerdt, F; Yuan, JP; Saxena, K; Martin, B; Kappel, S; Lindenau, C; Kramer, A; Naumann, S; Daum, S; Fischer, G; Dikic, I; Kaufmann, M; Strebhardt, K			Polo-like kinase 1-mediated phosphorylation stabilizes Pin1 by inhibiting its ubiquitination in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYL-PROLYL ISOMERASE; DEPENDENT PROLINE ISOMERIZATION; SACCHAROMYCES-CEREVISIAE CDC5; DOWN-REGULATION; CANCER-CELLS; DROSOPHILA POLO; CYCLIN B1; MITOSIS; PLK1; DOMAIN	The Polo-like kinase 1 (Plk1) is a key regulator of mitosis. It is reported that the human peptidyl-prolyl cis/trans-isomerase Pin1 binds to Plk1 from mitotic cell extracts in vitro. Here we demonstrate that Ser-65 in Pin1 is the major site for Plk1-specific phosphorylation, and the polo-box domain of Plk1 is required for this phosphorylation. Interestingly, the phosphorylation of Pin1 by Plk1 does not affect its isomerase activity but rather is linked to its protein stability. Pin1 is ubiquitinated in HeLa S3 cells, and substitution of Glu for Ser-65 reduces the ubiquitination of Pin1. Furthermore, inhibition of Plk1 activity by expression of a dominant negative form of Plk1 or by transfection of small interfering RNA targeted to Plk1 enhances the ubiquitination of Pin1 and subsequently reduces the amount of Pin1 in human cancer cells. Since previous reports suggested that Plk1 is a substrate of Pin1, our work adds a new dimension to this interaction of two important mitotic regulators.	Univ Frankfurt, Sch Med, Dept Gynecol & Obstet, D-60590 Frankfurt, Germany; Univ Frankfurt, Sch Med, Inst Biochem 2, D-60590 Frankfurt, Germany; Univ Frankfurt, Inst Organ Chem, D-60439 Frankfurt, Germany; Max Planck Res Unit, D-06120 Halle Saale, Germany	Goethe University Frankfurt; Goethe University Frankfurt; Goethe University Frankfurt; Max Planck Society	Eckerdt, F (corresponding author), Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA.		Dikic, Ivan/O-4650-2015; Strebhardt, Klaus/E-8765-2011	Dikic, Ivan/0000-0001-8156-9511; Strebhardt, Klaus/0000-0003-2173-9763				Abrieu A, 1998, J CELL SCI, V111, P1751; Carmena M, 1998, J CELL BIOL, V143, P659, DOI 10.1083/jcb.143.3.659; Cheng KY, 2003, EMBO J, V22, P5757, DOI 10.1093/emboj/cdg558; Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; Dai W, 2002, ONCOGENE, V21, P6195, DOI 10.1038/sj.onc.1205710; DAI W, 2003, FRONT BIOSCI, V8, P1128; de Carcer G, 2001, EMBO J, V20, P2878, DOI 10.1093/emboj/20.11.2878; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; DOCARMO AM, 2001, NAT CELL BIOL, V3, P421; Eckerdt F, 2005, ONCOGENE, V24, P267, DOI 10.1038/sj.onc.1208273; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Fujimori F, 1999, BIOCHEM BIOPH RES CO, V265, P658, DOI 10.1006/bbrc.1999.1736; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; HANES SD, 1989, YEAST, V5, P55, DOI 10.1002/yea.320050108; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Jacobs DM, 2002, J BIOMOL NMR, V23, P163, DOI 10.1023/A:1016364324096; Jang YJ, 2002, P NATL ACAD SCI USA, V99, P1984, DOI 10.1073/pnas.042689299; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lee KS, 1999, P NATL ACAD SCI USA, V96, P14360, DOI 10.1073/pnas.96.25.14360; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Lin CY, 2000, P NATL ACAD SCI USA, V97, P12589, DOI 10.1073/pnas.220423497; Liu JJ, 2005, CURR BIOL, V15, P1458, DOI 10.1016/j.cub.2005.07.030; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Lu KP, 2003, CANCER CELL, V4, P175, DOI 10.1016/S1535-6108(03)00218-6; Lu KP, 1996, NATURE, V380, P544; Lu KP, 2002, TRENDS CELL BIOL, V12, P164, DOI 10.1016/S0962-8924(02)02253-5; Lu PJ, 2002, J BIOL CHEM, V277, P2381, DOI 10.1074/jbc.C100228200; Matthess Y, 2005, ONCOGENE, V24, P2973, DOI 10.1038/sj.onc.1208472; May KM, 2002, J CELL BIOL, V156, P23, DOI 10.1083/jcb.200106150; Messenger MM, 2002, J BIOL CHEM, V277, P23054, DOI 10.1074/jbc.M200111200; Moshe Y, 2004, P NATL ACAD SCI USA, V101, P7937, DOI 10.1073/pnas.0402442101; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Rippmann JF, 2000, CELL GROWTH DIFFER, V11, P409; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Spankuch-Schmitt B, 2002, ONCOGENE, V21, P3162, DOI 10.1038/sj.onc.1205412; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Wulf G, 2003, BREAST CANCER RES, V5, P76, DOI 10.1186/bcr572; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; YEH E, 2004, NAT CELL BIOL; Yuan JP, 2002, CANCER RES, V62, P4186; Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011; Yuan JP, 1997, AM J PATHOL, V150, P1165; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	60	88	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36575	36583		10.1074/jbc.M504548200	http://dx.doi.org/10.1074/jbc.M504548200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16118204	hybrid			2022-12-27	WOS:000232901800007
J	Fischer, C; Sanchez-Ruderisch, H; Welzel, M; Wiedenmann, B; Sakai, T; Andre, S; Gabius, HJ; Khachigian, L; Detjen, KM; Rosewicz, S				Fischer, C; Sanchez-Ruderisch, H; Welzel, M; Wiedenmann, B; Sakai, T; Andre, S; Gabius, HJ; Khachigian, L; Detjen, KM; Rosewicz, S			Galectin-1 interacts with the alpha 5 beta 1 fibronectin receptor to restrict carcinoma cell growth via induction of p21 and p27	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUROBLASTOMA-CELLS; FACTOR GENE-TRANSCRIPTION; DNA-BINDING ACTIVITY; GANGLIOSIDE GM(1); CYCLE PROGRESSION; PROTEIN-KINASE; MAMMALIAN GALECTINS; SP1 PHOSPHORYLATION; INTEGRIN RECEPTORS; INTERFERON-ALPHA	Surface binding of galectin family members has the potential to link distinct glycan structures to growth regulation. Therefore, we addressed the antiproliferative potential of galectin-1 (Gal-1) in a panel of carcinoma cell lines. We discovered growth inhibition by Gal-1 in epithelial tumor cell lines from different origins and provide evidence that this effect requires functional interaction with the alpha 5 beta 1 integrin. Antiproliferative effects result from inhibition of the Ras-MEK-ERK pathway and consecutive transcriptional induction of p27. We have further identified two Sp1-binding sites in the p27 promoter as crucial for Gal-1 responsiveness. Inhibition of the Ras-MEK-ERK cascade by Gal-1 increased Sp1 transactivation and DNA binding due to reduced threonine phosphorylation of Sp1. Furthermore, Gal-1 induced p21 transcription and selectively increased p27 protein stability. Gal-1-mediated accumulation of p27 and p21 inhibited cyclin-dependent kinase 2 activity and ultimately resulted in G(1) cell cycle arrest and growth inhibition. These data define a novel mechanism whereby Gal-1 regulates epithelial tumor cell homeostasis via carbohydrate-dependent interaction with the alpha 5 beta 1 integrin.	Charite Univ Med Berlin, Med Klin Schwerpunkt Hepatol & Gastroenterol, D-13353 Berlin, Germany; Kyoto Prefectural Univ Med, Dept Prevent Med, Kamigyo Ku, Kyoto 6028566, Japan; Univ Munich, Tierarztliche Fak, Inst Physiol Chem, D-80539 Munich, Germany; Univ New S Wales, Prince Wales Hosp, Ctr Vasc Res, Sydney, NSW 2052, Australia	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Kyoto Prefectural University of Medicine; University of Munich; University of New South Wales Sydney	Fischer, C (corresponding author), Charite Univ Med Berlin, Med Klin Schwerpunkt Hepatol & Gastroenterol, Campus Virchow Klinikum,Augustenburger Pl 1, D-13353 Berlin, Germany.	katharina.detjen@charite.de	Khachigian, Levon/AAZ-7458-2020	Gabius, Hans-Joachim/0000-0003-3467-3900; Wiedenmann, Bertram/0000-0002-7890-2552; Khachigian, Levon/0000-0003-3446-0323; Sanchez Ruderisch, Hugo/0000-0001-9315-4508; Andre, Sabine/0000-0003-0850-0432				Adams L, 1996, BBA-MOL CELL RES, V1312, P137, DOI 10.1016/0167-4889(96)00031-6; Ahmad N, 2004, J BIOL CHEM, V279, P10841, DOI 10.1074/jbc.M312834200; Andre S, 1999, J CANCER RES CLIN, V125, P461, DOI 10.1007/s004320050303; Andre S, 2005, INT J CANCER, V114, P46, DOI 10.1002/ijc.20699; Andre S, 2004, EUR J BIOCHEM, V271, P118, DOI 10.1046/j.1432-1033.2003.03910.x; Andre S, 2001, CHEMBIOCHEM, V2, P822, DOI 10.1002/1439-7633(20011105)2:11<822::AID-CBIC822>3.0.CO;2-W; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; Berberat PO, 2001, J HISTOCHEM CYTOCHEM, V49, P539, DOI 10.1177/002215540104900414; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Bonello MR, 2004, J BIOL CHEM, V279, P2377, DOI 10.1074/jbc.M308254200; Brewer CF, 2002, BBA-GEN SUBJECTS, V1572, P255, DOI 10.1016/S0304-4165(02)00312-4; Cooper DNW, 2002, BBA-GEN SUBJECTS, V1572, P209, DOI 10.1016/S0304-4165(02)00310-0; Detjen KM, 2000, GASTROENTEROLOGY, V118, P735, DOI 10.1016/S0016-5085(00)70143-0; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Gabius HJ, 2004, CHEMBIOCHEM, V5, P740, DOI 10.1002/cbic.200300753; Gabius HJ, 1997, EUR J BIOCHEM, V243, P543, DOI 10.1111/j.1432-1033.1997.t01-1-00543.x; GABIUS HJ, 1984, J NATL CANCER I, V73, P1349; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; Giancotti FG, 2003, ANNU REV CELL DEV BI, V19, P173, DOI 10.1146/annurev.cellbio.19.031103.133334; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GU MJ, 1994, J CELL SCI, V107, P175; Hadari YR, 2000, J CELL SCI, V113, P2385; Haidweger E, 2001, J MOL BIOL, V306, P201, DOI 10.1006/jmbi.2000.4406; Hata Y, 1998, J BIOL CHEM, V273, P19294, DOI 10.1074/jbc.273.30.19294; Hughes RC, 2001, BIOCHIMIE, V83, P667; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; Klein S, 2002, MOL CELL BIOL, V22, P5912, DOI 10.1128/MCB.22.16.5912-5922.2002; Kopitz J, 1998, J BIOL CHEM, V273, P11205, DOI 10.1074/jbc.273.18.11205; Kopitz J, 2003, ONCOGENE, V22, P6277, DOI 10.1038/sj.onc.1206631; Kopitz J, 2001, J BIOL CHEM, V276, P35917, DOI 10.1074/jbc.M105135200; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; Levy Y, 2003, J BIOL CHEM, V278, P14533, DOI 10.1074/jbc.M207380200; Lopez-Lucendo MF, 2004, J MOL BIOL, V343, P957, DOI 10.1016/j.jmb.2004.08.078; Maeda N, 2003, J BIOL CHEM, V278, P18938, DOI 10.1074/jbc.M209673200; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; Minami S, 1997, FEBS LETT, V411, P1, DOI 10.1016/S0014-5793(97)00660-1; MIRANTI CK, 2002, NATURE CELL BIOL, V4, P83; Moiseeva EP, 1999, J VASC RES, V36, P47, DOI 10.1159/000025625; Moiseeva EP, 2003, BIOCHEM BIOPH RES CO, V310, P1010, DOI 10.1016/j.bbrc.2003.09.112; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; Plath T, 2000, J CELL BIOL, V150, P1467, DOI 10.1083/jcb.150.6.1467; Qiang YW, 2000, EXP HEMATOL, V28, P1147, DOI 10.1016/S0301-472X(00)00521-X; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; Schuppan D, 2003, HEPATOLOGY, V38, P289, DOI 10.1053/jhep.2003.50338; Siebert HC, 2003, BIOCHEMISTRY-US, V42, P14762, DOI 10.1021/bi035477c; Sturm A, 2004, J IMMUNOL, V173, P3825, DOI 10.4049/jimmunol.173.6.3825; TOWNSEND CM, 1993, ACTA ONCOL, V32, P125, DOI 10.3109/02841869309083900; van den Brule F, 2003, LAB INVEST, V83, P377, DOI 10.1097/01.LAB.0000059949.01480.40; Vespa GNR, 1999, J IMMUNOL, V162, P799; von Marschall Z, 2003, J NATL CANCER I, V95, P437, DOI 10.1093/jnci/95.6.437; Vrasidas I, 2003, ORG BIOMOL CHEM, V1, P803, DOI 10.1039/b210923a; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Yang RY, 2003, CELL MOL LIFE SCI, V60, P267, DOI 10.1007/s000180300022; Ye XB, 2002, J BIOL CHEM, V277, P31863, DOI 10.1074/jbc.M205544200; Zhang H, 2003, HEPATOLOGY, V38, P305, DOI 10.1053/jhep.2003.50345; Zhang Y, 1997, BBA-GENE STRUCT EXPR, V1353, P307, DOI 10.1016/S0167-4781(97)00063-8; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	61	153	158	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37266	37277		10.1074/jbc.M411580200	http://dx.doi.org/10.1074/jbc.M411580200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16105842	hybrid			2022-12-27	WOS:000232901800085
J	Henriksen, U; Fog, JU; Litman, T; Gether, U				Henriksen, U; Fog, JU; Litman, T; Gether, U			Identification of intra- and intermolecular disulfide bridges in the multidrug resistance transporter ABCG2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER RESISTANCE; HALF-TRANSPORTER; MONOCLONAL-ANTIBODY; PROTEIN; CELLS; MITOXANTRONE; OVEREXPRESSION; EXPRESSION; MXR; HETERODIMERIZATION	ABCG2 is an ATP binding cassette (ABC) half-transporter that plays a key role in multidrug resistance to chemotherapy. ABCG2 is believed to be a functional homodimer that has been proposed to be linked by disulfide bridges. We have investigated the structural and functional role of the only three cysteines predicted to be on the extracellular face of ABCG2. Upon mutation of Cys-592 or Cys-608 to alanine (C592A and C608A), ABCG2 migrated as a dimer in SDS-PAGE under non-reducing conditions; however, mutation of Cys-603 to Ala (C603A) caused the transporter to migrate as a single monomeric band. Despite this change, C603A displayed efficient membrane targeting and preserved transport function. Because the transporter migrated as a dimer in SDS-PAGE, when only Cys-603 was present (C592A-C608A), the data suggest that Cys-603 forms a symmetrical intermolecular disulfide bridge in the ABCG2 homodimer that is not essential for protein expression and function. In contrast to C603A, both C592A and C608A displayed impaired membrane targeting and function. Moreover, when only Cys-592 or Cys-608 were present ( C592A/C603A and C603A/ C608A), the transporter displayed impaired plasma membrane expression and function. The combined mutation (C592A/C608A) partially restored plasma membrane expression; however, although transport of mitoxantrone was almost normal, we observed impairment of BODIPY-prazosin transport. This supports the conclusion that Cys-592 and Cys-608 form an intramolecular disulfide bridge in ABCG2 that is critical for substrate specificity. Finally, mutation of all three cysteines simultaneously resulted in low expression and no measurable function. Altogether, our data are consistent with a scenario in which an inter- and an intramolecular disulfide bridge together are of fundamental importance for the structural and functional integrity of ABCG2.	Univ Copenhagen, Panum Inst, Dept Pharmacol, Mol Neuropharmacol Grp, DK-2200 Copenhagen, Denmark; Univ Copenhagen, Bioinformat Ctr, DK-2100 Copenhagen, Denmark	University of Copenhagen; University of Copenhagen	Gether, U (corresponding author), Univ Copenhagen, Panum Inst, Dept Pharmacol, Mol Neuropharmacol Grp, Bldg 18-6,Blegdamsvej 3, DK-2200 Copenhagen, Denmark.	gether@neuropharm.ku.dk		Gether, Ulrik/0000-0002-0020-3807; Litman, Thomas/0000-0002-6068-901X				Allikmets R, 1998, CANCER RES, V58, P5337; Brangi M, 1999, CANCER RES, V59, P5938; Cao W, 2004, BIOCHEM J, V378, P201, DOI 10.1042/BJ20031288; Davidson AL, 1997, J BACTERIOL, V179, P5458, DOI 10.1128/jb.179.17.5458-5464.1997; Diah SK, 2001, CANCER RES, V61, P5461; Diestra JE, 2002, J PATHOL, V198, P213, DOI 10.1002/path.1203; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Getz EB, 1999, ANAL BIOCHEM, V273, P73, DOI 10.1006/abio.1999.4203; Graf GA, 2004, J BIOL CHEM, V279, P24881, DOI 10.1074/jbc.M402634200; Graf GA, 2003, J BIOL CHEM, V278, P48275, DOI 10.1074/jbc.M310223200; Graf GA, 2002, J CLIN INVEST, V110, P659, DOI 10.1172/JCI200216000; Henriksen U, 2005, J CELL SCI, V118, P1417, DOI 10.1242/jcs.01729; Janvilisri T, 2003, J BIOL CHEM, V278, P20645, DOI 10.1074/jbc.M301358200; Kage K, 2002, INT J CANCER, V97, P626, DOI 10.1002/ijc.10100; Kim M, 2002, CLIN CANCER RES, V8, P22; Langosch D, 1996, J MOL BIOL, V263, P525, DOI 10.1006/jmbi.1996.0595; LEE JS, 1994, MOL PHARMACOL, V46, P627; LEMMON MA, 1994, NAT STRUCT BIOL, V1, P157, DOI 10.1038/nsb0394-157; Litman T, 2001, CELL MOL LIFE SCI, V58, P931, DOI 10.1007/PL00000912; Litman T, 2002, BBA-BIOMEMBRANES, V1565, P6, DOI 10.1016/S0005-2736(02)00492-3; Litman T, 2000, J CELL SCI, V113, P2011; Liu LX, 1999, J BIOL CHEM, V274, P32738, DOI 10.1074/jbc.274.46.32738; Maliepaard M, 2001, CANCER RES, V61, P3458; Miyake K, 1999, CANCER RES, V59, P8; Ozvegy C, 2002, J BIOL CHEM, V277, P47980, DOI 10.1074/jbc.M207857200; Ozvegy-Laczka C, 2005, J BIOL CHEM, V280, P4219, DOI 10.1074/jbc.M411338200; Polgar O, 2004, BIOCHEMISTRY-US, V43, P9448, DOI 10.1021/bi0497953; Rees S, 1996, BIOTECHNIQUES, V20, P102; Robey RW, 2001, CLIN CANCER RES, V7, P145; Rocchi E, 2000, BIOCHEM BIOPH RES CO, V271, P42, DOI 10.1006/bbrc.2000.2590; Ross DD, 2000, BLOOD, V96, P365, DOI 10.1182/blood.V96.1.365.013k46_365_368; Sauerbrey A, 2002, BRIT J HAEMATOL, V118, P147, DOI 10.1046/j.1365-2141.2002.03550.x; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; van Veen HW, 2000, EMBO J, V19, P2503, DOI 10.1093/emboj/19.11.2503; Volk EL, 2002, CANCER RES, V62, P5035; Xu JK, 2004, J BIOL CHEM, V279, P19781, DOI 10.1074/jbc.M310785200; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	37	102	108	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36926	36934		10.1074/jbc.M502937200	http://dx.doi.org/10.1074/jbc.M502937200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16107343	hybrid			2022-12-27	WOS:000232901800049
J	Kamiya, Y; Yamaguchi, Y; Takahashi, N; Arata, Y; Kasai, K; Ihara, Y; Matsuo, I; Ito, Y; Yamamoto, K; Kato, K				Kamiya, Y; Yamaguchi, Y; Takahashi, N; Arata, Y; Kasai, K; Ihara, Y; Matsuo, I; Ito, Y; Yamamoto, K; Kato, K			Sugar-binding properties of VIP36, an intracellular animal lectin operating as a cargo receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRONTAL AFFINITY-CHROMATOGRAPHY; CARBOHYDRATE-RECOGNITION DOMAIN; MANNOSE TYPE GLYCANS; N-LINKED GLYCANS; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; QUALITY-CONTROL; MISFOLDED GLYCOPROTEINS; LEGUMINOUS LECTINS; CRYSTAL-STRUCTURE	The vesicular integral protein of 36 kDa (VIP36) is an intracellular animal lectin that acts as a putative cargo receptor, which recycles between the Golgi and the endoplasmic reticulum. Although it is known that VIP36 interacts with glycoproteins carrying high mannose-type oligosaccharides, detailed analyses of the sugar-binding specificity that discriminates isomeric oligosaccharide structures have not yet been performed. In the present study, we have analyzed, using the frontal affinity chromatography (FAC) method, the sugar-binding properties of a recombinant carbohydrate recognition domain of VIP36 (VIP36-CRD). For this purpose, a pyridylaminated sugar library, consisting of 21 kinds of oligosaccharides, including isomeric structures, was prepared and subjected to FAC analyses. The FAC data have shown that glucosylation and trimming of the D1 mannosyl branch interfere with the binding of VIP36-CRD. VIP36-CRD exhibits a bell-shaped pH dependence of sugar binding with an optimal pH value of similar to 6.5. By inspection of the specificity and optimal pH value of the sugar binding of VIP36 and its subcellular localization, together with the organellar pH, we suggest that VIP36 binds glycoproteins that retain the intact D1 mannosyl branch in the cis-Golgi network and recycles to the endoplasmic reticulum where, due to higher pH, it releases its cargos, thereby contributing to the quality control of glycoproteins.	Nagoya City Univ, Grad Sch Pharmaceut Sci, Mizuho Ku, Nagoya, Aichi 4678603, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Kawaguchi 3321102, Japan; Okazaki Natl Res Inst, Inst Mol Sci, Aichi 4448787, Japan; GLYENCE Co Ltd, Naka Ku, Nagoya, Aichi 4608690, Japan; Teikyo Univ, Fac Pharmaceut Sci, Dept Biol Chem, Kanagawa 1990195, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Atom Bomb Dis Inst, Dept Biochem & Mol Biol Dis, Nagasaki 8528523, Japan; RIKEN, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan; Univ Tokyo, Grad Sch Frontier Sci, Chiba 2778562, Japan	Nagoya City University; Japan Science & Technology Agency (JST); National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); Teikyo University; Nagasaki University; RIKEN; University of Tokyo	Kato, K (corresponding author), Nagoya City Univ, Grad Sch Pharmaceut Sci, Mizuho Ku, 3-1 Tanabe Dori, Nagoya, Aichi 4678603, Japan.	kkato@phar.nagoya-cu.ac.jp	Yamaguchi, Yoshiki/N-5246-2015; Ito, Yukishige/ACL-6203-2022; Ito, Yukishige/M-5119-2014	Yamaguchi, Yoshiki/0000-0003-0100-5439; Ito, Yukishige/0000-0001-6251-7249; Ito, Yukishige/0000-0001-6251-7249; Kato, Koichi/0000-0001-7187-9612				Appenzeller C, 1999, NAT CELL BIOL, V1, P330, DOI 10.1038/14020; Appenzeller-Herzog C, 2004, J BIOL CHEM, V279, P12943, DOI 10.1074/jbc.M313245200; Arata Y, 2001, J BIOL CHEM, V276, P3068, DOI 10.1074/jbc.M008602200; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; Fiedler K, 1996, J CELL SCI, V109, P271; Fullekrug J, 1999, J CELL SCI, V112, P2813; Hara-Kuge S, 1999, GLYCOBIOLOGY, V9, P833, DOI 10.1093/glycob/9.8.833; Hara-Kuge S, 2004, GLYCOBIOLOGY, V14, P739, DOI 10.1093/glycob/cwh082; Hara-Kuge S, 2002, J BIOL CHEM, V277, P16332, DOI 10.1074/jbc.M112188200; Hauri HP, 2000, J CELL SCI, V113, P587; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Hirabayashi J, 2003, METHOD ENZYMOL, V362, P353; Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; Itin C, 1996, MOL BIOL CELL, V7, P483, DOI 10.1091/mbc.7.3.483; KASAI K, 1986, J CHROMATOGR, V376, P33, DOI 10.1016/S0378-4347(00)80822-1; Lee RT, 2000, GLYCOCONJUGATE J, V17, P543, DOI 10.1023/A:1011070425430; Matsuo I, 2003, J AM CHEM SOC, V125, P3402, DOI 10.1021/ja021288q; Mizushima T, 2004, NAT STRUCT MOL BIOL, V11, P365, DOI 10.1038/nsmb732; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; Moremen K. W., 2000, CARBOHYDRATES CHEM 2, V3, P81; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; Moussalli M, 1999, J BIOL CHEM, V274, P32539, DOI 10.1074/jbc.274.46.32539; Nawa D, 2004, GLYCOBIOLOGY, V14, P1108; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Schrag JD, 2003, TRENDS BIOCHEM SCI, V28, P49, DOI 10.1016/S0968-0004(02)00004-X; Spiro RG, 2004, CELL MOL LIFE SCI, V61, P1025, DOI 10.1007/s00018-004-4037-8; Takabayashi M, 2003, ANTI-CANCER DRUG, V14, P251, DOI 10.1097/00001813-200303000-00010; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; TOMIYA N, 1991, ANAL BIOCHEM, V193, P90, DOI 10.1016/0003-2697(91)90047-W; TOMIYA N, 1988, ANAL BIOCHEM, V171, P73, DOI 10.1016/0003-2697(88)90126-1; Trombetta ES, 1996, J BIOL CHEM, V271, P27509, DOI 10.1074/jbc.271.44.27509; Vassilakos A, 1998, BIOCHEMISTRY-US, V37, P3480, DOI 10.1021/bi972465g; Velloso LM, 2003, J MOL BIOL, V334, P845, DOI 10.1016/j.jmb.2003.10.031; Velloso LM, 2002, J BIOL CHEM, V277, P15979, DOI 10.1074/jbc.M112098200; Weisz OA, 2003, INT REV CYTOL, V226, P259, DOI 10.1016/S0074-7696(03)01005-2; Wu MM, 2001, J BIOL CHEM, V276, P33027, DOI 10.1074/jbc.M103917200; Yamamoto K, 2001, EMBO J, V20, P3082, DOI 10.1093/emboj/20.12.3082; YAMAMOTO S, 1989, J BIOCHEM-TOKYO, V105, P547, DOI 10.1093/oxfordjournals.jbchem.a122703; Yoshida Y, 2002, NATURE, V418, P438, DOI 10.1038/nature00890	44	71	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37178	37182		10.1074/jbc.M505757200	http://dx.doi.org/10.1074/jbc.M505757200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16129679	hybrid			2022-12-27	WOS:000232901800076
J	Kharel, Y; Lee, S; Snyder, AH; Sheasley-O'Neill, SL; Morris, MA; Setiady, Y; Zhu, R; Zigler, MA; Burcin, TL; Ley, K; Tung, KSK; Engelhard, VH; Macdonald, TL; Pearson-White, S; Lynch, KR				Kharel, Y; Lee, S; Snyder, AH; Sheasley-O'Neill, SL; Morris, MA; Setiady, Y; Zhu, R; Zigler, MA; Burcin, TL; Ley, K; Tung, KSK; Engelhard, VH; Macdonald, TL; Pearson-White, S; Lynch, KR			Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULATING MATURE LYMPHOCYTES; IMMUNOSUPPRESSANT; SPHINGOSINE-1-PHOSPHATE; 1-PHOSPHATE; RECEPTOR; RATS; MICE; PHOSPHORYLATION; IMMUNOMODULATOR; SEQUESTRATION	Immunotherapeutic drugs that mimic sphingosine 1-phosphate (S1P) disrupt lymphocyte trafficking and cause T helper and T effector cells to be retained in secondary lymphoid tissue and away from sites of inflammation. The prototypical therapeutic agent, 2-alkyl-2-amino-1,3-propanediol (FTY720), stimulates S1P signaling pathways only after it is phosphorylated by one or more unknown kinases. We generated sphingosine kinase 2 (SPHK2) null mice to demonstrate that this kinase is responsible for FTY720 phosphorylation and thereby its subsequent actions on the immune system. Both systemic and lymphocyte-localized sources of SPHK2 contributed to FTY720 induced lymphopenia. Although FTY720 was selectively activated in vivo by SPHK2, other S1P pro-drugs can be phosphorylated to cause lymphopenia through the action of additional sphingosine kinases. Our results emphasize the importance of SPHK2 expression in both lymphocytes and other tissues for immune modulation and drug metabolism.	Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Cardiovasc Res Ctr, Charlottesville, VA 22908 USA; Univ Virginia, Dept Biomed Engn, Charlottesville, VA 22908 USA; Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Chem, Charlottesville, VA 22908 USA; Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia; University of Virginia; University of Virginia; University of Virginia; University of Virginia	Lynch, KR (corresponding author), Univ Virginia Hlth Syst, Dept Pharmacol, 1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	KRLynch@virginia.edu	Pearson-White, Sonia/S-2570-2016	Engelhard, Victor/0000-0002-1741-0925	NCI NIH HHS [R01CA078400, R01 CA078400] Funding Source: Medline; NIAID NIH HHS [R01AI051420, R01 AI051420, R21 AI051420] Funding Source: Medline; NIGMS NIH HHS [R01GM067958, R01 GM067958] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078400] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051420, R21AI051420] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067958] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allende ML, 2004, J BIOL CHEM, V279, P52487, DOI 10.1074/jbc.M406512200; Billich A, 2003, J BIOL CHEM, V278, P47408, DOI 10.1074/jbc.M307687200; BOGGS DR, 1984, AM J HEMATOL, V16, P277, DOI 10.1002/ajh.2830160309; Bolick DT, 2005, ARTERIOSCL THROM VAS, V25, P976, DOI 10.1161/01.ATV.0000162171.30089.f6; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Brinkmann V, 2001, TRANSPLANTATION, V72, P764, DOI 10.1097/00007890-200109150-00002; Chiba K, 1998, J IMMUNOL, V160, P5037; Cinamon G, 2004, NAT IMMUNOL, V5, P713, DOI 10.1038/ni1083; DUNN TB, 1954, JNCI-J NATL CANCER I, V14, P1281; Graler MH, 2004, FASEB J, V18, P551, DOI 10.1096/fj.03-0910fje; Henning G, 2001, J EXP MED, V194, P1875, DOI 10.1084/jem.194.12.1875; Kiuchi M, 2000, J MED CHEM, V43, P2946, DOI 10.1021/jm000173z; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; Matsuura M, 2000, INT J IMMUNOPHARMACO, V22, P323, DOI 10.1016/S0192-0561(99)00088-0; Paugh SW, 2003, FEBS LETT, V554, P189, DOI 10.1016/S0014-5793(03)01168-2; Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC; Sanchez T, 2003, J BIOL CHEM, V278, P47281, DOI 10.1074/jbc.M306896200; Tedesco-Silva H, 2004, TRANSPLANTATION, V77, P1826, DOI 10.1097/01.tp.0000121761.02129.a6; Troncoso P, 2001, TRANSPLANT P, V33, P857, DOI 10.1016/S0041-1345(00)02349-6; Yanagawa Y, 1998, J IMMUNOL, V160, P5493; Yang ZD, 2003, CLIN IMMUNOL, V107, P30, DOI 10.1016/S1521-6616(02)00054-2	24	163	175	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36865	36872		10.1074/jbc.M506293200	http://dx.doi.org/10.1074/jbc.M506293200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16093248	hybrid			2022-12-27	WOS:000232901800042
J	Maceyka, M; Sankala, H; Hait, NC; Le Stunff, H; Liu, H; Toman, R; Collier, C; Zhang, M; Satin, LS; Merrill, AH; Milstien, S; Spiegel, S				Maceyka, M; Sankala, H; Hait, NC; Le Stunff, H; Liu, H; Toman, R; Collier, C; Zhang, M; Satin, LS; Merrill, AH; Milstien, S; Spiegel, S			SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CERAMIDE-INDUCED APOPTOSIS; PROTEIN-COUPLED RECEPTORS; ENDOPLASMIC-RETICULUM; GROWTH-FACTOR; SPHINGOSINE-1-PHOSPHATE PHOSPHOHYDROLASE; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; KEY REGULATOR; CELL-DEATH; CA2+	The potent sphingolipid metabolite sphingosine 1-phosphate is produced by phosphorylation of sphingosine catalyzed by sphingosine kinase (SphK) types 1 and 2. In contrast to pro-survival SphK1, the putative BH3-only protein SphK2 inhibits cell growth and enhances apoptosis. Here we show that SphK2 catalytic activity also contributes to its ability to induce apoptosis. Overexpressed SphK2 also increased cytosolic free calcium induced by serum starvation. Transfer of calcium to mitochondria was required for SphK2-induced apoptosis, as cell death and cytochrome c release was abrogated by inhibition of the mitochondrial Ca2+ transporter. Serum starvation increased the proportion of SphK2 in the endoplasmic reticulum and targeting SphK1 to the endoplasmic reticulum converted it from anti-apoptotic to pro-apoptotic. Overexpression of SphK2 increased incorporation of [H-3] palmitate, a substrate for both serine palmitoyltransferase and ceramide synthase, into C16-ceramide, whereas SphK1 decreased it. Electrospray ionization-mass spectrometry/mass spectrometry also revealed an opposite effect on ceramide mass levels. Importantly, specific down-regulation of SphK2 reduced conversion of sphingosine to ceramide in the recycling pathway and conversely, down-regulation of SphK1 increased it. Our results demonstrate that SphK1 and SphK2 have opposing roles in the regulation of ceramide biosynthesis and suggest that the location of sphingosine 1-phosphate production dictates its functions.	Virginia Commonwealth Univ, Sch Med, Dept Biochem, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Sch Med, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA; NIH, Lab Cellular & Mol Regulat, Bethesda, MD 20892 USA	Virginia Commonwealth University; Virginia Commonwealth University; University System of Georgia; Georgia Institute of Technology; National Institutes of Health (NIH) - USA	Spiegel, S (corresponding author), 1101 E Marshall St, Richmond, VA 23298 USA.	sspiegel@vcu.edu	LE STUNFF, Hervé/AAA-6882-2019; Maceyka, Michael/B-9277-2008	Merrill, Alfred/0000-0002-6673-968X	NATIONAL CANCER INSTITUTE [R01CA061774, P30CA016059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046409] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM069338] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH001039, ZIAMH001039] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA61774, P30 CA16059] Funding Source: Medline; NIDDK NIH HHS [R01DK46409] Funding Source: Medline; NIGMS NIH HHS [GM069338] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ancellin N, 2002, J BIOL CHEM, V277, P6667, DOI 10.1074/jbc.M102841200; Anliker B, 2004, J BIOL CHEM, V279, P20555, DOI 10.1074/jbc.R400013200; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Birchwood CJ, 2001, J BIOL CHEM, V276, P11712, DOI 10.1074/jbc.M010221200; Choi OH, 1996, NATURE, V380, P634; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Edsall LC, 2001, J NEUROCHEM, V76, P1573, DOI 10.1046/j.1471-4159.2001.00164.x; Ferrari D, 2002, CELL CALCIUM, V32, P413, DOI 10.1016/S0143416002002014; French KJ, 2003, CANCER RES, V63, P5962; Funato K, 2003, J BIOL CHEM, V278, P7325, DOI 10.1074/jbc.M209925200; Futerman AH, 2004, EMBO REP, V5, P777, DOI 10.1038/sj.embor.7400208; Futerman AH, 2005, TRENDS CELL BIOL, V15, P312, DOI 10.1016/j.tcb.2005.04.006; Germain M, 2002, J BIOL CHEM, V277, P18053, DOI 10.1074/jbc.M201235200; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hait NC, 2005, J BIOL CHEM, V280, P29462, DOI 10.1074/jbc.M502922200; Hait NC, 2002, FEBS LETT, V532, P97, DOI 10.1016/S0014-5793(02)03636-0; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200; Johnson KR, 2003, J BIOL CHEM, V278, P34541, DOI 10.1074/jbc.M301741200; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Jolly PS, 2004, J EXP MED, V199, P959, DOI 10.1084/jem.20030680; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Kolesnick R, 2003, ONCOGENE, V22, P5897, DOI 10.1038/sj.onc.1206702; Le Stunff H, 2002, J CELL BIOL, V158, P1039, DOI 10.1083/jcb.200203123; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200; Liu H, 2002, PROG NUCLEIC ACID RE, V71, P493, DOI 10.1016/S0079-6603(02)71049-0; Maceyka M, 2002, BBA-MOL CELL BIOL L, V1585, P193, DOI 10.1016/S1388-1981(02)00341-4; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; Mao CG, 1997, J BIOL CHEM, V272, P28690, DOI 10.1074/jbc.272.45.28690; Matlib MA, 1998, J BIOL CHEM, V273, P10223, DOI 10.1074/jbc.273.17.10223; MATTIE M, 1994, J BIOL CHEM, V269, P3181; Merrill AH, 2005, METHODS, V36, P207, DOI 10.1016/j.ymeth.2005.01.009; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nava VE, 2002, EXP CELL RES, V281, P115, DOI 10.1006/excr.2002.5658; Ng CKY, 2001, NATURE, V410, P596, DOI 10.1038/35069092; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Ogawa C, 2003, J BIOL CHEM, V278, P1268, DOI 10.1074/jbc.M209514200; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Olivera A, 2003, J BIOL CHEM, V278, P46452, DOI 10.1074/jbc.M308749200; Paris F, 2002, NAT MED, V8, P901, DOI 10.1038/nm0902-901; Pettus BJ, 2003, FASEB J, V17, P1411, DOI 10.1096/fj.02-1038com; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Pitson SM, 2002, J BIOL CHEM, V277, P49545, DOI 10.1074/jbc.M206687200; Reiss U, 2004, J BIOL CHEM, V279, P1281, DOI 10.1074/jbc.M309646200; Riebeling C, 2003, J BIOL CHEM, V278, P43452, DOI 10.1074/jbc.M307104200; Saba JD, 2004, CIRC RES, V94, P724, DOI 10.1161/01.RES.0000122383.60368.24; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shu XD, 2002, MOL CELL BIOL, V22, P7758, DOI 10.1128/MCB.22.22.7758-7768.2002; Sonnino S, 2000, BBA-REV BIOMEMBRANES, V1469, P63, DOI 10.1016/S0005-2736(00)00210-8; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; SULLARDS MC, 2001, SCI STKE, pL1; Suzuki E, 2004, P NATL ACAD SCI USA, V101, P14788, DOI 10.1073/pnas.0406536101; Taha TA, 2004, J BIOL CHEM, V279, P20546, DOI 10.1074/jbc.M401259200; Toman RE, 2004, J CELL BIOL, V166, P381, DOI 10.1083/jcb.200402016; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; vanEchtenDeckert G, 1997, J BIOL CHEM, V272, P15825, DOI 10.1074/jbc.272.25.15825; Venkataraman K, 2002, J BIOL CHEM, V277, P35642, DOI 10.1074/jbc.M205211200; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wu WC, 2003, ONCOGENE, V22, P3361, DOI 10.1038/sj.onc.1206285; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; Yamanaka M, 2004, J BIOL CHEM, V279, P53994, DOI 10.1074/jbc.M410144200; Yoshimoto T, 2003, J IMMUNOL, V171, P1352, DOI 10.4049/jimmunol.171.3.1352; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084; ZUHERINGDORF DM, 1998, EMBO J, V17, P2830	71	465	486	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37118	37129		10.1074/jbc.M502207200	http://dx.doi.org/10.1074/jbc.M502207200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16118219	hybrid			2022-12-27	WOS:000232901800070
J	Qin, S; Pande, AH; Nemec, KN; He, XM; Tatulian, SA				Qin, S; Pande, AH; Nemec, KN; He, XM; Tatulian, SA			Evidence for the regulatory role of the N-terminal helix of secretory phospholipase A(2) from studies on native and chimeric proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; BETA-SHEET STRUCTURE; INTERFACIAL ACTIVATION; INFRARED-SPECTROSCOPY; STRUCTURAL-CHANGES; MEMBRANE-BINDING; COILED-COILS; ALPHA-HELIX; AGKISTRODON PISCIVORUS; SECONDARY STRUCTURE	The phospholipase A(2) (PLA(2)) enzymes are activated by binding to phospholipid membranes. Although the N-terminal alpha-helix of group I/II PLA(2)s plays an important role in the productive mode membrane binding of the enzymes, its role in the structural aspects of membrane-induced activation of PLA(2)s is not well understood. In order to elucidate membrane-induced conformational changes in the N-terminal helix and in the rest of the PLA(2), we have created semisynthetic human group IB PLA(2) in which the N-terminal decapeptide is joined with the C-13-labeled fragment, as well as a chimeric protein containing the N-terminal decapeptide from human group IIA PLA(2) joined with a C-13-labeled fragment of group IB PLA(2). Infrared spectral resolution of the unlabeled and C-13-labeled segments suggests that the N-terminal helix of membrane-bound IB PLA(2) has a more rigid structure than the other helices. On the other hand, the overall structure of the chimeric PLA(2) is more rigid than that of the IB PLA(2), but the N-terminal helix is more flexible. A combination of homology modeling and polarized infrared spectroscopy provides the structure of membrane-bound chimeric PLA(2), which demonstrates remarkable similarity but also distinct differences compared with that of IB PLA(2). Correlation is delineated between structural and membrane binding properties of PLA(2)s and their N-terminal helices. Altogether, the data provide evidence that the N-terminal helix of group I/II PLA(2)s acts as a regulatory domain that mediates interfacial activation of these enzymes.	Univ Cent Florida, Biomol Sci Ctr, Orlando, FL 32826 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Mol Biol, Boston, MA 02114 USA; Univ Cent Florida, Dept Chem, Orlando, FL 32816 USA	State University System of Florida; University of Central Florida; Harvard University; Harvard Medical School; Massachusetts General Hospital; State University System of Florida; University of Central Florida	Tatulian, SA (corresponding author), Univ Cent Florida, Biomol Sci Ctr, 12722 Res Pkwy, Orlando, FL 32826 USA.	statulia@mail.ucf.edu			NHLBI NIH HHS [HL65524] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065524] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arni RK, 1996, TOXICON, V34, P827, DOI 10.1016/0041-0101(96)00036-0; Bahnson BJ, 2005, ARCH BIOCHEM BIOPHYS, V433, P96, DOI 10.1016/j.abb.2004.08.013; Baker SF, 1998, BIOCHEMISTRY-US, V37, P13203, DOI 10.1021/bi981223t; Barber-Armstrong W, 2004, J AM CHEM SOC, V126, P2339, DOI 10.1021/ja037863n; Barnett SM, 1997, J PHYS CHEM B, V101, P9421, DOI 10.1021/jp972086x; Beers SA, 2003, BIOCHEMISTRY-US, V42, P7326, DOI 10.1021/bi0343222; Berg OG, 2001, CHEM REV, V101, P2613, DOI 10.1021/cr990139w; Bezzine S, 2002, J BIOL CHEM, V277, P48523, DOI 10.1074/jbc.M203137200; Canaan S, 2002, J BIOL CHEM, V277, P30984, DOI 10.1074/jbc.M203649200; COHEN C, 1994, SCIENCE, V263, P488, DOI 10.1126/science.8290957; COOPER TM, 1990, BIOPOLYMERS, V30, P657, DOI 10.1002/bip.360300703; D'Antuono C, 2000, ARCH BIOCHEM BIOPHYS, V382, P39, DOI 10.1006/abbi.2000.1979; DONATO H, 1991, BIOCHEM J, V276, P13, DOI 10.1042/bj2760013; Gadd ME, 2000, BIOCHEMISTRY-US, V39, P9623, DOI 10.1021/bi000322f; Gelb MH, 1999, CURR OPIN STRUC BIOL, V9, P428, DOI 10.1016/S0959-440X(99)80059-1; Golding C, 1996, BIOCHEMISTRY-US, V35, P10931, DOI 10.1021/bi960905i; Han SK, 1997, J BIOL CHEM, V272, P3573, DOI 10.1074/jbc.272.26.16152; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; Heimburg T, 1996, BIOCHEMISTRY-US, V35, P1375, DOI 10.1021/bi9515883; Hristova K, 1999, J MOL BIOL, V290, P99, DOI 10.1006/jmbi.1999.2840; Huang R, 2004, J AM CHEM SOC, V126, P2346, DOI 10.1021/ja037998t; JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140; JAIN MK, 1993, BIOCHEMISTRY-US, V32, P11838, DOI 10.1021/bi00095a012; Jerala R, 1996, J BIOMOL NMR, V7, P107; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; KRIMM S, 1982, SCIENCE, V216, P407, DOI 10.1126/science.6280277; LIU XH, 1995, BIOCHEMISTRY-US, V34, P7322, DOI 10.1021/bi00022a005; MALIWAL BP, 1994, BIOCHEMISTRY-US, V33, P4509, DOI 10.1021/bi00181a010; Marsh D, 1999, BIOPHYS J, V77, P2630, DOI 10.1016/S0006-3495(99)77096-7; Masuda S, 2005, FEBS J, V272, P655, DOI 10.1111/j.1742-4658.2004.04489.x; MCINTOSH TJ, 1987, BIOCHEMISTRY-US, V26, P1783, DOI 10.1021/bi00380a042; Moran A, 2004, P NATL ACAD SCI USA, V101, P506, DOI 10.1073/pnas.2533089100; Murakami M, 2004, BIOL PHARM BULL, V27, P1158, DOI 10.1248/bpb.27.1158; NEMETHY G, 1967, NATURE, V214, P363, DOI 10.1038/214363a0; Othman R, 1996, BBA-LIPID LIPID MET, V1303, P92, DOI 10.1016/0005-2760(96)00083-5; Pan YH, 2001, BIOCHEMISTRY-US, V40, P609, DOI 10.1021/bi002514g; Pastrana-Rios B, 2001, BIOCHEMISTRY-US, V40, P9074, DOI 10.1021/bi0155145; Paul C, 2004, J AM CHEM SOC, V126, P5843, DOI 10.1021/ja038869f; Paul C, 2005, J AM CHEM SOC, V127, P5754, DOI 10.1021/ja042569w; Qin S, 2004, J MOL BIOL, V344, P71, DOI 10.1016/j.jmb.2004.09.034; Reisdorf WC, 1996, BIOCHEMISTRY-US, V35, P1383, DOI 10.1021/bi951589v; ROTHSCHILD KJ, 1979, SCIENCE, V204, P311, DOI 10.1126/science.432645; Ruan KC, 2002, BIOCHEM BIOPH RES CO, V293, P593, DOI 10.1016/S0006-291X(02)00247-4; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SCOTT DL, 1994, ADV PROTEIN CHEM, V45, P53; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Sreerama N, 1999, PROTEIN SCI, V8, P370; Surette ME, 1998, BIOCHEM J, V330, P915; Tatulian SA, 2005, J MOL BIOL, V351, P939, DOI 10.1016/j.jmb.2005.06.080; Tatulian SA, 1997, J MOL BIOL, V268, P809, DOI 10.1006/jmbi.1997.1014; Tatulian SA, 2003, BIOCHEMISTRY-US, V42, P11898, DOI 10.1021/bi034235+; Tatulian SA, 2003, BIOPHYS J, V84, P1773, DOI 10.1016/S0006-3495(03)74985-6; Tatulian SA, 2001, BIOPHYS J, V80, P789, DOI 10.1016/S0006-3495(01)76058-4; VANDENBERG B, 1995, J BIOMOL NMR, V5, P110, DOI 10.1007/BF00208802; VANDENBERG B, 1995, NAT STRUCT BIOL, V2, P402, DOI 10.1038/nsb0595-402; Venyaminov SY, 2001, PROTEINS, V45, P81, DOI 10.1002/prot.1126; WALL J, 1995, MOL MEMBR BIOL, V12, P183, DOI 10.3109/09687689509027506; Yu BZ, 2000, BIOCHEMISTRY-US, V39, P5702, DOI 10.1021/bi9925470; ZHOU NE, 1992, J BIOL CHEM, V267, P2664	59	37	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36773	36783		10.1074/jbc.M506789200	http://dx.doi.org/10.1074/jbc.M506789200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16103116	hybrid			2022-12-27	WOS:000232901800031
J	Barker, TH; Baneyx, G; Cardo-Vila, M; Workman, GA; Weaver, M; Menon, PM; Dedhar, S; Rempel, SA; Arap, W; Pasqualini, R; Vogel, V; Sage, EH				Barker, TH; Baneyx, G; Cardo-Vila, M; Workman, GA; Weaver, M; Menon, PM; Dedhar, S; Rempel, SA; Arap, W; Pasqualini, R; Vogel, V; Sage, EH			SPARC regulates extracellular matrix organization through its modulation of integrin-linked kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATASE TARGET SUBUNIT; RESONANCE ENERGY-TRANSFER; NULL MICE; MATRICELLULAR PROTEINS; CELL-MATRIX; ENDOTHELIAL-CELLS; SECRETED PROTEIN; CYSTEINE SPARC; FIBRONECTIN; BINDING	SPARC, a 32-kDa matricellular glycoprotein, mediates interactions between cells and their extracellular matrix, and targeted deletion of Sparc results in compromised extracellular matrix in mice. Fibronectin matrix provides provisional tissue scaffolding during development and wound healing and is essential for the stabilization of mature extracellular matrix. Herein, we report that SPARC expression does not significantly affect fibronectin-induced cell spreading but enhances fibronectin-induced stress fiber formation and cell-mediated partial unfolding of fibronectin molecules, an essential process in fibronectin matrix assembly. By phage display, we identify integrin-linked kinase as a potential binding partner of SPARC and verify the interaction by co-immunoprecipitation and colocalization in vitro. Cells lacking SPARC exhibit diminished fibronectin-induced integrin-linked kinase activation and integrin-linked kinase-dependent cell-contractile signaling. Furthermore, induced expression of SPARC in SPARC-null fibroblasts restores fibronectin-induced integrin-linked kinase activation, downstream signaling, and fibronectin unfolding. These data further confirm the function of SPARC in extracellular matrix organization and identify a novel mechanism by which SPARC regulates extracellular matrix assembly.	Virginia Mason, Benaroya Res Inst, Hope Heart Program, Seattle, WA 98101 USA; Univ Washington, Dept Bioengn, Seattle, WA 98101 USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Henry Ford Hosp, Barbara Jane Levy Lab, Hermelin Brain Tumor Ctr, Detroit, MI 48202 USA; British Columbia Canc Agcy, Jack Bell Res Ctr, Vancouver, BC V5Z 1L3, Canada; ETH, Swiss Fed Inst Technol, CH-8093 Zurich, Switzerland	Benaroya Research Institute; Virginia Mason Medical Center; University of Washington; University of Washington Seattle; University of Texas System; UTMD Anderson Cancer Center; Henry Ford Health System; Henry Ford Hospital; British Columbia Cancer Agency; University of British Columbia; Swiss Federal Institutes of Technology Domain; ETH Zurich	Sage, EH (corresponding author), Virginia Mason, Benaroya Res Inst, Hope Heart Program, 1201 9th Ave, Seattle, WA 98101 USA.	hsage@benaroyaresearch.org	Vogel, Viola/O-8025-2015	Vogel, Viola/0000-0003-2898-7671; Dedhar, Shoukat/0000-0003-4355-1657	NATIONAL CANCER INSTITUTE [R01CA086997] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY013180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040711] Funding Source: NIH RePORTER; NCI NIH HHS [CA 086997, R01 CA086997] Funding Source: Medline; NEI NIH HHS [EY13180] Funding Source: Medline; NIGMS NIH HHS [GM40711] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aycock RL, 2004, J INVEST DERMATOL, V123, P592, DOI 10.1111/j.0022-202X.2004.23316.x; Baneyx G, 2002, P NATL ACAD SCI USA, V99, P5139, DOI 10.1073/pnas.072650799; Baneyx G, 2001, P NATL ACAD SCI USA, V98, P14464, DOI 10.1073/pnas.251422998; Baugh L, 2004, J BIOMED MATER RES A, V69A, P525, DOI 10.1002/jbm.a.30026; Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7; Bradshaw AD, 2003, J INVEST DERMATOL, V120, P949, DOI 10.1046/j.1523-1747.2003.12241.x; Bradshaw AD, 2003, P NATL ACAD SCI USA, V100, P6045, DOI 10.1073/pnas.1030790100; Bradshaw AD, 2001, WOUND REPAIR REGEN, V9, P522, DOI 10.1046/j.1524-475x.2001.00522.x; Bradshaw AD, 2002, J HISTOCHEM CYTOCHEM, V50, P1; Bradshaw Amy D., 2000, Molecular Cell Biology Research Communications, V3, P345, DOI 10.1006/mcbr.2000.0237; Brakebusch C, 2003, EMBO J, V22, P2324, DOI 10.1093/emboj/cdg245; Brekken RA, 2004, J HISTOCHEM CYTOCHEM, V52, P735, DOI 10.1369/jhc.3A6245.2004; Brekken RA, 2003, J CLIN INVEST, V111, P487, DOI 10.1172/JCI200316804; Brekken RA, 2000, MATRIX BIOL, V19, P569, DOI 10.1016/S0945-053X(00)00105-0; Charboneau AL, 2002, INT J CANCER, V100, P181, DOI 10.1002/ijc.10470; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Deng JT, 2002, BIOCHEM J, V367, P517, DOI 10.1042/BJ20020522; Deng JT, 2001, J BIOL CHEM, V276, P16365, DOI 10.1074/jbc.M011634200; Falke JJ, 2001, TRENDS BIOCHEM SCI, V26, P257, DOI 10.1016/S0968-0004(00)01770-9; Gao M, 2003, P NATL ACAD SCI USA, V100, P14784, DOI 10.1073/pnas.2334390100; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Giordano RJ, 2001, NAT MED, V7, P1249, DOI 10.1038/nm1101-1249; Hagood JS, 1999, AM J PHYSIOL-LUNG C, V277, pL218, DOI 10.1152/ajplung.1999.277.1.L218; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Kiss E, 2002, BIOCHEM J, V365, P79, DOI 10.1042/BJ20011295; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; Magnusson MK, 1998, ARTERIOSCL THROM VAS, V18, P1363, DOI 10.1161/01.ATV.18.9.1363; MALAVAL L, 1987, J BONE MINER RES, V2, P457; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Muranyi A, 2002, BIOCHEM J, V366, P211, DOI 10.1042/BJ20020401; Murphy-Ullrich JE, 2001, J CLIN INVEST, V107, P785, DOI 10.1172/JCI12609; MURPHYULLRICH JE, 1995, J CELL BIOCHEM, V57, P341, DOI 10.1002/jcb.240570218; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Ottemann KM, 1999, SCIENCE, V285, P1751, DOI 10.1126/science.285.5434.1751; Parton RG, 2004, TRENDS CELL BIOL, V14, P141, DOI 10.1016/j.tcb.2004.02.001; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Puolakkainen P, 2003, AM J PATHOL, V162, P627, DOI 10.1016/S0002-9440(10)63856-4; Ran S, 2002, CANCER RES, V62, P6132; Robinson EE, 2004, MOL BIOL CELL, V15, P973, DOI 10.1091/mbc.E03-07-0528; SAGE EH, 1992, BIOCHEM CELL BIOL, V70, P56, DOI 10.1139/o92-008; SAGE EH, 2004, CURRENT PROTOCOLS CE; SAGE H, 1989, J CELL BIOL, V109, P341, DOI 10.1083/jcb.109.1.341; SAGE H, 1984, J BIOL CHEM, V259, P3993; Schmidt MHH, 2003, J CELL SCI, V116, P2845, DOI 10.1242/jcs.00522; Schonherr E, 1999, EUR J CELL BIOL, V78, P44, DOI 10.1016/S0171-9335(99)80006-5; Schwarzbauer JE, 1999, CURR OPIN CELL BIOL, V11, P622, DOI 10.1016/S0955-0674(99)00017-4; Sechler JL, 2001, J CELL BIOL, V154, P1081, DOI 10.1083/jcb.200102034; Sechler JL, 1997, MOL BIOL CELL, V8, P2563, DOI 10.1091/mbc.8.12.2563; Segrelles C, 2002, ONCOGENE, V21, P53, DOI 10.1038/sj.onc.1205032; Shi Q, 2004, J BIOL CHEM, V279, P52200, DOI 10.1074/jbc.M409630200; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; Sottile J, 2002, MOL BIOL CELL, V13, P3546, DOI 10.1091/mbc.E02-01-0048; Sweetwyne MT, 2004, J HISTOCHEM CYTOCHEM, V52, P723, DOI 10.1369/jhc.3A6153.2004; Velling T, 2002, J BIOL CHEM, V277, P37377, DOI 10.1074/jbc.M206286200; Vinogradova O, 2004, P NATL ACAD SCI USA, V101, P4094, DOI 10.1073/pnas.0400742101; WEAVER M, 2005, IN PRESS J CELL BIOC; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Xie D, 2004, CANCER RES, V64, P1987, DOI 10.1158/0008-5472.CAN-03-0666; Yamaji S, 2001, J CELL BIOL, V153, P1251, DOI 10.1083/jcb.153.6.1251; Yan Q, 2002, J CELL SCI, V115, P2747; YAN Q, 2005, IN PRESS INVEST OPHT; Yang ZT, 2000, MOL BIOL CELL, V11, P3353, DOI 10.1091/mbc.11.10.3353; Zhang YJ, 2004, J BIOL CHEM, V279, P41695, DOI 10.1074/jbc.M401563200	65	157	160	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36483	36493		10.1074/jbc.M504663200	http://dx.doi.org/10.1074/jbc.M504663200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16115889	hybrid			2022-12-27	WOS:000232726900082
J	Hekmat, O; Kim, YW; Williams, SJ; He, SM; Withers, SG				Hekmat, O; Kim, YW; Williams, SJ; He, SM; Withers, SG			Active-site peptide "fingerprinting" of glycosidases in complex mixtures by mass spectrometry - Discovery of a novel retaining beta-1,4-glycanase in Cellulomonas fimi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVITY-BASED PROBES; MODULAR XYLANASE; MECHANISMS; NUCLEOPHILE; IDENTIFICATION; BINDING; FAMILY; GLUCOSIDASE; SPECIFICITY; CELLULASES	New proteomics methods are required for targeting and identification of subsets of a proteome in an activity-based fashion. Here, we report the first gel-free, mass spectrometry-based strategy for mechanism-based profiling of retaining beta-endoglycosidases in complex proteomes. Using a biotinylated, cleavable 2-deoxy-2-fluoroxylobioside inactivator, we have isolated and identified the active-site peptides of target retaining beta-1,4-glycanases in systems of increasing complexity: pure enzymes, artificial proteomes, and the secreted proteome of the aerobic mesophilic soil bacterium Cellulomonas fimi. The active-site peptide of a new C. fimi beta-1,4-glycanase was identified in this manner, and the peptide sequence, which includes the catalytic nucleophile, is highly conserved among glycosidase family 10 members. The glycanase gene (GenBank(TM) accession number DQ146941) was cloned using inverse PCR techniques, and the protein was found to comprise a catalytic domain that shares similar to 70% sequence identity with those of xylanases from Streptomyces sp. and a family 2b carbohydrate-binding module. The new glycanase hydrolyzes natural and artificial xylo-configured substrates more efficiently than their cello-configured counterparts. It has a pH dependence very similar to that of known C. fimi retaining glycanases.	Univ British Columbia, Dept Chem, Prot Engn Network Ctr Excellence Canada, Vancouver, BC V6T 1Z1, Canada	University of British Columbia	Withers, SG (corresponding author), Univ British Columbia, Dept Chem, Prot Engn Network Ctr Excellence Canada, 2036 Main Mall, Vancouver, BC V6T 1Z1, Canada.	withers@chem.ubc.ca	Hekmat, Omid/AAU-4182-2021; Williams, Spencer/C-3545-2009	Williams, Spencer/0000-0001-6341-4364				Adam GC, 2004, J AM CHEM SOC, V126, P1363, DOI 10.1021/ja038441g; Adam GC, 2002, NAT BIOTECHNOL, V20, P805, DOI 10.1038/nbt714; Birsan C, 1998, BIOCHEM SOC T, V26, P156, DOI 10.1042/bst0260156; BLACK GW, 1995, BIOCHEM J, V307, P191, DOI 10.1042/bj3070191; Bogyo M, 2000, CHEM BIOL, V7, P27, DOI 10.1016/S1074-5521(00)00061-2; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; Bray MR, 1996, ACS SYM SER, V655, P64; BUCHERT J, 1994, BIORESOURCE TECHNOL, V50, P65, DOI 10.1016/0960-8524(94)90222-4; Clarke JH, 1996, FEMS MICROBIOL LETT, V139, P27, DOI 10.1016/0378-1097(96)00101-2; CLARKE JH, 1991, FEMS MICROBIOL LETT, V83, P305, DOI [10.1016/0378-1097(91)90493-T, 10.1111/j.1574-6968.1991.tb04481.x]; CLELAND WW, 1964, BIOCHEMISTRY-US, V3, P480, DOI 10.1021/bi00892a002; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Ducros V, 2000, J BIOL CHEM, V275, P23020, DOI 10.1074/jbc.275.30.23020; Godl K, 2003, P NATL ACAD SCI USA, V100, P15434, DOI 10.1073/pnas.2535024100; Greenbaum D, 2000, CHEM BIOL, V7, P569, DOI 10.1016/S1074-5521(00)00014-4; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; HAN JC, 1994, ANAL BIOCHEM, V220, P5, DOI 10.1006/abio.1994.1290; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Ichikawa M, 2001, BIOORG MED CHEM LETT, V11, P1769, DOI 10.1016/S0960-894X(01)00300-6; KEMPTON JB, 1992, BIOCHEMISTRY-US, V31, P9961, DOI 10.1021/bi00156a015; Kidd D, 2001, BIOCHEMISTRY-US, V40, P4005, DOI 10.1021/bi002579j; Kobe B, 1999, NATURE, V402, P373, DOI 10.1038/46478; Kumar S, 2004, P NATL ACAD SCI USA, V101, P7943, DOI 10.1073/pnas.0402323101; Kurogochi M, 2004, J BIOL CHEM, V279, P44704, DOI 10.1074/jbc.M401718200; Lawson SL, 1996, BIOCHEMISTRY-US, V35, P10110, DOI 10.1021/bi960586v; LEVER M, 1984, ANAL BIOCHEM, V139, P205, DOI 10.1016/0003-2697(84)90406-8; Lichtenthaler Hartmut K., METHODS ENZYMOLOGY, P350, DOI [10.1016/0076-6879(87)48036-1, DOI 10.1016/0076-6879(90)84256-G, DOI 10.1016/0076-6879(87)48036-1]; Liu YS, 1999, P NATL ACAD SCI USA, V96, P14694, DOI 10.1073/pnas.96.26.14694; Mackenzie LF, 1997, BIOCHEMISTRY-US, V36, P5893, DOI 10.1021/bi962962h; MEINKE A, 1993, J BACTERIOL, V175, P1910, DOI 10.1128/JB.175.7.1910-1918.1993; MIAO SC, 1994, BIOCHEMISTRY-US, V33, P7027, DOI 10.1021/bi00189a002; Notenboom V, 1998, BIOCHEMISTRY-US, V37, P4751, DOI 10.1021/bi9729211; OCHMAN H, 1988, GENETICS, V120, P621; Saghatelian A, 2004, P NATL ACAD SCI USA, V101, P10000, DOI 10.1073/pnas.0402784101; Speers AE, 2004, CHEMBIOCHEM, V5, P41, DOI 10.1002/cbic.200300721; Thompson J, 1998, J BIOL CHEM, V273, P27347, DOI 10.1074/jbc.273.42.27347; Tsai CS, 2002, ORG LETT, V4, P3607, DOI 10.1021/ol0265315; TULL D, 1991, J BIOL CHEM, V266, P15621; TULL D, 1994, BIOCHEMISTRY-US, V33, P6363, DOI 10.1021/bi00186a041; Vocadlo DJ, 2004, ANGEW CHEM INT EDIT, V43, P5338, DOI 10.1002/anie.200454235; Vocadlo DJ, 2003, P NATL ACAD SCI USA, V100, P9116, DOI 10.1073/pnas.1632821100; WAKARCHUK WW, 1994, PROTEIN SCI, V3, P467; Wakarchuk WW, 1998, PROTEIN ENG, V11, P295, DOI 10.1093/protein/11.4.295; WEICKERT MJ, 1989, J BACTERIOL, V171, P3656, DOI 10.1128/jb.171.7.3656-3666.1989; WHITE A, 1994, BIOCHEMISTRY-US, V33, P12546, DOI 10.1021/bi00208a003; Wicki J, 2002, METHOD ENZYMOL, V354, P84; WITHERS SG, 1987, J AM CHEM SOC, V109, P7530, DOI 10.1021/ja00258a047; Woodward J, 2000, NATURE, V405, P1014, DOI 10.1038/35016633; Zechel DL, 2000, ACCOUNTS CHEM RES, V33, P11, DOI 10.1021/ar970172+; Zhang H, 2003, NAT BIOTECHNOL, V21, P660, DOI 10.1038/nbt827; Zhou HL, 2001, NAT BIOTECHNOL, V19, P375, DOI 10.1038/86777; ZISER L, 1995, CARBOHYD RES, V274, P137, DOI 10.1016/0008-6215(95)00080-D	52	68	70	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35126	35135		10.1074/jbc.M508434200	http://dx.doi.org/10.1074/jbc.M508434200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16085650	hybrid			2022-12-27	WOS:000232561200009
J	Marathe, GK; Johnson, C; Billings, SD; Southall, MD; Pei, Y; Spandau, D; Murphy, RC; Zimmerman, GA; McIntyre, TM; Travers, JB				Marathe, GK; Johnson, C; Billings, SD; Southall, MD; Pei, Y; Spandau, D; Murphy, RC; Zimmerman, GA; McIntyre, TM; Travers, JB			Ultraviolet B radiation generates platelet-activating factor-like phospholipids underlying cutaneous damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HUMAN-ENDOTHELIAL-CELLS; UVB-INDUCED APOPTOSIS; FACTOR-RECEPTOR; HUMAN KERATINOCYTES; OXIDIZED PHOSPHOLIPIDS; CIGARETTE-SMOKING; MASS-SPECTROMETRY; HUMAN-NEUTROPHILS; HUMAN SKIN	Ultraviolet B light ( UVB) causes cutaneous inflammation and cell death, but the agents responsible are not defined. These studies examined the role of the platelet- activating factor ( PAF) signaling system in UVB- mediated effects. Expression of the PAF receptor in the PAF receptor- negative epidermoid cell line KB augmented apoptosis in response to UVB irradiation. Overexpression of the PAF receptor in primary human keratinocytes also enhanced UVB- mediated apoptosis in vitro, and it enhanced apoptosis in an in vivo model of human keratinocytes grafted onto severe combined immune- deficient ( SCID) mice. To define the mechanism by which UVB activates the PAF receptor, we used mass spectrometry to demonstrate significant amounts of the C-4 PAF analogs 1- alkyl- 2( butanoyl and butenoyl)- sn- glycero- 3- phosphocholine, as well as native PAF in an epidermal cell line after UVB irradiation. Supplementing the cells with the precursor phospholipid 1- hexadecyl- 2-arachidonoyl- sn- glycero- 3- phosphocholine ( HAPC) increased the amount of C-4 PAF analogs recovered after UVB exposure. We irradiated HAPC directly and found, even in the absence of a photosensitizer, fragmentation to C-4- PAF receptor ligands. We conclude UVB photo- oxidizes cellular phospholipids, creating PAF analogs that stimulate the PAF receptor to induce further PAF synthesis and apoptosis. PAF signaling may participate in the cutaneous inflammation that occurs during photo- aggravated dermatoses.	Univ Utah, Human Mol Biol & Genet Program, Salt Lake City, UT 84112 USA; Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA; Richard L Roudebush Vet Adm Med Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Dept Dermatol, Indianapolis, IN 46202 USA; Indiana Univ, HB Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; National Jewish Health	Marathe, GK (corresponding author), Lerner Res Inst, Dept Cell Biol, NC-10,9500 Euclid Ave, Cleveland, OH 44195 USA.	marathg@ccf.org	Murphy, Robert/AAO-5349-2020	Murphy, Robert/0000-0002-9430-6515; Marathe, Gopal/0000-0002-0025-6677; Travers, Jeffrey/0000-0001-7232-1039	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044513, R01HL062996, P01HL034303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001993] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL34303, HL62996, HL44513] Funding Source: Medline; NIAMS NIH HHS [AR01993] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alappatt C, 2000, ARCH DERMATOL RES, V292, P256, DOI 10.1007/s004030050483; Baltas E, 2003, SKIN PHARMACOL APPL, V16, P259, DOI 10.1159/000070849; Barber LA, 1998, J BIOL CHEM, V273, P18891, DOI 10.1074/jbc.273.30.18891; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chang H, 2003, FREE RADICAL RES, V37, P655, DOI 10.1080/1071576031000094907; Chen CH, 2003, CIRCULATION, V107, P2102, DOI 10.1161/01.CIR.0000065220.70220.F7; Countryman NB, 2000, J INVEST DERMATOL, V115, P267, DOI 10.1046/j.1523-1747.2000.00058.x; Dupre DJ, 2003, J BIOL CHEM, V278, P48228, DOI 10.1074/jbc.M304082200; Dy LC, 1999, J BIOL CHEM, V274, P26917, DOI 10.1074/jbc.274.38.26917; FRANKEL EN, 1984, PROG LIPID RES, V23, P197, DOI 10.1016/0163-7827(84)90011-0; Grundmann JU, 2004, SKIN PHARMACOL PHYS, V17, P37, DOI 10.1159/000074061; Heck DE, 2003, J BIOL CHEM, V278, P22432, DOI 10.1074/jbc.C300048200; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; HELLER R, 1992, J IMMUNOL, V149, P3682; ILIOU JP, 1992, LIPIDS, V27, P959, DOI 10.1007/BF02535572; IMAIZUMI TA, 1991, ATHEROSCLEROSIS, V87, P47, DOI 10.1016/0021-9150(91)90231-Q; Ishii I, 1998, J BIOL CHEM, V273, P9878, DOI 10.1074/jbc.273.16.9878; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; Lehr HA, 1997, J CLIN INVEST, V99, P2358, DOI 10.1172/JCI119417; Lewis DA, 2003, EXP CELL RES, V284, P316, DOI 10.1016/S0014-4827(02)00043-5; Li T, 2003, J BIOL CHEM, V278, P16614, DOI 10.1074/jbc.M211287200; Marathe GK, 2001, J LIPID RES, V42, P1430; Marathe GK, 2001, J LIPID RES, V42, P587; Marathe GK, 1999, J BIOL CHEM, V274, P28395, DOI 10.1074/jbc.274.40.28395; Marques SA, 2002, J PHARMACOL EXP THER, V300, P1026, DOI 10.1124/jpet.300.3.1026; Mass P, 2003, ARCH DERMATOL RES, V295, P71, DOI 10.1007/s00403-003-0403-x; McIntyre TM, 1999, J BIOL CHEM, V274, P25189, DOI 10.1074/jbc.274.36.25189; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MUELLER HW, 1984, J LIPID RES, V25, P383; OFLAHERTY JT, 1983, RES COMMUN CHEM PATH, V39, P291; OGURA R, 1991, J INVEST DERMATOL, V97, P1044, DOI 10.1111/1523-1747.ep12492553; PATEL KD, 1992, J BIOL CHEM, V267, P15168; Pei Y, 1998, J IMMUNOL, V161, P1954; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; REKDAL K, 1995, CHEM PHYS LIPIDS, V75, P127, DOI 10.1016/0009-3084(94)02413-Y; Richardson RM, 1996, J BIOL CHEM, V271, P28717, DOI 10.1074/jbc.271.45.28717; Robeva AS, 1996, BIOCHEM PHARMACOL, V51, P545, DOI 10.1016/0006-2952(95)02235-X; Sato S, 1999, ARCH DERMATOL RES, V291, P614, DOI 10.1007/s004030050463; Shimada A, 1998, J INVEST DERMATOL, V110, P889, DOI 10.1046/j.1523-1747.1998.00202.x; SIPES IG, 1991, ADV EXP MED BIOL, V283, P489; Spandau DF, 2000, EXP DERMATOL, V9, P252, DOI 10.1034/j.1600-0625.2000.009004252.x; Stewart MS, 1996, J INVEST DERMATOL, V106, P1086, DOI 10.1111/1523-1747.ep12339344; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; Subbanagounder G, 2002, J BIOL CHEM, V277, P7271, DOI 10.1074/jbc.M107602200; TANAKA T, 1993, BIOCHIM BIOPHYS ACTA, V1166, P264, DOI 10.1016/0005-2760(93)90107-K; TERAO J, 1984, ARCH BIOCHEM BIOPHYS, V235, P326, DOI 10.1016/0003-9861(84)90205-4; TOKUMURA A, 1989, J LIPID RES, V30, P219; Travers JB, 1999, J INVEST DERMATOL, V112, P279, DOI 10.1046/j.1523-1747.1999.00521.x; TRAVERS JB, 1995, J INVEST DERMATOL, V105, P816, DOI 10.1111/1523-1747.ep12326581; Walterscheid JP, 2002, J EXP MED, V195, P171, DOI 10.1084/jem.20011450; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232	52	78	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35448	35457		10.1074/jbc.M503811200	http://dx.doi.org/10.1074/jbc.M503811200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16115894	hybrid			2022-12-27	WOS:000232561200045
J	Rosenfeld, SS; Xing, J; Jefferson, GM; King, PH				Rosenfeld, SS; Xing, J; Jefferson, GM; King, PH			Docking and rolling, a model of how the mitotic motor Eg5 works	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIENTATIONAL FREEDOM; CRYSTAL-STRUCTURE; NECK LINKER; KINESIN; PROTEIN; STRAIN; MICROTUBULES; INHIBITION; MECHANISM; BINDING	Whereas kinesin I is designed to transport cargoes long distances in isolation, a closely related kinesin motor, Eg5, is designed to generate a sustained opposing force necessary for proper mitotic spindle formation. Do the very different roles for these evolutionarily related motors translate into differences in how they generate movement? We have addressed this question by examining when in the ATPase cycle the Eg5 motor domain and neck linker move through the use of a series of novel spectroscopic probes utilizing fluorescence resonance energy transfer, and we have compared our results to kinesin I. Our results are consistent with a model in which movement in Eg5 occurs in two sequential steps, an ATP- dependent docking of the neck linker, followed by a rotation or " rolling" of the entire motor domain on the microtubule surface that occurs with ATP hydrolysis. These two forms of movement are consistent with the functions of a motor designed to generate sustained opposing force, and hence, our findings support the argument that the mechanochemical features of a molecular motor are shaped more by the demands placed on it than by its particular family of origin.	Columbia Univ, Neurol Inst, Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL USA; Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA; Biurmingham Vet Affairs Med Ctr, Neurol Serv, Cambridge, MA 02138 USA	Columbia University; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Rosenfeld, SS (corresponding author), Columbia Univ, Neurol Inst, Coll Phys & Surg, Dept Neurol, Rm 204,710 W 168th St, New York, NY 10032 USA.	sr2327@columbia.edu		King, Peter/0000-0001-9391-7464	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048565] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR048565] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Blangy A, 1997, J BIOL CHEM, V272, P19418, DOI 10.1074/jbc.272.31.19418; Block SM, 2003, P NATL ACAD SCI USA, V100, P2351, DOI 10.1073/pnas.0436709100; Case RB, 2000, CURR BIOL, V10, P157, DOI 10.1016/S0960-9822(00)00316-X; Cheung H.C., 1991, TOPICS FLUORESCENCE, P127; Cochran JC, 2004, J BIOL CHEM, V279, P38861, DOI 10.1074/jbc.M404203200; COLE DG, 1994, J BIOL CHEM, V269, P22913; Cooke R, 2004, J GEN PHYSIOL, V123, P643, DOI 10.1085/jgp.200409089; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; DALE RE, 1979, BIOPHYS J, V26, P161, DOI 10.1016/S0006-3495(79)85243-1; DALE RE, 1974, BIOPOLYMERS, V13, P1573, DOI 10.1002/bip.1974.360130807; De la Cruz EM, 2000, BIOPHYS J, V79, P1524, DOI 10.1016/S0006-3495(00)76403-4; Endow SA, 2003, BIOESSAYS, V25, P1212, DOI 10.1002/bies.10358; HEIDECKER M, 1995, BIOCHEMISTRY-US, V37, P14428; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Hirose K, 2000, EMBO J, V19, P5308, DOI 10.1093/emboj/19.20.5308; Hoenger A, 2000, J MOL BIOL, V297, P1087, DOI 10.1006/jmbi.2000.3627; Holmes KC, 2000, PHILOS T R SOC B, V355, P419, DOI 10.1098/rstb.2000.0583; Kapitein LC, 2005, NATURE, V435, P114, DOI 10.1038/nature03503; Kashina AS, 1996, NATURE, V379, P270, DOI 10.1038/379270a0; Kikkawa M, 2001, NATURE, V411, P439, DOI 10.1038/35078000; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; Kull FJ, 2002, J CELL SCI, V115, P15; Lang MJ, 2002, BIOPHYS J, V83, P491, DOI 10.1016/S0006-3495(02)75185-0; Ma YZ, 1997, J BIOL CHEM, V272, P717, DOI 10.1074/jbc.272.2.717; Maliga Z, 2002, CHEM BIOL, V9, P989, DOI 10.1016/S1074-5521(02)00212-0; Marcus AI, 2005, J BIOL CHEM, V280, P11569, DOI 10.1074/jbc.M413471200; Moyer ML, 1998, BIOCHEMISTRY-US, V37, P800, DOI 10.1021/bi9711184; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Rice S, 2003, BIOPHYS J, V84, P1844, DOI 10.1016/S0006-3495(03)74992-3; Rosenfeld SS, 2003, J BIOL CHEM, V278, P18550, DOI 10.1074/jbc.M300849200; Rosenfeld SS, 2002, J BIOL CHEM, V277, P36731, DOI 10.1074/jbc.M205261200; Rosenfeld SS, 2001, J BIOL CHEM, V276, P40167, DOI 10.1074/jbc.M103899200; Schnitzer MJ, 2000, NAT CELL BIOL, V2, P718, DOI 10.1038/35036345; Sharp DJ, 1999, J CELL BIOL, V144, P125, DOI 10.1083/jcb.144.1.125; Sindelar CV, 2002, NAT STRUCT BIOL, V9, P844, DOI 10.1038/nsb852; Turner J, 2001, J BIOL CHEM, V276, P25496, DOI 10.1074/jbc.M100395200; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; Visscher K, 1999, NATURE, V400, P184, DOI 10.1038/22146; Xing J, 2000, J BIOL CHEM, V275, P35413, DOI 10.1074/jbc.M004232200; Yan YW, 2004, J MOL BIOL, V335, P547, DOI 10.1016/j.jmb.2003.10.074	41	57	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35684	35695		10.1074/jbc.M506561200	http://dx.doi.org/10.1074/jbc.M506561200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16115880	hybrid			2022-12-27	WOS:000232561200071
J	Miller, MS; Palmer, BM; Ruch, S; Martin, LA; Farman, GP; Wang, Y; Robbins, J; Irving, TC; Maughan, DW				Miller, MS; Palmer, BM; Ruch, S; Martin, LA; Farman, GP; Wang, Y; Robbins, J; Irving, TC; Maughan, DW			The essential light chain N-terminal extension alters force and fiber kinetics in mouse cardiac muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONMUSCLE MYOSIN-II; CONTRACTILE ACTIVATION; PHOSPHATE RELEASE; SARCOMERE-LENGTH; MOLECULAR MOTORS; ISOMETRIC FORCE; TRANSGENIC MICE; STRIATED-MUSCLE; BINDING-SITES; SMOOTH-MUSCLE	The functional significance of the actin-binding region at the N terminus of the cardiac myosin essential light chain (ELC) remains elusive. In a previous experiment, the endogenous ventricular ELC was replaced with a protein containing a 10-amino acid deletion at positions 5 - 14 (ELC1v Delta 5 - 14, referred to as 1v Delta 5 - 14), a region that interacts with actin (Sanbe, A., Gulick, J., Fewell, J., and Robbins, J. ( 2001) J. Biol. Chem. 276, 32682 - 32686). 1v Delta 5 - 14 mice showed no discernable mutant phenotype in skinned ventricular strips. However, because the myofilament lattice swells upon skinning, the mutant phenotype may have been concealed by the inability of the ELC to reach the actin- binding site. Using the same mouse model, we repeated earlier measurements and performed additional experiments on skinned strips osmotically compressed to the intact lattice spacing as determined by x-ray diffraction. 1v Delta 5 - 14 mice exhibited decreased maximum isometric tension without a change in calcium sensitivity. The decreased force was most evident in 5 - 6-month-old mice compared with 13 - 15-month-old mice and may account for the greater ventricular wall thickness in young 1v Delta 5 - 14 mice compared with age-matched controls. No differences were observed in unloaded shortening velocity at maximum calcium activation. However, 1v Delta 5 - 14 mice exhibited a significant difference in the frequency at which minimum complex modulus amplitude occurred, indicating a change in cross-bridge kinetics. We hypothesize that the ELC N-terminal extension interaction with actin inhibits the reversal of the power stroke, thereby increasing isometric force. Our results strongly suggest that an interaction between residues 5 - 14 of the ELC N terminus and the C-terminal residues of actin enhances cardiac performance.	Univ Vermont, Dept Mol Physiol & Biophys, Burlington, VT 05405 USA; IIT, Biophys Collaborat Access Team, Chicago, IL 60616 USA; IIT, Ctr Synchrotron Radiat Res & Instrumentat, Dept Biol Chem & Phys Sci, Chicago, IL 60616 USA; Childrens Hosp Res Fdn, Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA; Univ Cincinnati, Dept Pediat, Cincinnati, OH 45229 USA	University of Vermont; Illinois Institute of Technology; United States Department of Energy (DOE); Argonne National Laboratory; Illinois Institute of Technology; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Miller, MS (corresponding author), Univ Vermont, Dept Mol Physiol & Biophys, 127 HSRF Bldg,149 Beaumont Ave, Burlington, VT 05405 USA.	mmiller@cems.uvm.edu	Miller, Mark/B-6523-2008		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068034, P01HL069779] Funding Source: NIH RePORTER; NCRR NIH HHS [RR08630] Funding Source: Medline; NHLBI NIH HHS [R01 HL68034, R01 HL068034, P01 HL69779] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andreev OA, 1999, BIOCHEMISTRY-US, V38, P2480, DOI 10.1021/bi981706x; Blanchard E, 1999, CIRC RES, V84, P475, DOI 10.1161/01.RES.84.4.475; Bresnick AR, 1999, CURR OPIN CELL BIOL, V11, P26, DOI 10.1016/S0955-0674(99)80004-0; Davis JS, 2001, CELL, V107, P631, DOI 10.1016/S0092-8674(01)00586-4; EDMAN KAP, 1979, J PHYSIOL-LONDON, V291, P143, DOI 10.1113/jphysiol.1979.sp012804; Fewell JG, 1997, AM J PHYSIOL-HEART C, V273, pH1595, DOI 10.1152/ajpheart.1997.273.3.H1595; Fewell JG, 1998, J CLIN INVEST, V101, P2630, DOI 10.1172/JCI2825; Gao WD, 1998, J PHYSIOL-LONDON, V507, P175, DOI 10.1111/j.1469-7793.1998.175bu.x; GODT RE, 1982, J GEN PHYSIOL, V80, P279, DOI 10.1085/jgp.80.2.279; HAYASHIBARA T, 1994, BIOCHEMISTRY-US, V33, P12821, DOI 10.1021/bi00209a013; HUXLEY HE, 1990, J BIOL CHEM, V265, P8347; Irving T, 2001, J MUSCLE RES CELL M, V22, P675, DOI 10.1023/A:1016336024366; Irving TC, 2000, NUCL INSTRUM METH A, V448, P250, DOI 10.1016/S0168-9002(99)00732-9; Irving TC, 2000, AM J PHYSIOL-HEART C, V279, pH2568, DOI 10.1152/ajpheart.2000.279.5.H2568; Jones WK, 1996, J CLIN INVEST, V98, P1906, DOI 10.1172/JCI118992; KAWAI M, 1991, BIOPHYS J, V59, P329, DOI 10.1016/S0006-3495(91)82227-5; Kawai M, 1980, J Muscle Res Cell Motil, V1, P279, DOI 10.1007/BF00711932; KAWAI M, 1993, CIRC RES, V73, P35, DOI 10.1161/01.RES.73.1.35; Krenz M, 2003, J BIOL CHEM, V278, P17466, DOI 10.1074/jbc.M210804200; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; Millman BM, 1998, PHYSIOL REV, V78, P359, DOI 10.1152/physrev.1998.78.2.359; Moore JR, 2000, BIOPHYS J, V78, P1431, DOI 10.1016/S0006-3495(00)76696-3; Morano I, 1999, J MOL MED-JMM, V77, P544, DOI 10.1007/s001099900031; MORANO I, 1995, CIRC RES, V76, P720, DOI 10.1161/01.RES.76.5.720; MULIERI LA, 1989, CIRC RES, V65, P1441, DOI 10.1161/01.RES.65.5.1441; Nieznanska H, 2002, ACTA BIOCHIM POL, V49, P709; Rarick HM, 1996, J BIOL CHEM, V271, P27039, DOI 10.1074/jbc.271.43.27039; Sanbe A, 2001, J BIOL CHEM, V276, P32682, DOI 10.1074/jbc.M009975200; Sanbe A, 1999, J BIOL CHEM, V274, P21085, DOI 10.1074/jbc.274.30.21085; SANCHEZ A, 1991, J BIOL CHEM, V266, P22419; Schaub MC, 1998, CARDIOVASC RES, V37, P381, DOI 10.1016/S0008-6363(97)00258-7; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; STEPKOWSKI D, 1995, FEBS LETT, V374, P6, DOI 10.1016/0014-5793(95)01049-K; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P3654, DOI 10.1021/bi00258a020; SWEENEY HL, 1995, BIOPHYS J, V68, pS112; Sweeney HL, 1998, AM J RESP CRIT CARE, V158, pS95, DOI 10.1164/ajrccm.158.supplement_2.13tac400; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; Timson DJ, 1999, J BIOL CHEM, V274, P18271, DOI 10.1074/jbc.274.26.18271; Timson DJ, 2003, BIOCHIMIE, V85, P639, DOI 10.1016/S0300-9084(03)00131-7; TOHTONG R, 1995, NATURE, V374, P650, DOI 10.1038/374650a0; Wang G, 1997, BIOPHYS J, V73, P878, DOI 10.1016/S0006-3495(97)78121-9; Yang B, 1999, AM J PHYSIOL-HEART C, V277, pH1906, DOI 10.1152/ajpheart.1999.277.5.H1906	43	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34427	34434		10.1074/jbc.M508430200	http://dx.doi.org/10.1074/jbc.M508430200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16085933	hybrid			2022-12-27	WOS:000232403900008
J	Lee, JW; Kusumoto, R; Doherty, KM; Lin, GX; Zeng, WY; Cheng, WH; von Kobbe, C; Brosh, RM; Hu, JS; Bohr, VA				Lee, JW; Kusumoto, R; Doherty, KM; Lin, GX; Zeng, WY; Cheng, WH; von Kobbe, C; Brosh, RM; Hu, JS; Bohr, VA			Modulation of Werner syndrome protein function by a single mutation in the conserved RecQ domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOTOPICALLY ENRICHED PROTEINS; BLOOMS-SYNDROME PROTEIN; SYNDROME GENE-PRODUCT; DNA HELICASE; FLAP ENDONUCLEASE-1; SUBSTRATE-SPECIFICITY; COLI RECQ; D-LOOPS; BINDING; REPLICATION	Naturally occurring mutations in the human RECQ3 gene result in truncated Werner protein (WRN) and manifest as a rare premature aging disorder, Werner syndrome. Cellular and biochemical studies suggest a multifaceted role of WRN in DNA replication, DNA repair, recombination, and telomere maintenance. The RecQ C-terminal (RQC) domain of WRN was determined previously to be the major site of interaction for DNA and proteins. By using site-directed mutagenesis in the WRN RQC domain, we determined which amino acids might be playing a critical role in WRN function. A site-directed mutation at Lys-1016 significantly decreased WRN binding to fork or bubble DNA substrates. Moreover, the Lys-1016 mutation markedly reduced WRN helicase activity on fork, D-loop, and Holliday junction substrates in addition to reducing significantly the ability of WRN to stimulate FEN-1 incision activities. Thus, DNA binding mediated by the RQC domain is crucial for WRN helicase and its coordinated functions. Our nuclear magnetic resonance data on the three-dimensional structure of the wild-type RQC and Lys-1016 mutant proteins display a remarkable similarity in their structures.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Spanish Natl Canc Ctr, Ctr Nacl Invest Oncol, Breast & Gynaecol Canc Grp, Mol Pathol Program, Madrid, Spain; Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA; Univ Maryland, Ctr Biomol Struct & Org, College Pk, MD 20742 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Centro Nacional de Investigaciones Oncologicas (CNIO); University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, NIH, Box 1,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	bohrv@grc.nia.nih.gov	Bohr, Vilhelm/AAP-5931-2020; Brosh, Robert/AAR-6124-2020	von Kobbe, Cayetano/0000-0003-3895-3790	NATIONAL INSTITUTE ON AGING [ZIAAG000726, ZIAAG000741, Z01AG000741, Z01AG000726] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		BAX AGS, 1993, ACCOUNTS CHEM RES, V26, P31; Bernstein DA, 2003, EMBO J, V22, P4910, DOI 10.1093/emboj/cdg500; Bernstein DA, 2005, STRUCTURE, V13, P1173, DOI 10.1016/j.str.2005.04.018; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Brosh RM, 2002, J BIOL CHEM, V277, P23236, DOI 10.1074/jbc.M111446200; Brosh RM, 2001, EMBO J, V20, P5791; Brosh RM, 2001, J BIOL CHEM, V276, P3024, DOI 10.1074/jbc.M006784200; Choudhary S, 2004, J BIOL CHEM, V279, P34603, DOI 10.1074/jbc.M401901200; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Crabbe L, 2004, SCIENCE, V306, P1951, DOI 10.1126/science.1103619; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FOGH RH, 1994, EMBO J, V13, P3936, DOI 10.1002/j.1460-2075.1994.tb06709.x; Fry M, 1999, J BIOL CHEM, V274, P12797, DOI 10.1074/jbc.274.18.12797; Gajiwala KS, 2000, NATURE, V403, P916, DOI 10.1038/35002634; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; Goto M, 2000, CLIN EXP RHEUMATOL, V18, P760; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Hu JS, 1996, J AM CHEM SOC, V118, P8170, DOI 10.1021/ja9616239; Hu JS, 1997, J BIOMOL NMR, V9, P323, DOI 10.1023/A:1018691228238; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; KAPUSCINSKI J, 1979, NUCLEIC ACIDS RES, V6, P3535, DOI 10.1093/nar/6.11.3535; Kitao S, 1998, GENOMICS, V54, P443, DOI 10.1006/geno.1998.5595; Kyng KJ, 2003, P NATL ACAD SCI USA, V100, P12259, DOI 10.1073/pnas.2130723100; Lee JW, 2005, MECH AGEING DEV, V126, P79, DOI 10.1016/j.mad.2004.09.011; Littlefield O, 1999, NAT STRUCT BIOL, V6, P464; Liu JL, 2004, J BIOL CHEM, V279, P42794, DOI 10.1074/jbc.M405008200; Ma Y, 2000, ONCOGENE, V19, P4815, DOI 10.1038/sj.onc.1203834; Mer G, 2000, CELL, V103, P449, DOI 10.1016/S0092-8674(00)00136-7; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Moser MJ, 1999, HUM MUTAT, V13, P271, DOI 10.1002/(SICI)1098-1004(1999)13:4<271::AID-HUMU2>3.0.CO;2-Q; Opresko PL, 2004, MOL CELL, V14, P763, DOI 10.1016/j.molcel.2004.05.023; Opresko PL, 2003, CARCINOGENESIS, V24, P791, DOI 10.1093/carcin/bgg034; Opresko PL, 2001, J BIOL CHEM, V276, P44677, DOI 10.1074/jbc.M107548200; Oshima J, 1996, HUM MOL GENET, V5, P1909, DOI 10.1093/hmg/5.12.1909; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; Pucci B, 2004, J BIOL CHEM, V279, P49222, DOI 10.1074/jbc.M408967200; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; Sharma S, 2004, J BIOL CHEM, V279, P9847, DOI 10.1074/jbc.M309898200; SUN JZ, 2005, IN PRESS J BIOMOL NM, V32; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; van Brabant AJ, 2000, BIOCHEMISTRY-US, V39, P14617, DOI 10.1021/bi0018640; von Kobbe C, 2003, J BIOL CHEM, V278, P52997, DOI 10.1074/jbc.M308338200; von Kobbe C, 2002, J CELL SCI, V115, P3901, DOI 10.1242/jcs.00076; von Kobbe C, 2002, J BIOL CHEM, V277, P22035, DOI 10.1074/jbc.M200914200; Yu CE, 1997, AM J HUM GENET, V60, P330	51	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39627	39636		10.1074/jbc.M506112200	http://dx.doi.org/10.1074/jbc.M506112200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16150736	hybrid			2022-12-27	WOS:000233362200086
J	Van Velkinburgh, JC; Samaras, SE; Gerrish, K; Artner, I; Stein, R				Van Velkinburgh, JC; Samaras, SE; Gerrish, K; Artner, I; Stein, R			Interactions between areas I and II direct pdx-1 expression specifically to islet cell types of the mature and developing pancreas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN GENE-TRANSCRIPTION; NUCLEAR FACTOR 3-BETA; BETA-CELLS; HOMEODOMAIN PROTEIN; MICE; ELEMENTS; DIFFERENTIATION; IDENTIFICATION; MORPHOGENESIS; EPITHELIUM	PDX-1 regulates transcription of genes involved in islet beta cell function and pancreas development. Islet-specific expression is controlled by 5'-flanking sequences from base pair (bp) - 2917 to - 1918 in transgenic experiments, which encompasses both conserved (i.e. Area I (bp - 2761/ - 2457), Area II (bp - 2153/ - 1923)) and non-conserved pdx-1 sequences. However, only an Area II-driven transgene is independently active in vivo, albeit in only a fraction of islet PDX-1-producing cells. Our objective was to identify the sequences within the - 2917/ - 1918-bp region that act in conjunction with Area II to allow comprehensive expression in islet PDX-1(+) cells. In cell line-based transfection assays, only Area I effectively potentiated Area II activity. Both Area I and Area II functioned in an orientation-independent manner, whereas synergistic, enhancer-like activation was uniquely found with duplicated Area II. Chimeras of Area II and the generally active SV40 enhancer or the beta cell-specific insulin enhancer suggested that islet cell-enriched activators were necessary for Area I activation, because Area II-mediated stimulation was reduced by the SV40 enhancer and activated by the insulin enhancer. Several conserved sites within Area I were important in Area I/Area II activation, with binding at bp - 2614/ - 2609 specifically controlled by Nkx2.2, an insulin gene regulator that is required for terminal beta cell differentiation. The ability of Area I to modulate Area II activation was also observed in vivo, as an Area I/Area II-driven transgene recapitulated the endogenous pdx-1 expression pattern in developing and adult islet cells. These results suggest that Area II is a central pdx-1 control region, whose islet cell activity is uniquely modified by Area I regulatory factors.	Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	Stein, R (corresponding author), Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA.	Roland.Stein@vanderbilt.edu	van Velkinburgh, Jennifer/D-7205-2015	van Velkinburgh, Jennifer/0000-0002-4592-2397; Artner, Isabella/0000-0002-2895-5664	NATIONAL CANCER INSTITUTE [P30CA068485, T32CA009385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050203, P30DK020593, P60DK020593] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485, 5T32 CA09385-18] Funding Source: Medline; NIDDK NIH HHS [R01 DK-50203, DK20593, P60 DK20593] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1996, DEVELOPMENT, V122, P1409; Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; Ben-Shushan E, 2001, J BIOL CHEM, V276, P17533, DOI 10.1074/jbc.M009088200; Cissell MA, 2003, J BIOL CHEM, V278, P751, DOI 10.1074/jbc.M205905200; Clocquet AR, 2000, DIABETES, V49, P1856, DOI 10.2337/diabetes.49.11.1856; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; Gannon M, 2001, DEV BIOL, V238, P185, DOI 10.1006/dbio.2001.0359; Gerrish K, 2004, MOL ENDOCRINOL, V18, P533, DOI 10.1210/me.2003-0371; Gerrish K, 2000, J BIOL CHEM, V275, P3485, DOI 10.1074/jbc.275.5.3485; Gerrish K, 2001, J BIOL CHEM, V276, P47775, DOI 10.1074/jbc.M109244200; GUZ Y, 1995, DEVELOPMENT, V121, P11; HAN JH, 1986, P NATL ACAD SCI USA, V83, P110, DOI 10.1073/pnas.83.1.110; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Kataoka K, 2002, J BIOL CHEM, V277, P49903, DOI 10.1074/jbc.M206796200; Marshak S, 2000, MOL CELL BIOL, V20, P7583, DOI 10.1128/MCB.20.20.7583-7590.2000; Matsuoka T, 2003, MOL CELL BIOL, V23, P6049, DOI 10.1128/MCB.23.17.6049-6062.2003; McKinnon CM, 2001, DIABETOLOGIA, V44, P1203, DOI 10.1007/s001250100628; Melloul D, 2004, ANN NY ACAD SCI, V1014, P28, DOI 10.1196/annals.1294.003; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; Offield MF, 1996, DEVELOPMENT, V122, P983; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Olbrot M, 2002, P NATL ACAD SCI USA, V99, P6737, DOI 10.1073/pnas.102168499; ONDEK B, 1987, EMBO J, V6, P1017, DOI 10.1002/j.1460-2075.1987.tb04854.x; PESHAVARIA M, 1994, MOL ENDOCRINOL, V8, P806, DOI 10.1210/me.8.6.806; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; Pictet R., 1972, HDB PHYSL; Samaras SE, 2003, J BIOL CHEM, V278, P12263, DOI 10.1074/jbc.M210801200; Samaras SE, 2002, MOL CELL BIOL, V22, P4702, DOI 10.1128/MCB.22.13.4702-4713.2002; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; Servitja JM, 2004, DIABETOLOGIA, V47, P597, DOI 10.1007/s00125-004-1368-9; Sharma S, 1996, J BIOL CHEM, V271, P2294, DOI 10.1074/jbc.271.4.2294; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; Stoffers DA, 1999, ENDOCRINOLOGY, V140, P5374, DOI 10.1210/en.140.11.5374; Sussel L, 1998, DEVELOPMENT, V125, P2213; Watada H, 2000, P NATL ACAD SCI USA, V97, P9443, DOI 10.1073/pnas.97.17.9443; WHELAN J, 1989, MOL CELL BIOL, V9, P3253, DOI 10.1128/MCB.9.8.3253; WHELAN J, 1990, MOL CELL BIOL, V10, P1564, DOI 10.1128/MCB.10.4.1564; Wu KL, 1997, MOL CELL BIOL, V17, P6002, DOI 10.1128/MCB.17.10.6002; Zhao L, 2000, J BIOL CHEM, V275, P10532, DOI 10.1074/jbc.275.14.10532; ZHAO LJ, 2005, J BIOL CHEM	44	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38438	38444		10.1074/jbc.M508594200	http://dx.doi.org/10.1074/jbc.M508594200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16147997	hybrid			2022-12-27	WOS:000233239800040
J	Wei, QZ				Wei, QZ			Pitx2a binds to human papillomavirus type 18 E6 protein and inhibits E6-mediated p53 degradation in HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PITX2; ONCOPROTEIN; GENE; APOPTOSIS; TARGET; GROWTH; IMMORTALIZATION; UBIQUITINATION; IDENTIFICATION; SUPPRESSION	Binding of high risk human papillomavirus (HPV) E6 protein to E6-associated protein (E6AP), a cellular ubiquitin-protein ligase, enables E6AP to ubiquitinate p53, leading to p53 degradation in cervical cancer cells such as HeLa cells. Here we report that Pitx2a, a bicoid-type homeodomain transcription factor, can bind to HPV E6 protein and inhibit E6/E6AP-mediated p53 degradation. Deletion of the Pitx2a homeodomain abrogates its ability to bind to HPV E6 protein and to induce p53 accumulation in HeLa cells, suggesting that the homeodomain of Pitx2a is essential for inhibition of E6/E6AP-mediated p53 degradation. Recombinant Pitx2a can also block E6/E6AP-mediated p53 degradation in vitro, indicating that this function of Pitx2a is independent of its transcription activity. Pitx2a does not regulate Hdm2-mediated p53 degradation, because Pitx2a does not affect p53 protein levels in HPV-negative cells, such as HCT116, U2OS, and C33A cells. In addition, Pitx2a-induced p53 is transcriptionally active and maintains its specific DNA binding activity in HeLa cells. Taken together, these findings suggest that, by binding to E6, Pitx2a interferes with E6/E6AP-mediated p53 degradation, leading to the accumulation of functional p53 protein in HeLa cells.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA; NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA	Kansas State University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Wei, QZ (corresponding author), Kansas State Univ, Dept Biochem, 103 Willard Hall, Manhattan, KS 66506 USA.	weiq@ksu.edu			NHLBI NIH HHS [K22 HL071542, K22 HL071542-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K22HL071542] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alvarez-Salas LM, 1999, ANTISENSE NUCLEIC A, V9, P441, DOI 10.1089/oli.1.1999.9.441; Alvarez-Salas LM, 1998, P NATL ACAD SCI USA, V95, P1189, DOI 10.1073/pnas.95.3.1189; Arakawa H, 1998, P NATL ACAD SCI USA, V95, P4573, DOI 10.1073/pnas.95.8.4573; Baek SH, 2003, P NATL ACAD SCI USA, V100, P3245, DOI 10.1073/pnas.0330217100; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; Cho CW, 2002, EXP MOL MED, V34, P159, DOI 10.1038/emm.2002.23; Clawson GA, 2004, GENE THER, V11, P1331, DOI 10.1038/sj.gt.3302303; Croce CM, 1999, CANCER RES, V59, p1778S; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; Gage PJ, 1999, DEVELOPMENT, V126, P4643; Gao QS, 1999, MOL CELL BIOL, V19, P733; Grm HS, 2004, J MOL BIOL, V335, P971, DOI 10.1016/j.jmb.2003.10.079; Hamada K, 1996, GYNECOL ONCOL, V63, P219, DOI 10.1006/gyno.1996.0310; Hengstermann A, 2001, P NATL ACAD SCI USA, V98, P1218, DOI 10.1073/pnas.031470698; Hjalt TA, 2000, DEV DYNAM, V218, P195, DOI 10.1002/(SICI)1097-0177(200005)218:1<195::AID-DVDY17>3.0.CO;2-C; Huibregtse JM, 1996, SEMIN CANCER BIOL, V7, P317, DOI 10.1006/scbi.1996.0041; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Kao WH, 2000, J VIROL, V74, P6408, DOI 10.1128/JVI.74.14.6408-6417.2000; Kioussi C, 2002, CELL, V111, P673, DOI 10.1016/S0092-8674(02)01084-X; Kitamura K, 1999, DEVELOPMENT, V126, P5749; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin CR, 1999, NATURE, V401, P279, DOI 10.1038/45803; Lu MF, 1999, NATURE, V401, P276, DOI 10.1038/45797; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Martin DM, 2002, DEV BIOL, V252, P84, DOI 10.1006/dbio.2002.0835; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nguyen ML, 2003, J VIROL, V77, P6957, DOI 10.1128/JVI.77.12.6957-6964.2003; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Scheffner M, 2003, SEMIN CANCER BIOL, V13, P59, DOI 10.1016/S1044-579X(02)00100-1; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439; Tao MF, 2003, J VIROL, V77, P13232, DOI 10.1128/JVI.77.24.13232-13247.2003; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; Thomas MC, 2005, MOL CELL, V17, P251, DOI 10.1016/j.molcel.2004.12.016; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; Vande Pol SB, 1998, ONCOGENE, V16, P43, DOI 10.1038/sj.onc.1201504; Venturini F, 1999, NUCLEIC ACIDS RES, V27, P1585, DOI 10.1093/nar/27.7.1585; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wei Q, 2002, MOL BIOL CELL, V13, P683, DOI 10.1091/mbc.01-07-0358; Westmoreland JJ, 2001, J NEUROSCI, V21, P6810, DOI 10.1523/JNEUROSCI.21-17-06810.2001; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999	50	30	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37790	37797		10.1074/jbc.M502974200	http://dx.doi.org/10.1074/jbc.M502974200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16129685	hybrid, Green Accepted			2022-12-27	WOS:000233044500058
J	Kalvodova, L; Kahya, N; Schwille, P; Ehehalt, R; Verkade, P; Drechsel, D; Simons, K				Kalvodova, L; Kahya, N; Schwille, P; Ehehalt, R; Verkade, P; Drechsel, D; Simons, K			Lipids as modulators of proteolytic activity of BACE - Involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; BETA-SECRETASE; ALZHEIMERS-DISEASE; ASYMMETRIC VESICLES; CYTOSOLIC DOMAIN; RAFTS; MEMBRANES; GENERATION; RECEPTOR; NEURONS	The beta-secretase, BACE, is a membrane spanning aspartic protease, which cleaves the amyloid precursor protein (APP) in the first step of proteolytic processing leading to the formation of the neurotoxic beta-amyloid peptide (A beta). Previous results have suggested that the regulation of beta-secretase and BACE access to APP is lipid dependent, and involves lipid rafts. Using the baculovirus expression system, we have expressed recombinant human full-length BACE in insect cells and purified milligram amounts to homogeneity. We have studied partitioning of fluorophor-conjugated BACE between the liquid ordered and disordered phases in giant ( 10 - 150 mu m) unilamellar vesicles, and found similar to 20% to associate with the raft-like, liquid-ordered phase; the fraction associated with liquid-ordered phase increased upon cross-linking of raft lipids. To examine involvement of individual lipid species in modulating BACE activity, we have reconstituted the purified BACE in large ( similar to 100 nm) unilamellar vesicles, and determined its specific activity in vesicles of various lipid compositions. We have identified 3 groups of lipids that stimulate proteolytic activity of BACE: 1) neutral glycosphingolipids (cerebrosides), 2) anionic glycerophospholipids, and 3) sterols ( cholesterol).	Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; Bioinnovat Ctr, D-01307 Dresden, Germany; Heidelberg Univ, Dept Internal Med 4, D-69120 Heidelberg, Germany	Max Planck Society; Ruprecht Karls University Heidelberg	Simons, K (corresponding author), Max Planck Inst Mol Cell Biol & Genet, Pfotenhauerstr 108, D-01307 Dresden, Germany.	simons@mpi-cbg.de	Schwille, Petra/A-4983-2010; Verkade, Paul/N-7240-2014; Kalvodova, Lucie/A-1546-2013	Verkade, Paul/0000-0002-2497-1026; , Lucie/0000-0003-3270-9463; Simons, Kai/0000-0002-9231-9996; Ehehalt, Robert/0000-0003-4252-5801				Bodovitz S, 1996, J BIOL CHEM, V271, P4436; Bogdanov M, 1996, J BIOL CHEM, V271, P11615, DOI 10.1074/jbc.271.20.11615; Bouillot C, 1996, J BIOL CHEM, V271, P7640, DOI 10.1074/jbc.271.13.7640; Brink-van der Laan EV, 2004, BBA-BIOMEMBRANES, V1666, P275, DOI 10.1016/j.bbamem.2004.06.010; Buckland AG, 2000, BBA-MOL CELL BIOL L, V1483, P199, DOI 10.1016/S1388-1981(99)00188-2; Cordy JM, 2003, P NATL ACAD SCI USA, V100, P11735, DOI 10.1073/pnas.1635130100; de Almeida RFM, 2003, BIOPHYS J, V85, P2406, DOI 10.1016/S0006-3495(03)74664-5; De Strooper B, 2000, J CELL SCI, V113, P1857; DENKINS YM, 1986, BIOCHIM BIOPHYS ACTA, V862, P343, DOI 10.1016/0005-2736(86)90237-3; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; He XY, 2002, FEBS LETT, V524, P183, DOI 10.1016/S0014-5793(02)03052-1; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Kahya N, 2005, BIOCHEMISTRY-US, V44, P7479, DOI 10.1021/bi047429d; Kakio A, 2002, BIOCHEMISTRY-US, V41, P7385, DOI 10.1021/bi0255874; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; MCLAUGHLIN S, 1977, CURR TOP MEMBR TRANS, V9, P71; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; Pautot S, 2003, P NATL ACAD SCI USA, V100, P10718, DOI 10.1073/pnas.1931005100; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Poveda JA, 2002, BIOCHEMISTRY-US, V41, P12253, DOI 10.1021/bi0200099; Puglielli L, 2003, J BIOL CHEM, V278, P19777, DOI 10.1074/jbc.M300466200; Riddell DR, 2001, CURR BIOL, V11, P1288, DOI 10.1016/S0960-9822(01)00394-3; Rigaud JL, 2002, BRAZ J MED BIOL RES, V35, P753, DOI 10.1590/S0100-879X2002000700001; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; Rouvinski A, 2003, BIOCHEM BIOPH RES CO, V308, P750, DOI 10.1016/S0006-291X(03)01470-0; Russo T, 1998, FEBS LETT, V434, P1, DOI 10.1016/S0014-5793(98)00941-7; Selkoe Dennis J., 1994, Current Opinion in Neurobiology, V4, P708, DOI 10.1016/0959-4388(94)90014-0; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shogomori H, 2005, J BIOL CHEM, V280, P18931, DOI 10.1074/jbc.M500247200; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; Westmeyer GG, 2004, J BIOL CHEM, V279, P53205, DOI 10.1074/jbc.M410378200; Zha Q, 2004, MOL PSYCHIATR, V9, P946, DOI 10.1038/sj.mp.4001509	36	240	247	1	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36815	36823		10.1074/jbc.M504484200	http://dx.doi.org/10.1074/jbc.M504484200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16115865	hybrid			2022-12-27	WOS:000232901800036
J	Regue, M; Izquierdo, L; Fresno, S; Jimenez, N; Pique, N; Corsaro, MM; Parrilli, M; Naldi, T; Merino, S; Tomas, JM				Regue, M; Izquierdo, L; Fresno, S; Jimenez, N; Pique, N; Corsaro, MM; Parrilli, M; Naldi, T; Merino, S; Tomas, JM			The incorporation of glucosamine into enterobacterial core lipopolysaccharide - Two enzymatic steps are required	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLEBSIELLA-PNEUMONIAE; ESCHERICHIA-COLI; STRUCTURAL-CHARACTERIZATION; REGION; GENE; OLIGOSACCHARIDE; POLYSACCHARIDE; IDENTIFICATION; BIOSYNTHESIS; EXPRESSION	The core lipopolysaccharide (LPS) of Klebsiella pneumoniae is characterized by the presence of disaccharide alpha GlcN-(1,4)- alpha GalA attached by an alpha 1,3 linkage to L-glycero-D-manno-heptopyranose II (LD-HeppII). Previously it has been shown that the WabH enzyme catalyzes the incorporation of GlcNAc from UDP-GlcNAc to outer core LPS. The presence of GlcNAc instead of GlcN and the lack of UDP-GlcN in bacteria indicate that an additional enzymatic step is required. In this work we identified a new gene (wabN) in the K. pneumoniae core LPS biosynthetic cluster. Chemical and structural analysis of K. pneumoniae non-polar wabN mutants showed truncated core LPS with GlcNAc instead of GlcN. In vitro assays using LPS truncated at the level of D-galacturonic acid ( GalA) and cell-free extract containing WabH and WabN together led to the incorporation of GlcN, whereas none of them alone were able to do it. This result suggests that the later enzyme ( WabN) catalyzes the deacetylation of the core LPS containing the GlcNAc residue. Thus, the incorporation of the GlcN residue to core LPS in K. pneumoniae requires two distinct enzymatic steps. WabN homologues are found in Serratia marcescens and some Proteus strains that show the same disaccharide alpha GlcN-( 1,4)-alpha GalA attached by an alpha 1,3 linkage to LD-HeppII.	Univ Barcelona, Fac Biol, Dept Microbiol, E-08071 Barcelona, Spain; Univ Barcelona, Fac Farm, Dept Microbiol & Parasitol Sanitarias, E-08028 Barcelona, Spain; Univ Naples Federico II, Complesso Univ Monte S Angelo, Dipartimento Chim Organ & Biochim, I-80126 Naples, Italy	University of Barcelona; University of Barcelona; University of Naples Federico II	Tomas, JM (corresponding author), Univ Barcelona, Fac Biol, Dept Microbiol, Diagonal 645, E-08071 Barcelona, Spain.	jtomas@ub.edu	Merino, Susana/D-4342-2014; Tomas, Juan M/L-1398-2015; Corsaro, Maria Michela/T-6190-2019; Izquierdo, Luis/L-9291-2015	Merino, Susana/0000-0001-6040-4259; Tomas, Juan M/0000-0002-3575-7113; Corsaro, Maria Michela/0000-0002-6834-8682; Izquierdo, Luis/0000-0002-3704-9874; Pique, Nuria/0000-0002-7308-030X; Parrilli, Michelangelo/0000-0001-8858-3623; Jimenez, Natalia/0000-0002-7057-0426				CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Coderch N, 2004, J BACTERIOL, V186, P978, DOI 10.1128/JB.186.4.978-988.2004; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; Duchaud E, 2003, NAT BIOTECHNOL, V21, P1307, DOI 10.1038/nbt886; EMORI TG, 1993, CLIN MICROBIOL REV, V6, P428, DOI 10.1128/CMR.6.4.428-442.1993; Forsberg LS, 2000, J BIOL CHEM, V275, P18851, DOI 10.1074/jbc.M001090200; Frirdich E, 2004, J BIOL CHEM, V279, P27928, DOI 10.1074/jbc.M402549200; GABRIEL O, 1982, METHOD ENZYMOL, V83, P332; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; Gough J, 2001, J MOL BIOL, V313, P903, DOI 10.1006/jmbi.2001.5080; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hansen DS, 1998, J HOSP INFECT, V38, P119, DOI 10.1016/S0195-6701(98)90065-2; Hansen DS, 1999, J CLIN MICROBIOL, V37, P56, DOI 10.1128/JCM.37.1.56-62.1999; HERVAS JA, 1993, CLIN INFECT DIS, V16, P719, DOI 10.1093/clind/16.5.719; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; Izquierdo L, 2003, J BACTERIOL, V185, P7213, DOI 10.1128/JB.185.24.7213-7221.2003; Izquierdo L, 2002, MICROBIOL-SGM, V148, P3485, DOI 10.1099/00221287-148-11-3485; Izquierdo L, 2002, FEMS MICROBIOL LETT, V216, P211, DOI 10.1016/S0378-1097(02)01027-3; Link AJ, 1997, J BACTERIOL, V179, P6228, DOI 10.1128/jb.179.20.6228-6237.1997; Long SR, 1996, PLANT CELL, V8, P1885, DOI 10.1105/tpc.8.10.1885; Miller J. H., 1972, EXPT MOL GENETICS, P433; NASSIF X, 1989, INFECT IMMUN, V57, P546, DOI 10.1128/IAI.57.2.546-552.1989; Olsthoorn MMA, 1999, J MASS SPECTROM, V34, P622, DOI 10.1002/(SICI)1096-9888(199906)34:6<622::AID-JMS814>3.3.CO;2-M; ORSKOV I, 1984, METHOD MICROBIOL, V14, P143, DOI 10.1016/S0580-9517(08)70449-5; PRADEL E, 1991, J BACTERIOL, V173, P6428, DOI 10.1128/jb.173.20.6428-6431.1991; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Regue M, 2005, J BACTERIOL, V187, P4198, DOI 10.1128/JB.187.12.4198-4206.2005; Regue M, 2001, J BACTERIOL, V183, P3564, DOI 10.1128/JB.183.12.3564-3573.2001; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; Vinogradov E, 2002, AUST J CHEM, V55, P61, DOI 10.1071/CH01184; Vinogradov E, 2002, J BIOL CHEM, V277, P25070, DOI 10.1074/jbc.M202683200; Vinogradov E, 2001, CARBOHYD RES, V335, P291, DOI 10.1016/S0008-6215(01)00216-6; Vinogradov E, 2001, EUR J BIOCHEM, V268, P1722; Westphal O., 1965, METHODS CARBOHYDRATE, V5, P83, DOI DOI 10.1016/J.WATRES.2010.04.030	36	13	13	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36648	36656		10.1074/jbc.M506278200	http://dx.doi.org/10.1074/jbc.M506278200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16131489	hybrid			2022-12-27	WOS:000232901800016
J	Chuang, LC; Zhu, XN; Herrera, CR; Tseng, HM; Pfleger, CM; Block, K; Yew, PR				Chuang, LC; Zhu, XN; Herrera, CR; Tseng, HM; Pfleger, CM; Block, K; Yew, PR			The C-terminal domain of the Xenopus cyclin-dependent kinase inhibitor, p27(Xic1), is both necessary and sufficient for phosphorylation-independent proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK INHIBITOR; MEDIATED DEGRADATION; DNA-REPLICATION; S-PHASE; UBIQUITINATION; COMPLEX; P27(KIP1); CDC34; DIFFERENTIATION; PROMOTES	Cell cycle progression is regulated by cyclin-dependent kinases (CDKs), cyclins, and CDK inhibitors. In the frog, Xenopus laevis, the CDK inhibitor p27(Xic1) (Xic1) inhibits DNA synthesis by negatively regulating CDK2-cyclin E. Using the frog egg extract as a model system for the study of Xic1, studies have demonstrated that Xic1 protein levels are regulated by nuclear ubiquitination and proteolysis. To characterize the molecular mechanism that regulates Xic1 turnover, we have identified the minimal sequences of Xic1 that are necessary and sufficient for its nuclear ubiquitination and degradation. Using deletion mutagenesis, our studies indicated that the C-terminal 50 amino acids of Xic1 are critical for its proteolysis beyond a role in nuclear transport. Replacement of the Xic1 C terminus with the SV40 nuclear localization sequence resulted in the nuclear localization of Xic1 but not its ubiquitination or degradation. Our deletion studies also indicated that the CDK2-cyclin binding domain of Xic1 is important for its efficient retention in the nucleus. Further deletion analyses identified at least 3 lysine residues within the Xic1 C terminus that are targeted for specific ubiquitination. Importantly, our studies demonstrated that the Xic1 C-terminal 50 amino acids can serve as a nuclear degradation signal when fused to a stable heterologous nuclear protein. Moreover, a 30-amino-acid region within the C terminus of Xic1 can serve as a nuclear ubiquitination signal. To address the role of phosphorylation on Xic1 turnover, all the potential phosphorylation sites within the C-terminal 50 amino acids of Xic1 were mutated to alanine to prevent possible phosphorylation. This resulted in a Xic1 protein that was nevertheless degraded in a manner similar to wild-type Xic1, suggesting that phosphorylation of Xic1 is not critical for its nuclear ubiquitination or proteolysis.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of Texas System; University of Texas Health San Antonio; University of California System; University of California Berkeley	Yew, PR (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA.	yew@uthscsa.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066226] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R01-GM066226] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amati B, 1999, NAT CELL BIOL, V1, pE91, DOI 10.1038/12087; Block K, 2001, J BIOL CHEM, V276, P41049, DOI 10.1074/jbc.M106453200; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chen XY, 2004, MOL CELL, V16, P839, DOI 10.1016/j.molcel.2004.11.011; Chuang LC, 2005, J BIOL CHEM, V280, P35299, DOI 10.1074/jbc.M506429200; Chuang LC, 2001, J BIOL CHEM, V276, P1610, DOI 10.1074/jbc.M008896200; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Furstenthal L, 2001, NAT CELL BIOL, V3, P715, DOI 10.1038/35087026; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; Leclerc V, 1996, Prog Cell Cycle Res, V2, P197; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; Ohnuma S, 1999, CELL, V99, P499, DOI 10.1016/S0092-8674(00)81538-X; Roberts JM, 1999, CELL, V98, P129, DOI 10.1016/S0092-8674(00)81007-7; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shou WY, 1996, MOL BIOL CELL, V7, P457, DOI 10.1091/mbc.7.3.457; SU JY, 1995, P NATL ACAD SCI USA, V92, P10187, DOI 10.1073/pnas.92.22.10187; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Verma R, 1997, MOL BIOL CELL, V8, P1427, DOI 10.1091/mbc.8.8.1427; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Vernon AE, 2003, DEVELOPMENT, V130, P71, DOI 10.1242/dev.00180; Vernon AE, 2003, DEVELOPMENT, V130, P85, DOI 10.1242/dev.00193; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0; Yew PR, 1997, SCIENCE, V277, P1672, DOI 10.1126/science.277.5332.1672; Yew PR, 2001, J CELL PHYSIOL, V187, P1, DOI 10.1002/1097-4652(2001)9999:9999<1::AID-JCP1049>3.0.CO;2-O; You ZS, 2002, GENE DEV, V16, P1182, DOI 10.1101/gad.985302; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324	35	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35290	35298		10.1074/jbc.M506430200	http://dx.doi.org/10.1074/jbc.M506430200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16118210	hybrid			2022-12-27	WOS:000232561200027
J	Veldhuis, G; Gabellieri, E; Vos, EPP; Poolman, B; Strambini, GB; Broos, J				Veldhuis, G; Gabellieri, E; Vos, EPP; Poolman, B; Strambini, GB; Broos, J			Substrate-induced conformational changes in the membrane-embedded IICmtl-domain of the mannitol permease from Escherichia coli, EnzymeII(mtl), probed by tryptophan phosphorescence spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PHOSPHOTRANSFERASE SYSTEM; PROTEIN-LIGAND INTERACTIONS; TRIPLET-STATE LIFETIME; ENZYME-II; SUBUNIT INTERACTIONS; TRANSPORT PROTEIN; PHOSPHORYLATION; DIMER; IIMTL; RESONANCE	Membrane-bound transport proteins are expected to proceed via different conformational states during the translocation of a solute across the membrane. Tryptophan phosphorescence spectroscopy is one of the most sensitive methods used for detecting conformational changes in proteins. We employed this technique to study substrate-induced conformational changes in the mannitol permease, EnzymeII(mtl), of the phosphoenolpyruvate-dependent phosphotransferase system from Escherichia coli. Ten mutants containing a single tryptophan were engineered in the membrane embedded IICmtl-domain, harboring the mannitol translocation pathway. The mutants were characterized with respect to steady-state and time-resolved phosphorescence, yielding detailed, site-specific information of the Trp microenvironment and protein conformational homogeneity. The study revealed that the Trp environments vary from apolar, unstructured, and flexible sites to buried, highly homogeneous, rigid peptide cores. The most remarkable example of the latter was observed for position 97, because its long sub-second phosphorescence lifetime and highly structured spectra in both glassy and fluid media imply a well defined and rigid core around the probe that is typical of beta-sheet-rich structural motifs. The addition of mannitol had a large impact on most of the Trp positions studied. In the case of position 97, mannitol binding induced partial unfolding of the rigid protein core. On the contrary, for residue positions 126, 133, and 147, both steady-state and time-resolved data showed that mannitol binding induces a more ordered and homogeneous structure around these residues. The observations are discussed in context of the current mechanistic and structural model of EIImtl.	CNR, Ist Biofis, Area Ric, I-56124 Pisa, Italy; Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Biophys & Biophys Chem, NL-9747 AG Groningen, Netherlands	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR); University of Groningen	Broos, J (corresponding author), CNR, Ist Biofis, Area Ric, Via Moruzzi 1, I-56124 Pisa, Italy.	j.broos@rug.nl	Poolman, Bert/D-1882-2012	Gabellieri, Edi/0000-0003-0750-4095				[Anonymous], 1967, FLUORESCENCE PHOSPHO; BOER H, 1994, J BIOL CHEM, V269, P17863; Broos J, 2003, J BIOL CHEM, V278, P47578, DOI 10.1074/jbc.M309287200; Broos J, 2002, J AM CHEM SOC, V124, P6812, DOI 10.1021/ja017812v; Broos J, 2004, J AM CHEM SOC, V126, P22, DOI 10.1021/ja0385585; Broos J, 1999, BIOCHEMISTRY-US, V38, P9798, DOI 10.1021/bi991157a; Broos J, 2000, BIOCHEMISTRY-US, V39, P10877, DOI 10.1021/bi000803z; Cioni P, 2004, BIOPHYS J, V86, P1149, DOI 10.1016/S0006-3495(04)74189-2; ELFERINK MGL, 1990, J BACTERIOL, V172, P7119, DOI 10.1128/jb.172.12.7119-7125.1990; Galley W. C., 1976, CONCEPTS BIOCH FLUOR, V2, P409; Gonnelli M, 2005, PHOTOCHEM PHOTOBIOL, V81, P614, DOI 10.1562/2004-11-09-RA-367.1; GONNELLI M, 1995, BIOCHEMISTRY-US, V34, P13847, DOI 10.1021/bi00042a017; GRISAFI PL, 1989, J BACTERIOL, V171, P2719, DOI 10.1128/jb.171.5.2719-2727.1989; HERSHBERGER MV, 1980, BIOCHEMISTRY-US, V19, P2204, DOI 10.1021/bi00551a032; KHANDEKAR SS, 1989, J CELL BIOCHEM, V39, P207, DOI 10.1002/jcb.240390212; Koning RI, 1999, J MOL BIOL, V287, P845, DOI 10.1006/jmbi.1999.2650; LENGELER JW, 1994, BBA-BIOENERGETICS, V1188, P1, DOI 10.1016/0005-2728(94)90017-5; LOLKEMA JS, 1993, BIOCHEMISTRY-US, V32, P1396, DOI 10.1021/bi00057a002; LOLKEMA JS, 1990, BIOCHEMISTRY-US, V29, P10659, DOI 10.1021/bi00499a012; LOLKEMA JS, 1991, BIOCHEMISTRY-US, V30, P6716, DOI 10.1021/bi00241a012; Meijberg W, 1998, J BIOL CHEM, V273, P20785, DOI 10.1074/jbc.273.33.20785; Meijberg W, 1998, J BIOL CHEM, V273, P7949, DOI 10.1074/jbc.273.14.7949; PAS HH, 1987, BIOCHEMISTRY-US, V26, P6689, DOI 10.1021/bi00395a019; ROBILLARD GT, 1987, BIOCHEMISTRY-US, V26, P5796, DOI 10.1021/bi00392a032; Robillard GT, 1999, BBA-REV BIOMEMBRANES, V1422, P73, DOI 10.1016/S0304-4157(99)00002-7; ROBILLARD GT, 1996, HDB BIOL PHYS, V2, P549; ROOSSIEN FF, 1984, BIOCHEMISTRY-US, V23, P5682, DOI 10.1021/bi00319a003; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; STEPHAN MM, 1986, BIOCHEMISTRY-US, V25, P4046, DOI 10.1021/bi00362a009; STRAMBINI GB, 1995, J AM CHEM SOC, V117, P7646, DOI 10.1021/ja00134a008; Strambini GB, 2004, PHOTOCHEM PHOTOBIOL, V80, P462, DOI 10.1562/2004-06-22-RA-21.1; STRAMBINI GB, 1985, CHEM PHYS LETT, V115, P196, DOI 10.1016/0009-2614(85)80678-3; SUGIYAMA JE, 1991, P NATL ACAD SCI USA, V88, P9603, DOI 10.1073/pnas.88.21.9603; SWAVINGDIJKSTRA D, 1997, BIOCHEMISTRY-US, V36, P4860; SWAVINGDIJKSTRA D, 1996, BIOCHEMISTRY-US, V35, P6628; SWAVINGDIJKSTRA D, 1996, ANAL BIOCHEM, V240, P142; van Montfort BA, 2001, J BIOL CHEM, V276, P12756, DOI 10.1074/jbc.M010728200; Veldhuis G, 2005, BIOPHYS J, V89, P201, DOI 10.1529/biophysj.105.062877; Veldhuis G, 2004, BIOPHYS J, V86, P1959, DOI 10.1016/S0006-3495(04)74259-9; Vervoort EB, 2005, J MOL BIOL, V346, P733, DOI 10.1016/j.jmb.2004.12.011	40	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35148	35156		10.1074/jbc.M507061200	http://dx.doi.org/10.1074/jbc.M507061200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16093245	hybrid, Green Published			2022-12-27	WOS:000232561200011
J	Alzayady, KJ; Panning, MM; Kelley, GG; Wojcikiewicz, RJH				Alzayady, KJ; Panning, MM; Kelley, GG; Wojcikiewicz, RJH			Involvement of the p97-Ufd1-Npl4 complex in the regulated endoplasmic reticulum-associated degradation of inositol 1,4,5-trisphosphate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; PROTEIN-QUALITY CONTROL; INDUCED DOWN-REGULATION; SMOOTH-MUSCLE-CELLS; MEMBRANE-PROTEIN; RNA INTERFERENCE; TRISPHOSPHATE RECEPTORS; CONJUGATING ENZYMES; MAMMALIAN-CELLS; IN-VIVO	Inositol 1,4,5-trisphosphate (IP3) receptors form tetrameric, IP3-gated channels in endoplasmic reticulum membranes that govern the release of Ca2+ from this organelle. In response to activation of certain G protein-coupled receptors that persistently elevate IP3 concentration, IP3 receptors are ubiquitinated and degraded by the ubiquitin-proteasome pathway. IP3 receptor ubiquitination is mediated by the ubiquitin-conjugating enzyme, (mam)Ubc7, a component of the endoplasmic reticulum-associated degradation pathway. However, the mechanism by which ubiquitinated IP3 receptors are transferred to the proteasome is not known. Here, we examine this process and show in several mammalian cell types that the ATPase p97 associates with IP3 receptors in response to hormonal stimuli that induce IP3 receptor ubiquitination. To examine the functional relevance of the p97 interaction with IP3 receptors, we stably and specifically reduced p97 protein levels by 62 +/- 3% in Rat-1 fibroblasts using RNA interference. In these cells, endothelin-1- induced IP3 receptor degradation was markedly retarded and the accumulation of ubiquitinated IP3 receptors was markedly enhanced. These effects were reversed by expression of exogenous p97. In addition, Ufd1 and Npl4, which complex with p97, also associated with IP3 receptors upon hormonal stimulation. We conclude that the p97-Ufd1-Npl4 complex couples ubiquitinated IP3 receptors to proteasomal degradation and, thus, plays a key role in IP3 receptor processing. These data also establish that the p97-Ufd1-Npl4 complex mediates endoplasmic reticulum-associated degradation in mammalian cells.	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA; SUNY Upstate Med Univ, Dept Med, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Wojcikiewicz, RJH (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	wojcikir@upstate.edu		Panning Pearce, Margaret/0000-0002-5846-9632	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK049194, R01DK056294, R01DK049194] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56294, R01 DK049194, R29 DK049194, DK49194, R01 DK056294] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bays NW, 2001, MOL BIOL CELL, V12, P4114, DOI 10.1091/mbc.12.12.4114; Bays NW, 2002, CURR BIOL, V12, pR366, DOI 10.1016/S0960-9822(02)00862-X; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bokkala S, 1997, J BIOL CHEM, V272, P12454, DOI 10.1074/jbc.272.19.12454; Bosanac I, 2004, BBA-MOL CELL RES, V1742, P89, DOI 10.1016/j.bbamcr.2004.09.016; Braun S, 2002, EMBO J, V21, P615, DOI 10.1093/emboj/21.4.615; Bruderer RM, 2004, J BIOL CHEM, V279, P49609, DOI 10.1074/jbc.M408695200; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Dreveny I, 2004, BIOCHEM SOC T, V32, P715, DOI 10.1042/BST0320715; Elkabetz Y, 2004, J BIOL CHEM, V279, P3980, DOI 10.1074/jbc.M309938200; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Hatakeyama S, 2003, J BIOCHEM, V134, P1, DOI 10.1093/jb/mvg106; HIRSCH C, 2004, BIOCHIM BIOPHYS ACTA, V1695, P208; Jarosch E, 2003, INT REV CYTOL, V223, P39; Jellerette T, 2000, DEV BIOL, V223, P238, DOI 10.1006/dbio.2000.9675; Kaneko C, 2003, BIOCHEM BIOPH RES CO, V300, P297, DOI 10.1016/S0006-291X(02)02834-6; Kobayashi T, 2002, J BIOL CHEM, V277, P47358, DOI 10.1074/jbc.M207783200; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; Lilley BN, 2004, NATURE, V429, P834, DOI 10.1038/nature02592; Maki CG, 1996, CANCER RES, V56, P2649; McCracken AA, 2003, BIOESSAYS, V25, P868, DOI 10.1002/bies.10320; Medema RH, 2004, BIOCHEM J, V380, P593, DOI 10.1042/BJ20040260; Meyer HH, 2002, EMBO J, V21, P5645, DOI 10.1093/emboj/cdf579; MULDOON LL, 1989, J BIOL CHEM, V264, P8529; Oberdorf J, 1999, BIOCHEM J, V339, P453, DOI 10.1042/0264-6021:3390453; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Patterson RL, 2004, ANNU REV BIOCHEM, V73, P437, DOI 10.1146/annurev.biochem.73.071403.161303; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; Ravid T, 2000, J BIOL CHEM, V275, P35840, DOI 10.1074/jbc.M004793200; Saliba RS, 2002, J CELL SCI, V115, P2907; Sambrook J., 2001, MOL CLONING LAB MANU; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; Sipma H, 1998, CELL CALCIUM, V23, P11, DOI 10.1016/S0143-4160(98)90070-7; Sutcliffe JE, 2004, FEBS LETT, V567, P86, DOI 10.1016/j.febslet.2004.03.122; Taylor CW, 1999, CELL CALCIUM, V26, P237, DOI 10.1054/ceca.1999.0090; Taylor CW, 2004, TRENDS BIOCHEM SCI, V29, P210, DOI 10.1016/j.tibs.2004.02.010; Tiwari S, 2001, J BIOL CHEM, V276, P16193, DOI 10.1074/jbc.M007640200; Tovey SC, 2001, J CELL SCI, V114, P3979; Uchiyama K, 2002, J CELL BIOL, V159, P855, DOI 10.1083/jcb.200208112; Vermassen E, 2004, BIOL CELL, V96, P3, DOI 10.1016/j.biolcel.2003.11.004; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wang Q, 2004, J STRUCT BIOL, V146, P44, DOI 10.1016/j.jsb.2003.11.014; Wang YZ, 2004, J CELL BIOL, V164, P973, DOI 10.1083/jcb.200401010; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Webster JM, 2003, J BIOL CHEM, V278, P38238, DOI 10.1074/jbc.M305600200; Wojcik C, 2004, J CELL SCI, V117, P281, DOI 10.1242/jcs.00841; Wojcikiewicz RJH, 1999, GASTROENTEROLOGY, V116, P1194, DOI 10.1016/S0016-5085(99)70023-5; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; Wojcikiewicz RJH, 2004, TRENDS PHARMACOL SCI, V25, P35, DOI 10.1016/j.tips.2003.11.008; Wojcikiewicz RJH, 2003, J BIOL CHEM, V278, P940, DOI 10.1074/jbc.M206607200; WOJCIKIEWICZ RJH, 1994, J BIOL CHEM, V269, P7963; WOJCIKIEWICZ RJH, 1991, J BIOL CHEM, V266, P22234; Woodman PG, 2003, J CELL SCI, V116, P4283, DOI 10.1242/jcs.00817; Xu Q, 2004, MOL CANCER THER, V3, P1263; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Ye YH, 2004, NATURE, V429, P841, DOI 10.1038/nature02656; Zhu CC, 1999, J BIOL CHEM, V274, P3476, DOI 10.1074/jbc.274.6.3476; Zhu CC, 2000, BIOCHEM J, V348, P551, DOI 10.1042/0264-6021:3480551	66	41	43	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34530	34537		10.1074/jbc.M508890200	http://dx.doi.org/10.1074/jbc.M508890200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16103111	Green Accepted, hybrid			2022-12-27	WOS:000232403900021
J	Porras-Yakushi, TR; Whitelegge, JP; Miranda, TB; Clarke, S				Porras-Yakushi, TR; Whitelegge, JP; Miranda, TB; Clarke, S			A novel SET domain methyltransferase modifies ribosomal protein Rpl23ab in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRINSIC MEMBRANE-PROTEINS; IN-GEL DIGESTION; SACCHAROMYCES-CEREVISIAE; MASS-SPECTROMETRY; AFFINITY PURIFICATION; S-ADENOSYLMETHIONINE; COMPLEX INCLUDES; METHYLATION; IDENTIFICATION; GENERATION	In vivo studies have shown that the ribosomal large subunit protein L23a (Rpl23ab) in Saccharomyces cerevisiae is methylated at lysine residues. However, the gene encoding the methyltransferase responsible for the modification has not been identified. We show here that the yeast YPL208w gene product, a member of the SET domain family of methyltransferases, catalyzes the reaction, and we have now designated it Rkm1 ( ribosomal lysine ( K) methyltransferase 1). Yeast strains with deletion mutations in candidate SET domain-containing genes were in vivo labeled with S-adenosyl-L[ methyl-H-3] methionine. [H-3]] Methyl radioactivity was determined after lysates were fractionated by SDS gel electrophoresis. When compared with the parent strain or other candidate deletion strains, a loss of a radiolabeled 15-kDa species was observed in the rkm1 (Delta ypl208w) knock-out strain. Treatment of wild-type cell extracts with RNase or proteinase K demonstrated that the methyl-accepting substrate is a protein. Cellular lysates from parent and knockout strains were fractionated using high salt sucrose gradients. Analysis of the gradient fractions by SDS gel electrophoresis demonstrated that the 15-kDa methyl-accepting substrate elutes with the large ribosomal subunit. In vitro methylation experiments using purified ribosomes confirmed that the methyl-accepting substrate is a ribosomal protein. Amino acid analysis of the in vivo labeled 15 kDa polypeptide showed that it contains epsilon- [H-3] dimethyllysine residues. Mass spectrometry of tryptic peptides of the 15 kDa polypeptide identified it as Rpl23ab. Analysis of the intact masses of the large ribosomal subunit proteins by electrospray mass spectrometry confirmed that the substrate is Rpl23ab and that it is specifically dimethylated at two distinct sites by Rkm1. These results show that SET domain methyltransferases can be involved in translational roles as well as in the previously described transcriptional roles.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Pasarow Mass Spectrometry Lab, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Clarke, S (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 611 Charles E Young Dr E,Paul Boyer Hall 639, Los Angeles, CA 90095 USA.	clarke@mbi.ucla.edu			NIGMS NIH HHS [GM26020, GM07185] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026020, R37GM026020] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 2003, CELL CYCLE, V2, P369, DOI 10.4161/cc.2.4.419; Audhya A, 2003, EMBO J, V22, P4223, DOI 10.1093/emboj/cdg397; Ausubel F. M., 1999, SHORT PROTOCOLS MOL; Bachand F, 2004, EMBO J, V23, P2641, DOI 10.1038/sj.emboj.7600265; Boa S, 2003, YEAST, V20, P827, DOI 10.1002/yea.995; Branscombe TL, 2001, J BIOL CHEM, V276, P32971, DOI 10.1074/jbc.M105412200; Chern MK, 2002, J BIOL CHEM, V277, P15345, DOI 10.1074/jbc.M111379200; COLLART M, 1993, CURRENT PROTOCOLS MI; DELANGE RJ, 1970, J BIOL CHEM, V245, P3325; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; HARDY SJS, 1969, BIOCHEMISTRY-US, V8, P2897, DOI 10.1021/bi00835a031; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; HOUTZ RL, 1992, PLANT PHYSIOL, V98, P1170, DOI 10.1104/pp.98.3.1170; HRYCYNA CA, 1994, BIOCHEMISTRY-US, V33, P9806, DOI 10.1021/bi00198a053; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Inada T, 2002, RNA, V8, P948, DOI 10.1017/S1355838202026018; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; JONES RS, 1993, MOL CELL BIOL, V13, P6357, DOI 10.1128/MCB.13.10.6357; Kluck RM, 2000, J BIOL CHEM, V275, P16127, DOI 10.1074/jbc.275.21.16127; Krogan NJ, 2004, MOL CELL, V13, P225, DOI 10.1016/S1097-2765(04)00003-6; KRUISWIJK T, 1978, BIOCHEM J, V175, P221, DOI 10.1042/bj1750221; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee SW, 2002, P NATL ACAD SCI USA, V99, P5942, DOI 10.1073/pnas.082119899; LHOEST J, 1984, EUR J BIOCHEM, V141, P585, DOI 10.1111/j.1432-1033.1984.tb08233.x; LOBET Y, 1989, BIOCHIM BIOPHYS ACTA, V997, P224, DOI 10.1016/0167-4838(89)90191-X; Mueller EG, 1998, NUCLEIC ACIDS RES, V26, P2606, DOI 10.1093/nar/26.11.2606; MURPHY JT, 1972, J BACTERIOL, V109, P499, DOI 10.1128/JB.109.2.499-504.1972; Pijnappel WWMP, 2001, GENE DEV, V15, P2991, DOI 10.1101/gad.207401; Polevoda B, 2000, J BIOL CHEM, V275, P20508, DOI 10.1074/jbc.M001891200; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Rouillon A, 1999, J BIOL CHEM, V274, P28096, DOI 10.1074/jbc.274.40.28096; Schubert HL, 2003, TRENDS BIOCHEM SCI, V28, P329, DOI 10.1016/S0968-0004(03)00090-2; SHRAHL BD, 2002, MOL CELL BIOL, V22, P1298; STASSEN MJ, 1995, MECH DEVELOP, V52, P209, DOI 10.1016/0925-4773(95)00402-M; Swiercz R, 2005, BIOCHEM J, V386, P85, DOI 10.1042/BJ20041466; TOLEDO H, 1988, ARCH BIOL MED EXP, V21, P219; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; Whitelegge JP, 1998, PROTEIN SCI, V7, P1423, DOI 10.1002/pro.5560070619; Whitelegge Julian P, 2004, Methods Mol Biol, V251, P323	45	43	48	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34590	34598		10.1074/jbc.M507672200	http://dx.doi.org/10.1074/jbc.M507672200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16096273	hybrid			2022-12-27	WOS:000232403900027
J	Zhang, AS; West, AP; Wyman, AE; Bjorkman, PJ; Enns, CA				Zhang, AS; West, AP; Wyman, AE; Bjorkman, PJ; Enns, CA			Interaction of hemojuvelin with neogenin results in iron accumulation in human embryonic kidney 293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPULSIVE GUIDANCE MOLECULE; HEREDITARY HEMOCHROMATOSIS PROTEIN; JUVENILE HEMOCHROMATOSIS; EXPRESSION PATTERN; RECEPTOR NEOGENIN; GENE-MUTATIONS; CHROMOSOME 1Q; LOCUS MAPS; HFE; MOUSE	Type 2 hereditary hemochromatosis (HH) or juvenile hemochromatosis is an early onset, genetically heterogeneous, autosomal recessive disorder of iron overload. Type 2A HH is caused by mutations in the recently cloned hemojuvelin gene (HJV; also called HFE2) ( Papanikolaou, G., Samuels, M. E., Ludwig, E. H., MacDonald, M. L., Franchini, P. L., Dube, M. P., Andres, L., MacFarlane, J., Sakellaropoulos, N., Politou, M., Nemeth, E., Thompson, J., Risler, J. K., Zaborowska, C., Babakaiff, R., Radomski, C. C., Pape, T. D., Davidas, O., Christakis, J., Brissot, P., Lockitch, G., Ganz, T., Hayden, M. R., and Goldberg, Y. P. ( 2004) Nat. Genet. 36, 77 - 82), whereas Type 2B HH is caused by mutations in hepcidin. HJV is highly expressed in both skeletal muscle and liver. Mutations in HJV are implicated in the majority of diagnosed juvenile hemochromatosis patients. In this study, we stably transfected HJV cDNA into human embryonic kidney 293 cells and characterized the processing of HJV and its effect on iron homeostasis. Our results indicate that HJV is a glycosylphosphatidylinositol-linked protein and undergoes a partial autocatalytic cleavage during its intracellular processing. HJV co-immunoprecipitated with neogenin, a receptor involved in a variety of cellular signaling processes. It did not interact with the closely related receptor DCC( deleted in Colon Cancer). In addition, the HJV G320V mutant implicated in Type 2A HH did not co-immunoprecipitate with neogenin. Immunoblot analysis of ferritin levels and transferrin-Fe-55 accumulation studies indicated that the HJV-induced increase in intracellular iron levels in human embryonic kidney 293 cells is dependent on the presence of neogenin in the cells, thus linking these two proteins to intracellular iron homeostasis.	Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR 97239 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA	Oregon Health & Science University; California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute	Zhang, AS (corresponding author), Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, L215,3181 SW Sam Jackson Pk Blvd, Portland, OR 97239 USA.	zhanga@ohsu.edu			NIDDK NIH HHS [R01 DK60770, DK54488] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK054488, R01DK054488, R01DK060770] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arakawa H, 2004, NAT REV CANCER, V4, P978, DOI 10.1038/nrc1504; Barallobre MJ, 2000, DEVELOPMENT, V127, P4797; BARTON JC, 2004, BMC MED GENETICS; Brinks H, 2004, J NEUROSCI, V24, P3862, DOI 10.1523/JNEUROSCI.5296-03.2004; Camaschella C, 2002, SEMIN HEMATOL, V39, P242, DOI 10.1053/shem.2002.35635; Carlson H, 2005, BLOOD, V105, P2564, DOI 10.1182/blood-2004-03-1204; Davies PS, 2004, J BIOL CHEM, V279, P25085, DOI 10.1074/jbc.M400537200; De Gobbi M, 2002, BRIT J HAEMATOL, V117, P973, DOI 10.1046/j.1365-2141.2002.03509.x; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Gehrke SG, 2005, CLIN GENET, V67, P425, DOI 10.1111/j.1399-0004.2005.00413.x; Gross CN, 1998, J BIOL CHEM, V273, P22068, DOI 10.1074/jbc.273.34.22068; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Huang FW, 2004, BLOOD, V104, P2176, DOI 10.1182/blood-2004-01-0400; Janosi A, 2005, BLOOD, V105, P432, DOI 10.1182/blood-2004-09-3508; Kang JS, 2004, J CELL BIOL, V167, P493, DOI 10.1083/jcb.200405039; Keeling SL, 1997, ONCOGENE, V15, P691, DOI 10.1038/sj.onc.1201225; Krause A, 2000, FEBS LETT, V480, P147, DOI 10.1016/S0014-5793(00)01920-7; Krijt J, 2004, BLOOD, V104, P4308, DOI 10.1182/blood-2004-06-2422; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lanzara C, 2004, BLOOD, V103, P4317, DOI 10.1182/blood-2004-01-0192; Lebron JA, 1998, CELL, V93, P111, DOI 10.1016/S0092-8674(00)81151-4; Lee PL, 2004, BLOOD, V103, P4669, DOI 10.1182/blood-2004-01-0072; Levine SJ, 2004, J IMMUNOL, V173, P5343, DOI 10.4049/jimmunol.173.9.5343; Lidell ME, 2003, J BIOL CHEM, V278, P13944, DOI 10.1074/jbc.M210069200; Martinez AR, 2004, HAEMATOLOGICA, V89, P1441; Matsunaga E, 2004, NAT CELL BIOL, V6, P749, DOI 10.1038/ncb1157; Matsunaga E, 2004, DEV GROWTH DIFFER, V46, P481; Mawdsley DJ, 2004, DEV BIOL, V269, P302, DOI 10.1016/j.ydbio.2004.02.001; MENON AK, 1994, METHOD ENZYMOL, V230, P418; Meyerhardt JA, 1997, ONCOGENE, V14, P1129, DOI 10.1038/sj.onc.1200935; Monnier PP, 2002, NATURE, V419, P392, DOI 10.1038/nature01041; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Nicolas G, 2002, J CLIN INVEST, V110, P1037, DOI 10.1172/JCI200215686; Niederkofler V, 2004, J NEUROSCI, V24, P808, DOI 10.1523/JNEUROSCI.4610-03.2004; Nikolopoulos SN, 2005, CELL CYCLE, V4, P429, DOI 10.4161/cc.4.3.1547; Oldekamp J, 2004, GENE EXPR PATTERNS, V4, P283, DOI 10.1016/j.modgep.2003.11.008; Ordway GA, 2004, J EXP BIOL, V207, P3441, DOI 10.1242/jeb.01172; Papanikolaou G, 2004, NAT GENET, V36, P77, DOI 10.1038/ng1274; Papanikolaou G, 2002, BLOOD CELL MOL DIS, V29, P168, DOI 10.1006/bcmd.2002.0553; Papanikolaou G, 2001, BLOOD CELL MOL DIS, V27, P744, DOI 10.1006/bcmd.2001.0444; Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200; Parkin ET, 2004, J BIOL CHEM, V279, P11170, DOI 10.1074/jbc.M312105200; Pietrangelo A, 2004, NEW ENGL J MED, V350, P2383, DOI 10.1056/NEJMra031573; Rajagopalan S, 2004, NAT CELL BIOL, V6, P756, DOI 10.1038/ncb1156; Rivard SR, 2003, EUR J HUM GENET, V11, P585, DOI 10.1038/sj.ejhg.5201009; Roetto A, 1999, AM J HUM GENET, V64, P1388, DOI 10.1086/302379; Schmidtmer J, 2004, GENE EXPR PATTERNS, V4, P105, DOI 10.1016/S1567-133X(03)00144-3; Srinivasan K, 2003, DEV CELL, V4, P371, DOI 10.1016/S1534-5807(03)00054-6; Velcich A, 1999, ONCOGENE, V18, P2599, DOI 10.1038/sj.onc.1202610; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; Zhang AS, 2004, BLOOD, V103, P1509, DOI 10.1182/blood-2003-07-2378; Zhang AS, 2003, P NATL ACAD SCI USA, V100, P9500, DOI 10.1073/pnas.1233675100	53	117	123	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33885	33894		10.1074/jbc.M506207200	http://dx.doi.org/10.1074/jbc.M506207200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16103117	hybrid			2022-12-27	WOS:000232229700025
J	Tamayo, R; Tischler, AD; Camilli, A				Tamayo, R; Tischler, AD; Camilli, A			The EAL domain protein VieA is a cyclic diguanylate phosphodiesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O1 EL-TOR; VIBRIO-CHOLERAE; ACETOBACTER-XYLINUM; BIOFILM FORMATION; DI-GMP; NUCLEOTIDE PHOSPHODIESTERASE; GENETIC ORGANIZATION; CELLULOSE SYNTHESIS; ESCHERICHIA-COLI; GGDEF DOMAIN	The newly recognized bacterial second messenger 3', 5'-cyclic diguanylic acid ( cyclic diguanylate (c-di-GMP)) has been shown to regulate a wide variety of bacterial behaviors and traits. Biosynthesis and degradation of c-di-GMP have been attributed to the GGDEF and EAL protein domains, respectively, based primarily on genetic evidence. Whereas the GGDEF domain was demonstrated to possess diguanylate cyclase activity in vitro, the EAL domain has not been tested directly for c-di-GMP phosphodiesterase activity. This study describes the analysis of c-di-GMP hydrolysis by an EAL domain protein in a purified system. The Vibrio cholerae EAL domain protein VieA has been shown to inversely regulate biofilm-specific genes (vps) and virulence genes (ctxA), presumably by decreasing the cellular pool of c-di-GMP. VieA was maximally active at neutral pH, physiological ionic strength, and ambient temperatures and demonstrated c-di-GMP hydrolytic activity with a K-m of 0.06 mu M. VieA was unable to hydrolyze cGMP. The putative metal coordination site of the EAL domain, Glu(170), was demonstrated to be necessary for VieA activity. Furthermore, the divalent cations Mg2+ and Mn2+ were necessary for VieA activity; conversely, Ca2+ and Zn2+ were potent inhibitors of the VieA phosphodiesterase. Calcium inhibition of the VieA EAL domain provides a potential mechanism for regulation of c-di-GMP degradation.	Tufts Univ, Dept Mol Biol & Microbiol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA; Howard Hughes Med Inst, Boston, MA 02111 USA	Tufts University; Tufts University; Howard Hughes Medical Institute	Camilli, A (corresponding author), Tufts Univ, Dept Mol Biol & Microbiol, 136 Harrison Ave, Boston, MA 02111 USA.	Andrew.camilli@tufts.edu		Tischler, Anna/0000-0001-8404-0250	Howard Hughes Medical Institute Funding Source: Medline; NIAID NIH HHS [AI45746, R01 AI045746, R01 AI045746-03] Funding Source: Medline; NIDDK NIH HHS [P30DK34928, P30 DK034928] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausmees N, 2001, FEMS MICROBIOL LETT, V204, P163, DOI 10.1111/j.1574-6968.2001.tb10880.x; BOBROV AG, 2005, FEMS MICROBIOL LETT; CALLAHAN SM, 1995, J BIOL CHEM, V270, P17627, DOI 10.1074/jbc.270.29.17627; Camilli A, 1995, MOL MICROBIOL, V18, P671, DOI 10.1111/j.1365-2958.1995.mmi_18040671.x; Chan C, 2004, P NATL ACAD SCI USA, V101, P17084, DOI 10.1073/pnas.0406134101; DZIEJMAN M, 1994, MOL MICROBIOL, V13, P485, DOI 10.1111/j.1365-2958.1994.tb00443.x; Galperin MY, 2001, FEMS MICROBIOL LETT, V203, P11, DOI 10.1111/j.1574-6968.2001.tb10814.x; Garcia B, 2004, MOL MICROBIOL, V54, P264, DOI 10.1111/j.1365-2958.2004.04269.x; HERRINGTON DA, 1988, J EXP MED, V168, P1487, DOI 10.1084/jem.168.4.1487; Hidaka Y, 1997, FEBS LETT, V400, P238, DOI 10.1016/S0014-5793(96)01396-8; Hisert KB, 2005, MOL MICROBIOL, V56, P1234, DOI 10.1111/j.1365-2958.2005.04632.x; HUQ A, 1983, APPL ENVIRON MICROB, V45, P275, DOI 10.1128/AEM.45.1.275-283.1983; Imamura R, 1996, J BIOL CHEM, V271, P25423, DOI 10.1074/jbc.271.41.25423; Karaolis DKR, 2005, ANTIMICROB AGENTS CH, V49, P1029, DOI 10.1128/AAC.49.3.1029-1038.2005; KEIRNS JJ, 1974, ANAL BIOCHEM, V61, P336, DOI 10.1016/0003-2697(74)90400-X; Kierek K, 2003, P NATL ACAD SCI USA, V100, P14357, DOI 10.1073/pnas.2334614100; Kierek K, 2003, APPL ENVIRON MICROB, V69, P5079, DOI 10.1128/AEM.69.9.5079-5088.2003; Lee SH, 1998, J BACTERIOL, V180, P2298, DOI 10.1128/JB.180.9.2298-2305.1998; Lee SH, 1999, CELL, V99, P625, DOI 10.1016/S0092-8674(00)81551-2; Lee SH, 2001, P NATL ACAD SCI USA, V98, P6889, DOI 10.1073/pnas.111581598; MILLER VL, 1985, J BACTERIOL, V163, P580, DOI 10.1128/JB.163.2.580-585.1985; Pei JM, 2001, PROTEINS, V42, P210, DOI 10.1002/1097-0134(20010201)42:2<210::AID-PROT80>3.0.CO;2-8; ROSS P, 1986, CARBOHYD RES, V149, P101, DOI 10.1016/S0008-6215(00)90372-0; ROSS P, 1990, J BIOL CHEM, V265, P18933; Ryjenkov DA, 2005, J BACTERIOL, V187, P1792, DOI 10.1128/JB.187.5.1792-1798.2005; SCARLATO V, 1991, J BACTERIOL, V173, P7401, DOI 10.1128/jb.173.22.7401-7404.1991; Schoolnik GK, 2001, METHOD ENZYMOL, V336, P3, DOI 10.1016/S0076-6879(01)36573-4; Simm R, 2004, MOL MICROBIOL, V53, P1123, DOI 10.1111/j.1365-2958.2004.04206.x; Tal R, 1998, J BACTERIOL, V180, P4416, DOI 10.1128/JB.180.17.4416-4425.1998; TAMPLIN ML, 1990, APPL ENVIRON MICROB, V56, P1977, DOI 10.1128/AEM.56.6.1977-1980.1990; TAYLOR RK, 1987, P NATL ACAD SCI USA, V84, P2833, DOI 10.1073/pnas.84.9.2833; Tischler AD, 2004, MOL MICROBIOL, V53, P857, DOI 10.1111/j.1365-2958.2004.04155.x; Tischler AD, 2002, J BACTERIOL, V184, P4104, DOI 10.1128/JB.184.15.4104-4113.2002; TISCHLER ADA, 2005, IN PRESS INFECT IMMU; Watnick PI, 1999, MOL MICROBIOL, V34, P586, DOI 10.1046/j.1365-2958.1999.01624.x; WONG HC, 1990, P NATL ACAD SCI USA, V87, P8130, DOI 10.1073/pnas.87.20.8130; Yildiz FH, 1999, P NATL ACAD SCI USA, V96, P4028, DOI 10.1073/pnas.96.7.4028; Yildiz FH, 1998, J BACTERIOL, V180, P773, DOI 10.1128/JB.180.4.773-784.1998	38	211	223	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33324	33330		10.1074/jbc.M506500200	http://dx.doi.org/10.1074/jbc.M506500200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16081414	Green Accepted, Green Published, hybrid			2022-12-27	WOS:000232058100029
J	Jeyaraj, S; Dakhlallah, D; Hill, SR; Lee, BS				Jeyaraj, S; Dakhlallah, D; Hill, SR; Lee, BS			HuR stabilizes vacuolar H+-translocating ATPase mRNA during cellular energy depletion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AU-RICH ELEMENT; ACTIVATED PROTEIN-KINASE; CYTOPLASMIC SHUTTLING PROTEIN; RENAL TUBULAR-ACIDOSIS; BINDING PROTEIN; YEAST VACUOLAR; ELAV PROTEIN; PROTON PUMP; IN-VIVO; 3'-UNTRANSLATED REGION	V-ATPases are multisubunit membrane proteins that use ATP binding and hydrolysis to transport protons across membranes against a concentration gradient. Although some cell types express plasma membrane forms of these transporters, all eukaryotes require V-ATPases to maintain an acidic pH in membrane-bound compartments of endocytic and secretory networks to facilitate protein trafficking and processing. Mammalian cells that completely lack V-ATPases are not viable; yet, the abundance of V-ATPases can differ among cell types by an order of magnitude or more, requiring precise control of their expression. We previously showed that mRNA stability appears to play a major role in regulating overall abundance of V-ATPases. In this report, we demonstrate that the stability of V-ATPase mRNA is regulated through AU-rich elements in 3'-untranslated regions. Unlike some mRNAs that are short-lived due to the presence of these elements, V-ATPase mRNAs have half-lives of hours to days. However, during stress induced by ATP depletion, AU-rich elements are necessary to maintain stability of these transcripts and their presence in the cytoplasm. HuR, an RNA-binding protein that interacts with and stabilizes AU-rich mRNAs, shows increased binding to some V-ATPase mRNAs during ATP depletion. siRNA-mediated knockdown of HuR results in diminished V-ATPase expression. These results indicate that AU-rich elements and associated proteins can play a role in regulation of even very stable mRNAs by protecting against loss during cellular stress.	Ohio State Univ, Dept Physiol & Cell Biol, Coll Med, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Lee, BS (corresponding author), Ohio State Univ, Dept Physiol & Cell Biol, Coll Med, 302 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.	lee.2076@osu.edu	Lee, Beth S/E-9578-2010; dakhlallah, Duaa/C-1279-2014	Lee, Beth S/0000-0002-1468-6387; Dakhlallah, Duaa A/0000-0002-6288-4927	NIDDK NIH HHS [DK52131, R01 DK052131-10, R01 DK052131-08, R01 DK052131, R01 DK052131-09, R01 DK052131-07A1] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052131] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS GK, 1987, MOL CELL BIOL, V7, P3452, DOI 10.1128/MCB.7.10.3452; Atasoy U, 1998, J CELL SCI, V111, P3145; Bakheet T, 2003, NUCLEIC ACIDS RES, V31, P421, DOI 10.1093/nar/gkg023; Bakheet T, 2001, NUCLEIC ACIDS RES, V29, P246, DOI 10.1093/nar/29.1.246; Bevilacqua A, 2003, J CELL PHYSIOL, V195, P356, DOI 10.1002/jcp.10272; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; Breton S, 1996, NAT MED, V2, P470, DOI 10.1038/nm0496-470; Breton S, 1999, HISTOCHEM CELL BIOL, V111, P97, DOI 10.1007/s004180050339; CANFIELD PE, 1991, AM J PHYSIOL, V261, pF1038, DOI 10.1152/ajprenal.1991.261.6.F1038; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chen J, 2001, AM J PHYSIOL-RENAL, V280, pF619, DOI 10.1152/ajprenal.2001.280.4.F619; de Silanes IL, 2004, P NATL ACAD SCI USA, V101, P2987, DOI 10.1073/pnas.0306453101; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; FISH EM, 1994, AM J PHYSIOL-RENAL, V267, pF566, DOI 10.1152/ajprenal.1994.267.4.F566; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Fraser S, 2005, AM J PHYSIOL-RENAL, V288, pF578, DOI 10.1152/ajprenal.00190.2004; Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131; Frevel MAE, 2003, MOL CELL BIOL, V23, P425, DOI 10.1128/MCB.23.2.425-436.2003; Gallouzi IE, 2001, RNA, V7, P1348, DOI 10.1017/s1355838201016089; Gluck SL, 1996, ANNU REV PHYSIOL, V58, P427, DOI 10.1146/annurev.physiol.58.1.427; Gouble A, 2000, ONCOGENE, V19, P5377, DOI 10.1038/sj.onc.1203910; Huwiler A, 2003, J BIOL CHEM, V278, P51758, DOI 10.1074/jbc.M305722200; Inoue H, 1999, BBA-BIOENERGETICS, V1413, P130, DOI 10.1016/S0005-2728(99)00096-1; KANE PM, 1995, J BIOL CHEM, V270, P17025; Kane PM, 2000, J EXP BIOL, V203, P81; Karet FE, 1999, NAT GENET, V21, P84, DOI 10.1038/5022; Kornak U, 2000, HUM MOL GENET, V9, P2059, DOI 10.1093/hmg/9.13.2059; Lal A, 2004, EMBO J, V23, P3092, DOI 10.1038/sj.emboj.7600305; LEE BS, 1995, J BIOL CHEM, V270, P7320, DOI 10.1074/jbc.270.13.7320; Lee BS, 1997, J BIOL CHEM, V272, P174; Lee BS, 1999, J BONE MINER RES, V14, P2127, DOI 10.1359/jbmr.1999.14.12.2127; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Lu JY, 2004, J BIOL CHEM, V279, P12974, DOI 10.1074/jbc.M310433200; Lu M, 2004, J BIOL CHEM, V279, P8732, DOI 10.1074/jbc.M303871200; Lu M, 2001, J BIOL CHEM, V276, P30407, DOI 10.1074/jbc.M008768200; Meldrum KK, 2001, AM J PHYSIOL-REG I, V281, pR359, DOI 10.1152/ajpregu.2001.281.1.R359; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; Nishi T, 2000, J BIOL CHEM, V275, P6824, DOI 10.1074/jbc.275.10.6824; Padanilam BJ, 2003, AM J PHYSIOL-RENAL, V284, pF608, DOI 10.1152/ajprenal.00284.2002; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Sautin YY, 2005, MOL CELL BIOL, V25, P575, DOI 10.1128/MCB.25.2.575-589.2005; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Smardon AM, 2002, J BIOL CHEM, V277, P13831, DOI 10.1074/jbc.M200682200; Smith AN, 2003, MOL CELL, V12, P801, DOI 10.1016/S1097-2765(03)00397-6; Smith AN, 2000, NAT GENET, V26, P71, DOI 10.1038/79208; Su Y, 2003, J BIOL CHEM, V278, P20013, DOI 10.1074/jbc.M210077200; Sun-Wada GH, 2003, GENE, V302, P147, DOI 10.1016/S0378-1119(02)01099-5; UNDERHILL DM, 1995, THESIS WASHINGTON U; Van Why SK, 1999, AM J PHYSIOL-RENAL, V277, pF227, DOI 10.1152/ajprenal.1999.277.2.F227; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; Wang SP, 2002, J BIOL CHEM, V277, P8827, DOI 10.1074/jbc.M111959200; Wang W, 2002, MOL CELL BIOL, V22, P3425, DOI 10.1128/MCB.22.10.3425-3436.2002; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang WG, 2004, J BIOL CHEM, V279, P48376, DOI 10.1074/jbc.M409014200; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Westmark CJ, 2005, ONCOGENE, V24, P502, DOI 10.1038/sj.onc.1208224; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; Witzgall R, 1999, EXP NEPHROL, V7, P15; Xu T, 2001, J BIOL CHEM, V276, P24855, DOI 10.1074/jbc.M100637200; Yaman I, 2002, J BIOL CHEM, V277, P41539, DOI 10.1074/jbc.M204850200; Yeap BB, 2002, J BIOL CHEM, V277, P27183, DOI 10.1074/jbc.M202883200; Zeng Q, 2000, J CELL SCI, V113, P471; Zhang T, 2002, BIOCHEM SOC T, V30, P952, DOI 10.1042/BST0300952	66	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37957	37964		10.1074/jbc.M502883200	http://dx.doi.org/10.1074/jbc.M502883200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16155006	Green Accepted, hybrid			2022-12-27	WOS:000233044500078
J	Schmitz, C; Dorovkov, MV; Zhao, XY; Davenport, BJ; Ryazanov, AG; Perraud, AL				Schmitz, C; Dorovkov, MV; Zhao, XY; Davenport, BJ; Ryazanov, AG; Perraud, AL			The channel kinases TRPM6 and TRPM7 are functionally nonredundant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY HYPOCALCEMIA; ION CHANNELS; MG2+ HOMEOSTASIS; CATION CHANNELS; PROTEIN-KINASES; MAGNESIUM; HYPOMAGNESEMIA; TRANSPORT; MUTATION; FAMILY	TRPM7 and its closest homologue, TRPM6, are the only known fusions of an ion channel pore with a kinase domain. Deletion of TRPM7 in DT40 B-lymphocytes causes growth arrest, Mg2+ deficiency, and cell death within 24 - 48 h. Amazingly, in analogy to TRPM6-deficient patients who can live a normal life if provided with a Mg2+-rich diet, TRPM7-deficient DT40 B-lymphocytes show wild type cell growth if supplied with 5 - 10 mM Mg2+ concentrations in their extracellular medium. Here we have investigated the functional relationship between TRPM6 and TRPM7. We show that TRPM7 deficiency in DT40 cells cannot be complemented by heterologously expressed TRPM6. Nevertheless, both channels can influence each other's biological activity. Our data demonstrate that TRPM6 requires TRPM7 for surface expression in HEK-293 cells and also that TRPM6 is capable of cross-phosphorylating TRPM7 as assessed using a phosphothreonine-specific antibody but not vice versa. TRPM6 and TRPM7 coexpression studies in DT40 B-cells indicate that TRPM6 can modulate TRPM7 function. In conclusion, although TRPM6 and TRPM7 are closely related and deficiency in either one of these molecules severely affects Mg2+ homeostasis regulation, TRPM6 and TRPM7 do not appear to be functionally redundant but rather two unique and essential components of vertebrate ion homeostasis regulation.	Natl Jewish Med & Res Ctr, Integrated Dept Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO 80206 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Rutgers State University New Brunswick; Rutgers State University Medical Center	Perraud, AL (corresponding author), Natl Jewish Med & Res Ctr, Dept Immunol, 1400 Jackson St, Denver, CO 80206 USA.	perrauda@njc.org	ryazanov, alexey/J-8081-2017		NIAID NIH HHS [K08AI060926] Funding Source: Medline; NIGMS NIH HHS [R01GM068801] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI060926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068801] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aarts M, 2003, CELL, V115, P863, DOI 10.1016/S0092-8674(03)01017-1; Chubanov V, 2004, P NATL ACAD SCI USA, V101, P2894, DOI 10.1073/pnas.0305252101; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Clapham DE, 2002, SCIENCE, V295, P2228, DOI 10.1126/science.1070766; Dorovkov MV, 2004, J BIOL CHEM, V279, P50643, DOI 10.1074/jbc.C400441200; Drennan D, 2004, PROG BIOPHYS MOL BIO, V85, P1, DOI 10.1016/S0079-6107(03)00060-9; Fleig A, 2004, TRENDS PHARMACOL SCI, V25, P633, DOI 10.1016/j.tips.2004.10.004; Hermosura MC, 2005, P NATL ACAD SCI USA, V102, P11510, DOI 10.1073/pnas.0505149102; Hoenderop JGJ, 2005, J AM SOC NEPHROL, V16, P15, DOI 10.1681/ASN.2004070523; Kolisek M, 2003, EMBO J, V22, P1235, DOI 10.1093/emboj/cdg122; Konrad M, 2004, AM J PHYSIOL-RENAL, V286, pF599, DOI 10.1152/ajprenal.00312.2003; Kraft R, 2005, PFLUG ARCH EUR J PHY, V451, P204, DOI 10.1007/s00424-005-1428-0; Launay P, 2004, SCIENCE, V306, P1374, DOI 10.1126/science.1098845; Matsushita M, 2005, J BIOL CHEM, V280, P20793, DOI 10.1074/jbc.M413671200; MILLA PJ, 1979, GUT, V20, P1028, DOI 10.1136/gut.20.11.1028; Montell C, 2003, CURR BIOL, V13, pR799, DOI 10.1016/j.cub.2003.09.048; Montell Craig, 2005, Sci STKE, V2005, pre3, DOI 10.1126/stke.2722005re3; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; Perraud AL, 2004, MOL IMMUNOL, V41, P657, DOI 10.1016/j.molimm.2004.04.013; Prawitt D, 2003, P NATL ACAD SCI USA, V100, P15166, DOI 10.1073/pnas.2334624100; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; Ryazanov AG, 2002, FEBS LETT, V514, P26, DOI 10.1016/S0014-5793(02)02299-8; Ryazanova LV, 2001, MOL BIOL+, V35, P271, DOI 10.1023/A:1010499720185; Schlingmann KP, 2005, J PHYSIOL-LONDON, V566, P301, DOI 10.1113/jphysiol.2004.080200; Schlingmann KP, 2002, NAT GENET, V31, P166, DOI 10.1038/ng889; Schmitz C, 2004, PEDIATR RES, V55, P734, DOI 10.1203/01.PDR.0000117848.37520.A2; Schmitz C, 2003, CELL, V114, P191, DOI 10.1016/S0092-8674(03)00556-7; Ullrich ND, 2005, CELL CALCIUM, V37, P267, DOI 10.1016/j.ceca.2004.11.001; Voets T, 2004, J BIOL CHEM, V279, P19, DOI 10.1074/jbc.M311201200; Walder RY, 2002, NAT GENET, V31, P171, DOI 10.1038/ng901; WOLF FI, 2004, SCI STKE, pPE23; Yamaguchi H, 2001, MOL CELL, V7, P1047, DOI 10.1016/S1097-2765(01)00256-8; YAMAMOTO T, 1985, Magnesium, V4, P153; Zhang YF, 2003, CELL, V112, P293, DOI 10.1016/S0092-8674(03)00071-0	34	145	149	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37763	37771		10.1074/jbc.M509175200	http://dx.doi.org/10.1074/jbc.M509175200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16150690	hybrid			2022-12-27	WOS:000233044500055
J	Szatmari, E; Habas, A; Peng, Y; Zheng, JJ; Hagg, T; Hetman, M				Szatmari, E; Habas, A; Peng, Y; Zheng, JJ; Hagg, T; Hetman, M			A positive feedback loop between glycogen synthase kinase 3 beta and protein phosphatase 1 after stimulation of NR2B NMDA receptors in forebrain neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; SMALL-MOLECULE INHIBITORS; LONG-TERM DEPRESSION; CASEIN KINASE-II; HIPPOCAMPAL-NEURONS; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; GENE-TRANSCRIPTION; SIGNALING PATHWAY; INTACT-CELLS	N-methyl-D-aspartate receptors (NMDARs) are critical for neuronal plasticity and survival, whereas their excessive activation produces excitotoxicity and may accelerate neurodegeneration. Here, we report that stimulation of NMDARs in cultured rat hippocampal or cortical neurons and in the adult mouse brain in vivo disinhibited glycogen synthase kinase 3 beta (GSK3 beta) by protein phosphatase 1(PP1)-mediated dephosphorylation of GSK3 beta at the serine 9 residue. NMDA-triggered GSK3 beta activation was mediated by NMDAR that contained the NR2B subunit. Interestingly, GSK3 beta inhibition reduced inhibitory phosphorylation of the PP1 inhibitor 2 (I2) and attenuated serine 9 dephosphorylation by PP1. These data suggest existence of a feedback loop between GSK3 beta and PP1 that results in amplification of PP1 activation by GSK3 beta. In addition, GSK3 beta inhibition decreased PP1-mediated dephosphorylation of the cAMP-response element-binding protein ( CREB) at the serine 133 residue in NMDA-stimulated neurons. Conversely, overexpression of GSK3 beta abolished non-NR2B-mediated activation of CRE-driven transcription. These data suggest that cross-talk between GSK3 beta and PP1 contributes to NR2B NMDAR-induced inhibition of CREB signaling by non-NR2BNMDAR. The excessive activation of NR2B-PP1-GSK3 beta-PP1 circuitry may contribute to the deficits of CREB-dependent neuronal plasticity in neurodegenerative diseases.	Univ Louisville, KY Spinal Cord Injury Res Ctr, Louisville, KY 40292 USA; Univ Louisville, Dept Neurol Surg, Louisville, KY 40292 USA; Univ Louisville, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA; M Nencki Inst Expt Biol, PL-02093 Warsaw, Poland	University of Louisville; University of Louisville; University of Louisville; Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences	Hetman, M (corresponding author), Univ Louisville, KY Spinal Cord Injury Res Ctr, 511 S Floyd St,MDR616, Louisville, KY 40292 USA.	michal.hetman@louisville.edu			NCRR NIH HHS [P20-RR15576] Funding Source: Medline; NINDS NIH HHS [NS047341] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047341] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adamec E, 1997, BRAIN RES, V757, P93, DOI 10.1016/S0006-8993(97)00166-2; AITKEN A, 1984, BIOCHIM BIOPHYS ACTA, V790, P288, DOI 10.1016/0167-4838(84)90034-7; Arthur JSC, 2004, J NEUROSCI, V24, P4324, DOI 10.1523/JNEUROSCI.5227-03.2004; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; Beaulieu JM, 2004, P NATL ACAD SCI USA, V101, P5099, DOI 10.1073/pnas.0307921101; Bennecib M, 2000, FEBS LETT, V485, P87, DOI 10.1016/S0014-5793(00)02203-1; Bhat R, 2003, J BIOL CHEM, V278, P45937, DOI 10.1074/jbc.M306268200; Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; Bijur GN, 2000, J BIOL CHEM, V275, P7583, DOI 10.1074/jbc.275.11.7583; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brouillet E, 1999, PROG NEUROBIOL, V59, P427, DOI 10.1016/S0301-0082(99)00005-2; Carmichael J, 2002, J BIOL CHEM, V277, P33791, DOI 10.1074/jbc.m204861200; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Cross DAE, 2001, J NEUROCHEM, V77, P94, DOI 10.1046/j.1471-4159.2001.00251.x; Crowder RJ, 2000, J BIOL CHEM, V275, P34266, DOI 10.1074/jbc.M006160200; DEPAOLIROACH AA, 1984, J BIOL CHEM, V259, P2144; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; Emamian ES, 2004, NAT GENET, V36, P131, DOI 10.1038/ng1296; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; FLEMING LM, 1995, BIOCHEM J, V309, P41, DOI 10.1042/bj3090041; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Genoux D, 2002, NATURE, V418, P970, DOI 10.1038/nature00928; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; HEMMINGS BA, 1982, FEBS LETT, V150, P319, DOI 10.1016/0014-5793(82)80760-6; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Hetman M, 2002, J BIOL CHEM, V277, P49577, DOI 10.1074/jbc.M111227200; Hetman M, 2000, J NEUROSCI, V20, P2567; HOLMES CFB, 1986, BIOCHIM BIOPHYS ACTA, V870, P408, DOI 10.1016/0167-4838(86)90248-7; Hughes JP, 2003, J NEUROCHEM, V86, P25, DOI 10.1046/j.1471-4159.2003.01830.x; Impey S, 1996, NEURON, V16, P973, DOI 10.1016/S0896-6273(00)80120-8; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Jaworski J, 2003, J NEUROSCI, V23, P4519; Jiang HB, 2003, HUM MOL GENET, V12, P1, DOI 10.1093/hmg/ddg002; Kakinoki Y, 1997, J BIOL CHEM, V272, P32308, DOI 10.1074/jbc.272.51.32308; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kopnisky KL, 2003, NEUROSCIENCE, V116, P425, DOI 10.1016/S0306-4522(02)00573-0; KUDO Y, 1986, BRIT J PHARMACOL, V89, P191, DOI 10.1111/j.1476-5381.1986.tb11135.x; Leach C, 2003, J BIOL CHEM, V278, P26015, DOI 10.1074/jbc.M300782200; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Li XH, 2004, NEUROPSYCHOPHARMACOL, V29, P1426, DOI 10.1038/sj.npp.1300439; Lonze BE, 2002, NEURON, V34, P371, DOI 10.1016/S0896-6273(02)00686-4; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Mantamadiotis T, 2002, NAT GENET, V31, P47, DOI 10.1038/ng882; Morfini G, 2004, EMBO J, V23, P2235, DOI 10.1038/sj.emboj.7600237; MORI H, 1995, NEUROPHARMACOLOGY, V34, P1219, DOI 10.1016/0028-3908(95)00109-J; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Oliver C.J., 1998, FRONT BIOSCI, V3, P961; OLNEY JW, 1994, NEUROBIOL AGING, V15, P259, DOI 10.1016/0197-4580(94)90127-9; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; PAPAIOANNOU VE, 1993, LAB ANIM SCI, V43, P189; Pei JJ, 1997, J NEUROPATH EXP NEUR, V56, P70, DOI 10.1097/00005072-199701000-00007; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Sala C, 2000, J NEUROSCI, V20, P3529, DOI 10.1523/JNEUROSCI.20-10-03529.2000; SCHWARCZ R, 1984, EXP NEUROL, V84, P1, DOI 10.1016/0014-4886(84)90001-3; Shaw M, 1999, FEBS LETT, V461, P120, DOI 10.1016/S0014-5793(99)01434-9; Sheppeck JE, 1997, BIOORGAN MED CHEM, V5, P1739, DOI 10.1016/S0968-0896(97)00146-6; Shiurba RA, 1996, BRAIN RES, V737, P119, DOI 10.1016/0006-8993(96)00717-2; Song L, 2002, J BIOL CHEM, V277, P44701, DOI 10.1074/jbc.M206047200; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; TAKASHIMA A, 1993, P NATL ACAD SCI USA, V90, P7789, DOI 10.1073/pnas.90.16.7789; Terry-Lorenzo RT, 2002, J BIOL CHEM, V277, P46535, DOI 10.1074/jbc.M206960200; Thiels E, 1998, NEUROSCIENCE, V86, P1023, DOI 10.1016/S0306-4522(98)00135-3; Vanhoutte P, 2003, CURR OPIN NEUROBIOL, V13, P366, DOI 10.1016/S0959-4388(03)00073-4; WANG QM, 1995, J BIOL CHEM, V270, P18352, DOI 10.1074/jbc.270.31.18352; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; Westbrook Gary L., 1994, Current Opinion in Neurobiology, V4, P337, DOI 10.1016/0959-4388(94)90094-9; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xia ZG, 1996, J NEUROSCI, V16, P5425; Zhang F, 2003, J BIOL CHEM, V278, P33067, DOI 10.1074/jbc.M212635200	77	75	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37526	37535		10.1074/jbc.M502699200	http://dx.doi.org/10.1074/jbc.M502699200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16155008	hybrid			2022-12-27	WOS:000233044500029
J	Nishiya, T; Kajita, E; Miwa, S; DeFranco, AL				Nishiya, T; Kajita, E; Miwa, S; DeFranco, AL			TLR3 and TLR7 are targeted to the same intracellular compartments by distinct regulatory elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM LOCALIZATION; MANNOSE 6-PHOSPHATE RECEPTOR; TOLL-LIKE RECEPTOR-3; TRANSMEMBRANE DOMAIN; CYTOPLASMIC DOMAIN; MEMBRANE-PROTEINS; SUBCELLULAR-LOCALIZATION; GOLGI-APPARATUS; RETENTION; SIGNALS	Toll-like receptor (TLR) 3 and TLR7 are indispensable for host defense against viral infection by recognizing virus-derived RNAs and are localized to intracellular membranes via an unknown mechanism. We recently reported experiments with chimeric Toll-like receptors that suggested that the subcellular distribution of TLRs may be defined by their transmembrane and/or cytoplasmic domains. Here we demonstrate that the intracellular localization of TLR3 is achieved by a 23-amino acid sequence (Glu(727) to Asp(749)) present in the linker region between the transmembrane domain and Toll-interleukin 1 receptor resistance (TIR) domain. In contrast, the intracellular localization of TLR7 is achieved by its transmembrane domain. These elements also targeted a heterologous type I transmembrane protein CD25 to the intracellular compartment that contained TLR3 and TLR7. Despite their using distinct regulatory elements for intracellular localization, TLR3 was found to co-localize with TLR7. In addition, TLR3 and TLR7 were preferentially localized near phagosomes containing apoptotic cell particles. These findings reveal that TLR3 and TLR7 contain unique targeting sequences, which differentially lead them to the same intracellular compartments and adjacent to phagosomes containing apoptotic cell particles, where these receptors may access their ligands for the induction of immune responses against viral infection.	Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Hokkaido Univ, Grad Sch Med, Dept Cellular Pharmacol, Sapporo, Hokkaido 0608638, Japan	University of California System; University of California San Francisco; Hokkaido University	DeFranco, AL (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, Box 0414,HSE1001F,513 Pamassus Ave, San Francisco, CA 94143 USA.	defranco@cgl.ucsf.edu	Miwa, Soichi/D-8468-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020038, R01AI033442, R37AI020038] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20038, AI33442] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Fullekrug J, 1997, EUR J CELL BIOL, V74, P31; Funami K, 2004, INT IMMUNOL, V16, P1143, DOI 10.1093/intimm/dxh115; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; HILLEREHFELD A, 1995, BBA-REV BIOMEMBRANES, V1241, P177, DOI 10.1016/0304-4157(95)00004-B; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028; Lee J, 2003, P NATL ACAD SCI USA, V100, P6646, DOI 10.1073/pnas.0631696100; LUDWIG T, 1995, TRENDS CELL BIOL, V5, P202, DOI 10.1016/S0962-8924(00)89000-5; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Matsumoto M, 2003, J IMMUNOL, V171, P3154, DOI 10.4049/jimmunol.171.6.3154; MILLER J, 1985, J IMMUNOL, V134, P4212; Nishiya T, 2004, J BIOL CHEM, V279, P19008, DOI 10.1074/jbc.M311618200; O'Neill LAJ, 2004, TRENDS IMMUNOL, V25, P687, DOI 10.1016/j.it.2004.10.005; Onishi M, 1996, EXP HEMATOL, V24, P324; Sato K, 1997, P NATL ACAD SCI USA, V94, P9693, DOI 10.1073/pnas.94.18.9693; Sato K, 2003, MOL BIOL CELL, V14, P3605, DOI 10.1091/mbc.E02-12-0777; Sato M, 1996, J CELL BIOL, V134, P279, DOI 10.1083/jcb.134.2.279; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; TANG BL, 1992, J BIOL CHEM, V267, P10122; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; Wagner H, 2004, TRENDS IMMUNOL, V25, P381, DOI 10.1016/j.it.2004.04.011; WONG SH, 1992, J CELL BIOL, V117, P245, DOI 10.1083/jcb.117.2.245; YEE JK, 1994, METHOD CELL BIOL, V43, P99; Zhang HF, 2002, FEBS LETT, V532, P171, DOI 10.1016/S0014-5793(02)03669-4	29	170	176	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37107	37117		10.1074/jbc.M504951200	http://dx.doi.org/10.1074/jbc.M504951200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16105838	hybrid			2022-12-27	WOS:000232901800069
J	Fisher, E; Almaguer, C; Holic, R; Griac, P; Patton-Vogt, J				Fisher, E; Almaguer, C; Holic, R; Griac, P; Patton-Vogt, J			Glycerophosphocholine-dependent growth requires Gde1p (YPL110c) and Git1p in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; IN-VITRO; PHOSPHOLIPID BIOSYNTHESIS; GENE DISRUPTIONS; BUDDING YEAST; PHOSPHATIDYLCHOLINE; PHOSPHODIESTERASE; GLYCEROPHOSPHOINOSITOL; CHOLINE; METABOLISM	Glycerophosphocholine is formed via the deacylation of the phospholipid phosphatidylcholine. The protein encoded by Saccharomyces cerevisiae open reading frame YPL110c effects glycerophosphocholine metabolism in vivo, most likely by acting as a glycerophosphocholine phosphodiesterase. Deletion of YPL110c causes an accumulation of glycerophosphocholine in cells prelabeled with [C-14] choline. Correspondingly, overexpression of YPL110c results in reduced intracellular glycerophosphocholine in cells prelabeled with [C-14] choline. Glycerophospho[H-3] choline supplied in the growth medium accumulates to a much greater extent in the intracellular fraction of a YPL110 Delta strain than in a wild type strain. Furthermore, glycerophospho[H-3] choline accumulation requires the transporter encoded by GIT1, a known glycerophosphoinositol transporter. Growth on glycerophosphocholine as the sole phosphate source requires YPL110c and the Git1p permease. In contrast to glycerophosphocholine, glycerophosphoinositol metabolism is unaffected by deletion of YPL110c. The open reading frame YPL110c has been termed GDE1.	Duquesne Univ, Dept Biol Sci, Pittsburgh, PA 15282 USA; Slovak Acad Sci, Inst Anim Biochem & Genet, Ivanka Pri Dunaji 90028, Slovakia	Duquesne University; Slovak Academy of Sciences	Patton-Vogt, J (corresponding author), Duquesne Univ, Dept Biol Sci, Pittsburgh, PA 15282 USA.	pattonvogt@duq.edu	, Peter/ABA-9227-2020; Roman, Holic/X-7500-2018; Holic, Roman/AAC-8402-2019	, Peter/0000-0003-3538-0405; Roman, Holic/0000-0003-1347-4785; Holic, Roman/0000-0003-1347-4785	NIGMS NIH HHS [R01 GM059817, GM59817] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059817] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almaguer C, 2004, J BIOL CHEM, V279, P31937, DOI 10.1074/jbc.M403648200; ANGUS WW, 1972, ARCH BIOCHEM BIOPHYS, V151, P483, DOI 10.1016/0003-9861(72)90525-5; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; Baburina I, 1999, J BIOL CHEM, V274, P9400, DOI 10.1074/jbc.274.14.9400; Barbour SE, 1999, BBA-MOL CELL BIOL L, V1439, P77, DOI 10.1016/S1388-1981(99)00078-5; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; BAUERNSCHMITT HG, 1993, BIOCHIM BIOPHYS ACTA, V1150, P25; Beck T, 1999, J CELL BIOL, V146, P1227, DOI 10.1083/jcb.146.6.1227; Berrie CP, 1999, EUR J BIOCHEM, V266, P413, DOI 10.1046/j.1432-1327.1999.00870.x; BRZOSKA P, 1988, J BACTERIOL, V170, P4125, DOI 10.1128/jb.170.9.4125-4135.1988; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; Carman GM, 2004, BIOCHEM CELL BIOL, V82, P62, DOI 10.1139/o03-064; COOK SJ, 1989, BIOCHEM J, V263, P581, DOI 10.1042/bj2630581; DAWSON RMC, 1977, BIOCHEM J, V162, P241, DOI 10.1042/bj1620241; DAWSON RMC, 1979, BIOCHEM J, V182, P39, DOI 10.1042/bj1820039; Dowd SR, 2001, J BIOL CHEM, V276, P3756, DOI 10.1074/jbc.M003694200; DWON ED, 1996, AM J PHYSIOL, V270, pC200; Fallbrook A, 1999, BRAIN RES, V834, P207, DOI 10.1016/S0006-8993(99)01570-X; Geer LY, 2002, GENOME RES, V12, P1619, DOI 10.1101/gr.278202; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Glunde K, 2004, CANCER RES, V64, P4270, DOI 10.1158/0008-5472.CAN-03-3829; Hama H, 2000, METHODS, V20, P465, DOI 10.1006/meth.2000.0959; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Komatsu H, 2003, BBA-MOL CELL BIOL L, V1635, P67, DOI 10.1016/j.bbalip.2003.10.007; LEE KS, 1994, J BIOL CHEM, V269, P19725; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Merkel O, 1999, J BIOL CHEM, V274, P28121, DOI 10.1074/jbc.274.40.28121; Merkel O, 2005, BIOCHEM J, V387, P489, DOI 10.1042/BJ20041272; Mulder NJ, 2005, NUCLEIC ACIDS RES, V33, pD201, DOI 10.1093/nar/gki106; MUNSON RS, 1993, J BACTERIOL, V175, P4569, DOI 10.1128/JB.175.14.4569-4571.1993; Nelissen B, 1997, FEMS MICROBIOL REV, V21, P113, DOI 10.1111/j.1574-6976.1997.tb00347.x; NIKAWA J, 1990, J BIOL CHEM, V265, P15996; Ogawa N, 2000, MOL BIOL CELL, V11, P4309, DOI 10.1091/mbc.11.12.4309; PATTON JL, 1995, J BACTERIOL, V177, P3379, DOI 10.1128/jb.177.12.3379-3385.1995; Patton-Vogt JL, 1998, GENETICS, V149, P1707; Pinson B, 2004, J BIOL CHEM, V279, P35273, DOI 10.1074/jbc.M405398200; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Sok DE, 1998, NEUROCHEM RES, V23, P1061, DOI 10.1023/A:1020755918632; SPAIN BH, 1995, J BIOL CHEM, V270, P25435, DOI 10.1074/jbc.270.43.25435; STEINER MR, 1972, BIOCHIM BIOPHYS ACTA, V260, P222, DOI 10.1016/0005-2760(72)90035-5; TOMMASSEN J, 1991, MOL GEN GENET, V226, P321, DOI 10.1007/BF00273621; van der Rest B, 2004, BIOCHEM J, V379, P601, DOI 10.1042/BJ20031489; Voth WP, 2003, YEAST, V20, P985, DOI 10.1002/yea.1018; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WALKEY CJ, 1994, J BIOL CHEM, V269, P5742; Walter A, 2004, NEUROBIOL AGING, V25, P1299, DOI 10.1016/j.neurobiolaging.2004.02.016; Wheeler DL, 2003, NUCLEIC ACIDS RES, V31, P28, DOI 10.1093/nar/gkg033; Zaccheo O, 2004, J BIOL CHEM, V279, P24024, DOI 10.1074/jbc.M400830200; Zheng B, 2003, P NATL ACAD SCI USA, V100, P1745, DOI 10.1073/pnas.0337605100	50	57	63	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36110	36117		10.1074/jbc.M507051200	http://dx.doi.org/10.1074/jbc.M507051200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16141200	hybrid			2022-12-27	WOS:000232726900041
J	Jones, DC; Mehlert, A; Guther, MLS; Ferguson, MAJ				Jones, DC; Mehlert, A; Guther, MLS; Ferguson, MAJ			Deletion of the glucosidase II gene in Trypanosoma brucei reveals novel N-glycosylation mechanisms in the biosynthesis of variant surface glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOLIPID MEMBRANE ANCHOR; BLOOD-STREAM FORM; PROTEIN GLYCOSYLATION; STRUCTURAL-CHARACTERIZATION; QUALITY-CONTROL; LINKED GLYCANS; OLIGOSACCHARIDES; PRECURSORS; PATHWAY; IDENTIFICATION	The trypanosomatids are generally aberrant in their protein N-glycosylation pathways. However, protein N-glycosylation in the African trypanosome Trypanosoma brucei, etiological agent of human African sleeping sickness, is not well understood. Here, we describe the creation of a bloodstream-form T. brucei mutant that is deficient in the endoplasmic reticulum enzyme glucosidase II. Characterization of the variant surface glycoprotein, the main glycoprotein synthesized by the parasite with two N-glycosylation sites, revealed unexpected changes in the N-glycosylation of this molecule. Structural characterization by mass spectrometry, nuclear magnetic resonance spectroscopy, and chemical and enzymatic treatments revealed that one of the two glycosylation sites was occupied by conventional oligomannose structures, whereas the other accumulated unusual structures in the form of Glc alpha 1-3Man alpha 1 - 2Man alpha 1 - 2Man alpha 1 - 3(Man alpha 1 - 6) Man beta 1 - 4GlcNAc beta 1-4GlcNAc, Glc alpha 1 - 3Man alpha 1 - 2Man alpha 1 - 2Man alpha 1 - 3(GlcNAc beta 1-2Man alpha 1 - 6) Man beta 1 - 4GlcNAc beta 1 - 4GlcNAc, and Glc alpha 1 - 3Man alpha 1-2Man alpha 1 - 2Man alpha 1 - 3(Gal beta 1 - 4GlcNAc beta 1 - 2Man alpha 1 - 6) Man beta 1-4GlcNAc beta 1-4GlcNAc. The possibility that these structures might arise from Glc(1)Man(9)GlcNAc(2) by unusually rapid alpha-mannosidase processing was ruled out using a mixture of alpha-mannosidase inhibitors. The results suggest that bloodstream-form T. brucei can transfer both Man(9)GlcNAc(2) and Man(5)GlcNAc(2) to the variant surface glycoprotein in a site-specific manner and that, unlike organisms that transfer exclusively Glc(3)Man(9)GlcNAc(2), the T. brucei UDP-Glc: glycoprotein glucosyltransferase and glucosidase II enzymes can use Man(5)GlcNAc(2) and Glc(1)Man(5)GlcNAc(2), respectively, as their substrates. The ability to transfer Man(5)GlcNAc(2) structures to N-glycosylation sites destined to become Man(4-3)GlcNAc(2) or complex structures may have evolved as a mechanism to conserve dolichol-phosphate-mannose donors for glycosylphosphatidylinositol anchor biosynthesis and points to fundamental differences in the specificities of host and parasite glycosyltransferases that initiate the synthesis of complex N-glycans.	Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland	University of Dundee	Ferguson, MAJ (corresponding author), Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland.	m.a.j.ferguson@dundee.ac.uk	Ferguson, Michael A. J./F-7829-2010	Ferguson, Michael A. J./0000-0003-1321-8714	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Acosta-Serrano A, 2004, EUKARYOT CELL, V3, P255, DOI 10.1128/EC.3.2.255-263.2004; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Asano N, 2003, GLYCOBIOLOGY, V13, p93R, DOI 10.1093/glycob/cwg090; BANGS JD, 1988, J BIOL CHEM, V263, P17697; Caramelo JJ, 2004, J BIOL CHEM, V279, P46280, DOI 10.1074/jbc.M408404200; Conte L, 2003, MOL BIOL CELL, V14, P3529, DOI 10.1091/mbc.E03-04-0228; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; Cross GAM, 1996, BIOESSAYS, V18, P283, DOI 10.1002/bies.950180406; CROSS GAM, 1984, J CELL BIOCHEM, V24, P79, DOI 10.1002/jcb.240240107; DELACANAL L, 1987, J BIOL CHEM, V262, P11128; DOYLE P, 1986, MOL BIOCHEM PARASIT, V21, P93, DOI 10.1016/0166-6851(86)90083-6; FERGUSON MAJ, 1986, J BIOL CHEM, V261, P356; FERGUSON MAJ, 1994, GLYCOBIOLOGY PRACTIC, P349; Frenkel Z, 2003, J BIOL CHEM, V278, P34119, DOI 10.1074/jbc.M305929200; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; Hutchinson OC, 2003, MOL BIOCHEM PARASIT, V130, P127, DOI 10.1016/S0166-6851(03)00144-0; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Labriola C, 1999, MOL BIOL CELL, V10, P1381, DOI 10.1091/mbc.10.5.1381; LOW P, 1991, J BIOL CHEM, V266, P19250; MAYOR S, 1990, J BIOL CHEM, V265, P6164; Mehlert A, 2002, GLYCOBIOLOGY, V12, P607, DOI 10.1093/glycob/cwf079; Mehlert A, 1998, MOL BIOCHEM PARASIT, V91, P145, DOI 10.1016/S0166-6851(97)00187-4; Mehlert A, 1998, J MOL BIOL, V277, P379, DOI 10.1006/jmbi.1997.1600; MENON AK, 1990, J BIOL CHEM, V265, P9033; Milne KG, 2001, MOL BIOCHEM PARASIT, V112, P301, DOI 10.1016/S0166-6851(00)00369-8; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; PARODI AJ, 1993, GLYCOBIOLOGY, V3, P193, DOI 10.1093/glycob/3.3.193; PARODI AJ, 1982, J BIOL CHEM, V257, P7637; PARODI AJ, 1981, P NATL ACAD SCI-BIOL, V78, P6201, DOI 10.1073/pnas.78.10.6201; Petrescu AJ, 1997, EMBO J, V16, P4302, DOI 10.1093/emboj/16.14.4302; PREVIATO JO, 1986, MOL BIOCHEM PARASIT, V18, P343, DOI 10.1016/0166-6851(86)90091-5; RALTON JE, 1993, J BIOL CHEM, V268, P24183; Rudd PM, 1997, CRIT REV BIOCHEM MOL, V32, P1, DOI 10.3109/10409239709085144; Samuelson J, 2005, P NATL ACAD SCI USA, V102, P1548, DOI 10.1073/pnas.0409460102; SCHNEIDER P, 1995, METHOD ENZYMOL, V250, P614; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; Spiro RG, 2000, J BIOL CHEM, V275, P35657, DOI 10.1074/jbc.R000022200; Trombetta ES, 1996, J BIOL CHEM, V271, P27509, DOI 10.1074/jbc.271.44.27509; Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949; Trombetta ES, 2003, GLYCOBIOLOGY, V13, p77R, DOI 10.1093/glycob/cwg075; TURCO SJ, 1982, J BIOL CHEM, V257, P8674; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; YAGODNIK C, 1987, BIOCHEMISTRY-US, V26, P5937, DOI 10.1021/bi00392a054; ZAMZE SE, 1991, J BIOL CHEM, V266, P20244	46	58	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35929	35942		10.1074/jbc.M509130200	http://dx.doi.org/10.1074/jbc.M509130200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16120601	hybrid			2022-12-27	WOS:000232726900020
J	Jutras, I; Laplante, A; Boulais, J; Brunet, S; Thinakaran, G; Desjardins, M				Jutras, I; Laplante, A; Boulais, J; Brunet, S; Thinakaran, G; Desjardins, M			gamma-secretase is a functional component of phagosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; INTRAMEMBRANE PROTEOLYSIS; MEDIATED PHAGOCYTOSIS; INTERFERON-GAMMA; PRESENILIN; NICASTRIN; COMPLEX; MEMBRANE; BINDING; APH-1	gamma-Secretase is a high molecular mass protein complex that catalyzes the intramembrane cleavage of its protein substrates. Two proteins involved in phagocytosis, CD44 and the low density lipoprotein receptor-related protein, are gamma-secretase substrates, suggesting that this complex might regulate some aspects of phagocytosis. Our results indicate that the four components of gamma-secretase, viz. presenilin, nicastrin, APH-1, and PEN-2, are present and enriched on phagosome membranes from both murine macrophages and Drosophila S2 phagocytes. The gamma-secretase components form high molecular mass complexes in lipid microdomains of the phagosome membrane with the topology expected for the functional enzyme. In contrast to the majority of the phagosome proteins studied so far, which appear to associate transiently with this organelle, gamma-secretase resides on newly formed phagosomes and remains associated throughout their maturation into phagolysosomes. Finally, our results indicate that interferon-gamma stimulates gamma-secretase-dependent cleavages on phagosomes and that gamma-secretase activity may be involved in the phagocytic response of macrophages to inflammatory cytokines.	Univ Montreal, Dept Pathol & Biol Cellulaire, Montreal, PQ H3C 3J7, Canada; Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Caprion Pharmaceut Inc, Montreal, PQ H4S 2C8, Canada	Universite de Montreal; University of Chicago	Desjardins, M (corresponding author), Univ Montreal, Dept Pathol & Biol Cellulaire, 2900 Edouard Montpetit, Montreal, PQ H3T 1J4, Canada.	michel.desjardins@umontreal.ca	Boulais, jonathan/Y-4019-2019	Desjardins, Michel/0000-0002-5684-5980; Boulais, Jonathan/0000-0003-1848-0068	NATIONAL INSTITUTE ON AGING [R01AG019070, R01AG021495] Funding Source: NIH RePORTER; NIA NIH HHS [AG019070, AG021495] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bajno L, 2000, J CELL BIOL, V149, P697, DOI 10.1083/jcb.149.3.697; Brunet S, 2003, TRENDS CELL BIOL, V13, P629, DOI 10.1016/j.tcb.2003.10.006; Cao XW, 2004, J BIOL CHEM, V279, P24601, DOI 10.1074/jbc.M402248200; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Crystal AS, 2003, J BIOL CHEM, V278, P20117, DOI 10.1074/jbc.M213107200; Dermine JF, 2001, J BIOL CHEM, V276, P18507, DOI 10.1074/jbc.M101113200; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; Desjardins M, 2003, NAT REV IMMUNOL, V3, P280, DOI 10.1038/nri1053; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Erwig LP, 1999, BLOOD, V93, P1406, DOI 10.1182/blood.V93.4.1406.404k10_1406_1412; Farmery MR, 2003, J BIOL CHEM, V278, P24277, DOI 10.1074/jbc.M211992200; Gagnon E, 2002, CELL, V110, P119, DOI 10.1016/S0092-8674(02)00797-3; Gardai SJ, 2003, CELL, V115, P13, DOI 10.1016/S0092-8674(03)00758-X; Garin J, 2001, J CELL BIOL, V152, P165, DOI 10.1083/jcb.152.1.165; Gu YJ, 2004, J BIOL CHEM, V279, P31329, DOI 10.1074/jbc.M401548200; Gupta-Rossi N, 2004, J CELL BIOL, V166, P73, DOI 10.1083/jcb.200310098; Hansson CA, 2004, J BIOL CHEM, V279, P51654, DOI 10.1074/jbc.M404500200; Houde M, 2003, NATURE, V425, P402, DOI 10.1038/nature01912; Hu Y, 2003, J CELL BIOL, V161, P685, DOI 10.1083/jcb.200304014; Iwatsubo T, 2004, CURR OPIN NEUROBIOL, V14, P379, DOI 10.1016/j.conb.2004.05.010; Kim SH, 2004, J BIOL CHEM, V279, P48615, DOI 10.1074/jbc.C400396200; Kim SH, 2003, J BIOL CHEM, V278, P33992, DOI 10.1074/jbc.M305834200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Koo EH, 2004, NAT MED, V10, pS26, DOI 10.1038/nm1065; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Leemans JC, 2003, J CLIN INVEST, V111, P681, DOI 10.1172/JCI200316936; Li XJ, 1998, P NATL ACAD SCI USA, V95, P7109, DOI 10.1073/pnas.95.12.7109; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Liao YF, 2004, J BIOL CHEM, V279, P49523, DOI 10.1074/jbc.M402034200; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; May P, 2003, J BIOL CHEM, V278, P37386, DOI 10.1074/jbc.M305858200; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Nyabi O, 2003, J BIOL CHEM, V278, P43430, DOI 10.1074/jbc.M306957200; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Parent AT, 2005, J NEUROSCI, V25, P1540, DOI 10.1523/JNEUROSCI.3850-04.2005; Pasternak SH, 2003, J BIOL CHEM, V278, P26687, DOI 10.1074/jbc.M304009200; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; Runz H, 2002, J NEUROSCI, V22, P1679, DOI 10.1523/JNEUROSCI.22-05-01679.2002; Saura CA, 2000, J BIOL CHEM, V275, P17136, DOI 10.1074/jbc.M909624199; Schagger H, 2001, METHOD CELL BIOL, V65, P231, DOI 10.1016/S0091-679X(01)65014-3; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; TARDIEUX I, 1992, CELL, V71, P1117, DOI 10.1016/S0092-8674(05)80061-3; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Underhill DM, 2002, ANNU REV IMMUNOL, V20, P825, DOI 10.1146/annurev.immunol.20.103001.114744; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 2003, J CELL SCI, V116, P2839, DOI 10.1242/jcs.00651; Xu HX, 1998, NAT MED, V4, P447, DOI 10.1038/nm0498-447; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Yu CJ, 2001, J BIOL CHEM, V276, P43756, DOI 10.1074/jbc.C100410200; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436	60	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36310	36317		10.1074/jbc.M504069200	http://dx.doi.org/10.1074/jbc.M504069200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16103123	hybrid			2022-12-27	WOS:000232726900064
J	Bao, XF; Muramatsu, T; Sugahara, K				Bao, XF; Muramatsu, T; Sugahara, K			Demonstration of the pleiotrophin-binding oligosaccharide sequences isolated from chondroitin sulfate/dermatan sulfate hybrid chains of embryonic pig brains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVERSULFATED DERMATAN SULFATE; OUTGROWTH-PROMOTING ACTIVITY; PROTEIN LINKAGE REGION; NEURITE OUTGROWTH; GROWTH-FACTORS; CAENORHABDITIS-ELEGANS; HEXASACCHARIDE SEQUENCES; MOLECULAR-INTERACTIONS; NEURITOGENIC ACTIVITY; NEUROTROPHIC FACTORS	Mammalian brains contain significant amounts of chondroitin sulfate ( CS), dermatan sulfate ( DS), and CS/ DS hybrid chains. CS/ DS chains isolated from embryonic pig brains ( E- CS/ DS) promote the outgrowth of neurites in embryonic mouse hippocampal neurons in culture by interacting with pleiotrophin ( PTN), a heparin-binding growth factor. Here, we analyzed oligosaccharides isolated from E- CS/ DS, which showed that octasaccharides were the minimal size capable of interacting with PTN at a physiological salt concentration. Five and eight sequences were purified from fluorescently labeled PTN- bound and - unbound octasaccharide fractions, respectively, by enzymatic digestion followed by PTN- affinity chromatography. Their sequences were determined by enzymatic digestion in conjunction with high performance liquid chromatography, revealing a critical role for oversulfated D and/ or iD disaccharides in the low yet significant affinity for PTN, which is required for neuritogenesis. The critical D and iD units are GlcUA( 2- O- sulfate) beta 1 - 3GalNAc( 6- O- sulfate) and IdoUA( 2- O- sulfate) alpha 1 - 3GalNAc( 6- O- sulfate), respectively, where IdoUA represents L- iduronic acid. In contrast, high affinity interactions with PTN required decasaccharides with E units ( GlcUA beta 1 - 3GalNAc( 4, 6- O- disulfate)), B units ( GlcUA( 2- O- sulfate) beta 1 - 3GalNAc( 4- O- sulfate)), and/ or their IdoUA- containing counterparts ( iE and iB) in addition to D/ iD units, although the biological significance of such strong interactions remains to be investigated. Thus, chain size and composition are crucial to the interaction with PTN, and PTN binds to multiple sequences in E- CS/ DS chains with distinct affinity. Notably, not only heparan sulfate but also CS/ DS hybrid chain structures of mammalian brains contain a high degree of microheterogeneity with a cluster of oversulfated disaccharides and appear to play roles in regulating the functions of PTN.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan; Nagoya Univ, Sch Med, Dept Biochem, Nagoya, Aichi 4668550, Japan	Kobe Pharmaceutical University; Nagoya University	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, 4-19-1 Motoyama Kita Machi, Kobe, Hyogo 6588558, Japan.	k-sugar@kobepharma-u.ac.jp						Bandtlow CE, 2000, PHYSIOL REV, V80, P1267, DOI 10.1152/physrev.2000.80.4.1267; Bao XF, 2005, J BIOL CHEM, V280, P23184, DOI 10.1074/jbc.M503036200; Bao XF, 2005, J BIOL CHEM, V280, P9180, DOI 10.1074/jbc.M413423200; Bao XF, 2004, J BIOL CHEM, V279, P9765, DOI 10.1074/jbc.M310877200; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Clement AM, 1999, NEUROSCI LETT, V269, P125, DOI 10.1016/S0304-3940(99)00432-2; Clement AM, 1998, J BIOL CHEM, V273, P28444, DOI 10.1074/jbc.273.43.28444; Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; Hikino M, 2003, J BIOL CHEM, V278, P43744, DOI 10.1074/jbc.M308169200; Hwang HY, 2003, NATURE, V423, P439, DOI 10.1038/nature01634; Kawashima H, 2002, J BIOL CHEM, V277, P12921, DOI 10.1074/jbc.M200396200; Kinoshita A, 1999, ANAL BIOCHEM, V269, P367, DOI 10.1006/abio.1999.4027; Kitagawa H, 1997, J BIOL CHEM, V272, P31377, DOI 10.1074/jbc.272.50.31377; Kreuger J, 2005, BIOCHEM J, V389, P145, DOI 10.1042/BJ20042129; Kreuger J, 2001, J BIOL CHEM, V276, P30744, DOI 10.1074/jbc.M102628200; Lander AD, 1998, MATRIX BIOL, V17, P465, DOI 10.1016/S0945-053X(98)90093-2; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; Maeda N, 2003, J BIOL CHEM, V278, P35805, DOI 10.1074/jbc.M305530200; MCLEAN MW, 1984, EUR J BIOCHEM, V145, P607, DOI 10.1111/j.1432-1033.1984.tb08600.x; Mizuguchi S, 2003, NATURE, V423, P443, DOI 10.1038/nature01635; Moon LDF, 2001, NAT NEUROSCI, V4, P465, DOI 10.1038/87415; Nadanaka S, 1998, J BIOL CHEM, V273, P3296, DOI 10.1074/jbc.273.6.3296; Nadanaka S, 1999, FEBS LETT, V452, P185, DOI 10.1016/S0014-5793(99)00597-9; Nandini CD, 2005, J BIOL CHEM, V280, P4058, DOI 10.1074/jbc.M412074200; Nandini CD, 2004, J BIOL CHEM, V279, P50799, DOI 10.1074/jbc.M404746200; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; RHOMBERG AJ, 1997, LAB GUIDE GLYCOCONJU, P77; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; Sakko AJ, 2003, CANCER RES, V63, P4786; Silbert JE, 2002, IUBMB LIFE, V54, P177, DOI 10.1080/15216540214923; SUGAHARA K, 1995, J BIOL CHEM, V270, P7204, DOI 10.1074/jbc.270.13.7204; SUGAHARA K, 1994, CARBOHYD RES, V255, P145, DOI 10.1016/S0008-6215(00)90976-5; Sugahara K, 2003, CURR OPIN STRUC BIOL, V13, P612, DOI 10.1016/j.sbi.2003.09.011; Sugahara K, 1996, EUR J BIOCHEM, V239, P871, DOI 10.1111/j.1432-1033.1996.0871u.x; Sugahara K, 2000, TRENDS GLYCOSCI GLYC, V12, P321, DOI 10.4052/tigg.12.321; Takagi H, 2002, J CELL SCI, V115, P3309; Tanaka M, 2003, J NEUROSCI, V23, P2804, DOI 10.1523/jneurosci.23-07-02804.2003; Taylor KR, 2005, J BIOL CHEM, V280, P5300, DOI 10.1074/jbc.m410412200; Ueoka C, 1999, GLYCOCONJUGATE J, V16, P291, DOI 10.1023/A:1007022229813; Yamada S, 2002, J BIOL CHEM, V277, P31877, DOI 10.1074/jbc.M205078200; Yoshida K., 1993, DERMATAN SULFATE PRO, P55	43	58	59	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35318	35328		10.1074/jbc.M507304200	http://dx.doi.org/10.1074/jbc.M507304200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16120610	hybrid			2022-12-27	WOS:000232561200030
J	Kugimiya, F; Kawaguchi, H; Kamekura, S; Chikuda, H; Ohba, S; Yano, F; Ogata, N; Katagiri, T; Harada, Y; Azuma, Y; Nakamura, K; Chung, UG				Kugimiya, F; Kawaguchi, H; Kamekura, S; Chikuda, H; Ohba, S; Yano, F; Ogata, N; Katagiri, T; Harada, Y; Azuma, Y; Nakamura, K; Chung, UG			Involvement of endogenous bone morphogenetic protein (BMP)2 and BMP6 in bone formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CBFA1; DIFFERENTIATION; CHONDROCYTES; EXPRESSION	Although accumulated evidence has shown the bone anabolic effects of bone morphogenetic proteins ( BMPs) that were exogenously applied in vitro and in vivo, the roles of endogenous BMPs during bone formation remain to be clarified. This study initially investigated expression patterns of BMPs in the mouse long bone and found that BMP2 and BMP6 were the main subtypes expressed in hypertrophic chondrocytes that induce endochondral bone formation. We then examined the involvement of the combination of these BMPs in bone formation in vivo by generating the compound-deficient mice ( Bmp2 +/-; Bmp6 -/-). Under physiological conditions, these mice exhibited moderate growth retardation compared with the wild- type ( WT) littermates during the observation period up to 52 weeks of age. Both the fetal and adult compound- deficient mice showed a reduction in the trabecular bone volume with suppressed bone formation, but normal bone resorption, whereas the single deficient mice ( Bmp2 +/- or Bmp6 -/-) did not. When a fracture was created at the femoral midshaft and the bone healing was analyzed, the endochondral bone formation, but not intramembranous bone formation, was impaired by the compound deficiency. In the cultures of bone marrow cells, however, there was no difference in osteogenic differentiation between WT and compounddeficient cells in the presence or absence of the exogenous BMP2. We thus concluded that endogenous BMP2 and BMP6 cooperatively play pivotal roles in bone formation under both physiological and pathological conditions.	Univ Tokyo, Fac Med, Div Tissue Engn, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Fac Med, Div Sensory & Motor Syst Med, Bunkyo Ku, Tokyo 1138655, Japan; Saitama Med Sch, Div Pathophysiol, Res Ctr Genom Med, Hidaka, Saitama 3501241, Japan; Teijin Co Ltd, Tokyo 1918512, Japan	University of Tokyo; University of Tokyo; Saitama Medical University; Teijin Limited	Chung, UG (corresponding author), Univ Tokyo, Fac Med, Div Tissue Engn, Bunkyo Ku, Hongo 7-3-1, Tokyo 1138655, Japan.	uichung-tky@umin.ac.jp		Ohba, Shinsuke/0000-0002-6874-8539				Aubin JE, 1998, J CELL BIOCHEM, P73, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<73::AID-JCB11>3.0.CO;2-L; Chung UI, 2004, ENDOCR J, V51, P19, DOI 10.1507/endocrj.51.19; Chung UI, 2001, J CLIN INVEST, V107, P295, DOI 10.1172/JCI11706; Corral DA, 1998, P NATL ACAD SCI USA, V95, P13835, DOI 10.1073/pnas.95.23.13835; D'Angelo M, 2000, J CELL BIOCHEM, V77, P678, DOI 10.1002/(SICI)1097-4644(20000615)77:4<678::AID-JCB15>3.3.CO;2-G; Israel DI, 1996, GROWTH FACTORS, V13, P291, DOI 10.3109/08977199609003229; Jimenez MJG, 2001, J CELL BIOL, V155, P1333, DOI 10.1083/jcb.200106147; Kamekura S, 2005, OSTEOARTHR CARTILAGE, V13, P632, DOI 10.1016/j.joca.2005.03.004; Karsenty Gerard, 2000, P291; Kawabata Masahiro, 2000, P269; KAWAGUCHI H, 1994, ENDOCRINOLOGY, V135, P774, DOI 10.1210/en.135.2.774; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657; LEE KC, 1995, ENDOCRINOLOGY, V136, P453, DOI 10.1210/en.136.2.453; Long FX, 2004, DEVELOPMENT, V131, P1309, DOI 10.1242/dev.01006; Long FX, 2001, DEVELOPMENT, V128, P5099; Malaval L, 2001, J CELL BIOCHEM, P63; Mishina Y, 2004, J BIOL CHEM, V279, P27560, DOI 10.1074/jbc.M404222200; Nishida S, 2002, BONE, V30, P872, DOI 10.1016/S8756-3282(02)00725-1; Shimoaka T, 2004, J BIOL CHEM, V279, P15314, DOI 10.1074/jbc.M312525200; Solloway MJ, 1998, DEV GENET, V22, P321, DOI 10.1002/(SICI)1520-6408(1998)22:4<321::AID-DVG3>3.3.CO;2-7; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Zhang HB, 1996, DEVELOPMENT, V122, P2977; Zhao GQ, 2003, GENESIS, V35, P43, DOI 10.1002/gene.10167; Zhao M, 2002, J CELL BIOL, V157, P1049, DOI 10.1083/jcb.200109012	27	118	125	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35704	35712		10.1074/jbc.M505166200	http://dx.doi.org/10.1074/jbc.M505166200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16109715	hybrid			2022-12-27	WOS:000232561200073
J	Tzeng, SJ; Bolland, S; Inabe, K; Kurosaki, T; Pierce, SK				Tzeng, SJ; Bolland, S; Inabe, K; Kurosaki, T; Pierce, SK			The B cell inhibitory Fc receptor triggers apoptosis by a novel c-Abl family kinase-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; SIGNALS	The inhibitory Fc receptors function to regulate the antigen-driven activation and expansion of lymphocytes. In B cells, the Fc gamma RIIB1 is a potent inhibitor of B cell antigen receptor (BCR) signaling when coligated to the BCR by engagement of antigen-containing immune complexes. Inhibition is mediated by the recruitment of the inositol phosphatase, SHIP, to the Fc gamma RIIB1 phosphorylated tyrosine-based inhibitory motif (ITIM). Here we show that BCR-independent aggregation of the Fc gamma RIIB1 transduces an ITIM- and SHIP-independent proapoptotic signal that is dependent on members of the c-Abl tyrosine kinase family. These results define a novel Abl family kinase-dependent Fc gamma RIIB1 signaling pathway that functions independently of the BCR in controlling antigen-driven B cell responses.	NIAID, Immunogenet Lab, NIH, Rockville, MD 20852 USA; Kansai Med Univ, Inst Liver Res, Dept Mol Genet, Moriguchi, Osaka 5708506, Japan; RIKEN, Res Ctr Allergy & Immunol, Lab Lymphocyte Differentiat, Tsurumi Ku, Kanagawa 2300045, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Kansai Medical University; RIKEN	Pierce, SK (corresponding author), NIAID, Immunogenet Lab, NIH, Twinbrook 2,12441 Parklawn Dr,Rm 200B,MSC 8180, Rockville, MD 20852 USA.	spierce@nih.gov	Kurosaki, Tomohiro/D-1306-2009; Tzeng, Shiang-Jong/AED-3885-2022	Kurosaki, Tomohiro/0000-0002-6352-304X; Tzeng, Shiang-Jong/0000-0003-1633-020X	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000975, ZIAAI000975] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bolland S, 2000, IMMUNITY, V13, P277, DOI 10.1016/S1074-7613(00)00027-3; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; Davis RS, 2005, EUR J IMMUNOL, V35, P674, DOI 10.1002/eji.200425886; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Fong DC, 2000, J IMMUNOL, V165, P4453, DOI 10.4049/jimmunol.165.8.4453; Fukuyama H, 2005, NAT IMMUNOL, V6, P99, DOI 10.1038/ni1151; Gauld SB, 2002, SCIENCE, V296, P1641, DOI 10.1126/science.1071546; Hantschel O, 2004, NAT REV MOL CELL BIO, V5, P33, DOI 10.1038/nrm1280; Muljo SA, 2003, NAT IMMUNOL, V4, P31, DOI 10.1038/ni870; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; Pearse RN, 1999, IMMUNITY, V10, P753, DOI 10.1016/S1074-7613(00)80074-6; Phee H, 2001, MOL CELL BIOL, V21, P8615, DOI 10.1128/MCB.21.24.8615-8625.2001; Plattner R, 2003, NAT CELL BIOL, V5, P309, DOI 10.1038/ncb949; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; Reers M, 1995, METHOD ENZYMOL, V260, P406, DOI 10.1016/0076-6879(95)60154-6; Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453; Roose JP, 2003, PLOS BIOL, V1, P271, DOI 10.1371/journal.pbio.0000053; Tamir I, 2000, IMMUNITY, V12, P347, DOI 10.1016/S1074-7613(00)80187-9; Wong S, 2004, ANNU REV IMMUNOL, V22, P247, DOI 10.1146/annurev.immunol.22.012703.104753; Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622	20	61	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35247	35254		10.1074/jbc.M505308200	http://dx.doi.org/10.1074/jbc.M505308200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16115887	hybrid			2022-12-27	WOS:000232561200022
J	Murphy, PJM; Morishima, Y; Kovacs, JJ; Yao, TP; Pratt, WB				Murphy, PJM; Morishima, Y; Kovacs, JJ; Yao, TP; Pratt, WB			Regulation of the dynamics of hsp90 action on the glucocorticoid receptor by acetylation/deacetylation of the chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							7-AMINO ACID SEQUENCE; SHOCK-PROTEIN 90; ATP-BINDING; HSP90-BINDING IMMUNOPHILINS; DEPENDENT ACTIVATION; TERMINAL DOMAIN; AMINO-TERMINUS; P23; HEAT-SHOCK-PROTEIN-90; HDAC6	It is known that inhibition of histone deacetylases (HDACs) leads to acetylation of the abundant protein chaperone hsp90. In a recent study, we have shown that knockdown of HDAC6 by a specific small interfering RNA leads to hyperacetylation of hsp90 and that the glucocorticoid receptor (GR), an established hsp90 "client" protein, is defective in ligand binding, nuclear translocation, and gene activation in HDAC6-deficient cells ( Kovacs, J. J., Murphy, P. J. M., Gaillard, S., Zhao, X., Wu, J-T., Nicchitta, C. V., Yoshida, M., Toft, D. O., Pratt, W. B., and Yao, T-P. ( 2005) Mol. Cell 18, 601 - 607). Using human embryonic kidney wild-type and HDAC6( small interfering RNA) knockdown cells transiently expressing the mouse GR, we show here that the intrinsic properties of the receptor protein itself are not affected by HDAC6 knockdown, but the knockdown cytosol has a markedly decreased ability to assemble stable GR center dot hsp90 heterocomplexes and generate stable steroid binding activity under cell-free conditions. HDAC6 knockdown cytosol has the same ability to carry out dynamic GR center dot hsp90 heterocomplex assembly as wild-type cytosol. Addition of purified hsp90 to HDAC6 knockdown cytosol restores stable GR center dot hsp90 heterocomplex assembly to the level of wild-type cytosol. hsp90 from HDAC6 knockdown cytosol has decreased ATP-binding affinity, and it does not assemble stable GR center dot hsp90 heterocomplexes when it is a component of a purified five-protein assembly system. Incubation of knockdown cell hsp90 with purified HDAC6 converts the hsp90 to wild-type behavior. Thus, acetylation of hsp90 results in dynamic GR center dot hsp90 heterocomplex assembly/ disassembly, and this is manifest in the cell as a similar to 100-fold shift to the right in the steroid dose response for gene activation.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	University of Michigan System; University of Michigan; Duke University	Pratt, WB (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 1301 Med Sci Res Bldg 3, Ann Arbor, MI 48109 USA.	ymo@umich.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001004, Z01HD000711] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA028010] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [Z01EY000311] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL004231] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000898, Z01AI000881] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551, Z01DE000379] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031573, Z01DK032003, Z01DK070004, R37DK031573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES065078, Z01ES090087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS054022] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000726] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000047] Funding Source: NIH RePORTER; NCI NIH HHS [CA28010] Funding Source: Medline; NIDDK NIH HHS [DK31573] Funding Source: Medline; NINDS NIH HHS [R01 NS054022-01, R01 NS054022] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bender AT, 1999, J BIOL CHEM, V274, P1472, DOI 10.1074/jbc.274.3.1472; Billecke SS, 2004, J BIOL CHEM, V279, P30252, DOI 10.1074/jbc.M403864200; Dittmar KD, 1997, J BIOL CHEM, V272, P13047, DOI 10.1074/jbc.272.20.13047; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; Felts SJ, 2003, CELL STRESS CHAPERON, V8, P108, DOI 10.1379/1466-1268(2003)008<0108:PASPWC>2.0.CO;2; Galigniana MD, 2004, J BIOL CHEM, V279, P22483, DOI 10.1074/jbc.M402223200; Garnier C, 2002, J BIOL CHEM, V277, P12208, DOI 10.1074/jbc.M111874200; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; Harrell JM, 2004, J BIOL CHEM, V279, P54647, DOI 10.1074/jbc.M406863200; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Isaacs JS, 2003, CANCER CELL, V3, P213, DOI 10.1016/S1535-6108(03)00029-1; Kanelakis KC, 2003, METHOD ENZYMOL, V364, P159; Kaul S, 2002, J BIOL CHEM, V277, P36223, DOI 10.1074/jbc.M206748200; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; Marcu MG, 2000, J BIOL CHEM, V275, P37181, DOI 10.1074/jbc.M003701200; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Morishima Y, 2000, J BIOL CHEM, V275, P18054, DOI 10.1074/jbc.M000434200; Morishima Y, 2003, J BIOL CHEM, V278, P48754, DOI 10.1074/jbc.M309814200; Pratt WB, 2004, CELL SIGNAL, V16, P857, DOI 10.1016/j.cellsig.2004.02.004; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Soti C, 2002, J BIOL CHEM, V277, P7066, DOI 10.1074/jbc.M105568200; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Sullivan WP, 2002, J BIOL CHEM, V277, P45942, DOI 10.1074/jbc.M207754200; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; Xu M, 1998, J BIOL CHEM, V273, P13918, DOI 10.1074/jbc.273.22.13918; Yoshida M, 2001, CANCER CHEMOTH PHARM, V48, pS20, DOI 10.1007/s002800100300; Yu XD, 2002, J NATL CANCER I, V94, P504	36	133	137	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33792	33799		10.1074/jbc.M506997200	http://dx.doi.org/10.1074/jbc.M506997200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16087666	hybrid			2022-12-27	WOS:000232229700015
J	Wanamaker, CP; Green, WN				Wanamaker, CP; Green, WN			N-linked glycosylation is required for nicotinic receptor assembly but not for subunit associations with calnexin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTOCOMPATIBILITY COMPLEX-MOLECULES; TORPEDO ACETYLCHOLINE-RECEPTOR; ENDOPLASMIC-RETICULUM; CHAPERONE CALNEXIN; QUALITY-CONTROL; IN-VIVO; SURFACE EXPRESSION; BETA-SUBUNIT; PROTEIN; CALRETICULIN	We investigated how asparagine (N)-linked glycosylation affects assembly of acetylcholine receptors (AChRs) in the endoplasmic reticulum (ER). Block of N-linked glycosylation inhibited AChR assembly whereas block of glucose trimming partially blocked assembly at the late stages. Removal of each of seven glycans had a distinct effect on AChR assembly, ranging from no effect to total loss of assembly. Because the chaperone calnexin (CN) associates with N-linked glycans, we examined CN interactions with AChR subunits. CN rapidly associates with 50% or more of newly synthesized AChR subunits, but not with subunits after maturation. Block of N-linked glycosylation or trimming did not alter CN-AChR subunit associations nor did subunit mutations prevent N-linked glycosylation. Additionally, CN associations with subunits lacking N-linked glycans occurred without subunit aggregation or misfolding. Our data indicate that CN associates with AChR subunits without N-linked glycan interactions. Furthermore, CN-subunit associations only occur early in AChR assembly and have no role in events later that require N-linked glycosylation.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Univ Chicago, Comm Neurobiol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Green, WN (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, 947 E 58th St, Chicago, IL 60637 USA.	wgreen@midway.uchicago.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032693] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS032693-07, R01 NS032693-05A1, R01 NS032693-06, R01 NS032693-08, R01 NS032693] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON DJ, 1981, P NATL ACAD SCI-BIOL, V78, P5598, DOI 10.1073/pnas.78.9.5598; ARUNACHALAM B, 1995, J BIOL CHEM, V270, P2784, DOI 10.1074/jbc.270.6.2784; Basu S, 1999, J EXP MED, V189, P797, DOI 10.1084/jem.189.5.797; BLOUNT P, 1990, J CELL BIOL, V111, P2601, DOI 10.1083/jcb.111.6.2601; Cannon KS, 1996, J BIOL CHEM, V271, P14280, DOI 10.1074/jbc.271.24.14280; CARRENO BM, 1995, J IMMUNOL, V154, P5173; Chang W, 1997, J BIOL CHEM, V272, P28925, DOI 10.1074/jbc.272.46.28925; Christianson JC, 2004, EMBO J, V23, P4156, DOI 10.1038/sj.emboj.7600436; CLAUDIO T, 1989, J CELL BIOL, V108, P2277, DOI 10.1083/jcb.108.6.2277; CLAUDIO T, 1987, SCIENCE, V238, P1688, DOI 10.1126/science.3686008; Daniels R, 2003, MOL CELL, V11, P79, DOI 10.1016/S1097-2765(02)00821-3; Danilczyk UG, 2001, J BIOL CHEM, V276, P25532, DOI 10.1074/jbc.M100270200; Eertmoed AL, 1998, METHOD ENZYMOL, V293, P564; Ellgaard L, 2003, CELL BIOCHEM BIOPHYS, V39, P223, DOI 10.1385/CBB:39:3:223; Frickel EM, 2002, P NATL ACAD SCI USA, V99, P1954, DOI 10.1073/pnas.042699099; Gehle VM, 1997, MOL BRAIN RES, V45, P219, DOI 10.1016/S0169-328X(96)00256-2; GELMAN MS, 1995, J BIOL CHEM, V270, P15085, DOI 10.1074/jbc.270.25.15085; Green WN, 1998, J NEUROSCI, V18, P5555; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; Green WN, 1997, J BIOL CHEM, V272, P20945, DOI 10.1074/jbc.272.33.20945; GU Y, 1991, J CELL BIOL, V114, P799, DOI 10.1083/jcb.114.4.799; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Ihara Y, 1999, MOL CELL, V4, P331, DOI 10.1016/S1097-2765(00)80335-4; Jannatipour M, 1998, BIOCHEMISTRY-US, V37, P17253, DOI 10.1021/bi981785c; Jorgensen CS, 2000, EUR J BIOCHEM, V267, P2945, DOI 10.1046/j.1432-1033.2000.01309.x; Keller SH, 1996, J BIOL CHEM, V271, P22871, DOI 10.1074/jbc.271.37.22871; Keller SH, 1998, J BIOL CHEM, V273, P17064, DOI 10.1074/jbc.273.27.17064; Kleizen B, 2004, CURR OPIN CELL BIOL, V16, P343, DOI 10.1016/j.ceb.2004.06.012; Leach MR, 2004, J BIOL CHEM, V279, P9072, DOI 10.1074/jbc.M310788200; LEACH MR, 2002, J BIOL CHEM, V6, P6; LEE BS, 1991, J BIOL CHEM, V266, P11448; LOO TW, 1994, J BIOL CHEM, V269, P28683; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; MERLIE JP, 1982, J BIOL CHEM, V257, P2694; Molinari M, 2000, SCIENCE, V288, P331, DOI 10.1126/science.288.5464.331; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Nair S, 1999, J IMMUNOL, V162, P6426; OU WJ, 1995, J BIOL CHEM, V270, P18051, DOI 10.1074/jbc.270.30.18051; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; Parodi AJ, 2000, BIOCHEM J, V348, P1, DOI 10.1042/0264-6021:3480001; PAULSON HL, 1991, J CELL BIOL, V113, P1371, DOI 10.1083/jcb.113.6.1371; Pollock S, 2004, EMBO J, V23, P1020, DOI 10.1038/sj.emboj.7600119; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; ROSS AF, 1991, J CELL BIOL, V113, P623, DOI 10.1083/jcb.113.3.623; SAEDI MS, 1991, J CELL BIOL, V112, P1007, DOI 10.1083/jcb.112.5.1007; Schrag JD, 2001, MOL CELL, V8, P633, DOI 10.1016/S1097-2765(01)00318-5; SMITH MM, 1987, J BIOL CHEM, V262, P4367; SUMIKAWA K, 1992, J BIOL CHEM, V267, P6286; SUMIKAWA K, 1989, MOL BRAIN RES, V5, P183, DOI 10.1016/0169-328X(89)90034-X; Swanton E, 2003, EMBO J, V22, P2948, DOI 10.1093/emboj/cdg300; vanLeeuwen JEM, 1996, J BIOL CHEM, V271, P9660, DOI 10.1074/jbc.271.16.9660; WADA I, 1995, J BIOL CHEM, V270, P20298, DOI 10.1074/jbc.270.35.20298; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WILLIAMS DB, 1995, BIOCHEM CELL BIOL, V73, P123, DOI 10.1139/o95-015; YONG G, 1989, J CELL BIOL, V109, P729, DOI 10.1083/jcb.109.2.729; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009; ZHANG Q, 1995, J BIOL CHEM, V270, P3944, DOI 10.1074/jbc.270.8.3944	57	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33800	33810		10.1074/jbc.M501813200	http://dx.doi.org/10.1074/jbc.M501813200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16091366	Green Accepted, hybrid			2022-12-27	WOS:000232229700016
J	Meiling-Wesse, K; Epple, UD; Krick, R; Barth, H; Appelles, A; Voss, C; Eskelinen, EL; Thumm, M				Meiling-Wesse, K; Epple, UD; Krick, R; Barth, H; Appelles, A; Voss, C; Eskelinen, EL; Thumm, M			Trs85 (Gsg1), a component of the TRAPP complexes, is required for the organization of the preautophagosomal structure during selective autophagy via the Cvt pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLE TARGETING PATHWAY; YEAST SACCHAROMYCES-CEREVISIAE; AMINOPEPTIDASE-I; BUDDING YEAST; CYTOPLASM; PROTEIN; GENE; MEMBRANE; MUTANTS; VESICLE	Autophagosomes and Cvt vesicles are limited by two membrane layers. The biogenesis of these unconventional vesicles and the origin of their membranes are hardly understood. Here we identify in Saccharomyces cerevisiae Trs85, a nonessential component of the TRAPP complexes, to be required for the biogenesis of Cvt vesicles. The TRAPP complexes function in endoplasmic reticulum-to-Golgi and Golgi trafficking. Growing trs85 Delta cells show a defect in the organization of the preautophagosomal structure. Although proaminopeptidase I is normally recruited to the preautophagosomal structure, the recruitment of green fluorescent protein-Atg8 depends on Trs85. Autophagy proceeds in the absence of Trs85, albeit at a reduced rate. Our electron microscopic analysis demonstrated that the reduced autophagic rate of trs85 Delta cells does not result from a reduced size of the autophagosomes. Growing and starved cells lacking Trs85 did not show defects in vacuolar biogenesis; mature vacuolar proteinase B and carboxypeptidase Y were present. Also vacuolar acidification was normal in these cells. It is known that mutations impairing the integrity of the ER or Golgi block both autophagy and the Cvt pathway. But the phenotypes of trs85 Delta cells show striking differences to those seen in mutants with defects in the early secretory pathway. This suggests that Trs85 might play a direct role in the Cvt pathway and autophagy.	Univ Gottingen, Ctr Biochem & Mol Cell Biol, D-37073 Gottingen, Germany; Univ Kiel, Inst Biochem, D-24118 Kiel, Germany	University of Gottingen; University of Kiel	Thumm, M (corresponding author), Univ Gottingen, Ctr Biochem & Mol Cell Biol, Heinrich Dueker Weg 12, D-37073 Gottingen, Germany.	mthumm@uni-goettingen.de	Thumm, Michael/A-8033-2015; Eskelinen, Eeva-Liisa/AAF-3496-2019	Eskelinen, Eeva-Liisa/0000-0003-0006-7785; Thumm, Michael/0000-0003-3238-4857				AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; Barth H, 2002, FEBS LETT, V512, P173, DOI 10.1016/S0014-5793(02)02252-4; Barth H, 2001, FEBS LETT, V508, P23, DOI 10.1016/S0014-5793(01)03016-2; Barth H, 2001, GENE, V274, P151, DOI 10.1016/S0378-1119(01)00614-X; Campbell CL, 1998, J CELL SCI, V111, P2455; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Del Roso A, 2003, EXP GERONTOL, V38, P519, DOI 10.1016/S0531-5565(03)00002-0; Epple UD, 2003, J BIOL CHEM, V278, P7810, DOI 10.1074/jbc.M209309200; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; HARDING TM, 1995, J CELL BIOL, V131, P591, DOI 10.1083/jcb.131.3.591; Harding TM, 1996, J BIOL CHEM, V271, P17621, DOI 10.1074/jbc.271.30.17621; Huang WP, 2000, J BIOL CHEM, V275, P5845, DOI 10.1074/jbc.275.8.5845; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Hutchins MU, 1999, J CELL SCI, V112, P4079; Ishihara N, 2001, MOL BIOL CELL, V12, P3690, DOI 10.1091/mbc.12.11.3690; KAYTOR MD, 1995, YEAST, V11, P1147, DOI 10.1002/yea.320111205; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Kim J, 2002, J BIOL CHEM, V277, P763, DOI 10.1074/jbc.M109134200; Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X; Klionsky DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620; Lang T, 2000, J BACTERIOL, V182, P2125, DOI 10.1128/JB.182.8.2125-2133.2000; Leber R, 2001, J BIOL CHEM, V276, P29210, DOI 10.1074/jbc.M101438200; Levine B, 2005, CELL, V120, P159, DOI 10.1016/j.cell.2005.01.005; Meiling-Wesse K, 2004, J BIOL CHEM, V279, P37741, DOI 10.1074/jbc.M401066200; Meiling-Wesse K, 2002, FEBS LETT, V530, P174, DOI 10.1016/S0014-5793(02)03456-7; Meiling-Wesse K, 2002, FEBS LETT, V526, P71, DOI 10.1016/S0014-5793(02)03119-8; Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782; Nakamura N, 1997, J BIOCHEM, V121, P338; NODA T, 1995, BIOCHEM BIOPH RES CO, V210, P126, DOI 10.1006/bbrc.1995.1636; Noda T, 2002, TRENDS CELL BIOL, V12, P231, DOI 10.1016/S0962-8924(02)02278-X; NOTHWEHR SF, 1995, J CELL BIOL, V129, P35, DOI 10.1083/jcb.129.1.35; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Reggiori F, 2004, MOL BIOL CELL, V15, P2189, DOI 10.1091/mbc.E03-07-0479; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Sacher M, 2000, EUR J CELL BIOL, V79, P71, DOI 10.1078/S0171-9335(04)70009-6; Sacher M, 2001, MOL CELL, V7, P433, DOI 10.1016/S1097-2765(01)00190-3; Schlumpberger M, 1997, J BACTERIOL, V179, P1068, DOI 10.1128/jb.179.4.1068-1076.1997; Scott SV, 2000, J BIOL CHEM, V275, P25840, DOI 10.1074/jbc.M002813200; Scott SV, 2001, MOL CELL, V7, P1131, DOI 10.1016/S1097-2765(01)00263-5; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Shintani T, 2002, DEV CELL, V3, P825, DOI 10.1016/S1534-5807(02)00373-8; Straub M, 1997, J BACTERIOL, V179, P3875, DOI 10.1128/jb.179.12.3875-3883.1997; Stromhaug PE, 2004, MOL BIOL CELL, V15, P3553, DOI 10.1091/mbc.E04-02-0147; Suzuki K, 2002, DEV CELL, V3, P815, DOI 10.1016/S1534-5807(02)00359-3; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; Thumm M, 2002, MOL CELL, V10, P1257, DOI 10.1016/S1097-2765(02)00794-3; THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E	51	72	77	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33669	33678		10.1074/jbc.M501701200	http://dx.doi.org/10.1074/jbc.M501701200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16079147	hybrid			2022-12-27	WOS:000232058100069
